<SEC-DOCUMENT>0001299130-25-000061.txt : 20250317
<SEC-HEADER>0001299130-25-000061.hdr.sgml : 20250317
<ACCEPTANCE-DATETIME>20250317083207
ACCESSION NUMBER:		0001299130-25-000061
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		130
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250317
DATE AS OF CHANGE:		20250317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
		CENTRAL INDEX KEY:			0001299130
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				161590339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34899
		FILM NUMBER:		25742501

	BUSINESS ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-521-8000

	MAIL ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIFIC BIOSCIENCES OF CALIFORNIA INC
		DATE OF NAME CHANGE:	20050829

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOFLUIDICS INC
		DATE OF NAME CHANGE:	20040729
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pacb-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b8324ceb-4367-4432-9725-ed1f11bffb27,g:1109ce80-1fe4-4ba2-bf4d-c0b012b2f3c3,d:cb85bf3e8a0c45b3a91f3aa50919c5f5-->
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:pacb="http://www.pacificbiosciences.com/20241231" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pacb-20241231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-33">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-34">0001299130</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-35">False</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-36">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-74" name="pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition" id="f-527">P20D</ix:nonNumeric><ix:nonNumeric contextRef="c-162" name="pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition" id="f-661">P20D</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-814">http://fasb.org/us-gaap/2024#GoodwillAndIntangibleAssetImpairment</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-248" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-1000">0.2045157</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-224" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-1001">0.0465116</ix:nonFraction><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1008">http://fasb.org/us-gaap/2024#CostOfRevenue</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pacb-20241231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="unit"><xbrli:measure>pacb:unit</xbrli:measure></xbrli:unit><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:unit id="vote"><xbrli:measure>pacb:vote</xbrli:measure></xbrli:unit><xbrli:unit id="period"><xbrli:measure>pacb:period</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>pacb:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:NoteExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:NoteExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:NoteExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:BusinessCombinationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:BusinessCombinationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:BusinessCombinationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:LiquidityBonusEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:LiquidityBonusEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:LiquidityBonusEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-02</xbrli:startDate><xbrli:endDate>2023-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">pacb:AchievementOfMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-02</xbrli:startDate><xbrli:endDate>2023-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-20</xbrli:startDate><xbrli:endDate>2023-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-20</xbrli:startDate><xbrli:endDate>2023-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-20</xbrli:startDate><xbrli:endDate>2023-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-20</xbrli:startDate><xbrli:endDate>2023-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashCashEquivalentsAndInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashCashEquivalentsAndInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pacb:LaboratoryEquipmentAndMachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pacb:LaboratoryEquipmentAndMachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pacb:InProcessResearchAndDevelopmentIndefiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pacb:InProcessResearchAndDevelopmentIndefiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:CostOfRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:CostOfRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:CostOfRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-07</xbrli:startDate><xbrli:endDate>2024-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2010-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:ShelfOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-22</xbrli:startDate><xbrli:endDate>2022-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-18</xbrli:startDate><xbrli:endDate>2024-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:A2020PlanInducementPlanAndTheOmniomePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedAndPerformanceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedAndPerformanceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsPSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-07</xbrli:startDate><xbrli:endDate>2025-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-07</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.920%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December 31</ix:nonNumeric>, 2024</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">o</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-34899</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:230px"/></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">Pacific Biosciences of California, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.920%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">16-1590339</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">1305 O&#8217;Brien Drive</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Menlo Park</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">CA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">94025</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">94025</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">521-8000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.920%"><tr><td style="width:1.0%"/><td style="width:37.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">PACB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.920%"><tr><td style="width:1.0%"/><td style="width:23.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-25">o</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">o</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-27">x</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-28">o</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-29">x</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Aggregate market value of registrant&#8217;s common stock held by non-affiliates of the registrant on June 30, 2024 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter), based upon the closing price of common stock on such date as reported by NASDAQ Global Select Market, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" scale="6" id="f-30">371.4</ix:nonFraction> million. Shares of voting stock held by each officer and director have been excluded in that such persons may be deemed to be affiliates. This assumption regarding affiliate status is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Number of shares outstanding of the registrant&#8217;s common stock as of February&#160;28, 2025: <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">297,852,228</ix:nonFraction></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true">Portions of the registrant&#8217;s definitive Proxy Statement relating to its 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.920%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pacific Biosciences of California, Inc.</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Annual Report on Form 10-K </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For the Fiscal Year Ended December 31, 2024</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:77.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_13">PART I</a></span></div></td><td colspan="3" style="background-color:#df1995;padding:0 1pt"/><td colspan="3" style="background-color:#df1995;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_19">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_19">15</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_22">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_22">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_25">Item 1C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_25">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_22">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_28">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_28">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_28">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_31">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_31">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_31">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_34">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_34">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_34">60</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_37">PART II</a></span></div></td><td colspan="3" style="background-color:#df1995;padding:0 1pt"/><td colspan="3" style="background-color:#df1995;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_40">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_40">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_40">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_43">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_43">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_43">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_46">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_46">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_64">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_64">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_64">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_67">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_67">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_67">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_133">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_133">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_133">126</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_136">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_136">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_136">126</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_142">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_142">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_142">128</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_145">Item 9C</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_145">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_145">128</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_148">PART III</a></span></div></td><td colspan="3" style="background-color:#df1995;padding:0 1pt"/><td colspan="3" style="background-color:#df1995;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_151">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_151">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_151">129</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_154">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_154">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_154">129</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_157">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_157">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_157">129</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_160">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_160">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_160">129</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_163">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_163">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_163">129</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_166">PART IV</a></span></div></td><td colspan="3" style="background-color:#df1995;padding:0 1pt"/><td colspan="3" style="background-color:#df1995;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_169">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_169">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_169">130</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_172">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_172">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_172">133</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_175">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_175">134</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, including the sections titled &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contain or may contain forward-looking statements that are based on the beliefs and assumptions of the management of Pacific Biosciences of California, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) and on information currently available to our management. The statements contained in this Annual Report on Form 10-K that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the availability, uses, accuracy, sensitivity, advantages, compatibility, pricing, specifications, quality, or performance of, or benefits or expected benefits of using, our products or technologies, including the Revio</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Onso</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Vega</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our current and future products; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">improvements to our existing products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our strategic and commercial plans, including our expectations regarding our clinical strategy and Revio, Onso and Vega systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our market opportunity, including market size and expected market growth;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our expectations regarding the conversion of backlog to revenue and the pricing and gross margin for products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our manufacturing plans including developing and scaling of manufacturing and delivery of our products; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">any reductions or potential reductions in government funding, including for the National Institutes of Health (&#8220;NIH"), or targeted cancellations by the U.S. federal government of certain grants or contracts, could negatively impact our customers and reduce demand for our products and services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our research and development plans; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the anticipated impact of catastrophic events, including health epidemics or pandemics and military or other armed conflicts, on our business, business plans and results of operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">uncertainty regarding or potential chang</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es in diplomatic and trade relationships as a result of the recent change in the U.S. government administration;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the impact of tariffs recently imposed by the U.S. government and its trading partners in response, other possible tariffs or trade protection measures, import or export licensing requirements, new or different customs duties, trade embargoes and sanctions and other trade barriers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our product development plans, roadmaps, and objectives, including, among other things, statements relating to future uses, quality, or performance of, or benefits of using, products or technologies, updates, or improvements of our products; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our intentions regarding seeking regulatory approval for our products; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our competitive landscape, including competition in the short- and long-read sequencing technologies markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our expectations regarding collaborations and partnerships; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our expectations regarding unrecognized income tax benefits; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our expectations regarding market risk, including interest rate changes and general macroeconomic conditions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the sufficiency of cash, cash equivalents, and investments to fund projected operating requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the effects of recent accounting pronouncements on our financial statements; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">other future events. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can be identified by words such as: &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or similar expressions and the negatives of those terms. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading &#8220;Risk Factors&#8221; in this report and in other documents we file with the Securities and Exchange Commission ("SEC"). Given these risks and uncertainties, you should not place undue reliance on forward-looking statements. Also, forward-looking statements represent management&#8217;s beliefs and assumptions as of the date of this report. Except as required by law, we assume no obligation to update forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K also contains estimates, projections, and other information concerning our industry, our business, and the markets for our products, including data regarding the estimated size and estimated growth for those markets. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span><br/></span></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART I</span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_16"></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ITEM 1.  BUSINESS</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Overview</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing technology and our Sequencing by Binding (SBB</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) short-read sequencing technology. Our products address solutions across a broad set of applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Lo</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng-read sequencing was recognized by the journal </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature Methods</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as its &#8220;method of the year&#8221; for 2022 for its contributions to biological understanding and future potential. Long-read sequencing</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been applied to produce telomere-to-telomere genomes of humans, pangenome references, and has been recognized for its ability to provide more complete views of human variation</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus is on creating some of the world's most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recent Developments</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, we launched Vega</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a revolutionary new benchtop sequencer designed to make accurate long-read sequencing accessible to more laboratories than ever before. Vega delivers up to 60 gigabases of long reads per run and is designed to provide accurate HiFi reads and high-quality genomic, transcriptomic, and epigenetic data for individual labs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in the fourth quarter of 2024, we launched SPRQ chemistry for the Revio system.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SPRQ chemistry will increase the efficiency of loading on Revio SMRT</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cells, reducing DNA input requirements to just 500 ng, a 75% reduction. These lower input requirements will allow HiFi sequencing to support new sample types, like saliva and tumors. The chemistry is also expected to improve sequencing performance, providing an approximately 33% increase in sequencing yield per SMRT Cell. Collectively, these enhancements are designed to enable each Revio instrument to sequence up to 2,500 human whole genomes per year at a cost of just under $500 per human genome.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2024, we commenced commercial shipments for the PureTarget repeat expansion panel, a new solution designed to comprehensively analyze 20 genes associated with serious neurological disorders, including challenging-to-sequence genes with tandem repeat expansions.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also released the Nanobind PanDNA kit as a single kit that supports extraction of high quality DNA from many sample types, and the HiFi prep kit as a scalable and automation-friendly library prep for genomic samples.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Our Mission and Impact</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to enable the promise of genomics to better human health. Genomics is core to all biological processes, and our advanced genomics tools provide scientists and clinical researchers with the insights to better understand biology and health. The &#8220;promise of genomics&#8221; postulates that medicine, agriculture, public health, drug development, and other disciplines will be transformed by incorporating routine genomic information over the coming decades. We see early progress toward this transformation in the applied use of genomics in areas such as genetic disease, oncology, and sustainable food production. However, legacy genomics technologies have fundamental limitations in progressing these fields toward the promise of genomics. We believe that unleashing the full potential of genomics will require a level of accuracy and completeness inaccessible to legacy technologies. Accuracy and completeness are central to our product </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development strategy; thus, we have created some of the most innovative and high-quality genomics solutions on the market. Our products also have enhanced multi-omic capabilities to look beyond the genome to the transcriptome and epigenome, which we believe is key to understanding a full picture of biology.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">The Underlying Science</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genetic inheritance in living organisms is conveyed through a naturally occurring information storage system known as deoxyribonucleic acid, or DNA. DNA stores information in linear chains of the chemical bases adenine, cytosine, guanine, and thymine, represented by the symbols A, C, G, and T respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In humans, the genome is comprised of approximately three billion DNA base pairs, which are divided into 23 chromosomes ranging in size from 50 million to 250 million bases. A human carries two copies of the chromosomes, one inherited from each parent. Approximately 23,000 smaller regions within these chromosomes, called genes, contain the blueprints for protein production. The proteins synthesized from these blueprints essentially underlie the operation of all biological systems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genome sequencing reads the bases of long fragments of nucleic acids. Initial genome sequencing studies have shown that mutations in these DNA base pairs play a critical role in human disease, contributing to the burgeoning field of genomics. Since then, recent discoveries have highlighted additional complexities of DNA and RNA. These discoveries include the presence of chemical modifications to the bases, such as methylation, and post-translational modification, or the processing of RNA molecules after they are transcribed from the genome, both of which can affect protein synthesis. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Our Principal Markets </span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Researchers utilize our solutions in human genomics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.</span></div><div style="margin-top:6pt;text-align:justify"><img src="pacb-20241231_g2.jpg" alt="Principal Markets.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Human Genomics: Improving rare disease research and understanding</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to a World Health Organization publication, it is estimated that 400 million people worldwide are affected by up to 8,000 distinct rare diseases, with 80% of these believed to be genetic in nature. These genetic diseases are DNA differences, called variants, in the affected individuals. Variants range in size from single nucleotide substitutions to large losses or gains of entire chromosomes. Other sequencing technologies applied to rare disease diagnosis are technologically limited to interrogating small variants, representing only a subset of possible genomic variation. Consequently, most genetic disease cases are undiagnosed, leaving families on multi-year diagnostic odysseys. Sequencing the human genome with long and accurate reads enables the potential detection of all known classes of disease-causing variation. In addition, the ability of PacBio&#8217;s long-read sequencing technology to detect 5-Methylcytosine DNA methylation, an epigenetic modification shown to alter gene behavior, may enable further advances in research and development in genetic disease diagnosis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Infectious Disease and Microbiology: Understanding and tracking microbes and pathogens in support of global public health</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology has increased the scientific community&#8217;s understanding of microorganisms and viruses and their malignancy, transmission, and potential resistance to antibiotics or vaccines. Our sequencing technology delivers highly comprehensive and complete genomes, enabling federal agencies, public health organizations, and healthcare providers to conduct wide-ranging research and surveillance activities to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">generate high quality, complete genome assemblies, revealing variants of all known types, to gain a deeper understanding of community-acquired and hospital-associated infections and transmissions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">identify and characterize pathogens to inform regional, national, and global public health agencies for preparation and response to rapidly evolving microorganisms; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">characterize complex microbial communities to understand their role in human, animal, and environmental health.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oncology: Enable the discoveries of underlying causes of cancer, progression, and relapse</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Understanding tumor cells' cellular and molecular complexity is critical in developing more effective targeted cancer therapies. Single-cell transcriptomics is particularly impactful in defining cellular identity and function; however, other technologies miss critical information by only sequencing a portion of RNA. Our long-read RNA sequencing method, single-cell Iso-Seq (scIso-Seq), accurately detects molecular events such as RNA isoforms and expressed mutations and provides gene expression information at the single-cell level. We believe scIso-Seq is uniquely positioned to enable discoveries by researchers of the underlying causes of cancer initiation, progression, and relapse, as well as the discovery by researchers of novel diagnostic, prognostic, and predictive biomarkers that may inform future clinical tests. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As novel discoveries continue to be made using our long-read sequencing technology, we believe our SBB short-read sequencing technology will enable us to meet customers' demands in the expanding non-invasive testing market in oncology. Due to the small amounts of circulating tumor DNA (ctDNA) present in the blood of early-stage cancer patients and those with minimal residual disease (MRD), the presence of cancer often goes undetected, and a more sensitive assay will be required. Based on testing internally and at beta customer sites, we believe our SBB technology has the potential to offer higher accuracy than competitor sequencing technologies, which may in the future support our customers&#8217; development of more sensitive tests for the purpose of earlier detection and more robust monitoring of cancer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plant and Animal Sciences: Helping scientists answer biological questions for a healthier world </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Plant and Animal Sciences, academic, government and corporate researchers are using our technology to explore and catalog the genetic and biological diversity of organisms for the breeding, propagation, and production of crops and livestock while conserving the planet&#8217;s natural resources. Our HiFi sequencing enables researchers to build high quality de novo reference genomes and transcriptomes to study variations across species enabling improvements to global conservation initiatives and support the breeding and production of resilient and higher yielding crops to meet the world's growing population and demand.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Our Technology, Products, and Solutions</span></div></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:39.272%"><div style="margin-top:6pt;text-align:justify"><img src="pacb-20241231_g3.gif" alt="img_revio_onso_vega.gif" style="height:245px;margin-bottom:5pt;vertical-align:text-bottom;width:240px"/></div></div><div style="display:inline-block;max-width:0.909%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:59.819%"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed HiFi long-read sequencing based on Single-Molecule Real-Time (SMRT) technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. We are also expanding our genomic solutions with our short-read SBB chemistry, which offers sensitive sequencing for short-read applications.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales consist of sequencing instruments, nanofluidic chips (SMRT Cells), and reagents for preparing DNA and performing sequencing based on our SMRT technology; flow cells and reagents for preparing DNA and performing sequencing based on our SBB technology, reagents for DNA extraction based on our Nanobind technology; and the services we perform for customers.                                            </span></div></div></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HiFi Long-Read Sequencing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our HiFi long-read sequencing protocol was built upon our</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SMRT sequencing systems, including consumables and software, and offers customized end-to-end workflows for different sequencing applications. Highly accurate, long sequence reads simplify and accelerate data analysis algorithms, reducing the need for error correction and/or assembly, depending on the application.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers use our HiFi long-read sequencing platforms in a wide range of sequencing applications, including whole genome sequencing and </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome assembly, long-range phasing, targeted sequencing, full-length RNA and single-cell sequencing, characterization of metagenomic communities and other mixed DNA samples, viral genome sequencing, and others. Our technology is also capable of detecting epigenetic markers </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">simultaneously by analyzing the kinetics of DNA polymerization that is affected, and thereby detectable, by epigenetic markers such as 5-methylcytosine or N</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-methyladenine.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SMRT Technology</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary SMRT Technology enables the observation of DNA synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which in nature is a highly efficient and accurate process actuated by DNA polymerases. DNA polymerases attach to a strand of DNA to be replicated, examine the individual base at the point it is attached, and then determine which of the four building blocks, or nucleotides (A, C, G, or T), is required to complement that individual base. After determining which nucleotide is required, the polymerases incorporate that nucleotide into the growing strand being produced.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SMRT Sequencing is based on following the activity of DNA polymerase on individual DNA molecules in real time that occurs on our SMRT Cells that are monitored and analyzed within our HiFi long-read sequencing systems: the Revio system, Vega system, Sequel</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system, Sequel II system, and Sequel IIe system. Carried out on SMRTbell</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> templates, which attach hairpin adapters to the ends of double-stranded DNA molecules to be sequenced, SMRT sequencing allows for the successive sequencing of both the forward and reverse strands of the individual DNA molecule occurring multiple times, thereby allowing for the same base of the same molecule to be sequenced more than once in a sequencing run. The base calls from the serial observation of the molecule can be processed to generate the final base call in an analytical procedure called circular consensus sequencing, leading to what we have defined as our HiFi sequence reads, which have high accuracy typically being defined as having greater than 99% read accuracy, but often exceeding greater than 99.9% accuracy, according to research we performed in collaboration with other researchers, subsequently published in </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature Biotechnology</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2019. HiFi reads typically are 15-20 kilobases in size, depending on the input fragments, providing sufficient read length with our accuracy to support a multitude of applications across human health, plant and animal, and microbiology, according to research we performed in collaboration with other researchers, subsequently published in </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Scientific Data</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2020. According to an article published by </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Genome Research</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2024, users are able to increase rare disease solve rates using HiFi over short read sequencing. HiFi was also cited as having the ability to resolve complex rearrangements in rare disease cases, subsequently published in an article on </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature.com</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2024. The ability to generate single-DNA molecule sequence reads that are both long and highly accurate allows researchers to obtain more contiguous, complete, and accurate genomic data, thereby allowing for greater insights into the complexity of biological systems.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HiFi Long-Read Sequencing Instruments: Revio system, Vega system, and Sequel systems </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time. The instruments use extremely sensitive imaging systems to collect the light pulses emitted by fluorescent reagents allowing the observation of biological processes. Computer algorithms are used to translate the information that is captured by the optics system. Using the recorded information, light pulses are converted into either an A, C, G, or T base call with associated quality metrics. Once sequencing is started, the real-time data is delivered to the system&#8217;s primary analysis pipeline, which outputs base identity and quality values.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HiFi Consumables</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers purchase proprietary consumable products to run their PacBio systems, including our SMRT Cells and reagent kits. One SMRT Cell is consumed per sequencing reaction, and scientists can choose the number of SMRT Cells they use per experiment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer several reagent kits, each designed to address a specific step in the core sequencing workflow. A library preparation kit is used to convert DNA into SMRTbell double-stranded DNA library formats and includes typical molecular biology reagents, such as ligase, buffers, and exonucleases. Our binding/polymerase kits include our modified DNA polymerase and are used to bind SMRTbell libraries to the polymerase in preparation for sequencing. Our core sequencing kits contain reagents required for on-instrument, real-time sequencing, including phospholinked nucleotides.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed and are offering a new line of Kinnex</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> kits with companion SMRT Link software to enable high-throughput, scalable, cost-effective RNA applications including bulk RNA, single-cell RNA, and 16S rRNA sequencing. The Kinnex kits are built upon the Multiplexed Array Sequencing (MAS-Seq) method for concatenating smaller amplicons into larger fragments to sequence on PacBio's long read sequencers, significantly increasing the molecular yield. Throughput increase in these key RNA applications where the dynamic range of different RNA isoforms (bulk and single-cell) or microbial species (16S) can vary by orders of magnitude, enables characterization of these complex RNA samples while drastically reducing sequencing need.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">S</span><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BB Short-Read Sequencing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contrast to SMRT sequencing, SBB reads short fragments of DNA (hundreds of bases instead of kilobases) in a massively parallel manner. Current short-read next generation sequencing technologies available in the market incur various rates of errors in results. Researchers deploy multiple tactics to try to mitigate these effects, including oversampling or implementing complex library preparation methods, yet still face challenges, including missing rare variants.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> believe our proprietary SBB approach will enable researchers to address the gap in detecting rare variants, especially in complex heterogenous samples. Employing a two-phase sequencing chemistry, the SBB approach binds a dye-labeled nucleotide without incorporation into the DNA chain, then removes that base, then blocks and extends with a terminated nucleotide. Using nucleotides with single modifications, we incorporate more native bases, avoiding potential scarring due to fluorescent linker presence. This design helps avoid raw errors and we believe can help us develop a product with substantially greater accuracy than currently marketed short-read sequencing products. SBB enables simplified upfront library preparation, redefines coverage requirements, and reduces bioinformatic workload for downstream analysis. The accuracy of our novel sequencing approach has the potential to advance translational cancer research, drive higher fidelity single-cell applications, and broadly enable clinical sequencing&#8212;even in regions of the genome prone to sequencing errors with other short-read sequencing technologies.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SBB Short-Read Sequencing Instrument: Onso system </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Onso instrument conducts, monitors, and analyzes SBB biochemical reactions. The instrument uses extremely sensitive imaging systems to collect the light emitted by fluorescent reagents allowing the observation of biological processes. Computer algorithms are used to translate the information that is captured by the optics system. Using the recorded information, light pulses are converted into either an A, C, G, or T base call with associated quality metrics. Once sequencing is started, the imaging data is delivered to the system&#8217;s primary analysis pipeline, which outputs base identity and quality values.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SBB Consumables</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To complement our Onso instrument, we also sell a range of SBB consumable products including flow cells, clustering, and sequencing reagent kits. One flow cell and associated sequencing reagent pack is consumed per sequencing reaction. Each flow cell contains two lanes and scientists can choose to sequence different samples in each lane while additionally combining any number of flow cells needed per experiment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer several reagent kits, each designed to address a specific step in the core sequencing workflow. A library preparation kit is used to convert DNA into SBB compatible, double-stranded DNA library formats and includes typical molecular biology reagents, such as ligase, buffers, and exonucleases. Additionally for library preparation, our conversion kits include reagents to enable scientists to convert existing sequencing libraries into an SBB compatible format. Finally, our clustering and sequencing kits contain all reagents required for generating sequence ready clusters on flow cell and performing SBB sequencing reactions on instrument, respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Our Strategy for Growth</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our main objectives are to grow revenue and expand gross margins through the following four activities: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.41pt">Enabling the full-scale release of the Vega benchtop platform to broaden our market reach.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe this platform broadens the long-read market opportunity.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.41pt">Accelerating samples onto the Revio platform via SPRQ chemistry and application kits.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SPRQ chemistry enables the sub-$500 HiFi genome, improves methylation detection capabilities, and achieves a 75% reduction in DNA input requirements for human whole genome sequencing.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These features can drive more samples onto HiFi sequencing than ever before.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.41pt">Investing in future product launches to diversify our offerings.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continue to develop sequencing systems designed to increase throughput and lower the cost to sequence a genome, which we believe will allow us to address an even larger part of the market. Additionally, we continue to develop kitted-solutions, like our Kinnex Full-length RNA kits and PureTarget, and enhance our on-market sequencers with products like SPRQ chemistry to drive more sequencing volume. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.64pt">Progressing our clinical strategy to improve outcomes and create durability.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2024 Revio was increasingly being used in laboratory-developed test (&#8220;LDT&#8221;) and clinical research settings to consolidate multiple tests and address complex genetic challenges.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Marketing, Sales, Service, and Support</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our products through a global sales force and through distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America and South America. We plan to continue to invest in growing our marketing, sales, service, and support resources as we drive continued adoption of products, launch new products, and expand our customer base. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Customers</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations ("CROs"), pharmaceutical companies, and agricultural companies. In general, our customers will isolate, prepare, and analyze genetic samples using PacBio systems in their own laboratories, or they will send their genetic samples to third-party service providers who in turn will sequence the samples with PacBio systems and provide the sequence data back to the customer for further analysis. For example, customers in academic research institutions may have bacteria, animal, or human DNA samples isolated from various sources while agricultural biology companies may have DNA samples isolated from different strains of rice, corn, or other crops.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a significant portion of our revenue from a limited number of customers, many of whom make large purchases on a purchase-order basis. For the years ended December 31, 2024, and 2023, no customer accounted for 10% or more of our total revenue. For the year ended December 31, 2022, one customer exceeded 10% of our total revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the majority of our current customers are early adopters of sequencing technology. By focusing our efforts on high-value applications and developing whole product solutions around these applications, we seek to drive the adoption of our products across a broader customer base and into numerous large-scale projects. In general, the broader adoption of new technologies by mainstream customers can take a number of years.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Backlog</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, our product backlog was approximately $31.2&#160;million, compared to $18.7&#160;million as of December&#160;31, 2023. We define backlog as purchase orders or signed contracts from our customers, which we believe are firm and for which we have not yet recognized revenue. We expect to convert the majority of this </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">backlog to revenue during 2025; however, our ability to do so is subject to customers who may seek to cancel or delay their orders even if we are prepared to fulfill them.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Manufacturing</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture sequencing instruments, SMRT Cells, and reagents. Our key manufacturing and service facility in Menlo Park, California has received ISO 13485 and ISO 9001 certifications for the design, development, manufacture, distribution, installation, and servicing of its nucleic acid sequencing platforms. We utilize domestic and international subcontract manufacturers for components of the manufacturing process. We purchase both custom and off-the-shelf components from a large number of suppliers worldwide and subject them to significant quality specifications. We periodically conduct quality audits of most of our critical suppliers and have established a supplier qualification program. Some of the components required in our products are currently either sole sourced or single sourced.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development </span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically made and plan to continue to make significant investments in research and development. Our research and development efforts focus on programs to develop new and existing platforms, as well as increasing throughput and decreasing costs on behalf of our customers. We are currently developing higher throughput platforms that utilize our HiFi long-read sequencing and SBB short-read sequencing technologies. In addition to platform development, we also innovate across end-to-end workflows to improve usability, as well as develop new applications for the advancement of human health.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intellectual Property </span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing and maintaining a strong intellectual property portfolio is an important element of our business. We have sought, and will continue to seek, patent protection for our SMRT kit and SBB technology, for improvements to our SMRT kit and SBB technology, as well as for any of our other technologies where we believe such protection will be advantageous. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current patent portfolio, including patents exclusively licensed to us, is directed to various technologies, including SMRT nucleic acid sequencing and other methods for analyzing biological samples, zero-mode waveguide ("ZMW") arrays, surface treatments, phospholinked nucleotides and other reagents for use in nucleic acid sequencing, optical short-read nucleic acid sequencing, nucleic acid preparation, and purification components and systems, processes for identifying nucleotides within nucleic acid sequences, and processes for analysis and comparison of nucleic acid sequence data. Some of the patents and applications that we own, as well as some of the patents and applications that we have licensed from other parties, are subject to U.S. government march-in rights, whereby the U.S. government may disregard our exclusive patent rights on its own behalf or on behalf of third parties by imposing licenses in certain circumstances, such as if we fail to achieve practical application of the U.S. government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, U.S. government-funded inventions must be reported to the government and U.S. government funding must be disclosed in any resulting patent applications. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we own or hold exclusive licenses to 448 issued U.S. patents, 69 pending U.S. patent applications, 8 pending Patent Cooperation Treaty ("PCT") patent applications, 265 issued foreign patents, and 120 pending foreign patent applications. The full term of the issued U.S. patents will expire between 2025 and 2042. We also have non-exclusive patent licenses with various third parties to supplement our own large and robust patent portfolio.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Sequencing Solutions </span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a significant number of companies offering nucleic acid sequencing equipment or consumables. These include, but are not limited to, Illumina, Inc. (&#8220;Illumina&#8221;), BGI Genomics (also known as MGI or Complete Genomics), Thermo Fisher Scientific Inc. (&#8220;Thermo&#8221;), Oxford Nanopore Technologies Ltd. (&#8220;ONT Ltd.&#8221;), Roche Holding AG (&#8220;Roche&#8221;), Qiagen N.V. (&#8220;Qiagen&#8221;), Element Biosciences, Inc. (&#8220;Element&#8221;), Bionano Genomics, Inc. (&#8220;Bionano&#8221;), Ultima Genomics, Inc. (&#8220;Ultima&#8221;), Singular Genomics Systems, Inc. (&#8220;Singular&#8221;) and 10x Genomics, Inc. ("10x"). These companies may have different levels of financial, technical, manufacturing, administrative, and support resources available to them. We expect continued intense competition within the overall nucleic </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acid sequencing market as there are several companies developing new sequencing technologies, products and/or services. Increased competition may result in pricing pressures, which could harm our sales, profitability, or share of supply.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order for us to maintain and increase our sales, we will need to demonstrate that our products deliver superior performance and value as a result of our key differentiators. Our HiFi long-read sequencing will need to continue to deliver very high consensus accuracy and long-read lengths and include single-molecule, real-time resolution, with the ability to detect real-time kinetic information, fast time-to-result and flexibility, as well as support the breadth and depth of current and future applications.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Government Regulation</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, testing, manufacturing, marketing, post-market surveillance, distribution, advertising, and labeling of certain medical devices, including in vitro diagnostic products and laboratory-developed tests, are subject to regulation in the United States by the Center for Devices and Radiological Health of the U.S. Food and Drug Administration ("FDA") under the Federal Food, Drug, and Cosmetic Act ("FDCA") and comparable state and foreign regulatory agencies. FDA defines a medical device as an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component part or accessory, which is (i) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or (ii) intended to affect the structure or any function of the body of man or other animals and which does not achieve any of its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes. Medical devices to be commercially distributed in the United States must receive from the FDA either clearance of a pre-market notification, known as 510(k), or pre-market approval pursuant to the FDC Act prior to marketing, unless subject to an exemption.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently label and sell our products for research use only (&#8220;RUO&#8221;) and primarily sell them to research customers in various settings, including academic institutions, life sciences and research laboratories that conduct research, and biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Our current RUO products are not intended or promoted for use in clinical practice in the diagnosis of disease or other conditions, and they are labeled for research use only, not for use in diagnostic procedures. Accordingly, we believe our products, as we intend to market them, are not subject to regulation by the FDA. Rather, while FDA regulations require that RUO products be labeled for research use only and to market and distribute RUO products in accordance with the FDA RUO guidance, the regulations do not subject RUO products to the FDA&#8217;s jurisdiction or the broader pre- and post-market controls for medical devices. However, in the future, certain of our products or related applications, such as those that may be developed for clinical uses, could be subject to FDA regulation, or the FDA&#8217;s regulatory jurisdiction could be expanded to include our products. If we wish to label and expand product lines to address the diagnosis of disease, regulation by governmental authorities in the United States and other countries will become an increasingly significant factor in development, testing, production, and marketing. In the future, products that we may develop in the molecular diagnostic markets, depending on their intended use, may be regulated as medical devices or in vitro diagnostic products (&#8220;IVDs&#8221;) by the FDA and comparable agencies in other countries. In the U.S., if we market our products for use in performing clinical diagnostics, such products would be subject to regulation by the FDA under pre-market and post-market control as medical devices, unless an exemption applies, and we would be required to obtain either prior 510(k) clearance or prior pre-market approval from the FDA before commercializing the product. Obtaining the requisite regulatory approvals can be expensive and may involve considerable delay. Some countries have regulatory review processes that are substantially longer than U.S. processes. Failure to obtain regulatory approval in a timely manner and meet all of the local regulatory requirements including language and specific safety standards in any foreign country in which we plan to market our products could prevent us from marketing products in such countries or subject us to sanctions and fines. Changes to the current regulatory framework, including the imposition of additional or new regulations, could arise at any time during the development or marketing of our products. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, the FDA issued a final guidance on products labeled for research use only, which, among other things, reaffirmed that a company may not make any clinical or diagnostic claims about an RUO product, stating that merely including a labeling statement that the product is for research purposes only will not necessarily render the device exempt from the FDA&#8217;s clearance, approval, or other regulatory requirements if the totality of circumstances surrounding the distribution of the product indicates that the manufacturer knows its product is being used by customers for diagnostic uses or the manufacturer intends such a use. These circumstances </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may include, among other things, written or verbal marketing claims regarding a product&#8217;s performance in clinical diagnostic applications and a manufacturer&#8217;s provision of technical support for such activities. If FDA were to determine, based on the totality of circumstances, that our products labeled and marketed for RUO are intended for diagnostic purposes, they would be considered medical devices that will require clearance or approval prior to commercialization. Further, sales of devices for diagnostic purposes may subject us to additional healthcare regulation. We continue to monitor the changing legal and regulatory landscape to ensure our compliance with any applicable rules, laws and regulations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA classifies medical devices into one of three classes. Devices deemed to pose lower risk to the patient are placed in either Class I or II, which, unless an exemption applies, requires the manufacturer to submit a pre-market notification requesting FDA clearance for commercial distribution pursuant to Section 510(k) of the FDCA. This process, known as 510(k) clearance, requires that the manufacturer demonstrate that the device is substantially equivalent to a previously cleared and legally marketed 510(k) device or a &#8220;pre-amendment&#8221; Class III device for which pre-market approval applications (&#8220;PMAs&#8221;) have not been required by the FDA. This FDA review process typically takes from four to twelve months, although it can take longer. Most Class I devices are exempted from this 510(k) pre-market submission requirement. If no legally marketed predicate can be identified for a new device to enable the use of the 510(k) pathway, the device is automatically classified under the FDCA as Class III, which generally requires pre-market approval, or PMA approval. However, the FDA can reclassify or use &#8220;de novo classification&#8221; for a device that meets the FDCA standards for a Class II device, permitting the device to be marketed without PMA approval. To grant such a reclassification, FDA must determine that the FDCA&#8217;s general controls alone, or general controls and special controls together, are sufficient to provide a reasonable assurance of the device&#8217;s safety and effectiveness. The de novo classification route is generally less burdensome than the PMA approval process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting, or implantable devices, or those deemed not substantially equivalent to a legally marketed predicate device, are placed in Class III. Class III devices typically require PMA approval. To obtain PMA approval, an applicant must demonstrate the reasonable safety and effectiveness of the device based, in part, on data obtained in clinical studies. All clinical studies of investigational medical devices to determine safety and effectiveness must be conducted in accordance with FDA&#8217;s investigational device exemption (&#8220;IDE&#8221;) regulations, including the requirement for the study sponsor to submit an IDE application to FDA, unless exempt, which must become effective prior to commencing human clinical studies. PMA reviews generally last between one and two years, although they can take longer. Both the 510(k) and the PMA processes can be expensive and lengthy and may not result in clearance or approval. If we are required to submit our products for pre-market review by the FDA, we may be required to delay marketing and commercialization while we obtain pre-market clearance or approval from the FDA. There would be no assurance that we could ever obtain such clearance or approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All medical devices, including IVDs, that are regulated by the FDA are also subject to the quality system regulation. Obtaining the requisite regulatory approvals, including the FDA quality system inspections that are required for PMA approval, can be expensive and may involve considerable delay. The regulatory approval process for such products may be significantly delayed, may be significantly more expensive than anticipated, and may conclude without such products being approved by the FDA. Without timely regulatory approval, we will not be able to launch or successfully commercialize such diagnostic products. Changes to the current regulatory framework, including the imposition of additional or new regulations, could arise at any time during the development or marketing of our products. This may negatively affect our ability to obtain or maintain FDA or comparable regulatory clearance or approval of our products in the future. In addition, regulatory agencies may introduce new requirements that may change the regulatory requirements for us or our customers, or both.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, although our products are currently labeled and sold for research purposes only, the regulatory requirements related to marketing, selling, and supporting such products could be uncertain and depend on the totality of circumstances. This uncertainty exists even if such use by our customers occurs without our consent. If the FDA or other regulatory authorities assert that any of our RUO products are subject to regulatory clearance or approval, our business, financial condition, or results of operations could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in some cases, our customers, including laboratories that offer services as part of our certified service provider program, may use our RUO products in their own LDTs or in other FDA-regulated products for clinical diagnostic use. The FDA has historically exercised enforcement discretion in not enforcing the medical device regulations against LDTs and LDT manufacturers. The FDA has issued warning letters to genomics labs for illegally marketing genetic tests that claim to predict patients&#8217; responses to specific medications, noting that the FDA has not created a legal &#8220;carve-out&#8221; for LDTs and retains discretion to take action when appropriate, such as when certain genomic tests raise significant public health concerns. As laboratories and manufacturers </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">develop more complex genetic tests and diagnostic software, the FDA may increase its regulation of LDTs. Legislative and administrative proposals to amend the FDA's oversight of LDTs have been introduced in recent years, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (the &#8220;VALID Act&#8221;). In September 2022, Congress passed the FDA user fee reauthorization legislation without substantive FDA policy riders, including the VALID Act. In May 2024, the FDA issued a final rule that phases out its enforcement discretion for most LDTs and amends the FDA&#8217;s regulations to make explicit that in vitro diagnostics are medical devices under the FDCA, including when the manufacturer of the diagnostic product is a laboratory. This final rule is being challenged in federal courts. Further, in June 2024, the U.S. Supreme Court overruled the </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chevron</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">doctrine, which gives deference to regulatory agencies&#8217; statutory interpretations in litigation against federal government agencies, such as the FDA, where the law is ambiguous. This landmark Supreme Court decision may invite various stakeholders to bring lawsuits against the FDA to challenge longstanding decisions and policies of the FDA, including this LDT final rule. The new Trump administration, including changes in the leadership at the FDA, may issue new policies and regulations that can impact the compliance status of our products or that of our customers. If our products become subject to FDA regulation as medical devices, we would need to invest significant time and resources to ensure ongoing compliance with FDA quality system regulations and other post-market regulatory requirements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our products become subject to FDA regulation as medical devices, the regulatory clearance or approval and the maintenance of continued and post-market regulatory compliance for such products will be expensive, time-consuming, and uncertain both in timing and in outcome. Commercialization of such regulated medical devices can increase our exposure under additional laws. For example, medical device companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business and may constrain the financial arrangements and relationships through which we research, as well as sell, market and distribute any medical products for which we obtain marketing authorization. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, data privacy and security, and transparency laws and regulations related to payments and other transfers of value made to physicians and other healthcare providers. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, administrative, civil, and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and imprisonment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, to the extent we develop any clinical diagnostic assays, we may pursue payment for such products through a diverse and broad range of channels and seek coverage and reimbursement by government health insurance programs and commercial third-party payors for such products. In the United States, there is no uniform coverage for clinical laboratory tests. The extent of coverage and rate of payment for covered services or items vary from payor to payor. Obtaining coverage and reimbursement for such products can be uncertain, time-consuming, and expensive, and, even if favorable coverage and reimbursement status were attained for our tests, to the extent applicable, less favorable coverage policies and reimbursement rates may be implemented in the future. Changes in healthcare regulatory policies could also increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our products, decrease our revenue and adversely impact sales of, and pricing of and reimbursement for, our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales of medical devices are subject to foreign government regulations, which vary substantially from country to country. In the future, if we decide to distribute or market our diagnostic products as IVDs in Europe, such products are subject to regulation under the European Union (&#8220;EU&#8221;) IVD Medical Device Regulation (&#8220;IVDR&#8221;) EU 2017/746. Outside of the EU, regulatory approval needs to be sought on a country-by-country basis in order to market medical devices. Although there is a trend towards harmonization of a quality system, standards and regulations in each country may vary substantially, which can affect timelines of introduction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to the protection of our employees and the environment. Our operations require the use of hazardous materials that subject us to various federal, state, and local environmental and safety laws and regulations. We believe that we are in material compliance with current applicable laws and regulations. However, we could be held liable for damages and fines should contamination of the environment or individual exposures to hazardous substances occur. In addition, we cannot predict how changes in these laws and regulations, or the development of new laws and regulations, will affect our business operations or the cost of compliance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we must comply with complex foreign and U.S. laws and regulations, such as the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, and other local laws prohibiting corrupt payments to governmental </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">officials, anti-competition regulations and sanctions imposed by the U.S. Office of Foreign Assets Control, and other similar laws and regulations. Violations of these laws and regulations could result in fines and penalties, criminal sanctions, restrictions on our business conduct, and on our ability to offer our products in one or more countries, and could also materially affect our brand, our ability to attract and retain employees, our international operations, our business, and our operating results. Although we have implemented policies and procedures designed to ensure compliance with these laws and regulations, there can be no assurance that our employees, contractors, or agents will not violate our policies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to expand our business into multiple international markets, our success will depend, in large part, on our ability to anticipate and effectively manage these and other risks associated with our international operations. Any of these risks could harm our international operations and negatively impact our sales, adversely affecting our business, results of operations, financial condition, and growth prospects.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Human Capital</span></div></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:32.000%"><div style="margin-top:9pt;text-align:justify"><img src="pacb-20241231_g4.jpg" alt="2199023310903" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:220px"/></div></div><div style="display:inline-block;max-width:11.272%;min-width:10.272%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:56.728%"><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had 575 full-time employees. Of these employees, 207 were in research and development, 67 were in operations, 39 were in service, 187 were in marketing and sales, and 75 were in general and administration. With the exception of our field-based sales, marketing, and service teams, the majority of our employees are in California. None of our employees are represented by labor unions or are covered by a collective bargaining agreement with respect to their employment. We have not experienced any work stoppages, and we consider our relationship with our employees to be good.</span></div></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.363%"><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Talent Acquisition and Retention</span></div></div><div style="display:inline-block;max-width:7.272%;min-width:6.272%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.365%"></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize that our employees largely contribute to our success. To this end, we support business growth by seeking to attract and retain best-in-class talent. Our talent acquisition team uses internal and external resources to recruit highly skilled candidates globally.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Rewards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total rewards philosophy has been to invest in our workforce by offering competitive and fair compensation and benefits packages. We provide employees with compensation packages that include base salary, short-term incentives such as annual bonuses and commissions, and long-term equity awards. We also offer comprehensive employee benefits, which vary by country and region, such as life, disability, and health insurance, health savings and flexible spending accounts, time off benefits, paid parental leave, Employee Stock Purchase Program, and a 401(k) plan. It is our expressed intent to be an employer of choice in our industry by providing market-competitive compensation and benefits packages.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health, Safety, and Wellness</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health, safety, and wellness of our employees is a priority in which we have always invested and will continue to do so. We provide our employees and their families with access to a variety of innovative, flexible, and convenient health and wellness programs. Program benefits are intended to provide protection and security, so employees can have peace of mind concerning events that may require time away from work or that may impact their financial well-being. These programs are highlighted and updated regularly on our internal benefits platform.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity, Equity, and Inclusion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe a diverse workforce is critical to our success. Our mission is to value differences in races, ethnicities, religions, nationalities, genders, ages, sexual orientations, as well as education, skill sets and experience. We offer training programs on diversity awareness to help employees understand, recognize, respond, and prevent bias throughout the employee lifecycle. We are focused on inclusive hiring practices, fair and equitable treatment, organizational flexibility, and training and resources.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Training and Development</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe in encouraging employees to become lifelong learners by providing ongoing learning and leadership training opportunities. We provide a scaled learning platform of on-demand and virtual classroom learning focused on personal and professional development. While we strive to provide real-time recognition of employee performance, we have a formal annual review process not only to determine pay and equity adjustments tied to individual contributions, but to identify areas where training and development may be needed.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Available Information </span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website is located at </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.pacb.com</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information posted on, or that can be accessed through, our website is not incorporated by reference into this Annual Report on Form 10-K, and the inclusion of our website address is an inactive textual reference only. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act are available free of charge through the &#8220;Investor Relations&#8221; section of our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC also maintains a website that contains our SEC filings. The address of the site is www.sec.gov.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we use our website (including the blog section of our website) as well as our X (formerly Twitter) account (</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">@pacbio</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) as a channel of distribution for important company information and to comply with our disclosure obligations under Regulation FD. Important information, including press releases, analyst presentations, and financial information regarding us, as well as corporate governance information, is routinely posted and accessible on the &#8220;Investor Relations&#8221; section of the website, which is accessible by clicking on the tab labeled &#8220;Company - Investors&#8221; on our website home page. In addition, important information is routinely posted and accessible on the blog section of our website, which is accessible through our website at </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.pacb.com/blog</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as our X account (</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">@pacbio</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The contents of our website and our X account are not incorporated by reference into this Annual Report on Form 10-K or in any other report or document we file with the SEC, and any references to our website or X account are intended to be inactive textual references only.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1A.  RISK FACTORS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the risks and uncertainties described below, together with all of the other information in our public filings with the SEC, which could materially affect our business, financial condition, results of operations and prospects. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially affect our business, financial condition, results of operations and prospects. In addition, any worsening of the economic environment may exacerbate the risks described below, any of which could have a material impact on us. This situation is changing rapidly, and additional impacts may arise that we are not aware of currently.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal risks that could adversely affect our business, operations, and financial results. Such risks are discussed more fully below and include, but are not limited to, risks related to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to successfully market, commercialize, and sell current and future products and related maintenance services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to achieve profitability for our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to implement required expense reduction initiatives;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to repay our debt and fund our long-term operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to successfully leverage and integrate our acquisitions and future acquisitions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to successfully research, develop and timely manufacture our current and future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">management of new product introductions and transitions, resultant costs, and ability of new products to generate promised performance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">recent significant changes to our leadership team and resultant disruptions to our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">retention, recruitment, and training of senior management, key personnel, scientists and engineers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to further penetrate nucleic acid sequencing applications, as well as grow product demand;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our reliance on outsourcing to other companies for manufacturing certain components and sub-assemblies, some of which are sole-sourced;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the impact of tariffs recently imposed by the U.S. government and its trading partners in response, other possible tariffs or trade protection measures, import or export licensing requirements, new or different customs duties, trade embargoes and sanctions and other trade barriers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to consistently manufacture our instruments and consumables to meet customers&#8217; specifications, quantity, cost, or performance requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the high amount of competition we face in our industry;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to attract customers and increase sales of current and future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our reliance on a limited number of customers for a significant portion of our revenues, including academic, research and government institutions, which may be impacted by reductions in funding or targeted cancellations of certain grants or contracts by the U.S. federal government;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the complexity of our products giving rise to defects or errors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our unpredictable and lengthy sales cycles;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the possibility that our goodwill or intangible assets could become impaired;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">adverse effects resulting from political and economic tensions between the United States and other countries, including China and Russia, and other geopolitical uncertainties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">securing and maintaining patent or other intellectual property protection for our products and related improvements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">current and future legal proceedings filed against us claiming intellectual property infringement;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the potential adverse impact of health epidemics;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">potential cybersecurity incidents and security breaches;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">governmental regulations that burden operations or narrow the market for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">adverse effects resulting from enhanced trade tariffs, import restrictions, export restrictions, or other trade barriers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">evolving ethical, legal, privacy, social, and regulatory concerns regarding genetic testing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">volatility of the price of our common stock; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our stock price falling as a result of future offerings or sales of securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our risk factors are not guarantees that no such conditions exist as of the date hereof and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span id="i1c82068fb4244bd4a402f417590b7e43_665655"></span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercialization and sales of our current or future products may be unsuccessful or less successful than anticipated. While we plan to continue pursuing new products and expand into adjacent markets, we have limited experience in managing and selling multiple products and, as a result, may face challenges selling in new markets and fail to successfully carry out these initiatives, which may adversely impact our business, financial condition or results of operation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made and expect to continue making substantial investments to develop new products and enhance our existing products through our acquisitions and research and development efforts. For example, we commenced commercial shipments of Revio, our new long-read sequencing system in the first quarter of 2023, and commenced commercial shipments of Onso, our new SBB short-read platform, in the third quarter of 2023. We also began taking orders and shipping our new Vega benchtop long-read sequencing system in the fourth quarter of 2024. Our future success is substantially dependent on our ability to successfully develop and commercialize our products, as well as acquired technologies, which are anticipated to be used in demanding scientific research that requires substantial levels of accuracy and precision. In addition, we may not be successful in transitioning our prior generation products to our Revio and Vega products, or transitioning users of other third party sequencing platforms to our portfolio of products, and could incur related obsolete inventory charges and losses on firm purchase commitments. Customers may also be slower than we anticipate in making new capital equipment acquisitions, especially in the current economic environment. Due to challenges we may experience in developing and marketing our existing products and launching new products, we may not be able to effectively:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">manage the timeliness of our new product introductions and the rate at which sales of our new products may cannibalize sales of our existing products or manage sales and marketing of multiple sequencing platforms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">drive adoption of our current and future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">maintain our competitive position by continuing to attract and retain customers for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">provide appropriate levels of customer training and support for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">implement an effective marketing strategy to promote awareness of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">develop and implement an effective sales and distribution strategy for our current and future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">develop, manufacture and commercialize new products or achieve an acceptable return on our manufacturing or research and development efforts and expenses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">comply with regulatory requirements applicable to our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">anticipate and adapt to changes in our market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">accommodate customer expectations and demands with respect to our products, increase product adoption by our existing customers or develop new customer relationships;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">deliver our early access systems to our external early access testing sites or complete our external early access testing program on our currently expected timelines;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">overcome unexpected challenges discovered during early access testing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">complete the scientific and technical validation of new products on our currently expected timeline or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">deliver our future products in a timely manner to our customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">grow our market share by marketing and selling our products for new and additional applications;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">manage the significant burdens that expanding our existing or future products into current and new markets may impose on marketing, compliance, and other administrative and managerial resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">maintain and develop strategic relationships with vendors, manufacturers, and other industry partners to acquire necessary materials for the production of, and to develop, manufacture and commercialize, our existing or future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">adapt or scale our manufacturing activities to meet performance specifications and potential demand at a reasonable cost;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">avoid infringement and misappropriation of third-party intellectual property;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">obtain and maintain any necessary licenses to third-party intellectual property on commercially reasonable terms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">obtain valid and enforceable patents that give us a competitive advantage or enforce existing patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">protect our proprietary technology; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">attract, retain, and motivate qualified personnel.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks noted above, especially with respect to the marketing, sales, and commercialization of our products, may be heightened by the impact of current uncertain market and other conditions. In addition, a high percentage of our expenses is and will continue to be fixed. Accordingly, if we do not generate revenue as and when anticipated, we could suffer a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate goodwill and other intangible assets with indefinite useful lives for impairment annually and whenever events or changes in circumstances indicate that the fair value of such assets may be less than the carrying value. We also perform regular reviews to determine if any event has occurred that may indicate that the carrying values of our intangible assets with finite lives and other finite-lived assets are impaired. Events that would indicate impairment and trigger an interim impairment test include, but are not limited to, unexpected adverse business conditions, weak demand for a specific product line or business, economic factors, shifting focus to certain lines of business, unanticipated technological changes or competitive activities, loss of key personnel, changes in business strategy, and acts by governments or courts. The occurrence of any of these events, may require us to record future impairment charges. For example, we recorded $184.5 million of impairment charges during the year ended December 31, 2024 as described in additional detail in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_109">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_109">4</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_109">. Balance Sheet Components</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 8 of this Annual Report on Form 10-K. Any such charges may adversely affect our results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred losses to date, and we expect to continue to incur significant losses as we develop our business and may never achieve profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have generally incurred net losses each quarter since inception, and we cannot be certain if or when we will produce sufficient revenue from our operations to support our costs. Even if profitability is achieved in the future, we may not be able to sustain profitability on a consistent basis. We expect to continue to incur substantial losses and negative cash flow from operations for the foreseeable future. Although we initiated expense reduction plans during the second quarter of 2024, we do not expect to be profitable in 2025, and there can be no assurance that these expense reduction initiatives will be successful in helping us achieve profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net losses since inception and our expectation of incurring substantial losses and negative cash flow for the foreseeable future could:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">make it more difficult for us to satisfy our obligations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">limit our ability to fund future working capital, capital expenditures, research and development and other business opportunities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">increase the volatility of the price of our common stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">limit our flexibility to react to changes in our business and the industry in which we operate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">place us at a disadvantage to other companies that offer nucleic acid sequencing equipment or consumables; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">limit our ability to borrow additional funds.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, inflationary pressure, including as a result of supply shortages, has adversely impacted and could continue to adversely impact our financial results, and our operating costs may increase. We may not fully offset these cost increases by raising prices for our products and services, which could result in downward pressure on our margins. Further, our customers may choose to reduce their business with us if we increase our pricing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any or all of the foregoing may have a material adverse effect on our business, operations, financial condition, and prospects. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment in value of our tangible or intangible assets could also be recorded as a result of weaker economic conditions. </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on impairment considerations, see &#8220;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i1c82068fb4244bd4a402f417590b7e43_665655">&#8212;</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i1c82068fb4244bd4a402f417590b7e43_665655">The commercialization and sales of our current or future products may be unsuccessful or less successful than anticipated. While we plan to continue pursuing new products and expand into adjacent markets, we have limited experience in managing and selling multiple products and, as a result, may face challenges selling in new markets and fail to successfully carry out these initiatives, which may adversely impact our business, financial condition or results of operation.</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; above.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expense reduction initiatives could be disruptive to our operations and adversely affect our results of operations and financial condition, and we may not realize some or all of the anticipated benefits of these initiatives, whether in the time frame anticipated or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expense reduction initiatives comprise, among other things, workforce reductions, facilities downsizing and a refined pipeline of development activities. For example, during the second quarter of 2024 we initiated plans to reduce certain of our annualized run-rate operating expenses by the end of the year, with the intent of better aligning our organizational structure and resources with our strategic initiatives. The implementation of these expense reduction initiatives, including the impact of workforce reductions, could impair our ability to invest in developing, marketing and selling new and existing products, be disruptive to our operations, make it difficult to attract or retain employees, result in higher than anticipated charges, divert the attention of management, result in a loss of accumulated knowledge, impact our customer and supplier relationships, and otherwise adversely affect our results of operations and financial condition. In addition, our ability to complete our expense reduction initiatives and achieve the anticipated benefits within the expected time frame is subject to estimates and assumptions and may vary materially from our expectations, including as a result of factors that are beyond our control. Furthermore, our efforts to stabilize our business may not be successful.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span id="i1c82068fb4244bd4a402f417590b7e43_588171"></span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are not cash flow positive and may not have sufficient cash to make required payments under the terms of our debt or fund our long-term planned operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since inception, and we expect to continue to incur substantial losses and negative cash flow from operations for the foreseeable future. Additional funds may not be available on terms acceptable to us or at all. We have incurred significant debt, and we may incur additional debt in the future. As of December&#160;31, 2024, we had outstanding approximately $200.0&#160;million aggregate principal amount of our 1.50% Convertible Senior Notes due 2029 (the &#8220;2029 Notes&#8221;) and $441.0&#160;million aggregate principal amount of our 1.375% Convertible Senior Notes due 2030 (the &#8220;2030 Notes&#8221; and together with the 2029 Notes, the &#8220;Notes&#8221;). As discussed in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_112">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_112">5</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_112">. </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_112">Convertible Senior Notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Part II, Item 8 of this Annual Report on Form 10-K, we exchanged the remaining approximately $459.0&#160;million in aggregate principal amount of our 1.50% Convertible Senior Notes due 2028 (the &#8220;2028 Notes&#8221;) for (i) $200.0&#160;million aggregate principal amount of the 2029 Notes, (ii) 20,451,570 shares of common stock and (iii) $50.0&#160;million of cash (the &#8220;Exchange Transaction&#8221;). The Exchange Transaction closed on November 21, 2024. We may not have sufficient cash to make required payments under the terms of this debt, and should this occur, debt holders have rights senior to common stockholders to make claims on our assets. In addition, if we do not have sufficient cash to make the required payments at maturity, we may need to raise additional capital, which could result in dilution of our existing investors, or refinance or restructure our debt, which will depend on, among other things, the condition of the capital markets and our financial condition at such time, and which may be at higher interest rates. We may not be able to issue equity securities due to unacceptable terms and conditions to us in the capital markets. To the extent that we intend to raise additional funds through the sale of our common stock, downward fluctuations in our stock price could adversely affect such fundraising efforts. Furthermore, equity financings normally involve shares sold at a discount to the current market price and fundraising through sales of additional shares of common stock or other equity securities will have a dilutive effect on our existing investors. We may be required to seek equity financing at a time when the market price for our common stock is low, which would further dilute ownership for existing common stockholders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our growth will depend, in part, on our ability to fund our commercialization efforts and our efforts to develop new products and improve our existing products. To the extent our existing resources are not sufficient, it may require us to delay, or even not allow us to conduct any or all of these activities that we believe would be beneficial for our future growth. We may need to raise additional funds through public or private debt or equity financing or alternative financing arrangements, which may include collaborations or licensing arrangements. If we are unable to raise funds on favorable terms, or at all, we may have to reduce our cash burn rate and may not be able to support our commercialization efforts, launching of new products, or operations, or to increase or maintain the level of our research and development activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to generate sufficient cash flows or to raise adequate funds to finance our forecasted expenditures, we may have to make significant changes to our operations, including delaying or reducing the scope of, or eliminating some or all of, our development programs. We also may have to reduce sales, marketing, engineering, customer support or other resources devoted to our existing or new products, or we may need to cease operations. Any of these actions could materially impede our ability to achieve our business objectives and could materially harm our operating results, and there can be no assurance that any of these actions would be successful. If our cash, cash equivalents and investments are insufficient to fund our projected operating requirements and we are unable to raise capital, it could have a material adverse effect on our business, financial condition and results of operations and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have made acquisitions and, in the future, may continue to acquire businesses, technologies or assets, form joint ventures or make other strategic investments with companies that could adversely affect our operating results, dilute our stockholders&#8217; ownership, or cause us to incur debt or significant expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we have acquired and expect to continue to pursue acquisitions of complementary businesses, technologies, or assets. We may also pursue technology license arrangements, strategic alliances or investments that complement our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisitions and strategic transactions involve numerous risks, any of which could harm our business and negatively affect our financial condition and results of operations, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">intense competition for suitable acquisition targets, which could increase prices and adversely affect our ability to consummate deals on favorable or acceptable terms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">failure or material delay in closing a transaction;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">transaction-related lawsuits or claims;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties in integrating the technologies, operations, existing contracts, and personnel of an acquired company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties in retaining key employees or business partners of an acquired company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties in retaining suppliers, partners, or customers of an acquired company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">challenges with integrating the brand identity of an acquired company with our own;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">diversion of financial and management resources from existing operations or alternative acquisition opportunities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">failure to realize the anticipated benefits or synergies of a transaction;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties in developing technology post-acquisition;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">failure to identify the problems, liabilities, or other shortcomings or challenges of an acquired company or technology, including issues related to intellectual property, regulatory compliance practices, litigation, revenue recognition or other accounting practices, or employee or user issues;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">risks that regulatory bodies may enact new laws or promulgate new regulations that are adverse to an acquired company or business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">risks that regulatory bodies do not approve our acquisitions or business combinations or delay such approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">theft of our trade secrets or confidential information that we share with potential acquisition candidates or other potential strategic partners;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">risk that an acquired company or investment in new services cannibalizes a portion of our existing business; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">adverse market reaction to an acquisition or other strategic transaction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To finance any acquisitions or other strategic investments, we may raise additional funds, which could adversely affect our existing stockholders and our business. If the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. In addition, our stockholders may experience substantial dilution as a result of additional securities we may issue for acquisitions. Open market sales of substantial amounts of our common stock issued to stockholders of companies we acquire could also depress our stock price. Additional funds may not be available on terms that are favorable to us, or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to address the foregoing risks or other problems encountered in connection with past or future acquisitions of businesses, new technologies, services, and other assets and strategic investments, or if we fail to successfully integrate such acquisitions or investments, our business, financial condition, and results of operations could be adversely affected, including potential impairments of goodwill and intangible assets.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully develop and timely manufacture our current and future products, including with respect to SMRT Cells, Sequel, Sequel II/IIe, Revio, Onso, and Vega systems, and other SMRT Cell, HiFi, and SBB products under development, and related products, our business may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Considering the highly complex technologies involved in our products, there can be no assurance that we will be able to manufacture and commercialize our current and future products on a timely basis or continue providing adequate support for our existing products. The commercial success of our products, including the Sequel, Sequel II/IIe, Revio, Onso and Vega systems, and the products under development, including acquired technologies, depends on a number of factors, including performance and reliability of the systems, our anticipating and effectively addressing customer preferences and demands, the success of our sales and marketing efforts, effective forecasting and management of product demand, purchase commitments and inventory levels, effective management of manufacturing and supply costs, and the quality of our products, including consumables such as SMRT Cells and reagents. Should we face delays in or discover unexpected defects during the further development or manufacturing process of instruments or consumables related to our products, including with respect to SMRT Cells, reagents, Sequel, Sequel II/IIe, Revio, Onso, and Vega systems, and other SMRT Cell, HiFi, and SBB products under development, including acquired technologies, and including any delays or defects in software development or product functionality, the timing and success of the continued rollout and scaling of our products may be significantly impacted, which may materially and negatively impact our revenue and gross margin. The ability of our customers to successfully utilize our products will also depend on our ability to deliver high quality SMRT Cells and reagents. We have designed SMRT Cells and other consumables specifically for the Sequel, Sequel II/IIe, Revio and Vega systems, and may need to develop in the future, other customized SMRT Cells and consumables for our future products. Our production of the SMRT Cells for the Sequel and Sequel II/IIe systems has been and may in the future, including with respect to the Revio system, be below desired levels and yields, and we have experienced and may experience in the future manufacturing delays, product or quality defects, SMRT Cell variability, and other issues. The performance of our consumables is critical to our customers&#8217; successful utilization of our products, and any defects or performance issues with our consumables would adversely affect our business. All of the foregoing could have a material adverse effect on our ability to sell our products or result in other material adverse effects on our business, operations, financial condition, operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of our products is complex and costly. Problems in the design or quality of our products may have a material and adverse effect on our brand, business, financial condition, and operating results, and could result in us losing our certifications from the International Organization for Standardization (&#8220;ISO&#8221;). If we were to lose ISO certification, then our customers might choose not to purchase products from us and this could adversely impact our ability to develop products approved for clinical uses. Unanticipated problems with our products could divert substantial resources, which may impair our ability to support our new and existing products and could substantially increase our costs. If we encounter development challenges or discover errors in our products late in our development cycle, including during external beta testing, we may be forced to undertake design and/or production changes, delay product shipments or the scaling of manufacturing or supply. The completion of the production and external testing of our beta systems may also take longer than currently planned, cost more than currently expected and the scientific and technical validation may not be completed on our currently expected timelines or at all. Such testing may also expose fundamental flaws in our products that may cause us to abandon the further development of such products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the continued rollout of our current and future products, including with respect to the SMRT Cell, the Sequel, Sequel II/IIe, Revio, Onso and Vega systems, is delayed or is not successful or less successful than anticipated, then we may not be able to achieve an acceptable return, if any, on our substantial research and development efforts, and our business may be materially and adversely affected. The expenses or losses associated with delayed or unsuccessful product development or lack of market acceptance of our existing and new products, including the SMRT Cell and the Sequel, Sequel II/IIe, Revio, Onso and Vega systems could materially and adversely affect our business, operations, financial condition, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our research and development efforts may not result in the benefits that we anticipate, and our failure to successfully market, sell, and commercialize our current and future products could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have dedicated significant resources to developing our current products. We are also engaged in substantial and complex research and development efforts, which, if successful, may result in the introduction of new products in the future, including in connection with the SMRT Cell and the Sequel II/IIe, Revio, Onso and Vega systems, in addition to other products currently under development, including acquired technologies. Our research and development efforts are complex and require us to incur substantial expenses and we may not be able to develop, manufacture and commercialize new products or obtain regulatory approval if necessary. We may divert significant resources to research and development initiatives that do not result in commercialized products, and even if these efforts do result in commercialized products, there can be no assurance that such products will compete successfully in the market or achieve an acceptable return, if any, on our research and development efforts and expenses. Moreover, our joint research and development efforts with partners require significant management attention and operational resources. If we are unable to successfully manage such joint research and development efforts, our future results may be adversely impacted. Furthermore, we will need to continue to expand our internal capabilities or seek new partnerships or collaborations, or both, in order to successfully develop, market, sell and commercialize our products for and in the markets we seek to reach. If we are unable to do so or are delayed, then this could materially and adversely affect our business, operations, financial condition, and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must successfully manage new product introductions and transitions and the development of acquired technologies, for which we may incur significant costs during these transitions and development, and these efforts may not result in the benefits we anticipate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our products and services fail to deliver the performance, scalability or results expected by our current and future customers, or are not delivered on a timely basis, our reputation and credibility may suffer, our current and future sales and revenue may be materially harmed and our business may not succeed. For instance, if we are not able to successfully execute on the commercialization of the Revio HiFi long-read sequencing system, the Onso SBB short-read sequencing system, and the Vega benchtop long-read sequencing system, and each of their related consumables, and any future products that may be developed for research, medical and clinical uses, including acquired technologies, it could have a material adverse effect on our business, financial condition and results of operations. In addition, the introduction of future products, including with respect to future long-read and short-read products, and related consumables, has and may in the future lead to our limiting or ceasing development of further enhancements to our existing products as we focus our resources on new products, and has resulted and could in the future result in reduced marketplace acceptance and loss of sales of our existing products, materially adversely affecting our revenue and operating results. The introduction of new products, including the recent commercialization of our Revio, Onso and Vega systems, has had and may in the future also have a negative impact on our revenue in the near-term as our current and future customers have delayed or cancelled and may in the future delay or cancel orders of existing products in anticipation of new products and we may also be pressured to decrease prices for our existing products. Our experience in managing product transitions is limited, and we have experienced, and may in the future experience, difficulty in managing or forecasting customer reactions, purchasing decisions or transition requirements with respect to newly launched products. We have incurred and may continue to incur significant costs in completing these transitions, including costs of write-downs of our products, as current or future customers transition to new products. If we do not successfully manage these product transitions, including with respect to the Revio, Onso and Vega systems and each of their related consumables, and any future long-read and short-read products, our business, operations, financial condition, and prospects may be materially and adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected by epidemics or other public health emergencies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely impacted by the effects of epidemics or other public health emergencies. These impacts could include, but are not necessarily limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">shutdowns or business disruptions experienced by manufacturers, suppliers and other third parties with whom we conduct business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">disruptions or interruptions to our supply chains;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in applicable public health regulations that require us to modify our business practices and operations; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">disruption to customer demand for our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which any epidemic or other public health emergency impacts our business and financial results inherently depends on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of a particular public health matter and the actions to contain it or treat its impact, among others. Even after an epidemic or public health emergency has subsided, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may continue to experience an adverse impact to our business as a result of economic aftershocks, including recessionary effects and inflationary pressures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant changes to our leadership team and the resulting management transitions might harm our future operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in recent years experienced significant changes to our leadership team, and although we believe these leadership transitions are in the best interest of our stakeholders, these transitions may result in the loss of personnel with deep institutional or technical knowledge. Further, the transition could potentially disrupt our operations and relationships with employees, suppliers, partners, and customers due to added costs, operational inefficiencies, decreased employee morale and productivity and increased turnover. We must successfully recruit and integrate our new leadership team members within our organization to achieve our operating objectives; as such, the leadership </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transition</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may temporarily affect our business performance and results of operations while the new members of our leadership team become familiar with our business. In addition, our competitors may seek to use this transition and the related potential disruptions to gain a competitive advantage over us. Furthermore, these changes may increase our dependency on the other members of our leadership team that remain with us, who are not contractually obligated to remain employed with us and may leave at any time. Any such departure could be particularly disruptive given that we are already experiencing leadership transitions and, to the extent we experience additional management turnover, competition for top management is high such that it may take some time to find a candidate that meets our requirements. Our future operating results depend substantially upon the continued service of our key personnel and in significant part upon our ability to attract and retain qualified management personnel. If we are unable to mitigate these or other similar risks, our business, results of operations and financial condition may be materially and adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on the continuing efforts of our senior management team and other key personnel. If we lose members of our senior management team or other key personnel or are unable to successfully retain, recruit and train qualified scientists, engineers, sales personnel and other employees, our ability to maintain, develop and commercialize our products could be harmed and we may be unable to achieve our goals.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends upon the continuing services of members of our senior management team and scientific and engineering personnel. In particular, our scientists and engineers are critical to our technological and product innovations, and we will need to hire additional qualified personnel. Our industry, is characterized by high demand and intense competition for talent, and the turnover rate has been and may continue to be high. Our employees can leave our company with little to no prior notice and would be free to work for a competitor. We compete for qualified management and scientific personnel with other life science companies, academic institutions and research institutions, particularly those focusing on genomics. We also compete for qualified sales personnel to support the commercialization of our existing and new products. Workforce reductions, such as the workforce reduction we implemented in 2024, and other expense reduction efforts may be negatively received by potential or current employees, and accordingly result in attrition or difficulty in recruiting desirable candidates. Additionally, we may face challenges in retaining and recruiting key personnel due to sustained declines in our stock price that could reduce the retentive value of stock options, restricted stock units and other equity awards we issue as compensation. We may not be able to provide adequate cash or other incentives to adequately counterbalance any negative perceptions about the value of our equity awards. Moreover, the value of any equity awards that we do grant to our personnel may be significantly affected by movements in our stock price that are beyond our control. The loss of qualified employees, or an inability to attract, retain, and motivate employees, could prevent us from pursuing collaborations and materially and adversely affect our support of existing products, product development and launches, business growth prospects, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, changes to U.S. immigration policies, such as such as the implementation of more restrictive interpretations by the U.S. Citizenship and Immigration Services of regulatory requirements for H-1B and other visa programs, could restrain the flow of technical and professional talent into the U.S. and may inhibit our ability to hire qualified personnel. If some of our employees&#8217; temporary work permits expire and are not renewed, we may face increased turnover rates and labor shortages, which could result in higher labor costs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If one or more of our senior executives or other key personnel were unable or unwilling to continue in their present positions, we may not be able to replace them easily or at all, and other senior management may be required to divert attention from other aspects of the business. In addition, we do not have &#8220;key person&#8221; life insurance policies covering any member of our management team or other key personnel. The loss of any of these individuals or any inability to attract or retain qualified personnel, including scientists, engineers, sales personnel and others, could prevent us from pursuing collaborations and materially and adversely affect our support of existing products, product development and introductions, business growth prospects, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success is highly dependent on our ability to further penetrate nucleic acid sequencing applications as well as on the growth and expansion of the demand for our products. If our products fail to achieve and sustain sufficient market acceptance, we will not generate expected revenue and our business may not succeed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although nucleic acid sequencing technology is well-established, our SMRT Sequencing technology is relatively new and evolving. We cannot be sure that our current or future products will gain acceptance in the marketplace at levels sufficient to support our costs. Our success depends, in part, on our ability to expand overall demand for nucleic acid sequencing to include new applications that are not practicable with other current technologies and to introduce new products that capture a larger share of growing overall demand for sequencing. To accomplish this, we must successfully commercialize, and continue development of, our proprietary SMRT Sequencing technology for use in a variety of life science and other research applications, including uses by academic, government and clinical laboratories, as well as pharmaceutical, diagnostic, biotechnology, and agriculture companies, among others. However, we may be unsuccessful in these efforts and the sale and commercialization of our products may not grow sufficiently to cover our costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be successful in adding new products or securing additional customers for our current and future products. If we are unable to successfully develop acquired technologies and sell acquired technology products, we may fail to achieve our strategic commercial initiatives in connection with the planned release of new products and anticipated entry into new markets. Our ability to further penetrate existing applications and any new applications depends on a number of factors, including the cost, performance and perceived value associated with our products, as well as customers&#8217; willingness to adopt a different approach to nucleic acid sequencing. Potential customers may have already made significant investments in other sequencing technologies and may be unwilling to invest in new technologies. We are experiencing pricing pressures caused by industry competition and increased demand for lower-priced instruments and lower operational costs. We have limited experience commercializing and selling products outside of the academic and research settings, and we cannot guarantee success in acquiring additional customers. Furthermore, we cannot guarantee that our products will be satisfactory to potential customers or that our products will perform in accordance with customer expectations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nucleic acid sequencing applications are new and dynamic, and there can be no assurance that they will develop as quickly as we anticipate, that they will reach their full potential or that our products will be appropriate or competitive for these applications. As a result, we may be required to refocus our marketing efforts, and we may have to make changes to the specifications of our products to enhance our ability to enter particular applications more quickly. We may also need to delay full-scale commercial deployment of new products as we develop them in order to perform quality control and early access user testing. We also need to maintain reliable supply chains for the various components in our new products and consumables to support large-scale commercial production. Even if we are able to implement our technology successfully, we and/or our sales and distribution partners may fail to achieve or sustain market acceptance of our current or future products across the full range of our intended life science and other applications. We need to continue to expand and update our internal capabilities or to collaborate with other partners, or both, in order to successfully expand sales of our products in the applications that we seek to reach, which we may be unable to do at the scale required to support our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the demand for our products grows more slowly than anticipated, if we are unable to successfully scale or otherwise ensure sufficient manufacturing capacity for new products to meet demand, if we are not able to successfully market and sell our products, if competitors develop better or more cost-effective products, if our product launches and commercialization are not successful, or if we are unable to further grow our customer base or do not realize the growth with existing customers that we are expecting, our current and future sales and revenue may be materially and adversely harmed, or we may recognize an impairment loss, and our business may not succeed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on other companies for the manufacture of certain components and sub-assemblies and intend to outsource additional sub-assemblies in the future, some of which are sole sources. We may not be able to successfully scale the manufacturing process necessary to build and test multiple products on a full commercial basis, which could materially harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are complex and involve a large number of unique components, many of which require precise manufacturing. The nature of our products requires customized components that are currently available only from a limited number of sources, and in some cases, single sources. We have chosen to source certain critical components from a single source, including suppliers for our SMRT Cells, reagents, and instruments. We cannot assure you that product supplies will not be limited or interrupted, especially with respect to our sole source third-party manufacturing and supply collaborators, or that product supplies will be of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. We may be unable to negotiate binding agreements with our current and future sole source third-party manufacturing and supply collaborators or, in the event that such collaborators&#8217; services become interrupted for any reason, find replacement manufacturers to support our development and commercial activities at commercially reasonable terms. We do not always have arrangements in place for a redundant or second-source supply for our sole source vendors in the event they cease to provide their products or services to us or fail to provide sufficient quantities in a timely manner. If we are required to purchase these components from alternative sources, it could take several months or longer to qualify the alternative sources. If we are unable to source these product components from sole-source third-party manufacturing and supply collaborators for any reason, including in connection with acts of terrorism, hostilities, military conflict and acts of war, including between China and Taiwan, or secure a sufficient supply of these product components on a timely basis and at an acceptable cost, or if these components do not meet our expectations or specifications for quality and functionality, our operations and manufacturing would be materially and adversely affected, we could be unable to meet customer demand and our business and results of operations may be materially and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operations of our third-party manufacturing partners and suppliers have had and may in the future be disrupted by conditions unrelated to our business or operations or that are beyond our control, including but not limited to changing international trade policies, inflation, supply chain disruptions, and conditions&#160;&#160;&#160;&#160;related to epidemics or pandemics. If our manufacturing partners or suppliers are unable or fail to fulfill their obligations to us for any reason, we may not be able to manufacture our products and satisfy customer demand or our obligations under sales agreements in a timely manner, and our business could be harmed as a result. We have and may continue to face challenges in our supply chain, which has and may continue to adversely impact margins. During periods of shortage or delay, the price of components may increase or the components may not be available at all. Our suppliers have raised prices and may continue to raise prices that we may not be able to pass on to our customers, which could adversely affect our business, including our competitive position, market share, revenues, and profit margins in material ways. We may not be able to secure enough components at reasonable prices or of acceptable quality to build new products in a timely manner in the quantities or configurations needed. Various government policies have had, and may continue to have in the future, a negative impact on manufacturing and/or supply chains, in addition to customer demand for our products and demand through certain distributors. If as a result of global economic or political instability, such as the uncertainty in the Middle East, an escalation of the war in Ukraine, potential uncertainty related to Taiwan and its relationship with China, changing international trade policies, other disease outbreaks, or supply issues, we or our contractors could experience shortages, business disruptions or delays for materials sourced or manufactured in the affected countries, and their ability to supply us with instruments or product components may be affected. Occasionally, system components and reagents reach the end of their life cycles or become obsolete, requiring us to source alternatives. If we encounter delays or difficulties in securing the quality and quantity of materials we require for our products, our supply chain would be interrupted, which would adversely affect sales. If any of these events occur, our business and operating results could be harmed. Accordingly, if any of the foregoing occurs, our ability to commercialize our products, revenue and gross margins could suffer until lockdowns related to epidemics or pandemics are lifted, supply issues or business disruptions are resolved and/or other sources can be developed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current manufacturing process is also characterized by long lead times between the placement of orders for and delivery of our products. If we do not accurately anticipate our needs or if we receive insufficient components to manufacture our products on a timely basis to meet customer demand, our sales and our gross margin may be adversely affected, and our business could be materially harmed. If we are unable to reduce our manufacturing costs and establish and maintain reliable, high-volume manufacturing suppliers as we scale our operations and expand our product offerings, our business, operations, financial condition, and prospects could be materially and adversely harmed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to consistently manufacture our instruments and consumables, including SMRT Cells and reagents, to the necessary specifications or in quantities necessary to meet demand at an acceptable cost or at an acceptable performance level.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to successfully generate revenue from our products, we need to supply our customers with products that meet their expectations for quality and functionality in accordance with established specifications. Our customers have experienced variability in the performance of our products. We have experienced and may continue to experience delays, quality issues or other difficulties leading to customer dissatisfaction with our products. Our production of SMRT Cells, flow cells and of reagents for both our long- and short-read technologies, involve a long and complex manufacturing process and has been and may in the future be below desired yields and resulting output levels. We have experienced and may experience in the future manufacturing delays, product defects, variability in the performance of SMRT Cells, flow cells and other products, inadequate reserves for inventory, or other issues.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will be able to manufacture our products so that they consistently achieve the product specifications and quality that our customers expect, including any products developed for clinical uses. Problems in the design or quality of our products, including low manufacturing yields of SMRT Cells, flow cells, or sub-performing reagent lots may have a material adverse </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effect</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our brand, business, financial condition, and operating results, and could result in us losing our ISO certifications. If we were to lose our ISO certifications, then our customers might choose not to purchase products from us. There is also no assurance that we will be able to increase manufacturing yields and decrease costs, particularly if high rates of inflation continue, or that we will be successful in forecasting customer demand or manufacturing and supply costs, or that product supplies, including reagents or integrated chips, will not be limited or interrupted, or will be of satisfactory quality or continue to be available at acceptable prices. Furthermore, while we are undertaking efforts to increase our manufacturing scale and capability, we may not be able to increase manufacturing to meet anticipated demand or may experience downtime in our manufacturing facilities, including, for example, if our suppliers are unable to meet our increased demand at a time when the supply chain is under duress due to potential dislocations and disruptions in product and employee availability (whether due to pandemics, government policy or otherwise). An inability to manufacture products and components that consistently meet specifications, in necessary quantities and at commercially acceptable costs, will have a negative impact, and may have a material adverse effect on our business, product development timelines, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rapidly changing technology in life sciences and research diagnostics could make our products obsolete unless we continue to develop, manufacture and commercialize new and improved products and pursue new opportunities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is characterized by rapid and significant technological changes, frequent new product introductions and enhancements and evolving industry standards. These new and evolving technologies may be superior to, impair, or render obsolete the products we currently offer or the technologies currently underlying our products. Our future success depends on our ability to continually improve our products, to develop and introduce new products that address the evolving needs of our customers on a timely and cost-effective basis and to pursue new opportunities. These new opportunities may be outside the scope of our proven expertise or in areas where demand is unproven, and new products and services developed by us may not gain market acceptance or may not adequately perform to capture market share. Our inability to develop and introduce new products and to gain market acceptance of our existing and new products could harm our future operating results. Unanticipated difficulties or delays in replacing existing products with new products or in commercializing our existing or new products in sufficient quantities and of acceptable quality to meet customer demand, including with respect to the SMRT Cell and the Sequel, Sequel II/IIe, Revio, Onso and Vega systems, could diminish future demand for our products and may materially and adversely harm our future operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The size of the markets for our products, including our Revio, Onso and Vega instruments, may be smaller than estimated, and new market opportunities may not develop as quickly as we expect, or at all, limiting our ability to successfully sell our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for sequencing systems and consumables products is evolving, making it difficult to accurately predict the size of the markets for our current and future products, including our Revio, Onso and Vega instruments. Our estimates of the total addressable market for our current and future products are based on a number of internal and third-party estimates and assumptions that may be incorrect, including the assumptions that academic, governmental, corporate, or other sources of funding will continue to be available to life sciences researchers at times and in amounts necessary to allow them to purchase our products. In addition, sales of new products may take time to develop and mature and we cannot be certain that these market opportunities will develop as we expect. While we believe our assumptions and the data underlying our estimates of the total addressable market for our products are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates, or those underlying the third-party data we have used, may change at any time, thereby reducing the accuracy of our estimates. As a result, our estimates of the total addressable market and growth opportunities for our products may be incorrect.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future growth of the market for our current and future products depends on many factors beyond our control, including recognition and acceptance of our products by the research and scientific communities, the growth, prevalence and costs of competing products and solutions and the development of robust ecosystems supporting our products and their methodologies. For example, the market acceptance and growth of long-read sequencing technologies, like our Revio and Vega systems, depends on a variety of factors, including the availability and cost-effectiveness of related tools for high quality sample collection and preparation and advanced bioinformatic tools to process results; as well as the perceived advantages and disadvantages of long-read sequencing compared to short-read or other sequencing technologies: consequently, if potential customers conclude the costs of adopting long-read sequencing technologies outweigh the benefits, the market for our Revio and Vega systems may be negatively impaired. There can be no assurance that our current or future products will gain traction in the market. If the markets for our current and future products are smaller than estimated or do not develop as we expect, our growth may be limited, and it could materially and adversely affect our business, operations, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increased market adoption of our products by customers may depend on the availability of sample preparation and informatics tools, some of which may be developed by third parties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success may depend in part upon the development of sample preparation and software and informatics tools by third parties for use with our products. We cannot guarantee that product supplies, including reagents, will not be limited or interrupted, or will be of satisfactory quality or continue to be available at acceptable prices, or that third parties will develop tools that our current and future customers will find useful with our products, or that customers will adopt such third-party tools on a timely basis or at all. A lack of complementary sample preparation and informatics tools, or delayed updates of such tools, may impede the adoption of our products and may materially and adversely impact our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in a highly competitive industry and if we are not able to compete effectively, our business and operating results will likely be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a significant number of companies offering nucleic acid sequencing products and/or services, including Illumina, BGI Genomics (also known as MGI or Complete Genomics), Thermo, ONT Ltd., Roche, Bionano, and Qiagen. Other companies recently entering the market include Ultima, Element and Singular. Many of these companies currently have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater financial, technical, research and/or other resources, more experience in new product development, larger and more established manufacturing capabilities and marketing, sales, and support functions, and/or more established distribution channels to deliver products to customers than we do. These companies may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards, or customer requirements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also several companies that are in the process of developing or have already developed and commercialized new, competing or potentially competing technologies, products and/or services, including ONT Ltd. and its subsidiaries, against whom we have filed complaints for patent infringement in the U.S. District Court for the District of Delaware and, previously, with the U.S. International Trade Commission, in the High Court of England and Wales and in the District Court of Mannheim, Germany. ONT Ltd. previously filed claims against us in the High Court of England and Wales and the District Court of Mannheim, Germany, also for patent infringement. Roche is developing potentially competing sequencing products. Increased competition may result in pricing pressures, which could harm our sales, profitability or market share. Our failure to further enhance our existing products and to introduce new products to compete effectively could materially and adversely affect our business, operations, financial condition, and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to successfully increase sales of our current products or market and sell our future products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to achieve profitability depends, in part, on our ability to attract customers for our current and future products including Revio and Onso, and we may be unable to effectively market or sell our products or find appropriate partners to do so. To perform sales, marketing, distribution, and customer support functions successfully, we face a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to attract, retain and manage qualified sales, marketing, and service personnel necessary to expand market acceptance for our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the performance and commercial availability expectations of our existing and potential customers with respect to new and existing products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">availability of potential sales and distribution partners to sell our technologies, and our ability to attract and retain such sales and distribution partners;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the time and cost of maintaining and growing a specialized sales, marketing and service force for a particular application, which may be difficult to justify in light of the revenue generated; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our sales, marketing and service force may be unable to execute successful commercial activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have, and may in the future, use promotional pricing and similar measures to attract purchases of our products. These measures may not be successful in attracting purchases and, even if successful, may negatively impact our gross margins. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have enlisted and may continue to enlist third parties to assist with sales, equipment leasing, distribution and customer support. There is no guarantee that we will be successful in attracting desirable sales and distribution partners, that we will be able to enter into arrangements with such partners on terms favorable to us or that we will be able to retain such partners on a going-forward basis. If our sales and marketing efforts, or those of any of our third-party sales and distribution partners, are not successful, or our products do not perform in accordance with customer expectations, our technologies and products may not gain market acceptance, which could materially and adversely impact our business, operations, financial condition, and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Large purchases by a limited number of customers represent a significant portion of our revenue, and any loss or delay of expected purchases has resulted, and in the future could result, in material quarter-to-quarter fluctuations of our revenue or otherwise adversely affect our results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a significant portion of our revenue from a limited number of customers. For the years ended December&#160;31, 2024, and 2023, no customer accounted for 10% or more of our total revenue. For the year ended December&#160;31, 2022, one customer, who is our primary distributor in China, exceeded 10% of our total revenue. Many of these customers make large purchases on a purchase-order basis rather than pursuant to long-term contracts. As a consequence of the concentrated nature of our customer base and their purchasing behavior, our quarterly revenue and results of operations have fluctuated, and may fluctuate in the future, from quarter to quarter and are difficult to forecast. For example, the cancellation of orders or acceleration or delay in anticipated product purchases or the acceptance of shipped products by our larger customers has materially affected, and in the future could materially affect, our revenue and results of operations in any quarterly period. We have been, and may in the future be, unable to sustain or increase our revenue from our larger customers, or offset any discontinuation or decrease of purchases by our larger customers with purchases by new or other existing customers. To the extent one or more of our larger customers experience significant financial difficulty, bankruptcy or insolvency, this could have a material adverse effect on our sales and our ability to collect on receivables, which could materially and adversely harm our financial condition and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many of our customers, including some of our larger customers, have negotiated, or may in the future negotiate, volume-based discounts or other more favorable terms from us or our sales and distribution partners, which can and have had a negative effect on our gross margins or revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that such concentrated purchases will continue to contribute materially to our revenue for the foreseeable future and that our results of operations may fluctuate materially as a result of such larger customers&#8217; buying patterns. In addition, we may see consolidation of our customer base. The loss of one of our larger customers, a significant delay or reduction in its purchases, or any volume-based discount or other more favorable terms that we or our sales and distribution partner(s) may agree to provide, in light of the aggregated purchase volume or buying power resulting from such consolidation, has harmed, and in the future could harm, our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products are highly complex, have recurring support requirements and could have unknown defects or errors, which may give rise to claims against us or divert application of our resources from other purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are highly complex and may develop or contain undetected defects or errors. Our customers have previously experienced reliability issues with our existing products, including the Sequel and Sequel II/IIe systems. In addition, it is possible our customers could experience reliability issues with current or future products, including the Sequel II/IIe, Revio, Onso and Vega systems. Despite internal and external testing, defects, or errors may arise in our products, which could result in a failure to obtain, maintain, or increase market acceptance of our products, diversion of development resources, injury to our reputation and increased warranty, service, and maintenance costs. New products, including the Revio, Onso and Vega systems, or enhancements to our existing products, including the SMRT Cell and the Sequel II/IIe systems, in particular may contain undetected errors or performance problems that are discovered only after delivery to customers. If our products have reliability or other quality issues or require unexpected levels of support in the future, the market acceptance and utilization of our products may not grow to levels sufficient to support our costs and our reputation and business could be harmed. Low utilization rates of our products has and could in the future cause our revenue and gross margins to be adversely affected. We provide a warranty for our sequencing instruments and consumables, which is generally limited to replacing, repairing, or at our option, giving credit for any sequencing instrument or consumable with defects in material or workmanship. Service contracts for our sequencing instruments may be separately purchased. Defects or errors in our products may also discourage customers from purchasing our products. The costs incurred in correcting any defects or errors may be substantial and could materially and adversely affect our operating margins. If our service and support costs increase, our business and operations may be materially and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, such defects or errors could lead to the filing of product liability claims against us or against third parties whom we may have an obligation to indemnify against such claims, which could be costly and time-consuming to defend and result in substantial damages. Although we have product liability insurance, any product liability insurance that we have or procure in the future may not protect our business from the financial impact of a product liability claim. Moreover, we may not be able to obtain adequate insurance coverage on acceptable terms. Any insurance that we have or obtain will be subject to deductibles and coverage limits. A product liability claim could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant portion of our sales depends on customers&#8217; spending budgets that may be subject to significant and unexpected variation which could have a negative effect on the demand for our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our instruments represent significant capital expenditures for our customers in research applications. Current and potential customers for our current or future products include academic and government institutions, genome centers, medical research institutions, clinical laboratories, pharmaceutical, agricultural, biotechnology, diagnostic and chemical companies. Their spending budgets can have a significant effect on the demand for our products. Spending budgets are based on a wide variety of factors, including the allocation of available resources to make purchases, funding from government sources which is highly uncertain and subject to change, the spending priorities among various types of research equipment, policies regarding capital expenditures during economically uncertain periods and the potential impacts from health epidemics or pandemics. Any decrease in capital spending or change in spending priorities of our current and potential customers could significantly reduce the demand for our products. Any delay or reduction in purchases by current or potential customers or our inability to forecast fluctuations in demand could materially and adversely harm our future operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to convert our orders in backlog into revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our backlog represents product orders from our customers that we have confirmed but have not been able to fulfill, and, accordingly, for which we have not yet recognized revenue. We may not receive revenue from these orders, and any order backlog we report may not be indicative of our future revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many events can cause an order to be delayed or not completed at all, some of which may be out of our control, including the potential impacts from health epidemics or pandemics and our suppliers, especially our sole source suppliers, not being able to provide us with products or components. If we delay fulfilling customer orders or if customers reconsider their orders, those customers may seek to cancel or modify their orders with us. Customers may otherwise seek to cancel or delay their orders even if we are prepared to fulfill them. If our orders in backlog do not result in sales, our operating results may suffer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales cycles are unpredictable and lengthy, which makes it difficult to forecast revenue and may increase the magnitude of quarterly or annual fluctuations in our operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sales cycles for our sequencing instruments are lengthy because they represent a major capital expenditure and generally require the approval of our customers&#8217; senior management. This may contribute to substantial fluctuations in our quarterly or annual operating results, particularly during periods in which our sales volume is low. Because of these fluctuations, it is likely that in some future quarters our operating results will fall below the expectations of securities analysts or investors. If that happens, the market price of our stock would likely decrease. Past fluctuations in our quarterly and annual operating results have resulted in decreases in our stock price. Such fluctuations also mean that investors may not be able to rely on our operating results in any particular period as an indication of future performance. Sales to existing customers and the establishment of a business relationship with other potential customers is a lengthy process, generally taking several months and sometimes longer. Following the establishment of the relationship, the negotiation of purchase terms can be time-consuming, including as a result of seasonal factors, as discussed below, and a potential customer may require an extended evaluation and testing period. Our sales cycles may also lengthen, and those sales cycles may result in lower units sold per cycle, as we continue to introduce our Revio and Onso instruments and their associated consumables to the market, as our customers may have additional administrative, technical or other requirements associated with transitioning to new products and technologies. In anticipation of product orders, we may incur substantial costs before the sales cycle is complete and before we receive any customer payments. As a result, if a sale is not completed or is canceled or delayed, we may have incurred substantial expenses, making it more difficult for us to become profitable or otherwise negatively impacting our financial results. Even if our selling efforts are successful, the realization of revenue may be substantially delayed, our ability to forecast our future revenue may be more limited and our revenue may fluctuate significantly from quarter to quarter and year over year. For more information on the impact of these fluctuations on our results and stock price, see &#8220;&#8212;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i1c82068fb4244bd4a402f417590b7e43_586387">Our operating results fluctuate from quarter to quarter and year over year, which makes our future results difficult to predict and could negatively impact the market price of our common stock</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because some of our customers and suppliers are based in China, our business, financial condition and results of operations could be adversely affected by the political and economic tensions between the United States and China.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks associated with political conflicts between the U.S. and China. A portion of our revenue is generated from China. For the years ended December&#160;31, 2024, and 2023, no customer accounted for 10% or more of our total revenue. For the year ended December&#160;31, 2022, one customer, who is our primary distributor in China, exceeded 10% of our total revenue. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain c</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">omponents, some of which are critical components, of our products are manufactured in China. These components are either sourced directly from companies in China or indirectly from third parties that source from companies in China.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, we are subject to significant risks associated with the trading relationship between the U.S. and China, which is currently characterized by significant uncertainty. Tariffs imposed by the U.S. and China have increased, and may continue to increase, our costs. Additionally, export restrictions imposed by the U.S. may impact our ability to export certain products to customers or distributors in China and restrict our ability to use certain integrated circuits in our products, and it is possible that additional restrictions will be put in place that could impact our ability to provide our products to customers or distributors in China or source components from China. Moreover, the Chinese government may retaliate against U.S. trade restrictions in ways that could impact our business, including through the imposition of tariffs on imports from the U.S. and/or the imposition of export controls affecting the export of certain items from China. Given the relatively fluid regulatory environment in China and the United States and uncertainty how the U.S. or foreign governments will act with respect to export controls, tariffs, international trade agreements and policies, there could be additional import, export, tax, or other regulatory changes in the future. Any such changes could directly and adversely impact our financial results and results of operations. For more information, see &#8220;&#8212;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i1c82068fb4244bd4a402f417590b7e43_587936">Enhanced trade tariffs, import restrictions, export restrictions</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i1c82068fb4244bd4a402f417590b7e43_587936"> or other trade barriers may materially harm our business</a></span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks could include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">interruptions to operations in China as a result of potential disease outbreaks or natural catastrophic events, which have in the past and can result in the future in business closures, transportation restrictions, import and export complications and cause shortages in the supply of raw materials or disruptions in manufacturing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">product supply disruptions and increased costs as a result of heightened exposure to changes in the policies of the Chinese government, political unrest or unstable economic conditions in China; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the nationalization or other expropriation of private enterprises or intellectual property by the Chinese government.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Difficulties in this relationship may require us to take actions adverse to our business to comply with governmental restrictions on business and trade with China.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant risks associated with doing business with Taiwanese suppliers and manufacturers due to the tense relationship between Taiwan and mainland China.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our consumable chips are partly manufactured by a company based in Taiwan. Our supply of consumables chips and other critical components may be materially and adversely affected by diplomatic, geopolitical, military and other developments affecting the relationship between China and Taiwan. Recent military exercises in the Taiwan Strait have contributed to geopolitical uncertainty regarding the future of the relationship between China and Taiwan. Current or future diplomatic, geopolitical, military or other tensions between China and Taiwan, including trade disputes, may lead to circumstances that negatively affect the availability of such consumable chips and other critical components to us, which could limit or prohibit our ability to manufacture consumable chips and other critical components or lead to an increase in our supply costs if we cannot find a similar cost alternative supplier, which could materially and adversely impact our business, operations, prospects, financial condition and results, and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span id="i1c82068fb4244bd4a402f417590b7e43_586387"></span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results fluctuate from quarter to quarter and year over year, which makes our future results difficult to predict and could negatively impact the market price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products, particularly our sequencing instruments, are subject to significant seasonality due to several factors, including the procurement and budgeting cycles of many of our customers, especially government-funded customers, which often coincide with government fiscal year ends and significant holidays disrupting business and sales activities in key markets. These factors have contributed, and in the future may contribute, to substantial fluctuations in our quarterly operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results during any given period can also be impacted by numerous other factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">market acceptance for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to attract new customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the length of our sales cycles, as discussed above;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to achieve economies of scale and other manufacturing efficiencies at the rate we anticipate;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">publications of studies by us, our competitors or third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the timing and success of new product introductions by us or our competitors or other changes in the competitive dynamics of our industry, such as consolidation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the amount and timing of our costs and expenses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in our pricing policies or those of our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">general economic, industry and market conditions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the impact of catastrophic events, including health epidemics or pandemics and military or other armed conflicts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the regulatory environment in which we operate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">expenses associated with warranty obligations or unforeseen product quality issues;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the hiring, training, and retention of key employees, including our ability to grow our sales organization;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">litigation or other claims against us for intellectual property infringement or otherwise;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to obtain additional financing as necessary; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes or trends in new technologies and industry standards.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, it is possible that in some quarters our operating results will fall below the expectations of securities analysts or investors. If that happens, the market price of our common stock would likely decrease. These fluctuations, among other factors, also mean that our operating results in any particular period may not be relied upon as an indication of future performance. Additionally, any bankruptcy of a customer or other party with whom we do business, or the failure of any such party to make payments when due, or any breach or default by any such party, or the loss of any significant partnerships, could impact our revenue recognition or result in material losses to us, which may have a material adverse impact on our business. Seasonal or cyclical variations in our sales have in the past, and may in the future, become more or less pronounced over time, and have in the past materially affected, and may in the future materially affect, our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating losses and certain other tax attributes to offset future taxable income may be subject to substantial limitations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the Internal Revenue Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating losses (&#8220;NOLs&#8221;) and other pre-change tax attributes, such as research and development credits, to offset its post-change taxable income or tax liability. An &#8220;ownership change&#8221; is generally defined as a greater than 50% change (by value) in a corporation&#8217;s equity ownership by &#8220;5 percent shareholders&#8221; over a rolling three-year period. We believe that we have had one or more ownership changes, and as a result our existing NOLs are currently subject to limitation. Future changes in our stock ownership could result in additional ownership changes, including potentially material changes, under Sections 382 and 383. Further, California has enacted legislation that limits the use of state NOLs for tax years beginning on or after January 1, 2024 and before January 1, 2027. As a result of this legislation or other unforeseen reasons, we may not be able to utilize some or all of our NOLs even if we attain profitability.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law and differences in interpretation of tax laws and regulations could adversely impact our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in multiple jurisdictions and are subject to tax laws and regulations of the U.S. federal, state and local and non-U.S. governments. Tax laws, regulations and administrative practices in these jurisdictions may be subject to significant changes, with or without advance notice.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in tax laws, regulations or rulings, changes in interpretations of existing laws and regulations or changes in accounting principles could negatively and materially affect our financial position, cash flows, and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our facilities in California are located near earthquake faults, and the occurrence of an earthquake or other catastrophic disaster could cause damage to our facilities and equipment, which could require us to cease or curtail operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities in California are located near earthquake fault zones and are vulnerable to damage from earthquakes. We are also vulnerable to damage from other types of disasters, including fire, floods, power loss, communications failures and similar events. If any disaster were to occur, our ability to operate our business at our facilities would be seriously, or potentially completely, impaired. In addition, the nature of our activities could cause significant delays in our research programs and commercial activities and make it difficult for us to recover from a disaster. The insurance we maintain may not be adequate to cover our losses resulting from disasters or other business interruptions. Accordingly, an earthquake or other disaster could materially and adversely harm our ability to conduct business.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to secure patent or other intellectual property protection for our products and improvements to our products may reduce our ability to maintain any technological or competitive advantage over our current and potential competitors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to protect and enforce our intellectual property rights is uncertain and depends on complex legal and factual questions. Our ability to establish or maintain a technological or competitive advantage over our competitors may be diminished because of these uncertainties. For example:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">we or our licensors might not have been the first to make the inventions covered by each of our pending patent applications or issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">we or our licensors might not have been the first to file patent applications for these inventions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">it is possible that neither our pending patent applications nor the pending patent applications of our licensors will result in issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the scope of the patent protection we or our licensors obtain may not be sufficiently broad to prevent others from practicing our technologies, developing competing products, designing around our patented technologies or independently developing similar or alternative technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our and our licensors&#8217; patent applications or patents have been, are and may in the future be, subject to interference, opposition or similar administrative proceedings, which could result in those patent applications failing to issue as patents, those patents being held invalid or the scope of those patents being substantially reduced;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our enforcement of patents and proprietary rights in other countries may be problematic or unpredictable;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">we or our partners may not adequately protect our trade secrets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">we may not develop additional proprietary technologies that are patentable; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the patents of others may limit our freedom to operate and prevent us from commercializing our technology in accordance with our plans.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of these events could impair our ability to operate without infringing upon the proprietary rights of others or prevent us from establishing or maintaining a competitive advantage over our competitors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variability in intellectual property laws may adversely affect our intellectual property position.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property laws, and patent laws and regulations in particular, have been subject to significant variability either through administrative or legislative changes to such laws or regulations or changes or differences in judicial interpretation, and it is expected that such variability will continue to occur. Additionally, intellectual property laws and regulations differ by country. Variations in the patent laws and regulations or in interpretations of patent laws and regulations in the United States and other countries may diminish the value of our intellectual property and may change the impact of third-party intellectual property on us. Accordingly, we cannot predict the scope of the patents that may be granted to us with certainty, the extent to which we will be able to enforce our patents against third parties or the extent to which third parties may be able to enforce their patents against us.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of the intellectual property that is important to our business is owned by other companies or institutions and licensed to us, and changes to the rights we have licensed may adversely impact our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We license from third parties some of the intellectual property that is important to our business. If the third parties who license intellectual property to us fail to maintain the intellectual property that we have licensed, or lose rights to that intellectual property, the rights we have licensed may be reduced or eliminated, which would eliminate barriers against our competition. Termination of these licenses or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, or could subject us to claims of intellectual property infringement or contract breach in litigation or other administrative proceedings that could result in damage awards against us and injunctions that could prohibit us from selling our products. In addition, some of our licenses from third parties limit the field in which we can use the licensed technology. Therefore, for us to use such licensed technology in potential future applications that are outside the licensed field of use, we may be required to negotiate new licenses with our licensors or expand our rights under our existing licenses. We cannot be certain that we will be able to obtain such licenses or expanded rights on reasonable terms or at all. In the event a dispute with our licensors were to occur, our licensors may seek to renegotiate the terms of our licenses, increase the royalty rates that we pay to obtain and maintain those licenses, limit the field or scope of the licenses, or terminate the license agreements. In addition, we have limited rights to participate in the prosecution and enforcement of the patents and patent applications that we have licensed. If we fail to meet our obligations under these licenses, or if we have a dispute regarding the terms of the licenses, these third parties could terminate the licenses, which could subject us to claims of intellectual property infringement. As a result, we cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business. Further, because of the rapid pace of technological change in our industry, we may need to rely on key technologies developed or licensed by third parties, and we may not be able to obtain licenses and technologies from these third parties at all or on reasonable terms. The occurrence of these events may have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The measures that we use to protect the security of and enforce our intellectual property and other proprietary rights may not be adequate, which could result in the loss of legal protection for, and thereby diminish the value of, such intellectual property and other rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patents, we also rely upon trademarks, trade secrets, copyrights, and unfair competition laws, as well as license agreements and other contractual provisions, to protect our intellectual property and other proprietary rights. Despite these measures, any of our intellectual property rights could be challenged, invalidated, circumvented, or misappropriated. In addition, we attempt to protect our intellectual property and proprietary information by requiring our employees and consultants to enter into confidentiality and assignment of inventions agreements, and by entering into confidentiality agreements with our third-party development, manufacturing, sales, and distribution partners, who may also acquire, develop and/or commercialize alternative or competing products or provide services to our competitors. For example, Roche had certain access to our trade secrets and other proprietary information pursuant to an agreement we had entered into with Roche, subject to the confidentiality provisions thereof (certain of which provisions survive the termination of the agreement); however, Roche is developing potentially competing sequencing products. There can be no assurance that our measures have provided or will provide adequate protection for our intellectual property and proprietary information. These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets and other proprietary information may be disclosed to others, or others may gain access to or disclose our trade secrets and other proprietary information. Enforcing a claim that a third party illegally obtained and is using our trade secrets is expensive and time consuming, and the outcome is unpredictable. Additionally, others may independently develop proprietary information and techniques that are substantially equivalent to ours. The occurrence of these events may have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our intellectual property may be subject to challenges in the United States or foreign jurisdictions that could adversely affect our intellectual property position.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pending, issued and granted U.S. and foreign patents and patent applications have been, are and may in the future be, subject to challenges by ONT Ltd., Oxford Nanopore Technologies, Inc. ("ONT Inc.") and Metrichor, Ltd. (&#8220;Metrichor&#8221; and, together with ONT Ltd. and ONT Inc., &#8220;ONT&#8221;) in addition to other parties asserting prior invention by others or invalidity on various grounds, through proceedings, such as </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interferences</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, reexaminations, or opposition proceedings. Addressing these challenges to our intellectual property has been, and any future challenges can be, costly and distract management&#8217;s attention and resources. For example, we previously incurred significant legal expenses to litigate and settle a complaint seeking review of a patent interference decision of the U.S. Patent and Trademark Office. Additionally, ONT previously requested that the U.S. Patent and Trademark Office institute </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reviews of certain patents that we have asserted against ONT Inc. and ONT Ltd. in litigation proceedings for patent infringement. While none of the </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reviews requested by ONT were instituted by the U.S. Patent and Trademark Office, challenges of this nature before the Patent Trial and Appeal Board (&#8220;PTAB&#8221;) in the future could result in determinations that our patents or pending patent applications are unpatentable to us, or are invalidated or unenforceable in whole or in part and could require us to expend significant time, funds, and other resources in litigating such challenges. Accordingly, adverse rulings in such proceedings could negatively impact the scope of our intellectual property protection for our products and technology and could materially and adversely affect our business. Similar mechanisms for challenging the validity and enforceability of a patent exist in foreign patent offices and courts and may result in the revocation, cancellation, or amendment of any foreign patents we hold now or in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such products. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our technology is subject to &#8220;march-in&#8221; rights by the U.S. government.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our patented technology was developed with U.S. federal government funding. When new technologies are </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developed</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with U.S. government funding, the government obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise &#8220;march-in&#8221; rights to use or allow third parties to use our patented technology. The government can exercise its march-in rights if it determines that such action is necessary to (i) achieve practical application of the U.S. government-funded technology, (ii) alleviate health or safety needs, (iii) meet requirements of federal regulations, or (iv) give preference to U.S. industry. In addition, U.S. government-funded inventions must be reported to the government and such government funding must be disclosed in any resulting patent applications. Furthermore, our rights in such inventions are subject to government license rights and foreign manufacturing restrictions. The U.S. government has generally denied requests to exercise its march-in rights, even to provide access to potentially life-saving medications; however, if the U.S. government were to exercise its march-in rights to our patent technologies funded by the U.S. government, particularly for the benefit of one of more of our competitors, that may have a material adverse effect on our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are involved in legal proceedings to enforce our intellectual property rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property rights involve complex factual, scientific, and legal questions. We operate in an industry characterized by significant intellectual property litigation. Even though we may believe that we have a valid patent on a particular technology, other companies have from time to time taken, and may in the future take, actions that we believe violate our patent rights. For example, we were previously involved in legal proceedings with ONT and Harvard University in several United States and European jurisdictions. We have in the past received adverse rulings against us with respect to our complaint with the United States International Trade Commission for one of these proceedings. Legal actions to enforce our patent rights have been, and will continue to be, expensive, and may divert significant management time and resources. Adverse parties from previous legal actions have brought, and they and others may in the future bring, claims against us and/or our intellectual property. Litigation is a significant ongoing expense, recognized in sales, general and administrative expense, with an uncertain outcome, and has been, and may in the future be, a material expense for us. Our enforcement actions may not be successful, have given rise to legal claims against us and could result in some of our intellectual property rights being determined to be invalid or not enforceable. Furthermore, an adverse determination or judgement could lead to an award of damages against us, or the issuance of an injunction against us or our products that could prevent us from selling any products found to be infringing the intellectual property rights of another party.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been, are currently, and could in the future be, subject to legal proceedings with third parties who may claim that our products infringe or misappropriate their intellectual property rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are based on complex, rapidly developing technologies. We may not be aware of issued or previously filed patent applications that belong to third parties that mature into issued patents that cover some aspect of our products or their use. In addition, because patent litigation is complex and the outcome inherently uncertain, our belief that our products do not </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringe</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> third-party patents of which we are aware or that such third-party patents are invalid and unenforceable may be determined to be incorrect. As a result, third parties have claimed, and may in the future claim, that we infringe their patent rights and have filed, and may in the future file lawsuits or engage in other proceedings against us to enforce their patent rights. For example, we are involved in legal proceedings for alleged patent infringement and related matters in the United States with Personal Genomics of Taiwan, Inc. (&#8220;PGI&#8221;), Take2 Technologies, Ltd., and the Chinese University of Hong Kong. In addition, ONT Ltd. and Harvard University have, in the past, filed claims against us in the High Court of England and Wales and the District Court of Mannheim, Germany for patent infringement, and PGI has filed claims against us in the U.S. District Court for the District of Delaware and in the Wuhan People&#8217;s Court in China. We are aware of other issued patents and patent applications owned by third parties that could be construed to read on our products, and related maintenance and support services. Although we do not believe that our products or services infringe any valid issued patents, the third-party owners of these patents and applications may in the future claim that we infringe their patent rights and file lawsuits against us. In addition, as we enter new markets, our competitors and other third parties may claim that our products infringe their intellectual property rights as part of a business strategy to impede our successful entry into those markets. Furthermore, parties making claims against us may be able to obtain injunctive or other relief, which effectively could block our ability to further develop or commercialize products or services and could result in the award of substantial damages against us. Patent litigation between competitors in our industry is common. Additionally, we have certain obligations to many of our customers and suppliers to indemnify and defend them against claims by third parties that our products or their use infringe any intellectual property of these third parties. In defending ourselves against any of these claims, we have in the past incurred, and could in the future incur, to defend ourselves or our customers, substantial costs, and the attention of our management and technical personnel could be diverted. For example, we previously incurred significant legal expenses to litigate and settle a complaint alleging patent infringement. Even if we have an agreement that indemnifies us against such costs, the indemnifying party may be unable to uphold its contractual obligations. To avoid or settle legal claims, it may be necessary or desirable in the future to obtain licenses relating to one or more products or relating to current or future technologies, which could negatively affect our gross margins. We may not be able to obtain these licenses on commercially reasonable terms, or at all. We may be unable to modify our products so that they do not infringe the intellectual property rights of third parties. In some situations, the results of litigation or settlement of claims may require us to cease allegedly infringing activities which could prevent us from selling some or all of our products. The occurrence of these events may have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the course of our business, we may from time to time have access or be alleged to have access to confidential or proprietary information of others, which, though not patented, may be protected as trade secrets. Others could bring claims against us asserting that we improperly used their confidential or proprietary information, or that we misappropriated their technologies and incorporated those technologies into our products. A determination that we illegally used the confidential or proprietary information or misappropriated technologies of others in our products could result in us paying substantial damage awards or being prevented from further developing or selling some or all of our products, which could materially and adversely affect our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not yet registered some of our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. In addition, in the U.S. Patent and Trademark Office and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our use of &#8220;open source&#8221; software could adversely affect our ability to sell our products and subject us to possible litigation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the products or technologies developed and/or distributed by us incorporate &#8220;open source&#8221; software, and we may incorporate open source software into other products or technologies in the future. Some open source software licenses require that we disclose the source code for any modifications to such open source software that we make and distribute to one or more third parties, and that we license the source code for such modifications to third parties, including our competitors, at no cost. We monitor the use of open source software in our products to avoid uses in a manner that would require us to disclose or grant licenses under our source code that we wish to maintain as proprietary; however, there can be no assurance that such efforts have been or will be successful. In some circumstances, distribution of our software that includes or is linked with open source software could require that we disclose and license some or all of our proprietary source code in that software, which could include permitting the use of such software and source code at no cost to the user. Open source license terms are often ambiguous and there is little legal precedent governing the interpretation of these licenses. Successful claims made by the licensors of open source software that we have violated the terms of these licenses could result in unanticipated obligations, including being subject to significant damages, being enjoined from distributing products that incorporate open source software and being required to make available our proprietary source code pursuant to an open source license, which could substantially help our competitors develop products that are similar to or better than ours or otherwise materially and adversely affect our business.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Regulation</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are, and may become, subject to governmental regulations that may impose burdens on our operations, and the markets for our products may be narrowed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject, both directly and indirectly, to the adverse impact of government regulation of our operations and markets. For example, export of our instruments may be subject to strict regulatory control in a number of jurisdictions, and we could experience disruption in our supply chain as a result of certain geopolitical events and conflicts and any related political or economic responses and counter-responses or otherwise by various global actors. On January 15, 2025, the United States Department of Commerce&#8217;s Bureau of Industry and Security (&#8220;BIS&#8221;) issued an Interim Final Rule (&#8220;IFR&#8221;) implementing targeted export controls on certain analytical instruments that are highly suitable for generating large, detailed biological datasets based upon the potential to exploit these techniques for asymmetric military advantage. While the Company&#8217;s products would not be included under the current IFR, future BIS or other government regulations could potentially apply to our products and/or negatively impact our ability to export those products to certain countries and markets. Additionally, restrictions on the ability to send certain products and technology related to semiconductors, semiconductor manufacturing, and supercomputing to China continue to increase in both product and country scope and may impact our ability to provide products to customers or distributors worldwide. We have expanded and are continuing to expand the international jurisdictions into which we supply products, which increases the risks surrounding governmental regulations relating to our business. The need to or failure to satisfy export control criteria or to obtain necessary clearances could delay or prevent shipment of products, which could materially and adversely affect our revenue and profitability. Moreover, the life sciences industry, which is expected to continue to be one of the primary markets for our technology, has historically been heavily regulated. There are, for example, laws in several jurisdictions restricting research in genetic engineering, which may narrow our markets. Given the evolving nature of this industry, legislative bodies or regulatory authorities may adopt additional regulations that may adversely affect our market opportunities. Additionally, if ethical and other concerns surrounding the use of genetic information, diagnostics or therapies become widespread, there may be less demand for our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is also directly affected by a wide variety of government regulations applicable to business enterprises generally and to companies operating in the life science industry in particular. Failure to comply with government regulations or obtain or maintain necessary permits and licenses could result in a variety of fines or other censures or an interruption in our business operations which may have a negative impact on our ability to generate revenue and the cost of operating our business. In addition, changes to laws and government regulations could cause a material adverse effect on our business as we will need to adapt our business to comply with such changes. For example, a governmental prohibition on the use of human </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diagnostics or other regulations that negatively impact the research and development activities of our customers would adversely impact our commercialization of products on which we have expended significant research and development resources, which would in turn have a material adverse impact on our business and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products could become subject to government regulation as medical devices by the U.S. Food and Drug Administration or other domestic and international regulatory agencies even if we do not elect to seek regulatory clearance or approval to market our products for diagnostic purposes, which could increase our costs and impede or delay our commercialization efforts, thereby materially and adversely affecting our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are currently labeled and promoted as research use only (&#8220;RUO&#8221;) products and are not currently designed, or intended to be used, for clinical diagnostic tests or as medical devices. However, in the future, certain of our products or related applications, such as those that may be developed for clinical uses, could be subject to regulation by the FDA, or the FDA&#8217;s regulatory jurisdiction could be expanded to include our products. Also, even if our products are labeled, promoted, and intended as RUO, the FDA or comparable agencies of other countries could disagree with our conclusion that our products are intended for research use only or deem our sales, marketing and promotional efforts as being inconsistent with the FDA&#8217;s guidance on RUO products. For example, our customers may independently elect to use our RUO labeled products in their own LDTs for clinical diagnostic use, which could subject our products to government regulation, and the regulatory clearance or approval and maintenance process for such products may be uncertain, expensive, and time-consuming.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, in 2013, the FDA issued Final Guidance &#8220;Distribution of In Vitro Diagnostic Products Labeled for Research Use Only.&#8221; The guidance emphasizes that the FDA will review the totality of the circumstances when it comes to evaluating whether equipment and testing components are properly labeled as RUO. The final guidance states that merely including a labeling statement that the product is for research purposes only will not necessarily render the device exempt from the FDA&#8217;s clearance, approval, and other regulatory requirements if the circumstances surrounding the distribution, marketing and promotional practices indicate that the manufacturer knows its products are, or intends for its products to be, used for clinical diagnostic purposes. These circumstances may include written or verbal sales and marketing claims or links to articles regarding a product&#8217;s performance in clinical applications and a manufacturer&#8217;s provision of technical support for clinical applications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory requirements related to marketing, selling, and distribution of RUO products could change or be uncertain, even if clinical uses of our RUO products by our customers were done without our consent. If the FDA or other regulatory authorities assert that any of our RUO products are subject to regulatory clearance or approval, our business, financial condition, or results of operations could be adversely affected. In the event that we fail to obtain and maintain necessary regulatory clearances or approvals for products that we develop for clinical uses, or if clearances or approvals for future products and indications are delayed or not issued, our commercial operations may be materially harmed. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the product, which may limit the market for the product. We do not have experience in obtaining FDA approvals and no assurance can be given that we will be able to obtain or to maintain such approvals. Furthermore, any approvals that we may obtain can be revoked if safety or efficacy problems develop.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has historically exercised enforcement discretion in not enforcing the medical device regulations against laboratories developing and offering LDTs. In May 2024, the FDA issued a final rule that phases out its enforcement discretion for LDTs, unless exempt, and amends the FDA&#8217;s regulations to make explicit that in vitro diagnostics are medical devices under the FDCA, including when the manufacturer of the diagnostic product is a laboratory. The American Clinical Laboratory Association and a private laboratory have initiated litigation against the agency to challenge the implementation of this final rule. We will continue to evaluate the impact of this final rule, this litigation, as well as any future lawsuits brought against the FDA, and future legislative and administration actions on our business. Further, the U.S. Supreme Court recently overruled the </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chevron </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">doctrine, which gave deference to regulatory agencies&#8217; statutory interpretations in litigation against federal government agencies, such as the FDA, where the law is ambiguous. This landmark Supreme Court decision may invite various stakeholders to bring lawsuits against the FDA to challenge longstanding decisions of the FDA, which could undermine the FDA&#8217;s authority and lead to uncertainties in the industry. We cannot predict the full impact of this decision on our business or that of our customers. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future legislative or administrative actions can impact the sales of our products and how customers use our products, and may require us to change our business model in order to maintain compliance with applicable laws. Changes to the current regulatory framework, including the imposition of additional or new regulations, could arise at any time during the development or marketing of our products, which may negatively affect our ability to obtain or maintain FDA or comparable regulatory approval of our products, if required. Further, sales of devices for diagnostic purposes may subject us to additional healthcare regulation and enforcement by the applicable government agencies. Such laws include, without limitation, state and federal anti-kickback or anti-referral laws, healthcare fraud and abuse laws, false claims laws, privacy and security laws, Physician Payments Sunshine Act and related transparency and manufacturer reporting laws, and other laws and regulations applicable to medical device manufacturers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA determines our products or related applications should be subject to additional regulation as in vitro diagnostic devices based upon customers&#8217; use of our products for clinical diagnostic or therapeutic decision-making purposes, our ability to market and sell our products could be impeded and our business, prospects, results of operations and financial condition may be adversely affected. In addition, the FDA could consider our products to be misbranded or adulterated under the FDCA and subject to recall and/or other enforcement action.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">To the extent we elect to label and promote any of our products as medical devices, we would be required to obtain prior approval or clearance by the FDA or comparable foreign regulatory authority, which could take significant time and expense and could fail to result in a marketing authorization for the intended uses we believe are commercially attractive. Obtaining marketing authorization in one jurisdiction does not mean that we will be successful in obtaining marketing authorization in other jurisdictions where we conduct business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we elect to label and market our products for use as, or in the performance of, clinical diagnostics in the United States, thereby subjecting them to FDA regulation as medical devices, we would be required to obtain pre-market 510(k) clearance or pre-market approval from the FDA, unless an exception applies. It is possible, in the event we elect to submit 510(k) applications for certain of our products, that the FDA would take the position that a more burdensome pre-market application, such as a PMA or a </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> application is required for some of our products. If such applications were required, greater time and investment would be required to obtain FDA approval. Even if the FDA agreed that a 510(k) was appropriate, FDA clearance can be expensive and time consuming. It generally takes a significant amount of time to prepare a 510(k), including conducting appropriate testing on our products, and several months to years for the FDA to review a submission. Notwithstanding the effort and expense, FDA clearance or approval could be denied for some or all of our products for which we choose to market as a medical device or a clinical diagnostic device. Even if we were to seek and obtain regulatory approval or clearance, it may not be for the intended uses we request or that we believe are important or commercially attractive. There can be no assurance that future products for which we may seek pre-market clearance or approval will be approved or cleared by FDA or a comparable foreign regulatory authority on a timely basis, if at all, nor can there be assurance that labeling claims will be consistent with our anticipated claims or adequate to support continued adoption of such products. Compliance with FDA or comparable foreign regulatory authority regulations will require substantial costs, and subject us to heightened scrutiny by regulators and substantial penalties for failure to comply with such requirements or the inability to market our products. The lengthy and unpredictable pre-market clearance or approval process, as well as the unpredictability of the results of any required clinical studies, may result in our failing to obtain regulatory clearance or approval to market such products, which would significantly harm our business, results of operations, reputation, and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we sought and received regulatory clearance or approval for certain of our products, we would be subject to ongoing FDA obligations and continued regulatory oversight and review, including the general controls listed above and the FDA&#8217;s QSRs for our development and manufacturing operations. In addition, we would be required to obtain a new 510(k) clearance before we could introduce subsequent material modifications or improvements to such products. We could also be subject to additional FDA post-marketing obligations for such products, any or all of which would increase our costs and divert resources away from other projects. If we sought and received regulatory clearance or approval and are not able to maintain regulatory compliance with applicable laws, we could be prohibited from marketing our products for use as, or in the performance of, clinical diagnostics and/or could be subject to enforcement actions, including warning letters and adverse publicity, fines, injunctions, and civil penalties; recall or seizure of products; operating restrictions; and criminal prosecution.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if we decide to seek regulatory clearance or approval for certain of our products in countries outside of the United States or if a foreign regulatory authority determines that our products are regulated as medical devices, we would be subject to extensive medical device laws and regulations outside of the United States. Sales of such products outside the United States will likely be subject to foreign regulatory requirements, which can vary greatly from country to country. As a result, the time required to obtain clearances or approvals outside the United States may differ from that required to obtain FDA clearance or approval and we may not be able to obtain foreign regulatory approvals on a timely basis or at all. In Europe, we would need to comply with the Medical Device Regulation 2017/745 and In Vitro Diagnostic Regulation 2017/746, which could make obtaining regulatory approvals in Europe more challenging. In addition, the FDA regulates exports of medical devices. The number and scope of these requirements are increasing. Unlike many of the other companies offering nucleic acid sequencing equipment or consumables, this is an area where we do not have expertise. We, or our other third-party sales and distribution partners, may not be able to obtain regulatory approvals in such countries or may incur significant costs in obtaining or maintaining our foreign regulatory approvals. In addition, the export by us of certain of our products, which have not yet been cleared for domestic commercial distribution, may be subject to FDA or other export restrictions. Failure to comply with these regulatory requirements or obtain and maintain required approvals, clearances and certifications could impair our ability to commercialize our products for diagnostic use outside of the United States. Any action brought against us for violations of these laws or regulations, even if successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business.</span></div><div style="margin-top:9pt;text-align:justify"><span id="i1c82068fb4244bd4a402f417590b7e43_587936"></span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enhanced trade tariffs, import restrictions, export restrictions, or other trade barriers may materially harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to expand our international operations as part of our growth strategy and have experienced an increasing concentration of sales in certain regions outside the United States, especially the Asia-Pacific region, as discussed above. There is currently significant uncertainty about the future relationship between the United States and various other countries, most significantly China, with respect to trade policies, treaties, government regulations and tariffs. Starting in September 2018, the U.S. Trade Representative (the &#8220;USTR&#8221;) enacted various tariffs ranging from 7.5% to 25% on the import of Chinese products, including non-U.S. components and materials that may be used in our products. Since that time, USTR has enacted further tariff increases on certain Chinese products, in some instances raising the additional tariffs on these projects to up to 100%. In February 2025, the U.S. government also enacted an additional 10% ad valorem tariff on almost all imports of Chinese-origin goods, and in March 2025, this tariff was further escalated to 20% ad valorem. Additionally, China also has imposed tariffs on imports into China from the United States. These tariffs have and could continue to raise our costs. Furthermore, tariffs, trade restrictions, or trade barriers that have been, and may in the future be, placed on products such as ours by foreign governments, especially China, have raised, and could further raise, amounts paid for some or all of our products, which may result in the loss of customers and our business, and our financial condition and results of operations may be harmed. In February 2025, the Trump Administration also announced new 25% tariffs on imports from Canada and Mexico, which were temporarily suspended subject to further negotiations, and partially implemented with respect to goods not eligible for duty-free import under the U.S.-Mexico-Canada Agreement as of March 2025. U.S. tariffs of 25% have also been implemented on a wider array of imported steel and aluminum items as of March 2025. Additional tariffs on a wider range of countries may be forthcoming. Further tariffs may be imposed that could cover imports of additional components and materials used in our products, including for example semiconductor chips, or our business may be adversely impacted by retaliatory trade measures taken by China, Canada, the EU, or other countries, including restricted access to components or materials used in our products or increased amounts that must be paid for our products, which could materially harm our business, financial condition, and results of operations. We may be unable to make changes in our supply chain quickly enough to avoid the impact of new or potential tariffs. Uncertainty regarding the scope and amount of potential additional tariffs may also result in disruptions in our supply chain, particularly if such changes in applicable or potential tariffs makes current or planned production unprofitable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the U.S. government has continued to increase controls imposed in 2022 restricting the ability to send certain products and technology related to semiconductors, semiconductor manufacturing, and supercomputing. In 2023 and 2024, the U.S. government expanded the list of advanced integrated circuits subject to heightened export controls, including certain hardware containing these specified integrated circuits, expanded the list of destinations requiring export authorization for such items, and added new restrictions based on the headquarters location of the parties involved. As of May 2025, regulations would further expand the controls to impose a worldwide licensing requirement. In many cases, these licenses are subject to a policy of denial and will not be issued. These existing and future controls may impact our ability to export certain products to customers or distributors in China or other locations and restrict our ability to use certain integrated circuits in our products. The U.S. government also continues to add additional entities in China and other countries to restricted party lists impacting the ability of U.S. companies to provide items to these entities. Moreover, in November 2018, the U.S. Commerce Department&#8217;s Bureau of Industry and Security (&#8220;BIS&#8221;) released an advance notice of proposed rulemaking to control the export of emerging technologies. This notice included &#8220;[b]iotechnology, including nanobiology; synthetic biology; genomic and genetic engineering; or neurotech&#8221; as possible areas of increased export controls. Since 2018, the U.S. government has continued to provide updated lists of emerging technologies subject to national security consents. These lists continue to include biotechnologies including &#8220;[g]enome and protein engineering including design tools&#8221; and &#8220;[b]iomanufacturing and bioprocessing technologies.&#8221; Therefore, it is possible that our ability to export our products to customers or distributors may be further restricted in the future. For example, on January 15, 2025, BIS issued an IFR implementing targeted export controls on certain analytical instruments that are highly suitable for generating large, detailed biological datasets based upon the potential to exploit these techniques for asymmetric military advantage. While the Company&#8217;s products would not be included under the current IFR, future BIS or other government regulations could potentially apply to our products and/or negatively impact our ability to export those products to certain countries and markets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chinese government has introduced retaliatory measures in response to existing or future U.S. export controls, tariffs and other trade restrictions and it is possible that the Chinese or U.S. governments will implement additional retaliatory measures which could impact our business. For example, in December 2024, China announced a new export control regime that includes stringent export controls</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on exports of germanium and gallium, and in February 2025 implemented additional export controls regulating the export of resources including tungsten, tellurium, bismuth, indium, and molybdenum. It also is possible that additional restrictions will be put in place that could impact our ability to provide our products to customers or distributors in China or source components from China. The continued threats of tariffs, trade restrictions and trade barriers could have a generally disruptive impact on the global economy and, therefore, negatively impact our sales. Given the relatively fluid regulatory environment in China and the United States and uncertainty how the U.S. or foreign governments will act with respect to export controls, tariffs, international trade agreements and policies, there could be additional tax or other regulatory changes in the future. Any such changes could directly and adversely impact our financial results and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our international business could expose us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Engaging in international business inherently involves a number of difficulties and risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">required compliance with existing and changing foreign regulatory requirements and laws that are or may be applicable to our business in the future, such as the European Union&#8217;s General Data Protection Regulation (&#8220;GDPR&#8221;), the UK General Data Protection Regulation and other data privacy requirements, labor and employment regulations, anti-competition regulations, the U.K. Bribery Act of 2010 and other anti-corruption laws, regulations relating to the use of certain hazardous substances or chemicals in commercial products, and require the collection, reuse, and recycling of waste from products we manufacture;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">required compliance with U.S. laws such as the Foreign Corrupt Practices Act, and other U.S. federal laws and trade and economic sanctions and other regulations established by the Office of Foreign Asset Control;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">export requirements and import or trade restrictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">laws and business practices favoring local companies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">restrictions on both inbound and outbound cross-border investment;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">foreign currency exchange, longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in social, economic, and political conditions or in laws, regulations and policies governing foreign trade, manufacturing, research and development, and investment both domestically as well as in the other countries and jurisdictions in which we operate and into which we may sell our products including as a result of ongoing geopolitical tensions related to the political uncertainty and military actions associated with the war in Ukraine, resulting sanctions imposed by the U.S. and other countries, and retaliatory actions taken by Russia in response to such sanctions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements, and other trade barriers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties and costs of staffing and managing foreign operations; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties protecting, maintaining, enforcing, or procuring intellectual property rights and defending against intellectual property claims under the law and judicial systems of other countries.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If one or more of these risks occurs, it could require us to dedicate significant resources to remedy such occurrence, and if we are unsuccessful in finding a solution, our financial results will suffer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations involve the use of hazardous materials, and we must comply with environmental, health and safety laws, which can be expensive and may adversely affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development and manufacturing activities involve the use of hazardous materials, including chemicals and biological materials, and some of our products include hazardous materials. Accordingly, we are subject to federal, state, local and foreign laws, regulations, and permits relating to environmental, health and safety matters, including, among others, those governing the use, storage, handling, exposure to and disposal of hazardous materials and wastes, the health and safety of our employees, and the shipment, labeling, collection, recycling, treatment, and disposal of products containing hazardous materials. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence. For example, under certain circumstances and under certain environmental laws, we could be held liable for costs relating to contamination at our or our predecessors&#8217; past or present facilities and at third-party waste disposal sites. We could also be held liable for damages arising out of human exposure to hazardous materials. There can be no assurance that violations of environmental, health and safety laws will not occur as a result of human error, accident, equipment failure or other causes. The failure to comply with past, present or future laws could result in the imposition of substantial fines and penalties, remediation costs, property damage and personal injury claims, investigations, the suspension of production or product sales, loss of permits or a cessation of operations. Any of these events could harm our business, operating results, and financial condition. We also expect that our operations will be affected by new environmental, health and safety laws and regulations on an ongoing basis, or more stringent enforcement of existing laws and regulations. New laws or changes to existing laws may result in additional costs and may increase penalties associated with violations or require us to change the content of our products or how we manufacture them, which could have a material adverse effect on our business, operating results, and financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ethical, legal, privacy, data protection and social concerns or governmental restrictions surrounding the use of genetic information could reduce demand for our technology.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products may be used to provide genetic information about humans, agricultural crops and other living organisms. The information obtained from our products could be used in a variety of applications which may have underlying ethical, legal, privacy, data protection and social concerns, including the genetic engineering or modification of agricultural products or testing for genetic predisposition for certain medical conditions. Governmental authorities could, for safety, social or other purposes, call for limits on or regulation of the use of genetic testing, and may consider or adopt such regulations or other restrictions. Such concerns or governmental restrictions could limit the use of our products or be costly and burdensome to comply with, and actual or perceived violations of any such restrictions may lead to the imposition of substantial fines and penalties, remediation costs, claims and litigation, regulatory investigations and proceedings, and other liability, any of which could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulations related to conflict minerals has caused us to incur, and will continue to cause us to incur, additional expenses and could limit the supply and increase the costs of certain materials used in the manufacture of our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to requirements under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 that require us to conduct diligence and report on whether or not our products contain conflict minerals. These requirements could adversely affect the sourcing, availability and pricing of the materials used in the manufacture of components used in our products. Furthermore, the complex nature of our products requires components and materials that may be available only from a limited number of sources and, in some cases, from only a single source. We have incurred, and will continue to incur, additional costs to comply with the disclosure requirements, including costs related to conducting diligence procedures to determine the sources of conflict minerals that may be used or necessary to the production of our products and, if applicable, potential changes to components, processes, or sources of supply as a consequence of such verification activities. We may face reputational harm if we determine that certain of our products contain minerals that are not determined to be conflict free or if we are unable to alter our processes or sources of supply to avoid using such materials. In such circumstances, the reputational harm could materially and adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Owning Our Common Stock</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been, is, and may continue to be, highly volatile, and you may be unable to sell your shares at or above the price you paid to acquire them.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock is highly volatile, and we expect it to continue to be volatile for the foreseeable future in response to many risk factors listed in this section, and others beyond our control, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">actual or anticipated fluctuations in our financial condition and operating results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">announcements of new products, technological innovations or strategic partnerships by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">announcements by us, our customers, partners, or suppliers relating directly or indirectly to our products, services or technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">overall conditions in our industry and market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">addition or loss of significant customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in laws or regulations applicable to our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">actual or anticipated changes in our growth rate relative to our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, capital commitments or achievement of significant milestones;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">additions or departures of key personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">competition from existing products or new products that may emerge;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">issuance of new or updated research or reports by securities analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">disputes or other developments related to proprietary rights, including patents, litigation matters or our ability to obtain intellectual property protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">sales of our common stock by us or our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">stock price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">reports, guidance and ratings issued by securities or industry analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">operating results below the expectations of securities analysts or investors; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">general economic and market conditions, which could be impacted by various events including health epidemics or pandemics, interest rate fluctuations, increases in fuel prices, foreign currency fluctuations, changing international trade policies, acts of terrorism, hostilities or the perception that hostilities may be imminent, military conflict and acts of war, including further political uncertainty and military actions associated with the war in Ukraine and the related response, including sanctions or other restrictive actions, by the United States and/or other countries.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the forgoing occurs, it would cause our stock price or trading volume to decline. Stock markets in general and the market for companies in our industry in particular have experienced price and volume fluctuations; these fluctuations have been, and may continue to be, exacerbated by current macroeconomic trends and geopolitical events. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market price of our common stock. You may not realize any return on your investment in us and may lose some or all of your investment. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We have been a party to this type of litigation in the past and may be the target of this type of litigation again in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could reduce the market price that our common stock might otherwise attain and may dilute your voting power and your ownership interest in us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales could occur, could adversely affect the market price of our common stock and may make it more difficult for existing stockholders to sell their common stock at a time and price that they deem appropriate and may dilute their voting power and ownership interest in us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our stockholders sell, or indicate an intent to sell, a large number of shares of our common stock in the public market, it could cause our stock price to fall, particularly if such sales occur over a short period of time (for example, following delivery of shares upon achievement of milestones in our acquisition agreements). We may also issue shares of common stock or securities convertible into our common stock in connection with a financing, acquisition, our equity incentive plans, or otherwise. Any such issuances would result in dilution to our existing stockholders and the market price of our common stock may be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of ownership by our principal stockholders may result in control by such stockholders of the composition of our board of directors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our existing principal stockholders, holders of Notes, executive officers, directors, and their affiliates beneficially own, or following conversion of the Notes could own, a significant number of our outstanding shares of common stock. In addition, such parties may acquire additional control by purchasing stock that we issue in connection with our future fundraising efforts. These parties may now and in the future be able to exercise a significant level of control over all matters requiring stockholder approval, including the election of directors. This control could have the effect of delaying or preventing a change of control of our company or changes in management and will make the approval of certain transactions difficult or impossible without the support of these stockholders.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management and limit the market price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may have the effect of delaying or preventing a change of control or changes in our management. Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">authorize our board of directors to issue, without further action by the stockholders, up to 50,000,000 shares of undesignated preferred stock and up to approximately 1,000,000,000 shares of authorized but unissued shares of common stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">specify that special meetings of our stockholders can be called only by our board of directors, the Chair of the Board, the Chief Executive Officer or the President;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">establish advance notice procedures for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered terms (until our board of directors is fully declassified beginning with the 2027 annual meeting of stockholders);</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">provide that our directors may be removed only for cause; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated bylaws designate a state or federal court located within the State of Delaware as the exclusive forum for certain stockholder litigation matters, and also provide that the federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, each of which could limit our stockholders&#8217; ability to choose the judicial forum for disputes with us or our directors, officers, stockholders, or employees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) will, to the fullest extent permitted by law, be the sole and exclusive forum for: (i) any derivative action or proceeding brought on our behalf&#894; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, stockholders, officers, or other employees to us or our stockholders&#894; (iii) any action arising pursuant to any provision of the Delaware General Corporation Law; (iv) any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws&#894; or (v) any action asserting a claim governed by the internal affairs doctrine, except as to each of (i) through (v) above, for any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated bylaws also provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act including, without limitation and for the avoidance of doubt, any auditor, underwriter, expert, control person or other defendant.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any person or entity purchasing, holding or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to the foregoing bylaw provisions. Although we believe these exclusive forum provisions benefit us by providing increased consistency in the application of Delaware law and federal securities laws in the types of lawsuits to which each applies, the exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum of its choosing for disputes with us or any of our directors, stockholders, officers or other employees, which may discourage lawsuits with respect to such claims against us and our current and former directors, stockholders, officers or other employees. In addition, a stockholder that is unable to bring a claim in the judicial forum of its choosing may be required to incur additional costs in the pursuit of actions which are subject to the exclusive forum provisions described above. Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder as a result of our exclusive forum provisions. Further, in the event a court finds either exclusive forum provision contained in our bylaws to be unenforceable or inapplicable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our large number of authorized but unissued shares of common stock may potentially dilute existing stockholders&#8217; stockholdings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a significant number of authorized but unissued shares of common stock. Our board of directors may issue shares of common stock from this authorized but unissued pool from time to time without stockholder approval, resulting in the dilution of our existing stockholders.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends for the foreseeable future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any dividends on our common stock and do not intend to pay any dividends in the foreseeable future. We anticipate that we will retain all of our future earnings for use in the operation of our business and for general corporate purposes. Any determination to pay dividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Our Notes</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not have the ability to raise the funds necessary to settle conversions of the Notes in cash or to repurchase the Notes upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had outstanding approximately $200.0&#160;million aggregate principal amount of our 2029 Notes and $441.0&#160;million aggregate principal amount of our 2030 Notes. The 2029 Notes will mature on August 15, 2029, subject to earlier conversion, redemption or repurchase, including upon a fundamental change. The 2030 Notes will mature on December 15, 2030, subject to earlier conversion, redemption or repurchase, including upon a fundamental change. The 2029 Notes and the 2030 Notes are collectively referred to as the Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of each series of Notes will have the right to require us to repurchase all or a portion of their Notes upon the occurrence of a fundamental change before the maturity date at a repurchase price equal to 100% of the principal amount of the Notes of the applicable series to be repurchased, plus unpaid interest to, but excluding, the applicable maturity date. In addition, upon conversion of the Notes of a series, unless we elect to deliver solely shares of our common stock to settle such conversion (other than paying cash in lieu of delivering any fractional share), we will be required to settle a portion or all of our conversion obligation in cash in respect of the Notes being converted. Moreover, we will be required to repay the Notes of the applicable series in cash at the applicable maturity unless earlier converted, redeemed, or repurchased. However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of Notes surrendered therefor or pay cash with respect to Notes being converted or at their maturity.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ability to repurchase the Notes or to pay cash upon conversions of Notes or at the applicable maturity may be limited by law, regulatory authority or agreements governing our future indebtedness. Our failure to repurchase Notes of a series at a time when the repurchase is required by the applicable indenture or to pay cash upon conversions such Notes or at the applicable maturity as required by the applicable indenture would constitute a default under such indenture. A default under either indenture or the occurrence of a fundamental change under either indenture itself could also lead to a default under agreements governing our future indebtedness. Moreover, the occurrence of a fundamental change under either indenture could constitute an event of default under any such agreement. If the payment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness or to pay cash amounts due upon conversion, upon required repurchase or at maturity of the applicable series of Notes.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Side Letter to our 2029 Notes imposes operating restrictions on us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 21, 2024, in connection with the issuance of the 2029 Notes, the Company and SB Northstar LP (&#8220;SBN&#8221;) entered into a letter agreement (the &#8220;Letter Agreement&#8221;) pursuant to which the Company and SBN agreed that, for so long as SBN and its affiliates hold at least $180 million aggregate principal amount of the 2029 Notes, the Company and its subsidiaries are subject to certain negative covenants that restrict the Company&#8217;s and its subsidiaries&#8217; ability to incur additional indebtedness and create liens, in each case, subject to the exceptions set forth in the Letter Agreement, including exceptions which permit the Company to incur up to $75 million in aggregate principal amount of secured indebtedness pursuant to Credit Facilities (as defined in the Letter Agreement).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Letter Agreement restricts the ability of the Company and its subsidiaries from guaranteeing any indebtedness or incurring certain indebtedness outside of the ordinary course of business unless, in each case, the Company and its subsidiaries concurrently provide a guarantee of the Company&#8217;s obligations under the 2029 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These covenants may adversely affect our ability to finance our operations, meet or otherwise address our capital needs, pursue business opportunities or react to market conditions, or otherwise restrict our activities or business plans. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A breach of any of the covenants under the Letter Agreement could result in an event of default under the 2029 Notes. As of December 31, 2024, we were in compliance with all covenants under the Letter Agreement. However, if an event of default occurs, SBN could accelerate our obligations under the 2029 Notes. Any such acceleration could result in an event of default under our other indebtedness, including the 2030 Notes.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the Notes are converted, it may adversely affect our financial condition and operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of either series of Notes are entitled to convert their respective series of Notes at any time at their option. If one or more holders elect to convert the Notes of the applicable series, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation in cash, which could adversely affect our liquidity. In addition, issuances of shares of common stock upon conversion of our Notes could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. The existence of the Notes may encourage short selling by market participants because the conversion of the Notes could depress the price of our common stock. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">General Risk Factors</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General conditions in the global economy and in the global financial markets could adversely affect our results of operations, and the overall demand for nucleic acid sequencing products may be particularly vulnerable to unfavorable economic conditions. A global financial crisis, inflation or a global or regional political disruption, as well as acts of terrorism, hostilities, military conflict and acts of war, including any further escalation of the conflict in the Middle East and the war in Ukraine, as well as the related responses, could cause extreme volatility in the capital and credit markets. A severe or prolonged economic downturn or political disruption could result in a variety of risks to our business, including weakened demand for our products and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our product and services. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment in value of our tangible or intangible assets could also be recorded as a result of weaker economic conditions. </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business. For more information on impairment considerations, see &#8220;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i1c82068fb4244bd4a402f417590b7e43_665655">&#8212;The commercialization and sales of our current or future products may be unsuccessful or less successful than anticipated. While we plan to continue pursuing new products and expand into adjacent markets, we have limited experience in managing and selling multiple products and, as a result, may face challenges selling in new markets and fail to successfully carry out these initiatives, which may adversely impact our business, financial condition or results of operation.</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; above.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delivery of our products could be delayed or disrupted by factors beyond our control, and we could lose customers as a result.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party carriers for the timely delivery of our products. As a result, we are subject to carrier disruptions and increased costs that are beyond our control. Any failure to deliver products to our customers in a safe and timely manner may damage our reputation and brand and could cause us to lose customers. If our relationship with any of these third-party carriers is terminated or impaired or if any of these carriers are unable to deliver our products, the delivery of our products by our customers may be delayed, which could harm our business and financial results. The failure to deliver our products in a safe and timely manner may harm our relationship with our customers, increase our costs and otherwise disrupt our operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Doing business internationally creates operational and financial risks for our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently conduct operations in various countries and jurisdictions, and continue to expand to new international jurisdictions as part of our growth strategy and have experienced an increasing concentration of sales in certain regions outside the U.S. We sell directly and through distribution partners throughout Europe, the Asia-Pacific region, Mexico, Brazil, and South Africa and have a significant portion of our sales and customer support personnel in Europe and the Asia-Pacific region. As a result, we or our distribution partners may be subject to additional regulations and increased diversion of management time and efforts. Conducting and launching operations on an international scale requires close coordination of activities across multiple jurisdictions and time zones and consumes significant management resources. If we fail to coordinate and manage these activities effectively, our business, financial condition or results of operations could be materially and adversely affected and failure to comply with laws and regulations applicable to business operations in foreign jurisdictions may also subject us to significant liabilities and other penalties. International operations entail a variety of other risks, including, without limitation:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">challenges in staffing and managing foreign operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">potentially longer sales cycles and more time required to engage and educate customers on the benefits of our platform outside of the United States;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the potential need for localized software and documentation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">reduced protection for intellectual property rights in some countries and practical difficulties of enforcing intellectual property and contract rights abroad;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">defending against intellectual property claims in other countries;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">restrictions on both inbound and outbound cross-border investment, including enhanced oversight by the Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;) and substantial restrictions on investment from China;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">U.S. and foreign government trade restrictions, including those which may impose restrictions on the importation, exportation, re-exportation, sale, shipment or other transfer of programming, technology, components, and/or services to foreign persons;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in diplomatic and trade relationships, including new tariffs, trade protection measures, import or export licensing requirements, trade embargoes, sanctions, and other trade barriers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">tariffs imposed by the U.S. on goods from other countries and tariffs imposed by other countries on U.S. goods, which may be imposed on products such as ours, the scope and duration of which, if implemented, remains uncertain;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">deterioration of political relations among, between, and within the U.S., Russia, China, Japan, Korea, Mexico, Canada, the United Kingdom (&#8220;U.K.&#8221;), and the European Union ("E.U."), which could have a material adverse effect on our sales and operations in these countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in social, political, and economic conditions or in laws, regulations and policies governing foreign trade, manufacturing, development, and investment both domestically as well as in the other countries and jurisdictions into which we sell our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties in obtaining export licenses or in overcoming other trade barriers and restrictions resulting in delivery delays;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">fluctuations in currency exchange rates and the related effect on our results of operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">increased financial accounting and reporting burdens and complexities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">potential limits to travel as a result of epidemics or pandemics;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">disruptions to global trade due to disease outbreaks or conflicts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">potential increases on tariffs or restrictions on trade generally; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">significant taxes or other burdens of complying with a variety of foreign laws and regulations, including laws and regulations relating to privacy and data protection such as the E.U. General Data Protection Regulation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conducting our international operations, we are subject to U.S. laws relating to our international activities, such as the Foreign Corrupt Practices Act of 1977, as well as foreign laws relating to our activities in other countries, such as the United Kingdom Bribery Act of 2010. Additionally, the inclusion of one of our foreign customers on any applicable U.S. Government sanctioned persons list, including but not limited to the U.S. Department of Commerce&#8217;s List of Denied Persons and the U.S. Department of Treasury&#8217;s List of Specially Designated Nationals and Blocked Persons List, could be material to our earnings. Failure to comply with these laws may subject us to claims or financial and/or other penalties in the United States and/or foreign countries that could materially and adversely impact our operations or financial condition. These risks have become increasingly prevalent as we have expanded our sales into countries that are generally recognized as having a higher risk of corruption.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks related to the current global economic environment, which could delay or prevent our customers from purchasing our products, which could in turn harm our business, financial condition, and results of operations. The state of the global economy continues to be uncertain. The current global economic conditions and uncertain credit markets and concerns regarding the availability of credit pose a risk that could impact customer demand for our products, as well as our ability to manage normal commercial relationships with our customers, suppliers, and creditors, including financial institutions. If the current global economic environment deteriorates, our business could be negatively affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, changes in the value of the relevant currencies may affect the cost of certain items required in our operations. Changes in currency exchange rates may also affect the relative prices at which we are able to sell products in the same market. Our revenue from international customers may be negatively impacted as increases in the U.S. dollar relative to our international customers&#8217; local currencies could make our products more expensive, impacting our ability to compete or as a result of financial or other instability in such locations which could result in decreased sales of our products. Our costs of materials from international suppliers may also increase as the value of the U.S. dollar decreases relative to their local currency. Foreign policies and actions regarding currency valuation could result in actions by the United States and other countries to offset the effects of such fluctuations. Such actions may materially and adversely impact our financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of complex foreign and U.S. laws and regulations could result in fines and penalties, criminal sanctions against us, our officers, or our employees, prohibitions on the conduct of our business and on our ability to offer our products and services in one or more countries, and could also materially affect our brand, our international growth efforts, our ability to attract and retain employees, our business, and our operating results. Even if we implement policies or procedures designed to ensure compliance with these laws and regulations, there can be no assurance that our distribution partners, our employees, contractors, or agents will not violate our policies and subject us to potential claims or penalties.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, which would adversely affect our business and our stock price.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that we have adequate internal financial and accounting controls and procedures in place to produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be evaluated frequently. We may in the future discover areas of our internal financial and accounting controls and procedures that need improvement. Operating as a public company requires sufficient resources within the accounting and finance functions in order to produce timely financial information, ensure the level of segregation of duties, and maintain adequate internal control over financial reporting customary for a U.S. public company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within our company will have been detected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404 of the Sarbanes-Oxley Act, we perform periodic evaluations of our internal control over financial reporting. While we have in the past performed this evaluation and concluded that our internal control over financial reporting was operating effectively, there can be no assurance that in the future material weaknesses or significant deficiencies will not exist or otherwise be discovered. In addition, if we are unable to produce accurate financial statements on a timely basis, investors could lose confidence in the reliability of our financial statements, which could cause the market price of our common stock to decline and make it more difficult for us to finance our operations and growth.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively impacted by changes in the United States political environment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products depend on the availability of genetic data and its utilization in clinical research by academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, CROs, pharmaceutical companies, and agricultural companies. As a result, changes in the regulatory environment affecting such institutions could adversely affect our business or results of operations. For example, reduced allocations to government agencies that fund research and development activities, such as the recent announcements regarding NIH funding involving a cap on the institute&#8217;s indirect funding rates, or targeted cancellations by the U.S. federal government of certain grants or contracts may significantly impact the markets in which we compete.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant ongoing uncertainty with respect to potential legislation, regulation and government policy at the federal level, as well as the state and local levels. Specific legislative and regulatory proposals discussed during election campaigns and more recently that might materially impact us include, but are not limited to, changes to spending priorities and potential reductions in research funding. Uncertainty about U.S. government funding has posed, and may continue to pose, a risk as customers may choose to postpone or reduce spending in response to actual or anticipated restraints on funding. To the extent changes in the political environment have a negative impact on us or on our markets, our business, results of operation and financial condition could be materially and adversely impacted in the future.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruption of critical information technology systems or material breaches in the security of our systems could harm our business, customer relations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information technology (&#8220;IT&#8221;) helps us to operate efficiently, interface with customers, maintain financial accuracy and efficiently and accurately produce our financial statements. IT systems are used extensively in virtually all aspects of our business, including in our products, sales forecast, order fulfillment and billing, customer service, logistics, and management of data from running samples on our products. Our success depends, in part, on the continued and uninterrupted performance of our IT systems. Our IT systems, including those used in our products, may be vulnerable to damage from a variety of sources, including telecommunications or network failures, power loss, natural disasters, human acts, computer viruses, ransomware, computer denial-of-service attacks, unauthorized access to customer or employee data or company trade secrets, and other attempts to harm our systems. Furthermore, there may be a heightened risk of potential cybersecurity incidents and security breaches to which we could be vulnerable by state-sponsored or affiliated actors or others in connection with political uncertainty and conflict in the Middle East and the war in Ukraine. Certain of our systems are not redundant, and our disaster recovery planning is not sufficient for every eventuality. Despite any precautions we may take, such problems could result in, among other consequences, disruption of our operations, which could harm our reputation and financial results. Some of our IT infrastructure still utilizes outdated legacy systems, software and hardware, some of which may be approaching end-of-life or end of support, and that may be particularly susceptible to cybersecurity breaches, errors and operational failures. Upgrading, replacing and enhancing such infrastructure may be expensive and put the continuity of our operations at risk while a failure to do so may make us more susceptible to the risks discussed above.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not allocate and effectively manage the resources necessary to build and sustain the proper IT infrastructure, including those used in our products, we could be subject to transaction errors, processing inefficiencies, loss of customers, business disruptions or loss of or damage to intellectual property. If our data management systems do not effectively collect, store, process and report relevant data for the operation of our business, whether due to equipment malfunction or constraints, software deficiencies or human error, our ability to effectively plan, forecast and execute our business plan and comply with applicable laws and regulations will be impaired, perhaps materially. Any such impairment could materially and adversely affect our reputation, financial condition, results of operations, cash flows and the timeliness with which we report our internal and external operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, our proprietary business information and that of our customers, suppliers and business partners, and personal information of our customers and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our IT infrastructure may be vulnerable to attacks by hackers, computer viruses, malicious codes, ransomware, unauthorized access attempts, and cyber- or phishing-attacks, or breached or otherwise disrupted due to employee error, malfeasance, faulty password management or other disruptions. Third parties may attempt to fraudulently induce employees or other persons into disclosing usernames, passwords or other sensitive information, which may in turn be used to access our IT systems, commit identity theft or carry out other unauthorized or illegal activities. Any such breach or incident could compromise our systems and networks and the information stored or otherwise processed there could be accessed, publicly disclosed, lost, stolen or otherwise processed in an unauthorized manner. We engage third-party vendors and service providers to store and otherwise process some of our data, including sensitive and personal information. Our vendors and service providers may also be the targets of the risks described above, including cyber-attacks, malicious software, ransomware, phishing schemes, and fraud. Our ability to monitor our vendors and service providers&#8217; data security is limited, and, in any event, third parties may be able to circumvent those security measures, resulting in the unauthorized access to, misuse, disclosure, loss or destruction of our data, including sensitive and personal information, and disruption of our or our third-party service providers&#8217; systems. We and our third-party service providers may face difficulties in identifying, or promptly responding to, potential security breaches and other instances of unauthorized access to, or disclosure, other processing, or loss or unavailability of, information. Any hacking or other attack on our or our third-party service providers&#8217; or vendors&#8217; systems, and any unauthorized access to, or disclosure, other processing, or loss or unavailability of, information suffered by us or our third-party service providers or vendors, or the perception that any of these have occurred, could result in legal claims or proceedings, loss of intellectual property, liability under laws that protect the privacy of personal information, negative publicity, disruption of our operations and damage to our reputation, and data integrity issues, which could divert our management&#8217;s attention from the operation of our business and materially and adversely affect our business, revenues and competitive position. Moreover, we may need to increase our efforts to train our personnel to detect and defend against cyber- or phishing-attacks, which are becoming more sophisticated and frequent, and we may need to implement additional protective measures to reduce the risk of potential security breaches and security incidents, which could cause us to incur significant additional expenses. Retaliatory acts by Russia in response to Western sanctions or otherwise in connection with the war in Ukraine could include cyber-attacks that could disrupt the economy generally or that may either directly or indirectly impact our operations specifically.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our insurance may be insufficient to cover our losses resulting from cyber-attacks, breaches, or other interruptions, and any incidents may result in loss of, or increased costs of, such insurance. The successful assertion of one or more large claims against us that exceed available insurance coverage, the occurrence of changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, or denials of coverage, could have a material adverse effect on our business, including our financial condition, results of operations and reputation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our use of artificial intelligence and machine learning technologies may result in reputational harm or liability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incorporated and may continue to incorporate additional artificial intelligence and machine learning, or AIML, technologies into our sequencing platforms, marketing programs, and analysis software, and these solutions and features are advantageous to describing, enhancing, and maximizing the capabilities of our differentiated technologies and to our future growth over time. We rely and expect to rely on AIML technologies such as basecalling, variant calling, epigenetic analysis and tertiary analysis, but there can be no assurance that we will realize the desired or anticipated benefits from AIML or any at all. We may also fail to properly implement or utilize AIML technologies. Our competitors or other third parties may incorporate AIML into their products, platforms, software and services or otherwise within their business more quickly or more successfully than us, which could impair our ability to compete effectively and adversely affect our results of operations. Additionally, our use of AIML technologies may expose us to additional claims, demands and proceedings by private parties and regulatory authorities and subject us to legal liability as well as brand and reputational harm. For example, if output from AIML technologies or that they assist in producing are or are alleged to be deficient, inaccurate, or biased, or for such output, or such technologies or their development or deployment, including the collection, use, or other processing of data used to train or create such AIML technologies, to alleged to infringe upon or to have misappropriated third-party intellectual property rights or to violate applicable laws, regulations, or other actual or asserted legal obligations to which we are or may become subject, then our business, financial condition, and results of operations may be adversely affected. The legal, regulatory, and policy environments around AIML are evolving rapidly, and we may become subject to new and evolving legal and other obligations. These and other developments may require us to make significant changes to our use of AIML, including by limiting or restricting our use of AIML, and may require us to make significant changes to our policies and practices, which may necessitate expenditure of significant time, expense, and other resources. AIML also presents emerging ethical issues, and if our use of AIML becomes controversial, we may experience brand or reputational harm.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to, and may in the future become subject to additional, U.S. federal and state laws and regulations imposing obligations on how we collect, store and process personal information. Our actual or perceived failure to comply with such obligations could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our future customer base, and thereby decrease our revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we currently, and in the future will, collect, store, transfer, use or process sensitive data, including personal information of employees, and intellectual property and proprietary business information owned or controlled by ourselves and other parties. The secure processing, storage, maintenance, and transmission of this critical information are vital to our operations and business strategy. We are, and may increasingly become, subject to various laws and regulations, as well as contractual obligations, relating to data privacy and security in the jurisdictions in which we operate. The regulatory environment related to data privacy and security is increasingly rigorous, with new and constantly changing requirements applicable to our business, and enforcement practices are likely to remain uncertain for the foreseeable future. These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible that they will be interpreted and applied in ways that may have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, various federal and state regulators, including governmental agencies like the Consumer Financial Protection </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bureau</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Federal Trade Commission, have adopted, or are considering adopting, laws and regulations concerning personal information and data security. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to personal information than federal, international or other state laws, and such laws may differ from each other, all of which may complicate compliance efforts. For example, the California Consumer Privacy Act (&#8220;CCPA&#8221;), which increases privacy rights for California residents and imposes obligations on companies that process their personal information, came into effect on January 1, 2020. Among other things, the CCPA requires covered companies to provide new disclosures to California consumers and provide such consumers new data protection and privacy rights, including the ability to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches that result in the loss of personal information. This private right of action may increase the likelihood of, and risks associated with, data breach litigation. In November 2020, California also passed the California Privacy Rights Act, or (&#8220;CPRA&#8221;), which significantly expanded the CCPA as of January 1, 2023, including by introducing additional obligations such as data minimization and storage limitations and granting additional rights to consumers, among others. The enactment of the CCPA has prompted similar legislative developments in other states, and numerous other states have proposed, and in certain cases enacted, legislation relating to privacy and data security, many of which are similar to the CCPA and CPRA. Similar laws are being considered by other state legislatures. In addition, laws in all 50 U.S. states require businesses to provide notice to consumers whose personal information has been disclosed as a result of a data breach. State laws are changing rapidly and there has been discussion in the U.S. Congress of a new comprehensive federal data privacy law. These and future laws and regulations may increase our compliance costs and potential liability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, regulations promulgated pursuant to the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), establish privacy and security standards that limit the use and disclosure of individually identifiable health information (known as &#8220;protected health information&#8221;) and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can require complex factual and statistical analyses and may be subject to changing interpretation. Although we take measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or disrupted, breached or otherwise compromised due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or disruption could compromise our networks and the information stored there could be accessed, manipulated, publicly disclosed, lost, stolen, made unavailable, or otherwise processed without authorization. Any such disruption, access, breach, unavailability, theft, loss or other unauthorized processing of information, or the perception that any of these has occurred could result in legal claims or proceedings, and liability under federal or state laws that protect the privacy of personal information, such as the HIPAA, the Health Information Technology for Economic and Clinical Health Act, and regulatory penalties. Notice of breaches must be made to affected individuals, the Secretary of the Department of Health and Human Services, and for extensive breaches, notice may need to be made to the media or state attorneys general. Such a notice could harm our reputation and our ability to compete.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have in place formal policies and procedures related to the storage, collection, and processing of information, and have conducted data privacy audits, we continue to evaluate our compliance needs, including the need to conduct additional internal and external data privacy audits or adopt additional policies and procedures, to ensure our compliance with all applicable data protection laws and regulations. Additionally, we do not currently have policies and procedures in place for assessing our third-party vendors&#8217; compliance with applicable data protection laws and regulations. All of these evolving compliance and operational requirements impose significant costs, such as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants, which are likely to increase over time. In addition, such requirements may require us to modify our data processing practices and policies, distract management or divert resources from other initiatives and projects, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Any failure or perceived failure by us or our third-party vendors, collaborators, contractors and consultants to comply with any applicable federal, state or similar foreign laws and regulations relating to data privacy and security, could result in damage to our reputation, as well as proceedings or litigation by governmental agencies or other third parties, including class action privacy litigation in certain jurisdictions, which would subject us to significant fines, sanctions, awards, penalties or judgments, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increased scrutiny of our environmental, social or governance responsibilities may result in additional costs and risks, and may adversely impact our reputation, employee retention, and willingness of customers and suppliers to do business with us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investor advocacy groups, institutional investors, investment funds, proxy advisory services, stockholders, and customers are increasingly focused on environmental, social, and governance (&#8220;ESG&#8221;) practices of companies. Additionally, public interest and legislative pressure related to public companies&#8217; ESG practices continues to grow. For example, the SEC has adopted final rules regarding climate-related disclosures in public companies&#8217; periodic reporting. Following several legal challenges, the SEC has issued an order staying the implementation of such rules.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the SEC prevails and lifts the stay on implementation, our compliance costs may increase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our ESG practices fail to meet regulatory requirements or investor or other industry stakeholders' evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, support for local communities, board and employee diversity, human capital management, employee health and safety practices, product quality, supply chain management, corporate governance and transparency, and employing ESG strategies in our operations, our brand, reputation and employee retention may be negatively impacted and customers and suppliers may be unwilling to do business with us and potential or current investors may elect to invest in other companies with ESG practices that are perceived to be better than ours. In addition, ESG reporting and disclosure may result in additional costs and require additional resources to monitor, report, and comply with our various ESG practices as well as additional attention from our board of directors and management. If we fail to adopt ESG standards or practices as quickly as stakeholders desire, report on our ESG efforts or practices accurately, or satisfy the expectations of stakeholders, or comply with applicable regulatory requirements, our reputation, business, financial performance, and growth may be adversely impacted.</span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_22"></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1B.  UNRESOLVED STAFF COMMENTS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_25"></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1C.  CYBERSECURITY</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risk Management and Strategy</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-38" continuedAt="f-38-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-37" continuedAt="f-37-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-39">We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes.</ix:nonNumeric> We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-37-1"><ix:continuation id="f-38-1" continuedAt="f-38-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct periodic risk assessments to identify cybersecurity threats, as well as assessments in the event of a material change in our business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following these risk assessments, we evaluate whether and how to re-design, implement, and maintain reasonable safeguards to minimize identified risks; reasonably address any identified gaps in existing safeguards; and regularly monitor the effectiveness of our safeguards. We devote resources and designate high-level personnel, including our Vice President and Head of Information Technology who reports to our Chief Operating Officer, to manage the risk assessment and mitigation process. </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-38-2">As part of our overall risk management system, we monitor and test our safeguards, including through annual third-party vulnerability assessments. We train our employees on these safeguards, in collaboration with human resources, IT, and departmental management. Personnel at all levels and departments are made aware of our cybersecurity policies through training.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-40">We engage assessors, consultants, auditors, or other third parties in connection with our risk assessment processes.</ix:nonNumeric> These service providers assist us in designing and implement our cybersecurity policies and procedures, as well as to monitor and test our safeguards.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-41">We have established procedures to evaluate and respond to cybersecurity incidents, including cybersecurity incidents at third-party service providers which have a potential to impact our data and systems. Our cybersecurity risk management is intended to address such risks, as well as other risks related to third parties.</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-42">We have not previously experienced a cybersecurity incident that was determined to be material.</ix:nonNumeric> For additional information regarding whether any risks from cybersecurity threats are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to Item 1A, &#8220;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_19">Risk Factors</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; in this Annual Report on Form 10-K.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Governance</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-43" escape="true">One of the key functions of our board of directors is to provide oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through the audit committee.</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-45" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-44" escape="true">Our Vice President and Head of <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-46">Information Technology and our cyber committee, which includes Facilities, HR, IT, Legal, and Management</ix:nonNumeric>, are primarily responsible to assess and manage our material risks from cybersecurity threats.</ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-47" escape="true">Our Vice President and Head of Information Technology has years of cybersecurity experience and expertise including holding numerous applicable cybersecurity certifications, such as ISC2 Certified Information Systems Security Professional (CISSP).</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-48" continuedAt="f-48-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Vice President and Head of Information Technology and our management committee on cybersecurity oversee our cybersecurity policies and processes, including those described in &#8220;Risk Management and Strategy&#8221; above. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-49" continuedAt="f-49-1" escape="true">Our Vice President and Head of Information Technology is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents by leading cybersecurity risk management and working directly with our IT team. Our Vice President and Head of Information Technology also provides appropriate information and updates to our management committee on cybersecurity.</ix:nonNumeric></span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-49-1"><ix:continuation id="f-48-1">Our Vice President and Head of Information Technology and representatives from our management committee on cybersecurity provide annual briefings to the audit committee regarding our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-50" escape="true">Our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-51">audit committee</ix:nonNumeric> provides regular updates to the board of directors on such reports.</ix:nonNumeric></ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 2.  PROPERTIES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters, research and development facilities, and manufacturing and distribution centers are located in Menlo Park, California, where we lease approximately 180,200 square feet under a lease expiring on October 31, 2027. Additionally, our European headquarters is located in London, where we lease approximately 7,300 square feet under a lease expiring November 30, 2026. Including these leases, we lease approximately 191,000 square feet globally.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing facilities, together with suitable additional or alternative space available on commercially reasonable terms, will be sufficient to meet our needs. </span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_31"></div><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 3.  LEGAL PROCEEDINGS</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">U.S. District Court Proceedings</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2019, Personal Genomics of Taiwan, Inc. (&#8220;PGI&#8221;) filed a complaint in the U.S. District Court for the District of Delaware against us for patent infringement (C.A. No. 19-cv-1810) (the &#8220;PGI District Court matter&#8221;). The matter from this complaint is based on PGI&#8217;s U.S. Patent No. 7,767,441 (the &#8220;&#8216;441 Patent&#8221;).</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complaint alleges that our Sequel systems and Sequel II systems infringe the &#8216;441 Patent. The complaint seeks unspecified monetary damages and an order enjoining us from infringing the &#8217;441 Patent.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On November 20, 2019, we filed our answer to the complaint, denying infringement and seeking declaratory judgements of non-infringement and invalidity of the &#8216;441 Patent.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2020, we filed a petition requesting institution of an inter-partes review ("IPR") to the Patent Trial and Appeals Board (the &#8220;Board&#8221;) at the United States Patent Office </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IPR2020-01163)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> requesting the Board to find a set of claims in the &#8216;441 Patent invalid. On June 27, 2020, we filed a second petition </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IPR2020-01200) </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requesting institution of an IPR requesting the Board to find another set of claims in the &#8216;441 Patent invalid. The two petitions (the &#8220;PacBio IPR Petitions&#8221;) together asserted that all of the claims relevant to the PGI complaint are invalid. On January 19, 2021, the Board ordered that both PacBio IPR Petitions be instituted on all grounds presented. On January 18, 2022, the Board issued decisions on the two IPRs. In one IPR, all challenged claims were found unpatentable, including PGI&#8217;s core device claims. In the second IPR, the Board did not find the disputed claims unpatentable. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PGI and PacBio each </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appealed to the U.S. Court of Appeals for the Federal Circuit, which </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affirmed both IPR decisions on</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> January 9, 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2020, the court ordered a stay of the PGI District Court matter based on a joint stipulation by the parties pending a final written decision on the IPRs. Following the final written decisions on the IPRs described above, on February 2, 2022, the judge ordered that the PGI District Court matter be reopened. However, in a subsequent order dated September 15, 2022, the judge stayed the PGI District Court matter pending a final decision by the U.S. Court of Appeals for the Federal Circuit regarding the appeal described above. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 26, 2024, we moved to transfer the case from the District of Delaware to the Northern District of California and that motion was granted on June 18, 2024. On March 18, 2024, the parties filed a joint status report in which PGI requested the Court set a revised scheduling order and we requested grant of our motion to transfer and proposed an alternate scheduling order. A case management conference was held on October 10, 2024 and the Court set a trial date of October 5, 2026. </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to vigorously defend against the remaining claims.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2022, Take2 Technologies, Ltd. (&#8220;Take2&#8221;) and the Chinese University of Hong Kong </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;CUHK&#8221;) </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filed a complaint in the U.S. District Court for Delaware against us alleging infringement of U.S. Patent No. 11,091,794 (the &#8220;&#8217;794 Patent&#8221;) (C.A. No. 22- cv-01595)</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Take2 District Court matter&#8221;)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The complaint alleges that our Sequel II systems, Sequel IIe systems, and Revio systems that operate version 11.0 or later of the SMRT Link software, infringe the &#8216;794 Patent. The complaint seeks unspecified monetary damages and an order enjoining us from infringing the &#8217;794 Patent. We filed a motion to dismiss on February 14, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was denied on March 25, 2024</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We also filed a motion to transfer the case</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the District of Delaware</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Northern District of California which was granted on August 2, 2023 . The case was transferred on August 16, 2023 (C.A. No. 5:23-cv-04166). Take2 filed a motion to disqualify our in-house legal department from representing PacBio in the district court action on September 20, 2023. We opposed Take2&#8217;s disqualification motion on October 4, 2023. An oral hearing on the disqualification motion was held on October 26, 2023 and the court issued orders on November 6 and December 4 of 2023 partially granting the motion.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While some members of the in-house legal department were disqualified, General Counsel for PacBio was not disqualified and continues to represent PacBio in the </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Take2 District Court matter. </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We filed a petition </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for inter partes review at </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Board (</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR2024-00028) challenging the validity of</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> all claims of the &#8217;794 patent </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on October 17, 2023. The CUHK filed a preliminary response to the petition on January 26, 2024. On April 22, 2024, we filed our answer to the complaint, denying infringement and seeking declaratory judgments of non-infringement and invalidity of the &#8216;794 Patent. On April 24, 2024, the Board granted institution of IPR2024-00028 on the validity of all claims of the &#8217;794 patent. On May 2, 2024, the parties filed a joint stipulation and proposed order to stay the Take2 District Court matter pending inter partes review. On May 3, 2024, the Court granted the motion to stay, and the case currently remains stayed. Briefing is complete in IPR2024-00028 and an oral hearing took place on January 23, 2025. The Board is scheduled to issue a final decision on or before April 24, 2025 that addresses the validity of all claims of the &#8217;794 patent. On March 7, 2025, we entered into a purchase agreement with CUHK to purchase the &#8216;794 patent. In connection with our purchase of the &#8216;794 Patent, each of Take2 and CUHK, on the one hand, and PacBio, on the other hand, agreed to waive and seek the discharge of all outstanding litigation claims and patent-related challenges, including with respect to the Take2 District Court matter and IPR2024-00028. The agreement to discharge the litigation claims and the patent challenge remains subject to approval by the Northern District of California and the Board, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Proceedings in China</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2020, PGI filed a complaint in the Wuhan Intermediate People&#8217;s Court in China alleging infringement of one or more claims of China patent No. CN101743321B (the &#8220;CN321 Patent&#8221;), which is related to the &#8216;441 Patent. On November 23, 2020, we filed an Invalidation Petition at the China National Intellectual Property Administration ("CNIPA") demonstrating the invalidity of the claims in the CN321 Patent on grounds of insufficient disclosure, and the lack of support, essential technical features, clarity, novelty, and inventiveness. A hearing in the invalidation proceeding at the CNIPA was held on April 29, 2021. On September 2, 2021, the CNIPA issued its decision on the Invalidation Petition and determined that all claims (1-61) of the CN321 patent were invalid. On December 1, 2021, PGI filed an appeal with the Beijing IP Court, contesting the CNIPA decision. We filed a petition with the Wuhan Intermediate People&#8217;s court requesting dismissal of the infringement action based on the CNIPA invalidation decision, and PGI filed a petition to withdraw its complaint. The Wuhan Intermediate People&#8217;s court granted PGI&#8217;s petition and dismissed the infringement action in May 2022.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Proceedings</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also be involved in a variety of other claims, lawsuits, investigations, and proceedings relating to securities laws, product liability, patent infringement, contract disputes, employment, and other matters that arise in the normal course of our business. In addition, third parties may, from time to time, assert claims against us in the form of letters and other communications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We currently do not believe that the ultimate outcome of any of the matters described above is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 4.  MINE SAFETY DISCLOSURES</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART II</span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_40"></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 5.  MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on The Nasdaq Global Select Market under the symbol &#8220;PACB.&#8221;</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Holders of Record</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 28, 2025, there were approximately 85 stockholders of record of our common stock, although we believe that there are a significantly larger number of beneficial owners of our common stock.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dividend Policy</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividend on our common stock and have no present plans to do so. We intend to retain earnings for use in the operation and expansion of our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Performance Graph</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance graph included in this Annual Report on Form 10-K shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or incorporated by reference into any filing of Pacific Biosciences under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph shows a comparison from December 31, 2019 through December&#160;31, 2024 of the cumulative total return for our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index. Such returns are based on historical results and are not intended to suggest future performance. Data for The Nasdaq Composite Index and the Nasdaq Biotechnology Index assume reinvestment of dividends.</span></div><div style="margin-top:6pt;text-align:center"><img src="pacb-20241231_g5.jpg" alt="Picture4.jpg" style="height:548px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as previously reported on our Current Reports on Form 8-K filed with the SEC on November 7, 2024 and November 22, 2024, there were no unregistered sales of equity securities by us during 2024.</span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_43"></div><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 6.  [RESERVED]</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 7.  MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes included in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should read the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management&#8217;s Discussion and Analysis (MD&amp;A) is organized in the following sections: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Overview and Outlook </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Results of Operations </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Liquidity and Capital Resources</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Off Balance Sheet Arrangements</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Critical Accounting Policies and Estimates</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Recent Accounting Pronouncements</span></div></td></tr></table></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_49"></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OVERVIEW AND OUTLOOK</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About PacBio</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing technology and our Sequencing by Binding (SBB) short-read sequencing technology. Our products address solutions across a broad set of applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-read sequencing was recognized by the journal </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature Methods</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as its &#8220;method of the year&#8221; for 2022 for its contributions to biological understanding and future potential. Long-read sequencing</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been applied to produce telomere-to-telomere genomes of humans, pangenome references, and has been recognized for its ability to provide more complete views of human variation</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus is on creating some of the world&#8217;s most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, CROs, pharmaceutical companies, and agricultural companies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Strategic Objectives</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Though challenging, 2024 was a productive year for PacBio as we launched products, improved our financial flexibility, and made progress in reducing cash burn.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Looking ahead to 2025, our main objectives are to grow revenue and expand gross margins through the following four activities: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.41pt">Enabling the full-scale release of the Vega benchtop platform to broaden our market reach.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe this platform broadens the long-read market opportunity.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.41pt">Accelerating samples onto the Revio platform via SPRQ chemistry and application kits.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SPRQ chemistry enables the sub-$500 HiFi genome, improves methylation detection capabilities, and achieves a 75% reduction in DNA input requirements for human whole genome sequencing.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These features can drive more samples onto HiFi sequencing than ever before. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.41pt">Investing in future product launches to diversify our offerings.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continue to develop sequencing systems designed to increase throughput and lower the cost to sequence a genome, which we believe will allow us to address an even larger part of the market. Additionally, we continue to develop kitted-solutions, like our Kinnex Full-length RNA kits and PureTarget, and enhance our on-market sequencers with products like SPRQ chemistry to drive more sequencing volume. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.41pt">Progressing our clinical strategy to improve outcomes and create durability.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2024 Revio was increasingly being used in LDT and clinical research settings to consolidate multiple tests and address complex genetic challenges.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to believe that with the capabilities of our HiFi chemistry and SMRT technology, we can be a market leader in whole-genome clinical sequencing. Leading institutions have adopted our products to study rare and inherited disease. We believe the market opportunity for clinical sequencing is significant and could drive substantial revenue growth for the company. We plan to continue to pursue partner collaborations where the technologies being developed or applications being considered extend beyond whole-genome clinical sequencing. Collaborative arrangements add to the awareness of our products and service offerings and may drive new applications for use of our technology.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Overview</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key highlights of our 2024 consolidated financial results include the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"><tr><td style="width:1.0%"/><td style="width:22.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.865%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue of</span></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit of</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Loss of</span></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-right:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and investments of</span></div></td></tr><tr><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:18pt;font-weight:700;line-height:100%">$154 M</span></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:18pt;font-weight:700;line-height:100%">$37 M</span></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:18pt;font-weight:700;line-height:100%">$474 M</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-right:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:18pt;font-weight:700;line-height:100%">$390 M</span></td></tr><tr><td colspan="3" style="background-color:#009ca2;border-bottom:1pt solid #009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">compared to $201 M in the prior year</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-bottom:1pt solid #009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">representing 24% of gross margin</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-bottom:1pt solid #009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">compared to $334 M in the prior year</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-bottom:1pt solid #009ca2;border-left:1pt solid #009ca2;border-right:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">compared to $631 M last year</span></div></td></tr></table></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Revenue decreased $46.5 million, or 23%, to $154.0 million for the year ended December&#160;31, 2024, as compared to $200.5 million for the year ended December&#160;31, 2023. Revenue was comprised of $65.8 million in instrument revenue, approximately $70.3 million in consumables revenue and $17.9 million in service and other revenue for the year ended December&#160;31, 2024. The decrease was primarily due to lower Revio unit sales and lower average selling prices, which was partially offset by higher consumable sales. While we do not expect Vega to meaningfully impact Revio sales, we are mindful that there may be some cases where potential customers take more time to assess our new offerings, which may prolong some sales cycles. We ended the year with cumulative shipments of 270 Revio systems.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Gross profit decreased for the year ended December&#160;31, 2024, primarily due to the decrease in revenue described above, $4.4 million of restructuring charges, and an increase of $7.4 million in amortization of acquired intangible assets, partially offset by lower inventory adjustments. During the year ended December&#160;31, 2023 we recognized an increase of approximately $4.6 million of inventory adjustments primarily related to excess consumables inventory resulting from faster-than-expected decline in demand of Sequel II/IIe consumables due primarily to a faster than expected ramp on the Revio system. Gross margins may also be affected by product mix, manufacturing efficiencies, warranty cost improvements, average selling price fluctuations, future product launches, changes to inventory reserves, and costs of raw materials.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Loss from operations increased $139.8 million or 42%, to $474.3 million for the year ended December&#160;31, 2024, as compared to $334.5 million for the year ended December&#160;31, 2023. Operating expenses increased $124.3 million primarily driven by $184.5 million of impairment charges, $20.8 million of restructuring charges, and an increase of $11.8 million in amortization of acquired intangible assets, partially offset by a $15.9 million decrease in the change in the fair value of the contingent consideration, a $9.0 million decrease in non-recurring merger-related costs, and a decrease in research and development expenses primarily driven by a decrease in personnel and related expenses due to restructuring activities.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Cash, cash equivalents, and investments were $389.9 million at December&#160;31, 2024, which represents a 38% decrease compared to the balance of $631.4 million at December&#160;31, 2023. The decrease in cash includes approximately $50.2 million of payments made in conjunction with the convertible notes exchange transaction in November 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The median sales cycle for Revio instrument purchases continues to be elongated. We believe this has been caused by, among other reasons, the uncertainty surrounding the funding for new capital equipment, in particular, uncertainty in the United States related to NIH and academic funding; procurement delays; small-to-mid-size existing customers yet to increase their sample volumes to drive an upgrade to Revio; new customers, which have shown they have longer sales cycles compared to existing PacBio customers; and sample volumes materializing slower than expected for some potential Revio customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our consumables revenue was also impacted primarily by slower-than-expected ramp-up in sequencing by our small- to mid-sized customers, many of whom are new to PacBio; sample delays impacting sequencing volume at certain large customers; and some service providers in China operating at lower utilization as a result of the difficult funding environment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Macroeconomic dynamics impacting the Company in the future may include rising inflation, geopolitical tensions, volatile capital markets, tariffs, uncertainty in the United States related to NIH and academic funding, and fluctuating exchange rates. These factors could continue to impact our revenues and results of operations in future periods; however, the magnitude and duration of these impacts is uncertain and inherently unpredictable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, we evaluate our significant estimates, including those related to the valuation of goodwill, indefinite-lived and finite-lived assets. However, these estimates could change in future periods based on events or changes in circumstances, which could result in material future impairment charges. We recorded $184.5 million of impairment charges during the year ended December 31, 2024. See additional discussion below in Results of Operations, as well as </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_109">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_109">4</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_109">. Balance Sheet Components</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 8 of this Annual Report on Form 10-K for further information. Additionally, refer to the Critical Accounting Policies and Estimates section later in this Item 7 for further discussion on the Company's asset impairment assessments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_19">Risk Factors</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section for further discussion.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> detailed discussion of our consolidated financial results comparison between </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is presented below. A discussion of the changes in our results of operations between the years ended </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, has been omitted from this Annual Report on Form 10-K but may be found in </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annual Report on </span><span style="background-color:#ffffff;color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001299130/000129913024000054/pacb-20231231.htm">Form 10-K</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, filed with the Securities and Exchange Commission on </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;28, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is incorporated herein by reference, and is available free of charge on the SEC&#8217;s website at www.sec.gov and our corporate website (www.pacb.com).</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2024 and 2023</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136,149&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,723)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,865&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,649&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,014&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,521&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,507)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Revenue:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of product revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,284&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,568&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,284)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of service and other revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,057&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,754&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(697)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,393&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,983&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,410&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on purchase commitment</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,436&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,438)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost of revenue </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,732&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,741&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,009)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 64pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,282&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,780&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,498)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expense:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134,922&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,170&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52,248)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales, general and administrative </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,017&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,500&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger-related expenses</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,042&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,042)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(850)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,060&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,910)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,006&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,157&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,849&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expense </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">511,595&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387,247&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,348&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(474,313)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(334,467)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(139,846)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,033)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on debt restructuring</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,407&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,407&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,412)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,343)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,783&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,684&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,901)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></div></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,535)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(318,159)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,624&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,424)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,740&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,851)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(306,735)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,116)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Revenue</span></div></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:32.000%"><div style="margin-top:6pt;text-align:justify"><img src="pacb-20241231_g6.jpg" alt="549755831602" style="height:192px;margin-bottom:5pt;vertical-align:text-bottom;width:172px"/></div><div style="margin-top:15pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:0.000%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:68.000%"><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue decreased $46.5 million, or 23%, to $154.0 million for the year ended December&#160;31, 2024, as compared to $200.5 million for the year ended December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in product revenue resulted primarily from a decrease of $54.7 million in instrument revenue, partially offset by an increase of approximately $6.9 million in consumable revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service and other revenue increased approximately $1.3 million to $17.9 million for the year ended December&#160;31, 2024 as compared to $16.6 million for the year ended December&#160;31, 2023.</span></div></div></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Instrument Revenue</span></div></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:31.636%"><div style="margin-top:6pt;text-align:justify"><img src="pacb-20241231_g7.jpg" alt="549755832682" style="height:153px;margin-bottom:5pt;vertical-align:text-bottom;width:172px"/></div></div><div style="display:inline-block;max-width:0.000%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:68.364%"><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instrument revenue decreased $54.7 million, or 45%, to $65.8 million for the year ended December&#160;31, 2024, as compared to $120.5 million for the year ended December&#160;31, 2023, primarily due to the sale of 97 Revio systems during the year ended December&#160;31, 2024 compared to 173 Revio systems during the year ended December&#160;31, 2023.</span></div></div></div><div style="margin-top:15pt;text-align:justify"><span><br/></span></div><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consumables Revenue</span></div></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:31.563%"><div style="margin-top:9pt;text-align:justify"><img src="pacb-20241231_g8.jpg" alt="549755833272" style="height:153px;margin-bottom:5pt;vertical-align:text-bottom;width:172px"/></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:0.072%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:68.365%"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumables revenue increased approximately $6.9 million, or 11%, to $70.3 million for the year ended December&#160;31, 2024, as compared to $63.4 million for the year ended December&#160;31, 2023. The increase in consumable sales was primarily due to higher Revio consumables and library preparation sales attributable to the growth in the Revio instrument installed base, partially offset by a decline in Sequel II and IIe consumables as customers transition to Revio. We expect Revio consumable sales to increase as the installed base grows. While we expect to see a decline in Sequel II and IIe consumable sales resulting from the product transition, there is uncertainty as to the rate at which these sales will decline.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Revenue, Gross Profit, and Gross Margin</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenue decreased $35.3 million, or 28%, for the year ended December&#160;31, 2024, compared to the year ended December&#160;31, 2023 primarily driven by the decrease in revenue described above and lower inventory adjustments. During the year ended December&#160;31, 2023, we recognized an increase of approximately $4.6 million of inventory adjustments primarily related to excess consumables inventory resulting from faster-than-expected decline in demand of Sequel II/IIe consumables due primarily to a faster than expected ramp on the Revio system. These decreases were partially offset by restructuring charges in cost of revenue of $4.4 million, including $3.6&#160;million of charges for excess inventory due to a decrease in internal demand relating to the expense reduction initiatives during the year ended December&#160;31, 2024. Cost of revenue included amortization attributable to acquired intangible assets of $9.4 million and $2.0 million that are related to sales generating activities during the years ended December&#160;31, 2024 and 2023, respectively. Cost of revenue included share-based compensation expense of $5.7 million and $5.4 million during the years ended December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss on purchase commitment was $1.0 million and $3.4 million for the years ended December&#160;31, 2024 and 2023, respectively. The purchase commitment loss is based on an estimate of future excess inventory related to supply agreements, for which we do not expect to have related sales.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit decreased $15.5 million, or 29% to $37.3 million for the year ended December&#160;31, 2024, compared to $52.8 million for the year ended December&#160;31, 2023. Gross margin was 24% for the year ended December&#160;31, 2024, compared to gross margin of 26% for the year ended December&#160;31, 2023. The decrease was primarily due to the decrease in revenue described above, restructuring charges, and an increase of $7.4 million in amortization of acquired intangible assets, partially offset by lower inventory adjustments. Gross margins may also be affected by product mix, manufacturing efficiencies, warranty cost improvements, average selling price fluctuations, future product launches, changes to inventory reserves, and costs of raw materials.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development Expense</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense decreased by $52.2 million, or 28%, to $134.9 million for the year ended December&#160;31, 2024, compared to $187.2 million for the year ended December&#160;31, 2023. The decrease was primarily driven by a decrease in personnel and related expenses due to restructuring activities, as well as the transition of products from development to commercialization. We incurred restructuring charges of $5.9 million, primarily related to employee separation benefits during the year ended December&#160;31, 2024. Research and development expense included share-based compensation of $19.2 million and $22.4 million during the years ended December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sales, General, and Administrative Expense</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales, general and administrative expense increased by $5.2 million, or 3%, to $175.0 million for the year ended December&#160;31, 2024, compared to $169.8 million for the year ended December&#160;31, 2023. The increase was primarily driven by restructuring charges of $14.9 million, primarily related to employee separation benefits and lease-related costs during the year ended December&#160;31, 2024, partially offset by a decrease in personnel expenses. We expect to incur an additional $0.9 million of remaining estimated restructuring costs through 2025 relating to the actions taken in 2024. Sales, general, and administrative expense included share-based compensation expenses of $46.2 million and $44.3 million during the years ended December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Impairment Charges</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified indicators of impairment primarily relating to significant declines in our stock price and market capitalization compared to net book value, increases in the carrying value of the reporting unit, and changes in the amount and timing of expected future cash flows due to macroeconomic headwinds, among others, and performed interim impairment tests during the year ended December&#160;31, 2024. The impairment tests showed the carrying amounts of our goodwill and in-process research and development ("IPR&amp;D") exceeded fair values. As a result, we recorded $184.5 million of impairment charges for the year ended December&#160;31, 2024. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_109">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_109">4</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_109">. </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_109">Balance Sheet </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_109">Components</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 8 of this Annual Report on Form 10-K for further details.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Merger-Related Expenses</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merger-related expenses of $9.0 million during the year ended December 31, 2023, consist of $4.9 million of transaction costs arising from the acquisition of Apton, $2.8 million of compensation expense resulting from the liquidity event bonus plan in connection with the Apton acquisition, and $1.3 million of share-based compensation expense resulting from the acceleration of certain equity awards in connection with the Apton acquisition. We recognized $1.3 million of share-based compensation expense for the acceleration that was not attributable to pre-combination services.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amortization of Acquired Intangible Assets</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets of $18.0 million and $6.2 million during the years ended December&#160;31, 2024 and 2023, respectively, consists of amortization expense attributable to acquired intangible assets that are not directly related to sales generating activities.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Change in Fair Value of Contingent Consideration</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration during the year ended December&#160;31, 2024, represents the remeasurement impact of the Apton contingent consideration due upon the achievement of the milestone. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration during the year ended December&#160;31, 2023, represents the remeasurement impact of the Omniome and Apton contingent consideration liability  due upon the achievement of the respective milestone. The Omniome milestone was achieved in September 2023.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Loss on Extinguishment of Debt</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt of $2.0 million during the year ended December&#160;31, 2023, represents the loss resulting from the difference in the fair value of the 2030 Notes and the principal, in addition to the write-off of the unamortized debt issuance costs on the portion of the 2028 Notes that were exchanged as part of the debt modification during the year ended December 31, 2023.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Gain on Debt Restructuring</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on debt restructuring of $154.4 million during the year ended December&#160;31, 2024, represents the gain resulting from the Exchange Transaction, which qualified as a troubled debt restructuring under Accounting Standards Codification ("ASC") 470-60, Debt - Troubled Debt Restructurings by Debtors. Since the undiscounted cash flows of the new 2029 Notes were less than the carrying amount of the exchanged 2028 Notes, the carrying value of the 2029 Notes was determined based on the total undiscounted cash flows. The gain was calculated as the difference between the carrying amount of the old debt and the carrying amount of the new debt, adjusted for debt issuance costs. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_112">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_112">5</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_112">. Convertible Senior Notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 8 of this Annual Report on Form 10-K for further details.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Interest Expense</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the year ended December&#160;31, 2024 was $13.4 million compared to $14.3 million for the year ended December&#160;31, 2023 and was primarily comprised of interest on the Notes.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Income, Net</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in other income, net was primarily driven by lower investment income due to lower cash and investment balances.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Income Tax Provision (Benefit)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded an income tax provision of $0.3 million for the year ended December&#160;31, 2024. A deferred income tax benefit of $11.4 million for the year ended December&#160;31, 2023, is related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Apton acquisition. Accordingly, this benefit from income taxes is reflected on our consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2023. We maintain a valuation allowance on the net deferred tax assets of our U.S. entities as we have concluded that it is more likely than not that we will not realize our deferred tax assets.</span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_55"></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity, other than our holdings of cash, cash equivalents, and investments, has primarily been through the issuance of debt or equity securities, together with cash flow from operating activities. For example, in January 2023, as discussed in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_124">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_124">9</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_124">. Stockholders&#8217; Equity</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Part II, Item 8 of this Annual Report on Form 10-K, we issued and sold an aggregate of 20,125,000 shares of our common stock in a follow-on public offering for aggregate gross proceeds of approximately $201.3 million. We have historically incurred, and expect to continue to incur, operating losses and generate negative cash flows from operations on an annual basis due to the investments we intend to make as described in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_52">Results of Operations</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above, and as a result, we may require additional capital resources to execute our strategic initiatives to grow our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We approved and implemented certain efficiency and expense reduction initiatives during 2024. These expense reduction initiatives included workforce reductions, facilities downsizing and a refined pipeline of development programs.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Investments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had $389.9 million in cash, cash equivalents, and investments, compared to $631.4 million at December&#160;31, 2023. The decrease was primarily attributable to $206.1 million cash used in operating activities during the year ended December&#160;31, 2024 and an additional $50.2 million of payments made in conjunction with the convertible notes exchange transaction in November 2024.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Senior Notes</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;9, 2021, we entered into an investment agreement with SB Northstar LP (&#8220;SBN&#8221;), a subsidiary of SoftBank Group Corp., relating to the issuance and sale to SBN of $900.0 million in aggregate principal amount of our 2028 Notes. The 2028 Notes were issued on February&#160;16, 2021</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, as of November 21, 2024, no 2028 Notes were outstanding.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we entered into a privately negotiated exchange agreement with a holder of our outstanding 2028 Notes, pursuant to which we issued $441.0 million in aggregate principal amount of our 2030 Notes in exchange for $441.0 million principal amount of the 2028 Notes, leaving approximately $459.0 million in aggregate principal amount outstanding of our 2028 Notes. Interest on the 2030 Notes is payable semi-annually in arrears on June 15 and December 15 commencing on December 15, 2023. The 2030 Notes will mature on December 15, 2030, subject to earlier conversion, redemption, or repurchase.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, we entered into an exchange agreement with SBN, pursuant to which we agreed to exchange the remaining approximately $459.0 million in aggregate principal amount of 2028 Notes outstanding for (i) $200.0 million aggregate principal amount of the 2029 Notes, (ii) 20,451,570 shares of common stock (the &#8220;Exchange Shares&#8221;) and (iii) $50.0 million of cash. The exchange and issuances closed on November 21, 2024 (the &#8220;Closing Date&#8221;). The 2029 Notes, the Exchange Shares, and shares of common stock issuable upon conversion of the 2029 Notes are subject to certain lock-up restrictions for a six-month period (the &#8220;Lock-Up Period&#8221;) beginning on the Closing Date of the Exchange Transaction; the lock-up restrictions will terminate immediately prior to the consummation of any change in control of the Company. The 2029 Notes bear interest at a rate of 1.50% per annum. Interest on the 2029 Notes is payable semi-annually in arrears on February 15 and August 15 and commencing on February 15, 2025. The 2029 Notes will mature on August 15, 2029, subject to earlier conversion, redemption or repurchase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are convertible at the option of the holder at any time from the expiration of the Lock-Up Period until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2029 Notes are convertible into shares of our common stock based on an initial conversion rate of 204.5157 shares of common stock per $1,000 principal amount of the 2029 Notes (which is equal to an initial conversion price of approximately $4.89 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2029 Notes, we may elect to settle such conversion obligation in shares of our common stock, cash or a combination of shares of our common stock and cash.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2030 Notes are convertible into shares of our common stock based on an initial conversion rate of 46.5116 shares of common stock per $1,000 principal amount of the 2030 Notes (which is equal to an initial conversion price of approximately $21.50 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2030 Notes, we may elect to settle such conversion obligation in shares of our common stock, cash or a combination of shares of our common stock and cash.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With certain exceptions, upon a change of control of our company or the failure of our common stock to be listed on certain stock exchanges, the holders of the Notes may require that we repurchase all or part of the principal amount of those Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture governing the 2029 Notes and the 2030 Notes include customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the Notes under the respective indentures. The indentures also include customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on November 21, 2024, in connection with the issuance of the 2029 Notes, the Company and SBN entered into the Letter Agreement pursuant to which the Company and SBN agreed that, for so long as SBN and its affiliates hold at least $180 million aggregate principal amount of the 2029 Notes, the Company and its subsidiaries are subject to certain negative covenants that restrict the Company&#8217;s and its subsidiaries&#8217; ability to incur additional indebtedness and create liens, in each case, subject to the exceptions set forth in the Letter Agreement, including exceptions which permit the Company to incur up to $75 million in aggregate principal amount of secured indebtedness pursuant to Credit Facilities (as defined in the Letter Agreement).</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Letter Agreement restricts the ability of the Company and its subsidiaries from guaranteeing any indebtedness or incurring certain indebtedness outside of the ordinary course of business unless, in each case, the Company and its subsidiaries concurrently provide a guarantee of the Company&#8217;s obligations under the 2029 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_112">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_112">5</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_112">. Convertible Senior Notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 8 of this Annual Report on Form 10-K for further details.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Additional Capital Requirements</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash, cash equivalents, and investments will be sufficient to fund our projected operating and capital requirements for at least the next 12 months from the date of filing of this Annual Report on Form 10-K for the year ended December&#160;31, 2024. Operating needs include planned costs to operate our business, including costs to fund working capital and capital expenditures. Recent and expected working and other capital requirements, in addition to the above matters, include: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Our purchase orders and contractual obligations of approximately $57.6 million as of December&#160;31, 2024, which consist of open purchase orders and contractual obligations in the ordinary course of business, including commitments with contract manufacturers and suppliers for which we have not received the goods or services. A majority of these purchase obligations are due within a year. Although open purchase orders are considered enforceable and legally binding, the terms generally allow us the option to cancel, reschedule and adjust our requirements based on our business needs prior to the delivery of goods or performance of services.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">As described in more detail in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_118">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_118">7</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_118"> - Commitments and Contingencies</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 8 of this Annual Report on Form 10-K we signed a Supply Agreement, which was most recently amended in September 2024, with a supplier for the purchase of certain products over the period of 2023 through 2027. As part of the Supply Agreement, we made a $9.0 million deposit during the year ended December 31, 2022, and an additional deposit of $6.0 million in 2023, to secure the supply of certain products through the term of the contract. $3.0 million was refunded to us during the year ended December&#160;31, 2024. If we breach the minimum volume purchase commitment during any applicable year, the supplier is entitled to retain a portion or all of the deposit corresponding to that year. If we terminate the Supply Agreement before January 15, 2027, Supplier will refund the remaining balance of the Deposit. If the supplier breaches its minimum volume supply commitment during any applicable year or portions thereof, our remedies include termination, pursuit of damages, or pursuit of specific performance.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Our research and development expenditures of $134.9 million in 2024 and $187.2 million in 2023. While we expect to continue our investment in research and development in 2025, including enhancements of our existing products, and continued development of other new technology and products, we expect research and development expenses to decline in 2025 as compared to the year ended December 31, 2024 due to recent product transitions.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Cash outflows for capital expenditures of $6.2 million in 2024 and $8.8 million in 2023. We expect to continue to invest in capital expenditures in fiscal 2025 to continue to support manufacturing and expansion of our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Amounts related to future lease payments for operating lease obligations at December&#160;31, 2024, totaling $27.4 million, with $11.5 million expected to be paid within the next 12 months. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_1009">Note 12</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_1009">.</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_1009"> </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_1009">Subsequent Events</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 8 of this Annual Report on Form 10-K for further details on our lease amendment entered into on March 7, 2025.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Payments related to licensing and other arrangements, which are cancellable license agreements with third parties for certain patent rights and technology. Under the terms of these agreements, we may be obligated to pay royalties based on revenue from the sales of licensed products, or minimum royalties, whichever is greater, and license maintenance fees. The future license maintenance fees and minimum royalty payments under the license agreements are not deemed to be material.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Payments related to acquisitions. See &#8220;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ib4009b4d271e45cb81349041984636fa_0-0-1-1-148034">&#8212;</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ib4009b4d271e45cb81349041984636fa_0-0-1-1-148034">Contingent Consideration</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below for further details on potential payments related to our recent acquisitions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements and the adequacy of our available funds will depend on many factors, including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to successfully commercialize and develop products and solutions that address customer needs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the pace of adoption of our products and our ability to obtain new customers in markets; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the progress of our research and development programs and our ability to initiate or expand research programs; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to manage manufacturing and production costs, including purchase obligations, and litigation costs, including the costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the extent to which we engage in collaborations with partners and acquire other businesses or technologies.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If economic, financial, business, or other factors adversely affect our ability to fund our projected operating cash requirements, we may be required to obtain funding through traditional or alternative sources of financing. We cannot be certain that funds will be available on favorable terms, or at all. If we are required and unable to raise additional capital when desired, our business, operating results, and financial condition may be adversely affected. See our risk factor captioned &#8220;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i1c82068fb4244bd4a402f417590b7e43_588171">We are not cash flow positive and may not have sufficient cash to make required payments under the terms of our debt or fund our long-term planned operations</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for more information.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Flow Summary</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206,058)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(259,173)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash provided by investing activities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,004&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,604&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42,987)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,891&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125,041)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(145,678)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash in operating activities include the development of future products and product enhancements, manufacturing, and support functions related to our sales, general, and administrative activities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the year ended December&#160;31, 2024, of $206.1 million was due primarily to a $309.9 million net loss that included non-cash items such as impairment charges of $184.5 million, share-based compensation of $71.0 million, amortization of intangible assets of $27.4 million, depreciation of $13.8 million, and amortization of right-of-use assets of $12.2 million, offset by a gain on debt restructuring of $154.4 million, and accretion of discount and amortization of premium on marketable securities, net of $13.0 million. Cash flow impact from changes in net operating assets and liabilities of $40.6 million, was primarily driven by an increase of $8.3 million in inventory, net, as well as decreases of $26.3 million in accrued expenses and $11.9 million in operating lease liabilities. These uses of cash were partially offset by a decrease of $9.1 million in accounts receivable, net.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the year ended December 31, 2023, of $259.2 million was due primarily to a $306.7 million net loss that was partially offset by non-cash items such as share-based compensation of $72.1 million, a change in the estimated fair value of contingent consideration of $15.1 million, depreciation of $11.5 million, inventory provision of $10.6 million, amortization of intangible assets of $8.3 million, and amortization of right-of-use assets of $6.8 million, offset by accretion of discount and amortization of premium on marketable securities, net of $12.8 million, and deferred income taxes of $11.4 million. Cash flow impact from changes in net operating assets and liabilities of $59.0 million, was primarily attributable to increases of $17.8 million in accounts receivable, net, $13.8 million in inventory, net, $9.0 million in prepaid expenses and other assets, and decreases of $14.9 million in contingent consideration liability, $10.4 million in deferred revenue, and $8.8 million in operating lease liabilities, partially offset by increases of $13.1 million in accrued expenses, and $2.4 million in other liabilities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investing activities consist primarily of purchases, sales and maturities of investments as well as capital expenditures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities for the year ended December&#160;31, 2024, was due primarily to maturities of investments of $594.0 million partially offset by purchases of investments of $498.6 million and capital expenditures of $6.2 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities for the year ended December 31, 2023, was due primarily to maturities of investments of $769.5 million partially offset by purchases of investments of $756.6 million and capital expenditures of $8.8 million.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities during the year ended December&#160;31, 2024, was primarily due to payments made in conjunction with the convertible notes exchange of $50.2 million partially offset by proceeds of $7.7 million from the issuance of common stock through our equity compensation plans.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities during the year ended December 31, 2023, resulted from net proceeds from issuance of common stock under equity offerings of $189.2 million, proceeds of $15.3 million from the issuance of common stock through our equity compensation plans, partially offset by $86.4 million due to the payment of contingent consideration, $7.4 million due to the payment of debt issuance costs, and $1.8 million due to the payment of notes payable.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we did not have any off-balance sheet arrangements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we enter into standard indemnification arrangements. Pursuant to these arrangements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology, or from claims relating to our performance or non-performance under a contract, any defective products supplied by us, or any acts or omissions, or willful misconduct, committed by us or any of our employees, agents or representatives. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments we could be required to make under these agreements is not determinable because it involves claims that may be made against us in future periods but have not yet been made. To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between us and such third parties in connection with such fundraising efforts. To the extent that such indemnification obligations apply to the lawsuits described in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_31">Legal Proceedings</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 3 of this Annual Report on Form 10-K, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification agreements has been recorded as of December&#160;31, 2024.</span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_58"></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based upon our consolidated financial statements, which we have prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, cost of revenue, and operating expenses, and related disclosure of contingent assets and liabilities. Management based its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue Recognition</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables; service and other revenue consist primarily of revenue earned from product maintenance agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods are transferred to our customers, or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Invoicing typically occurs upon shipment, or delivery in the case of an instrument, and payment is typically due within 30 days from invoice. In instances where the right to payment or transfer of title is contingent upon customer acceptance of the product, revenue is deferred until the acceptance criteria has been met. Revenue from instrument service contracts is recognized as the services are rendered, typically evenly over the contract term. Revenue from development agreements generally includes upfront and milestone payments. Revenue for these agreements is recognized when each distinct performance obligation is satisfied.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into, or periodically modify, contracts with customers that include a combination of promised products and services, resulting in arrangements containing multiple performance obligations. We determine whether each product or service is distinct, in order to identify the performance obligations in the contract and allocate the contract transaction price among the distinct performance obligations. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Therefore, instrument revenue is recognized upon transfer of control of the asset to the customer, which is generally upon delivery for sales made to our non-distributor customers and upon shipment for sales made to our distributor customers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for contracts with multiple performance obligations is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using historical average selling prices combined with an assessment of current market conditions. If the standalone selling price is not directly observable, we rely on estimates by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices, and other observable inputs. We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts and sales taxes collected on behalf of governmental authorities. We update the transaction price for expected consideration, subject to constraint. Where we expect, at contract inception, the timing of payments to be consistent with the transfer of goods or services or the contract duration to be one year or less, we do not adjust the transaction price for the effects of a significant financing component. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically modify existing contracts with customers, which could change the scope or the price of the contract, or both. When a contract modification occurs, we exercise judgment to determine if the modification should be accounted for as: (i) a separate contract, (ii) the termination of the original contract and creation of a new contract, (iii) a cumulative catch-up adjustment to the original contract, or a combination thereof. Further, contract modifications require the identification and evaluation of the performance obligations of the modified contract, allocation of revenue to the remaining performance obligations and determination of the period of recognition for each identified performance obligation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our agreements provide options to customers which can be exercised at a future date, such as the option to purchase our product at discounted prices, among others. In accounting for customer options, we determine whether an option is a material right and this may require us to exercise judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right and, therefore, a performance obligation. If the contract gives the customer the option to acquire additional goods or services at their normal standalone selling prices, we would likely determine that the option is not a material right and, therefore, account for it when the customer exercises the option. If the standalone selling price of the option is not directly observable, an estimated standalone selling price is utilized which considers adjustments for discounts that the customer could receive without exercising the option and the likelihood that the option will be exercised. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we generally provide a one-year warranty on instruments. We accrue the cost of the assurance warranty when revenue of the instrument is recognized. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee sales commissions are generally recorded as selling, general, and administrative expense when incurred as the amortization period for such costs, if capitalized, would have been one year or less.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inventories</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out (&#8220;FIFO&#8221;) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs. Determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Combinations</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. The fair values assigned, defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between willing market participants, are based on estimates and assumptions determined by management. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, contingent consideration can be earned by the sellers upon completion of certain future performance milestones. In these cases, a liability is recorded on the acquisition date for an estimate of the acquisition date fair value of the contingent consideration. Changes in the fair value of contingent consideration subsequent to the acquisition date are recognized in operating expenses on our consolidated statements of operations and comprehensive loss.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically use the discounted cash flow method to value our acquired intangible assets. This method requires significant management judgment to forecast future operating results and utilizes significant assumptions such as assumed revenue projections, discount rates and obsolescence factors. The estimates we use to value and amortize intangible assets are consistent with the plans and estimates that we use to manage our business and are based on available historical information and industry estimates and averages. If the subsequent actual results and updated projections of the underlying business activity change compared with the assumptions and projections used to develop these values, we could experience impairment charges. In addition, we have estimated the economic lives of certain acquired assets and these lives are used to calculate depreciation and amortization expense. If our estimates of the economic lives change, depreciation or amortization expense could be accelerated or extended. We capitalize in-process research and development ("IPR&amp;D"), which is considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded on our consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired $55.0 million of IPR&amp;D, and $52.3 million of goodwill in connection with the acquisition of Apton Biosystems, Inc. in the third quarter of 2023. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets with Indefinite Lives </span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8212;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Impairment Assessment</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other intangible assets with indefinite useful lives (i.e., IPR&amp;D) are not amortized, however they are tested annually for impairment, as of the first day of the second and third quarter of our fiscal year, respectively, and whenever events or changes in circumstances indicate that it is more likely than not that the fair value is less than the carrying value. Events that would indicate impairment and trigger an interim impairment test include, but are not limited to, unexpected adverse business conditions, weak demand for a specific product line or business, economic factors, shifting focus to certain lines of business, unanticipated technological changes or competitive activities, loss of key personnel, changes in business strategy and acts by governments or courts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level. We have one reporting unit, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We generally perform our impairment test using a combination of an income and a market approach to determine the fair value of goodwill. The income approach utilizes estimated discounted cash flows, while the market approach utilizes comparable company information. If a quantitative assessment is performed, the evaluation includes management estimates of cash flow projections based on internal future projections and/or use of a market approach by looking at market values of comparable companies, including the observable implied multiples of those companies. Key assumptions include, but are not limited to, revenue and operating income growth rates, discount rates and other factors. We consider peer revenues and earnings trading multiples from companies that have operational and financial characteristics that are similar to the asset under measurement and estimated weighted-average costs of capital. Different assumptions from those made in our analysis could materially affect projected cash flows and the evaluation of assets for impairment. We also consider our market capitalization as a part of our analysis. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions used in the income approach during the fourth quarter of 2024, included revenue growth expectations and a discount rate of <ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="pacb:GoodwillImpairmentDiscountedCashFlowModelDiscountRate" scale="-2" id="f-52">12.0</ix:nonFraction>%. The discount rate was based on the weighted average cost of capital, determined using market, peer company, industry data, and related risk factors. The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. An increase of <ix:nonFraction unitRef="number" contextRef="c-4" decimals="4" name="pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" scale="-4" id="f-53">100</ix:nonFraction> basis points to the discount rate used in our assessment would have resulted in additional goodwill impairment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="pacb:AdditionalGoodwillImpairmentChangeInDiscountRate" format="ixt:num-dot-decimal" scale="6" id="f-54">95</ix:nonFraction>&#160;million. The assessed fair value was deemed reasonable based on a market capitalization reconciliation. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_109">Note 4. Balance Sheet Components</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 8 of this Annual Report on Form 10-K for further information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the IPR&amp;D impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the IPR&amp;D is less than the carrying amount. The qualitative factors include, but are not limited to, macroeconomic conditions, industry-specific conditions, and company-specific conditions. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the IPR&amp;D is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the IPR&amp;D with the carrying value. If the carrying amount of the IPR&amp;D exceeds the fair value, we record an impairment loss based on the difference. We generally perform our impairment test using an income approach to determine the fair value of IPR&amp;D. The income approach utilizes estimated discounted cash flows. If a quantitative assessment is performed, the evaluation includes management estimates of cash flow projections based on internal future projections. Key assumptions include, but are not limited to, revenue projections, revenue growth rates, discount rates and other factors. Different assumptions from those made in our analysis could materially affect projected cash flows and the evaluation of assets for impairment. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative impairment test. There is substantial risk inherent in forecasting revenues and spend associated with research and development, including assumptions around the timing and level of resources and investment to be made.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions used in the income approach during the fourth quarter of 2024, included revenue growth assumptions, a discount rate of <ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="pacb:IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" scale="-2" id="f-55">14.0</ix:nonFraction>%, and an obsolescence factor of <ix:nonNumeric contextRef="c-4" name="pacb:IntangibleAssetImpairmentDiscountedCashFlowModelTerm" format="ixt-sec:duryear" id="f-56">13</ix:nonNumeric> years. The carrying value of the IPR&amp;D exceeded its estimated fair value, and we recorded an impairment of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="f-57">40.0</ix:nonFraction> million in the fourth quarter of 2024, primarily due to a decrease in projected cash flows. An increase of <ix:nonFraction unitRef="number" contextRef="c-4" decimals="4" name="pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" scale="-4" id="f-58">100</ix:nonFraction> basis points to the discount rate used in our analysis would have resulted in additional IPR&amp;D impairment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="pacb:AdditionalIntangibleAssetImpairmentChangeInDiscountRate" format="ixt:num-dot-decimal" scale="6" id="f-59">5</ix:nonFraction>&#160;million. A decrease of <ix:nonNumeric contextRef="c-4" name="pacb:IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" format="ixt-sec:durwordsen" id="f-60">one year</ix:nonNumeric> to the obsolescence factor used in our analysis would have resulted in additional IPR&amp;D impairment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="pacb:AdditionalIntangibleAssetImpairmentChangeInTerm" format="ixt:num-dot-decimal" scale="6" id="f-61">5</ix:nonFraction>&#160;million. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_109">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_109">4</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_109">. </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_109">Balance Sheet Components</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 8 of this Annual Report on Form 10-K for further information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions and estimates about future values are complex and often subjective. They can be affected by a variety of factors, including external factors such as industry and economic trends, and internal factors such as changes in our business strategy and our internal forecasts. For example, if our future operating results do not meet current forecasts or if we experience a sustained decline in our market capitalization that is determined to be indicative of a reduction in fair value of our reporting unit, or if there is a delay in development of the IPR&amp;D or lower projected sales, we may be required to record future impairment charges for goodwill and intangible assets with indefinite lives. Impairment charges could materially decrease our future results of operations and result in lower asset values on our balance sheet. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intangible Assets and Other Finite-Lived Assets </span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8212;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Impairment Assessment</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize finite-lived intangibles assets and generally amortize them on a straight-line basis over the estimated useful lives. We review intangible assets with finite lives and other finite-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset or asset group may not be recoverable. We assess the recoverability of assets based on the estimated undiscounted future cash flows expected to result from the use and eventual disposition of the asset. If the undiscounted future cash flows are less than the carrying amount, we estimate the fair value of the assets and record an impairment loss if the carrying value exceeds the fair value. In light of the changes in circumstances that led to the recoverability assessment, we also assess the remaining estimated useful life of the assets. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to net book value, significant changes in the ability of an asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to estimate the fair values of identifiable intangible assets with finite lives and other finite-lived assets, we estimate the present value of future cash flows from those assets. The key assumptions that we use in our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash flow model are the amount and timing of estimated future cash flows to be generated by the asset over an extended period of time and a rate of return that considers the relative risk of achieving the cash flows, the time value of money, and other factors that a willing market participant would consider. Management judgment is required to estimate the amount and timing of future cash flows and the relative risk of achieving those cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions and estimates about future values and remaining useful lives are complex and often subjective. They can be affected by a variety of factors, including external factors such as industry and economic trends, and internal factors such as changes in our business strategy and our internal forecasts. For example, if our future operating results do not meet current forecasts or if we experience a sustained decline in our market capitalization that is determined to be indicative of a reduction in fair value of the asset group, we may be required to record future impairment charges. Impairment charges could materially decrease our future results of operations and result in lower asset values on our balance sheet.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span id="ib4009b4d271e45cb81349041984636fa_0-0-1-1-148034"></span><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contingent Consideration</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Omniome in the third quarter of 2021, we entered into an arrangement where we were obligated to pay $200 million in cash and equity dependent upon the achievement of a milestone event upon the first commercial shipment of products developed from our acquired sequencing technology. In the third quarter of 2023, we commenced customer shipments of the Onso short-read sequencing instrument. The milestone payment associated with PacBio&#8217;s acquisition of Omniome was triggered in September 2023 once both the Onso instrument and related consumables had been shipped to one customer. Consequently, we paid the former Omniome securityholders milestone consideration of an aggregate of approximately $100.9 million in cash and approximately 9.0 million shares of our common stock in October 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Apton, we entered into an arrangement where we are obligated to pay former holders of Apton's outstanding equity interests $25.0 million upon the achievement of $50 million in revenue associated with a high throughput sequencer using Apton's technology, provided that the milestone event occurs prior to the five-year anniversary of the closing date of the acquisition, which we may elect to pay in cash, shares of our common stock or a combination of cash and shares of our common stock. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_97">Note 2. Business Acquisitions</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 8 of this Annual Report on Form 10-K for further information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability was measured at fair value as of the acquisition date and is remeasured periodically at each reporting date, with changes in fair value recorded as change in fair value of contingent consideration on our consolidated statements of operations and comprehensive loss. For the Apton contingent consideration, the initial measurement and post-acquisition remeasurement required estimates and assumptions using a Monte Carlo simulation to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate to determine the total fair value of the contingent consideration payment as of each reporting period. This method requires significant management judgment, including risk-adjusted forecasted revenues for products and services leveraging Apton's technology and an estimated credit spread. &#160;&#160;&#160;&#160;Assumptions and estimates about future values are complex and often subjective. They can be affected by a variety of factors, including external factors such as industry and economic trends, and internal factors such as changes in our business strategy and our internal forecasts. Future changes in our estimates could result in expenses or gains. For the Omniome contingent consideration, the initial measurement and post-acquisition remeasurement required estimates and assumptions using a scenario-based method that considers a range of potential outcomes of milestone achievement dates and assigned probabilities of occurrence for each outcome. Outcomes were discounted to present value, which was then weighted by the probability of each scenario to determine the total fair value of the contingent consideration payment as of each reporting period. This method requires significant management judgment, including the probability of achieving certain future milestones and discount rates. Refer to </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_106">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_106">3</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_106">. Financial Instruments</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion on valuation assumptions.</span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_61"></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECENT ACCOUNTING PRONOUNCEMENTS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_94">Note 1. Organization and Significant Accounting Policies</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, subsection titled &#8220;Recent Accounting Pronouncements&#8221;, in Part II, Item 8 of this Annual Report on Form 10-K for information regarding applicable recent accounting pronouncements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:15pt;padding-left:55.44pt;text-align:justify;text-indent:-55.44pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 7A.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Interest Rate and Market Risk</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio is exposed to market risk from changes in interest rates. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and cash equivalents and investments. We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we maintain a portfolio of cash equivalents and investments in a variety of securities of high credit quality. The securities in our investment portfolio are not leveraged, are classified as available for sale and are, due to their short-term nature, subject to minimal interest rate risk. The fair market value of our fixed rate securities may be adversely impacted by increases in interest rates while income earned may decline as a result of decreases in interest rates. A hypothetical 100 basis-point (one percentage point) increase or decrease in interest rates compared to rates on December&#160;31, 2024 would have affected the fair value of our investment portfolio by approximately $2.1 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the 2029 Notes were recorded at the undiscounted cash flow amount on our consolidated balance sheets. The 2030 Notes were recorded at fair value as of the closing date of the related exchange transaction, less debt issuance costs, on our consolidated balance sheets. Because the 2029 Notes and 2030 Notes have fixed annual interest rates of 1.50% and 1.375%, respectively, we do not have any economic interest rate exposure or financial statement risk associated with changes in interest rates. The fair value of the Notes, however, may fluctuate when interest rates and the market price of our stock changes. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_112">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_112">5</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_112">. Convertible Senior Notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 8 of this Annual Report on Form 10-K for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Exchange Risk</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue, expense, and capital purchasing activities are primarily transacted in U.S. dollars; however, a portion of our operations is conducted in foreign currencies. As a result, we have foreign exchange exposures relating to non-U.S. dollar denominated cash flows and monetary assets and liabilities that are denominated in currencies other than U.S. dollars. The value of the amounts is exposed to changes in currency exchange rates from the time the transactions are originated, until the time the cash settlement is converted into U.S. dollars. Our foreign currency exposure is primarily concentrated in the Euro. A 10% strengthening of the U.S. dollar exchange rate against all currencies with which we have exposure, after taking into account offsetting positions at December&#160;31, 2024 would have resulted in a $1.8 million decrease in the carrying amounts of those net assets. Actual gains and losses in the future may differ materially from these hypothetical gains and losses based on changes in the timing and amount of foreign currency exchange rate movements and our actual exposure. Our international operations are subject to risks typical of international operations, including, but not limited to, differing economic conditions, changes in political climate, differing tax structures, other regulations and restrictions, and foreign exchange rate volatility.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div></td></tr></table></div><div style="margin-top:15pt;text-align:center"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements </span></div><div style="margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page(s)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_73">Report of Independent Registered Public Accounting Firm (PCAOB ID: </a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-62">42</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_73">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_73">82</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_79">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_79">85</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_549755814571">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_549755814571">86</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_85">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_85">87</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_88">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_88">88</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_91">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_91">90</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Pacific Biosciences of California, Inc.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Pacific Biosciences of California, Inc. (the Company) as of December&#160;31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">,</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2024, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December&#160;31, 2024, based on criteria established in Internal Control&#8211;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated March&#160;17, 2025 expressed an unqualified opinion thereon.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:61.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Revenue recognition - Identification and evaluation of performance obligations</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Description of the Matter </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2024, the Company recognized revenue of $154.0 million, including $136.1 million of product revenue, which consists primarily of instrument sales and related consumables. As described in Note 1 to the consolidated financial statements, the Company may enter into, or periodically modify, contracts with customers that include a combination of promised products and services, resulting in arrangements containing multiple performance obligations. The Company identifies performance obligations for promises to transfer distinct products or services to a customer. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts with customers may contain non-standard terms, requiring management to evaluate if there are additional performance obligations. For example, certain customer contracts provide options to customers which can be exercised at a future date, such as the option to purchase products at discounted prices. The Company assesses whether the specified discounts constitute material rights and, therefore, are performance obligations that are included in the allocation of the transaction price.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing management&#8217;s identification and evaluation of certain performance obligations was challenging and involved a higher degree of judgment due to their non-standard nature.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">How We Addressed the Matter in Our Audit </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of the Company&#8217;s internal controls addressing management&#8217;s identification and evaluation of performance obligations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures included, among others, reading executed contracts for a sample of arrangements and evaluating whether all performance obligations were appropriately identified and accounted for based on terms of the contracts (including specified discounts on current and future purchase options).</span></div><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:61.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Impairment assessment of goodwill and indefinite-lived intangible assets</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Description of the Matter </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company&#8217;s goodwill and indefinite-lived intangible assets balances were $317.8 million and $15.0 million, respectively. As discussed in Note 1 to the consolidated financial statements, goodwill and indefinite-lived intangible assets are tested for impairment at least annually at the reporting unit level and asset level, respectively, or more frequently if indicators of impairment exist.  The Company is comprised of one reporting unit.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 4 to the consolidated financial statements, the Company identified interim indicators of impairment in 2024, resulting in total impairment charges of $184.5 million for the year ended December 31, 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the Company's interim impairment assessments was more complex due to the higher estimation uncertainty in determining the fair value of the reporting unit and the indefinite-lived intangible asset under the income approach. Significant assumptions used in the income approach included revenue growth expectations and the selected discount rate.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">How We Addressed the Matter in Our Audit </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company&#8217;s process for determining the fair value of the reporting unit and the indefinite-lived intangible asset. This included controls over management&#8217;s review of the revenue growth rates and the discount rate. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures included, among others, evaluating the Company's valuation methodology and performing a sensitivity analysis of the assumptions to evaluate the change in the fair value resulting from changes in the assumptions to identify the assumptions that have the most significant impact on the fair value amount. We evaluated the reasonableness of projected revenue growth used within the valuations against analyst expectations, industry and market data and other guideline companies within the same industry. We also involved valuation specialists to assist in evaluating the Company&#8217;s selection of the discount rates. In addition, we inspected the Company&#8217;s reconciliation of the fair value of the reporting unit to the market capitalization of the Company and assessed the results.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-63">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2011.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-64">San Mateo, California</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;17, 2025</span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_76"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current assets </span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-65">55,370</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-66">179,911</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Investments </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-67">334,561</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-68">451,505</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">27,524</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">36,615</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-71">58,755</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-72">56,676</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">18,781</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">17,040</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-75">690</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-76">300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total current assets </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">495,681</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">742,047</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-79">30,505</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-80">36,432</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-81">16,091</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-82">32,593</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">2,422</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-85">389,572</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-86">456,984</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-87">317,761</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-88">462,261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other long-term assets </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-89">9,305</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-90">13,274</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total assets </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-91">1,260,447</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-92">1,746,013</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accounts payable </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-93">16,590</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-94">15,062</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-95">22,595</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-96">45,708</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Deferred revenue, current </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-97">13,864</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-98">16,342</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-99">10,026</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-100">9,591</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other liabilities, current </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-101">3,224</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-102">8,326</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total current liabilities </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-103">66,299</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-104">95,029</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Deferred revenue, non-current </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-105">5,900</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-106">5,530</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Contingent consideration liability, non-current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-107">18,700</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-108">19,550</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-109">14,914</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-110">31,606</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Convertible senior notes, net, non-current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-111">647,494</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-112">892,243</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other liabilities, non-current </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-113">546</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-114">751</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total liabilities </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-115">753,853</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-116">1,044,709</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Commitments and contingencies </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-117"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-7" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-118"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-119"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-120">0.001</ix:nonFraction></ix:nonFraction> par value:</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Authorized <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-121"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-122">50,000</ix:nonFraction></ix:nonFraction> shares; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-123"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-124"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-125"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-126">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding </span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-128">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-129"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-130">0.001</ix:nonFraction></ix:nonFraction> par value:</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Authorized <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-131"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-132">1,000,000</ix:nonFraction></ix:nonFraction> shares; issued and outstanding <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-133"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-134">294,418</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-135"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-136">267,744</ix:nonFraction></ix:nonFraction> shares at December&#160;31, 2024 and December&#160;31, 2023, respectively </span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-137">294</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-138">268</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Additional paid-in capital </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-139">2,654,804</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-140">2,539,892</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-141">422</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-142">219</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accumulated deficit </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-143">2,148,926</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-144">1,839,075</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-145">506,594</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-146">701,304</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-147">1,260,447</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-148">1,746,013</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_91">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_549755814571"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-149">136,149</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-150">183,872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-151">108,699</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-152">17,865</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-153">16,649</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-154">19,605</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-155">154,014</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-156">200,521</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-157">128,304</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Revenue:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of product revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-158">92,284</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-159">127,568</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-160">60,932</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of service and other revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-161">14,057</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-162">14,754</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-163">13,899</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="f-164">9,393</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="f-165">1,983</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="f-166">733</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on purchase commitment</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pacb:LossOnPurchaseCommitment" scale="3" id="f-167">998</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="pacb:LossOnPurchaseCommitment" format="ixt:num-dot-decimal" scale="3" id="f-168">3,436</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="pacb:LossOnPurchaseCommitment" format="ixt:num-dot-decimal" scale="3" id="f-169">3,705</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost of revenue </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-170">116,732</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-171">147,741</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-172">79,269</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-173">37,282</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-174">52,780</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-175">49,035</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expense:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-176">134,922</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-177">187,170</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-178">193,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales, general and administrative </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-179">175,017</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-180">169,818</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-181">160,854</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-182">184,500</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-183">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-184">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger-related expenses</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:fixed-zero" scale="3" id="f-185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-186">9,042</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:fixed-zero" scale="3" id="f-187">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-188">850</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-189">15,060</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-190">2,377</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pacb:AmortizationOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-191">18,006</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="pacb:AmortizationOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-192">6,157</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="pacb:AmortizationOfAcquiredIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-193">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expense </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-194">511,595</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-195">387,247</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-196">356,231</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-197">474,313</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-198">334,467</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-199">307,196</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-200">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-201">2,033</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-202">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on debt restructuring</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-203">154,407</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:fixed-zero" scale="3" id="f-204">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:fixed-zero" scale="3" id="f-205">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-206">13,412</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-207">14,343</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-208">14,690</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-209">23,783</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-210">32,684</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-211">7,638</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-212">309,535</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-213">318,159</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-214">314,248</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-215">316</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-216">11,424</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-217">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-218">309,851</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-219">306,735</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-220">314,248</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-221">203</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-222">4,984</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-223">3,678</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-224">309,648</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-225">301,751</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-226">317,926</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-227"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-228">1.13</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-229"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-230">1.21</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-231"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-232">1.40</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted </span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-233"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-234">1.59</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-235"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-236">1.21</ix:nonFraction></ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-237"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-238">1.40</ix:nonFraction></ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding used in calculating net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-239"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-240">274,488</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-241"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-242">253,629</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-243"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-244">224,550</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted </span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-245">288,366</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-246">253,629</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-247">224,550</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_91">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.024%"/><td style="width:0.1%"/></tr><tr style="height:25pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Common Stock </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Additional <br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Accumulated<br/>Other<br/>Comprehensive <br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Accumulated <br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7.5pt;font-weight:400;line-height:108%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Balance at December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-248">220,978</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-249">221</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-250">2,009,945</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-251">1,087</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-252">1,218,092</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-253">790,987</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-254">314,248</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-255">314,248</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Other comprehensive loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-256">3,678</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-257">3,678</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Issuance of common stock in conjunction with equity plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-258">5,527</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-259">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-260">11,224</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-261">11,230</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Share-based compensation expense</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-262">78,613</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-263">78,613</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Balance at December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-264">226,505</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-265">227</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-266">2,099,782</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-267">4,765</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-268">1,532,340</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-269">562,904</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-270">306,735</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-271">306,735</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Other comprehensive income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-272">4,984</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-273">4,984</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Issuance of common stock following milestone achievement</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="3" id="f-274">8,988</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-275">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="3" id="f-276">84,752</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="3" id="f-277">84,761</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Issuance of common stock in acquisition of Apton</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-278">6,121</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="f-279">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-280">76,636</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-281">76,642</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Issuance of common stock in connection with Apton liquidity event bonus plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-3" name="pacb:StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" scale="3" id="f-282">169</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" format="ixt:num-dot-decimal" scale="3" id="f-283">2,111</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" format="ixt:num-dot-decimal" scale="3" id="f-284">2,111</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-285">20,125</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-286">20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-287">189,180</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-288">189,200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Issuance of common stock in conjunction with equity plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-289">5,836</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-290">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-291">15,313</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-292">15,319</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Share-based compensation expense</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-293">72,118</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-294">72,118</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Balance at December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-295">267,744</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-296">268</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-297">2,539,892</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-298">219</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-299">1,839,075</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-300">701,304</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net loss</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-301">309,851</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-302">309,851</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Other comprehensive income</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-303">203</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-304">203</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Issuance of common stock in conjunction with equity plans</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-305">6,222</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-306">6</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-307">7,697</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-308">7,703</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Issuance of common stock in conjunction with convertible notes exchange</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="3" id="f-309">20,452</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="f-310">20</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="3" id="f-311">36,179</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="3" id="f-312">36,199</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-313">71,036</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-314">71,036</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-315">294,418</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-316">294</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-317">2,654,804</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-318">422</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-319">2,148,926</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-320">506,594</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_91">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="18" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-321">309,851</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-322">306,735</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-323">314,248</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-324">13,774</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-325">11,463</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-326">9,480</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-327">27,412</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-328">8,261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="f-329">913</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-330">12,165</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-331">6,810</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-332">6,925</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-333">71,036</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-334">72,118</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-335">78,613</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-336">184,500</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-338">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger-related compensation expense</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NoncashMergerRelatedCosts" format="ixt:fixed-zero" scale="3" id="f-339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NoncashMergerRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-340">3,395</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NoncashMergerRelatedCosts" format="ixt:fixed-zero" scale="3" id="f-341">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-343">2,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-344">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on debt restructuring</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-345">154,407</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:fixed-zero" scale="3" id="f-346">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:fixed-zero" scale="3" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of discount and amortization of premium on marketable securities, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-348">13,044</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-349">12,840</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="f-350">244</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in the estimated fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-351">850</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-352">15,060</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-353">2,377</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory provision</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="f-354">4,618</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="f-355">10,584</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="f-356">6,027</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="f-357">205</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-358">11,424</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:fixed-zero" scale="3" id="f-359">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-360">628</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-361">1,059</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-362">918</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in assets and liabilities </span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-363">9,091</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-364">17,829</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-365">5,455</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-366">8,320</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-367">13,841</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-368">33,906</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-369">2,228</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-370">8,984</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-371">12,324</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-372">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-373">206</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-374">1,025</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-375">26,342</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-376">13,103</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-377">3,651</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-378">2,108</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-379">10,420</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-380">3,734</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-381">11,920</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-382">8,759</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-383">7,724</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liability</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pacb:IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="pacb:IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-385">14,882</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="pacb:IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-386">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-387">4,612</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-388">2,449</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="f-389">887</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-390">206,058</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-391">259,173</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-392">263,211</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property and equipment </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-393">6,188</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-394">8,843</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-395">16,750</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-397">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="f-398">179</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for purchases of acquired entities, net of cash acquired</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="f-400">102</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-401">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of investments </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-402">498,635</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-403">756,567</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-404">442,788</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales of investments </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-405">34,856</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="f-406">595</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="f-407">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities of investments </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-408">593,971</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-409">769,521</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-410">575,800</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-411">124,004</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-412">4,604</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-413">116,083</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity offerings, net of issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-415">189,200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-416">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock from equity plans</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-417">7,703</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-418">15,319</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-419">11,230</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-421">7,375</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-422">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-424">86,411</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-425">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="18" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments made in conjunction with convertible notes exchange</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pacb:PaymentsInConjunctionWithNotesExchange" format="ixt:num-dot-decimal" scale="3" id="f-426">50,200</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="pacb:PaymentsInConjunctionWithNotesExchange" format="ixt:fixed-zero" scale="3" id="f-427">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="pacb:PaymentsInConjunctionWithNotesExchange" format="ixt:fixed-zero" scale="3" id="f-428">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable principal payoff </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="f-429">490</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-430">1,842</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-431">1,608</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-432">42,987</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-433">108,891</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-434">9,622</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-435">125,041</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-436">145,678</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-437">137,506</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-438">182,633</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-439">328,311</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-440">465,817</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-441">57,592</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-442">182,633</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-443">328,311</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-444">55,370</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-445">179,911</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-446">325,089</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash at end of period </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-447">2,222</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-448">2,722</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-449">3,222</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-450">57,592</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-451">182,633</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-452">328,311</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-453">14,805</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-454">15,687</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-455">14,049</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory transferred to property and equipment </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="pacb:TransferOfInventoryToPropertyAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-456">4,194</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="pacb:TransferOfInventoryToPropertyAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-457">3,984</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="pacb:TransferOfInventoryToPropertyAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-458">2,812</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment transferred to inventory</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" format="ixt:num-dot-decimal" scale="3" id="f-459">2,572</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" format="ixt:num-dot-decimal" scale="3" id="f-460">7,022</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="3" id="f-461">715</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use asset and liability additions and modifications</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-462">18,253</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-463">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-464">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in conjunction with convertible notes exchange</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-465">36,199</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-466">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-467">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in acquisition of Apton and Omniome</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-469">76,642</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-470">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in connection with Apton liquidity event bonus plan</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-472">2,111</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-473">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible notes exchange</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NotesIssued1" format="ixt:fixed-zero" scale="3" id="f-474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NotesIssued1" format="ixt:num-dot-decimal" scale="3" id="f-475">441,000</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NotesIssued1" format="ixt:fixed-zero" scale="3" id="f-476">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock following milestone achievement</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-477">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-478">84,761</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-479">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_91">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></td></tr></table></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_94"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-480" continuedAt="f-480-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 1.  ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Overview</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing technology and our Sequencing by Binding (SBB) short-read sequencing technology. Our products address solutions across a broad set of applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Long-read sequencing was recognized by the journal Nature Methods as its &#8220;method of the year&#8221; for 2022 for its contributions to biological understanding and future potential. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-read sequencing</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been applied to produce telomere-to-telomere genomes of humans, pangenome references, and has been recognized for its ability to provide more complete views of human variation</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus is on creating some of the world's most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to &#8220;PacBio,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; and &#8220;our&#8221; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-481" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-482" continuedAt="f-482-1" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-482-1">The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates, including those relating to the valuation of inventory, fair value of contingent consideration, valuation of acquired intangible assets, useful lives assigned to finite-lived assets, asset impairment assessments, computation of provisions for income taxes, and valuations related to our convertible senior notes. While the extent of the potential impact of current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of December&#160;31, 2024. Actual results could differ materially from these estimates.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-483" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Functional Currency</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. dollar is the functional currency of our international operations. We remeasure foreign subsidiaries monetary assets and liabilities to the U.S. dollar and record net gains or losses from remeasurement in other income, net, on our consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-480-1" continuedAt="f-480-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-484" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#8217; securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive income (loss) in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net. We have the ability to hold, and do not intend to sell investments in unrealized loss positions before the recovery of their amortized cost bases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities, and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash includes cash that is not readily available for use in the Company&#8217;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-485" continuedAt="f-485-1" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Concentration and Other Risks</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist principally of interest-bearing investments and trade receivables. We maintain cash, cash equivalents, and investments with various major financial institutions. The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing. At December&#160;31, 2024, most of our cash was deposited with U.S. financial institutions. Our investment policy generally restricts the amount of credit exposure to any one issuer. There is no limit to the percentage of the portfolio that may be maintained in securities issued by the U.S. Treasury and U.S. Government Agencies, or other securities fully backed by U.S. Treasury or Government agencies. We have not experienced significant credit losses from financial institutions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trade receivables are derived from revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers&#8217; financial condition and, generally, require no collateral from our customers. The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review our trade receivables including consideration of factors such as historical experience, the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. We have not experienced any significant credit losses to date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, and 2023, no customer accounted for 10% or more of our total revenue. For the year ended December&#160;31, 2022, one customer exceeded <ix:nonFraction unitRef="number" contextRef="c-61" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-486">10</ix:nonFraction>% of our total revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, <ix:nonFraction unitRef="number" contextRef="c-62" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-487">36</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-63" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-488">49</ix:nonFraction>% of our accounts receivable were from domestic customers, respectively. As of December&#160;31, 2024, no customer represented 10% or more of our net accounts receivable. As of December&#160;31, 2023, one customer represented <ix:nonFraction unitRef="number" contextRef="c-64" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-489">10</ix:nonFraction>% of our net accounts receivable.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-485-1">We currently purchase several key parts and components used in the manufacture of our products from a limited number of suppliers. Generally, we have been able to obtain an adequate supply of such parts and components but in certain instances have incurred additional costs to secure a supply of constrained material. An extended interruption in the supply of parts and components currently obtained from our suppliers could adversely affect our business and consolidated financial statements.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-480-2" continuedAt="f-480-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-490" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inventory, Net</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value on a first-in, first-out (&#8220;FIFO&#8221;) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs. Determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-491" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Property and Equipment, Net</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, reviewed regularly for impairment, and depreciated over the estimated useful lives of the assets, using the straight-line method. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred. Transfers of assets between property and equipment, net, and inventory are transferred at standard cost and recognized at carrying value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-492" continuedAt="f-492-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated useful lives of the major classes of property and equipment are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-65" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-493">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-66" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-494">10</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-67" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-495">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-68" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-496">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-69" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-497">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-70" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-498">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-71" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-499">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-72" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-500">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-73" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-501">5</ix:nonNumeric> years</span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-502" continuedAt="f-502-1" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Operating Leases</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-502-1">We have various operating lease agreements for office, research and development, manufacturing and distribution facilities, including our headquarters location in Menlo Park, California. As of December 31, 2024, these leases had remaining lease terms that expire between 2025 and 2027. We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. Operating lease expense is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-503" continuedAt="f-503-1" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Combinations</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-480-3" continuedAt="f-480-4"><ix:continuation id="f-503-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, contingent consideration can be earned by the sellers upon completion of certain future performance milestones. In these cases, a liability is recorded on the acquisition date for an estimate of the acquisition date fair value of the contingent consideration. These estimates require significant management judgment, including probabilities of achieving certain future milestones. Changes in the fair value of the contingent consideration subsequent to the acquisition date are recognized in operating expense on our consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded on our consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-504" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets with Indefinite Lives</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and capitalized in-process research and development (&#8220;IPR&amp;D&#8221;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is assessed for impairment and then amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually. We perform annual impairment testing of goodwill as of the first day of the second quarter, or more frequently if indicators of impairment exist. We perform annual impairment testing of IPR&amp;D as of the first day of the third quarter, or more frequently if indicators of impairment exist. Events that would indicate impairment and trigger an interim impairment test include, but are not limited to, unexpected adverse business conditions, weak demand for a specific product line or business, economic factors, shifting focus to certain lines of business, unanticipated technological changes or competitive activities, loss of key personnel, changes in business strategy and acts by governments or courts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level. We have <ix:nonFraction unitRef="unit" contextRef="c-1" decimals="0" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-505">one</ix:nonFraction> reporting unit, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test. We generally perform our impairment test using a combination of an income and a market approach to determine the fair value of goodwill. The income approach utilizes estimated discounted cash flows, while the market approach utilizes comparable company information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the IPR&amp;D impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the IPR&amp;D is less than the carrying amount. The qualitative factors include, but are not limited to, macroeconomic conditions, industry-specific conditions, and company-specific conditions. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the IPR&amp;D is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the IPR&amp;D with the carrying value. If the carrying amount of the IPR&amp;D exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative impairment test.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-480-4" continuedAt="f-480-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="f-506" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intangible Assets and Other Finite-Lived Assets</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangibles assets include our acquired developed technology and customer relationships. We capitalize finite-lived intangibles assets and generally amortize them on a straight-line basis over the estimated useful lives. Intangible assets purchased as part of an acquisition are included in Intangible assets, net, on our consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review intangible assets with finite lives and other finite-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. We assess the recoverability of assets based on the estimated undiscounted future cash flows expected to result from the use and eventual disposition of the asset. If the undiscounted future cash flows are less than the carrying amount, the asset is impaired. In light of the changes in circumstances that led to the recoverability assessment, we also assess the remaining estimated useful life of the assets. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to net book value, significant changes in the ability of an asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to estimate the fair values of identifiable intangible assets with finite lives and other finite-lived assets, we estimate the present value of future cash flows from those assets. The key assumptions that we use in our cash flow model are the amount and timing of estimated future cash flows to be generated by the asset over an extended period of time and a rate of return that considers the relative risk of achieving the cash flows, the time value of money, and other factors that a willing market participant would consider. Management judgment is required to estimate the amount and timing of future cash flows and the relative risk of achieving those cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-507" continuedAt="f-507-1" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue Recognition</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables; service and other revenue consist primarily of revenue earned from product maintenance agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods are transferred to our customers, or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Invoicing typically occurs upon shipment, or delivery in the case of an instrument, and payment is typically due within 30 days from invoice. In instances where the right to payment or transfer of title is contingent upon customer acceptance of the product, revenue is deferred until the acceptance criteria has been met. Revenue from instrument service contracts is recognized as the services are rendered, typically evenly over the contract term. Revenue from development agreements generally includes upfront and milestone payments. Revenue for these agreements is recognized when each distinct performance obligation is satisfied.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into, or periodically modify, contracts with customers that include a combination of promised products and services, resulting in arrangements containing multiple performance obligations. We determine whether each product or service is distinct, in order to identify the performance obligations in the contract and allocate the contract transaction price among the distinct performance obligations. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Therefore, instrument revenue is recognized upon transfer of control of the asset to the customer, which is generally upon delivery for sales made to our non-distributor customers and upon shipment for sales made to our distributor customers. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-480-5" continuedAt="f-480-6"><ix:continuation id="f-507-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for contracts with multiple performance obligations is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using historical average selling prices combined with an assessment of current market conditions. If the standalone selling price is not directly observable, we rely on estimates by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices, and other observable inputs. We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts and sales taxes collected on behalf of governmental authorities. We update the transaction price for expected consideration, subject to constraint. Where we expect, at contract inception, the timing of payments to be consistent with the transfer of goods or services or the contract duration to be one year or less, we do not adjust the transaction price for the effects of a significant financing component </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically modify existing contracts with customers, which could change the scope or the price of the contract, or both. When a contract modification occurs, we exercise judgment to determine if the modification should be accounted for as: (i) a separate contract, (ii) the termination of the original contract and creation of a new contract, (iii) a cumulative catch-up adjustment to the original contract, or a combination thereof. Further, contract modifications require the identification and evaluation of the performance obligations of the modified contract, allocation of revenue to the remaining performance obligations and determination of the period of recognition for each identified performance obligation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our agreements provide options to customers which can be exercised at a future date, such as the option to purchase our product at discounted prices, among others. In accounting for customer options, we determine whether an option is a material right and this may require us to exercise judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right and, therefore, a performance obligation. If the contract gives the customer the option to acquire additional goods or services at their normal standalone selling prices, we would likely determine that the option is not a material right and, therefore, account for it when the customer exercises the option. If the standalone selling price of the option is not directly observable, an estimated standalone selling price is utilized which considers adjustments for discounts that the customer could receive without exercising the option and the likelihood that the option will be exercised. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we generally provide a <ix:nonNumeric contextRef="c-1" name="pacb:StandardProductWarrantyPeriod" format="ixt-sec:durwordsen" id="f-508">one-year</ix:nonNumeric> warranty on instruments. We accrue the cost of the assurance warranty when revenue of the instrument is recognized. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee sales commissions are generally recorded as selling, general, and administrative expense when incurred as the amortization period for such costs, if capitalized, would have been one year or less.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-509" continuedAt="f-509-1" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Revenue</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue reflects the direct cost of product components, third-party manufacturing services, and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain, and support our instruments, consumables, and services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing overhead is predominantly comprised of labor and facility costs. We capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support our installed customer base. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-480-6" continuedAt="f-480-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-510" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists primarily of expenses for personnel engaged in the development of our core technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, partner development costs, facilities costs, and other related overhead. We expense research and development costs during the period in which the costs are incurred. We defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" id="f-511" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Credit Losses</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade accounts receivable</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review the allowance by considering factors such as the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. Credit loss expense was immaterial for the years ended December&#160;31, 2024, 2023, and 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-sale debt securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities. We regularly assess whether our securities in an unrealized loss position are credit related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income. Unrealized losses that are not credit related are included in accumulated other comprehensive income (loss). The unrealized losses on our investments are mainly attributable to government securities, including U.S. government and U.S. agency bond securities, impacted by movements in market rates and not due to issuer credit risk. We have the ability to hold and do not intend to sell the investments in unrealized loss positions before the recovery of their amortized cost bases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruptions associated with epidemics or pandemics, or other customer-specific factors.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-512" continuedAt="f-512-1" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Income Taxes</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. The effect of a change in tax rates on the deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-512-1">We regularly review our positions taken relative to income taxes. To the extent our tax positions are more likely than not going to result in additional taxes, we accrue the estimated amount of tax related to such uncertain positions.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-513" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share-Based Compensation</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize share-based compensation expense for share-based payments, including stock options, restricted stock units, performance stock units and stock issued under our employee stock purchase plan ("ESPP") based on the grant-date fair value. We estimate the fair value of stock options and ESPP using an option-pricing model. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_124">Note 9. Stockholders&#8217; Equity</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information regarding share-based compensation.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-480-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-514" continuedAt="f-514-1" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Comprehensive Income (Loss)</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-514-1">Other comprehensive income (loss) is comprised of unrealized gains (losses) on our investment securities.</ix:continuation> </span></div><ix:continuation id="f-509-1"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Shipping and Handling</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to shipping and handling are included in cost of revenues for all periods presented.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-515" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Earnings per Share</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing diluted net loss by the weighted-average number of shares of common stock outstanding and potentially dilutive shares outstanding during the period. We calculate the potential dilutive effect of outstanding stock options, restricted stock units, and common stock issuable pursuant to our ESPP, using the treasury stock method. Potentially dilutive common shares issuable upon conversion of convertible senior notes are determined using the if-converted method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="pacb:RecentlyAdoptedAccountingStandardsPolicyTextBlock" id="f-516" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This ASU improves segment disclosure requirements, primarily through enhanced disclosure requirements for significant segment expenses on an annual and interim basis. The improved disclosure requirements apply to all public entities that are required to report segment information, including those with only one reportable segment. The standard was effective for us beginning in fiscal year 2024 and interim periods within fiscal year 2025. We adopted this ASU for our fiscal year ending December 31, 2024 and applied the amendments retrospectively to all prior periods presented in the consolidated financial statements. There was no impact on the Company&#8217;s reportable segments identified. Additional required disclosures have been included in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_130">Note 11. Segment and Geographic Information</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-517" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Pending Adoption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-04, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt With Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard will be effective for us beginning in the first quarter of fiscal year 2026, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-04 on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to provide disaggregated disclosures, within the notes to the financial statements, of specified categories of expenses that are included in line items on the face of the income statement. The standard will be effective for us beginning in fiscal year 2027, and interim periods within fiscal year 2028, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard will be effective for us beginning in fiscal year 2025, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2023-09 on the consolidated financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-518" continuedAt="f-518-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 2.  BUSINESS ACQUISITIONS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Apton Biosystems</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2023, we acquired Apton Biosystems, Inc. (&#8220;Apton&#8221;), a California-based genomics company focused on developing a high throughput short-read sequencer using highly differentiated optics and image processing, paired with novel clustering and chemistry (the &#8220;Apton acquisition&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Apton acquisition, all outstanding equity securities of Apton were cancelled in exchange for shares of our common stock with a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="f-519">76.6</ix:nonFraction> million, cash of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="f-520">0.2</ix:nonFraction> million, and contingent consideration with an estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-521">18.5</ix:nonFraction> million. Excluded from consideration transferred was $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="pacb:StockBasedCompensationExpenseExcludedFromConsiderationTransferred" scale="6" id="f-522">1.3</ix:nonFraction> million attributable to accelerated share-based compensation expense. The fair value of the <ix:nonFraction unitRef="shares" contextRef="c-74" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-523">6,121,571</ix:nonFraction> common shares issued was determined based on the closing market price of our common stock on the acquisition date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Apton acquisition, contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-524">25.0</ix:nonFraction>&#160;million, which we may elect to pay in cash, shares of our common stock or a combination of cash and shares of our common stock, is due upon the achievement of a milestone, defined as the achievement of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="pacb:BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" format="ixt:num-dot-decimal" scale="6" id="f-525">50.0</ix:nonFraction>&#160;million in revenue associated with Apton's technology, provided that the milestone event occurs prior to the <ix:nonNumeric contextRef="c-75" name="pacb:BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" format="ixt-sec:durwordsen" id="f-526">five-year</ix:nonNumeric> anniversary of the closing date of the acquisition. At this time, the number of shares, if any, to be issued in connection with the achievement of the specified milestone is not known and will be calculated based on the daily volume-weighted average price of our common stock for the <span style="-sec-ix-hidden:f-527">twenty</span> trading days ending on and including the fifth trading day immediately prior to the occurrence of the specified milestone. Upon achievement of the milestone, we may pay cash in lieu of our common stock to ensure that the issuance of our common stock does not exceed <ix:nonFraction unitRef="number" contextRef="c-77" decimals="3" name="pacb:PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" scale="-2" id="f-528">19.9</ix:nonFraction>% of our outstanding shares of common stock then outstanding.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized on our consolidated statements of operations and comprehensive loss. The fair value of the contingent consideration liability is calculated, with the assistance from a third-party valuation firm, using a Monte Carlo simulation to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was accounted for as a business combination and, accordingly, the total fair value of the consideration transferred was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values on the acquisition date. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="f-529" continuedAt="f-529-1" escape="true">As of December 31, 2023, the major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-529-1"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="f-530">97</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-531">55,000</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-532">52,287</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets, current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" id="f-533">153</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-534">11,338</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-535">2,191</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-536">94,008</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have finalized the purchase price allocation for the </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apton acquisition. There</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were no material adjustments from those amounts disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred costs related to the Apton acquisition of approximately $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="f-537">9.0</ix:nonFraction>&#160;million during the year ended December 31, 2023, which are included in merger-related expenses on our consolidated statement of operations and comprehensive loss. Merger-related expenses include $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" format="ixt:num-dot-decimal" scale="6" id="f-538">2.8</ix:nonFraction>&#160;million relating to a liquidity event bonus plan that was treated as a separate transaction and included the issuance of <ix:nonFraction unitRef="shares" contextRef="c-80" decimals="0" name="pacb:StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" format="ixt:num-dot-decimal" scale="0" id="f-539">168,621</ix:nonFraction> shares of common stock that were issued with a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" format="ixt:num-dot-decimal" scale="6" id="f-540">2.1</ix:nonFraction>&#160;million based on the closing market price of our common stock on the acquisition date. As a result, the total shares issued in connection with the Apton acquisition were <ix:nonFraction unitRef="shares" contextRef="c-79" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="6" id="f-541">6.3</ix:nonFraction>&#160;million shares of common stock. </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-518-1">The excess of the value of consideration paid over the aggregate fair value of those net assets has been recorded as goodwill. We recognized goodwill of $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-542">52.3</ix:nonFraction>&#160;million, which is primarily attributable to the synergies expected to occur from the integration of Apton and is not deductible for income tax purposes. We allocated $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="f-543">55.0</ix:nonFraction> million of the purchase price to acquired IPR&amp;D. The fair value of the IPR&amp;D was determined, with the assistance of a third-party valuation firm, using an income approach based on a forecast of expected future cash flows. Expected future cash flows utilize significant assumptions such as revenue projections and discount rate.</ix:continuation> </span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_106"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="f-544" continuedAt="f-544-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 3.  FINANCIAL INSTRUMENTS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy established under GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 1: quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-545" continuedAt="f-545-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-545-1">The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.</ix:continuation> </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-544-1" continuedAt="f-544-2"><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-546" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-547">55,370</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-550">55,370</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-551">70,172</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-552">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-553">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-554">70,172</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-556">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-559">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-560">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-561">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-562">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-563">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-564">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-566">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-567">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-568">109,739</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-569">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-570">109,739</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-571">55,370</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-572">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-574">55,370</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-575">70,172</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-576">109,739</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-577">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-578">179,911</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-583">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-584">9,947</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-585">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-586">9,947</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-588">46,905</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-590">46,905</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-591">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-592">88,579</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-593">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-594">88,579</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-595">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-596">287,656</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-597">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-598">287,656</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-599">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-600">352,979</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-601">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-602">352,979</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-603">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-604">334,561</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-605">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-606">334,561</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-607">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-608">451,505</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-609">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-610">451,505</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" scale="3" id="f-611">690</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-612">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" scale="3" id="f-614">690</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" scale="3" id="f-615">300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-616">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-617">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" scale="3" id="f-618">300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-619">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-620">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-622">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-623">2,422</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-624">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-625">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-626">2,422</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-627">57,592</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-628">334,561</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-630">392,153</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-631">72,894</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-632">561,244</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-633">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-634">634,138</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration - Apton acquisition</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-635">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-636">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-637">18,700</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-638">18,700</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-639">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-640">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-641">19,550</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-642">19,550</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities measured at fair value </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-645">18,700</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-646">18,700</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-647">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-648">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-649">19,550</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-650">19,550</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and our valuation techniques did not change compared to the prior year.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contingent Consideration - Apton</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify contingent consideration, which was incurred in connection with the acquisition of Apton, within Level 3 as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value. Estimates and assumptions used in the Monte Carlo simulation include risk-adjusted forecasted revenues for products and services leveraging Apton's technology and an estimated credit spread.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of the contingent consideration liability based on the simulated revenue of the Company through the <ix:nonNumeric contextRef="c-75" name="pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" format="ixt-sec:durwordsen" id="f-651">five-year</ix:nonNumeric> anniversary of the closing date of the acquisition. As of December&#160;31, 2024, the key input used in the determination of the fair value included projected revenues of the Company relating to the high-throughput short-read products and services leveraging Apton's technology. The assumptions used in our valuation are inherently subject to uncertainty. A decrease in the projected revenues would result in a decrease in the fair value of the liability. The discount rates used are the sum of the U.S. risk-free rate and the estimated subordinated credit spread for CCC+ credit rating, which ranges from <ix:nonFraction unitRef="number" contextRef="c-158" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-652">9.4</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-159" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-653">9.6</ix:nonFraction>%. Changes in our estimated subordinated credit spread can result in changes in the fair value of the contingent consideration liability, where a lower credit spread may result in an increased liability valuation.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-544-2" continuedAt="f-544-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-654" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the contingent consideration liability related to the Apton acquisition for the year ended December&#160;31, 2024 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance as of December 31, 2023</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-655">19,550</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in estimated fair value</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-656">850</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance as of December 31, 2024</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-657">18,700</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the fair value are recorded as the change in fair value of contingent consideration on our consolidated statement of operations and comprehensive loss.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contingent Consideration - Omniome</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2023, we achieved the commercial milestone in connection with the 2021 acquisition of Omniome. Consequently, former Omniome securityholders were entitled to receive as milestone consideration, among other things, an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-658">100.9</ix:nonFraction>&#160;million in cash and approximately <ix:nonFraction unitRef="shares" contextRef="c-161" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="6" id="f-659">9.0</ix:nonFraction>&#160;million shares of our common stock, representing $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="6" id="f-660">95.9</ix:nonFraction>&#160;million divided by the volume-weighted average of the trading prices of our common stock for the <span style="-sec-ix-hidden:f-661">twenty</span> trading days ending with and including the trading day that was two days immediately prior to the achievement of the milestone. The $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="6" id="f-662">95.9</ix:nonFraction>&#160;million represents the $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="6" id="f-663">100.0</ix:nonFraction>&#160;million that was to be paid in shares of our common stock offset by $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="6" id="f-664">4.1</ix:nonFraction>&#160;million attributable to stock options issued by PacBio in replacement of Omniome&#8217;s unvested options as part of the transaction, pursuant to the terms of the Omniome merger agreement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the achievement of the commercial milestone, $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="pacb:PaymentsForContingentConsiderationRevenueAchievementMilestone" format="ixt:num-dot-decimal" scale="6" id="f-665">101.3</ix:nonFraction>&#160;million of the contingent consideration, which includes certain payroll taxes, was paid during the year ended December 31, 2023. Additionally, <ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-666">8,988,391</ix:nonFraction> shares were issued at a value of $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="6" id="f-667">84.8</ix:nonFraction>&#160;million to the former Omniome securityholders.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-544-3" continuedAt="f-544-4"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="f-668" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash, cash equivalents, restricted cash, and investments:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized<br/>Cost </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-669">55,370</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-670">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-671">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-672">55,370</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="f-673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-676">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-677">55,370</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-680">55,370</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="f-681">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-682">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-683">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-685">46,746</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-686">184</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-687">25</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-688">46,905</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-689">287,393</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-690">418</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-691">155</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-692">287,656</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-693">334,139</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-694">602</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-695">180</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-696">334,561</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and investments </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-697">389,509</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-698">602</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-699">180</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-700">389,931</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-701">690</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-702">690</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-703">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-704">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-705">70,172</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-706">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-707">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-708">70,172</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="f-709">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-710">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-711">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-712">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-713">109,786</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-714">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-715">60</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-716">109,739</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-717">179,958</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-718">13</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-719">60</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-720">179,911</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-721">9,947</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-722">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-723">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-724">9,947</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-725">88,263</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-726">373</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-727">57</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-728">88,579</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-729">353,029</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-730">478</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-731">528</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-732">352,979</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-733">451,239</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-734">851</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-735">585</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-736">451,505</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and investments </span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-737">631,197</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-738">864</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-739">645</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-740">631,416</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-741">300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-742">300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-743">2,422</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-744">2,422</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of December&#160;31, 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" format="ixt:num-dot-decimal" scale="3" id="f-745">238,957</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through 5 years </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" format="ixt:num-dot-decimal" scale="3" id="f-746">95,604</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-747">334,561</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-544-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income included in other income, net on our consolidated statements of operations and comprehensive loss was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="f-748">24.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="f-749">32.8</ix:nonFraction>&#160;million for the years ended December&#160;31, 2024 and 2023, respectively.</span></div></ix:continuation><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_109"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-750" continuedAt="f-750-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOTE 4.  BALANCE SHEET COMPONENTS </span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Inventory, Net</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-751" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, net, consisted of the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchased materials</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-752">45,270</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-753">32,434</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-754">22,172</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-755">27,653</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-756">14,081</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-757">15,746</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory, gross</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="f-758">81,523</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="f-759">75,833</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory reserve</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="f-760">22,768</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="f-761">19,157</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory, net</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-762">58,755</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-763">56,676</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Property and Equipment, Net</span></td></tr></table></div><ix:continuation id="f-492-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment and machinery </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-764">47,273</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-765">44,907</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-766">33,770</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-767">35,226</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-768">18,882</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-769">19,528</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-770">7,280</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-771">6,628</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-772">2,972</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-773">3,594</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-774">2,276</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-775">1,343</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-776">112,453</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-777">111,226</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-778">81,948</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-779">74,794</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-780">30,505</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-781">36,432</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress consists of capitalizable costs that have been incurred for the construction of finite-lived assets and is primarily comprised of amounts that will be classified as lab equipment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense during the years ended December&#160;31, 2024, 2023, and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-782">13.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-783">11.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-784">9.5</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the interim impairment test of goodwill in the second and fourth quarter of 2024, we also performed a recoverability test for the definite-lived asset group, which includes property and equipment, noting <ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-785"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-786">no</ix:nonFraction></ix:nonFraction> impairment.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-750-1" continuedAt="f-750-2"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Goodwill and Intangible Assets</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is reviewed for impairment at least annually as of the first day of the second quarter, or more frequently if an event occurs indicating impairment. We performed our annual assessment for goodwill impairment, noting <ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-787">no</ix:nonFraction> impairment. Based primarily on the sustained decrease in our stock price during the second quarter and overall market capitalization as of the end of the second quarter of 2024 as well as other factors, we concluded that there was an indicator that it was more likely than not that the fair value of the reporting unit was less than its carrying amount that required an interim impairment test be performed on goodwill. As a result of the interim impairment test performed as of June 30, 2024, we concluded that the carrying amount of the entity-level reporting unit exceeded fair value and recorded $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-788">93.2</ix:nonFraction> million of goodwill impairment. The impairment charge is included on our consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decline in the fair value of the reporting unit below its carrying value as of June 30, 2024 resulted primarily from the decline in our stock price and changes in the timing of expected future cash flows as compared to our initial long-term plan, due to continued impact of longer than expected median sales cycles resulting from various factors. We performed our impairment test using a combination of an income and a market approach to determine the fair value of the reporting unit. The income approach utilized estimated discounted cash flows, while the market approach utilized comparable company information. Significant assumptions used in the income approach included revenue growth expectations and a selected discount rate of <ix:nonFraction unitRef="number" contextRef="c-2" decimals="3" name="pacb:GoodwillImpairmentDiscountedCashFlowModelDiscountRate" scale="-2" id="f-789">12.0</ix:nonFraction>%. The discount rate was based on the weighted average cost of capital, determined using market, peer company, industry data, and related risk factors. The assessment is a level 3 fair value measurement due to its reliance on certain unobservable inputs and significant management judgment. The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. An increase of <ix:nonFraction unitRef="number" contextRef="c-2" decimals="4" name="pacb:GoodwillImpairmentIncreaseInBasisPointDiscountRate" scale="-4" id="f-790">100</ix:nonFraction> basis points to the discount rate used in our assessment would have resulted in additional goodwill impairment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="pacb:AdditionalGoodwillImpairmentChangeInDiscountRate" format="ixt:num-dot-decimal" scale="6" id="f-791">85</ix:nonFraction>&#160;million. The assessed fair value was deemed reasonable based on a market capitalization reconciliation and a supportable control premium. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the fourth quarter of 2024, we concluded that the significant increase in the carrying value of the reporting unit resulting primarily from the debt restructuring during the quarter and changes in the timing and amount of expected future cash flows due to macroeconomic headwinds, among other factors, indicated that it was more likely than not that the fair value of the reporting unit was less than its carrying amount that required an interim impairment test be performed on goodwill. As a result of the impairment test performed as of December 31, 2024, we concluded that the carrying amount of the entity-level reporting unit exceeded fair value and recorded $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-792">51.3</ix:nonFraction>&#160;million of goodwill impairment. The impairment charge is included on our consolidated statements of operations and comprehensive loss for the year ended December 31, 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed our impairment test consistent with the approach used to determine the fair value of the reporting unit in the second quarter of 2024. Significant assumptions used in the income approach included revenue growth expectations and a selected discount rate of <ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="pacb:GoodwillImpairmentDiscountedCashFlowModelDiscountRate" scale="-2" id="f-793">12.0</ix:nonFraction>%. The assessment is a Level 3 fair value measurement due to its reliance on certain unobservable inputs and significant management judgment. The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. An increase of <ix:nonFraction unitRef="number" contextRef="c-4" decimals="4" name="pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" scale="-4" id="f-794">100</ix:nonFraction> basis points to the discount rate used in our assessment would have resulted in additional goodwill impairment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="pacb:AdditionalGoodwillImpairmentChangeInDiscountRate" format="ixt:num-dot-decimal" scale="6" id="f-795">95</ix:nonFraction>&#160;million. The assessed fair value was deemed reasonable based on a market capitalization reconciliation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the impairments, the carrying value of goodwill now approximates fair value. Changes in our future operating results, cash flows, share price, market capitalization or discount rates, among others, used when conducting future goodwill impairment tests could affect the estimated implied fair value of goodwill and may result in additional impairment charges in the future.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-796" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to goodwill during the year ended December&#160;31, 2024 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-797">462,261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-798">144,500</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-799">317,761</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-750-2" continuedAt="f-750-3"><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include developed technology, customer relationships, and acquired IPR&amp;D.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Apton acquisition in August 2023, we allocated $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="f-800">55.0</ix:nonFraction> million of the purchase price to IPR&amp;D. As of December&#160;31, 2024, the research and development project had not been completed or abandoned and, therefore, the IPR&amp;D is not currently subject to amortization. During the year ended December 31, 2023, acquired IPR&amp;D of $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-801">400.0</ix:nonFraction> million as a result of the Omniome acquisition in September 2021 was completed and became subject to amortization.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D is reviewed for impairment at least annually, or more frequently if an event occurs indicating the potential for impairment. Based on the interim impairment test of goodwill in the second quarter of 2024 and our annual IPR&amp;D impairment assessment in the third quarter of 2024, <ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-802">no</ix:nonFraction> impairment of IPR&amp;D was identified.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the fourth quarter of 2024, we concluded that due to significant macroeconomic uncertainties and the related changes in the timing and amount of expected future cash flows, among other factors, it was more likely than not that the fair value of the IPR&amp;D was less than its carrying amount that required an interim impairment test be performed on IPR&amp;D. We performed our impairment test by comparing the carrying value of the IPR&amp;D to its estimated fair value, which was determined by the income approach, using a discounted cash flow model. Significant estimates and assumptions used in the income approach, which represent a Level 3 fair value measurement, include revenue growth assumptions, a selected discount rate of <ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="pacb:IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" scale="-2" id="f-803">14.0</ix:nonFraction>%, and a selected obsolescence factor of <ix:nonNumeric contextRef="c-4" name="pacb:IntangibleAssetImpairmentDiscountedCashFlowModelTerm" format="ixt-sec:duryear" id="f-804">13</ix:nonNumeric> years. The discount rate was based primarily on the weighted average cost of capital, determined using market, peer company, industry data, and related risk factors. Based on our analysis, the carrying value of the IPR&amp;D exceeded its estimated fair value, and we recorded an impairment of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="f-805">40.0</ix:nonFraction> million in the fourth quarter of 2024. The impairment charge is included on our consolidated statements of operations and comprehensive loss for the year ended December 31, 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. An increase of <ix:nonFraction unitRef="number" contextRef="c-4" decimals="4" name="pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" scale="-4" id="f-806">100</ix:nonFraction> basis points to the discount rate used in our analysis would have resulted in additional IPR&amp;D impairment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="pacb:AdditionalIntangibleAssetImpairmentChangeInDiscountRate" format="ixt:num-dot-decimal" scale="6" id="f-807">5</ix:nonFraction>&#160;million. A decrease of <ix:nonNumeric contextRef="c-4" name="pacb:IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" format="ixt-sec:durwordsen" id="f-808">one year</ix:nonNumeric> to the obsolescence factor used in our analysis would have resulted in additional IPR&amp;D impairment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="pacb:AdditionalIntangibleAssetImpairmentChangeInTerm" format="ixt:num-dot-decimal" scale="6" id="f-809">5</ix:nonFraction>&#160;million. We also performed a recoverability test for the definite-lived asset group, which includes developed technology, noting <ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-810"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-811">no</ix:nonFraction></ix:nonFraction> impairment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the impairment, the carrying value of the IPR&amp;D now approximates fair value. Changes in macroeconomic conditions, industry-specific conditions and company-specific conditions may impact the estimates and assumptions used when conducting future IPR&amp;D impairment tests. These changes could affect the estimated fair value of the IPR&amp;D and may result in additional impairment charges in the future.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock" id="f-812" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to IPR&amp;D during the year ended December&#160;31, 2024 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-813">55,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-814">Impairment charge</span></span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-815">40,000</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-816">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="f-817" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to IPR&amp;D, we had the following acquired finite-lived intangible assets as of December&#160;31, 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated <br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-198" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-818">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-819">411,179</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-820">36,607</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-821">374,572</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-199" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-822">2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-823">360</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-824">360</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-825">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-826">411,539</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-827">36,967</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-828">374,572</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense of intangibles was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AdjustmentForAmortization" scale="6" id="f-829">27.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:AdjustmentForAmortization" scale="6" id="f-830">8.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="f-831">0.9</ix:nonFraction>&#160;million for the years ended December&#160;31, 2024, 2023, and 2022, respectively. For the years ended December&#160;31, 2024, 2023, and 2022 amortization expense of intangibles in cost of revenue was $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-832">9.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-833">2.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-834">0.7</ix:nonFraction>&#160;million, respectively. For the years ended December&#160;31, 2024, 2023, and 2022, amortization expense of intangibles in operating expenses was $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-835">18.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-836">6.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-837">0.2</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-750-3" continuedAt="f-750-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets is included within our cost of revenue if the costs and expenses related to the intangible assets are attributable to revenue generating activities. Amortization expense for intangible assets that are not directly related to sales generating activities are amortized to operating expenses. For developed technology intangible assets that are utilized in both revenue generating activities and in research and development activities, we allocate the amortization expense between cost of revenue and operating expenses. The finite-lived intangible assets are amortized using the straight-line method over their estimated useful lives.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-838" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of acquisition-related intangible assets with finite lives is estimated as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-839">27,412</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-840">27,412</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-841">27,412</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-842">27,412</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="f-843">27,412</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030 and thereafter</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-844">237,512</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-845">374,572</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Accrued Expenses</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="pacb:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" id="f-846" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-847">11,706</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-848">29,337</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:AccruedTenantImprovementsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-849">2,470</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="pacb:AccruedTenantImprovementsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-850">2,834</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchase commitments</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractualObligationDueInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="f-851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractualObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-852">2,613</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued product development costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:AccruedProductDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-853">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="pacb:AccruedProductDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-854">1,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued professional services and legal fees</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-855">824</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-856">2,641</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory accrual</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LossContingencyAccrualProductLiabilityNet" format="ixt:num-dot-decimal" scale="3" id="f-857">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LossContingencyAccrualProductLiabilityNet" scale="3" id="f-858">353</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warranty accrual</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" format="ixt:num-dot-decimal" scale="3" id="f-859">3,100</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" format="ixt:num-dot-decimal" scale="3" id="f-860">4,681</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-861">2,147</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-862">2,216</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-863">22,595</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-864">45,708</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Warranties</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide a one-year warranty on instruments. In addition, we provide a limited warranty on consumables. At the time revenue is recognized, an accrual is established for estimated warranty costs based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranties are recorded as part of accrued expenses on our consolidated balance sheets and warranty expense is recorded as a component of cost of product revenue on our consolidated statements of operations and comprehensive loss. There were no material changes in estimates for the periods presented below. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-750-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock" id="f-865" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-866">4,681</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-867">1,651</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions charged to cost of product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" format="ixt:num-dot-decimal" scale="3" id="f-868">6,144</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" format="ixt:num-dot-decimal" scale="3" id="f-869">8,227</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repairs and replacements</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProductWarrantyAccrualPayments" format="ixt:num-dot-decimal" scale="3" id="f-870">7,725</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProductWarrantyAccrualPayments" format="ixt:num-dot-decimal" scale="3" id="f-871">5,197</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-872">3,100</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-873">4,681</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Deferred Revenue</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had a total of $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-874">19.8</ix:nonFraction> million of deferred revenue, $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-875">13.9</ix:nonFraction> million of which was recorded as deferred revenue, current and $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-876">5.9</ix:nonFraction> million of which was recorded as deferred revenue, non-current, which primarily relates to deferred service contract revenues and is scheduled to be recognized in the next <ix:nonNumeric contextRef="c-207" name="pacb:ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" format="ixt-sec:durwordsen" id="f-877">five years</ix:nonNumeric>. Revenue recorded in the year ended December&#160;31, 2024 includes $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-878">14.9</ix:nonFraction> million that was included in deferred revenue, current as of December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly enter into contracts with multiple performance obligations. These contracts are believed to be firm as of the balance sheet date. However, we may allow customers to make product substitutions or certain modifications at our discretion. The timing of shipments depends on several factors, including agreed upon shipping schedules, which may span multiple quarters. Most performance obligations are generally satisfied within a year of the contract execution date. As of December&#160;31, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-879">58.6</ix:nonFraction> million, of which approximately <ix:nonFraction unitRef="number" contextRef="c-4" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="f-880">62</ix:nonFraction>% is expected to be converted to revenue in 2025, approximately <ix:nonFraction unitRef="number" contextRef="c-208" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="f-881">30</ix:nonFraction>% in the following <ix:nonNumeric contextRef="c-208" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen" id="f-882">twelve months</ix:nonNumeric>, and the remainder thereafter.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Liabilities, Current</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="f-883" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities, current, consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued Employee Stock Purchase Plan</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-884">2,014</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-885">3,715</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term loan</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShortTermBorrowings" format="ixt:fixed-zero" scale="3" id="f-886">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShortTermBorrowings" scale="3" id="f-887">490</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-888">1,210</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-889">4,121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities, current</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-890">3,224</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-891">8,326</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-892" continuedAt="f-892-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 5.  CONVERTIBLE SENIOR NOTES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2029 Convertible Senior Notes</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 7, 2024, we entered into an exchange agreement with SB Northstar LP (&#8220;SBN&#8221;), a subsidiary of SoftBank Group Corp., pursuant to which we have agreed to exchange the remaining approximately $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-893">459.0</ix:nonFraction>&#160;million in aggregate principal amount of 2028 Notes outstanding for (i) $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-894">200.0</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-210" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-895">1.50</ix:nonFraction>% Convertible Senior Notes due 2029 (the &#8220;2029 Notes&#8221;), (ii) <ix:nonFraction unitRef="shares" contextRef="c-211" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-896">20,451,570</ix:nonFraction> shares of common stock (the &#8220;Exchange Shares&#8221;) and (iii) $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="pacb:PaymentsInConjunctionWithNotesExchange" format="ixt:num-dot-decimal" scale="6" id="f-897">50.0</ix:nonFraction>&#160;million of cash (the &#8220;2024 Exchange Transaction&#8221;). The Exchange Shares were issued on November 21, 2024 (the &#8220;Closing Date&#8221;). The 2029 Notes, the Exchange Shares, and shares of common stock issuable upon conversion of the 2029 Notes are subject to certain lock-up restrictions for a <ix:nonNumeric contextRef="c-213" name="pacb:HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" format="ixt-sec:durwordsen" id="f-898">six-month</ix:nonNumeric> period (the &#8220;Lock-Up Period&#8221;) beginning on the Closing Date of the 2024 Exchange Transaction; the lock-up restrictions will terminate immediately prior to the consummation of any change in control of the Company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any conversion of the 2029 Notes, SBN will not be entitled to be issued a number of shares of the Company&#8217;s common stock which would cause SBN's beneficial ownership of common stock to exceed either <ix:nonFraction unitRef="number" contextRef="c-212" decimals="4" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-899">9.9</ix:nonFraction>% of the total number of issued and outstanding shares of common stock or <ix:nonFraction unitRef="number" contextRef="c-212" decimals="4" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-900">9.9</ix:nonFraction>% of the combined voting power of all of the securities of the Company, in each case, following such conversion.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are governed by an indenture (the &#8220;2029 Indenture&#8221;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2029 Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-210" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-901">1.50</ix:nonFraction>% per annum. Interest on the 2029 Notes is payable semi-annually in arrears on February 15 and August 15 and commencing on February 15, 2025. The 2029 Notes will mature on August 15, 2029, subject to earlier conversion, redemption or repurchase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are convertible at the option of the holder at any time from the expiration of the Lock-Up Period until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2029 Notes are convertible into shares of our common stock based on an initial conversion rate of 204.5157 shares of common stock per $1,000 principal amount of the 2029 Notes (which is equal to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-210" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-902">4.89</ix:nonFraction> per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2029 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after August 20, 2027, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2029 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="c-211" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-903">150</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonFraction unitRef="d" contextRef="c-211" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-904">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="d" contextRef="c-211" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-905">30</ix:nonFraction> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of <ix:nonFraction unitRef="number" contextRef="c-211" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-906">100</ix:nonFraction>% of the principal amount of such 2029 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a Fundamental Change (as defined in the 2029 Indenture), the holders of the 2029 Notes may require that we repurchase all or part of the principal amount of the 2029 Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are subject to certain debt and lien covenants as well as springing guarantees, in each case, the terms of which are set forth in a second letter agreement between the Company and SBN entered into in connection with the Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the 2029 Notes under the 2029 Indenture. The 2029 Indenture also includes customary covenants for convertible notes of this type.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-892-1" continuedAt="f-892-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first <ix:nonNumeric contextRef="c-211" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-907">360</ix:nonNumeric> calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2029 Notes at a rate equal to (i) <ix:nonFraction unitRef="number" contextRef="c-214" decimals="4" name="pacb:DebtInstrumentInterestInTheEventOfDefault" scale="-2" id="f-908">0.25</ix:nonFraction>% per annum of the principal amount of the 2029 Notes outstanding for each day during the first <ix:nonNumeric contextRef="c-214" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-909">180</ix:nonNumeric> calendar days of the <ix:nonNumeric contextRef="c-211" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-910">360</ix:nonNumeric>-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) <ix:nonFraction unitRef="number" contextRef="c-215" decimals="4" name="pacb:DebtInstrumentAdditionalInterestInEventOfDefault" scale="-2" id="f-911">0.50</ix:nonFraction>% per annum of the principal amount of the 2029 Notes outstanding for each day from, and including, the <ix:nonNumeric contextRef="c-216" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-912">181</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day to, and including, the <ix:nonNumeric contextRef="c-217" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-913">360</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2029 Indenture). On the <ix:nonNumeric contextRef="c-215" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-914">361</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such <ix:nonNumeric contextRef="c-215" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-915">361</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day), the 2029 Notes shall be subject to acceleration as provided for in the 2029 Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2029 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2029 Notes were not issued at a substantial premium; therefore, the 2029 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the 2029 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exchange qualified as a troubled debt restructuring under ASC 470-60 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Troubled Debt Restructurings by Debtors</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Since the undiscounted cash flows of the 2029 Notes were less than the carrying amount of the exchanged 2028 Notes, the carrying value of the 2029 Notes was determined based on the total undiscounted cash flows. As a result, no interest expense will be recognized for the 2029 Notes. The Company recorded a gain on debt restructuring of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-916">154.4</ix:nonFraction>&#160;million, which resulted in a decrease of basic net loss per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="pacb:RestructuringOfDebtPricePerShare" scale="0" id="f-917">0.56</ix:nonFraction>, during the year ended December&#160;31, 2024 on our consolidated statements of operations and comprehensive loss. The gain was calculated as the difference between the carrying amount of the old debt and the carrying amount of the new debt, adjusted for debt issuance costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2029 Notes of approximately $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-918">3.1</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="pacb:DebtIssuanceCostLenderFees" format="ixt:num-dot-decimal" scale="6" id="f-919">0.2</ix:nonFraction>&#160;million of lender fees, which were recorded as a reduction to the gain on debt restructuring on our consolidated statements of operations and comprehensive loss. We also paid accrued but unpaid interest of $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="6" id="f-920">1.8</ix:nonFraction>&#160;million on the 2028 Notes in connection with the 2024 Exchange Transaction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not receive any cash proceeds from the 2024 Exchange Transaction. In exchange for issuing the 2029 Notes, Exchange Shares and paying $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="pacb:PaymentsInConjunctionWithNotesExchange" format="ixt:num-dot-decimal" scale="6" id="f-921">50.0</ix:nonFraction>&#160;million of cash pursuant to the 2024 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. Following the closing of the 2024 Exchange Transaction, <ix:nonFraction unitRef="usd" contextRef="c-209" decimals="0" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="f-922">no</ix:nonFraction> amounts were outstanding on the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the liability for the 2029 Notes as of December&#160;31, 2024 is $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-923">214.2</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-924">212.0</ix:nonFraction>&#160;million is included as convertible senior notes, net, non-current, and $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-925">2.2</ix:nonFraction>&#160;million is included as accrued expenses on our consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the estimated fair value (Level 2) of the 2029 Notes was $<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="f-926">175.0</ix:nonFraction>&#160;million. The fair value of the 2029 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-892-2" continuedAt="f-892-3"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2030 Convertible Senior Notes</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we entered into a privately negotiated exchange agreement with a holder of our outstanding <ix:nonFraction unitRef="number" contextRef="c-222" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-927">1.50</ix:nonFraction>% Convertible Senior Notes due 2028 (the &#8220;2028 Notes&#8221;), pursuant to which we issued $<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-928">441.0</ix:nonFraction>&#160;million in aggregate principal amount of our <ix:nonFraction unitRef="number" contextRef="c-223" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-929">1.375</ix:nonFraction>% Convertible Senior Notes due 2030 (the &#8220;2030 Notes&#8221; and together with the 2029 Notes, the &#8220;Notes&#8221;) in exchange for $<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-930">441.0</ix:nonFraction>&#160;million principal amount of the 2028 Notes (the &#8220;2023 Exchange Transaction&#8221;), pursuant to exemptions from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder. The 2030 Notes were issued on June&#160;30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are governed by an indenture (the &#8220;2030 Indenture&#8221;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2030 Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-223" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-931">1.375</ix:nonFraction>% per annum. Interest on the 2030 Notes is payable semi-annually in arrears on June 15 and December 15, commencing on December 15, 2023. The 2030 Notes will mature on December&#160;15, 2030, subject to earlier conversion, redemption or repurchase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2030 Notes are convertible into shares of our common stock based on an initial conversion rate of 46.5116 shares of common stock per $1,000 principal amount of the 2030 Notes (which is equal to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-223" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-932">21.50</ix:nonFraction> per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2030 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after June 20, 2028, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2030 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="c-224" decimals="2" name="pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice" scale="-2" id="f-933">150</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="c-224" name="pacb:DebtInstrumentRedemptionPriceTradingDays" format="ixt-sec:durday" id="f-934">20</ix:nonNumeric> trading days (whether or not consecutive) during any <ix:nonNumeric contextRef="c-224" name="pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays" format="ixt-sec:durday" id="f-935">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of <ix:nonFraction unitRef="number" contextRef="c-224" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-936">100</ix:nonFraction>% of the principal amount of such 2030 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a Fundamental Change (as defined in the 2030 Indenture), the holders of the 2030 Notes may require that we repurchase all or part of the principal amount of the 2030 Notes at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="c-224" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-937">100</ix:nonFraction>% of the principal amount of the notes to be repurchased, plus any accrued and unpaid interest up to, but excluding, the fundamental change repurchase date, and all unpaid interest from the fundamental change repurchase date thereon, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the 2030 Notes under the 2030 Indenture. The 2030 Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first <ix:nonNumeric contextRef="c-224" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-938">360</ix:nonNumeric> calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2030 Notes at a rate equal to (i) <ix:nonFraction unitRef="number" contextRef="c-224" decimals="4" name="pacb:DebtInstrumentInterestInTheEventOfDefault" scale="-2" id="f-939">0.25</ix:nonFraction>% per annum of the principal amount of the 2030 Notes outstanding for each day during the first <ix:nonNumeric contextRef="c-225" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-940">180</ix:nonNumeric> calendar days of the <ix:nonNumeric contextRef="c-224" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-941">360</ix:nonNumeric>-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) <ix:nonFraction unitRef="number" contextRef="c-224" decimals="4" name="pacb:DebtInstrumentAdditionalInterestInEventOfDefault" scale="-2" id="f-942">0.50</ix:nonFraction>% per annum of the principal amount of the 2030 Notes outstanding for each day from, and including, the <ix:nonNumeric contextRef="c-226" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-943">181</ix:nonNumeric>st calendar day to, and including, the <ix:nonNumeric contextRef="c-227" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-944">360</ix:nonNumeric>th calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2030 Indenture). On the <ix:nonNumeric contextRef="c-228" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-945">361</ix:nonNumeric>st day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such <ix:nonNumeric contextRef="c-228" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-946">361</ix:nonNumeric>st day), the 2030 Notes shall be subject to acceleration as provided for in the 2030 Indenture.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-892-3" continuedAt="f-892-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2030 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2030 Notes were not issued at a substantial premium; therefore, the 2030 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the 2030 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Exchange Transaction was accounted for as an extinguishment driven by the change in fair value of the embedded conversion option. We recorded a loss on extinguishment of debt of approximately $<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-947">2.0</ix:nonFraction> million in connection with the 2023 Exchange Transaction during the year ended December 31, 2023, which represents the difference between the fair value and the principal amount of the 2030 Notes of the debt at the modification date, plus unamortized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="f-948">1.5</ix:nonFraction> million related to the respective portion of the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2030 Notes of approximately $<ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="f-949">7.3</ix:nonFraction> million, which were recorded as debt issuance costs and are presented as a reduction to the 2030 Notes on our consolidated balance sheets. The debt issuance costs are amortized to interest expense using the effective interest method over the term of the 2030 Notes, resulting in an effective interest rate of <ix:nonFraction unitRef="number" contextRef="c-223" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-950">1.6</ix:nonFraction>%. We also paid accrued but unpaid interest of $<ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="6" id="f-951">2.5</ix:nonFraction> million on the 2028 Notes in connection with the 2023 Exchange Transaction on June 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not receive any cash proceeds from the 2023 Exchange Transaction. In exchange for issuing the 2030 Notes pursuant to the 2023 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. Following the closing of the 2023 Exchange Transaction, $<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-952">459.0</ix:nonFraction> million in aggregate principal amount of 2028 Notes remained outstanding with terms unchanged.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-953" continuedAt="f-953-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current on our consolidated balance sheets as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-954">441,000</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-955">441,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt premium</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="3" id="f-956">453</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="3" id="f-957">524</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="f-958">5,959</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="f-959">6,907</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-960">435,494</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-961">434,617</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="pacb:ScheduleOfInterestExpenseTableTextBlock" id="f-962" continuedAt="f-962-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2030 Notes for the years ended December&#160;31, 2024, 2023, and 2022 was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-963">6,081</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-964">3,032</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:fixed-zero" scale="3" id="f-965">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-966">950</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-967">463</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="f-968">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-969">7,031</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-970">3,495</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="f-971">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the estimated fair value (Level 2) of the 2030 Notes was $<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="f-972">293.9</ix:nonFraction> million. The fair value of the 2030 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-892-4"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2028 Convertible Senior Notes</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;9, 2021, we entered into an investment agreement with SBN relating to the issuance and sale to SBN of $<ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-973">900.0</ix:nonFraction> million in aggregate principal amount of the 2028 Notes. The 2028 Notes were issued on February&#160;16, 2021 and bore interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-239" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-974">1.50</ix:nonFraction>% per annum. As discussed above, in June 2023 we completed an exchange of $<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-975">441.0</ix:nonFraction> million in aggregate principal amount of our 2028 Notes for $<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-976">441.0</ix:nonFraction> million aggregate principal amount of the 2030 Notes, leaving approximately $<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-977">459.0</ix:nonFraction> million in aggregate principal amount of 2028 Notes outstanding. Also as discussed above, in November 2024 we completed an exchange of the remaining $<ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-978">459.0</ix:nonFraction>&#160;million in aggregate principal amount of the 2028 Notes outstanding for (i) $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-979">200.0</ix:nonFraction>&#160;million aggregate principal amount of the 2029 Notes, (ii) the Exchange Shares and (iii) $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="pacb:PaymentsInConjunctionWithNotesExchange" format="ixt:num-dot-decimal" scale="6" id="f-980">50.0</ix:nonFraction>&#160;million of cash. As of December&#160;31, 2024 <ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="f-981">no</ix:nonFraction> amounts were outstanding on the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2028 Notes of approximately $<ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="f-982">4.5</ix:nonFraction> million, which were recorded as debt issuance costs and are presented as a reduction to the 2028 Notes on our consolidated balance sheets. The debt issuance costs were amortized to interest expense using the effective interest method over the term of the 2028 Notes, resulting in an effective interest rate of <ix:nonFraction unitRef="number" contextRef="c-239" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-983">1.6</ix:nonFraction>%. In connection with the 2024 Exchange Transaction, the remaining unamortized debt issuance costs related to the 2028 Notes of $<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="f-984">1.1</ix:nonFraction> million were extinguished by offsetting the carrying amount of the convertible senior notes. </span></div><ix:continuation id="f-953-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2028 Notes is included as convertible senior notes, net, non-current on our consolidated balance sheets as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-985">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-986">459,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:fixed-zero" scale="3" id="f-987">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="f-988">1,374</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="3" id="f-989">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-990">457,626</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:continuation id="f-962-1"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2028 Notes was as follows for the years ended December&#160;31, 2024, 2023, and 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-991">6,139</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-992">10,133</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-993">13,500</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-994">289</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-995">472</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-996">617</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-997">6,428</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-998">10,605</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-999">14,117</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_900"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-1002" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 6.  RESTRUCTURING</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, we implemented an expense reduction initiative that included workforce reductions, the closing of our San Diego office, and other actions to reduce annualized run-rate operating expenses.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-1003" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the pre-tax restructuring charges are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended</span></div><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative amount incurred to date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee separation costs</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-1004">10,008</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="3" id="f-1005">10,008</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-1006">15,214</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="3" id="f-1007">15,214</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="-sec-ix-hidden:f-1008"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restructuring charges</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-1009">25,222</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="3" id="f-1010">25,222</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> For the year ended December&#160;31, 2024, cumulative charges incurred to date include $<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="f-1011">14.9</ix:nonFraction> million in sales, general and administrative expense; $<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="f-1012">5.9</ix:nonFraction> million in research and development expense; and $<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="f-1013">4.4</ix:nonFraction> million in cost of revenue.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative charges incurred to date include employee separation costs comprised of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1014">5.5</ix:nonFraction>&#160;million related to salaries, wages and other employee benefits paid to terminated employees pursuant to the Worker Adjustment and Retraining Notification (WARN) Act and approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-1015">4.5</ix:nonFraction>&#160;million of severance costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other costs in the year ended December&#160;31, 2024 are primarily related to accelerated amortization and depreciation of $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" name="us-gaap:RestructuringReserveAcceleratedDepreciation" format="ixt:num-dot-decimal" scale="6" id="f-1016">8.1</ix:nonFraction>&#160;million for the right-of-use asset, leasehold improvements, and furniture and fixtures relating to the abandonment of the San Diego office. We also incurred cumulative charges to date for excess inventory of $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-1017">3.6</ix:nonFraction>&#160;million primarily relating to a decrease in internal demand resulting from the expense reduction initiatives which were recognized in cost of product revenues. The accelerated amortization and depreciation, which was recognized in sales, general and administrative expense, was determined as a result of the Company's change in estimate pertaining to its remaining useful life of the San Diego office utilizing the estimated date on which it planned to abandon the San Diego office. The lease liability pertaining to the San Diego office was also remeasured during the year ended December&#160;31, 2024 resulting in a reduction in the operating lease liability balance of $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-1018">4.4</ix:nonFraction>&#160;million, which was offset against the right-of-use asset on our consolidated balance sheets. We exited our San Diego office in September 2024.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-1019" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the liabilities related to the restructuring is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Separation Costs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expense recorded in YTD 2024</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-1020">10,008</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-1021">2,816</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-1022">12,824</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid during YTD 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-1023">10,008</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-1024">2,646</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-1025">12,654</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount recorded in current liabilities as of December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-1026">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-1027">170</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-1028">170</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated total restructuring costs to still be incurred</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:fixed-zero" scale="3" id="f-1029">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" scale="3" id="f-1030">946</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" scale="3" id="f-1031">946</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above excludes noncash activities and amounts incurred relating to the San Diego office lease liability. The ending balance of the San Diego office lease liability as of December&#160;31, 2024 is $<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-1032">2.6</ix:nonFraction>&#160;million, and is included in operating lease liabilities, current on our consolidated balance sheets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other restructuring costs are expected to be incurred and paid by the end of 2025.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LossContingencyDisclosures" id="f-1033" continuedAt="f-1033-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 7.  COMMITMENTS AND CONTINGENCIES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Leases</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. All of our leases are operating leases. Lease payments comprise the base rent per the term of the lease. Lease expense for these leases is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period those payments are incurred.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often have options to renew lease terms for buildings. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors.</span></div><ix:nonNumeric contextRef="c-1" name="pacb:LesseeOperatingLeaseDescriptionTableTextBlock" id="f-1034" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the maturities of our operating lease liabilities were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1035">11,481</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1036">8,780</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1037">7,110</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="f-1038">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:fixed-zero" scale="3" id="f-1039">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="f-1040">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-1041">27,371</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-1042">2,431</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of operating lease liabilities </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1043">24,940</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1044">10,026</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1045">14,914</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1046">24,940</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our incremental borrowing rate to determine the present value of lease payments, as the implicit rates in our leases are not readily determinable. The weighted-average discount rate used to measure our operating lease liabilities was <ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1047">7.7</ix:nonFraction>%. The weighted-average remaining lease term for our operating leases as of December&#160;31, 2024 was <ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1048">2.7</ix:nonNumeric> years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the present value of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsForRent" scale="6" id="f-1049">14.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:PaymentsForRent" format="ixt:num-dot-decimal" scale="6" id="f-1050">12.1</ix:nonFraction>&#160;million for the years ended December&#160;31, 2024 and 2023, respectively, and were included in operating cash flows.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease Costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-1051">14.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-1052">10.4</ix:nonFraction> million for the years ended December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Contingencies</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-1033-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see subsection titled </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_31">Legal Proceedings</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Part I, Item 3 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnification</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations" format="ixt:fixed-zero" scale="0" id="f-1053">No</ix:nonFraction> additional liability associated with such indemnification obligations has been recorded as of December&#160;31, 2024.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Purchase Commitments</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we enter into agreements to purchase goods or services or license intellectual property, certain of which are not cancellable without penalty. For those agreements with variable terms, we do not estimate the total obligation beyond any minimum quantities or pricing as of the reporting date. Licensing agreements under which we commit to ongoing minimum royalty payments, some of which are subject to adjustment, may be terminated under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our purchase orders and contractual obligations are approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PurchaseObligation" scale="6" id="f-1054">57.6</ix:nonFraction> million as of December&#160;31, 2024, which consist of open purchase orders and contractual obligations in the ordinary course of business, including commitments with contract manufacturers and suppliers for which we have not received the goods or services. A majority of these purchase obligations are due within a year. Although open purchase orders are considered enforceable and legally binding, the terms generally allow us the option to cancel, reschedule and adjust our requirements based on our business needs prior to the delivery of goods or performance of services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a loss on purchase commitment of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" scale="6" id="f-1055">1.0</ix:nonFraction> million for the year ended December&#160;31, 2024, which was recorded as part of accrued expenses on our consolidated balance sheet and is included in the aforementioned purchase orders and contractual obligations amount. The purchase commitment loss is based on an estimate of future excess inventory related to supply agreements with third-party vendors, for which we do not expect to have related sales.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a long-term supply agreement, which was most recently amended in September 2024 (the &#8220;Supply Agreement&#8221;), for the purchase of certain products with a semiconductor manufacturer (&#8220;Supplier&#8221;). The Supply Agreement provides for minimum purchase commitments through 2027 in exchange for guaranteed capacity at Supplier. We are responsible for providing certain materials to allow our Supplier to perform its obligations under the contract.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid our Supplier a deposit of $<ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-5" name="us-gaap:PaymentsForDeposits" scale="6" id="f-1056">9.0</ix:nonFraction> million in November 2022 and an additional deposit of $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:PaymentsForDeposits" scale="6" id="f-1057">6.0</ix:nonFraction> million in 2023, for a total of $<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-5" name="us-gaap:PaymentsForDeposits" scale="6" id="f-1058">15.0</ix:nonFraction> million (the &#8220;Deposit&#8221;). The Deposit is fully refundable to us, in accordance with the Supply Agreement, if we meet the minimum volume purchase commitment for the applicable year. $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="pacb:RefundFromDeposits" scale="6" id="f-1059">3.0</ix:nonFraction> million was refunded to us during the year ended December&#160;31, 2024. As of December&#160;31, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DepositsAssetsCurrent" scale="6" id="f-1060">4.0</ix:nonFraction> million related to the Deposit was included in prepaid expenses and other current assets on our consolidated balance sheets and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DepositsAssetsNoncurrent" scale="6" id="f-1061">8.0</ix:nonFraction> million related to the Deposit was included in other long-term assets on our consolidated balance sheets, as we believe it is probable the minimum volume purchase commitment level will be achieved.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1062" continuedAt="f-1062-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 8.  INCOME TAXES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes both in the United States and certain foreign jurisdictions in which we operate, and we use estimates in determining our provisions for income taxes. Significant management judgement is required in determining our provision for income taxes, deferred tax assets and liabilities, and valuation allowances recorded against net deferred tax assets in accordance with U.S. GAAP. These estimates and judgements occur in the calculation of tax credits, benefits, and deductions, and in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes, as well as the interest and penalties related to uncertain tax positions. Significant changes to these estimates may result in an increase or decrease to our tax provision in the current or subsequent period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="pacb:ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" scale="-2" id="f-1063">50</ix:nonFraction>% likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether the factors underlying the sustainability assertion have changed and the amount of the recognized tax benefit is still appropriate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for Global Intangible Low-taxed Income as a period cost.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024, 2023, and 2022 income/(loss) before taxes from U.S. operations were ($<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-1064">311.0</ix:nonFraction>) million, ($<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-1065">318.9</ix:nonFraction>) million, and ($<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-1066">315.7</ix:nonFraction>) million, respectively, and income/(loss) before taxes from foreign operations was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="f-1067">1.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="f-1068">0.7</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="f-1069">1.8</ix:nonFraction> million, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Income Tax Provision (Benefit)</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1070" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision (benefit) consists of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-1071">521</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1072">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1073">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="f-1074">8</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1075">9,956</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1076">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-1077">197</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1078">1,468</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1079">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1080">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1081">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1082">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-1083">205</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1084">11,424</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1085">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1086">316</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1087">11,424</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1088">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1089" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of 21% to pretax loss as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Statutory tax rate </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1090">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1091">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1092">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State tax rate, net of federal benefit</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1093">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1094">3.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1095">4.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1096">10.8</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1097">20.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1098">25.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="pacb:EffectiveIncomeTaxRateReconciliationTaxCredit" scale="-2" id="f-1099">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="pacb:EffectiveIncomeTaxRateReconciliationTaxCredit" scale="-2" id="f-1100">2.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="pacb:EffectiveIncomeTaxRateReconciliationTaxCredit" scale="-2" id="f-1101">2.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1102">3.7</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1103">2.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1104">2.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger Expenses</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" format="ixt:fixed-zero" scale="-2" id="f-1105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" scale="-2" id="f-1106">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" format="ixt:fixed-zero" scale="-2" id="f-1107">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairment</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="f-1108">9.8</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="-2" id="f-1109">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="-2" id="f-1110">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1111">0.2</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1112">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1113">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1114">0.1</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1115">3.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1116">0.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-1062-1" continuedAt="f-1062-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1117" continuedAt="f-1117-1" escape="true">Significant components of our deferred tax assets for federal and state income taxes are as follows:</ix:nonNumeric></span></div><ix:continuation id="f-1117-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1118">434,122</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1119">435,488</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1120">91,416</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1121">83,922</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and experimental expenses</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-1122">73,281</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="pacb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-1123">63,196</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" format="ixt:num-dot-decimal" scale="3" id="f-1124">10,506</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" format="ixt:num-dot-decimal" scale="3" id="f-1125">16,872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancellation of indebtedness income and interest expense</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-1126">20,424</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="pacb:DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-1127">14,907</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1128">18,195</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1129">18,584</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1130">5,618</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="pacb:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1131">9,510</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1132">653,562</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1133">642,479</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1134">558,794</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1135">525,703</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets:</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1136">94,768</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1137">116,776</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1138">91,504</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1139">109,488</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-1140">261</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-1141">548</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:DeferredTaxLiabilitiesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1142">3,549</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="pacb:DeferredTaxLiabilitiesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1143">7,491</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1144">95,314</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1145">117,527</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="f-1146">546</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="f-1147">751</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, we maintained a valuation allowance against our net deferred tax assets which totaled $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-1148">558.8</ix:nonFraction> million, including net operating loss carryforwards and research and development credits of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1149">434.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1150">91.4</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. We regularly assess the need for a valuation allowance against our deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that our deferred income tax assets will be realized. In evaluating our ability to recover our deferred income tax assets within the jurisdiction from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. We maintain a valuation allowance on the net deferred tax assets of our U.S. entities as we have concluded that it is more likely than not that we will not realize our deferred tax assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, the Company's valuation allowance increased to $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-1151">558.8</ix:nonFraction> million, primarily because of an increase in our credits and capitalized research &amp; experimental expenses that were fully offset by a valuation allowance. For the year ended December&#160;31, 2023, the Company's valuation allowance increased to $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-1152">525.7</ix:nonFraction> million, primarily because of an increase in our net operating losses, credits, and capitalized research and experimental expenses that were fully offset by a valuation allowance. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had a net operating loss carryforward for federal income tax purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1153">1,704.2</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-5" name="pacb:OperatingLossCarryforwardsAmountSubjectToExpiration" scale="6" id="f-1154">783.2</ix:nonFraction> million is subject to expiration beginning in 2025. We had a total state net operating loss carryforward of approximately $<ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1155">1,170.6</ix:nonFraction> million, which is subject to annual expirations. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have federal credits of approximately $<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1156">64.4</ix:nonFraction> million, a portion of which will begin to expire in 2025 if not utilized and state research credits of approximately $<ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1157">54.6</ix:nonFraction> million, which have no expiration date. These tax credits are subject to the same limitations discussed above.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-1062-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-1158" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, our total unrecognized tax benefit was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1159">17.7</ix:nonFraction> million. A reconciliation of the beginning and ending unrecognized tax benefit balance is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1160">8,335</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in balance related to tax positions taken in prior year </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-1161">10</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1162">2,085</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1163">10,410</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken in prior year </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1164">2,044</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1165">2,100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1166">14,554</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in balance related to tax positions taken in prior year </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-1167">6</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1168">3,128</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2024</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1169">17,676</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December&#160;31, 2024 and 2023, we had <ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt-sec:numwordsen" scale="0" id="f-1170"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt-sec:numwordsen" scale="0" id="f-1171">no</ix:nonFraction></ix:nonFraction> accrued interest or penalties due to our net operating losses available to offset any tax adjustment. If total unrecognized tax benefits were realized in the future, it would not result in any tax benefit as we currently have a full valuation allowance. We file U.S. federal and various state income tax returns. For U.S. federal and state income tax purposes, the statute of limitations currently remains open for the years ending December 31, 2021 to present and December 31, 2020 to present, respectively. In addition, all of the net operating losses and research and development credit carryforwards that may be utilized in future years may be subject to examination. We are not currently under examination by income tax authorities in any jurisdiction.</span></div></ix:continuation><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_124"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1172" continuedAt="f-1172-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 9.  STOCKHOLDERS' EQUITY</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Common and Preferred Stock</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Certificate of Incorporation, as amended and restated in October 2010 in connection with the closing of our initial public offering, authorizes us to issue <ix:nonFraction unitRef="shares" contextRef="c-264" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1173">1,000,000,000</ix:nonFraction> shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-264" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1174">0.001</ix:nonFraction> par value common stock and <ix:nonFraction unitRef="shares" contextRef="c-264" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1175">50,000,000</ix:nonFraction> shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-264" decimals="3" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1176">0.001</ix:nonFraction> par value preferred stock. As of December&#160;31, 2024 and 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-1177"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-1178"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-1179"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-1180">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of preferred stock issued or outstanding.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stockholders are entitled to dividends when and if declared by our board of directors. There have been <ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" format="ixt:fixed-zero" scale="0" id="f-1181">no</ix:nonFraction> dividends declared to date. The holder of each share of common stock is entitled to <ix:nonNumeric contextRef="c-1" name="us-gaap:CommonStockVotingRights" id="f-1183"><ix:nonFraction unitRef="vote" contextRef="c-1" decimals="INF" name="pacb:CommonStockVotingRightsNumberOfVotesPerShareOwned" format="ixt-sec:numwordsen" scale="0" id="f-1182">one</ix:nonFraction></ix:nonNumeric> vote. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Underwritten Public Equity Offerings</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we entered into an underwriting agreement, relating to the public offering of <ix:nonFraction unitRef="shares" contextRef="c-265" decimals="-5" name="pacb:PublicOfferingShares" format="ixt:num-dot-decimal" scale="6" id="f-1184">17.5</ix:nonFraction>&#160;million shares of our common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-266" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1185">0.001</ix:nonFraction> par value per share, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-266" decimals="2" name="pacb:OfferingShareAmountMaximum" scale="0" id="f-1186">10.00</ix:nonFraction> per share. Under the terms of the underwriting agreement, we also granted the underwriters a <ix:nonNumeric contextRef="c-265" name="pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod" format="ixt-sec:durday" id="f-1187">30</ix:nonNumeric>-day option to purchase up to an additional <ix:nonFraction unitRef="shares" contextRef="c-265" decimals="-5" name="pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares" format="ixt:num-dot-decimal" scale="6" id="f-1188">2.6</ix:nonFraction>&#160;million shares of our common stock, which was subsequently exercised in full, and the offering, including the sale of shares of common stock subject to the underwriters' option, closed in January 2023. In total, we sold <ix:nonFraction unitRef="shares" contextRef="c-267" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1189">20.1</ix:nonFraction>&#160;million shares of our common stock. We paid a commission equal to <ix:nonFraction unitRef="number" contextRef="c-265" decimals="4" name="pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" scale="-2" id="f-1190">5.75</ix:nonFraction>% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-1191">189.7</ix:nonFraction>&#160;million, excluding approximately $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-1192">0.5</ix:nonFraction>&#160;million of offering expenses.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-1172-1" continuedAt="f-1172-2"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Equity Plans</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), the 2020 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), and the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#8220;Omniome Plan&#8221;) allow for the issuance of stock options, restric</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ted units and awards, and performance-based awards. The 2010 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) allows eligible employees to acquire common stock at a discounted price through payroll deductions during designated offering periods.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 25, 2022, stockholders approved an amendment to the 2020 Plan, and we reserved an additional <ix:nonFraction unitRef="shares" contextRef="c-268" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-1193">18.0</ix:nonFraction>&#160;million shares of our common stock for issuance pursuant to equity awards granted under the 2020 Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2024, stockholders approved an amendment to the 2020 Plan, and we reserved an additional <ix:nonFraction unitRef="shares" contextRef="c-269" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-1194">20.0</ix:nonFraction>&#160;million shares of our common stock for issuance pursuant to equity awards granted under the 2020 Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had <ix:nonFraction unitRef="shares" contextRef="c-270" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1195">28.4</ix:nonFraction>&#160;million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan. Shares remaining and available for future issuance reflect shares that may become eligible to vest upon the achievement of maximum targets for certain equity awards.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Stock Options</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-1196" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for time-based awards:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(shares in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average<br/>exercise price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-271" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1197">13,011</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-271" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1198">10.63</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-272" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-1199">493</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-272" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1200">1.99</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-272" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-1201">515</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-272" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1202">3.15</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-272" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1203">2,153</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-272" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1204">8.89</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-272" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="f-1205">327</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-272" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1206">5.81</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-273" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1207">10,509</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-273" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1208">11.09</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of the outstanding options presented in the table above as of December&#160;31, 2024, totaled $<ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="f-1209">0.1</ix:nonFraction> million, and had a weighted-average remaining contractual life of <ix:nonNumeric contextRef="c-275" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1210">5.4</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of outstanding options represents the total pre-tax intrinsic value (i.e. the difference between $<ix:nonFraction unitRef="usdPerShare" contextRef="c-276" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-1211">1.83</ix:nonFraction>, our closing stock price on the last trading day of our fourth quarter of 2024, and the option exercise price multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December&#160;31, 2024. The aggregate intrinsic value changes at each reporting date based on the fair market value of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vested and exercisable options as of December&#160;31, 2024, totaled <ix:nonFraction unitRef="shares" contextRef="c-274" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-1212">9,429,082</ix:nonFraction> shares, had an aggregate intrinsic value that was not significant, a weighted-average exercise price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-275" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1213">11.26</ix:nonFraction>, and a weighted-average remaining contractual life of <ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1214">5.1</ix:nonNumeric> years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vested and expected to vest options as of December&#160;31, 2024, totaled <ix:nonFraction unitRef="shares" contextRef="c-274" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1215">10,957,644</ix:nonFraction> shares, had an aggregate intrinsic value of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="f-1216">0.1</ix:nonFraction> million, a weighted-average exercise price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-1217">11.13</ix:nonFraction>, and a weighted-average remaining contractual life of <ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1218">5.4</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during the years ended December&#160;31, 2024, 2023, and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1219">0.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1220">8.8</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1221">5.0</ix:nonFraction> million, respectively. The total intrinsic value of options exercised represents the difference between our closing stock price on the exercise date and the option exercise price, multiplied by the number of in-the-money options exercised.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of all options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1222">1.40</ix:nonFraction> in 2024, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1223">7.32</ix:nonFraction> in 2023, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1224">5.93</ix:nonFraction> in 2022, each determined by the Black-Scholes option valuation method.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-1172-2" continuedAt="f-1172-3"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restricted Stock Units ("RSU") and Performance Stock Units ("PSU")</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have awarded both Restricted Stock Units (RSUs) and Performance Stock Units (PSUs). Each RSU represents the right to receive <ix:nonFraction unitRef="shares" contextRef="c-277" decimals="0" name="pacb:ShareInstrumentNumberOfSharesConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-1225">one</ix:nonFraction> share of our common stock upon meeting the required service-based vesting conditions. RSUs typically vest over <ix:nonNumeric contextRef="c-277" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1226">four years</ix:nonNumeric>, with equal annual installments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, PSUs were granted and are based on performance against predefined revenue targets and require continued employment throughout the vesting period. These shares become issuable after the third year of the performance period. Achieving the maximum revenue goal allows up to <ix:nonFraction unitRef="number" contextRef="c-278" decimals="2" name="pacb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" scale="-2" id="f-1227">200</ix:nonFraction>% of the target PSU shares to become eligible for vesting, while failing to meet the minimum revenue goal results in no shares vesting.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-1228" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the time-based RSU and PSU activity: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(shares in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units (RSUs)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Stock Units (PSUs)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RSU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PSU</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-279" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1229">11,308</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-280" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-1230">541</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-279" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1231">12.06</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-280" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1232">9.43</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-277" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1233">12,722</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-281" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-1234">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-277" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1235">5.02</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-281" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-277" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1237">3,801</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-281" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-1238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-277" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1239">12.43</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-281" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-277" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1241">6,018</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-281" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-1242">149</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-277" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1243">7.90</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-281" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1244">9.43</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-282" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1245">14,211</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-283" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-1246">392</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-282" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1247">7.41</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-283" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1248">9.43</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of shares vested related to RSUs during the years ended December&#160;31, 2024, 2023, and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-1249">47.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-1250">39.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-1251">39.2</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of all RSUs granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-277" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1252">5.02</ix:nonFraction> in 2024, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-284" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1253">9.65</ix:nonFraction> in 2023, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-285" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1254">10.15</ix:nonFraction> in 2022. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, a total of <ix:nonFraction unitRef="shares" contextRef="c-286" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="f-1255">33.5</ix:nonFraction>&#160;million shares of our common stock have been reserved for issuance under the ESPP, which allows eligible employees to acquire common stock at a discounted price through payroll deductions during designated offering periods. Each offering period typically consists of <ix:nonFraction unitRef="period" contextRef="c-286" decimals="INF" name="pacb:NumberOfPurchasePeriods" format="ixt-sec:numwordsen" scale="0" id="f-1256">four</ix:nonFraction> purchase periods, each lasting approximately <ix:nonNumeric contextRef="c-287" name="pacb:PurchasePeriodOfEmployeeStockPurchasePlan" format="ixt-sec:durwordsen" id="f-1257">six months</ix:nonNumeric>. Shares are purchased at the lower of <ix:nonFraction unitRef="number" contextRef="c-287" decimals="2" name="pacb:PercentageOfFairMarketValueAtWhichStockCanBePurchased" scale="-2" id="f-1258">85</ix:nonFraction>% of the fair market value of the common stock at either the beginning of the offering period or the end of the purchase period. If the stock price at the end of a purchase period is lower than at the start of the offering period, the existing offering period will be reset, and a new offering period will begin. The ESPP provides for an annual increase to the shares available for issuance at the beginning of each fiscal year equal to the lesser of <ix:nonFraction unitRef="number" contextRef="c-287" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-1259">2</ix:nonFraction>% of the common shares then outstanding, <ix:nonFraction unitRef="shares" contextRef="c-286" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1260">4,000,000</ix:nonFraction> shares, or an amount determined by the ESPP&#8217;s administrator.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023, and 2022, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-287" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="0" id="f-1261">1,906,529</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares, <ix:nonFraction unitRef="shares" contextRef="c-288" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="0" id="f-1262">1,735,058</ix:nonFraction> shares, and <ix:nonFraction unitRef="shares" contextRef="c-289" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="0" id="f-1263">1,878,168</ix:nonFraction> shares of common stock were purchased under the ESPP, respectivel</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y. As of December&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-286" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1264">14.3</ix:nonFraction>&#160;million sh</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares of our common stock remain available for issuance under our ESPP.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Share-based Compensation</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-1265" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1266">5,691</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1267">5,399</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1268">4,802</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1269">19,172</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1270">22,435</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1271">30,676</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1272">46,173</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1273">44,284</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1274">43,135</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1275">71,036</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1276">72,118</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1277">78,613</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1278">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1279">0.6</ix:nonFraction> million of share-based compensation cost was capitalized in inventory, net, on our consolidated balance sheets, respectively. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-1172-3" continuedAt="f-1172-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate forfeitures related to our share-based compensation plans. The estimated forfeiture rate is based on historical data, trends, and other relevant factors, such as employee turnover rates and expectations about future forfeitures. The estimated forfeiture rate is reviewed periodically and adjusted as necessary to reflect changes in these factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit of share-based compensation expense was immaterial for the years ended December&#160;31, 2024, 2023, and 2022 due to a valuation allowance on the net deferred tax assets of our U.S. entities, for which we have concluded that it is more likely than not that we will not realize our deferred tax assets.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Determining Fair Value</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of share options granted using the Black-Scholes valuation method and a single option award approach. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSU awards granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting period. For shares purchased under the ESPP, we estimate the grant-date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Term &#8211; The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, considering the contractual terms of the stock options and vesting schedules.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Volatility &#8211; The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Dividend &#8211; We have never paid dividends on our shares and, accordingly, the dividend yield percentage is <ix:nonFraction unitRef="number" contextRef="c-15" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1280"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1281"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1282">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction> for all periods.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Risk-Free Interest Rate &#8211; The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference observable market prices of similar or identical instruments in active markets. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1283" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-302" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1284">4.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-303" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1285">4.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-304" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1286">4.6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-302" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-1287">81</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-302" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-1288">93</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-303" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-1289">77</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-303" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-1290">78</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-304" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-1291">70</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-304" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-1292">76</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-302" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-1293">3.48</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="c-302" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-1294">4.32</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-303" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-1295">3.73</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="c-303" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-1296">4.60</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-304" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-1297">0.41</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="c-304" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-1298">3.66</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-302" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1299">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-303" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1300">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-304" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1301">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-302" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1302">1.40</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-303" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1303">7.32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-304" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1304">5.93</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from option exercises for the years ended December&#160;31, 2024, 2023, and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-1305">1.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-1306">6.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-1307">3.4</ix:nonFraction> million, respectively. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-1172-4"><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESPP</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="f-1308" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares to be issued under the ESPP was estimated using the following assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-305" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1309">0.5</ix:nonNumeric> - <ix:nonNumeric contextRef="c-306" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1310">2.0</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-307" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1311">0.5</ix:nonNumeric> - <ix:nonNumeric contextRef="c-308" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1312">2.0</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-309" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1313">0.5</ix:nonNumeric> - <ix:nonNumeric contextRef="c-310" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1314">2.0</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-311" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-1315">81</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-311" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-1316">118</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-312" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-1317">79</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-312" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-1318">97</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-313" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-1319">70</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-313" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-1320">97</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-311" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-1321">3.9</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-311" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-1322">5.3</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-312" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-1323">4.9</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-312" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-1324">5.5</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-313" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-1325">0.6</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-313" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-1326">3.5</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-311" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1327">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-312" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1328">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-313" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1329">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-311" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1330">1.53</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-312" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1331">5.34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-313" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1332">4.28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received through the ESPP for the years ended December&#160;31, 2024, 2023, and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-1333">6.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-1334">8.8</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-1335">7.8</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-1336">80.1</ix:nonFraction> million of total unrecognized compensation expense related to stock options, restricted stock, and ESPP shares was expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-314" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1337">2.2</ix:nonNumeric> years.</span></div></ix:continuation><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_127"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1338" continuedAt="f-1338-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 10.  NET LOSS PER SHARE</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-1339" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of the basic and diluted net loss per share amounts presented on our consolidated statements of operations and comprehensive loss: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net loss</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1340">309,851</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1341">306,735</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1342">314,248</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net loss</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1343">309,851</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1344">306,735</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1345">314,248</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Interest charges applicable to convertible notes (2028 Notes)</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:InterestOnConvertibleDebtNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1346">6,428</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:InterestOnConvertibleDebtNetOfTax" format="ixt:fixed-zero" scale="3" id="f-1347">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:InterestOnConvertibleDebtNetOfTax" format="ixt:fixed-zero" scale="3" id="f-1348">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Gain on debt restructuring (2029 Notes)</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-1349">154,407</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:fixed-zero" scale="3" id="f-1350">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:fixed-zero" scale="3" id="f-1351">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net loss</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1352">457,830</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1353">306,735</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1354">314,248</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in computing basic net loss per share</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1355"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1356">274,488</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1357"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1358">253,629</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1359"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1360">224,550</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net loss per share</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1361"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1362">1.13</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1363"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1364">1.21</ix:nonFraction></ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1365"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1366">1.40</ix:nonFraction></ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in computing basic net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1367">274,488</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1368">253,629</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1369">224,550</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Weighted average shares issuable upon conversion of convertible notes (2028 Notes)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-245" decimals="INF" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1370">9,395</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-246" decimals="INF" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-1371">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-247" decimals="INF" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-1372">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Weighted average shares issuable upon conversion of convertible notes (2029 Notes)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-315" decimals="INF" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1373">4,483</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-316" decimals="INF" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-1374">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-317" decimals="INF" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-1375">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in computing diluted net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1376">288,366</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1377">253,629</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1378">224,550</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net loss per share</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1379"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1380">1.59</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1381"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1382">1.21</ix:nonFraction></ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1383"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1384">1.40</ix:nonFraction></ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-1338-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-1385" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares issuable upon conversion of the convertible senior notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible senior notes</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-318" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1386">20,512</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-319" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1387">31,063</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-320" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1388">20,690</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity awards</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-321" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1389">34,136</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-322" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1390">27,246</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-323" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1391">27,291</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_97">Note 2. Business Acquisitions</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for detailed information on contingently issuable shares that would be due upon achievement of a milestone. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_124">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_124">9</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_124">. Stockholders&#8217; Equity</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for detailed information on equity awards.</span></div></ix:continuation><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_130"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1392" continuedAt="f-1392-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 11.  SEGMENT AND GEOGRAPHIC INFORMATION</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are organized as, and operate in, <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1393">one</ix:nonFraction> reportable segment: the development, manufacturing, and marketing of integrated platforms for genetic analysis. Our chief operating decision-maker (CODM) is our Chief Executive Officer. Our CODM reviews financial information presented on a consolidated basis for the purposes of evaluating financial performance and allocating resources.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a regular basis, our CODM reviews:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">total revenues by category</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">total expenses and expenses by function, including sales and marketing and general and administrative, which include depreciation and share-based compensation</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">net loss per share</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assets are primarily located in the United States of America and not allocated to any specific region, and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:continuation id="f-1392-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1394" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the segment profit or loss, including significant segment expenses is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1395">154,014</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1396">200,521</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1397">128,304</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1398">116,732</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1399">147,741</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1400">79,269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1401">134,922</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1402">187,170</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1403">193,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-1404">87,244</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-1405">79,287</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-1406">84,465</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1407">87,773</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1408">90,531</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1409">76,389</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-1410">184,500</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-1411">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-1412">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger-related expenses</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:fixed-zero" scale="3" id="f-1413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-1414">9,042</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:fixed-zero" scale="3" id="f-1415">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-1416">850</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-1417">15,060</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-1418">2,377</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1419">18,006</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1420">6,157</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-1421">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-1422">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-1423">2,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-1424">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on debt restructuring</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-1425">154,407</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:fixed-zero" scale="3" id="f-1426">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:fixed-zero" scale="3" id="f-1427">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1428">10,371</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1429">18,341</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1430">7,052</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1431">316</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1432">11,424</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1433">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net loss</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1434">309,851</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1435">306,735</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1436">314,248</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-1437" escape="true"><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by geographic location is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Americas </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1438">78,711</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1439">105,410</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1440">69,561</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East, and Africa</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1441">34,594</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1442">40,658</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1443">22,598</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia-Pacific</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1444">40,709</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1445">54,453</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1446">36,145</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1447">154,014</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1448">200,521</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1449">128,304</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes United States revenue of $<ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1450">75.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1451">100.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1452">66.8</ix:nonFraction> million for the years ended December 31, 2024, 2023, and 2022, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="f-1453" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by category is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instrument revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1454">65,776</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1455">120,451</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1456">48,719</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumable revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1457">70,373</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1458">63,421</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1459">59,980</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1460">136,149</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1461">183,872</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1462">108,699</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1463">17,865</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1464">16,649</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1465">19,605</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1466">154,014</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1467">200,521</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1468">128,304</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_1009"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1469" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 12.  SUBSEQUENT EVENTS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 7, 2025, we entered into an amendment to our existing lease for our corporate headquarters, research and development facilities, and manufacturing and distribution centers in Menlo Park, California. The lease amendment extends the term from the prior expiration on October 31, 2027 to its new expiration on April 30, 2034. We will pay approximately $<ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-5" name="pacb:OperatingLeaseExpectedBaseRentExpense" scale="6" id="f-1470">97.7</ix:nonFraction> million in base rent over the life of the amended lease, and receive base rent abatement of approximately $<ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-5" name="pacb:LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" format="ixt:num-dot-decimal" scale="6" id="f-1471">11.6</ix:nonFraction>&#160;million for the period beginning on March 1, 2025 and ending on July 31, 2026. We are also entitled to a tenant improvement allowance of $<ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-5" name="us-gaap:TenantImprovements" format="ixt:num-dot-decimal" scale="6" id="f-1472">7.2</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 7, 2025, we entered into an agreement to acquire certain technology and related intellectual property from the Chinese University of Hong Kong for $<ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1473">9.7</ix:nonFraction>&#160;million.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_136"></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 9A.  CONTROLS AND PROCEDURES</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Interim Chief Financial Officer, and our Chief Accounting Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a&#8211;15(e) and 15d&#8211;15(e) of the Exchange Act) as of the end of the period covered by this Annual Report on Form 10&#8211;K. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgement in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our Chief Executive Officer and Interim Chief Financial Officer and our principal accounting officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of the end of the period covered by this report. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Management's Report on Internal Control Over Financial Reporting</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f). Pacific Biosciences of California, Inc.&#8217;s internal control over financial reporting is designed to provide reasonable assurance to the Company&#8217;s management and board of directors regarding the preparation and fair presentation of published financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2024. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). Based on our assessment, we concluded that, as of December&#160;31, 2024, the Company&#8217;s internal control over financial reporting was effective based on those criteria.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s internal control over financial reporting as of December&#160;31, 2024 has been audited by Ernst &amp; Young LLP, the independent registered public accounting firm who also audited the Company&#8217;s financial statements. Ernst &amp; Young&#8217;s attestation report on the Company&#8217;s internal control over financial reporting appears on page </span><span style="color:#0070c0;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0070c0;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_139">127</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the year ended December&#160;31, 2024, that have materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Pacific Biosciences of California, Inc.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Pacific Biosciences of California, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2024, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Pacific Biosciences of California, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2024, based on the COSO criteria.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2024 consolidated financial statements of the Company and our report dated March&#160;17, 2025 expressed an unqualified opinion thereon.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion</span><span style="color:#000000;font-family:'EYInterstate Light',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Mateo, California </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;17, 2025</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 9B.  OTHER INFORMATION</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Securities Trading Plans of Directors and Executive Officers</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During our last fiscal quarter, none of our directors or officers, as defined in Rule 16a-1(f), <ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1474"><ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1475">adopted</ix:nonNumeric></ix:nonNumeric> and/or <ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1476"><ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1477">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; each as defined in Item 408 of Regulation S-K.</span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_145"></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 9C.  DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_148"></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART III</span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_151"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 10.  DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_154"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 11.  EXECUTIVE COMPENSATION</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_157"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. </span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_160"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. </span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_163"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. </span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_166"></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART IV</span></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_169"></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 15.  EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div></td></tr></table></div><div style="margin-top:9pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.69pt">The following documents are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K: </span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.76pt">Financial Statements</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: See Index to Consolidated Financial Statements under Item 8 of this Annual Report on Form 10-K. </span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.76pt">Financial Statement Schedules</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: All schedules are omitted because they are not required, are not applicable or the information is included in the Consolidated Financial Statements or notes thereto. </span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.76pt">Exhibits</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We have filed or incorporated by reference into this Annual Report on Form 10-K, the exhibits listed on the accompanying Exhibit Index immediately below. </span></div><div style="margin-top:9pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.51pt">Financial Statement Schedules: See Item 15(a)(2), above. </span></div><div style="margin-top:9pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.89pt">Exhibits: Refer to the </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2013cc21a604ead9766507cf0adcfc3_803">Exhibit Index</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that follows. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span id="if2013cc21a604ead9766507cf0adcfc3_803"></span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"><tr><td style="width:1.0%"/><td style="width:7.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:58.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporated by reference herein</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000119312511075269/dex31.htm">Amended and Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 23, 2011</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913022000128/pacb-20221103xex3_1.htm">Third Amended and Restated Bylaws of Pacific Biosciences of California, Inc.</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 7, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913024000146/exhibit31-certificateofame.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Pacific Biosciences of California, Inc. to declassify the Board</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 20, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">3.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913024000146/exhibit32-certificateofame.htm">Certificate of Amendment to the Certificate of Incorporation of Pacific Biosciences of California, Inc. to limit the liability of officers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 20, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000119312510221497/dex41.htm">Specimen Common Stock Certificate</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 1, 2010</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-exx42xdescriptionofse.htm">Description of Registrant&#8217;s securities registered under Section 12 of the Exchange Act</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000049/pacb-20210216xex4_1.htm">Indenture, dated February 16, 2021, between Pacific Biosciences of California, Inc., and U.S. Bank National Association, as Trustee</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 4, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000049/pacb-20210216xex4_1.htm">Form of 1.50% Convertible Senior Notes due 2028 (included in Exhibit 4.3)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 4, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000110465923077161/tm2320097d1_ex4-1.htm">Indenture, dated as of June 30, 2023, by and between Pacific Biosciences of California, Inc. and U.S. Bank Trust Company, National Association, as Trustee</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000110465923077161/tm2320097d1_ex4-1.htm">Form of 1.375% Convertible Senior Note due 2030 (included in Exhibit 4.5)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">4.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001299130/000129913024000189/exhibit41final.htm">Indenture, dated as of November 21, 2024, by and between Pacific Biosciences of California, Inc. and U.S. Bank Trust Company, National Association, as Trustee.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 22, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001299130/000129913024000189/exhibit41final.htm">Form of 1.50% Convertible Senior Note due 2029 (included in Exhibit 4.7)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 22, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000119312510189512/dex101.htm">Form of Director and Executive Officer Indemnification Agreement</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 16, 2010</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.2+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000119312510189512/dex104.htm">2010 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 16, 2010</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.3+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913018000031/pacb-20180331xex10_1.htm">2010 Equity Incentive Plan forms of agreement</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.4+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000119312510189512/dex105.htm">2010 Employee Stock Purchase Plan and forms of agreement thereunder</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 16, 2010</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.5+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000119312510189512/dex106.htm">2010 Outside Director Equity Incentive Plan </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 16, 2010</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.6+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913018000031/pacb-20180331xex10_2.htm">2010 Outside Director Equity Incentive Plan forms of agreement</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.7+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000110465922065284/tm2216796d1_ex10-1.htm">2020 Equity Incentive Plan, as amended</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 20, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.8+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000110465922065284/tm2216796d1_ex10-2.htm">Form of Global Stock Option Agreement under the Pacific Biosciences of California, Inc., 2020 Equity Incentive Plan, as amended</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 20, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.9+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000110465922065284/tm2216796d1_ex10-3.htm">Form of Global Restricted Stock Unit Agreement under the Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan, as amended</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 20, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.10+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000216/pacb-20210930xex10_4.htm">Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc., and related forms of agreement thereunder</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 5, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.11+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000223/pacb-20211119xex10_1.htm">Pacific Biosciences of California, Inc. 2020 Inducement Equity Incentive Plan, as amended, and forms of agreement thereunder</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 19, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.12+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913020000148/pacb-20200930xex10_2.htm">Letter Relating to Employment Terms by and between the Registrant and Susan G. Kim effective September 28, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 3, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.13+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-exx1013xpacbiochangei.htm">Form of Change in Control and Severance Agreement for executive officers</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.14+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_15.htm">Letter Relating to Employment Terms by and between the Registrant and Christian O. Henry effective September 14, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.15+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-exx1015xpacbioxceoame.htm">Amended Change in Control and Severance Agreement by and between the Registrant and Christian O. Henry dated</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-exx1015xpacbioxceoame.htm"> December 11, 2024</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.16+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_18.htm">Letter Relating to Employment Terms by and between the Registrant and Mark Van Oene effective January 8, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"><tr><td style="width:1.0%"/><td style="width:7.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:58.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.17+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-exx1017xpacbioxarchan.htm">Amended Change in Control and Severance Agreement by and between the Registrant and Mark Van Oene dated December 12, 2024</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.18&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-exx1018xpacbxleaseedg.htm">Lease Agreement by and between the Registrant and Menlo Park Portfolio II, LLC, dated July 22, 2015</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.19&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-exx1019xfirstamendmen.htm">First Amendment to Lease Agreement by and between the Registrant and Menlo Park Portfolio II, LLC, dated December 23, 2016</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.20</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-exx1020xpacbioseconda.htm">Second Amendment to Lease Agreement by and between the Registrant and Menlo Park Portfolio II, LLC, dated December 30, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.21</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-exx1021xpacbiox1305ob.htm">Third Amendment to Lease Agreement by and between the Registrant and Menlo Park Portfolio II, LLC, dated March 7, 2025</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.22</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000119312521035435/d121704dex101.htm">Investment Agreement, dated as of February 9, 2021, between Pacific Biosciences of California, Inc. and SB Northstar LP.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.23+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913021000192/pacb-20210630xex10_2.htm">Letter Relating to Employment Terms by and between the Registrant and Michele Farmer effective May 17, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 6, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.24</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000119312521219136/d198514dex101.htm">Agreement and Plan of Merger of Reorganization among Pacific Biosciences of California, Inc., Apollo Acquisition Corp., Apollo Acquisition Sub, LLC, Omniome, Inc. and Shareholder Representative Services, LLC, as securityholder representative, dated as of July 19, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 20, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.25</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000119312521219136/d198514dex102.htm">Securities Purchase Agreement, dated as of July 19, 2021, by and between Pacific Biosciences of California, Inc., and each of the Investors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 20, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.26+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000110465923006228/tm234149d1_ex99-3.htm">Letter Relating to Employment Terms by and between the Registrant and Jeff Eidel effective August 16, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 24, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.27+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001299130/000129913024000198/exhibit101-separationagree.htm">Separation Agreement and Release, by and between the Company and Jeff Eidel, dated December 6, 2024 and effective December 13, 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K/A</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 13, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.28+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000110465923006228/tm234149d1_ex99-4.htm">Change in Control and Severance Agreement by and between the Registrant and Susan G. Kim effective February 3, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 24, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000110465923074397/tm2319528d1_ex10-1.htm">Letter Agreement, dated June 23, 2023, between the Company and Chimera Investment LLC</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 23, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.30</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001299130/000110465924115291/tm2427787d2_ex10-1.htm">Letter Agreement, dated November 7, 2024, between the Company and SB Northstar LP</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 7, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.31</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001299130/000129913024000189/exhibit101.htm">Letter Agreement, dated November 21, 2024, between the Company and SB Northstar LP</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 22, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.32+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913024000054/pacb-20231231xexx1028.htm">Form of Performance-Based Restricted Stock Unit Award Agreement under the Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan, as amended</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 28, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.33+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-exx1033xpacbiooutside.htm">Outside Director Compensation Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">19.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-exx191xpacbioinsidert.htm"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-1478">Insider Trading Policy</ix:nonNumeric></a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">21.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-exx211x2024.htm">List of Subsidiaries of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-exx231x2024.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-exx311x2024.htm">Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-exx312x2024.htm">Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">32.1*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-exx321x2024.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furnished herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">32.2*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-exx322x2024.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furnished herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">97.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913024000054/pacb-20231231xexx971.htm">Compensation Recovery Policy</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 28, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"><tr><td style="width:1.0%"/><td style="width:7.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:58.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive File (formatted as inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan. </span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain confidential information contained in this Exhibit was omitted by means of marking such portions with brackets because (i) the identified confidential information is not material and (ii) the company customarily and actually treats that information as private or confidential.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The certifications attached as Exhibit 32.1 and 32.2 that accompany this Annual Report on Form 10-K are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Pacific Biosciences of California, Inc. under the Securities Act or the Exchange Act, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></div></td></tr></table></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_172"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 16.  FORM 10-K SUMMARY</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133</span></div></td></tr></table></div></div></div><div id="icb85bf3e8a0c45b3a91f3aa50919c5f5_175"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pacific Biosciences of California, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March&#160;17, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christian O. Henry </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christian O. Henry</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">President, Chief Executive Officer and Interim Chief Financial Officer</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March&#160;17, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michele Farmer </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michele Farmer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vice President and Chief Accounting Officer </span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Christian O. Henry, Brett Atkins, and Michele Farmer, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for each individual in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or the individual&#8217;s substitute, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.962%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Christian O. Henry </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director, President, Chief Executive Officer and Interim Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer and Principal Financial Officer)</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christian O. Henry</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Michele Farmer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President and Chief Accounting Officer (Principal Accounting Officer)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michele Farmer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ John F. Milligan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John F. Milligan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ William W. Ericson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William W. Ericson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Randall S. Livingston</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Randall S. Livingston</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Marshall L. Mohr</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marshall L. Mohr</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Kathy Ordo&#241;ez</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathy Ordo&#241;ez</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Lucy Shapiro</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lucy Shapiro</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Christopher M. Smith</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher M. Smith</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Hannah A. Valantine</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hannah A. Valantine</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20241231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2024 Form 10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136</span></div></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>pacb-exx42xdescriptionofse.htm
<DESCRIPTION>EX-4.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i86c08de397b74a999fee1efba7f88592_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-right:0.3pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 4.2 </font></div><div style="margin-top:12pt;padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REGISTERED PURSUANT TO SECTION 12 OF THE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-top:12pt;padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DESCRIPTION OF CAPITAL STOCK</font></div><div style="margin-top:12pt;padding-right:0.3pt;text-indent:28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following information describes our common stock and preferred stock, as well as certain provisions of our amended and restated certificate of incorporation (as amended, the &#8220;amended and restated certificate of incorporation&#8221;) and amended and restated bylaws. This summary does not purport to be complete and is qualified in its entirety by the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, copies of which have been filed as exhibits to this Annual Report on Form 10-K, as well as to the applicable provisions of the Delaware General Corporation Law.</font></div><div style="margin-top:12pt;padding-right:0.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">General</font></div><div style="margin-top:12pt;padding-right:0.3pt;text-indent:28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Our authorized capital stock consists of 1,000,000,000 shares of common stock with a $0.001 par value per share, and 50,000,000 shares of undesignated preferred stock with a $0.001 par value per share. Our board of directors may establish the rights, powers and preferences of the preferred stock from time to time. </font></div><div style="margin-top:12pt;padding-right:0.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="margin-top:12pt;padding-right:0.3pt;text-indent:28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each holder of our common stock is entitled to one vote for each share on each matter properly submitted to stockholders on which the holders of common stock are entitled to vote. Subject to any preferential rights of any outstanding preferred stock, holders of our common stock are entitled to receive ratably the dividends and other distributions, if any, as may be declared from time to time by the board of directors out of any assets or funds legally available therefor. We have never declared or paid any cash dividend on our capital stock and do not anticipate paying any cash dividends in the foreseeable future. In the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in our assets remaining after the payment of liabilities and any preferential rights of any outstanding preferred stock.</font></div><div style="margin-top:12pt;padding-right:0.3pt;text-indent:28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Holders of our common stock have no preemptive or conversion rights or other subscription rights, and there are no redemption or sinking fund provisions applicable to the common stock. The outstanding shares of common stock are fully paid and non-assessable. The rights and powers of the holders of our common stock are subject to, and may be adversely affected by, the rights, powers and preferences of the holders of shares of any series of preferred stock that we may designate and issue in the future.</font></div><div style="margin-top:12pt;padding-right:0.3pt;text-indent:28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Our common stock is listed on the NASDAQ Global Select Market under the symbol &#8220;PACB.&#8221; The transfer agent and registrar for the common stock is Computershare Trust Company, N.A. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-right:0.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Preferred Stock</font></div><div style="margin-top:12pt;padding-right:0.3pt;text-indent:28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Under the terms of our amended and restated certificate of incorporation, our board of directors is authorized to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, powers, preferences and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. Subject to limitations under applicable law, there are no restrictions presently on the repurchase or redemption of any shares of our preferred stock.</font></div><div style="margin-top:12pt;padding-right:0.3pt;text-indent:28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The issuance of shares of preferred stock will affect, and may adversely affect, the rights of holders of common stock. It is not possible to state the actual effect of the issuance of any shares of preferred stock on the rights of holders of common stock until our board of directors determines the specific rights attached to that preferred stock. The effects of issuing additional preferred stock could include one or more of the following&#58;</font></div><div style="margin-top:12pt;padding-left:56.7pt;padding-right:0.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.15pt">restricting dividends on the common stock&#59;</font></div><div style="margin-top:12pt;padding-left:56.7pt;padding-right:0.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.15pt">diluting the voting power of the common stock&#59;</font></div><div style="margin-top:12pt;padding-left:56.7pt;padding-right:0.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.15pt">impairing the liquidation rights of the common stock&#59; or</font></div><div style="margin-top:12pt;padding-left:56.7pt;padding-right:0.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.15pt">delaying or preventing changes in control or management of our company.</font></div><div style="margin-top:12pt;padding-right:0.3pt;text-indent:28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preferred stock will be fully paid and nonassessable upon issuance.</font></div><div style="margin-top:12pt;padding-right:0.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effect of Certain Provisions of our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws and the Delaware Anti-Takeover Statute</font></div><div style="margin-top:12pt;padding-right:0.3pt;text-indent:28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Some provisions of Delaware law and our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could make the following transactions more difficult&#58;</font></div><div style="margin-top:12pt;padding-left:56.7pt;padding-right:0.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.15pt">acquisition of us by means of a tender offer&#59;</font></div><div style="margin-top:12pt;padding-left:56.7pt;padding-right:0.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.15pt">acquisition of us by means of a proxy contest or otherwise&#59; or</font></div><div style="margin-top:12pt;padding-left:56.7pt;padding-right:0.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.15pt">removal of our incumbent officers and directors.</font></div><div style="margin-top:12pt;padding-right:0.3pt;text-indent:28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Those provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids and to promote stability in our management. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors.</font></div><div style="margin-top:12pt;padding-right:0.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws</font></div><div style="margin-top:6pt;padding-right:0.3pt;text-indent:28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and our amended and restated bylaws provide for the following&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:56.7pt;padding-right:0.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:24.15pt">Undesignated Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Our board of directors may issue one or more series of preferred stock with voting or other rights, powers or preferences that could impede the success of any attempt to change control of our company. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company.</font></div><div style="margin-top:12pt;padding-left:56.7pt;padding-right:0.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:24.15pt">Stockholder Special Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Our amended and restated certificate of incorporation and amended and restated bylaws provide that in general a special meeting of stockholders may be called only by our board of directors, its chairperson, our chief executive officer or our president (in the absence of a chief executive officer).</font></div><div style="margin-top:12pt;padding-left:56.7pt;padding-right:0.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:24.15pt">Requirements for Advance Notification of Stockholder Nominations and Proposals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination by stockholders of candidates for election as directors.</font></div><div style="margin-top:12pt;padding-left:54pt;padding-right:0.3pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:22.8pt">Board Classification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Our board of directors is divided into three classes, designated Class I, Class II and Class III. The directors in each class have been elected to serve for a three-year term, one class being elected each year by our stockholders. At our annual meeting of stockholders held in 2025 (the &#8220;2025 Annual Meeting&#8221;), the successors of the Class&#160;III directors whose terms expire at the 2025 Annual Meeting will each be elected for a term expiring at our annual meeting of stockholders held in 2026 (the &#8220;2026 Annual Meeting&#8221;). At the 2026 Annual Meeting, the successors of the directors whose terms expire at the 2026 Annual Meeting (including the Class I directors and the successors of the directors elected at the 2025 Annual Meeting) will each be elected for a term expiring at our annual meeting of stockholders held in 2027 (the &#8220;2027 Annual Meeting&#8221;). At the 2027 Annual Meeting and at all annual meetings thereafter, all directors will be elected for terms expiring at the next annual meeting of stockholders. While our classified board structure will be phased out so that our board of directors will be fully declassified by the 2027 Annual Meeting, this system of electing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </font></div><div style="margin-top:12pt;padding-left:56.7pt;padding-right:0.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:24.15pt">Limits on Ability of Stockholders to Act by Written Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. We have provided in our amended and restated certificate of incorporation and our amended and restated bylaws that, except as otherwise expressly provided by the terms of any series of preferred stock permitting the holders of such series of preferred stock to act by written consent, our stockholders may not act by written consent. This limit on the ability of our stockholders to act by written consent may lengthen the amount of time required to take stockholder actions. As a result, a holder controlling a majority of our capital stock would not be able to amend our amended and restated bylaws or remove directors without holding a meeting of our stockholders called in accordance with our amended and restated certificate of incorporation and amended and restated bylaws.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:56.7pt;padding-right:0.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:24.15pt">Election and Removal of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that establish specific procedures for appointing and removing members of our board of directors. Under our amended and restated certificate of incorporation and amended and restated bylaws, subject to the rights of holders of any series of preferred stock with respect to the election of directors, and except as otherwise provided by resolution of our board of directors, vacancies and newly created directorships resulting from an increase in the authorized number of directors elected by all of the stockholders having the right to vote as a single class may be filled only by the affirmative vote of a majority of the directors then serving on the board of directors. Under our amended and restated certificate of incorporation and amended and restated bylaws, and subject to the rights of holders of any series of preferred stock with respect to the election of directors, directors may be removed from office in the manner provided in Section&#160;141(k) of the Delaware General Corporation Law. </font></div><div style="margin-top:12pt;padding-left:56.7pt;padding-right:0.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:24.15pt">No Cumulative Voting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Delaware General Corporation Law provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless our amended and restated certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation and amended and restated bylaws do not expressly provide for cumulative voting. Without cumulative voting, a minority stockholder may not be able to gain as many seats on our board of directors as the stockholder would be able to gain if cumulative voting were permitted. The absence of cumulative voting makes it more difficult for a minority stockholder to gain a seat on our board of directors to influence our board of directors&#8217; decision regarding a takeover.</font></div><div style="margin-top:12pt;padding-right:0.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Delaware Anti-Takeover Statute</font></div><div style="margin-top:6pt;padding-right:0.3pt;text-indent:28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We are subject to the provisions of Section 203 of the Delaware General Corporation Law regulating corporate takeovers. In general, Section 203 prohibits a publicly-held Delaware corporation from engaging, under certain circumstances, in a business combination with an interested stockholder for a period of three years following the date the person became an interested stockholder unless&#58;</font></div><div style="margin-top:6pt;padding-left:56.7pt;padding-right:0.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.15pt">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59;</font></div><div style="margin-top:6pt;padding-left:56.7pt;padding-right:0.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.15pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not for determining the outstanding voting stock owned by the interested stockholder, (i) shares owned by persons who are directors and also officers, and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:56.7pt;padding-right:0.3pt;text-indent:-28.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.15pt">at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66-2&#47;3% of the outstanding voting stock which is not owned by the interested stockholder.</font></div><div style="margin-top:12pt;padding-right:0.3pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with its affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation&#8217;s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that Section 203 may discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>3
<FILENAME>pacb-exx1013xpacbiochangei.htm
<DESCRIPTION>EX-10.13
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="iacaf9767f10b4dc5958ac7ba2156ccd7_1"></div><div style="min-height:75.96pt;width:100%"><div style="margin-top:6pt;padding-left:72pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.13</font></div><div style="margin-top:6pt;padding-left:36pt;padding-right:36pt;text-align:center"><img alt="pacb-20221231x10kg0011a.jpg" src="pacb-20221231x10kg0011a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"></div><div style="margin-top:6pt;padding-left:36pt;padding-right:36pt;text-align:center"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CHANGE IN CONTROL AND SEVERANCE AGREEMENT</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Change in Control and Severance Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into by and between &#91;__________&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Pacific Biosciences of California, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), effective as of &#91;_________&#93;, 202&#91;_&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">It is expected that the Company from time to time will consider the possibility of an acquisition by another company or other change in control.  The Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) recognizes that such considerations can be a distraction to Executive and can cause Executive to consider alternative employment opportunities.  The Board has determined that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of Executive, notwithstanding the possibility, threat or occurrence of such a termination of employment or the occurrence of a Change in Control (as defined herein) of the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The Board believes that it is in the best interests of the Company and its stockholders to provide Executive with an incentive to continue Executive&#8217;s employment and to motivate Executive to maximize the value of the Company for the benefit of its stockholders.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The Board believes that it is imperative to provide Executive with certain severance benefits upon Executive&#8217;s termination of employment in connection with a Change in Control.  These benefits will provide Executive with enhanced financial security, incentive and encouragement to remain with the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Certain capitalized terms used in the Agreement are defined in Section 6 below.</font></div><div style="margin-top:12pt;padding-right:-18pt;text-align:center;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AGREEMENT</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the mutual covenants contained herein, the parties hereto agree as follows&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Term of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement will have an initial term of three (3) years commencing on the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Initial Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  On the third anniversary of the Effective Date, this Agreement will renew automatically for additional one (1) year terms (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Additional Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), unless either party provides the other party with written notice of non-renewal at least sixty (60) days prior to the date of automatic renewal.  Notwithstanding the foregoing provisions of this paragraph, if a Change in Control occurs when there are fewer than twelve (12) months remaining during the Initial Term or an Additional Term, the term of this Agreement will extend automatically through the date that is twelve (12) months following the effective date of the Change in Control.  If Executive becomes entitled to benefits under Section 3(a) or Section&#160;3(b) during the term of this Agreement, the Agreement will not terminate until all of the obligations of the parties hereto with respect to this Agreement have been satisfied.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-1-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.96pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and Executive acknowledge that Executive&#8217;s employment is and will continue to be at-will, as defined under applicable law.  No payments, benefits, or provisions under this Agreement will confer upon Executive any right to continue Executive&#8217;s employment with the Company, nor will they interfere with or limit in any way the right of the Company or Executive to terminate such relationship at any time, with or without cause, to the extent permitted by applicable laws.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination without Cause or Other than Death or Disability or Resignation for Good Reason Other than During the Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If a Qualifying Termination occurs other than during the Change in Control Period, then subject to Section&#160;4, Executive will receive the following severance from the Company&#58; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will receive a lump sum cash payment equal to twelve (12)&#160;months of Executive&#8217;s salary, less any applicable withholdings.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Continued Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive elects continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for Executive and Executive&#8217;s eligible dependents (as applicable), within the time period prescribed pursuant to COBRA, Executive will receive Company-paid group health, dental and vision coverage for Executive and Executive&#8217;s eligible dependents, as applicable, at the coverage levels in effect immediately prior to the termination of Executive&#8217;s employment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">COBRA Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) until the earliest of&#58; (A)&#160;a period of twelve (12)&#160;months from the last date of employment of the Executive with the Company, (B)&#160;the date upon which Executive and&#47;or Executive&#8217;s eligible dependents becomes covered under similar plans, or (C)&#160;the expiration of Executive&#8217;s and Executive&#8217;s eligible dependents&#8217; (as applicable) eligibility for continuation coverage under COBRA.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Termination without Cause or Other than Death or Disability or Resignation for Good Reason During the Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If a Qualifying Termination occurs during the Change in Control Period, then subject to Section&#160;4, Executive will receive the following severance from the Company&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will receive a lump sum cash payment equal to twelve (12)&#160;months of Executive&#8217;s salary, less any applicable withholdings. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prorated Target Bonus Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will receive a lump sum cash payment equal to Executive&#8217;s annualized target bonus in effect for the year in which the Qualifying Termination occurs, provided that such amount will be prorated based on a fraction, the numerator of which is the number of days during which Executive was employed with the Company (or its successor) in the year that the Qualifying Termination occurs, and the denominator of which is the total number of days in such year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Prorated Bonus Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Continued Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive elects continuation coverage pursuant to COBRA for Executive and Executive&#8217;s eligible dependents (as applicable), within the time period prescribed pursuant to COBRA, the Company will provide the COBRA Severance until the earliest of&#58; (A)&#160;a period of twelve (12)&#160;months from the last date of employment of the Executive with the Company, (B)&#160;the date upon which Executive and&#47;or Executive&#8217;s eligible</font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.96pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">dependents becomes covered under similar plans, or (C)&#160;the expiration of Executive&#8217;s and Executive&#8217;s eligible dependents&#8217; (as applicable) eligibility for continuation coverage under COBRA.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  One hundred percent (100%) of the unvested portion of the Executive&#8217;s then-outstanding equity awards (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will immediately vest and, to the extent applicable, become exercisable, as of the date of such termination.  To the extent that an Award is subject to performance-based vesting at the time of such termination, such performance goals will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions met, unless specifically provided otherwise under the applicable Award agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Awards will remain exercisable, to the extent applicable, following Executive&#8217;s termination for the period prescribed in the applicable equity plan and agreement for each Award.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Other Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment with the Company terminates other than as set forth in Section&#160;3(a) or 3(b) above, then (i) all vesting will terminate immediately with respect to Executive&#8217;s outstanding Awards, (ii) all payments of compensation by the Company to Executive hereunder will terminate immediately (except as to amounts already earned), and (iii)&#160;Executive will only be eligible for severance benefits in accordance with the Company&#8217;s established policies, if any, as then in effect. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Accrued Amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On any termination of Executive&#8217;s employment with the Company, Executive will be entitled to receive all accrued but unpaid vacation, expense reimbursements, wages, and other benefits due to Executive under any Company-provided plans, policies, and arrangements. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Non-duplication of Payment or Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of this Agreement to the contrary, if Executive is entitled to any cash severance, continued health coverage severance benefits, vesting acceleration of any Awards, or other severance or separation benefits similar to those provided under this Agreement, by operation of applicable law or under a plan, policy, contract, or arrangement sponsored by or to which the Company is a party other than this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Other Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then the corresponding severance payments and benefits under this Agreement will be reduced by the amount of Other Benefits paid or provided to Executive.  For the avoidance of doubt, in the event of a Qualifying&#160;Termination under which Executive becomes entitled to severance under Section 3(b),&#160;any severance payments and benefits to be provided to the Executive under Section&#160;3(b) will be reduced by the corresponding severance payments or benefits, as applicable, that already were provided to the Executive under Section&#160;3(a).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Conditions to Receipt of Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Release of Claims Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The receipt of any severance payments or benefits pursuant to this Agreement is subject to Executive signing and not revoking a separation agreement and release of claims in a form acceptable to the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which must become effective and irrevocable no later than the sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) day following Executive&#8217;s termination of employment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Release Deadline Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). If the Release does not become effective and irrevocable by the Release Deadline Date, Executive&#160;will forfeit any right to severance payments or benefits under this Agreement.  No severance payments and benefits under Section 3(a) or 3(b) of this Agreement will be paid or provided until the Release becomes effective and irrevocable, and any such severance payments and benefits otherwise payable between the date of Executive&#8217;s termination of employment and the date the Release becomes effective and irrevocable (including, if applicable, the lump sum cash payment under Section 4(c) below) will be paid, subject to the requirements of</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.96pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section&#160;4(d) below, on the Company&#8217;s first regularly scheduled payroll date on or following the date the Release becomes effective and irrevocable.  Any restricted stock units, performance units, performance shares, and&#47;or similar full value awards that accelerate vesting under this Agreement (&#8220;Full Value Awards&#8221;) will be settled (subject to Section&#160;4(d) below and the terms of any award agreement or other Company plan, policy, or arrangement governing the settlement timing of such award to the extent such terms specifically require different payment timing in order to comply with the requirements of Section&#160;409A, as applicable (the &#8220;Full Value Settlement Provisions&#8221;), on a date within ten (10) days following the date the Release becomes effective and irrevocable. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Confidential Information and Invention Assignment Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive&#8217;s receipt of any payments or benefits under Sections 3(a) and&#160;3(b) will be subject to Executive continuing to comply with the terms of any confidential information and invention assignment agreement executed by Executive in favor of the Company and the provisions of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">COBRA Severance Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the provisions of Sections&#160;3(a)(ii) and 3(b)(ii), if the Company determines in its sole discretion that it cannot provide the COBRA Severance without potentially violating applicable laws (including, without limitation, Section 2716 of the Public Health Service Act and the Employee Retirement Income Security Act of 1974, as amended), then in lieu of such COBRA Severance, and subject to any delay required by this Section&#160;4, the Company will provide to Executive a taxable lump sum cash payment in an amount equal to the product of (x)&#160;the number of months of Salary severance specified in Section&#160;3(a)(i) or&#160;3(b)(i), as applicable, multiplied by (y)&#160;the monthly COBRA premium that Executive otherwise would be required to pay to continue the group health, dental and vision coverage for Executive and Executive&#8217;s eligible dependents, as applicable, as in effect on the date of termination of Executive&#8217;s employment (which amount will be based on the premium for the first month of COBRA coverage for Executive and Executive&#8217;s eligible dependents), which payment will be made regardless of whether Executive elects COBRA continuation coverage (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Taxable Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  For the avoidance of doubt, the Taxable Payment may be used for any purpose, including, but not limited to continuation coverage under COBRA, and will be subject to all applicable tax withholdings.  Notwithstanding anything to the contrary under this Agreement, if the Company determines in its sole discretion at any time that it cannot provide the COBRA Severance or the Taxable Payment without violating applicable law (including, without limitation, Section&#160;2716 of the Public Health Service Act and the Employee Retirement Income Security Act of 1974, as amended), Executive will not receive any COBRA Severance or Taxable Amount under this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">Notwithstanding anything to the contrary in this Agreement, no severance payments or benefits payable to Executive, if any, pursuant to this Agreement that, when considered together with any other severance payments or separation benefits, is considered deferred compensation under Internal Revenue Code Section 409A (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Deferred Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will be payable until Executive has a &#8220;separation from service&#8221; within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and the Treasury Regulations and guidance thereunder, and any applicable state law equivalent, as each may be promulgated, amended or modified from time to time (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Section&#160;409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Similarly, no severance payable to Executive, if any, pursuant to this Agreement that otherwise would be exempt from Section 409A pursuant to Treasury Regulations Section 1.409A-1(b)(9) will be payable until Executive has a &#8220;separation from service&#8221; within the meaning of Section 409A.  To the extent required to be exempt from or comply with</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.96pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section&#160;409A, references to the termination of Executive&#8217;s employment or similar phrases used in this Agreement will mean Executive&#8217;s &#8220;separation from service&#8221; within the meaning of Section&#160;409A. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">  Any severance payments or benefits under this Agreement that would be considered Deferred Payments will be paid on, or, in the case of installments, will not commence until, the sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) day following Executive&#8217;s separation from service, or, if later, such time as required by Section&#160;4(d)(iii) (or with respect to Full Value Awards, such time or times as required by any applicable Full Value Settlement Provisions).  Except as required by Section 4(d)(iii) and any applicable Full Value Settlement Provisions, any Deferred Payments payable in installments that would have been made to Executive during the sixty&#160;(60) day period immediately following Executive&#8217;s separation from service but for the preceding sentence will be paid to Executive on the sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) day following Executive&#8217;s separation from service and the remaining payments shall be made as provided in this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">   Further, if Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A at the time of Executive&#8217;s separation from service (other than due to death), any Deferred Payments that otherwise are payable within the first six (6) months following Executive&#8217;s separation from service will become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date of Executive&#8217;s separation from service.  All subsequent Deferred Payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.  Notwithstanding anything herein to the contrary, in the event of Executive&#8217;s death following Executive&#8217;s separation from service but prior to the six (6) month anniversary of Executive&#8217;s separation from service (or any later delay date), then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of Executive&#8217;s death and all other Deferred Payments will be payable in accordance with the payment schedule applicable to each payment or benefit.  Each payment and benefit payable under the Agreement is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt"> Any amount paid under this Agreement that satisfies the requirements of the &#8220;short-term deferral&#8221; rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments for purposes of clause (i) above.  Any amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that is within the limit set forth thereunder will not constitute Deferred Payments for purposes of clause (i) above.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.02pt"> The foregoing provisions are intended to comply with, or be exempt from, the requirements of Section 409A so that none of the severance payments and benefits to be provided under the Agreement will be subject to the additional tax imposed under Section 409A, and any ambiguities and ambiguous terms herein will be interpreted to so comply or be exempt.  Executive and the Company agree to work together in good faith to consider amendments to the Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to Executive under Section 409A.  In no event will the Company or any of its subsidiaries or other affiliates have any obligation, responsibility or liability to reimburse, indemnify or hold harmless Executive for any taxes imposed, or other costs incurred, as result of Section 409A. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Limitation on Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that the severance and other benefits provided for in this Agreement or otherwise that Executive would receive from the Company or any other party</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.96pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whether in connection with the provisions of this Agreement or otherwise (the &#8220;Payments&#8221;) would (i) constitute &#8220;parachute payments&#8221; within the meaning of Section 280G of the Code and (ii)&#160;but for this Section&#160;5, would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments will be either&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">delivered in full, or</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">delivered as to such lesser extent which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code,</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the receipt by Executive on an after-tax basis, of the greatest amount of Payments, notwithstanding that all or some portion of such Payments may be taxable under Section 4999 of the Code.  If a reduction in severance and other benefits constituting &#8220;parachute payments&#8221; is necessary so that benefits are delivered to a lesser extent, reduction will occur in the following order&#58; (i) reduction of cash payments in reverse chronological order (that is, the cash payment owed on the latest date following the occurrence of the event triggering the excise tax under Code Section&#160;4999 will be the first cash payment to be reduced)&#59; (ii)&#160;cancellation of equity awards granted &#8220;contingent on a change in ownership or control&#8221; (within the meaning of Code Section 280G) in the reverse order of date of grant of the equity awards (that is, the most recently granted equity awards will be cancelled first), (iii)&#160;reduction of accelerated vesting of equity awards in the reverse order of date of grant of the equity awards (that is, the vesting of the most recently granted equity awards will be cancelled first)&#59; (iv) reduction of employee benefits in reverse chronological order (that is, the benefit owed on the latest date following the occurrence of the event triggering such excise tax will be the first benefit to be reduced).  In no event will Executive have any discretion with respect to the ordering of Payment reductions.  Executive will be solely responsible for the payment of all personal tax liability that is incurred as a result of the payments and benefits received under this Agreement, and neither the Company nor any parent, subsidiary or other affiliate of the Company will have any responsibility, liability or obligation to reimburse, indemnify or hold harmless Executive for any of those payments of personal tax liability.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Company and Executive otherwise agree in writing, any determination required under this Section&#160;5 will be made in writing by a nationally recognized accounting or valuation firm (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Firm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) selected by the Company, whose determination will be conclusive and binding upon Executive and the Company for all purposes.  For purposes of making the calculations required by this Section&#160;5, the Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code.  The Company and Executive will furnish to the Firm such information and documents as the Firm may reasonably request in order to make a determination under this Section.  The Company will bear all costs and make all payments required to be made to the Firm for the Firm&#8217;s services that are rendered in connection with any calculations contemplated by this Section&#160;5.  The Company will have no liability to Executive for the determinations of the Firm. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Definition of Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For purposes of this Agreement, the following terms referred to in this Agreement will have the following meanings&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) conviction of any felony&#59; (ii) conviction of any crime involving moral turpitude or dishonesty that causes, or is likely to cause, material harm to the Company&#59; (iii)&#160;participation in a fraud or willful act of dishonesty against the Company that causes,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.96pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or is likely to cause, material harm to the Company&#59; (iv)&#160;intentional and material damage to the Company&#8217;s property&#59; or (v)&#160;material breach of the Company&#8217;s Proprietary Information and Inventions Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the first occurrence of any of the following on or after the Effective Date&#58; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt"> A change in the ownership of the Company which occurs on the date that any one person, or more than one person acting as a group (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than 50% of the total voting power of the stock of the Company&#59; provided, however, that for purposes of this subsection (i), the acquisition of additional stock by any one Person, who is considered to own more than 50% of the total voting power of the stock of the Company will not be considered a Change in Control.  Further, if the stockholders of the Company immediately before such change in ownership continue to retain immediately after the change in ownership, in substantially the same proportions as their ownership of shares of the Company&#8217;s voting stock immediately prior to the change in ownership, direct or indirect beneficial ownership of fifty percent (50%) or more of the total voting power of the stock of the Company or of the ultimate parent entity of the Company, such event will not be considered a Change in Control under this subsection (i).  For this purpose, indirect beneficial ownership will include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations or other business entities which own the Company, as the case may be, either directly or through one or more subsidiary corporations or other business entities&#59; or</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt"> A change in the effective control of the Company which occurs on the date that a majority of members of the Board (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is replaced during any twelve (12) month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election.  For purposes of this subsection (ii), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control&#59; or</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">  A change in the ownership of a substantial portion of the Company&#8217;s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12) month period ending on the date of the most recent acquisition by such Person) assets from the Company that have a total gross fair market value equal to or more than 50% of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions&#59; provided, however, that for purposes of this subsection (iii), the following will not constitute a change in the ownership of a substantial portion of the Company&#8217;s assets&#58; (A) a transfer to an entity that is controlled by the Company&#8217;s stockholders immediately after the transfer, or (B) a transfer of assets by the Company to&#58; (1) a stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to the Company&#8217;s stock, (2) an entity, 50% or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (3) a Person, that owns, directly or indirectly, 50% or more of the total value or voting power of all the outstanding stock of the Company, or (4) an entity, at least 50% of the total value or voting power of which is owned, directly or indirectly, by a Person described in this subsection (iii)(B)(3).  For purposes of this subsection (iii), gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.96pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this definition of Change in Control, persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, a transaction will not be deemed a Change in Control unless the transaction qualifies as a change in control event within the meaning of Section&#160;409A.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Further and for the avoidance of doubt, a transaction will not constitute a Change in Control if&#58; (i) its sole purpose is to change the jurisdiction of the Company&#8217;s incorporation, or (ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#8217;s securities immediately before such transaction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the period beginning upon the date that is three (3) months prior to a Change in Control and continuing through the date that is twelve (12) months following a Change in Control. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Executive is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Executive&#8217;s termination of his or her employment with the Company within thirty (30) days following the expiration of any cure period (discussed below) following the occurrence of one or more of the following, without Executive&#8217;s express written consent&#58; (i)&#160;a material reduction of Executive&#8217;s duties, authority, or responsibilities, relative to Employee&#8217;s duties, authority, or responsibilities as in effect immediately prior to such reduction&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that a reduction in duties, authority, or responsibilities solely by virtue of the Company being acquired and made part of a larger entity (for example, where Executive retains essentially the same responsibility and duties of the subsidiary, business unit or division substantially containing the Company&#8217;s business following a Change in Control) shall not constitute &#8220;Good Reason&#8221;&#59; (ii)&#160;a material reduction by the Company in Executive&#8217;s annualized base pay as in effect immediately prior to such reduction (in other words, a reduction of more than ten percent (10%) of Executive&#8217;s annualized base compensation in any one year, other than a reduction applicable to executives generally that does not adversely affect Executive to a greater extent than other similarly situated executives)&#59; (iii)&#160;the relocation of Executive&#8217;s principal place of performing his or her duties as an employee of the Company by more than fifty (50) miles&#59; or (iv)&#160;the failure of the Company to obtain the assumption of this Agreement by a successor.  In order for an event to qualify as Good Reason, Executive must not terminate employment with the Company without first providing the Company with written notice of the acts or omissions constituting the grounds for &#8220;Good Reason&#8221; within ninety (90) days of the initial existence of the grounds for &#8220;Good Reason&#8221; and a reasonable cure period of not less than thirty (30) days following the date of such notice.  To the extent Executive&#8217;s primary work location is not the Company&#8217;s corporate offices due to a shelter-in-place order, quarantine order, or similar work-from-home requirement that applies to Executive, Executive&#8217;s primary office location, from which a change in location under the foregoing clause&#160;(iii) will be measured, will be considered the Company&#8217;s office location where Executive&#8217;s employment with the Company primarily was based immediately prior to the commencement of such shelter-in-place order, quarantine order, or similar work-from-home requirement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.96pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Qualifying Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means either (i)&#160;the Company terminates Executive&#8217;s employment with the Company for a reason other than (A)&#160;Cause, (B)&#160;Executive&#8217;s death, or (C)&#160;Executive&#8217;s Disability or (ii)&#160;Executive resigns for Good Reason.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Executive&#8217;s base salary as in effect immediately prior to the termination of Executive&#8217;s employment (unless such termination occurs as a result of clause (ii) of the definition of &#8220;Good Reason&#8221; under Section 6(e), in which case the amount will be equal to Executive&#8217;s base salary as in effect immediately prior to such reduction) or, if greater in the case of a Qualifying Termination during the Change in Control Period, as in effect immediately prior to the Change in Control. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">The Company&#8217;s Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any successor to the Company (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company&#8217;s business and&#47;or assets will assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession.  For all purposes under this Agreement, the term &#8220;Company&#8221; will include any successor to the Company&#8217;s business and&#47;or assets which executes and delivers the assumption agreement described in this Section&#160;7(a) or which becomes bound by the terms of this Agreement by operation of law.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Executive&#8217;s Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The terms of this Agreement and all rights of Executive hereunder will inure to the benefit of, and be enforceable by, Executive&#8217;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.  Notwithstanding the foregoing, none of the rights of Executive to receive any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and distribution.  Any other attempted assignment, transfer, conveyance, or other disposition of Executive&#8217;s right to compensation or other benefits will be null and void.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notices and all other communications contemplated by this Agreement will be in writing and will be deemed to have been duly given (a)&#160;upon actual delivery to the party to be notified, (b) twenty-four (24) hours after confirmed facsimile transmission, (c)&#160;one&#160;(1) business day after deposit with a recognized overnight courier, or (d)&#160;three&#160;(3) business days after deposit with the U.S. Postal Service by first class certified or registered mail, return receipt requested, postage prepaid, addressed&#58; (i)&#160;if to Executive, at the address Executive will have most recently furnished to the Company in writing, or (ii)&#160;if to the Company, to its corporate headquarters and all notices will be directed to the General Counsel of the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any termination of Executive&#8217;s employment by the Company for Cause or by Executive for Good Reason or as a result of a voluntary resignation will be communicated by a notice of termination to the other party hereto given in accordance with Section&#160;8(a) of this Agreement.  Such notice will indicate the specific termination provision in this Agreement relied upon, will set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination under the provision so indicated, and will specify the termination date (which will be not more than thirty (30) days after the giving of such notice or in the case of</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-9-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.96pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive&#8217;s resignation for Good Reason, in accordance with the requirements under Section&#160;6(e)).  The failure by Executive to include in the notice any fact or circumstance which contributes to a showing of Good Reason will not waive any right of Executive hereunder or preclude Executive from asserting such fact or circumstance in enforcing Executive&#8217;s rights hereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Resignation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The termination of Executive&#8217;s employment for any reason also will constitute, without any further required action by Executive, Executive&#8217;s voluntary resignation from all officer and&#47;or director positions held at the Company or any of its subsidiaries or affiliates, and at the Board&#8217;s request, Executive will execute any documents reasonably necessary to reflect the resignations. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Miscellaneous Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">No Duty to Mitigate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will not be required to mitigate the amount of any payment contemplated by this Agreement, nor will any such payment be reduced by any earnings that Executive may receive from any other source except as specified in Sections&#160;3(e), 4(d) and 5.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No provision of this Agreement will be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive).  No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party will be considered a waiver of any other condition or provision or of the same condition or provision at another time.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All captions and section headings used in this Agreement are for convenient reference only and do not form a part of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement constitutes the entire agreement of the parties hereto and supersedes in their entirety all prior representations, understandings, undertakings or agreements (whether oral or written and whether expressed or implied) of the parties.  No waiver, alteration, or modification of any of the provisions of this Agreement will be binding unless in writing and signed by duly authorized representatives of the parties hereto and which specifically mention this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The validity, interpretation, construction, and performance of this Agreement will be governed by the laws of the State of California (with the exception of its conflict of laws provisions).  Any claims or legal actions by one party against the other arising out of the relationship between the parties contemplated herein (whether or not arising under this Agreement) will be commenced or maintained in any state or federal court located in San Mateo County, California, and Executive and the Company hereby submit to the jurisdiction and venue of any such court.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The invalidity, illegality, or unenforceability of any provision or provisions of this Agreement will not affect the validity, legality or enforceability of any other provision hereof, which will remain in full force and effect, and this Agreement will be construed and enforced as if the invalid, illegal, or unenforceable provision had not been included.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company (and any parent, subsidiary or other affiliate of the Company, as applicable) will have the right and authority to deduct from any payments or benefits all</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-10-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.96pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable federal, state, local, and&#47;or non-U.S. taxes or other required withholdings and payroll deductions (&#8220;Withholdings&#8221;).  Prior to the payment of any amounts or provision of any benefits under this Agreement, the Company (and any parent, subsidiary or other affiliate of the Company, as applicable) is permitted to deduct or withhold, or require Executive to remit to the Company, an amount sufficient to satisfy any applicable Withholdings with respect to such payments and benefits.  Neither the Company nor any parent, subsidiary or other affiliate of the Company will have any responsibility, liability or obligation to pay Executive&#8217;s taxes arising from or relating to any payments or benefits under this Agreement. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">o  O  o</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-11-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.96pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the Effective Date set forth above.</font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COMPANY&#160;&#160;&#160;&#160;PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:216pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXECUTIVE&#160;&#160;&#160;&#160;By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#91;_________________________&#93;</font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-12-</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>4
<FILENAME>pacb-exx1015xpacbioxceoame.htm
<DESCRIPTION>EX-10.15
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i117919e44026445d93667097ad6e8012_1"></div><div style="min-height:79.02pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.15</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><img alt="pacb-20221231x10kg0012a.jpg" src="pacb-20221231x10kg0012a.jpg" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:192px"></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Amended and Restated Change in Control and Severance Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into by and between Christian O. Henry (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Pacific Biosciences of California, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), effective as of December 11, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and supersedes and replaces the Change in Control and Severance Agreement entered into between the Company and Executive and effective February 3, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Prior Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">It is expected that the Company from time to time will consider the possibility of an acquisition by another company or other change in control.  The Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) recognizes that such considerations can be a distraction to Executive and can cause Executive to consider alternative employment opportunities.  The Board has determined that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of Executive, notwithstanding the possibility, threat or occurrence of such a termination of employment or the occurrence of a Change in Control (as defined herein) of the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The Board believes that it is in the best interests of the Company and its stockholders to provide Executive with an incentive to continue Executive&#8217;s employment and to motivate Executive to maximize the value of the Company for the benefit of its stockholders.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The Board believes that it is imperative to provide Executive with certain severance benefits upon Executive&#8217;s termination of employment in connection with a Change in Control.  These benefits will provide Executive with enhanced financial security, incentive and encouragement to remain with the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Certain capitalized terms used in the Agreement are defined in Section 6 below.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AGREEMENT</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the mutual covenants contained herein, the parties hereto agree as follows&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Term of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement will have an initial term of three (3) years commencing on the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Initial Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  On the third anniversary of the Effective Date, this Agreement will renew automatically for additional one (1) year terms (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Additional Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), unless either party provides the other party with written notice of non-renewal at least sixty (60) days prior to the date of automatic renewal.  Notwithstanding the foregoing provisions of this</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">paragraph, if a Change in Control occurs when there are fewer than twelve (12) months remaining during the Initial Term or an Additional Term, the term of this Agreement will extend automatically through the date that is twelve (12) months following the effective date of the Change in Control.  If Executive becomes entitled to benefits under Section 3(a) or Section&#160;3(b) during the term of this Agreement, the Agreement will not terminate until all of the obligations of the parties hereto with respect to this Agreement have been satisfied.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and Executive acknowledge that Executive&#8217;s employment is and will continue to be at-will, as defined under applicable law.  No payments, benefits, or provisions under this Agreement will confer upon Executive any right to continue Executive&#8217;s employment with the Company, nor will they interfere with or limit in any way the right of the Company or Executive to terminate such relationship at any time, with or without cause, to the extent permitted by applicable laws.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination without Cause or Other than Death or Disability or Resignation for Good Reason Other than During the Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If a Qualifying Termination occurs other than during the Change in Control Period, then subject to Section&#160;4, Executive will receive the following severance from the Company&#58; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt;text-decoration:underline">Base Salary Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will receive a lump sum cash payment equal to eighteen (18)&#160;months of Executive&#8217;s Salary (unless such termination occurs as a result of clause (ii) of the definition of Good Reason, in which case the amount will be equal to eighteen (18) months of Executive&#8217;s Salary as in effect immediately prior to such Salary reduction).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt;text-decoration:underline">Continued Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive elects continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for Executive and Executive&#8217;s eligible dependents (as applicable), within the time period prescribed pursuant to COBRA, Executive will receive Company-paid group health, dental and vision coverage for Executive and Executive&#8217;s eligible dependents, as applicable, at the coverage levels in effect immediately prior to the termination of Executive&#8217;s employment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">COBRA Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) until the earliest of&#58; (A)&#160;a period of eighteen (18) months from the last date of employment of the Executive with the Company, (B)&#160;the date upon which Executive and&#47;or Executive&#8217;s eligible dependents becomes covered under similar plans, or (C)&#160;the expiration of Executive&#8217;s and Executive&#8217;s eligible dependents&#8217; (as applicable) eligibility for continuation coverage under COBRA.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Acceleration of Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each of Executive&#8217;s then-outstanding equity awards (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)  that are, as of the date of termination of employment with the Company, to vest solely based on continued service to the Company, will immediately vest as to the number of shares of Common Stock subject to each such Equity Award that otherwise would have vested had Executive remained an employee of the Company through the six (6) month anniversary of the Qualifying Termination.  For the avoidance of doubt, in the event of the Executive&#8217;s Qualifying Termination outside the Change in Control Period, any unvested portion of the Executive&#8217;s then-outstanding Equity Awards will remain outstanding until the earlier of (x)&#160;3 months following the Qualifying Termination or (y)&#160;the occurrence of a Change in Control, solely so that any benefits</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">due on a Qualifying Termination during the Change in Control Period can be provided if a Change in Control occurs within 3 months following the Qualifying Termination (provided that in no event will the Executive&#8217;s stock options or similar equity awards remain outstanding beyond the equity award&#8217;s maximum term to expiration). If no Change in Control occurs within 3 months following a Qualifying Termination outside the Change in Control Period, any unvested portion of the Executive&#8217;s equity awards automatically and permanently will be forfeited on the&#160;3-month&#160;anniversary of the day following the date of such Qualifying Termination without having vested.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Termination without Cause or Other than Death or Disability or Resignation for Good Reason During the Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If a Qualifying Termination occurs during the Change in Control Period, then subject to Section&#160;4, Executive will receive the following severance from the Company&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt;text-decoration:underline">Base Salary Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will receive a lump sum cash payment equal to eighteen (18) months&#160;of Executive&#8217;s Salary (unless such termination occurs as a result of clause (ii) of the definition of Good Reason, in which case the amount will be equal to eighteen (18) months of Executive&#8217;s Salary as in effect immediately prior to such Salary reduction).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt;text-decoration:underline">Prorated Target Bonus Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will receive a lump sum cash payment equal to Executive&#8217;s annualized target bonus in effect for the year in which the Qualifying Termination occurs, provided that such amount will be prorated based on a fraction, the numerator of which is the number of days during which Executive was employed with the Company (or its successor) in the year that the Qualifying Termination occurs, and the denominator of which is the total number of days in such year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Prorated Bonus Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Continued Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive elects continuation coverage pursuant to COBRA for Executive and Executive&#8217;s eligible dependents (as applicable), within the time period prescribed pursuant to COBRA, the Company will provide the COBRA Severance until the earliest of&#58; (A)&#160;a period of eighteen (18) months from the last date of employment of the Executive with the Company, (B)&#160;the date upon which Executive and&#47;or Executive&#8217;s eligible dependents becomes covered under similar plans, or (C)&#160;the expiration of Executive&#8217;s and Executive&#8217;s eligible dependents&#8217; (as applicable) eligibility for continuation coverage under COBRA.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  One hundred percent (100%) of the unvested portion of the Executive&#8217;s then-outstanding Equity Awards will immediately vest and, to the extent applicable, become exercisable, as of the date of such termination.  To the extent that an Equity Award is subject to performance-based vesting at the time of such termination, such performance goals will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions met, unless specifically provided otherwise under the applicable Equity Award agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Equity Awards will remain exercisable, to the extent applicable, following Executive&#8217;s termination for the period prescribed in the applicable equity plan and agreement for each Equity Award.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Other Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment with the Company terminates other than as set forth in Section&#160;3(a) or 3(b) above, then (i) all vesting will terminate immediately with respect to Executive&#8217;s outstanding Equity Awards, (ii) all payments of compensation by the Company to Executive hereunder will terminate immediately (except as to amounts already earned),</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and (iii)&#160;Executive will only be eligible for severance benefits in accordance with the Company&#8217;s established policies, if any, as then in effect. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Accrued Amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On any termination of Executive&#8217;s employment with the Company, Executive will be entitled to receive all accrued but unpaid vacation, expense reimbursements, wages, and other benefits due to Executive under any Company-provided plans, policies, and arrangements. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Non-duplication of Payment or Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of this Agreement to the contrary, if Executive is entitled to any cash severance, continued health coverage severance benefits, vesting acceleration of any Equity Awards, or other severance or separation benefits similar to those provided under this Agreement, by operation of applicable law or under a plan, policy, contract, or arrangement sponsored by or to which the Company is a party other than this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Other Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then the corresponding severance payments and benefits under this Agreement will be reduced by the amount of Other Benefits paid or provided to Executive.  For the avoidance of doubt, in the event of a Qualifying&#160;Termination under which Executive becomes entitled to severance under Section 3(b),&#160;any severance payments and benefits to be provided to the Executive under Section&#160;3(b) will be reduced by the corresponding severance payments or benefits, as applicable, that already were provided to the Executive under Section&#160;3(a).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Conditions to Receipt of Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Release of Claims Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The receipt of any severance payments or benefits pursuant to this Agreement is subject to Executive signing and not revoking a separation agreement and release of claims in a form acceptable to the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which must become effective and irrevocable no later than the sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) day following Executive&#8217;s termination of employment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Release Deadline Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). If the Release does not become effective and irrevocable by the Release Deadline Date, Executive&#160;will forfeit any right to severance payments or benefits under this Agreement.  No severance payments and benefits under Section 3(a) or 3(b) of this Agreement will be paid or provided until the Release becomes effective and irrevocable, and any such severance payments and benefits otherwise payable between the date of Executive&#8217;s termination of employment and the date the Release becomes effective and irrevocable (including, if applicable, the lump sum cash payment under Section 4(c) below) will be paid, subject to the requirements of Section&#160;4(d) below, on the Company&#8217;s first regularly scheduled payroll date on or following the date the Release becomes effective and irrevocable.  Any restricted stock units, performance units, performance shares, and&#47;or similar full value awards that accelerate vesting under this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Full Value Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will be settled (subject to Section&#160;4(d) below and the terms of any award agreement or other Company plan, policy, or arrangement governing the settlement timing of such award to the extent such terms specifically require different payment timing in order to comply with the requirements of Section&#160;409A, as applicable (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Full Value Settlement Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), on a date within ten (10) days following the date the Release becomes effective and irrevocable. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Confidential Information and Invention Assignment Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive&#8217;s receipt of any payments or benefits under Sections 3(a) and&#160;3(b) will be subject to Executive continuing to comply with the terms of any confidential information and invention assignment agreement executed by Executive in favor of the Company and the provisions of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">COBRA Severance Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the provisions of Sections&#160;3(a)(ii) and 3(b)(ii), if the Company determines in its sole discretion that it cannot provide the COBRA Severance without potentially violating applicable laws (including, without limitation, Section 2716 of the Public Health Service Act and the Employee Retirement Income Security Act of 1974, as amended), then in lieu of such COBRA Severance, and subject to any delay required by this Section&#160;4, the Company will provide to Executive a taxable lump sum cash payment in an amount equal to the product of (x)&#160;the number of months of Salary severance specified in Section&#160;3(a)(i) or&#160;3(b)(i), as applicable, multiplied by (y)&#160;the monthly COBRA premium that Executive otherwise would be required to pay to continue the group health, dental and vision coverage for Executive and Executive&#8217;s eligible dependents, as applicable, as in effect on the date of termination of Executive&#8217;s employment (which amount will be based on the premium for the first month of COBRA coverage for Executive and Executive&#8217;s eligible dependents), which payment will be made regardless of whether Executive elects COBRA continuation coverage (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Taxable Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  For the avoidance of doubt, the Taxable Payment may be used for any purpose, including, but not limited to continuation coverage under COBRA, and will be subject to all applicable tax withholdings.  Notwithstanding anything to the contrary under this Agreement, if the Company determines in its sole discretion at any time that it cannot provide the COBRA Severance or the Taxable Payment without violating applicable law (including, without limitation, Section&#160;2716 of the Public Health Service Act and the Employee Retirement Income Security Act of 1974, as amended), Executive will not receive any COBRA Severance or Taxable Amount under this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">Notwithstanding anything to the contrary in this Agreement, no severance payments or benefits payable to Executive, if any, pursuant to this Agreement that, when considered together with any other severance payments or separation benefits, is considered deferred compensation under Internal Revenue Code Section 409A (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Deferred Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will be payable until Executive has a &#8220;separation from service&#8221; within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and the Treasury Regulations and guidance thereunder, and any applicable state law equivalent, as each may be promulgated, amended or modified from time to time (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Section&#160;409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Similarly, no severance payable to Executive, if any, pursuant to this Agreement that otherwise would be exempt from Section 409A pursuant to Treasury Regulations Section 1.409A-1(b)(9) will be payable until Executive has a &#8220;separation from service&#8221; within the meaning of Section 409A.  To the extent required to be exempt from or comply with Section&#160;409A, references to the termination of Executive&#8217;s employment or similar phrases used in this Agreement will mean Executive&#8217;s &#8220;separation from service&#8221; within the meaning of Section&#160;409A. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">Any severance payments or benefits under this Agreement that would be considered Deferred Payments will be paid on, or, in the case of installments, will not commence until, the sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) day following Executive&#8217;s separation from service, or, if later, such time as required by Section&#160;4(d)(iii) (or with respect to Full Value Awards, such time or times as required by any applicable Full Value Settlement Provisions).  Except as required by Section 4(d)(iii) and any applicable Full Value Settlement Provisions, any Deferred Payments payable in installments that would have been made to Executive during the sixty&#160;(60) day period immediately following Executive&#8217;s separation from service but for the preceding sentence will be paid to Executive on the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) day following Executive&#8217;s separation from service and the remaining payments shall be made as provided in this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">Further, if Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A at the time of Executive&#8217;s separation from service (other than due to death), any Deferred Payments that otherwise are payable within the first six (6) months following Executive&#8217;s separation from service will become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date of Executive&#8217;s separation from service.  All subsequent Deferred Payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.  Notwithstanding anything herein to the contrary, in the event of Executive&#8217;s death following Executive&#8217;s separation from service but prior to the six (6) month anniversary of Executive&#8217;s separation from service (or any later delay date), then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of Executive&#8217;s death and all other Deferred Payments will be payable in accordance with the payment schedule applicable to each payment or benefit.  Each payment and benefit payable under the Agreement is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt">Any amount paid under this Agreement that satisfies the requirements of the &#8220;short-term deferral&#8221; rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments for purposes of clause (i) above.  Any amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that is within the limit set forth thereunder will not constitute Deferred Payments for purposes of clause (i) above.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.02pt">The foregoing provisions are intended to comply with, or be exempt from, the requirements of Section 409A so that none of the severance payments and benefits to be provided under the Agreement will be subject to the additional tax imposed under Section 409A, and any ambiguities and ambiguous terms herein will be interpreted to so comply or be exempt.  Executive and the Company agree to work together in good faith to consider amendments to the Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to Executive under Section 409A.  In no event will the Company or any of its subsidiaries or other affiliates have any obligation, responsibility or liability to reimburse, indemnify or hold harmless Executive for any taxes imposed, or other costs incurred, as result of Section 409A. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Limitation on Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that the severance and other benefits provided for in this Agreement or otherwise that Executive would receive from the Company or any other party whether in connection with the provisions of this Agreement or otherwise (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) would (i) constitute &#8220;parachute payments&#8221; within the meaning of Section 280G of the Code and (ii)&#160;but for this Section&#160;5, would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments will be either&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">delivered in full, or</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">delivered as to such lesser extent which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code,</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the receipt by Executive on an after-tax basis, of the greatest amount of Payments, notwithstanding that all or some portion of such Payments may be taxable under Section 4999 of the Code.  If a reduction in severance and other benefits constituting &#8220;parachute payments&#8221; is necessary so that benefits are delivered to a lesser extent, reduction will occur in the following order&#58; (i) reduction of cash payments in reverse chronological order (that is, the cash payment owed on the latest date following the occurrence of the event triggering the excise tax under Code Section&#160;4999 will be the first cash payment to be reduced)&#59; (ii)&#160;cancellation of equity awards granted &#8220;contingent on a change in ownership or control&#8221; (within the meaning of Code Section 280G) in the reverse order of date of grant of the equity awards (that is, the most recently granted equity awards will be cancelled first), (iii)&#160;reduction of accelerated vesting of equity awards in the reverse order of date of grant of the equity awards (that is, the vesting of the most recently granted equity awards will be cancelled first)&#59; (iv) reduction of employee benefits in reverse chronological order (that is, the benefit owed on the latest date following the occurrence of the event triggering such excise tax will be the first benefit to be reduced).  In no event will Executive have any discretion with respect to the ordering of Payment reductions.  Executive will be solely responsible for the payment of all personal tax liability that is incurred as a result of the payments and benefits received under this Agreement, and neither the Company nor any parent, subsidiary or other affiliate of the Company will have any responsibility, liability or obligation to reimburse, indemnify or hold harmless Executive for any of those payments of personal tax liability.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Company and Executive otherwise agree in writing, any determination required under this Section&#160;5 will be made in writing by a nationally recognized accounting or valuation firm (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Firm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) selected by the Company, whose determination will be conclusive and binding upon Executive and the Company for all purposes.  For purposes of making the calculations required by this Section&#160;5, the Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code.  The Company and Executive will furnish to the Firm such information and documents as the Firm may reasonably request in order to make a determination under this Section.  The Company will bear all costs and make all payments required to be made to the Firm for the Firm&#8217;s services that are rendered in connection with any calculations contemplated by this Section&#160;5.  The Company will have no liability to Executive for the determinations of the Firm. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Definition of Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For purposes of this Agreement, the following terms referred to in this Agreement will have the following meanings&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) conviction of any felony&#59; (ii) conviction of any crime involving moral turpitude or dishonesty that causes, or is likely to cause, material harm to the Company&#59; (iii)&#160;participation in a fraud or willful act of dishonesty against the Company that causes, or is likely to cause, material harm to the Company&#59; (iv)&#160;intentional and material damage to the Company&#8217;s property&#59; or (v)&#160;material breach of the Company&#8217;s Proprietary Information and Inventions Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the first occurrence of any of the following on or after the Effective Date&#58; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt"> A change in the ownership of the Company which occurs on the date that any one person, or more than one person acting as a group (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than 50% of the total voting power of the stock of the Company&#59; provided, however, that for purposes of this subsection (i), the acquisition of additional stock by any one Person, who is considered to own more than 50% of the total voting power of the stock of the Company will not be considered a Change in Control.  Further, if the stockholders of the Company immediately before such change in ownership continue to retain immediately after the change in ownership, in substantially the same proportions as their ownership of shares of the Company&#8217;s voting stock immediately prior to the change in ownership, direct or indirect beneficial ownership of fifty percent (50%) or more of the total voting power of the stock of the Company or of the ultimate parent entity of the Company, such event will not be considered a Change in Control under this subsection (i).  For this purpose, indirect beneficial ownership will include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations or other business entities which own the Company, as the case may be, either directly or through one or more subsidiary corporations or other business entities&#59; or</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">  A change in the effective control of the Company which occurs on the date that a majority of members of the Board (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is replaced during any twelve (12) month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election.  For purposes of this subsection (ii), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control&#59; or</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">   A change in the ownership of a substantial portion of the Company&#8217;s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12) month period ending on the date of the most recent acquisition by such Person) assets from the Company that have a total gross fair market value equal to or more than 50% of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions&#59; provided, however, that for purposes of this subsection (iii), the following will not constitute a change in the ownership of a substantial portion of the Company&#8217;s assets&#58; (A) a transfer to an entity that is controlled by the Company&#8217;s stockholders immediately after the transfer, or (B) a transfer of assets by the Company to&#58; (1) a stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to the Company&#8217;s stock, (2) an entity, 50% or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (3) a Person, that owns, directly or indirectly, 50% or more of the total value or voting power of all the outstanding stock of the Company, or (4) an entity, at least 50% of the total value or voting power of which is owned, directly or indirectly, by a Person described in this subsection (iii)(B)(3).  For purposes of this subsection (iii), gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this definition of Change in Control, persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company.</font></div><div style="margin-top:12pt;text-indent:108pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, a transaction will not be deemed a Change in Control unless the transaction qualifies as a change in control event within the meaning of Section&#160;409A.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Further and for the avoidance of doubt, a transaction will not constitute a Change in Control if&#58; (i) its sole purpose is to change the jurisdiction of the Company&#8217;s incorporation, or (ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#8217;s securities immediately before such transaction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the period beginning upon the date that is three (3) months prior to a Change in Control and continuing through the date that is twelve (12) months following a Change in Control. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Executive is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Executive&#8217;s termination of his or her employment with the Company within thirty (30) days following the expiration of any cure period (discussed below) following the occurrence of one or more of the following, without Executive&#8217;s express written consent&#58; (i)&#160;a material reduction of Executive&#8217;s duties, authority, or responsibilities, relative to Employee&#8217;s duties, authority, or responsibilities as in effect immediately prior to such reduction&#59; (ii)&#160;a material reduction by the Company in Executive&#8217;s annualized base pay as in effect immediately prior to such reduction (in other words, a reduction of more than ten percent (10%) of Executive&#8217;s annualized base compensation in any one year&#59; (iii)&#160;the relocation of Executive&#8217;s principal place of performing his or her duties as an employee of the Company by more than fifty (50) miles&#59; or (iv)&#160;the failure of the Company to obtain the assumption of this Agreement by a successor.  In order for an event to qualify as Good Reason, Executive must not terminate employment with the Company without first providing the Company with written notice of the acts or omissions constituting the grounds for &#8220;Good Reason&#8221; within ninety (90) days of the initial existence of the grounds for &#8220;Good Reason&#8221; and a reasonable cure period of not less than thirty (30) days following the date of such notice.  To the extent Executive&#8217;s primary work location is not the Company&#8217;s corporate offices due to a shelter-in-place order, quarantine order, or similar work-from-home requirement that applies to Executive, Executive&#8217;s primary office location, from which a change in location under the foregoing clause&#160;(iii) will be measured, will be considered the Company&#8217;s office location where Executive&#8217;s employment with the Company primarily was based immediately prior to the commencement of such shelter-in-place order, quarantine order, or similar work-from-home requirement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Qualifying Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means either (i)&#160;the Company terminates Executive&#8217;s employment with the Company for a reason other than (A)&#160;Cause, (B)&#160;Executive&#8217;s death, or (C)&#160;Executive&#8217;s Disability or (ii)&#160;Executive resigns for Good Reason.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Executive&#8217;s base salary as in effect immediately prior to the termination of Executive&#8217;s employment (unless such termination occurs as a result of clause (ii) of the definition of &#8220;Good Reason&#8221; under Section 6(e), in which case the amount will be equal to</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-9-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive&#8217;s base salary as in effect immediately prior to such reduction) or, if greater in the case of a Qualifying Termination during the Change in Control Period, as in effect immediately prior to the Change in Control. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">The Company&#8217;s Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any successor to the Company (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company&#8217;s business and&#47;or assets will assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession.  For all purposes under this Agreement, the term &#8220;Company&#8221; will include any successor to the Company&#8217;s business and&#47;or assets which executes and delivers the assumption agreement described in this Section&#160;7(a) or which becomes bound by the terms of this Agreement by operation of law.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Executive&#8217;s Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The terms of this Agreement and all rights of Executive hereunder will inure to the benefit of, and be enforceable by, Executive&#8217;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.  Notwithstanding the foregoing, none of the rights of Executive to receive any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and distribution.  Any other attempted assignment, transfer, conveyance, or other disposition of Executive&#8217;s right to compensation or other benefits will be null and void.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notices and all other communications contemplated by this Agreement will be in writing and will be deemed to have been duly given (a)&#160;upon actual delivery to the party to be notified, (b) twenty-four (24) hours after confirmed facsimile transmission, (c)&#160;one&#160;(1) business day after deposit with a recognized overnight courier, or (d)&#160;three&#160;(3) business days after deposit with the U.S. Postal Service by first class certified or registered mail, return receipt requested, postage prepaid, addressed&#58; (i)&#160;if to Executive, at the address Executive will have most recently furnished to the Company in writing, or (ii)&#160;if to the Company, to its corporate headquarters and all notices will be directed to the General Counsel of the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any termination of Executive&#8217;s employment by the Company for Cause or by Executive for Good Reason or as a result of a voluntary resignation will be communicated by a notice of termination to the other party hereto given in accordance with Section&#160;8(a) of this Agreement.  Such notice will indicate the specific termination provision in this Agreement relied upon, will set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination under the provision so indicated, and will specify the termination date (which will be not more than thirty (30) days after the giving of such notice or in the case of Executive&#8217;s resignation for Good Reason, in accordance with the requirements under Section&#160;6(e)).  The failure by Executive to include in the notice any fact or circumstance which contributes to a showing of Good Reason will not waive any right of Executive hereunder or preclude Executive from asserting such fact or circumstance in enforcing Executive&#8217;s rights hereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-10-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Resignation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The termination of Executive&#8217;s employment for any reason also will constitute, without any further required action by Executive, Executive&#8217;s voluntary resignation from all officer and&#47;or director positions held at the Company or any of its subsidiaries or affiliates, and at the Board&#8217;s request, Executive will execute any documents reasonably necessary to reflect the resignations. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Miscellaneous Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">No Duty to Mitigate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will not be required to mitigate the amount of any payment contemplated by this Agreement, nor will any such payment be reduced by any earnings that Executive may receive from any other source except as specified in Sections&#160;3(e), 4(d) and 5.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No provision of this Agreement will be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive).  No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party will be considered a waiver of any other condition or provision or of the same condition or provision at another time.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All captions and section headings used in this Agreement are for convenient reference only and do not form a part of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement constitutes the entire agreement of the parties hereto and supersedes in their entirety all prior representations, understandings, undertakings or agreements (whether oral or written and whether expressed or implied) of the parties, including the Prior Agreement.  No waiver, alteration, or modification of any of the provisions of this Agreement will be binding unless in writing and signed by duly authorized representatives of the parties hereto and which specifically mention this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The validity, interpretation, construction, and performance of this Agreement will be governed by the laws of the State of California (with the exception of its conflict of laws provisions).  Any claims or legal actions by one party against the other arising out of the relationship between the parties contemplated herein (whether or not arising under this Agreement) will be commenced or maintained in any state or federal court located in San Mateo County, California, and Executive and the Company hereby submit to the jurisdiction and venue of any such court.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The invalidity, illegality, or unenforceability of any provision or provisions of this Agreement will not affect the validity, legality or enforceability of any other provision hereof, which will remain in full force and effect, and this Agreement will be construed and enforced as if the invalid, illegal, or unenforceable provision had not been included.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company (and any parent, subsidiary or other affiliate of the Company, as applicable) will have the right and authority to deduct from any payments or benefits all applicable federal, state, local, and&#47;or non-U.S. taxes or other required withholdings and payroll deductions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Withholdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Prior to the payment of any amounts or provision of any benefits under this Agreement, the Company (and any parent, subsidiary or other affiliate of the Company, as</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-11-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable) is permitted to deduct or withhold, or require Executive to remit to the Company, an amount sufficient to satisfy any applicable Withholdings with respect to such payments and benefits.  Neither the Company nor any parent, subsidiary or other affiliate of the Company will have any responsibility, liability or obligation to pay Executive&#8217;s taxes arising from or relating to any payments or benefits under this Agreement. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">o  O  o</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-12-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day and year set forth below.</font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COMPANY&#160;&#160;&#160;&#160;PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; William Ericson&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; &#160;&#160;&#160;&#160;William Ericson</font></div><div style="margin-top:12pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;Compensation Committee Chair </font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of the Board of Directors</font></div><div style="margin-top:12pt;text-align:justify;text-indent:216pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXECUTIVE&#160;&#160;&#160;&#160;CHRISTIAN O. HENRY</font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Christian O. Henry&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; &#160;&#160;&#160;&#160;President and Chief Executive Officer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-13-</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>5
<FILENAME>pacb-exx1017xpacbioxarchan.htm
<DESCRIPTION>EX-10.17
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="iade91ac42a914f598855743207e4266d_1"></div><div style="min-height:79.02pt;width:100%"><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.17</font></div><div style="text-align:center"><img alt="pacb-20221231x10kg001a.jpg" src="pacb-20221231x10kg001a.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:201px"></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Amended and Restated Change in Control and Severance Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into by and between Mark Van Oene (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Pacific Biosciences of California, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), effective as of December 12, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and supersedes and replaces the Prior Agreement.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">It is expected that the Company from time to time will consider the possibility of an acquisition by another company or other change in control.  The Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) recognizes that such considerations can be a distraction to Executive and can cause Executive to consider alternative employment opportunities.  The Board has determined that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of Executive, notwithstanding the possibility, threat or occurrence of such a termination of employment or the occurrence of a Change in Control (as defined herein) of the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The Board believes that it is in the best interests of the Company and its stockholders to provide Executive with an incentive to continue Executive&#8217;s employment and to motivate Executive to maximize the value of the Company for the benefit of its stockholders.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The Board believes that it is imperative to provide Executive with certain severance benefits upon Executive&#8217;s termination of employment in connection with a Change in Control.  These benefits will provide Executive with enhanced financial security, incentive and encouragement to remain with the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Certain capitalized terms used in the Agreement are defined in Section 6 below.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AGREEMENT</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the mutual covenants contained herein, the parties hereto agree as follows&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Term of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement will have an initial term of three (3) years commencing on the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Initial Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  On the third anniversary of the Effective Date, this Agreement will renew automatically for additional one (1) year terms (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Additional Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), unless either party provides the other party with written notice of non-renewal at least sixty (60) days prior to the date of automatic renewal.  Notwithstanding the foregoing provisions of this paragraph, if a Change in Control occurs when there are fewer than twelve (12) months remaining during the Initial Term or an Additional Term, the term of this Agreement will extend automatically through the date that is twelve (12) months following the effective date of the Change in Control.  If Executive becomes entitled to benefits under Section 3(a) or Section&#160;3(b) during the term of this</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-1-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement, the Agreement will not terminate until all of the obligations of the parties hereto with respect to this Agreement have been satisfied.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and Executive acknowledge that Executive&#8217;s employment is and will continue to be at-will, as defined under applicable law.  No payments, benefits, or provisions under this Agreement will confer upon Executive any right to continue Executive&#8217;s employment with the Company, nor will they interfere with or limit in any way the right of the Company or Executive to terminate such relationship at any time, with or without cause, to the extent permitted by applicable laws.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination without Cause or Other than Death or Disability or Resignation for Good Reason Other than During the Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If a Qualifying Termination occurs other than during the Change in Control Period, then subject to Section&#160;4, Executive will receive the following severance from the Company&#58; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt;text-decoration:underline">Base Salary Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will receive a lump sum cash payment equal to twelve (12)&#160;months of Executive&#8217;s salary, less any applicable withholdings.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt;text-decoration:underline">Continued Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive elects continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for Executive and Executive&#8217;s eligible dependents (as applicable), within the time period prescribed pursuant to COBRA, Executive will receive Company-paid group health, dental and vision coverage for Executive and Executive&#8217;s eligible dependents, as applicable, at the coverage levels in effect immediately prior to the termination of Executive&#8217;s employment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">COBRA Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) until the earliest of&#58; (A)&#160;a period of twelve (12)&#160;months from the last date of employment of the Executive with the Company, (B)&#160;the date upon which Executive and&#47;or Executive&#8217;s eligible dependents becomes covered under similar plans, or (C)&#160;the expiration of Executive&#8217;s and Executive&#8217;s eligible dependents&#8217; (as applicable) eligibility for continuation coverage under COBRA.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Termination without Cause or Other than Death or Disability or Resignation for Good Reason During the Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If a Qualifying Termination occurs during the Change in Control Period, then subject to Section&#160;4, Executive will receive the following severance from the Company&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt;text-decoration:underline">Base Salary Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will receive a lump sum cash payment equal to twelve (12)&#160;months of Executive&#8217;s salary, less any applicable withholdings. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt;text-decoration:underline">Prorated Target Bonus Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will receive a lump sum cash payment equal to Executive&#8217;s annualized target bonus in effect for the year in which the Qualifying Termination occurs, provided that such amount will be prorated based on a fraction, the numerator of which is the number of days during which Executive was employed with the Company (or its successor) in the year that the Qualifying Termination occurs, and the denominator of which is the total number of days in such year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Prorated Bonus Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt;text-decoration:underline">Continued Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive elects continuation coverage pursuant to COBRA for Executive and Executive&#8217;s eligible dependents (as applicable), within the time period prescribed pursuant to COBRA, the Company will provide the COBRA</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Severance until the earliest of&#58; (A)&#160;a period of twelve (12)&#160;months from the last date of employment of the Executive with the Company, (B)&#160;the date upon which Executive and&#47;or Executive&#8217;s eligible dependents becomes covered under similar plans, or (C)&#160;the expiration of Executive&#8217;s and Executive&#8217;s eligible dependents&#8217; (as applicable) eligibility for continuation coverage under COBRA.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  One hundred percent (100%) of the unvested portion of the Executive&#8217;s then-outstanding equity awards (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will immediately vest and, to the extent applicable, become exercisable, as of the date of such termination.  To the extent that an Award is subject to performance-based vesting at the time of such termination, such performance goals will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions met, unless specifically provided otherwise under the applicable Award agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Awards will remain exercisable, to the extent applicable, following Executive&#8217;s termination for the period prescribed in the applicable equity plan and agreement for each Award.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Other Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment with the Company terminates other than as set forth in Section&#160;3(a) or 3(b) above, then (i) all vesting will terminate immediately with respect to Executive&#8217;s outstanding Awards, (ii) all payments of compensation by the Company to Executive hereunder will terminate immediately (except as to amounts already earned), and (iii)&#160;Executive will only be eligible for severance benefits in accordance with the Company&#8217;s established policies, if any, as then in effect. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Accrued Amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On any termination of Executive&#8217;s employment with the Company, Executive will be entitled to receive all accrued but unpaid vacation, expense reimbursements, wages, and other benefits due to Executive under any Company-provided plans, policies, and arrangements. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Non-duplication of Payment or Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of this Agreement to the contrary, if Executive is entitled to any cash severance, continued health coverage severance benefits, vesting acceleration of any Awards, or other severance or separation benefits similar to those provided under this Agreement, by operation of applicable law or under a plan, policy, contract, or arrangement sponsored by or to which the Company is a party other than this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Other Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then the corresponding severance payments and benefits under this Agreement will be reduced by the amount of Other Benefits paid or provided to Executive.  For the avoidance of doubt, in the event of a Qualifying&#160;Termination under which Executive becomes entitled to severance under Section 3(b),&#160;any severance payments and benefits to be provided to the Executive under Section&#160;3(b) will be reduced by the corresponding severance payments or benefits, as applicable, that already were provided to the Executive under Section&#160;3(a).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Conditions to Receipt of Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Release of Claims Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The receipt of any severance payments or benefits pursuant to this Agreement is subject to Executive signing and not revoking a separation agreement and release of claims in a form acceptable to the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which must become effective and irrevocable no later than the sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) day following Executive&#8217;s termination of employment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Release Deadline Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). If the Release does not become effective and irrevocable by the Release Deadline Date, Executive&#160;will forfeit any right to severance payments or benefits under this Agreement.  No severance payments and benefits under Section 3(a) or 3(b) of this Agreement will be paid or provided until the Release becomes effective and irrevocable, and any such severance payments and benefits otherwise payable between the date of Executive&#8217;s termination of</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employment and the date the Release becomes effective and irrevocable (including, if applicable, the lump sum cash payment under Section 4(c) below) will be paid, subject to the requirements of Section&#160;4(d) below, on the Company&#8217;s first regularly scheduled payroll date on or following the date the Release becomes effective and irrevocable.  Any restricted stock units, performance units, performance shares, and&#47;or similar full value awards that accelerate vesting under this Agreement (&#8220;Full Value Awards&#8221;) will be settled (subject to Section&#160;4(d) below and the terms of any award agreement or other Company plan, policy, or arrangement governing the settlement timing of such award to the extent such terms specifically require different payment timing in order to comply with the requirements of Section&#160;409A, as applicable (the &#8220;Full Value Settlement Provisions&#8221;), on a date within ten (10) days following the date the Release becomes effective and irrevocable. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Confidential Information and Invention Assignment Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive&#8217;s receipt of any payments or benefits under Sections 3(a) and&#160;3(b) will be subject to Executive continuing to comply with the terms of any confidential information and invention assignment agreement executed by Executive in favor of the Company and the provisions of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">COBRA Severance Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the provisions of Sections&#160;3(a)(ii) and 3(b)(ii), if the Company determines in its sole discretion that it cannot provide the COBRA Severance without potentially violating applicable laws (including, without limitation, Section 2716 of the Public Health Service Act and the Employee Retirement Income Security Act of 1974, as amended), then in lieu of such COBRA Severance, and subject to any delay required by this Section&#160;4, the Company will provide to Executive a taxable lump sum cash payment in an amount equal to the product of (x)&#160;the number of months of Salary severance specified in Section&#160;3(a)(i) or&#160;3(b)(i), as applicable, multiplied by (y)&#160;the monthly COBRA premium that Executive otherwise would be required to pay to continue the group health, dental and vision coverage for Executive and Executive&#8217;s eligible dependents, as applicable, as in effect on the date of termination of Executive&#8217;s employment (which amount will be based on the premium for the first month of COBRA coverage for Executive and Executive&#8217;s eligible dependents), which payment will be made regardless of whether Executive elects COBRA continuation coverage (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Taxable Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  For the avoidance of doubt, the Taxable Payment may be used for any purpose, including, but not limited to continuation coverage under COBRA, and will be subject to all applicable tax withholdings.  Notwithstanding anything to the contrary under this Agreement, if the Company determines in its sole discretion at any time that it cannot provide the COBRA Severance or the Taxable Payment without violating applicable law (including, without limitation, Section&#160;2716 of the Public Health Service Act and the Employee Retirement Income Security Act of 1974, as amended), Executive will not receive any COBRA Severance or Taxable Amount under this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">Notwithstanding anything to the contrary in this Agreement, no severance payments or benefits payable to Executive, if any, pursuant to this Agreement that, when considered together with any other severance payments or separation benefits, is considered deferred compensation under Internal Revenue Code Section 409A (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Deferred Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will be payable until Executive has a &#8220;separation from service&#8221; within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and the Treasury Regulations and guidance thereunder, and any applicable state law equivalent, as each may be promulgated, amended or modified from time to time (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Section&#160;409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Similarly, no severance payable to Executive, if any, pursuant to this Agreement that otherwise would be exempt from Section 409A pursuant to Treasury Regulations Section 1.409A-1(b)(9) will be payable until Executive has a &#8220;separation from service&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within the meaning of Section 409A.  To the extent required to be exempt from or comply with Section&#160;409A, references to the termination of Executive&#8217;s employment or similar phrases used in this Agreement will mean Executive&#8217;s &#8220;separation from service&#8221; within the meaning of Section&#160;409A. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">   Any severance payments or benefits under this Agreement that would be considered Deferred Payments will be paid on, or, in the case of installments, will not commence until, the sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) day following Executive&#8217;s separation from service, or, if later, such time as required by Section&#160;4(d)(iii) (or with respect to Full Value Awards, such time or times as required by any applicable Full Value Settlement Provisions).  Except as required by Section 4(d)(iii) and any applicable Full Value Settlement Provisions, any Deferred Payments payable in installments that would have been made to Executive during the sixty&#160;(60) day period immediately following Executive&#8217;s separation from service but for the preceding sentence will be paid to Executive on the sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) day following Executive&#8217;s separation from service and the remaining payments shall be made as provided in this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">    Further, if Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A at the time of Executive&#8217;s separation from service (other than due to death), any Deferred Payments that otherwise are payable within the first six (6) months following Executive&#8217;s separation from service will become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date of Executive&#8217;s separation from service.  All subsequent Deferred Payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.  Notwithstanding anything herein to the contrary, in the event of Executive&#8217;s death following Executive&#8217;s separation from service but prior to the six (6) month anniversary of Executive&#8217;s separation from service (or any later delay date), then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of Executive&#8217;s death and all other Deferred Payments will be payable in accordance with the payment schedule applicable to each payment or benefit.  Each payment and benefit payable under the Agreement is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.69pt">  Any amount paid under this Agreement that satisfies the requirements of the &#8220;short-term deferral&#8221; rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments for purposes of clause (i) above.  Any amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that is within the limit set forth thereunder will not constitute Deferred Payments for purposes of clause (i) above.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.02pt">    The foregoing provisions are intended to comply with, or be exempt from, the requirements of Section 409A so that none of the severance payments and benefits to be provided under the Agreement will be subject to the additional tax imposed under Section 409A, and any ambiguities and ambiguous terms herein will be interpreted to so comply or be exempt.  Executive and the Company agree to work together in good faith to consider amendments to the Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to Executive under Section 409A.  In no event will the Company or any of its subsidiaries or other affiliates have any obligation, responsibility or liability to reimburse, indemnify or hold harmless Executive for any taxes imposed, or other costs incurred, as result of Section 409A.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Limitation on Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that the severance and other benefits provided for in this Agreement or otherwise that Executive would receive from the Company or any other party whether in connection with the provisions of this Agreement or otherwise (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) would (i) constitute &#8220;parachute payments&#8221; within the meaning of Section 280G of the Code and (ii)&#160;but for this Section&#160;5, would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments will be either&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">delivered in full, or</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">delivered as to such lesser extent which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code,</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the receipt by Executive on an after-tax basis, of the greatest amount of Payments, notwithstanding that all or some portion of such Payments may be taxable under Section 4999 of the Code.  If a reduction in severance and other benefits constituting &#8220;parachute payments&#8221; is necessary so that benefits are delivered to a lesser extent, reduction will occur in the following order&#58; (i) reduction of cash payments in reverse chronological order (that is, the cash payment owed on the latest date following the occurrence of the event triggering the excise tax under Code Section&#160;4999 will be the first cash payment to be reduced)&#59; (ii)&#160;cancellation of equity awards granted &#8220;contingent on a change in ownership or control&#8221; (within the meaning of Code Section 280G) in the reverse order of date of grant of the equity awards (that is, the most recently granted equity awards will be cancelled first), (iii)&#160;reduction of accelerated vesting of equity awards in the reverse order of date of grant of the equity awards (that is, the vesting of the most recently granted equity awards will be cancelled first)&#59; (iv) reduction of employee benefits in reverse chronological order (that is, the benefit owed on the latest date following the occurrence of the event triggering such excise tax will be the first benefit to be reduced).  In no event will Executive have any discretion with respect to the ordering of Payment reductions.  Executive will be solely responsible for the payment of all personal tax liability that is incurred as a result of the payments and benefits received under this Agreement, and neither the Company nor any parent, subsidiary or other affiliate of the Company will have any responsibility, liability or obligation to reimburse, indemnify or hold harmless Executive for any of those payments of personal tax liability.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Company and Executive otherwise agree in writing, any determination required under this Section&#160;5 will be made in writing by a nationally recognized accounting or valuation firm (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Firm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) selected by the Company, whose determination will be conclusive and binding upon Executive and the Company for all purposes.  For purposes of making the calculations required by this Section&#160;5, the Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code.  The Company and Executive will furnish to the Firm such information and documents as the Firm may reasonably request in order to make a determination under this Section.  The Company will bear all costs and make all payments required to be made to the Firm for the Firm&#8217;s services that are rendered in connection with any calculations contemplated by this Section&#160;5.  The Company will have no liability to Executive for the determinations of the Firm.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Definition of Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For purposes of this Agreement, the following terms referred to in this Agreement will have the following meanings&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) conviction of any felony&#59; (ii) conviction of any crime involving moral turpitude or dishonesty that causes, or is likely to cause, material harm to the Company&#59; (iii)&#160;participation in a fraud or willful act of dishonesty against the Company that causes, or is likely to cause, material harm to the Company&#59; (iv)&#160;intentional and material damage to the Company&#8217;s property&#59; or (v)&#160;material breach of the Company&#8217;s Proprietary Information and Inventions Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the first occurrence of any of the following on or after the Effective Date&#58; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt"> A change in the ownership of the Company which occurs on the date that any one person, or more than one person acting as a group (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than 50% of the total voting power of the stock of the Company&#59; provided, however, that for purposes of this subsection (i), the acquisition of additional stock by any one Person, who is considered to own more than 50% of the total voting power of the stock of the Company will not be considered a Change in Control.  Further, if the stockholders of the Company immediately before such change in ownership continue to retain immediately after the change in ownership, in substantially the same proportions as their ownership of shares of the Company&#8217;s voting stock immediately prior to the change in ownership, direct or indirect beneficial ownership of fifty percent (50%) or more of the total voting power of the stock of the Company or of the ultimate parent entity of the Company, such event will not be considered a Change in Control under this subsection (i).  For this purpose, indirect beneficial ownership will include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations or other business entities which own the Company, as the case may be, either directly or through one or more subsidiary corporations or other business entities&#59; or</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt">  A change in the effective control of the Company which occurs on the date that a majority of members of the Board (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is replaced during any twelve (12) month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election.  For purposes of this subsection (ii), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control&#59; or</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.03pt">   A change in the ownership of a substantial portion of the Company&#8217;s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12) month period ending on the date of the most recent acquisition by such Person) assets from the Company that have a total gross fair market value equal to or more than 50% of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions&#59; provided, however, that for purposes of this subsection (iii), the following will not constitute a change in the ownership of a substantial portion of the Company&#8217;s assets&#58; (A) a transfer to an entity that is controlled by the Company&#8217;s stockholders immediately after the transfer, or (B) a transfer of assets by the Company to&#58; (1) a stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to the Company&#8217;s stock, (2) an entity, 50% or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (3) a Person, that owns, directly or indirectly, 50% or more of the total value or voting power of all the outstanding stock of the Company, or (4) an entity, at least 50% of the total value or voting power of which is owned, directly or indirectly,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by a Person described in this subsection (iii)(B)(3).  For purposes of this subsection (iii), gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this definition of Change in Control, persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, a transaction will not be deemed a Change in Control unless the transaction qualifies as a change in control event within the meaning of Section&#160;409A.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Further and for the avoidance of doubt, a transaction will not constitute a Change in Control if&#58; (i) its sole purpose is to change the jurisdiction of the Company&#8217;s incorporation, or (ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#8217;s securities immediately before such transaction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the period beginning upon the date that is three (3) months prior to a Change in Control and continuing through the date that is twelve (12) months following a Change in Control. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Executive is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Executive&#8217;s termination of his or her employment with the Company within thirty (30) days following the expiration of any cure period (discussed below) following the occurrence of one or more of the following, without Executive&#8217;s express written consent&#58; (i)&#160;a material reduction of Executive&#8217;s duties, authority, or responsibilities, relative to Employee&#8217;s duties, authority, or responsibilities as in effect immediately prior to such reduction&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that a reduction in duties, authority, or responsibilities solely by virtue of the Company being acquired and made part of a larger entity (for example, where Executive retains essentially the same responsibility and duties of the subsidiary, business unit or division substantially containing the Company&#8217;s business following a Change in Control) shall not constitute &#8220;Good Reason&#8221;&#59; (ii)&#160;a material reduction by the Company in Executive&#8217;s annualized base pay as in effect immediately prior to such reduction (in other words, a reduction of more than ten percent (10%) of Executive&#8217;s annualized base compensation in any one year, other than a reduction applicable to executives generally that does not adversely affect Executive to a greater extent than other similarly situated executives)&#59; (iii)&#160;the relocation of Executive&#8217;s principal place of performing his or her duties as an employee of the Company by more than fifty (50) miles&#59; or (iv)&#160;the failure of the Company to obtain the assumption of this Agreement by a successor.  In order for an event to qualify as Good Reason, Executive must not terminate employment with the Company without first providing the Company with written notice of the acts or omissions constituting the grounds for &#8220;Good Reason&#8221; within ninety (90) days of the initial existence of the grounds for &#8220;Good Reason&#8221; and a reasonable cure period of not less than thirty (30) days following the date of such notice.  To the extent Executive&#8217;s primary work location is not the Company&#8217;s corporate offices due to a shelter-in-place order, quarantine order, or similar work-from-home requirement that applies to Executive, Executive&#8217;s primary office location, from which a change in location under the foregoing clause&#160;(iii) will be</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">measured, will be considered the Company&#8217;s office location where Executive&#8217;s employment with the Company primarily was based immediately prior to the commencement of such shelter-in-place order, quarantine order, or similar work-from-home requirement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Prior Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Prior Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Change in Control and Severance Agreement previously made and entered into by and between Executive and the Company, effective as of January 8, 2021.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Qualifying Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means either (i)&#160;the Company terminates Executive&#8217;s employment with the Company for a reason other than (A)&#160;Cause, (B)&#160;Executive&#8217;s death, or (C)&#160;Executive&#8217;s Disability or (ii)&#160;Executive resigns for Good Reason.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Executive&#8217;s base salary as in effect immediately prior to the termination of Executive&#8217;s employment (unless such termination occurs as a result of clause (ii) of the definition of &#8220;Good Reason&#8221; under Section 6(e), in which case the amount will be equal to Executive&#8217;s base salary as in effect immediately prior to such reduction) or, if greater in the case of a Qualifying Termination during the Change in Control Period, as in effect immediately prior to the Change in Control. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">The Company&#8217;s Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any successor to the Company (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company&#8217;s business and&#47;or assets will assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession.  For all purposes under this Agreement, the term &#8220;Company&#8221; will include any successor to the Company&#8217;s business and&#47;or assets which executes and delivers the assumption agreement described in this Section&#160;7(a) or which becomes bound by the terms of this Agreement by operation of law.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Executive&#8217;s Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The terms of this Agreement and all rights of Executive hereunder will inure to the benefit of, and be enforceable by, Executive&#8217;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.  Notwithstanding the foregoing, none of the rights of Executive to receive any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and distribution.  Any other attempted assignment, transfer, conveyance, or other disposition of Executive&#8217;s right to compensation or other benefits will be null and void.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notices and all other communications contemplated by this Agreement will be in writing and will be deemed to have been duly given (a)&#160;upon actual delivery to the party to be notified, (b) twenty-four (24) hours after confirmed facsimile transmission, (c)&#160;one&#160;(1) business day after deposit with a recognized overnight courier, or (d)&#160;three&#160;(3) business days after deposit with the U.S. Postal Service by first class certified or registered mail, return receipt requested, postage prepaid, addressed&#58; (i)&#160;if to Executive, at the address Executive will have most recently furnished to the Company in writing, or (ii)&#160;if to the Company, to its corporate headquarters and all notices will be directed to the General Counsel of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-9-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any termination of Executive&#8217;s employment by the Company for Cause or by Executive for Good Reason or as a result of a voluntary resignation will be communicated by a notice of termination to the other party hereto given in accordance with Section&#160;8(a) of this Agreement.  Such notice will indicate the specific termination provision in this Agreement relied upon, will set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination under the provision so indicated, and will specify the termination date (which will be not more than thirty (30) days after the giving of such notice or in the case of Executive&#8217;s resignation for Good Reason, in accordance with the requirements under Section&#160;6(e)).  The failure by Executive to include in the notice any fact or circumstance which contributes to a showing of Good Reason will not waive any right of Executive hereunder or preclude Executive from asserting such fact or circumstance in enforcing Executive&#8217;s rights hereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Resignation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The termination of Executive&#8217;s employment for any reason also will constitute, without any further required action by Executive, Executive&#8217;s voluntary resignation from all officer and&#47;or director positions held at the Company or any of its subsidiaries or affiliates, and at the Board&#8217;s request, Executive will execute any documents reasonably necessary to reflect the resignations. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Miscellaneous Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">No Duty to Mitigate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will not be required to mitigate the amount of any payment contemplated by this Agreement, nor will any such payment be reduced by any earnings that Executive may receive from any other source except as specified in Sections&#160;3(e), 4(d) and 5.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No provision of this Agreement will be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive).  No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party will be considered a waiver of any other condition or provision or of the same condition or provision at another time.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All captions and section headings used in this Agreement are for convenient reference only and do not form a part of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement constitutes the entire agreement of the parties hereto and supersedes in their entirety all prior representations, understandings, undertakings or agreements (whether oral or written and whether expressed or implied) of the parties, including the Prior Agreement.  No waiver, alteration, or modification of any of the provisions of this Agreement will be binding unless in writing and signed by duly authorized representatives of the parties hereto and which specifically mention this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The validity, interpretation, construction, and performance of this Agreement will be governed by the laws of the State of California (with the exception of its conflict of laws provisions).  Any claims or legal actions by one party against the other arising out of the relationship between the parties contemplated herein (whether or not arising under this Agreement) will be commenced or maintained in any state or federal court located in San Mateo County, California, and Executive and the Company hereby submit to the jurisdiction and venue of any such court.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-10-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The invalidity, illegality, or unenforceability of any provision or provisions of this Agreement will not affect the validity, legality or enforceability of any other provision hereof, which will remain in full force and effect, and this Agreement will be construed and enforced as if the invalid, illegal, or unenforceable provision had not been included.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company (and any parent, subsidiary or other affiliate of the Company, as applicable) will have the right and authority to deduct from any payments or benefits all applicable federal, state, local, and&#47;or non-U.S. taxes or other required withholdings and payroll deductions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Withholdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Prior to the payment of any amounts or provision of any benefits under this Agreement, the Company (and any parent, subsidiary or other affiliate of the Company, as applicable) is permitted to deduct or withhold, or require Executive to remit to the Company, an amount sufficient to satisfy any applicable Withholdings with respect to such payments and benefits.  Neither the Company nor any parent, subsidiary or other affiliate of the Company will have any responsibility, liability or obligation to pay Executive&#8217;s taxes arising from or relating to any payments or benefits under this Agreement. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">o  O  o</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-11-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:79.02pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the Effective Date set forth above.</font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COMPANY&#160;&#160;&#160;&#160;PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Natalie Welch&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; &#160;&#160;&#160;&#160;Natalie Welch</font></div><div style="margin-top:12pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;Chief People Officer</font></div><div style="margin-top:12pt;text-align:justify;text-indent:216pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXECUTIVE&#160;&#160;&#160;&#160;By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Mark Van Oene&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Mark van Oene</font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-12-</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>6
<FILENAME>pacb-exx1018xpacbxleaseedg.htm
<DESCRIPTION>EX-10.18
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i2d022a045d8745628529eecf262f7746_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-right:0.3pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;10.18</font></div><div style="margin-bottom:6pt;padding-right:0.3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY &#91;***&#93; IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE (I) IT IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEASE</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BY AND BETWEEN</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MENLO PARK PORTFOLIO II, LLC, LESSOR</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC., a Delaware corporation,</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LESSEE</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Menlo Business Park</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1315 O&#8217;Brien Drive &#91;To be re-addressed to 1305 O&#8217;Brien Drive&#93;</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Menlo Park, California 94025</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">July 22, 2015</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:77.75pt;padding-right:77.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.207%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 5.12pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option to Extend</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of First Offer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monthly Base Rent</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional Rent&#59; Operating Expenses and Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of Rent</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Security Deposit</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Use</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hazardous Materials</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes on Lessee&#8217;s Property</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indemnification</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warm Shell Work&#59; Market Ready Improvements&#59; Tenant Improvements</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintenance and Repairs&#59; Alterations&#59; Surrender and Restoration</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilities and Services</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liens</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assignment and Subletting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-Waiver</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holding Over</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Damage or Destruction</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eminent Domain</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remedies</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessee&#8217;s Personal Property</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notices</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estoppel Certificate</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Signage</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real Estate Brokers</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parking</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subordination&#59; Attornment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.470%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.06pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- i -</font></td><td colspan="3" style="padding:2px 5.12pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WEST&#92;258445808.17 </font></td></tr></table></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:77.75pt;padding-right:77.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div style="padding-left:77.75pt;padding-right:77.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(continued)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.900%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 5.12pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No Termination Right</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessor&#8217;s Entry</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attorneys&#8217; Fees</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quiet Enjoyment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Information</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SDN List</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:4.12pt;padding-right:4.12pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </font></td></tr></table></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SCHEDULE OF EXHIBITS</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.340%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT &#8220;A&#8221;</font></td><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Land</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT &#8220;B&#8221;</font></td><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Menlo Business Park Master Plan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT &#8220;C&#8221;</font></td><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Floor Plan of Building #3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT &#8220;D&#8221;</font></td><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commencement Memorandum</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT &#8220;E&#8221;</font></td><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee&#8217;s Hazardous Materials</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT &#8220;F&#8221;</font></td><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work Letter</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.420%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.12pt;padding-right:4.12pt;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCHEDULE &#8220;F-1&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of Warm Shell</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.12pt;padding-right:4.12pt;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCHEDULE &#8220;F-2&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preliminary Budget for Warm Shell Work</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.12pt;padding-right:4.12pt;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCHEDULE &#8220;F-3&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Space Plans for Market Ready Improvements and Tenant Improvements</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.12pt;padding-right:4.12pt;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCHEDULE &#8220;F-4&#8221; </font></div></td><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preliminary Combined Budget and List of Inclusions&#47;Exclusions for Market Ready Improvements and Tenant Improvements</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.12pt;padding-right:4.12pt;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCHEDULE &#8220;F-5&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Schedule</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.340%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT &#8220;G&#8221;</font></td><td colspan="3" style="padding:2px 1pt 2px 5.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee&#8217;s Property </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.470%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.06pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- ii -</font></td><td colspan="3" style="padding:2px 5.12pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WEST&#92;258445808.17 </font></td></tr></table></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">L E A S E</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Menlo Business Park<br>Building #3<br>1315 O&#8217;Brien Drive &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">to become 1305 O&#8217;Brien Drive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#93;<br>Menlo Park, California 94025</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIS LEASE, referred to herein as this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; is made and entered into as of July 22, 2015, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) by and between MENLO PARK PORTFOLIO II, LLC, a Delaware limited liability company &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Lessor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; and PACIFIC BIOSCIENCES OF CALIFORNIA, INC., a Delaware corporation, hereafter referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Lessee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">RECITALS&#58;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.Lessor is the owner of the real property located in Menlo Business Park, Menlo Park, California, commonly referred to as 1315 O&#8217;Brien Drive &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">to be re-addressed 1305 O&#8217;Brien Drive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#93;, more particularly described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit &#8220;A&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attached hereto and incorporated by reference herein, together with all easements and appurtenances thereto (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Land</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and the existing buildings thereon, referred to as Building #3, containing approximately 217,770 rentable square feet and all other improvements located thereon (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Land and Improvements are referred to herein collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; The Property is shown as a part of the Menlo Business Park Master Plan and is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit &#8220;B&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and incorporated by reference herein, and identifies the properties that comprise the Menlo Business Park. Building #3 is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; The floor plan of the Building is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit &#8220;C&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and incorporated by reference herein.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B.Lessor and Lessee wish to enter into this Lease of the Premises defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upon the terms and conditions set forth herein.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOW, THEREFORE, the parties agree as follows&#58;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessor hereby leases to Lessee, and Lessee leases from Lessor, at the rental rate and upon the terms and conditions set forth herein, the Premises (as hereinafter defined). Beginning on the Commencement Date (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Lessor hereby leases to Lessee, and Lessee leases from Lessor, the portion of the Building consisting of approximately One Hundred Eighty Thousand (180,000) rentable square feet, as shown on the floor plan of the Building attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit &#8220;C&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Building is currently estimated to be approximately Two Hundred Seventeen Thousand Seven Hundred Seventy (217,770) rentable square feet. Lessor and Lessee acknowledge that the Building will be re-measured in accordance with the Dripline BOMA standard following the Effective Date. Following such re-measurement of the Building, Lessee&#8217;s Pro Rata Share of the Building and the Park Expenses (as both shares are described in Paragraph 6(a) below) shall be adjusted based on such re-measurement of the Building. The parties hereby acknowledge and agree that the re-measurement of the Building shall not impact the rentable square footage of the Premises as set forth herein. Throughout the term of this Lease, Lessee shall also have the non-exclusive right to use Lessee&#8217;s share of the on-site parking spaces pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the non-exclusive </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1</font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">right to use the common areas of the Building and the other Improvements on the Property intended for use in common by the tenants of the Property. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)The term of this Lease (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) shall commence on the date that is the later of April 15, 2016, or the date by which all of the following conditions have occurred (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#58; (1) Lessor shall have delivered possession of the Premises to Lessee in broom clean condition, (2) the Work has been Substantially Completed (as defined in the Work Letter attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit &#8220;F&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereto) including the Tenant Improvements summarized on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-3&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-4&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit &#8220;F&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attached hereto, and (3) Lessor shall have caused the issuance of a Temporary Certificate of Occupancy (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">TCO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) or such other documentation from the City of Menlo Park (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">City</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) specifying that the Premises can be legally occupied. The Commencement Date shall be confirmed in writing by Lessor and Lessee by the execution and delivery of the Commencement Memorandum in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit &#8220;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)The Term of this Lease shall expire, unless sooner terminated in accordance with the provisions hereof or as permitted by law, on the last day of the one hundred thirty-second (132nd) full calendar month after the Commencement Date.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)Except as specifically provided otherwise in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if possession of the Premises is not delivered in the condition required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lessor shall not be subject to any liability therefor, nor shall such failure affect the validity of this Lease, or the obligations of Lessee hereunder, but in such case, Lessee shall not, except as otherwise provided herein, be obligated to pay rent or perform any other obligation of Lessee under the terms of this Lease until possession of the Premises is delivered to Lessee in the condition referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)If the Commencement Date has not occurred by October 15, 2016, which date shall be extended one (1) day for each day of Tenant Delay (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2(c)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit &#8220;F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (such date, as extended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Abatement Trigger Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), then Lessee shall be entitled to receive a credit toward Base Rent in an amount equal to one (1) day of Base Rent next coming due under the Lease for each day beyond the Abatement Trigger Date until the Commencement Date occurs up to a total credit amount equal to ninety (90) days of Base Rent. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)If the Architectural CUP and the Use CUP (as defined below, and, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Use CUPs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) are not obtained with the fifteen (15) day appeal period having lapsed without appeal by September 30, 2015 (or, if appealed, the City has not confirmed the Use CUPs in all material respects by September 30, 2015), Lessee may notify Lessor in writing of its election to terminate this Lease prior to the receipt of the Use CUPs, in which event the parties shall be discharged from all further obligations hereunder except to the extent any obligations expressly survive the expiration or termination of this Lease.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)If the Use CUPs are not obtained by September 15, 2015, then, on September 16, 2015, Lessor shall give Lessee written notice of such failure, and, if Lessor </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonably believes that either (a) the Use CUPs will never be issued by the City or will not be issued within a reasonable time that will allow Lessor to complete the Work by December 31, 2016 or (b) the Use CUPs may be issued by the City after September 30, 2015, but that modifications to the provisions and conditions of such Use CUPs by the City will prevent Lessor from completing the Work by December 31, 2016, then, on September 30, 2015, Lessor may notify Lessee of its written election to terminate this Lease effective as of September 30, 2015, in which event the parties shall be discharged from all further obligations hereunder except to the extent any obligations expressly survive the expiration or termination of this Lease&#59; provided, however, that Lessor may not exercise such right to cancel this Lease unless (i) between September 15, 2015 and September 30, 2015, Lessor cooperates with Lessee and uses good faith efforts to develop and implement a strategy to cause the City to issue the Use CUPs by September 30, 2015 and in a manner that allows the Work to be completed by December 31, 2016 (provided that Lessee cooperates with Lessor and uses good faith efforts in connection with developing and implementing such strategy which cooperation may include good faith efforts to cause Lessee&#8217;s current landlord to cooperate as necessary) and (ii) Lessor has used its good faith efforts to obtain the Use CUPs in such form prior to September 15, 2015. Notwithstanding the foregoing, if the Use CUPs are issued at any time between September 16, 2015 and September 30, 2015, inclusive, in a form that will allow Lessor to complete the Work by December 31, 2016, then Lessor shall have no right to terminate the Lease under this paragraph.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)If the Building Permit (defined below) for the Market Ready Improvements and Tenant Improvements have not been issued by March 11, 2016, which date shall be extended one (1) day for each day of Tenant Delay (such date, as extended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Cancellation Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), then Lessee may terminate this Lease on written notice to Lessor given any time after March 11, 2016 and prior to issuance of the Building Permit for the Market Ready Improvements and the Tenant Improvements. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)If the Commencement Date has not occurred by December 31, 2016, which date shall be extended one (1) day for each day of Tenant Delay, then Lessee may terminate this Lease on written notice to the Lessor given prior to the occurrence of the Commencement Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Second Cancellation Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Lease is terminated as herein provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 2(c)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2(c)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2(c)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2(c)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lessor shall refund to Lessee any pre-paid Rent and the Security Deposit within five (5) business days thereafter.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)If Substantial Completion of the Work is delayed as the result of a Tenant Delay, the Commencement Date shall occur on the date Substantial Completion of the Work would have occurred but for the Tenant Delays (as determined in accordance with this Lease and the Work Letter) and Lessor shall have no liability for any damages arising from a Tenant Delay. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)Lessee acknowledges that the applicable ordinance of the City requires that Lessee must obtain a Conditional Use Permit for Hazardous Materials (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Haz Mat CUP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) from the City if Lessee maintains on the Premises five (5) gallons or more of Hazardous Materials (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Accordingly, for the period from the Lessee&#8217;s first Early Entry, defined below, until the date Lessee obtains the Haz Mat CUP from the City permitting </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessee to maintain on the Premises five (5) gallons or more of Hazardous Materials (estimated to be approximately seventy-five (75) days), Lessee shall maintain less than five (5) gallons of Hazardous Materials on the Premises. Lessee shall promptly apply for and shall use its commercially reasonable good faith diligent efforts to comply with the City&#8217;s requirements for the issuance to Lessee of the Haz Mat CUP. Lessor shall assist Lessee in the filing and processing of the application for the Haz Mat CUP, and Lessee shall pay all costs associated with such efforts, including but not limited to the costs and fees incurred by Green Environment and DES Architects&#47;Engineers as well as City fees associated with the Haz Mat CUP&#59; provided, however, Lessor shall not be responsible for the issuance of the Haz Mat CUP. Lessee shall deliver a copy of the Haz Mat CUP to Lessor and Lessee shall comply with the provisions thereof. </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)Lessee acknowledges that in addition to the Haz Mat CUP described above to be obtained by Lessee, Lessor must obtain an architectural control use permit (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Architectural CUP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), a change of use permit (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Use CUP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and a building permit (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Building Permit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (cumulatively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Critical Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) from the City prior to the commencement of construction of any Market Ready Improvements (defined in the Work Letter) and Tenant Improvements (both more particularly described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-3&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-4&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit &#8220;F&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). As consideration for its time, effort and expense, including the engagement of third party services in connection with the design and engineering of the both the Market Ready Improvements and the Tenant Improvements and engaging in the permitting application and approval process for the Critical Permits, and subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Work Letter, Lessee agrees to reimburse Lessor (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Lessee&#8217;s Share of the Permit Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) for fifty percent (50%) of the total third party costs, fees and expenses incurred by Lessor associated with the design and permitting of the Premises until Lessor receives the Use CUPs from the City and the fifteen (15) day appeal period has lapsed without appeal (or, if appealed, the City has confirmed the Use CUPs in all material respects) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CUP Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), such reimbursement not to exceed Two Hundred Thousand Dollars ($200,000). Lessee shall remit to Lessor, Lessee&#8217;s Share of the Permit Expenses within ten (10) days of Lessee&#8217;s receipt of invoice therefor, from time to time. Following the issuance of the Use CUPs and the lapse of the fifteen (15) day appeal period without appeal (or, if appealed, the City has confirmed the Use CUPs in all material respects), Lessor&#8217;s and Lessee&#8217;s payment obligations with respect to the CUP Costs shall be determined in accordance with the percentage allocation of costs set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Lease (i.e., to the extent such costs are part of the Tenant Improvement Shortfall, Lessee shall pay Lessee&#8217;s Tenant Improvement Shortfall percentage thereof on a monthly basis and receive a credit for any payment in excess of Lessee&#8217;s Tenant Improvement Shortfall percentage paid by Lessee up to the fifty percent (50%) paid prior to the issuance of the permits and lapse of the appeal period discussed above). To the extent Lessee paid to Lessor Share of Permit Expenses for any portion of the Cup Costs necessary in obtaining the Use CUPs, those fees shall not be refundable and Lessee shall have no right to reimbursement from Lessor for such fees if Lessee terminates this Lease in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraphs 2(c)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2(c)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2(c)(iv) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2(c)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)Provided Lessor has first received (i) the first month&#8217;s Base Rent (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Work Letter) and (ii) the insurance certificates required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 12(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, from and after the Effective Date, Lessee may have access to the Premises subject to the following requirements&#58; (1) Lessee shall first coordinate its access into the construction zone </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with both Lessor and the General Contractor by providing each reasonable advance notice, a description of any work to be performed by Lessee during such access and any additional information which may be required by either the General Contractor or Lessor, and (2) Lessee agrees to abide by all of the General Contractor&#8217;s safety requirements, including being personally escorted by a representative of the General Contractor at all times while in the construction zone if determined necessary in the sole but reasonable discretion of the General Contractor. Such access to the Premises prior to the Commencement Date shall be referred to herein as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Early Entry</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. During the course of any Early Entry, all terms and conditions of this Lease, except for the obligation to pay Monthly Base Rent (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below), Additional Rent (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below) and utilities pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below, shall apply. Lessor shall have the right to impose additional reasonable conditions upon Lessee&#8217;s Early Entry and if Lessor and the General Contractor determine it is reasonably necessary to do so, Lessor may revoke Lessee&#8217;s Early Entry for the protection of persons and property in the construction zone. Lessee shall not interfere with the construction of the Work (defined in the Work Letter) including the Tenant Improvements and any such interference resulting in a delay in the Construction Schedule (attached to the Work Letter as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-5&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) shall be eligible to be a Tenant Delay pursuant to the terms of the Work Letter.</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Option to Extend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)Lessor hereby grants to Lessee one (1) option to extend the Term of this Lease (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Option to Extend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) for a period of sixty (60) months (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Extended Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) immediately following the expiration of the Term. Lessee may exercise the Option to Extend by giving written notice of exercise to Lessor at least twelve (12) months but no more than fifteen (15) months prior to the expiration of the initial Term of this Lease (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Option Exercise Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), time being of the essence&#59; provided that if (i) at any time between the date of delivery of the exercise notice by Lessee and the end of the initial Term there is an uncured default continuing beyond any applicable notice and cure periods, or (ii) Lessee is then occupying and conducting operations for the Use permitted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in less than fifty-one percent (51%) of the Premises, then such notice shall be void and of no force or effect. The Extended Term, if the Option to Extend is exercised, shall be upon the same terms and conditions as the initial Term of this Lease, including the payment by Lessee of the Additional Rent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, except that (1) Lessee shall pay Monthly Base Rent, as determined as set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, during the Extended Term, (2) there shall be no additional option to extend, and (3) Lessee shall accept the Premises in their then &#8220;as is&#8221; condition. If Lessee does not exercise the Option to Extend in a timely manner the Option to Extend shall lapse, time being of the essence.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)The Option to Extend granted to Lessee by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is granted for the personal benefit of the named Lessee and any Permitted Transferees only, and shall be exercisable only by the herein named Lessee and any Permitted Transferees. The Option to Extend may not be exercised by any assignee or transferred to or exercised by any sublessee (nor exercised by Lessee on behalf of any sublessee (except to the extent that Lessee is then subleasing not more than forty-nine percent (49%) of the Premises)) other than any Permitted Transferee.</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)The Monthly Base Rent for the Premises during the Extended Term shall be determined pursuant to the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and shall equal the then current fair market rental for the Premises on the commencement date of the Extended Term as determined by agreement between the Lessor and Lessee reached prior to the expiration of the Option Exercise Period, if possible, and by the process of broker appraisal if the parties cannot reach agreement.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)Upon the written request by Lessee to Lessor received by Lessor at any time during the thirty (30) day period prior to the expiration of the Option Exercise Period and prior to the exercise by Lessee of the Option to Extend, Lessor shall give Lessee written notice of Lessor&#8217;s good faith opinion of the amount equal to the fair market rental value of the Premises for the Extended Term. Thereafter, upon the request of Lessee, Lessor and Lessee shall enter into good faith negotiations during the remainder of the thirty (30) days prior to the expiration of the Option Exercise Period in an effort to reach agreement on the initial Monthly Base Rent for the Premises during the Extended Term.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Lessor and Lessee are unable to agree upon the amount equal to the fair market rental value of the Premises for the Extended Term, and thereafter, prior to the expiration of the Option Exercise Period, Lessee exercises the Option to Extend, said amount shall be determined by a licensed commercial real estate broker with at least ten (10) years of experience in the Menlo Park office&#47;R&#38;D&#47;manufacturing rental market, (hereinafter the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Arbitrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The fair market rental determination shall be performed by one Arbitrator if the parties are able to agree upon one Arbitrator. If the parties are unable to agree upon one Arbitrator, then each party shall appoint an Arbitrator and the two Arbitrators shall select a third Arbitrator. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If only one Arbitrator is selected, that Arbitrator shall notify the parties in simple letter form of its determination of the amount equal to the fair market Monthly Base Rent for the Premises on the commencement date of the Extended Term within fifteen (15) days following its selection. Said appraisal shall be binding on the parties as the appraised current &#8220;fair market rental&#8221; for the Premises which shall be based upon what a willing new lessee would pay and a willing lessor would accept at arm&#8217;s length for comparable premises in Menlo Park of similar age, size, quality of construction and specifications (excluding the value of any improvements to the Premises made at Lessee&#8217;s cost with Lessor&#8217;s prior written consent except as otherwise permitted herein) for a lease similar to this Lease and taking into consideration that there will be no free rent, improvement allowance, period of vacancy or other rent concessions, taken as a whole. If multiple Arbitrators are selected, each Arbitrator shall within ten (10) days of being selected make its determination of the amount equal to the fair market Monthly Base Rent for the Premises on the commencement date of the Extended Term in simple letter form. If two (2) or more of the Arbitrators agree on said amount, such agreement shall be binding upon the parties. If multiple Arbitrators are selected and two (2) Arbitrators are unable to agree on said amount, the amount equal to the fair market Monthly Base Rent for the Premises on the commencement date of the Extended Term shall be determined by taking the mean average of the appraisals&#59; provided, that any high or low appraisal, differing from the middle appraisal by more than ten percent (10%) of the middle appraisal, shall be disregarded in calculating the average.</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If only one Arbitrator is selected, then each party shall pay one-half of the fees and expenses of that Arbitrator. If three Arbitrators are selected, each party shall bear the fees and expenses of the Arbitrator it selects and one-half of the fees and expenses of the third Arbitrator.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)Thereafter, provided that Lessee has previously given timely notice to Lessor of the exercise by Lessee of the Option to Extend, Lessor and Lessee shall execute an amendment to this Lease stating that the initial Monthly Base Rent for the Premises during the Extended Term shall be equal to the determination by appraisal.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Right of First Offer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessor and Lessee acknowledge that Lessor may (but is not obligated to) construct a new building (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">New Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) adjacent to the Building in which the Premises are located. Subject to the currently existing rights set forth in the existing leases of any existing lessees in the Menlo Business Park, if, during the Term, any space in the Building or space in the New Building becomes available for direct lease for the first time during the Term hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Available Space</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), (note, not all vacant space shall be considered Available Space and it is Lessor who shall determine when space is Available Space hereunder in its sole and absolute discretion), then Lessor shall first offer to lease the Available Space to Lessee by delivering notice to Lessee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Availability Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Lessor&#8217;s obligation to provide Lessee with the Availability Notice hereunder shall be a one-time occurrence as Available Space in the Building and&#47;or Available Space in the New Building (if any) becomes available and Lessee&#8217;s right hereunder shall be a one-time right as to each of the Building and the New Building, accordingly. The Availability Notice shall set forth the terms upon which Lessor would be willing to lease the Available Space to a third party, as determined by Lessor in its sole discretion. Lessee shall have five (5) business days after receipt of the Availability Notice to unconditionally accept in writing or reject the terms set forth in the Availability Notice, it being understood that Lessee&#8217;s failure to respond within such five (5) business day period shall be deemed a rejection of such terms. If Lessee does not unconditionally accept in writing the terms set forth in the Availability Notice within such five (5) business day period, then Lessee&#8217;s rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall lapse and terminate and Lessor shall be entitled to lease the Available Space to any other party on substantially the same terms as contained in the Availability Notice&#59; provided that the rental rate (taking into account adjustments for any differences between so called &#8220;net&#8221; leases and &#8220;gross&#8221; leases) shall be no less, and the lessee improvement allowance, if any, shall be no more than that originally offered to Lessee in the Availability Notice. If Lessee accepts in writing the terms set forth in the Availability Notice, then for the period starting on the date of Lessor&#8217;s delivery of the Availability Notice to Lessee and ending thirty (30) days thereafter (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Waiting Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), Lessor shall not enter into any binding agreement to lease the Available Space with any other party or market the Available Space for lease. During the Waiting Period, Lessor and Lessee shall enter into a written amendment to this Lease or a new lease (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Definitive Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), consistent with the terms set forth in the Availability Notice and otherwise on the terms and conditions of this Lease. If Lessee and Lessor fail to execute and deliver a Definitive Lease Agreement within the Waiting Period, then Lessee&#8217;s rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall lapse and terminate, and Lessor shall be entitled to lease the Available Space to any other party on such term as Lessor desires. Lessor shall not be required to offer the Available Space to Lessee during any period in which an event of default has occurred and is continuing. Furthermore, unless expressly mentioned and approved in the written consent of Lessor to any assignment or subletting as provided in this Lease, the </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">right of first offer to lease under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is granted for the personal benefit of the named Lessee herein and any Permitted Transferee and may not be exercised by any assignee or sublessee (other than a Permitted Transferee) nor exercised by Lessee on behalf of a sublessee. </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Monthly Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)Commencing on the Commencement Date and continuing on the first day of each calendar month thereafter until the end of the Term, Lessee shall pay to Lessor in monthly installments in advance the Monthly Base Rent for the Premises in lawful money of the United States as follows&#58;</font></div><div style="padding-left:78.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:1.0%"></td><td style="width:19.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.364%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Months</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Square Feet</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#47;SF&#47;Mo.&#47;NNN</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monthly Base Rent</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-12</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.00*</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$540,000.00*</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-24</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.15</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$567,000.00</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-36</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.20</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$576,000.00</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37-48</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.25</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$585,000.00</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49-60</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.35</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$603,000.00</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61-72</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.45</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$621,000.00</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73-84</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.55</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$639,000.00</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85-96</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.65</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$657,000.00</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97-108</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.75</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$675,000.00</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109-120</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.85</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$693,000.00</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121-132</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.95</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$711,000.00</font></td></tr></table></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Lessee&#8217;s Monthly Base Rent shall be abated for the first six (6) months of the Lease Term following the Commencement Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Abatement Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), if and for so long as Lessee is not in material monetary default under this Lease. If Lessee cures such material monetary default under this Lease during the Abatement Period, then following such cure Lessee&#8217;s Monthly Base Rent shall continue to be abated as of the date of such cure&#59; provided, however, that Lessee shall not be entitled to extend the Abatement Period for the period of time that Lessee was in material monetary default of the Lease and shall not be entitled to recoup any portion of Monthly Base Rent attributable to the period of time that Lessee was in material monetary default of the Lease. In the event a dispute regarding whether a material monetary default has occurred for purposes of determining if Lessee is entitled to Abated Base Rent in accordance with the terms of this Paragraph results in litigation or other proceeding and Lessee </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prevails in such litigation or other proceeding, then Lessee shall be entitled to abate the Monthly Base Rent attributable to the period of time that Lessee was improperly determined to be in material monetary default of the Lease. The total eligible abatement of Monthly Base Rent pursuant to the foregoing based on the assumption that Lessee is not in material monetary default during the Abatement Period shall be Three Million, Two Hundred Forty Thousand and no&#47;100s Dollars ($3,240,000.00). The foregoing abatement of Monthly Base Rent payable by Lessee shall not be construed as an abatement of any other rent, Additional Rent, or charges payable under this Lease. If Lessee defaults under the terms of this Lease, and such default results in the termination of this Lease in accordance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) of this Lease, then the unamortized amount of the abatement of Monthly Base Rent through the date of such termination (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Abated Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), amortized on a straight-line basis over the initial Term, shall immediately become due and payable as part of Additional Rent under this Lease as of the day prior to such termination. In such event, as a part of the recovery set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lessor shall be entitled to recover, in addition to any other amounts due from Lessee, the amount of the Abated Base Rent due under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as Additional Rent. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Work Letter, (i) upon the execution and delivery of this Lease by Lessee, Lessee shall pay to Lessor the sum of Five Hundred Forty Thousand and no&#47;100s Dollars ($540,000.00) which shall be applied to the installment of Monthly Base Rent due for the first month in which Monthly Base Rent is due following the Commencement Date and (ii) upon thirty (30) days after the City&#8217;s issuance of the Use CUPs and the lapse of the fifteen (15) day appeal period without appeal (or, if appealed, the City has confirmed the Use CUPs in all material respects), Lessee shall pay to Lessor the sum of One Million Six Hundred Twenty Thousand and no&#47;100s Dollars ($1,620,000.00) which shall be applied to the installments of Monthly Base Rent due for the second, third and fourth months in which Monthly Base Rent is due following the Commencement Date. Thereafter, Monthly Base Rent shall be paid monthly in advance on the first day of each calendar month. Lessee shall also pay to Lessor no later than March 15, 2016, the amount of One Hundred Eighty Thousand and no&#47;100s Dollars ($180,000.00) or Lessor&#8217;s then current estimate of Additional Rent (as hereinafter defined), which amount shall be applied to the Additional Rent for the first calendar month of the Term.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon thirty (30) days after the City&#8217;s issuance of the Use CUPs and the lapse of the fifteen (15) day appeal period without appeal (or, if appealed, the City has confirmed the Use CUPs in all material respects), and subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Work Letter, Lessee shall deliver to Lessor the Security Deposit (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below). </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Rent&#59; Operating Expenses and Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)In addition to the Monthly Base Rent payable by Lessee pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, commencing on the Commencement Date, Lessee shall pay to Lessor, as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Additional Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; (1) Lessee&#8217;s Pro Rata Share (as defined in in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) of the Operating Expenses (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below) of the Property, (2) Lessee&#8217;s Pro Rata Share of the operating expenses for the Menlo Business Park of which the Property is a part in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (such expenses referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Park Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and (3) Lessee&#8217;s Pro Rata Share of the Taxes (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below). &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Lessee&#8217;s </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pro Rata Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall be equal to the ratio of the number of square feet of the Premises to the rentable square footage of the Building (currently, Lessee&#8217;s Pro Rata Share is 82.66% (180,000&#47;217,770))&#59; provided, however, that Lessee&#8217;s &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pro Rata Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; with respect to Park Expenses shall instead be equal to Lessee&#8217;s Pro Rata Share multiplied by the ratio of the number of square feet of the Land allocable to the Property to the total number of square feet of land in Menlo Business Park, as shown on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit &#8220;B&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as such land may be expanded or reduced from time to time by additions or subtractions to the Park (currently, Lessee&#8217;s Pro Rata Share with respect to Park Expenses is 19.58% (180,000&#47;217,770 * 23.68%)). Upon the earlier of commencement of the construction of the New Building or the Parking Structure or the demolition of the Building required in connection therewith, the rentable square footage of the Building, Lessee&#8217;s Pro-Rata Share and Lessee&#8217;s Pro-Rata Share with respect to Park Expenses shall be adjusted in a fair and reasonable manner and the definition of Property shall be re-defined in a fair and reasonable manner. The Park Expenses currently include maintenance of the common areas of Menlo Business Park, parking lot lighting (cost of electricity and maintenance of the fixtures), maintenance of the network conduit, all landscape maintenance and irrigation of Menlo Business Park, Lessor&#8217;s insurance coverages of Menlo Business Park, security patrol and real estate and other taxes for land and improvements to the Menlo Business Park which are for the benefit of all occupants of the Menlo Business Park. The Park Expenses may include other commercially reasonable items from time to time during the term of this Lease but shall exclude any expense that is properly allocated to the owner or to the lessees of any other building in the Menlo Business Park. Monthly Base Rent and Additional Rent are referred to herein collectively as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; as used herein, shall include all commercially reasonable direct costs actually incurred by Lessor in the management, operation, maintenance, repair and replacement of the Property, including the cost of all maintenance, repairs, and restoration of the Property performed by Lessor pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraphs 15(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">15(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof, as determined by generally accepted accounting principles (unless excluded by this Lease), including, but not limited to&#58;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personal property taxes related to the Premises&#59; any parking taxes or parking levies imposed on the Premises in the future by any governmental agency&#59; a management fee charged for the management and operation of the Menlo Business Park, in an amount equal to (i) four percent (4%) of the total gross income received by Lessor from the Lessee (including Monthly Base Rent and Additional Rent) until the earlier of the date Lessor commences demolition of the Building in connection with the construction of the New Building or the Parking Structure or three (3) years from the Commencement Date and (ii) three percent (3%) of the total gross income received by Lessor from the Lessee (including Monthly Base Rent and Additional Rent) thereafter (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Property Management Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and not just Lessee&#8217;s Pro Rata Share of this fee&#59; water and sewer charges&#59; waste disposal&#59; commercially reasonable insurance premiums for insurance coverages maintained by Lessor pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof&#59; license, permit, and inspection fees&#59; charges for electricity, heating, air conditioning, gas, and any other utilities (including, without limitation, any temporary or permanent utility surcharge or other exaction) to the extent such utilities are not separately metered and payable directly by Lessee&#59; security&#59; maintenance, repair, and replacement of the roof membrane&#59; painting and repairing, interior and exterior&#59; maintenance and replacement of floor and window coverings&#59; repair, maintenance and </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">replacement of air conditioning, heating, mechanical and electrical systems, elevators (if any), plumbing and sewage systems&#59; janitorial service (if provided by Lessor)&#59; landscaping, gardening, and tree trimming&#59; glazing&#59; repair, maintenance, cleaning, sweeping, striping, and resurfacing of the parking area&#59; exterior Building lighting and parking lot lighting&#59; supplies, materials, equipment and tools used in the maintenance of the Property&#59; costs for accounting services incurred in the calculation of Operating Expenses and Taxes as defined herein&#59; and the cost of any other capital expenditures for any improvements or changes to the Building which are required by laws, ordinances, or other governmental regulations adopted after the Commencement Date, or for any items or capital expenditures voluntarily made by Lessor which are intended to and have the effect of reducing Operating Expenses&#59; provided, however, that except for capital improvements required because of Lessee&#8217;s specific use of the Property, if Lessor is required to or voluntarily makes such capital improvements, Lessor shall amortize the cost of said improvements over the useful life of said improvements calculated in accordance with generally accepted accounting principles (together with interest on the unamortized balance at the rate equal to the effective rate of interest on Lessor&#8217;s bank line of credit at the time of completion of said improvements, but in no event in excess of ten percent (10%) per annum) as an Operating Expense in accordance with generally accepted accounting principles, except that with respect to capital improvements made to save Operating Expenses such amortization shall not be at a rate greater than the actual savings in Operating Expenses (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Permitted Capital Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59; the Compensation (defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">subsection (d)(6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) below) of any employee or building manager, provided any such employee or building manager who does not devote substantially all of his or her employed time to the Menlo Business Park shall be prorated to reflect time spent on operating and managing the Menlo Business Park vis-&#224;-vis time spent on matters unrelated to operating and managing the Menlo Business Park&#59; and, Operating Expenses shall also include any other reasonable expense or charge actually incurred by Lessor, whether or not described herein not specifically excluded by other provisions of this Lease, which in accordance with generally accepted accounting principles would be considered an expense of managing, operating, maintaining, and repairing the Property. Notwithstanding the foregoing, Lessee shall have the option of paying Lessee&#8217;s Pro Rata Share of any such cost for capital expenditures in a single lump-sum payment without incurring interest expense on such amounts.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the preceding, in conjunction with the allocation of service, maintenance, repair and replacement responsibilities pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, below, so long as Lessee satisfies the Maintenance Requirements (defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the parties agree that Lessee shall directly assume responsibility for, contract directly with any service providers for, and pay directly for the following, which amounts shall, for so long as this arrangement is permitted by Lessor, be excluded from Operating Expenses above&#58;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) all service, maintenance, repair and replacement of heating, ventilation, air conditioning, mechanical and electrical systems within the Premises or serving the Premises from the rooftop pad or the equipment pads immediately adjacent to the Premises&#59; and,</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) all service, maintenance, repair and replacement of plumbing and interior sewage systems within the Premises. </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)Real property taxes and assessments upon the Property, during each lease year or partial lease year during the term of this Lease are referred to herein as &#8220;Taxes.&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean&#58;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)all real estate taxes, assessments, charges and any other taxes which are levied or assessed against the Property including the Land, the Building, and all improvements located thereon, including any increase in Taxes resulting from a reassessment following any transfer of ownership of the Property or any interest therein or following any improvements to the Property&#59; and</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)all other taxes which may be levied in lieu of real estate taxes, assessments, and other fees, charges, and levies, general and special, ordinary and extraordinary, unforeseen as well as foreseen, of any kind and nature by any authority having the direct or indirect power to tax, including without limitation any governmental authority or any improvement or other district or division thereof, for public improvements, services, or benefits which are assessed, levied, confirmed, imposed, or become a lien (1) upon the Property, and&#47;or any legal or equitable interest of Lessor in any part thereof&#59; or (2) upon this transaction or any document to which Lessee is a party creating or transferring any interest in the Property&#59; and (3) any tax or excise, however described, imposed in addition to, or in substitution partially or totally of, any tax previously included within the definition of &#8220;Taxes&#8221; or any tax the nature of which was previously included in the definition &#8220;Taxes.&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not included within the definition of &#8220;Taxes&#8221; and Park Expenses are any net income, profits, transfer, franchise, estate, gift, rental income, or inheritance taxes imposed by any governmental authority. &#8220;Taxes&#8221; also shall not include penalties or interest charges assessed on delinquent Taxes so long as Lessee is not in default in the payment of Monthly Base Rent or Additional Rent beyond applicable notice and cure periods.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to any assessments which may be levied against or upon the Property or the Land, which under the laws then in force may be evidenced by improvement or other bonds, or may be paid in annual installments, only the amount of such annual installment (with appropriate proration of any partial year) and statutory interest shall be included within the computation of the annual Taxes levied against the Property.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)Notwithstanding anything to the contrary herein, the following costs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) shall be excluded from the definition of Operating Expenses and Park Expenses&#58;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)Costs occasioned by the act, omission or violation of law by Lessor, any other occupant of Menlo Business Park, or their respective agents, employees or contractors&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)Costs for which Lessor has a right of reimbursement from others, including reimbursement from insurance&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)Interest, charges and fees incurred on debt or payments on any deed of trust or ground lease on the Property, or Menlo Business Park&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)Advertising or promotional costs or other costs incurred by Lessor in procuring tenants for the Property or other portions of Menlo Business Park&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)Costs incurred in repairing, maintaining or replacing any structural elements of the Building for which Lessor is responsible pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)Any wages, bonuses or other compensation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of employees above the grade of building manager&#59; any Compensation of any officer or director of Lessor&#59; </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)General office overhead and general and administrative expenses of Lessor, except as specifically provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)Leasing expenses and broker commissions payable by Lessor&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)Costs occasioned by casualties or by the exercise of the power of eminent domain&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)Costs to correct any construction defect in the Building or the Premises existing on the Commencement Date&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)Costs of any renovation, improvement, painting or redecorating of any portion of the Property or the Menlo Business Park not made available for Lessee&#8217;s use&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)Costs incurred in connection with negotiations or disputes with any other tenant or occupant of the Menlo Business Park and costs arising from the violation by Lessor or any other tenant or occupant of the Menlo Business Park of the terms and conditions of any other lease or agreement&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)Costs incurred in connection with the presence of any Hazardous Materials on the Property or on other property in Menlo Business Park that were not caused by or the result of a release by Lessee or its employees, agents, contractors, invitees, sublessees, successors or assigns&#59; and</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)Expense reserves&#59; </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15)Capital costs except Permitted Capital Expenses (for clarification, Permitted Capital Expenses may include replacement or large scale repair of equipment, machinery and systems if Lessor elects not to expense same)&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16)Costs occasioned by the willful misconduct or gross negligence&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17)Costs paid to affiliates of Lessor for services that exceed the competitive cost for services and materials rendered by qualified unrelated persons or entities of similar skill, competence and experience in an arm&#8217;s length transaction&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)Costs for sculpture, paintings, fountains or other objects of art&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19)Charitable and political donations&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20)Costs not normally included in reimbursable operating expenses by lessors of comparable buildings in the vicinity of the Building or which under generally accepted management practices would not be considered an expense of managing, operating, maintaining, or repairing the Building, or unless relating to a feature of the Building not present in similar buildings in the vicinity of the Building, that are not then being incurred by such similar buildings&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21)Costs for services not provided to Lessee under the Lease or of a nature that are payable directly or provided by Lessee under the Lease, including without limitation, janitorial, refuse removal and utilities that are separately metered to the Premises&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22)Costs in connection with maintenance of any rooftop garden located on the roof of the Building&#59; and</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23)Costs to obtain the Critical Permits&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24)Insurance cost increases caused by the activities of another occupant of Menlo Business Park&#59; and</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25)Any fee, profit or Compensation retained by Lessor or its affiliates for management and administration of the Property or the Menlo Business Park other than the Property Management Fee, provided, however, that the Property Management Fee does not include and Operating Expenses shall include any Compensation paid to accountants, building engineers or any other specialist employed by Lessor wholly dedicated to the Park or a reasonable allocation of such Compensation if not wholly dedicated to the Park as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessor shall at all times use its commercially reasonable efforts to operate the Property in an economically reasonable manner at costs not disproportionately higher than those experienced by other comparable premises in the market area in which the Property is located (Menlo Park).</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)Throughout the term of this Lease, as close as reasonably possible to the end of each calendar year thereafter but no later than April 1 of the following year, Lessor shall notify Lessee of the Operating Expenses, Taxes and Park Expenses estimated by Lessor for each </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">following calendar year. Concurrently with such notice, Lessor shall provide a description of such Operating Expenses, Taxes and Park Expenses. Commencing on the Commencement Date, and on the first (1st) day of each calendar month thereafter, Lessee shall pay to Lessor, as Additional Rent, one-twelfth (1&#47;12th) of the estimated Operating Expenses, Taxes and Park Expenses. If at any time during any such calendar year, it appears to Lessor that the Operating Expenses, Taxes or Park Expenses for such year will vary from Lessor&#8217;s estimate, Lessor may, by written notice to Lessee, revise Lessor&#8217;s estimate for such year and the Additional Rent payments by Lessee for such year shall thereafter be based upon such revised estimate. Lessor shall furnish to Lessee with such revised estimate written verification showing that the actual Operating Expenses, Taxes or Park Expenses are greater than Lessor&#8217;s estimate. The increase in the monthly installments of Additional Rent resulting from Lessor&#8217;s revised estimate shall not be retroactive, but the Additional Rent for each calendar year shall be subject to adjustment between Lessor and Lessee after the close of the calendar year, as provided below.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within approximately ninety (90) days after the expiration of each calendar year of the Term, Lessor shall furnish Lessee a statement certified by a responsible employee or agent of Lessor (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) with respect to such year, prepared by an employee or agent of Lessor, showing the actual Operating Expenses, Taxes and Park Expenses for such year broken down by component expenses, and the total payments made by Lessee for such year on the basis of any previous estimate of such Operating Expenses, Taxes and Park Expenses, all in sufficient detail for verification by Lessee. Unless Lessee raises any objections to the Operating Statement within ninety (90) days after receipt of the same, such statement shall conclusively be deemed correct and Lessee shall have no right thereafter to dispute such statement or any item therein or the computation of Operating Expenses and&#47;or Taxes and&#47;or Park Expenses. Upon giving Lessor five (5) days&#8217; advance written notice, Lessee or its accountants shall have the right to inspect and audit Lessor&#8217;s books and records with respect to the Operating Statement in an office of Lessor, or Lessor&#8217;s agent, during normal business hours, once each Lease Year to verify actual Operating Expenses and&#47;or Taxes and&#47;or Park Expenses. Should Lessee retain any accountant or accounting firm to audit or inspect Lessor&#8217;s books and records pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, such accountant or accounting firm shall be one of national standing and retained on an hourly rate basis or based upon a fixed fee and shall not be paid on a contingency basis and shall execute a commercially reasonable confidentiality agreement regarding such audit and inspection. Lessor&#8217;s books and records shall be kept in accord with generally accepted accounting principles. If Lessee&#8217;s audit of the Operating Expenses and&#47;or Taxes and&#47;or Park Expenses for any year reveals a net overcharge of more than five percent (5%), Lessor shall promptly reimburse Lessee for the cost of the audit&#59; otherwise, Lessee shall bear the cost of Lessee&#8217;s audit. If Lessee reasonably objects to Lessor&#8217;s Operating Statement, Lessee shall nonetheless continue to pay on a monthly basis the Operating Expenses, Taxes and Park Expenses based upon Lessor&#8217;s most current estimate until such dispute is resolved.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Lessee&#8217;s Pro Rata Share of the Operating Expenses and Taxes and Lessee&#8217;s Pro Rata Share of Park Expenses for any year as finally determined exceed the total payments made by Lessee for such year based on Lessor&#8217;s estimates, Lessee shall pay to Lessor the deficiency, within thirty (30) days after the receipt of Lessor&#8217;s Operating Statement. If the total payments made by Lessee based on Lessor&#8217;s estimate of the Operating Expenses and&#47;or Taxes and&#47;or Park Expenses exceed the Lessee&#8217;s Pro Rata Share of Operating Expenses and&#47;or Taxes and&#47;or </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessee&#8217;s Pro Rata Share of Park Expenses as finally determined, Lessee&#8217;s extra payment, plus the cost of an audit, if any, which is the responsibility of Lessor pursuant to the terms set forth herein shall be credited against payments of Monthly Base Rent and Additional Rent next due hereunder or returned within thirty (30) days if the Term has expired or this Lease has been terminated.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the expiration or termination of this Lease, within thirty (30) days after Lessee&#8217;s receipt of Lessor&#8217;s Operating Statement or the completion of Lessee&#8217;s audit regarding the Operating Expenses and&#47;or Taxes and&#47;or Park Expenses for the calendar year in which this Lease terminates, Lessee shall pay to Lessor or shall receive from Lessor, as the case may be, an amount equal to the difference between the Operating Expenses and&#47;or Taxes and&#47;or Park Expenses for such year, as finally determined, and the amount previously paid by Lessee on account thereof (prorated to the expiration date or the termination date of this Lease). </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Payment of Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)All Rent shall be due and payable in lawful money of the United States of America made payable to and addressed to&#58; Menlo Park Portfolio II, LLC, P.O. Box 310300, Property&#58; 435610, Des Moines, IA 50331-0300 without deduction or offset and without prior demand or notice, unless otherwise specified herein. Monthly Base Rent and Additional Rent shall be payable monthly, in advance, on the first day of each month. Additional Rent shall be payable monthly, in advance, on the first day of each month for the entire Premises for the entire term of his Lease. Lessee&#8217;s obligation to pay Rent for any partial month at the commencement of the term, for any partial month immediately prior to a rental adjustment date (if the rental adjustment date is other than the first day of the calendar month), and for any partial month at the expiration or termination of the term shall be based upon the number of days in such month. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)If any installment of Monthly Base Rent, Additional Rent or any other sum due from Lessee is not received by Lessor within five (5) days after the same is due, Lessee shall pay to Lessor an additional sum equal to five percent (5%) of the amount overdue as a late charge. The parties agree that this late charge represents a fair and reasonable estimate of the costs that Lessor will incur by reason of the late payment by Lessee. Acceptance of any late charge shall not constitute a waiver of Lessee&#8217;s default with respect to the overdue amount. Any amount not paid within ten (10) days after Lessee&#8217;s receipt of written notice that such amount is due shall bear interest from the date due until paid at the lesser rate of (1) the prime rate of interest as published in the Wall Street Journal, plus two percent (2%) or (2) the maximum rate allowed by law (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Interest Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), in addition to the late payment charge.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.655%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initials&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessor</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Security Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Work Letter, Lessee shall deposit with Lessor not later than thirty (30) days after the issuance of the Use CUP and the lapse of the fifteen (15) day appeal period without appeal (or, if appealed, the City has confirmed the Use CUPs in all material respects), the sum of Four Million Five Hundred Thousand and no&#47;100s Dollars ($4,500,000.00) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Security Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which shall be in the form of an irrevocable standby letter of credit (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Letter of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;) as security for Lessee&#8217;s faithful performance of </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessee&#8217;s obligations under this Lease. Provided that no monetary event of default beyond applicable notice and cure periods with respect to the payment of Rent is occurring or has occurred more than one time within the last twelve (12) months prior to each Reduction Date and provided that no monetary event of default beyond applicable notice and cure periods with respect to monetary obligations other than the payment of Rent and which obligations are equal to or greater than Fifty Thousand Dollars ($50,000.00) is occurring or has occurred more than one time within the last twelve (12) months prior to each Reduction Date, then the Security Deposit shall be reduced on each Reduction Date by the following amounts&#58; </font></div><div style="padding-left:78.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.833%"><tr><td style="width:1.0%"></td><td style="width:38.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.740%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.37pt;padding-right:4.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reduction </font></div><div style="padding-left:4.37pt;padding-right:4.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Security Deposit </font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First day of 31st Month</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,000,000.00</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First day of 43rd Month</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3,500,000.00</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First day of 55the Month</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3,000,000.00</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First day of 67th Month</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,500,000.00</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First day of 79th Month</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,000,000.00</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First day of 91st Month</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 3.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,500,000.00</font></td></tr></table></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(The schedule as set forth above, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Security Reduction Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). If Lessee is not permitted to reduce the Security Deposit on any given Reduction Date for failure to meet the requirements above, provided Lessee meets them on a future Reduction Date, Lessee may resume the reductions in accordance with the Security Reduction Schedule. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Lessee fails to pay Monthly Base Rent or Additional Rent or charges due hereunder within applicable notice and cure periods, or otherwise defaults beyond applicable notice and cure periods under this Lease (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Lessor may use, apply or retain all or any portion of said Security Deposit to the extent reasonably necessary to cure the default, for the payment of any amount due Lessor, and to reimburse or compensate Lessor for any liability, cost, expense, loss or damage (including attorneys&#8217; fees) which Lessor may suffer or incur by reason thereof. If Lessor uses or applies all or any portion of the Security Deposit, Lessee shall within ten (10) days after written request therefor deposit with Lessor the amount sufficient to restore the Security Deposit to the original amount required by this Lease. Lessor shall not be required to keep all or any part of the Security Deposit separate from its general accounts. In no event or circumstance shall Lessee have the right to any use of the Security Deposit and, </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specifically, Lessee may not use the Security Deposit as a credit or to otherwise offset any payments required hereunder, including, but not limited to, Rent or any portion thereof. Lessee waives (i) California Civil Code Section 1950.7 and any and all other laws, rules and regulations applicable to security deposits in the commercial context (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Security Deposit Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and (ii) any and all rights, duties and obligations either party may now have, or in the future will have, relating to or arising from the Security Deposit Laws. Notwithstanding anything to the contrary herein, the Security Deposit may be retained and applied by Lessor (a) to offset Rent which is unpaid either before or after termination of this Lease, and (b) against other damages suffered by Lessor before or after termination of this Lease that are recoverable by Lessor in accordance with the terms and conditions of this Lease, but the remainder of the Security Deposit, if any, shall be returned to Lessee within sixty (60) days after the Premises are delivered to Lessor in the condition required for surrender pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No part of the Security Deposit shall be considered to be held in trust, to bear interest or other increment for its use, or to be prepayment for any moneys to be paid by Lessee under this Lease. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Substantial Completion of the Work, Lessee shall have the option of substituting cash for all or any portion of such Letter of Credit, and, Lessor shall reasonably cooperate with Lessee to accommodate an amendment or replacement of such letter of credit in connection with any such election by Lessee&#59; provided, however, the combination of the cash portion of the Security Deposit and the amount of the Letter of Credit shall at all times equal Four Million Five Hundred Thousand and no&#47;100s Dollars ($4,500,000.00), subject to reduction of such amount in accordance with the limits set forth in the Security Reduction Schedule set forth above. The Letter of Credit shall be issued to Lessor, as beneficiary, in form and substance reasonably satisfactory to Lessor. The Letter of Credit shall be subject to the International Standby Practices of 1998, International Chamber of Commerce Publication No. 590 subject to the following&#58; (1) notwithstanding Rule 4.09(c) of ISP98 and regardless of whether the words &#34;exact&#34; or &#34;identical&#34; or similar words are used in this Letter of Credit, a document presented under this Letter of Credit need not reproduce the wording in this Letter of Credit exactly, including typographical errors, punctuation, spacing, blank lines and spaces, and the like&#59; and (2) notwithstanding Rule 5.06(c)(i) of ISP98, the presenter shall not be precluded from asserting an objection to a notice of discrepancy solely by reason of having requested that the documents be forwarded or that a waiver be sought. Lessor may draw upon the Letter of Credit, without prejudice to any other remedy provided in the Lease or by Applicable Law, to the extent necessary to satisfy an event of default by Lessee under this Lease. Any such draw on the Letter of Credit shall not constitute a waiver of any other rights of Lessor with respect to such event of default. The Letter of Credit shall be issued by a bank reasonably approved by Lessor and whose deposits are insured by the FDIC (such approved, issuing bank being referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which Bank must have a short term Fitch Rating which is not less than &#8220;F2&#8221;, a long term Fitch Rating which is not less than &#8220;BBB&#8221;, a short term rating from Standard and Poor&#8217;s Financial Services, LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">S&#38;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of not less than &#8220;A2&#8221;, a long term S&#38;P rating of not less than &#8220;BBB&#8221;, a short term rating from Moody&#8217;s Investor Service, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Moody&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of not less than &#8220;P2&#8221;, and a long term Moody&#8217;s rating of not less than &#8220;Baa3&#8221; (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Bank Credit Rating Threshold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Lessor hereby approves of Wells Fargo Bank as an approved Bank. The Letter of Credit shall have an expiration date not earlier than the thirtieth (30th) day after the expiration of the Term (or, in the alternative, have a term of not less than one (1) year and be automatically renewable for an additional one (1) year period unless notice of non-renewal is </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">given by the issuer to Lessor not later than sixty (60) days prior to the expiration thereof) and shall provide that Lessor may make partial and multiple draws thereunder for any sum which Lessor may reasonably expend or may be required to expend by reason of such default by Lessee, up to the amount thereof. In addition, the Letter of Credit shall provide that, in the event of Lessor's assignment or other transfer of its interest in this Lease, the Letter of Credit shall be freely transferable by Lessor, without charge and without recourse, to the assignee or transferee of such interest and the bank shall confirm the same to Lessor and such assignee or transferee. The Letter of Credit shall provide for payment to Lessor upon the issuer's receipt of a sight draft from Lessor together with Lessor's certificate certifying that Lessor is entitled to such payment pursuant to the provisions of this Lease, and with no other conditions, shall be in form and content reasonably satisfactory to Lessor. If the Letter of Credit has an expiration date earlier than the thirtieth (30th) day after the expiration of the Term, then throughout the Term (including any renewal or extension of the Term) Lessee shall provide evidence of renewal of the Letter of Credit to Lessor at least sixty (60) days prior to the date the Letter of Credit expires. If Lessor draws on the Letter of Credit pursuant to the terms hereof, Lessee shall immediately replenish the Letter of Credit or provide Lessor with an additional letter of credit conforming to the requirement of this paragraph. In addition to the other reasons set forth herein entitling Lessor to draw down on the Letter of Credit, Lessor, or its then managing agent, shall also have the right to draw down an amount up to the face amount of the Letter of Credit if the applicable rating of the Bank has been reduced below the Bank's Credit Rating Threshold, and Lessee has failed to provide Lessor with a replacement letter of credit, conforming in all respects to the requirements of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, within twenty-five (25) days following Lessor's written demand therefor (with no other notice or cure or grace period being applicable thereto, notwithstanding anything in this Lease to the contrary). In addition, in the event the Bank is placed into receivership or conservatorship by the Federal Deposit Insurance Corporation or any successor or similar entity, then, effective as of the date such receivership or conservatorship occurs, said Letter of Credit shall be deemed to fail to meet the requirements of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and, within twenty-five (25) days following Lessor's notice to Lessee of such receivership or conservatorship, Lessee shall replace such Letter of Credit with a substitute letter of credit from a different issuer (which issuer shall meet or exceed the Bank's Credit Rating Threshold) and that complies in all respects with the requirements of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessee's failure to deliver any replacement, additional or extension of the Letter of Credit, or evidence of renewal of the Letter of Credit, within the time specified under this Lease shall entitle Lessor to draw upon the Letter of Credit then in effect and, at Lessor's election, constitute an event of default under this Lease. If Lessor liquidates the Letter of Credit as provided in the preceding sentence, Lessor shall hold the funds received from the Letter of Credit as security for Lessee's performance under this Lease in accordance with the requirements with respect to cash as set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Lessor shall not be required to segregate such Security Deposit from its other funds and no interest shall accrue or be payable to Lessee with respect thereto. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Lessee is entitled to any reduction in the Security Deposit as more particularly set forth herein, then Lessor shall cooperate in a commercially reasonable manner with Lessee upon Lessee's request to replace or amend the then existing Letter of Credit to accommodate such reduction. </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessee may only use and occupy the Premises for general office uses, administrative purposes, research and development, laboratory, light manufacturing and related uses which are permitted under applicable laws including zoning ordinances, the covenants, conditions and restrictions for Menlo Business Park, and the City of Menlo Park and for no other use without the Lessor&#8217;s prior written consent. Notwithstanding the preceding, the manufacture of integrated circuits using any caustic or toxic substance which poses a meaningful risk of accelerated deterioration or damage to the Building is expressly prohibited. Any use of the Premises by Lessee or by any sublessee or assignee approved by Lessor pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall comply with the provisions of this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> Paragraph 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; as used in this Lease shall include any substance defined or regulated as radioactive, flammable, toxic, a biohazard, medical waste, &#8220;hazardous material&#8221;, &#8220;extremely hazardous material&#8221;, &#8220;hazardous waste&#8221;, &#8220;hazardous substance,&#8221; &#8220;toxic substance,&#8221; &#8220;industrial process waste,&#8221; or &#8220;special waste&#8221; in any Environmental Laws as hereafter defined. Hazardous Materials shall include, but not be limited to, petroleum, gasoline, natural gas, natural gas liquids, liquefied natural gas, synthetic gas, and&#47;or crude oil or any products, by-products or fractions thereof.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)Lessee shall not engage in any activity in or on the Premises or the Property which constitutes a Reportable Use of Hazardous Materials without the express prior written consent of Lessor and timely compliance (at Lessee&#8217;s expense) with all Environmental Laws. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Reportable Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean (i) the installation or use of any above or below ground storage tank, (ii) the generation, possession, storage, use, transportation, or disposal of Hazardous Materials that require a permit from, or with respect to which a report, notice, registration or business plan is required to be filed with, any governmental authority, and&#47;or (iii) the presence at the Premises or the Property of Hazardous Materials with respect to which any Environmental Law requires that a notice be given to persons entering or occupying the Premises, or the Property, or neighboring properties. Notwithstanding the foregoing, subject to the provision of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 2(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (including the requirement that Lessee shall obtain a Haz Mat CUP from the City before Lessee maintains on the Premises five (5) gallons or more of any Hazardous Materials) Lessee may use the Hazardous Materials on the Premises that are listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit &#8220;E&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attached hereto and incorporated by reference herein, and any ordinary and customary office supplies, cleaning materials, and other materials reasonably required to be used in the normal course of Lessee&#8217;s agreed use of the Premises, so long as any such use is in compliance with all Environmental Laws, and does not expose the Premises, the Property, or neighboring property to any meaningful risk of contamination or damage. In addition, Lessor may condition its consent to any Reportable Use upon receiving such additional assurances as Lessor reasonably deems necessary to protect itself, the public, the Premises and the Property, and&#47;or the environment against damage, contamination, injury and&#47;or liability, including, but not limited to, the installation (and removal on or before Lease expiration or termination) of any protective modifications installed by Lessee (such as concrete encasements). Lessor shall be entitled to request a copy of Lessee&#8217;s Hazardous Materials Business Plan at any time during the Lease Term and Lessee shall provide such Plan to Lessor within five (5) business of such request.</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean and include any Federal, State, or local statute, law, ordinance, code, rule, regulation, order, or decree regulating, relating to, or imposing liability or standards of conduct concerning, any hazardous, toxic, or dangerous waste, substance, element, compound, mixture or material, as now or at any time hereafter in effect including, without limitation, California Health and Safety Code &#167;&#167;25100 et seq., &#167;&#167;25300 et seq., Sections 25281(f) and 25501 of the California Health and Safety Code, Section 13050 of the Water Code, the Federal Comprehensive Environmental Response, Compensation and Liability Act, as amended, 42 U.S.C. &#167;&#167;9601 et seq. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CERCLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Superfund Amendments and Reauthorization Act, 42 U.S.C. &#167;&#167;9601 et seq., the Federal Toxic Substances Control Act, 15 U.S.C. &#167;&#167;2601 et seq., the Federal Resource Conservation and Recovery Act as amended, 42 U.S.C. &#167;&#167;6901 et seq., the Federal Hazardous Material Transportation Act, 49 U.S.C. &#167;&#167;1801 et seq., the Federal Clean Air Act, 42 U.S.C. &#167;7401 et seq., the Federal Water Pollution Control Act, 33 U.S.C. &#167;1251 et seq., the River and Harbors Act of 1899, 33 U.S.C. &#167;&#167;401 et seq., and all rules and regulations of the EPA, the California Environmental Protection Agency, or any other state or federal department, board or any other agency or governmental board or entity having jurisdiction over the environment, as any of the foregoing have been, or are hereafter amended.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)If Lessee knows, or has reasonable cause to believe, that Hazardous Materials have come to be located in, on, under or about the Premises or the Property, other than as previously consented to by Lessor or otherwise permitted under this Lease, Lessee shall promptly give written notice of such fact to Lessor and provide Lessor with a copy of any report, notice, claim or other documentation which it has concerning the presence of such Hazardous Materials. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)Lessee and Lessee&#8217;s agents, employees, and contractors shall not cause any Hazardous Materials to be discharged or released into the Building or into the plumbing or sewage system of the Building or into or onto the Land underlying or adjacent to the Building in violation of any Environmental Laws. Lessee shall promptly, at Lessee&#8217;s expense, take all investigatory and&#47;or remedial action reasonably recommended, whether or not formally ordered or required, for the cleanup of any contamination in violation of Environmental Laws or the terms of this Lease caused by Lessee or caused by any of Lessee&#8217;s employees, agents, or contractors, and for the maintenance, security and&#47;or monitoring of the Premises, the Property, or neighboring properties if such contamination is caused by a release or emission of any Hazardous Materials by Lessee or by any of Lessee&#8217;s employees, agents, or contractors. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Work Letter, Lessee shall indemnify, defend and hold Lessor and its agents, employees, and lenders and the Premises and the Property harmless from any and all claims, damages, fines, judgments, penalties, costs, liabilities or losses (including, without limitation, any and all sums paid for settlement of claims, attorneys&#8217; fees, consultant and expert fees) arising during or after the term of this Lease out of or involving any Hazardous Materials brought on to the Premises, the Property, or Menlo Business Park by or for Lessee or by anyone under Lessee&#8217;s control in violation of Environmental Laws or the terms of this Lease. Lessee&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 10(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall include, but not be limited to, the effects of any contamination or injury to person, property or the environment created or </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suffered by Lessee, and the cost of investigation (including consultants&#8217; and attorneys&#8217; fees and testing), removal, remediation, restoration and&#47;or abatement thereof, or of any contamination therein involved, as required by Environmental Laws, and shall survive the expiration or earlier termination of this Lease. No termination, cancellation or release agreement entered into by Lessor and Lessee shall release Lessee from its obligations under this Lease with respect to Hazardous Materials, unless specifically so agreed by Lessor in writing at the time of such agreement.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)Lessor represents and warrants to Lessee that prior to the execution of this Lease, Lessor delivered to Lessee the most recent Phase I environmental report, dated December 2014, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 1 Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) on the Building. To Lessor&#8217;s actual knowledge, except as otherwise provided in the Phase 1 Report, Lessor represents and warrants to Lessee that no Hazardous Materials currently exist in, on or under any portion of the Premises in violation of applicable environmental law. For purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 10(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Lessor&#8217;s actual knowledge&#8221; shall mean the current actual knowledge of John C. Tarlton, President of Tarlton Properties, Inc., without any duty to make investigation or inquiry. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes on Lessee&#8217;s Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessee shall pay before delinquency any and all taxes, assessments, license fees, and public charges levied, assessed, or imposed and which become payable during the Term and any extension thereof upon Lessee&#8217;s equipment, fixtures, furniture, and personal property installed or located in the Premises or on the Property.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)Lessee shall, at Lessee&#8217;s sole cost and expense, provide and keep in force commencing with the Commencement Date of the Term and continuing during the Term, (i) a commercial general liability insurance policy with a recognized casualty insurance company qualified to do business in California, insuring against liability occasioned by any occurrence in, on, about, or related to the Premises, or arising out of the condition, use, occupancy, alteration or maintenance of the Premises and covering the contractual liability referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 13(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Lease, having a combined single limit for both bodily injury and property damage in an amount not less than One Million Dollars ($1,000,000) per occurrence and Two Million Dollars ($2,000,000) annual aggregate, and with excess umbrella liability insurance of not less than Six Million Dollars ($6,000,000.00) (limits requirement may be met through a combination of primary and excess&#47;umbrella liability policies)&#59; (ii) an &#8220;all risk&#8221; or &#8220;Special Cause of Loss&#8221; property policy on all of its equipment, trade fixtures, inventory, fixtures, and personal property in, on or about the Premises including but not limited to Lessee&#8217;s Property described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit &#8220;G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and all alterations made by Lessee or Lessor following the Commencement Date hereof within the Premises in an amount not less than one hundred percent (100%) of the full replacement cost valuation&#59; (iii) workers&#8217; compensation insurance, as required by law and employers&#8217; liability insurance with a limit of not less than One Million Dollars ($1,000,000.00) per accident and per disease with a One Million Dollar ($1,000,000.00) disease limit each employee, (iv) boiler and machinery insurance&#59; (v) business interruption insurance in such amounts as will reimburse Lessee for direct and indirect loss of earnings and incurred costs attributable to the perils commonly covered by Lessee&#8217;s property insurance described above but in no less than One Million Dollars ($1,000,000), and (vi) such other types and amounts of </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insurance as Lessor or its lender may reasonably require which are customarily required of comparable tenants of comparable buildings in the vicinity of the Building&#59; provided, however, the Lessor&#8217;s right to require new or additional coverage or increase policy limits under this clause (vi) shall not be exercised more than three (3) times in total during the initial 132 month Term of the Lease. All such insurance carried by Lessee shall be in a form reasonably satisfactory to Lessor and its mortgage lender and shall be carried with companies that have a general policyholder&#8217;s rating of not less than &#8220;A&#8221; and a financial rating of not less than Class &#8220;X&#8221; in the most current edition of Best&#8217;s Insurance Reports or such similar rating as may be reasonably selected by Lessor. Lessee shall endeavor in good faith to cause its commercial general liability policy to provide that the insurer shall endeavor give Lessor thirty (30) days prior written notice of any cancellation. Lessee shall not reduce any of its insurance coverages required in (i) through (vi) above below the minimum amount(s) required by this Lease or cancel such insurance except after at least thirty (30) days&#8217; prior written notice to Lessor by Lessee, provided however, that if such notice is first received from Lessee&#8217;s commercial general liability carrier as requested above, Lessee need not provide a second notice of the same cancellation. On or before the earlier to occur of (i) the date on which any Lessee party first enters the Premises for any reason, including, without limitation prior to the Early Entry, or (ii) the Commencement Date and upon renewal of such policies not less than five (5) days prior to the expiration of the term of such coverage, Lessee shall deliver to Lessor certificates of insurance confirming such coverage and that all insurance requirements set forth herein have been met. Notwithstanding the preceding, if Lessee does not provide a certificate evidencing renewal at least five (5) days in advance of the expiration date of the term of any insurance coverage, Lessor will agree to accept such a certificate from Lessee&#8217;s insurance carrier within five (5) days following the expiration of the term and renewal of the policy&#59; provided that Lessee first obtains, not less than ten (10) days prior to the expiration of the term of such coverage, from its insurance broker, a letter addressed to Lessor certifying to Lessor that Lessee intends to renew such coverage and is taking such action as are reasonably necessary to renew its policy(ies) in question prior to the expiration of any such coverage. To the fullest extent permitted by law, the commercial general liability and property insurance policies required to be carried by Lessee hereunder shall include Menlo Park Portfolio II, LLC and Tarlton Properties, Inc. as &#8220;Additional Insured&#8221;, c&#47;o Tarlton Properties, Inc., 1530 O&#8217;Brien Drive, Suite C, Menlo Park, CA 94025, and such other persons as Lessor may reasonably request from time to time as additional insureds with respect to liability arising out of this Lease or the operations of Lessee by ISO form is CG 2011 01 96 or its equivalent (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Additional Insureds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) or as loss payee, as applicable. Such insurance shall provide primary coverage without contribution from any other insurance carried by or for the benefit of Lessor, Lessor&#8217;s property manager, or other Additional Insured and Lessor&#8217;s insurance shall be in excess thereto. In no event shall the limits of such insurance be considered as limiting the liability of Lessee under this Lease. If Lessee fails to procure and maintain the insurance required hereunder, Lessor may, but shall not be required to, order such insurance at Lessee&#8217;s expense and Lessee shall reimburse Lessor for all costs incurred by Lessor with respect thereto. Lessee&#8217;s reimbursement to Lessor for such amounts shall be deemed Additional Rent, and shall include all sums disbursed, incurred or deposited by Lessor, including Lessor&#8217;s costs, expenses and reasonable attorneys&#8217; fees with interest thereon at the Interest Rate. </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)Lessor shall obtain and carry in Lessor&#8217;s name, as insured, as an Operating Expense of the Property as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, during the Term, &#8220;all risk&#8221; property </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insurance coverage (with rental loss insurance coverage for a period of one year), flood insurance, public liability and property damage insurance, and Lessor may obtain and carry insurance against such other risks or casualties as Lessor shall reasonably determine, including, but not limited to, insurance coverages required of Lessor by the beneficiary of any deed of trust which encumbers the Property, including earthquake insurance coverage insuring Lessor&#8217;s interest in the Property in amounts deemed reasonable by Lessor or its lender from time to time. The proceeds of any such insurance shall be payable solely to Lessor, and Lessee shall have no right or interest therein. Lessor shall have no obligation to insure against loss by Lessee to Lessee&#8217;s equipment, fixtures, furniture, inventory, or other personal property of Lessee in or about the Premises occurring from any cause whatsoever. Lessor agrees that its property insurance deductible shall at all times be reasonable and not exceed those of prudent landlords, comparable in size to Lessor, and for comparable buildings in the Bay Area of California.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)Notwithstanding anything to the contrary contained in this Lease, the parties release each other, and their respective authorized representatives, employees, officers, directors, shareholders, managers, members, trustees, beneficiaries, assignees, subtenants, invitees, successors, agents, contractors and property managers, from any claims for damage to the Premises or the Property and to the fixtures, personal property, leasehold improvements and alterations of either Lessor or Lessee in or on the Premises or the Property, to the extent that are caused by or result from risks required by this Lease to be insured against or actually insured against under any property insurance policies carried by the parties and in force at the time of any such damage, whichever is greater. This waiver applies whether or not the loss is due to the negligence (sole, separate or otherwise) of Lessor or Lessee or their respective authorized representatives, employees, officers, directors, shareholders, managers, members, trustees, beneficiaries, assignees, subtenants, invitees, successors, agents, contractors and property managers. Subject to the foregoing, this release and waiver shall be complete and total even if such loss or damage may have been caused by the negligence of the other party, its managers, members, employees, agents, contractors, property managers or invitees. Lessee covenants that the insurance policies required to be maintained by Lessee under this Lease will contain waiver of subrogation endorsements. All of Lessor&#8217;s and Lessee&#8217;s repair and indemnity obligations under this Lease shall be subject to the waiver contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 12(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> excepting any repairs necessitated by the acts or omissions of Lessee, its employees, agents, contractors, sublessees, assigns or invitees if the cost of such repair does not exceed Lessor&#8217;s property coverage deductible&#59; then, in such case, Lessee shall remain liable for either the repair or the cost thereof as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This release and waiver of subrogation does not and shall not apply to any damage to persons or property resulting from any environmental liability of Lessee pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)Subject to the waiver of subrogation set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 12(c) and to Section 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Work Letter, Lessee shall indemnify, defend, and hold harmless Lessor from claims, suits, actions, or liabilities for personal injury, death or for loss or damage to property that arise from (1) any activity, work or thing done by Lessee in the Premises, the Property or the Park or permitted by Lessee in the Premises or on the rooftop equipment pad or on the equipment pads or in the bunkers immediately adjacent to the Premises, to the extent access to </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such pads and bunkers are controlled by Lessee to the same extent Lessee controls access to the Premises, (2) bodily injury or damage to property which arises in or about the Property or the Park to the extent the injury or damage to property results from the actual or alleged acts, omissions or willful misconduct of Lessee, its employees, agents or contractors, and (3) based on any event of default by Lessee in the performance of any obligation on Lessee&#8217;s part to be performed under this Lease. Lessee also waives all claims against Lessor and its employees, agents and contractors for damages to property, or to goods, wares, and merchandise stored in, upon, or about the Premises or the Property, and for injuries to persons in, upon, or about the Premises or the Property from any cause arising at any time, except to the extent caused by the active negligence or willful misconduct by Lessor or its employees, agents or contractors. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)Subject to the waiver of subrogation set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 12(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lessor shall indemnify, defend, and hold harmless Lessee from claims, suits, actions, or liabilities for personal injury, death or for loss or damage to property that arise from bodily injury or damage to property which arises in or about the Property to the extent the injury or damage to property results from the active negligent acts or willful misconduct of Lessor, its employees, agents or contractors. As used herein, &#8220;active negligence&#8221; of any party shall mean that party&#8217;s participation in an affirmative act of negligence, knowledge about or compliance in a negligent act, or failure to perform (after a reasonable period of time) a precise duty which that party is obligated to perform hereunder. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)In the absence of comparative or concurrent negligence on the part of Lessee or Lessor, their respective agents, affiliates, and subsidiaries, or their respective officers, directors, members, employees or contractors, the foregoing indemnities by Lessee and Lessor shall also include reasonable costs, expenses and attorneys&#8217; fees incurred in connection with any indemnified claim or incurred by the indemnitee in successfully establishing the right to indemnity. The indemnitor shall have the right to assume the defense of any claim subject to the foregoing indemnities with counsel reasonably satisfactory to the indemnitee. The indemnitee agrees to cooperate fully with the indemnitor and its counsel in any matter where the indemnitor elects to defend, provided the indemnitor shall promptly reimburse the indemnitee for reasonable costs and expenses incurred in connection with its duty to cooperate.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing indemnities shall survive the expiration or earlier termination of this Lease and are conditioned upon the indemnitee providing prompt notice to the indemnitor of any claim or occurrence that is likely to give rise to a claim, suit, action or liability that will fall within the scope of the foregoing indemnities, along with sufficient details that will enable the indemnitor to make a reasonable investigation of the claim.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the claim is caused by the joint negligence or willful misconduct of Lessee and Lessor or by the indemnitor party and a third party unrelated to the indemnitor party (except indemnitor&#8217;s agents, officers, employees or invitees), the indemnitor&#8217;s duty to indemnify and defend shall be proportionate to the indemnitor&#8217;s allocable share of joint negligence or willful misconduct.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)Lessor shall not be liable to Lessee for any damage caused by any act or negligence of any other occupant of the Building or any other owner or occupant of adjoining or </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contiguous property, nor for overflow, breakage, or leakage of water, steam, gas, or electricity from pipes, wires, or otherwise in the Premises or the Building, except to the extent caused by the gross negligence or willful misconduct by Lessor or Lessor&#8217;s employees, agents, or contractors. Except as otherwise provided herein, Lessee will pay for damage to the Premises or the Property caused by the misuse or neglect of the Premises or the Property by Lessee or its employees, agents, contractors, assigns or subtenants, including but not limited to, the breakage of glass in the Building. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warm Shell Work&#59; Market Ready Improvements&#59; Tenant Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)Lessor shall cause to be constructed the improvements and modifications to the Premises and the Building (i) described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-1&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-2&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Work Letter attached hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Warm Shell Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), (ii) as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-4&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Work Letter (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Market Ready Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Tenant Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Warm Shell Work, the Market Ready Improvements and the Tenant Improvements are collectively referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The costs of the Warm Shell Work shall be paid for by Lessor. The cost of BMR fees assessed by the City of Menlo Park associated with the Work (but not any alterations or improvements made by Lessee after the Commencement Date) shall be paid for by Lessor. The costs of the Market Ready Improvements and the Tenant Improvements shall be shared by Lessor and Lessee as set forth herein and in the Work Letter. Lessor agrees to pay the costs (y) to complete the Market Ready Improvements up to the total amount of Nine Million Nine Hundred Thousand Dollars ($9,900,000.00) which amount equates to Fifty-Five Dollars ($55.00) per rentable square foot of the Premises (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Lessor&#8217;s Contribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and (z) to complete the Tenant Improvements up to a total amount of Two Million Seven Hundred Thousand ($2,700,000.00) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Tenant Improvement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, that any amounts remaining in each allowance can be used for either category of work. Lessor shall disburse Lessor&#8217;s Contribution and the Tenant Improvement Allowance, as applicable, directly to the applicable design professionals, contractors, materialmen or other laborers in connection with the construction of the Market Ready Improvements and the Tenant Improvements. At Lessee&#8217;s election made by written notice to Lessor at any time prior to Lessor&#8217;s execution of the Construction Contract (as defined in the Work Letter), Lessee may re-allocate the dollar amounts attributable to a particular line item in the budget for the Warm Shell Work as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-2&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Work Letter attached hereto, for use of such amounts towards the completion of a similar line item of work in the budget for the Market Ready Improvements and Tenant Improvements as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-4&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Work Letter attached hereto&#59; provided, however, that Lessee shall not be permitted to exercise such re-allocation rights with respect to any structural portions of the Work or for any portion of the Work that is related to the exterior of the Building. If Lessee elects to re-allocate any dollar amounts from the Warm Shell Work as set forth in the immediately preceding sentence, then the parties hereby agree and acknowledge that thereafter Lessor shall have no obligation to complete such item of the Warm Shell Work attributable to the funds re-allocated by Lessee and the definition of the Warm Shell Work shall be deemed so amended and Lessor&#8217;s Contribution shall be increased by such re-allocated amount. Except as otherwise provided herein or in the Work Letter, Lessee shall be liable for all fees and costs of the design and construction of the Market Ready Improvements and the Tenant Improvements in excess of the Lessor&#8217;s Contribution and the Tenant Improvement Allowance (such amount referred to herein </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Tenant Improvement Shortfall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Lessee shall pay the Tenant Improvement Shortfall upon written request from Lessor accompanied by invoices reflecting such amounts due within thirty (30) days following Lessor&#8217;s delivery of such payment request as more particularly described in the Work Letter. The Tenant Improvement Shortfall shall be invoiced and paid monthly as the construction costs are incurred during construction in proportion to the amount of Landlord&#8217;s Contribution and the Tenant Improvement Allowance combined fall short of the Final Budget cost. By way of example only, if the total project costs are budgeted to be Twenty Million Dollars ($20,000,000.00), Lessee&#8217;s Tenant Improvement Shortfall percentage would be thirty seven percent (37%) and Lessee would be invoiced thirty-seven percent (37%) of the actual construction costs each month commencing with the first invoices following Lessor&#8217;s completion of the Warm Shell Work. Following completion of the Work and final determination of the cost of the Work and the Tenant Improvement Shortfall, the parties shall review and reconcile any underpayments or overpayments by Lessee of the Tenant Improvement Shortfall. Lessor shall employ Tarlton Properties, Inc. as construction manager for the Tenant Improvements at a fee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Lessor Supervision Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) equal to four percent (4%) of hard construction costs of the Market Ready Improvements and the Tenant Improvements (i.e., the amounts paid to any general contractor, subcontractors, vendors, and suppliers for labor and materials for the construction of the Market Ready Improvements and the Tenant Improvements). The Work shall be constructed on an &#8220;open book&#8221; basis and Lessee shall have the right to reasonably audit and inspect all relevant costs, books and records related to the Work in Lessor&#8217;s office during normal business hours upon not less than forty-eight hours&#8217; advance written notice to Lessor. Lessee must complete its final audit and review within thirty (30) days of Lessor&#8217;s payment of final invoices for the Work. </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)The Work shall be constructed in accordance with all Applicable Laws and the terms of this Lease, in a good and workmanlike manner and using new materials and equipment of good quality. Upon delivery of the Premises to Lessee, Lessor and Lessee shall coordinate a walk-through of the Premises and Lessor and Lessee shall complete a punch list indicating any deficiencies in the Work (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Punch List</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Lessor shall cause such items set forth in the Punch List to be completed within a reasonable period of time thereafter as may be required for compliance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedules &#8220;F-1&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F-2&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the Work Letter. Lessor agrees to (i) use reasonable efforts to assign any assignable warranties or guaranties provided by the contractors or manufacturers of equipment to be maintained by Lessee pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (if any) provided as part of the Work to Lessee or, at Lessee&#8217;s option, to enforce same with respect to any defect discovered in such equipment within one (1) year after the Commencement Date and (ii) to enforce all other warranties or guaranties with respect to any defect discovered in the Work within one (1) year after the Commencement Date. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)Lessee waives all right to make repairs at the expense of Lessor, or to deduct the costs thereof from the Rent, and Lessee waives all rights under Section 1941 and 1942 of the Civil Code of the State of California. At the expiration or sooner termination of this Lease, Lessee shall surrender the Premises in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, except for ordinary wear and tear, damage caused by casualty, and alterations or other improvements made by Lessee with Lessor&#8217;s prior written consent which Lessee is not required to remove.</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)Lessee shall have no responsibility for and neither Lessor&#8217;s Contribution nor the Tenant Improvement Allowance shall be used for the following&#58; (a) costs for improvements which are not shown on or described in the Tenant Improvement Documents unless otherwise approved by Lessee in a Change Order (except for Lessee&#8217;s obligation to share any fire-proofing costs, if required)&#59; (b) costs to complete the Warm Shell Work&#59; (c) costs incurred due to the presence of Hazardous Materials in the Premises, the Property or the surrounding area present as of the Effective Date&#59; (d) attorneys' fees incurred in connection with negotiation of construction contracts, and attorneys' fees, experts' fees and other costs in connection with disputes with third parties&#59; (e) interest and other costs of financing construction costs&#59; (f) costs recovered by Lessor upon account of warranties and insurance&#59; (g) restoration costs in excess of insurance proceeds as a consequence of casualties&#59; (h) provided Lessee promptly pays its Tenant Improvement Shortfall as and when invoiced, and for any increases in costs resulting from Tenant Delays or Change Orders, penalties and late charges attributable to Lessor's failure to pay construction costs for which Lessor is responsible hereunder (not including any costs associated with construction, installation or equipment directly contracted for by Lessee)&#59; (i) costs incurred as a consequence of Lessor Delay, (j) any fees or general conditions of the General Contractor (defined in the Work Letter) in excess of&#58; </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Division 1 (including&#58; supervision and general conditions and other overhead) by percentage&#58; 5.04% </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Contractor's fee by percentage&#58; 3.75%</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or (k) any third party fees, costs, overhead, management or supervision fees of Lessor or its affiliates other than the Lessor Supervision Fee. Lessor agrees to use commercially reasonable efforts to enforce the terms of the Lessor&#8217;s construction contracts during the course of construction. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)Lessor and Lessee have agreed that Lessor shall pay for fifty percent of the cost of fire-proofing, if any, required in the Premises, as part of the Warm Shell Work, and, Lessor shall pay for the remaining fifty percent (50%) of such fireproofing cost from the Lessor&#8217;s Contribution for Market Ready Improvements.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Maintenance and Repairs&#59; Alterations&#59; Surrender and Restoration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)Lessor shall, at Lessor&#8217;s sole expense, keep in good order, condition, and repair and replace when necessary, the structural elements of the roof (excluding the roof membrane which Lessor shall maintain, but the cost of which shall be included as an Operating Expense as permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the structural elements of the foundation and exterior walls (except the interior faces thereof) of the Building, and other structural elements of the Building and the Property as &#8220;structural elements&#8221; are defined in building codes applicable to the Building, excluding any alterations, structural or otherwise, made by Lessee to the Building which are not approved in writing by Lessor prior to the construction or installation thereof by Lessee. Subject to any termination right in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, below, Lessor shall perform and construct, and Lessee shall not be responsible for performing or constructing, any repairs, maintenance, or improvements (1) required as a result of any casualty damage except to the extent caused by Lessee, its employees, agents, contractors, assigns, sublessee or invitees up to </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the amount of Lessor&#8217;s deductible, which shall be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below, or as a result of any taking pursuant to the exercise of the power of eminent domain, or (2) for which Lessor has a right of reimbursement from third parties based on construction or other warranties, contractor guarantees, or insurance claims. </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)Lessor shall provide or cause to be provided and shall supervise the performance of, as an Operating Expense of the Property as permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof, all services and work relating to the operation, maintenance, repair, and replacement, as needed, of the Property, HVAC, mechanical, electrical and plumbing systems in the Building&#59; the interior of the Building&#59; the roof membrane&#59; the outside areas of the Property&#59; landscaping, tree trimming, resurfacing and restriping of the parking lot, repairing and maintaining the walkways&#59; exterior building painting, exterior building lighting, parking lot lighting, and exterior security patrol. In the event Lessee provides Lessor with written notice of the need for any repairs, Lessor shall commence any such repairs promptly following receipt by Lessor of such notice and Lessor shall diligently prosecute such repairs to completion. Lessor shall make available during normal business hours for Lessee&#8217;s review and copy, Lessor&#8217;s service, maintenance, repair and replacement records, such records to be located at the office of Lessor in the Menlo Business Park.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the preceding, subject to Lessee&#8217;s satisfactory performance of the obligations described herein below in Lessor&#8217;s sole but reasonable discretion and subject to the conditions provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, below, so long as (x) Pacific Biosciences of California, Inc. or any Permitted Transferee (provided that in the case of a Permitted Transferee, the senior personnel in charge of the Systems Repairs (as defined below) shall remain the same before and after the Permitted Transferee becomes the named entity under the Lease) remains the named tenant entity under this Lease, (y) occupies and operates its business in not less than 51% of the Premises, and (z) if any sublease exists, so long as Pacific Biosciences of California, Inc. remains one hundred percent (100%) responsible for all service, maintenance, repair and replacement of the systems set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(b)(i) and (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, below, for the entirety of the Premises whether subleased or not, (the items set forth in Subsections (x), (y) and (z) collectively referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maintenance Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the parties agree that Lessee shall directly assume responsibility for, contract directly with any service providers for, and pay directly for the following (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Systems Repairs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) all service, maintenance, repair and replacement of heating, ventilation, air conditioning, mechanical and electrical systems within the Premises or serving the Premises from the rooftop pad or the equipment pads immediately adjacent to the Premises&#59; and,</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) all service, maintenance, repair and replacement of plumbing and interior sewage systems within the Premises.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further notwithstanding Lessee&#8217;s assumption of responsibility under Paragraph </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">15(b)(i) and (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, above, Lessor, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lessee, shall throughout the Term of the Lease, maintain all fire systems including the wet system (including the P.I.V.) and the fire alarm monitoring system, the electrical incoming switch gear (including the main switch gear), the Building </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">envelope, all back flow systems and the elevator. All such costs shall be included in Operating Expenses, subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessee&#8217;s right to perform such service, maintenance, repair and replacement as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(b)(i) and (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is non-transferable as more particularly described below.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)Subject to the foregoing and except as provided elsewhere in this Lease, Lessee shall at all times use and occupy the Premises and maintain the systems described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(b)(i) and (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, above, in a manner which keeps the Premises in good and safe order, condition, and repair, including the performance of all regularly scheduled service as required by any manufacturer&#8217;s recommended service plan and&#47;or required for the maintenance of any warranty provided by such manufacturer. Lessor may, at Lessor&#8217;s reasonable discretion, obtain on an annual basis an inspection report of the HVAC system from a separate HVAC service firm designated by Lessor for the purpose of monitoring the performance of the HVAC maintenance and repair work performed by the HVAC service firm which performs the regular repair and maintenance. The cost of such inspection report shall be an Operating Expense pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to the release of claims and waiver of subrogation contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraphs 12(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">13(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if Lessor is required to make any repairs to the Property by reason of Lessee&#8217;s negligent acts or omissions, Lessor may add the cost of such repairs to the next installment of Rent which shall thereafter become due, and Lessee shall promptly pay the same upon receipt of an invoice therefor. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If at any time after the first (1st) anniversary of the Commencement Date, Pacific Biosciences of California, Inc. (the named tenant hereunder) (i) assigns this Lease by operation of law or otherwise other than to a Permitted Transferee, (ii) fails to provide copies of all service contracts and all service, maintenance, repair and replacement records (whether performed by Lessee&#8217;s trained and certified personnel or by outside vendors) with respect to Systems Repairs required to be performed by Lessee in the Premises to Lessor on a timely basis, without necessity of request therefor, (iii) fails to require that all vendors maintain insurance reasonably satisfactory to Lessor naming Lessor and the Additional Insureds named in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as &#8220;Additional Insured&#8221;, (iv) fails to perform the Systems Repairs in accordance with the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (v) fails to provide such service, maintenance, repair or replacement at quality and frequency levels at least equal to the quality and frequency levels Lessor would maintain if it were providing such services (as evidenced by Lessor&#8217;s maintenance of the balance of the Menlo Business Park), or (vi) fails to satisfy any of the Maintenance Requirements, and following such breach Lessee fails to commence a cure of any breach of the obligations set forth in (ii), (iii), (iv), (v) or (vi) within five (5) business days after receipt of written notice from Lessor and, thereafter, to diligently prosecute the cure to completion three (3) or more times in a twelve (12) month period then, the Parties agree that Lessor may, in its discretion, elect to assume or resume responsibility for maintenance, repair and replacement of the systems described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">(ii),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above, and include the cost in Operating Expenses as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding the cure period set forth in the immediately preceding sentence, the parties hereby agree and acknowledge that if Lessee fails more than once in a twelve (12) month period to cure a breach of any of the obligations set forth in (ii), (iii), (iv), (v) or (vi) within a reasonable time after receipt of written notice from Lessor, then Lessor may elect to assume or resume responsibility for maintenance, </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">repair and replacement of the systems as set forth herein. Any such election by Lessor shall be effective immediately upon written notice to the Lessee of Lessor&#8217;s intent to assume or resume such service, maintenance, repair and replacement. Any Lessor notice referred to above must set forth in reasonable detail the nature and extent of the failure referencing pertinent Lease provisions. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All vendors selected by Lessee in the performance of its service, maintenance and repair obligations hereunder shall be from Lessor&#8217;s approved vendor list. Lessee agrees to provide Lessor with a copy of Lessee&#8217;s internal maintenance programs and procedures within ten (10) days of the Commencement Date hereof, and again at any time upon receipt of Lessor&#8217;s request therefor. Lessor and Lessee shall schedule a joint inspection of the Premises not less than once per calendar year for the purpose of verifying that all service, repairs, maintenance and replacements performed by Lessee hereunder are being performed in a reasonable and satisfactory manner. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)Lessee shall not install or construct any alterations, improvements or additions without the prior written consent of Lessor, which consent shall not be unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, Lessee may, from time to time, at its own cost and expense and without the consent of Lessor (but with advance notice to Lessor) make nonstructural alterations to the interior of the Premises provided that&#58; (i) such alterations do not affect or penetrate the structural portions of the Premises or the Building, the roof or exterior appearance of the Premises or Building or materially and adversely affects any mechanical, electrical, plumbing, sewer, life safety, HVAC or other system in the Building&#59; (ii) such alterations do not require a building permit or other governmental authorization&#59; (iii) the cost of which in any one instance or in any one calendar year is Thirty Thousand and 00&#47;100 Dollars ($30,000.00) or less, further provided Lessee (1) first notifies Lessor in writing of any such alterations at least fifteen (15) days prior to commencing any such work&#59; and (2) such alterations otherwise comply with the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and all Rules and Regulation, Building regulations and Lessor&#8217;s engineering and design requirements for the Building, as applicable (such alterations hereinafter (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Permitted Alterations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Except for Permitted Alterations, Lessee shall not make any additional alterations, improvements, or additions to the Premises without delivering to Lessor a complete set of plans and specifications for such work, obtaining and delivering copies to Lessor of all permits or other governmental approvals required for such work and obtaining Lessor&#8217;s prior written consent thereto, which consent shall not be unreasonably delayed, conditioned or withheld. All alterations and additions shall be installed by Lessee&#8217;s employees or by a licensed contractor approved by Lessor, at Lessee's sole expense in compliance with all Applicable Laws, rules, regulations and ordinances. Lessee shall keep the Premises and the Property on which the Premises are situated free from any liens arising out of any work performed, materials furnished or obligations incurred by or on behalf of Lessee. If any Permitted Alterations or other non-structural alterations to the interior of the Premises exceed Thirty Thousand and 00&#47;100 Dollars ($30,000.00) in any one instance or in any calendar year, Lessee shall employ, at Lessee&#8217;s expense, Tarlton Properties, Inc. as construction manager for such alterations at a fee equal to five percent (5%) of the first Two Hundred Fifty Thousand Dollars ($250,000.00) of hard construction costs (i.e., the amounts paid to any general contractor, subcontractors, vendors, and suppliers for labor and materials for the construction of the alterations or improvements) and then four percent (4%) of such hard construction costs in </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">excess of Two Hundred Fifty Thousand Dollars ($250,000.00). Lessor may condition its consent to, among other things, Lessee agreeing in writing to remove any such alterations prior to the expiration of the Lease Term and Lessee agreeing to restore the Premises to its condition prior to such alterations at Lessee&#8217;s expense. For alterations requiring Lessor&#8217;s consent, Lessor shall have no right to require Lessee to remove alterations unless Lessor shall advise Lessee in writing at the time consent is granted whether Lessor will require Lessee to remove any alterations from the Premises prior to the expiration or sooner termination of this Lease. Lessee agrees that Lessor may obtain updated architectural drawings, in each and every instance of an alteration to the Building performed by or on behalf of Lessee, and Lessee agrees to reimburse Lessor for the cost to update architectural plans and drawings within thirty (30) days of receipt of invoice therefor.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessor and Lessee shall schedule a joint inspection of the Premises not less than once per calendar year for the purpose of verifying that all alterations made by Lessee within the Premises are in fact Permitted Alterations and have been performed in accordance with the requirements provided above. Notwithstanding anything to the contrary contained herein, if Lessee performs alterations in the Premises which required Lessor&#8217;s advance written consent when none was obtained, which required a building permit or other governmental authorization when none was obtained or otherwise failed to comply with the requirements of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(d),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> then Lessor may revoke Lessee&#8217;s right to perform Permitted Alterations without first obtaining Lessor&#8217;s prior written consent, in each instance, which consent shall not be unreasonably withheld, conditioned or delayed.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All alterations, trade fixtures, equipment and personal property installed in the Premises solely at Lessee&#8217;s expense, including, without limitation, the items described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit &#8220;G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; attached hereto, (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Lessee&#8217;s Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) shall during the term of this Lease remain Lessee&#8217;s property and Lessee shall be entitled to all depreciation, amortization and other tax benefits with respect thereto (as to the cost of the Work paid for by Lessee). Upon the expiration or sooner termination of this Lease, all alterations, fixtures and improvements to the Premises, whether made by Lessor or installed by Lessee at Lessee&#8217;s expense, shall be surrendered by Lessee with the Premises and shall become the property of Lessor&#59; provided, however, that Lessee&#8217;s Property may be removed by Lessee. Lessee shall repair to Lessor&#8217;s reasonable satisfaction all damage to the Premises occasioned by removal of Lessee&#8217;s Property. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)Lessee shall, at Lessee&#8217;s sole cost and expense, fully, diligently and in a timely manner, comply with all present and future &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; which term is used in this Lease to mean all laws, rules, regulations, ordinances, directives, orders, covenants, permits of all governmental agencies and authorities, easements and restrictions of record, the requirements of any applicable fire insurance underwriter or rating bureau or board of fire underwriters relating in any manner to the Premises and&#47;or with respect to Lessee&#8217;s use or occupancy of the Premises (including but not limited to matters pertaining to industrial hygiene, environmental conditions on, in, under or about the Premises, including soil and groundwater conditions, subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof, and the use, generation, manufacture, production, installation, maintenance, removal, transportation, storage, spill, or release of any Hazardous Materials (which are addressed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof)), now in effect or which may hereafter come into effect. Lessee shall, within five (5) days after receipt of </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessor&#8217;s written request, provide Lessor with copies of all documents and information, including but not limited to permits, registrations, manifests, applications, reports and certificates, evidencing Lessee&#8217;s compliance with any Applicable Laws specified by Lessor, and shall immediately upon receipt, notify Lessor in writing (with copies of any documents involved) of any threatened or actual claim, notice, citation, warning, complaint or report pertaining to or involving failure by Lessee or the Premises to comply with any Applicable Laws. Notwithstanding the foregoing, any changes or repairs to the Property of any nature which would be considered a capital expenditure under generally accepted accounting principles to the Premises shall be made by Lessor at Lessee&#8217;s expense if such repairs or changes are required by reason of the specific nature of the use of the Premises by Lessee. If such changes or repairs are not required by reason of the specific nature of Lessee&#8217;s use of the Premises and are capital expenditures, the cost of such changes or repairs shall be treated as an Operating Expense and amortized in accordance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lessor, Lessor&#8217;s agents, employees, contractors and designated representatives, and the holders of any mortgages, deeds of trust or ground leases on the Premises (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) shall have the right to enter the Premises at any time in the case of an emergency, and otherwise at reasonable times on not less than twenty-four (24) hours&#8217; notice, for the purpose of inspecting the condition of the Premises and for verifying compliance by Lessee with this Lease and all Applicable Laws, and Lessor shall be entitled to employ experts and&#47;or consultants in connection therewith to advise Lessor with respect to Lessee&#8217;s activities, including but not limited to Lessee&#8217;s installation, operation, use, monitoring, maintenance, or removal of any Hazardous Substance on or from the Premises. The costs and expenses of any such inspections shall be paid by the party requesting same, unless a default or breach of this Lease by Lessee or a violation of Applicable Laws or a contamination, caused or materially contributed to by Lessee, is found to exist or to be imminent, or unless the inspection is requested or ordered by a governmental authority as the result of any such existing or imminent violation or contamination. In such case, Lessee shall upon request reimburse Lessor or Lessor&#8217;s Lender, as the case may be, for the costs and expenses of such inspections.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)During the term of this Lease, Lessee shall comply, at Lessee&#8217;s expense, with all of the covenants, conditions, and restrictions affecting the Premises which are recorded in the Official Records of San Mateo County, California, and which are in effect as of the date of this Lease.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)Lessee shall surrender the Premises on or before the last day of the lease Term or any earlier termination date, in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 14(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with all of the improvements to the Premises (including the Tenant Improvements), parts, and surfaces thereof clean and free of debris and in the operating order, condition, and state of repair existing as of the Commencement Date, ordinary wear and tear, the elements, acts of God, casualties, condemnation, alterations or other interior improvements which it is permitted to surrender at the termination of this Lease and repairs that Lessee is not responsible for under this Lease, excepted. Lessee&#8217;s failure to surrender the Premises in accordance with the terms and conditions of this Lease, including, without limitation, this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be deemed to be a material default under the Lease. &#8220;Ordinary wear and tear&#8221; shall not include any damage or deterioration that would have been prevented by good maintenance practice or by Lessee </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performing all of its obligations under this Lease. Notwithstanding the foregoing, prior to the last day of the Term (or earlier termination of the Lease), Lessee shall (i) patch any holes in the walls of the Premises and paint any damaged areas to match the surrounding walls&#59; (ii) replace any broken or damaged ceiling tiles in the Premises&#59; and (iii) vacuum and steam clean all carpets and replace any damaged areas of the carpets to match the surrounding carpet. In addition to the foregoing, the obligations of Lessee shall include the repair of any damage occasioned by the installation, maintenance, or removal of Lessee&#8217;s trade fixtures, furnishings, equipment, and alterations, and the restoration by Lessee of the Premises to its condition upon completion of the Work. Lessee shall not be required to remove the Work but shall remove all personal property, equipment and (A) any Alterations made after the Commencement Date if Lessor provided notice of its requirement of such removal and restoration upon expiration or sooner termination of the Lease term pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the time it consented thereto, or (B) if Lessee made any such alterations, additions, or improvements without obtaining Lessor&#8217;s required prior written consent in breach of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and within a reasonable time after the expiration or sooner termination of the Lease term Lessor gives written notice to Lessee requiring Lessee to perform such removal and restoration. Prior to the expiration of the term of this Lease or any earlier termination date, Lessee shall, at Lessee&#8217;s expense, obtain written closure reports from the San Mateo County Health Department and from the Menlo Park Fire Protection District with respect to any Hazardous Materials used, stored, or released by Lessee on or about the Premises. Both written closure reports shall provide written certification that all Hazardous Materials have been removed from the Premises and that no further action is required in connection with the closure of the Premises. Any removal and remediation of Hazardous Materials by Lessee shall be certified in writing as (1) complete and (2) having been properly performed, by the San Mateo County Health Department and the Menlo Park Fire Protection District and a copy of such written certifications shall be delivered by Lessee to Lessor no later than the last day of the Term of this Lease.</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Utilities and Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)Lessee shall contract for and pay for all separately metered electricity, water and gas, and Lessor shall contract for and pay for, and Lessee shall reimburse Lessor therefor pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as an Operating Expense pursuant to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, all common area electricity, gas, water, sewer, utility and other service charges. Lessee shall contract for and pay for janitorial service, refuse pick-up and any telephone, data or other communications services, any special utilities that serve only the Premises (e.g., distilled water, process gasses, etc.). </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)Lessor shall not be liable to Lessee for any interruption or failure of any utility services to the Building or the Premises unless caused by the active negligence or willful acts of Lessor. Lessee shall not be relieved from the performance of any covenant or agreement in this Lease because of any such failure. Lessor shall make all repairs to the Premises required to restore such services to the Premises and the cost thereof shall be payable by Lessee pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a current Operating Expense, or as a capital improvement which is amortized over its useful life (together with interest thereon) as an Operating Expense in accordance with generally accepted accounting principles as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; provided, however, that Lessee shall have the option to pay for Lessee&#8217;s Pro Rata Share of any such improvement as a </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">single lump-sum payment to avoid future interest costs described therein, and further provided that if such failure is caused by the active negligence or willful acts of Lessor, then Lessor shall bear such costs. Notwithstanding anything to the contrary contained in this Lease, if Lessee is prevented from using, and does not use, the Premises or any portion thereof, for thirty (30) consecutive days (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Eligibility Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), as a result of (i) any failure by Lessor to provide to the Premises any of the essential utilities and services required to be provided by Lessor pursuant to this Lease, or (ii) any failure by Lessor to provide access to the Premises (each failure which shall be an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Interruption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), then Lessee&#8217;s obligation to pay Rent shall be abated, as the case may be, from and after the first (1st) day following the Eligibility Period and continuing until such time that Lessee continues to be so prevented from using, and does not use, the Premises or a portion thereof as a result of the Interruption, in the proportion that the rentable square feet of the portion of the Premises that Lessee is prevented from using, and does not use in the Premises bears to the total rentable square feet of the Premises&#59; provided, however, that Lessee shall only be entitled to such abatement of Rent if the Interruption described in clauses (i) or (ii) of this sentence arises out of or results from Lessor&#8217;s active negligence or willful misconduct&#59; provided, further, that Lessee shall not be entitled to abatement or reduction of Rent to the extent the matters described in clauses (i) or (ii) above arise out of or results from an Interruption outside of Lessor&#8217;s reasonable control. To the extent Lessee shall be entitled to abatement of Rent because of a Casualty pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or a taking pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, then the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 16(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall not apply.</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessee agrees to keep the Premises free from all liens arising out of any work performed, materials furnished, or obligations incurred by Lessee. Lessee shall give Lessor at least ten (10) calendar days prior written notice before commencing any work of improvement on the Premises, the contract price for which exceeds Ten Thousand and 00&#47;100 Dollars ($10,000.00). Lessor shall have the right to post notices of non-responsibility with respect to any such work. If Lessee shall, in good faith, contest the validity of any such lien, claim or demand, then Lessee shall, at its sole expense, defend and protect itself, Lessor and the Property against the same, and shall pay and satisfy any such adverse judgment that may be rendered thereon before the enforcement thereof against the Lessor or the Property. If Lessor shall require, Lessee shall furnish to Lessor a surety bond satisfactory to Lessor in an amount equal to one and one-half times the amount of such contested claim or demand, indemnifying Lessor against liability for the same, as required by law for the holding of the Property free from the effect of such lien or claim.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assignment and Subletting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)Except as otherwise provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lessee shall not assign this Lease, or any interest, voluntarily or involuntarily, and shall not sublet the Premises or any part thereof, or any right or privilege appurtenant thereto, or suffer any other person (the agents and servants of Lessee excepted) to occupy or use the Premises, or any portion thereof, without the prior written consent of Lessor in each instance pursuant to the terms and conditions set forth below, which consent shall not be unreasonably withheld or delayed, subject to the following provisions&#59; provided, however, Lessee shall not assign this Lease, or any interest, voluntarily or involuntarily, and shall not sublet the Premises or any part thereof, or any right or privilege appurtenant thereto, or suffer any other person (the agents and servants of Lessee excepted) to </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">occupy or use the Premises, or any portion thereof, if Lessee shall be in default under this Lease past any applicable cure period.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)Prior to any assignment or sublease which Lessee desires to make, other than a Permitted Transfer (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 18(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below), Lessee shall provide to Lessor the name and address of the proposed assignee or sublessee, and true and complete copies of all documents relating to Lessee&#8217;s prospective agreement to assign or sublease, a copy of a then current financial statement for such proposed assignee or sublessee, and any other relevant information reasonably requested by Lessor within five (5) days after receipt of notice of the proposed assignment or sublease and Lessee shall specify all consideration to be received by Lessee for such assignment or sublease in the form of lump sum payments, installments of rent, or otherwise. For purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the term &#8220;consideration&#8221; shall include all money or other consideration received by Lessee for such assignment or sublease. Within ten (10) days after the receipt of such documentation and other information, Lessor (1) shall notify Lessee in writing that Lessor elects to consent to the proposed assignment or sublease subject to the terms and conditions hereinafter set forth&#59; (2) shall notify Lessee in writing that Lessor refuses such consent, specifying reasonable grounds for such refusal&#59; or (3) except with respect to a Permitted Transferee, if at the time Lessee requests that Lessor consent to an assignment or sublease for all or substantially all of the remaining Lease Term, Lessee is not conducting on-going operations for the use permitted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, above, in at least fifty-one percent (51%) of the Building, Lessor may notify Lessee that Lessor elects to terminate this Lease, provided that with respect to a proposed sublease of a portion of the Premises Lessor&#8217;s termination right shall apply only to the proposed sublease space, and specifying the effective date of termination which shall be the same as the commencement date of the proposed sublease. If Lessor elects to terminate this Lease pursuant to the foregoing provision, upon the effective date of termination, Lessor and Lessee shall each be released and discharged from any liability or obligation to the other under this Lease accruing thereafter with respect to the Premises or the portion thereof to which the termination applies, except for any obligations then outstanding and except for any indemnity obligations which survive the expiration or termination of this Lease by the express terms hereof, and Lessee agrees that Lessor may enter into a direct lease with such proposed assignee or sublessee without any obligation or liability to Lessee.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In deciding whether to consent to any proposed assignment or sublease, Lessor may take into account whether reasonable conditions have been satisfied, including, but not limited to, the following&#58;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)In Lessor&#8217;s reasonable judgment, the proposed assignee or subtenant is engaged in such a business, that the Premises, or the relevant part thereof, will be used in such a manner which complies with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and Lessee or the proposed assignee or sublessee submits to Lessor documentary evidence reasonably satisfactory to Lessor that such proposed use constitutes a permitted use of the Premises pursuant to the ordinances and regulations of the City of Menlo Park&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)The proposed assignee or subtenant is a reputable entity or individual with sufficient financial net worth so as to reasonably indicate that it will be able to meet its obligations under this Lease or the sublease in a timely manner&#59; </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)If at the time of the proposed transfer, Lessor has substantially similar space available for rent in the Menlo Business Park, the proposed assignee or subtenant is not a tenant of the Building or any other building in the Menlo Business Park&#59; and,</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)The proposed assignment or sublease is approved by Lessor&#8217;s mortgage lender if such lender has the right to approve or disapprove proposed assignments or subleases. Lessor shall use its good faith efforts to obtain such approval from its lender within ten (10) days after receipt by Lessor of Lessee&#8217;s written request for consent and the documentation and information referred to in the first sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 18(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)As a condition to Lessor&#8217;s granting its consent to any assignment or sublease, except with respect to any Permitted Transferees, (1) Lessor may require that Lessee pay to Lessor, as and when received by Lessee, fifty percent (50%) of the amount of any excess of the consideration received by Lessee in connection with said assignment or sublease over and above the Monthly Base Rent and Additional Rent fixed by this Lease and payable by Lessee to Lessor, after deducting (A) a standard leasing commission payable by Lessee in consummating such assignment or sublease, (B) the cost of reasonable tenant improvements performed specifically for the sublease and required to be made to the Premises to effectuate the sublease, provided that such improvements are performed in compliance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Lease, and (C) reasonable attorneys&#8217; fees incurred by Lessor in negotiating and reviewing the assignment or sublease documentation&#59; and (2) Lessee and the proposed assignee or sublessee shall demonstrate to Lessor&#8217;s reasonable satisfaction that each of the criteria referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">subparagraph (b</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) above is satisfied.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)Each assignment or sublease agreement to which Lessor has consented shall be an instrument in writing in form satisfactory to Lessor, and shall be executed by both Lessee and the assignee or sublessee, as the case may be. Each such assignment or sublease agreement shall recite that it is and shall be subject and subordinate to the provisions of this Lease, that the assignee or sublessee accepts such assignment or sublease, that Lessor&#8217;s consent thereto shall not constitute a consent to any subsequent assignment or subletting by Lessee or the assignee or sublessee, and, except as otherwise set forth in a sublease approved by Lessor, agrees to perform all of the obligations of Lessee hereunder (to the extent such obligations relate to the portion of the Premises assigned or subleased), and that the termination of this Lease shall, at Lessor&#8217;s sole election, constitute a termination of every such assignment or sublease. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)In the event Lessor shall consent to an assignment or sublease, Lessee shall nonetheless remain primarily liable for all obligations and liabilities of Lessee under this Lease, including but not limited to the payment of Rent.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)Notwithstanding the foregoing, Lessee may, without Lessor&#8217;s prior written consent and without any participation by Lessor in assignment and subletting proceeds, but with prior notice and documentation, as required pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 18(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, provided to Lessor, sublet a portion or the entire Premises or assign this Lease to (i) a subsidiary, affiliate, division or corporation controlling, controlled by or under common control with Lessee (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59; (ii) to </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a successor corporation to Lessee by merger, consolidation or reorganization&#59; or (iii) to a purchaser of substantially all of Lessee&#8217;s assets located on the Premises (each such transaction referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Permitted Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and each of the foregoing transferees referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Permitted Transferee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), provided that any such Permitted Transferee that is an affiliate shall have a then current verifiable net worth immediately following the Permitted Transfer at least equal to that of Lessee on the Effective Date of this Lease and any such other Permitted Transferee not an affiliate shall have a then current verifiable net worth immediately following the Permitted Transfer which is at least equal to that of Lessee immediately prior to the Permitted Transfer or, if in any Permitted Transfer, the then current verifiable net worth of the Permitted Transferee (whether an affiliate or not) is less than required herein, such Permitted Transferee shall have the financial resources sufficient, in Lessor&#8217;s reasonable good faith judgment, to perform the obligations under the assignment or sublease, as applicable. Lessee&#8217;s foregoing rights in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 18(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to assign this Lease or to sublease all or a portion of the entire Premises shall be subject to the following conditions&#58; (1) Lessee shall not be in default hereunder past any applicable cure period at the time of the sublease or assignment&#59; (2) in the case of an assignment or subletting to an affiliate, Lessee shall remain liable to Lessor hereunder if Lessee is a surviving entity&#59; (3) the transferee or successor entity (in each case, if different than Lessee) shall expressly assume in writing all of Lessee&#8217;s obligations hereunder&#59; and (4) Lessee shall provide Lessor with prior notice of such proposed transfer and deliver to Lessor all documents reasonably requested by Lessor relating to such transfer, including but not limited to documentation sufficient to establish such proposed transferee&#8217;s (other than an affiliate) then current verifiable net worth prior to the transfer at least equal to that of Lessee on the Commencement Date of this Lease, or, if less, financial resources sufficient, in Lessor&#8217;s reasonable good faith judgment, to perform the obligations under the assignment or sublease, as applicable&#59; provided, however, that Lessee not be required to comply with the foregoing requirements regarding net worth or financial resources if the entity acquiring Lessee shall provide a guaranty of this Lease. </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)Neither the sale nor transfer of Lessee&#8217;s capital stock shall be deemed an assignment, subletting, or other transfer of this Lease or the Premises, provided, that in the event of the sale, transfer or issuance of Lessee&#8217;s securities in connection with a transaction described in Paragraph 18(f), the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 18(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall apply.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)Subject to the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> any assignment or sublease (if such consent is required hereunder) without Lessor&#8217;s prior written consent shall at Lessor&#8217;s election be void. The consent by Lessor to any assignment or sublease shall not constitute a waiver of the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including the requirement of Lessor&#8217;s prior written consent, with respect to any subsequent assignment or sublease. If Lessee shall purport to assign this Lease, or sublease all or any portion of the Premises, or permit any person or persons other than Lessee to occupy the Premises, without Lessor&#8217;s prior written consent (if such consent is required hereunder), Lessor may collect Rent from the person or persons then or thereafter occupying the Premises and apply the net amount collected to the Rent reserved herein, but no such collection shall be deemed a waiver of Lessor&#8217;s rights and remedies under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or the acceptance of any such purported assignee, sublessee, or occupant, or a release of Lessee from the further performance by Lessee of covenants on the part of Lessee herein contained.</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)Lessee shall not hypothecate or encumber its interest under this Lease or any rights of Lessee hereunder, or enter into any license or concession agreement respecting all or any portion of the Premises, without Lessor&#8217;s prior written consent which consent Lessor may grant or withhold in Lessor&#8217;s absolute discretion without any liability to Lessee. Lessee&#8217;s granting of any such encumbrance, license, or concession agreement shall constitute an assignment for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)In the event of any sale or exchange of the Premises by Lessor and assignment of this Lease by Lessor, Lessor shall, upon providing Lessee with written confirmation that the assignee has assumed all obligations of Lessor under this Lease and Lessor has delivered any Security Deposit held by Lessor to Lessor&#8217;s successor in interest, be and hereby is entirely relieved of all liability under any and all of Lessor&#8217;s covenants and obligations contained in or derived from this Lease with respect to the period commencing with the consummation of the sale or exchange and assignment.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)Lessee hereby acknowledges that the foregoing terms and conditions are reasonable and, therefore, that Lessor has the remedy described in California Civil Code Section 1951.4 (Lessor may continue the Lease in effect after Lessee&#8217;s breach and abandonment and recover Rent as it becomes due, if Lessee has the right to sublet or assign, subject only to reasonable limitations).</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)No waiver of any provision of this Lease shall be implied by any failure of Lessor to enforce any remedy for the violation of that provision, even if that violation continues or is repeated. Any waiver by Lessor of any provision of this Lease must be in writing. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)No receipt of Lessor of a lesser payment than the Rent required under this Lease shall be considered to be other than on account of the earliest Rent due, and no endorsement or statement on any check or letter accompanying a payment or check shall be considered an accord and satisfaction. Lessor may accept checks or payments without prejudice to Lessor&#8217;s right to recover all amounts due and pursue all other remedies provided for in this Lease.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessor&#8217;s receipt of any Rent or other payment from Lessee after giving notice to Lessee terminating this Lease shall in no way reinstate, continue, or extend the Lease term or affect the termination notice given by Lessor before the receipt of such Rent or payment. After serving notice terminating this Lease, filing an action, or obtaining final judgment for possession of the Premises, Lessor may receive and collect any Rent, and the payment of that Rent shall not waive or affect such prior notice, action, or judgment.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Holding Over</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessee shall vacate the Premises and deliver the same to Lessor upon the expiration or sooner termination of this Lease. In the event of holding over by Lessee after the expiration or termination of this Lease, such holding over shall be on a month-to-month tenancy and all of the terms and provisions of this Lease shall be applicable during such period, </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except that in addition to the payment of Additional Rent, Lessee shall pay Lessor as Monthly Base Rent during such holdover an amount equal to the greater of (i) one hundred fifty percent (150%) of the Monthly Base Rent in effect at the expiration of the Term, or (ii) the then market rent for comparable research and development&#47;office space. If such holdover is without Lessor&#8217;s written consent, Lessee shall be liable to Lessor for all costs, expenses, and consequential damages incurred by Lessor as a result of such holdover, including but not limited to damages resulting from Lessor&#8217;s inability to timely deliver possession of the Premises to a new tenant. The rental payable during such holdover period without Lessor&#8217;s written consent shall be payable to Lessor on demand.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Damage or Destruction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)In the event of a total destruction of the Building during the term from any cause, either party may elect to terminate this Lease by giving written notice of termination to the other party within thirty (30) days after the casualty occurs. A total destruction shall be deemed to have occurred for this purpose if the Building or the Premises that are the subject of this Lease are destroyed to the extent of seventy-five percent (75%) or more of the replacement cost thereof. If the Lease is not terminated, Lessor shall repair and restore the Premises in a diligent manner and this Lease shall continue in full force and effect, except that Monthly Base Rent and Additional Rent of the Premises which are the subject of this Lease shall be abated in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 21(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 21(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the event of a partial destruction of the Building or the Premises to an extent less than seventy-five percent (75%) of the replacement cost thereof, and if Lessor reasonably believes that the damage thereto can be repaired, reconstructed, or restored within a period of two hundred seventy (270) days from the date of casualty, there are at least twelve (12) months remaining in the Term of this Lease, and the casualty is from a cause which is insured under Lessor&#8217;s &#8220;all risk&#8221; property insurance, or is insured under any other coverage then carried by Lessor, Lessor shall forthwith repair the same back to the condition described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedules &#8220;F-1&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#8220;F-2&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#8220;F-3&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#8220;F-4&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and this Lease shall continue in full force and effect, except that Monthly Base Rent and Additional Rent shall be abated in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 21(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below. All insurance proceeds available from the fire and property damage insurance carried by Lessor shall be paid to and become the property of Lessor. All insurance proceeds from Lessee&#8217;s fire and property damage insurance covering the Tenant Improvements but excluding proceeds for Lessee&#8217;s Personal Property shall also be paid to Lessor, as loss payee thereunder. If any of the foregoing conditions are not met, Lessor shall have the option of either repairing and restoring the Building and Improvements, or terminating this Lease by giving written notice of termination to Lessee within sixty (60) days after the casualty. Notwithstanding anything to the contrary contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lessor shall not have the right to terminate this Lease if the cost to repair the damage to the Building or to restore the Premises would cost less than five percent (5%) of the replacement cost of the Building, regardless of whether or not the casualty is insured, provided that there are at least twelve (12) months remaining in the Term of this Lease. If the cost to restore the Premises exceeds five percent (5%) of the replacement cost, and Lessor elects to terminate this Lease, Lessee may nullify the effect of such termination by giving Lessor written notice within ten (10) days after receipt by Lessee of Lessor&#8217;s notice of termination that Lessee shall reimburse Lessor </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the costs to restore the Premises in excess of the insurance proceeds available, which costs exceed five percent (5%) of the replacement cost, in which event this Lease shall remain in effect, provided that Rent abatement shall not extend beyond the date that the restoration is completed.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)Lessor&#8217;s election to repair and restore the Building and Improvements or to terminate this Lease under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 21(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, shall be made and written notice thereof shall be given to Lessee within sixty (60) days after the casualty. Notwithstanding the foregoing, in the event of a partial destruction of the Building or the Property to an extent less than seventy-five percent (75%) of the Building or Premises, or if the damage thereto cannot be repaired, reconstructed, or restored within a period of one hundred eighty (180) days from the date a building permit is issued for reconstruction, Lessee may terminate this Lease by giving written notice of termination to Lessor within sixty (60) days after the casualty. The foregoing shall not affect Lessor&#8217;s termination rights under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 21(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)In the event of repair, reconstruction, or restoration as provided herein, the Monthly Base Rent and Additional Rent shall be abated in proportion to the extent to which Lessee&#8217;s use of the Premises is completely impaired and Lessee does not use such portion of the Premises during the period of repair from the date of the casualty until such repair is Substantially Completed.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)With respect to any destruction of the Building and the Work which Lessor is obligated to repair, or may elect to repair, under the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the provisions of Section 1932, Subdivision 2, and of Section 1933, Subdivision 4, of the Civil Code of the State of California are waived by the parties. Provided Lessor receives sufficient insurance proceeds from Lessee&#8217;s fire and property insurance to repair or replace any alterations in the Premises constructed after the Commencement Date damaged in the casualty event, Lessor&#8217;s obligation to repair and restore the Building and Improvements shall include the Work referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 14(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any future-installed alterations. Lessor&#8217;s time for completion of the repairs and restoration of the Building and Improvements referred to above shall be extended by a period equal to any delays caused by Tenant Delay or force majeure. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)In the event of termination of this Lease pursuant to any of the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Monthly Base Rent and Additional Rent shall be apportioned on a per diem basis and shall be paid to the date of the casualty. In no event shall Lessor be liable to Lessee for any damages resulting to Lessee from the occurrence of such casualty, or from the repairing or restoration of the Building and Improvements, or from the termination of this Lease as provided herein, nor shall Lessee be relieved thereby from any of Lessee&#8217;s obligations hereunder, except to the extent and upon the conditions expressly set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Eminent Domain</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)If the whole or any substantial part of the Property or the Premises is taken or condemned by any competent public authority for any public use or purpose, the term of this Lease shall end upon the earlier to occur of the date when the possession of the part so taken shall be required for such use or purpose or the vesting of title in such public authority. Rent </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall be apportioned as of the date of such termination. Any award arising from the condemnation of any portion of the Property or the settlement thereof shall belong to and be paid to Lessor. However, Lessee may file a separate claim at Lessee&#8217;s sole cost and expense for (i) leasehold improvements installed at Lessee&#8217;s expense or other property owned by Lessee, and (ii) reasonable costs of moving by Lessee to another location in San Mateo County or surrounding areas within the San Francisco Bay Area. In all events, Lessor shall be solely entitled to any award with respect to the real property, including the bonus value of the leasehold.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)If there is a partial taking of the Property by eminent domain which is not a substantial part of the Property and the Premises remain reasonably suitable for continued use and occupancy by Lessee for the purposes referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Lessor shall complete any necessary repairs in a diligent manner and this Lease shall remain in full force and effect with a just and proportionate abatement of the Monthly Base Rent and Additional Rent, based on the extent to which Lessee&#8217;s use of the Premises is completely impaired thereafter. If after a partial taking, the Premises are not reasonably suitable for Lessee&#8217;s continued use and occupancy for the uses permitted herein, Lessee may terminate this Lease effective on the earlier of the date title vests in the public authority or the date possession is taken. Subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 22(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the entire award for such taking shall be the property of Lessor.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If (a) Lessee fails to make any payment of Rent or any other sum due under this Lease within five (5) days after receipt by Lessee of written notice from Lessor&#59; or (b) Lessee breaches any other term, provision or covenant of this Lease (except a breach as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 23(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below) for thirty (30) days after receipt by Lessee of written notice from Lessor or such shorter time period specified in this Lease (unless such default is incapable of cure within thirty (30) days and Lessee commences cure as soon as reasonably practical within such thirty (30) day period and thereafter diligently prosecutes the cure to completion within a reasonable time not to exceed sixty (60) days after commencing the cure)&#59; or (c) after the first (1st) anniversary of the Commencement Date, Lessee breaches the provisions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(c)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(c)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(c)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(c)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(c)(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Lease, and, following such breach, either (i) fails to commence to cure such breach within five (5) business days after receipt of written notice from Lessor and, thereafter, to diligently prosecute the cure to completion three (3) or more times in a twelve (12) month period, or (ii) fails more than once in a twelve (12) month period to cure such breach within a reasonable time after receipt of written notice from Lessor&#59; or (d) Lessee&#8217;s interest herein, or any part thereof, is assigned or transferred, either voluntarily or by operation of law (except as expressly permitted by other provisions of this Lease)&#59; or (e) Lessee makes a general assignment for the benefit of its creditors&#59; or (f) if this Lease is rejected (i) by a bankruptcy trustee for Lessee, (ii) by Lessee as debtor in possession, or (iii) by failure of Lessee as a bankrupt debtor to act timely in assuming or rejecting this Lease&#59; then any of such events shall constitute an event of default and breach of this Lease by Lessee and Lessor may, at its option, elect the remedies specified in either </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">subparagraph (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">(b</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) below. Any Lessor notice referred to above must set forth in reasonable detail the nature and extent of the failure referencing pertinent Lease provisions. Any such rejection of this Lease referred to above shall not cause an automatic termination of this Lease. Whenever in this Lease reference is made to a default by Lessee, such reference shall refer to an event of default as defined in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)Lessor may repossess the Premises and remove all persons and property therefrom. If Lessor repossesses the Premises because of a breach of this Lease, this Lease shall terminate and Lessor may recover from Lessee&#58;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)the worth at the time of award of the unpaid Rent which had been earned at the time of termination including interest thereon at a rate equal to the discount rate established by the Federal Reserve Bank of San Francisco for member banks, plus one percent (1%), or the maximum legal rate of interest, whichever is less, from the time of termination until paid&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)the worth at the time of award of the amount by which the unpaid Rent which would have been earned after termination until the time of award exceeds the amount of such rental loss that Lessee proves could have been reasonably avoided, including interest thereon at a rate equal to the Federal discount rate plus one percent (1%) per annum, or the maximum legal rate of interest, whichever is less, from the time of termination until paid&#59;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)the worth at the time of award of the amount by which the unpaid Rent for the balance of the term after the time of award exceeds the amount of such rental loss for the same period that Lessee proves could be reasonably avoided discounted at the discount rate established by the Federal Reserve Bank of San Francisco for member banks at the time of the award plus one percent (1%)&#59; and</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)any other amount necessary to compensate Lessor for all the detriment proximately caused by Lessee&#8217;s breach or by Lessee&#8217;s failure to perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)If Lessor does not repossess the Premises, then this Lease shall continue in effect for so long as Lessor does not terminate Lessee&#8217;s right to possession and Lessor may enforce all of its rights and remedies under this Lease, including the right to recover the Rent and other sums due from Lessee hereunder. For the purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the following do not constitute a repossession of the Premises by Lessor or a termination of the Lease by Lessor&#58;</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)Acts of maintenance or preservation by Lessor or efforts by Lessor to relet the Premises&#59; or</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)The appointment of a receiver by Lessor to protect Lessor&#8217;s interests under this Lease.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)Lessor&#8217;s failure to perform or observe any of its obligations under this Lease or to correct a breach of any warranty or representation made in this Lease within thirty (30) days after receipt of written notice from Lessee setting forth in reasonable detail the nature and extent of the failure referencing pertinent Lease provisions or if more than thirty (30) days is required to cure the breach, Lessor&#8217;s failure to begin curing within the thirty (30) day period and diligently prosecute the cure to completion, shall constitute a default. If Lessor commits a </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">default, Lessee&#8217;s sole remedy shall be to institute an action against Lessor for damages or for equitable or injunctive relief, but Lessee shall not have the right to punitive damages, consequential damages, rent abatement, offset against Rent, or to terminate this Lease in the event of any default by Lessor.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)All covenants and agreements to be performed by Lessee under this Lease shall be at its sole cost and expense and without abatement of Rent or other sums due under this Lease, unless otherwise specified in this Lease. If Lessee shall fail to pay any sum of money required to be paid by Lessee under this Lease or shall fail to perform any other act on Lessee&#8217;s part to be performed under this Lease within the time periods described in the first paragraph of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 23(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lessor may, but shall not be obligated so to do and without waiving or releasing Lessee from any obligations of Lessee, make any such payment or perform any such other act on Lessee&#8217;s part to be made or performed as provided in this Lease. All sums paid by Lessor, whether to fulfill Lessee&#8217;s unfulfilled payment obligations, to perform Lessee&#8217;s unfulfilled performance obligations, or to compel Lessee to fulfill or perform its obligations under this Lease, and all incidental costs, including attorneys&#8217; fees, plus an administrative fee of five percent (5%) of all amounts so expended by Lessor, shall be deemed additional rent hereunder and shall be payable to Lessor upon demand. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Lessee&#8217;s Personal Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If any personal property of Lessee remains on the Premises after (1) Lessor terminates this Lease pursuant to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> Paragraph 23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above following an event of default by Lessee, or (2) after the expiration of the Lease Term or after the termination of this Lease pursuant to any other provisions hereof, Lessor shall give written notice thereof to Lessee pursuant to applicable law. Lessor shall thereafter release, store, and dispose of any such personal property of Lessee in accordance with the provisions of applicable law.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All notices, demands, consents or approvals (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) which may or are required to be given by either party to the other under this Lease shall be in writing and shall be deemed to have been fully given (a) when received or refused, if personally delivered, (b) three (3) business days after being deposited in the United States mail, postage prepaid, sent by Certified or Registered Mail, or (d) one (1) business day after being deposited with a nationally recognized overnight courier service. Each Notice shall be addressed to Lessor and Lessee at the following address, or to such place as either party may from time to time designate in a written notice to the other party&#58; </font></div><div style="padding-left:144pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Lessor&#58;</font></div><div style="padding-left:180pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Menlo Park Portfolio II, LLC</font></div><div style="padding-left:180pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c&#47;o Tarlton Properties, Inc.</font></div><div style="padding-left:180pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1530 O&#8217;Brien Drive, Suite C</font></div><div style="padding-left:180pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Menlo Park, California 94025</font></div><div style="padding-left:180pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attention&#58; John C. Tarlton, President</font></div><div style="padding-left:180pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Telephone&#58; (650) 330-3600</font></div><div style="padding-left:144pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Lessee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; </font></div><div style="padding-left:144pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to Commencement Date&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:180pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Biosciences of California, Inc. </font></div><div style="padding-left:180pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1380 Willow Rd.</font></div><div style="padding-left:180pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Menlo Park, California 94025</font></div><div style="padding-left:180pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attention&#58; General Counsel</font></div><div style="padding-left:180pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Telephone&#58; (650) 521-8000</font></div><div style="padding-left:144pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the Commencement Date&#58;</font></div><div style="padding-left:180pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Biosciences of California, Inc. </font></div><div style="padding-left:180pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1315 or 1305 O&#8217;Brien Drive, Building #3</font></div><div style="padding-left:180pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Menlo Park, California 94025</font></div><div style="padding-left:180pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attention&#58; General Counsel</font></div><div style="padding-left:180pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Telephone&#58; (650) 521-8000</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Estoppel Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessee and Lessor shall within ten (10) days following request by the other party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Requesting Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), execute and deliver to the Requesting Party an estoppel certificate (1) certifying that this Lease has not been modified and certifying that this Lease is in full force and effect, or, if modified, stating the nature of such modification and certifying that this Lease, as so modified, is in full force and effect&#59; (2) stating the date to which the Rent and other charges are paid in advance, if at all&#59; (3) stating the amount of any Security Deposit held by Lessor&#59; (4) acknowledging that there are not, to the responding party&#8217;s then current actual knowledge without inquiry, any uncured defaults on the part of the Requesting Party hereunder, or if there are uncured defaults on the part of the Requesting Party, stating the nature of such uncured defaults&#59; and (5) any other provisions reasonably requested by either party.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Signage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessee shall have the use of Lessee&#8217;s Pro Rata Share of the monument sign and lobby sign for Building #3 for Lessee&#8217;s signage. Lessee may place Lessee&#8217;s vinyl lettering signage on the glass near the front door entrance to the Building and in the interior of the Building, subject to Lessor&#8217;s reasonable requirements and consent and subject to the requirements of the City of Menlo Park. All of Lessee&#8217;s signage shall comply with the City of Menlo Park sign ordinances and regulations and shall be subject to Lessor&#8217;s approval as to the specific location, size and design thereof. The cost of the installation of Lessee&#8217;s signage on the monument, on the glass near the front entrance to the Building and within the interior of the Building shall be paid by Lessee. All signage shall be subject to Lessor&#8217;s prior approval and any additional signage (if any), if approved, shall be installed at Lessee&#8217;s expense. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Real Estate Brokers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessee&#8217;s broker is Cornish and Carey Newmark Knight Frank (CCNKF) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Lessee&#8217;s Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and Lessor&#8217;s broker is Kidder Matthews (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Lessor&#8217;s Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and collectively with Lessee&#8217;s Broker, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Lessor shall pay a leasing commission to the Brokers pursuant to a separate agreement. Each party represents and warrants to the other party that it has not had any dealings with any real estate broker, finder, or other person with respect to this Lease other than Lessee&#8217;s Broker and Lessor&#8217;s Broker and each party shall hold harmless the other party from all damages, expenses, and liabilities resulting from any </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claims that may be asserted against the other party by any broker, finder, or other person with whom the other party has or purportedly has dealt, other than the above named brokers. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Parking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessee shall have the right to three (3) parking spaces per thousand rentable square feet of the Premises at no additional cost to Lessee during the initial term of the Lease, in the parking area for the Building or nearby parking areas in Menlo Business Park, subject to such rules and regulations for such parking facilities which may be established or altered by Lessor at any time from time to time during the Lease Term&#59; provided, however, that if Lessor builds a parking structure in the Menlo Business Park during the Lease Term (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Parking Structure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), Lessor shall grant to Lessee the non-exclusive use of Two Hundred Ten (210) unreserved on-site vehicular parking spaces within such structure at no additional base rent to Lessee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the initial Term of the Lease&#59; provided, however, that the parties agree and acknowledge that the Lessee&#8217;s Pro-Rata Share and Lessee&#8217;s Pro-Rata Share with respect to the Parking Structure shall be adjusted in a fair and reasonable manner if and when the Parking Structure is built. Vehicles of Lessee or its employees shall not park in driveways or occupy parking spaces or other areas reserved for deliveries, or loading or unloading. Notwithstanding anything to the contrary herein, Lessee shall not be required to comply with any new rule or regulation or be bound by any new covenant, condition, restriction or other encumbrance on the Property unless the same applies non-discriminatorily to all occupants of the Property, does not unreasonably interfere with Lessee&#8217;s use of the Premises or Lessee&#8217;s parking rights and does not materially increase the obligations or decrease the rights of Lessee with respect to parking under this Lease. The parties further acknowledge and agree that Lessor has filed a Transportation Demand Management Plan (&#8220;TDMP&#8221;) with the City of Menlo Park and, as the same may be amended from time to time, Lessee shall provide to the coordinator of the TDMP information pertinent to car and van pooling, and Lessee shall comply with other reasonable TDMP reporting requirements. Lessee shall be entitled to the same rights and benefits of such TDMP as all tenants of the Menlo Business Park subject to the TDMP during the Lease Term. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Subordination&#59; Attornment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)This Lease, without any further instrument, shall at all times be subject and subordinate to the lien of any and all mortgages and deeds of trust (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Instrument</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) which may now or hereafter be placed on, against or affect Lessor&#8217;s estate in the real property of which the Premises form a part, and to all advances made or hereafter to be made upon the security thereof, and to all renewals, modifications, consolidations, replacements and extensions thereof. This clause shall be self-operative and no further instrument of subordination need be required by any owner or holder of any Security Instrument provided however, that in consideration of Lessee&#8217;s agreement to subordinate this Lease to any future Security Instrument, such subordination shall be subject to the receipt by Lessee of a subordination non-disturbance and attornment agreement in a commercially reasonable form provided by the holder of such future Security Instrument, which requires the holder of such Security Instrument to accept this Lease, and not to disturb Lessee&#8217;s possession, so long as an event of Lessee's default has not occurred and be continuing (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SNDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), executed by the holder of such Security Instrument. </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)In confirmation of such subordination, Lessee covenants and agrees to execute and deliver within ten (10) days of Lessor&#8217;s request any certificate or other instrument which Lessor may reasonably deem proper to evidence such subordination in commercially reasonable form (which document recognizes Lessee&#8217;s rights under this Lease), without expense to Lessee&#59; provided, however, that if any person or persons purchasing or otherwise acquiring the real property of which the Premises form a part by any sale, sales and&#47;or other proceedings under such mortgages and&#47;or deeds of trust, shall elect to continue this Lease in full force and effect in the same manner and with like effect as if such person or persons had been named as Lessor herein, then this Lease shall continue in full force and effect as aforesaid, and Lessee hereby attorns and agrees to attorn to such person or persons in writing upon request.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)If Lessee is notified in writing of Lessor&#8217;s default under any deed of trust affecting the Premises and if Lessee is instructed in writing by the party giving notice to make Lessee&#8217;s rental payments to such beneficiary, Lessee shall comply with such request without liability to Lessor (and with full credit of any amounts paid to such party by Lessee to the corresponding amounts owed to Lessor) until Lessee receives written confirmation that such default has been cured by Lessor and that the deed of trust has been reinstated.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Termination Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except as expressly provided herein, Lessee shall not have the right to terminate this Lease as a result of any default by Lessor, and Lessee&#8217;s remedies in the event of a default by Lessor shall be limited to the remedy set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 23(c</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Lessee expressly waives the defense of constructive eviction.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Lessor&#8217;s Entry</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except in the case of an emergency and except for permitted entry during Lessee&#8217;s normal working hours for scheduled maintenance, both of which may occur without prior notice to Lessee, Lessor and Lessor&#8217;s agents shall provide Lessee with at least twenty-four (24) hours&#8217; notice prior to entry of the Premises. Lessor may enter the Premises for any reasonable purpose related to Lessor&#8217;s ownership of the Property. Such entry by Lessor and Lessor&#8217;s agents shall not impair Lessee&#8217;s operations more than reasonably necessary and shall comply with Lessee&#8217;s reasonable security measures, if any. Lessor and Lessor&#8217;s agents shall at all times be accompanied by Lessee during any such entry except in case of emergency and except for janitorial work (if provided by Lessor). Lessor may enter the Premises at any time without prior notice to Lessee if the Premises are vacant, if Lessee is no longer conducting its ordinary business at the Premises, or if Lessee has made a general assignment for the benefit of creditors.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Attorneys&#8217; Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If any action at law or in equity shall be brought to recover any Rent under this Lease, or for or on account of any breach of or to enforce or interpret any of the provisions of this Lease or for recovery of the possession of the Premises, the prevailing party shall be entitled to recover from the other party costs of suit and reasonable attorneys&#8217; fees, the amount of which shall be fixed by the court and shall be made a part of any judgment rendered.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Quiet Enjoyment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon payment by Lessee of the Rent for the Premises and the observance and performance of all of the covenants, conditions, and provisions on Lessee&#8217;s part to be observed and performed under this Lease within applicable notice and cure periods, Lessee </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall have quiet enjoyment and possession of the Premises for the entire term hereof subject to all of the provisions of this Lease.</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessee represents and warrants to Lessor that all financial and other information that it has provided to Lessor prior to the date of this Lease is true, correct and complete. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SDN List</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessee represents and warrants to Lessor that Lessee is not, and the entities that own or control Lessee, or that may be owned or controlled by Lessee (in all cases, other than through the ownership of publicly traded, direct or indirect ownership interests) (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Subject Lessee Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) are not, (i) in violation of any Applicable Laws relating to terrorism or money laundering, or (ii) among the individuals or entities identified on any list compiled pursuant to Executive Order 13224 or published by the Office of Foreign Assets Control, U.S. Department of the Treasury (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) for the purpose of identifying suspected terrorists or on the most current list published by the OFAC at its official website, http&#58;&#47;&#47;www.treas.gov&#47;ofac&#47;tllsdn.pdf or any replacement website or other replacement official publication of such list which identifies an &#8220;Specially Designated National&#8221; or &#8220;blocked person&#8221; (either of which are referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SDN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). If at any time during the Lease Term Lessor discovers that Lessee has breached the foregoing representations and warranties, or Lessor reasonably believes that Lessee or any Subject Lessee Party is in violation of any Applicable Laws relating to terrorism or money laundering or that Lessee or any Subject Lessee Party is identified as an SDN, Lessee shall be deemed in default under this Lease following three (3) days written notice from Lessor to Lessee unless, within such three day period, Lessee delivers written evidence, reasonably acceptable to Lessor, that Lessee is not in violation of such Applicable Laws or that Lessee (or the Subject Lessee Party, as applicable) is not a person or entity identified as an SDN. Except as otherwise expressly provided in the foregoing sentence, and without further notice, any default by Lessee under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be deemed an incurable default by Lessee and, in addition to any other rights and remedies that Lessor may have upon such default, Lessor shall also have the right to immediately terminate this Lease upon written notice to Lessee and recover possession of the Premises.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)Nothing contained in this Lease shall be deemed or construed by the parties hereto or by any third person to create the relationship of principal and agent or of partnership or of joint venture of any association between Lessor and Lessee, and neither the method of computation of Rent nor any other provisions contained in this Lease nor any acts of the parties hereto shall be deemed to create any relationship between Lessor and Lessee other than the relationship of landlord and tenant.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)Each and all of the provisions of this Lease shall be binding upon and inure to the benefit of the parties hereto, and except as otherwise specifically provided elsewhere in this Lease, their respective heirs, executors, administrators, successors, and assigns, subject at all times, nevertheless, to all agreements and restrictions contained elsewhere in this Lease with respect to the assignment, transfer, encumbering, or subletting of all or any part of Lessee&#8217;s interest in this Lease.</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)The captions of the paragraphs of this Lease are for convenience only and shall not be considered or referred to in resolving questions of interpretation or construction.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)This Lease is and shall be considered to be the only agreement between the parties hereto and their representatives and agents. All negotiations and oral agreements acceptable to both parties have been merged into and are included herein. There are no other representations or warranties between the parties and all reliance with respect to representations is solely upon the representations and agreements contained in this instrument.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)The laws of the State of California shall govern the validity, performance, and enforcement of this Lease. Notwithstanding which of the parties may be deemed to have prepared this Lease, this Lease shall not be interpreted either for or against Lessor or Lessee, but this Lease shall be interpreted in accordance with the general tenor of the language in an effort to reach an equitable result.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)Time is of the essence with respect to the performance of each of the covenants and agreements contained in this Lease.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)Recourse by Lessee for breach of this Lease by Lessor shall be expressly limited to the amount of Lessor&#8217;s interest in the Property and the rents, issues, insurance, condemnation, and sales proceeds actually received by Lessor, and profits therefrom, and in the event of any such breach or default by Lessor, Lessee hereby waives the right to proceed against any other assets of Lessor or against any other assets of any manager or member of Lessor.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)Any provision or provisions of this Lease which shall be found to be invalid, void or illegal by a court of competent jurisdiction, shall in no way affect, impair, or invalidate any other provisions hereof, and the remaining provisions hereof shall nevertheless remain in full force and effect.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)This Lease may be modified in writing only, signed by the parties in interest at the time of such modification.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)Each party represents to the other that the person signing this Lease on its behalf is properly authorized to do so.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)No binding agreement between the parties with respect to the Premises shall arise or become effective until this Lease has been duly executed by both Lessee and Lessor and a fully executed copy of this Lease has been delivered to both Lessee and Lessor.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(l)Lessor and Lessee each acknowledge that the content of this Lease and any related documents are confidential information. Lessor and Lessee shall keep such confidential information strictly confidential and, except to the extent required by applicable law, including, but not limited to any securities laws or regulations or court order, shall not disclose such confidential information to any person or entity other than to such party&#8217;s financial, legal, or accounting advisors, or such party&#8217;s employees, officers, directors, shareholders, lender, space </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">planning consultants, architects and contractors, and prospective assignees or subtenants of Lessee or any prospective buyer of the Property, or in any dispute proceeding between the parties relating to this Lease. Notwithstanding the foregoing, Lessor and Lessee shall not be obligated to keep confidential&#58; (i) information that is or becomes available to the public other than as a result of Lessor&#8217;s or Lessee&#8217;s disclosure in violation of this Lease&#59; (ii) information that is or becomes available on a non-confidential basis to Lessor or Lessee from a source other than Lessor or Lessee, as applicable&#59; (iii) information that was known to Lessor or Lessee on a non-confidential basis prior to the disclosure of such information to Lessor or Lessee, as applicable, under protection of this Lease&#59; or (iv) information released from confidential treatment by written consent of Lessor or Lessee, as applicable. Neither Lessor or Lessee shall send out any press releases about the execution and delivery of this Lease without the other party&#8217;s prior written consent, which consent shall not be unreasonably withheld. A violation of this subparagraph (l) shall not permit either party to terminate this Lease. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(m)Except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 23(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the rights and remedies that either party may have under this Lease or at law or in equity, upon any breach, are distinct, separate and cumulative and shall not be deemed inconsistent with each other, and no one of them shall be deemed to be exclusive of any other.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(n)Lessee waives any claim for consequential damages which Lessee may have against Lessor for breach of or failure to perform or observe the requirements and obligations created by this Lease.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(o)Lessor and Lessee each agree to and they hereby do, to the maximum extent permitted by law, waive trial by jury in any action, proceeding or counterclaim brought by either of the parties hereto against the other on any matters whatsoever arising out of or in any way connected with this Lease, the relationship of Lessor and Lessee, Lessee&#8217;s use or occupancy of the Premises and&#47;or any claim of injury or damage, and any statutory remedy.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(p)This Lease shall not be recorded.</font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(q)Lessee hereby waives any and all rights under and benefits of California Civil Code Section 1938 and acknowledges that neither the Building nor the Premises has undergone inspection by a Certified Access Specialist (CASp). </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(r)In the event that the Lessee is permitted and elects to contract directly for the provision of electricity, gas and&#47;or water services to the Premises with the third-party provider thereof (all in Lessor's reasonable discretion), Lessee shall within ten (10) business days following its receipt of written request from Lessor, provide Lessor with a copy of each requested invoice from the applicable utility provider. Lessee acknowledges that pursuant to California Public Resources Code Section 25402.10 and the regulations adopted pursuant thereto (collectively the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Energy Disclosure Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;), Lessor may be required to disclose information concerning Lessee&#8217;s energy usage at the Building to certain third parties, including, without limitation, prospective purchasers, lenders and tenants of the Building (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Lessee Energy Use Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;). Lessee hereby (A) consents to all such Lessee Energy Use Disclosures, and (B) acknowledges that Lessor shall not be required to notify Lessee of any </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessee Energy Use Disclosure. Further, Lessee hereby releases Lessor from any and all losses, costs, damages, expenses and liabilities relating to, arising out of and&#47;or resulting from any Lessee Energy Use Disclosure. The terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 37(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Lease shall survive the expiration or earlier termination of this Lease</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(s)Whenever this Lease requires an approval, consent, determination, selection or judgment by either Lessor or Lessee, unless another standard is expressly set forth, such approval, consent, determination, selection or judgment and any conditions imposed thereby shall be reasonable and shall not be unreasonably withheld or delayed and, in exercising any right or remedy hereunder, each party shall at all times act reasonably and in good faith.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;SIGNATURES ON FOLLOWING PAGES&#93;</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Lessor and Lessee have duly executed this Lease as of the date first set forth herein.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lessor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MENLO PARK PORTFOLIO II, LLC, </font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a Delaware limited liability company</font></div><div style="padding-left:72.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.380%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PREHC MENLO PARK PORTFOLIO II MEMBER, LLC,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Its&#58; Co-Managing Member</font></td></tr></table></div><div style="padding-left:72.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRINCIPAL REAL ESTATE INVESTORS, LLC,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a Delaware limited liability company, authorized signatory</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:72.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.256%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael S. Bensen</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael S. Bensen</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assistant Managing Director Asset Management</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:72.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.256%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Troy A. Koerselman</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Troy A. Koerselman</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assistant Managing Director Asset Management</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="padding-left:72.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TPI INVESTORS 11, LLC,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A California limited liability company</font></td></tr></table></div><div style="padding-left:72.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TARLTON PROPERTIES, INC., a California corporation</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managing Member</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:72.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.256%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John C. Tarlton</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John C. Tarlton</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CEO</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;SIGNATURE OF LESSEE ON FOLLOWING PAGE&#93;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.288%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.38pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">S-1</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.38pt"><font><br></font></div></td></tr></table></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lessee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC., </font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a Delaware corporation</font></div><div style="padding-left:72.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.617%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Ben Gong</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Printed Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ben Gong</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VP Finance</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="padding-left:72.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.617%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Printed Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:72pt;padding-right:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.617%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.288%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WEST&#92;258445808.17</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">S-2</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.38pt"><font><br></font></div></td></tr></table></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT &#8220;A&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">THE LAND</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real property in the City of Menlo Park, County of San Mateo, State of California, described as follows&#58;</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PARCEL A, AS SHOWN ON PARCEL MAP FOR THE PURPOSE OF ELIMINATING THE LINE BETWEEN LOTS 3 AND 4 OF MENLO BUSINESS PARK, ETC., FILED FEBRUARY 27, 1987, IN BOOK 58 OF PARCEL MAPS, PAGE 74, SAN MATEO COUNTY RECORDS.</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APN&#58; 055-472-030</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JPN&#58; 111-050-000-03T, 111-040-000-04T</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exhibit &#8220;A&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WEST&#92;258445808.17 </font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT &#8220;B&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">MENLO BUSINESS PARK MASTER PLAN</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(See Attached)</font></div><div style="margin-top:12pt;padding-left:43pt;padding-right:43pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;B&#8221;</font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i2d022a045d8745628529eecf262f7746_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:43pt;padding-right:43pt;text-align:center"><img alt="image_01a.jpg" src="image_01a.jpg" style="height:490px;margin-bottom:5pt;vertical-align:text-bottom;width:864px"></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;B&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i2d022a045d8745628529eecf262f7746_7"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT &#8220;C&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Floor Plan of Premises in Building #3</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(See Attached)</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;C&#8221;</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:808px;margin-bottom:5pt;vertical-align:text-bottom;width:556px"></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;C&#8221;</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT &#8220;D&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Commencement Memorandum</font></div><div style="padding-left:72.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.935%"><tr><td style="width:1.0%"></td><td style="width:4.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.411%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To&#58;</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">__________ 2014</font></td></tr></table></div><div style="margin-bottom:12pt;padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Re&#58;Lease dated July ___, 2016 between MENLO PARK PORTFOLIO II, LLC, hereafter referred to as Lessor, and PACIFIC BIOSCIENCES OF CALIFORNIA, INC., a Delaware corporation, Lessee, concerning the Premises consisting of approximately One Hundred Eighty Thousand (180,000) rentable square feet in the building commonly known as 1305 O&#8217;Brien Drive, Menlo Park, California.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gentlemen&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the subject Lease, we hereby confirm the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.That the Premises have been unconditionally accepted by Lessee, except as noted on the attached.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.That Lessee has possession of the Premises and acknowledges that pursuant to the Lease, the initial term of the Lease commenced on__________, 2016 (the &#8220;Commencement Date&#8221;), and shall expire on __________________, 201_.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.That in accordance with the provisions of the Lease, Monthly Base Rent and Additional Rent commenced to accrue on__________, 2016.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.Thereafter, Rent is due and payable in advance on the first day of each month during the term of the Lease. Rent checks should be made payable to Lessor, c&#47;o Tarlton Properties, Inc., 1530 O&#8217;Brien Drive, Suite C Menlo Park, California 94025.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">AGREED AND ACCEPTED</font></div><div style="padding-left:78.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.980%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.12pt;padding-right:4.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">LESSEE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.12pt;padding-right:4.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">LESSOR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;D&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WEST&#92;258445808.17 </font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT &#8220;E&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Lessee&#8217;s Hazardous Materials</font></div><div style="margin-bottom:24pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(See Attached)</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;E&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WEST&#92;258445808.17 </font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><img alt="image_2a.jpg" src="image_2a.jpg" style="height:775px;margin-bottom:5pt;vertical-align:text-bottom;width:550px"></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;E&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WEST&#92;258445808.17 </font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><img alt="image_3a.jpg" src="image_3a.jpg" style="height:777px;margin-bottom:5pt;vertical-align:text-bottom;width:550px"></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;E&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WEST&#92;258445808.17 </font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><img alt="image_4a.jpg" src="image_4a.jpg" style="height:437px;margin-bottom:5pt;vertical-align:text-bottom;width:540px"></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;E&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WEST&#92;258445808.17 </font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT &#8220;F&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Work Letter </font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(See Attached)</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;F&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT &#8220;F&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WORK LETTER </font></div><div style="padding-left:144pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)The purpose of this Work Letter is to set forth (i) what work is to be performed by Lessor as part of the Warm Shell Work as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-1&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attached to this Work Letter, and the preliminary budget for the Warm Shell Work as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-2&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (ii) certain information regarding the Market Ready Improvements and Tenant Improvements, including the space plans for the Market Ready Improvements and the Tenant Improvements in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-3&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attached to this Work Letter, and the preliminary combined budget and list of inclusions and exclusions for the Market Ready Improvements and Tenant Improvements in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-4&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attached to this Work Letter. Furthermore, this Work Letter (y) sets forth the mechanics for completion of the construction of the Warm Shell, Market Ready Improvements, and Tenant Improvements and (z) establishes a time schedule for Substantial Completion (as defined below in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) of construction of the same (a preliminary construction schedule is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-5&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Warm Shell Work, Market Ready Improvements and Tenant Improvements are hereinafter collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)Except as defined in this Work Letter to the contrary, all terms utilized in this Work Letter shall have the same meaning ascribed to them in the Lease. When work, services, consents or approvals are to be provided by or on behalf of Lessor or Lessee, the term &#8220;Lessor&#8221; and &#8220;Lessee&#8221; shall include such parties&#8217; employees and authorized agents.</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)The provisions of the Lease, except where clearly inconsistent or inapplicable to this Work Letter, are incorporated into this Work Letter&#59; provided, however, that the provisions of this Work Letter shall govern the Work rather than the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Lease.</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)The Market Ready Improvements and the Tenant Improvements shall be constructed pursuant to this Work Letter by (or on behalf of) Lessee, with the cost thereof to be shared by Lessor and Lessee as described in Paragraph 14 of the Lease.</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)The Warm Shell Work shall be constructed pursuant to this Work Letter by (or on behalf of) Lessor, at Lessor&#8217;s sole cost and expense.</font></div><div style="margin-top:12pt;padding-left:126pt;padding-right:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Design Period, Construction Period and Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessee shall be permitted Early Entry into the Premises prior to the Commencement Date in accordance with the terms and conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 2(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Lease.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Delay of Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;F&#8221;</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:76.5pt;padding-right:72pt;text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)The parties shall attempt in good faith to resolve any dispute arising out of or relating to approval of the Tenant Improvement Documents (as defined in Paragraph 3(b) below) in accordance with the terms set forth in this Work Letter. If Lessee has not approved such documents by 5&#58;00 pm Pacific Standard Time on the applicable date set forth in Paragraph 3(c) below, then within two (2) business days following such failure, both Lessor and Lessee shall provide the other with written notice (each such notice, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Design Dispute Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) that shall include with reasonable particularity (1) a statement of each party&#8217;s position and a summary of arguments supporting that position and (2) the name and title of the executive who will represent that party and of any other person who will accompany the executive. </font></div><div style="padding-left:76.5pt;padding-right:72pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within two (2) business days after the date required for delivery of the Design Dispute Notices, the designated executives of both parties shall meet at a mutually acceptable time and place. Unless otherwise agreed in writing by the negotiating parties, the above-described negotiation shall end at the close of the first meeting of executives described above (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">First Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Such closure shall not preclude continuing or later negotiations, if desired.</font></div><div style="padding-left:76.5pt;padding-right:72pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the parties fail to resolve the dispute at this First Meeting, the parties shall initiate binding arbitration proceedings with an arbitrator experienced in resolving disputes related to the design of commercial properties (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Design Arbitrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), to be mutually agreed upon and retained by the parties in writing upon execution of this Lease or within twenty-one (21) days thereafter. If the parties fail to agree upon a Design Arbitrator within such twenty-one day period, either party may apply to the American Arbitration Association to appoint an Arbitrator, and the parties shall split all associated administrative fees from the American Arbitration Association and hereby consent to the jurisdiction of the American Arbitration Association for such purposes. The Design Arbitrator shall only have the authority to choose between the positions (including the amount of Tenant Delay and Lessor Delay) set forth in the Design Dispute Notices, as well as to determine the amount of Tenant Delay and Lessor Delay, which shall be equal to the number of days that elapse from the applicable Final Approval Date set forth in Paragraph 3(c) to the date that the dispute regarding the Tenant Improvement Documents is resolved by the Design Arbitrator. If the Design Arbitrator selects the Lessee&#8217;s position, the delay shall be a Lessor Delay. If the Design Arbitrator selects the Lessor&#8217;s position, the delay shall be a Tenant Delay. The Design Arbitrator shall render a decision within ten (10) business days following the conclusion of the First Meeting.</font></div><div style="padding-left:76.5pt;padding-right:72pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parties agree to enter into a separate Agreement with the Design Arbitrator, which shall include the following provisions&#58; the parties shall agree (i) to split equally all fees of the Design Arbitrator in connection with the Design Arbitrator&#8217;s services, and payment of such fees to the arbitrator shall be enforceable by any court of competent jurisdiction&#59; (ii) to the extent allowable under applicable law, to defend and indemnify (subject to Section 14 below), the Design Arbitrator from claims, damages or causes of action (including reasonable attorneys&#8217; fees) arising out of the parties&#8217; acts or omissions under this Lease or the acts or omissions of any contractor or design professional providing services or labor or materials in connection with the Work. </font></div><div style="padding-left:76.5pt;padding-right:72pt;text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)With respect to delays other than the delays described in subparagraph (i) above, no Lessor Delay or Tenant Delay shall be deemed to have occurred </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;F&#8221;</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:76.5pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hereunder or in the Lease unless and until the party claiming such a delay has provided written notice to the other party specifying the action or inaction that such notifying party contends constitutes a Lessor Delay or Tenant Delay, as applicable as soon as possible, but not later than three (3) business days after the occurrence of such delay. The Lessor Delay or Tenant Delay, as set forth in such notice, shall be deemed to have occurred commencing as of the date that the event triggering the delay occurred and continuing for the number of days the performance in question was in fact delayed as a direct result of such action or inaction, provided that the party claiming such delay exercises commercially reasonable efforts to mitigate, if reasonably possible, the delaying effect of the complained of action or inaction.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Certain Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Force Majeure Delay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Force Majeure Delay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; as used in the Lease or this Work Letter shall mean any delay in the performance of any act or thing required hereunder which is attributable to strikes, lock-outs, weather conditions, casualties, acts of God, labor troubles, inability by the exercise of reasonable diligence to procure materials, inability by the exercise of reasonable diligence to obtain supplies, parts, employees or necessary services, failure of power, governmental laws, orders or regulations, actions of governmental authorities, riots, insurrection, war or other causes beyond the reasonable control of such party, or for any cause due to any act or neglect of the other party hereto or its respective servants, agents, employees, licensees, or any person claiming by, through or under them.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Lessor Delay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Lessor Delay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; as used in the Lease or this Work Letter shall mean any delay in the Substantial Completion of the Work (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below) in accordance with the timelines provided in the Construction Schedule attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-5&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as the same may be adjusted by Change Order, to the extent due to (i) Lessor&#8217;s failure to deliver the Tenant Improvement Documents by the dates set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below and (ii) any Lessor Delay specified in this Work Letter or in the Lease, including, without limitation, any Lessor Delay agreed upon in writing following the First Meeting (defined above) or determined by the Design Arbitrator as set forth above. </font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Tenant Delay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Tenant Delay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; as used in the Lease or this Work Letter shall mean any delay in the Substantial Completion of the Work (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below) in accordance with the timelines provided in the Construction Schedule attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-5&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as the same may be adjusted by Change Order, to the extent due to (a) any material interference by Lessee with the work of the General Contractor or its subcontractors during Lessee&#8217;s Early Entry&#59; (b) a written Change Order (as defined below) requested by Lessee, but only to the extent of the Tenant Delay specified in such Change Order&#59; (c) any Tenant Delay specified in this Work Letter or in the Lease, including, without limitation, any Tenant Delay agreed upon in writing following the First Meeting (defined above) or determined by the Design Arbitrator as set forth above&#59; (d) the inclusion of any so-called &#8220;long lead&#8221; materials in the improvements (such as fabrics, paneling, carpeting or other items that are not readily available within industry standard lead times &#91;e.g., custom made items that require time to procure beyond that customarily required for standard items, or items that are currently out of stock and will require extra time to back order&#93; and for which suitable substitutes exist)&#59; provided, however, that if any such &#8220;long lead&#8221; item is not specified in the Schedules attached to </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;F&#8221;</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this Work Letter, its inclusion shall not constitute a Tenant Delay unless Lessor has notified Lessee that such item is a &#8220;long lead&#8221; item and has given Lessee a reasonable period of time to approve the inclusion of the item prior to the time at which it would delay Substantial Completion of the Work&#59; (e) Lessee&#8217;s failure to provide, within a reasonable period of time, information requested by Lessor that is reasonably necessary for the Substantial Completion of the Work&#59; and (f) Lessee&#8217;s failure to make any payment required under this Work Letter within the period specified therefor (it being acknowledged that if Lessee fails to make or otherwise delays making such payments, Lessor may stop work rather than incur costs which Lessee is obligated to fund but has not yet funded and any delay from such a work stoppage will be a Tenant Delay). Lessee shall be liable for, and shall pay all costs and expenses incurred by Lessor to the extent caused by a Tenant Delay. </font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Substantial Completion or Substantially Completed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessor&#8217;s Work shall be &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Substantially Completed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and Lessor shall have attained &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Substantial Completion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of the Work when all of the Work is completed in accordance with the approved Documents and all requirements of Applicable Laws other than (i) non-material punch-list items, and (ii) Lessor has obtained a Temporary Certificate of Occupancy (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">TCO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) for the Premises or such other documentation from the City specifying that the Premises can be legally occupied. Notwithstanding the foregoing, Lessor shall promptly and diligently pursue the completion of all such non-material punch-list items within the Premises within a reasonable period of time.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preparation of Plans and Construction Schedule and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Delivery of all plans and drawings referred to in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be electronic, unless otherwise agreed by Lessor and Lessee. Lessor and Lessee shall arrange for the construction of the Work in accordance with the following schedule&#58;</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Selection of Architect and Engineer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to Lessee&#8217;s approval, not to be unreasonably withheld, conditioned or delayed, Lessor shall select an architect (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Designer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and an engineer (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Engineer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) familiar with all rules, regulations, instructions and procedures promulgated by Lessor with respect to design and&#47;or construction in the Building (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Building Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and with all Applicable Laws. Lessee&#8217;s failure to approve the selection of the Engineer or the Designer within three (3) business days of Lessor&#8217;s delivery of written notice of such selection to Lessee shall be deemed Tenant Delay. Thereafter, Lessor shall engage and manage the Designer and Engineer.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If, following the engagement of the Designer or the Engineer, Lessor unilaterally decides to terminate either the Designer or the Engineer, any delay in the Substantial Completion of the Work caused by or attributable to such termination shall be deemed Lessor Delay. If, following the engagement of the Designer or the Engineer, Lessee unilaterally decides to direct Lessor to terminate either the Designer or the Engineer, any delay in the Substantial Completion of the Work caused by or attributable to such termination shall be deemed Tenant Delay. If Lessor and Lessee mutually decide to terminate the Designer or the Engineer, the parties shall execute a Change Order to revise the construction schedule to account for any delay in the Substantial Completion of the Work, and there shall be no Tenant Delay or Lessor Delay associated with such mutual termination.</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;F&#8221;</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Building Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessor shall cause the Designer to electronically submit to the Lessee the Schematic Design Documents, the Design Development Documents, and the Construction Documents for the Market Ready Improvements and the Tenant Improvements (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Tenant Improvement Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) by the dates set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below. Lessor shall also cause Designer to electronically submit to Lessee the Schematic Design Documents, the Design Development Documents, and the Construction Documents for the Warm Shell Work when the same are available. Lessee shall have the right to review and approve the Tenant Improvement Documents&#59; provided, however, that so long as the Tenant Improvement Documents are consistent with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-3&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-4&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attached to this Work Letter, Lessee&#8217;s approval shall not be unreasonably withheld, conditioned, or delayed and such approval shall otherwise be given within the time frames in this Section 3. Prior to the approval dates set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below, if Lessee requests that Lessor make any changes to the Tenant Improvement Documents, Lessee and Lessor shall work together in good faith to promptly agree upon any changes to the Tenant Improvement Documents necessary to cause the Tenant Improvement Documents to be consistent with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-3&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-4&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attached to this Work Letter, and any previously approved Tenant Improvement Documents.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Final Approval of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Provided that Lessor shall deliver to Lessee the Tenant Improvement Documents at least five (5) days in advance of the dates set forth below, Lessee shall approve the Tenant Improvement Documents by the dates set forth below (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Final Approval Dates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Lessee&#8217;s failure to approve the Tenant Improvement Documents by the applicable Final Approval Date shall be eligible for Tenant Delay as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above and Lessor&#8217;s failure to submit the Tenant Improvement Documents at least five (5) days in advance of the Final Approval Dates shall be eligible for Lessor Delay as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above.</font></div><div style="padding-left:78.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.173%"><tr><td style="width:1.0%"></td><td style="width:54.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.216%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 5.37pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Tenant Improvement Document&#58;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 5.37pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Final Approval Date&#58;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 5.37pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schematic Design Documents</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 5.37pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 20, 2015</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 5.37pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Design Development Documents</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 5.37pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 19, 2015</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 5.37pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Documents</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 5.37pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 8, 2015</font></td></tr></table></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General Contractor and Review of Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Selection of General Contractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessor intends to use ACT as a general contractor to construct the Work (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">General Contractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which was selected through a competitive bidding process. As soon as reasonably practicable, General Contractor shall cause to be prepared, and delivered to Lessor and Lessee, a cost estimate for the Work, separately identifying costs of (1) the Warm Shell Work, and (2) the Market Ready Improvements and the Tenant Improvements, collectively. Lessor and Lessee shall cooperate to achieve efficiencies in the cost of the Work and to value-engineer the cost of the Work and shall confer and negotiate in good faith to reach agreement on a Final Budget for the Work (such approved budget, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Final Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Lessor shall enter into a construction contract with the General Contractor (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Construction Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in the amount of the Final Budget. Lessor shall provide Lessee with a copy of the proposed Construction Contract prior to execution for Lessee&#8217;s approval and shall provide Lessee with a copy of the approved Construction Contract following execution thereof with General Contractor. Lessee&#8217;s approval of the Construction Contract shall not be </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;F&#8221;</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unreasonably withheld, conditioned, or delayed. If Lessee objects to any term(s) of the proposed Construction Contract, Lessee shall promptly work with Lessor to resolve such concerns so as not to delay Substantial Completion of the Work. Lessee&#8217;s failure to timely approve the Construction Contract shall be a Tenant Delay.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, Lessee shall have the right to direct Lessor in writing to terminate the General Contractor&#8217;s work on the Market Ready Improvements and the Tenant Improvements and to select an alternate contractor to complete Market Ready Improvements and the Tenant Improvements, but shall have no right to direct Lessor to terminate the General Contractor&#8217;s performance of the Warm Shell Work. Any delay in Substantial Completion of the Work caused by Lessee&#8217;s exercise of this termination right, including without limitation delay caused by selection of an alternate contractor and&#47;or delay caused by having two general contractors completing different portions of the Work, shall be deemed to be a Tenant Delay. In the event that Lessee elects to terminate the General Contractor, Lessee further agrees that it will reimburse or compensate Lessor for any liability, cost, expense, loss or damage (including attorneys&#8217; fees) which Lessor may suffer or incur by reason of Lessee&#8217;s election to terminate the General Contractor, including without limitation Lessor&#8217;s defense of a breach of contract action by the General Contractor for wrongful termination. Lessee further agrees that Lessee shall be solely responsible to reimburse Lessor for any increases in the costs to complete the Work due to Lessee&#8217;s election to terminate the General Contractor.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Lessor&#8217;s Review Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessee agrees and understands that the review of all of the plans pursuant to this Work Letter by Lessor is solely to protect the interests of Lessor in the Building and the Premises, and Lessor shall not be the guarantor of, nor responsible for, the correctness or accuracy of any such plans or compliance of such plans with Applicable Laws. </font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Permits and Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessee and Lessor shall cooperate in efforts to obtain all permits and approvals that may be required to construct the Work, and for Lessee to occupy the Premises (including all Critical Permits as defined in the Lease, which shall be obtained by Lessor).</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Tenant Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Tenant Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall include, to the extent specified in the Tenant Improvement Documents, all signage, freestanding workstations, built-in related cabinets, reception desks, all telecommunication equipment and related wiring, and all carpets and floor coverings, but Tenant Improvements shall not include any personal property or trade fixtures of Lessee.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Construction of the Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Promptly after Lessor and Lessee have approved the Tenant Improvement Documents and the Final Budget, the General Contractor shall (i) provide Lessor and Lessee with a construction schedule, which shall incorporate and include any of Lessee&#8217;s subcontractors (including without limitation, furniture vendors, subcontractors for IT, cabling, AV and security), and (ii) commence construction of the Work. The Work shall be performed in a diligent, good and workman like manner using new materials. The Work shall comply in all respects with the following&#58; (a) the City of Menlo Park Building Code and other state, federal, city or quasi-governmental laws, codes, ordinances and regulations, as each may </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;F&#8221;</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">apply according to the rulings of the controlling public official, agent or other person&#59; (b) applicable standards of the American Insurance Association (formerly, the National Board of Fire Underwriters) and the National Electrical Code&#59; and (c) building material manufacturer&#8217;s specifications. Lessee hereby acknowledges that the Lessor may be required to cause union only labor to be utilized on some portions of the Work, including, without limitation, mechanical, electrical and plumbing. At the conclusion of construction, the General Contractor and Designer shall notify Lessor and Lessee of the Substantial Completion of the Work. At the conclusion of construction, the General Contractor shall also deliver to Lessor (who shall deliver copies of the same to Lessee) (i) &#8220;As-Built&#8221; plans of the Work in hard copy together with a digital copy (in such commercially reasonable format as shall be designated by Lessor), and (ii) lien waivers&#47;releases from the General Contractor and all of its sub-contractors reflecting that the cost of the Work has been paid in full. </font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Weekly Job Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. General Contractor shall conduct weekly job meetings on site. Lessor shall have the right, but not an obligation, to attend any job meeting. During each such job meeting the General Contractor shall among other things provide a report as to the construction and progress against the Tenant Improvement construction schedule.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Change Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the event that Lessee desires to make any changes to the approved Tenant Improvement Documents, Lessee shall seek Lessor&#8217;s prior written approval of any such changes before they are made and such changes, as well as any Tenant Delay resulting therefrom, must be identified in an approved written &#8220;Change Order&#8221; prior to proceeding with such changes. </font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the dates set forth in the construction schedule attached to this Work Letter as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall also be done via a written Change Order approved by Lessor.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Lessee Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All improvements or alterations constructed in the Premises by Lessee or Lessee&#8217;s contractors prior to the Commencement Date shall be subject to the following requirements&#58;</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Any such entry into the Premises by Lessee or Lessee&#8217;s contractors shall be subject to the prior written consent of the Lessor, which consent may be withheld by Lessor in Lessor&#8217;s sole discretion&#59; provided, however, that Early Entry for the purposes set forth in Section 2(f) of the Lease shall be governed by that Section. </font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Such work shall not proceed until Lessor has approved in writing (1) the amount and coverage of public liability and property insurance, with Lessor, its property manager and mortgagor named as additional insureds, carried by Lessee&#8217;s contractor and (2) a schedule for the work.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) All work shall be done in conformity with a valid permit when required, a copy of which shall be furnished to Lessor before such work is commenced. In any case, all such work shall be performed in accordance with all Applicable Laws. </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;F&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Staging Area&#47;Coordination of Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessee shall cause its contractors and their subcontractors to schedule all deliveries to the Building with Lessor&#8217;s designated project representative at such times as shall be reasonably directed by such designated representative. Lessee shall direct that its contractors and materialmen use only those areas outside of the Premises for staging and material assembly that are designated from time to time by Lessor&#8217;s project representative. Lessee shall require that all of its contractors and materialmen use reasonable efforts to coordinate their activities within the Building and the Building site with Lessor&#8217;s designated project representative so as to avoid when possible disruption to the Work or work of others within the Building. </font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All contractors shall provide the following insurance coverages&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General Coverages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. General Contractor (and all sub-contractors) shall carry, to the extent required by law, worker&#8217;s compensation insurance covering all of their respective employees, and shall also carry public liability insurance, including property damage, all with limits, in form and with companies as are required to be carried by Lessee as set forth in the Lease.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Special Coverages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessor shall carry &#8220;Builder&#8217;s All Risk&#8221; insurance in an amount reasonably approved by Lessor covering the construction of the Work and the premiums for such shall be included in the cost of construction. Such &#8220;Builder&#8217;s Risk&#8221; insurance shall be in amounts and shall include such extended coverage endorsements as may be reasonably required by Lessor including, but not limited to, the requirement that the General Contractor and all sub-contractors shall carry excess liability and Products and Completed Operation Coverage insurance, each in amounts not less than $1,000,000 per incident, $3,000,000 in aggregate, and in form and with companies as are required to be carried by Lessee as set forth in the Lease.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessor shall carry property insurance for the Warm Shell Work, Market Ready Improvements, and Tenant Improvements. Lessee shall be responsible for carrying property insurance for any other alterations.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessor reserves the right to carry flood or earthquake insurance if Lessor, in its sole discretion, determines that such coverage is necessary.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Certificates for all insurance carried pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be delivered to Lessor before the commencement of construction of the Work and before the General Contractor&#8217;s equipment is moved onto the site. All such policies of insurance must contain a provision that the company writing said policy will endeavor to give Lessor thirty (30) days prior written notice of any termination or lapse of the effective date or any reduction in the amounts of such insurance. In the event that the Work is damaged by any cause during the course of the construction thereof, Lessor shall promptly repair (or cause the same to be repaired) at no cost to Lessee. The General Contractor and all sub-contractors shall maintain all of the foregoing insurance coverage in force until the Work is fully completed. All policies carried under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall insure Lessor and Lessee, as their interests may appear, as well as the General Contractor and sub-contractors. All insurance, except Workers&#8217; </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;F&#8221;</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation, maintained by the General Contractor and all subcontractors shall preclude subrogation claims by the insurer against anyone insured thereunder. Such insurance shall provide that it is primary insurance as respects the owner and that any other insurance maintained by owner is excess and noncontributing with the insurance required hereunder. The requirements for the foregoing insurance shall not derogate from the provisions for indemnification of Lessor by Lessee under the Lease, as reaffirmed under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Work Letter.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Casualties during Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessee shall carry insurance coverage for loss of use and business interruption caused by casualties that occur during construction, and Lessor shall have no liability to Lessee for loss of use or business interruption damages caused by casualties during construction. Lessor shall carry insurance coverage for lost rent caused by casualties that occur during construction, and Lessee shall have no liability to Lessor for lost rent damages caused by casualties during construction. </font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warm Shell</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessor shall construct the Warm Shell Work at Lessor&#8217;s cost and expense. Lessor hereby agrees that the Warm Shell Work shall be constructed substantially in accordance with the material elements of the description of the Warm Shell Work attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-1&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to this Work Letter.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Delivery of Premises to Lessee and Condition of Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessor shall deliver possession of the Premises to Lessee subject punch list items, Force Majeure and Tenant Delays with the Work Substantially Completed at the time set forth in the Lease.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Construction Period Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessor and Lessee agree that, notwithstanding anything in the Lease or this Work Letter to the contrary, the following provisions shall apply during the Construction Period (defined below)&#58; </font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)The parties acknowledge that the estimated costs to complete the Warm Shell Work, the Market Ready Improvements and the Tenant Improvements are currently $33,000,000 as set forth on the budgets attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-2&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> Schedule &#8220;F-4&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessor is responsible for paying the cost of the Warm Shell Work, estimated to be $11,400,000 as described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule &#8220;F-2&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lessor is also responsible for funding the Lessor&#8217;s Contribution (as defined in Paragraph 14(a) of the Lease) for the Market Ready Improvements in the amount of $9,900,000 and the Tenant Improvement Allowance (as defined in Paragraph 14(a) of the Lease) for the Tenant Improvements in the amount of $2,700,000. Lessee is responsible for reimbursing Lessor for the Tenant Improvement Shortfall (as defined in Paragraph 14(a) of the Lease), which amount is currently estimated to be $9,000,000. During the period from the Effective Date of this Lease through Substantial Completion of the Work (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Construction Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Lease also requires Lessee to prepay Base Rent in the amount of $2,160,000 and Additional Rent in the amount of $180,000 and deliver to Lessor a Security Deposit in the amount of $4,500,000 in the form of a Letter of Credit. Accordingly, Lessee&#8217;s aggregate cash outlay during the Construction Period is expected to be $11,340,,000 compared with Lessor&#8217;s total cash outlay of $24,000,000 and estimated total project costs of $33,000,000 (with Lessee&#8217;s portion of such costs expected to be 34%, but such percentage will be reduced by the inclusion in Project Costs (defined below) of the portion of Lessor&#8217;s acquisition costs for the Project </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;F&#8221;</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attributable to the value of the Building). All of Lessee&#8217;s cash outlays during the Construction Period are expected to be paid directly to Lessor.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)Lessor agrees that, during the Construction Period, the amount it collects from Lessee (estimated to be $11,340,000), together with the amount of any obligation of Lessee to indemnify Lessor for damage claims caused by or resulting from Lessee&#8217;s own acts or failures to act related to completion of construction, which amounts shall calculated to include (i) the accreted value of any payments previously made by Lessee plus (ii) the present value of the maximum amount that Lessee could be required to pay as of that point in time (whether or not construction is completed) discounted at Lessee&#8217;s incremental borrowing rate, shall not in any one instance exceed 89.9% of the project costs then incurred by Lessor at any time during the Construction Period (i.e., &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Project Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall be the sum of costs capitalized by Lessor under generally accepted accounting principles in connection with the Work (estimated to be $33,000,000), the portion of Lessor&#8217;s acquisition costs for the Project attributable to the value of the Building and other costs related to the Property paid by Lessor to third parties other than lenders or owners of Lessor)&#59; provided, however, that to the extent any such amount or obligation would exceed 89.9% of the then incurred Project Costs and Lessee&#8217;s obligation to make such payment or satisfy such obligation is not allowed because the foregoing threshold is exceeded, Lessee&#8217;s payment obligations with respect thereto shall not be excused but shall be deferred until the 89.9% test is satisfied or the Construction Period ends, whichever is earlier. Lessor further agrees that during the Construction Period, the Tenant Improvement Shortfall shall not be applied to any structural improvements to the Building, utility or insurance costs of Lessor, or costs that are general in nature (as opposed to costs specific to Lessee&#8217;s requirements), which costs will be paid for by Lessor as part of Lessor&#8217;s estimated contribution to the project costs. The Tenant Improvement Shortfall, estimated at $9,000,000, shall only be directed toward improvements that are specific to Lessee&#8217;s requirements. Consistent with the foregoing, Lessee may request from Lessor from time to time Lessor&#8217;s certification as to the current amount of the total Project Costs incurred to date at that time and that the amounts paid or to be paid by Lessee are not reimbursement for the items prohibited by this clause, and Lessor shall endeavor to provide supporting documentation upon Lessee&#8217;s reasonable request for purposes of determining Lessee&#8217;s accounting treatment.</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)Lessor agrees that, during the Construction Period, with respect to any indemnity obligation of Lessee arising at any time during the Construction Period, (i) the term &#8220;Lessor&#8221; shall mean and shall be limited to Menlo Park Portfolio II, LLC (or any entity that that succeeds to Menlo Park Portfolio II, LLC&#8217;s interest as Lessor under the Lease) and shall not include any other person or entity&#59; provided, however, that Lessor may include in any claim owed by Lessee to Lessor any amount which Lessor shall pay or be obligated to indemnify any other person or entity, and (ii) any such indemnity obligation shall be limited to damage claims caused by or resulting from Lessee&#8217;s or its agent&#8217;s own acts or failures to act. In addition, Lessor agrees that, during the Construction Period, Lessor shall only draw upon the Letter of Credit for actual damages incurred by Lessor caused by or resulting from Lessee&#8217;s or its agent&#8217;s own acts or failures to act. </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EXHIBIT &#8220;F&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SCHEDULE &#8220;F-1&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Description of Warm Shell Work</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1315 O&#8217;BRIEN DRIVE</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WARM SHELL DEFINITION</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE BASE SITEWORK &#47; BUILDING </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1315 O&#8217;Brien Drive is an existing building that will be renovated. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sitework&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The existing site will include new asphalt paving and striping in some areas as well as renovated landscape areas on the southern, O&#8217;Brien Drive, street frontage. New site signage will be installed as required by current T24 and ADA accessibility standards. A total of 366 parking spaces will be associated with the R&#38;D building.</font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Building&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base building is an existing 2-story building that will be renovated both inside and outside. Interior demolition will consist of clearing the space of any and all office finishes, including ceilings, carpeting, interior walls, demolishing all existing bathrooms and bringing the space to a cold shell level. This demolition will also include removal and reuse of existing HVAC units and unused MEP infrastructure back to its source currently supporting the building. Exterior demolition will consist removing the center portion of the southern wall of the building, allowing the construction of a new 2-story lobby&#47;entry way with an open stairway to the second floor. All shell interior construction will be designed to allow for expansion for future tenants improvements.</font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3. The building will be renovated, providing a &#8220;warm shell&#8221;, construction Type III-B building with the envelope, structure, building core (including elevators, stairs and restrooms), interior finishes, mechanical, electrical and safety systems as described below. </font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ENVELOPE </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The building is to be fully enclosed and watertight. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1. Exterior walls are constructed of concrete, metal panels, glass and aluminum punched windows and storefront glazing systems. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2. Windows and glazing systems to use high-performance, low-e, insulated glass. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3. Roofing is an existing single-ply membrane, installed in 2011. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4. Exterior architectural building elements and finishes may include architectural steel, metal panels, painted &#47; textured concrete, canopies, trellises and sunshade &#47; light shelf devices. </font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUILDING STRUCTURE </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#1a1a1a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The existing building was designed per the seismic standards of the 1979 Uniform Building Code. The lateral load resisting system will be voluntarily upgraded per Chapter 34 Section 3404.5 of the 2013 California Building Code </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1. Building configuration is partial 2 stories, above grade with floor to floor height of 15&#8217;6&#8221;+- in the 2 story areas and 31&#8217;0&#8221;+- in the high bay areas. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2. The primary building structure is constructed of tilt-up concrete panels ranging 6.25&#8221; &#8211; 10&#8221; thick with a lateral system of concrete shear walls and steel braced frames. The steel structure includes columns, steel trusses, steel roof deck, and raised equipment platform above roof. The roof platform will be 8,000 SF (approx), located near Column lines D-H and column line 4-6 and will have sufficient load carrying capacity for evaporative mechanical equipment totaling 300 tons of cooling capacity.</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SCHEDULE &#8220;F-1&#8221;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3. The foundation system of the building consists of perimeter spread footings and concrete column pads. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4. The first level reinforced concrete slab-on-grade is 8&#8221; thick. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5. The second floor slab is a 5&#8221; thick concrete filled metal deck supported by steel beams and trusses. It is designed for up to 150 psf live load. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6. The roof structure is a metal deck supported by steel beams and trusses. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7. Steel interior tube columns vary in size from 6&#8221;x6&#8221; up to 10&#8221;x10&#8221; square. They are predominantly located on a +&#47;- 40&#8217;x40&#8217; column grid layout and at +&#47;- 20&#8217;x40&#8217; at the 2 story areas. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.8. A new approximately 8000 square foot structural steel roof equipment platform will be placed above the existing roof structure above the existing second floor mezzanine and will support new HVAC units. Roof screens will be attached around the perimeter of the platforms to block the roof equipment from &#8220;line-of-sight&#8221;. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.9. Exterior walls are constructed of concrete, metal panels, glass and aluminum punched windows and storefront glazing systems. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.10. The primary structural frame, exterior bearing walls, interior bearing walls and floor construction with associated secondary members will be fire rated construction as required for the proposed warm shell build out. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.11. Roof construction and associated secondary members to be fire rated construction as required for the proposed warm shell build out. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.12. Stair and mechanical shaft enclosures to be fire rated construction as required for the proposed warm shell build out. </font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUILDING CORE </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The building has common and core areas included in the base building and will incorporate elevators, stairs, main lobby, restrooms, janitor closets, MPOE for utilities, mechanical shafts and fire sprinkler riser rooms. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elevators&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two (2) elevators will be provided. The first being an electric track system similar to Kone &#8220;Ecospace&#8221;. The other elevator will be a hydroelectric freight elevator with a 1,500lb capacity (minimum). These elevators will serve 2 levels&#58; first level and second level only. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stairs&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three (3) stairwells will be provided to accommodate code required exiting for undivided tenant spaces. Stairwell enclosure finishes include painted walls, building standard doors and exposed concrete floors. Lighting, fire protection, code required signage and other infrastructure systems to be installed as required. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Main Lobby&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The main lobby is a two-story atrium with a glass, 2-story glazed storefront entrance system that opens to the front plaza. The lobby stair will also have a steel and cable or glass handrail system. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restrooms&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two (2) main restroom cores will be fully finished and functional, one on each floor level. Finishes to include&#58; 4.1.1. Ceramic tile on floors and &#8216;wet&#8217; walls </font></div><div style="padding-left:108pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4.1. Solid surface countertops </font></div><div style="padding-left:108pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4.2. Laminate toilet partitions</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SCHEDULE &#8220;F-1&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:108pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4.3. Stainless steel accessories </font></div><div style="padding-left:108pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4.4. Finished ceiling systems and lighting </font></div><div style="padding-left:108pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4.5. Plumbing Fixtures to include&#58; 4.1.6.1. (24) Water Closets (Floor Mounted) </font></div><div style="padding-left:144pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4.5.1. (6) Urinals </font></div><div style="padding-left:144pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4.5.2. (25) Lavatories </font></div><div style="padding-left:144pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4.5.3. (8) Showers </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Janitor&#8217;s Closets&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restrooms to include janitor&#47;storage closet on each floor level. </font></div><div style="margin-bottom:3.45pt;padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Main Electrical Room&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The main electrical room &#47;MPOE will have a minimum of two services totaling 5000 amps. All services will be 277&#47;480 VAC, three phase, four wire electrical services. Lighting and distribution panels will be installed for building core elements. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Telephone &#47; Data Closet&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A telephone &#47; data closet will be provided on the ground floor. </font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTERIOR FINISHES </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1. The main building lobby may incorporate concrete, glass, stone, wood, steel and other materials consistent with a class A office building. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2. Interior surfaces of the exterior building walls will be exposed glass&#47;aluminum, painted concrete or insulated furred walls as required to meet minimum title 24 energy compliance standards for the base building shell. Painted gypsum board, taped and finished, and other interior finishes are excluded from warm shell and will be a part of tenant improvements. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3. Interior gypsum wallboard or shaft wall at core elements to be provided with paint finish and fire-taped as required. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4. Restrooms to be completely finished out as described above. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5. No ceilings are to be installed except in restrooms (gypsum board) and main building lobby the extent of which is to be determined. </font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MECHANICAL </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operational heating, ventilation and air conditioning systems will provide conditioned air to all core element areas as required by code. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1. Mechanical plant designed to exceed Title 24 standards. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2. All finished core and lobby areas will have a completed mechanical system per Landlord&#8217;s minimum HVAC criteria. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.3. Mechanical systems to be evaporative based units, 360 ton minimum capacity with the capability of future expansion by tenant. DDC Building Management System to be provided and function to control base building systems. Tenant will be allowed to install connectivity to the DDC for improved operational and energy efficiency integration. Where appropriate based on building height, as required by code life safety smoke control systems including stair and vestibule pressurization fans, ducting, shafts and floor by floor smoke control through dedicated fan systems or through the central air conditioning systems. </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SCHEDULE &#8220;F-1&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4. The natural gas supply to the building will be metered separately for the warehouse and R&#38;D tenant.</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELECTRICAL </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fully operational main electric service including main switchboard to serve base building shell lighting, power loads and base building electrical, mechanical and equipment loads. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1. The MPOE will have a minimum of two services totaling 5000 amps. All services will be 277&#47;480 VAC, three phase, four wire electrical services. A minimum of 4000 amps at 277&#47;480 VAC, three phase, four wire electrical service will be provided for the R&#38;D portion of the building. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.2. Lighting will be installed in improved areas to meet local building codes and new Title-24 requirements. Fire alarm will be design &#38; installed in accordance with local codes. </font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SAFETY AND SECURITY </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fully operational life safety and access systems for building shell.</font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.1. Base building is to be fully sprinklered and monitored as required by current building and fire codes. Fire sprinkler riser and wet sprinkler systems are provided for an undivided occupancy with upturned heads, typical. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.2. Life safety system distribution (smoke detectors, annunciators, strobes, etc.) as required by code for core and common areas. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3. Lobby and other designated entrances will be equipped with card reader access with a minimum of four total perimeter doors. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.4. An emergency generator will be provided to support Fire and Life Safety systems.</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MISCELLANEOUS </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1. Base building to be compliant with applicable building codes, including Title 24 and ADA requirements. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.2. Exterior plazas to include paving systems, seating, landscaping, irrigation and lighting. </font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3. Bicycle lockers and bike racks to be provided. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.4. Men&#8217;s and Women&#8217;s locker and shower facilities to be provided on first floor of the building. </font></div><div style="padding-left:108pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.5. Base Building shall include all common area facilities, including&#59; loading areas, main telecommunications point of entry (MPOE) room, transformer, main switch gear room and other facilities required to service the entire building shell. All such rooms to be complete and operational.</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SCHEDULE &#8220;F-1&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SCHEDULE &#8220;F-2&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preliminary Budget for Warm Shell Work</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SCHEDULE &#8220;F-2&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WEST&#92;259130145.9 </font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SCHEDULE &#8220;F-3&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Space Plans for Market Ready Improvements and Tenant Improvements</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Schedule &#8220;F-3&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WEST&#92;259130145.9 </font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SCHEDULE &#8220;F-4&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preliminary Combined Budget and List of Inclusions and Exclusions for Market Ready Improvements and Tenant Improvements</font></div><div style="padding-left:72pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Schedule &#8220;F-4&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt"><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SCHEDULE &#8220;F-5&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Construction Schedule</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attached.</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exhibit &#8220;F&#8221;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i2d022a045d8745628529eecf262f7746_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:center"><img alt="image_5a.jpg" src="image_5a.jpg" style="height:559px;margin-bottom:5pt;vertical-align:text-bottom;width:933px"></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exhibit &#8220;F&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i2d022a045d8745628529eecf262f7746_13"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT &#8220;G&#8221;</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Lessee&#8217;s Property</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Card access system including panels, card readers, door proximity readers - interior</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Security cameras and system</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">EHS equipment AED, fire extinguishers, first aid kits, spill, kits, signage, Eye washes, showers</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">AV equipment</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">White boards</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Cold rooms and refrigeration systems</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Pre-action fire system, tanks, panels and monitor</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Liquid Nitrogen tank and evaporator</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Air compressors</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Racks and warehouse shelves</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">DI water system &#8211; excluding distribution</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Hard-wall office furniture (all items)</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Free-standing open office furniture components where viable and not tied down (file cabinets, bookshelves, credenzas)&#59; and workstations</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Conference room tables</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Office chairs including conference rooms, break areas, etc.</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Lab space components where viable and not anchored (i.e., free-standing tables, glass ware cabinets, flammable storage&#47;chemical cabinets, all lab stools, etc.)</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Non built-in lab, office and lunch&#47;break room equipment</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Lobby Desks </font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Autoclave</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Fume, Bio and Laminar flow hoods</font></div><div style="padding-left:121.5pt;padding-right:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">Emergency generator and transfer switch </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>7
<FILENAME>pacb-exx1019xfirstamendmen.htm
<DESCRIPTION>EX-10.19
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="icbb8914708f746b3be0923cb31dac5e9_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-right:0.3pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;10.19</font></div><div style="margin-bottom:6pt;padding-right:0.3pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY &#91;***&#93; IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE (I) IT IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL.</font></div><div style="padding-right:0.2pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div style="margin-bottom:18pt;padding-left:0.1pt;padding-right:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FIRST AMENDMENT TO LEASE</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIS FIRST AMENDMENT TO LEASE (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is made as of December 23, 2016 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), by and between MENLO PARK PORTFOLIO II, LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Lessor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and PACIFIC BIOSCIENCES OF CALIFORNIA, INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Lessee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:0.1pt;padding-right:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A. Lessor and Lessee entered into that certain Lease, dated as of July 22, 2015 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), pertaining to the premises located at 1315 O&#8217;Brien Drive, Menlo Park, California (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B. Lessor and Lessee desire to amend the Lease as set forth herein. Unless otherwise defined herein, all capitalized terms in this Amendment shall have the same meaning ascribed to them in the Lease.</font></div><div style="margin-bottom:12pt;padding-left:0.1pt;padding-right:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TERMS AND CONDITIONS</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration of the mutual covenants herein contained, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Lessor and Lessee agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Premises&#59; Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Lease defined the Premises as a portion of the Building consisting of approximately One Hundred Eighty Thousand (180,000) rentable square feet, as shown on the floor plan of the Building attached to the Lease as Exhibit &#8220;C.&#8221; As contemplated in the Lease, Lessor has re-measured the Building and the Building is equal to approximately One Hundred Ninety Thousand Three Hundred Eighty Nine (190,389) rentable square feet. Paragraph 1 of the Lease is hereby amended to define the Premises as the portion of the Building consisting of approximately 180,231 rentable square feet, as shown on the floor plan attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit &#8220;A&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The floor plan attached to the Lease as Exhibit &#8220;C&#8221; is hereby deleted and replaced with the floor plan attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit &#8220;A&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Commencement Date&#59; Substantial Completion Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to the provisions of this Amendment, the initial Term of the Lease commenced on October 25, 2016 (the &#8220;Commencement Date&#8221;), and shall expire on October 31, 2027. Notwithstanding the foregoing, Lessor and Lessee acknowledge that, as of the date of this Amendment, (i) a portion of the Premises (the &#8220;Construction Area&#8221;) has not been delivered to Lessee, (ii) Lessor has not obtained a TCO as to the Construction Area and (iii) the Work is not yet Substantially Completed. Accordingly, Lessor remains obligated to cause the Work to be Substantially Completed, to deliver the Construction Area to Lessee in the required condition and to obtain a final TCO as to the Construction Area (the date Lessor causes all of the foregoing to be satisfied is referred to herein and in the Lease as the &#8220;Substantial Completion Date&#8221;). Pursuant to Paragraph 14(b) of the Lease, as modified herein, Lessor agrees to (i) use reasonable efforts to assign any assignable warranties or guaranties provided by the contractors or manufacturers of equipment to be maintained by Lessee pursuant to Paragraph 15 (if any) provided as part of the Work to Lessee or, at Lessee&#8217;s option, to enforce same with respect to any defect discovered in such equipment within one (1) year after the Substantial Completion Date and (ii) to enforce all other warranties or guaranties with respect to any defect discovered in the Work</font></div><div style="margin-top:12pt;padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">WEST&#92;274613282.7</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-right:0.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within one (1) year after the Substantial Completion Date. The parties hereby agree and acknowledge that subject to the waiver of subrogation set forth in Paragraph 12(c) of the Lease and to Section 14 of the Work letter, the indemnification obligations of Lessee and Lessor shall be as set forth in Paragraph 13 of the Lease. Notwithstanding anything to the contrary in the Lease or this Amendment, Lessee shall not be liable or responsible for any injury or damages (including attorneys' and consultants' fees) of any type or nature, arising from any occurrence or cause within the Construction Area prior to the Substantial Completion Date, except to the extent such injury or damage is caused by Lessee or Lessee&#8217;s employees, agents or contractors.</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; appearing in the first sentence of Paragraph 6(a) of the Lease and the second sentence of Paragraph 6(e) is hereby deleted and replaced with &#8220;December 15, 2016&#8221; so that Lessee&#8217;s obligation to commence paying Additional Rent to Lessor commenced as of December 15, 2016.</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Monthly Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The chart in Paragraph 5(a) of the Lease is hereby deleted in its entirety and replaced with the following chart&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.271%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.687%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.12pt;padding-right:4.32pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.12pt;padding-right:4.32pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.12pt;padding-right:4.32pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.12pt;padding-right:4.32pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.12pt;padding-right:4.32pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.12pt;padding-right:4.32pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Months</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Square Feet</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$&#47;SF&#47;Mo.&#47;NNN</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monthly Base Rent</font></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent Commencement Date -12</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180,231</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.996</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$540,000.00*</font></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13-24</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180,231</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.145</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$567,000.00</font></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25-36</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180,231</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.196</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$576,000.00</font></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37-48</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180,231</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.246</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$585,000.00</font></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49-60</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180,231</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.346</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$603,000.00</font></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61-72</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180,231</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.45</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$621,000.00</font></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73-84</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180,231</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.55</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$639,000.00</font></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85-96</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180,231</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.645</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$657,000.00</font></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97-108</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180,231</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.745</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$675,000.00</font></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109-120</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180,231</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.845</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$693,000.00</font></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121-132</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180,231</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.945</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:4.47pt;padding-right:4.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$711,000.00</font></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;padding-left:4.34pt;padding-right:4.34pt;text-align:center"><font><br></font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Monthly Base Rent Credit&#59; Additional Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Pursuant to Paragraph 2(c)(i) of the Lease, Lessee is entitled to receive a credit towards Monthly Base Rent next coming due under the Lease in an amount equal to One Hundred Seventy Seven Thousand Five Hundred Thirty Four and 25&#47;100 Dollars ($177,534.25), which amount is equal to ten (10) days of Monthly Base Rent. Notwithstanding anything to the contrary in the Lease, if the Substantial Completion Date has not occurred by January 31, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second Abatement Trigger Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), then Lessee shall be entitled to receive a credit towards Monthly Base </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.288%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WEST&#92;274613282.7</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2.28pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-right:0.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent next coming due under the Lease in the amount of $ 17,753.42 per day for each day beyond the Second Abatement Trigger Date until the Substantial Completion Date occurs. </font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Paragraph 12(a) of the Lease is hereby amended to provide that Lessee shall, at Lessee&#8217;s sole cost and expense, provide and keep in force the insurance policies described in Paragraph 12 commencing as of December 31, 2016. In addition, the requirement of Lessee to provide property insurance in clause (ii) of Paragraph 12(a) is hereby amended to require Lessee to provide such property insurance as to alterations by Lessee in the Premises and as to alterations made by Lessor in the Premises after the Substantial Completion Date.</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warranties and Guaranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The last sentence of Paragraph 14(b) of the Lease is deleted in its entirety and replaced with the following language,</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Lessor agrees to (i) use reasonable efforts to assign any assignable warranties or guaranties provided by the contractors or manufacturers of equipment to be maintained by Lessee pursuant to Paragraph 15 (if any) provided as part of the Work to Lessee or, at Lessee&#8217;s option, to enforce same with respect to any defect discovered in such equipment within one (1) year after the Substantial Completion Date and (ii) to enforce all other warranties or guaranties with respect to any defect discovered in the Work within one (1) year after the Substantial Completion Date.</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Maintenance and Repairs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The second full paragraph of Paragraph 15(c) of the Lease is hereby deleted in its entirety and replaced with the following language,</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;If at any time after the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) anniversary of the Substantial Completion Date, Pacific Biosciences of California, Inc. (the named tenant hereunder) (i) assigns this Lease by operation of law or otherwise other than to a Permitted Transferee, (ii) fails to provide copies of all service contracts and all service, maintenance, repair and replacement records (whether performed by Lessee&#8217;s trained and certified personnel or by outside vendors) with respect to Systems Repairs required to be performed by Lessee in the Premises to Lessor on a timely basis, without necessity of request therefor, (iii) fails to require that all vendors maintain insurance reasonably satisfactory to Lessor naming Lessor and the Additional Insureds named in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as &#8220;Additional Insured&#8221;, (iv) fails to perform the Systems Repairs in accordance with the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (v) fails to provide such service, maintenance, repair or replacement at quality and frequency levels at least equal to the quality and frequency levels Lessor would maintain if it were providing such services (as evidenced by Lessor&#8217;s maintenance of the balance of the Menlo Business Park), or (vi) fails to satisfy any of the Maintenance Requirements, and following such breach Lessee fails to commence a cure of any breach of the obligations set forth in (ii), (iii), (iv), (v) or (vi) within five (5) business days after receipt of written notice from Lessor and, thereafter, to diligently prosecute the cure to completion three (3) or more times in a twelve (12) month period then, the Parties agree that Lessor may, in its discretion, elect to assume or resume responsibility for maintenance, repair and replacement of the systems described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 15(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">(ii),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above, and include the cost in Operating Expenses as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding the cure period set forth in the immediately preceding sentence, the parties hereby agree and acknowledge that if Lessee fails more than once in a twelve (12) month period to cure a breach of any of the obligations set forth in (ii), (iii), (iv), (v) or (vi) within a reasonable time after receipt of written notice from Lessor, then Lessor may elect to assume or resume responsibility for maintenance, repair and replacement of the systems as set forth herein. Any such election by Lessor shall be effective immediately upon written notice to the Lessee of Lessor&#8217;s intent to assume or resume such service, maintenance, repair and replacement. Any Lessor notice referred to above must set forth in reasonable detail the nature and extent of the failure referencing pertinent Lease provisions.&#8221;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.288%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WEST&#92;274613282.7</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2.28pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr></table></div><div style="padding-right:0.2pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Maintenance Programs and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The second sentence of the third paragraph of Paragraph 15(c) is hereby deleted in its entirety and replaced with the following language,</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Lessee agrees to provide Lessor with a copy of Lessee&#8217;s internal maintenance programs and procedures within one hundred eighty (180) days of the Commencement Date hereof, and again at any time upon receipt of Lessor&#8217;s request therefor.&#8221; </font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Surrender&#47;Restoration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Paragraph 15(h) of the Lease is hereby amended to provide that the state of repair for purposes of determining Lessee&#8217;s obligation to surrender the Premises shall not be as of the Commencement Date, but rather the state of repair existing as of Substantial Completion Date.</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Modifications to the Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Lease is further modified as follows&#58;</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The term &#8220;Commencement Date&#8221; in Paragraph 6(d)(10) of the Lease is hereby replaced with the term &#8220;Substantial Completion Date&#8221;, as defined in this Amendment.</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The term &#8220;Commencement Date&#8221; in first sentence of Paragraph 23 of the Lease is hereby replaced with the term &#8220;Substantial Completion Date&#8221;, as defined in this Amendment.</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Continuing Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All of the terms and conditions of the Lease shall remain in full force and effect, as the Lease is amended by this Amendment.</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If any provision of this Amendment conflicts with the Lease, the provisions of this Amendment shall control.</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warranty of Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each party represents and warrants to the other that the person signing this Amendment is duly and validly authorized to do so on behalf of the entity it purports to so bind, and if such party is a limited liability company or a corporation, that such limited liability company or corporation has full right and authority to enter into this Amendment and to perform all of its obligations hereunder and that it has obtained all necessary consents and approvals to enter into this Amendment.</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No binding agreement between the parties pursuant hereto shall arise or become effective until this Amendment has been duly executed by both Lessor and Lessee and a fully executed copy of this Amendment has been delivered to both Lessor and Lessee. This Amendment may be executed in one or more counterparts, each of which shall be an original, but all of which, taken together, shall constitute one and the same Amendment.</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Amendment is governed by the Electronic Signatures in Global and National Commerce Act (15 U.S.C. &#167;&#167; 7001 et seq.) and the laws of the State of California without regard to its conflicts of law rules.</font></div><div style="margin-bottom:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div style="margin-bottom:12pt;padding-left:0.1pt;padding-right:0.1pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signatures continue on the next page&#93;</font></div><div style="margin-bottom:12pt;padding-left:0.1pt;padding-right:0.1pt;text-align:center;text-indent:36pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.288%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WEST&#92;274613282.7</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2.28pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr></table></div><div style="padding-right:0.2pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-right:0.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Lessor and Lessee have duly executed this Amendment as of the date first set forth above.</font></div><div style="padding-left:72.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.096%"><tr><td style="width:1.0%"></td><td style="width:8.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.991%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lessor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MENLO PARK PORTFOLIO II, LLC,</font></div></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a Delaware limited liability company</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font></div></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PREHC MENLO PARK PORTFOLIO II MEMBER, LLC,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a Delaware limited liability company</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Its&#58; Co-Managing Member</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font></div></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRINCIPAL REAL ESTATE INVESTORS, LLC,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a Delaware limited liability company, authorized signatory</font></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Kevin Anderegg</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; </font></div></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kevin Anderegg</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; </font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assistant Managing Director</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Sara Hoffman</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; </font></div></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sara Hoffman</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; </font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assistant Financial Controller</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font></div></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TPI INVESTORS 11, LLC, a California limited liability company</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font></div></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TARLTON PROPERTIES, INC., a California corporation</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Its&#58; </font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managing Member</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; John C. Tarlton</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; </font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">John C. Tarlton</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CEO</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lessee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.,</font></div></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a Delaware corporation</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ben Gong</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Printed Name&#58; </font></div></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ben Gong</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Its&#58; </font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VP Finance</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Printed Name&#58; </font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Its&#58; </font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr></table></div><div style="margin-top:12pt;padding-right:0.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WEST&#92;274613282.7</font></div><div style="padding-right:0.2pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:0.1pt;padding-right:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT &#8220;A&#8221;</font></div><div style="padding-left:0.1pt;padding-right:0.1pt;text-align:center"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div style="margin-bottom:12pt;padding-left:0.1pt;padding-right:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Floor Plan </font></div><div style="margin-bottom:12pt;padding-left:0.1pt;padding-right:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;See Attached&#93;</font></div><div style="padding-left:0.1pt;padding-right:0.1pt;text-align:center"><font style="font-family:'Tahoma',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.288%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2.18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WEST&#92;274613282.7</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2.28pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:-2.18pt"><font><br></font></div></td></tr></table></div><div style="padding-right:0.2pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:0.1pt;padding-right:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>8
<FILENAME>pacb-exx1020xpacbioseconda.htm
<DESCRIPTION>EX-10.20
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie73579ecf41d4d639a69e66a4e488c1a_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.20</font></div></div><div style="margin-bottom:18pt;padding-left:72pt;padding-right:72pt;text-align:center;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SECOND AMENDMENT TO LEASE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THIS SECOND AMENDMENT TO LEASE (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is made as of December 30, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), by and between MENLO PARK PORTFOLIO II, LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lessor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and PACIFIC BIOSCIENCES OF CALIFORNIA, INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lessee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;Lessor and Lessee entered into that certain Lease, dated as of July 22, 2015, as amended by that certain First Amendment to Lease, dated as of December 23, 2016 and that certain Commencement Date Memorandum, dated December 23, 2016 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), pertaining to the premises located at 1315 O&#8217;Brien Drive, Menlo Park, California (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;Lessor and Lessee desire to amend the Lease as set forth herein.  Unless otherwise defined herein, all capitalized terms in this Amendment shall have the same meaning ascribed to them in the Lease.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">TERMS AND CONDITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In consideration of the mutual covenants herein contained, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Lessor and Lessee agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Lessee&#8217;s Pro Rata Share of Operating Expenses and Park Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  From and after the Effective Date, Lessee&#8217;s Pro Rata Share of Operating Expenses appearing in Paragraph 6(a) of the Lease is hereby revised and thereafter shall be equal to Eighty-Two and Seventy-Six hundredths percent (82.76%).  From and after the Effective Date, Lessee&#8217;s Pro Rata Share of Park Expenses appearing in Paragraph 6(a) of the Lease is hereby revised and thereafter shall be equal to Twenty-Three and Seventy-Five hundredths percent (23.75%). The Pro Rata Share of Park Expenses (23.75%) is comprised of the following (the Cost Pools)&#58; Security Service &#61; 15.48%&#59; Amenities Service &#61; 21.14%&#59; Landscape Service &#61; 7.51%.  The foregoing Pro Rata Share figures shall be applicable during the entire Lease Term (including prior years). Lessee&#8217;s Pro Rata Share of Park Expenses shall only be subject to adjustment if a new building is constructed on the Property or any other new building is constructed or parcel added to the Menlo Business Park, in which event Lessee&#8217;s Pro Rate Share of Park Expenses will be adjusted in a fair and reasonable manner if and when such new building is constructed on the Property or any other new building is constructed or parcel added to the Menlo Business Park.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Lessee&#8217;s Pro Rata Share of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Effective as of January 1, 2017, Lessee&#8217;s Pro Rata Share of the Taxes appearing in Paragraph 6(a) of the Lease is hereby revised and shall be equal to Eighty-Two and Seventy-Six hundredths percent (82.76%).    </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Final Resolution for Period Prior to December 31, 2018.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  As a result of the adjustment to Lessee&#8217;s Pro Rata Share of Operating Expenses and Lessee&#8217;s Pro Rata Share of Park Expenses, as set forth in Section 1 above, Lessee shall receive a credit in the amount of (a) Ninety Nine Thousand Three Hundred Eighty Three and 69&#47;100 Dollars ($99,383.69) and (b) Eighty Ninety Thousand Two Hundred Forty Two and 11&#47;100 Dollars ($89,242.11), respectively, which amounts shall be credited against payments of Additional Rent next due hereunder.  Additionally, as a result of the adjustment to Lessee&#8217;s Pro Rata Share of the Taxes as set forth in Section 2 above, Lessee shall receive a credit in the amount of Two Hundred Twelve Thousand One Hundred Sixteen and 58&#47;100 Dollars ($212,116.58), which amount shall be credited against payments of Additional Rent next due hereunder.  Lessor and Lessee agree that there shall be no</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> further credits, payments, adjustments or reconciliations for Operating Expenses, Park Expenses or Taxes related to any period prior to December 31, 2018, other than as expressly set forth in this Section 3.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Commencing as of January 1, 2020 and continuing during the initial term of the Lease, Lessee shall receive a credit in the amount of Ten Thousand and 00&#47;100 Dollars ($10,000.00) per month (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Monthly Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) towards Lessee&#8217;s obligation to pay Lessee&#8217;s Pro Rata Share of Operating Expenses, Park Expenses and Taxes as set forth in Paragraph 6 of the Lease.  The Operating Statement provided by Lessor to Lessee pursuant to Paragraph 6(e) shall include a line item for the total Monthly Credit applicable to each calendar year of the initial term. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Parking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The first sentence of Paragraph 29 is hereby deleted in its entirety and replaced with the following language,</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Lessee shall have the right to use Four Hundred Twenty-Five (425) parking spaces at no additional cost to Lessee during the initial term of the Lease, in the parking area for the Building or nearby parking areas in Menlo Business Park, subject to such rules and regulations for such parking facilities which may be established or altered by Lessor at any time from time to time during the Lease Term&#59; provided, however, that if Lessor builds a parking structure in the Menlo Business Park during the Lease Term (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Parking Structure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Lessor shall grant to Lessee the non-exclusive use of One Hundred (100) unreserved on-site vehicular parking spaces within such structure at no additional base rent to Lessee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">for the initial Term of the Lease&#59; provided, however, that the parties agree and acknowledge that the Lessee&#8217;s Pro-Rata Share of Operating Expenses, Taxes or Park Expenses shall be adjusted in a fair and reasonable manner if and when the Parking Structure is built to include the costs, taxes or expenses related to the Parking Structure (provided, that, in no event shall Operating Expenses, Taxes or Park Expenses include costs, taxes or expenses related to the intial design, construction or replacement of the Parking Structure) and such adjustments would be finalized upon completion of the Parking Structure using the following % calculations&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Parking Structure Operating Expense Percentage&#58; Lessee parking spaces &#47;total number of parking spaces in the Parking Structure. Sample calculation based on current estimated number of Parking Structure spaces&#58; 100&#47;689 &#61; 14.51%  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Taxes&#58; final cost to build Lessee&#8217;s 100 spaces&#47;final assessors value of entire project including the Parking structure and building, future TI&#8217;s and land. Sample calculation based on current estimates&#58; $6,634,300 &#47; ($127,096,170 + $39,000,000 + $7,300,000) &#61; 3.83%.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Continuing Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All of the terms and conditions of the Lease shall remain in full force and effect, as the Lease is amended by this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If any provision of this Amendment conflicts with the Lease, the provisions of this Amendment shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Warranty of Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each party represents and warrants to the other that the person signing this Amendment is duly and validly authorized to do so on behalf of the entity it purports to so bind, and if such party is a limited liability company or a corporation, that such limited liability company or corporation has full right and authority to enter into this Amendment and to perform all of its obligations hereunder and that it has obtained all necessary consents and approvals to enter into this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No binding agreement between the parties pursuant hereto shall arise or become effective until this Amendment has been duly executed by both Lessor and Lessee and a fully executed copy of this Amendment has been delivered to both Lessor and Lessee.  This Amendment may be</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">executed in one or more counterparts, each of which shall be an original, but all of which, taken together, shall constitute one and the same Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Amendment is governed by the Electronic Signatures in Global and National Commerce Act (15 U.S.C. &#167;&#167; 7001 et seq.) and the laws of the State of California without regard to its conflicts of law rules.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Signatures continue on the next page&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><div id="ie73579ecf41d4d639a69e66a4e488c1a_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#96;</font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lessor and Lessee have duly executed this Amendment as of the date first set forth above.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.012%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lessor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MENLO PARK PORTFOLIO II, LLC, </font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a Delaware limited liability company</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;GAVI PREHC HC, LLC, </font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;a Delaware limited liability company</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Its&#58;  Co-Managing Member</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:38.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;PRINCIPAL REAL ESTATE INVESTORS, LLC,&#160;&#160;&#160;&#160;</font></div><div style="padding-left:38.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;a Delaware limited liability company, authorized signatory</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:38.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:74.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Jeffrey D. Uittenbogaard</font></div><div style="padding-left:74.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Jeffrey D. Uittenbogaard</font></div><div style="padding-left:74.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Investment Director Asset Management</font></div><div style="padding-left:74.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:38.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;      TPI INVESTORS 11, LLC, a California limited liability company</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58;      TARLTON PROPERTIES, INC., a California corporation</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Its&#58;       Managing Member</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;          By&#58; &#47;s&#47; Ronald W. Krietemeyer</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; Ronald W. Krietemeyer</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Chief Operating Officer</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lessee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC., </font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a Delaware corporation</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Ben Gong</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Printed Name&#58;  Ben Gong</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Its&#58; VP, Finance</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>9
<FILENAME>pacb-exx1021xpacbiox1305ob.htm
<DESCRIPTION>EX-10.21
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ieb2726b68bcb448a913ba22ca4c46d6f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.21</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIRD AMENDMENT TO LEASE <br></font></div><div style="margin-bottom:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">THIS THIRD AMENDMENT TO LEASE (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) is made as of February 27, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">MENLO PARK PORTFOLIO II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Lessor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Lessee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Lessor and Lessee are parties to that certain Lease, dated as of July 22, 2015, as amended by that certain First Amendment to Lease, dated as of December 23, 2016, as further amended by that certain Commencement Date Memorandum, dated December 23, 2016, and as further amended by that certain Second Amendment to Lease, dated December 30, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Second Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; and as collectively amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), with respect to certain premises located at 1305 O&#8217;Brien Drive, Menlo Park, California&#160;(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The existing Term of the Lease will expire on October 31, 2027. Lessor and Lessee desire to amend the Lease to extend the Term of the Lease and modify other provisions of the Lease, all as more particularly set forth herein.  Capitalized terms used and not otherwise defined herein shall have the same meanings ascribed to them in the Lease.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TERMS AND CONDITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Lessor and Lessee agree that the Lease is amended as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:27pt;text-decoration:underline">Extension of the Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Effective as of the date hereof, the Term of the Lease is hereby extended for an additional period of seventy-eight (78) months (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Extended Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) so that the Extended Term shall commence on November 1, 2027 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Revised Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) and expire unless terminated sooner pursuant to the terms of the Lease, on April 30, 2034 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Revised Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  All references to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; in the Lease and this Amendment shall be deemed references to the Term as extended by this Amendment and all references to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; shall be deemed references to the Revised Expiration Date.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Monthly Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:22.7pt;text-decoration:underline">Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Effective as of the Revised Commencement Date and in addition to Additional Rent and all other costs and expenses payable by Lessee pursuant to the Lease, Lessee shall pay the following Monthly Base Rent for the Premises in accordance with the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Paragraph 6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Lease&#58;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.463%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PERIOD</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Square Feet</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$&#47;SF&#47;Mo.&#47;NNN</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MONTHLY BASE RENT</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:15.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11&#47;1&#47;2027-10&#47;31&#47;2028</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">180,231</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$5.70</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;$1,027,316.70</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:15.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11&#47;1&#47;2028-10&#47;31&#47;2029</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">180,231</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$5.87</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;$1,058,136.20</font></div></td></tr></table></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.463%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:15.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11&#47;1&#47;2029-10&#47;31&#47;2030</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">180,231</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6.05</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;$1,089,880.29</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:15.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11&#47;1&#47;2030-10&#47;31&#47;2031</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">180,231</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6.23</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;$1,122,576.70</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:15.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11&#47;1&#47;2031-10&#47;31&#47;2032</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">180,231</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6.42</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;$1,156,254.00</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:15.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11&#47;1&#47;2032-10&#47;31&#47;2033</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.83pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">180,231</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6.61</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;$1,190,941.62</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:15.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11&#47;1&#47;2033-4&#47;30&#47;2034</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.83pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">180,231</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6.81</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;$1,226,669.86</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:22.02pt;text-decoration:underline">Abatement of Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lessee&#8217;s Monthly Base Rent shall be abated for the first seventeen (17) full months following the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Abatement Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), if and for so long as Lessee is not in material default under the Lease beyond all applicable notice and cure periods (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). The total eligible abatement of Monthly Base Rent pursuant to the foregoing based on the assumptions that the Abatement Period commences on March 1, 2025 and ends July 31, 2026 and that Lessee is not in Default during the Abatement Period shall be Eleven Million Six Hundred Forty-One Thousand  Sixty-Four and 52&#47;100 Dollars ($11,641,064.52). The foregoing abatement of Monthly Base Rent payable by Lessee shall not be construed as an abatement of any other rent, Additional Rent, or charges payable under the Lease, as amended by this Amendment, including without limitation, Lessee&#8217;s Pro Rata Share of Operating Expenses of the Property, Lessee&#8217;s Pro Rata Share of the Park Expenses and Lessee&#8217;s Pro Rata Share of Taxes in accordance with the terms of the Lease. If Lessee Defaults under the terms of this Lease, and such Default results in the termination of this Lease in accordance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Paragraph 23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Lease, then the amount of the abated Monthly Base Rent through the date of such termination (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Abated Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) shall immediately become due and payable as part of Additional Rent under this Lease as of the day prior to such termination. In such event, as a part of the recovery set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Paragraph 23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Lease, Lessor shall be entitled to recover, in addition to any other amounts due from Lessee, the amount of the Abated Base Rent due under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> as Additional Rent.  Notwithstanding the foregoing or anything to the contrary set forth in the Lease or this Amendment, at any time during the Abatement Period, Lessor shall have the right (but not the obligation), in its sole and absolute discretion, to pay Lessee all or a portion of the total amount of the then unamortized amount of the abated Monthly Base Rent during the Abatement Period, in which event (i) Lessee&#8217;s obligation to pay Monthly Base Rent shall automatically be reinstated for the remainder of the Abatement Period covered by Lessor&#8217;s lump sum payment, at the then-applicable amounts and otherwise in accordance with the terms of the Lease and this Amendment, and (ii) Lessee shall not be entitled to any additional abated Monthly Base Rent under this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:27pt;text-decoration:underline">Additional Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  During the Extended Term and in addition to the Monthly Base Rent set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of this Amendment, Lessee shall continue to pay all Additional Rent for the Premises, including without limitation, Lessee&#8217;s Pro Rata Share of Operating Expenses of the Property, Lessee&#8217;s Pro Rata Share of the Park Expenses and Lessee&#8217;s Pro Rata Share of Taxes in accordance with the terms of the Lease, as amended herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:27pt;text-decoration:underline">Lessee&#8217;s Pro Rata Share of Operating Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  From and after the Effective Date, Lessee&#8217;s Pro Rata Share of Operating Expenses of the Property appearing in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Paragraph 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:10.00pt">&#160;&#160;&#160;&#160;2</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">the Second Amendment is hereby revised and thereafter shall be equal to Ninety-Four and Sixty-Six hundredths percent (94.66%) (180,231&#47;190,389).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:27pt;text-decoration:underline">Lessee&#8217;s Pro Rata Share of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. From and after the Effective Date, Lessee&#8217;s Pro Rata Share of Taxes appearing in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Paragraph 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Second Amendment is hereby revised and thereafter shall be equal to Ninety-Four and Sixty-Six hundredths percent (94.66%).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Tenant Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:22.7pt;text-decoration:underline">Approved Space Plan&#59; Tenant Improvement Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Following execution of this Amendment, Lessor and Lessee shall work cooperatively to approve the scope of and complete detailed plans for the construction of certain improvements and modifications to the Premises (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Tenant Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). Rather than a single, comprehensive space plan, the Tenant Improvements shall be completed on a phased basis, with Lessee submitting various project-specific space plans for approval (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Approved Space Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) throughout the period from the Effective Date of this Amendment through the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Outside Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; (as defined below). For each phase, Lessor shall cause the Tenant Improvements to be constructed in the Premises in accordance with the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. For each Approved Space Plan submitted by Lessee, subject to Lessee&#8217;s approval, not to be unreasonably withheld, conditioned, or delayed, Lessor shall select an architect (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Architect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) and an engineer (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Engineer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) familiar with the Building Requirements and with all Applicable Laws. Lessor shall engage and manage the Architect and Engineer to prepare, based upon and in conformity with each Approved Space Plan, detailed specifications and engineered working drawings for the respective Tenant Improvements (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Tenant Improvement Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). Lessor and Lessee shall mutually agree upon a schedule of dates for deliveries and receipt of approvals for each phase (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). Lessee shall have the right to review and approve the Tenant Improvement Documents for each phase&#59; provided, however, that so long as the Tenant Improvement Documents are consistent with the applicable Approved Space Plan, Lessee&#8217;s approval shall not be unreasonably withheld, conditioned, or delayed, and such approval shall otherwise be given within the timeframes set forth in the Schedule. Prior to the approval dates set forth in the Schedule, if Lessee requests that Lessor make any changes to the Tenant Improvement Documents, Lessor and Lessee shall work together in good faith to promptly agree upon any changes necessary to ensure the Tenant Improvement Documents are consistent with the applicable Approved Space Plan and any previously approved Tenant Improvement Documents. Provided that Lessor delivers to Lessee the Tenant Improvement Documents in compliance with the dates set forth in the Schedule for each phase, Lessee shall approve the Tenant Improvement Documents by the applicable final approval dates (&#8220;Final Approval Dates&#8221;) specified in the Schedule. Lessee&#8217;s failure to approve the Tenant Improvement Documents by the applicable Final Approval Date shall constitute a Lessee delay, and Lessor&#8217;s failure to submit the Tenant Improvement Documents at least five (5) days in advance of the applicable Final Approval Dates shall constitute a Lessor delay.      </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:22.02pt;text-decoration:underline">General Contractor&#59; Construction Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Following completion of each phase of the Tenant Improvement Documents and subject to Lessee&#8217;s approval, not to be unreasonably withheld, conditioned, or delayed, Lessor shall select a general contractor (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">General</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:10.00pt">&#160;&#160;&#160;&#160;3</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Contractor&#8221;) familiar with the Building Requirements and with all Applicable Laws. As soon as reasonably practicable, the General Contractor shall cause to be prepared, and delivered to Lessor and Lessee, a cost estimate for each phase of the Tenant Improvements. Lessor and Lessee shall cooperate to achieve efficiencies in the cost of the Tenant Improvements and shall confer and negotiate in good faith to reach agreement on a Final Budget for each phase of the Tenant Improvements (such approved budget, the &#8220;Final Budget&#8221;). Lessor shall use commercially reasonable efforts to enter into a commercially reasonable stipulated sum construction contract with the General Contractor (the &#8220;Construction Contract&#8221;) in the amount of the Final Budget applicable to each phase of the Tenant Improvements. In no event shall the contract sum under the Construction Contract increase without Lessee&#8217;s prior written consent, not to be unreasonably withheld, conditioned, or delayed.  Lessor shall provide Lessee with a copy of the proposed Construction Contract prior to execution for Lessee's approval and shall provide Lessee with a copy of the approved Construction Contract following execution thereof with General Contractor. Lessee&#8217;s approval of the Construction Contract shall not be unreasonably withheld, conditioned, or delayed. If Lessee objects to any term(s) of the proposed Construction Contract, Lessee shall promptly work with Lessor to resolve such concerns so as not to delay completion of the Tenant Improvements. Lessee&#8217;s failure to timely approve the Construction Contract shall be a Lessee delay.  Lessee agrees and understands that the review of the plans pursuant to this Section 6 by Lessor is solely to protect the interests of Lessor in the Building and the Premises, and Lessor shall not be the guarantor of, nor responsible for, the correctness or accuracy of any such plans or compliance of such plans with Applicable Laws&#59; provided, however, Lessor shall obtain all necessary permits from the City or applicable governmental agency with jurisdiction for each Approved Space Plans as required by Applicable Laws.  Lessor agrees to (i) use reasonable efforts to assign any assignable warranties or guaranties provided by the contractors or manufacturers of equipment to be maintained by Lessee pursuant to the Lease (if any) provided as part of the Tenant Improvements or, at Lessee's option, to enforce the same with respect to any defect discovered in such equipment within one (1) year after the substantial completion date of the applicable phase of the Tenant Improvements and (ii) to enforce all other warranties and guaranties with respect to any defect discovered in the Tenant Improvements within one (1) year after the substantial completion date of the applicable phase of the Tenant Improvements.  Lessor agrees to obtain a one-year warranty against construction defects in the Tenant Improvements for a period of one year following substantial construction applicable to each phase of the Tenant Improvements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:22.7pt;text-decoration:underline">Construction Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Promptly after Lessor and Lessee have approved the applicable phase of the Tenant Improvement Documents and its corresponding Final Budget, the General Contractor shall (i) provide Lessor and Lessee with a construction schedule (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Construction Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) and (ii) commence construction of the Tenant Improvements. Each phase of the Tenant Improvements shall be performed in accordance with the approved Tenant Improvement Documents, Final Budget, and Construction Schedule applicable thereto in a diligent, good and workmanlike manner using new materials. The Tenant Improvements shall comply in all respects with the following&#58; (a) the City of Menlo Park Building Code and other state, federal, city or quasi-governmental laws, codes, ordinances and regulations, as each may apply according to the rulings of the controlling public official, agent or other person&#59; (b) applicable standards of the American Insurance Association (formerly, the National Board of Fire</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:10.00pt">&#160;&#160;&#160;&#160;4</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Underwriters) and the National Electrical Code&#59; and (c) building material manufacturer's specifications. Lessee hereby acknowledges that the Lessor may be required to cause union-only labor to be utilized on some portions of the Tenant Improvements, including, without limitation, mechanical, electrical and plumbing. Lessee acknowledges that the Tenant Improvements will be performed during Lessee&#8217;s occupancy and use of the Premises, and may result in inconvenience to Lessee.  Lessee will fully cooperate with Lessor&#8217;s efforts to efficiently complete the Tenant Improvements.   Lessor shall use reasonable efforts to minimize interference with Lessee's use and occupancy of the Premises during the performance of the Tenant Improvements, and Lessor shall perform the Tenant Improvements in a manner which will&#160;ensure&#160;a secure and safe work site is maintained at all times, mitigate noise throughout the Premises, keep the Premises clean of dust and debris, and which provides customary protective measures for areas of the Premises in the immediate vicinity of the Tenant Improvements. Without limiting the foregoing, at Tenant&#8217;s request, the Construction Schedule shall provide that all disruptive Tenant Improvements shall be performed outside of ordinary business hours.  Lessee hereby agrees that the performance of the Tenant Improvements shall in no way constitute a constructive eviction of Lessee or entitle Lessee to any abatement of rent payable pursuant to the Lease.  At the conclusion of construction, the General Contractor and Designer shall notify Lessor and Lessee of the substantial completion of the Tenant Improvements. At the conclusion of construction, the General Contractor shall also deliver to Lessor (who shall deliver copies of the same to Lessee) (i) &#8220;As-Built&#8221; plans of the Tenant Improvements in hard copy together with a digital copy (in such commercially reasonable format as shall be designated by Lessor), and (ii) lien waivers&#47;releases from the General Contractor and all of its sub-contractors reflecting that the cost of the Tenant Improvements has been paid in full.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:22.02pt;text-decoration:underline">Change Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In the event that Lessee desires to make any changes to the approved Tenant Improvement Documents, Lessee shall seek Lessor&#8217;s prior written approval of any such changes before they are made and such changes, as well as any Lessee delay or change in the Final Budget resulting therefrom, must be identified in an approved written &#8220;Change Order&#8221; prior to proceeding with such changes. Changes requested by Lessee to the dates set forth in the Schedule and&#47;or the Construction Schedule shall also be done via a written Change Order approved by Lessor. Change Orders for work on any Approved Space Plan submitted prior to the Outside Date but completed afterward shall follow the same procedures set forth in this section.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Tenant Improvement Allowance&#59; Tenant Improvement Shortfall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lessor shall contribute up to, but not exceeding Seven Million Two Hundred Nine Thousand Two Hundred Forty and 00&#47;100 Dollars ($7,209,240.00) which amount equates to Forty Dollars ($40.00) per rentable square foot of the Premises (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Tenant Improvement Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) for costs relating to the initial design and construction of the Tenant Improvements. The Tenant Improvement Allowance shall be used to pay for the cost of (i) the construction drawings for the Tenant Improvements within the Premises, (ii) engineering required in connection with the performance of such work, (iii) all permit fees required by any administrative or governmental agency in connection with the performance of the Tenant Improvements or other costs expended in obtaining approvals and permits, (iv) General Contractor, subcontractors, vendors, and suppliers costs and charges for materials, supplies and labor, contractor&#8217;s profit, overhead and general conditions, (v) Change Orders, and (vi) Supervision Fee (as defined below). Lessee shall be liable</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:10.00pt">&#160;&#160;&#160;&#160;5</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">for all fees and costs of the design and construction of the Tenant Improvements in excess of the Tenant Improvement Allowance (such amount referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Tenant Improvement Shortfall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). Lessor shall disburse the Tenant Improvement Allowance directly to the applicable design professionals, contractors, materialmen or other laborers in connection with the construction of the Tenant Improvements. Lessee shall pay the Tenant Improvement Shortfall upon written request from Lessor accompanied by invoices reflecting such amounts due within thirty (30) days following Lessor&#8217;s delivery of such payment request. The Tenant Improvement Shortfall shall be invoiced and paid monthly as the construction costs are incurred during construction of the Tenant Improvements and shall be payable in proportion to the percentage that the Tenant Improvement Shortfall bears to the total cost of the Tenant Improvements. Following completion of each phase of the Tenant Improvements and final determination of the cost of the Tenant Improvement Shortfall for that phase, the parties shall review and reconcile any underpayments or overpayments by Lessee of the Tenant Improvement Shortfall. Lessor shall employ Tarlton Properties, Inc. as construction manager for the Tenant Improvements at a fee (the &#8220;Supervision Fee&#8221;) equal to three percent (3%) of hard construction costs of the Tenant Improvements (i.e., the amounts paid to any general contractor, subcontractors, vendors, and suppliers for labor and materials for the construction of the Tenant Improvements). The Tenant Improvements shall be constructed on an &#8220;open book&#8221; basis and Lessee shall have the right to reasonably audit and inspect all relevant costs, books and records related to the Tenant Improvements in Lessor&#8217;s office during normal business hours upon not less than forty-eight hours&#8217; advance written notice to Lessor. Lessee must complete its final audit and review within sixty (60) days of Lessor&#8217;s payment of final invoices for the Tenant Improvements. Lessee shall have no responsibility for and the Tenant Improvement Allowance shall not be used for the following&#58;  (a) attorneys' fees, experts' fees and other costs in connection with disputes with third parties&#59; (b) interest and other costs of financing construction costs, if any, incurred by Lessor&#59; (c) costs incurred as a consequence of Lessor Delay&#59; (d) costs recovered by Lessor upon account of warranties and insurance&#59; (e) provided Lessee promptly pays its Tenant Improvement Shortfall as and when invoiced, and for increases in costs resulting from Tenant Delays or Change Orders, penalties and late charges attributable to Lessor's failure to pay construction costs for which Lessor is responsible hereunder (not including any costs associated with construction, installation or equipment directly contracted for by Lessee)&#59; and (f) construction management and overhead charges of Lessor other than the Supervision Fee. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:24.03pt;text-decoration:underline">Outside Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  If any portion of the Tenant Improvement Allowance is not used by Lessee prior to December 31, 2027 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Outside Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), such portion shall be deemed waived with no further obligation by Lessor with respect thereto&#59; provided, however, if Lessee and Lessor have approved the Tenant Improvement Documents for one or more Approved Space Plans by October 1, 2027, and there remains Tenant Improvement Allowance funds available, such remaining funds may be applied towards such Approved Space Plan(s) within the time period set forth herein, even if the associated Tenant Improvements are completed after the Outside Date, but in no event shall the Tenant Improvement Allowance funds be available for any project after December 31, 2028.  Notwithstanding the foregoing, if all necessary permits with respect to an Approved Space Plan have been obtained and construction work has commenced on the project prior to December 31, 2028, then Lessee shall have until June 30, 2029 to use any remaining Tenant Improvement Allowance funds available for such project.  If the total cost of the Tenant</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:10.00pt">&#160;&#160;&#160;&#160;6</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Improvements is less than the amount of the Tenant Improvement Allowance, and provided that Lessee is not in Default under this Lease, then Lessee shall have the option, exercised by written notice to Lessor delivered prior to the Outside Date, to use an amount equal to the difference between the total cost of the Tenant Improvements and the Tenant Improvement Allowance, such amount not to exceed $10.00 per rentable square foot of the Premises (the &#8220;Excess Allowance&#8221;) to pay for Lessee&#8217;s furniture, fixtures and equipment within the Premises (the &#8220;FF&#38;E Credit&#8221;).  If Lessee does not use all of the Excess Allowance prior to December 31, 2028, as may be extended as set forth above, then such unused portion of the Excess Allowance shall thereafter be deemed waived with no further obligation by Lessor with respect thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:27pt;text-decoration:underline">Option to Extend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  All references to the &#8220;Extended Term&#8221; in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Paragraph 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Lease shall be deemed references to the Second Extended Term (as hereinafter defined) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Paragraph 3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Lease is hereby deleted in its entirety and replaced with the following language&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;(a)&#160;&#160;&#160;&#160;Lessor hereby grants to Lessee one (1) option to extend the Term of this Lease (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Option to Extend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) for a period of ten (10) years (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Second Extended Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) immediately following the expiration of the Extended Term. Lessee may exercise the Option to Extend by giving written notice of exercise to Lessor at least nine (9) months but no more than twelve (12) months prior to the expiration of the Extended Term of this Lease (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Option Exercise Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), time being of the essence&#59; provided that if (i) at any time between the date of delivery of the exercise notice by Lessee and the end of the Extended Term there is an uncured Default continuing beyond any applicable notice and cure periods, or (ii) Lessee is then occupying and conducting operations for the Use permitted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Paragraph 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Lease in less than fifty-one percent (51%) of the Premises, then such notice shall be void and of no force or effect. The Second Extended Term, if the Option to Extend is exercised, shall be upon the same terms and conditions as the Extended Term of this Lease, including the payment by Lessee of the Additional Rent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Paragraph 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Lease, except that (A) Lessee shall pay Monthly Base Rent, as determined as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Paragraph 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of this Lease, during the Second Extended Term, (B) there shall be no additional option to extend, and (C) Lessee shall accept the Premises in their then &#8220;as is&#8221; condition and Lessor shall have no obligation to provide a tenant improvement allowance. If Lessee does not exercise the Option to Extend in a timely manner the Option to Extend shall lapse, time being of the essence.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:27pt;text-decoration:underline">Condition of the Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Expect as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> above, Lessor shall have no obligation whatsoever to construct leasehold improvements for Lessee or to repair or refurbish the Premises (except for Lessor&#8217;s express repair and maintenance obligations set forth in the Lease).  Subject to the foregoing, the taking of possession of the Premises by Lessee shall be conclusive evidence that Lessee accepts the same &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">AS IS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; and that the Premises is suited for the use intended by Lessee and was in good and satisfactory condition as of the Effective Date.  Lessee acknowledges that neither Lessor nor Lessor&#8217;s agents has made any representation or warranty as to the condition of the Premises or the Building or its suitability for Lessee&#8217;s purposes.  Lessee represents and warrants to Lessor that (a)&#160;its sole intended use of the Premises is for uses set forth</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:10.00pt">&#160;&#160;&#160;&#160;7</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">in the Lease, (b)&#160;it does not intend to use the Premises for any other purpose, and (c)&#160;prior to executing this Amendment it has made such investigations as it deems appropriate with respect to the suitability of the Premises for its intended use and has determined that the Premises is suitable for such intended use.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:27pt;text-decoration:underline">Assignment and Subletting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Paragraph 18(b)(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Lease is hereby deleted in its entirety and shall have no further force or effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Security Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lessor is currently holding a Security Deposit in the form of a Letter of Credit in the amount of $1,500,000.00 pursuant to the terms and conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Paragraph 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Lease.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Deletion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Effective as of the Revised Commencement Date, Paragraph 4 of the Second Amendment (Credit) shall be deleted and have no further force and effect. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Civil Code Section 1938 Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. For purposes of Section 1938(a) of the California Civil Code, Lessor hereby discloses to Lessee, and Lessee hereby acknowledges that neither the Building nor the Premises has undergone inspection by a Certified Access Specialist (CASp) (defined by California Civil Code Section 55.52). Pursuant to California Civil Code Section 1938, Lessee is hereby notified that a CASp can inspect the Premises and determine whether the Premises complies with all of the applicable construction-related accessibility standards under state law.  Although state law does not require a CASp inspection of the Premises, Lessor may not prohibit Lessee from obtaining a CASp inspection of the Premises for the occupancy of the Lessee, if requested by Lessee.  Lessor and Lessee shall mutually agree on the arrangements for the time and manner of any CASp inspection, the payment of the fee for the CASp inspection and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the Premises.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">OFAC List Representation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lessee hereby represents and warrants to Lessor that neither Lessee nor any of its officers, directors, or affiliates is or will be an entity or person&#58; (i)&#160;that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order 13224 issued on September 24, 2001 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">EO 13224</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;)&#59; (ii)&#160;whose name appears on the United States Treasury Department&#8217;s Office of Foreign Assets Control (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) most current list of &#8220;Specifically Designated National and Blocked Persons&#8221; (which list may be published from time to time in various mediums including, but not limited to, the OFAC website, http&#58;www.treas.gov&#47;ofac&#47;t11sdn.pdf)&#59; (iii)&#160;who commits, threatens to commit or supports &#8220;terrorism,&#8221; as that term is defined in EO 13224&#59; or (iv)&#160;who is otherwise affiliated with any entity or person listed above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Real Estate Brokers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lessee&#8217;s broker is Savills, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Lessee&#8217;s Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) and Lessor&#8217;s broker is CBRE, Inc., (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Lessor&#8217;s Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; and collectively, with Lessee&#8217;s Broker, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  Each party represents and warrants to the other party that it has not had any dealings with or engaged any other broker, finder or other person other than the Brokers who would be entitled to any commission or fees in respect of the negotiation, execution or delivery of this</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:10.00pt">&#160;&#160;&#160;&#160;8</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Amendment, and each party shall indemnify, defend and hold harmless the other party from all damages, expenses, and liabilities resulting from any claims that may be asserted against the other party by such broker, finder or other person on the basis of any arrangements or agreements made or alleged to have been made by or on behalf of such party.  Lessor shall pay a leasing commission to the Brokers pursuant to the terms of a separate written agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Continuing Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  All of the terms and conditions of the Lease shall remain in full force and effect, as the Lease is amended by this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  If any provision of this Amendment conflicts with the Lease, the provisions of this Amendment shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Warranty of Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Each party represents and warrants to the other that the person signing this Amendment is duly and validly authorized to do so on behalf of the entity it purports to so bind, and if such party is a limited liability company or a corporation, that such limited liability company or corporation has full right and authority to enter into this Amendment and to perform all of its obligations hereunder and that it has obtained all necessary consents and approvals to enter into this Amendment, including from the holder of any Security Instrument, if any exists. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. No binding agreement between the parties pursuant hereto shall arise or become effective. until this Amendment has been duly executed by both Lessor and Lessee and a fully executed copy of this Amendment has been delivered to both Lessor and Lessee. This Amendment may be executed in one or more counterparts, each of which shall be an original, but all of which, taken together, shall constitute one and the same Amendment</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Amendment is governed by the Electronic Signatures in Global and National Commerce Act (15 U.S.C.</font><font style="color:#282626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#167;&#167; 7001 et seq.) and the laws of the State of California without regard to its conflicts of law rule.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SIGNATURES ON NEXT PAGE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">)</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:10.00pt">&#160;&#160;&#160;&#160;9</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><div id="ieb2726b68bcb448a913ba22ca4c46d6f_4"></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the parties hereto have executed this Amendment as of the date first above written.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LESSOR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MENLO PARK PORTFOLIO II, LLC, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware limited liability company</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160; GAVI MENLO PARK PORTFOLIO II MEMBER, LLC,</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;a Delaware limited liability company,</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;its Co-Managing Member</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160; PRINCIPAL REAL ESTATE INVESTORS, LLC, </font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a Delaware limited liability company, its authorized signatory </font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By &#47;s&#47; Alex Mather</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; Alex Mather</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Managing Director</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By &#47;s&#47; Joel Woehler</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; Joel Woehler</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Managing Director</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160; TPI INVESTORS 11, LLC, </font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a California limited liability company, its managing member </font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58;&#160;TARLTON PROPERTIES, INC., a California corporation </font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By &#47;s&#47; Elizabeth Krietemeyer</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; Elizabeth Krietemeyer</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Senior Vice President</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LESSEE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.,</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Mark Van Oene</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Mark Van Oene</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Its&#58; Chief Operating Officer</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:10.00pt">&#160;&#160;&#160;&#160;10</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>10
<FILENAME>pacb-exx1033xpacbiooutside.htm
<DESCRIPTION>EX-10.33
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i84841179587244b18471e196d064705d_1"></div><div style="min-height:55.62pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.33</font></div></div><div style="margin-top:3pt;padding-left:80.97pt;padding-right:80.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:217%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC. OUTSIDE DIRECTOR COMPENSATION POLICY</font></div><div style="padding-left:81pt;padding-right:81pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Effective as of April 6, 2024</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pacific Biosciences of California, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) believes that providing cash and equity compensation to its members of the Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; and members of the Board, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) represents an effective tool to attract, retain and reward Directors who are not Employees of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Outside Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). This Outside Director Compensation Policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is intended to formalize the Company&#8217;s policy regarding cash compensation and grants of equity awards to its Outside Directors. Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning given such term in the Company&#8217;s 2020 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Each Outside Director will be solely responsible for any tax obligations incurred by such Outside Director as a result of the equity and cash payments such Outside Director receives under this Policy.</font></div><div style="margin-top:12pt;padding-left:0.45pt;padding-right:0.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy will be effective as of April 6, 2024 (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;padding-left:40.1pt;text-indent:-16.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.1pt;text-decoration:underline">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">ASH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"> C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">OMPENSATION</font></div><div style="margin-top:1.1pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Annual Cash Retainer</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Outside Director will be paid an annual cash retainer of $40,000. There are no per- meeting attendance fees for attending Board meetings. This cash compensation will be paid quarterly in equal installments in advance.</font></div><div style="margin-top:12pt;padding-left:5.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Committee Annual Cash Retainer</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As of the Effective Date, each Outside Director who serves as the lead Outside Director or Board chair, or the chair or a member of a committee of the Board, will be eligible to earn additional annual fees (paid quarterly in equal installments in advance) as follows&#58;</font></div><div style="margin-top:7pt"><font><br></font></div><div style="padding-left:39.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.895%"><tr><td style="width:1.0%"></td><td style="width:82.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.316%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:13.30pt">Lead Independent Director&#47;Board Chair&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-0.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:13.30pt">$40,000</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chair of Audit Committee&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-0.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$20,000</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Member of Audit Committee&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-0.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$10,000</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chair of Compensation Committee&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:-0.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$14,000</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Member of Compensation Committee&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-0.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$7,000</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chair of Corporate Governance and Nominating Committee&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-0.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$10,000</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Member of Corporate Governance and Nominating Committee&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-0.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$5,000</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.80pt">Chair of Science and Technology Committee&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-0.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.80pt">$10,000</font></div></td></tr></table></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i84841179587244b18471e196d064705d_4"></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:39.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.895%"><tr><td style="width:1.0%"></td><td style="width:82.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.316%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.30pt">Member of Science and Technology Committee&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.30pt">$5,000</font></div></td></tr></table></div><div style="margin-top:6.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For clarity, each Outside Director who serves as the chair of a committee will not receive both the additional annual fee as the chair of the committee and the additional annual fee as a member of the committee.</font></div><div style="margin-top:12pt;padding-left:40.1pt;text-indent:-16.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.1pt;text-decoration:underline">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">QUITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"> C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">OMPENSATION</font></div><div style="margin-top:1.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Outside Directors will be eligible to receive all types of Awards (except Incentive Stock Options) under the Plan (or the applicable equity plan in place at the time of grant), including discretionary Awards not covered under this Policy. All grants of Awards to Outside Directors pursuant to Section 2 of this Policy will be automatic and nondiscretionary, except as otherwise provided herein, and will be made in accordance with the following provisions&#58;</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt;text-decoration:underline">No Discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No person will have any discretion to select which Outside Directors will be granted any Awards under this Policy or to determine the number of Shares to be covered by such Awards.</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.07pt;text-decoration:underline">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to adjustment pursuant to the applicable terms of the Plan, each individual who first becomes an Outside Director following the Effective Date automatically will be granted an Award of Nonstatutory Stock Options (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Option Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and an Award of Restricted Stock Units (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; and together with the Initial Option Award, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that have an aggregate Value (as defined below) as of such Initial Awards&#8217; grant date equal to $450,000, with the Initial Option Award having a Value equal to fifty percent (50%) of such dollar amount and the Initial RSU Award having a Value equal to fifty percent (50%) of such dollar amount&#59; provided that in no event will the aggregate number of Shares subject to the Initial Awards granted to an Outside Director exceed 127,000 Shares. The Initial Awards will be made on the first date on which such individual first becomes an Outside Director (the first date as an Outside Director, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Start Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), whether through election by the stockholders of the Company or appointment by the Board to fill a vacancy. If an individual was a member of the Board and also an Employee, becoming an Outside Director due to termination of employment will not entitle the Outside Director to any Initial Awards. Each Initial Option Award will be scheduled to vest as to one-third (1&#47;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) of the Shares subject to the Initial Option Award on the one (1) year anniversary of the Outside Director&#8217;s Initial Start Date, and thereafter, in equal installments on a monthly basis for the next twenty-four (24) months on the same day of the month as the Outside Director&#8217;s Initial Start Date (or if a particular month does not have a corresponding day within that month, then the last day of that month), in each case subject to the Outside Director continuing to be a Director through the applicable vesting date. Each Initial RSU Award will be scheduled to vest as to one-third (1&#47;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) of the Shares subject to the Initial RSU Award on the one (1), two (2), and three (3) year anniversaries of the Outside Director&#8217;s Initial Start Date, in each case subject to the Outside Director continuing to be a Director through the applicable vesting date.</font></div><div style="margin-top:11.95pt;padding-left:6pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt;text-decoration:underline">Annual Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to adjustment pursuant to the applicable terms of the Plan, effective as of the date of each Annual Meeting (as defined below) occurring after the Effective Date (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual Meeting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), each individual who is an Outside Director as of such date</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.356%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 2 -</font></div></td></tr></table></div></div></div><div id="i84841179587244b18471e196d064705d_7"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3pt;padding-left:5.95pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">will be automatically granted an Award of Nonstatutory Stock Options (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual Option Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and an Award of Restricted Stock Units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; and together with the Annual Option Award, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) with an aggregate Value as of such Annual Awards&#8217; grant date equal to $200,000, with the Annual Option Award having a Value equal to fifty percent (50%) of such dollar amount and the Annual RSU Award having a Value equal to fifty percent (50%) of such dollar amount&#59; provided that in no event will the aggregate number of Shares subject to the Annual Awards granted to an Outside Director as of an Annual Meeting Date exceed 55,000 Shares. Further, the Value of the first Annual Awards to be granted to an Outside Director will be prorated based on the number of months of continuous service such Outside Director provided as a member of the Board during the twelve (12) month period immediately preceding such Annual Meeting Date (with any partial month of service provided rounded up to the nearest whole month) to the extent such individual&#8217;s service as a member of the Board commenced after the date of the immediately preceding Annual Meeting. For purposes of clarity, an individual who is an Outside Director as of an Annual Meeting Date who resigns from such Outside Director role or otherwise ceases to be an Outside Director as of such date, will not be granted any Annual Awards on such date, and an individual who first becomes an Outside Director as of an Annual Meeting Date will be eligible to receive Initial Awards pursuant to subsection (b) above but not any Annual Awards with respect to such Annual Meeting Date. The Annual Option Award will be scheduled to vest monthly over one (1) year, on the same day of the month as the Annual Option Award&#8217;s date of grant (or if a particular month does not have a corresponding day within that month, then the last day of that month) or if earlier, on the date of the next annual meeting of the Company&#8217;s stockholders occurring after the Annual Award&#8217;s date of grant, provided such Outside Director continues to serve as a Director through the applicable vesting dates. The Annual RSU Award will be scheduled to vest on the one (1) year anniversary of the Annual RSU Award&#8217;s date of grant or if earlier, on the date of the next annual meeting of the Company&#8217;s stockholders occurring after the Annual Award&#8217;s date of grant, provided such Outside Director continues to serve as a Director through such vesting date.</font></div><div style="margin-top:6pt;padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.02pt;text-decoration:underline">Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of this Policy, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to an Award or Options or Restricted Stock Units, its grant date fair value (determined in accordance with U.S. generally accepted accounting principles), or such other methodology the Board or Compensation Committee may determine prior to the grant of the Award becoming effective, as applicable&#59; provided, however, that any Award of Options or Restricted Stock Units will cover only a whole number of Shares, such that any fractional Share that otherwise would result from a given Value will be rounded down and will not become subject to such Award. For purposes of clarity, in the event that the Share limit set forth in subsection (b) or (c) above is exceeded, then the aggregate Value of the Initial Awards or Annual Awards, as applicable, will be reduced (while the 50&#47;50 mix of Options and Restricted Stock Units based on Value is maintained) until the aggregate number of Shares subject to such Awards ceases to exceed such Share limit.</font></div><div style="margin-top:6pt;padding-left:6pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt;text-decoration:underline">Other Terms of Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of this Policy, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an annual meeting of the Company&#8217;s stockholders (after giving effect to any postponements and adjournments with respect thereto). Each Award granted under this Policy will be evidenced by the applicable form of Award agreement as approved by the Board or the Compensation Committee of the Board, as applicable, for use thereunder. The per Share exercise price of an Option granted under this Policy will be one hundred percent (100%) of the Fair Market Value on the Option&#8217;s date of grant. The maximum term to expiration of an Option granted under this Policy</font></div><div style="height:44.46pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.356%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 3 -</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3pt;padding-left:5.95pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">will be ten (10) years, subject to earlier termination as provided in the Plan and the Award agreement governing the terms of the Option. Awards granted pursuant to this Policy are subject to the terms and conditions of the Plan, including for clarity, and without limitation, that the number of Shares to be covered by an Award is subject to the number of Shares available for issuance under the Plan as of the grant date of such Award (and accordingly, will be subject to reduction on a prorated basis to the extent Awards to be granted pursuant to the Policy as of a given date would cover a number of Shares that exceeds the number of Shares available for issuance under the Plan).</font></div><div style="margin-top:12pt;padding-left:40.1pt;text-indent:-16.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.1pt;text-decoration:underline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">DDITIONAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"> P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">ROVISIONS</font></div><div style="margin-top:1.1pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All provisions of the Plan not inconsistent with this Policy will apply to Awards granted to Outside Directors.</font></div><div style="margin-top:12pt;padding-left:40.1pt;text-indent:-16.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.1pt;text-decoration:underline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">DJUSTMENTS</font></div><div style="margin-top:1.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, reclassification, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs (other than any ordinary dividends or other ordinary distributions), the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under this Policy, will adjust the number of Shares issuable pursuant to Awards granted under this Policy.</font></div><div style="margin-top:12.05pt;padding-left:40.1pt;text-indent:-16.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.1pt;text-decoration:underline">L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">IMITATIONS</font></div><div style="margin-top:1.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Outside Director may be granted, in any Fiscal Year, Awards (the value of which will be based on their grant date fair value determined in accordance with U.S. generally accepted accounting principles) and any other compensation (including without limitation any cash retainers or fees) that, in the aggregate, exceed $500,000, provided that such amount is increased to $1,000,000 in the Fiscal Year of his or her initial service as an Outside Director. Any Awards or other compensation provided to an individual for his or her services as an Employee, or for his or her services as a Consultant other than as an Outside Director, will be excluded for purposes of this Section.</font></div><div style="margin-top:11.95pt;padding-left:42pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;text-decoration:underline">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">ECTION </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">409A</font></div><div style="margin-top:6pt;padding-left:6pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In no event will cash payments under this Policy be paid after the later of (i) the 15th day of the 3rd month following the end of the Company&#8217;s fiscal year in which the compensation is earned or expenses are incurred, as applicable, or (ii) the 15th day of the 3rd month following the end of the calendar year in which the compensation is earned or expenses are incurred, as applicable, in compliance with the &#8220;short-term deferral&#8221; exception under Section 409A of the Internal Revenue Code of 1986, as amended, and the final regulations and guidance thereunder, as may be amended from time to time (together, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). It is the intent of this Policy that this Policy and all payments hereunder be exempt from or otherwise comply with the requirements of Section 409A so that none of the compensation to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities or ambiguous terms herein will</font></div><div style="height:44.46pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.356%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 4 -</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3pt;padding-left:6pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">be interpreted to be so exempt or comply. In no event will the Company or any of its Parent or Subsidiaries have any responsibility, obligation, or liability to reimburse, indemnify, or hold harmless an Outside Director for any taxes imposed, or other costs incurred, as a result of Section 409A.</font></div><div style="margin-top:12pt;padding-left:40.1pt;text-indent:-16.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.1pt;text-decoration:underline">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">EVISIONS</font></div><div style="margin-top:1.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Board may amend, alter, suspend or terminate this Policy at any time and for any reason. Further, the Board may provide for cash, equity-based or other compensation to Outside Directors in addition to the compensation provided under this Policy. No amendment, alteration, suspension or termination of this Policy will materially impair the rights of an Outside Director with respect to compensation that already has been paid or awarded, unless otherwise mutually agreed between the Outside Director and the Company. Termination of this Policy will not affect the Board&#8217;s or the Compensation Committee&#8217;s ability to exercise the powers granted to it under the Plan with respect to Awards granted under the Plan pursuant to this Policy prior to the date of such termination.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*</font></div><div style="height:44.46pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.356%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 5 -</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>11
<FILENAME>pacb-exx191xpacbioinsidert.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i61cf0a5a6c374b818f6df75b9f627b35_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 19.1</font></div></div><div style="padding-left:106pt;padding-right:106pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:40px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"></div><div style="margin-top:11.4pt;text-align:center"><font><br></font></div><div style="padding-left:135.05pt;padding-right:135.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:225%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC. INSIDER TRADING POLICY</font></div><div style="margin-top:0.2pt;padding-left:135.15pt;padding-right:135.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(As amended and restated on October 30, 2024)</font></div><div style="margin-top:11.95pt;padding-left:78.1pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:25.41pt">POLICY OVERVIEW</font></div><div style="margin-top:11.95pt;padding-left:41.95pt;padding-right:36.55pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pacific Biosciences of California, Inc. (together with any subsidiaries, collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) has adopted this Insider Trading Policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to help you comply with the federal and state securities laws and regulations that govern trading in securities and to help the Company minimize its own legal and reputational risk. This Policy amends and restates any prior policy previously adopted by the Company regarding the subject matter hereof.</font></div><div style="margin-top:12pt;padding-left:41.95pt;padding-right:33.95pt;text-align:justify;text-indent:36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It is your responsibility to understand and follow this Policy. Insider trading is illegal and a violation of this Policy. In addition to your own liability for insider trading, the Company, as well as individual directors, officers and other supervisory personnel, could face liability. Even the appearance of insider trading can lead to government investigations or lawsuits that are time-consuming, expensive and can lead to criminal and civil liability, including damages and fines, imprisonment and bars on serving as an officer or director of a public company, not to mention irreparable damage to both your and the Company&#8217;s reputation.</font></div><div style="margin-top:11.95pt;padding-left:41.9pt;padding-right:36.7pt;text-align:justify;text-indent:36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For purposes of this Policy, a Compliance Officer means either the Company&#8217;s Chief Financial Officer or General Counsel (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Compliance Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). A Compliance Officer may designate others, from time to time, to assist with the execution of his or her duties under this Policy.</font></div><div style="margin-top:12.05pt;padding-left:78pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.02pt">POLICY STATEMENT</font></div><div style="margin-top:12pt;padding-left:42pt;padding-right:36.6pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:21.65pt;text-decoration:underline">No Trading on Material Nonpublic Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. It is illegal for anyone to trade in securities on the basis of material nonpublic information. If you are in possession of material nonpublic information about the Company, you are prohibited from&#58;</font></div><div style="margin-top:11.75pt;padding-left:132.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.37pt">using it to transact in securities of the Company&#59;</font></div><div style="margin-top:11.8pt;padding-left:132.1pt;padding-right:36.65pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:27.8pt">disclosing it to other directors, officers, employees, consultants, contractors or advisors whose roles do not require them to have the information&#59;</font></div><div style="margin-top:11.5pt;padding-left:132.1pt;padding-right:36.6pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:28.42pt">disclosing it to anyone outside of the Company, including family, friends, business associates, investors or consulting firms, without prior written authorization from a Compliance Officer&#59; or</font></div><div style="margin-top:12pt;padding-left:132.1pt;padding-right:36.6pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:27.8pt">using it to express an opinion or make a recommendation about trading in the Company&#8217;s securities.</font></div><div style="margin-top:11.5pt;padding-left:42pt;padding-right:36.45pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, if you learn of material nonpublic information through your service with the Company that could be expected to affect the trading price of the securities of another company, you cannot (x) use that information to trade, directly or indirectly through others, or (y) provide that information to another person in order to trade, in the securities of that other company. Any such action will be deemed a violation of this Policy.</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i61cf0a5a6c374b818f6df75b9f627b35_4"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:42pt;padding-right:36.45pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.65pt;text-decoration:underline">No Disclosure of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. You may not at any time disclose material nonpublic information about the Company or about another company that you obtained in connection with your service with the Company to friends, family members or any other person or entity that the Company has not authorized to know such information. In addition, you must handle the confidential information of others in accordance with any related non-disclosure agreements and other obligations that the Company has with them and limit your use of the confidential information to the purpose for which it was disclosed.</font></div><div style="margin-top:11.95pt;padding-left:41.95pt;padding-right:36.6pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If you receive an inquiry for information from someone outside of the Company, such as a stock analyst, or a request for sensitive information outside the ordinary course of business from someone outside of the Company, such as a business partner, vendor, supplier or salesperson, then you should refer the inquiry to a Compliance Officer. Responding to a request yourself may violate this Policy and, in some circumstances, the law. Please consult a Compliance Officer for more details.</font></div><div style="margin-top:12pt;padding-left:41.95pt;padding-right:36.65pt;text-align:justify;text-indent:36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.65pt;text-decoration:underline">Definition of Material Nonpublic Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Material information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means information that a reasonable investor would be substantially likely to consider important in deciding whether to buy, hold or sell securities or would view as significantly altering the total mix of information available in the marketplace about the issuer of the securities. In general, any information that could reasonably be expected to affect the market price of a security is likely to be material. Either positive or negative information may be material.</font></div><div style="margin-top:12.1pt;padding-left:41.95pt;padding-right:36.7pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It is not possible to define all categories of &#8220;material&#8221; information. However, some examples of information that could be regarded as material include, but are not limited to&#58;</font></div><div style="margin-top:11.9pt;padding-left:132.1pt;padding-right:33.85pt;text-align:justify;text-indent:-28.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.97pt">financial results, key metrics, financial condition, earnings pre-announcements, guidance, projections or forecasts, particularly if inconsistent with the Company&#8217;s guidance or the expectations of the investment community&#59;</font></div><div style="margin-top:12.25pt;padding-left:132.1pt;text-indent:-28.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.3pt">restatements of financial results, or material impairments, write-offs or restructurings&#59;</font></div><div style="margin-top:11.8pt;padding-left:132.05pt;padding-right:36.65pt;text-align:justify;text-indent:-28.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.92pt">changes in independent auditors, or notification that the Company may no longer rely on an audit report&#59;</font></div><div style="margin-top:12.15pt;padding-left:132.05pt;text-indent:-28.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.3pt">business plans or budgets&#59;</font></div><div style="margin-top:11.8pt;padding-left:132.05pt;padding-right:36.75pt;text-align:justify;text-indent:-28.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:20.97pt">creation of significant financial obligations, or any significant default under or acceleration of any financial obligation&#59;</font></div><div style="margin-top:11.65pt;padding-left:132.05pt;text-indent:-28.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.14pt">impending bankruptcy or financial liquidity problems&#59;</font></div><div style="margin-top:11.85pt;padding-left:132.05pt;padding-right:33.85pt;text-align:justify;text-indent:-28.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.35pt">significant developments involving business relationships, including execution, modification or termination of significant agreements or orders with customers, suppliers, distributors, manufacturers or other business partners&#59;</font></div><div style="margin-top:12.05pt;padding-left:132.05pt;padding-right:36.65pt;text-align:justify;text-indent:-28.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.3pt">significant information relating to the operation of any product or service, such as new products or services, major modifications or performance issues, defects or recalls, significant pricing changes or other announcements of a significant nature&#59;</font></div><div style="margin-top:12pt;padding-left:132.1pt;padding-right:36.5pt;text-align:justify;text-indent:-28.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:22.8pt">significant developments in research and development, relating to the Company&#8217;s clinical studies, including, without limitation, status, results and communications with regulatory agencies, or relating to intellectual property&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:5.262%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 2 -</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:132.1pt;padding-right:36.65pt;text-align:justify;text-indent:-28.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.8pt">significant legal or regulatory developments, whether positive or negative, actual or threatened, including litigation or resolving litigation&#59;</font></div><div style="margin-top:12.05pt;padding-left:132.1pt;padding-right:36.5pt;text-align:justify;text-indent:-28.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.3pt">major events involving the Company&#8217;s securities, including calls of securities for redemption, adoption of stock repurchase programs, option repricings, stock splits, changes in dividend policies, public or private securities offerings, modification to the rights of security holders or notice of delisting&#59;</font></div><div style="margin-top:11.9pt;padding-left:132.1pt;padding-right:36.65pt;text-align:justify;text-indent:-28.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.8pt">significant corporate events, such as a pending or proposed merger, joint venture or tender offer, a significant investment, the acquisition or disposition of a significant business or asset or a change in control of the Company&#59;</font></div><div style="margin-top:12.2pt;padding-left:132.1pt;text-indent:-28.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.3pt">major personnel changes, such as changes in senior management or employee layoffs&#59;</font></div><div style="margin-top:11.95pt;padding-left:132.1pt;text-indent:-28.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">n.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.3pt">data breaches or other cybersecurity events&#59;</font></div><div style="margin-top:11.95pt;padding-left:132.1pt;text-indent:-28.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.3pt">updates regarding any prior material disclosure that has materially changed&#59; and</font></div><div style="margin-top:12.05pt;padding-left:132.1pt;text-indent:-28.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">p.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.3pt">the existence of a special blackout period.</font></div><div style="margin-top:11.85pt;padding-left:41.95pt;padding-right:36.65pt;text-align:justify;text-indent:36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Material nonpublic information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means material information that is not generally known or made available to the public. Even if information is widely known throughout the Company, it may still be nonpublic. Generally, in order for information to be considered public, it must be made generally available through media outlets or SEC filings.</font></div><div style="margin-top:11.55pt;padding-left:41.95pt;padding-right:36.6pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">After the release of information, a reasonable period of time must elapse in order to provide the public an opportunity to absorb and evaluate the information provided. As a general rule, at least one Full Trading Day must pass after the dissemination of information before such information is considered public. A &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Full Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has elapsed after trading in the Company&#8217;s stock on The NASDAQ Stock Market has opened and subsequently closed.</font></div><div style="margin-top:11.95pt;padding-left:78.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a rule of thumb, if you think something might be material nonpublic information, it probably is.</font></div><div style="margin-top:0.1pt;padding-left:42pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You can always reach out to a Compliance Officer if you have questions.</font></div><div style="margin-top:12pt;padding-left:42pt;padding-right:36.65pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.65pt;text-decoration:underline">Designated Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each market transaction in the Company&#8217;s stock by a director, officer, employee or contractor must be executed by a broker designated by the Company unless the insider has received prior written a different broker. The Company&#8217;s current designated broker is Morgan Stanley through its &#8220;Shareworks by Morgan Stanley&#8221; services only.</font></div><div style="margin-top:12.05pt;padding-left:78.1pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:25.41pt">PERSONS COVERED BY THIS POLICY</font></div><div style="margin-top:11.95pt;padding-left:42.05pt;padding-right:36.6pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy applies to you if you are a director, officer, employee, consultant, contractor or advisor (for example, auditor or attorney) of the Company, both inside and outside of the United States. To the extent applicable to you, this Policy also covers your immediate family members, persons with whom you share a household, persons who are your economic dependents and any entity whose transactions in securities you influence, direct or control. You are responsible for making sure that these other individuals and entities comply with this Policy.</font></div><div style="margin-top:11.9pt;padding-left:42.15pt;padding-right:36.45pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy continues to apply even if you leave the Company or are otherwise no longer affiliated with or providing services to the Company, for as long as you remain in possession of material nonpublic information. In addition, if you are subject to a trading blackout under this Policy at the time you leave the</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:5.262%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 3 -</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:41.95pt;padding-right:25.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Company, you must abide by the applicable trading restrictions until at least the end of the relevant blackout period.</font></div><div style="margin-top:12.15pt;padding-left:78.05pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:25.41pt">TRADING COVERED BY THIS POLICY</font></div><div style="margin-top:11.85pt;padding-left:41.95pt;padding-right:36.65pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as discussed in Section <a href="#i61cf0a5a6c374b818f6df75b9f627b35_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">H</a> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exceptions to Trading Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), this Policy applies to all transactions involving the Company&#8217;s securities or other companies&#8217; securities for which you possess material nonpublic information obtained in connection with your service with the Company. This Policy therefore applies to&#58;</font></div><div style="margin-top:12pt;padding-left:41.95pt;padding-right:36.65pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.7pt">any purchase, sale, loan or other transfer or disposition of any equity securities (including common stock, options, restricted stock units, warrants and preferred stock) and debt securities (including debentures, bonds and notes) of the Company and such other companies, whether direct or indirect (including transactions made on your behalf by money managers), and any offer to engage in the foregoing transactions&#59;</font></div><div style="margin-top:12pt;padding-left:41.95pt;padding-right:36.65pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.7pt">any disposition in the form of a gift of any securities of the Company&#59;</font></div><div style="margin-top:12pt;padding-left:41.95pt;padding-right:36.65pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.7pt">any distribution to holders of interests in an entity if the entity is subject to this Policy&#59; and</font></div><div style="margin-top:11.85pt;padding-left:41.95pt;padding-right:36.65pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:21.7pt">any other arrangement that generates gains or losses from or based on changes in the prices of such securities including derivative securities (for example, exchange-traded put or call options, swaps, caps and collars), hedging and pledging transactions, short sales and certain arrangements regarding participation in benefit plans, and any offer to engage in the foregoing transactions.</font></div><div style="margin-top:11.55pt;padding-left:41.95pt;padding-right:36.65pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There are no exceptions from insider trading laws or this Policy based on the size of the transaction or the type of consideration received.</font></div><div style="margin-top:12.1pt;padding-left:78.1pt;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.07pt">TRADING RESTRICTIONS</font></div><div style="margin-top:11.85pt;padding-left:41.95pt;padding-right:36.65pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">Subject to the exceptions set forth below, this Policy restricts trading during certain periods and by certain people as follows&#58;</font></div><div style="margin-top:11.55pt;padding-left:41.9pt;padding-right:36.65pt;text-align:justify;text-indent:36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.7pt;text-decoration:underline">Quarterly Blackout Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as discussed in Section <a href="#i61cf0a5a6c374b818f6df75b9f627b35_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">H</a> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exceptions to Trading Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), all directors, officers, employees, consultants, contractors and advisors of the Company must refrain from conducting transactions involving the Company&#8217;s securities during quarterly blackout periods. To the extent applicable to you, quarterly blackout periods also cover your immediate family members, persons with whom you share a household, persons who are your economic dependents, and any entity whose transactions in securities you influence, direct or control. Even if you are not specifically identified as being subject to quarterly blackout periods, you should exercise caution when engaging in transactions during quarterly blackout periods because of the heightened risk of insider trading exposure.</font></div><div style="margin-top:12pt;padding-left:41.95pt;padding-right:36.5pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Quarterly blackout periods will start at the close of regular trading two weeks prior to the end of each fiscal quarter and will end after one Full Trading Day has elapsed following the public disclosure of financial results for that fiscal quarter.</font></div><div style="margin-top:11.95pt;padding-left:41.95pt;padding-right:36.55pt;text-align:justify;text-indent:36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The prohibition against trading during the blackout period also means that brokers cannot fulfill open orders on your behalf or on behalf of your immediate family members, persons with whom you share a household, persons who are your economic dependents, or any entity whose transactions in securities you influence, direct or control, during the blackout period, including &#8220;limit orders&#8221; to buy or sell stock at a specific price or better and &#8220;stop orders&#8221; to buy or sell stock once the price of the stock reaches a specified</font></div><div><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:5.262%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 4 -</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.9pt;padding-left:42pt;padding-right:25.15pt;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">price. If you are subject to blackout periods or pre-clearance requirements, you should so inform any broker with whom such an open order is placed at the time it is placed.</font></div><div style="margin-top:12.05pt;padding-left:42pt;padding-right:25.15pt;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From time to time, the Company may identify other persons who should be subject to quarterly blackout periods.</font></div><div style="margin-top:12pt;padding-left:41.95pt;padding-right:36.6pt;text-align:justify;text-indent:40.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.25pt;text-decoration:underline">Special Blackout Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company always retains the right to impose additional or longer trading blackout periods at any time on any or all of its directors, officers, employees, consultants, contractors and advisors. A Compliance Officer will notify you if you are subject to a special blackout period by providing to you a notice in writing or via email substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If you are notified that you are subject to a special blackout period, you may not engage in any transaction involving the Company&#8217;s securities until the special blackout period has ended other than the transactions that are covered by the exceptions below. You also may not disclose to anyone else that the Company has imposed a special blackout period. To the extent applicable to you, special blackout periods also cover your immediate family members, persons with whom you share a household, persons who are your economic dependents, and any entity whose transactions in securities you influence, direct or control.</font></div><div style="margin-top:12pt;padding-left:42pt;padding-right:36.5pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.65pt;text-decoration:underline">Regulation BTR Blackouts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Directors and officers may also be subject to trading blackouts pursuant to Regulation Blackout Trading Restriction, or Regulation BTR, under U.S. federal securities laws. In general, Regulation BTR prohibits any director or officer from engaging in certain transactions involving the Company&#8217;s securities during periods when 401(k) plan participants are prevented from purchasing, selling or otherwise acquiring or transferring an interest in certain securities held in individual account plans. Any profits realized from a transaction that violates Regulation BTR are recoverable by the Company, regardless of the intentions of the director or officer effecting the transaction. In addition, individuals who engage in such transactions are subject to sanction by the SEC as well as potential criminal liability. The Company will notify directors and officers if they are subject to a blackout trading restriction under Regulation BTR. Failure to comply with an applicable trading blackout in accordance with Regulation BTR is a violation of law and this Policy.</font></div><div style="margin-top:12.05pt;padding-left:78.1pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.64pt">PROHIBITED TRANSACTIONS</font></div><div style="margin-top:11.95pt;padding-left:42.05pt;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You may not engage in any of the following types of transactions other than as noted below, regardless of whether you have material nonpublic information or not.</font></div><div style="margin-top:11.9pt;padding-left:42pt;padding-right:36.6pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.65pt;text-decoration:underline">Short Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. You may not engage in short sales (meaning the sale of a security that must be borrowed to make delivery) or &#8220;sell short against the box&#8221; (meaning the sale of a security with a delayed delivery) if such sales involve the Company&#8217;s securities.</font></div><div style="margin-top:12.1pt;padding-left:41.85pt;padding-right:36.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.9pt;text-decoration:underline">Derivative Securities and Hedging Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. You may not, directly or indirectly, (a) trade in publicly-traded options, such as puts and calls, and other derivative securities with respect to the Company&#8217;s securities (other than stock options, restricted stock units and other compensatory awards issued to you by the Company) or (b) purchase financial instruments (including prepaid variable forward contracts, equity swaps, collars and exchange funds), or otherwise engage in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in the market value of Company equity securities either (i) granted to you by the Company as part of your compensation or (ii) held, directly or indirectly, by you.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:5.262%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 5 -</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:42pt;padding-right:36.75pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:21.65pt;text-decoration:underline">Pledging Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. If you are required to comply with the blackout periods or pre-clearance requirements under this Policy, you may not pledge the Company&#8217;s securities as collateral for any loan or as part of any other pledging transaction.</font></div><div style="margin-top:11.6pt;padding-left:42pt;padding-right:36.6pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:21.65pt;text-decoration:underline">Margin Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">. If you are required to comply with the blackout periods or pre-clearance requirements under this Policy, you may not hold the Company&#8217;s common stock in margin accounts.</font></div><div style="margin-top:11.65pt;padding-left:78.1pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:24.8pt">PRE-CLEARANCE OF TRADES</font></div><div style="margin-top:11.8pt;padding-left:41.9pt;padding-right:25.15pt;text-indent:36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s directors and officers and any other persons identified by a Compliance Officer as being subject to pre-clearance requirements must obtain pre-clearance prior to trading the Company&#8217;s securities. If you are subject to pre-clearance requirements, you should submit a pre-clearance request in the form attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to the Company&#8217;s stock administration team (&#91;***&#93;) prior to your desired trade date. The pre-clearance request must be made on the form provided by the Company&#8217;s stock administration team. The person requesting pre-clearance will be asked to certify that he or she is not in possession of material nonpublic information about the Company. A Compliance Officer is under no obligation to approve a transaction submitted for pre-clearance and may determine not to permit the transaction.</font></div><div style="margin-top:12.05pt;padding-left:41.95pt;padding-right:36.65pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If a Compliance Officer is the requester, then the other Compliance Officer, or the Company&#8217;s Chief Executive Officer, or their delegate, must pre-clear or deny any trade. At the recommendation of a Compliance Officer, trades made by the Chief Executive Officer and other officers also must be approved by a committee of the Company&#8217;s board of directors.</font></div><div style="margin-top:12.05pt;padding-left:41.95pt;padding-right:36.55pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All trades must be executed on the day of, or within the next two business days after, any pre- clearance.</font></div><div style="margin-top:12pt;padding-left:41.95pt;padding-right:36.45pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Even after preclearance, a person may not trade the Company&#8217;s securities if they become subject to a blackout period or aware of material nonpublic information prior to the trade being executed.</font></div><div style="margin-top:11.9pt;padding-left:41.95pt;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">From time to time, the Company may identify other persons who should be subject to the pre- clearance requirements set forth above.</font></div><div style="margin-top:11.65pt;padding-left:78.1pt;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:24.85pt">EXCEPTIONS TO TRADING RESTRICTIONS</font></div><div style="margin-top:11.95pt;padding-left:41.9pt;padding-right:36.7pt;text-align:justify;text-indent:36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There are no unconditional &#8220;safe harbors&#8221; for trades made at particular times, and all persons subject to this Policy should exercise good judgment at all times. Even when a quarterly blackout period is not in effect, you may be prohibited from engaging in transactions involving the Company&#8217;s securities because you possess material nonpublic information, are subject to a special blackout period or are otherwise restricted under this Policy.</font></div><div style="margin-top:12pt;padding-left:41.9pt;padding-right:36.7pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other than the limited exceptions set forth below, any other exceptions to this Policy must be approved by a Compliance Officer, in consultation with the Company&#8217;s board of directors or an independent committee of the board of directors.</font></div><div style="margin-top:11.95pt;padding-left:41.95pt;padding-right:36.7pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following are certain limited exceptions to the quarterly and special blackout period restrictions and pre-clearance requirements imposed by the Company under this Policy&#58;</font></div><div style="margin-top:12pt;padding-left:41.95pt;padding-right:36.7pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.7pt">stock option exercises where the purchase price of such stock options is paid in cash and there is no other associated market activity&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:5.262%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 6 -</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:41.95pt;padding-right:36.65pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.7pt">purchases pursuant to the employee stock purchase plan&#59; however, this exception does not apply to subsequent sales of the shares&#59;</font></div><div style="margin-top:12.05pt;padding-left:41.95pt;padding-right:36.65pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.7pt">receipt and vesting of stock options, restricted stock units, restricted stock or other equity compensation awards from the Company&#59;</font></div><div style="margin-top:12pt;padding-left:41.95pt;padding-right:36.6pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.7pt">net share withholding with respect to equity awards where shares are withheld by the Company in order to satisfy tax withholding requirements, (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">x</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) as required by either the Company&#8217;s board of directors (or a committee thereof) or the award agreement governing such equity award or (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">y</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) as you elect, if permitted by the Company, so long as the election is irrevocable and made in writing at a time when a trading blackout is not in place and you are not in possession of material nonpublic information&#59;</font></div><div style="margin-top:12pt;padding-left:42pt;padding-right:36.65pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.65pt">sell to cover transactions where shares are sold on your behalf upon vesting of equity awards and sold in order to satisfy tax withholding requirements, (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">x</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) as required by either the Company&#8217;s board of directors (or a committee thereof) or the award agreement governing such equity award or (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">y</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) as you elect, if permitted by the Company, so long as the election is irrevocable and made in writing at a time when a trading blackout is not in place and you are not in possession of material nonpublic information&#59; however, this exception does not apply to any other market sale for the purposes of paying required withholding&#59;</font></div><div style="margin-top:11.9pt;padding-left:41.95pt;padding-right:36.65pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:21.7pt">transactions made pursuant to a valid 10b5-1 trading plan approved by the Company (see Section I (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:118%">10b5-1 Trading Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">) below)&#59;</font></div><div style="margin-top:11.55pt;padding-left:41.95pt;padding-right:36.65pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.7pt">purchases of the Company&#8217;s stock in the 401(k) plan resulting from periodic contributions to the plan based on your payroll contribution election&#59; provided, however, that the blackout period restrictions and pre-clearance requirements do apply to elections you make under the 401(k) plan to (a) increase or decrease the amount of your contributions under the 401(k) plan if such increase or decrease will increase or decrease the amount of your contributions that will be allocated to a Company stock fund, (b) increase or decrease the percentage of your contributions that will be allocated to a Company stock fund, (c) move balances into or out of a Company stock fund, (d) borrow money against your 401(k) plan account if the loan will result in liquidation of some or all of your Company stock fund balance, and (e) prepay a plan loan if the pre-payment will result in the allocation of loan proceeds to a Company stock fund&#59;</font></div><div style="margin-top:12pt;padding-left:41.95pt;padding-right:36.7pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.7pt">transfers by will or the laws of descent or distribution and, provided that prior written notice is provided to a Compliance Officer, distributions or transfers (such as certain tax planning or estate planning transfers) that effect only a change in the form of beneficial interest without changing your pecuniary interest in the Company&#8217;s securities&#59; and</font></div><div style="margin-top:11.9pt;padding-left:41.95pt;padding-right:36.65pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:21.7pt">changes in the number of the Company&#8217;s securities you hold due to a stock split or a stock dividend that applies equally to all securities of a class, or similar transactions&#59;</font></div><div style="margin-top:11.5pt;padding-left:41.95pt;padding-right:36.55pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If there is a Regulation BTR blackout (and no quarterly or special blackout period), then the limited exceptions set forth in Regulation BTR will apply. Please be aware that even if a transaction is subject to an exception to this Policy, you will need to separately assess whether the transaction complies with applicable law.</font></div><div style="margin-top:12.15pt;padding-left:78.1pt;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:29.12pt">10B5-1 TRADING PLANS</font></div><div style="margin-top:11.85pt;padding-left:41.95pt;padding-right:36.55pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company permits its directors, officers and employees to adopt written 10b5-1 trading plans in order to mitigate the risk of trading on material nonpublic information. These plans allow for individuals to enter into a prearranged trading plan as long as the plan is not established or modified during a blackout period or when the individual is otherwise in possession of material nonpublic information. To be approved</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:5.262%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 7 -</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:41.9pt;padding-right:36.6pt;text-align:justify;text-indent:0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">by the Company and qualify for the exception to this Policy, any 10b5-1 trading plan adopted by a director, officer or employee must be submitted to a Compliance Officer for approval and comply with the requirements set forth in the Requirements for Trading Plans attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If a Compliance Officer is the requester, then the Company&#8217;s Chief Executive Officer, the other Compliance Officer or their delegate, must approve the written 10b5-1 trading plan.</font></div><div style="margin-top:12.15pt;padding-left:78.1pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">J.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.85pt">SECTION 16 COMPLIANCE</font></div><div style="margin-top:11.8pt;padding-left:41.95pt;padding-right:36.65pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">All of the Company&#8217;s officers and directors and certain other individuals are required to comply with Section 16 of the Securities and Exchange Act of 1934 and related rules and regulations which set forth reporting obligations, limitations on &#8220;short swing&#8221; transactions, which are certain matching purchases and sales of the Company&#8217;s securities within a six-month period, and limitations on short sales.</font></div><div style="margin-top:11.55pt;padding-left:42pt;padding-right:36.65pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">To ensure transactions subject to Section 16 requirements are reported on time, each person subject to these requirements must provide the Company with detailed information (for example, trade date, number of shares, exact price, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:117%">etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">) about his or her transactions involving the Company&#8217;s securities.</font></div><div style="margin-top:11.55pt;padding-left:42pt;padding-right:36.5pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">The Company is available to assist in filing Section 16 reports, but the obligation to comply with Section 16 is personal. If you have any questions, you should check with a Compliance Officer.</font></div><div style="margin-top:11.65pt;padding-left:78.1pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">K.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:24.8pt">VIOLATIONS OF THIS POLICY</font></div><div style="margin-top:11.95pt;padding-left:42pt;padding-right:36.6pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Company directors, officers, employees, consultants, contractors and advisors who violate this Policy will be subject to disciplinary action by the Company, including ineligibility for future Company equity or incentive programs or termination of employment or an ongoing relationship with the Company. The Company has full discretion to determine whether this Policy has been violated based on the information available.</font></div><div style="margin-top:12pt;padding-left:41.9pt;padding-right:36.65pt;text-align:justify;text-indent:36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There are also serious legal consequences for individuals who violate insider trading laws, including large criminal and civil fines, significant imprisonment terms and disgorgement of any profits gained or losses avoided. You may also be liable for improper securities trading by any person (commonly referred to as a &#8220;tippee&#8221;) to whom you have disclosed material nonpublic information that you have learned through your position at the Company or made recommendations or expressed opinions about securities trading on the basis of such information.</font></div><div style="margin-top:11.9pt;padding-left:41.8pt;padding-right:36.75pt;text-align:justify;text-indent:36.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Please consult with your personal legal and financial advisors as needed. Note that the Company&#8217;s legal counsel, both internal and external, represent the Company and not you personally. There may be instances where you suffer financial harm or other hardship or are otherwise required to forego a planned transaction because of the restrictions imposed by this Policy or under securities laws. If you were aware of the material nonpublic information at the time of the trade, it is not a defense that you did not &#8220;use&#8221; the information for the trade. Personal financial emergency or other personal circumstances are not mitigating factors under securities laws and will not excuse your failure to comply with this Policy. In addition, a blackout or trading-restricted period will not extend the term of your options. As a consequence, you may be prevented from exercising your options by this Policy or as a result of a blackout or other restriction on your trading, and as a result your options may expire by their term. In such instances, the Company cannot extend the term of your options and has no obligation or liability to replace the economic value or lost benefit to you. It is your responsibility to manage your economic interests and to consider potential trading restrictions when determining whether to exercise your options.</font></div><div><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:5.262%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 8 -</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:78.1pt;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">L.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.07pt">PROTECTED ACTIVITY NOT PROHIBITED</font></div><div style="margin-top:11.8pt;padding-left:42pt;padding-right:36.65pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nothing in this Policy, or any related guidelines or other documents or information provided in connection with this Policy, shall in any way limit or prohibit you from engaging in any of the protected activities set forth in the Company&#8217;s Whistleblower Policy, as amended from time to time.</font></div><div style="margin-top:12.2pt;padding-left:78.1pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">M.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.97pt">REPORTING</font></div><div style="margin-top:11.85pt;padding-left:42pt;padding-right:36.6pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If you believe someone is violating this Policy or otherwise using material nonpublic information that they learned through their position at the Company to trade securities, you should report it to a Compliance Officer, or if a Compliance Officer is implicated in your report, then you should report it in accordance with the Company&#8217;s Whistleblower Policy.</font></div><div style="margin-top:12.15pt;padding-left:78.1pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">N.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:25.41pt">AMENDMENTS</font></div><div style="margin-top:11.8pt;padding-left:42pt;padding-right:36.55pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company reserves the right to amend this Policy at any time, for any reason, subject to applicable laws, rules and regulations, and with or without notice, although it will attempt to provide notice in advance of any change. Unless otherwise permitted by this Policy, any amendments must be approved by the Board of Directors of the Company.</font></div><div><font><br></font></div><div style="margin-top:11.35pt"><font><br></font></div><div style="padding-left:42pt;padding-right:36.55pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Nothing in this Insider Trading Policy creates or implies an employment contract or term of employment. Employment at the Company is employment at-will. Employment at-will may be terminated with or without cause and with or without notice at any time by the employee or the Company. Nothing in this Insider Trading Policy shall limit the right to terminate employment at-will. No employee of the Company has any authority to enter into any agreement for employment for a specified period of time or to make any agreement or representation contrary to the Company&#8217;s policy of employment at-will. Only the Chief Executive Officer of the Company has the authority to make any such agreement, which must be in writing.</font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41.95pt;padding-right:36.65pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">The policies in this Insider Trading Policy do not constitute a complete list of Company policies or a complete list of the types of conduct that can result in discipline, up to and including discharge.</font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:5.262%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 9 -</font></div></td></tr></table></div></div></div><div id="i61cf0a5a6c374b818f6df75b9f627b35_7"></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.25pt;padding-left:139.67pt;padding-right:139.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-top:6.05pt;padding-left:139.62pt;padding-right:139.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PRE-CLEARANCE CHECKLIST</font></div><div style="margin-top:6.9pt;padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.146%"><tr><td style="width:1.0%"></td><td style="width:65.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:11.05pt">Person proposing to trade&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-right:-301.43pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proposed trade (type and amount)&#58;</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manner of trade&#58;</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proposed trade date&#58;</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:10.50pt">Affiliate of the Company&#58;</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:2.5pt;padding-right:-2.63pt"><img alt="box.jpg" src="box.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:9px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Yes      </font><img alt="box.jpg" src="box.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:9px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> No</font></div></td></tr></table></div><div style="margin-top:6.05pt;padding-left:46.55pt"><img alt="box.jpg" src="box.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:9px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No blackout period. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proposed trade will not be made during a quarterly or special blackout period.</font></div><div style="margin-top:6pt;padding-left:46.55pt"><img alt="box.jpg" src="box.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:9px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No pension fund blackout under Regulation BTR.* </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no pension fund blackout period in effect.</font></div><div style="margin-top:5.9pt;padding-left:46.55pt"><img alt="box.jpg" src="box.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:9px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No prohibition under Insider Trading Policy. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The person confirmed that the proposed trade is not prohibited under the Insider Trading Policy.</font></div><div style="margin-top:6.05pt;padding-left:46.55pt"><img alt="box.jpg" src="box.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:9px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No 10b5-1 trading plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The person does not have an outstanding 10b5-1 trading plan, and has confirmed that the proposed trade will not occur during the term of a 10b5-1 trading plan.</font></div><div style="margin-top:6.05pt;padding-left:46.6pt;text-indent:-0.05pt"><img alt="box.jpg" src="box.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:9px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 16 compliance.* </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The person confirmed that the proposed trade will not give rise to any potential liability under Section 16 as a result of matched past (or intended future) transactions.</font></div><div style="margin-top:5.9pt;padding-left:46.55pt"><img alt="box.jpg" src="box.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:9px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 4 filing.* </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Form 4 has been or will be completed and will be timely filed with the SEC, if applicable.</font></div><div style="margin-top:6.05pt;padding-left:46.55pt"><img alt="box.jpg" src="box.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:9px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 144 compliance (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Response required only from affiliates of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">).</font></div><div style="margin-top:6pt;padding-left:78.1pt"><img alt="box.jpg" src="box.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:9px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The &#8220;current public information&#8221; requirement has been met (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, all 10-Ks, 10-Qs and other relevant reports during the last 12 months have been filed)&#59;</font></div><div style="margin-top:6.05pt;padding-left:78.1pt"><img alt="box.jpg" src="box.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:9px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares that the person proposes to trade are not restricted or, if restricted, the applicable holding period has been met&#59;</font></div><div style="margin-top:5.95pt;padding-left:78.1pt"><img alt="box.jpg" src="box.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:9px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volume limitations (greater of 1% of outstanding securities of the same class or the average weekly trading volume during the last four weeks) are not exceeded, and the person is not part of an aggregated group&#59;</font></div><div style="margin-top:6pt;padding-left:78.1pt"><img alt="box.jpg" src="box.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:9px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manner of sale requirements will be met (a &#8220;brokers&#8217; transaction&#8221; or directly with a market maker or a &#8220;riskless principal transaction&#8221;)&#59; and</font></div><div style="margin-top:6.05pt;padding-left:78.1pt"><img alt="box.jpg" src="box.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:9px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Form 144, if applicable, has been completed and will be timely filed with the SEC.</font></div><div style="margin-top:3.05pt;padding-left:46.55pt;padding-right:5.25pt;text-align:justify"><img alt="box.jpg" src="box.jpg" style="height:9px;margin-bottom:5pt;vertical-align:text-bottom;width:9px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 10b-5 concerns. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The person has been reminded that trading is prohibited when in possession of any material nonpublic information regarding the Company that has not been adequately disclosed to the public. The individual has discussed with a Compliance Officer any information known to the individual or a Compliance Officer that the individual believes may be material.</font></div><div style="margin-top:5.95pt;padding-left:28.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">* </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applies if the individual is a director or an officer subject to Section 16 of the Securities Exchange Act of 1934.</font></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.983%"><tr><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Signature of Compliance Officer)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Print name of Compliance Officer)</font></td></tr></table></div><div style="margin-top:1.6pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10.55pt;padding-right:5.25pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I am not aware of material nonpublic information regarding the Company. I am not trading on the basis of any material nonpublic information. The transaction is in accordance with the Insider Trading Policy and applicable law. I intend to comply with any applicable reporting and disclosure requirements on a timely basis. I understand that I must execute the trade by the end of the second trading day after the date on which the trade is cleared by a Compliance Officer. I understand that by signing below, I am not obligated to execute the trade.</font></div><div style="margin-top:0.05pt;padding-right:5.25pt;text-align:justify;text-indent:-0.01pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.983%"><tr><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.139%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Signature of person proposing to trade)</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:6pt;padding-left:34.12pt;padding-right:34.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit A</font></div><div style="height:0pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i61cf0a5a6c374b818f6df75b9f627b35_10"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:135.17pt;padding-right:135.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT B</font></div><div style="margin-top:11.95pt;padding-left:135.07pt;padding-right:135.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM OF SPECIAL BLACKOUT NOTICE</font></div><div style="margin-top:12.05pt;padding-left:135.1pt;padding-right:135.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">COMPANY LETTERHEAD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div><div style="margin-top:11.95pt;padding-left:135.07pt;padding-right:135.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div><div style="margin-top:12.1pt;padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">CONFIDENTIAL COMMUNICATION</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pacific Biosciences of California, Inc.</font></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1305 O&#8217;Brien Drive</font></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Menlo Park, CA 94025</font></div><div style="margin-top:12pt;padding-left:45pt;padding-right:388.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dear &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Insert Name</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;padding-right:36.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pacific Biosciences of California, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) has imposed a special blackout period in accordance with the terms of the Company&#8217;s Insider Trading Policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Pursuant to the Policy, and subject to the exceptions stated in the Policy, you may not engage in any transaction involving the securities of the Company until you receive official notice that the special blackout period is no longer in effect.</font></div><div style="margin-top:12pt;padding-left:45pt;padding-right:36.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You may not disclose to others the fact that a special blackout period has been imposed. In addition, you should take care to handle any confidential information in your possession in accordance with the Company&#8217;s policies.</font></div><div style="margin-top:12pt;padding-left:45pt;padding-right:36.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If you have any questions at all, please contact Brett Atkins at &#91;***&#93;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or Susan Kim at &#91;***&#93;.</font></div><div style="margin-top:11.6pt;padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sincerely,</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.65pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:46.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Compliance Officer</font></div><div style="height:43.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.119%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit B</font></div></td></tr></table></div></div></div><div id="i61cf0a5a6c374b818f6df75b9f627b35_13"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:166.35pt;padding-right:166.35pt;text-align:center;text-indent:76.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:225%">EXHIBIT C REQUIREMENTS FOR TRADING PLANS</font></div><div style="margin-top:0.1pt;padding-left:37.45pt;padding-right:36.7pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For transactions under a trading plan to be exempt from (A) the prohibitions in the Insider Trading Policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of Pacific Biosciences of California, Inc. (together with any subsidiaries, collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) with respect to transactions made while aware of material nonpublic information and (B) the pre-clearance procedures and blackout periods established under the Policy, the trading plan must comply with the affirmative defense set forth in Exchange Act Rule 10b5-1 and must meet the following requirements (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Trading Plan Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-top:12.05pt;padding-left:91.4pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.7pt">The trading plan must be in writing and signed by the person adopting the trading plan.</font></div><div style="margin-top:12.05pt;padding-left:91.35pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.7pt">The trading plan must be adopted at a time when&#58;</font></div><div style="margin-top:11.85pt;padding-left:122.9pt;padding-right:37pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:19.37pt">the person adopting the trading plan is not aware of any material nonpublic information&#59; and</font></div><div style="margin-top:12pt;padding-left:123pt;padding-right:36.75pt;text-indent:-27.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">there is no quarterly, special or other trading blackout in effect with respect to the person adopting the plan.</font></div><div style="margin-top:12.05pt;padding-left:37.3pt;padding-right:36.95pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:26.35pt">The trading plan must be entered in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1, and the person adopting the trading plan must act in good faith with respect to the trading plan.</font></div><div style="margin-top:11.55pt;padding-left:37.3pt;padding-right:36.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.45pt">The trading plan must include representations that, on the date of the adoption of the trading plan, the person adopting the trading plan&#58;</font></div><div style="margin-top:12.15pt;padding-left:122.85pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:19.37pt">is not aware of material nonpublic information about the securities or the Company&#59; and</font></div><div style="margin-top:11.85pt;padding-left:122.85pt;padding-right:36.85pt;text-indent:-27.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:18.8pt">is adopting the trading plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1.</font></div><div style="margin-top:11.5pt;padding-left:37.3pt;padding-right:36.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:26.45pt">The person adopting the trading plan may not have entered into or altered a corresponding or hedging transaction or position with respect to the securities subject to the trading plan and must agree not to enter into any such transaction while the trading plan is in effect.</font></div><div style="margin-top:11.65pt;padding-left:37.45pt;padding-right:36.7pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.25pt">The first trade under the trading plan may not occur until the expiration of a cooling-off period consisting of the later of (a) 90 calendar days after the adoption of the trading plan and (b) two business days after the filing by the Company of its financial results in a Form 10-Q or Form 10-K for the completed fiscal quarter in which the trading plan was adopted (but, in any event, this required cooling-off period is subject to a maximum of 120 days after adoption of the trading plan).</font></div><div style="margin-top:12pt;padding-left:37.45pt;padding-right:36.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:26.3pt">The trading plan must have a minimum term of one year (starting from the date of adoption of the trading plan).</font></div><div style="margin-top:11.5pt;padding-left:37.4pt;padding-right:36.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.35pt">No transactions may occur during the term of the trading plan (except for the &#8220;Exceptions to Trading Restrictions&#8221; identified in the Policy and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">bona fide </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">gifts) except for those transactions specified in the trading plan. In addition, the person adopting the trading plan may not have an outstanding (and may not subsequently enter into any additional) trading plan except as permitted by Rule 10b5-1. For example, as contemplated by Rule 10b5-1, a person may adopt a new trading plan before the scheduled termination date</font></div><div style="text-align:justify"><font><br></font></div><div style="height:39.78pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.794%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit C</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:37.5pt;padding-right:36.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of an existing trading plan, so long as the first scheduled trade under the new trading plan does not occur prior to the last scheduled trade(s) of the existing trading plan and otherwise complies with these guidelines. Termination of the existing trading plan prior to its scheduled termination date may impact the timing of the first trade or the availability of the affirmative defense for the new trading plan&#59; therefore, persons adopting a new trading plan are advised to exercise caution and consult with a Compliance Officer prior to the early termination of an existing trading plan.</font></div><div style="margin-top:11.95pt;padding-left:37.45pt;padding-right:36.5pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.25pt">Any modification or change to the amount, price or timing of transactions under the trading plan is deemed the termination of the trading plan, and the adoption of a new trading plan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Therefore, a Modification must be submitted to a Compliance Officer for approval in accordance with Section I of the Policy and is subject to the same conditions as a new trading plan as set forth in Sections 1 through 8 herein.</font></div><div style="margin-top:12pt;padding-left:37.45pt;padding-right:36.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:20.8pt">Within the one year preceding the adoption or a Modification of a trading plan, a person may not have otherwise adopted or made a Modification to a plan more than once.</font></div><div style="margin-top:11.5pt;padding-left:37.45pt;padding-right:36.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:20.85pt">A person may adopt a trading plan designed to cover a single trade only once in any consecutive 12-month period except as permitted by Rule 10b5-1.</font></div><div style="margin-top:11.5pt;padding-left:37.4pt;padding-right:36.8pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.8pt">If the person that adopted the trading plan terminates the plan prior to its stated duration, he or she may not trade in the Company&#8217;s securities until after the expiration of 30 calendar days following termination and then only in accordance with the Policy.</font></div><div style="margin-top:11.95pt;padding-left:37.45pt;padding-right:36.75pt;text-align:justify;text-indent:35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:20.9pt">The Company must be promptly notified of any Modification or termination of the trading plan, including any suspension of trading under the trading plan.</font></div><div style="margin-top:11.55pt;padding-left:37.45pt;padding-right:36.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.8pt">The Company must have authority to require the suspension of the plan if there are legal regulatory or contractual restrictions applicable to the Company or the person that adopted the trading plan, or to require the cancellation of the trading plan at any time, subject to any reasonable broker notice requirements as may be set forth in the trading plan.</font></div><div style="margin-top:12pt;padding-left:37.45pt;padding-right:36.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.8pt">If the trading plan grants discretion to a stockbroker or other person with respect to the execution of trades under the trading plan&#58;</font></div><div style="margin-top:12.05pt;padding-left:123pt;padding-right:36.7pt;text-indent:-27.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:19.42pt">the person adopting the trading plan may not exercise any subsequent influence over how, when or whether to effect purchases or sales under the plan&#59;</font></div><div style="margin-top:11.85pt;padding-left:122.95pt;padding-right:36.9pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:18.75pt">the person adopting the trading plan may not confer with the person administering the trading plan regarding the Company or its securities&#59; and</font></div><div style="margin-top:11.6pt;padding-left:123.1pt;padding-right:36.7pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:19.37pt">the person administering the trading plan must provide prompt notice to the Company of the execution of a transaction pursuant to the plan.</font></div><div style="margin-top:11.65pt;padding-left:91.45pt;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.2pt">All transactions under the trading plan must be in accordance with applicable law.</font></div><div style="margin-top:11.8pt;padding-left:37.5pt;padding-right:36.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:20.75pt">Any exceptions to the Trading Plan Requirements must be approved by a Compliance Officer or, in the case of directors and officers who are subject Section 16 of the Securities Exchange Act of 1934, by a Compliance Officer in consultation with the Company&#8217;s board of directors or an independent committee of the board of directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:39.78pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.794%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit C</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.9pt;padding-left:37.55pt;padding-right:36.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.75pt">The trading plan (including any Modification) must meet such other requirements as a Compliance Officer may determine.</font></div><div style="margin-top:12.05pt;padding-left:37.55pt;padding-right:36.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.7pt">Any trading plans adopted or modified prior to February 27, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) are permitted to continue in place until all trades are executed thereunder or they expire by their terms (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Grandfathered Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). If the person undertakes a Modification of a Grandfathered Plan on or after the Effective Date, then the Modification must meet all of the requirements set forth herein.</font></div><div style="height:39.78pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.794%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit C</font></div></td></tr></table></div></div></div><div id="i61cf0a5a6c374b818f6df75b9f627b35_16"></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.45pt;padding-left:137.17pt;padding-right:137.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">M E M O R A N D U M</font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">To&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Directors, officers, employees, consultants, contractors and advisors of Company</font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">From&#58;&#160;&#160;&#160;&#160;Pacific Biosciences of California, Inc.</font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Re&#58;&#160;&#160;&#160;&#160;Insider Trading Policy</font></div><div style="margin-top:10.7pt;text-align:center"><img alt="line1.jpg" src="line1.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:643px"></div><div style="margin-top:12.5pt;padding-left:37.5pt;padding-right:36.55pt;text-align:justify;text-indent:0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attached is a copy of our Insider Trading Policy, which governs transactions involving trading in securities by directors, officers, employees, consultants, contractors and advisors of Pacific Biosciences of California, Inc. (together with any subsidiaries, collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). As described in the Insider Trading Policy, violations of insider trading laws can result in significant civil and criminal liability. Accordingly, please carefully review the materials provided.</font></div><div style="margin-top:12pt;padding-left:37.45pt;padding-right:36.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">After reading the Insider Trading Policy, please sign the receipt and acknowledgment at the bottom of this memorandum and return it to a Compliance Officer. The Insider Trading Policy applies to you regardless of whether you sign the receipt and acknowledgment at the bottom of this memorandum and return it to a Compliance Officer.</font></div><div style="margin-top:11.55pt;padding-left:37.45pt;padding-right:36.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If you have any questions about the Insider Trading Policy or insider trading laws generally or about any transaction involving the securities of the Company, please contact Brett Atkins at &#91;***&#93;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or Susan Kim at &#91;***&#93;.</font></div><div style="margin-top:12.1pt;padding-left:37.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attachment(s)</font></div><div style="margin-top:12.05pt;padding-left:37.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Receipt and Acknowledgment</font></div><div style="margin-top:11.9pt;padding-left:78.1pt;text-indent:-18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.3pt">I have received and read the Insider Trading Policy.</font></div><div style="margin-top:5.95pt;padding-left:78.1pt;padding-right:36.65pt;text-indent:-18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.3pt">I have received satisfactory answers to any questions that I had regarding the Insider Trading Policy and insider trading in general.</font></div><div style="margin-top:6.05pt;padding-left:78.1pt;text-indent:-18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.3pt">I understand and acknowledge that the Insider Trading Policy applies to me.</font></div><div style="margin-top:5.95pt;padding-left:78.1pt;text-indent:-18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.3pt">I understand and agree to comply with the Insider Trading Policy.</font></div><div style="margin-top:5.85pt;padding-left:78.05pt;padding-right:36.7pt;text-align:justify;text-indent:-18.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">I understand that my failure to comply in all respects with the Insider Trading Policy is a basis for termination of my employment or other service relationship with the Company as well as any other appropriate discipline.</font></div><div style="margin-top:6pt;padding-left:78.1pt;padding-right:36.6pt;text-align:justify;text-indent:-18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.3pt">I understand and agree that the Company may give stop transfer and other instructions to the Company&#8217;s transfer agent with respect to transactions that the Company considers to be in contravention of the Insider Trading Policy.</font></div><div><font><br></font></div><div style="margin-top:12pt;padding-left:41.95pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.958%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.400%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Print name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>12
<FILENAME>pacb-exx211x2024.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ic1d80f6184564fb186c8df413e83cd0d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit 21.1 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">LIST OF SUBSIDIARIES</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.420%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Subsidiary name</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Jurisdiction</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Type</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pacific Biosciences International LLC</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Domestic</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pacific Biosciences Canada Limited</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Canada (Ontario)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pacific Biosciences Germany GmbH</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Germany (Munich)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pacific Biosciences Japan GK</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan (Tokyo)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pacific Biosciences (Shanghai) Co., Ltd.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">China (Shanghai)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PacBio Singapore Pte. Limited</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Singapore</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pacific Biosciences UK, Ltd.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">United Kingdom (London)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Omniome, LLC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Domestic</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Circulomics Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Maryland</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Domestic</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PacBio B.V.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Netherlands (Amsterdam)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PacBio of Korea, Yuhan Hoesa</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Korea</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apton Biosystems LLC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Domestic</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>13
<FILENAME>pacb-exx231x2024.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i0997609cfdff452eab40d96993271883_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Interstate Light',sans-serif;font-size:10pt;font-weight:700;line-height:151%">Exhibit 23.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Registration Statements (Forms S-8 Nos. 333-241687, 333-251153, 333-253669, 333-255342, 333-259671, 333-261251, 333-263101, 333-265249, 333-270122, 333-277486 and 333-280353) pertaining to the Pacific Biosciences of California, Inc. 2010 Employee Stock Purchase Plan, the Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan, the Pacific Biosciences of California, Inc. 2020 Inducement Equity Incentive Plan, and the Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc.,</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Registration Statements and Post-Effective Amendments No. 1 to the Registration Statements (Forms S-8 Nos. 333-170211, 333-179810, 333-186065, 333-193437, 333-201678, 333-209157, 333-215746, 333-222696, 333-229368, 333-236061) pertaining to the Pacific Biosciences of California, Inc. 2010 Equity Incentive Plan, Pacific Biosciences of California, Inc. 2010 Employee Stock Purchase Plan, Pacific Biosciences of California, Inc. 2010 Outside Director Equity Incentive Plan, Pacific Biosciences of California, Inc. 2005 Stock Plan and Pacific Biosciences of California, Inc. 2004 Equity Incentive Plan, and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Registration Statement (Form S-3 No. 333-279269) and related prospectus of Pacific Biosciences of California, Inc.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated March&#160;17, 2025, with respect to the consolidated financial statements of Pacific Biosciences of California, Inc. and the effectiveness of internal control over financial reporting of Pacific Biosciences of California, Inc. included in this Annual Report (Form 10-K) of Pacific Biosciences of California, Inc. for the year ended December&#160;31, 2024.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Mateo, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;17, 2025</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>14
<FILENAME>pacb-exx311x2024.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="iaf29f16a80de47ef945f3eb5301c0348_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1 </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT RULES 13a-14(a)&#47;15d-14(a), AS ADOPTED PURSUANT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christian Henry, certify that&#58; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">I have reviewed this annual report on Form 10-K of Pacific Biosciences of California, Inc.&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;17, 2025</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christian O. Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christian O. Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Interim Chief Financial Officer<br>(Principal Executive Officer and Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>15
<FILENAME>pacb-exx312x2024.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i0a319f239d02402bb680f38f622644f8_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2 </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT RULES 13a-14(a)&#47;15d-14(a), AS ADOPTED PURSUANT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christian Henry, certify that&#58; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">I have reviewed this annual report on Form 10-K of Pacific Biosciences of California, Inc.&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;17, 2025</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christian O. Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christian O. Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Interim Chief Financial Officer<br>(Principal Executive Officer and Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>16
<FILENAME>pacb-exx321x2024.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i4e7859550c614a32a5562a497128916a_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1 </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CEO Furnished Pursuant to 18 U.S.C. Section 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant To </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of The Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Pacific Biosciences of California, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2024, as filed with the Securities and Exchange Commission on the date hereof, I, Christian Henry, Chief Executive Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge, </font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the Annual Report of the Company on Form 10-K for the period ended December&#160;31, 2024 (the &#8220;Report&#8221;), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and </font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;17, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christian O. Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christian O. Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Interim Chief Financial Officer<br>(Principal Executive Officer and Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>17
<FILENAME>pacb-exx322x2024.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5fbdf72b179c453298e4d36e7a0de346_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2 </font></div><div style="margin-top:6pt;padding-left:36pt;padding-right:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CFO Furnished Pursuant to 18 U.S.C. Section 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant To </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of The Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Pacific Biosciences of California, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2024, as filed with the Securities and Exchange Commission on the date hereof, I, Christian Henry, Interim Chief Financial Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge, </font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the Annual Report of the Company on Form 10-K for the period ended December&#160;31, 2024 (the &#8220;Report&#8221;), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and </font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;17, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christian O. Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christian O. Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Interim Chief Financial Officer<br>(Principal Executive Officer and Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>pacb-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b8324ceb-4367-4432-9725-ed1f11bffb27,g:1109ce80-1fe4-4ba2-bf4d-c0b012b2f3c3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pacb="http://www.pacificbiosciences.com/20241231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pacificbiosciences.com/20241231">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.pacificbiosciences.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.pacificbiosciences.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>9952154 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>9952156 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONS" roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONS">
        <link:definition>9952157 - Disclosure - BUSINESS ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTS" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS">
        <link:definition>9952158 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTS" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS">
        <link:definition>9952159 - Disclosure - BALANCE SHEET COMPONENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTES" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES">
        <link:definition>9952160 - Disclosure - CONVERTIBLE SENIOR NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURING" roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURING">
        <link:definition>9952161 - Disclosure - RESTRUCTURING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>9952162 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.pacificbiosciences.com/role/INCOMETAXES">
        <link:definition>9952163 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITY">
        <link:definition>9952164 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARE" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARE">
        <link:definition>9952165 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATION" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION">
        <link:definition>9952166 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTS">
        <link:definition>9952167 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9955511 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9955512 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONSTables" roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTables">
        <link:definition>9955513 - Disclosure - BUSINESS ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSTables" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables">
        <link:definition>9955514 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSTables" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables">
        <link:definition>9955515 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESTables" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables">
        <link:definition>9955516 - Disclosure - CONVERTIBLE SENIOR NOTES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGTables" roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGTables">
        <link:definition>9955517 - Disclosure - RESTRUCTURING (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESTables" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables">
        <link:definition>9955518 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESTables">
        <link:definition>9955519 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>9955520 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARETables" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables">
        <link:definition>9955521 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONTables" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables">
        <link:definition>9955522 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>9955523 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES- Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails">
        <link:definition>9955524 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of The Major Classes of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONSNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails">
        <link:definition>9955525 - Disclosure - BUSINESS ACQUISITIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails" roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails">
        <link:definition>9955526 - Disclosure - BUSINESS ACQUISITIONS - Schedule of Business Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>9955527 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails">
        <link:definition>9955528 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails">
        <link:definition>9955529 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails">
        <link:definition>9955530 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails">
        <link:definition>9955531 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofInventoryDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails">
        <link:definition>9955532 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails">
        <link:definition>9955533 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails">
        <link:definition>9955534 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSNarrativeDetails_1" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails_1">
        <link:definition>9955534 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofGoodwillDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofGoodwillDetails">
        <link:definition>9955535 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails">
        <link:definition>9955536 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails">
        <link:definition>9955537 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails">
        <link:definition>9955538 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Finite Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails">
        <link:definition>9955539 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails">
        <link:definition>9955540 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails">
        <link:definition>9955541 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Other Liabilities, Current (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails">
        <link:definition>9955542 - Disclosure - CONVERTIBLE SENIOR NOTES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails">
        <link:definition>9955543 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails">
        <link:definition>9955544 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails" roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails">
        <link:definition>9955545 - Disclosure - RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails">
        <link:definition>9955546 - Disclosure - RESTRUCTURING - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails">
        <link:definition>9955547 - Disclosure - RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails">
        <link:definition>9955548 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1">
        <link:definition>9955548 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>9955549 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>9955550 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails" roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails">
        <link:definition>9955551 - Disclosure - INCOME TAXES - Schedule of Components of Income Tax Provision (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails" roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails">
        <link:definition>9955552 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Federal Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9955553 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofReconciliationofUnrecognizedTaxBenefitAccountsDetails" roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofUnrecognizedTaxBenefitAccountsDetails">
        <link:definition>9955554 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Unrecognized Tax Benefit Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>9955555 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails">
        <link:definition>9955556 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails">
        <link:definition>9955557 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Time-Based RSUs Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>9955558 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails">
        <link:definition>9955559 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Fair Value of Employee Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails">
        <link:definition>9955560 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails">
        <link:definition>9955561 - Disclosure - NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails">
        <link:definition>9955562 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails">
        <link:definition>9955563 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails">
        <link:definition>9955564 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails">
        <link:definition>9955565 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails">
        <link:definition>9955566 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>9955567 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="pacb_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_ServiceAndOtherMember" abstract="false" name="ServiceAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_LossOnPurchaseCommitment" abstract="false" name="LossOnPurchaseCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_AmortizationOfAcquiredIntangibleAssets" abstract="false" name="AmortizationOfAcquiredIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_IncomeLossPerShareAbstract" abstract="true" name="IncomeLossPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" abstract="false" name="StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" abstract="false" name="StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_AptonAndOmniomeMember" abstract="true" name="AptonAndOmniomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_NoteExchangeMember" abstract="true" name="NoteExchangeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_BusinessCombinationMember" abstract="true" name="BusinessCombinationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_LiquidityBonusEventMember" abstract="true" name="LiquidityBonusEventMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_MilestoneAchievementMember" abstract="true" name="MilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability" abstract="false" name="IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_PaymentsInConjunctionWithNotesExchange" abstract="false" name="PaymentsInConjunctionWithNotesExchange" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_TransferOfInventoryToPropertyAndEquipment" abstract="false" name="TransferOfInventoryToPropertyAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" abstract="true" name="SupplementalBalanceSheetComponentsDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" abstract="false" name="RecentlyAdoptedAccountingStandardsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" abstract="false" name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="pacb_ScheduleOfInterestExpenseTableTextBlock" abstract="false" name="ScheduleOfInterestExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="pacb_LesseeOperatingLeaseDescriptionTableTextBlock" abstract="false" name="LesseeOperatingLeaseDescriptionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="pacb_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_DomesticCustomersMember" abstract="false" name="DomesticCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_StandardProductWarrantyPeriod" abstract="false" name="StandardProductWarrantyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_AptonMember" abstract="true" name="AptonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_AchievementOfMilestoneMember" abstract="false" name="AchievementOfMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" abstract="false" name="StockBasedCompensationExpenseExcludedFromConsiderationTransferred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" abstract="false" name="BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" abstract="false" name="StockIssuedDuringPeriodAverageTradingPeriodAcquisition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" abstract="false" name="PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_CashAndMoneyMarketFundsMember" abstract="true" name="CashAndMoneyMarketFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" abstract="false" name="UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_ShortTermRestrictedCashFairValueDisclosure" abstract="false" name="ShortTermRestrictedCashFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_LongTermRestrictedCashFairValueDisclosure" abstract="false" name="LongTermRestrictedCashFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_FinancialInstrumentsTable" abstract="true" name="FinancialInstrumentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_OmniomeIncMember" abstract="false" name="OmniomeIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_OmniomeMember" abstract="true" name="OmniomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_FinancialInstrumentsLineItems" abstract="true" name="FinancialInstrumentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone" abstract="false" name="PaymentsForContingentConsiderationRevenueAchievementMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_CashCashEquivalentsAndInvestmentsMember" abstract="false" name="CashCashEquivalentsAndInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_LaboratoryEquipmentAndMachineryMember" abstract="false" name="LaboratoryEquipmentAndMachineryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_ScheduleOfBalanceSheetComponentsTable" abstract="true" name="ScheduleOfBalanceSheetComponentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" abstract="false" name="InProcessResearchAndDevelopmentIndefiniteLivedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_CostOfRevenueMember" abstract="true" name="CostOfRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_BalanceSheetComponentsLineItems" abstract="true" name="BalanceSheetComponentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate" abstract="false" name="GoodwillImpairmentDiscountedCashFlowModelDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate" abstract="false" name="GoodwillImpairmentIncreaseInBasisPointDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="pacb_AdditionalGoodwillImpairmentChangeInDiscountRate" abstract="false" name="AdditionalGoodwillImpairmentChangeInDiscountRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" abstract="false" name="IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" abstract="false" name="IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" abstract="false" name="IntangibleAssetImpairmentDiscountedCashFlowModelTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" abstract="false" name="AdditionalIntangibleAssetImpairmentChangeInDiscountRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" abstract="false" name="IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" abstract="false" name="AdditionalIntangibleAssetImpairmentChangeInTerm" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" abstract="false" name="ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_AccruedTenantImprovementsCurrent" abstract="false" name="AccruedTenantImprovementsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_AccruedProductDevelopmentCostsCurrent" abstract="false" name="AccruedProductDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" abstract="false" name="AccruedEmployeeStockPurchasePlanLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_A2028ConvertibleSeniorNotesMember" abstract="false" name="A2028ConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_A2029NotesMember" abstract="true" name="A2029NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_A2030ConvertibleSeniorNotesMember" abstract="true" name="A2030ConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_ExchangeTransactionMember" abstract="true" name="ExchangeTransactionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_DebtInstrumentConvertibleTermsOfConversionAxis" abstract="true" name="DebtInstrumentConvertibleTermsOfConversionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_DebtInstrumentConvertibleTermsOfConversionDomain" abstract="true" name="DebtInstrumentConvertibleTermsOfConversionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_DebtConversionTermsOneMember" abstract="true" name="DebtConversionTermsOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_DebtConversionTermsTwoMember" abstract="true" name="DebtConversionTermsTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" abstract="false" name="HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_DebtInstrumentDebtDefaultCalendarDays" abstract="false" name="DebtInstrumentDebtDefaultCalendarDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_DebtInstrumentInterestInTheEventOfDefault" abstract="false" name="DebtInstrumentInterestInTheEventOfDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_DebtInstrumentAdditionalInterestInEventOfDefault" abstract="false" name="DebtInstrumentAdditionalInterestInEventOfDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_RestructuringOfDebtPricePerShare" abstract="false" name="RestructuringOfDebtPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pacb_DebtIssuanceCostLenderFees" abstract="false" name="DebtIssuanceCostLenderFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" abstract="false" name="DebtInstrumentRedemptionPricePercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_DebtInstrumentRedemptionPriceTradingDays" abstract="false" name="DebtInstrumentRedemptionPriceTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" abstract="false" name="DebtInstrumentRedemptionPriceConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_EmployeeSeparationCostsMember" abstract="true" name="EmployeeSeparationCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_SanDiegoOfficeMember" abstract="true" name="SanDiegoOfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" abstract="false" name="RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_BalanceSheetClassificationAbstract" abstract="true" name="BalanceSheetClassificationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" abstract="false" name="AdditionalLiabilityAssociatedWithIndemnificationObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_RefundFromDeposits" abstract="false" name="RefundFromDeposits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" abstract="false" name="ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_OperatingLossCarryforwardsAmountSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsAmountSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCredit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" abstract="false" name="DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" abstract="false" name="DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_DeferredTaxAssetsOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_DeferredTaxLiabilitiesRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_StockholdersEquityTable" abstract="true" name="StockholdersEquityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_EquityIncentivePlan2020Member" abstract="false" name="EquityIncentivePlan2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_EmployeeStockPurchasePlanMember" abstract="false" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_OptionsToPurchaseCommonStockMember" abstract="false" name="OptionsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_TimeBasedAndPerformanceBasedOptionsMember" abstract="false" name="TimeBasedAndPerformanceBasedOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_TimeBasedRestrictedStockUnitsRsusMember" abstract="false" name="TimeBasedRestrictedStockUnitsRsusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_TimeBasedRestrictedStockUnitsPSUMember" abstract="true" name="TimeBasedRestrictedStockUnitsPSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_ShelfOfferingMember" abstract="true" name="ShelfOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" abstract="true" name="A2020PlanInducementPlanAndTheOmniomePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_StockholdersEquityLineItems" abstract="true" name="StockholdersEquityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" abstract="false" name="CommonStockVotingRightsNumberOfVotesPerShareOwned" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:positiveIntegerItemType"/>
  <xs:element id="pacb_PublicOfferingShares" abstract="false" name="PublicOfferingShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pacb_OfferingShareAmountMaximum" abstract="false" name="OfferingShareAmountMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" abstract="false" name="PublicOfferingOptionToPurchaseAdditionalSharesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" abstract="false" name="PublicOfferingOptionToPurchaseAdditionalSharesShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" abstract="false" name="PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_ShareInstrumentNumberOfSharesConversionRatio" abstract="false" name="ShareInstrumentNumberOfSharesConversionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="pacb_NumberOfPurchasePeriods" abstract="false" name="NumberOfPurchasePeriods" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pacb_PurchasePeriodOfEmployeeStockPurchasePlan" abstract="false" name="PurchasePeriodOfEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" abstract="false" name="PercentageOfFairMarketValueAtWhichStockCanBePurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_TimeBasedStockOptionMember" abstract="false" name="TimeBasedStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_StockBasedCompensationMember" abstract="false" name="StockBasedCompensationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_A2029ConvertibleSeniorNotesMember" abstract="true" name="A2029ConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_InstrumentMember" abstract="false" name="InstrumentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_ConsumableMember" abstract="false" name="ConsumableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_OperatingLeaseExpectedBaseRentExpense" abstract="false" name="OperatingLeaseExpectedBaseRentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" abstract="false" name="LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>pacb-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b8324ceb-4367-4432-9725-ed1f11bffb27,g:1109ce80-1fe4-4ba2-bf4d-c0b012b2f3c3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_549e13d6-ce21-4002-9ecd-d3ec8fbe9d25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_eba03abf-979f-44b6-8ab8-fd5c1ee7e6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_549e13d6-ce21-4002-9ecd-d3ec8fbe9d25" xlink:to="loc_us-gaap_LiabilitiesCurrent_eba03abf-979f-44b6-8ab8-fd5c1ee7e6cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c454cb1c-d3c5-4d73-816d-90b7ec9f6eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_549e13d6-ce21-4002-9ecd-d3ec8fbe9d25" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c454cb1c-d3c5-4d73-816d-90b7ec9f6eb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9c19bbd8-9497-4522-9301-7246a46dd610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_549e13d6-ce21-4002-9ecd-d3ec8fbe9d25" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9c19bbd8-9497-4522-9301-7246a46dd610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_21634508-3e2e-4470-b885-f813a6603729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_549e13d6-ce21-4002-9ecd-d3ec8fbe9d25" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_21634508-3e2e-4470-b885-f813a6603729" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e0a96324-3c5b-45eb-95b7-30d12771df01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_549e13d6-ce21-4002-9ecd-d3ec8fbe9d25" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e0a96324-3c5b-45eb-95b7-30d12771df01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_12857096-70c4-4549-811f-4e4f97cba395" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_549e13d6-ce21-4002-9ecd-d3ec8fbe9d25" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_12857096-70c4-4549-811f-4e4f97cba395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_896d1a25-e761-43f9-8f7d-2a2a9620dd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_065ea558-5693-4ce7-8869-cfc7e5b8f43e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_896d1a25-e761-43f9-8f7d-2a2a9620dd6e" xlink:to="loc_us-gaap_Liabilities_065ea558-5693-4ce7-8869-cfc7e5b8f43e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_953d23b2-70ad-4820-9252-c775443d56dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_896d1a25-e761-43f9-8f7d-2a2a9620dd6e" xlink:to="loc_us-gaap_StockholdersEquity_953d23b2-70ad-4820-9252-c775443d56dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fcee762c-bcfd-4d05-9f13-12cf576b4aee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_896d1a25-e761-43f9-8f7d-2a2a9620dd6e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fcee762c-bcfd-4d05-9f13-12cf576b4aee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_10eb77f1-93a3-4b24-8b44-e276dcf373c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8d4c60d7-5e20-4217-bb71-5c48a003fca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_10eb77f1-93a3-4b24-8b44-e276dcf373c4" xlink:to="loc_us-gaap_AssetsCurrent_8d4c60d7-5e20-4217-bb71-5c48a003fca4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d1e28383-7b98-48af-b6d5-13e4db3d7935" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_10eb77f1-93a3-4b24-8b44-e276dcf373c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d1e28383-7b98-48af-b6d5-13e4db3d7935" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_521a32f8-5cab-46a6-9c38-6f5f3c90a663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_10eb77f1-93a3-4b24-8b44-e276dcf373c4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_521a32f8-5cab-46a6-9c38-6f5f3c90a663" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_cfe28e11-f08b-4fa7-b2a9-3533984bb912" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_10eb77f1-93a3-4b24-8b44-e276dcf373c4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_cfe28e11-f08b-4fa7-b2a9-3533984bb912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_12c88bee-3907-4d41-8af6-5c3a63e3c0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_10eb77f1-93a3-4b24-8b44-e276dcf373c4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_12c88bee-3907-4d41-8af6-5c3a63e3c0cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a45f11d6-3fc4-43a8-956c-49b30e0b696b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_10eb77f1-93a3-4b24-8b44-e276dcf373c4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a45f11d6-3fc4-43a8-956c-49b30e0b696b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_96867513-5adc-47a2-b6e1-3b897ffdc588" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_10eb77f1-93a3-4b24-8b44-e276dcf373c4" xlink:to="loc_us-gaap_Goodwill_96867513-5adc-47a2-b6e1-3b897ffdc588" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b4800599-be63-407d-bd45-7c7c680f289a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_aeb8ce95-7390-4d4c-bed5-38fee1c0fd06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b4800599-be63-407d-bd45-7c7c680f289a" xlink:to="loc_us-gaap_AccountsPayableCurrent_aeb8ce95-7390-4d4c-bed5-38fee1c0fd06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e9134f6c-f060-4cc4-802c-dd8ba6bf82a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b4800599-be63-407d-bd45-7c7c680f289a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e9134f6c-f060-4cc4-802c-dd8ba6bf82a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d717e1d9-eb61-416d-8ad1-e79edd31328f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b4800599-be63-407d-bd45-7c7c680f289a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d717e1d9-eb61-416d-8ad1-e79edd31328f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_30d2b957-2f8d-40f9-8be6-d725b298d5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b4800599-be63-407d-bd45-7c7c680f289a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_30d2b957-2f8d-40f9-8be6-d725b298d5bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d542869d-bb7a-4cc1-b69c-6ba42ff421cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b4800599-be63-407d-bd45-7c7c680f289a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d542869d-bb7a-4cc1-b69c-6ba42ff421cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6067af4a-fe76-4792-b800-00bb2920d3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3167073b-ad4e-4bab-a4b3-97e655aa1388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6067af4a-fe76-4792-b800-00bb2920d3bf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3167073b-ad4e-4bab-a4b3-97e655aa1388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_147f927a-202e-421a-90c2-28242925d0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6067af4a-fe76-4792-b800-00bb2920d3bf" xlink:to="loc_us-gaap_ShortTermInvestments_147f927a-202e-421a-90c2-28242925d0a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_880bb43c-77d5-4162-ace8-d4ef0717ecab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6067af4a-fe76-4792-b800-00bb2920d3bf" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_880bb43c-77d5-4162-ace8-d4ef0717ecab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2bddf9b3-0e19-4953-bc7f-a6ae83df1c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6067af4a-fe76-4792-b800-00bb2920d3bf" xlink:to="loc_us-gaap_InventoryNet_2bddf9b3-0e19-4953-bc7f-a6ae83df1c8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1dc745f9-f175-44bb-a790-3e7b720c0241" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6067af4a-fe76-4792-b800-00bb2920d3bf" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1dc745f9-f175-44bb-a790-3e7b720c0241" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_70d67790-5d83-4dfe-9ae6-dc8adb5e7460" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6067af4a-fe76-4792-b800-00bb2920d3bf" xlink:to="loc_us-gaap_RestrictedCashCurrent_70d67790-5d83-4dfe-9ae6-dc8adb5e7460" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_04a8960a-3841-4638-b512-e5e7353de36e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c6493f4e-d25a-43e1-ac63-eef3862b6ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_04a8960a-3841-4638-b512-e5e7353de36e" xlink:to="loc_us-gaap_PreferredStockValue_c6493f4e-d25a-43e1-ac63-eef3862b6ca4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e11561d4-44db-4f19-80da-627ce3d06b76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_04a8960a-3841-4638-b512-e5e7353de36e" xlink:to="loc_us-gaap_CommonStockValue_e11561d4-44db-4f19-80da-627ce3d06b76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_37b8d7e3-fb15-4c02-9a59-7090dbe61758" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_04a8960a-3841-4638-b512-e5e7353de36e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_37b8d7e3-fb15-4c02-9a59-7090dbe61758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5fd2d00e-dbc9-40bc-a74d-3b666c61b10a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_04a8960a-3841-4638-b512-e5e7353de36e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5fd2d00e-dbc9-40bc-a74d-3b666c61b10a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8f7d3c2d-d645-4839-a8a7-9a986a5bf26b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_04a8960a-3841-4638-b512-e5e7353de36e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8f7d3c2d-d645-4839-a8a7-9a986a5bf26b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_76ecd0ba-bbf5-4615-aa32-dfbc588d96a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e8348450-7e5e-4958-bb63-5f92edc6a078" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_76ecd0ba-bbf5-4615-aa32-dfbc588d96a2" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e8348450-7e5e-4958-bb63-5f92edc6a078" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_268d084b-722f-4880-854d-5056e420490b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_76ecd0ba-bbf5-4615-aa32-dfbc588d96a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_268d084b-722f-4880-854d-5056e420490b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_d016bf3b-d03d-4957-9d73-5e0664b64ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_76ecd0ba-bbf5-4615-aa32-dfbc588d96a2" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_d016bf3b-d03d-4957-9d73-5e0664b64ad9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_55168fd6-48e6-482b-87d8-7e340009e1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_76ecd0ba-bbf5-4615-aa32-dfbc588d96a2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_55168fd6-48e6-482b-87d8-7e340009e1e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmortizationOfAcquiredIntangibleAssets_12863eb0-e3a8-4c1b-85b0-5203804b0774" xlink:href="pacb-20241231.xsd#pacb_AmortizationOfAcquiredIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_76ecd0ba-bbf5-4615-aa32-dfbc588d96a2" xlink:to="loc_pacb_AmortizationOfAcquiredIntangibleAssets_12863eb0-e3a8-4c1b-85b0-5203804b0774" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f69f330e-2641-433b-841f-d999546a80df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_76ecd0ba-bbf5-4615-aa32-dfbc588d96a2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f69f330e-2641-433b-841f-d999546a80df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7886d4bc-d785-4874-a35b-0a1e96914f32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9eea47f5-cafa-4ef5-9558-60032d4a47f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7886d4bc-d785-4874-a35b-0a1e96914f32" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9eea47f5-cafa-4ef5-9558-60032d4a47f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3cbb4329-6ffa-4dce-a8fc-9c0475888581" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7886d4bc-d785-4874-a35b-0a1e96914f32" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3cbb4329-6ffa-4dce-a8fc-9c0475888581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_67e0cd8e-e8a0-4630-8dcb-fff548bc4b87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fe35c718-fa26-4c1b-aaf5-804f0c4e922e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_67e0cd8e-e8a0-4630-8dcb-fff548bc4b87" xlink:to="loc_us-gaap_NetIncomeLoss_fe35c718-fa26-4c1b-aaf5-804f0c4e922e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_3204cfc7-b3e2-4639-a0ca-8cd08639f4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_67e0cd8e-e8a0-4630-8dcb-fff548bc4b87" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_3204cfc7-b3e2-4639-a0ca-8cd08639f4d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b37533d4-6da8-496e-8e1c-b7494d931951" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1e840493-7cfb-4fce-abe8-083074d7ea09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b37533d4-6da8-496e-8e1c-b7494d931951" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1e840493-7cfb-4fce-abe8-083074d7ea09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cd92e40a-3665-4f11-a8f5-10f5a16e87f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b37533d4-6da8-496e-8e1c-b7494d931951" xlink:to="loc_us-gaap_OperatingIncomeLoss_cd92e40a-3665-4f11-a8f5-10f5a16e87f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_99c0e7de-0a2e-4a4c-b204-a888ab8428c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b37533d4-6da8-496e-8e1c-b7494d931951" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_99c0e7de-0a2e-4a4c-b204-a888ab8428c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_e6085a10-9981-49db-b597-865a39f1241c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b37533d4-6da8-496e-8e1c-b7494d931951" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_e6085a10-9981-49db-b597-865a39f1241c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_65a0b861-7f13-4d2e-bbab-e8db58ca7b72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b37533d4-6da8-496e-8e1c-b7494d931951" xlink:to="loc_us-gaap_InterestExpenseNonoperating_65a0b861-7f13-4d2e-bbab-e8db58ca7b72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_5a288809-1399-4b03-bd30-343c83a528db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_24eb847e-4d8b-44f2-8e08-c206ee2625c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_5a288809-1399-4b03-bd30-343c83a528db" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_24eb847e-4d8b-44f2-8e08-c206ee2625c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_96f345ad-9d18-4019-b533-1857f225de31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_5a288809-1399-4b03-bd30-343c83a528db" xlink:to="loc_us-gaap_CostOfRevenue_96f345ad-9d18-4019-b533-1857f225de31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1231b9db-9256-4b66-b062-ec350f9e7455" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_19ab6a67-2372-4c4d-bf98-937c115b34e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1231b9db-9256-4b66-b062-ec350f9e7455" xlink:to="loc_us-gaap_GrossProfit_19ab6a67-2372-4c4d-bf98-937c115b34e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_372f8a0c-a2a7-4d72-9686-9adb9bb1a905" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1231b9db-9256-4b66-b062-ec350f9e7455" xlink:to="loc_us-gaap_OperatingExpenses_372f8a0c-a2a7-4d72-9686-9adb9bb1a905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_d5950ee3-c82c-4a71-8363-37f68e5f7d78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_1b34ef14-243f-4417-8afe-ecc8a2f0b692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_d5950ee3-c82c-4a71-8363-37f68e5f7d78" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_1b34ef14-243f-4417-8afe-ecc8a2f0b692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_89893e53-99be-48c3-bcdc-a63abea9ddaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_d5950ee3-c82c-4a71-8363-37f68e5f7d78" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_89893e53-99be-48c3-bcdc-a63abea9ddaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LossOnPurchaseCommitment_fd75684c-b253-466f-bda6-05e442ea0450" xlink:href="pacb-20241231.xsd#pacb_LossOnPurchaseCommitment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_d5950ee3-c82c-4a71-8363-37f68e5f7d78" xlink:to="loc_pacb_LossOnPurchaseCommitment_fd75684c-b253-466f-bda6-05e442ea0450" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec1440c8-67ed-4db1-bb36-68c22756862b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8afafef1-cf04-4244-9d7f-ff2502755e68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec1440c8-67ed-4db1-bb36-68c22756862b" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8afafef1-cf04-4244-9d7f-ff2502755e68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_1e515c93-e568-4a74-aff9-f688060d8b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec1440c8-67ed-4db1-bb36-68c22756862b" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_1e515c93-e568-4a74-aff9-f688060d8b0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_bb2cd011-9452-4a1e-97f6-51a58f026227" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec1440c8-67ed-4db1-bb36-68c22756862b" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_bb2cd011-9452-4a1e-97f6-51a58f026227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_90c90bac-dd44-464f-868f-5ceff84512bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec1440c8-67ed-4db1-bb36-68c22756862b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_90c90bac-dd44-464f-868f-5ceff84512bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsInConjunctionWithNotesExchange_00bc469f-dd73-4c58-9f1c-1ea8b24e8d97" xlink:href="pacb-20241231.xsd#pacb_PaymentsInConjunctionWithNotesExchange"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec1440c8-67ed-4db1-bb36-68c22756862b" xlink:to="loc_pacb_PaymentsInConjunctionWithNotesExchange_00bc469f-dd73-4c58-9f1c-1ea8b24e8d97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_88f48912-1ddd-44a9-b90a-b4bf8d516b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec1440c8-67ed-4db1-bb36-68c22756862b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_88f48912-1ddd-44a9-b90a-b4bf8d516b3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8449585a-ec95-46b7-85a8-bf205bd70c03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_c4847d97-77f8-473a-881c-3fe16a5d4937" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8449585a-ec95-46b7-85a8-bf205bd70c03" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_c4847d97-77f8-473a-881c-3fe16a5d4937" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e48e2a46-f428-42f9-a7be-42396982279c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8449585a-ec95-46b7-85a8-bf205bd70c03" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e48e2a46-f428-42f9-a7be-42396982279c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ce70d1be-a7f9-46f7-aef9-9b275083a6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9612ba92-46a2-49e8-a34a-c4a3afb2f23f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ce70d1be-a7f9-46f7-aef9-9b275083a6d9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9612ba92-46a2-49e8-a34a-c4a3afb2f23f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5f0b10bb-ed47-4ff8-9ed5-961481609578" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ce70d1be-a7f9-46f7-aef9-9b275083a6d9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5f0b10bb-ed47-4ff8-9ed5-961481609578" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_05e240aa-33f8-4e97-a8e5-922d397e723f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ce70d1be-a7f9-46f7-aef9-9b275083a6d9" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_05e240aa-33f8-4e97-a8e5-922d397e723f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_e76081fb-1102-49cc-b96b-787170778eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ce70d1be-a7f9-46f7-aef9-9b275083a6d9" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_e76081fb-1102-49cc-b96b-787170778eaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_a5158dac-9fe5-45f6-9f5e-8952a051b2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ce70d1be-a7f9-46f7-aef9-9b275083a6d9" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_a5158dac-9fe5-45f6-9f5e-8952a051b2e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_b00e1631-6d9a-4d76-a1bd-b1e79d3dc4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ce70d1be-a7f9-46f7-aef9-9b275083a6d9" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_b00e1631-6d9a-4d76-a1bd-b1e79d3dc4ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a3ab5137-4b3e-4307-9cdb-af0c257c2584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a3ab5137-4b3e-4307-9cdb-af0c257c2584" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_9b8c95a4-a202-4d33-a96d-4b00dd0227f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_Depreciation_9b8c95a4-a202-4d33-a96d-4b00dd0227f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability_c5f091d8-2b31-43ac-956f-5a18af9f9217" xlink:href="pacb-20241231.xsd#pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability_c5f091d8-2b31-43ac-956f-5a18af9f9217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_06c71b5f-48aa-4ed8-9ecf-94a2081fa384" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_06c71b5f-48aa-4ed8-9ecf-94a2081fa384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashMergerRelatedCosts_f9fd7189-25be-4383-9f21-6154089c6a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashMergerRelatedCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_NoncashMergerRelatedCosts_f9fd7189-25be-4383-9f21-6154089c6a5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4c33809a-75b8-401a-9724-ab1810c5d5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4c33809a-75b8-401a-9724-ab1810c5d5d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_f99c67a6-eb51-48b8-8405-a29bdd0277b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_f99c67a6-eb51-48b8-8405-a29bdd0277b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0f6b98b0-1ad5-4f38-94fc-afaa640928dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0f6b98b0-1ad5-4f38-94fc-afaa640928dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_bf2bc5ab-81a8-4028-9e3c-6841cf0fb58d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_bf2bc5ab-81a8-4028-9e3c-6841cf0fb58d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_4913b278-74a4-4743-871b-20bbfdd0aab9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_InventoryWriteDown_4913b278-74a4-4743-871b-20bbfdd0aab9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_4751587d-be8c-4f17-a0cc-1a06b83ef542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_4751587d-be8c-4f17-a0cc-1a06b83ef542" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_510d748f-e17f-496a-b5df-663b92cb1ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_510d748f-e17f-496a-b5df-663b92cb1ef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1a95a270-ec9d-4101-aa3f-2953f800d575" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1a95a270-ec9d-4101-aa3f-2953f800d575" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_897eac6c-2403-4f48-8e1c-7fdc8a2864a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_897eac6c-2403-4f48-8e1c-7fdc8a2864a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b7e0863e-e402-47e8-9017-3c2d0ba1d627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b7e0863e-e402-47e8-9017-3c2d0ba1d627" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a9202e22-836f-4a7c-ab18-b14efdba7d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a9202e22-836f-4a7c-ab18-b14efdba7d4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9540e979-0ca6-481b-a5dd-68abe6f58d47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9540e979-0ca6-481b-a5dd-68abe6f58d47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f77635fd-76b0-41ad-bb66-a974e570c7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f77635fd-76b0-41ad-bb66-a974e570c7ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_53ebc709-4f29-4919-9ef4-23712fbeedbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_NetIncomeLoss_53ebc709-4f29-4919-9ef4-23712fbeedbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_97868727-0de3-4937-bf44-9eeba590e467" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_97868727-0de3-4937-bf44-9eeba590e467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7cab7744-c311-480d-9461-ae587b8a7490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7cab7744-c311-480d-9461-ae587b8a7490" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_b9418a8a-7568-4ea0-a6ad-0d0e66f0e93c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:calculationArc order="22" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_b9418a8a-7568-4ea0-a6ad-0d0e66f0e93c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7016c277-982f-4bed-9859-737a44cb88c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="23" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20c65b8b-f055-47a2-9a92-2f80c443078b" xlink:to="loc_us-gaap_ShareBasedCompensation_7016c277-982f-4bed-9859-737a44cb88c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_df8d1f31-d8ef-437b-a2d7-45e22a6b456d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abd31f0b-7d12-453f-8ff4-2c6a330d4967" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_df8d1f31-d8ef-437b-a2d7-45e22a6b456d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abd31f0b-7d12-453f-8ff4-2c6a330d4967" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_849e2e02-49f9-4d20-b21f-099565bc1e65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_df8d1f31-d8ef-437b-a2d7-45e22a6b456d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_849e2e02-49f9-4d20-b21f-099565bc1e65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0675085a-5c4a-49cd-baea-8462f86c656f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_df8d1f31-d8ef-437b-a2d7-45e22a6b456d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0675085a-5c4a-49cd-baea-8462f86c656f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_daa33a58-d8c1-4e1a-9cdd-837b7b4cecaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b22a9cbd-86e6-4abf-92aa-f6d7e1a54b35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_daa33a58-d8c1-4e1a-9cdd-837b7b4cecaa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b22a9cbd-86e6-4abf-92aa-f6d7e1a54b35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1d43cb40-5adb-4cd9-a281-3143e53f7443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_daa33a58-d8c1-4e1a-9cdd-837b7b4cecaa" xlink:to="loc_us-gaap_Goodwill_1d43cb40-5adb-4cd9-a281-3143e53f7443" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_f454934c-2f22-4710-a057-e2b5fe52b3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_daa33a58-d8c1-4e1a-9cdd-837b7b4cecaa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_f454934c-2f22-4710-a057-e2b5fe52b3d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f9f2ebde-bd28-408d-b9ce-820d060d43a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_daa33a58-d8c1-4e1a-9cdd-837b7b4cecaa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f9f2ebde-bd28-408d-b9ce-820d060d43a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_cd013631-ba2d-4374-be4e-41440c804c94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_daa33a58-d8c1-4e1a-9cdd-837b7b4cecaa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_cd013631-ba2d-4374-be4e-41440c804c94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_efbd4990-4191-4e8d-8491-8883e9932d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_daa33a58-d8c1-4e1a-9cdd-837b7b4cecaa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_efbd4990-4191-4e8d-8491-8883e9932d7c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_09e85b69-ace7-4eff-bd24-89c37bbeac1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d428f539-457e-47c0-802d-444e8c39bba7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_09e85b69-ace7-4eff-bd24-89c37bbeac1a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d428f539-457e-47c0-802d-444e8c39bba7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_f4c492ab-78a7-425f-aa10-337c23a1acad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_09e85b69-ace7-4eff-bd24-89c37bbeac1a" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_f4c492ab-78a7-425f-aa10-337c23a1acad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_e5ce4744-1568-48b6-a189-81a982d529b7" xlink:href="pacb-20241231.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_09e85b69-ace7-4eff-bd24-89c37bbeac1a" xlink:to="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_e5ce4744-1568-48b6-a189-81a982d529b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashFairValueDisclosure_c70fb855-015c-43ac-a3b5-1803bd1b6dd7" xlink:href="pacb-20241231.xsd#pacb_LongTermRestrictedCashFairValueDisclosure"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_09e85b69-ace7-4eff-bd24-89c37bbeac1a" xlink:to="loc_pacb_LongTermRestrictedCashFairValueDisclosure_c70fb855-015c-43ac-a3b5-1803bd1b6dd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_e01cea7d-af60-4b54-bbe1-8cbeabac0ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e5dfadd5-5dec-4b66-b513-ae26b39cde33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_e01cea7d-af60-4b54-bbe1-8cbeabac0ba4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e5dfadd5-5dec-4b66-b513-ae26b39cde33" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_885a4888-5cea-4a52-8032-e64b9d18b14f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_eb612aba-009f-479b-b105-fcabed638c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_885a4888-5cea-4a52-8032-e64b9d18b14f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_eb612aba-009f-479b-b105-fcabed638c3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bede7a9f-582d-4bb2-8107-dc096e86109b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_885a4888-5cea-4a52-8032-e64b9d18b14f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bede7a9f-582d-4bb2-8107-dc096e86109b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_38069e30-5a7f-408c-9827-505532b186ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_885a4888-5cea-4a52-8032-e64b9d18b14f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_38069e30-5a7f-408c-9827-505532b186ea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_b28385f6-4cff-40cd-a524-73d92b921abe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_a5ec43ea-82e2-4922-b058-35fc7c364b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_b28385f6-4cff-40cd-a524-73d92b921abe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_a5ec43ea-82e2-4922-b058-35fc7c364b2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_d2ffc5db-fd15-443e-9a80-7293c42854b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_b28385f6-4cff-40cd-a524-73d92b921abe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_d2ffc5db-fd15-443e-9a80-7293c42854b8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_64386d5b-c3f6-4b93-85f5-650ba571aa9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_e48e22fb-67cc-42fc-bb68-735d330dcc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_64386d5b-c3f6-4b93-85f5-650ba571aa9b" xlink:to="loc_us-gaap_InventoryWorkInProcess_e48e22fb-67cc-42fc-bb68-735d330dcc3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_77156660-b7f6-4e8f-baae-eaccdd495b76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_64386d5b-c3f6-4b93-85f5-650ba571aa9b" xlink:to="loc_us-gaap_InventoryRawMaterials_77156660-b7f6-4e8f-baae-eaccdd495b76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_7efd919a-2090-4bef-88a6-0039d266aae8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_64386d5b-c3f6-4b93-85f5-650ba571aa9b" xlink:to="loc_us-gaap_InventoryFinishedGoods_7efd919a-2090-4bef-88a6-0039d266aae8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d5ee00b0-f783-46b2-aff8-337f65060bad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_66b1fbad-ee75-45e5-97c3-e2a67ea47627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d5ee00b0-f783-46b2-aff8-337f65060bad" xlink:to="loc_us-gaap_InventoryValuationReserves_66b1fbad-ee75-45e5-97c3-e2a67ea47627" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_032dc5e0-1e41-4638-9e51-d01e2b7fcd79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d5ee00b0-f783-46b2-aff8-337f65060bad" xlink:to="loc_us-gaap_InventoryGross_032dc5e0-1e41-4638-9e51-d01e2b7fcd79" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5857f909-4cd1-4f2b-baca-2c8cf146db1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4459e7fe-cebc-4e5c-9aab-5c3ca4fbad4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5857f909-4cd1-4f2b-baca-2c8cf146db1d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4459e7fe-cebc-4e5c-9aab-5c3ca4fbad4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1a89711c-bb8b-409a-8bcb-d966a0c9cd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5857f909-4cd1-4f2b-baca-2c8cf146db1d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1a89711c-bb8b-409a-8bcb-d966a0c9cd7d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1cba74ba-4cc8-4587-bd75-dd1fc2b9433f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8c24a52b-d1a4-4fab-8485-25e194a67941" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1cba74ba-4cc8-4587-bd75-dd1fc2b9433f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8c24a52b-d1a4-4fab-8485-25e194a67941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f01185a9-239a-4de0-854b-deeb04a38a60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1cba74ba-4cc8-4587-bd75-dd1fc2b9433f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f01185a9-239a-4de0-854b-deeb04a38a60" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_492f3934-3c70-4714-984d-d5b071fe29ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_790976d1-f36a-49c4-8ca9-9c7016218d97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_492f3934-3c70-4714-984d-d5b071fe29ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_790976d1-f36a-49c4-8ca9-9c7016218d97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_89a82af8-0cda-4cd1-b0ca-3b0855ef09ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_492f3934-3c70-4714-984d-d5b071fe29ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_89a82af8-0cda-4cd1-b0ca-3b0855ef09ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_22db5a34-04e3-44b1-a9e7-1373e9a22790" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_492f3934-3c70-4714-984d-d5b071fe29ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_22db5a34-04e3-44b1-a9e7-1373e9a22790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f37570d9-4684-4d8a-a299-5cb744f8577b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_492f3934-3c70-4714-984d-d5b071fe29ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f37570d9-4684-4d8a-a299-5cb744f8577b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_82ac6018-73a4-4543-8eda-09fac43651f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_492f3934-3c70-4714-984d-d5b071fe29ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_82ac6018-73a4-4543-8eda-09fac43651f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_89d941c6-24f0-41b4-8454-82968f2dcaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_492f3934-3c70-4714-984d-d5b071fe29ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_89d941c6-24f0-41b4-8454-82968f2dcaa7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5b66db9e-039b-4cc2-b6fe-dba61284ba48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5ba2c526-ba6e-46c3-bf5a-9c9eba6cfcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5b66db9e-039b-4cc2-b6fe-dba61284ba48" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5ba2c526-ba6e-46c3-bf5a-9c9eba6cfcdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedProductDevelopmentCostsCurrent_9cb0d175-9ab1-4908-b42c-02c08adc442a" xlink:href="pacb-20241231.xsd#pacb_AccruedProductDevelopmentCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5b66db9e-039b-4cc2-b6fe-dba61284ba48" xlink:to="loc_pacb_AccruedProductDevelopmentCostsCurrent_9cb0d175-9ab1-4908-b42c-02c08adc442a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_69ecac23-dde3-445e-9270-7a415c8d78dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5b66db9e-039b-4cc2-b6fe-dba61284ba48" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_69ecac23-dde3-445e-9270-7a415c8d78dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedTenantImprovementsCurrent_5a355c14-e3dc-4449-a125-df8be9e950bf" xlink:href="pacb-20241231.xsd#pacb_AccruedTenantImprovementsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5b66db9e-039b-4cc2-b6fe-dba61284ba48" xlink:to="loc_pacb_AccruedTenantImprovementsCurrent_5a355c14-e3dc-4449-a125-df8be9e950bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a37c09fb-ba6c-407e-bbdb-b9849b55bab8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5b66db9e-039b-4cc2-b6fe-dba61284ba48" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a37c09fb-ba6c-407e-bbdb-b9849b55bab8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProductLiabilityNet_b07d4b95-ae5b-423e-ac04-896df997d3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProductLiabilityNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5b66db9e-039b-4cc2-b6fe-dba61284ba48" xlink:to="loc_us-gaap_LossContingencyAccrualProductLiabilityNet_b07d4b95-ae5b-423e-ac04-896df997d3aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_939b7dad-327a-4740-b9ed-bc28e9b529c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5b66db9e-039b-4cc2-b6fe-dba61284ba48" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_939b7dad-327a-4740-b9ed-bc28e9b529c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_333c05a5-4c20-417d-896b-acdb0c18d57a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5b66db9e-039b-4cc2-b6fe-dba61284ba48" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_333c05a5-4c20-417d-896b-acdb0c18d57a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5958331e-34a9-41b0-bada-de3ea6e5facd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_2a1234b4-0c58-4e94-9b6e-516960b38e35" xlink:href="pacb-20241231.xsd#pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_5958331e-34a9-41b0-bada-de3ea6e5facd" xlink:to="loc_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_2a1234b4-0c58-4e94-9b6e-516960b38e35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_1f78362b-d413-443c-9574-97190771af94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_5958331e-34a9-41b0-bada-de3ea6e5facd" xlink:to="loc_us-gaap_ShortTermBorrowings_1f78362b-d413-443c-9574-97190771af94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_91b4125b-12ba-42c5-b1cc-41e054894bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_5958331e-34a9-41b0-bada-de3ea6e5facd" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_91b4125b-12ba-42c5-b1cc-41e054894bc3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f15307c4-e24e-486a-b248-b1c7335db0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_d0e739ac-beeb-45cb-80b2-bca154a9fb13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_f15307c4-e24e-486a-b248-b1c7335db0ed" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_d0e739ac-beeb-45cb-80b2-bca154a9fb13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_4122d283-a4aa-4de1-912a-97017c0ca77a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_f15307c4-e24e-486a-b248-b1c7335db0ed" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_4122d283-a4aa-4de1-912a-97017c0ca77a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_20b8ae1f-c489-4b5d-80e8-5156a723db3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_f15307c4-e24e-486a-b248-b1c7335db0ed" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_20b8ae1f-c489-4b5d-80e8-5156a723db3a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_85734a45-d67c-4b01-bae8-99bd49f07f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_247f4c41-82fe-4ead-ad0f-1d42c49ccd65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_85734a45-d67c-4b01-bae8-99bd49f07f29" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_247f4c41-82fe-4ead-ad0f-1d42c49ccd65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_981d5c66-d76a-4c0b-8833-406ace8e11fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_85734a45-d67c-4b01-bae8-99bd49f07f29" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_981d5c66-d76a-4c0b-8833-406ace8e11fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_535ee5f9-e33d-43cf-ba7c-75d17c3af4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7a4dc544-a091-4d2e-8374-8ac91d6b05df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_535ee5f9-e33d-43cf-ba7c-75d17c3af4e7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7a4dc544-a091-4d2e-8374-8ac91d6b05df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ab545db1-d371-4331-a438-e5058229ce0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_535ee5f9-e33d-43cf-ba7c-75d17c3af4e7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ab545db1-d371-4331-a438-e5058229ce0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_728ac6af-cc62-4a12-ad6c-7f4d56ab7ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_812f5dd6-7b58-498e-b3a7-90a35a61cf87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_728ac6af-cc62-4a12-ad6c-7f4d56ab7ba0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_812f5dd6-7b58-498e-b3a7-90a35a61cf87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_29644b2b-7837-40d8-a257-5f72547a1aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_728ac6af-cc62-4a12-ad6c-7f4d56ab7ba0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_29644b2b-7837-40d8-a257-5f72547a1aa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c1bf9e4b-ede3-4856-bfe0-088bae4775c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_728ac6af-cc62-4a12-ad6c-7f4d56ab7ba0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c1bf9e4b-ede3-4856-bfe0-088bae4775c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f74de926-4c98-4b18-b018-6a16ceef1fde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_728ac6af-cc62-4a12-ad6c-7f4d56ab7ba0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f74de926-4c98-4b18-b018-6a16ceef1fde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a08377f5-e3ee-4076-a7b6-e1b3de21dc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_728ac6af-cc62-4a12-ad6c-7f4d56ab7ba0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a08377f5-e3ee-4076-a7b6-e1b3de21dc9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b12aab3a-c113-49fa-907e-cefa5e7804c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_728ac6af-cc62-4a12-ad6c-7f4d56ab7ba0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b12aab3a-c113-49fa-907e-cefa5e7804c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1" xlink:type="simple" xlink:href="pacb-20241231.xsd#COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e889438-fd33-454f-987e-eb8f90daffee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a27029cd-d33e-43e7-9bd4-22775f1a285a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e889438-fd33-454f-987e-eb8f90daffee" xlink:to="loc_us-gaap_OperatingLeaseLiability_a27029cd-d33e-43e7-9bd4-22775f1a285a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2574369b-b066-4c0e-9679-8a13b5f3a35c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e889438-fd33-454f-987e-eb8f90daffee" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2574369b-b066-4c0e-9679-8a13b5f3a35c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3445096f-7282-4768-a990-8d1280dd4ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d5313904-5f83-4ac5-acf7-44a91b7271f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3445096f-7282-4768-a990-8d1280dd4ec7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d5313904-5f83-4ac5-acf7-44a91b7271f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_360db18c-e07a-46e7-8cd5-9dfab1b72ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3445096f-7282-4768-a990-8d1280dd4ec7" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_360db18c-e07a-46e7-8cd5-9dfab1b72ca5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0f4f757a-4130-4e18-bccf-245f575dd0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_52a83eba-fab4-4006-996f-1f633c69b7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0f4f757a-4130-4e18-bccf-245f575dd0b3" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_52a83eba-fab4-4006-996f-1f633c69b7f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c9e32684-96dd-407f-b4cc-0c8f8e4b7fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0f4f757a-4130-4e18-bccf-245f575dd0b3" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c9e32684-96dd-407f-b4cc-0c8f8e4b7fd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9a2d461c-6f3c-4252-9c9b-a0e465d8dae8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0f4f757a-4130-4e18-bccf-245f575dd0b3" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9a2d461c-6f3c-4252-9c9b-a0e465d8dae8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_314bcb82-089a-4cf0-ae7e-a5abf4025afb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_0fadd90e-69f1-4faf-823b-06ce372bc4bf" xlink:href="pacb-20241231.xsd#pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_314bcb82-089a-4cf0-ae7e-a5abf4025afb" xlink:to="loc_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_0fadd90e-69f1-4faf-823b-06ce372bc4bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0f358d5c-b7c5-4b54-8af8-26586aa3a555" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_314bcb82-089a-4cf0-ae7e-a5abf4025afb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0f358d5c-b7c5-4b54-8af8-26586aa3a555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_5617e63c-fe76-43d7-9381-7c2bfed76ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_314bcb82-089a-4cf0-ae7e-a5abf4025afb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_5617e63c-fe76-43d7-9381-7c2bfed76ec2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_e727bc6d-240d-4a27-b716-a83488ee62f3" xlink:href="pacb-20241231.xsd#pacb_EffectiveIncomeTaxRateReconciliationTaxCredit"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_314bcb82-089a-4cf0-ae7e-a5abf4025afb" xlink:to="loc_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_e727bc6d-240d-4a27-b716-a83488ee62f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_55792c49-80f7-43a6-8454-75c72016485c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_314bcb82-089a-4cf0-ae7e-a5abf4025afb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_55792c49-80f7-43a6-8454-75c72016485c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e2451788-9e72-4e88-b066-1367da24eaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_314bcb82-089a-4cf0-ae7e-a5abf4025afb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e2451788-9e72-4e88-b066-1367da24eaf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_a1619e80-f563-45ca-af65-587bf395af32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_314bcb82-089a-4cf0-ae7e-a5abf4025afb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_a1619e80-f563-45ca-af65-587bf395af32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e5f2803d-20ef-49cc-8f4a-833fac3f1119" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_314bcb82-089a-4cf0-ae7e-a5abf4025afb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e5f2803d-20ef-49cc-8f4a-833fac3f1119" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8be9f14a-a1b5-47d9-a2d2-194f60bc3497" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense_02a8fcdc-6304-49fb-935b-bf1e97f6d4be" xlink:href="pacb-20241231.xsd#pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8be9f14a-a1b5-47d9-a2d2-194f60bc3497" xlink:to="loc_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense_02a8fcdc-6304-49fb-935b-bf1e97f6d4be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6a410253-75f7-4778-ae54-e054c6f23cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8be9f14a-a1b5-47d9-a2d2-194f60bc3497" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6a410253-75f7-4778-ae54-e054c6f23cf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetsOperatingLeaseLiabilities_d6c67403-2020-44a0-8f0f-9169d2dfc989" xlink:href="pacb-20241231.xsd#pacb_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8be9f14a-a1b5-47d9-a2d2-194f60bc3497" xlink:to="loc_pacb_DeferredTaxAssetsOperatingLeaseLiabilities_d6c67403-2020-44a0-8f0f-9169d2dfc989" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_34fca953-7990-4f67-adf8-594a2b048c07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8be9f14a-a1b5-47d9-a2d2-194f60bc3497" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_34fca953-7990-4f67-adf8-594a2b048c07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_1cac726b-4a17-45fa-b6f5-d54e5bad7da3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8be9f14a-a1b5-47d9-a2d2-194f60bc3497" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_1cac726b-4a17-45fa-b6f5-d54e5bad7da3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_b0344422-ed8e-4ddd-81b7-91d9ce92d6c3" xlink:href="pacb-20241231.xsd#pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8be9f14a-a1b5-47d9-a2d2-194f60bc3497" xlink:to="loc_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_b0344422-ed8e-4ddd-81b7-91d9ce92d6c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_220e3a02-4ae4-4070-bb1a-18f38a070120" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8be9f14a-a1b5-47d9-a2d2-194f60bc3497" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_220e3a02-4ae4-4070-bb1a-18f38a070120" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7f9fa3f2-545c-4b21-8efe-f6a958a60ead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b415a821-bcc0-4955-8cbb-19c6d5775d54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_7f9fa3f2-545c-4b21-8efe-f6a958a60ead" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b415a821-bcc0-4955-8cbb-19c6d5775d54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d8f49951-67b6-446c-8248-b27587af91c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_7f9fa3f2-545c-4b21-8efe-f6a958a60ead" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d8f49951-67b6-446c-8248-b27587af91c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b48d3ae7-66d4-4fab-aed1-550b3fa1a72e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxLiabilitiesRightOfUseAssets_f7d27c4b-b034-4465-b0be-ee43d4652bb5" xlink:href="pacb-20241231.xsd#pacb_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_b48d3ae7-66d4-4fab-aed1-550b3fa1a72e" xlink:to="loc_pacb_DeferredTaxLiabilitiesRightOfUseAssets_f7d27c4b-b034-4465-b0be-ee43d4652bb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ec3e0c5e-0f64-4114-9805-7270ec3089a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_b48d3ae7-66d4-4fab-aed1-550b3fa1a72e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ec3e0c5e-0f64-4114-9805-7270ec3089a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3c7d528d-bba6-4d52-8cdc-f58dfc69bf79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_b48d3ae7-66d4-4fab-aed1-550b3fa1a72e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3c7d528d-bba6-4d52-8cdc-f58dfc69bf79" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_87d58ef8-fc21-4efb-9645-696566c8e5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_a9e61e9b-8b56-4189-9f1b-c591746b2f24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_87d58ef8-fc21-4efb-9645-696566c8e5dd" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_a9e61e9b-8b56-4189-9f1b-c591746b2f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_ea10c62c-48ec-468b-b5f2-7cff82189680" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_87d58ef8-fc21-4efb-9645-696566c8e5dd" xlink:to="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_ea10c62c-48ec-468b-b5f2-7cff82189680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_feb41332-43e7-4bbe-9631-d09d578968a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_87d58ef8-fc21-4efb-9645-696566c8e5dd" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_feb41332-43e7-4bbe-9631-d09d578968a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1e789b5c-d1d4-4bfa-b797-ffa6684290f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_7589272e-bb0f-4e8d-aac4-9bb14e195012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1e789b5c-d1d4-4bfa-b797-ffa6684290f2" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_7589272e-bb0f-4e8d-aac4-9bb14e195012" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8a94bfec-23e5-42a6-8e42-589b907352bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1e789b5c-d1d4-4bfa-b797-ffa6684290f2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8a94bfec-23e5-42a6-8e42-589b907352bf" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>pacb-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b8324ceb-4367-4432-9725-ed1f11bffb27,g:1109ce80-1fe4-4ba2-bf4d-c0b012b2f3c3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9c68479e-86da-44b9-a018-509505bc2832" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_StatementTable_9c68479e-86da-44b9-a018-509505bc2832" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_54839321-cc42-4523-9d1b-9685d1ffb674" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9c68479e-86da-44b9-a018-509505bc2832" xlink:to="loc_srt_ProductOrServiceAxis_54839321-cc42-4523-9d1b-9685d1ffb674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_54839321-cc42-4523-9d1b-9685d1ffb674_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_54839321-cc42-4523-9d1b-9685d1ffb674" xlink:to="loc_srt_ProductsAndServicesDomain_54839321-cc42-4523-9d1b-9685d1ffb674_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a0798a82-03e8-4f96-ab2a-16f265a0ea4b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_54839321-cc42-4523-9d1b-9685d1ffb674" xlink:to="loc_srt_ProductsAndServicesDomain_a0798a82-03e8-4f96-ab2a-16f265a0ea4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7f2a8479-dcb5-406e-a19b-3adf7f00c867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0798a82-03e8-4f96-ab2a-16f265a0ea4b" xlink:to="loc_us-gaap_ProductMember_7f2a8479-dcb5-406e-a19b-3adf7f00c867" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_8a3830d7-db85-4fa9-8757-41f3c85dfba6" xlink:href="pacb-20241231.xsd#pacb_ServiceAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0798a82-03e8-4f96-ab2a-16f265a0ea4b" xlink:to="loc_pacb_ServiceAndOtherMember_8a3830d7-db85-4fa9-8757-41f3c85dfba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0aaf1c19-a030-4637-a3a5-728b9dd627f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_RevenuesAbstract_0aaf1c19-a030-4637-a3a5-728b9dd627f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7732e604-46d7-4552-b7a7-e44f9ea8c295" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_0aaf1c19-a030-4637-a3a5-728b9dd627f0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7732e604-46d7-4552-b7a7-e44f9ea8c295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_6faeeb1c-04ce-4130-a7a7-42fb964ebafc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_CostOfRevenueAbstract_6faeeb1c-04ce-4130-a7a7-42fb964ebafc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_d5df03bf-e40d-45bb-a14b-6deaf68d10e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6faeeb1c-04ce-4130-a7a7-42fb964ebafc" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_d5df03bf-e40d-45bb-a14b-6deaf68d10e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_9932d41f-8309-45f0-8817-c57b907f6a16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6faeeb1c-04ce-4130-a7a7-42fb964ebafc" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_9932d41f-8309-45f0-8817-c57b907f6a16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LossOnPurchaseCommitment_03c27262-25f5-4bf7-b4e6-3ba652853327" xlink:href="pacb-20241231.xsd#pacb_LossOnPurchaseCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6faeeb1c-04ce-4130-a7a7-42fb964ebafc" xlink:to="loc_pacb_LossOnPurchaseCommitment_03c27262-25f5-4bf7-b4e6-3ba652853327" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_472c8cc2-f35e-4448-b782-5790b717459f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6faeeb1c-04ce-4130-a7a7-42fb964ebafc" xlink:to="loc_us-gaap_CostOfRevenue_472c8cc2-f35e-4448-b782-5790b717459f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_a6d9cb28-4a7e-456d-8a0a-ebf9d744ab86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_GrossProfit_a6d9cb28-4a7e-456d-8a0a-ebf9d744ab86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d2da1ab7-9df1-493d-993f-cee5d61d20bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d2da1ab7-9df1-493d-993f-cee5d61d20bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1c18b833-acc1-4bea-b746-3e57176e65ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1c18b833-acc1-4bea-b746-3e57176e65ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_3b3f148b-6fc6-4051-9644-12676c2ee84a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_3b3f148b-6fc6-4051-9644-12676c2ee84a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_9488b1cf-55ff-4738-aedd-4ecda4e07917" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_9488b1cf-55ff-4738-aedd-4ecda4e07917" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e0de5280-215b-4ebd-9b29-f59163543b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e0de5280-215b-4ebd-9b29-f59163543b9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmortizationOfAcquiredIntangibleAssets_f22ce76b-07ea-404f-ad1f-55ce378b7711" xlink:href="pacb-20241231.xsd#pacb_AmortizationOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:to="loc_pacb_AmortizationOfAcquiredIntangibleAssets_f22ce76b-07ea-404f-ad1f-55ce378b7711" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_dca1e045-752e-4dd7-b559-a6317d889555" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:to="loc_us-gaap_OperatingExpenses_dca1e045-752e-4dd7-b559-a6317d889555" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a806e3d8-4cfb-4d58-a88b-e48b6c4bac01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_OperatingIncomeLoss_a806e3d8-4cfb-4d58-a88b-e48b6c4bac01" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_76f06ea8-5323-4015-bad9-dcd9f99d32cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_76f06ea8-5323-4015-bad9-dcd9f99d32cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_b37a84ac-7343-4789-8385-b1d60e3d80dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_b37a84ac-7343-4789-8385-b1d60e3d80dd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_584e49e6-05da-4de9-94b8-b2581595e868" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_InterestExpenseNonoperating_584e49e6-05da-4de9-94b8-b2581595e868" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_83b6bd89-4a54-43b8-897b-f7c9f3c1e02b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_83b6bd89-4a54-43b8-897b-f7c9f3c1e02b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4e35972e-dc56-4cbd-a765-4aefe59044a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4e35972e-dc56-4cbd-a765-4aefe59044a7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b523b30f-a3e2-4531-beb8-56cfe8327792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b523b30f-a3e2-4531-beb8-56cfe8327792" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5aae1128-7517-47ea-93a4-5022d23ad766" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_NetIncomeLoss_5aae1128-7517-47ea-93a4-5022d23ad766" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_84e5f566-3966-4d1e-a05d-7729d7a83079" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_84e5f566-3966-4d1e-a05d-7729d7a83079" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5d7e76ea-c37a-40b1-9301-9aa550918017" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_84e5f566-3966-4d1e-a05d-7729d7a83079" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5d7e76ea-c37a-40b1-9301-9aa550918017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_37493bc5-2506-40b6-aa92-c9acb0678dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_37493bc5-2506-40b6-aa92-c9acb0678dbc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeLossPerShareAbstract_bf2d3ee4-c8a4-4f8b-b099-734001d0f694" xlink:href="pacb-20241231.xsd#pacb_IncomeLossPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_pacb_IncomeLossPerShareAbstract_bf2d3ee4-c8a4-4f8b-b099-734001d0f694" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_39275742-6a6b-4af4-bfdc-630a6cc0c583" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeLossPerShareAbstract_bf2d3ee4-c8a4-4f8b-b099-734001d0f694" xlink:to="loc_us-gaap_EarningsPerShareBasic_39275742-6a6b-4af4-bfdc-630a6cc0c583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_783f7dbe-d819-4cd7-bd2d-ea04b385b036" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeLossPerShareAbstract_bf2d3ee4-c8a4-4f8b-b099-734001d0f694" xlink:to="loc_us-gaap_EarningsPerShareDiluted_783f7dbe-d819-4cd7-bd2d-ea04b385b036" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_c3da896f-4e34-456d-aaa7-664aa020836a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_c3da896f-4e34-456d-aaa7-664aa020836a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a982e493-ea0e-4a29-9cb6-2c1539205015" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_c3da896f-4e34-456d-aaa7-664aa020836a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a982e493-ea0e-4a29-9cb6-2c1539205015" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2070caf0-19da-45f0-8031-458b633f4809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_c3da896f-4e34-456d-aaa7-664aa020836a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2070caf0-19da-45f0-8031-458b633f4809" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_15a3501d-3a41-41e6-bcc2-e161f54ee8de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_31b04cf1-02e4-4de5-ac48-7b71188cb1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_15a3501d-3a41-41e6-bcc2-e161f54ee8de" xlink:to="loc_us-gaap_StatementTable_31b04cf1-02e4-4de5-ac48-7b71188cb1d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5f4ea3ac-4ced-4397-b74a-bd72dc613a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_31b04cf1-02e4-4de5-ac48-7b71188cb1d8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5f4ea3ac-4ced-4397-b74a-bd72dc613a8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5f4ea3ac-4ced-4397-b74a-bd72dc613a8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5f4ea3ac-4ced-4397-b74a-bd72dc613a8b" xlink:to="loc_us-gaap_EquityComponentDomain_5f4ea3ac-4ced-4397-b74a-bd72dc613a8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9c45f2c2-b675-4c89-85c6-cbaa0466e145" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5f4ea3ac-4ced-4397-b74a-bd72dc613a8b" xlink:to="loc_us-gaap_EquityComponentDomain_9c45f2c2-b675-4c89-85c6-cbaa0466e145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c8358a61-5883-4db5-92cd-66dd675bab05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9c45f2c2-b675-4c89-85c6-cbaa0466e145" xlink:to="loc_us-gaap_CommonStockMember_c8358a61-5883-4db5-92cd-66dd675bab05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5ebf0611-b968-46c0-b8fb-9a546f705dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9c45f2c2-b675-4c89-85c6-cbaa0466e145" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5ebf0611-b968-46c0-b8fb-9a546f705dbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_073ae830-fecd-4292-b20a-d2f55274b6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9c45f2c2-b675-4c89-85c6-cbaa0466e145" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_073ae830-fecd-4292-b20a-d2f55274b6a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3113d804-1cfc-4283-8167-805fadb602c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9c45f2c2-b675-4c89-85c6-cbaa0466e145" xlink:to="loc_us-gaap_RetainedEarningsMember_3113d804-1cfc-4283-8167-805fadb602c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15a3501d-3a41-41e6-bcc2-e161f54ee8de" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_70854a84-7933-4267-abb3-304b53c0a0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_70854a84-7933-4267-abb3-304b53c0a0f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c07a6575-864e-42ff-bc1e-e961c2d82548" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockholdersEquity_c07a6575-864e-42ff-bc1e-e961c2d82548" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e1ff218-7b3a-48a2-a3cf-a99a979d1f35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_NetIncomeLoss_9e1ff218-7b3a-48a2-a3cf-a99a979d1f35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_8657ae8c-bf11-4e86-98f3-8983e3ac0041" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_8657ae8c-bf11-4e86-98f3-8983e3ac0041" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_6f451315-1448-40c1-8f24-fbc40f89e7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_6f451315-1448-40c1-8f24-fbc40f89e7ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_33546d02-f1b2-4653-a4f9-dfc17966746c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_33546d02-f1b2-4653-a4f9-dfc17966746c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2351a121-9a6d-4225-acd3-b407e781c458" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2351a121-9a6d-4225-acd3-b407e781c458" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fac26b0d-c98d-4fef-9c49-867407f8d22d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fac26b0d-c98d-4fef-9c49-867407f8d22d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_4e0b24fb-9b3b-4884-bd5e-5419c44ecfd3" xlink:href="pacb-20241231.xsd#pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_4e0b24fb-9b3b-4884-bd5e-5419c44ecfd3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_550961f9-8821-4c43-9068-0e140b9f2c08" xlink:href="pacb-20241231.xsd#pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_550961f9-8821-4c43-9068-0e140b9f2c08" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7fb3847c-909d-48d0-910f-6da3759bb67a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7fb3847c-909d-48d0-910f-6da3759bb67a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2780016c-9968-40ae-a4f2-c0827251b51c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2780016c-9968-40ae-a4f2-c0827251b51c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4dd9d293-88cc-4527-8f56-70d24a989652" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4dd9d293-88cc-4527-8f56-70d24a989652" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_80397d9d-8302-42e2-a3da-66e8410be8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_80397d9d-8302-42e2-a3da-66e8410be8fa" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_70747bdb-c397-41c1-bfaa-017948f00018" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_70747bdb-c397-41c1-bfaa-017948f00018" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_266de281-792c-4e61-8977-37332542810f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_266de281-792c-4e61-8977-37332542810f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0839e8ad-c018-4310-bbc5-0811c017c832" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0839e8ad-c018-4310-bbc5-0811c017c832" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9c21df6f-6094-4067-8dcb-056df669c64b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_591ef9b4-feac-4907-9a65-cb29ebd9e0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b577beea-9d9e-407f-a66d-8f86e36f1363" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_StatementTable_b577beea-9d9e-407f-a66d-8f86e36f1363" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_89c70b38-524f-462b-bed3-bf2be5cda39c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b577beea-9d9e-407f-a66d-8f86e36f1363" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_89c70b38-524f-462b-bed3-bf2be5cda39c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_89c70b38-524f-462b-bed3-bf2be5cda39c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89c70b38-524f-462b-bed3-bf2be5cda39c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_89c70b38-524f-462b-bed3-bf2be5cda39c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1531ee13-3131-415c-96cb-4736c833b4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89c70b38-524f-462b-bed3-bf2be5cda39c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1531ee13-3131-415c-96cb-4736c833b4e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonAndOmniomeMember_35426be3-ecec-4b9a-841c-f9d58b63fc32" xlink:href="pacb-20241231.xsd#pacb_AptonAndOmniomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1531ee13-3131-415c-96cb-4736c833b4e9" xlink:to="loc_pacb_AptonAndOmniomeMember_35426be3-ecec-4b9a-841c-f9d58b63fc32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9d20adae-ac01-4488-9655-7142e55c4f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b577beea-9d9e-407f-a66d-8f86e36f1363" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9d20adae-ac01-4488-9655-7142e55c4f5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d20adae-ac01-4488-9655-7142e55c4f5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9d20adae-ac01-4488-9655-7142e55c4f5f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d20adae-ac01-4488-9655-7142e55c4f5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388efb0c-4cc0-4dce-a851-07412134b6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9d20adae-ac01-4488-9655-7142e55c4f5f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388efb0c-4cc0-4dce-a851-07412134b6f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_NoteExchangeMember_2a2905ef-e569-45b6-b4c9-e0b63a7df29b" xlink:href="pacb-20241231.xsd#pacb_NoteExchangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388efb0c-4cc0-4dce-a851-07412134b6f2" xlink:to="loc_pacb_NoteExchangeMember_2a2905ef-e569-45b6-b4c9-e0b63a7df29b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationMember_92e083ea-09f4-45f5-8b9a-061a16d2030a" xlink:href="pacb-20241231.xsd#pacb_BusinessCombinationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388efb0c-4cc0-4dce-a851-07412134b6f2" xlink:to="loc_pacb_BusinessCombinationMember_92e083ea-09f4-45f5-8b9a-061a16d2030a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LiquidityBonusEventMember_44fa5b1c-9fdb-433b-8bf4-edfc74fc6bac" xlink:href="pacb-20241231.xsd#pacb_LiquidityBonusEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388efb0c-4cc0-4dce-a851-07412134b6f2" xlink:to="loc_pacb_LiquidityBonusEventMember_44fa5b1c-9fdb-433b-8bf4-edfc74fc6bac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MilestoneAchievementMember_450de2f9-2de5-45dc-a7d6-42e389cbc6ed" xlink:href="pacb-20241231.xsd#pacb_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388efb0c-4cc0-4dce-a851-07412134b6f2" xlink:to="loc_pacb_MilestoneAchievementMember_450de2f9-2de5-45dc-a7d6-42e389cbc6ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67ce84c8-d6ce-4a45-9c1b-374ba318593e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67ce84c8-d6ce-4a45-9c1b-374ba318593e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c9f78ef8-3961-43c1-9498-83920bd00324" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67ce84c8-d6ce-4a45-9c1b-374ba318593e" xlink:to="loc_us-gaap_NetIncomeLoss_c9f78ef8-3961-43c1-9498-83920bd00324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67ce84c8-d6ce-4a45-9c1b-374ba318593e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a306d788-4552-4ef9-b2ce-563741445301" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_Depreciation_a306d788-4552-4ef9-b2ce-563741445301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_638c7243-5f20-4e4a-bf5a-3f298d8b3c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_638c7243-5f20-4e4a-bf5a-3f298d8b3c1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3be20a3b-8bb9-4672-9feb-9c2ef92e4023" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3be20a3b-8bb9-4672-9feb-9c2ef92e4023" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4c8c9db3-b841-4674-b93e-e334edd151c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_ShareBasedCompensation_4c8c9db3-b841-4674-b93e-e334edd151c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_b7221b8f-c84d-491c-8143-a0943348f24a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_b7221b8f-c84d-491c-8143-a0943348f24a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashMergerRelatedCosts_b35dac6e-b5f5-4e77-99eb-7254f4833d50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashMergerRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_NoncashMergerRelatedCosts_b35dac6e-b5f5-4e77-99eb-7254f4833d50" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_852bc4fe-63eb-4caa-ad21-072eea3205aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_852bc4fe-63eb-4caa-ad21-072eea3205aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_ebf57581-c5ac-4905-b4a6-b5ee1a2fcdec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_ebf57581-c5ac-4905-b4a6-b5ee1a2fcdec" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_24bec309-3d1d-44be-8689-b0242584b73e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_24bec309-3d1d-44be-8689-b0242584b73e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_990dae20-c3d6-4b4d-9bf2-6b43c8e86881" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_990dae20-c3d6-4b4d-9bf2-6b43c8e86881" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_2f89df17-7fec-4cc7-9cf6-ac5244b8f28e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_InventoryWriteDown_2f89df17-7fec-4cc7-9cf6-ac5244b8f28e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_4a132c8d-e2d1-4a9c-bc06-deb5e52dbb23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_4a132c8d-e2d1-4a9c-bc06-deb5e52dbb23" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c08b44f1-bd22-42b0-b9cb-491de5ffe7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c08b44f1-bd22-42b0-b9cb-491de5ffe7a8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67ce84c8-d6ce-4a45-9c1b-374ba318593e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ced8d5fe-5f4b-4fea-911d-ce859917f9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ced8d5fe-5f4b-4fea-911d-ce859917f9f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1e68078a-ab6d-432e-817a-0cc44020849d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1e68078a-ab6d-432e-817a-0cc44020849d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b8449a4c-1470-40e6-9881-193a6304b418" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b8449a4c-1470-40e6-9881-193a6304b418" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_39c5e81f-55c1-4737-ac96-211886ba2545" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_39c5e81f-55c1-4737-ac96-211886ba2545" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7ad58c8f-9c55-4525-9e61-5727a2106803" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7ad58c8f-9c55-4525-9e61-5727a2106803" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_028b4642-f867-4d5d-bfba-cbfae4b04acb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_028b4642-f867-4d5d-bfba-cbfae4b04acb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e37fb3dd-2f49-4cb0-aca0-e1aab4c8e67d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e37fb3dd-2f49-4cb0-aca0-e1aab4c8e67d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability_780d5a4f-d8f8-4c4a-9a59-a671b7ac7c17" xlink:href="pacb-20241231.xsd#pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability_780d5a4f-d8f8-4c4a-9a59-a671b7ac7c17" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c4c5b510-1fc5-4843-bcd7-4d815b8c3773" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c4c5b510-1fc5-4843-bcd7-4d815b8c3773" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_faf10fb0-19cf-4ae2-ac23-056351e7e2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67ce84c8-d6ce-4a45-9c1b-374ba318593e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_faf10fb0-19cf-4ae2-ac23-056351e7e2d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e38c33ea-3687-45eb-8f55-4c097c1700da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e38c33ea-3687-45eb-8f55-4c097c1700da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_db471b77-e47e-466d-acbe-f3d7c9130909" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_db471b77-e47e-466d-acbe-f3d7c9130909" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_488a1040-5afd-4d55-a057-ae73f29a94fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_488a1040-5afd-4d55-a057-ae73f29a94fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_620a92a6-1cad-4141-8f1a-f285915fc089" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_620a92a6-1cad-4141-8f1a-f285915fc089" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_599c9db1-b153-4b9c-8498-886a3b81e41d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_599c9db1-b153-4b9c-8498-886a3b81e41d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_c538b804-8153-46a8-a4cb-d96180d7fdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_c538b804-8153-46a8-a4cb-d96180d7fdb5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e61bae6-a304-4b42-adce-51e6e642cfc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e61bae6-a304-4b42-adce-51e6e642cfc4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f8746aa0-418e-4e72-8a2e-e04fd43f9615" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f8746aa0-418e-4e72-8a2e-e04fd43f9615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8c9ff493-7e91-4380-b60c-c81c85c7f7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8c9ff493-7e91-4380-b60c-c81c85c7f7b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_eadba61a-958d-4e8b-a535-9278c97d010f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_eadba61a-958d-4e8b-a535-9278c97d010f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_0ae7996d-a680-4551-a944-450ec70415ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_0ae7996d-a680-4551-a944-450ec70415ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsInConjunctionWithNotesExchange_0916e3e0-2987-4eb7-a011-7cc8fdb06d79" xlink:href="pacb-20241231.xsd#pacb_PaymentsInConjunctionWithNotesExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:to="loc_pacb_PaymentsInConjunctionWithNotesExchange_0916e3e0-2987-4eb7-a011-7cc8fdb06d79" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_a19aaa6f-674a-468c-889a-462b4d31c202" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_a19aaa6f-674a-468c-889a-462b4d31c202" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e028b593-5a5b-43b4-9ad9-5f2a5bc889ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e028b593-5a5b-43b4-9ad9-5f2a5bc889ce" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_962846d0-5d28-4d16-a5a2-c88fbdc4ff26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_962846d0-5d28-4d16-a5a2-c88fbdc4ff26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4221073-416c-430e-bb64-18a09dbb7ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4221073-416c-430e-bb64-18a09dbb7ddc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8892b9b5-af96-4843-99b0-bd39612a3068" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c9794fe-1805-4e20-ad49-c7e24be698ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c9794fe-1805-4e20-ad49-c7e24be698ea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_d5d44145-af67-4b4a-acd1-da35cd4e0c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_d5d44145-af67-4b4a-acd1-da35cd4e0c7b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01fd5c69-2a81-4f05-8f93-28561a1c1e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_b17626d0-889e-48d3-a9b9-3c4c9a728be4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_b17626d0-889e-48d3-a9b9-3c4c9a728be4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_062bbca4-d210-4c99-9ed7-562c5350f652" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b17626d0-889e-48d3-a9b9-3c4c9a728be4" xlink:to="loc_us-gaap_InterestPaidNet_062bbca4-d210-4c99-9ed7-562c5350f652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e6d7a302-8e86-4955-95b1-ef186cf8440c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e6d7a302-8e86-4955-95b1-ef186cf8440c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TransferOfInventoryToPropertyAndEquipment_98610ba2-ef21-48bf-a080-45dd66902076" xlink:href="pacb-20241231.xsd#pacb_TransferOfInventoryToPropertyAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e6d7a302-8e86-4955-95b1-ef186cf8440c" xlink:to="loc_pacb_TransferOfInventoryToPropertyAndEquipment_98610ba2-ef21-48bf-a080-45dd66902076" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_580732e7-7e5b-403e-91b0-fa29596c1d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e6d7a302-8e86-4955-95b1-ef186cf8440c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_580732e7-7e5b-403e-91b0-fa29596c1d3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b88a8ba7-f938-49eb-9d4a-9f41012eccc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e6d7a302-8e86-4955-95b1-ef186cf8440c" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b88a8ba7-f938-49eb-9d4a-9f41012eccc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_ccad17ac-1c0e-4783-a448-bd3dd2b8ffb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e6d7a302-8e86-4955-95b1-ef186cf8440c" xlink:to="loc_us-gaap_StockIssued1_ccad17ac-1c0e-4783-a448-bd3dd2b8ffb6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesIssued1_cafc8168-8704-4f63-bbd2-6ac72547c2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e6d7a302-8e86-4955-95b1-ef186cf8440c" xlink:to="loc_us-gaap_NotesIssued1_cafc8168-8704-4f63-bbd2-6ac72547c2b3" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_14bfa4a9-9c67-4486-a8bb-1955bdd824df" xlink:href="pacb-20241231.xsd#pacb_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_33a3ec3c-943b-44de-9dff-2b4d5b4bfbc3" xlink:href="pacb-20241231.xsd#pacb_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_14bfa4a9-9c67-4486-a8bb-1955bdd824df" xlink:to="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_33a3ec3c-943b-44de-9dff-2b4d5b4bfbc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c50b3316-e027-47c5-a3e3-61c3a6e6c112" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_33a3ec3c-943b-44de-9dff-2b4d5b4bfbc3" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c50b3316-e027-47c5-a3e3-61c3a6e6c112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c50b3316-e027-47c5-a3e3-61c3a6e6c112_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c50b3316-e027-47c5-a3e3-61c3a6e6c112" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c50b3316-e027-47c5-a3e3-61c3a6e6c112_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fff12d7-4c15-4e55-a492-0a82a5bd93d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c50b3316-e027-47c5-a3e3-61c3a6e6c112" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fff12d7-4c15-4e55-a492-0a82a5bd93d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_cc28a458-04ac-4f00-8dab-1a4a4face8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fff12d7-4c15-4e55-a492-0a82a5bd93d7" xlink:to="loc_us-gaap_SalesRevenueNetMember_cc28a458-04ac-4f00-8dab-1a4a4face8cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_03081fd9-5d3e-4376-b9dd-bf6656f7b5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fff12d7-4c15-4e55-a492-0a82a5bd93d7" xlink:to="loc_us-gaap_AccountsReceivableMember_03081fd9-5d3e-4376-b9dd-bf6656f7b5cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_67b24d19-8655-406f-9d3a-efab363843f9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_33a3ec3c-943b-44de-9dff-2b4d5b4bfbc3" xlink:to="loc_srt_MajorCustomersAxis_67b24d19-8655-406f-9d3a-efab363843f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_67b24d19-8655-406f-9d3a-efab363843f9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_67b24d19-8655-406f-9d3a-efab363843f9" xlink:to="loc_srt_NameOfMajorCustomerDomain_67b24d19-8655-406f-9d3a-efab363843f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ef205d31-28c9-423f-95f3-82c75c6856bb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_67b24d19-8655-406f-9d3a-efab363843f9" xlink:to="loc_srt_NameOfMajorCustomerDomain_ef205d31-28c9-423f-95f3-82c75c6856bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CustomerOneMember_3c51a0f0-ecd8-4eb7-a723-d22d948ef30d" xlink:href="pacb-20241231.xsd#pacb_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ef205d31-28c9-423f-95f3-82c75c6856bb" xlink:to="loc_pacb_CustomerOneMember_3c51a0f0-ecd8-4eb7-a723-d22d948ef30d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DomesticCustomersMember_64b3d11f-0c8e-4133-a000-0a0ff4ed7178" xlink:href="pacb-20241231.xsd#pacb_DomesticCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ef205d31-28c9-423f-95f3-82c75c6856bb" xlink:to="loc_pacb_DomesticCustomersMember_64b3d11f-0c8e-4133-a000-0a0ff4ed7178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_30c05153-f113-458f-ace1-b1bd315a4edf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_33a3ec3c-943b-44de-9dff-2b4d5b4bfbc3" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_30c05153-f113-458f-ace1-b1bd315a4edf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_30c05153-f113-458f-ace1-b1bd315a4edf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_30c05153-f113-458f-ace1-b1bd315a4edf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_30c05153-f113-458f-ace1-b1bd315a4edf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_7b823634-cb2a-469d-9a26-3cc3a6c87eca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_30c05153-f113-458f-ace1-b1bd315a4edf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_7b823634-cb2a-469d-9a26-3cc3a6c87eca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c9f52deb-51ff-4f60-817f-fc2654f784d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_7b823634-cb2a-469d-9a26-3cc3a6c87eca" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c9f52deb-51ff-4f60-817f-fc2654f784d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a0698528-9eb4-4ca9-838c-b45efdd4405c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_14bfa4a9-9c67-4486-a8bb-1955bdd824df" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a0698528-9eb4-4ca9-838c-b45efdd4405c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_a3c1ff7d-4830-4bd2-b96c-9561b6ef2a68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_14bfa4a9-9c67-4486-a8bb-1955bdd824df" xlink:to="loc_us-gaap_NumberOfReportableSegments_a3c1ff7d-4830-4bd2-b96c-9561b6ef2a68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod_d330055f-198a-456a-9b55-bbd565b1031d" xlink:href="pacb-20241231.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_14bfa4a9-9c67-4486-a8bb-1955bdd824df" xlink:to="loc_pacb_StandardProductWarrantyPeriod_d330055f-198a-456a-9b55-bbd565b1031d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1721772d-b0c2-4e81-a378-3b86d9b1ded7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a4b9f7e-ed5d-4512-ba09-57b0a04ffddb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1721772d-b0c2-4e81-a378-3b86d9b1ded7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a4b9f7e-ed5d-4512-ba09-57b0a04ffddb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_16c5fe3f-61e4-40e8-a190-6aa099766155" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a4b9f7e-ed5d-4512-ba09-57b0a04ffddb" xlink:to="loc_srt_RangeAxis_16c5fe3f-61e4-40e8-a190-6aa099766155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_16c5fe3f-61e4-40e8-a190-6aa099766155_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_16c5fe3f-61e4-40e8-a190-6aa099766155" xlink:to="loc_srt_RangeMember_16c5fe3f-61e4-40e8-a190-6aa099766155_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4d655431-bfaa-4a62-8848-6e61d858db46" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_16c5fe3f-61e4-40e8-a190-6aa099766155" xlink:to="loc_srt_RangeMember_4d655431-bfaa-4a62-8848-6e61d858db46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2557ac55-582c-4e7d-9079-4463a8051ec5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4d655431-bfaa-4a62-8848-6e61d858db46" xlink:to="loc_srt_MinimumMember_2557ac55-582c-4e7d-9079-4463a8051ec5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_10d6cf35-66f1-4f14-b40b-6a25c01c49c2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4d655431-bfaa-4a62-8848-6e61d858db46" xlink:to="loc_srt_MaximumMember_10d6cf35-66f1-4f14-b40b-6a25c01c49c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22efa9cb-c13a-43d7-805c-a723ed2148da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a4b9f7e-ed5d-4512-ba09-57b0a04ffddb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22efa9cb-c13a-43d7-805c-a723ed2148da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22efa9cb-c13a-43d7-805c-a723ed2148da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22efa9cb-c13a-43d7-805c-a723ed2148da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22efa9cb-c13a-43d7-805c-a723ed2148da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c19cf22-c9a7-4894-bd29-1b1a23ad9ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22efa9cb-c13a-43d7-805c-a723ed2148da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c19cf22-c9a7-4894-bd29-1b1a23ad9ab2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_96d2e97e-b7ab-4d66-a884-d0f8f1ce97d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c19cf22-c9a7-4894-bd29-1b1a23ad9ab2" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_96d2e97e-b7ab-4d66-a884-d0f8f1ce97d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_2eaca6b3-4469-409a-8244-2f4a87692e20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c19cf22-c9a7-4894-bd29-1b1a23ad9ab2" xlink:to="loc_us-gaap_EquipmentMember_2eaca6b3-4469-409a-8244-2f4a87692e20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_21019b0e-2ae8-4d31-bc2e-1bd83cd69d13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c19cf22-c9a7-4894-bd29-1b1a23ad9ab2" xlink:to="loc_us-gaap_ComputerEquipmentMember_21019b0e-2ae8-4d31-bc2e-1bd83cd69d13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_dd489f02-dbf1-4d48-967f-407f3002deb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c19cf22-c9a7-4894-bd29-1b1a23ad9ab2" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_dd489f02-dbf1-4d48-967f-407f3002deb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9f7c25fb-fca2-4941-83e3-4a2f6939e454" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c19cf22-c9a7-4894-bd29-1b1a23ad9ab2" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9f7c25fb-fca2-4941-83e3-4a2f6939e454" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_259077c3-2dd2-42bd-bb05-2d32f0d9d000" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1721772d-b0c2-4e81-a378-3b86d9b1ded7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_259077c3-2dd2-42bd-bb05-2d32f0d9d000" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BUSINESSACQUISITIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_57c0f26d-f2a0-496d-ad9d-4a87ab9b2993" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_57c0f26d-f2a0-496d-ad9d-4a87ab9b2993" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8860e791-6aab-4e33-8337-86cf60061cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_57c0f26d-f2a0-496d-ad9d-4a87ab9b2993" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8860e791-6aab-4e33-8337-86cf60061cdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8860e791-6aab-4e33-8337-86cf60061cdc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8860e791-6aab-4e33-8337-86cf60061cdc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8860e791-6aab-4e33-8337-86cf60061cdc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db8ddc9f-6fac-45e3-b89f-0439e39ca78e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8860e791-6aab-4e33-8337-86cf60061cdc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db8ddc9f-6fac-45e3-b89f-0439e39ca78e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_b9649809-dbcd-452b-b9d8-8c5ac75584b9" xlink:href="pacb-20241231.xsd#pacb_AptonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db8ddc9f-6fac-45e3-b89f-0439e39ca78e" xlink:to="loc_pacb_AptonMember_b9649809-dbcd-452b-b9d8-8c5ac75584b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_60a48dcd-6a66-40c3-8673-6fd6b2504094" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_57c0f26d-f2a0-496d-ad9d-4a87ab9b2993" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_60a48dcd-6a66-40c3-8673-6fd6b2504094" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_60a48dcd-6a66-40c3-8673-6fd6b2504094_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_60a48dcd-6a66-40c3-8673-6fd6b2504094" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_60a48dcd-6a66-40c3-8673-6fd6b2504094_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_a3c5e380-30b0-49c2-803a-8dd3ceec8ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_60a48dcd-6a66-40c3-8673-6fd6b2504094" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_a3c5e380-30b0-49c2-803a-8dd3ceec8ea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AchievementOfMilestoneMember_01bbf23b-8c53-4bda-a8bb-34ef986d7364" xlink:href="pacb-20241231.xsd#pacb_AchievementOfMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_a3c5e380-30b0-49c2-803a-8dd3ceec8ea3" xlink:to="loc_pacb_AchievementOfMilestoneMember_01bbf23b-8c53-4bda-a8bb-34ef986d7364" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_20f74dd4-b165-4eeb-bad0-ce3bdc34d2b5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_57c0f26d-f2a0-496d-ad9d-4a87ab9b2993" xlink:to="loc_srt_RangeAxis_20f74dd4-b165-4eeb-bad0-ce3bdc34d2b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_20f74dd4-b165-4eeb-bad0-ce3bdc34d2b5_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_20f74dd4-b165-4eeb-bad0-ce3bdc34d2b5" xlink:to="loc_srt_RangeMember_20f74dd4-b165-4eeb-bad0-ce3bdc34d2b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_23653b97-6e4b-4886-941a-5e33551fa052" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_20f74dd4-b165-4eeb-bad0-ce3bdc34d2b5" xlink:to="loc_srt_RangeMember_23653b97-6e4b-4886-941a-5e33551fa052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ab0f6d92-f3a1-44d5-8196-bc15aead2eb0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_23653b97-6e4b-4886-941a-5e33551fa052" xlink:to="loc_srt_MaximumMember_ab0f6d92-f3a1-44d5-8196-bc15aead2eb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_04edb6ad-b74a-4f6f-8750-0562a5643c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_57c0f26d-f2a0-496d-ad9d-4a87ab9b2993" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_04edb6ad-b74a-4f6f-8750-0562a5643c9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_04edb6ad-b74a-4f6f-8750-0562a5643c9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04edb6ad-b74a-4f6f-8750-0562a5643c9c" xlink:to="loc_us-gaap_EquityComponentDomain_04edb6ad-b74a-4f6f-8750-0562a5643c9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7772bf1d-f9b1-4afc-b3dc-fa5540c576a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04edb6ad-b74a-4f6f-8750-0562a5643c9c" xlink:to="loc_us-gaap_EquityComponentDomain_7772bf1d-f9b1-4afc-b3dc-fa5540c576a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4410aadc-abeb-44fa-908d-c01394e622a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7772bf1d-f9b1-4afc-b3dc-fa5540c576a5" xlink:to="loc_us-gaap_CommonStockMember_4410aadc-abeb-44fa-908d-c01394e622a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_ed85355a-d58c-4f22-a9c6-bb58ea8d9264" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_ed85355a-d58c-4f22-a9c6-bb58ea8d9264" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_af1e1e8a-f5e4-449e-b9a0-2e600764d495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_af1e1e8a-f5e4-449e-b9a0-2e600764d495" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_63a729ca-439c-41d6-9022-35471a37ba6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_63a729ca-439c-41d6-9022-35471a37ba6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_e4253886-e109-4f68-b9b7-cac2ef107177" xlink:href="pacb-20241231.xsd#pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_e4253886-e109-4f68-b9b7-cac2ef107177" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_c4ec0b68-7802-4c38-bce7-ff4596fa0580" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_c4ec0b68-7802-4c38-bce7-ff4596fa0580" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_a5194552-ef68-4601-876f-151fde240c9a" xlink:href="pacb-20241231.xsd#pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_a5194552-ef68-4601-876f-151fde240c9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod_a41ec8c6-4fd2-4936-aec1-8be9da84d433" xlink:href="pacb-20241231.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod_a41ec8c6-4fd2-4936-aec1-8be9da84d433" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_1cc96cf1-4def-41f1-8209-70e5f73c653f" xlink:href="pacb-20241231.xsd#pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_1cc96cf1-4def-41f1-8209-70e5f73c653f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_cb5fa543-42b3-40d3-bd44-199ea514ca57" xlink:href="pacb-20241231.xsd#pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_cb5fa543-42b3-40d3-bd44-199ea514ca57" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_136b65e4-6122-45eb-bc37-3b9631f54ced" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_136b65e4-6122-45eb-bc37-3b9631f54ced" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_a45577ed-53ec-4041-bd38-6ed225739a64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_a45577ed-53ec-4041-bd38-6ed225739a64" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_a6ca6e4b-158d-4184-91e7-3d83a86924da" xlink:href="pacb-20241231.xsd#pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_a6ca6e4b-158d-4184-91e7-3d83a86924da" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_ef79516b-de21-4fb1-8c20-bbcc16f6bbf2" xlink:href="pacb-20241231.xsd#pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_ef79516b-de21-4fb1-8c20-bbcc16f6bbf2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_b6716ce6-bca6-4149-8d8b-9ff78323da10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_b6716ce6-bca6-4149-8d8b-9ff78323da10" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_7c9589ee-b8f5-4673-a9bf-6827df6d4bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_7c9589ee-b8f5-4673-a9bf-6827df6d4bf1" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d05902a-e2e5-4eb1-8431-fdb0e096978d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d05902a-e2e5-4eb1-8431-fdb0e096978d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_850e86b6-acb1-4445-9e6b-2853cf182eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d05902a-e2e5-4eb1-8431-fdb0e096978d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_850e86b6-acb1-4445-9e6b-2853cf182eeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_850e86b6-acb1-4445-9e6b-2853cf182eeb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_850e86b6-acb1-4445-9e6b-2853cf182eeb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_850e86b6-acb1-4445-9e6b-2853cf182eeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5152809-f677-44ed-ac78-28013c62a354" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_850e86b6-acb1-4445-9e6b-2853cf182eeb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5152809-f677-44ed-ac78-28013c62a354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_abcde161-e1eb-4798-97e5-b1cf587da10a" xlink:href="pacb-20241231.xsd#pacb_AptonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5152809-f677-44ed-ac78-28013c62a354" xlink:to="loc_pacb_AptonMember_abcde161-e1eb-4798-97e5-b1cf587da10a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_9f7e4968-5afc-4155-bda2-beea1f899304" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_9f7e4968-5afc-4155-bda2-beea1f899304" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1b80c9df-e9d4-4553-ad00-43d8ecdc1e83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1b80c9df-e9d4-4553-ad00-43d8ecdc1e83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_748a9803-71b8-4fbf-b92e-6734ef8c7687" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:to="loc_us-gaap_Goodwill_748a9803-71b8-4fbf-b92e-6734ef8c7687" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_fab013e1-c73e-4789-91fa-5aaec90bd968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_fab013e1-c73e-4789-91fa-5aaec90bd968" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_34e35444-7ec9-4243-b8db-3ed09330d9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_34e35444-7ec9-4243-b8db-3ed09330d9cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_bdca2d43-cffb-4ca8-aaa3-3c53a3f156c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_bdca2d43-cffb-4ca8-aaa3-3c53a3f156c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_7919b91e-b3e6-4bde-9c92-c549e9af3a24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_7919b91e-b3e6-4bde-9c92-c549e9af3a24" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_daa486bb-7130-4862-b191-e76435f5c22f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cf734908-57ff-4f5c-9f4a-5c0c85459f11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_daa486bb-7130-4862-b191-e76435f5c22f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cf734908-57ff-4f5c-9f4a-5c0c85459f11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_565d37b6-0866-43cf-bf3e-f16bda743615" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cf734908-57ff-4f5c-9f4a-5c0c85459f11" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_565d37b6-0866-43cf-bf3e-f16bda743615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_565d37b6-0866-43cf-bf3e-f16bda743615_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_565d37b6-0866-43cf-bf3e-f16bda743615" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_565d37b6-0866-43cf-bf3e-f16bda743615_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_caf698eb-06e6-4ed9-8091-9a40861789e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_565d37b6-0866-43cf-bf3e-f16bda743615" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_caf698eb-06e6-4ed9-8091-9a40861789e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_db4a9203-0240-41ac-914f-0ea5acefdf11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_caf698eb-06e6-4ed9-8091-9a40861789e1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_db4a9203-0240-41ac-914f-0ea5acefdf11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_351184bc-105d-470e-9d2b-146ae13f812c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_caf698eb-06e6-4ed9-8091-9a40861789e1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_351184bc-105d-470e-9d2b-146ae13f812c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3ec1fd51-0f6a-43b4-9da0-dfc5b1ec4a53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_caf698eb-06e6-4ed9-8091-9a40861789e1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3ec1fd51-0f6a-43b4-9da0-dfc5b1ec4a53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_02e1c735-3cc9-4a5d-b775-ded6727f361f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cf734908-57ff-4f5c-9f4a-5c0c85459f11" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_02e1c735-3cc9-4a5d-b775-ded6727f361f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_02e1c735-3cc9-4a5d-b775-ded6727f361f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_02e1c735-3cc9-4a5d-b775-ded6727f361f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_02e1c735-3cc9-4a5d-b775-ded6727f361f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f1a8e3d-f632-4f32-8efb-5bd197dfd6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_02e1c735-3cc9-4a5d-b775-ded6727f361f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f1a8e3d-f632-4f32-8efb-5bd197dfd6a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_467d0a37-3c07-45b1-ae3d-92687a689412" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f1a8e3d-f632-4f32-8efb-5bd197dfd6a3" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_467d0a37-3c07-45b1-ae3d-92687a689412" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CashAndMoneyMarketFundsMember_5e3f151a-b6a1-4702-a558-9df866a8854a" xlink:href="pacb-20241231.xsd#pacb_CashAndMoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_467d0a37-3c07-45b1-ae3d-92687a689412" xlink:to="loc_pacb_CashAndMoneyMarketFundsMember_5e3f151a-b6a1-4702-a558-9df866a8854a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b0fdb72b-9277-4ab8-ba93-6e5f309df00d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_467d0a37-3c07-45b1-ae3d-92687a689412" xlink:to="loc_us-gaap_CommercialPaperMember_b0fdb72b-9277-4ab8-ba93-6e5f309df00d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d929757d-93c0-4cfb-a256-7a7bd0ac3b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_467d0a37-3c07-45b1-ae3d-92687a689412" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d929757d-93c0-4cfb-a256-7a7bd0ac3b4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_baf41d58-3e26-4517-8646-6e44bfb65f17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f1a8e3d-f632-4f32-8efb-5bd197dfd6a3" xlink:to="loc_us-gaap_InvestmentsMember_baf41d58-3e26-4517-8646-6e44bfb65f17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_1436d4e7-7915-4d0a-9e84-6da89da303b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_baf41d58-3e26-4517-8646-6e44bfb65f17" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_1436d4e7-7915-4d0a-9e84-6da89da303b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_383feb7c-a1f4-4cfc-816a-4775bbb8fbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_baf41d58-3e26-4517-8646-6e44bfb65f17" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_383feb7c-a1f4-4cfc-816a-4775bbb8fbb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_069e2d30-6a92-4546-a3db-6a991f2ac3bd" xlink:href="pacb-20241231.xsd#pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_baf41d58-3e26-4517-8646-6e44bfb65f17" xlink:to="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_069e2d30-6a92-4546-a3db-6a991f2ac3bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6e7a9d10-ab80-49e4-a398-bc877ecb53e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cf734908-57ff-4f5c-9f4a-5c0c85459f11" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6e7a9d10-ab80-49e4-a398-bc877ecb53e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e7a9d10-ab80-49e4-a398-bc877ecb53e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6e7a9d10-ab80-49e4-a398-bc877ecb53e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e7a9d10-ab80-49e4-a398-bc877ecb53e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_266422ff-ade1-4b46-8b18-b26e3285f7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6e7a9d10-ab80-49e4-a398-bc877ecb53e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_266422ff-ade1-4b46-8b18-b26e3285f7ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_40f2f3de-ae81-4b17-95d3-51a10b868b5b" xlink:href="pacb-20241231.xsd#pacb_AptonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_266422ff-ade1-4b46-8b18-b26e3285f7ba" xlink:to="loc_pacb_AptonMember_40f2f3de-ae81-4b17-95d3-51a10b868b5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a8f7ab42-22c2-4086-9df4-3758b69f2211" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cf734908-57ff-4f5c-9f4a-5c0c85459f11" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a8f7ab42-22c2-4086-9df4-3758b69f2211" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a8f7ab42-22c2-4086-9df4-3758b69f2211_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a8f7ab42-22c2-4086-9df4-3758b69f2211" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a8f7ab42-22c2-4086-9df4-3758b69f2211_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b26ae5fd-d083-43bb-82d4-4e7096596c20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a8f7ab42-22c2-4086-9df4-3758b69f2211" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b26ae5fd-d083-43bb-82d4-4e7096596c20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_29e7bb96-80d3-4a52-8753-fd42e61b1cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b26ae5fd-d083-43bb-82d4-4e7096596c20" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_29e7bb96-80d3-4a52-8753-fd42e61b1cc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_7e209ca8-a3d6-4956-b2c8-4ccf0e6d2faf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b26ae5fd-d083-43bb-82d4-4e7096596c20" xlink:to="loc_us-gaap_InvestmentsMember_7e209ca8-a3d6-4956-b2c8-4ccf0e6d2faf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0fb0430b-1670-4746-99dc-a4570f315407" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_daa486bb-7130-4862-b191-e76435f5c22f" xlink:to="loc_us-gaap_AssetsAbstract_0fb0430b-1670-4746-99dc-a4570f315407" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b7e99bb9-1de1-40ab-becf-5ce44bd5e59e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_0fb0430b-1670-4746-99dc-a4570f315407" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b7e99bb9-1de1-40ab-becf-5ce44bd5e59e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_e49c126a-54e3-482f-a615-fb906275438e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_0fb0430b-1670-4746-99dc-a4570f315407" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_e49c126a-54e3-482f-a615-fb906275438e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_92fd62ae-8ccb-4a12-a7d6-8362baa82aae" xlink:href="pacb-20241231.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_0fb0430b-1670-4746-99dc-a4570f315407" xlink:to="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_92fd62ae-8ccb-4a12-a7d6-8362baa82aae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashFairValueDisclosure_2b74cf31-95b5-4e85-b4f1-45f102e48a3e" xlink:href="pacb-20241231.xsd#pacb_LongTermRestrictedCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_0fb0430b-1670-4746-99dc-a4570f315407" xlink:to="loc_pacb_LongTermRestrictedCashFairValueDisclosure_2b74cf31-95b5-4e85-b4f1-45f102e48a3e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ef749ad6-c276-4b14-bf26-9e447e4a50c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_0fb0430b-1670-4746-99dc-a4570f315407" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ef749ad6-c276-4b14-bf26-9e447e4a50c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_c8849036-7410-42c3-b284-2ab3f7768796" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_daa486bb-7130-4862-b191-e76435f5c22f" xlink:to="loc_us-gaap_LiabilitiesAbstract_c8849036-7410-42c3-b284-2ab3f7768796" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ba157d3d-dd25-43de-a7d1-572b203a7053" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_c8849036-7410-42c3-b284-2ab3f7768796" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ba157d3d-dd25-43de-a7d1-572b203a7053" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_bbacd2b3-ba54-421f-bbb0-b04005eaf3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_c8849036-7410-42c3-b284-2ab3f7768796" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_bbacd2b3-ba54-421f-bbb0-b04005eaf3dd" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#FINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:href="pacb-20241231.xsd#pacb_FinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsTable_9d008767-fcb5-4010-a5a7-95f34e5bc39e" xlink:href="pacb-20241231.xsd#pacb_FinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_pacb_FinancialInstrumentsTable_9d008767-fcb5-4010-a5a7-95f34e5bc39e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_195fe47e-f0be-42e2-8abd-48586137e4d7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_FinancialInstrumentsTable_9d008767-fcb5-4010-a5a7-95f34e5bc39e" xlink:to="loc_srt_RangeAxis_195fe47e-f0be-42e2-8abd-48586137e4d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_195fe47e-f0be-42e2-8abd-48586137e4d7_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_195fe47e-f0be-42e2-8abd-48586137e4d7" xlink:to="loc_srt_RangeMember_195fe47e-f0be-42e2-8abd-48586137e4d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b4e96bb-ff2e-45c8-b97c-6830b6a0e484" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_195fe47e-f0be-42e2-8abd-48586137e4d7" xlink:to="loc_srt_RangeMember_9b4e96bb-ff2e-45c8-b97c-6830b6a0e484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b4acb3ab-3f6f-48c6-9d6f-eeec4b008283" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9b4e96bb-ff2e-45c8-b97c-6830b6a0e484" xlink:to="loc_srt_MinimumMember_b4acb3ab-3f6f-48c6-9d6f-eeec4b008283" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f4b6054f-095e-45d6-9b9f-15b0a1d9a4ac" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9b4e96bb-ff2e-45c8-b97c-6830b6a0e484" xlink:to="loc_srt_MaximumMember_f4b6054f-095e-45d6-9b9f-15b0a1d9a4ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_00fd38d0-a1c0-4585-bcf4-52aafe95cb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_FinancialInstrumentsTable_9d008767-fcb5-4010-a5a7-95f34e5bc39e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_00fd38d0-a1c0-4585-bcf4-52aafe95cb4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00fd38d0-a1c0-4585-bcf4-52aafe95cb4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_00fd38d0-a1c0-4585-bcf4-52aafe95cb4e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00fd38d0-a1c0-4585-bcf4-52aafe95cb4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c79e4116-7354-4f43-8674-5ae9caae305f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_00fd38d0-a1c0-4585-bcf4-52aafe95cb4e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c79e4116-7354-4f43-8674-5ae9caae305f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_6b1a7659-45f9-4647-ad4b-39e678605e45" xlink:href="pacb-20241231.xsd#pacb_OmniomeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c79e4116-7354-4f43-8674-5ae9caae305f" xlink:to="loc_pacb_OmniomeIncMember_6b1a7659-45f9-4647-ad4b-39e678605e45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_2e3e6d06-483b-4f83-8451-983df7726529" xlink:href="pacb-20241231.xsd#pacb_AptonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c79e4116-7354-4f43-8674-5ae9caae305f" xlink:to="loc_pacb_AptonMember_2e3e6d06-483b-4f83-8451-983df7726529" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeMember_14ccbe4d-a6cd-4284-94d1-33b4cbdd1a1d" xlink:href="pacb-20241231.xsd#pacb_OmniomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c79e4116-7354-4f43-8674-5ae9caae305f" xlink:to="loc_pacb_OmniomeMember_14ccbe4d-a6cd-4284-94d1-33b4cbdd1a1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_51557073-a6b4-4757-a0bd-1adc15ce2989" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_FinancialInstrumentsTable_9d008767-fcb5-4010-a5a7-95f34e5bc39e" xlink:to="loc_us-gaap_AwardTypeAxis_51557073-a6b4-4757-a0bd-1adc15ce2989" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51557073-a6b4-4757-a0bd-1adc15ce2989_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_51557073-a6b4-4757-a0bd-1adc15ce2989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51557073-a6b4-4757-a0bd-1adc15ce2989_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ebd2d81-1cd5-4cfe-8d02-8b3b2d52877a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_51557073-a6b4-4757-a0bd-1adc15ce2989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ebd2d81-1cd5-4cfe-8d02-8b3b2d52877a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a80d90cd-706c-4fee-adab-44e5928bab43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ebd2d81-1cd5-4cfe-8d02-8b3b2d52877a" xlink:to="loc_us-gaap_CommonStockMember_a80d90cd-706c-4fee-adab-44e5928bab43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b17586bf-f2eb-4ae9-8d97-f75d12462b07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ebd2d81-1cd5-4cfe-8d02-8b3b2d52877a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b17586bf-f2eb-4ae9-8d97-f75d12462b07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_ad0125f8-c64c-4d31-9c9d-4d78d56d22ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_FinancialInstrumentsTable_9d008767-fcb5-4010-a5a7-95f34e5bc39e" xlink:to="loc_us-gaap_ValuationTechniqueAxis_ad0125f8-c64c-4d31-9c9d-4d78d56d22ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_ad0125f8-c64c-4d31-9c9d-4d78d56d22ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_ad0125f8-c64c-4d31-9c9d-4d78d56d22ec" xlink:to="loc_us-gaap_ValuationTechniqueDomain_ad0125f8-c64c-4d31-9c9d-4d78d56d22ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_8b73c6cf-52e3-4dd2-895b-ad93901167d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_ad0125f8-c64c-4d31-9c9d-4d78d56d22ec" xlink:to="loc_us-gaap_ValuationTechniqueDomain_8b73c6cf-52e3-4dd2-895b-ad93901167d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember_4e7df836-2ea2-4346-81d5-d5467e459629" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_8b73c6cf-52e3-4dd2-895b-ad93901167d1" xlink:to="loc_us-gaap_IncomeApproachValuationTechniqueMember_4e7df836-2ea2-4346-81d5-d5467e459629" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_9ac5b008-ab3e-42db-836c-6594a0e253a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_FinancialInstrumentsTable_9d008767-fcb5-4010-a5a7-95f34e5bc39e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_9ac5b008-ab3e-42db-836c-6594a0e253a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9ac5b008-ab3e-42db-836c-6594a0e253a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9ac5b008-ab3e-42db-836c-6594a0e253a6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9ac5b008-ab3e-42db-836c-6594a0e253a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cb763c12-b7e9-4888-a648-6c33cb318431" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9ac5b008-ab3e-42db-836c-6594a0e253a6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cb763c12-b7e9-4888-a648-6c33cb318431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_040b764e-dc49-4751-b00a-c0a152215b42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cb763c12-b7e9-4888-a648-6c33cb318431" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_040b764e-dc49-4751-b00a-c0a152215b42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_91664781-a25f-45e0-a53c-bd906e15a77c" xlink:href="pacb-20241231.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_91664781-a25f-45e0-a53c-bd906e15a77c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_e80fc0d0-f5c2-4a99-9f35-d87b44033e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_e80fc0d0-f5c2-4a99-9f35-d87b44033e4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_ba23e965-bdbc-4c90-adce-ad5f8737eb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_ba23e965-bdbc-4c90-adce-ad5f8737eb4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_baa93d69-d152-4cbf-9e71-337eb8be00ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_baa93d69-d152-4cbf-9e71-337eb8be00ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_767653a5-bb21-4cc3-a364-32fee48e082c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_767653a5-bb21-4cc3-a364-32fee48e082c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_cb66ae75-3fd9-42cf-b4ad-752ec38660c1" xlink:href="pacb-20241231.xsd#pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_cb66ae75-3fd9-42cf-b4ad-752ec38660c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone_aca715f3-ce14-4079-9659-6002f0ed0c66" xlink:href="pacb-20241231.xsd#pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone_aca715f3-ce14-4079-9659-6002f0ed0c66" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_d00ff1df-c0da-42c1-9312-b46deb188eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_d00ff1df-c0da-42c1-9312-b46deb188eaf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_18819b0f-f24c-4298-a94c-d070c4e7168b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_18819b0f-f24c-4298-a94c-d070c4e7168b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_fbfe0daa-6451-4fbe-a7cc-a1a74ff4471f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_us-gaap_InvestmentIncomeNet_fbfe0daa-6451-4fbe-a7cc-a1a74ff4471f" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c305486b-ce8d-476a-9a7a-8d2e7054d4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80c6c428-2ca0-4c54-bdd4-6d49d3f4a371" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c305486b-ce8d-476a-9a7a-8d2e7054d4bb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80c6c428-2ca0-4c54-bdd4-6d49d3f4a371" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_301b2cd0-5f00-43dd-9896-13c84dd4d72d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80c6c428-2ca0-4c54-bdd4-6d49d3f4a371" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_301b2cd0-5f00-43dd-9896-13c84dd4d72d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_301b2cd0-5f00-43dd-9896-13c84dd4d72d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_301b2cd0-5f00-43dd-9896-13c84dd4d72d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_301b2cd0-5f00-43dd-9896-13c84dd4d72d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5533c963-002c-4a47-97f0-6271ee671107" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_301b2cd0-5f00-43dd-9896-13c84dd4d72d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5533c963-002c-4a47-97f0-6271ee671107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d81a40e3-68e7-4a58-88a3-b88fbd4eba45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5533c963-002c-4a47-97f0-6271ee671107" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d81a40e3-68e7-4a58-88a3-b88fbd4eba45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_737f7fbd-845d-4f03-a331-22420ed585d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c305486b-ce8d-476a-9a7a-8d2e7054d4bb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_737f7fbd-845d-4f03-a331-22420ed585d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8653097a-87d1-469f-8a27-5baacfa30962" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_737f7fbd-845d-4f03-a331-22420ed585d6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8653097a-87d1-469f-8a27-5baacfa30962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9ea1b80e-7ad0-41ab-98c7-5c0dccca3bde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_737f7fbd-845d-4f03-a331-22420ed585d6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9ea1b80e-7ad0-41ab-98c7-5c0dccca3bde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f4424b6d-fc23-4294-b3cd-846cf27c4d78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_987d0ec2-cc16-4e41-b626-6cf366ee2daa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3e754b1a-2d26-42e4-a107-dc6d8ee81988" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_987d0ec2-cc16-4e41-b626-6cf366ee2daa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3e754b1a-2d26-42e4-a107-dc6d8ee81988" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_195f47b7-ba9b-4b1f-8511-10b75dd3adf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3e754b1a-2d26-42e4-a107-dc6d8ee81988" xlink:to="loc_us-gaap_FinancialInstrumentAxis_195f47b7-ba9b-4b1f-8511-10b75dd3adf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_195f47b7-ba9b-4b1f-8511-10b75dd3adf3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_195f47b7-ba9b-4b1f-8511-10b75dd3adf3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_195f47b7-ba9b-4b1f-8511-10b75dd3adf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4e85d56-cb7c-442c-8af9-20d21031f018" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_195f47b7-ba9b-4b1f-8511-10b75dd3adf3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4e85d56-cb7c-442c-8af9-20d21031f018" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CashCashEquivalentsAndInvestmentsMember_ec33cbe8-4481-4570-b9e1-e7b6ceb5d752" xlink:href="pacb-20241231.xsd#pacb_CashCashEquivalentsAndInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4e85d56-cb7c-442c-8af9-20d21031f018" xlink:to="loc_pacb_CashCashEquivalentsAndInvestmentsMember_ec33cbe8-4481-4570-b9e1-e7b6ceb5d752" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_af9591bb-bacd-4f41-8624-41dd850fe2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CashCashEquivalentsAndInvestmentsMember_ec33cbe8-4481-4570-b9e1-e7b6ceb5d752" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_af9591bb-bacd-4f41-8624-41dd850fe2d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CashAndMoneyMarketFundsMember_48ce2de9-a479-4391-8d93-71dd0c53df41" xlink:href="pacb-20241231.xsd#pacb_CashAndMoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_af9591bb-bacd-4f41-8624-41dd850fe2d1" xlink:to="loc_pacb_CashAndMoneyMarketFundsMember_48ce2de9-a479-4391-8d93-71dd0c53df41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_08711aa0-dfa7-4c54-b3d6-6c1ff3a6e53c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_af9591bb-bacd-4f41-8624-41dd850fe2d1" xlink:to="loc_us-gaap_CommercialPaperMember_08711aa0-dfa7-4c54-b3d6-6c1ff3a6e53c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f3589b24-0b8a-4946-905a-fa2f3321cd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_af9591bb-bacd-4f41-8624-41dd850fe2d1" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f3589b24-0b8a-4946-905a-fa2f3321cd0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_bd5d5805-c5b6-46e6-9f79-3270227fea93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CashCashEquivalentsAndInvestmentsMember_ec33cbe8-4481-4570-b9e1-e7b6ceb5d752" xlink:to="loc_us-gaap_InvestmentsMember_bd5d5805-c5b6-46e6-9f79-3270227fea93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_81e2f167-8f0e-4010-9970-eb82d2090417" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_bd5d5805-c5b6-46e6-9f79-3270227fea93" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_81e2f167-8f0e-4010-9970-eb82d2090417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_cb7da060-d579-4b0e-b082-2e9c02b530d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_bd5d5805-c5b6-46e6-9f79-3270227fea93" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_cb7da060-d579-4b0e-b082-2e9c02b530d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_b979124d-5e02-4fe7-8747-163fe5ededc4" xlink:href="pacb-20241231.xsd#pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_bd5d5805-c5b6-46e6-9f79-3270227fea93" xlink:to="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_b979124d-5e02-4fe7-8747-163fe5ededc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_7ff29f32-2c47-40b5-9cb3-478049bcce24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_987d0ec2-cc16-4e41-b626-6cf366ee2daa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_7ff29f32-2c47-40b5-9cb3-478049bcce24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_85013851-3d9e-4154-8c59-4717c89b05d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_987d0ec2-cc16-4e41-b626-6cf366ee2daa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_85013851-3d9e-4154-8c59-4717c89b05d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7d514559-0911-49eb-815b-5d4beaac3f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_987d0ec2-cc16-4e41-b626-6cf366ee2daa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7d514559-0911-49eb-815b-5d4beaac3f9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_e894d836-7750-482e-b8d0-1ece00a64140" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_987d0ec2-cc16-4e41-b626-6cf366ee2daa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_e894d836-7750-482e-b8d0-1ece00a64140" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_bb4ea406-4a18-457b-8249-37ab213f424d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_987d0ec2-cc16-4e41-b626-6cf366ee2daa" xlink:to="loc_us-gaap_RestrictedCashCurrent_bb4ea406-4a18-457b-8249-37ab213f424d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e76a602a-7573-488a-bf5a-0318454a440e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_987d0ec2-cc16-4e41-b626-6cf366ee2daa" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e76a602a-7573-488a-bf5a-0318454a440e" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5580aef2-56b2-43f4-a9dc-0368f76ab440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a47133a-0c08-4b56-ab40-c1b61f2357ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5580aef2-56b2-43f4-a9dc-0368f76ab440" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a47133a-0c08-4b56-ab40-c1b61f2357ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_005133a7-a656-48c7-a92f-c29c17e7afc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a47133a-0c08-4b56-ab40-c1b61f2357ca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_005133a7-a656-48c7-a92f-c29c17e7afc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_005133a7-a656-48c7-a92f-c29c17e7afc2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_005133a7-a656-48c7-a92f-c29c17e7afc2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_005133a7-a656-48c7-a92f-c29c17e7afc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a82935e9-bb17-47ba-9376-5868c1e26ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_005133a7-a656-48c7-a92f-c29c17e7afc2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a82935e9-bb17-47ba-9376-5868c1e26ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LaboratoryEquipmentAndMachineryMember_7c8c8a77-00ba-4324-80bd-25bbe30b2094" xlink:href="pacb-20241231.xsd#pacb_LaboratoryEquipmentAndMachineryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a82935e9-bb17-47ba-9376-5868c1e26ee0" xlink:to="loc_pacb_LaboratoryEquipmentAndMachineryMember_7c8c8a77-00ba-4324-80bd-25bbe30b2094" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_42089266-02b5-4036-b22b-3725c5134e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a82935e9-bb17-47ba-9376-5868c1e26ee0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_42089266-02b5-4036-b22b-3725c5134e4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_bcb9d226-a48c-4741-9c20-de90f0b69dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a82935e9-bb17-47ba-9376-5868c1e26ee0" xlink:to="loc_us-gaap_ComputerEquipmentMember_bcb9d226-a48c-4741-9c20-de90f0b69dfa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ae717482-628b-42e9-b4e0-34f6109eb076" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a82935e9-bb17-47ba-9376-5868c1e26ee0" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ae717482-628b-42e9-b4e0-34f6109eb076" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f8aea217-6ddf-4b3a-8460-d2188d9df709" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a82935e9-bb17-47ba-9376-5868c1e26ee0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f8aea217-6ddf-4b3a-8460-d2188d9df709" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_1c4e6778-9cf3-4319-b0db-2079f344683d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a82935e9-bb17-47ba-9376-5868c1e26ee0" xlink:to="loc_us-gaap_ConstructionInProgressMember_1c4e6778-9cf3-4319-b0db-2079f344683d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fcb948ca-c582-4c79-9515-db1a19c86683" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5580aef2-56b2-43f4-a9dc-0368f76ab440" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fcb948ca-c582-4c79-9515-db1a19c86683" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_77beef20-c236-4c8e-8a1a-ad217460a872" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5580aef2-56b2-43f4-a9dc-0368f76ab440" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_77beef20-c236-4c8e-8a1a-ad217460a872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_de5f6213-6686-4131-9ff8-f5b1641a6806" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5580aef2-56b2-43f4-a9dc-0368f76ab440" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_de5f6213-6686-4131-9ff8-f5b1641a6806" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:href="pacb-20241231.xsd#pacb_BalanceSheetComponentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:href="pacb-20241231.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_155b8f86-15fe-44f2-9bc6-9af28d1d46ca" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_srt_ProductOrServiceAxis_155b8f86-15fe-44f2-9bc6-9af28d1d46ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_155b8f86-15fe-44f2-9bc6-9af28d1d46ca_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_155b8f86-15fe-44f2-9bc6-9af28d1d46ca" xlink:to="loc_srt_ProductsAndServicesDomain_155b8f86-15fe-44f2-9bc6-9af28d1d46ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8760d7a2-eb0f-4480-8540-1ccf48d9ba8e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_155b8f86-15fe-44f2-9bc6-9af28d1d46ca" xlink:to="loc_srt_ProductsAndServicesDomain_8760d7a2-eb0f-4480-8540-1ccf48d9ba8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_5fefb495-d38f-4ea3-9348-09aaa08cdcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8760d7a2-eb0f-4480-8540-1ccf48d9ba8e" xlink:to="loc_us-gaap_ServiceMember_5fefb495-d38f-4ea3-9348-09aaa08cdcd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_41f11799-e0eb-419d-be10-2f82533702f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_41f11799-e0eb-419d-be10-2f82533702f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41f11799-e0eb-419d-be10-2f82533702f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_41f11799-e0eb-419d-be10-2f82533702f0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41f11799-e0eb-419d-be10-2f82533702f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68991ca4-671f-4735-9978-aa14403a86fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_41f11799-e0eb-419d-be10-2f82533702f0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68991ca4-671f-4735-9978-aa14403a86fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_95b76fd2-4c28-4edc-8ac9-0d8cf4c28864" xlink:href="pacb-20241231.xsd#pacb_AptonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68991ca4-671f-4735-9978-aa14403a86fb" xlink:to="loc_pacb_AptonMember_95b76fd2-4c28-4edc-8ac9-0d8cf4c28864" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_c7ea09c1-47cb-45b0-8878-5ad04a05e746" xlink:href="pacb-20241231.xsd#pacb_OmniomeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68991ca4-671f-4735-9978-aa14403a86fb" xlink:to="loc_pacb_OmniomeIncMember_c7ea09c1-47cb-45b0-8878-5ad04a05e746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_71ea22a9-037d-43e9-aaec-d416f645943a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_71ea22a9-037d-43e9-aaec-d416f645943a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_71ea22a9-037d-43e9-aaec-d416f645943a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_71ea22a9-037d-43e9-aaec-d416f645943a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_71ea22a9-037d-43e9-aaec-d416f645943a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b506a6a7-64f2-4074-8876-e8d71513c3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_71ea22a9-037d-43e9-aaec-d416f645943a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b506a6a7-64f2-4074-8876-e8d71513c3d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_15d37398-fa65-4ac2-8e0e-cfe4e18ad9bf" xlink:href="pacb-20241231.xsd#pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b506a6a7-64f2-4074-8876-e8d71513c3d0" xlink:to="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_15d37398-fa65-4ac2-8e0e-cfe4e18ad9bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e1ed33c-223a-4cae-9eeb-37031ef947d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e1ed33c-223a-4cae-9eeb-37031ef947d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e1ed33c-223a-4cae-9eeb-37031ef947d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e1ed33c-223a-4cae-9eeb-37031ef947d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e1ed33c-223a-4cae-9eeb-37031ef947d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9f516d77-4581-4d5a-b915-94a232313dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e1ed33c-223a-4cae-9eeb-37031ef947d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9f516d77-4581-4d5a-b915-94a232313dfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_5d681038-3612-41b7-8d95-60ee644cdcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9f516d77-4581-4d5a-b915-94a232313dfa" xlink:to="loc_us-gaap_CustomerRelationshipsMember_5d681038-3612-41b7-8d95-60ee644cdcf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_f312af66-b139-411b-b353-fbab7b7cfcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9f516d77-4581-4d5a-b915-94a232313dfa" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_f312af66-b139-411b-b353-fbab7b7cfcb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2667cd69-4afa-4822-93f0-9c7684c79a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2667cd69-4afa-4822-93f0-9c7684c79a2b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2667cd69-4afa-4822-93f0-9c7684c79a2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2667cd69-4afa-4822-93f0-9c7684c79a2b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2667cd69-4afa-4822-93f0-9c7684c79a2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a93ba8cf-798f-42d3-92cb-668af0376195" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2667cd69-4afa-4822-93f0-9c7684c79a2b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a93ba8cf-798f-42d3-92cb-668af0376195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CostOfRevenueMember_ef5708e8-607e-4008-864a-e4742870045e" xlink:href="pacb-20241231.xsd#pacb_CostOfRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a93ba8cf-798f-42d3-92cb-668af0376195" xlink:to="loc_pacb_CostOfRevenueMember_ef5708e8-607e-4008-864a-e4742870045e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_b9f0122a-d425-4414-a62e-49958f4fb7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a93ba8cf-798f-42d3-92cb-668af0376195" xlink:to="loc_us-gaap_OperatingExpenseMember_b9f0122a-d425-4414-a62e-49958f4fb7e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b431ae7f-8688-4e86-9c7e-87a549b5d626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b431ae7f-8688-4e86-9c7e-87a549b5d626" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cd835b21-6b47-4fb7-939b-bcb3d1bacca9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_Depreciation_cd835b21-6b47-4fb7-939b-bcb3d1bacca9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_f11450ad-9a81-4b98-8a4c-a65606bc6e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_f11450ad-9a81-4b98-8a4c-a65606bc6e6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e5a42ba1-83e8-42e9-91b0-a9ffe2afc7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e5a42ba1-83e8-42e9-91b0-a9ffe2afc7a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_633b6fab-ea80-48e2-86eb-8ceade6a3280" xlink:href="pacb-20241231.xsd#pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_633b6fab-ea80-48e2-86eb-8ceade6a3280" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_b08797fe-2cdc-4497-aade-f02e689013fb" xlink:href="pacb-20241231.xsd#pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_b08797fe-2cdc-4497-aade-f02e689013fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_49f4044a-7a39-4f99-811a-9f16e1a24587" xlink:href="pacb-20241231.xsd#pacb_AdditionalGoodwillImpairmentChangeInDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_49f4044a-7a39-4f99-811a-9f16e1a24587" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_c5efbb66-7236-4ec5-906a-c6d3852d306a" xlink:href="pacb-20241231.xsd#pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_c5efbb66-7236-4ec5-906a-c6d3852d306a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_cc799f08-85d4-4ca0-82f8-54103250f1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_cc799f08-85d4-4ca0-82f8-54103250f1f2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_426ec79a-c44a-49ee-a3c9-1d2b48f0737d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_426ec79a-c44a-49ee-a3c9-1d2b48f0737d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_490173a2-5f68-446d-a3ad-30121d555b52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_490173a2-5f68-446d-a3ad-30121d555b52" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_85746f5b-22bb-460f-a595-7c49b3bfa10d" xlink:href="pacb-20241231.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_85746f5b-22bb-460f-a595-7c49b3bfa10d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_2aebea0e-6a98-453f-93b9-fea253141632" xlink:href="pacb-20241231.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_2aebea0e-6a98-453f-93b9-fea253141632" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2b7e0a17-5e5c-4055-b10b-e6e669341345" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2b7e0a17-5e5c-4055-b10b-e6e669341345" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_c6532952-ba60-4287-b3de-4b5d7e10932f" xlink:href="pacb-20241231.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_c6532952-ba60-4287-b3de-4b5d7e10932f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_88808126-a625-44db-b0cb-5b2749674a8e" xlink:href="pacb-20241231.xsd#pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_88808126-a625-44db-b0cb-5b2749674a8e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_17abff36-001c-4e8c-b435-fc02f0b9ff30" xlink:href="pacb-20241231.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_17abff36-001c-4e8c-b435-fc02f0b9ff30" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_b0d2580b-d2ea-44ec-8b3f-1626324a53a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_AdjustmentForAmortization_b0d2580b-d2ea-44ec-8b3f-1626324a53a0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d04c6c14-91ca-4061-bd45-721f07eb1656" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d04c6c14-91ca-4061-bd45-721f07eb1656" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_575bfd78-580c-4602-b4c2-6e0e4673387c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ContractWithCustomerLiability_575bfd78-580c-4602-b4c2-6e0e4673387c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c78fe66f-d731-4815-b96f-83dc926b33fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c78fe66f-d731-4815-b96f-83dc926b33fd" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9ef92fa3-6aaf-45c2-b4a0-1d35db8f7a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9ef92fa3-6aaf-45c2-b4a0-1d35db8f7a0f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_d83d5284-0cce-4f99-8beb-c5105ffcc5da" xlink:href="pacb-20241231.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_d83d5284-0cce-4f99-8beb-c5105ffcc5da" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_73d94771-916e-46bf-a057-18bd9ff68310" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_73d94771-916e-46bf-a057-18bd9ff68310" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c668a41a-8fbd-44a8-8577-b1da22b7a457" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c668a41a-8fbd-44a8-8577-b1da22b7a457" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_a669e804-cf44-4fec-a655-7cc0d74892bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_a669e804-cf44-4fec-a655-7cc0d74892bb" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_62e00b91-31cd-4b6a-ac90-e6a968172731" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_62e00b91-31cd-4b6a-ac90-e6a968172731" xlink:type="arc" order="25"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails_1" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:href="pacb-20241231.xsd#pacb_BalanceSheetComponentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:href="pacb-20241231.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_155b8f86-15fe-44f2-9bc6-9af28d1d46ca" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_srt_ProductOrServiceAxis_155b8f86-15fe-44f2-9bc6-9af28d1d46ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_155b8f86-15fe-44f2-9bc6-9af28d1d46ca_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_155b8f86-15fe-44f2-9bc6-9af28d1d46ca" xlink:to="loc_srt_ProductsAndServicesDomain_155b8f86-15fe-44f2-9bc6-9af28d1d46ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8760d7a2-eb0f-4480-8540-1ccf48d9ba8e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_155b8f86-15fe-44f2-9bc6-9af28d1d46ca" xlink:to="loc_srt_ProductsAndServicesDomain_8760d7a2-eb0f-4480-8540-1ccf48d9ba8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_5fefb495-d38f-4ea3-9348-09aaa08cdcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8760d7a2-eb0f-4480-8540-1ccf48d9ba8e" xlink:to="loc_us-gaap_ServiceMember_5fefb495-d38f-4ea3-9348-09aaa08cdcd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_41f11799-e0eb-419d-be10-2f82533702f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_41f11799-e0eb-419d-be10-2f82533702f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41f11799-e0eb-419d-be10-2f82533702f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_41f11799-e0eb-419d-be10-2f82533702f0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41f11799-e0eb-419d-be10-2f82533702f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68991ca4-671f-4735-9978-aa14403a86fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_41f11799-e0eb-419d-be10-2f82533702f0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68991ca4-671f-4735-9978-aa14403a86fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_95b76fd2-4c28-4edc-8ac9-0d8cf4c28864" xlink:href="pacb-20241231.xsd#pacb_AptonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68991ca4-671f-4735-9978-aa14403a86fb" xlink:to="loc_pacb_AptonMember_95b76fd2-4c28-4edc-8ac9-0d8cf4c28864" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_c7ea09c1-47cb-45b0-8878-5ad04a05e746" xlink:href="pacb-20241231.xsd#pacb_OmniomeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68991ca4-671f-4735-9978-aa14403a86fb" xlink:to="loc_pacb_OmniomeIncMember_c7ea09c1-47cb-45b0-8878-5ad04a05e746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_71ea22a9-037d-43e9-aaec-d416f645943a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_71ea22a9-037d-43e9-aaec-d416f645943a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_71ea22a9-037d-43e9-aaec-d416f645943a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_71ea22a9-037d-43e9-aaec-d416f645943a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_71ea22a9-037d-43e9-aaec-d416f645943a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b506a6a7-64f2-4074-8876-e8d71513c3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_71ea22a9-037d-43e9-aaec-d416f645943a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b506a6a7-64f2-4074-8876-e8d71513c3d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_15d37398-fa65-4ac2-8e0e-cfe4e18ad9bf" xlink:href="pacb-20241231.xsd#pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b506a6a7-64f2-4074-8876-e8d71513c3d0" xlink:to="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_15d37398-fa65-4ac2-8e0e-cfe4e18ad9bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e1ed33c-223a-4cae-9eeb-37031ef947d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e1ed33c-223a-4cae-9eeb-37031ef947d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e1ed33c-223a-4cae-9eeb-37031ef947d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e1ed33c-223a-4cae-9eeb-37031ef947d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e1ed33c-223a-4cae-9eeb-37031ef947d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9f516d77-4581-4d5a-b915-94a232313dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e1ed33c-223a-4cae-9eeb-37031ef947d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9f516d77-4581-4d5a-b915-94a232313dfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_5d681038-3612-41b7-8d95-60ee644cdcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9f516d77-4581-4d5a-b915-94a232313dfa" xlink:to="loc_us-gaap_CustomerRelationshipsMember_5d681038-3612-41b7-8d95-60ee644cdcf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_f312af66-b139-411b-b353-fbab7b7cfcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9f516d77-4581-4d5a-b915-94a232313dfa" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_f312af66-b139-411b-b353-fbab7b7cfcb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2667cd69-4afa-4822-93f0-9c7684c79a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2667cd69-4afa-4822-93f0-9c7684c79a2b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2667cd69-4afa-4822-93f0-9c7684c79a2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2667cd69-4afa-4822-93f0-9c7684c79a2b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2667cd69-4afa-4822-93f0-9c7684c79a2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a93ba8cf-798f-42d3-92cb-668af0376195" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2667cd69-4afa-4822-93f0-9c7684c79a2b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a93ba8cf-798f-42d3-92cb-668af0376195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CostOfRevenueMember_ef5708e8-607e-4008-864a-e4742870045e" xlink:href="pacb-20241231.xsd#pacb_CostOfRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a93ba8cf-798f-42d3-92cb-668af0376195" xlink:to="loc_pacb_CostOfRevenueMember_ef5708e8-607e-4008-864a-e4742870045e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_b9f0122a-d425-4414-a62e-49958f4fb7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a93ba8cf-798f-42d3-92cb-668af0376195" xlink:to="loc_us-gaap_OperatingExpenseMember_b9f0122a-d425-4414-a62e-49958f4fb7e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cd835b21-6b47-4fb7-939b-bcb3d1bacca9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_Depreciation_cd835b21-6b47-4fb7-939b-bcb3d1bacca9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_f11450ad-9a81-4b98-8a4c-a65606bc6e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_f11450ad-9a81-4b98-8a4c-a65606bc6e6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e5a42ba1-83e8-42e9-91b0-a9ffe2afc7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e5a42ba1-83e8-42e9-91b0-a9ffe2afc7a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_633b6fab-ea80-48e2-86eb-8ceade6a3280" xlink:href="pacb-20241231.xsd#pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_633b6fab-ea80-48e2-86eb-8ceade6a3280" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_b08797fe-2cdc-4497-aade-f02e689013fb" xlink:href="pacb-20241231.xsd#pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_b08797fe-2cdc-4497-aade-f02e689013fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_49f4044a-7a39-4f99-811a-9f16e1a24587" xlink:href="pacb-20241231.xsd#pacb_AdditionalGoodwillImpairmentChangeInDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_49f4044a-7a39-4f99-811a-9f16e1a24587" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_c5efbb66-7236-4ec5-906a-c6d3852d306a" xlink:href="pacb-20241231.xsd#pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_c5efbb66-7236-4ec5-906a-c6d3852d306a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_cc799f08-85d4-4ca0-82f8-54103250f1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_cc799f08-85d4-4ca0-82f8-54103250f1f2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_426ec79a-c44a-49ee-a3c9-1d2b48f0737d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_426ec79a-c44a-49ee-a3c9-1d2b48f0737d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_490173a2-5f68-446d-a3ad-30121d555b52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_490173a2-5f68-446d-a3ad-30121d555b52" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_85746f5b-22bb-460f-a595-7c49b3bfa10d" xlink:href="pacb-20241231.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_85746f5b-22bb-460f-a595-7c49b3bfa10d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_2aebea0e-6a98-453f-93b9-fea253141632" xlink:href="pacb-20241231.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_2aebea0e-6a98-453f-93b9-fea253141632" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2b7e0a17-5e5c-4055-b10b-e6e669341345" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2b7e0a17-5e5c-4055-b10b-e6e669341345" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_c6532952-ba60-4287-b3de-4b5d7e10932f" xlink:href="pacb-20241231.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_c6532952-ba60-4287-b3de-4b5d7e10932f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_88808126-a625-44db-b0cb-5b2749674a8e" xlink:href="pacb-20241231.xsd#pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_88808126-a625-44db-b0cb-5b2749674a8e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_17abff36-001c-4e8c-b435-fc02f0b9ff30" xlink:href="pacb-20241231.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_17abff36-001c-4e8c-b435-fc02f0b9ff30" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_b0d2580b-d2ea-44ec-8b3f-1626324a53a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_AdjustmentForAmortization_b0d2580b-d2ea-44ec-8b3f-1626324a53a0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d04c6c14-91ca-4061-bd45-721f07eb1656" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d04c6c14-91ca-4061-bd45-721f07eb1656" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_575bfd78-580c-4602-b4c2-6e0e4673387c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ContractWithCustomerLiability_575bfd78-580c-4602-b4c2-6e0e4673387c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c78fe66f-d731-4815-b96f-83dc926b33fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c78fe66f-d731-4815-b96f-83dc926b33fd" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9ef92fa3-6aaf-45c2-b4a0-1d35db8f7a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9ef92fa3-6aaf-45c2-b4a0-1d35db8f7a0f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_d83d5284-0cce-4f99-8beb-c5105ffcc5da" xlink:href="pacb-20241231.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_d83d5284-0cce-4f99-8beb-c5105ffcc5da" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_73d94771-916e-46bf-a057-18bd9ff68310" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_73d94771-916e-46bf-a057-18bd9ff68310" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c668a41a-8fbd-44a8-8577-b1da22b7a457" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c668a41a-8fbd-44a8-8577-b1da22b7a457" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_a669e804-cf44-4fec-a655-7cc0d74892bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_a669e804-cf44-4fec-a655-7cc0d74892bb" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_62e00b91-31cd-4b6a-ac90-e6a968172731" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_62e00b91-31cd-4b6a-ac90-e6a968172731" xlink:type="arc" order="25"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7ab99f69-96bf-48e6-b337-d3abe7d2e6df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_aaced155-97cb-4b46-8b1b-7fd1c699120e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7ab99f69-96bf-48e6-b337-d3abe7d2e6df" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_aaced155-97cb-4b46-8b1b-7fd1c699120e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_de7b4fa6-3a3f-4d43-b738-834eea291498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_aaced155-97cb-4b46-8b1b-7fd1c699120e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_de7b4fa6-3a3f-4d43-b738-834eea291498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_de7b4fa6-3a3f-4d43-b738-834eea291498_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_de7b4fa6-3a3f-4d43-b738-834eea291498" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_de7b4fa6-3a3f-4d43-b738-834eea291498_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a94f99fb-8db5-4c66-ac59-200eb494146d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_de7b4fa6-3a3f-4d43-b738-834eea291498" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a94f99fb-8db5-4c66-ac59-200eb494146d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_66409ab7-654d-4b2a-a5ea-1561b34879eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a94f99fb-8db5-4c66-ac59-200eb494146d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_66409ab7-654d-4b2a-a5ea-1561b34879eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_e86fd79b-fc8e-44df-86a0-56191b4871bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7ab99f69-96bf-48e6-b337-d3abe7d2e6df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_e86fd79b-fc8e-44df-86a0-56191b4871bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_98b5991a-f307-4e74-8ae1-25a9153047c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_e86fd79b-fc8e-44df-86a0-56191b4871bc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_98b5991a-f307-4e74-8ae1-25a9153047c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_040fbe29-6115-4c4c-8b23-9306089f37a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_e86fd79b-fc8e-44df-86a0-56191b4871bc" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_040fbe29-6115-4c4c-8b23-9306089f37a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7bcb6e40-387f-4b85-a094-52ac132a21d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_a28048ed-10dc-4300-8ce1-a212f839a877" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_e86fd79b-fc8e-44df-86a0-56191b4871bc" xlink:to="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_a28048ed-10dc-4300-8ce1-a212f839a877" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50369918-2f28-4468-b26e-f1e23825d6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8a718001-e96d-4336-bbb9-344be5c090b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50369918-2f28-4468-b26e-f1e23825d6a4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8a718001-e96d-4336-bbb9-344be5c090b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0d9e474-915b-4dd7-b4d3-2363301d7331" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8a718001-e96d-4336-bbb9-344be5c090b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0d9e474-915b-4dd7-b4d3-2363301d7331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a0d9e474-915b-4dd7-b4d3-2363301d7331_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0d9e474-915b-4dd7-b4d3-2363301d7331" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a0d9e474-915b-4dd7-b4d3-2363301d7331_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53ae7ff0-e880-4fe4-ac33-bfc53860b564" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0d9e474-915b-4dd7-b4d3-2363301d7331" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53ae7ff0-e880-4fe4-ac33-bfc53860b564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_d9b40faa-bef6-4da9-9704-a14e82f5e3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53ae7ff0-e880-4fe4-ac33-bfc53860b564" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_d9b40faa-bef6-4da9-9704-a14e82f5e3ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_a24ba237-5a9d-453b-abfb-478bf3b28fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53ae7ff0-e880-4fe4-ac33-bfc53860b564" xlink:to="loc_us-gaap_CustomerRelationshipsMember_a24ba237-5a9d-453b-abfb-478bf3b28fa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e4a40831-3d47-4802-8526-9ccd91641e80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50369918-2f28-4468-b26e-f1e23825d6a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e4a40831-3d47-4802-8526-9ccd91641e80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e1444e99-0f01-443c-94b2-ce8f547d4e45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50369918-2f28-4468-b26e-f1e23825d6a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e1444e99-0f01-443c-94b2-ce8f547d4e45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_df61eeb0-38a8-4e8e-bba9-87d5fc63d2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50369918-2f28-4468-b26e-f1e23825d6a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_df61eeb0-38a8-4e8e-bba9-87d5fc63d2cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72067fee-4ffc-4721-bb4d-80b20665fb76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50369918-2f28-4468-b26e-f1e23825d6a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72067fee-4ffc-4721-bb4d-80b20665fb76" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONVERTIBLESENIORNOTESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_78fa20a9-a0e9-4d72-b4a4-fb58b16a1a66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentTable_78fa20a9-a0e9-4d72-b4a4-fb58b16a1a66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6c0cec73-c0c4-4215-9c6f-ba863441b870" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_78fa20a9-a0e9-4d72-b4a4-fb58b16a1a66" xlink:to="loc_us-gaap_DebtInstrumentAxis_6c0cec73-c0c4-4215-9c6f-ba863441b870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6c0cec73-c0c4-4215-9c6f-ba863441b870_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6c0cec73-c0c4-4215-9c6f-ba863441b870" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6c0cec73-c0c4-4215-9c6f-ba863441b870_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_025258c0-0f1c-4ce7-886c-d6dd8c3ce18e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6c0cec73-c0c4-4215-9c6f-ba863441b870" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_025258c0-0f1c-4ce7-886c-d6dd8c3ce18e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_1023e28b-f60a-4302-bae0-a1a40e4e78db" xlink:href="pacb-20241231.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_025258c0-0f1c-4ce7-886c-d6dd8c3ce18e" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_1023e28b-f60a-4302-bae0-a1a40e4e78db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2029NotesMember_184ea9f2-98a5-4b43-b19a-4c380d6d95c5" xlink:href="pacb-20241231.xsd#pacb_A2029NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_025258c0-0f1c-4ce7-886c-d6dd8c3ce18e" xlink:to="loc_pacb_A2029NotesMember_184ea9f2-98a5-4b43-b19a-4c380d6d95c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_3264fe8e-03bd-4410-960b-ff3358d964cb" xlink:href="pacb-20241231.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_025258c0-0f1c-4ce7-886c-d6dd8c3ce18e" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_3264fe8e-03bd-4410-960b-ff3358d964cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ExchangeTransactionMember_43a817a4-b8f2-4aad-837d-294f86098639" xlink:href="pacb-20241231.xsd#pacb_ExchangeTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_025258c0-0f1c-4ce7-886c-d6dd8c3ce18e" xlink:to="loc_pacb_ExchangeTransactionMember_43a817a4-b8f2-4aad-837d-294f86098639" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d470a1d1-6bb6-4519-8d8f-5eee3ccaaf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_78fa20a9-a0e9-4d72-b4a4-fb58b16a1a66" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d470a1d1-6bb6-4519-8d8f-5eee3ccaaf9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d470a1d1-6bb6-4519-8d8f-5eee3ccaaf9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d470a1d1-6bb6-4519-8d8f-5eee3ccaaf9a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d470a1d1-6bb6-4519-8d8f-5eee3ccaaf9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_990dd277-0cda-4eb7-8603-cc2d45ab0cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d470a1d1-6bb6-4519-8d8f-5eee3ccaaf9a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_990dd277-0cda-4eb7-8603-cc2d45ab0cd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_8ed55b4a-0f86-4bb2-92b7-3628cc68e5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_990dd277-0cda-4eb7-8603-cc2d45ab0cd8" xlink:to="loc_us-gaap_ConvertibleDebtMember_8ed55b4a-0f86-4bb2-92b7-3628cc68e5a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_ac4f1fb0-49d0-454b-bc44-fda3fe2ca0bd" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_78fa20a9-a0e9-4d72-b4a4-fb58b16a1a66" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_ac4f1fb0-49d0-454b-bc44-fda3fe2ca0bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_ac4f1fb0-49d0-454b-bc44-fda3fe2ca0bd_default" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_ac4f1fb0-49d0-454b-bc44-fda3fe2ca0bd" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_ac4f1fb0-49d0-454b-bc44-fda3fe2ca0bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_25054d4d-450c-46ca-a193-254027a12470" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_ac4f1fb0-49d0-454b-bc44-fda3fe2ca0bd" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_25054d4d-450c-46ca-a193-254027a12470" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsOneMember_4cb49cc9-f0f8-4b27-8eff-de41c36b9001" xlink:href="pacb-20241231.xsd#pacb_DebtConversionTermsOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_25054d4d-450c-46ca-a193-254027a12470" xlink:to="loc_pacb_DebtConversionTermsOneMember_4cb49cc9-f0f8-4b27-8eff-de41c36b9001" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsTwoMember_1dcacc38-fbe2-431a-a767-b8da8ea40cc5" xlink:href="pacb-20241231.xsd#pacb_DebtConversionTermsTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_25054d4d-450c-46ca-a193-254027a12470" xlink:to="loc_pacb_DebtConversionTermsTwoMember_1dcacc38-fbe2-431a-a767-b8da8ea40cc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ad314757-1607-46e8-95b5-235d53d67dd2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_78fa20a9-a0e9-4d72-b4a4-fb58b16a1a66" xlink:to="loc_srt_RangeAxis_ad314757-1607-46e8-95b5-235d53d67dd2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ad314757-1607-46e8-95b5-235d53d67dd2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ad314757-1607-46e8-95b5-235d53d67dd2" xlink:to="loc_srt_RangeMember_ad314757-1607-46e8-95b5-235d53d67dd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_430a8775-4360-4f46-8311-da96c58c9e1c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ad314757-1607-46e8-95b5-235d53d67dd2" xlink:to="loc_srt_RangeMember_430a8775-4360-4f46-8311-da96c58c9e1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_87ecb6ea-bd5d-4821-bdb1-3b8331103224" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_430a8775-4360-4f46-8311-da96c58c9e1c" xlink:to="loc_srt_MinimumMember_87ecb6ea-bd5d-4821-bdb1-3b8331103224" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a7526f70-f083-4ddb-819a-accea11d5955" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_430a8775-4360-4f46-8311-da96c58c9e1c" xlink:to="loc_srt_MaximumMember_a7526f70-f083-4ddb-819a-accea11d5955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_564cadd9-4c17-4694-8dc1-fdd8efcb2fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_564cadd9-4c17-4694-8dc1-fdd8efcb2fe7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9eb125df-cd71-455c-b442-2968d7510434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9eb125df-cd71-455c-b442-2968d7510434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f7c6bfab-c4fb-4ff3-becf-69e695520f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f7c6bfab-c4fb-4ff3-becf-69e695520f9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_a5d3f97b-975e-49b4-a9bb-e308ec7cfbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_a5d3f97b-975e-49b4-a9bb-e308ec7cfbbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsInConjunctionWithNotesExchange_5d876e83-e0d6-42e1-9f96-8d122268a285" xlink:href="pacb-20241231.xsd#pacb_PaymentsInConjunctionWithNotesExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_PaymentsInConjunctionWithNotesExchange_5d876e83-e0d6-42e1-9f96-8d122268a285" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_0eeb49d8-2619-4992-b4a0-5c6f771c0882" xlink:href="pacb-20241231.xsd#pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_0eeb49d8-2619-4992-b4a0-5c6f771c0882" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_69cba4fd-65cd-4a5d-a4dd-7d33b1212e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_69cba4fd-65cd-4a5d-a4dd-7d33b1212e6e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_5863df01-d169-49a0-bb64-ceccec7025b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_5863df01-d169-49a0-bb64-ceccec7025b2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_57be8a3f-fafa-4beb-ac25-8564e589eac7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_57be8a3f-fafa-4beb-ac25-8564e589eac7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_411dd9d9-38e2-4938-9b3d-b3a1e7c01cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_411dd9d9-38e2-4938-9b3d-b3a1e7c01cc3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_1d64dde4-1d18-40c4-8337-aeeb67332836" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_1d64dde4-1d18-40c4-8337-aeeb67332836" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f7fa463e-8e05-453f-938c-c77869963e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f7fa463e-8e05-453f-938c-c77869963e1d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_e96e4a4e-0d16-4b28-94f5-bd91a78f776c" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentDebtDefaultCalendarDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_e96e4a4e-0d16-4b28-94f5-bd91a78f776c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_11b99071-157e-4384-b367-1729400c31d3" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentInterestInTheEventOfDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_11b99071-157e-4384-b367-1729400c31d3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_6eae88bc-b4f1-4f2a-8ec1-e1e5dae3cb29" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_6eae88bc-b4f1-4f2a-8ec1-e1e5dae3cb29" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_1a5f7ce9-875a-4a7d-af40-9b566a6c7d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_1a5f7ce9-875a-4a7d-af40-9b566a6c7d0f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringOfDebtPricePerShare_c0327254-c559-4853-a883-43276c57d428" xlink:href="pacb-20241231.xsd#pacb_RestructuringOfDebtPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_RestructuringOfDebtPricePerShare_c0327254-c559-4853-a883-43276c57d428" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_d6fef718-44ad-42d5-8606-eb135cddeaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_d6fef718-44ad-42d5-8606-eb135cddeaf8" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtIssuanceCostLenderFees_a424b78e-dba5-4c68-828c-5bed4b952f08" xlink:href="pacb-20241231.xsd#pacb_DebtIssuanceCostLenderFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_DebtIssuanceCostLenderFees_a424b78e-dba5-4c68-828c-5bed4b952f08" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_7072a792-8bfe-4324-9875-09edab483b01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_7072a792-8bfe-4324-9875-09edab483b01" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ea459e75-5b8b-4d49-8695-65406974f898" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_LongTermDebt_ea459e75-5b8b-4d49-8695-65406974f898" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_84fb9fa6-d1db-4c30-9f8f-4aee32c33a24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_ConvertibleNotesPayable_84fb9fa6-d1db-4c30-9f8f-4aee32c33a24" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_05b2a92c-7329-4d27-8d8e-489badce4569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_05b2a92c-7329-4d27-8d8e-489badce4569" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ef20fc47-ab2d-4fe2-8cb9-c04e3f3e5b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ef20fc47-ab2d-4fe2-8cb9-c04e3f3e5b5f" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_75d4e64e-3988-4f5e-8f4d-dd9a9c38bd98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_75d4e64e-3988-4f5e-8f4d-dd9a9c38bd98" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_cce6535a-a3a2-4eef-b916-89cd6f2f094c" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_cce6535a-a3a2-4eef-b916-89cd6f2f094c" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_0be250c7-50aa-4c13-97df-933e4dafa271" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_0be250c7-50aa-4c13-97df-933e4dafa271" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_d4b27b4e-4092-4a1f-8550-2f240b302b60" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_d4b27b4e-4092-4a1f-8550-2f240b302b60" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0907b477-f701-4077-b8f5-0e658fc42104" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0907b477-f701-4077-b8f5-0e658fc42104" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6a92eeb3-8e54-4e29-a7e7-a916d3fa54c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6a92eeb3-8e54-4e29-a7e7-a916d3fa54c7" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_14fb5d2e-c955-4e45-90b1-bdeb0235a3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_14fb5d2e-c955-4e45-90b1-bdeb0235a3f0" xlink:type="arc" order="30"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2357534f-cf67-472c-aa89-57434dc23a56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8fc86ad4-c250-46a9-8bbf-39066c336391" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2357534f-cf67-472c-aa89-57434dc23a56" xlink:to="loc_us-gaap_DebtInstrumentTable_8fc86ad4-c250-46a9-8bbf-39066c336391" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f912f951-a51b-47c7-ad84-4274d532c8df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8fc86ad4-c250-46a9-8bbf-39066c336391" xlink:to="loc_us-gaap_DebtInstrumentAxis_f912f951-a51b-47c7-ad84-4274d532c8df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f912f951-a51b-47c7-ad84-4274d532c8df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f912f951-a51b-47c7-ad84-4274d532c8df" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f912f951-a51b-47c7-ad84-4274d532c8df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_60c99e11-d988-45a5-853c-f2694c880dff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f912f951-a51b-47c7-ad84-4274d532c8df" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_60c99e11-d988-45a5-853c-f2694c880dff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_58d23e23-c1ed-463d-8f8a-8e924f1e8bff" xlink:href="pacb-20241231.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_60c99e11-d988-45a5-853c-f2694c880dff" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_58d23e23-c1ed-463d-8f8a-8e924f1e8bff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_6b13a536-e23d-4d1f-b4e8-a4145421329e" xlink:href="pacb-20241231.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_60c99e11-d988-45a5-853c-f2694c880dff" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_6b13a536-e23d-4d1f-b4e8-a4145421329e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_118844dd-3b4d-460a-8d43-d8e5cc5b6b90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2357534f-cf67-472c-aa89-57434dc23a56" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_118844dd-3b4d-460a-8d43-d8e5cc5b6b90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_459f0cd4-4a3a-4e94-8bd7-dffc081499ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2357534f-cf67-472c-aa89-57434dc23a56" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_459f0cd4-4a3a-4e94-8bd7-dffc081499ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_a6e2324c-1081-4125-b468-e70e9ac7d7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2357534f-cf67-472c-aa89-57434dc23a56" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_a6e2324c-1081-4125-b468-e70e9ac7d7c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_aa68480f-ef29-447b-99e2-228bab3061c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2357534f-cf67-472c-aa89-57434dc23a56" xlink:to="loc_us-gaap_LongTermDebt_aa68480f-ef29-447b-99e2-228bab3061c4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_69291a50-9e92-48e1-8e2c-8c232f373888" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0385dd2b-e723-4d4c-b898-3187101703dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69291a50-9e92-48e1-8e2c-8c232f373888" xlink:to="loc_us-gaap_DebtInstrumentTable_0385dd2b-e723-4d4c-b898-3187101703dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_14bcb6e9-8c97-40cf-958c-03f3726f6d31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0385dd2b-e723-4d4c-b898-3187101703dc" xlink:to="loc_us-gaap_DebtInstrumentAxis_14bcb6e9-8c97-40cf-958c-03f3726f6d31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_14bcb6e9-8c97-40cf-958c-03f3726f6d31_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_14bcb6e9-8c97-40cf-958c-03f3726f6d31" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_14bcb6e9-8c97-40cf-958c-03f3726f6d31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_eef559c3-625a-4617-a98d-ac1fa431f695" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_14bcb6e9-8c97-40cf-958c-03f3726f6d31" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_eef559c3-625a-4617-a98d-ac1fa431f695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_1c461c15-1736-4a99-b251-e61a914402ff" xlink:href="pacb-20241231.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eef559c3-625a-4617-a98d-ac1fa431f695" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_1c461c15-1736-4a99-b251-e61a914402ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_87aeb2cd-26ac-4dd7-9a6b-0f3506d0515c" xlink:href="pacb-20241231.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eef559c3-625a-4617-a98d-ac1fa431f695" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_87aeb2cd-26ac-4dd7-9a6b-0f3506d0515c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_c5c41175-73ba-4d82-b655-a75c065774c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69291a50-9e92-48e1-8e2c-8c232f373888" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_c5c41175-73ba-4d82-b655-a75c065774c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_f2a8222a-9e67-4bd7-ab19-38d9248e0c80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69291a50-9e92-48e1-8e2c-8c232f373888" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_f2a8222a-9e67-4bd7-ab19-38d9248e0c80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_233f8a19-a93c-45b8-856a-a78e11f0a732" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69291a50-9e92-48e1-8e2c-8c232f373888" xlink:to="loc_us-gaap_InterestExpenseDebt_233f8a19-a93c-45b8-856a-a78e11f0a732" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_5b5a494c-a94c-48c2-90f6-af40761b0c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bad4bafc-e2d2-4f40-8c3e-2f42000bb5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5b5a494c-a94c-48c2-90f6-af40761b0c0d" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bad4bafc-e2d2-4f40-8c3e-2f42000bb5fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_78d0d19a-e04e-426d-8011-75ed41e683f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bad4bafc-e2d2-4f40-8c3e-2f42000bb5fc" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_78d0d19a-e04e-426d-8011-75ed41e683f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_78d0d19a-e04e-426d-8011-75ed41e683f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_78d0d19a-e04e-426d-8011-75ed41e683f7" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_78d0d19a-e04e-426d-8011-75ed41e683f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d38e565a-e5bb-44f4-9f17-4e43c3f64b31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_78d0d19a-e04e-426d-8011-75ed41e683f7" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d38e565a-e5bb-44f4-9f17-4e43c3f64b31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeSeparationCostsMember_b97cf1aa-fd6c-479b-b20c-596925000842" xlink:href="pacb-20241231.xsd#pacb_EmployeeSeparationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d38e565a-e5bb-44f4-9f17-4e43c3f64b31" xlink:to="loc_pacb_EmployeeSeparationCostsMember_b97cf1aa-fd6c-479b-b20c-596925000842" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_ad8638c7-8172-4086-9f0a-d5d19c0ba757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d38e565a-e5bb-44f4-9f17-4e43c3f64b31" xlink:to="loc_us-gaap_OtherRestructuringMember_ad8638c7-8172-4086-9f0a-d5d19c0ba757" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a8cde1cc-73d8-4106-8521-bde053f32d09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bad4bafc-e2d2-4f40-8c3e-2f42000bb5fc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a8cde1cc-73d8-4106-8521-bde053f32d09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a8cde1cc-73d8-4106-8521-bde053f32d09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a8cde1cc-73d8-4106-8521-bde053f32d09" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a8cde1cc-73d8-4106-8521-bde053f32d09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3bbd3562-ce3e-4a61-92fd-2ca270d54397" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a8cde1cc-73d8-4106-8521-bde053f32d09" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3bbd3562-ce3e-4a61-92fd-2ca270d54397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_732ebc2d-6b8d-4716-b7ae-5b7ea70102c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bbd3562-ce3e-4a61-92fd-2ca270d54397" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_732ebc2d-6b8d-4716-b7ae-5b7ea70102c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ab2c22b0-6dc8-4199-bd7a-a173f3664381" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bbd3562-ce3e-4a61-92fd-2ca270d54397" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ab2c22b0-6dc8-4199-bd7a-a173f3664381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_3f7e360e-1a69-4586-836d-1ebecb78759d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bbd3562-ce3e-4a61-92fd-2ca270d54397" xlink:to="loc_us-gaap_CostOfSalesMember_3f7e360e-1a69-4586-836d-1ebecb78759d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_c484e994-76cd-4d05-a59d-d0d4542a985a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bad4bafc-e2d2-4f40-8c3e-2f42000bb5fc" xlink:to="loc_us-gaap_RestructuringPlanAxis_c484e994-76cd-4d05-a59d-d0d4542a985a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_c484e994-76cd-4d05-a59d-d0d4542a985a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_c484e994-76cd-4d05-a59d-d0d4542a985a" xlink:to="loc_us-gaap_RestructuringPlanDomain_c484e994-76cd-4d05-a59d-d0d4542a985a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_6a132373-06ae-4adb-b940-0a2981d9fb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_c484e994-76cd-4d05-a59d-d0d4542a985a" xlink:to="loc_us-gaap_RestructuringPlanDomain_6a132373-06ae-4adb-b940-0a2981d9fb9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SanDiegoOfficeMember_69940bd7-4353-4903-8831-03edd2d27d51" xlink:href="pacb-20241231.xsd#pacb_SanDiegoOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_6a132373-06ae-4adb-b940-0a2981d9fb9a" xlink:to="loc_pacb_SanDiegoOfficeMember_69940bd7-4353-4903-8831-03edd2d27d51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_4e62e3fd-2674-4eb4-8dfc-78ce5e0908bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5b5a494c-a94c-48c2-90f6-af40761b0c0d" xlink:to="loc_us-gaap_RestructuringCharges_4e62e3fd-2674-4eb4-8dfc-78ce5e0908bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_2793cfc5-7e51-450d-a418-a219202e7eff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5b5a494c-a94c-48c2-90f6-af40761b0c0d" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_2793cfc5-7e51-450d-a418-a219202e7eff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5ee6a2ae-22a8-46ba-9228-dfc094323eef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5b5a494c-a94c-48c2-90f6-af40761b0c0d" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5ee6a2ae-22a8-46ba-9228-dfc094323eef" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#RESTRUCTURINGNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_85cb0e18-7094-419d-aff4-49cad4daf637" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d34de9c5-c334-4497-a71a-33685b2d8e31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_85cb0e18-7094-419d-aff4-49cad4daf637" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d34de9c5-c334-4497-a71a-33685b2d8e31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_9c34183c-cb9d-482d-bb2e-5d5978a61f40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d34de9c5-c334-4497-a71a-33685b2d8e31" xlink:to="loc_us-gaap_RestructuringPlanAxis_9c34183c-cb9d-482d-bb2e-5d5978a61f40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_9c34183c-cb9d-482d-bb2e-5d5978a61f40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_9c34183c-cb9d-482d-bb2e-5d5978a61f40" xlink:to="loc_us-gaap_RestructuringPlanDomain_9c34183c-cb9d-482d-bb2e-5d5978a61f40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_904bc911-4696-4058-8cf8-4ba4e3f92106" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_9c34183c-cb9d-482d-bb2e-5d5978a61f40" xlink:to="loc_us-gaap_RestructuringPlanDomain_904bc911-4696-4058-8cf8-4ba4e3f92106" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SanDiegoOfficeMember_8e85c8a2-8e33-477b-8f15-31d26848b25c" xlink:href="pacb-20241231.xsd#pacb_SanDiegoOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_904bc911-4696-4058-8cf8-4ba4e3f92106" xlink:to="loc_pacb_SanDiegoOfficeMember_8e85c8a2-8e33-477b-8f15-31d26848b25c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_0951f41b-2999-4fe2-9ec4-490a096b8a86" xlink:href="pacb-20241231.xsd#pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_85cb0e18-7094-419d-aff4-49cad4daf637" xlink:to="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_0951f41b-2999-4fe2-9ec4-490a096b8a86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_c4249307-5ff6-4aa7-a151-58e883d58135" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_85cb0e18-7094-419d-aff4-49cad4daf637" xlink:to="loc_us-gaap_SeveranceCosts1_c4249307-5ff6-4aa7-a151-58e883d58135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_a9aa651d-5cbb-437d-9548-f21c7abafb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_85cb0e18-7094-419d-aff4-49cad4daf637" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_a9aa651d-5cbb-437d-9548-f21c7abafb3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_6d43e000-6ead-4c55-8b9b-b50008a20fea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_85cb0e18-7094-419d-aff4-49cad4daf637" xlink:to="loc_us-gaap_InventoryWriteDown_6d43e000-6ead-4c55-8b9b-b50008a20fea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_810b0a56-58e6-40c8-a703-ecaa20bc0afc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_85cb0e18-7094-419d-aff4-49cad4daf637" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_810b0a56-58e6-40c8-a703-ecaa20bc0afc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1f7c5fab-0fbd-4bfb-b676-b45479f59b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_85cb0e18-7094-419d-aff4-49cad4daf637" xlink:to="loc_us-gaap_OperatingLeaseLiability_1f7c5fab-0fbd-4bfb-b676-b45479f59b47" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8e0ea90c-f509-43d8-9e9b-1d3c22ffee0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4c12c786-de0c-42f4-abc3-31de379779ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e0ea90c-f509-43d8-9e9b-1d3c22ffee0b" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4c12c786-de0c-42f4-abc3-31de379779ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1f7bc0ab-e363-4d21-85f8-080c878d54b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4c12c786-de0c-42f4-abc3-31de379779ac" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1f7bc0ab-e363-4d21-85f8-080c878d54b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1f7bc0ab-e363-4d21-85f8-080c878d54b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1f7bc0ab-e363-4d21-85f8-080c878d54b8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1f7bc0ab-e363-4d21-85f8-080c878d54b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1140224b-fe46-4d52-a3a0-e56146ce1fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1f7bc0ab-e363-4d21-85f8-080c878d54b8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1140224b-fe46-4d52-a3a0-e56146ce1fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeSeparationCostsMember_400510dc-f074-4569-a1f8-5fdf536595a3" xlink:href="pacb-20241231.xsd#pacb_EmployeeSeparationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1140224b-fe46-4d52-a3a0-e56146ce1fd8" xlink:to="loc_pacb_EmployeeSeparationCostsMember_400510dc-f074-4569-a1f8-5fdf536595a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_fcf11f71-aa9b-4445-964b-78fb3e7c6ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1140224b-fe46-4d52-a3a0-e56146ce1fd8" xlink:to="loc_us-gaap_OtherRestructuringMember_fcf11f71-aa9b-4445-964b-78fb3e7c6ab0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_927ae0df-eb36-4de7-a853-7fc859d29936" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e0ea90c-f509-43d8-9e9b-1d3c22ffee0b" xlink:to="loc_us-gaap_RestructuringCharges_927ae0df-eb36-4de7-a853-7fc859d29936" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_7dbf090f-b7b2-44b1-b285-de10fa5cae71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e0ea90c-f509-43d8-9e9b-1d3c22ffee0b" xlink:to="loc_us-gaap_PaymentsForRestructuring_7dbf090f-b7b2-44b1-b285-de10fa5cae71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_badb6960-0b8e-4370-91c0-011acc5df858" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e0ea90c-f509-43d8-9e9b-1d3c22ffee0b" xlink:to="loc_us-gaap_RestructuringReserve_badb6960-0b8e-4370-91c0-011acc5df858" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_9e0158a9-00c5-4b05-933d-e3d9727a4f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e0ea90c-f509-43d8-9e9b-1d3c22ffee0b" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_9e0158a9-00c5-4b05-933d-e3d9727a4f6f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:href="pacb-20241231.xsd#pacb_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommitmentsAndContingenciesTable_29804910-acd6-48a0-988d-68b1e5a74336" xlink:href="pacb-20241231.xsd#pacb_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_pacb_CommitmentsAndContingenciesTable_29804910-acd6-48a0-988d-68b1e5a74336" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b6ab77bd-3c71-44eb-b85f-dc8758a5eb89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_CommitmentsAndContingenciesTable_29804910-acd6-48a0-988d-68b1e5a74336" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b6ab77bd-3c71-44eb-b85f-dc8758a5eb89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6ab77bd-3c71-44eb-b85f-dc8758a5eb89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b6ab77bd-3c71-44eb-b85f-dc8758a5eb89" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6ab77bd-3c71-44eb-b85f-dc8758a5eb89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8301f108-23cf-4c31-9f23-5dfa79293ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b6ab77bd-3c71-44eb-b85f-dc8758a5eb89" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8301f108-23cf-4c31-9f23-5dfa79293ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_32cb2e72-25aa-44af-9867-e16ed7cecd7b" xlink:href="pacb-20241231.xsd#pacb_OmniomeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8301f108-23cf-4c31-9f23-5dfa79293ad2" xlink:to="loc_pacb_OmniomeIncMember_32cb2e72-25aa-44af-9867-e16ed7cecd7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d73dd2e4-a8de-4b1c-861a-b450712e4f94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d73dd2e4-a8de-4b1c-861a-b450712e4f94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_565c561e-b6bd-44ac-8d43-8b43dbac5501" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_565c561e-b6bd-44ac-8d43-8b43dbac5501" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRent_a79a230c-8c4e-4a47-9494-9fb0efc1916e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_PaymentsForRent_a79a230c-8c4e-4a47-9494-9fb0efc1916e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_25932e06-0257-4ce6-b5f8-73523e618120" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_OperatingLeaseCost_25932e06-0257-4ce6-b5f8-73523e618120" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_b6bd4906-7af9-4903-82b4-19f60d188a91" xlink:href="pacb-20241231.xsd#pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_b6bd4906-7af9-4903-82b4-19f60d188a91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_0f1cc9b7-49ff-4b81-b4a8-7437fc3cc385" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_PurchaseObligation_0f1cc9b7-49ff-4b81-b4a8-7437fc3cc385" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_f3180233-b8e6-4d8c-a42e-ad909676573e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_f3180233-b8e6-4d8c-a42e-ad909676573e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDeposits_f16ca1d2-b1f6-4fca-8f38-ae4767eb75ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForDeposits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_PaymentsForDeposits_f16ca1d2-b1f6-4fca-8f38-ae4767eb75ba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RefundFromDeposits_e078d14e-342e-489c-aea8-5be54a407e87" xlink:href="pacb-20241231.xsd#pacb_RefundFromDeposits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_pacb_RefundFromDeposits_e078d14e-342e-489c-aea8-5be54a407e87" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_5a962e4a-3db3-432a-98bc-dd9f9ff24009" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_DepositsAssetsCurrent_5a962e4a-3db3-432a-98bc-dd9f9ff24009" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_a5b5c647-78fb-4079-b36f-79ec8f5ad1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_a5b5c647-78fb-4079-b36f-79ec8f5ad1e4" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:href="pacb-20241231.xsd#pacb_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeTaxesTable_75035856-440b-4f68-92ae-da074118102d" xlink:href="pacb-20241231.xsd#pacb_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_pacb_IncomeTaxesTable_75035856-440b-4f68-92ae-da074118102d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6403539a-26d7-4086-ac67-48f4430f33ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_IncomeTaxesTable_75035856-440b-4f68-92ae-da074118102d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6403539a-26d7-4086-ac67-48f4430f33ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6403539a-26d7-4086-ac67-48f4430f33ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6403539a-26d7-4086-ac67-48f4430f33ae" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6403539a-26d7-4086-ac67-48f4430f33ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_dd93ab3a-c8e1-4a70-893f-e01c363f8dde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6403539a-26d7-4086-ac67-48f4430f33ae" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_dd93ab3a-c8e1-4a70-893f-e01c363f8dde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_8fc145f2-650e-4a2e-b52a-3161705edc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_dd93ab3a-c8e1-4a70-893f-e01c363f8dde" xlink:to="loc_us-gaap_DomesticCountryMember_8fc145f2-650e-4a2e-b52a-3161705edc0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_6ea67e03-9d27-450d-b07b-0639b7a5b76d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_dd93ab3a-c8e1-4a70-893f-e01c363f8dde" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_6ea67e03-9d27-450d-b07b-0639b7a5b76d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition_c38313f9-9218-4b86-81d2-28a43defe265" xlink:href="pacb-20241231.xsd#pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition_c38313f9-9218-4b86-81d2-28a43defe265" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_925d10ed-7342-468c-bfb3-b329c37acea3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_925d10ed-7342-468c-bfb3-b329c37acea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_24cc3630-5b49-4406-9989-f566e0e327e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_24cc3630-5b49-4406-9989-f566e0e327e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c50c81b7-42ea-4186-b057-5154837bbbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c50c81b7-42ea-4186-b057-5154837bbbbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_8a6ead11-4569-404a-a315-66a2df51dabf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_8a6ead11-4569-404a-a315-66a2df51dabf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_2a0aae5a-8389-4084-beb3-22d2f47b78a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_2a0aae5a-8389-4084-beb3-22d2f47b78a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration_ad2d08aa-7a8b-4b2e-a285-7d843965eae4" xlink:href="pacb-20241231.xsd#pacb_OperatingLossCarryforwardsAmountSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration_ad2d08aa-7a8b-4b2e-a285-7d843965eae4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c773ebf6-afde-4a39-9693-d371ddc1ad07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c773ebf6-afde-4a39-9693-d371ddc1ad07" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_dcb15790-b025-4935-b110-6b1aa7f8fd99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_dcb15790-b025-4935-b110-6b1aa7f8fd99" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:href="pacb-20241231.xsd#pacb_StockholdersEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockholdersEquityTable_c6160fae-8564-4630-a366-efe7e3379338" xlink:href="pacb-20241231.xsd#pacb_StockholdersEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_StockholdersEquityTable_c6160fae-8564-4630-a366-efe7e3379338" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_db644013-e2ac-4646-8bd2-63857dde66f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_StockholdersEquityTable_c6160fae-8564-4630-a366-efe7e3379338" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_db644013-e2ac-4646-8bd2-63857dde66f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_db644013-e2ac-4646-8bd2-63857dde66f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_db644013-e2ac-4646-8bd2-63857dde66f9" xlink:to="loc_us-gaap_EquityComponentDomain_db644013-e2ac-4646-8bd2-63857dde66f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f38b5566-f9aa-4cbc-aea2-d791373b824d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_db644013-e2ac-4646-8bd2-63857dde66f9" xlink:to="loc_us-gaap_EquityComponentDomain_f38b5566-f9aa-4cbc-aea2-d791373b824d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d1fd9dc3-6ee4-4305-b1d0-2f91986e538d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f38b5566-f9aa-4cbc-aea2-d791373b824d" xlink:to="loc_us-gaap_CommonStockMember_d1fd9dc3-6ee4-4305-b1d0-2f91986e538d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_b7b75e62-2af9-4db9-bcaa-efcf15a70057" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_StockholdersEquityTable_c6160fae-8564-4630-a366-efe7e3379338" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_b7b75e62-2af9-4db9-bcaa-efcf15a70057" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_b7b75e62-2af9-4db9-bcaa-efcf15a70057_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_b7b75e62-2af9-4db9-bcaa-efcf15a70057" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_b7b75e62-2af9-4db9-bcaa-efcf15a70057_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_ded931a2-b3f5-4e2b-81d7-824ce0e56204" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_b7b75e62-2af9-4db9-bcaa-efcf15a70057" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_ded931a2-b3f5-4e2b-81d7-824ce0e56204" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EquityIncentivePlan2020Member_1080ddd5-5f38-41cf-9dcf-5ab7234a3613" xlink:href="pacb-20241231.xsd#pacb_EquityIncentivePlan2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_ded931a2-b3f5-4e2b-81d7-824ce0e56204" xlink:to="loc_pacb_EquityIncentivePlan2020Member_1080ddd5-5f38-41cf-9dcf-5ab7234a3613" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_a2ccd617-bc32-4b24-8150-63cfe28f38db" xlink:href="pacb-20241231.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_ded931a2-b3f5-4e2b-81d7-824ce0e56204" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_a2ccd617-bc32-4b24-8150-63cfe28f38db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c007b5c7-f5da-49c8-8601-a9140976dd17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_StockholdersEquityTable_c6160fae-8564-4630-a366-efe7e3379338" xlink:to="loc_us-gaap_AwardTypeAxis_c007b5c7-f5da-49c8-8601-a9140976dd17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c007b5c7-f5da-49c8-8601-a9140976dd17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c007b5c7-f5da-49c8-8601-a9140976dd17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c007b5c7-f5da-49c8-8601-a9140976dd17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67833b2b-05d9-42b9-8144-34831eaa9626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c007b5c7-f5da-49c8-8601-a9140976dd17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67833b2b-05d9-42b9-8144-34831eaa9626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember_43f6762a-4b55-48c4-9594-9ee1b700f72c" xlink:href="pacb-20241231.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67833b2b-05d9-42b9-8144-34831eaa9626" xlink:to="loc_pacb_OptionsToPurchaseCommonStockMember_43f6762a-4b55-48c4-9594-9ee1b700f72c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedAndPerformanceBasedOptionsMember_89439990-e45b-49bf-b466-0fdbb78bf684" xlink:href="pacb-20241231.xsd#pacb_TimeBasedAndPerformanceBasedOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67833b2b-05d9-42b9-8144-34831eaa9626" xlink:to="loc_pacb_TimeBasedAndPerformanceBasedOptionsMember_89439990-e45b-49bf-b466-0fdbb78bf684" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_052ef6a7-4b84-45c6-8278-7053070a2ec8" xlink:href="pacb-20241231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67833b2b-05d9-42b9-8144-34831eaa9626" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_052ef6a7-4b84-45c6-8278-7053070a2ec8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_1b3334e6-7073-47d3-9ec1-96b981737982" xlink:href="pacb-20241231.xsd#pacb_TimeBasedRestrictedStockUnitsPSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67833b2b-05d9-42b9-8144-34831eaa9626" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_1b3334e6-7073-47d3-9ec1-96b981737982" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cecba661-1192-42e7-8d3a-214ceac90b92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_StockholdersEquityTable_c6160fae-8564-4630-a366-efe7e3379338" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cecba661-1192-42e7-8d3a-214ceac90b92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cecba661-1192-42e7-8d3a-214ceac90b92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cecba661-1192-42e7-8d3a-214ceac90b92" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cecba661-1192-42e7-8d3a-214ceac90b92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1cd4b0af-ac47-401e-900f-50552b718184" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cecba661-1192-42e7-8d3a-214ceac90b92" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1cd4b0af-ac47-401e-900f-50552b718184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShelfOfferingMember_7c9ce1cf-c434-41eb-bd5c-b197a0781b33" xlink:href="pacb-20241231.xsd#pacb_ShelfOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1cd4b0af-ac47-401e-900f-50552b718184" xlink:to="loc_pacb_ShelfOfferingMember_7c9ce1cf-c434-41eb-bd5c-b197a0781b33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_24eb2db7-6eed-46d1-9fd7-d4c8f46ab11c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_StockholdersEquityTable_c6160fae-8564-4630-a366-efe7e3379338" xlink:to="loc_us-gaap_PlanNameAxis_24eb2db7-6eed-46d1-9fd7-d4c8f46ab11c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_24eb2db7-6eed-46d1-9fd7-d4c8f46ab11c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_24eb2db7-6eed-46d1-9fd7-d4c8f46ab11c" xlink:to="loc_us-gaap_PlanNameDomain_24eb2db7-6eed-46d1-9fd7-d4c8f46ab11c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a8eae2fb-d03d-47f6-98cc-6b913688b09e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_24eb2db7-6eed-46d1-9fd7-d4c8f46ab11c" xlink:to="loc_us-gaap_PlanNameDomain_a8eae2fb-d03d-47f6-98cc-6b913688b09e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_3920d829-bbf9-4885-be76-6200da21c47c" xlink:href="pacb-20241231.xsd#pacb_A2020PlanInducementPlanAndTheOmniomePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a8eae2fb-d03d-47f6-98cc-6b913688b09e" xlink:to="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_3920d829-bbf9-4885-be76-6200da21c47c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7b8d1251-0ddf-43f5-85f4-8bbe847fca77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7b8d1251-0ddf-43f5-85f4-8bbe847fca77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a1badd3b-c8e0-49d1-aa70-34d0b44debc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a1badd3b-c8e0-49d1-aa70-34d0b44debc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_381a646a-d940-4cb9-a7e7-35a460d48a70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_381a646a-d940-4cb9-a7e7-35a460d48a70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_014f63b7-678c-4cc7-9d91-9cf3cc1250ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_014f63b7-678c-4cc7-9d91-9cf3cc1250ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_408f60b4-27b9-495f-ba38-a58fee6e84d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_PreferredStockSharesIssued_408f60b4-27b9-495f-ba38-a58fee6e84d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_eb2a3a21-5f14-4c95-9fe0-671acb069f36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_eb2a3a21-5f14-4c95-9fe0-671acb069f36" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_772ead8a-54f4-4c03-a865-154c2d453f33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_772ead8a-54f4-4c03-a865-154c2d453f33" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockVotingRights_85e76b8e-4932-4c72-a1a5-ec8f8a38d2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_CommonStockVotingRights_85e76b8e-4932-4c72-a1a5-ec8f8a38d2bb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_9569051c-1291-43f8-b19a-2e7fa6756224" xlink:href="pacb-20241231.xsd#pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_9569051c-1291-43f8-b19a-2e7fa6756224" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingShares_78e190e1-48a9-428e-b0fb-cb5aa9126686" xlink:href="pacb-20241231.xsd#pacb_PublicOfferingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_PublicOfferingShares_78e190e1-48a9-428e-b0fb-cb5aa9126686" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OfferingShareAmountMaximum_2b3e203f-2ac1-4dca-92a3-8e192c12b811" xlink:href="pacb-20241231.xsd#pacb_OfferingShareAmountMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_OfferingShareAmountMaximum_2b3e203f-2ac1-4dca-92a3-8e192c12b811" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_dbfe8968-30ce-4483-b0f6-8c3ec03eceb8" xlink:href="pacb-20241231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_dbfe8968-30ce-4483-b0f6-8c3ec03eceb8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_36d20c05-25cc-4ee9-92cf-9f75c73768e0" xlink:href="pacb-20241231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_36d20c05-25cc-4ee9-92cf-9f75c73768e0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7e54938f-0d5b-44e3-a975-2fb83e0417a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7e54938f-0d5b-44e3-a975-2fb83e0417a2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_6b471f4e-1b7e-4400-8f0b-237921b02c46" xlink:href="pacb-20241231.xsd#pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_6b471f4e-1b7e-4400-8f0b-237921b02c46" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_79f89a9c-29d5-45d9-aeb0-392fff7c3a3c" xlink:href="pacb-20241231.xsd#pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_79f89a9c-29d5-45d9-aeb0-392fff7c3a3c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_39bb7962-05fb-4a7d-96be-51d25e669b36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_39bb7962-05fb-4a7d-96be-51d25e669b36" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1043a286-cd28-477c-b151-70c5c6a3942e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1043a286-cd28-477c-b151-70c5c6a3942e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_56aa45cb-2305-410d-9842-f623645f4adc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_56aa45cb-2305-410d-9842-f623645f4adc" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4c62e178-88ba-45e5-970a-b22175764b52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4c62e178-88ba-45e5-970a-b22175764b52" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e4fb5bab-b277-4898-9e5d-b049ff39bc03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e4fb5bab-b277-4898-9e5d-b049ff39bc03" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_249da8fd-a52e-49bb-9f08-029ceef1cca7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_SharePrice_249da8fd-a52e-49bb-9f08-029ceef1cca7" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_135185bd-6dc2-4110-8875-bd098348d49f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_135185bd-6dc2-4110-8875-bd098348d49f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_718df4e0-2511-47f8-a972-9f35c40520dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_718df4e0-2511-47f8-a972-9f35c40520dd" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_42237a89-9d45-446a-86da-21f044adbac9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_42237a89-9d45-446a-86da-21f044adbac9" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_eb5267f5-cd4b-4340-b9d9-69f1891e0527" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_eb5267f5-cd4b-4340-b9d9-69f1891e0527" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_aa1dc330-12fd-450c-b70e-69db4e702dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_aa1dc330-12fd-450c-b70e-69db4e702dc5" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7d1e1bb2-9872-4cfa-8900-8ad3104c3a61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7d1e1bb2-9872-4cfa-8900-8ad3104c3a61" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_db7f81fa-5fa2-467a-9ce1-8e4c2441f301" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_db7f81fa-5fa2-467a-9ce1-8e4c2441f301" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9f14fd8d-2129-4623-af71-f5597ce48c67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9f14fd8d-2129-4623-af71-f5597ce48c67" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_712beaab-ecfa-46d7-a7cd-7e707a62bf18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_712beaab-ecfa-46d7-a7cd-7e707a62bf18" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareInstrumentNumberOfSharesConversionRatio_5350c994-4874-4429-8fd9-479318759c32" xlink:href="pacb-20241231.xsd#pacb_ShareInstrumentNumberOfSharesConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_ShareInstrumentNumberOfSharesConversionRatio_5350c994-4874-4429-8fd9-479318759c32" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_838bf6a7-9d67-4701-a1c5-f79ce93b99e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_838bf6a7-9d67-4701-a1c5-f79ce93b99e1" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_8d744f93-5eda-45f2-b621-b6594047e7d6" xlink:href="pacb-20241231.xsd#pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_8d744f93-5eda-45f2-b621-b6594047e7d6" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_e158822f-05c8-44d6-b425-569d025deda4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_e158822f-05c8-44d6-b425-569d025deda4" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6fe5aee4-d582-4106-ae9f-ae5797ba97d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6fe5aee4-d582-4106-ae9f-ae5797ba97d3" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b1b3c05b-d444-48fe-8ec1-3fd47567d296" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b1b3c05b-d444-48fe-8ec1-3fd47567d296" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_NumberOfPurchasePeriods_8c425b56-a383-4064-b26f-72f35c182085" xlink:href="pacb-20241231.xsd#pacb_NumberOfPurchasePeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_NumberOfPurchasePeriods_8c425b56-a383-4064-b26f-72f35c182085" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PurchasePeriodOfEmployeeStockPurchasePlan_db06dd73-bfe6-4573-9242-1de8a8e171c5" xlink:href="pacb-20241231.xsd#pacb_PurchasePeriodOfEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_PurchasePeriodOfEmployeeStockPurchasePlan_db06dd73-bfe6-4573-9242-1de8a8e171c5" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_87cbc54e-ddff-4ec3-b742-a9e26fab794c" xlink:href="pacb-20241231.xsd#pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_87cbc54e-ddff-4ec3-b742-a9e26fab794c" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_efa99ea8-ede0-4ba1-849d-2189deda340e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_efa99ea8-ede0-4ba1-849d-2189deda340e" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_67bace9f-5209-42e5-b32b-d76ee2311df5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_CommonStockSharesIssued_67bace9f-5209-42e5-b32b-d76ee2311df5" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_61bb77f0-f089-4ef0-a944-91a8ed07446e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_61bb77f0-f089-4ef0-a944-91a8ed07446e" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_3d3ae0f1-5c90-417f-b413-72e19b45ff38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_3d3ae0f1-5c90-417f-b413-72e19b45ff38" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_73648a49-c01f-4009-987c-e9be9048928c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_73648a49-c01f-4009-987c-e9be9048928c" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e16ab560-882d-4671-b41a-527915ea440b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e16ab560-882d-4671-b41a-527915ea440b" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_955f9433-efe3-4ca3-b593-2690d80fc2be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_955f9433-efe3-4ca3-b593-2690d80fc2be" xlink:type="arc" order="46"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_de133da7-1b55-46c6-91bd-43901ad7cc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_8a7dd50a-e507-45fb-8eaa-6e56d154e542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_de133da7-1b55-46c6-91bd-43901ad7cc2a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_8a7dd50a-e507-45fb-8eaa-6e56d154e542" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c2c23d63-5c02-4b23-b936-071d85c6a022" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_8a7dd50a-e507-45fb-8eaa-6e56d154e542" xlink:to="loc_us-gaap_AwardTypeAxis_c2c23d63-5c02-4b23-b936-071d85c6a022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2c23d63-5c02-4b23-b936-071d85c6a022_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c2c23d63-5c02-4b23-b936-071d85c6a022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2c23d63-5c02-4b23-b936-071d85c6a022_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af78ccef-5219-4738-83a0-a1a72be65793" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c2c23d63-5c02-4b23-b936-071d85c6a022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af78ccef-5219-4738-83a0-a1a72be65793" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedStockOptionMember_b7586421-92e5-46ca-ae1a-ecb08f503a1c" xlink:href="pacb-20241231.xsd#pacb_TimeBasedStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af78ccef-5219-4738-83a0-a1a72be65793" xlink:to="loc_pacb_TimeBasedStockOptionMember_b7586421-92e5-46ca-ae1a-ecb08f503a1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_311e744d-56f7-40a2-9b7c-32dca6df0991" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_de133da7-1b55-46c6-91bd-43901ad7cc2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_311e744d-56f7-40a2-9b7c-32dca6df0991" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_eacaa3f5-6de0-4adb-82c4-2c0584c3f6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_311e744d-56f7-40a2-9b7c-32dca6df0991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_eacaa3f5-6de0-4adb-82c4-2c0584c3f6e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a6bfcb6d-330d-49b9-a0cc-32f89f2e39c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_311e744d-56f7-40a2-9b7c-32dca6df0991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a6bfcb6d-330d-49b9-a0cc-32f89f2e39c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d316e94a-6d52-4509-878d-cd4173838f91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_311e744d-56f7-40a2-9b7c-32dca6df0991" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d316e94a-6d52-4509-878d-cd4173838f91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f90c8e2a-124e-450b-83d6-f20f83f7e2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_311e744d-56f7-40a2-9b7c-32dca6df0991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f90c8e2a-124e-450b-83d6-f20f83f7e2d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_872e462f-d2cb-40e9-a85e-f9548816a898" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_311e744d-56f7-40a2-9b7c-32dca6df0991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_872e462f-d2cb-40e9-a85e-f9548816a898" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_89e69228-fee1-4bc6-ae46-c7b20c7adecd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cc4bb716-f909-4702-81aa-07594af93b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_de133da7-1b55-46c6-91bd-43901ad7cc2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cc4bb716-f909-4702-81aa-07594af93b1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c66779b6-c2ef-49ea-8bdc-19a12c443516" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cc4bb716-f909-4702-81aa-07594af93b1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c66779b6-c2ef-49ea-8bdc-19a12c443516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f4250667-ba16-4c4e-9430-f342da382707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cc4bb716-f909-4702-81aa-07594af93b1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f4250667-ba16-4c4e-9430-f342da382707" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e3149392-2a90-46da-855d-1d037bb72dec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cc4bb716-f909-4702-81aa-07594af93b1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e3149392-2a90-46da-855d-1d037bb72dec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c7d0d014-dbac-432b-9c8f-12921a570442" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cc4bb716-f909-4702-81aa-07594af93b1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c7d0d014-dbac-432b-9c8f-12921a570442" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_101f49d8-8c05-4577-a61a-52e83d065d67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cc4bb716-f909-4702-81aa-07594af93b1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_101f49d8-8c05-4577-a61a-52e83d065d67" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_df9b8768-5bda-4191-ab35-7c62a6ad98bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c17d620d-952f-4185-8e4c-9d47d1b6ac46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6dc1cf9-67c1-4dc5-b153-aa298ca16406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c17d620d-952f-4185-8e4c-9d47d1b6ac46" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6dc1cf9-67c1-4dc5-b153-aa298ca16406" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_80f49a77-a6a8-47c2-95c7-94870dd45d39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6dc1cf9-67c1-4dc5-b153-aa298ca16406" xlink:to="loc_us-gaap_AwardTypeAxis_80f49a77-a6a8-47c2-95c7-94870dd45d39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80f49a77-a6a8-47c2-95c7-94870dd45d39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_80f49a77-a6a8-47c2-95c7-94870dd45d39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80f49a77-a6a8-47c2-95c7-94870dd45d39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cba438f-08d6-49e7-9890-19b2081309a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_80f49a77-a6a8-47c2-95c7-94870dd45d39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cba438f-08d6-49e7-9890-19b2081309a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_9b466413-199a-4a30-a778-c257e7462308" xlink:href="pacb-20241231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cba438f-08d6-49e7-9890-19b2081309a3" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_9b466413-199a-4a30-a778-c257e7462308" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_9fc8eccd-611b-4cba-8ba9-e1a565aac3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cba438f-08d6-49e7-9890-19b2081309a3" xlink:to="loc_us-gaap_PerformanceSharesMember_9fc8eccd-611b-4cba-8ba9-e1a565aac3dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e30680ad-1a36-4ff0-8d10-26df3863038b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c17d620d-952f-4185-8e4c-9d47d1b6ac46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e30680ad-1a36-4ff0-8d10-26df3863038b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_327b9058-e9c1-4b20-82a5-7c527e962377" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e30680ad-1a36-4ff0-8d10-26df3863038b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_327b9058-e9c1-4b20-82a5-7c527e962377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e892d054-9222-45fe-bd1d-8ff4d4ca052d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e30680ad-1a36-4ff0-8d10-26df3863038b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e892d054-9222-45fe-bd1d-8ff4d4ca052d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_56ef6faa-207d-485d-9a27-61ca7464e771" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e30680ad-1a36-4ff0-8d10-26df3863038b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_56ef6faa-207d-485d-9a27-61ca7464e771" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0091912e-43b0-4eb8-a2db-d9b6fcb981c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e30680ad-1a36-4ff0-8d10-26df3863038b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0091912e-43b0-4eb8-a2db-d9b6fcb981c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_20ecc7e3-fc52-4107-b8ed-d739e2f770f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_74a1e6d3-b1d8-4b3e-96df-a1d11b608bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c17d620d-952f-4185-8e4c-9d47d1b6ac46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_74a1e6d3-b1d8-4b3e-96df-a1d11b608bc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1b855264-7d0a-487e-bd00-c568066facd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_74a1e6d3-b1d8-4b3e-96df-a1d11b608bc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1b855264-7d0a-487e-bd00-c568066facd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93442a11-475f-49ac-9807-40b66593567f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_74a1e6d3-b1d8-4b3e-96df-a1d11b608bc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93442a11-475f-49ac-9807-40b66593567f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a2feea30-718b-491a-b9da-0ce973df6d84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_74a1e6d3-b1d8-4b3e-96df-a1d11b608bc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a2feea30-718b-491a-b9da-0ce973df6d84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8a3740c3-d688-474f-b2a2-d10ebfd7d0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_74a1e6d3-b1d8-4b3e-96df-a1d11b608bc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8a3740c3-d688-474f-b2a2-d10ebfd7d0ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_43edb9cd-5a96-447d-a736-0ea5e4831773" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_59b7bbd1-0687-4e24-9972-d58d95474e43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d53fb934-96fc-47e9-9433-af3247e75f52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_59b7bbd1-0687-4e24-9972-d58d95474e43" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d53fb934-96fc-47e9-9433-af3247e75f52" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e2f8c598-3420-4d3f-bcb4-d18e93c345bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d53fb934-96fc-47e9-9433-af3247e75f52" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e2f8c598-3420-4d3f-bcb4-d18e93c345bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e2f8c598-3420-4d3f-bcb4-d18e93c345bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e2f8c598-3420-4d3f-bcb4-d18e93c345bc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e2f8c598-3420-4d3f-bcb4-d18e93c345bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4af18d48-e22c-4280-b194-374bc1e82c32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e2f8c598-3420-4d3f-bcb4-d18e93c345bc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4af18d48-e22c-4280-b194-374bc1e82c32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_a1c3f0f0-2aea-4ea5-91e5-446003288237" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4af18d48-e22c-4280-b194-374bc1e82c32" xlink:to="loc_us-gaap_CostOfSalesMember_a1c3f0f0-2aea-4ea5-91e5-446003288237" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_aa3ae6ae-732e-4570-a8e5-0e3fb111e3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4af18d48-e22c-4280-b194-374bc1e82c32" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_aa3ae6ae-732e-4570-a8e5-0e3fb111e3e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_73c8bfd9-3094-45ec-9412-16c4d2a642be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4af18d48-e22c-4280-b194-374bc1e82c32" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_73c8bfd9-3094-45ec-9412-16c4d2a642be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationMember_ea2ebc42-73ad-4409-aab0-07fdf3ace766" xlink:href="pacb-20241231.xsd#pacb_StockBasedCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4af18d48-e22c-4280-b194-374bc1e82c32" xlink:to="loc_pacb_StockBasedCompensationMember_ea2ebc42-73ad-4409-aab0-07fdf3ace766" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_22560a5c-c874-4f79-ad24-9e713a72adb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_59b7bbd1-0687-4e24-9972-d58d95474e43" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_22560a5c-c874-4f79-ad24-9e713a72adb7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2665382a-a433-4952-8cc7-c94d99502565" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2665382a-a433-4952-8cc7-c94d99502565" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f4a3ec53-0c22-428d-9781-3c8df0ce932b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2665382a-a433-4952-8cc7-c94d99502565" xlink:to="loc_us-gaap_AwardTypeAxis_f4a3ec53-0c22-428d-9781-3c8df0ce932b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4a3ec53-0c22-428d-9781-3c8df0ce932b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f4a3ec53-0c22-428d-9781-3c8df0ce932b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4a3ec53-0c22-428d-9781-3c8df0ce932b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4b24a6ea-f344-45ef-a5a4-48c4e87443d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f4a3ec53-0c22-428d-9781-3c8df0ce932b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4b24a6ea-f344-45ef-a5a4-48c4e87443d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember_21eb0592-36e6-4aa4-b4ba-1cc97a54a0a8" xlink:href="pacb-20241231.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4b24a6ea-f344-45ef-a5a4-48c4e87443d1" xlink:to="loc_pacb_OptionsToPurchaseCommonStockMember_21eb0592-36e6-4aa4-b4ba-1cc97a54a0a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_55363a67-d669-4457-878e-f17921ebc2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_55363a67-d669-4457-878e-f17921ebc2e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_fc67a2ae-c161-4dcd-a9b4-2008ffaf3b53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_fc67a2ae-c161-4dcd-a9b4-2008ffaf3b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5aa07a40-d77c-441a-9253-7f7e6bd3c822" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5aa07a40-d77c-441a-9253-7f7e6bd3c822" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_77775409-a8dc-4a29-acd1-9207de40561d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_77775409-a8dc-4a29-acd1-9207de40561d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_22b01ae0-6e7d-4a82-9cbb-f17932b0fe1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_22b01ae0-6e7d-4a82-9cbb-f17932b0fe1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_31127536-a637-425c-8c70-752704dc130f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_31127536-a637-425c-8c70-752704dc130f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b00e6194-f920-4e12-aecf-fdc50e1b398a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b00e6194-f920-4e12-aecf-fdc50e1b398a" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5146c76c-20e2-4eed-8997-b5d1a298d99e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5146c76c-20e2-4eed-8997-b5d1a298d99e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1b2e4ff-46d5-484b-b650-ca629f8c146c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5146c76c-20e2-4eed-8997-b5d1a298d99e" xlink:to="loc_srt_RangeAxis_b1b2e4ff-46d5-484b-b650-ca629f8c146c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1b2e4ff-46d5-484b-b650-ca629f8c146c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b1b2e4ff-46d5-484b-b650-ca629f8c146c" xlink:to="loc_srt_RangeMember_b1b2e4ff-46d5-484b-b650-ca629f8c146c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_48303685-08dc-41e8-aad0-d1868e2656e5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b1b2e4ff-46d5-484b-b650-ca629f8c146c" xlink:to="loc_srt_RangeMember_48303685-08dc-41e8-aad0-d1868e2656e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_000b8af1-a426-48de-a279-7136fd04c4e6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_48303685-08dc-41e8-aad0-d1868e2656e5" xlink:to="loc_srt_MinimumMember_000b8af1-a426-48de-a279-7136fd04c4e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_19225955-2c06-4466-8d8a-2cee2fd96237" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_48303685-08dc-41e8-aad0-d1868e2656e5" xlink:to="loc_srt_MaximumMember_19225955-2c06-4466-8d8a-2cee2fd96237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2b7b0959-efcc-4e86-b782-ddaa9e2ad335" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5146c76c-20e2-4eed-8997-b5d1a298d99e" xlink:to="loc_us-gaap_PlanNameAxis_2b7b0959-efcc-4e86-b782-ddaa9e2ad335" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2b7b0959-efcc-4e86-b782-ddaa9e2ad335_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2b7b0959-efcc-4e86-b782-ddaa9e2ad335" xlink:to="loc_us-gaap_PlanNameDomain_2b7b0959-efcc-4e86-b782-ddaa9e2ad335_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ec81109f-033d-406b-bffe-241a65c13d92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2b7b0959-efcc-4e86-b782-ddaa9e2ad335" xlink:to="loc_us-gaap_PlanNameDomain_ec81109f-033d-406b-bffe-241a65c13d92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_44f53df3-fafb-427f-92e1-5295372e549e" xlink:href="pacb-20241231.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ec81109f-033d-406b-bffe-241a65c13d92" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_44f53df3-fafb-427f-92e1-5295372e549e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2f5e5673-a376-43a3-830f-f4ee0a5cc803" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2f5e5673-a376-43a3-830f-f4ee0a5cc803" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_f5917b75-28e1-49fa-aa5b-d71512527a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_f5917b75-28e1-49fa-aa5b-d71512527a1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7f3a1bb8-94fb-4291-b530-c23ef32bf371" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7f3a1bb8-94fb-4291-b530-c23ef32bf371" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_08e89613-0a65-49fc-a2c8-653c81db3c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_08e89613-0a65-49fc-a2c8-653c81db3c6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d243e31c-6237-4254-9e27-bea48db2e135" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d243e31c-6237-4254-9e27-bea48db2e135" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bfaa0c86-3606-421b-a04f-42f87d84434e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bfaa0c86-3606-421b-a04f-42f87d84434e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_482917fc-2ea3-4614-8792-c068d86f7b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_482917fc-2ea3-4614-8792-c068d86f7b0a" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_fecb6de3-c3ef-471c-b08e-ac4d6d991fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_d4f34220-acb1-48c1-887e-bbb78fc7f4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_fecb6de3-c3ef-471c-b08e-ac4d6d991fa3" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_d4f34220-acb1-48c1-887e-bbb78fc7f4c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_61bb9b2d-3bd9-4491-8ab5-37023acd6587" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_d4f34220-acb1-48c1-887e-bbb78fc7f4c1" xlink:to="loc_us-gaap_DebtInstrumentAxis_61bb9b2d-3bd9-4491-8ab5-37023acd6587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_61bb9b2d-3bd9-4491-8ab5-37023acd6587_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_61bb9b2d-3bd9-4491-8ab5-37023acd6587" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_61bb9b2d-3bd9-4491-8ab5-37023acd6587_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d7f0fe8f-b0e4-4530-b626-82d5fe086f62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_61bb9b2d-3bd9-4491-8ab5-37023acd6587" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d7f0fe8f-b0e4-4530-b626-82d5fe086f62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_48a7667f-e601-42bd-b7bf-00ad9192fb77" xlink:href="pacb-20241231.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7f0fe8f-b0e4-4530-b626-82d5fe086f62" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_48a7667f-e601-42bd-b7bf-00ad9192fb77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2029ConvertibleSeniorNotesMember_240debd1-47f8-4d70-b162-37080f399f36" xlink:href="pacb-20241231.xsd#pacb_A2029ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7f0fe8f-b0e4-4530-b626-82d5fe086f62" xlink:to="loc_pacb_A2029ConvertibleSeniorNotesMember_240debd1-47f8-4d70-b162-37080f399f36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_31cc9b92-3f31-449b-9d7e-cbd92db358f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageRateOfTimeDepositsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_fecb6de3-c3ef-471c-b08e-ac4d6d991fa3" xlink:to="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_31cc9b92-3f31-449b-9d7e-cbd92db358f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_31d6e02f-590f-4828-9578-a329a3de78e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_31cc9b92-3f31-449b-9d7e-cbd92db358f3" xlink:to="loc_us-gaap_NetIncomeLossAbstract_31d6e02f-590f-4828-9578-a329a3de78e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_50c24eca-f8d8-4ca2-9514-30cebc09332d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_31d6e02f-590f-4828-9578-a329a3de78e4" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_50c24eca-f8d8-4ca2-9514-30cebc09332d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_135df2a0-6661-4351-8c3e-799a959a9d91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_50c24eca-f8d8-4ca2-9514-30cebc09332d" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_135df2a0-6661-4351-8c3e-799a959a9d91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_d9f9f744-8545-4d1e-be6c-052a07faf5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_31d6e02f-590f-4828-9578-a329a3de78e4" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_d9f9f744-8545-4d1e-be6c-052a07faf5b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3965f220-4a0b-45bd-a6f4-930423b357d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_84c9fe54-054a-41b9-b462-cf22ae74591b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_d9f9f744-8545-4d1e-be6c-052a07faf5b4" xlink:to="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_84c9fe54-054a-41b9-b462-cf22ae74591b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_a64ed2ac-7547-4e1b-983c-a6571b5cd4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_d9f9f744-8545-4d1e-be6c-052a07faf5b4" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_a64ed2ac-7547-4e1b-983c-a6571b5cd4a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_82c7247e-7cbc-48e7-8c4c-5df2a989b71b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_d9f9f744-8545-4d1e-be6c-052a07faf5b4" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_82c7247e-7cbc-48e7-8c4c-5df2a989b71b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4c3aa752-0d96-4c96-865f-9a918518f506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_31cc9b92-3f31-449b-9d7e-cbd92db358f3" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4c3aa752-0d96-4c96-865f-9a918518f506" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_18e53717-2386-485e-9244-85c02379e0df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4c3aa752-0d96-4c96-865f-9a918518f506" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_18e53717-2386-485e-9244-85c02379e0df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28aea69b-e89f-4335-951f-01186a102533" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_18e53717-2386-485e-9244-85c02379e0df" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28aea69b-e89f-4335-951f-01186a102533" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f2db238f-3169-41d1-8e02-95337c6bea53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_18e53717-2386-485e-9244-85c02379e0df" xlink:to="loc_us-gaap_EarningsPerShareBasic_f2db238f-3169-41d1-8e02-95337c6bea53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_21f30f60-aeee-424c-ac74-4825ebf375b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4c3aa752-0d96-4c96-865f-9a918518f506" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_21f30f60-aeee-424c-ac74-4825ebf375b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d9bca92e-b01c-4b06-9e10-5c43f36aac86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_79196abb-6c91-4f48-89fc-cf2dd81a476d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_21f30f60-aeee-424c-ac74-4825ebf375b0" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_79196abb-6c91-4f48-89fc-cf2dd81a476d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d0d5b7f9-6688-4710-bee4-a2357ae21a11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_21f30f60-aeee-424c-ac74-4825ebf375b0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d0d5b7f9-6688-4710-bee4-a2357ae21a11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e1ab9d54-dd02-4e0a-b77a-e846ea69eb49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_21f30f60-aeee-424c-ac74-4825ebf375b0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e1ab9d54-dd02-4e0a-b77a-e846ea69eb49" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cbe488ce-3471-4968-a3ca-b06527b2e158" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e9e113a4-c17c-43db-a5b4-eac71314cbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cbe488ce-3471-4968-a3ca-b06527b2e158" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e9e113a4-c17c-43db-a5b4-eac71314cbd5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_45f36d09-d672-4b07-a1d2-9f708361c37b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e9e113a4-c17c-43db-a5b4-eac71314cbd5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_45f36d09-d672-4b07-a1d2-9f708361c37b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45f36d09-d672-4b07-a1d2-9f708361c37b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_45f36d09-d672-4b07-a1d2-9f708361c37b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45f36d09-d672-4b07-a1d2-9f708361c37b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_142b104c-24e1-47b1-a815-22d9429de16b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_45f36d09-d672-4b07-a1d2-9f708361c37b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_142b104c-24e1-47b1-a815-22d9429de16b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_278c43e0-d9a0-4c79-8622-98fe7c586f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_142b104c-24e1-47b1-a815-22d9429de16b" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_278c43e0-d9a0-4c79-8622-98fe7c586f3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_968b08e6-569c-4aa2-85eb-12dfcf49cf14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_142b104c-24e1-47b1-a815-22d9429de16b" xlink:to="loc_us-gaap_StockCompensationPlanMember_968b08e6-569c-4aa2-85eb-12dfcf49cf14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8296c722-3bc4-4a3d-a6ee-e03c107a0ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cbe488ce-3471-4968-a3ca-b06527b2e158" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8296c722-3bc4-4a3d-a6ee-e03c107a0ee5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7255cdb4-71ec-4794-97c3-12fbf7cda34a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8740cb6-b3f3-4f49-befe-546964c5776b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7255cdb4-71ec-4794-97c3-12fbf7cda34a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8740cb6-b3f3-4f49-befe-546964c5776b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9fb38cb2-25d7-4e22-97c3-779bf3fdb1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8740cb6-b3f3-4f49-befe-546964c5776b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9fb38cb2-25d7-4e22-97c3-779bf3fdb1ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9fb38cb2-25d7-4e22-97c3-779bf3fdb1ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9fb38cb2-25d7-4e22-97c3-779bf3fdb1ec" xlink:to="loc_us-gaap_SegmentDomain_9fb38cb2-25d7-4e22-97c3-779bf3fdb1ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_aaabd6a7-b3cd-481c-b3be-f8a512578f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9fb38cb2-25d7-4e22-97c3-779bf3fdb1ec" xlink:to="loc_us-gaap_SegmentDomain_aaabd6a7-b3cd-481c-b3be-f8a512578f7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ReportableSegmentMember_58761a78-5baa-4a52-9966-3ca4ddc69853" xlink:href="pacb-20241231.xsd#pacb_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_aaabd6a7-b3cd-481c-b3be-f8a512578f7a" xlink:to="loc_pacb_ReportableSegmentMember_58761a78-5baa-4a52-9966-3ca4ddc69853" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_47d2ff6b-edde-46fd-8703-861179179ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7255cdb4-71ec-4794-97c3-12fbf7cda34a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_47d2ff6b-edde-46fd-8703-861179179ba6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7255cdb4-71ec-4794-97c3-12fbf7cda34a" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_77dd2a1e-a531-4ff4-9bc9-34b7dfa3af96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_CostOfRevenue_77dd2a1e-a531-4ff4-9bc9-34b7dfa3af96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3b166a82-fa62-472c-909e-3f1f4af69be4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3b166a82-fa62-472c-909e-3f1f4af69be4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_0da537e8-7356-4141-8e92-f28018929534" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_SellingAndMarketingExpense_0da537e8-7356-4141-8e92-f28018929534" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_dff8a682-9988-4865-a763-d39975494a83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_dff8a682-9988-4865-a763-d39975494a83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_6e3952b3-f750-401b-ac02-653bf0ec2c35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_6e3952b3-f750-401b-ac02-653bf0ec2c35" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_6430e09d-a5d9-48d4-a8c8-d9745421207c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_6430e09d-a5d9-48d4-a8c8-d9745421207c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_37185622-ed52-4d75-9a65-b8d4964eb52c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_37185622-ed52-4d75-9a65-b8d4964eb52c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f0f3671a-f948-4c33-917e-67b932dee7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f0f3671a-f948-4c33-917e-67b932dee7bb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b09422a3-bf99-42a5-8a2b-7468ee4d54ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b09422a3-bf99-42a5-8a2b-7468ee4d54ec" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_4f6df34f-6f64-49c2-b51d-a9baecbcfcd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_4f6df34f-6f64-49c2-b51d-a9baecbcfcd5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4e28681c-dfe7-4e6d-8943-b391df068082" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7255cdb4-71ec-4794-97c3-12fbf7cda34a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4e28681c-dfe7-4e6d-8943-b391df068082" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8e8d3da4-9ef5-4156-a85b-277eab1dd0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7255cdb4-71ec-4794-97c3-12fbf7cda34a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8e8d3da4-9ef5-4156-a85b-277eab1dd0b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a4d49ff1-f801-404d-9396-7e53a2708879" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7255cdb4-71ec-4794-97c3-12fbf7cda34a" xlink:to="loc_us-gaap_NetIncomeLoss_a4d49ff1-f801-404d-9396-7e53a2708879" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0c727c04-24b0-4efd-a45c-888afa607868" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_aec59ea6-2db5-48da-a7fc-6c769e56628b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0c727c04-24b0-4efd-a45c-888afa607868" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_aec59ea6-2db5-48da-a7fc-6c769e56628b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dd7ffa3a-a75c-48e9-ba85-15f1803785dd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_aec59ea6-2db5-48da-a7fc-6c769e56628b" xlink:to="loc_srt_StatementGeographicalAxis_dd7ffa3a-a75c-48e9-ba85-15f1803785dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dd7ffa3a-a75c-48e9-ba85-15f1803785dd_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_dd7ffa3a-a75c-48e9-ba85-15f1803785dd" xlink:to="loc_srt_SegmentGeographicalDomain_dd7ffa3a-a75c-48e9-ba85-15f1803785dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f6c32c79-9bc5-409f-923b-1d5317c22dc3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_dd7ffa3a-a75c-48e9-ba85-15f1803785dd" xlink:to="loc_srt_SegmentGeographicalDomain_f6c32c79-9bc5-409f-923b-1d5317c22dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember_c2d4c00e-b082-4464-a268-e750217edde2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AmericasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f6c32c79-9bc5-409f-923b-1d5317c22dc3" xlink:to="loc_srt_AmericasMember_c2d4c00e-b082-4464-a268-e750217edde2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_f4c4abb2-f991-42b4-9c17-e3552cfefbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f6c32c79-9bc5-409f-923b-1d5317c22dc3" xlink:to="loc_us-gaap_EMEAMember_f4c4abb2-f991-42b4-9c17-e3552cfefbc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_b85adb4a-dc89-4ffa-90b4-1dc4a4a1de70" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f6c32c79-9bc5-409f-923b-1d5317c22dc3" xlink:to="loc_srt_AsiaPacificMember_b85adb4a-dc89-4ffa-90b4-1dc4a4a1de70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_72cf957f-b804-48fd-a4d4-ebc409cbf49a" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f6c32c79-9bc5-409f-923b-1d5317c22dc3" xlink:to="loc_country_US_72cf957f-b804-48fd-a4d4-ebc409cbf49a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c8ad4f61-86c1-44a7-b172-3dbe457150b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0c727c04-24b0-4efd-a45c-888afa607868" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c8ad4f61-86c1-44a7-b172-3dbe457150b7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f9c48fca-3e74-49c3-a71a-44980e0b8dae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4affe986-90d6-42d0-9535-b99ad29763fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f9c48fca-3e74-49c3-a71a-44980e0b8dae" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4affe986-90d6-42d0-9535-b99ad29763fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bea23cc8-7ec3-48c9-af36-4fe9896f533f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4affe986-90d6-42d0-9535-b99ad29763fb" xlink:to="loc_srt_ProductOrServiceAxis_bea23cc8-7ec3-48c9-af36-4fe9896f533f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bea23cc8-7ec3-48c9-af36-4fe9896f533f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bea23cc8-7ec3-48c9-af36-4fe9896f533f" xlink:to="loc_srt_ProductsAndServicesDomain_bea23cc8-7ec3-48c9-af36-4fe9896f533f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_02ba0bf8-41b7-43a9-9694-c8a1c3148d2a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bea23cc8-7ec3-48c9-af36-4fe9896f533f" xlink:to="loc_srt_ProductsAndServicesDomain_02ba0bf8-41b7-43a9-9694-c8a1c3148d2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d0ecda9c-dd82-44d1-96fe-505ffb43ecca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_02ba0bf8-41b7-43a9-9694-c8a1c3148d2a" xlink:to="loc_us-gaap_ProductMember_d0ecda9c-dd82-44d1-96fe-505ffb43ecca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InstrumentMember_c5c5db01-2d90-4282-933b-2387c987fe90" xlink:href="pacb-20241231.xsd#pacb_InstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_d0ecda9c-dd82-44d1-96fe-505ffb43ecca" xlink:to="loc_pacb_InstrumentMember_c5c5db01-2d90-4282-933b-2387c987fe90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConsumableMember_13d235ae-ca33-4cca-a6fa-528dbc1a87e3" xlink:href="pacb-20241231.xsd#pacb_ConsumableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_d0ecda9c-dd82-44d1-96fe-505ffb43ecca" xlink:to="loc_pacb_ConsumableMember_13d235ae-ca33-4cca-a6fa-528dbc1a87e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_255405a6-9a56-427c-b781-c8cc1083dc30" xlink:href="pacb-20241231.xsd#pacb_ServiceAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_02ba0bf8-41b7-43a9-9694-c8a1c3148d2a" xlink:to="loc_pacb_ServiceAndOtherMember_255405a6-9a56-427c-b781-c8cc1083dc30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0c16ef7d-0779-4f53-a9d2-e2c5debb1954" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f9c48fca-3e74-49c3-a71a-44980e0b8dae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0c16ef7d-0779-4f53-a9d2-e2c5debb1954" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_62fc034b-16a3-4c2c-b542-0dfc8b4f069f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_063c0b9b-bb90-4036-a6d1-06cfb19556d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_62fc034b-16a3-4c2c-b542-0dfc8b4f069f" xlink:to="loc_us-gaap_SubsequentEventTable_063c0b9b-bb90-4036-a6d1-06cfb19556d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4d65a0be-91c7-4770-90d6-e59396a2490b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_063c0b9b-bb90-4036-a6d1-06cfb19556d3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4d65a0be-91c7-4770-90d6-e59396a2490b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4d65a0be-91c7-4770-90d6-e59396a2490b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4d65a0be-91c7-4770-90d6-e59396a2490b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4d65a0be-91c7-4770-90d6-e59396a2490b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7130a8dc-a2dd-4b60-ad73-79cde21953da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4d65a0be-91c7-4770-90d6-e59396a2490b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7130a8dc-a2dd-4b60-ad73-79cde21953da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7e504c23-dfab-4b49-bb7b-aec111822798" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7130a8dc-a2dd-4b60-ad73-79cde21953da" xlink:to="loc_us-gaap_SubsequentEventMember_7e504c23-dfab-4b49-bb7b-aec111822798" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OperatingLeaseExpectedBaseRentExpense_563198e5-2406-48ef-b916-f2c2ebae8596" xlink:href="pacb-20241231.xsd#pacb_OperatingLeaseExpectedBaseRentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_62fc034b-16a3-4c2c-b542-0dfc8b4f069f" xlink:to="loc_pacb_OperatingLeaseExpectedBaseRentExpense_563198e5-2406-48ef-b916-f2c2ebae8596" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount_5ba7942f-6721-4fda-85c6-07a63ed37d80" xlink:href="pacb-20241231.xsd#pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_62fc034b-16a3-4c2c-b542-0dfc8b4f069f" xlink:to="loc_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount_5ba7942f-6721-4fda-85c6-07a63ed37d80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_eac11e97-1b40-4f45-8acb-bbe6f49d180e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_62fc034b-16a3-4c2c-b542-0dfc8b4f069f" xlink:to="loc_us-gaap_TenantImprovements_eac11e97-1b40-4f45-8acb-bbe6f49d180e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_ffe94d24-7ef3-41ba-899a-3994ed3df373" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_62fc034b-16a3-4c2c-b542-0dfc8b4f069f" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_ffe94d24-7ef3-41ba-899a-3994ed3df373" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="691"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>pacb-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b8324ceb-4367-4432-9725-ed1f11bffb27,g:1109ce80-1fe4-4ba2-bf4d-c0b012b2f3c3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_70b27487-9b01-4deb-8232-6c7ddf8b9adb_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government &amp; agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a6e7f11d-032e-4167-aa03-fc4cb01d2d50_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember_0466f884-599a-4bc1-b169-b38aa536013e_terseLabel_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember_label_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Based Restricted Stock Units Rsus [Member]</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember_documentation_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time-Based Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:href="pacb-20241231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:to="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b2a001ee-b207-4671-a85a-3edebc365449_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashMergerRelatedCosts_184efbf4-d944-44b3-9d6d-6b17f39912d9_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashMergerRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger-related compensation expense</link:label>
    <link:label id="lab_us-gaap_NoncashMergerRelatedCosts_label_en-US" xlink:label="lab_us-gaap_NoncashMergerRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Merger Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashMergerRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashMergerRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashMergerRelatedCosts" xlink:to="lab_us-gaap_NoncashMergerRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_afb1afcb-2156-47dc-8a55-7d3ab2cfe2ab_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_fc88f7c0-5874-4ec3-8ed8-ef187e5a2ba9_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_266f0674-f967-451a-a6f0-475e82136cc6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_f41b24ab-cd6b-4b2e-a088-c77da03e0ff5_terseLabel_en-US" xlink:label="lab_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Employee Stock Purchase Plan</link:label>
    <link:label id="lab_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_label_en-US" xlink:label="lab_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Stock Purchase Plan Liability, Current</link:label>
    <link:label id="lab_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_documentation_en-US" xlink:label="lab_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Employee Stock Purchase Plan Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" xlink:href="pacb-20241231.xsd#pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" xlink:to="lab_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7798a8c2-e619-4400-9a3c-28aa44bc48ea_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_e03de8be-d887-4f09-b39d-f8336d714e40_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_319bf361-c5a9-4ffb-8531-91276b499093_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Indefinite-Lived [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Indefinite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_f9e2d7d7-6820-4514-9bca-933ca6e3cfe6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0db092b9-7681-48e4-89cb-546124d10812_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_76bb3308-1819-4046-aa26-afa5bfb7002a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, dividends declared (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember_bdf3cb90-2d14-4698-aa81-1df87e27b450_terseLabel_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time Based Restricted Stock Units PSU</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember_label_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Based Restricted Stock Units PSU [Member]</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember_documentation_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time Based Restricted Stock Units PSU</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:href="pacb-20241231.xsd#pacb_TimeBasedRestrictedStockUnitsPSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:to="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_b0727de3-e2fe-43bf-a19e-a3e2e9bf50af_terseLabel_en-US" xlink:label="lab_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in basis point discount rate</link:label>
    <link:label id="lab_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_label_en-US" xlink:label="lab_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill Impairment, Increase In Basis Point Discount Rate</link:label>
    <link:label id="lab_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_documentation_en-US" xlink:label="lab_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill Impairment, Increase In Basis Point Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate" xlink:href="pacb-20241231.xsd#pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate" xlink:to="lab_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition_0b781b63-43dc-445c-92d4-28ed70ad305f_terseLabel_en-US" xlink:label="lab_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probability of benefit realized upon settlement uncertain tax position</link:label>
    <link:label id="lab_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition_label_en-US" xlink:label="lab_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Probability Of Benefit Realized Upon Settlement Uncertain Tax Position</link:label>
    <link:label id="lab_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition_documentation_en-US" xlink:label="lab_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Probability of benefit Realized Upon Settlement Uncertain Tax Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" xlink:href="pacb-20241231.xsd#pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" xlink:to="lab_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_e98e7e42-a1e9-4e6d-944e-aff726d7eea3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ScheduleOfInterestExpenseTableTextBlock_b0af7246-9d66-4402-8f90-fa4b4c1c6733_terseLabel_en-US" xlink:label="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Interest Expense</link:label>
    <link:label id="lab_pacb_ScheduleOfInterestExpenseTableTextBlock_label_en-US" xlink:label="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Interest Expense [Table Text Block]</link:label>
    <link:label id="lab_pacb_ScheduleOfInterestExpenseTableTextBlock_documentation_en-US" xlink:label="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Interest Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:href="pacb-20241231.xsd#pacb_ScheduleOfInterestExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:to="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_3ef6ded5-78fc-4710-9845-97a3fa34e179_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b061b971-c07a-452c-8e82-130048f409ee_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_583cbcb9-91fa-4dac-b1e9-6acf8fe10ef2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_9de8ac04-28a0-48c1-ab7b-92f756ace377_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ExchangeTransactionMember_65a7a7f7-5084-41c6-acaa-6cf9eba274c9_terseLabel_en-US" xlink:label="lab_pacb_ExchangeTransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange Transaction</link:label>
    <link:label id="lab_pacb_ExchangeTransactionMember_label_en-US" xlink:label="lab_pacb_ExchangeTransactionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange Transaction [Member]</link:label>
    <link:label id="lab_pacb_ExchangeTransactionMember_documentation_en-US" xlink:label="lab_pacb_ExchangeTransactionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exchange Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ExchangeTransactionMember" xlink:href="pacb-20241231.xsd#pacb_ExchangeTransactionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ExchangeTransactionMember" xlink:to="lab_pacb_ExchangeTransactionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_30ef6e67-7168-4df3-9706-18df2f1e441c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_77c84622-08d4-4908-988b-43568162ac12_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_da948b3f-8de8-459a-8294-03a55ace117c_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_0d6a6f66-3f15-40ac-adde-bd11cfdc1bf2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AccruedTenantImprovementsCurrent_05854953-8f98-4b69-af24-d3c125d31a10_terseLabel_en-US" xlink:label="lab_pacb_AccruedTenantImprovementsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest payable</link:label>
    <link:label id="lab_pacb_AccruedTenantImprovementsCurrent_label_en-US" xlink:label="lab_pacb_AccruedTenantImprovementsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Tenant Improvements, Current</link:label>
    <link:label id="lab_pacb_AccruedTenantImprovementsCurrent_documentation_en-US" xlink:label="lab_pacb_AccruedTenantImprovementsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Tenant Improvements, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedTenantImprovementsCurrent" xlink:href="pacb-20241231.xsd#pacb_AccruedTenantImprovementsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AccruedTenantImprovementsCurrent" xlink:to="lab_pacb_AccruedTenantImprovementsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_e1bd7957-356b-4c86-bb9c-c0709b364cd3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_7de30894-df00-4fd8-9553-e1d1f3dc44d4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone_35cc5232-cedc-4574-a641-27cd685c6c51_terseLabel_en-US" xlink:label="lab_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone revenue</link:label>
    <link:label id="lab_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone_label_en-US" xlink:label="lab_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Contingent Consideration, Revenue Achievement Milestone</link:label>
    <link:label id="lab_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone_documentation_en-US" xlink:label="lab_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Contingent Consideration, Revenue Achievement Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone" xlink:href="pacb-20241231.xsd#pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone" xlink:to="lab_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5067d8ff-8b4b-4841-b493-1a54937e1e01_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_37b4bb37-d0dc-4b1f-91bd-b625253ded56_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_45e8003b-a080-46aa-ae44-a9cb3214d8fc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_0124e80d-25b7-4aaa-99c1-37ef7fe6246b_terseLabel_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment, discounted cash flow model, term (in years)</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_label_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Discounted Cash Flow Model, Term</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_documentation_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Discounted Cash Flow Model, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:href="pacb-20241231.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:to="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0829f9c7-cb67-4c91-9e99-3b20df80b957_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_ed9a3653-afb8-467a-a57a-4cd185440a94_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_15fcb9e4-dc59-47d2-adc9-baac4ec55e2c_terseLabel_en-US" xlink:label="lab_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional goodwill impairment</link:label>
    <link:label id="lab_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_label_en-US" xlink:label="lab_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Goodwill Impairment, Change In Discount Rate</link:label>
    <link:label id="lab_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_documentation_en-US" xlink:label="lab_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Goodwill Impairment, Change In Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate" xlink:href="pacb-20241231.xsd#pacb_AdditionalGoodwillImpairmentChangeInDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate" xlink:to="lab_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_102229ff-73ea-4ca6-b13f-5f2d3467ab6c_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_24c55cc1-f31b-4679-b76a-7cf891f50be0_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_51357acf-dd32-41d6-941f-a3b65e3953e2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_28a17846-e7b4-4c2a-a38c-795f2431d541_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_2bcbceea-5a56-45a5-954a-a7a0e3e14d37_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock_73c48825-5828-4996-aa3a-28589caab990_terseLabel_en-US" xlink:label="lab_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock_label_en-US" xlink:label="lab_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Standards [Policy Text Block]</link:label>
    <link:label id="lab_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock_documentation_en-US" xlink:label="lab_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" xlink:href="pacb-20241231.xsd#pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" xlink:to="lab_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_8700f448-c723-465f-be0d-649186a29e89_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_04858ffa-026a-4bf2-9eca-5c126fe4ad9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d3b8b58-0e1a-4611-9668-bbc99a18b0a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0ccb5752-16b4-4542-9050-c5aa7be5ded3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_74f2f0d7-ad24-4063-827f-dfb4b69287d8_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6d5a0496-4931-48e4-b448-30d41c7ddada_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from the computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_NumberOfPurchasePeriods_d482a46f-966d-4064-b233-00e764dff378_terseLabel_en-US" xlink:label="lab_pacb_NumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of purchase periods</link:label>
    <link:label id="lab_pacb_NumberOfPurchasePeriods_label_en-US" xlink:label="lab_pacb_NumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Purchase Periods</link:label>
    <link:label id="lab_pacb_NumberOfPurchasePeriods_documentation_en-US" xlink:label="lab_pacb_NumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of purchase periods.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_NumberOfPurchasePeriods" xlink:href="pacb-20241231.xsd#pacb_NumberOfPurchasePeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_NumberOfPurchasePeriods" xlink:to="lab_pacb_NumberOfPurchasePeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_bb02ab01-f7d4-4224-a4b0-765c5cc701ec_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_2e8a891a-8d24-411d-843c-3514fc68c668_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance as of December&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_Goodwill_f6ddb4c0-0f78-4456-a534-e6272e127c00_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance as of December&#160;31, 2024</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualPayments_3cbf9bdd-29f2-473b-ab0f-a59da97e6eff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repairs and replacements</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Decrease for Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualPayments" xlink:to="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OmniomeMember_9087970e-9447-47a0-ad5e-6d12265f5cb3_terseLabel_en-US" xlink:label="lab_pacb_OmniomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Omniome</link:label>
    <link:label id="lab_pacb_OmniomeMember_label_en-US" xlink:label="lab_pacb_OmniomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Omniome [Member]</link:label>
    <link:label id="lab_pacb_OmniomeMember_documentation_en-US" xlink:label="lab_pacb_OmniomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Omniome</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeMember" xlink:href="pacb-20241231.xsd#pacb_OmniomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OmniomeMember" xlink:to="lab_pacb_OmniomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_90aa5fcd-adba-457e-953b-c14e73b4f027_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_fc6b87f5-a46c-4207-9675-3396f3be4d81_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_d53deb1e-564a-4e93-9b87-ed54338ca352_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b80a21da-7b8e-4607-9050-6b831f375fa8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76f3e02f-eb53-4780-9243-afd8bb063a4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_e849097f-c446-499e-95a9-93fc14aa8686_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2b579120-d809-4b2d-ab8f-54307d10fada_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_5037e81c-3ac0-47fa-a2b4-5fca57146a76_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_86eb111c-e785-49e1-97ef-09db0a673709_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_bea6ec12-2940-460a-8e06-d4618a539c0a_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_fdac3707-cc14-4e5c-a0a4-ce44781e7758_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_f90a9f6a-b280-48fb-b467-e6a9eee49d38_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_e1d20906-67c8-4ef4-a7d6-054d8b969b1d_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory, gross</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_907f83a8-50ef-401e-aa60-6de45da5fc2e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0760609f-e3d4-4b4c-bd93-7c2b48997200_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_aac96a63-a59d-41f7-a3c2-a207d6d9d7b2_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_6abffa60-d85d-418a-a87a-ef2b37b1e5a0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_928c313c-6cd8-4b0a-af6e-6da0635a2dc7_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_4c1eb396-cbdd-45a1-a718-bae61ac842af_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb9e38e4-550a-4fe9-b1ee-fb09d7f87572_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_58128308-1ba9-4bb4-9637-a7b07c3631b7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Functional Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f6f60a46-e0ef-4787-9769-b383a6a9eb0a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9fc72b60-319b-42bb-864d-0249da59d232_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_d0cc5129-e5ba-4214-bbe1-94a6d023d60b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_742adcce-6ef4-4980-8979-8129d0adb203_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_5683cc3f-b27b-4f16-9aa4-fe83a833efd0_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_6effbdd7-68fa-4539-abd8-b4c594d83664_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_0088066b-117a-467b-91de-061f0b551b29_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock purchased under plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Ownership Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_58f8fe45-efd1-4171-ab60-c11fee4e6303_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e8e506b-c955-4050-b95a-86ed93ac70bd_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_27832ddc-6699-440f-86d9-81ff3ccf00f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0a77eb7c-8ad3-4bbf-bed2-2cec61935611_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0d6e08dc-3c57-4f35-9abc-9c9b262a2ed2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_425af8f1-8c77-4514-9413-836a0b49f71b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets with Indefinite Lives</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_81fdfc2d-34db-42a3-b7dd-7c9973e4aeb4_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_61e17594-85a5-43b8-b2d1-2b0141c91a96_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_677648fe-d6a9-41d4-9a92-3ca22b7bdc2d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_90e5dc14-b351-4963-9d2a-55df548decc2_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in computing diluted net (loss) income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ReportableSegmentMember_2f266b68-0cfb-416b-96a9-1c182111bcce_terseLabel_en-US" xlink:label="lab_pacb_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_pacb_ReportableSegmentMember_label_en-US" xlink:label="lab_pacb_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_pacb_ReportableSegmentMember_documentation_en-US" xlink:label="lab_pacb_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ReportableSegmentMember" xlink:href="pacb-20241231.xsd#pacb_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ReportableSegmentMember" xlink:to="lab_pacb_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_FinancialInstrumentsTable_3561d54f-5b91-4ca1-9779-c04825c2784d_terseLabel_en-US" xlink:label="lab_pacb_FinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Table]</link:label>
    <link:label id="lab_pacb_FinancialInstrumentsTable_label_en-US" xlink:label="lab_pacb_FinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Table]</link:label>
    <link:label id="lab_pacb_FinancialInstrumentsTable_documentation_en-US" xlink:label="lab_pacb_FinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsTable" xlink:href="pacb-20241231.xsd#pacb_FinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_FinancialInstrumentsTable" xlink:to="lab_pacb_FinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_cadb40df-8f7c-474b-8a98-4c0952028463_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_2c556437-73ae-4194-9600-414a605561c6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ab7b5394-84c5-4ab5-9b6b-420f8e1e5b07_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2f1d46c0-b017-4cc3-b53f-e1491ba30c5a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_73329d00-242d-4152-8f4c-e52f6d75c420_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_b607d403-dd4a-4a7d-8d40-68ef570f0725_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_42d7cc80-2bce-4058-b48e-b7ddcac829d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0fbd1b66-1af5-4fc2-87fc-8a5b7c68cce8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_f5ef0a7b-0946-4875-abd1-c6c02f0b26b5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_ee8c2a54-7f7b-41a5-b4e2-0358c643ac7f_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on debt restructuring</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_301de478-2ef6-4cff-bbce-236614e418a4_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on debt restructuring</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_b7702f54-a840-412c-9e1e-3a2866f186d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Gain on debt restructuring (2029 Notes)</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_ed10439d-877f-4e2e-a6ba-2e39b72a6faf_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_1f97b559-c57c-48bb-a688-10b9ad5abf6a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Rate of Time Deposits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageRateOfTimeDepositsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:to="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_7867ef7d-991a-4937-a844-1d5948e42d4f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_6eea1a61-5fc7-4e0e-b0ec-b33d0db50f61_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_NoteExchangeMember_069c79a8-e359-4217-9a19-aba80f24b5d2_terseLabel_en-US" xlink:label="lab_pacb_NoteExchangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note Exchange</link:label>
    <link:label id="lab_pacb_NoteExchangeMember_label_en-US" xlink:label="lab_pacb_NoteExchangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note Exchange [Member]</link:label>
    <link:label id="lab_pacb_NoteExchangeMember_documentation_en-US" xlink:label="lab_pacb_NoteExchangeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Note Exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_NoteExchangeMember" xlink:href="pacb-20241231.xsd#pacb_NoteExchangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_NoteExchangeMember" xlink:to="lab_pacb_NoteExchangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_003099f9-826b-4c1e-960b-9ae2f7de094e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_c8f92064-408a-4a2b-b981-8a460c883686_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5e6a6ecc-5943-4c77-9189-ad52c152339d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_1aea6396-228a-4bfd-be55-e159408ccf02_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in conjunction with convertible notes exchange</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b1bf38a0-44c8-4037-83f7-0e41c0a2ba74_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger-related expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_824afc1b-e1ce-4211-b22c-3bc7f46b9574_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issuable upon conversion of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ffbc5255-347a-4b23-aef6-32874d4752ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1eecf606-defb-48f5-99c9-8ec5943cdd7d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AptonAndOmniomeMember_e10d2265-5438-4794-b74b-e87608637dbb_terseLabel_en-US" xlink:label="lab_pacb_AptonAndOmniomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Apton And Omniome</link:label>
    <link:label id="lab_pacb_AptonAndOmniomeMember_label_en-US" xlink:label="lab_pacb_AptonAndOmniomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Apton And Omniome [Member]</link:label>
    <link:label id="lab_pacb_AptonAndOmniomeMember_documentation_en-US" xlink:label="lab_pacb_AptonAndOmniomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Apton And Omniome</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonAndOmniomeMember" xlink:href="pacb-20241231.xsd#pacb_AptonAndOmniomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AptonAndOmniomeMember" xlink:to="lab_pacb_AptonAndOmniomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_03e48c1e-2233-4d9f-aab6-ce4f0b711bd7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_55daa661-cfab-4eec-9d21-46a34744af4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_EmployeeSeparationCostsMember_d51af475-a68e-400c-8f0a-f28760eefb58_terseLabel_en-US" xlink:label="lab_pacb_EmployeeSeparationCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee separation costs</link:label>
    <link:label id="lab_pacb_EmployeeSeparationCostsMember_label_en-US" xlink:label="lab_pacb_EmployeeSeparationCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Separation Costs [Member]</link:label>
    <link:label id="lab_pacb_EmployeeSeparationCostsMember_documentation_en-US" xlink:label="lab_pacb_EmployeeSeparationCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Separation Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeSeparationCostsMember" xlink:href="pacb-20241231.xsd#pacb_EmployeeSeparationCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_EmployeeSeparationCostsMember" xlink:to="lab_pacb_EmployeeSeparationCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BalanceSheetComponentsLineItems_8b07af49-eb79-4df1-8de8-e9aa869b9997_terseLabel_en-US" xlink:label="lab_pacb_BalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Components [Line Items]</link:label>
    <link:label id="lab_pacb_BalanceSheetComponentsLineItems_label_en-US" xlink:label="lab_pacb_BalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Components [Line Items]</link:label>
    <link:label id="lab_pacb_BalanceSheetComponentsLineItems_documentation_en-US" xlink:label="lab_pacb_BalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Balance Sheet Components [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BalanceSheetComponentsLineItems" xlink:href="pacb-20241231.xsd#pacb_BalanceSheetComponentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BalanceSheetComponentsLineItems" xlink:to="lab_pacb_BalanceSheetComponentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7d8636a9-2499-41f2-ba4f-e74bb9993795_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_aed3ac59-13f9-4ba0-9922-f66ef3f0580d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_6008e867-b707-4117-856d-f7802b81df76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Profit or Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_3a66076f-ec5d-4278-bd3f-0d0dfbcfe5a7_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_eb228b03-b4eb-4060-86d4-541baee25711_verboseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_273ff648-b2bd-480c-8409-7754ad8531af_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0c2fe802-b046-490c-8927-617405b7224d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_09b1603d-c631-4018-bf3e-e49394581d0d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liability, non-current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_152e4c11-9e46-4945-9e26-8722cc4e839a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Finite Lives</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_6b8b27e3-50ba-4a6b-9e87-700cfacfe9db_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6249cb00-7f4e-4122-a20f-4ace10c53e9a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock_8219171d-d223-448f-80b3-87bb9d425b93_terseLabel_en-US" xlink:label="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases</link:label>
    <link:label id="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock_label_en-US" xlink:label="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Description [Table Text Block]</link:label>
    <link:label id="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock_documentation_en-US" xlink:label="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Description [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:href="pacb-20241231.xsd#pacb_LesseeOperatingLeaseDescriptionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:to="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems_5b48cc8a-8ffd-4d76-be3f-a320a8733e3d_terseLabel_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="pacb-20241231.xsd#pacb_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_5cfb4cd0-60b9-4df1-99bc-9c3025ec1a55_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_bd2a2de1-07ad-4fcd-ba3e-407ce9ce64de_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6b30216c-6b86-48b8-8ac8-182d8333426f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1247c92d-3cad-4e0b-a572-dea3b4c145cb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_432af8a2-54cd-4f40-aaec-a6022ec483c3_terseLabel_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment, discounted cash flow model, discount rate</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_label_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Discounted Cash Flow Model, Discount Rate</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_documentation_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Discounted Cash Flow Model, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:href="pacb-20241231.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:to="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5e252167-5e2c-4abd-83f2-2dd3dc3efd50_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options expired, weighted average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_320f87a5-c926-41a4-8901-dd2a06dc030f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_11d37187-fb3e-4bfa-b2d7-3875b3ab3f15_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_bda1ee5e-8dcc-4f9a-891c-325b1f82a3ad_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5afb7ea1-d9d2-4ae5-b683-92f08563b1e4_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_98994dca-c8b2-4d16-8414-1987c75c89b8_terseLabel_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment, increase in term (in years)</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_label_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Increase In Obsolescence Factor, Term</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_documentation_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Increase In Obsolescence Factor, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:href="pacb-20241231.xsd#pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:to="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_013e84db-ed6a-4650-a8d0-23fa0977140a_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_d7bf1152-bb48-403c-bfda-d874713c0e98_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_b4d50e60-d117-4331-9d69-4cdccffffa8d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b48dd159-5b09-42e6-b087-0916c467f1dc_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_71e2aabe-f961-4a51-bec3-527d975edc9e_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_03342c0e-f9b7-4c9e-b475-d17436847a45_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger-related expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_1c7a6895-03d2-4035-982c-e094430f6975_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Axis]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_label_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Axis]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:to="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_5b82f9b1-8108-4253-951d-49b86b6c9bb5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_5e593288-1de0-40dc-a2af-c2bee9921458_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_2c28a93b-b939-45a9-bc9d-5d7b8531c487_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_89d01c67-881a-4898-b25a-edeec41b4e1a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_af4d5036-5f13-4fcb-8cdd-8bb1b4301bdb_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted net (loss) income per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0351e4ea-ca68-4dfc-9c90-b8296a9ad8e4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Loss) income before taxes from U.S. operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_3eec3fd2-b7a3-4c9a-8cbe-fa35d19eb0cf_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CashCashEquivalentsAndInvestmentsMember_5617f274-a0df-4535-8d94-1b43f381dec0_terseLabel_en-US" xlink:label="lab_pacb_CashCashEquivalentsAndInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents, and investments</link:label>
    <link:label id="lab_pacb_CashCashEquivalentsAndInvestmentsMember_label_en-US" xlink:label="lab_pacb_CashCashEquivalentsAndInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Cash Equivalents And Investments [Member]</link:label>
    <link:label id="lab_pacb_CashCashEquivalentsAndInvestmentsMember_documentation_en-US" xlink:label="lab_pacb_CashCashEquivalentsAndInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CashCashEquivalentsAndInvestmentsMember" xlink:href="pacb-20241231.xsd#pacb_CashCashEquivalentsAndInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CashCashEquivalentsAndInvestmentsMember" xlink:to="lab_pacb_CashCashEquivalentsAndInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f1cee6d4-8c78-41bc-8b3f-9cee8cf1daee_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_095dda66-511d-46b9-ac65-12d898cbc98d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_d718383f-b76b-4a27-a03c-2c8c72d988f0_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Other Finite-Lived Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_693fc683-fe74-40dc-a3a9-31158c51af42_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_3ddc21f3-26c4-456c-a49f-7dfb4f4ed112_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_667b9451-1ef0-4168-a435-fdb1062004a4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_6a202c5b-cb52-440f-887c-d5540e27f361_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warranty accrual</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_f34dcf58-085b-430c-aa86-ce3d6a4e8a30_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ff397204-0ae4-4f9e-abe4-9cbcb3667e94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of shares vested related to RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_67105639-4c40-4f0b-960c-5c1c367f46a2_terseLabel_en-US" xlink:label="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount eligible to vest upon achievement of goal</link:label>
    <link:label id="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_label_en-US" xlink:label="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal</link:label>
    <link:label id="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_documentation_en-US" xlink:label="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:href="pacb-20241231.xsd#pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:to="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceTradingDays_4e2448d1-de45-493f-943c-720814bd67e3_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt redemption, trading days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceTradingDays_label_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Trading Days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceTradingDays_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:to="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2489d5c0-e5d0-4a52-9960-d0b280367a24_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b09a1daa-21df-4c0b-a9d4-c51465cdcf29_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_0683dd2c-9fc8-4eca-bfaf-3ed1e92bcc06_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits, current</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent" xlink:to="lab_us-gaap_DepositsAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1f8c57a1-b41e-41cf-97c4-d407b6c18c20_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DomesticCustomersMember_a5051d59-a9f5-4da4-be9d-4a18284b839c_terseLabel_en-US" xlink:label="lab_pacb_DomesticCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Customers</link:label>
    <link:label id="lab_pacb_DomesticCustomersMember_label_en-US" xlink:label="lab_pacb_DomesticCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Customers [Member]</link:label>
    <link:label id="lab_pacb_DomesticCustomersMember_documentation_en-US" xlink:label="lab_pacb_DomesticCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Domestic Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DomesticCustomersMember" xlink:href="pacb-20241231.xsd#pacb_DomesticCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DomesticCustomersMember" xlink:to="lab_pacb_DomesticCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_e8bb13f5-64bf-4cb2-886d-c0fb8efd1aa7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_c0a1d81a-b485-4d2a-9249-d67fb74c25e8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_99aa8b63-84d9-441b-8ad9-e3bd7b4e5286_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accruals and reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_0452319f-5a03-496f-b3fa-17b7d23e38e9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory provision</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4f386da-8965-451f-9d61-41b875c125f8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_450ffca3-f5cf-461f-b2c8-ee8f546631b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_d22bab63-a2d5-49d8-a693-1ccb166df811_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_9b2c51c0-57cc-4b71-a8d4-8b43d1346af7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_7aaa7795-ac00-4a44-baa3-1fd9baa75d9b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_59ae4f15-3de1-4454-9bfd-a2588deae1fb_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_33898115-4e1b-4d2c-b69c-48a6c248320e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_986cdbf8-1ebf-440d-ba90-ad841d34a37f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PaymentsInConjunctionWithNotesExchange_5b9d4240-7553-448f-abe2-4447a50b21ad_terseLabel_en-US" xlink:label="lab_pacb_PaymentsInConjunctionWithNotesExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments made in conjunction with convertible notes exchange</link:label>
    <link:label id="lab_pacb_PaymentsInConjunctionWithNotesExchange_label_en-US" xlink:label="lab_pacb_PaymentsInConjunctionWithNotesExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments In Conjunction With Notes Exchange</link:label>
    <link:label id="lab_pacb_PaymentsInConjunctionWithNotesExchange_documentation_en-US" xlink:label="lab_pacb_PaymentsInConjunctionWithNotesExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments In Conjunction With Notes Exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsInConjunctionWithNotesExchange" xlink:href="pacb-20241231.xsd#pacb_PaymentsInConjunctionWithNotesExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PaymentsInConjunctionWithNotesExchange" xlink:to="lab_pacb_PaymentsInConjunctionWithNotesExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_5925fc44-7d75-4367-81cc-dc7fc2c4543e_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_e203945e-01d9-4996-bece-fc15ad25e73b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense recorded in YTD 2024</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_87a0e759-bd03-40c7-8519-0758c3a6b2f8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_49dc14af-9135-4ffa-b33e-29969de7bfd7_verboseLabel_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with Apton liquidity event bonus plan (in shares)</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_d4096bb5-55d7-496e-81a6-476456fb2670_terseLabel_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with liquidity event bonus plan (in shares)</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_label_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions, Liquidity Bonus Plan</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_documentation_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions, Liquidity Bonus Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" xlink:href="pacb-20241231.xsd#pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" xlink:to="lab_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_540bae19-bd62-428f-8380-2c19a123a51c_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Domain]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_label_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Domain]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:to="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_c3e61cbc-faf3-4ba0-bc8c-fb63be215797_terseLabel_en-US" xlink:label="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">WARN act and other employee benefits</link:label>
    <link:label id="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_label_en-US" xlink:label="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Worker Adjustment and Retraining Notification (WARN) Act and Other Employee Benefits</link:label>
    <link:label id="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_documentation_en-US" xlink:label="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Worker Adjustment and Retraining Notification (WARN) Act and Other Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:href="pacb-20241231.xsd#pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:to="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_cdf9720d-20c8-4bf1-8962-e6a45fb8bcf7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_a4abfd97-f3cb-4987-b1da-44b33ba1fb07_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9ec8ca47-f9b8-4977-a9b5-8c8b3ada528c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8bc762-9c2d-4f5d-89ce-6c2500840cb5_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Option, Eligible Item or Group [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8f8f0f15-c032-457d-b167-9c2d79763e48_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning, outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_95acf180-6a81-4c55-80ce-c3414cdf646f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending, outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d0b93810-649b-4949-bc83-54aa069432cf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_7ca04eb0-5b12-47b6-8e90-70acf84529ca_terseLabel_en-US" xlink:label="lab_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of fair market value at which stock can be purchased</link:label>
    <link:label id="lab_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_label_en-US" xlink:label="lab_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Fair Market Value At Which Stock Can Be Purchased</link:label>
    <link:label id="lab_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_documentation_en-US" xlink:label="lab_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of fair market value at which stock can be purchased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" xlink:href="pacb-20241231.xsd#pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" xlink:to="lab_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_42cb9518-3e0a-498f-b93b-1060fd6b0cce_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsTable_d1707e81-41fd-4343-b31e-54039e09c72d_terseLabel_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Components [Table]</link:label>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsTable_label_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Components [Table]</link:label>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsTable_documentation_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Components [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:href="pacb-20241231.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:to="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_3e5ed0ca-655c-47d6-b03a-e7a8b6966610_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative amount incurred to date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_6f89e1d5-a25d-4fc2-b3f1-73b02126a0e1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CommitmentsAndContingenciesTable_2293013f-03e1-42f8-be42-bcf1e227b5cc_terseLabel_en-US" xlink:label="lab_pacb_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_pacb_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_pacb_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_pacb_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_pacb_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommitmentsAndContingenciesTable" xlink:href="pacb-20241231.xsd#pacb_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CommitmentsAndContingenciesTable" xlink:to="lab_pacb_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5bb4f55d-3dc0-4236-95b1-80c837485655_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8971e53e-d098-465c-943a-b82e2b441495_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4c20b23b-4dba-4d05-9f4c-4afbaca0be5b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_71edd43a-5f3e-4798-8228-09145c85d833_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8d9ea590-6165-4021-9823-cc96b29e4274_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_eb3fe101-dab9-4db7-98d8-648185a15ac7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_69ab3dd3-bac4-4097-860e-d5ed1128a4dc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_23f61f68-6ae6-4ad3-91ba-59b3a71a63ea_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_634b4a55-b4f1-4b75-8b00-bd79fc534138_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ee5d73e-1852-4c46-8a01-61e6f28ab3cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value, granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OperatingLeaseExpectedBaseRentExpense_3a360698-9646-4fba-999d-8c3cc91d70e5_terseLabel_en-US" xlink:label="lab_pacb_OperatingLeaseExpectedBaseRentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, base rent expense</link:label>
    <link:label id="lab_pacb_OperatingLeaseExpectedBaseRentExpense_label_en-US" xlink:label="lab_pacb_OperatingLeaseExpectedBaseRentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expected Base Rent, Expense</link:label>
    <link:label id="lab_pacb_OperatingLeaseExpectedBaseRentExpense_documentation_en-US" xlink:label="lab_pacb_OperatingLeaseExpectedBaseRentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Expected Base Rent, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OperatingLeaseExpectedBaseRentExpense" xlink:href="pacb-20241231.xsd#pacb_OperatingLeaseExpectedBaseRentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OperatingLeaseExpectedBaseRentExpense" xlink:to="lab_pacb_OperatingLeaseExpectedBaseRentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_9afeae60-ab6c-42de-8203-b04e65f3aad2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_154689e7-7bc0-415b-95c6-91e41945e257_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding used in calculating &#8206;net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_d3f8ed4f-ca93-4b9e-a6d4-5547add2a45b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_f500db57-fc4d-4070-9ddd-2979384d12c1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_174e9f47-0a44-41dd-b4b4-259ad4ad04dc_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_5f3e55d8-8868-489d-ae3e-a8aa66d3c3f3_terseLabel_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional intangible asset impairment, change in discount rate</link:label>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_label_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Intangible Asset Impairment, Change In Discount Rate</link:label>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_documentation_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Intangible Asset Impairment, Change In Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:href="pacb-20241231.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:to="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2077dd74-2392-41eb-bc55-b843bcb682ad_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_EmployeeStockPurchasePlanMember_07d0ac8a-2626-40ab-bf61-83611fc06876_terseLabel_en-US" xlink:label="lab_pacb_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_pacb_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_pacb_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_pacb_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_pacb_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember" xlink:href="pacb-20241231.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_EmployeeStockPurchasePlanMember" xlink:to="lab_pacb_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_112661eb-25fd-4931-9aec-b6ad22396314_terseLabel_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition, anniversary</link:label>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_label_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Liability, Measurement Period</link:label>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_documentation_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Liability, Measurement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:href="pacb-20241231.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:to="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0e1c2de3-7706-4a6f-94d3-8d9d6d4b8e99_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_0c83b79d-43ac-4a76-80a5-367cba132f8f_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IncomeTaxesTable_0749978e-6139-46eb-9f52-4ed21d46745a_terseLabel_en-US" xlink:label="lab_pacb_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_pacb_IncomeTaxesTable_label_en-US" xlink:label="lab_pacb_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_pacb_IncomeTaxesTable_documentation_en-US" xlink:label="lab_pacb_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeTaxesTable" xlink:href="pacb-20241231.xsd#pacb_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IncomeTaxesTable" xlink:to="lab_pacb_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_659cbb4b-eb19-4a2d-bf88-da49e1cc8d6e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_612ccca0-be2f-4e7d-b6c7-20df7898d68b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_6f29f1a4-543e-4eac-b4c3-3b74b3dfe222_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BusinessCombinationMember_4dd7b03d-13ea-440d-9d8e-c9d5a9a93abb_terseLabel_en-US" xlink:label="lab_pacb_BusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination</link:label>
    <link:label id="lab_pacb_BusinessCombinationMember_label_en-US" xlink:label="lab_pacb_BusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Member]</link:label>
    <link:label id="lab_pacb_BusinessCombinationMember_documentation_en-US" xlink:label="lab_pacb_BusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationMember" xlink:href="pacb-20241231.xsd#pacb_BusinessCombinationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BusinessCombinationMember" xlink:to="lab_pacb_BusinessCombinationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5d61a527-5a52-41bb-9b3d-5496555f597c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2fa408cc-d31b-4d79-a90a-51f1e43c0de4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_a2710e3f-9c76-4924-81d4-c6aa0d8598b4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_aac5edeb-4ddf-469d-bc3c-9725ab675777_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_9b0c3390-adc3-4c7b-8477-699b92ca48f8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other costs</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AmericasMember_fa98d862-43cb-4ab8-bcdc-df4826b77a97_terseLabel_en-US" xlink:label="lab_srt_AmericasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Americas</link:label>
    <link:label id="lab_srt_AmericasMember_label_en-US" xlink:label="lab_srt_AmericasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Americas [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AmericasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AmericasMember" xlink:to="lab_srt_AmericasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtIssuanceCostLenderFees_8802d5e7-2bcb-4fe4-8aa4-983f4b223a9f_terseLabel_en-US" xlink:label="lab_pacb_DebtIssuanceCostLenderFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance cost, lender fees</link:label>
    <link:label id="lab_pacb_DebtIssuanceCostLenderFees_label_en-US" xlink:label="lab_pacb_DebtIssuanceCostLenderFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Cost, Lender Fees</link:label>
    <link:label id="lab_pacb_DebtIssuanceCostLenderFees_documentation_en-US" xlink:label="lab_pacb_DebtIssuanceCostLenderFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Issuance Cost, Lender Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtIssuanceCostLenderFees" xlink:href="pacb-20241231.xsd#pacb_DebtIssuanceCostLenderFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtIssuanceCostLenderFees" xlink:to="lab_pacb_DebtIssuanceCostLenderFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2e470415-01d4-4ce7-ac1b-f6b6a0bb1444_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c3edd2f8-88bc-4ed4-971b-694639e90ad5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_c17cb3cd-0cd7-4abc-bf42-c89506304fe0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_d68dec77-3d01-44b4-b619-bf9a482a5b14_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_fde7cc30-720b-4e7a-bcf4-073dc86df8ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_549b5a1c-93c8-4ff4-a22b-d2703a688164_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, weighted average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_4be6d713-17d6-4383-a75b-916bfb311bcf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2761d29a-9cde-41a9-8b83-855b8e66e2a5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_4a596786-88d1-4280-9cef-80fc3019389f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets, current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bb0ff0a7-02ad-443a-9b6b-3855d8ab30b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_dc9b0d2d-7970-4d4c-97a7-78e3032f5d6f_terseLabel_en-US" xlink:label="lab_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Accrued Expenses And Other Current Liabilities [Table Text Block]</link:label>
    <link:label id="lab_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the components of accrued expenses and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:href="pacb-20241231.xsd#pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8c250c58-afd4-41e5-b587-8d8fcbd3caba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in the Estimated Fair Value of Contingent Consideration Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_0f0adbde-741c-41e0-a8f3-a6dc40e4769f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c583db20-96db-4361-8403-74b1c9f2c60e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_fe254e07-ff45-4a47-9c82-8291bc8bba04_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ab4485f6-32ab-427f-9ce0-5fef89b59442_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest or penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2e22e4b1-93e1-45a2-adac-767aaa9e015d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt conversion, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued_50420c5a-4e3b-47cb-92ab-7940f6d4b16f_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions charged to cost of product revenue</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Increase for Warranties Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualWarrantiesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:to="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3211d1df-7f94-4ab7-81e5-8ba4bda27715_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5600799a-e29e-4796-81b0-bd936b33c8c3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_ea319d55-1dba-43af-aa62-7d5bb30db5c3_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">SEGMENT AND GEOGRAPHIC INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_bdd8a6b5-7068-4744-a6d2-117085579aff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paid accrued but unpaid interest</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b1b0f7b8-5a1a-4215-b7be-a91402829115_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_5a6e9e64-c61c-4233-a4ee-e0a45e4f1124_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_dfc24af8-e1d3-4017-acdc-e62b629e3df0_terseLabel_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public offering, option to purchase additional shares (in shares)</link:label>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_label_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Offering, Option to Purchase Additional Shares, Shares</link:label>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_documentation_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Offering, Option to Purchase Additional Shares, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:href="pacb-20241231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:to="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_574a9908-9d27-4d76-91df-e4eda695f131_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_c417bd23-f5ec-49b0-a0a3-f22655f1280d_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_88f061a2-18bf-438b-906a-200cb0137780_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ab6955c4-4089-4699-8ae2-c20f0f06da19_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a8c502c8-8622-46f7-9f56-55f32c6ee993_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_fc34e909-7927-4531-b12d-e62c8d7d9fae_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_bc689304-9487-458f-aea2-8beceb5c0bc3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments:</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_f7ca25cd-3a74-4f26-8dfe-c5fa786be0ae_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_17990b8d-ca95-42b9-b332-6925b172956e_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_ca2712e7-fb58-4e18-ab78-618c3e0bd8c7_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance as of December 31, 2023</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_8a7edf3b-9185-4fc0-bedc-802e8a9aa935_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance as of December 31, 2024</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_f0363ff9-fdf6-4df2-9e62-7947d5ec97e6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ShelfOfferingMember_730986f6-9dc4-4587-b6c9-b5a983fa61e1_terseLabel_en-US" xlink:label="lab_pacb_ShelfOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shelf Offering</link:label>
    <link:label id="lab_pacb_ShelfOfferingMember_label_en-US" xlink:label="lab_pacb_ShelfOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shelf Offering [Member]</link:label>
    <link:label id="lab_pacb_ShelfOfferingMember_documentation_en-US" xlink:label="lab_pacb_ShelfOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shelf Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShelfOfferingMember" xlink:href="pacb-20241231.xsd#pacb_ShelfOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ShelfOfferingMember" xlink:to="lab_pacb_ShelfOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2029NotesMember_e4ea7c20-f372-4b0d-94e6-3c9ddf31abef_terseLabel_en-US" xlink:label="lab_pacb_A2029NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029 Notes</link:label>
    <link:label id="lab_pacb_A2029NotesMember_label_en-US" xlink:label="lab_pacb_A2029NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2029 Notes [Member]</link:label>
    <link:label id="lab_pacb_A2029NotesMember_documentation_en-US" xlink:label="lab_pacb_A2029NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2029 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2029NotesMember" xlink:href="pacb-20241231.xsd#pacb_A2029NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2029NotesMember" xlink:to="lab_pacb_A2029NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PublicOfferingShares_c005c7aa-4e99-42ff-a281-69ff3c4de0fa_terseLabel_en-US" xlink:label="lab_pacb_PublicOfferingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public offering (in shares)</link:label>
    <link:label id="lab_pacb_PublicOfferingShares_label_en-US" xlink:label="lab_pacb_PublicOfferingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Offering, Shares</link:label>
    <link:label id="lab_pacb_PublicOfferingShares_documentation_en-US" xlink:label="lab_pacb_PublicOfferingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Offering, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingShares" xlink:href="pacb-20241231.xsd#pacb_PublicOfferingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PublicOfferingShares" xlink:to="lab_pacb_PublicOfferingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_ced92156-0143-4c52-a06a-c5a1db5d0c94_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional interest in the event of default</link:label>
    <link:label id="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_label_en-US" xlink:label="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Interest in the Event of Default</link:label>
    <link:label id="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Interest in the Event of Default</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:to="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d10258fc-3805-4624-af28-c434275a25e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24501dea-270b-43f5-a684-fbbe7f06e284_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_61285d48-cd07-4996-b59a-be5823b85fdb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_8951239b-1a9d-4d38-bf30-f0775fb9f3fe_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, percentage</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_6acf4721-f129-439e-b371-400630850ed1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3cc92143-9ac2-4b23-b129-43a644a95a0a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_7309e041-4156-42fe-9e9c-2801853c0d53_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_137befed-8c26-4381-a241-faa2f395b23c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CommitmentsAndContingenciesLineItems_84d6547d-8c3d-4b48-9591-d5ece69fc574_terseLabel_en-US" xlink:label="lab_pacb_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_pacb_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_pacb_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_pacb_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_pacb_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommitmentsAndContingenciesLineItems" xlink:href="pacb-20241231.xsd#pacb_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems" xlink:to="lab_pacb_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_3f11d7f3-8d5a-41ed-864d-43e7b7fed96c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_861081b8-6f87-444f-84b7-9d4720a03e33_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CustomerOneMember_12a12aef-c9aa-4b02-862d-6ac0b4425356_terseLabel_en-US" xlink:label="lab_pacb_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer One</link:label>
    <link:label id="lab_pacb_CustomerOneMember_label_en-US" xlink:label="lab_pacb_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_pacb_CustomerOneMember_documentation_en-US" xlink:label="lab_pacb_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CustomerOneMember" xlink:href="pacb-20241231.xsd#pacb_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CustomerOneMember" xlink:to="lab_pacb_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_25f5ee83-de0d-411c-80e6-a46be03036e9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_407c88ff-894c-4b15-83fe-de4ed3080918_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_df2802fe-9225-4beb-8c0e-262f5cd30a12_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_c7f25d48-8675-4e15-856a-4a991d1947b7_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Stock Units (PSUs)</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2d103469-baa4-4609-8e4b-f02086f5b0cc_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CostOfRevenueMember_3152b613-8fc6-40b9-bfc3-55324f9d771c_terseLabel_en-US" xlink:label="lab_pacb_CostOfRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost Of Revenue</link:label>
    <link:label id="lab_pacb_CostOfRevenueMember_label_en-US" xlink:label="lab_pacb_CostOfRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost Of Revenue [Member]</link:label>
    <link:label id="lab_pacb_CostOfRevenueMember_documentation_en-US" xlink:label="lab_pacb_CostOfRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cost Of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CostOfRevenueMember" xlink:href="pacb-20241231.xsd#pacb_CostOfRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CostOfRevenueMember" xlink:to="lab_pacb_CostOfRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_ba2584ff-6162-4939-841a-9c4e88503d3e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b1ebbe87-a10f-4f8f-aa7f-a7921edaf6a7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f5eb18d4-2078-492b-a974-c833a202ef60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CONVERTIBLE SENIOR NOTES</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6f737988-8df8-40cb-a893-1dc298a4eead_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_a7fa2c65-c276-400c-8ca7-a314124493d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount of notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AptonMember_f967fc4f-21df-420b-b388-7c6571d2edf2_terseLabel_en-US" xlink:label="lab_pacb_AptonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Apton</link:label>
    <link:label id="lab_pacb_AptonMember_label_en-US" xlink:label="lab_pacb_AptonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Apton [Member]</link:label>
    <link:label id="lab_pacb_AptonMember_documentation_en-US" xlink:label="lab_pacb_AptonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Apton</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember" xlink:href="pacb-20241231.xsd#pacb_AptonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AptonMember" xlink:to="lab_pacb_AptonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_362cd5f2-af52-49d1-89e5-bd21ca5bce0e_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_7ed7a761-2c59-4636-bb89-7829f912efd9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_f79d9880-ab55-4829-80d7-bda8933372a5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard and Extended Product Warranty Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrual" xlink:to="lab_us-gaap_ProductWarrantyAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1349e0f8-9214-48ba-ae76-1afcd818e5df_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_ed4c683c-5e07-463c-87e9-3c8a930fc6a7_terseLabel_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional intangible asset impairment, change in term</link:label>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_label_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Intangible Asset Impairment, Change In Term</link:label>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_documentation_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Intangible Asset Impairment, Change In Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:href="pacb-20241231.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:to="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_7da2ff84-2326-4444-b7ae-cdb0d0a2fe29_terseLabel_en-US" xlink:label="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of outstanding shares of common to be issued in merger</link:label>
    <link:label id="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_label_en-US" xlink:label="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of outstanding shares of common to be issued in merger</link:label>
    <link:label id="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_documentation_en-US" xlink:label="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of outstanding shares of common to be issued in merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:href="pacb-20241231.xsd#pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:to="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount_fa2c2487-8e25-4e84-a4dc-4c2b5cc133b6_terseLabel_en-US" xlink:label="lab_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease base rent abatement</link:label>
    <link:label id="lab_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount_label_en-US" xlink:label="lab_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Base Rent Abatement, Amount</link:label>
    <link:label id="lab_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount_documentation_en-US" xlink:label="lab_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Base Rent Abatement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" xlink:href="pacb-20241231.xsd#pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" xlink:to="lab_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e7f5838-b81c-4094-aa85-2210bb32dedd_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3906c405-5098-44df-ad24-864c8f7772ca_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f752ff8e-845a-40ef-a34f-abdefcceedfc_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets, indefinite-lived (excluding goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_74e480a1-27d3-45c9-9ce4-b591b4dafa05_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_89b24bfc-8285-446b-87c9-b4f4acdbf521_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4020ff59-fcb2-4b43-8222-2915aaf5b46d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_14c0fec1-39d4-42c2-9ad4-0736247336e7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchased materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_35a37540-8b82-4d77-b6e5-2281cdb5cd97_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0120fec9-b103-4a52-b02e-2721a771145e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_0611259d-e888-43fb-a0fc-a00281e88a01_negatedTerseLabel_en-US" xlink:label="lab_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Share-based compensation expense excluded from consideration transferred</link:label>
    <link:label id="lab_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_label_en-US" xlink:label="lab_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense excluded from consideration transferred</link:label>
    <link:label id="lab_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_documentation_en-US" xlink:label="lab_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense excluded from consideration transferred.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" xlink:href="pacb-20241231.xsd#pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" xlink:to="lab_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability_485664a3-45d6-4deb-a2b5-ac94211a6665_terseLabel_en-US" xlink:label="lab_pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liability</link:label>
    <link:label id="lab_pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability_label_en-US" xlink:label="lab_pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability</link:label>
    <link:label id="lab_pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability_documentation_en-US" xlink:label="lab_pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability" xlink:href="pacb-20241231.xsd#pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability" xlink:to="lab_pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_c5c80b6c-3986-4695-9c21-3989f09fd079_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity awards</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_189fd62f-e17e-4596-9318-b6f6f2c4f829_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_94467a77-82bb-4715-800a-fef623662665_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_6bafbc4a-bed5-47ce-87b2-a548327837e2_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, net, non-current</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9eceb151-c890-4bcc-8f1d-a64d70bf4242_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_3386433d-b1ad-43a4-97b5-c375015b3f8d_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualProductLiabilityNet_b3b63839-4b0c-4c48-9d47-afd503d92c98_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProductLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualProductLiabilityNet_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProductLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Product Liability, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProductLiabilityNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProductLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProductLiabilityNet" xlink:to="lab_us-gaap_LossContingencyAccrualProductLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_235901ca-0768-40eb-813e-11674b75b7d6_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:to="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_RestructuringOfDebtPricePerShare_52db9922-26e5-426c-b85c-0a89ffec6b66_terseLabel_en-US" xlink:label="lab_pacb_RestructuringOfDebtPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring of debt (in dollar per share)</link:label>
    <link:label id="lab_pacb_RestructuringOfDebtPricePerShare_label_en-US" xlink:label="lab_pacb_RestructuringOfDebtPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Of Debt Price Per Share</link:label>
    <link:label id="lab_pacb_RestructuringOfDebtPricePerShare_documentation_en-US" xlink:label="lab_pacb_RestructuringOfDebtPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Of Debt Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringOfDebtPricePerShare" xlink:href="pacb-20241231.xsd#pacb_RestructuringOfDebtPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_RestructuringOfDebtPricePerShare" xlink:to="lab_pacb_RestructuringOfDebtPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_11276b41-3ce1-46fc-a96f-bd9f55d90173_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued purchase commitments</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_e8ce726a-abdd-4863-9c5b-b33e7331e309_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5c6ad586-0d19-4e3c-a1d0-1edb8f199d2b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a64cd4c9-81de-4a4e-ace7-b7b77dbd570d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_49944be7-f78c-4133-b9b6-b3d424f45bf0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a8ec0284-2a28-46f6-b2c4-2f92a0624fff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_85dd20f2-a358-4b79-abdd-79f926535b89_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_639a789f-a555-4cfd-bbb4-8f4a1f38f267_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of outstanding common stock used to determine annual plan increase</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_cbe18338-d7b4-4fe4-8d85-cf94ba23bd46_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_65b16bc4-0515-49ec-964b-c4f03f7e734c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5e776a55-ac3a-4915-a43d-c928f43c03d7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Federal Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f8e9c60-7519-4682-991b-2cd10ecb07fc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_71bba3f2-dcee-4f66-b552-6d4d99bddbe5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_c1812f1c-58de-400c-9832-805abf3c5198_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Geographic Location</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2ed74c95-c74b-4dec-8c8d-242aa4bab3c8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock following milestone achievement (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_8d886e6f-01a3-41fa-bf9f-94306ddb5b3c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OptionsToPurchaseCommonStockMember_cdc7998a-0da5-4dce-a3cc-48072050a3aa_terseLabel_en-US" xlink:label="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options To Purchase Common Stock</link:label>
    <link:label id="lab_pacb_OptionsToPurchaseCommonStockMember_label_en-US" xlink:label="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options To Purchase Common Stock [Member]</link:label>
    <link:label id="lab_pacb_OptionsToPurchaseCommonStockMember_documentation_en-US" xlink:label="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options to purchase common stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember" xlink:href="pacb-20241231.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OptionsToPurchaseCommonStockMember" xlink:to="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_f21ab7e7-cfe4-44d1-b3fd-4fff692d13a8_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_4497ee3a-4aef-4b10-9d29-60e772b9f9a3_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_70cdb5ba-6215-4cdb-a8ad-b6fa8426d118_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ebfbfc4c-2a50-4db2-9435-e5b64c182694_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6bb5d6db-dcd5-433e-9207-025a6d6a915d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d6899b4e-4a86-4c60-83e6-073cc69420f4_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DeferredTaxAssetsOperatingLeaseLiabilities_3403fc93-abba-40ca-b792-b5efe8e762a2_terseLabel_en-US" xlink:label="lab_pacb_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_pacb_DeferredTaxAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_pacb_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:label id="lab_pacb_DeferredTaxAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_pacb_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:href="pacb-20241231.xsd#pacb_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_pacb_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_13b7c83e-4f4f-4107-847b-e1b7f41e6696_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ShortTermRestrictedCashFairValueDisclosure_f638dd0c-2856-4f93-a3bf-560ffbf9bef0_terseLabel_en-US" xlink:label="lab_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term restricted cash</link:label>
    <link:label id="lab_pacb_ShortTermRestrictedCashFairValueDisclosure_label_en-US" xlink:label="lab_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Restricted Cash Fair Value Disclosure</link:label>
    <link:label id="lab_pacb_ShortTermRestrictedCashFairValueDisclosure_documentation_en-US" xlink:label="lab_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-Term Restricted Cash Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:href="pacb-20241231.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:to="lab_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_93ee1a88-e848-4a47-9126-04b8118c559e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1f983b88-648c-425d-8394-1cc032c52b8a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_d1cb5dda-2775-4766-a7d9-d89840535058_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6513f351-bebf-48cc-8cd1-fde27020447e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_d266d162-52f5-4e98-90f6-15291c16ec93_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory reserve</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_f9ce5b90-a9a9-4125-b08b-fc6f500ff7b8_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_InstrumentMember_c5bf6e1b-0391-4171-9109-7113d7689d5d_terseLabel_en-US" xlink:label="lab_pacb_InstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instrument revenue</link:label>
    <link:label id="lab_pacb_InstrumentMember_label_en-US" xlink:label="lab_pacb_InstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Instrument [Member]</link:label>
    <link:label id="lab_pacb_InstrumentMember_documentation_en-US" xlink:label="lab_pacb_InstrumentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InstrumentMember" xlink:href="pacb-20241231.xsd#pacb_InstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_InstrumentMember" xlink:to="lab_pacb_InstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_f2976fae-26fb-4c27-9fac-4bfedfd4865d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_14d1710d-5301-4382-af53-0a2b7aa23226_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_99ab675c-b2ea-4463-9c3d-84dcc490ed36_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease in balance related to tax positions taken in prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PurchasePeriodOfEmployeeStockPurchasePlan_e7828091-c609-4d61-92aa-98b2fb46bb00_terseLabel_en-US" xlink:label="lab_pacb_PurchasePeriodOfEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase period of ESPP</link:label>
    <link:label id="lab_pacb_PurchasePeriodOfEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_pacb_PurchasePeriodOfEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Period Of Employee Stock Purchase Plan</link:label>
    <link:label id="lab_pacb_PurchasePeriodOfEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_pacb_PurchasePeriodOfEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase period of employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PurchasePeriodOfEmployeeStockPurchasePlan" xlink:href="pacb-20241231.xsd#pacb_PurchasePeriodOfEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PurchasePeriodOfEmployeeStockPurchasePlan" xlink:to="lab_pacb_PurchasePeriodOfEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_f73a329c-8887-4855-b33f-13ad885aeddd_totalLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_dfa5850b-c74b-4910-b44f-3cfbaea8f535_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_fe804a61-87b6-4d56-8984-5d6638014b7e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_84bf1928-c8d1-4a57-91d4-7916b8660dc4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_93775a64-e6c4-40c2-b921-380e7810e981_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_280f25c0-f888-457f-af84-eccf5bf26611_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IncomeTaxesLineItems_46410fba-b120-48c3-942e-5c90488b7e48_terseLabel_en-US" xlink:label="lab_pacb_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_pacb_IncomeTaxesLineItems_label_en-US" xlink:label="lab_pacb_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_pacb_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_pacb_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeTaxesLineItems" xlink:href="pacb-20241231.xsd#pacb_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IncomeTaxesLineItems" xlink:to="lab_pacb_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b273120e-cda4-4628-bcff-53716aaf5003_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c437614c-66d7-4489-96d3-33164780b7c5_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in computing basic net (loss) income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OfferingShareAmountMaximum_6ef7aee6-087a-4fae-98c8-8e2e61eecf55_terseLabel_en-US" xlink:label="lab_pacb_OfferingShareAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock offering price (in usd per share)</link:label>
    <link:label id="lab_pacb_OfferingShareAmountMaximum_label_en-US" xlink:label="lab_pacb_OfferingShareAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering Share Amount Maximum</link:label>
    <link:label id="lab_pacb_OfferingShareAmountMaximum_documentation_en-US" xlink:label="lab_pacb_OfferingShareAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Offering Share Amount Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OfferingShareAmountMaximum" xlink:href="pacb-20241231.xsd#pacb_OfferingShareAmountMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OfferingShareAmountMaximum" xlink:to="lab_pacb_OfferingShareAmountMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a26a8cca-1512-41b0-9e8d-677a8690c4c5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_5418fb4a-39c4-4e7e-a542-8fef60c3524c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional services and legal fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_00d7054a-f126-43f1-a780-10b8681e7078_terseLabel_en-US" xlink:label="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred service revenue, noncurrent, recognition period</link:label>
    <link:label id="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_label_en-US" xlink:label="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent, Recognition Period</link:label>
    <link:label id="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_documentation_en-US" xlink:label="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent, Recognition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:href="pacb-20241231.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:to="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_0ff82f9e-fb9d-4a16-b828-3387d55bc84d_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_fb23bc30-283f-4d28-a803-299d49c6c42f_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Revenue, Net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_dd107a9c-ff12-4a67-8efa-f640c8f33d90_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_8f71a4d4-f78e-4a8e-a7d4-ef072cf91e2c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_857ed814-067a-4496-a974-41740f6d53c5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_3a1df9e0-17ef-40c6-813b-84ad158a6cd7_terseLabel_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with Apton liquidity event bonus plan</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_label_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions, Liquidity Bonus Plan</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_documentation_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions, Liquidity Bonus Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" xlink:href="pacb-20241231.xsd#pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" xlink:to="lab_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_ad2d6b7a-2dd2-49f1-a846-b365bde31597_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_f7fbeac8-2e03-4263-9c90-c4c140f96dfe_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Revenue:</link:label>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenueAbstract" xlink:to="lab_us-gaap_CostOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_e2e775ba-f618-4342-bdc8-7047e7782e21_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, acquired during period</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_7eaf0508-a28c-469f-98a1-f68a716265ad_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_2e5976ae-9e20-45c8-b4d4-045b59ad50f6_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c7999b98-59c6-4970-8faa-fe2233a8d88c_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_d6dbbb2c-c9d1-4a4d-8ed7-9a4e18a3fd50_terseLabel_en-US" xlink:label="lab_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger Expenses</link:label>
    <link:label id="lab_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_label_en-US" xlink:label="lab_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Merger Expense, Percent</link:label>
    <link:label id="lab_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_documentation_en-US" xlink:label="lab_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Merger Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" xlink:href="pacb-20241231.xsd#pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" xlink:to="lab_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_1b084250-82b7-4c96-9294-d48b4d82b859_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_fe50bdf4-c486-418a-8b51-5a85345b8f73_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities, current</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_dbdc3d6e-c29e-4eb8-aaf5-4af21a65bf03_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other liabilities, current</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForDeposits_9612ea08-cd78-4746-9690-0658254fbc60_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for deposits to supplier</link:label>
    <link:label id="lab_us-gaap_PaymentsForDeposits_label_en-US" xlink:label="lab_us-gaap_PaymentsForDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForDeposits" xlink:to="lab_us-gaap_PaymentsForDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentDebtDefaultCalendarDays_1ec96a13-e903-420f-827a-d1547bf7a0f9_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, debt default, calendar days</link:label>
    <link:label id="lab_pacb_DebtInstrumentDebtDefaultCalendarDays_label_en-US" xlink:label="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Debt Default, Calendar Days</link:label>
    <link:label id="lab_pacb_DebtInstrumentDebtDefaultCalendarDays_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Debt Default, Calendar Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentDebtDefaultCalendarDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:to="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_ec3e7f9d-3b16-485e-b28c-a2dd03ce432b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OmniomeIncMember_ce1c1d19-fd9a-4444-a173-96953c91b63b_terseLabel_en-US" xlink:label="lab_pacb_OmniomeIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Omniome, Inc</link:label>
    <link:label id="lab_pacb_OmniomeIncMember_label_en-US" xlink:label="lab_pacb_OmniomeIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Omniome Inc [Member]</link:label>
    <link:label id="lab_pacb_OmniomeIncMember_documentation_en-US" xlink:label="lab_pacb_OmniomeIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Omniome, Inc. (&#8220;Omniome&#8221;), a San Diego-based company developing a highly differentiated, proprietary short-read DNA sequencing platform capable of delivering high accuracy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember" xlink:href="pacb-20241231.xsd#pacb_OmniomeIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OmniomeIncMember" xlink:to="lab_pacb_OmniomeIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockholdersEquityLineItems_3a85d712-bafb-4b41-873f-2e31548786ba_terseLabel_en-US" xlink:label="lab_pacb_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity [Line Items]</link:label>
    <link:label id="lab_pacb_StockholdersEquityLineItems_label_en-US" xlink:label="lab_pacb_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity [Line Items]</link:label>
    <link:label id="lab_pacb_StockholdersEquityLineItems_documentation_en-US" xlink:label="lab_pacb_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders' Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockholdersEquityLineItems" xlink:href="pacb-20241231.xsd#pacb_StockholdersEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockholdersEquityLineItems" xlink:to="lab_pacb_StockholdersEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9bfc1618-f50a-47f2-9fd1-c20e41a7ebdf_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f41478b0-21d9-48de-9804-0b06b95a82b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2028ConvertibleSeniorNotesMember_ceeeb101-c20c-48e5-a700-3edc9f2de44b_terseLabel_en-US" xlink:label="lab_pacb_A2028ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028 Convertible Senior Notes</link:label>
    <link:label id="lab_pacb_A2028ConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_pacb_A2028ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2028 Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_pacb_A2028ConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_pacb_A2028ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember" xlink:href="pacb-20241231.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2028ConvertibleSeniorNotesMember" xlink:to="lab_pacb_A2028ConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_bf746892-c1bd-48be-9f73-1e04e3dd3061_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_3cbb9d2c-a3c4-44f6-8941-17c1d9b3600c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_b6e77ed8-eb63-49fa-922e-6a3201da8bb8_terseLabel_en-US" xlink:label="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Components [Abstract]</link:label>
    <link:label id="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_label_en-US" xlink:label="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Components [Abstract]</link:label>
    <link:label id="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_documentation_en-US" xlink:label="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Components Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:href="pacb-20241231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_8e1b23a1-2000-4c7e-8deb-6bd4b1ca9d6c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_26330c62-d3f6-43ff-9685-1fce1b8eb309_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_44bb9bde-81c5-4b1e-9675-522737503efe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in operating lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f81bbfc3-97f5-4bb0-bbbd-8a312b3c8014_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_294f74c2-3615-4ac0-8727-8b666bc3e9f4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_cfac24a6-fc86-49dd-b3f2-f52a322025f6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_256fa5a3-135a-43fe-b9d9-e511a760966f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_bee85ff3-4abe-4e51-b064-0bb7c6eb8a0d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_5f08757d-0e5c-43c4-841c-60a4324cc8d2_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_5c8009da-aaf0-4e95-b232-8c5eaea4089c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14757db8-8766-46eb-b269-12c834cf95dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock remain available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_95fe4796-1937-4f25-b54d-a3d7d9d99038_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_7f5aef19-7fe0-484f-97c2-1c1f8074a165_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_98b81cc4-3b15-4e37-bd75-67b345ed9a5a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_24bf4c9f-1353-4da3-9822-c75b7b1635b2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_0e9f2907-5e10-4cf5-9e6a-01d66e4ae77b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_eb6ef40f-a301-4873-bea3-9ee65f6718b3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in balance related to tax positions taken in prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AmortizationOfAcquiredIntangibleAssets_c74965e4-0661-4f55-bd36-d6a40de844e5_terseLabel_en-US" xlink:label="lab_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_pacb_AmortizationOfAcquiredIntangibleAssets_label_en-US" xlink:label="lab_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Acquired Intangible Assets</link:label>
    <link:label id="lab_pacb_AmortizationOfAcquiredIntangibleAssets_documentation_en-US" xlink:label="lab_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization Of Acquired Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:href="pacb-20241231.xsd#pacb_AmortizationOfAcquiredIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:to="lab_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockBasedCompensationMember_91863f19-185d-49d2-a7be-9b54c00252db_terseLabel_en-US" xlink:label="lab_pacb_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation</link:label>
    <link:label id="lab_pacb_StockBasedCompensationMember_label_en-US" xlink:label="lab_pacb_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Based Compensation [Member]</link:label>
    <link:label id="lab_pacb_StockBasedCompensationMember_documentation_en-US" xlink:label="lab_pacb_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-based compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationMember" xlink:href="pacb-20241231.xsd#pacb_StockBasedCompensationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockBasedCompensationMember" xlink:to="lab_pacb_StockBasedCompensationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_44bce23e-4095-41c3-8bd5-9e8e75187334_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_ca41e4c0-7c98-456e-b468-dea7872b3ddf_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion of discount and amortization of premium on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_343f31b9-590d-4228-b460-3b43aa8d1116_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestOnConvertibleDebtNetOfTax_dac1cb41-2d13-4927-b58f-51e5edb8b25a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Add: Interest charges applicable to convertible notes (2028 Notes)</link:label>
    <link:label id="lab_us-gaap_InterestOnConvertibleDebtNetOfTax_label_en-US" xlink:label="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest on Convertible Debt, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:to="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_bd652f96-deeb-4caa-b34c-c6fe896dfd35_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_bd966b40-1cc7-49f7-9ef8-38cb38eae0f3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4e892b45-ec49-4218-bfcb-5bd7715881bf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_97349143-9ec5-4bab-9f54-4152a4274c9a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_5e00d44b-faca-4733-a637-405b04280901_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in conjunction with convertible notes exchange (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_e7df966b-0565-45a7-b696-13ea5f833594_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation cost capitalized in inventory</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StandardProductWarrantyPeriod_5f95a315-f2f0-4dca-9a61-b5df6f2f1d7c_terseLabel_en-US" xlink:label="lab_pacb_StandardProductWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product warranty period</link:label>
    <link:label id="lab_pacb_StandardProductWarrantyPeriod_label_en-US" xlink:label="lab_pacb_StandardProductWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard Product Warranty, Period</link:label>
    <link:label id="lab_pacb_StandardProductWarrantyPeriod_documentation_en-US" xlink:label="lab_pacb_StandardProductWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Standard Product Warranty, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod" xlink:href="pacb-20241231.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StandardProductWarrantyPeriod" xlink:to="lab_pacb_StandardProductWarrantyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_e19a8a7d-362e-4a4e-9f44-ed5d38f808b3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7b157952-65e2-4041-8b1c-5397069fe5a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_cc79be1a-f171-4f30-b85e-1586dd7de6db_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of share consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_2772adbb-ba69-4443-890b-0dd88ad48b14_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_72e920b6-9715-4d2e-affb-186557c4f7d3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42a35518-0725-4ade-af6b-e3d5844cbbb0_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_0dc30eea-4770-41a1-a211-29917e571b68_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_d530c709-f101-4055-add4-5dc260d52d93_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_8d105c28-dc42-4524-a964-9cb966a8c4e4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_3da2b562-14e2-4ce1-8f5c-b65c3c3ec2a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Pre-Tax Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5657908c-0391-42a0-9660-9de9f0fcbb8d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_e743eadf-b9c4-4ace-835a-3cbd5e6e3e74_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe, Middle East, and Africa</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_15fb8681-7b1e-4f3f-9daf-60098a651417_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt redemption, consecutive trading days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_label_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Consecutive Trading Days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:to="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_15f5e072-65b6-4797-9c9c-b41163eba2cd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_e8e1a78e-07d8-4159-b9cb-5ee7936fef95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid during YTD 2024</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_e7e6e0e3-4d18-4d7e-8d77-d5d71e680770_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Revenue and Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f97773a3-b8af-401f-ae01-3b84190bf01a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_50367b18-fd17-45f8-a089-84c777a9d749_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_414fb055-4db4-470a-88fb-a4c6a96a415b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2239ddc6-a453-471a-9a28-03b1a60fcb72_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_FinancialInstrumentsLineItems_66c838d4-fa9f-42f0-93f7-5d95d5b1a808_terseLabel_en-US" xlink:label="lab_pacb_FinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Line Items]</link:label>
    <link:label id="lab_pacb_FinancialInstrumentsLineItems_label_en-US" xlink:label="lab_pacb_FinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Line Items]</link:label>
    <link:label id="lab_pacb_FinancialInstrumentsLineItems_documentation_en-US" xlink:label="lab_pacb_FinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Instruments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsLineItems" xlink:href="pacb-20241231.xsd#pacb_FinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_FinancialInstrumentsLineItems" xlink:to="lab_pacb_FinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_61f79db9-377e-42a5-bc34-f37abd045184_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_2d19eb61-b300-4e1e-a547-3e4d1727d439_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_74bca530-c15d-4bef-a46e-6b9d638301a2_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_edb58928-f02e-4357-8b75-457db09c793b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_3cf85aa2-59d4-4918-8f43-dd6e2d2067c1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeApproachValuationTechniqueMember_70791b2a-a9a2-4152-8c6f-c8500fd62ff8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation, Income Approach</link:label>
    <link:label id="lab_us-gaap_IncomeApproachValuationTechniqueMember_label_en-US" xlink:label="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation, Income Approach [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeApproachValuationTechniqueMember" xlink:to="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_8edafec3-3628-490e-bdb3-07ddc5aeec08_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f03c5878-57e1-43f0-b4bd-998893cc5ff0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ShareInstrumentNumberOfSharesConversionRatio_4e11d9f5-b3b5-4b83-b971-9423a18f3722_terseLabel_en-US" xlink:label="lab_pacb_ShareInstrumentNumberOfSharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ratio of number of shares into which the share instrument may be converted</link:label>
    <link:label id="lab_pacb_ShareInstrumentNumberOfSharesConversionRatio_label_en-US" xlink:label="lab_pacb_ShareInstrumentNumberOfSharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Instrument, Number of Shares, Conversion Ratio</link:label>
    <link:label id="lab_pacb_ShareInstrumentNumberOfSharesConversionRatio_documentation_en-US" xlink:label="lab_pacb_ShareInstrumentNumberOfSharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares into which the share instrument may be converted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareInstrumentNumberOfSharesConversionRatio" xlink:href="pacb-20241231.xsd#pacb_ShareInstrumentNumberOfSharesConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ShareInstrumentNumberOfSharesConversionRatio" xlink:to="lab_pacb_ShareInstrumentNumberOfSharesConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6f877ea4-7f88-48b7-ada0-b0f50d1f7d09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_f8732ac3-9cb2-4f3b-a693-8e5f21712e03_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term loan</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1ea108f0-4438-4584-9ab8-5f7e72747997_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_c8aeed2a-665a-4f90-8eaf-02850e5277a2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_7574b2c2-59aa-4610-abb3-3e2b18d40b58_terseLabel_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public offering, option to purchase additional shares, period</link:label>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_label_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Offering, Option to Purchase Additional Shares, Period</link:label>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_documentation_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Offering, Option to Purchase Additional Shares, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:href="pacb-20241231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:to="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d192f5be-9bb8-4fc0-b50b-c8f79c081607_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_962f8363-8ad1-4f47-953a-b12e7eb81765_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ServiceAndOtherMember_ef93511e-c879-4d25-9cab-d9aeab7ba268_terseLabel_en-US" xlink:label="lab_pacb_ServiceAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service and other revenue</link:label>
    <link:label id="lab_pacb_ServiceAndOtherMember_label_en-US" xlink:label="lab_pacb_ServiceAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service And Other [Member]</link:label>
    <link:label id="lab_pacb_ServiceAndOtherMember_documentation_en-US" xlink:label="lab_pacb_ServiceAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember" xlink:href="pacb-20241231.xsd#pacb_ServiceAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ServiceAndOtherMember" xlink:to="lab_pacb_ServiceAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_8b27467f-2ce0-4dda-ac3b-3fc5098eab87_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TransferOfInventoryToPropertyAndEquipment_c70cbaf5-223b-49fe-bf23-37ae7605d947_terseLabel_en-US" xlink:label="lab_pacb_TransferOfInventoryToPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory transferred to property and equipment</link:label>
    <link:label id="lab_pacb_TransferOfInventoryToPropertyAndEquipment_label_en-US" xlink:label="lab_pacb_TransferOfInventoryToPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfer of Inventory to Property and Equipment</link:label>
    <link:label id="lab_pacb_TransferOfInventoryToPropertyAndEquipment_documentation_en-US" xlink:label="lab_pacb_TransferOfInventoryToPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transfer of Inventory to Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TransferOfInventoryToPropertyAndEquipment" xlink:href="pacb-20241231.xsd#pacb_TransferOfInventoryToPropertyAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TransferOfInventoryToPropertyAndEquipment" xlink:to="lab_pacb_TransferOfInventoryToPropertyAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_338fadf4-4b8b-42a1-a79d-6914d9007383_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_LossOnPurchaseCommitment_731bb0b6-5f69-4592-ad52-dbea5f4085fc_terseLabel_en-US" xlink:label="lab_pacb_LossOnPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on purchase commitment</link:label>
    <link:label id="lab_pacb_LossOnPurchaseCommitment_label_en-US" xlink:label="lab_pacb_LossOnPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss On Purchase Commitment</link:label>
    <link:label id="lab_pacb_LossOnPurchaseCommitment_documentation_en-US" xlink:label="lab_pacb_LossOnPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss On Purchase Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LossOnPurchaseCommitment" xlink:href="pacb-20241231.xsd#pacb_LossOnPurchaseCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_LossOnPurchaseCommitment" xlink:to="lab_pacb_LossOnPurchaseCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_3f59d67d-7211-48a1-b6db-032a92569bbc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_89dc4f8e-3d8e-4bfc-a8a8-61582ca53e81_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_169b92b5-37b9-467b-bf1d-ad7ba017798c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash paid for purchases of acquired entities, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_42422b36-26e8-46f8-8f93-4b4a64557f25_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_7a7cc9f1-3ea3-4526-81c5-b5277f725364_negatedTerseLabel_en-US" xlink:label="lab_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_label_en-US" xlink:label="lab_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit</link:label>
    <link:label id="lab_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_documentation_en-US" xlink:label="lab_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" xlink:href="pacb-20241231.xsd#pacb_EffectiveIncomeTaxRateReconciliationTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" xlink:to="lab_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_b33a4c9a-1ed7-4402-9093-b16effd9452c_terseLabel_en-US" xlink:label="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lock-up period restriction</link:label>
    <link:label id="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_label_en-US" xlink:label="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Holding Period For Transfer, Assignment Or Sale Of Founder Shares</link:label>
    <link:label id="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_documentation_en-US" xlink:label="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Holding Period For Transfer, Assignment Or Sale Of Founder Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:href="pacb-20241231.xsd#pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:to="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_4b2b412b-b912-41a8-91e5-8f2392212c15_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_9424d9d3-4570-4ec1-80fb-f1a0786fa0a6_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_fbfc7074-aebb-4fda-8eec-8515b72653ba_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7ec5e27e-2e71-4e02-9adf-f501b9c74498_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_8623d723-c1a5-425d-8d5b-b00743353d6e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_LiquidityBonusEventMember_f3ab309b-19cf-48f4-bfa4-3e373326ccd7_terseLabel_en-US" xlink:label="lab_pacb_LiquidityBonusEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity Bonus Event</link:label>
    <link:label id="lab_pacb_LiquidityBonusEventMember_label_en-US" xlink:label="lab_pacb_LiquidityBonusEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity Bonus Event [Member]</link:label>
    <link:label id="lab_pacb_LiquidityBonusEventMember_documentation_en-US" xlink:label="lab_pacb_LiquidityBonusEventMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liquidity Bonus Event</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LiquidityBonusEventMember" xlink:href="pacb-20241231.xsd#pacb_LiquidityBonusEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_LiquidityBonusEventMember" xlink:to="lab_pacb_LiquidityBonusEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8099d674-f142-45a0-89f0-4aedafb61fe2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_c55b2344-ecbc-4b1f-a4c0-b71a00ff29e5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_751fc02e-2126-4716-8ac6-6e1fa9a0fed7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_9f74bfe1-5fc0-40a2-8485-12e7c355a905_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_78da2b30-e4d3-4997-a5d2-befca65e12b9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_63519fb3-e080-4a11-96e9-0066431d3a6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_a7fd5a5c-f57d-4f13-8d5f-4ed591e2a1a7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate outstanding balance</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_ba1c2a30-0731-4292-b842-b1fe61e4397b_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_a7700da6-b842-49ee-9ebb-145620f99cc6_terseLabel_en-US" xlink:label="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-Process Research and Development Indefinite Lived</link:label>
    <link:label id="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_label_en-US" xlink:label="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research And Development Indefinite Lived [Member]</link:label>
    <link:label id="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_documentation_en-US" xlink:label="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-process research and development indefinite lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:href="pacb-20241231.xsd#pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:to="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentInterestInTheEventOfDefault_021f2af7-f08c-42e8-8263-5ca413e031b1_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest in the event of default</link:label>
    <link:label id="lab_pacb_DebtInstrumentInterestInTheEventOfDefault_label_en-US" xlink:label="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest in the Event of Default</link:label>
    <link:label id="lab_pacb_DebtInstrumentInterestInTheEventOfDefault_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest in the Event of Default</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentInterestInTheEventOfDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:to="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_84547e99-45a9-4ddc-88d7-382d95206d4c_terseLabel_en-US" xlink:label="lab_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment, discount rate</link:label>
    <link:label id="lab_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_label_en-US" xlink:label="lab_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill Impairment, Discounted Cash Flow Model, Discount Rate</link:label>
    <link:label id="lab_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_documentation_en-US" xlink:label="lab_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill Impairment, Discounted Cash Flow Model, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate" xlink:href="pacb-20241231.xsd#pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate" xlink:to="lab_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_c3c4066b-1cbf-4e6a-a470-28ee99ea303b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_0b22b8f6-ee2c-4dbd-9b97-8f64f8ae2d18_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtConversionTermsTwoMember_c1049090-1d71-48a7-83af-8c7188d603f8_terseLabel_en-US" xlink:label="lab_pacb_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Two</link:label>
    <link:label id="lab_pacb_DebtConversionTermsTwoMember_label_en-US" xlink:label="lab_pacb_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Two [Member]</link:label>
    <link:label id="lab_pacb_DebtConversionTermsTwoMember_documentation_en-US" xlink:label="lab_pacb_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsTwoMember" xlink:href="pacb-20241231.xsd#pacb_DebtConversionTermsTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtConversionTermsTwoMember" xlink:to="lab_pacb_DebtConversionTermsTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_8f4f472d-d64a-44e8-b4c0-25d4e2ed75ea_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_RefundFromDeposits_41f21f3e-da9e-408b-aaca-3d7e6b351610_terseLabel_en-US" xlink:label="lab_pacb_RefundFromDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Refund from deposits</link:label>
    <link:label id="lab_pacb_RefundFromDeposits_label_en-US" xlink:label="lab_pacb_RefundFromDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Refund From Deposits</link:label>
    <link:label id="lab_pacb_RefundFromDeposits_documentation_en-US" xlink:label="lab_pacb_RefundFromDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refund From Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RefundFromDeposits" xlink:href="pacb-20241231.xsd#pacb_RefundFromDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_RefundFromDeposits" xlink:to="lab_pacb_RefundFromDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_014d4b6b-e3ed-4e7c-9084-9f3811ee11f6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_28edd11e-9508-4941-9ab0-14e54335ada0_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets include acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_b81fdc16-64a9-4d94-a738-c3d1e0fac0a1_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_932b7b9a-1cb4-4197-b66c-c8302bdf12c3_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_d2b26e04-3d35-4bed-8164-436e4cf962cd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_0c4e51da-5e96-4835-9bca-49ed91651211_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0cb02bbc-6846-495e-93dd-079832843a88_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockholdersEquityTable_bc3c2ac1-bb1e-4100-9f91-70fbc6564064_terseLabel_en-US" xlink:label="lab_pacb_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity [Table]</link:label>
    <link:label id="lab_pacb_StockholdersEquityTable_label_en-US" xlink:label="lab_pacb_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity [Table]</link:label>
    <link:label id="lab_pacb_StockholdersEquityTable_documentation_en-US" xlink:label="lab_pacb_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders' Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockholdersEquityTable" xlink:href="pacb-20241231.xsd#pacb_StockholdersEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockholdersEquityTable" xlink:to="lab_pacb_StockholdersEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_26b7a335-6e89-4f36-b261-ebdc0d57d459_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_e9ffc63f-0b48-495a-a2fc-1203bcd33393_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_EquityIncentivePlan2020Member_ca5aeb09-10ec-4008-9957-71389a06a108_terseLabel_en-US" xlink:label="lab_pacb_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Equity Incentive Plan</link:label>
    <link:label id="lab_pacb_EquityIncentivePlan2020Member_label_en-US" xlink:label="lab_pacb_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan2020 [Member]</link:label>
    <link:label id="lab_pacb_EquityIncentivePlan2020Member_documentation_en-US" xlink:label="lab_pacb_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EquityIncentivePlan2020Member" xlink:href="pacb-20241231.xsd#pacb_EquityIncentivePlan2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_EquityIncentivePlan2020Member" xlink:to="lab_pacb_EquityIncentivePlan2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8042f4bc-947b-4b1b-a9d6-73fa86f0a7fc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BUSINESS ACQUISITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_c371b743-a060-4b81-87cd-39431e139b25_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a41e7e8c-89fe-4583-94b7-29db7ab81823_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_deb0ef1c-cc93-4dd0-8e37-0cc9ed086dc8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_a3d13bc0-25ab-425b-91f5-bc38571d217a_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_135d1fd4-78d0-4f04-b17d-e8c3077005e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_c063beaf-1504-426f-ba79-5263d501fa89_terseLabel_en-US" xlink:label="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional liability associated with indemnification obligations</link:label>
    <link:label id="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_label_en-US" xlink:label="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Liability Associated With Indemnification Obligations</link:label>
    <link:label id="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_documentation_en-US" xlink:label="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Liability Associated With Indemnification Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:href="pacb-20241231.xsd#pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:to="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_78dc4d08-1e7f-4c8c-a8c6-e0d36860d4a9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9e03de71-0bdf-4806-8f69-22e874319b87_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in conjunction with equity plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_62319dc3-5edd-4d8b-b38f-d952931634e5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_5eb77969-3c6c-47a7-b3c6-fec04b745cca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets From Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c9d184c2-c6c4-4fce-b334-954ca9b1d83a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_b2ad8531-d27e-47e8-9a38-f918438f7007_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_176be9f1-ec6c-4a82-b7b8-f183ee22c228_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_349b7b34-ab6d-4094-94ab-db4ef9cb6a64_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_85b28bbb-1869-42d1-92ba-1d33f43d854b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_label_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDisclosures" xlink:to="lab_us-gaap_LossContingencyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_59a87d7e-c258-49b2-8080-de9f9f24cf7e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d76bcd4c-a086-414f-931b-370ce9992d9d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Pronouncements Pending Adoption</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d1df85d9-cefa-482f-91a9-1098e78fd13b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_87098934-2f32-45b0-a9bc-6faf7bb81145_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_72f73cb7-e9a2-44ec-a952-eca0e8600456_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d0d2a175-265d-44be-b45c-df6abbab5cbd_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_c0ffdbed-3885-40b8-975c-23dd974a4dc8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_f4278eee-1fe6-4b80-be48-5dbd8fa9e73e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_1e949818-ad6e-4795-bda1-335b0f6e2f22_terseLabel_en-US" xlink:label="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone revenue</link:label>
    <link:label id="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_label_en-US" xlink:label="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Revenue Achievement Milestone</link:label>
    <link:label id="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_documentation_en-US" xlink:label="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:href="pacb-20241231.xsd#pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:to="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_125e9271-b457-4302-95e4-085169165b64_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RESTRUCTURING</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_3b172a4d-1ccb-4955-a6cb-b98627e80749_terseLabel_en-US" xlink:label="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_label_en-US" xlink:label="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_1595624e-5509-47bc-bc03-d321a7650c6e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rates</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4d5fef48-0d4d-4800-9de3-215db89c4c38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_4105d6d4-6be4-4403-9db7-78940f601b09_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_88f883c4-d5be-419c-bd2f-d581959920a6_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TenantImprovements_957ebde2-c162-4376-8963-0ab900f3557e_terseLabel_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvement allowance</link:label>
    <link:label id="lab_us-gaap_TenantImprovements_label_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TenantImprovements" xlink:to="lab_us-gaap_TenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_ed864812-bafc-4588-858c-e01d5b640773_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_c87cbc32-0f30-4d59-8f35-5ccb88388f60_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ba9041c2-8d39-43e5-b26c-621299bbfb66_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Diluted net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_a07c72f1-6760-4008-9a0a-5847fad3e099_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_60672b94-0afb-48b5-b945-d7b4bbdefafe_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_ed7cc816-4c19-4505-8ca2-fb8eb679ca1c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_9c5d593b-9962-476e-b28b-da8e28c4e838_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7792b81d-0850-4582-8d5b-5793dd8b3b0e_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_212c56e3-c10c-4780-ad9f-100fab591e72_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_cf6b45ec-c6fe-45ee-a101-8fc9f37696c4_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2fcb67f0-f7db-4a97-9e43-76c7f6209cb3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_bdc6975d-0576-4467-8a1a-18ce26baa068_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2648c213-a6c1-4867-b0c4-7afccadbac39_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_fdc10f4a-e761-40f6-9455-1d104effd01c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60957395-ea31-446d-a186-ecde31a3e4cf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a70f43a8-1027-4600-9c45-bf84012238f0_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset and liability additions and modifications</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_13986682-0bb2-472d-93b9-150023447e6c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_18384e63-2593-4a01-ae65-fa592bba9105_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_4d762304-7011-467d-8444-d2264eae0cb0_terseLabel_en-US" xlink:label="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Plan, Inducement Plan, And The Omniome Plan</link:label>
    <link:label id="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_label_en-US" xlink:label="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Plan, Inducement Plan, And The Omniome Plan [Member]</link:label>
    <link:label id="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_documentation_en-US" xlink:label="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Plan, Inducement Plan, And The Omniome Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:href="pacb-20241231.xsd#pacb_A2020PlanInducementPlanAndTheOmniomePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:to="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0a90c345-2d73-4f40-b11a-7be0fcb42e66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8ebf0797-9691-4939-bc05-cde288c18d70_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_2256790b-fc09-42b3-bec0-a70a7821e004_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_324bb689-5d59-4641-b959-11f760a54a0a_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_5650ac10-7586-4a59-9b34-e3bc286a0646_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_a48e65a5-8c6d-49a0-84e3-05714634773c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e4652be0-ea4b-4bd3-991d-cee1d84c9a56_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_b8668df8-aad8-48ae-840b-c7a5246fefcb_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TimeBasedStockOptionMember_30520d35-8086-4952-8ad5-524471484a9b_terseLabel_en-US" xlink:label="lab_pacb_TimeBasedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time-Based Stock Option</link:label>
    <link:label id="lab_pacb_TimeBasedStockOptionMember_label_en-US" xlink:label="lab_pacb_TimeBasedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Based Stock Option [Member]</link:label>
    <link:label id="lab_pacb_TimeBasedStockOptionMember_documentation_en-US" xlink:label="lab_pacb_TimeBasedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time-based stock option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedStockOptionMember" xlink:href="pacb-20241231.xsd#pacb_TimeBasedStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TimeBasedStockOptionMember" xlink:to="lab_pacb_TimeBasedStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_LongTermRestrictedCashFairValueDisclosure_1cb6fddd-d3ec-407a-8518-ed526cd91ad4_terseLabel_en-US" xlink:label="lab_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_pacb_LongTermRestrictedCashFairValueDisclosure_label_en-US" xlink:label="lab_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Restricted Cash Fair Value Disclosure</link:label>
    <link:label id="lab_pacb_LongTermRestrictedCashFairValueDisclosure_documentation_en-US" xlink:label="lab_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Restricted Cash Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:href="pacb-20241231.xsd#pacb_LongTermRestrictedCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:to="lab_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_9f24c6c3-81ec-4d50-9f0d-44278ab0c60c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expense:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_e77b7ff0-b1c9-458e-880e-21dd35d0b351_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives of The Major Classes of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_fb6522b6-45be-445d-9511-e47b47aba82b_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_2c4c69e5-cff2-49c0-b87f-0e4b4d67b2a8_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Loss, Financial Instrument [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_e84c7fc2-f79f-4621-bb17-12ce7cd69cf6_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asia-Pacific</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_fccf49a8-457f-4724-9206-b91935628c53_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_89771fdb-6095-442a-a19b-384b797c7e29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_ffb97002-797a-421e-8210-db32e9160970_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_f9dd5eef-5375-4487-9d26-12735ccc8b8e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BalanceSheetClassificationAbstract_3156eabb-4de8-4587-8063-9944ffa1ac14_terseLabel_en-US" xlink:label="lab_pacb_BalanceSheetClassificationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Classification</link:label>
    <link:label id="lab_pacb_BalanceSheetClassificationAbstract_label_en-US" xlink:label="lab_pacb_BalanceSheetClassificationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Classification [Abstract]</link:label>
    <link:label id="lab_pacb_BalanceSheetClassificationAbstract_documentation_en-US" xlink:label="lab_pacb_BalanceSheetClassificationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Balance Sheet Classification [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BalanceSheetClassificationAbstract" xlink:href="pacb-20241231.xsd#pacb_BalanceSheetClassificationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BalanceSheetClassificationAbstract" xlink:to="lab_pacb_BalanceSheetClassificationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4f03e913-618b-4c4a-8b65-300e141465bc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_9962e04a-1e74-4476-960c-ec6ce47bf0e2_terseLabel_en-US" xlink:label="lab_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government &amp; agency securities</link:label>
    <link:label id="lab_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Us Government Corporations And Agencies Securities Not Included With Cash And Cash Equivalents [Member]</link:label>
    <link:label id="lab_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_documentation_en-US" xlink:label="lab_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">US Government Corporations and Agencies Securities, , Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:href="pacb-20241231.xsd#pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_aeaeec2d-2453-4e7e-87ac-442f2719ef95_terseLabel_en-US" xlink:label="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commissions, percentage of gross proceeds</link:label>
    <link:label id="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_label_en-US" xlink:label="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering</link:label>
    <link:label id="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_documentation_en-US" xlink:label="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:href="pacb-20241231.xsd#pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:to="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_b55edcb4-2523-43a2-b376-394617a287a5_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1a02b24f-5f67-48e8-a1b9-ff0f3e7f0c32_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AchievementOfMilestoneMember_d3380f7a-0e85-42d9-b419-34e3da2448ed_terseLabel_en-US" xlink:label="lab_pacb_AchievementOfMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of Milestone</link:label>
    <link:label id="lab_pacb_AchievementOfMilestoneMember_label_en-US" xlink:label="lab_pacb_AchievementOfMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement Of Milestone [Member]</link:label>
    <link:label id="lab_pacb_AchievementOfMilestoneMember_documentation_en-US" xlink:label="lab_pacb_AchievementOfMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon achievement of a milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AchievementOfMilestoneMember" xlink:href="pacb-20241231.xsd#pacb_AchievementOfMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AchievementOfMilestoneMember" xlink:to="lab_pacb_AchievementOfMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_90802c0c-cabe-45e2-95c5-e92a9568803f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_214bfdee-54e8-4907-ac49-7c8cbfc239ee_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_885467a7-d2bc-45e8-85a2-3d47a5397812_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e46a6a27-8e0e-4233-bbb1-6361f7280c1f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_24b0a206-9fc0-4b33-9dfa-bf9c228de8d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_58bac5cc-1fb1-4138-96d8-9e886d74fb88_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_c91734c7-59d2-4bd4-83c5-736adda1297e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_48dbf83f-26ab-4474-b664-0f9f05604fa4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_c1e8ffc0-8304-429b-8249-0304db4ca1b5_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_86f06f66-b5d2-4f19-a44c-5387367f4b2c_periodStartLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance as of December&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_2a9f858e-1fbf-4db7-9019-7edb425df904_periodEndLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance as of December&#160;31, 2024</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_7739aa84-720f-4d0b-a01e-59c781f52cba_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayable" xlink:to="lab_us-gaap_ConvertibleNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88486dc4-a9fb-4462-b9d3-fc3ed3c2b079_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_6fa74e4e-bdd3-4798-9c10-3f98cf4613c1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock from equity plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_d2a1757c-e6a1-4a6b-a5aa-041c34397ff3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment transferred to inventory</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Transfers and Changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesIssued1_70180177-2464-4240-9b61-6d5226aac79a_terseLabel_en-US" xlink:label="lab_us-gaap_NotesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes exchange</link:label>
    <link:label id="lab_us-gaap_NotesIssued1_label_en-US" xlink:label="lab_us-gaap_NotesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesIssued1" xlink:to="lab_us-gaap_NotesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_f659a8ea-4b71-460a-8919-c02836fef4ee_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger related transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_0b13343d-cc03-450c-a7bf-a092f33858d0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_9b21522e-d653-457e-9e32-87e9a1c818e1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b470bfa3-98b0-47ce-ac51-6a91ade61c51_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration_20fdd149-a9d9-4ea5-a1a6-e55311aafff2_terseLabel_en-US" xlink:label="lab_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, subject to expiration</link:label>
    <link:label id="lab_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration_label_en-US" xlink:label="lab_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Amount Subject To Expiration</link:label>
    <link:label id="lab_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration_documentation_en-US" xlink:label="lab_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Amount Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration" xlink:href="pacb-20241231.xsd#pacb_OperatingLossCarryforwardsAmountSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration" xlink:to="lab_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_a4b4ed21-25d5-4f62-ac4e-48c34b5d07a9_terseLabel_en-US" xlink:label="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock from underwritten public equity offerings, net of issuance costs</link:label>
    <link:label id="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_label_en-US" xlink:label="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock, Net of Issuance Costs</link:label>
    <link:label id="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity, net of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:href="pacb-20241231.xsd#pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:to="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_050fa4cf-c94e-4278-974f-769f57664cfb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt premium</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_1177cfd9-19c9-4a87-a8db-246768585f2d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CashAndMoneyMarketFundsMember_dba0f426-f6de-4cee-a02e-f5e5da1af47a_terseLabel_en-US" xlink:label="lab_pacb_CashAndMoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and money market funds</link:label>
    <link:label id="lab_pacb_CashAndMoneyMarketFundsMember_label_en-US" xlink:label="lab_pacb_CashAndMoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Money Market Funds [Member]</link:label>
    <link:label id="lab_pacb_CashAndMoneyMarketFundsMember_documentation_en-US" xlink:label="lab_pacb_CashAndMoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and money market funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CashAndMoneyMarketFundsMember" xlink:href="pacb-20241231.xsd#pacb_CashAndMoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CashAndMoneyMarketFundsMember" xlink:to="lab_pacb_CashAndMoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_5f1af33c-6155-4335-82b8-5f88922094f2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_834617dc-dbe1-4552-9577-58e38f803f42_terseLabel_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average trading period</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_label_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Average Trading Period, Acquisition</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_documentation_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Average Trading Period, Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:href="pacb-20241231.xsd#pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:to="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_99b15018-533c-4661-9261-95118f4cefe7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesTable_77d074bf-b472-47f2-bb87-cfcf9f921b0b_terseLabel_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:href="pacb-20241231.xsd#pacb_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_01d8af16-6125-40d8-83ed-5fa3b19660cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_c969895c-c361-4035-9aae-3860cba00b40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Time-Based RSUs Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_950873af-5fb3-4d25-af81-07a43412c8ce_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TimeBasedAndPerformanceBasedOptionsMember_7cdb616d-d866-417e-bcea-96cd7f434fe5_terseLabel_en-US" xlink:label="lab_pacb_TimeBasedAndPerformanceBasedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time-Based and Performance-Based Options</link:label>
    <link:label id="lab_pacb_TimeBasedAndPerformanceBasedOptionsMember_label_en-US" xlink:label="lab_pacb_TimeBasedAndPerformanceBasedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Based And Performance Based Options [Member]</link:label>
    <link:label id="lab_pacb_TimeBasedAndPerformanceBasedOptionsMember_documentation_en-US" xlink:label="lab_pacb_TimeBasedAndPerformanceBasedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time-based and performance-based options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedAndPerformanceBasedOptionsMember" xlink:href="pacb-20241231.xsd#pacb_TimeBasedAndPerformanceBasedOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TimeBasedAndPerformanceBasedOptionsMember" xlink:to="lab_pacb_TimeBasedAndPerformanceBasedOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a7c1f392-6457-43f4-9ec8-186c3f714620_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_576a15ad-0506-4433-b9c7-424410e2a140_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_f17a69e7-450d-4c34-8f18-1c3020c687f0_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets, finite-lived</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_df761805-c064-4ac9-b0af-002c6b50feab_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of offering expense</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AccruedProductDevelopmentCostsCurrent_0d8c63b7-4cac-4624-9ffb-78bd5fbee297_terseLabel_en-US" xlink:label="lab_pacb_AccruedProductDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued product development costs</link:label>
    <link:label id="lab_pacb_AccruedProductDevelopmentCostsCurrent_label_en-US" xlink:label="lab_pacb_AccruedProductDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Product Development Costs, Current</link:label>
    <link:label id="lab_pacb_AccruedProductDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_pacb_AccruedProductDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Product Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedProductDevelopmentCostsCurrent" xlink:href="pacb-20241231.xsd#pacb_AccruedProductDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AccruedProductDevelopmentCostsCurrent" xlink:to="lab_pacb_AccruedProductDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_4ad9019c-969b-4bf8-b83e-e060e56c813d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock following milestone achievement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_9c5f1b37-f7e0-4292-aa7c-0aef4cad01e8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on purchase commitment</link:label>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_label_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Firm Purchase Commitment, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:to="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_02bbc8aa-39fa-476d-b6fd-30ac0f6cf8ae_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030 and thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_0dff3240-6d0a-4ae0-9343-79e24471de09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Impaired Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Impaired Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:to="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod_70387b58-3674-4de9-bcd0-b705028c21a7_terseLabel_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anniversary</link:label>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod_label_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Closing Date Period</link:label>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod_documentation_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Closing Date Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" xlink:href="pacb-20241231.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" xlink:to="lab_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_d57a395e-29ac-4ff0-910d-352c7ef7cf15_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in conjunction with equity plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_153ce9a3-5c87-4d13-b43c-be13a84dfd36_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in balance related to tax positions taken during current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8aa94a19-8f09-4e5f-a58e-f349c95282e2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_a62f41fe-460e-4bba-84cd-c27205163c6a_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_912427e7-741f-46c4-8ba6-ca80a1744671_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2d166ac4-bf72-4d14-8f40-1c5b34f7f8a5_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1591d238-b3ec-4bfc-a043-d53a2c43d371_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_8bc5af6f-43ce-4bb7-8a49-4f18bad182c0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_b2bae194-b14e-4004-8b70-86b04bed18b8_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_a2e29b28-11e1-42c9-8036-aba1307666ec_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_b7ba01a1-f039-4311-af8f-fbff78b58f83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ba8a1096-da68-477a-89f1-78faa4e9876d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_7c6aa4f6-887b-4125-80e5-e562c7845828_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e5d176f9-f65c-4fcf-aa3c-caa1d36b231e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_742be71d-4e7b-419b-85a9-012355c7e354_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in the estimated fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_378de573-dc0e-4d54-a204-df70630f6383_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9f6a60a5-a7e2-4242-aff2-1de22f4fa837_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c26c95be-72cb-4065-8693-ba1f11f5f153_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense_6a0905b8-44da-49ea-a2c2-011eede64c0d_terseLabel_en-US" xlink:label="lab_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancellation of indebtedness income and interest expense</link:label>
    <link:label id="lab_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense_label_en-US" xlink:label="lab_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Cancellation Of Indebtedness Income And Interest Expense</link:label>
    <link:label id="lab_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense_documentation_en-US" xlink:label="lab_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Cancellation Of Indebtedness Income And Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" xlink:href="pacb-20241231.xsd#pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" xlink:to="lab_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_416b20a2-e129-44c4-af9b-01ee0ce51ea8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_a9e9e3a4-8a79-47ce-a3d2-464fd9720955_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_5ebe87c5-dc8f-47e1-aefa-4b4420be9137_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ff40a9bb-fc48-4881-95a3-306859437c19_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_ef509ef2-ba25-49e1-ad9a-361252b2beed_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_dc3f7deb-a2ca-48ce-8c1a-679dfb7f4991_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_25740a78-2504-40be-a5a8-6c5a966c9a51_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated total restructuring costs to still be incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6ac19af4-ca95-41cd-ab08-e6f21622c0a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_3ac4e6d4-646b-428b-bf6a-39bb97c37684_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_533d7114-eb5e-41af-bc6e-097b1f196c24_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_df98d9f3-0bdd-445c-b618-6312eaea5c0b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_3e41b755-bdcb-46fd-917a-0d3c666dea44_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtConversionTermsOneMember_107dd722-639f-43f1-8e42-9be6c72749bf_terseLabel_en-US" xlink:label="lab_pacb_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms One</link:label>
    <link:label id="lab_pacb_DebtConversionTermsOneMember_label_en-US" xlink:label="lab_pacb_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms One [Member]</link:label>
    <link:label id="lab_pacb_DebtConversionTermsOneMember_documentation_en-US" xlink:label="lab_pacb_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsOneMember" xlink:href="pacb-20241231.xsd#pacb_DebtConversionTermsOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtConversionTermsOneMember" xlink:to="lab_pacb_DebtConversionTermsOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_83b088e2-d3ab-431f-93fa-1c007f9d83d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, exercisable, number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AuditInformationAbstract_label_en-US" xlink:label="lab_pacb_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_pacb_AuditInformationAbstract_documentation_en-US" xlink:label="lab_pacb_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AuditInformationAbstract" xlink:href="pacb-20241231.xsd#pacb_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AuditInformationAbstract" xlink:to="lab_pacb_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_32d6b20b-a683-44ad-8f1f-650e5a4943b3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_273c8b92-057d-4dfe-9294-8f0e7b95dad3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DeferredTaxLiabilitiesRightOfUseAssets_5e557799-9087-489a-a2eb-a79ca49e0ee1_negatedLabel_en-US" xlink:label="lab_pacb_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_pacb_DeferredTaxLiabilitiesRightOfUseAssets_label_en-US" xlink:label="lab_pacb_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right-of-use Assets</link:label>
    <link:label id="lab_pacb_DeferredTaxLiabilitiesRightOfUseAssets_documentation_en-US" xlink:label="lab_pacb_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right-of-use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxLiabilitiesRightOfUseAssets" xlink:href="pacb-20241231.xsd#pacb_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="lab_pacb_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_0a6184ad-3005-49f8-b398-0df3a54abea0_terseLabel_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment, increase in basis point discount rate</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_label_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Increase In Basis Point Discount Rate</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_documentation_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Increase In Basis Point Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:href="pacb-20241231.xsd#pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:to="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_b968dccd-688a-4419-be72-45c12c2c0300_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_86816cd7-c80b-42c2-8558-b408c9625f76_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_881503da-ffa6-4fe2-9732-4be962042deb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_b233b8f4-829b-4a31-b606-401a08a3a8e3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_48fe98ac-dda1-4ae4-864d-b45d45a8a6a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_LaboratoryEquipmentAndMachineryMember_3f8ce953-0bb0-4a82-85f0-76c61c510d41_terseLabel_en-US" xlink:label="lab_pacb_LaboratoryEquipmentAndMachineryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment and machinery</link:label>
    <link:label id="lab_pacb_LaboratoryEquipmentAndMachineryMember_label_en-US" xlink:label="lab_pacb_LaboratoryEquipmentAndMachineryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment And Machinery [Member]</link:label>
    <link:label id="lab_pacb_LaboratoryEquipmentAndMachineryMember_documentation_en-US" xlink:label="lab_pacb_LaboratoryEquipmentAndMachineryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory Equipment And Machinery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LaboratoryEquipmentAndMachineryMember" xlink:href="pacb-20241231.xsd#pacb_LaboratoryEquipmentAndMachineryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_LaboratoryEquipmentAndMachineryMember" xlink:to="lab_pacb_LaboratoryEquipmentAndMachineryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a95aa4d1-46b2-4b25-9182-f774199fd670_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5662edc5-a036-48c0-a7d2-3a6af8d28771_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1623bccd-850f-447c-b7f1-45f5fe167c47_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_MilestoneAchievementMember_cfe56bf0-8b48-402b-ad24-8fb75e70d49a_terseLabel_en-US" xlink:label="lab_pacb_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Achievement</link:label>
    <link:label id="lab_pacb_MilestoneAchievementMember_label_en-US" xlink:label="lab_pacb_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:label id="lab_pacb_MilestoneAchievementMember_documentation_en-US" xlink:label="lab_pacb_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MilestoneAchievementMember" xlink:href="pacb-20241231.xsd#pacb_MilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_MilestoneAchievementMember" xlink:to="lab_pacb_MilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2029ConvertibleSeniorNotesMember_1b523720-39ff-47c6-9700-0b01ed17557a_terseLabel_en-US" xlink:label="lab_pacb_A2029ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029 Convertible Senior Notes</link:label>
    <link:label id="lab_pacb_A2029ConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_pacb_A2029ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2029 Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_pacb_A2029ConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_pacb_A2029ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2029 Convertible Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2029ConvertibleSeniorNotesMember" xlink:href="pacb-20241231.xsd#pacb_A2029ConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2029ConvertibleSeniorNotesMember" xlink:to="lab_pacb_A2029ConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_18f9c372-2240-49fa-b3ed-8a0b77296ced_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated depreciation</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_27bba58b-83a3-4f25-bcde-8b6ce25470ad_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_5e7580e7-2f7c-420a-8bff-329c41fa88f6_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_74c27823-b6ce-4ae5-bd78-898441d68c74_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_902aab0d-c329-4ddd-a59f-813cda01acdf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_110c6a13-3cd4-473c-b972-5310809092ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Reserve for Product Warranties</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Product Warranty Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_851deda4-7af3-4714-9623-86ef54b48c7b_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d0a71d1f-029b-438a-a495-b3fd89789646_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_a3e2389b-3cca-4ae8-8e96-75d57658af1e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_9c8a524b-a9be-4703-8edc-65e845397960_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment, Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_281f9e2a-c4fa-425a-9c6a-171c4cf0c629_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_873f773d-54f4-473c-b2d1-b033a040439d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e9581488-5e56-4194-a31c-ce676647d268_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c5c878b6-155d-428c-9c94-7c1cfad2b30d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ConsumableMember_e8832915-040d-4caa-9752-3c9c139ad41f_terseLabel_en-US" xlink:label="lab_pacb_ConsumableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consumable revenue</link:label>
    <link:label id="lab_pacb_ConsumableMember_label_en-US" xlink:label="lab_pacb_ConsumableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumable [Member]</link:label>
    <link:label id="lab_pacb_ConsumableMember_documentation_en-US" xlink:label="lab_pacb_ConsumableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consumable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConsumableMember" xlink:href="pacb-20241231.xsd#pacb_ConsumableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ConsumableMember" xlink:to="lab_pacb_ConsumableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_59a8d24f-a76e-4e2e-8a97-e39fe9e6cf80_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_9df90f87-b729-42e5-a639-8b2eecbddf90_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ab4260a5-10e9-4423-bdcd-854c7c8516c3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_7836fbc8-8b2a-4c6e-9170-047d1bd98f0e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_SanDiegoOfficeMember_488ddd26-6501-4dab-aca6-ea55761e4614_terseLabel_en-US" xlink:label="lab_pacb_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">San Diego Office</link:label>
    <link:label id="lab_pacb_SanDiegoOfficeMember_label_en-US" xlink:label="lab_pacb_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:label id="lab_pacb_SanDiegoOfficeMember_documentation_en-US" xlink:label="lab_pacb_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">San Diego Office</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SanDiegoOfficeMember" xlink:href="pacb-20241231.xsd#pacb_SanDiegoOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_SanDiegoOfficeMember" xlink:to="lab_pacb_SanDiegoOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_f7f1c4ff-b3ae-418e-bb0d-dedb6223d278_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6aa8f12f-e4a2-4c6d-bb6d-609656580d83_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_03354e36-ce71-46a7-bd05-846866572ec1_terseLabel_en-US" xlink:label="lab_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research and experimental expenses</link:label>
    <link:label id="lab_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:label id="lab_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="pacb-20241231.xsd#pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="lab_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_e42d1fed-3e77-432e-9af1-ddda9e9cd8ff_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in acquisition of Apton</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_ba32419e-20f3-4305-8aa3-6c59de1946cb_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in acquisition of Apton (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_a76773b5-7524-47f6-8eb6-104ec91c94ff_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1a0edb14-53db-463c-b1bf-6369f0ddf664_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State tax rate, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_7eaecef0-464f-494c-87de-b3c225c4258f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6c96c113-899a-43a0-b4d4-1cd56c109c1d_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_b5d07ce1-7d1a-4208-ace8-7b44ccd649b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_12c2e98e-d039-47be-9eda-c2358704e49f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_6f2d8ff1-b2e5-44c9-92da-7397789cf3a4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_30a41e6e-1173-47c1-a79c-d8b20c80e08b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_999d29d8-ce8c-4045-86c6-bf9d3eb68609_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_1820a42a-27af-43b5-8604-13556cf56963_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b4b532f5-1637-47eb-8a67-cf51b857bb95_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_454ccfb1-9af7-46b8-acce-c23cd5974109_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic net (loss) income per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_80f2a584-4b75-4c2d-9182-73c47cd460f0_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock under equity offerings, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_c4b4f971-6ef4-42f9-9bcc-0e0b2ec76a01_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2030ConvertibleSeniorNotesMember_71f9763a-450d-4516-a03a-d39d7517493f_terseLabel_en-US" xlink:label="lab_pacb_A2030ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030 Convertible Senior Notes</link:label>
    <link:label id="lab_pacb_A2030ConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_pacb_A2030ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2030 Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_pacb_A2030ConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_pacb_A2030ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2030 Convertible Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember" xlink:href="pacb-20241231.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2030ConvertibleSeniorNotesMember" xlink:to="lab_pacb_A2030ConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IncomeLossPerShareAbstract_032c9383-70a1-4b33-b534-e02bea11a54f_terseLabel_en-US" xlink:label="lab_pacb_IncomeLossPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_pacb_IncomeLossPerShareAbstract_label_en-US" xlink:label="lab_pacb_IncomeLossPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Loss per Share Abstrct</link:label>
    <link:label id="lab_pacb_IncomeLossPerShareAbstract_documentation_en-US" xlink:label="lab_pacb_IncomeLossPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Loss per Share Abstract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeLossPerShareAbstract" xlink:href="pacb-20241231.xsd#pacb_IncomeLossPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IncomeLossPerShareAbstract" xlink:to="lab_pacb_IncomeLossPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fc87d060-0ea8-4d3e-b6bd-50f140830c5d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_b3bf9f4f-cc8e-473c-a31c-00f42a94ca5c_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_eda8c493-dc58-4d17-b1bb-2edd331cc9e0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6e491a05-ebd8-45e6-b9b9-2db310283f69_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_d87f5700-5fcf-48d5-90c2-c842764482a8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration and Other Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c254fa02-313c-4608-97be-98fd72f65d87_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8adca214-e2fe-418c-99d2-cc367d1d5807_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRent_3107672a-fbef-4ff1-ab24-649a5cb74f10_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRent_label_en-US" xlink:label="lab_us-gaap_PaymentsForRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRent" xlink:to="lab_us-gaap_PaymentsForRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_cfa452bc-f209-4a4e-98a6-6e252ecdf9df_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Notes payable principal payoff</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_cf10c2bd-b57b-4f2e-89aa-8c558911c341_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_f366dcda-4f5a-4655-b84d-016fa152cf57_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6be5710b-1957-46e6-82dc-d542b5d79ef3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_2d278cd4-53c2-46b4-b4d7-85af576c7166_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e61ba9b5-9b99-49e9-9bbe-87edb2db9695_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_379c3eca-71ca-4570-b8c6-c8c05c29b132_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_402b7e1d-3946-4f10-b9d2-c87822c34e25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_512c29b8-73cb-48aa-8b5c-e99ac7afb5f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_632fe812-1bb7-4e56-92d3-340d4ba8dabd_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3e0187c6-4971-4281-b4cf-659da15178fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_388e14fe-a0d0-412b-9c14-37060ec426a9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_0c285f6b-08fe-4fb3-b862-d18948cd3b4d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_96d19fa1-48f6-4af2-b057-dd75cbc27ea1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e3531f9e-17f9-4bca-ae6f-5abd18fc02e8_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2fc87ff3-fda8-4fbc-bce3-d42d8e982512_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_18444f2a-acf0-4b61-870d-254cfa5684c1_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_b048ffd2-ebe9-4290-956c-dd7a4464b4d5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_130ff952-e5a5-4a32-aa23-ffeac5017721_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_d0dd9993-8ff1-4d53-a753-043260dc6473_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before taxes from foreign operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e7b16af3-fc7f-477c-9c21-c656732474de_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_06f8e3a3-f94e-4846-a9bf-89d40718c5c4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_d976f254-85ec-4fe9-a379-c52bbbe9748b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c3abd47a-d155-4492-bd2d-95a98ad545e2_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_f016b098-cc66-4dea-bf64-1f011c928b34_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt redemption, percentage of conversion price</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_label_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Conversion Price</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:to="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7fe4daef-a410-4e7d-8cbd-cace4e3c0aac_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_33c93297-eaf5-409a-87fe-49ab55f8ffc4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_76df869a-e8ab-4dfd-8409-f8172d9f7a78_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_6b81de20-a053-4550-b2ec-00dd0f319dc6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_c60e8c84-02f2-4963-b3c2-f3ae739df0cc_terseLabel_en-US" xlink:label="lab_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Voting right of common stock share holders, number of votes</link:label>
    <link:label id="lab_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_label_en-US" xlink:label="lab_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes Per Share Owned</link:label>
    <link:label id="lab_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_documentation_en-US" xlink:label="lab_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes Per Share Owned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" xlink:href="pacb-20241231.xsd#pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" xlink:to="lab_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockVotingRights_06b36976-8b1c-472f-9a0f-590abcb1896a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockVotingRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Voting right of common stock share holders</link:label>
    <link:label id="lab_us-gaap_CommonStockVotingRights_label_en-US" xlink:label="lab_us-gaap_CommonStockVotingRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Voting Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockVotingRights" xlink:to="lab_us-gaap_CommonStockVotingRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_73760b25-90a9-4937-9c71-009026052716_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BALANCE SHEET COMPONENTS</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7fbc4ef2-7f17-45ec-b51a-238a584d225e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_088affb1-0494-44a1-b0c4-f985fd8fc284_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Combination</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9d1daf9d-b524-4492-a585-a7c070f30753_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c5ba1b4b-6358-4b07-8ff2-3de4f834056f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_1a0c42a0-cba2-4764-9314-b8c243f76d54_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_5fbafd05-b1fc-40ce-9c99-c797a6ea2759_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_71e72c8f-4040-4a18-ace0-5f5b930394aa_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Unrecognized Tax Benefit Accounts</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_149d8926-b314-40fb-bc38-1f87503a153d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_6716ec05-5684-4603-bba7-3a10038e3ecc_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c9d38fb2-107d-49a6-8acf-726b790e18aa_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_1c1b7914-420c-46c6-81ac-913aa1dca00a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_fb41ae90-1635-48a3-90c1-370a3fee2cd0_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_dd6a9313-c7f6-4eb3-9b23-12564745360c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5673b58-eca7-4361-ad10-9dca2c79fa09_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_6d1274ad-0e1e-41cd-85a7-4cdd0f201473_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_29f3f0f0-7fe9-4e64-b09d-601cf3d993de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Provision (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_2892efce-192c-4652-b0d2-0009a6c0f624_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount recorded in current liabilities as of December 31, 2024</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_3980598f-15ba-4aa4-817d-9dce4fafaedc_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Add: Weighted average shares issuable upon conversion of convertible notes (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0d18eda0-16fc-453b-af41-96e16e05a2cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>pacb-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b8324ceb-4367-4432-9725-ed1f11bffb27,g:1109ce80-1fe4-4ba2-bf4d-c0b012b2f3c3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/Cover" xlink:type="simple" xlink:href="pacb-20241231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d42bf5c8-01a2-4b10-936a-26e665e58c6b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_DocumentType_d42bf5c8-01a2-4b10-936a-26e665e58c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_eb0f7549-407a-4e28-980a-b69315c7da62" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_DocumentAnnualReport_eb0f7549-407a-4e28-980a-b69315c7da62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e77a75f0-82b9-4ca0-8640-52419da7cd62" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_CurrentFiscalYearEndDate_e77a75f0-82b9-4ca0-8640-52419da7cd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b946b54c-5a38-4590-a826-7726df84f9a6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_DocumentPeriodEndDate_b946b54c-5a38-4590-a826-7726df84f9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_2ebae160-17c9-4e63-975c-d67d30ab8894" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_DocumentTransitionReport_2ebae160-17c9-4e63-975c-d67d30ab8894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_58fc762d-6439-4f35-a021-a93210d85a62" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityFileNumber_58fc762d-6439-4f35-a021-a93210d85a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b43c97ee-0e41-4235-964e-66034b56c298" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityRegistrantName_b43c97ee-0e41-4235-964e-66034b56c298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d15879e3-4773-4ac6-9a37-caef96b0a75b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d15879e3-4773-4ac6-9a37-caef96b0a75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_638cec6d-1684-42eb-b72a-5930a1d928e2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityTaxIdentificationNumber_638cec6d-1684-42eb-b72a-5930a1d928e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3b8522c3-7e90-4c38-b0c1-712f27e48105" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityAddressAddressLine1_3b8522c3-7e90-4c38-b0c1-712f27e48105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d5ac7be1-302a-4dcc-90d8-5785cb29ec4b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityAddressCityOrTown_d5ac7be1-302a-4dcc-90d8-5785cb29ec4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_daedc32f-710e-4530-b48b-0c5bbcdead2d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityAddressStateOrProvince_daedc32f-710e-4530-b48b-0c5bbcdead2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f3f2100a-2d1d-4f5f-8347-b59ff03dd516" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityAddressPostalZipCode_f3f2100a-2d1d-4f5f-8347-b59ff03dd516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7d44dc52-83db-427e-a00e-1a946bdbe3cc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_CityAreaCode_7d44dc52-83db-427e-a00e-1a946bdbe3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_25a20078-96d4-450f-8f6d-4cb5ca458d49" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_LocalPhoneNumber_25a20078-96d4-450f-8f6d-4cb5ca458d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a45c8db3-8feb-4f74-81b8-2533d7f77a91" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_Security12bTitle_a45c8db3-8feb-4f74-81b8-2533d7f77a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_52e99e4d-7f20-4eab-b09d-27a89cf71c5f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_TradingSymbol_52e99e4d-7f20-4eab-b09d-27a89cf71c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7264443d-3f01-41bc-a78e-6b3d80323437" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_SecurityExchangeName_7264443d-3f01-41bc-a78e-6b3d80323437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_45edd60c-9844-4731-aa35-7bbe1a0aaead" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_45edd60c-9844-4731-aa35-7bbe1a0aaead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_558083b2-0e67-44f1-9f2d-2f3cf7065905" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityVoluntaryFilers_558083b2-0e67-44f1-9f2d-2f3cf7065905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8ecae1aa-d793-41f2-9125-16398ec71bc5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityCurrentReportingStatus_8ecae1aa-d793-41f2-9125-16398ec71bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_de40b9dd-052b-43e4-ba43-7244ba74c61f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityInteractiveDataCurrent_de40b9dd-052b-43e4-ba43-7244ba74c61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1df612d4-b243-4325-8acc-918a4d9aa6ce" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityFilerCategory_1df612d4-b243-4325-8acc-918a4d9aa6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_59d21bce-1197-4e3c-99f7-baeceb89cb68" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntitySmallBusiness_59d21bce-1197-4e3c-99f7-baeceb89cb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6fc952a2-5920-4412-969a-8d81a0baf4d1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityEmergingGrowthCompany_6fc952a2-5920-4412-969a-8d81a0baf4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_5b1dd82f-1ea9-45e4-8643-30ff51cb7869" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_IcfrAuditorAttestationFlag_5b1dd82f-1ea9-45e4-8643-30ff51cb7869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_bc73d36a-739a-4cd6-a9ee-75a6c7331754" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_bc73d36a-739a-4cd6-a9ee-75a6c7331754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_157c9141-96a1-40d3-ad95-bff5636c0fd1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityShellCompany_157c9141-96a1-40d3-ad95-bff5636c0fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_70853517-f0cf-42bf-88b3-a3bcbb4feb13" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityPublicFloat_70853517-f0cf-42bf-88b3-a3bcbb4feb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_920bbf9f-5068-40b6-84d0-df4b28dffab9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_920bbf9f-5068-40b6-84d0-df4b28dffab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_94d1cd65-0a9c-48fa-8d33-c48ac59487d1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_94d1cd65-0a9c-48fa-8d33-c48ac59487d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a593a0b4-2fd6-407e-8bf1-aceedbd62df0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a593a0b4-2fd6-407e-8bf1-aceedbd62df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e738e146-c61c-4c9a-8753-eeda72986431" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_EntityCentralIndexKey_e738e146-c61c-4c9a-8753-eeda72986431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_eea8db73-c9b8-41a6-be28-3179d10a7961" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_AmendmentFlag_eea8db73-c9b8-41a6-be28-3179d10a7961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b20dc9b3-9975-4109-953c-84fc8de23e06" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_87336c5c-c4e6-4b62-ab8b-bc6fc1001bdc" xlink:to="loc_dei_DocumentFiscalYearFocus_b20dc9b3-9975-4109-953c-84fc8de23e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/AuditInformation" xlink:type="simple" xlink:href="pacb-20241231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AuditInformationAbstract_5b17e1f7-ba72-402c-b783-900cdc91262e" xlink:href="pacb-20241231.xsd#pacb_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_84dab970-6c71-485f-96e9-f73bd2865b84" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_AuditInformationAbstract_5b17e1f7-ba72-402c-b783-900cdc91262e" xlink:to="loc_dei_AuditorName_84dab970-6c71-485f-96e9-f73bd2865b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_f078f2d7-bcee-480b-935c-1ce6c3dbd96a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_AuditInformationAbstract_5b17e1f7-ba72-402c-b783-900cdc91262e" xlink:to="loc_dei_AuditorLocation_f078f2d7-bcee-480b-935c-1ce6c3dbd96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_48468e7f-1a69-43a7-b6e1-efdf27e608f1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_AuditInformationAbstract_5b17e1f7-ba72-402c-b783-900cdc91262e" xlink:to="loc_dei_AuditorFirmId_48468e7f-1a69-43a7-b6e1-efdf27e608f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4993cb2a-6afd-4d19-8d96-ae2705837ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a622ee4d-e0e1-4343-b989-64b9832e844f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4993cb2a-6afd-4d19-8d96-ae2705837ffb" xlink:to="loc_us-gaap_AssetsAbstract_a622ee4d-e0e1-4343-b989-64b9832e844f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_628859b5-c19a-4b33-b45c-dd7f6625c3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a622ee4d-e0e1-4343-b989-64b9832e844f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_628859b5-c19a-4b33-b45c-dd7f6625c3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d101a8f0-7f8f-4df8-8297-cdceb8dcf652" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_628859b5-c19a-4b33-b45c-dd7f6625c3c4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d101a8f0-7f8f-4df8-8297-cdceb8dcf652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_1155c4b2-2a25-4727-9337-1f4eaed94020" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_628859b5-c19a-4b33-b45c-dd7f6625c3c4" xlink:to="loc_us-gaap_ShortTermInvestments_1155c4b2-2a25-4727-9337-1f4eaed94020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_39a895f9-b36b-486b-b394-e1494b1cadf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_628859b5-c19a-4b33-b45c-dd7f6625c3c4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_39a895f9-b36b-486b-b394-e1494b1cadf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2280cc89-3215-4e61-a35c-5935101ca72a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_628859b5-c19a-4b33-b45c-dd7f6625c3c4" xlink:to="loc_us-gaap_InventoryNet_2280cc89-3215-4e61-a35c-5935101ca72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8e7c57d0-61e6-4fed-9b8f-45fc14e562db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_628859b5-c19a-4b33-b45c-dd7f6625c3c4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8e7c57d0-61e6-4fed-9b8f-45fc14e562db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_faf1630e-1201-4d58-b2f6-474040e0d822" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_628859b5-c19a-4b33-b45c-dd7f6625c3c4" xlink:to="loc_us-gaap_RestrictedCashCurrent_faf1630e-1201-4d58-b2f6-474040e0d822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_78197391-06c7-4fe4-b211-dd828960c8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_628859b5-c19a-4b33-b45c-dd7f6625c3c4" xlink:to="loc_us-gaap_AssetsCurrent_78197391-06c7-4fe4-b211-dd828960c8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7f859c43-ba3a-49d9-8a9b-eca2b5dc3da6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a622ee4d-e0e1-4343-b989-64b9832e844f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7f859c43-ba3a-49d9-8a9b-eca2b5dc3da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_083c73e1-5b7f-412b-8a7f-845f7a9b9f71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a622ee4d-e0e1-4343-b989-64b9832e844f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_083c73e1-5b7f-412b-8a7f-845f7a9b9f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b2dfb6e9-8ed5-4122-b737-586574259bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a622ee4d-e0e1-4343-b989-64b9832e844f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b2dfb6e9-8ed5-4122-b737-586574259bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f0966204-e664-4d48-b399-7504245514fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a622ee4d-e0e1-4343-b989-64b9832e844f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f0966204-e664-4d48-b399-7504245514fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3c508a9c-d030-4128-8ab2-5d8317d1c23e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a622ee4d-e0e1-4343-b989-64b9832e844f" xlink:to="loc_us-gaap_Goodwill_3c508a9c-d030-4128-8ab2-5d8317d1c23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_52269384-cc0d-40fd-930f-b0dfbdd979a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a622ee4d-e0e1-4343-b989-64b9832e844f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_52269384-cc0d-40fd-930f-b0dfbdd979a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6db3713d-130d-424a-80be-294393e741db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a622ee4d-e0e1-4343-b989-64b9832e844f" xlink:to="loc_us-gaap_Assets_6db3713d-130d-424a-80be-294393e741db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_872b6599-500e-4870-9bbe-c92de6ce1929" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4993cb2a-6afd-4d19-8d96-ae2705837ffb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_872b6599-500e-4870-9bbe-c92de6ce1929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c063fbcf-c928-4e83-9ae4-388981bb6fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_872b6599-500e-4870-9bbe-c92de6ce1929" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c063fbcf-c928-4e83-9ae4-388981bb6fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1669fb44-d072-402f-a96f-89c8a49a01cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c063fbcf-c928-4e83-9ae4-388981bb6fcd" xlink:to="loc_us-gaap_AccountsPayableCurrent_1669fb44-d072-402f-a96f-89c8a49a01cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_817fa456-f3e2-4ab0-a77c-34c90d3cc2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c063fbcf-c928-4e83-9ae4-388981bb6fcd" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_817fa456-f3e2-4ab0-a77c-34c90d3cc2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1b37c938-2912-4acf-8bd3-0da28b92f26a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c063fbcf-c928-4e83-9ae4-388981bb6fcd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1b37c938-2912-4acf-8bd3-0da28b92f26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_efba5084-23a5-43fb-933e-5f6b940a27b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c063fbcf-c928-4e83-9ae4-388981bb6fcd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_efba5084-23a5-43fb-933e-5f6b940a27b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_9b5a4a08-55a6-4273-924e-47d3d1a23217" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c063fbcf-c928-4e83-9ae4-388981bb6fcd" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_9b5a4a08-55a6-4273-924e-47d3d1a23217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_324f4519-9d68-4a4b-8f0a-cc5eb8d56880" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c063fbcf-c928-4e83-9ae4-388981bb6fcd" xlink:to="loc_us-gaap_LiabilitiesCurrent_324f4519-9d68-4a4b-8f0a-cc5eb8d56880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_724737a9-749b-4ba5-9dd8-c79350730ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_872b6599-500e-4870-9bbe-c92de6ce1929" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_724737a9-749b-4ba5-9dd8-c79350730ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_893d07da-5c1e-4a04-8fd7-f2111ae79e35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_872b6599-500e-4870-9bbe-c92de6ce1929" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_893d07da-5c1e-4a04-8fd7-f2111ae79e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_79ce856a-4120-454a-943c-f429fef136a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_872b6599-500e-4870-9bbe-c92de6ce1929" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_79ce856a-4120-454a-943c-f429fef136a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_04bc7196-65a8-46ce-9d02-0fb494718ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_872b6599-500e-4870-9bbe-c92de6ce1929" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_04bc7196-65a8-46ce-9d02-0fb494718ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a3de80e5-d375-4e48-9d9d-2cc3741fcf66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_872b6599-500e-4870-9bbe-c92de6ce1929" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a3de80e5-d375-4e48-9d9d-2cc3741fcf66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_39bdd5d5-c6f7-4ad2-ad85-c2c4d8413cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_872b6599-500e-4870-9bbe-c92de6ce1929" xlink:to="loc_us-gaap_Liabilities_39bdd5d5-c6f7-4ad2-ad85-c2c4d8413cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1c0b12a3-f111-4fd3-8961-72cbf17308dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_872b6599-500e-4870-9bbe-c92de6ce1929" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1c0b12a3-f111-4fd3-8961-72cbf17308dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a2dda733-5229-4b0b-9bc3-c3ce210fe9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_872b6599-500e-4870-9bbe-c92de6ce1929" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a2dda733-5229-4b0b-9bc3-c3ce210fe9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_bff84e02-44f5-446f-94fa-a1024294de03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2dda733-5229-4b0b-9bc3-c3ce210fe9cf" xlink:to="loc_us-gaap_PreferredStockValue_bff84e02-44f5-446f-94fa-a1024294de03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f9ea8c38-45f6-4bdb-b522-8c0de3b0f8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2dda733-5229-4b0b-9bc3-c3ce210fe9cf" xlink:to="loc_us-gaap_CommonStockValue_f9ea8c38-45f6-4bdb-b522-8c0de3b0f8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_219b0c07-f140-4972-bc3e-39b4587f3b24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2dda733-5229-4b0b-9bc3-c3ce210fe9cf" xlink:to="loc_us-gaap_AdditionalPaidInCapital_219b0c07-f140-4972-bc3e-39b4587f3b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9d49cbc5-84fd-42b9-92af-e810bb54c816" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2dda733-5229-4b0b-9bc3-c3ce210fe9cf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9d49cbc5-84fd-42b9-92af-e810bb54c816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_36b0c09d-ebbd-4a49-a003-74bca46a98d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2dda733-5229-4b0b-9bc3-c3ce210fe9cf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_36b0c09d-ebbd-4a49-a003-74bca46a98d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_174880ce-5df4-436c-8398-583e0d8845e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2dda733-5229-4b0b-9bc3-c3ce210fe9cf" xlink:to="loc_us-gaap_StockholdersEquity_174880ce-5df4-436c-8398-583e0d8845e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5cc570ca-98b1-47c1-9e19-9cef0bd96f66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_872b6599-500e-4870-9bbe-c92de6ce1929" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5cc570ca-98b1-47c1-9e19-9cef0bd96f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f4980410-8237-46f9-8d65-1ec8806ec52c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1f961c28-3a18-4c50-99f9-af9be833e498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4980410-8237-46f9-8d65-1ec8806ec52c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1f961c28-3a18-4c50-99f9-af9be833e498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6f32811b-f699-421c-a443-186487b4874c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4980410-8237-46f9-8d65-1ec8806ec52c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6f32811b-f699-421c-a443-186487b4874c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3dd1c651-fc48-458b-a5d4-8de8215688a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4980410-8237-46f9-8d65-1ec8806ec52c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3dd1c651-fc48-458b-a5d4-8de8215688a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_da969ac9-62c1-4624-96dc-afd50f9e7052" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4980410-8237-46f9-8d65-1ec8806ec52c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_da969ac9-62c1-4624-96dc-afd50f9e7052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9cf44c5f-d97c-436f-a2f1-965e055c4b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4980410-8237-46f9-8d65-1ec8806ec52c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9cf44c5f-d97c-436f-a2f1-965e055c4b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7f6ae2af-bae4-465f-adf6-bdb0e7db50f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4980410-8237-46f9-8d65-1ec8806ec52c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7f6ae2af-bae4-465f-adf6-bdb0e7db50f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0cf99376-7649-436c-bc66-810f2778113f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4980410-8237-46f9-8d65-1ec8806ec52c" xlink:to="loc_us-gaap_CommonStockSharesIssued_0cf99376-7649-436c-bc66-810f2778113f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5d7984bb-6445-43d2-94c6-fac39023a25f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4980410-8237-46f9-8d65-1ec8806ec52c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5d7984bb-6445-43d2-94c6-fac39023a25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_3b6f8ed0-ec3d-49b3-8a4c-dda4f6cd8fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9c68479e-86da-44b9-a018-509505bc2832" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3b6f8ed0-ec3d-49b3-8a4c-dda4f6cd8fa2" xlink:to="loc_us-gaap_StatementTable_9c68479e-86da-44b9-a018-509505bc2832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_54839321-cc42-4523-9d1b-9685d1ffb674" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9c68479e-86da-44b9-a018-509505bc2832" xlink:to="loc_srt_ProductOrServiceAxis_54839321-cc42-4523-9d1b-9685d1ffb674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a0798a82-03e8-4f96-ab2a-16f265a0ea4b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_54839321-cc42-4523-9d1b-9685d1ffb674" xlink:to="loc_srt_ProductsAndServicesDomain_a0798a82-03e8-4f96-ab2a-16f265a0ea4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7f2a8479-dcb5-406e-a19b-3adf7f00c867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a0798a82-03e8-4f96-ab2a-16f265a0ea4b" xlink:to="loc_us-gaap_ProductMember_7f2a8479-dcb5-406e-a19b-3adf7f00c867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_8a3830d7-db85-4fa9-8757-41f3c85dfba6" xlink:href="pacb-20241231.xsd#pacb_ServiceAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a0798a82-03e8-4f96-ab2a-16f265a0ea4b" xlink:to="loc_pacb_ServiceAndOtherMember_8a3830d7-db85-4fa9-8757-41f3c85dfba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9c68479e-86da-44b9-a018-509505bc2832" xlink:to="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0aaf1c19-a030-4637-a3a5-728b9dd627f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_RevenuesAbstract_0aaf1c19-a030-4637-a3a5-728b9dd627f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7732e604-46d7-4552-b7a7-e44f9ea8c295" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0aaf1c19-a030-4637-a3a5-728b9dd627f0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7732e604-46d7-4552-b7a7-e44f9ea8c295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_6faeeb1c-04ce-4130-a7a7-42fb964ebafc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_CostOfRevenueAbstract_6faeeb1c-04ce-4130-a7a7-42fb964ebafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_d5df03bf-e40d-45bb-a14b-6deaf68d10e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6faeeb1c-04ce-4130-a7a7-42fb964ebafc" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_d5df03bf-e40d-45bb-a14b-6deaf68d10e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_9932d41f-8309-45f0-8817-c57b907f6a16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6faeeb1c-04ce-4130-a7a7-42fb964ebafc" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_9932d41f-8309-45f0-8817-c57b907f6a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LossOnPurchaseCommitment_03c27262-25f5-4bf7-b4e6-3ba652853327" xlink:href="pacb-20241231.xsd#pacb_LossOnPurchaseCommitment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6faeeb1c-04ce-4130-a7a7-42fb964ebafc" xlink:to="loc_pacb_LossOnPurchaseCommitment_03c27262-25f5-4bf7-b4e6-3ba652853327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_472c8cc2-f35e-4448-b782-5790b717459f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6faeeb1c-04ce-4130-a7a7-42fb964ebafc" xlink:to="loc_us-gaap_CostOfRevenue_472c8cc2-f35e-4448-b782-5790b717459f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_a6d9cb28-4a7e-456d-8a0a-ebf9d744ab86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_GrossProfit_a6d9cb28-4a7e-456d-8a0a-ebf9d744ab86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d2da1ab7-9df1-493d-993f-cee5d61d20bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d2da1ab7-9df1-493d-993f-cee5d61d20bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1c18b833-acc1-4bea-b746-3e57176e65ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1c18b833-acc1-4bea-b746-3e57176e65ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_3b3f148b-6fc6-4051-9644-12676c2ee84a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_3b3f148b-6fc6-4051-9644-12676c2ee84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_9488b1cf-55ff-4738-aedd-4ecda4e07917" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_9488b1cf-55ff-4738-aedd-4ecda4e07917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e0de5280-215b-4ebd-9b29-f59163543b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e0de5280-215b-4ebd-9b29-f59163543b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmortizationOfAcquiredIntangibleAssets_f22ce76b-07ea-404f-ad1f-55ce378b7711" xlink:href="pacb-20241231.xsd#pacb_AmortizationOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:to="loc_pacb_AmortizationOfAcquiredIntangibleAssets_f22ce76b-07ea-404f-ad1f-55ce378b7711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_dca1e045-752e-4dd7-b559-a6317d889555" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7672c600-be70-4bfd-af64-53ada7ebc137" xlink:to="loc_us-gaap_OperatingExpenses_dca1e045-752e-4dd7-b559-a6317d889555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a806e3d8-4cfb-4d58-a88b-e48b6c4bac01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_OperatingIncomeLoss_a806e3d8-4cfb-4d58-a88b-e48b6c4bac01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_76f06ea8-5323-4015-bad9-dcd9f99d32cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_76f06ea8-5323-4015-bad9-dcd9f99d32cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_b37a84ac-7343-4789-8385-b1d60e3d80dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_b37a84ac-7343-4789-8385-b1d60e3d80dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_584e49e6-05da-4de9-94b8-b2581595e868" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_InterestExpenseNonoperating_584e49e6-05da-4de9-94b8-b2581595e868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_83b6bd89-4a54-43b8-897b-f7c9f3c1e02b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_83b6bd89-4a54-43b8-897b-f7c9f3c1e02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4e35972e-dc56-4cbd-a765-4aefe59044a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4e35972e-dc56-4cbd-a765-4aefe59044a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b523b30f-a3e2-4531-beb8-56cfe8327792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b523b30f-a3e2-4531-beb8-56cfe8327792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5aae1128-7517-47ea-93a4-5022d23ad766" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_NetIncomeLoss_5aae1128-7517-47ea-93a4-5022d23ad766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_84e5f566-3966-4d1e-a05d-7729d7a83079" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_84e5f566-3966-4d1e-a05d-7729d7a83079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5d7e76ea-c37a-40b1-9301-9aa550918017" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_84e5f566-3966-4d1e-a05d-7729d7a83079" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5d7e76ea-c37a-40b1-9301-9aa550918017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_37493bc5-2506-40b6-aa92-c9acb0678dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_37493bc5-2506-40b6-aa92-c9acb0678dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeLossPerShareAbstract_bf2d3ee4-c8a4-4f8b-b099-734001d0f694" xlink:href="pacb-20241231.xsd#pacb_IncomeLossPerShareAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_pacb_IncomeLossPerShareAbstract_bf2d3ee4-c8a4-4f8b-b099-734001d0f694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_39275742-6a6b-4af4-bfdc-630a6cc0c583" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeLossPerShareAbstract_bf2d3ee4-c8a4-4f8b-b099-734001d0f694" xlink:to="loc_us-gaap_EarningsPerShareBasic_39275742-6a6b-4af4-bfdc-630a6cc0c583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_783f7dbe-d819-4cd7-bd2d-ea04b385b036" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeLossPerShareAbstract_bf2d3ee4-c8a4-4f8b-b099-734001d0f694" xlink:to="loc_us-gaap_EarningsPerShareDiluted_783f7dbe-d819-4cd7-bd2d-ea04b385b036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_c3da896f-4e34-456d-aaa7-664aa020836a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_526f418d-a98d-4d2d-80a3-625c3cf1eb24" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_c3da896f-4e34-456d-aaa7-664aa020836a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a982e493-ea0e-4a29-9cb6-2c1539205015" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_c3da896f-4e34-456d-aaa7-664aa020836a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a982e493-ea0e-4a29-9cb6-2c1539205015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2070caf0-19da-45f0-8031-458b633f4809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_c3da896f-4e34-456d-aaa7-664aa020836a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2070caf0-19da-45f0-8031-458b633f4809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_fe39134b-f36a-460f-ae5d-ef829577eeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_31b04cf1-02e4-4de5-ac48-7b71188cb1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fe39134b-f36a-460f-ae5d-ef829577eeaa" xlink:to="loc_us-gaap_StatementTable_31b04cf1-02e4-4de5-ac48-7b71188cb1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5f4ea3ac-4ced-4397-b74a-bd72dc613a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_31b04cf1-02e4-4de5-ac48-7b71188cb1d8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5f4ea3ac-4ced-4397-b74a-bd72dc613a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9c45f2c2-b675-4c89-85c6-cbaa0466e145" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5f4ea3ac-4ced-4397-b74a-bd72dc613a8b" xlink:to="loc_us-gaap_EquityComponentDomain_9c45f2c2-b675-4c89-85c6-cbaa0466e145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c8358a61-5883-4db5-92cd-66dd675bab05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9c45f2c2-b675-4c89-85c6-cbaa0466e145" xlink:to="loc_us-gaap_CommonStockMember_c8358a61-5883-4db5-92cd-66dd675bab05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5ebf0611-b968-46c0-b8fb-9a546f705dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9c45f2c2-b675-4c89-85c6-cbaa0466e145" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5ebf0611-b968-46c0-b8fb-9a546f705dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_073ae830-fecd-4292-b20a-d2f55274b6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9c45f2c2-b675-4c89-85c6-cbaa0466e145" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_073ae830-fecd-4292-b20a-d2f55274b6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3113d804-1cfc-4283-8167-805fadb602c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9c45f2c2-b675-4c89-85c6-cbaa0466e145" xlink:to="loc_us-gaap_RetainedEarningsMember_3113d804-1cfc-4283-8167-805fadb602c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_15a3501d-3a41-41e6-bcc2-e161f54ee8de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_31b04cf1-02e4-4de5-ac48-7b71188cb1d8" xlink:to="loc_us-gaap_StatementLineItems_15a3501d-3a41-41e6-bcc2-e161f54ee8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15a3501d-3a41-41e6-bcc2-e161f54ee8de" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_70854a84-7933-4267-abb3-304b53c0a0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_70854a84-7933-4267-abb3-304b53c0a0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c07a6575-864e-42ff-bc1e-e961c2d82548" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockholdersEquity_c07a6575-864e-42ff-bc1e-e961c2d82548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e1ff218-7b3a-48a2-a3cf-a99a979d1f35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_NetIncomeLoss_9e1ff218-7b3a-48a2-a3cf-a99a979d1f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_8657ae8c-bf11-4e86-98f3-8983e3ac0041" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_8657ae8c-bf11-4e86-98f3-8983e3ac0041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_6f451315-1448-40c1-8f24-fbc40f89e7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_6f451315-1448-40c1-8f24-fbc40f89e7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_33546d02-f1b2-4653-a4f9-dfc17966746c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_33546d02-f1b2-4653-a4f9-dfc17966746c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2351a121-9a6d-4225-acd3-b407e781c458" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2351a121-9a6d-4225-acd3-b407e781c458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fac26b0d-c98d-4fef-9c49-867407f8d22d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fac26b0d-c98d-4fef-9c49-867407f8d22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_4e0b24fb-9b3b-4884-bd5e-5419c44ecfd3" xlink:href="pacb-20241231.xsd#pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_4e0b24fb-9b3b-4884-bd5e-5419c44ecfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_550961f9-8821-4c43-9068-0e140b9f2c08" xlink:href="pacb-20241231.xsd#pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_550961f9-8821-4c43-9068-0e140b9f2c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7fb3847c-909d-48d0-910f-6da3759bb67a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7fb3847c-909d-48d0-910f-6da3759bb67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2780016c-9968-40ae-a4f2-c0827251b51c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2780016c-9968-40ae-a4f2-c0827251b51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4dd9d293-88cc-4527-8f56-70d24a989652" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4dd9d293-88cc-4527-8f56-70d24a989652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_80397d9d-8302-42e2-a3da-66e8410be8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_80397d9d-8302-42e2-a3da-66e8410be8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_70747bdb-c397-41c1-bfaa-017948f00018" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_70747bdb-c397-41c1-bfaa-017948f00018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_266de281-792c-4e61-8977-37332542810f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_266de281-792c-4e61-8977-37332542810f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0839e8ad-c018-4310-bbc5-0811c017c832" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0839e8ad-c018-4310-bbc5-0811c017c832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9c21df6f-6094-4067-8dcb-056df669c64b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_StockholdersEquity_9c21df6f-6094-4067-8dcb-056df669c64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_591ef9b4-feac-4907-9a65-cb29ebd9e0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea5bf1e6-c994-40b5-a15b-c505f9094ec6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_591ef9b4-feac-4907-9a65-cb29ebd9e0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_381d5952-1a1f-4f4f-a687-17bccfbb62d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b577beea-9d9e-407f-a66d-8f86e36f1363" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_381d5952-1a1f-4f4f-a687-17bccfbb62d7" xlink:to="loc_us-gaap_StatementTable_b577beea-9d9e-407f-a66d-8f86e36f1363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_89c70b38-524f-462b-bed3-bf2be5cda39c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b577beea-9d9e-407f-a66d-8f86e36f1363" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_89c70b38-524f-462b-bed3-bf2be5cda39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1531ee13-3131-415c-96cb-4736c833b4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89c70b38-524f-462b-bed3-bf2be5cda39c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1531ee13-3131-415c-96cb-4736c833b4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonAndOmniomeMember_35426be3-ecec-4b9a-841c-f9d58b63fc32" xlink:href="pacb-20241231.xsd#pacb_AptonAndOmniomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1531ee13-3131-415c-96cb-4736c833b4e9" xlink:to="loc_pacb_AptonAndOmniomeMember_35426be3-ecec-4b9a-841c-f9d58b63fc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9d20adae-ac01-4488-9655-7142e55c4f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b577beea-9d9e-407f-a66d-8f86e36f1363" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9d20adae-ac01-4488-9655-7142e55c4f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388efb0c-4cc0-4dce-a851-07412134b6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9d20adae-ac01-4488-9655-7142e55c4f5f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388efb0c-4cc0-4dce-a851-07412134b6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_NoteExchangeMember_2a2905ef-e569-45b6-b4c9-e0b63a7df29b" xlink:href="pacb-20241231.xsd#pacb_NoteExchangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388efb0c-4cc0-4dce-a851-07412134b6f2" xlink:to="loc_pacb_NoteExchangeMember_2a2905ef-e569-45b6-b4c9-e0b63a7df29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationMember_92e083ea-09f4-45f5-8b9a-061a16d2030a" xlink:href="pacb-20241231.xsd#pacb_BusinessCombinationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388efb0c-4cc0-4dce-a851-07412134b6f2" xlink:to="loc_pacb_BusinessCombinationMember_92e083ea-09f4-45f5-8b9a-061a16d2030a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LiquidityBonusEventMember_44fa5b1c-9fdb-433b-8bf4-edfc74fc6bac" xlink:href="pacb-20241231.xsd#pacb_LiquidityBonusEventMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388efb0c-4cc0-4dce-a851-07412134b6f2" xlink:to="loc_pacb_LiquidityBonusEventMember_44fa5b1c-9fdb-433b-8bf4-edfc74fc6bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MilestoneAchievementMember_450de2f9-2de5-45dc-a7d6-42e389cbc6ed" xlink:href="pacb-20241231.xsd#pacb_MilestoneAchievementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388efb0c-4cc0-4dce-a851-07412134b6f2" xlink:to="loc_pacb_MilestoneAchievementMember_450de2f9-2de5-45dc-a7d6-42e389cbc6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b577beea-9d9e-407f-a66d-8f86e36f1363" xlink:to="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67ce84c8-d6ce-4a45-9c1b-374ba318593e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67ce84c8-d6ce-4a45-9c1b-374ba318593e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c9f78ef8-3961-43c1-9498-83920bd00324" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67ce84c8-d6ce-4a45-9c1b-374ba318593e" xlink:to="loc_us-gaap_NetIncomeLoss_c9f78ef8-3961-43c1-9498-83920bd00324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67ce84c8-d6ce-4a45-9c1b-374ba318593e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a306d788-4552-4ef9-b2ce-563741445301" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_Depreciation_a306d788-4552-4ef9-b2ce-563741445301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_638c7243-5f20-4e4a-bf5a-3f298d8b3c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_638c7243-5f20-4e4a-bf5a-3f298d8b3c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3be20a3b-8bb9-4672-9feb-9c2ef92e4023" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3be20a3b-8bb9-4672-9feb-9c2ef92e4023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4c8c9db3-b841-4674-b93e-e334edd151c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_ShareBasedCompensation_4c8c9db3-b841-4674-b93e-e334edd151c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_b7221b8f-c84d-491c-8143-a0943348f24a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_b7221b8f-c84d-491c-8143-a0943348f24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashMergerRelatedCosts_b35dac6e-b5f5-4e77-99eb-7254f4833d50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashMergerRelatedCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_NoncashMergerRelatedCosts_b35dac6e-b5f5-4e77-99eb-7254f4833d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_852bc4fe-63eb-4caa-ad21-072eea3205aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_852bc4fe-63eb-4caa-ad21-072eea3205aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_ebf57581-c5ac-4905-b4a6-b5ee1a2fcdec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_ebf57581-c5ac-4905-b4a6-b5ee1a2fcdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_24bec309-3d1d-44be-8689-b0242584b73e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_24bec309-3d1d-44be-8689-b0242584b73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_990dae20-c3d6-4b4d-9bf2-6b43c8e86881" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_990dae20-c3d6-4b4d-9bf2-6b43c8e86881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_2f89df17-7fec-4cc7-9cf6-ac5244b8f28e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_InventoryWriteDown_2f89df17-7fec-4cc7-9cf6-ac5244b8f28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_4a132c8d-e2d1-4a9c-bc06-deb5e52dbb23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_4a132c8d-e2d1-4a9c-bc06-deb5e52dbb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c08b44f1-bd22-42b0-b9cb-491de5ffe7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f109e0b-a6a5-4bdd-99ae-0e2f360a475d" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c08b44f1-bd22-42b0-b9cb-491de5ffe7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67ce84c8-d6ce-4a45-9c1b-374ba318593e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ced8d5fe-5f4b-4fea-911d-ce859917f9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ced8d5fe-5f4b-4fea-911d-ce859917f9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1e68078a-ab6d-432e-817a-0cc44020849d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1e68078a-ab6d-432e-817a-0cc44020849d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b8449a4c-1470-40e6-9881-193a6304b418" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b8449a4c-1470-40e6-9881-193a6304b418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_39c5e81f-55c1-4737-ac96-211886ba2545" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_39c5e81f-55c1-4737-ac96-211886ba2545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7ad58c8f-9c55-4525-9e61-5727a2106803" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7ad58c8f-9c55-4525-9e61-5727a2106803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_028b4642-f867-4d5d-bfba-cbfae4b04acb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_028b4642-f867-4d5d-bfba-cbfae4b04acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e37fb3dd-2f49-4cb0-aca0-e1aab4c8e67d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e37fb3dd-2f49-4cb0-aca0-e1aab4c8e67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability_780d5a4f-d8f8-4c4a-9a59-a671b7ac7c17" xlink:href="pacb-20241231.xsd#pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability_780d5a4f-d8f8-4c4a-9a59-a671b7ac7c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c4c5b510-1fc5-4843-bcd7-4d815b8c3773" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb574158-1c6c-419a-996d-b882aa9d60fa" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c4c5b510-1fc5-4843-bcd7-4d815b8c3773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_faf10fb0-19cf-4ae2-ac23-056351e7e2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67ce84c8-d6ce-4a45-9c1b-374ba318593e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_faf10fb0-19cf-4ae2-ac23-056351e7e2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e38c33ea-3687-45eb-8f55-4c097c1700da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e38c33ea-3687-45eb-8f55-4c097c1700da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_db471b77-e47e-466d-acbe-f3d7c9130909" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_db471b77-e47e-466d-acbe-f3d7c9130909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_488a1040-5afd-4d55-a057-ae73f29a94fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_488a1040-5afd-4d55-a057-ae73f29a94fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_620a92a6-1cad-4141-8f1a-f285915fc089" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_620a92a6-1cad-4141-8f1a-f285915fc089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_599c9db1-b153-4b9c-8498-886a3b81e41d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_599c9db1-b153-4b9c-8498-886a3b81e41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_c538b804-8153-46a8-a4cb-d96180d7fdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_c538b804-8153-46a8-a4cb-d96180d7fdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e61bae6-a304-4b42-adce-51e6e642cfc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cbc9b66b-8ea6-40c1-8a2e-65eb45d3059e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e61bae6-a304-4b42-adce-51e6e642cfc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f8746aa0-418e-4e72-8a2e-e04fd43f9615" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f8746aa0-418e-4e72-8a2e-e04fd43f9615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8c9ff493-7e91-4380-b60c-c81c85c7f7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8c9ff493-7e91-4380-b60c-c81c85c7f7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_eadba61a-958d-4e8b-a535-9278c97d010f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_eadba61a-958d-4e8b-a535-9278c97d010f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_0ae7996d-a680-4551-a944-450ec70415ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_0ae7996d-a680-4551-a944-450ec70415ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsInConjunctionWithNotesExchange_0916e3e0-2987-4eb7-a011-7cc8fdb06d79" xlink:href="pacb-20241231.xsd#pacb_PaymentsInConjunctionWithNotesExchange"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:to="loc_pacb_PaymentsInConjunctionWithNotesExchange_0916e3e0-2987-4eb7-a011-7cc8fdb06d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_a19aaa6f-674a-468c-889a-462b4d31c202" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_a19aaa6f-674a-468c-889a-462b4d31c202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e028b593-5a5b-43b4-9ad9-5f2a5bc889ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9df4cd36-72de-4eba-b0bf-0e9ec8e56fe3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e028b593-5a5b-43b4-9ad9-5f2a5bc889ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_962846d0-5d28-4d16-a5a2-c88fbdc4ff26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_962846d0-5d28-4d16-a5a2-c88fbdc4ff26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4221073-416c-430e-bb64-18a09dbb7ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4221073-416c-430e-bb64-18a09dbb7ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8892b9b5-af96-4843-99b0-bd39612a3068" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8892b9b5-af96-4843-99b0-bd39612a3068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c9794fe-1805-4e20-ad49-c7e24be698ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c9794fe-1805-4e20-ad49-c7e24be698ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_d5d44145-af67-4b4a-acd1-da35cd4e0c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_d5d44145-af67-4b4a-acd1-da35cd4e0c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01fd5c69-2a81-4f05-8f93-28561a1c1e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01fd5c69-2a81-4f05-8f93-28561a1c1e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_b17626d0-889e-48d3-a9b9-3c4c9a728be4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_b17626d0-889e-48d3-a9b9-3c4c9a728be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_062bbca4-d210-4c99-9ed7-562c5350f652" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b17626d0-889e-48d3-a9b9-3c4c9a728be4" xlink:to="loc_us-gaap_InterestPaidNet_062bbca4-d210-4c99-9ed7-562c5350f652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e6d7a302-8e86-4955-95b1-ef186cf8440c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c24cf287-35ed-47bb-ac14-4ca1bdabb66b" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e6d7a302-8e86-4955-95b1-ef186cf8440c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TransferOfInventoryToPropertyAndEquipment_98610ba2-ef21-48bf-a080-45dd66902076" xlink:href="pacb-20241231.xsd#pacb_TransferOfInventoryToPropertyAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e6d7a302-8e86-4955-95b1-ef186cf8440c" xlink:to="loc_pacb_TransferOfInventoryToPropertyAndEquipment_98610ba2-ef21-48bf-a080-45dd66902076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_580732e7-7e5b-403e-91b0-fa29596c1d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e6d7a302-8e86-4955-95b1-ef186cf8440c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_580732e7-7e5b-403e-91b0-fa29596c1d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b88a8ba7-f938-49eb-9d4a-9f41012eccc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e6d7a302-8e86-4955-95b1-ef186cf8440c" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b88a8ba7-f938-49eb-9d4a-9f41012eccc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_ccad17ac-1c0e-4783-a448-bd3dd2b8ffb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e6d7a302-8e86-4955-95b1-ef186cf8440c" xlink:to="loc_us-gaap_StockIssued1_ccad17ac-1c0e-4783-a448-bd3dd2b8ffb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesIssued1_cafc8168-8704-4f63-bbd2-6ac72547c2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesIssued1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e6d7a302-8e86-4955-95b1-ef186cf8440c" xlink:to="loc_us-gaap_NotesIssued1_cafc8168-8704-4f63-bbd2-6ac72547c2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="pacb-20241231.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cc860e39-b23a-4318-bb5c-245044bfe48a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_faadb255-87d2-439a-a147-09c0a71a708d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cc860e39-b23a-4318-bb5c-245044bfe48a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_faadb255-87d2-439a-a147-09c0a71a708d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONS" xlink:type="simple" xlink:href="pacb-20241231.xsd#BUSINESSACQUISITIONS"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_dc9550f8-acc1-440c-9cf1-757db708e318" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_fc1ced73-538f-4154-8480-b70552b7fe06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_dc9550f8-acc1-440c-9cf1-757db708e318" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_fc1ced73-538f-4154-8480-b70552b7fe06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="pacb-20241231.xsd#FINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_7710887e-540c-47f0-874b-058b3d9c1305" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_40939173-d101-4abb-ac0e-2071cdefc6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_7710887e-540c-47f0-874b-058b3d9c1305" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_40939173-d101-4abb-ac0e-2071cdefc6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTS"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a750e3fa-f57b-4d35-ac30-426a9578543b" xlink:href="pacb-20241231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_5eed4feb-12ce-4fb5-b8ad-6591979733b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a750e3fa-f57b-4d35-ac30-426a9578543b" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_5eed4feb-12ce-4fb5-b8ad-6591979733b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONVERTIBLESENIORNOTES"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7bdb3771-f60c-455b-8f61-6c1718a0d3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_107aff65-0b9b-4d4e-9324-9578e92a8b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7bdb3771-f60c-455b-8f61-6c1718a0d3ef" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_107aff65-0b9b-4d4e-9324-9578e92a8b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURING" xlink:type="simple" xlink:href="pacb-20241231.xsd#RESTRUCTURING"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURING" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c04881f2-a102-43ad-a262-c2be506c7f08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_f3fee44b-67ba-40d0-9250-6c9f1f9ecb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c04881f2-a102-43ad-a262-c2be506c7f08" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_f3fee44b-67ba-40d0-9250-6c9f1f9ecb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="pacb-20241231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_db176c67-62f5-4341-8687-54601af5e5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures_327a05ed-02b2-4f1b-a5fe-051d49f7dbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_db176c67-62f5-4341-8687-54601af5e5c4" xlink:to="loc_us-gaap_LossContingencyDisclosures_327a05ed-02b2-4f1b-a5fe-051d49f7dbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXES" xlink:type="simple" xlink:href="pacb-20241231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_563cd8e7-53c7-45d7-b6ca-4d957981046f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_05034ca0-46f0-4c8f-8e65-ba1ffaa277b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_563cd8e7-53c7-45d7-b6ca-4d957981046f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_05034ca0-46f0-4c8f-8e65-ba1ffaa277b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="pacb-20241231.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d04c300c-b242-4cf6-9cf4-5ec4509d2387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0a1b0ee6-ba29-472a-bc90-e2fc4f969427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d04c300c-b242-4cf6-9cf4-5ec4509d2387" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0a1b0ee6-ba29-472a-bc90-e2fc4f969427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARE" xlink:type="simple" xlink:href="pacb-20241231.xsd#NETLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_bba329c2-90ef-4608-999c-6cf3094c73ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_95d38251-edf4-4b72-b285-95fbfe43c23f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bba329c2-90ef-4608-999c-6cf3094c73ea" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_95d38251-edf4-4b72-b285-95fbfe43c23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION" xlink:type="simple" xlink:href="pacb-20241231.xsd#SEGMENTANDGEOGRAPHICINFORMATION"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9c63c4d4-dea6-4cfc-9927-9142df74ecd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_bc63ab83-0e62-481e-b73a-7b874c5caced" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9c63c4d4-dea6-4cfc-9927-9142df74ecd0" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_bc63ab83-0e62-481e-b73a-7b874c5caced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="pacb-20241231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_e5e23cc5-bb53-4670-8bd3-f5bdc895ae06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_60f0a391-a9c2-42e3-8e88-6cf4bab8b52f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_e5e23cc5-bb53-4670-8bd3-f5bdc895ae06" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_60f0a391-a9c2-42e3-8e88-6cf4bab8b52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="pacb-20241231.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f079497e-9346-4ad3-afc5-eb22a1c9c292" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f079497e-9346-4ad3-afc5-eb22a1c9c292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_0be90130-14c4-4b95-a9e4-794e1055f376" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_UseOfEstimates_0be90130-14c4-4b95-a9e4-794e1055f376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1e6a7ef7-be83-4f88-a995-bddd64643181" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1e6a7ef7-be83-4f88-a995-bddd64643181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6fa32e51-0ee1-41ca-89fc-f15a79546ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6fa32e51-0ee1-41ca-89fc-f15a79546ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_fd7b2e74-cde6-4c07-b5b5-93f6ba0f0d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_fd7b2e74-cde6-4c07-b5b5-93f6ba0f0d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_c50a5053-bddc-4869-a504-75e715f82ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_c50a5053-bddc-4869-a504-75e715f82ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a6700f3c-4827-4b8c-940a-1c8d5c2cd7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a6700f3c-4827-4b8c-940a-1c8d5c2cd7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_a86f2234-6df5-4059-ae0f-4c2a5aa7a9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_a86f2234-6df5-4059-ae0f-4c2a5aa7a9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_682cab75-ec77-4a83-8fc0-a545d9e5a299" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_682cab75-ec77-4a83-8fc0-a545d9e5a299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_384b4d68-6cc8-44c8-a1f5-0aa072f4369b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_384b4d68-6cc8-44c8-a1f5-0aa072f4369b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_4d1e7cd9-950c-4889-9d46-be0810c3a0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_4d1e7cd9-950c-4889-9d46-be0810c3a0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_ac669a3b-1680-4212-b847-a04dfedf31db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_ac669a3b-1680-4212-b847-a04dfedf31db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_5fcd7128-67f2-4602-b705-8b0a5e5a2b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_5fcd7128-67f2-4602-b705-8b0a5e5a2b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_fe9e368e-f7dc-4120-9d34-ea83909a7458" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_fe9e368e-f7dc-4120-9d34-ea83909a7458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_e80e4b13-d75f-4beb-aaa6-b4a47813ee6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_e80e4b13-d75f-4beb-aaa6-b4a47813ee6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_e1e41536-034a-4b1e-a108-4ca567bbedb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_e1e41536-034a-4b1e-a108-4ca567bbedb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12e4f31d-3141-4e96-9f9f-4e82bb89cb77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12e4f31d-3141-4e96-9f9f-4e82bb89cb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_7a77aaa4-36ff-4409-92bc-8d961a33b159" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_7a77aaa4-36ff-4409-92bc-8d961a33b159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_c0085304-bea8-45ad-aeff-4516fa7d74e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_c0085304-bea8-45ad-aeff-4516fa7d74e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock_33d40482-b348-46f3-87bc-93d58f918969" xlink:href="pacb-20241231.xsd#pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock_33d40482-b348-46f3-87bc-93d58f918969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ef7804f2-7ba9-4bb3-ac59-0f39bd2c472a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ef7804f2-7ba9-4bb3-ac59-0f39bd2c472a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_ff1e5aac-7eb0-4382-a5ab-019684698ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88859eab-30d5-46a1-b3ce-73ef0442a112" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_ff1e5aac-7eb0-4382-a5ab-019684698ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="pacb-20241231.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7b6a43ef-9f31-4c21-912a-943b0643c9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_55418e27-23c9-4232-9bd8-dd46e6b10827" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7b6a43ef-9f31-4c21-912a-943b0643c9b8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_55418e27-23c9-4232-9bd8-dd46e6b10827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTables" xlink:type="simple" xlink:href="pacb-20241231.xsd#BUSINESSACQUISITIONSTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3fd87c61-6f7e-46e6-a952-576a17c8264d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_9597b753-68df-4e47-a17f-00467020123e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3fd87c61-6f7e-46e6-a952-576a17c8264d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_9597b753-68df-4e47-a17f-00467020123e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="pacb-20241231.xsd#FINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5a256d78-7b5d-4ab9-b743-51d72897c81a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_77b8e6f3-c3d8-4506-9833-4478ed3fb61e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5a256d78-7b5d-4ab9-b743-51d72897c81a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_77b8e6f3-c3d8-4506-9833-4478ed3fb61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2e680fde-b548-4ea4-bb41-130be9ed4295" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5a256d78-7b5d-4ab9-b743-51d72897c81a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2e680fde-b548-4ea4-bb41-130be9ed4295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_8ba95cbf-8292-4192-b6d1-6b958d635f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5a256d78-7b5d-4ab9-b743-51d72897c81a" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_8ba95cbf-8292-4192-b6d1-6b958d635f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_922d3a59-caa0-4fb2-86e9-e195382d11fd" xlink:href="pacb-20241231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b9acd452-e7e6-4817-8356-b602a129b5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_922d3a59-caa0-4fb2-86e9-e195382d11fd" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b9acd452-e7e6-4817-8356-b602a129b5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_86d99e7d-9cfd-4a35-81eb-af71394fc617" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_922d3a59-caa0-4fb2-86e9-e195382d11fd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_86d99e7d-9cfd-4a35-81eb-af71394fc617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_0c3df2d4-96ac-4ab7-ac28-0b0dddb55505" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_922d3a59-caa0-4fb2-86e9-e195382d11fd" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_0c3df2d4-96ac-4ab7-ac28-0b0dddb55505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_ea41c05f-5e7b-4470-9fe3-d74a8fc9b9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_922d3a59-caa0-4fb2-86e9-e195382d11fd" xlink:to="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_ea41c05f-5e7b-4470-9fe3-d74a8fc9b9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_fd1cb898-5064-47b8-aeed-6e22797a2e22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_922d3a59-caa0-4fb2-86e9-e195382d11fd" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_fd1cb898-5064-47b8-aeed-6e22797a2e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c8ddab88-6f5f-4ddb-8137-526a2f845c54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_922d3a59-caa0-4fb2-86e9-e195382d11fd" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c8ddab88-6f5f-4ddb-8137-526a2f845c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_cc74a4d3-bb34-4b2f-b330-a0a8f4b5bfe2" xlink:href="pacb-20241231.xsd#pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_922d3a59-caa0-4fb2-86e9-e195382d11fd" xlink:to="loc_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_cc74a4d3-bb34-4b2f-b330-a0a8f4b5bfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_c8f7d8e3-0a01-46d0-bf12-634837b2dcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_922d3a59-caa0-4fb2-86e9-e195382d11fd" xlink:to="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_c8f7d8e3-0a01-46d0-bf12-634837b2dcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_99011a12-259f-47e0-b338-fae74a698b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_922d3a59-caa0-4fb2-86e9-e195382d11fd" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_99011a12-259f-47e0-b338-fae74a698b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONVERTIBLESENIORNOTESTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a62533ab-0f53-411c-b917-26c9535d4603" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_a96afd2d-2d14-45c1-acdc-04f4edb30226" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a62533ab-0f53-411c-b917-26c9535d4603" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_a96afd2d-2d14-45c1-acdc-04f4edb30226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfInterestExpenseTableTextBlock_6118f83f-3e5e-482c-84f8-e844dc32d041" xlink:href="pacb-20241231.xsd#pacb_ScheduleOfInterestExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a62533ab-0f53-411c-b917-26c9535d4603" xlink:to="loc_pacb_ScheduleOfInterestExpenseTableTextBlock_6118f83f-3e5e-482c-84f8-e844dc32d041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGTables" xlink:type="simple" xlink:href="pacb-20241231.xsd#RESTRUCTURINGTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_65805978-b690-4c5f-93d3-b08d15134629" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_8d114a97-e66e-4496-8cd4-cbb4b01de89b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_65805978-b690-4c5f-93d3-b08d15134629" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_8d114a97-e66e-4496-8cd4-cbb4b01de89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5256d5bb-2359-4d79-b933-014f3ab78314" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_65805978-b690-4c5f-93d3-b08d15134629" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5256d5bb-2359-4d79-b933-014f3ab78314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="pacb-20241231.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8346ebf3-2858-45dd-a485-af7c6d7022c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LesseeOperatingLeaseDescriptionTableTextBlock_c5d05886-4eca-4f5c-9fbf-5c3f78fecbda" xlink:href="pacb-20241231.xsd#pacb_LesseeOperatingLeaseDescriptionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8346ebf3-2858-45dd-a485-af7c6d7022c1" xlink:to="loc_pacb_LesseeOperatingLeaseDescriptionTableTextBlock_c5d05886-4eca-4f5c-9fbf-5c3f78fecbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="pacb-20241231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0c30ac02-2ee3-4682-bf69-824fb7ad3f77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_088ccd11-d315-4c1a-99af-c69d13dae61e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0c30ac02-2ee3-4682-bf69-824fb7ad3f77" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_088ccd11-d315-4c1a-99af-c69d13dae61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c98ffd43-ad24-49e1-b3f0-0c2fd7fb90fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0c30ac02-2ee3-4682-bf69-824fb7ad3f77" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c98ffd43-ad24-49e1-b3f0-0c2fd7fb90fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_781912f6-7198-4054-bfed-af4c1257ee52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0c30ac02-2ee3-4682-bf69-824fb7ad3f77" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_781912f6-7198-4054-bfed-af4c1257ee52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_7ceb3c4f-41ce-4a08-b12b-2f6c4d167a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0c30ac02-2ee3-4682-bf69-824fb7ad3f77" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_7ceb3c4f-41ce-4a08-b12b-2f6c4d167a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="pacb-20241231.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fcbebdd8-e476-47c1-9e65-04ddee952555" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ec2645d3-8f65-493b-9c0e-d1bea2c084cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fcbebdd8-e476-47c1-9e65-04ddee952555" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ec2645d3-8f65-493b-9c0e-d1bea2c084cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_7e90ac70-8f2c-4718-83fd-13a1cc533a10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fcbebdd8-e476-47c1-9e65-04ddee952555" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_7e90ac70-8f2c-4718-83fd-13a1cc533a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5e01c9c6-6fa9-4263-91db-272c2cc37fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fcbebdd8-e476-47c1-9e65-04ddee952555" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5e01c9c6-6fa9-4263-91db-272c2cc37fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_93b2ef34-5819-4b0a-96ff-5447437fc813" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fcbebdd8-e476-47c1-9e65-04ddee952555" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_93b2ef34-5819-4b0a-96ff-5447437fc813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_f14c163a-8e34-458c-95c2-f4e53a2f6f27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fcbebdd8-e476-47c1-9e65-04ddee952555" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_f14c163a-8e34-458c-95c2-f4e53a2f6f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables" xlink:type="simple" xlink:href="pacb-20241231.xsd#NETLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1a71f08f-f5cc-49e2-bac4-51a16470bb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fcbfd0c9-0b1b-4276-b484-965053f0de9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1a71f08f-f5cc-49e2-bac4-51a16470bb3d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fcbfd0c9-0b1b-4276-b484-965053f0de9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3e084d6f-a5b4-4dbd-9578-634ce4e78f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1a71f08f-f5cc-49e2-bac4-51a16470bb3d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3e084d6f-a5b4-4dbd-9578-634ce4e78f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables" xlink:type="simple" xlink:href="pacb-20241231.xsd#SEGMENTANDGEOGRAPHICINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_aa375c9a-7225-4b56-afa2-70bd62363a29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_e8a8edfa-d44b-45c3-a42a-0102d410c904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_aa375c9a-7225-4b56-afa2-70bd62363a29" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_e8a8edfa-d44b-45c3-a42a-0102d410c904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_631e153d-644e-4a84-aee2-a87fedfc31dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_aa375c9a-7225-4b56-afa2-70bd62363a29" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_631e153d-644e-4a84-aee2-a87fedfc31dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_6b2c2faa-a4ce-44b5-acb3-c517a2a0ecb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_aa375c9a-7225-4b56-afa2-70bd62363a29" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_6b2c2faa-a4ce-44b5-acb3-c517a2a0ecb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_752be3af-5b02-454d-b95b-b39c067762fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_33a3ec3c-943b-44de-9dff-2b4d5b4bfbc3" xlink:href="pacb-20241231.xsd#pacb_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_752be3af-5b02-454d-b95b-b39c067762fb" xlink:to="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_33a3ec3c-943b-44de-9dff-2b4d5b4bfbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c50b3316-e027-47c5-a3e3-61c3a6e6c112" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_33a3ec3c-943b-44de-9dff-2b4d5b4bfbc3" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c50b3316-e027-47c5-a3e3-61c3a6e6c112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fff12d7-4c15-4e55-a492-0a82a5bd93d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c50b3316-e027-47c5-a3e3-61c3a6e6c112" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fff12d7-4c15-4e55-a492-0a82a5bd93d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_cc28a458-04ac-4f00-8dab-1a4a4face8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fff12d7-4c15-4e55-a492-0a82a5bd93d7" xlink:to="loc_us-gaap_SalesRevenueNetMember_cc28a458-04ac-4f00-8dab-1a4a4face8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_03081fd9-5d3e-4376-b9dd-bf6656f7b5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fff12d7-4c15-4e55-a492-0a82a5bd93d7" xlink:to="loc_us-gaap_AccountsReceivableMember_03081fd9-5d3e-4376-b9dd-bf6656f7b5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_67b24d19-8655-406f-9d3a-efab363843f9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_33a3ec3c-943b-44de-9dff-2b4d5b4bfbc3" xlink:to="loc_srt_MajorCustomersAxis_67b24d19-8655-406f-9d3a-efab363843f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ef205d31-28c9-423f-95f3-82c75c6856bb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_67b24d19-8655-406f-9d3a-efab363843f9" xlink:to="loc_srt_NameOfMajorCustomerDomain_ef205d31-28c9-423f-95f3-82c75c6856bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CustomerOneMember_3c51a0f0-ecd8-4eb7-a723-d22d948ef30d" xlink:href="pacb-20241231.xsd#pacb_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ef205d31-28c9-423f-95f3-82c75c6856bb" xlink:to="loc_pacb_CustomerOneMember_3c51a0f0-ecd8-4eb7-a723-d22d948ef30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DomesticCustomersMember_64b3d11f-0c8e-4133-a000-0a0ff4ed7178" xlink:href="pacb-20241231.xsd#pacb_DomesticCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ef205d31-28c9-423f-95f3-82c75c6856bb" xlink:to="loc_pacb_DomesticCustomersMember_64b3d11f-0c8e-4133-a000-0a0ff4ed7178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_30c05153-f113-458f-ace1-b1bd315a4edf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_33a3ec3c-943b-44de-9dff-2b4d5b4bfbc3" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_30c05153-f113-458f-ace1-b1bd315a4edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_7b823634-cb2a-469d-9a26-3cc3a6c87eca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_30c05153-f113-458f-ace1-b1bd315a4edf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_7b823634-cb2a-469d-9a26-3cc3a6c87eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c9f52deb-51ff-4f60-817f-fc2654f784d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_7b823634-cb2a-469d-9a26-3cc3a6c87eca" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c9f52deb-51ff-4f60-817f-fc2654f784d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_14bfa4a9-9c67-4486-a8bb-1955bdd824df" xlink:href="pacb-20241231.xsd#pacb_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_33a3ec3c-943b-44de-9dff-2b4d5b4bfbc3" xlink:to="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_14bfa4a9-9c67-4486-a8bb-1955bdd824df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a0698528-9eb4-4ca9-838c-b45efdd4405c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_14bfa4a9-9c67-4486-a8bb-1955bdd824df" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a0698528-9eb4-4ca9-838c-b45efdd4405c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_a3c1ff7d-4830-4bd2-b96c-9561b6ef2a68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_14bfa4a9-9c67-4486-a8bb-1955bdd824df" xlink:to="loc_us-gaap_NumberOfReportableSegments_a3c1ff7d-4830-4bd2-b96c-9561b6ef2a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod_d330055f-198a-456a-9b55-bbd565b1031d" xlink:href="pacb-20241231.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_14bfa4a9-9c67-4486-a8bb-1955bdd824df" xlink:to="loc_pacb_StandardProductWarrantyPeriod_d330055f-198a-456a-9b55-bbd565b1031d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0973ac45-952d-4c20-804f-57774f619499" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a4b9f7e-ed5d-4512-ba09-57b0a04ffddb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0973ac45-952d-4c20-804f-57774f619499" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a4b9f7e-ed5d-4512-ba09-57b0a04ffddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_16c5fe3f-61e4-40e8-a190-6aa099766155" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a4b9f7e-ed5d-4512-ba09-57b0a04ffddb" xlink:to="loc_srt_RangeAxis_16c5fe3f-61e4-40e8-a190-6aa099766155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4d655431-bfaa-4a62-8848-6e61d858db46" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_16c5fe3f-61e4-40e8-a190-6aa099766155" xlink:to="loc_srt_RangeMember_4d655431-bfaa-4a62-8848-6e61d858db46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2557ac55-582c-4e7d-9079-4463a8051ec5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4d655431-bfaa-4a62-8848-6e61d858db46" xlink:to="loc_srt_MinimumMember_2557ac55-582c-4e7d-9079-4463a8051ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_10d6cf35-66f1-4f14-b40b-6a25c01c49c2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4d655431-bfaa-4a62-8848-6e61d858db46" xlink:to="loc_srt_MaximumMember_10d6cf35-66f1-4f14-b40b-6a25c01c49c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22efa9cb-c13a-43d7-805c-a723ed2148da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a4b9f7e-ed5d-4512-ba09-57b0a04ffddb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22efa9cb-c13a-43d7-805c-a723ed2148da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c19cf22-c9a7-4894-bd29-1b1a23ad9ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22efa9cb-c13a-43d7-805c-a723ed2148da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c19cf22-c9a7-4894-bd29-1b1a23ad9ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_96d2e97e-b7ab-4d66-a884-d0f8f1ce97d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c19cf22-c9a7-4894-bd29-1b1a23ad9ab2" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_96d2e97e-b7ab-4d66-a884-d0f8f1ce97d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_2eaca6b3-4469-409a-8244-2f4a87692e20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c19cf22-c9a7-4894-bd29-1b1a23ad9ab2" xlink:to="loc_us-gaap_EquipmentMember_2eaca6b3-4469-409a-8244-2f4a87692e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_21019b0e-2ae8-4d31-bc2e-1bd83cd69d13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c19cf22-c9a7-4894-bd29-1b1a23ad9ab2" xlink:to="loc_us-gaap_ComputerEquipmentMember_21019b0e-2ae8-4d31-bc2e-1bd83cd69d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_dd489f02-dbf1-4d48-967f-407f3002deb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c19cf22-c9a7-4894-bd29-1b1a23ad9ab2" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_dd489f02-dbf1-4d48-967f-407f3002deb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9f7c25fb-fca2-4941-83e3-4a2f6939e454" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c19cf22-c9a7-4894-bd29-1b1a23ad9ab2" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9f7c25fb-fca2-4941-83e3-4a2f6939e454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1721772d-b0c2-4e81-a378-3b86d9b1ded7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a4b9f7e-ed5d-4512-ba09-57b0a04ffddb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1721772d-b0c2-4e81-a378-3b86d9b1ded7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_259077c3-2dd2-42bd-bb05-2d32f0d9d000" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1721772d-b0c2-4e81-a378-3b86d9b1ded7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_259077c3-2dd2-42bd-bb05-2d32f0d9d000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BUSINESSACQUISITIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8ab5335d-ad59-453f-93f1-adfc54090b35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_57c0f26d-f2a0-496d-ad9d-4a87ab9b2993" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8ab5335d-ad59-453f-93f1-adfc54090b35" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_57c0f26d-f2a0-496d-ad9d-4a87ab9b2993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8860e791-6aab-4e33-8337-86cf60061cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_57c0f26d-f2a0-496d-ad9d-4a87ab9b2993" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8860e791-6aab-4e33-8337-86cf60061cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db8ddc9f-6fac-45e3-b89f-0439e39ca78e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8860e791-6aab-4e33-8337-86cf60061cdc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db8ddc9f-6fac-45e3-b89f-0439e39ca78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_b9649809-dbcd-452b-b9d8-8c5ac75584b9" xlink:href="pacb-20241231.xsd#pacb_AptonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db8ddc9f-6fac-45e3-b89f-0439e39ca78e" xlink:to="loc_pacb_AptonMember_b9649809-dbcd-452b-b9d8-8c5ac75584b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_60a48dcd-6a66-40c3-8673-6fd6b2504094" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_57c0f26d-f2a0-496d-ad9d-4a87ab9b2993" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_60a48dcd-6a66-40c3-8673-6fd6b2504094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_a3c5e380-30b0-49c2-803a-8dd3ceec8ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_60a48dcd-6a66-40c3-8673-6fd6b2504094" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_a3c5e380-30b0-49c2-803a-8dd3ceec8ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AchievementOfMilestoneMember_01bbf23b-8c53-4bda-a8bb-34ef986d7364" xlink:href="pacb-20241231.xsd#pacb_AchievementOfMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_a3c5e380-30b0-49c2-803a-8dd3ceec8ea3" xlink:to="loc_pacb_AchievementOfMilestoneMember_01bbf23b-8c53-4bda-a8bb-34ef986d7364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_20f74dd4-b165-4eeb-bad0-ce3bdc34d2b5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_57c0f26d-f2a0-496d-ad9d-4a87ab9b2993" xlink:to="loc_srt_RangeAxis_20f74dd4-b165-4eeb-bad0-ce3bdc34d2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_23653b97-6e4b-4886-941a-5e33551fa052" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_20f74dd4-b165-4eeb-bad0-ce3bdc34d2b5" xlink:to="loc_srt_RangeMember_23653b97-6e4b-4886-941a-5e33551fa052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ab0f6d92-f3a1-44d5-8196-bc15aead2eb0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_23653b97-6e4b-4886-941a-5e33551fa052" xlink:to="loc_srt_MaximumMember_ab0f6d92-f3a1-44d5-8196-bc15aead2eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_04edb6ad-b74a-4f6f-8750-0562a5643c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_57c0f26d-f2a0-496d-ad9d-4a87ab9b2993" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_04edb6ad-b74a-4f6f-8750-0562a5643c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7772bf1d-f9b1-4afc-b3dc-fa5540c576a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04edb6ad-b74a-4f6f-8750-0562a5643c9c" xlink:to="loc_us-gaap_EquityComponentDomain_7772bf1d-f9b1-4afc-b3dc-fa5540c576a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4410aadc-abeb-44fa-908d-c01394e622a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7772bf1d-f9b1-4afc-b3dc-fa5540c576a5" xlink:to="loc_us-gaap_CommonStockMember_4410aadc-abeb-44fa-908d-c01394e622a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_57c0f26d-f2a0-496d-ad9d-4a87ab9b2993" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_ed85355a-d58c-4f22-a9c6-bb58ea8d9264" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_ed85355a-d58c-4f22-a9c6-bb58ea8d9264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_af1e1e8a-f5e4-449e-b9a0-2e600764d495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_af1e1e8a-f5e4-449e-b9a0-2e600764d495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_63a729ca-439c-41d6-9022-35471a37ba6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_63a729ca-439c-41d6-9022-35471a37ba6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_e4253886-e109-4f68-b9b7-cac2ef107177" xlink:href="pacb-20241231.xsd#pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_e4253886-e109-4f68-b9b7-cac2ef107177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_c4ec0b68-7802-4c38-bce7-ff4596fa0580" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_c4ec0b68-7802-4c38-bce7-ff4596fa0580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_a5194552-ef68-4601-876f-151fde240c9a" xlink:href="pacb-20241231.xsd#pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_a5194552-ef68-4601-876f-151fde240c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod_a41ec8c6-4fd2-4936-aec1-8be9da84d433" xlink:href="pacb-20241231.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod_a41ec8c6-4fd2-4936-aec1-8be9da84d433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_1cc96cf1-4def-41f1-8209-70e5f73c653f" xlink:href="pacb-20241231.xsd#pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_1cc96cf1-4def-41f1-8209-70e5f73c653f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_cb5fa543-42b3-40d3-bd44-199ea514ca57" xlink:href="pacb-20241231.xsd#pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_cb5fa543-42b3-40d3-bd44-199ea514ca57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_136b65e4-6122-45eb-bc37-3b9631f54ced" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_136b65e4-6122-45eb-bc37-3b9631f54ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_a45577ed-53ec-4041-bd38-6ed225739a64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_a45577ed-53ec-4041-bd38-6ed225739a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_a6ca6e4b-158d-4184-91e7-3d83a86924da" xlink:href="pacb-20241231.xsd#pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_a6ca6e4b-158d-4184-91e7-3d83a86924da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_ef79516b-de21-4fb1-8c20-bbcc16f6bbf2" xlink:href="pacb-20241231.xsd#pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_ef79516b-de21-4fb1-8c20-bbcc16f6bbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_b6716ce6-bca6-4149-8d8b-9ff78323da10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_b6716ce6-bca6-4149-8d8b-9ff78323da10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_7c9589ee-b8f5-4673-a9bf-6827df6d4bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e47eb41-5dd2-429f-b354-87b01192b3bb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_7c9589ee-b8f5-4673-a9bf-6827df6d4bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6fcab4d6-bba5-40a7-b1ea-96fe451baf31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d05902a-e2e5-4eb1-8431-fdb0e096978d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6fcab4d6-bba5-40a7-b1ea-96fe451baf31" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d05902a-e2e5-4eb1-8431-fdb0e096978d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_850e86b6-acb1-4445-9e6b-2853cf182eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d05902a-e2e5-4eb1-8431-fdb0e096978d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_850e86b6-acb1-4445-9e6b-2853cf182eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5152809-f677-44ed-ac78-28013c62a354" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_850e86b6-acb1-4445-9e6b-2853cf182eeb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5152809-f677-44ed-ac78-28013c62a354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_abcde161-e1eb-4798-97e5-b1cf587da10a" xlink:href="pacb-20241231.xsd#pacb_AptonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5152809-f677-44ed-ac78-28013c62a354" xlink:to="loc_pacb_AptonMember_abcde161-e1eb-4798-97e5-b1cf587da10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d05902a-e2e5-4eb1-8431-fdb0e096978d" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_9f7e4968-5afc-4155-bda2-beea1f899304" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_9f7e4968-5afc-4155-bda2-beea1f899304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1b80c9df-e9d4-4553-ad00-43d8ecdc1e83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1b80c9df-e9d4-4553-ad00-43d8ecdc1e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_748a9803-71b8-4fbf-b92e-6734ef8c7687" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:to="loc_us-gaap_Goodwill_748a9803-71b8-4fbf-b92e-6734ef8c7687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_fab013e1-c73e-4789-91fa-5aaec90bd968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_fab013e1-c73e-4789-91fa-5aaec90bd968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_34e35444-7ec9-4243-b8db-3ed09330d9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_34e35444-7ec9-4243-b8db-3ed09330d9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_bdca2d43-cffb-4ca8-aaa3-3c53a3f156c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_bdca2d43-cffb-4ca8-aaa3-3c53a3f156c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_7919b91e-b3e6-4bde-9c92-c549e9af3a24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30eaaafe-ae02-4664-b0b0-bc60ca0e21ca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_7919b91e-b3e6-4bde-9c92-c549e9af3a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2ae477d3-3688-45ea-868a-031ba8dfcfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cf734908-57ff-4f5c-9f4a-5c0c85459f11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2ae477d3-3688-45ea-868a-031ba8dfcfe1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cf734908-57ff-4f5c-9f4a-5c0c85459f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_565d37b6-0866-43cf-bf3e-f16bda743615" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cf734908-57ff-4f5c-9f4a-5c0c85459f11" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_565d37b6-0866-43cf-bf3e-f16bda743615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_caf698eb-06e6-4ed9-8091-9a40861789e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_565d37b6-0866-43cf-bf3e-f16bda743615" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_caf698eb-06e6-4ed9-8091-9a40861789e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_db4a9203-0240-41ac-914f-0ea5acefdf11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_caf698eb-06e6-4ed9-8091-9a40861789e1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_db4a9203-0240-41ac-914f-0ea5acefdf11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_351184bc-105d-470e-9d2b-146ae13f812c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_caf698eb-06e6-4ed9-8091-9a40861789e1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_351184bc-105d-470e-9d2b-146ae13f812c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3ec1fd51-0f6a-43b4-9da0-dfc5b1ec4a53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_caf698eb-06e6-4ed9-8091-9a40861789e1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3ec1fd51-0f6a-43b4-9da0-dfc5b1ec4a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_02e1c735-3cc9-4a5d-b775-ded6727f361f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cf734908-57ff-4f5c-9f4a-5c0c85459f11" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_02e1c735-3cc9-4a5d-b775-ded6727f361f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f1a8e3d-f632-4f32-8efb-5bd197dfd6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_02e1c735-3cc9-4a5d-b775-ded6727f361f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f1a8e3d-f632-4f32-8efb-5bd197dfd6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_467d0a37-3c07-45b1-ae3d-92687a689412" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f1a8e3d-f632-4f32-8efb-5bd197dfd6a3" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_467d0a37-3c07-45b1-ae3d-92687a689412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CashAndMoneyMarketFundsMember_5e3f151a-b6a1-4702-a558-9df866a8854a" xlink:href="pacb-20241231.xsd#pacb_CashAndMoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_467d0a37-3c07-45b1-ae3d-92687a689412" xlink:to="loc_pacb_CashAndMoneyMarketFundsMember_5e3f151a-b6a1-4702-a558-9df866a8854a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b0fdb72b-9277-4ab8-ba93-6e5f309df00d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_467d0a37-3c07-45b1-ae3d-92687a689412" xlink:to="loc_us-gaap_CommercialPaperMember_b0fdb72b-9277-4ab8-ba93-6e5f309df00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d929757d-93c0-4cfb-a256-7a7bd0ac3b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_467d0a37-3c07-45b1-ae3d-92687a689412" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d929757d-93c0-4cfb-a256-7a7bd0ac3b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_baf41d58-3e26-4517-8646-6e44bfb65f17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f1a8e3d-f632-4f32-8efb-5bd197dfd6a3" xlink:to="loc_us-gaap_InvestmentsMember_baf41d58-3e26-4517-8646-6e44bfb65f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_1436d4e7-7915-4d0a-9e84-6da89da303b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_baf41d58-3e26-4517-8646-6e44bfb65f17" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_1436d4e7-7915-4d0a-9e84-6da89da303b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_383feb7c-a1f4-4cfc-816a-4775bbb8fbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_baf41d58-3e26-4517-8646-6e44bfb65f17" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_383feb7c-a1f4-4cfc-816a-4775bbb8fbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_069e2d30-6a92-4546-a3db-6a991f2ac3bd" xlink:href="pacb-20241231.xsd#pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_baf41d58-3e26-4517-8646-6e44bfb65f17" xlink:to="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_069e2d30-6a92-4546-a3db-6a991f2ac3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6e7a9d10-ab80-49e4-a398-bc877ecb53e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cf734908-57ff-4f5c-9f4a-5c0c85459f11" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6e7a9d10-ab80-49e4-a398-bc877ecb53e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_266422ff-ade1-4b46-8b18-b26e3285f7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6e7a9d10-ab80-49e4-a398-bc877ecb53e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_266422ff-ade1-4b46-8b18-b26e3285f7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_40f2f3de-ae81-4b17-95d3-51a10b868b5b" xlink:href="pacb-20241231.xsd#pacb_AptonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_266422ff-ade1-4b46-8b18-b26e3285f7ba" xlink:to="loc_pacb_AptonMember_40f2f3de-ae81-4b17-95d3-51a10b868b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a8f7ab42-22c2-4086-9df4-3758b69f2211" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cf734908-57ff-4f5c-9f4a-5c0c85459f11" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a8f7ab42-22c2-4086-9df4-3758b69f2211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b26ae5fd-d083-43bb-82d4-4e7096596c20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a8f7ab42-22c2-4086-9df4-3758b69f2211" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b26ae5fd-d083-43bb-82d4-4e7096596c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_29e7bb96-80d3-4a52-8753-fd42e61b1cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b26ae5fd-d083-43bb-82d4-4e7096596c20" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_29e7bb96-80d3-4a52-8753-fd42e61b1cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_7e209ca8-a3d6-4956-b2c8-4ccf0e6d2faf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b26ae5fd-d083-43bb-82d4-4e7096596c20" xlink:to="loc_us-gaap_InvestmentsMember_7e209ca8-a3d6-4956-b2c8-4ccf0e6d2faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_daa486bb-7130-4862-b191-e76435f5c22f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cf734908-57ff-4f5c-9f4a-5c0c85459f11" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_daa486bb-7130-4862-b191-e76435f5c22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0fb0430b-1670-4746-99dc-a4570f315407" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_daa486bb-7130-4862-b191-e76435f5c22f" xlink:to="loc_us-gaap_AssetsAbstract_0fb0430b-1670-4746-99dc-a4570f315407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b7e99bb9-1de1-40ab-becf-5ce44bd5e59e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0fb0430b-1670-4746-99dc-a4570f315407" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b7e99bb9-1de1-40ab-becf-5ce44bd5e59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_e49c126a-54e3-482f-a615-fb906275438e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0fb0430b-1670-4746-99dc-a4570f315407" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_e49c126a-54e3-482f-a615-fb906275438e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_92fd62ae-8ccb-4a12-a7d6-8362baa82aae" xlink:href="pacb-20241231.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0fb0430b-1670-4746-99dc-a4570f315407" xlink:to="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_92fd62ae-8ccb-4a12-a7d6-8362baa82aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashFairValueDisclosure_2b74cf31-95b5-4e85-b4f1-45f102e48a3e" xlink:href="pacb-20241231.xsd#pacb_LongTermRestrictedCashFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0fb0430b-1670-4746-99dc-a4570f315407" xlink:to="loc_pacb_LongTermRestrictedCashFairValueDisclosure_2b74cf31-95b5-4e85-b4f1-45f102e48a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ef749ad6-c276-4b14-bf26-9e447e4a50c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0fb0430b-1670-4746-99dc-a4570f315407" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ef749ad6-c276-4b14-bf26-9e447e4a50c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_c8849036-7410-42c3-b284-2ab3f7768796" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_daa486bb-7130-4862-b191-e76435f5c22f" xlink:to="loc_us-gaap_LiabilitiesAbstract_c8849036-7410-42c3-b284-2ab3f7768796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ba157d3d-dd25-43de-a7d1-572b203a7053" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c8849036-7410-42c3-b284-2ab3f7768796" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ba157d3d-dd25-43de-a7d1-572b203a7053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_bbacd2b3-ba54-421f-bbb0-b04005eaf3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c8849036-7410-42c3-b284-2ab3f7768796" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_bbacd2b3-ba54-421f-bbb0-b04005eaf3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#FINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_80a4d140-e7f6-406d-98fa-10ba1bd0c093" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsTable_9d008767-fcb5-4010-a5a7-95f34e5bc39e" xlink:href="pacb-20241231.xsd#pacb_FinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_80a4d140-e7f6-406d-98fa-10ba1bd0c093" xlink:to="loc_pacb_FinancialInstrumentsTable_9d008767-fcb5-4010-a5a7-95f34e5bc39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_195fe47e-f0be-42e2-8abd-48586137e4d7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsTable_9d008767-fcb5-4010-a5a7-95f34e5bc39e" xlink:to="loc_srt_RangeAxis_195fe47e-f0be-42e2-8abd-48586137e4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b4e96bb-ff2e-45c8-b97c-6830b6a0e484" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_195fe47e-f0be-42e2-8abd-48586137e4d7" xlink:to="loc_srt_RangeMember_9b4e96bb-ff2e-45c8-b97c-6830b6a0e484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b4acb3ab-3f6f-48c6-9d6f-eeec4b008283" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9b4e96bb-ff2e-45c8-b97c-6830b6a0e484" xlink:to="loc_srt_MinimumMember_b4acb3ab-3f6f-48c6-9d6f-eeec4b008283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f4b6054f-095e-45d6-9b9f-15b0a1d9a4ac" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9b4e96bb-ff2e-45c8-b97c-6830b6a0e484" xlink:to="loc_srt_MaximumMember_f4b6054f-095e-45d6-9b9f-15b0a1d9a4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_00fd38d0-a1c0-4585-bcf4-52aafe95cb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsTable_9d008767-fcb5-4010-a5a7-95f34e5bc39e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_00fd38d0-a1c0-4585-bcf4-52aafe95cb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c79e4116-7354-4f43-8674-5ae9caae305f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_00fd38d0-a1c0-4585-bcf4-52aafe95cb4e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c79e4116-7354-4f43-8674-5ae9caae305f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_6b1a7659-45f9-4647-ad4b-39e678605e45" xlink:href="pacb-20241231.xsd#pacb_OmniomeIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c79e4116-7354-4f43-8674-5ae9caae305f" xlink:to="loc_pacb_OmniomeIncMember_6b1a7659-45f9-4647-ad4b-39e678605e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_2e3e6d06-483b-4f83-8451-983df7726529" xlink:href="pacb-20241231.xsd#pacb_AptonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c79e4116-7354-4f43-8674-5ae9caae305f" xlink:to="loc_pacb_AptonMember_2e3e6d06-483b-4f83-8451-983df7726529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeMember_14ccbe4d-a6cd-4284-94d1-33b4cbdd1a1d" xlink:href="pacb-20241231.xsd#pacb_OmniomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c79e4116-7354-4f43-8674-5ae9caae305f" xlink:to="loc_pacb_OmniomeMember_14ccbe4d-a6cd-4284-94d1-33b4cbdd1a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_51557073-a6b4-4757-a0bd-1adc15ce2989" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsTable_9d008767-fcb5-4010-a5a7-95f34e5bc39e" xlink:to="loc_us-gaap_AwardTypeAxis_51557073-a6b4-4757-a0bd-1adc15ce2989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ebd2d81-1cd5-4cfe-8d02-8b3b2d52877a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_51557073-a6b4-4757-a0bd-1adc15ce2989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ebd2d81-1cd5-4cfe-8d02-8b3b2d52877a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a80d90cd-706c-4fee-adab-44e5928bab43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ebd2d81-1cd5-4cfe-8d02-8b3b2d52877a" xlink:to="loc_us-gaap_CommonStockMember_a80d90cd-706c-4fee-adab-44e5928bab43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b17586bf-f2eb-4ae9-8d97-f75d12462b07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ebd2d81-1cd5-4cfe-8d02-8b3b2d52877a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b17586bf-f2eb-4ae9-8d97-f75d12462b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_ad0125f8-c64c-4d31-9c9d-4d78d56d22ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsTable_9d008767-fcb5-4010-a5a7-95f34e5bc39e" xlink:to="loc_us-gaap_ValuationTechniqueAxis_ad0125f8-c64c-4d31-9c9d-4d78d56d22ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_8b73c6cf-52e3-4dd2-895b-ad93901167d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_ad0125f8-c64c-4d31-9c9d-4d78d56d22ec" xlink:to="loc_us-gaap_ValuationTechniqueDomain_8b73c6cf-52e3-4dd2-895b-ad93901167d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember_4e7df836-2ea2-4346-81d5-d5467e459629" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_8b73c6cf-52e3-4dd2-895b-ad93901167d1" xlink:to="loc_us-gaap_IncomeApproachValuationTechniqueMember_4e7df836-2ea2-4346-81d5-d5467e459629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_9ac5b008-ab3e-42db-836c-6594a0e253a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsTable_9d008767-fcb5-4010-a5a7-95f34e5bc39e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_9ac5b008-ab3e-42db-836c-6594a0e253a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cb763c12-b7e9-4888-a648-6c33cb318431" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9ac5b008-ab3e-42db-836c-6594a0e253a6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cb763c12-b7e9-4888-a648-6c33cb318431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_040b764e-dc49-4751-b00a-c0a152215b42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cb763c12-b7e9-4888-a648-6c33cb318431" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_040b764e-dc49-4751-b00a-c0a152215b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:href="pacb-20241231.xsd#pacb_FinancialInstrumentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsTable_9d008767-fcb5-4010-a5a7-95f34e5bc39e" xlink:to="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_91664781-a25f-45e0-a53c-bd906e15a77c" xlink:href="pacb-20241231.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_91664781-a25f-45e0-a53c-bd906e15a77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_e80fc0d0-f5c2-4a99-9f35-d87b44033e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_e80fc0d0-f5c2-4a99-9f35-d87b44033e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_ba23e965-bdbc-4c90-adce-ad5f8737eb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_ba23e965-bdbc-4c90-adce-ad5f8737eb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_baa93d69-d152-4cbf-9e71-337eb8be00ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_baa93d69-d152-4cbf-9e71-337eb8be00ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_767653a5-bb21-4cc3-a364-32fee48e082c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_767653a5-bb21-4cc3-a364-32fee48e082c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_cb66ae75-3fd9-42cf-b4ad-752ec38660c1" xlink:href="pacb-20241231.xsd#pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_cb66ae75-3fd9-42cf-b4ad-752ec38660c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone_aca715f3-ce14-4079-9659-6002f0ed0c66" xlink:href="pacb-20241231.xsd#pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone_aca715f3-ce14-4079-9659-6002f0ed0c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_d00ff1df-c0da-42c1-9312-b46deb188eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_d00ff1df-c0da-42c1-9312-b46deb188eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_18819b0f-f24c-4298-a94c-d070c4e7168b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_18819b0f-f24c-4298-a94c-d070c4e7168b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_fbfe0daa-6451-4fbe-a7cc-a1a74ff4471f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_2286853b-7df9-4d8e-851e-7d7fa405043f" xlink:to="loc_us-gaap_InvestmentIncomeNet_fbfe0daa-6451-4fbe-a7cc-a1a74ff4471f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_85c5c984-d5a1-4546-9453-5f54b7277b60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80c6c428-2ca0-4c54-bdd4-6d49d3f4a371" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_85c5c984-d5a1-4546-9453-5f54b7277b60" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80c6c428-2ca0-4c54-bdd4-6d49d3f4a371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_301b2cd0-5f00-43dd-9896-13c84dd4d72d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80c6c428-2ca0-4c54-bdd4-6d49d3f4a371" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_301b2cd0-5f00-43dd-9896-13c84dd4d72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5533c963-002c-4a47-97f0-6271ee671107" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_301b2cd0-5f00-43dd-9896-13c84dd4d72d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5533c963-002c-4a47-97f0-6271ee671107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d81a40e3-68e7-4a58-88a3-b88fbd4eba45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5533c963-002c-4a47-97f0-6271ee671107" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d81a40e3-68e7-4a58-88a3-b88fbd4eba45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c305486b-ce8d-476a-9a7a-8d2e7054d4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80c6c428-2ca0-4c54-bdd4-6d49d3f4a371" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c305486b-ce8d-476a-9a7a-8d2e7054d4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_737f7fbd-845d-4f03-a331-22420ed585d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c305486b-ce8d-476a-9a7a-8d2e7054d4bb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_737f7fbd-845d-4f03-a331-22420ed585d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8653097a-87d1-469f-8a27-5baacfa30962" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_737f7fbd-845d-4f03-a331-22420ed585d6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8653097a-87d1-469f-8a27-5baacfa30962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9ea1b80e-7ad0-41ab-98c7-5c0dccca3bde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_737f7fbd-845d-4f03-a331-22420ed585d6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9ea1b80e-7ad0-41ab-98c7-5c0dccca3bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f4424b6d-fc23-4294-b3cd-846cf27c4d78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_737f7fbd-845d-4f03-a331-22420ed585d6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f4424b6d-fc23-4294-b3cd-846cf27c4d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_fbad509c-149d-4f55-991f-64a2e0626ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3e754b1a-2d26-42e4-a107-dc6d8ee81988" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_fbad509c-149d-4f55-991f-64a2e0626ce1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3e754b1a-2d26-42e4-a107-dc6d8ee81988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_195f47b7-ba9b-4b1f-8511-10b75dd3adf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3e754b1a-2d26-42e4-a107-dc6d8ee81988" xlink:to="loc_us-gaap_FinancialInstrumentAxis_195f47b7-ba9b-4b1f-8511-10b75dd3adf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4e85d56-cb7c-442c-8af9-20d21031f018" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_195f47b7-ba9b-4b1f-8511-10b75dd3adf3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4e85d56-cb7c-442c-8af9-20d21031f018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CashCashEquivalentsAndInvestmentsMember_ec33cbe8-4481-4570-b9e1-e7b6ceb5d752" xlink:href="pacb-20241231.xsd#pacb_CashCashEquivalentsAndInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4e85d56-cb7c-442c-8af9-20d21031f018" xlink:to="loc_pacb_CashCashEquivalentsAndInvestmentsMember_ec33cbe8-4481-4570-b9e1-e7b6ceb5d752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_af9591bb-bacd-4f41-8624-41dd850fe2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CashCashEquivalentsAndInvestmentsMember_ec33cbe8-4481-4570-b9e1-e7b6ceb5d752" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_af9591bb-bacd-4f41-8624-41dd850fe2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CashAndMoneyMarketFundsMember_48ce2de9-a479-4391-8d93-71dd0c53df41" xlink:href="pacb-20241231.xsd#pacb_CashAndMoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_af9591bb-bacd-4f41-8624-41dd850fe2d1" xlink:to="loc_pacb_CashAndMoneyMarketFundsMember_48ce2de9-a479-4391-8d93-71dd0c53df41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_08711aa0-dfa7-4c54-b3d6-6c1ff3a6e53c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_af9591bb-bacd-4f41-8624-41dd850fe2d1" xlink:to="loc_us-gaap_CommercialPaperMember_08711aa0-dfa7-4c54-b3d6-6c1ff3a6e53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f3589b24-0b8a-4946-905a-fa2f3321cd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_af9591bb-bacd-4f41-8624-41dd850fe2d1" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f3589b24-0b8a-4946-905a-fa2f3321cd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_bd5d5805-c5b6-46e6-9f79-3270227fea93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CashCashEquivalentsAndInvestmentsMember_ec33cbe8-4481-4570-b9e1-e7b6ceb5d752" xlink:to="loc_us-gaap_InvestmentsMember_bd5d5805-c5b6-46e6-9f79-3270227fea93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_81e2f167-8f0e-4010-9970-eb82d2090417" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_bd5d5805-c5b6-46e6-9f79-3270227fea93" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_81e2f167-8f0e-4010-9970-eb82d2090417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_cb7da060-d579-4b0e-b082-2e9c02b530d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_bd5d5805-c5b6-46e6-9f79-3270227fea93" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_cb7da060-d579-4b0e-b082-2e9c02b530d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_b979124d-5e02-4fe7-8747-163fe5ededc4" xlink:href="pacb-20241231.xsd#pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_bd5d5805-c5b6-46e6-9f79-3270227fea93" xlink:to="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_b979124d-5e02-4fe7-8747-163fe5ededc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_987d0ec2-cc16-4e41-b626-6cf366ee2daa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3e754b1a-2d26-42e4-a107-dc6d8ee81988" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_987d0ec2-cc16-4e41-b626-6cf366ee2daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_7ff29f32-2c47-40b5-9cb3-478049bcce24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_987d0ec2-cc16-4e41-b626-6cf366ee2daa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_7ff29f32-2c47-40b5-9cb3-478049bcce24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_85013851-3d9e-4154-8c59-4717c89b05d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_987d0ec2-cc16-4e41-b626-6cf366ee2daa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_85013851-3d9e-4154-8c59-4717c89b05d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7d514559-0911-49eb-815b-5d4beaac3f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_987d0ec2-cc16-4e41-b626-6cf366ee2daa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7d514559-0911-49eb-815b-5d4beaac3f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_e894d836-7750-482e-b8d0-1ece00a64140" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_987d0ec2-cc16-4e41-b626-6cf366ee2daa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_e894d836-7750-482e-b8d0-1ece00a64140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_bb4ea406-4a18-457b-8249-37ab213f424d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_987d0ec2-cc16-4e41-b626-6cf366ee2daa" xlink:to="loc_us-gaap_RestrictedCashCurrent_bb4ea406-4a18-457b-8249-37ab213f424d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e76a602a-7573-488a-bf5a-0318454a440e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_987d0ec2-cc16-4e41-b626-6cf366ee2daa" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e76a602a-7573-488a-bf5a-0318454a440e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_e7dbdd87-8188-4e72-adb9-e893dd4aaf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_ccc80de9-4a43-456f-af89-4245dfd285b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_e7dbdd87-8188-4e72-adb9-e893dd4aaf8b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_ccc80de9-4a43-456f-af89-4245dfd285b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_4f7acd8d-2a87-49a5-81cd-ecf3f01f77a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_e7dbdd87-8188-4e72-adb9-e893dd4aaf8b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_4f7acd8d-2a87-49a5-81cd-ecf3f01f77a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_47332287-6e1f-48ed-81a1-4890197b5a05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_e7dbdd87-8188-4e72-adb9-e893dd4aaf8b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_47332287-6e1f-48ed-81a1-4890197b5a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_e0c91089-b4d9-4fb9-9859-a51097f084a0" xlink:href="pacb-20241231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_ce3348d3-8382-483a-887b-79771f815a71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_e0c91089-b4d9-4fb9-9859-a51097f084a0" xlink:to="loc_us-gaap_InventoryRawMaterials_ce3348d3-8382-483a-887b-79771f815a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_3dab5484-59ae-4c57-91a2-80a924bf8635" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_e0c91089-b4d9-4fb9-9859-a51097f084a0" xlink:to="loc_us-gaap_InventoryWorkInProcess_3dab5484-59ae-4c57-91a2-80a924bf8635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_9988b7dd-3070-44ad-bd59-d5a3852f9853" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_e0c91089-b4d9-4fb9-9859-a51097f084a0" xlink:to="loc_us-gaap_InventoryFinishedGoods_9988b7dd-3070-44ad-bd59-d5a3852f9853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_3846a670-6b62-4367-abdf-4915add56763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_e0c91089-b4d9-4fb9-9859-a51097f084a0" xlink:to="loc_us-gaap_InventoryGross_3846a670-6b62-4367-abdf-4915add56763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_d42db358-b061-4a85-8c89-8fc09f8d742d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_e0c91089-b4d9-4fb9-9859-a51097f084a0" xlink:to="loc_us-gaap_InventoryValuationReserves_d42db358-b061-4a85-8c89-8fc09f8d742d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c2c0364d-62ed-48e5-9b41-5f6760c4295e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_e0c91089-b4d9-4fb9-9859-a51097f084a0" xlink:to="loc_us-gaap_InventoryNet_c2c0364d-62ed-48e5-9b41-5f6760c4295e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_7c303789-68d9-47a9-aadc-6fee71414cb3" xlink:href="pacb-20241231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a47133a-0c08-4b56-ab40-c1b61f2357ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_7c303789-68d9-47a9-aadc-6fee71414cb3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a47133a-0c08-4b56-ab40-c1b61f2357ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_005133a7-a656-48c7-a92f-c29c17e7afc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a47133a-0c08-4b56-ab40-c1b61f2357ca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_005133a7-a656-48c7-a92f-c29c17e7afc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a82935e9-bb17-47ba-9376-5868c1e26ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_005133a7-a656-48c7-a92f-c29c17e7afc2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a82935e9-bb17-47ba-9376-5868c1e26ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LaboratoryEquipmentAndMachineryMember_7c8c8a77-00ba-4324-80bd-25bbe30b2094" xlink:href="pacb-20241231.xsd#pacb_LaboratoryEquipmentAndMachineryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a82935e9-bb17-47ba-9376-5868c1e26ee0" xlink:to="loc_pacb_LaboratoryEquipmentAndMachineryMember_7c8c8a77-00ba-4324-80bd-25bbe30b2094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_42089266-02b5-4036-b22b-3725c5134e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a82935e9-bb17-47ba-9376-5868c1e26ee0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_42089266-02b5-4036-b22b-3725c5134e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_bcb9d226-a48c-4741-9c20-de90f0b69dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a82935e9-bb17-47ba-9376-5868c1e26ee0" xlink:to="loc_us-gaap_ComputerEquipmentMember_bcb9d226-a48c-4741-9c20-de90f0b69dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ae717482-628b-42e9-b4e0-34f6109eb076" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a82935e9-bb17-47ba-9376-5868c1e26ee0" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ae717482-628b-42e9-b4e0-34f6109eb076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f8aea217-6ddf-4b3a-8460-d2188d9df709" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a82935e9-bb17-47ba-9376-5868c1e26ee0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f8aea217-6ddf-4b3a-8460-d2188d9df709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_1c4e6778-9cf3-4319-b0db-2079f344683d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a82935e9-bb17-47ba-9376-5868c1e26ee0" xlink:to="loc_us-gaap_ConstructionInProgressMember_1c4e6778-9cf3-4319-b0db-2079f344683d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5580aef2-56b2-43f4-a9dc-0368f76ab440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a47133a-0c08-4b56-ab40-c1b61f2357ca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5580aef2-56b2-43f4-a9dc-0368f76ab440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fcb948ca-c582-4c79-9515-db1a19c86683" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5580aef2-56b2-43f4-a9dc-0368f76ab440" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fcb948ca-c582-4c79-9515-db1a19c86683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_77beef20-c236-4c8e-8a1a-ad217460a872" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5580aef2-56b2-43f4-a9dc-0368f76ab440" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_77beef20-c236-4c8e-8a1a-ad217460a872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_de5f6213-6686-4131-9ff8-f5b1641a6806" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5580aef2-56b2-43f4-a9dc-0368f76ab440" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_de5f6213-6686-4131-9ff8-f5b1641a6806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_3c8c23c0-1b65-4595-bc0b-99fe739da451" xlink:href="pacb-20241231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:href="pacb-20241231.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_3c8c23c0-1b65-4595-bc0b-99fe739da451" xlink:to="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_155b8f86-15fe-44f2-9bc6-9af28d1d46ca" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_srt_ProductOrServiceAxis_155b8f86-15fe-44f2-9bc6-9af28d1d46ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8760d7a2-eb0f-4480-8540-1ccf48d9ba8e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_155b8f86-15fe-44f2-9bc6-9af28d1d46ca" xlink:to="loc_srt_ProductsAndServicesDomain_8760d7a2-eb0f-4480-8540-1ccf48d9ba8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_5fefb495-d38f-4ea3-9348-09aaa08cdcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8760d7a2-eb0f-4480-8540-1ccf48d9ba8e" xlink:to="loc_us-gaap_ServiceMember_5fefb495-d38f-4ea3-9348-09aaa08cdcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_41f11799-e0eb-419d-be10-2f82533702f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_41f11799-e0eb-419d-be10-2f82533702f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68991ca4-671f-4735-9978-aa14403a86fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_41f11799-e0eb-419d-be10-2f82533702f0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68991ca4-671f-4735-9978-aa14403a86fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_95b76fd2-4c28-4edc-8ac9-0d8cf4c28864" xlink:href="pacb-20241231.xsd#pacb_AptonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68991ca4-671f-4735-9978-aa14403a86fb" xlink:to="loc_pacb_AptonMember_95b76fd2-4c28-4edc-8ac9-0d8cf4c28864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_c7ea09c1-47cb-45b0-8878-5ad04a05e746" xlink:href="pacb-20241231.xsd#pacb_OmniomeIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68991ca4-671f-4735-9978-aa14403a86fb" xlink:to="loc_pacb_OmniomeIncMember_c7ea09c1-47cb-45b0-8878-5ad04a05e746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_71ea22a9-037d-43e9-aaec-d416f645943a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_71ea22a9-037d-43e9-aaec-d416f645943a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b506a6a7-64f2-4074-8876-e8d71513c3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_71ea22a9-037d-43e9-aaec-d416f645943a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b506a6a7-64f2-4074-8876-e8d71513c3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_15d37398-fa65-4ac2-8e0e-cfe4e18ad9bf" xlink:href="pacb-20241231.xsd#pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b506a6a7-64f2-4074-8876-e8d71513c3d0" xlink:to="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_15d37398-fa65-4ac2-8e0e-cfe4e18ad9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e1ed33c-223a-4cae-9eeb-37031ef947d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e1ed33c-223a-4cae-9eeb-37031ef947d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9f516d77-4581-4d5a-b915-94a232313dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e1ed33c-223a-4cae-9eeb-37031ef947d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9f516d77-4581-4d5a-b915-94a232313dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_5d681038-3612-41b7-8d95-60ee644cdcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9f516d77-4581-4d5a-b915-94a232313dfa" xlink:to="loc_us-gaap_CustomerRelationshipsMember_5d681038-3612-41b7-8d95-60ee644cdcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_f312af66-b139-411b-b353-fbab7b7cfcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9f516d77-4581-4d5a-b915-94a232313dfa" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_f312af66-b139-411b-b353-fbab7b7cfcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2667cd69-4afa-4822-93f0-9c7684c79a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2667cd69-4afa-4822-93f0-9c7684c79a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a93ba8cf-798f-42d3-92cb-668af0376195" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2667cd69-4afa-4822-93f0-9c7684c79a2b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a93ba8cf-798f-42d3-92cb-668af0376195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CostOfRevenueMember_ef5708e8-607e-4008-864a-e4742870045e" xlink:href="pacb-20241231.xsd#pacb_CostOfRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a93ba8cf-798f-42d3-92cb-668af0376195" xlink:to="loc_pacb_CostOfRevenueMember_ef5708e8-607e-4008-864a-e4742870045e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_b9f0122a-d425-4414-a62e-49958f4fb7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a93ba8cf-798f-42d3-92cb-668af0376195" xlink:to="loc_us-gaap_OperatingExpenseMember_b9f0122a-d425-4414-a62e-49958f4fb7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b431ae7f-8688-4e86-9c7e-87a549b5d626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b431ae7f-8688-4e86-9c7e-87a549b5d626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:href="pacb-20241231.xsd#pacb_BalanceSheetComponentsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_8dce95fd-d47f-4cbc-9d10-bed9d19355d6" xlink:to="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cd835b21-6b47-4fb7-939b-bcb3d1bacca9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_Depreciation_cd835b21-6b47-4fb7-939b-bcb3d1bacca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_f11450ad-9a81-4b98-8a4c-a65606bc6e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_f11450ad-9a81-4b98-8a4c-a65606bc6e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e5a42ba1-83e8-42e9-91b0-a9ffe2afc7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e5a42ba1-83e8-42e9-91b0-a9ffe2afc7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_633b6fab-ea80-48e2-86eb-8ceade6a3280" xlink:href="pacb-20241231.xsd#pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_633b6fab-ea80-48e2-86eb-8ceade6a3280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_b08797fe-2cdc-4497-aade-f02e689013fb" xlink:href="pacb-20241231.xsd#pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_b08797fe-2cdc-4497-aade-f02e689013fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_49f4044a-7a39-4f99-811a-9f16e1a24587" xlink:href="pacb-20241231.xsd#pacb_AdditionalGoodwillImpairmentChangeInDiscountRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_49f4044a-7a39-4f99-811a-9f16e1a24587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_c5efbb66-7236-4ec5-906a-c6d3852d306a" xlink:href="pacb-20241231.xsd#pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_c5efbb66-7236-4ec5-906a-c6d3852d306a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_cc799f08-85d4-4ca0-82f8-54103250f1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_cc799f08-85d4-4ca0-82f8-54103250f1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_426ec79a-c44a-49ee-a3c9-1d2b48f0737d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_426ec79a-c44a-49ee-a3c9-1d2b48f0737d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_490173a2-5f68-446d-a3ad-30121d555b52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_490173a2-5f68-446d-a3ad-30121d555b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_85746f5b-22bb-460f-a595-7c49b3bfa10d" xlink:href="pacb-20241231.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_85746f5b-22bb-460f-a595-7c49b3bfa10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_2aebea0e-6a98-453f-93b9-fea253141632" xlink:href="pacb-20241231.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_2aebea0e-6a98-453f-93b9-fea253141632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2b7e0a17-5e5c-4055-b10b-e6e669341345" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2b7e0a17-5e5c-4055-b10b-e6e669341345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_c6532952-ba60-4287-b3de-4b5d7e10932f" xlink:href="pacb-20241231.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_c6532952-ba60-4287-b3de-4b5d7e10932f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_88808126-a625-44db-b0cb-5b2749674a8e" xlink:href="pacb-20241231.xsd#pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_88808126-a625-44db-b0cb-5b2749674a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_17abff36-001c-4e8c-b435-fc02f0b9ff30" xlink:href="pacb-20241231.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInTerm"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_17abff36-001c-4e8c-b435-fc02f0b9ff30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_b0d2580b-d2ea-44ec-8b3f-1626324a53a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_AdjustmentForAmortization_b0d2580b-d2ea-44ec-8b3f-1626324a53a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d04c6c14-91ca-4061-bd45-721f07eb1656" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d04c6c14-91ca-4061-bd45-721f07eb1656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_575bfd78-580c-4602-b4c2-6e0e4673387c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ContractWithCustomerLiability_575bfd78-580c-4602-b4c2-6e0e4673387c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c78fe66f-d731-4815-b96f-83dc926b33fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c78fe66f-d731-4815-b96f-83dc926b33fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9ef92fa3-6aaf-45c2-b4a0-1d35db8f7a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9ef92fa3-6aaf-45c2-b4a0-1d35db8f7a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_d83d5284-0cce-4f99-8beb-c5105ffcc5da" xlink:href="pacb-20241231.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_d83d5284-0cce-4f99-8beb-c5105ffcc5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_73d94771-916e-46bf-a057-18bd9ff68310" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_73d94771-916e-46bf-a057-18bd9ff68310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c668a41a-8fbd-44a8-8577-b1da22b7a457" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c668a41a-8fbd-44a8-8577-b1da22b7a457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_a669e804-cf44-4fec-a655-7cc0d74892bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_a669e804-cf44-4fec-a655-7cc0d74892bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_62e00b91-31cd-4b6a-ac90-e6a968172731" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_9c5649aa-52cc-4332-b02d-fd6e8f42ac31" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_62e00b91-31cd-4b6a-ac90-e6a968172731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofGoodwillDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d21776fe-3fa6-44e4-ba7c-6852639a2554" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_d695b5a9-c7a5-4cf4-99fd-1bde05918504" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d21776fe-3fa6-44e4-ba7c-6852639a2554" xlink:to="loc_us-gaap_GoodwillRollForward_d695b5a9-c7a5-4cf4-99fd-1bde05918504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f4afca58-69b0-4be4-9333-d711b99fa2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d695b5a9-c7a5-4cf4-99fd-1bde05918504" xlink:to="loc_us-gaap_Goodwill_f4afca58-69b0-4be4-9333-d711b99fa2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4df5c189-ad40-4987-aab7-f4b2479f85fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d695b5a9-c7a5-4cf4-99fd-1bde05918504" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4df5c189-ad40-4987-aab7-f4b2479f85fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_827bc736-2c66-44ac-80e8-178c71128f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d695b5a9-c7a5-4cf4-99fd-1bde05918504" xlink:to="loc_us-gaap_Goodwill_827bc736-2c66-44ac-80e8-178c71128f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_25ed5670-09cc-4417-af0c-33a36c3d2e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_aaced155-97cb-4b46-8b1b-7fd1c699120e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_25ed5670-09cc-4417-af0c-33a36c3d2e5f" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_aaced155-97cb-4b46-8b1b-7fd1c699120e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_de7b4fa6-3a3f-4d43-b738-834eea291498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_aaced155-97cb-4b46-8b1b-7fd1c699120e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_de7b4fa6-3a3f-4d43-b738-834eea291498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a94f99fb-8db5-4c66-ac59-200eb494146d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_de7b4fa6-3a3f-4d43-b738-834eea291498" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a94f99fb-8db5-4c66-ac59-200eb494146d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_66409ab7-654d-4b2a-a5ea-1561b34879eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a94f99fb-8db5-4c66-ac59-200eb494146d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_66409ab7-654d-4b2a-a5ea-1561b34879eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7ab99f69-96bf-48e6-b337-d3abe7d2e6df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_aaced155-97cb-4b46-8b1b-7fd1c699120e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7ab99f69-96bf-48e6-b337-d3abe7d2e6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_e86fd79b-fc8e-44df-86a0-56191b4871bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7ab99f69-96bf-48e6-b337-d3abe7d2e6df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_e86fd79b-fc8e-44df-86a0-56191b4871bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_98b5991a-f307-4e74-8ae1-25a9153047c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_e86fd79b-fc8e-44df-86a0-56191b4871bc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_98b5991a-f307-4e74-8ae1-25a9153047c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_040fbe29-6115-4c4c-8b23-9306089f37a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_e86fd79b-fc8e-44df-86a0-56191b4871bc" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_040fbe29-6115-4c4c-8b23-9306089f37a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7bcb6e40-387f-4b85-a094-52ac132a21d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_e86fd79b-fc8e-44df-86a0-56191b4871bc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7bcb6e40-387f-4b85-a094-52ac132a21d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_a28048ed-10dc-4300-8ce1-a212f839a877" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_e86fd79b-fc8e-44df-86a0-56191b4871bc" xlink:to="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_a28048ed-10dc-4300-8ce1-a212f839a877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a232f29c-4bb6-45d3-9efc-41481827eb8b" xlink:href="pacb-20241231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8a718001-e96d-4336-bbb9-344be5c090b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a232f29c-4bb6-45d3-9efc-41481827eb8b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8a718001-e96d-4336-bbb9-344be5c090b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0d9e474-915b-4dd7-b4d3-2363301d7331" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8a718001-e96d-4336-bbb9-344be5c090b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0d9e474-915b-4dd7-b4d3-2363301d7331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53ae7ff0-e880-4fe4-ac33-bfc53860b564" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0d9e474-915b-4dd7-b4d3-2363301d7331" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53ae7ff0-e880-4fe4-ac33-bfc53860b564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_d9b40faa-bef6-4da9-9704-a14e82f5e3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53ae7ff0-e880-4fe4-ac33-bfc53860b564" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_d9b40faa-bef6-4da9-9704-a14e82f5e3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_a24ba237-5a9d-453b-abfb-478bf3b28fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_53ae7ff0-e880-4fe4-ac33-bfc53860b564" xlink:to="loc_us-gaap_CustomerRelationshipsMember_a24ba237-5a9d-453b-abfb-478bf3b28fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50369918-2f28-4468-b26e-f1e23825d6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8a718001-e96d-4336-bbb9-344be5c090b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50369918-2f28-4468-b26e-f1e23825d6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e4a40831-3d47-4802-8526-9ccd91641e80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50369918-2f28-4468-b26e-f1e23825d6a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e4a40831-3d47-4802-8526-9ccd91641e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e1444e99-0f01-443c-94b2-ce8f547d4e45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50369918-2f28-4468-b26e-f1e23825d6a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e1444e99-0f01-443c-94b2-ce8f547d4e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_df61eeb0-38a8-4e8e-bba9-87d5fc63d2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50369918-2f28-4468-b26e-f1e23825d6a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_df61eeb0-38a8-4e8e-bba9-87d5fc63d2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72067fee-4ffc-4721-bb4d-80b20665fb76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50369918-2f28-4468-b26e-f1e23825d6a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72067fee-4ffc-4721-bb4d-80b20665fb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a2d15e70-2edc-4a64-9d80-e175939adb81" xlink:href="pacb-20241231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_09339d38-0937-457f-aaad-4583bd545b25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a2d15e70-2edc-4a64-9d80-e175939adb81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_09339d38-0937-457f-aaad-4583bd545b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b5383ae4-f512-41a7-afa1-0cd0f8fccc92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a2d15e70-2edc-4a64-9d80-e175939adb81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b5383ae4-f512-41a7-afa1-0cd0f8fccc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6ca92fd3-1ac3-4730-9988-c3260d1859fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a2d15e70-2edc-4a64-9d80-e175939adb81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6ca92fd3-1ac3-4730-9988-c3260d1859fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_865b33fc-ec09-4b72-ac93-6fa945fc7a91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a2d15e70-2edc-4a64-9d80-e175939adb81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_865b33fc-ec09-4b72-ac93-6fa945fc7a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_7257402e-bbaf-4d34-a2c4-f1e02ad0d838" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a2d15e70-2edc-4a64-9d80-e175939adb81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_7257402e-bbaf-4d34-a2c4-f1e02ad0d838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5b466791-b393-408f-a5a7-d3d055d351fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a2d15e70-2edc-4a64-9d80-e175939adb81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5b466791-b393-408f-a5a7-d3d055d351fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_728b4ea6-1b7b-429a-9e95-1f9a656bfae4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a2d15e70-2edc-4a64-9d80-e175939adb81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_728b4ea6-1b7b-429a-9e95-1f9a656bfae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c03bcb5e-ca12-485b-95aa-54ef5a302a0c" xlink:href="pacb-20241231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c9e56e6f-de76-46f5-bcfc-2ac9ef6e26da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c03bcb5e-ca12-485b-95aa-54ef5a302a0c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c9e56e6f-de76-46f5-bcfc-2ac9ef6e26da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedTenantImprovementsCurrent_81b15033-cc00-48c2-94f2-22e936378833" xlink:href="pacb-20241231.xsd#pacb_AccruedTenantImprovementsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c03bcb5e-ca12-485b-95aa-54ef5a302a0c" xlink:to="loc_pacb_AccruedTenantImprovementsCurrent_81b15033-cc00-48c2-94f2-22e936378833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_2d2435b8-c86e-45b6-8114-336463e5d41c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c03bcb5e-ca12-485b-95aa-54ef5a302a0c" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_2d2435b8-c86e-45b6-8114-336463e5d41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedProductDevelopmentCostsCurrent_f6572232-f52e-48ea-bf56-37c9e4c45b92" xlink:href="pacb-20241231.xsd#pacb_AccruedProductDevelopmentCostsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c03bcb5e-ca12-485b-95aa-54ef5a302a0c" xlink:to="loc_pacb_AccruedProductDevelopmentCostsCurrent_f6572232-f52e-48ea-bf56-37c9e4c45b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_63fe594f-aa14-4b62-b21a-700afda94ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c03bcb5e-ca12-485b-95aa-54ef5a302a0c" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_63fe594f-aa14-4b62-b21a-700afda94ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProductLiabilityNet_cc95b47a-1772-4342-ba99-6def0f3f3a87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProductLiabilityNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c03bcb5e-ca12-485b-95aa-54ef5a302a0c" xlink:to="loc_us-gaap_LossContingencyAccrualProductLiabilityNet_cc95b47a-1772-4342-ba99-6def0f3f3a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_1b9d4b6b-b4d3-4a14-bb37-2bf49a5bd3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c03bcb5e-ca12-485b-95aa-54ef5a302a0c" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_1b9d4b6b-b4d3-4a14-bb37-2bf49a5bd3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ca813bd4-b8a8-4e09-9af1-dc55df7e05f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c03bcb5e-ca12-485b-95aa-54ef5a302a0c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ca813bd4-b8a8-4e09-9af1-dc55df7e05f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8edd2d5a-8391-4bae-9920-ba75ea23e7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c03bcb5e-ca12-485b-95aa-54ef5a302a0c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8edd2d5a-8391-4bae-9920-ba75ea23e7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c8f11e55-5323-45fb-82dc-9443329010f6" xlink:href="pacb-20241231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_e982530e-1344-4080-ae1c-aeb936795d91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c8f11e55-5323-45fb-82dc-9443329010f6" xlink:to="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_e982530e-1344-4080-ae1c-aeb936795d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual_f25b34f6-9e40-4740-a949-e2c70d34b4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_e982530e-1344-4080-ae1c-aeb936795d91" xlink:to="loc_us-gaap_ProductWarrantyAccrual_f25b34f6-9e40-4740-a949-e2c70d34b4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued_dc110d11-942a-4d97-baca-15fbddfe93e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualWarrantiesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_e982530e-1344-4080-ae1c-aeb936795d91" xlink:to="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued_dc110d11-942a-4d97-baca-15fbddfe93e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualPayments_2826b2ff-b3dc-463e-b253-5dee77e676dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_e982530e-1344-4080-ae1c-aeb936795d91" xlink:to="loc_us-gaap_ProductWarrantyAccrualPayments_2826b2ff-b3dc-463e-b253-5dee77e676dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual_d9951856-61bf-436f-9708-ceb05bf51f35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_e982530e-1344-4080-ae1c-aeb936795d91" xlink:to="loc_us-gaap_ProductWarrantyAccrual_d9951856-61bf-436f-9708-ceb05bf51f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_74704d95-ddf3-4524-b3b3-8b57d01dbffe" xlink:href="pacb-20241231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_53c7a3ce-ee1c-4f4a-a366-8c518a5464f1" xlink:href="pacb-20241231.xsd#pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_74704d95-ddf3-4524-b3b3-8b57d01dbffe" xlink:to="loc_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_53c7a3ce-ee1c-4f4a-a366-8c518a5464f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_e3027092-07f5-4574-bb9f-03c328ac05ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_74704d95-ddf3-4524-b3b3-8b57d01dbffe" xlink:to="loc_us-gaap_ShortTermBorrowings_e3027092-07f5-4574-bb9f-03c328ac05ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_7aca4ed9-11a0-4c1a-a9e8-a1608af96d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_74704d95-ddf3-4524-b3b3-8b57d01dbffe" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_7aca4ed9-11a0-4c1a-a9e8-a1608af96d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a1145dd9-6ad8-4118-8321-7ce91b7eebaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_74704d95-ddf3-4524-b3b3-8b57d01dbffe" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a1145dd9-6ad8-4118-8321-7ce91b7eebaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONVERTIBLESENIORNOTESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2ea7c432-ac13-48b7-9d69-f3ed061ca5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_78fa20a9-a0e9-4d72-b4a4-fb58b16a1a66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2ea7c432-ac13-48b7-9d69-f3ed061ca5fc" xlink:to="loc_us-gaap_DebtInstrumentTable_78fa20a9-a0e9-4d72-b4a4-fb58b16a1a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6c0cec73-c0c4-4215-9c6f-ba863441b870" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78fa20a9-a0e9-4d72-b4a4-fb58b16a1a66" xlink:to="loc_us-gaap_DebtInstrumentAxis_6c0cec73-c0c4-4215-9c6f-ba863441b870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_025258c0-0f1c-4ce7-886c-d6dd8c3ce18e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6c0cec73-c0c4-4215-9c6f-ba863441b870" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_025258c0-0f1c-4ce7-886c-d6dd8c3ce18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_1023e28b-f60a-4302-bae0-a1a40e4e78db" xlink:href="pacb-20241231.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_025258c0-0f1c-4ce7-886c-d6dd8c3ce18e" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_1023e28b-f60a-4302-bae0-a1a40e4e78db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2029NotesMember_184ea9f2-98a5-4b43-b19a-4c380d6d95c5" xlink:href="pacb-20241231.xsd#pacb_A2029NotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_025258c0-0f1c-4ce7-886c-d6dd8c3ce18e" xlink:to="loc_pacb_A2029NotesMember_184ea9f2-98a5-4b43-b19a-4c380d6d95c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_3264fe8e-03bd-4410-960b-ff3358d964cb" xlink:href="pacb-20241231.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_025258c0-0f1c-4ce7-886c-d6dd8c3ce18e" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_3264fe8e-03bd-4410-960b-ff3358d964cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ExchangeTransactionMember_43a817a4-b8f2-4aad-837d-294f86098639" xlink:href="pacb-20241231.xsd#pacb_ExchangeTransactionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_025258c0-0f1c-4ce7-886c-d6dd8c3ce18e" xlink:to="loc_pacb_ExchangeTransactionMember_43a817a4-b8f2-4aad-837d-294f86098639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d470a1d1-6bb6-4519-8d8f-5eee3ccaaf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78fa20a9-a0e9-4d72-b4a4-fb58b16a1a66" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d470a1d1-6bb6-4519-8d8f-5eee3ccaaf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_990dd277-0cda-4eb7-8603-cc2d45ab0cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d470a1d1-6bb6-4519-8d8f-5eee3ccaaf9a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_990dd277-0cda-4eb7-8603-cc2d45ab0cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_8ed55b4a-0f86-4bb2-92b7-3628cc68e5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_990dd277-0cda-4eb7-8603-cc2d45ab0cd8" xlink:to="loc_us-gaap_ConvertibleDebtMember_8ed55b4a-0f86-4bb2-92b7-3628cc68e5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_ac4f1fb0-49d0-454b-bc44-fda3fe2ca0bd" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78fa20a9-a0e9-4d72-b4a4-fb58b16a1a66" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_ac4f1fb0-49d0-454b-bc44-fda3fe2ca0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_25054d4d-450c-46ca-a193-254027a12470" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_ac4f1fb0-49d0-454b-bc44-fda3fe2ca0bd" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_25054d4d-450c-46ca-a193-254027a12470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsOneMember_4cb49cc9-f0f8-4b27-8eff-de41c36b9001" xlink:href="pacb-20241231.xsd#pacb_DebtConversionTermsOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_25054d4d-450c-46ca-a193-254027a12470" xlink:to="loc_pacb_DebtConversionTermsOneMember_4cb49cc9-f0f8-4b27-8eff-de41c36b9001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsTwoMember_1dcacc38-fbe2-431a-a767-b8da8ea40cc5" xlink:href="pacb-20241231.xsd#pacb_DebtConversionTermsTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_25054d4d-450c-46ca-a193-254027a12470" xlink:to="loc_pacb_DebtConversionTermsTwoMember_1dcacc38-fbe2-431a-a767-b8da8ea40cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ad314757-1607-46e8-95b5-235d53d67dd2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78fa20a9-a0e9-4d72-b4a4-fb58b16a1a66" xlink:to="loc_srt_RangeAxis_ad314757-1607-46e8-95b5-235d53d67dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_430a8775-4360-4f46-8311-da96c58c9e1c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ad314757-1607-46e8-95b5-235d53d67dd2" xlink:to="loc_srt_RangeMember_430a8775-4360-4f46-8311-da96c58c9e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_87ecb6ea-bd5d-4821-bdb1-3b8331103224" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_430a8775-4360-4f46-8311-da96c58c9e1c" xlink:to="loc_srt_MinimumMember_87ecb6ea-bd5d-4821-bdb1-3b8331103224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a7526f70-f083-4ddb-819a-accea11d5955" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_430a8775-4360-4f46-8311-da96c58c9e1c" xlink:to="loc_srt_MaximumMember_a7526f70-f083-4ddb-819a-accea11d5955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78fa20a9-a0e9-4d72-b4a4-fb58b16a1a66" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_564cadd9-4c17-4694-8dc1-fdd8efcb2fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_564cadd9-4c17-4694-8dc1-fdd8efcb2fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9eb125df-cd71-455c-b442-2968d7510434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9eb125df-cd71-455c-b442-2968d7510434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f7c6bfab-c4fb-4ff3-becf-69e695520f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f7c6bfab-c4fb-4ff3-becf-69e695520f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_a5d3f97b-975e-49b4-a9bb-e308ec7cfbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_a5d3f97b-975e-49b4-a9bb-e308ec7cfbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsInConjunctionWithNotesExchange_5d876e83-e0d6-42e1-9f96-8d122268a285" xlink:href="pacb-20241231.xsd#pacb_PaymentsInConjunctionWithNotesExchange"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_PaymentsInConjunctionWithNotesExchange_5d876e83-e0d6-42e1-9f96-8d122268a285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_0eeb49d8-2619-4992-b4a0-5c6f771c0882" xlink:href="pacb-20241231.xsd#pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_0eeb49d8-2619-4992-b4a0-5c6f771c0882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_69cba4fd-65cd-4a5d-a4dd-7d33b1212e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_69cba4fd-65cd-4a5d-a4dd-7d33b1212e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_5863df01-d169-49a0-bb64-ceccec7025b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_5863df01-d169-49a0-bb64-ceccec7025b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_57be8a3f-fafa-4beb-ac25-8564e589eac7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_57be8a3f-fafa-4beb-ac25-8564e589eac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_411dd9d9-38e2-4938-9b3d-b3a1e7c01cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_411dd9d9-38e2-4938-9b3d-b3a1e7c01cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_1d64dde4-1d18-40c4-8337-aeeb67332836" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_1d64dde4-1d18-40c4-8337-aeeb67332836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f7fa463e-8e05-453f-938c-c77869963e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f7fa463e-8e05-453f-938c-c77869963e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_e96e4a4e-0d16-4b28-94f5-bd91a78f776c" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentDebtDefaultCalendarDays"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_e96e4a4e-0d16-4b28-94f5-bd91a78f776c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_11b99071-157e-4384-b367-1729400c31d3" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentInterestInTheEventOfDefault"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_11b99071-157e-4384-b367-1729400c31d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_6eae88bc-b4f1-4f2a-8ec1-e1e5dae3cb29" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_6eae88bc-b4f1-4f2a-8ec1-e1e5dae3cb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_1a5f7ce9-875a-4a7d-af40-9b566a6c7d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_1a5f7ce9-875a-4a7d-af40-9b566a6c7d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringOfDebtPricePerShare_c0327254-c559-4853-a883-43276c57d428" xlink:href="pacb-20241231.xsd#pacb_RestructuringOfDebtPricePerShare"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_RestructuringOfDebtPricePerShare_c0327254-c559-4853-a883-43276c57d428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_d6fef718-44ad-42d5-8606-eb135cddeaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_d6fef718-44ad-42d5-8606-eb135cddeaf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtIssuanceCostLenderFees_a424b78e-dba5-4c68-828c-5bed4b952f08" xlink:href="pacb-20241231.xsd#pacb_DebtIssuanceCostLenderFees"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_DebtIssuanceCostLenderFees_a424b78e-dba5-4c68-828c-5bed4b952f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_7072a792-8bfe-4324-9875-09edab483b01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_7072a792-8bfe-4324-9875-09edab483b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ea459e75-5b8b-4d49-8695-65406974f898" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_LongTermDebt_ea459e75-5b8b-4d49-8695-65406974f898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_84fb9fa6-d1db-4c30-9f8f-4aee32c33a24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_ConvertibleNotesPayable_84fb9fa6-d1db-4c30-9f8f-4aee32c33a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_05b2a92c-7329-4d27-8d8e-489badce4569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_05b2a92c-7329-4d27-8d8e-489badce4569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ef20fc47-ab2d-4fe2-8cb9-c04e3f3e5b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ef20fc47-ab2d-4fe2-8cb9-c04e3f3e5b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_75d4e64e-3988-4f5e-8f4d-dd9a9c38bd98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_75d4e64e-3988-4f5e-8f4d-dd9a9c38bd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_cce6535a-a3a2-4eef-b916-89cd6f2f094c" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_cce6535a-a3a2-4eef-b916-89cd6f2f094c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_0be250c7-50aa-4c13-97df-933e4dafa271" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_0be250c7-50aa-4c13-97df-933e4dafa271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_d4b27b4e-4092-4a1f-8550-2f240b302b60" xlink:href="pacb-20241231.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_d4b27b4e-4092-4a1f-8550-2f240b302b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0907b477-f701-4077-b8f5-0e658fc42104" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0907b477-f701-4077-b8f5-0e658fc42104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6a92eeb3-8e54-4e29-a7e7-a916d3fa54c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6a92eeb3-8e54-4e29-a7e7-a916d3fa54c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_14fb5d2e-c955-4e45-90b1-bdeb0235a3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3f743b6a-7165-49a8-ad30-7850cc0aae30" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_14fb5d2e-c955-4e45-90b1-bdeb0235a3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0b225d2f-4da8-4f3d-913f-b6b207b683be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8fc86ad4-c250-46a9-8bbf-39066c336391" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0b225d2f-4da8-4f3d-913f-b6b207b683be" xlink:to="loc_us-gaap_DebtInstrumentTable_8fc86ad4-c250-46a9-8bbf-39066c336391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f912f951-a51b-47c7-ad84-4274d532c8df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8fc86ad4-c250-46a9-8bbf-39066c336391" xlink:to="loc_us-gaap_DebtInstrumentAxis_f912f951-a51b-47c7-ad84-4274d532c8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_60c99e11-d988-45a5-853c-f2694c880dff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f912f951-a51b-47c7-ad84-4274d532c8df" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_60c99e11-d988-45a5-853c-f2694c880dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_58d23e23-c1ed-463d-8f8a-8e924f1e8bff" xlink:href="pacb-20241231.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_60c99e11-d988-45a5-853c-f2694c880dff" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_58d23e23-c1ed-463d-8f8a-8e924f1e8bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_6b13a536-e23d-4d1f-b4e8-a4145421329e" xlink:href="pacb-20241231.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_60c99e11-d988-45a5-853c-f2694c880dff" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_6b13a536-e23d-4d1f-b4e8-a4145421329e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2357534f-cf67-472c-aa89-57434dc23a56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8fc86ad4-c250-46a9-8bbf-39066c336391" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2357534f-cf67-472c-aa89-57434dc23a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_118844dd-3b4d-460a-8d43-d8e5cc5b6b90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2357534f-cf67-472c-aa89-57434dc23a56" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_118844dd-3b4d-460a-8d43-d8e5cc5b6b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_459f0cd4-4a3a-4e94-8bd7-dffc081499ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2357534f-cf67-472c-aa89-57434dc23a56" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_459f0cd4-4a3a-4e94-8bd7-dffc081499ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_a6e2324c-1081-4125-b468-e70e9ac7d7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2357534f-cf67-472c-aa89-57434dc23a56" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_a6e2324c-1081-4125-b468-e70e9ac7d7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_aa68480f-ef29-447b-99e2-228bab3061c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2357534f-cf67-472c-aa89-57434dc23a56" xlink:to="loc_us-gaap_LongTermDebt_aa68480f-ef29-447b-99e2-228bab3061c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3bed06e8-0a04-438c-b223-e740653da077" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0385dd2b-e723-4d4c-b898-3187101703dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3bed06e8-0a04-438c-b223-e740653da077" xlink:to="loc_us-gaap_DebtInstrumentTable_0385dd2b-e723-4d4c-b898-3187101703dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_14bcb6e9-8c97-40cf-958c-03f3726f6d31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0385dd2b-e723-4d4c-b898-3187101703dc" xlink:to="loc_us-gaap_DebtInstrumentAxis_14bcb6e9-8c97-40cf-958c-03f3726f6d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_eef559c3-625a-4617-a98d-ac1fa431f695" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_14bcb6e9-8c97-40cf-958c-03f3726f6d31" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_eef559c3-625a-4617-a98d-ac1fa431f695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_1c461c15-1736-4a99-b251-e61a914402ff" xlink:href="pacb-20241231.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eef559c3-625a-4617-a98d-ac1fa431f695" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_1c461c15-1736-4a99-b251-e61a914402ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_87aeb2cd-26ac-4dd7-9a6b-0f3506d0515c" xlink:href="pacb-20241231.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eef559c3-625a-4617-a98d-ac1fa431f695" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_87aeb2cd-26ac-4dd7-9a6b-0f3506d0515c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_69291a50-9e92-48e1-8e2c-8c232f373888" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0385dd2b-e723-4d4c-b898-3187101703dc" xlink:to="loc_us-gaap_DebtInstrumentLineItems_69291a50-9e92-48e1-8e2c-8c232f373888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_c5c41175-73ba-4d82-b655-a75c065774c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69291a50-9e92-48e1-8e2c-8c232f373888" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_c5c41175-73ba-4d82-b655-a75c065774c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_f2a8222a-9e67-4bd7-ab19-38d9248e0c80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69291a50-9e92-48e1-8e2c-8c232f373888" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_f2a8222a-9e67-4bd7-ab19-38d9248e0c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_233f8a19-a93c-45b8-856a-a78e11f0a732" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69291a50-9e92-48e1-8e2c-8c232f373888" xlink:to="loc_us-gaap_InterestExpenseDebt_233f8a19-a93c-45b8-856a-a78e11f0a732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ab8ba037-89b4-40b9-9de8-5afe080e72e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bad4bafc-e2d2-4f40-8c3e-2f42000bb5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ab8ba037-89b4-40b9-9de8-5afe080e72e2" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bad4bafc-e2d2-4f40-8c3e-2f42000bb5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_78d0d19a-e04e-426d-8011-75ed41e683f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bad4bafc-e2d2-4f40-8c3e-2f42000bb5fc" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_78d0d19a-e04e-426d-8011-75ed41e683f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d38e565a-e5bb-44f4-9f17-4e43c3f64b31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_78d0d19a-e04e-426d-8011-75ed41e683f7" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d38e565a-e5bb-44f4-9f17-4e43c3f64b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeSeparationCostsMember_b97cf1aa-fd6c-479b-b20c-596925000842" xlink:href="pacb-20241231.xsd#pacb_EmployeeSeparationCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d38e565a-e5bb-44f4-9f17-4e43c3f64b31" xlink:to="loc_pacb_EmployeeSeparationCostsMember_b97cf1aa-fd6c-479b-b20c-596925000842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_ad8638c7-8172-4086-9f0a-d5d19c0ba757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d38e565a-e5bb-44f4-9f17-4e43c3f64b31" xlink:to="loc_us-gaap_OtherRestructuringMember_ad8638c7-8172-4086-9f0a-d5d19c0ba757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a8cde1cc-73d8-4106-8521-bde053f32d09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bad4bafc-e2d2-4f40-8c3e-2f42000bb5fc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a8cde1cc-73d8-4106-8521-bde053f32d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3bbd3562-ce3e-4a61-92fd-2ca270d54397" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a8cde1cc-73d8-4106-8521-bde053f32d09" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3bbd3562-ce3e-4a61-92fd-2ca270d54397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_732ebc2d-6b8d-4716-b7ae-5b7ea70102c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bbd3562-ce3e-4a61-92fd-2ca270d54397" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_732ebc2d-6b8d-4716-b7ae-5b7ea70102c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ab2c22b0-6dc8-4199-bd7a-a173f3664381" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bbd3562-ce3e-4a61-92fd-2ca270d54397" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ab2c22b0-6dc8-4199-bd7a-a173f3664381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_3f7e360e-1a69-4586-836d-1ebecb78759d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bbd3562-ce3e-4a61-92fd-2ca270d54397" xlink:to="loc_us-gaap_CostOfSalesMember_3f7e360e-1a69-4586-836d-1ebecb78759d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_c484e994-76cd-4d05-a59d-d0d4542a985a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bad4bafc-e2d2-4f40-8c3e-2f42000bb5fc" xlink:to="loc_us-gaap_RestructuringPlanAxis_c484e994-76cd-4d05-a59d-d0d4542a985a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_6a132373-06ae-4adb-b940-0a2981d9fb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_c484e994-76cd-4d05-a59d-d0d4542a985a" xlink:to="loc_us-gaap_RestructuringPlanDomain_6a132373-06ae-4adb-b940-0a2981d9fb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SanDiegoOfficeMember_69940bd7-4353-4903-8831-03edd2d27d51" xlink:href="pacb-20241231.xsd#pacb_SanDiegoOfficeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_6a132373-06ae-4adb-b940-0a2981d9fb9a" xlink:to="loc_pacb_SanDiegoOfficeMember_69940bd7-4353-4903-8831-03edd2d27d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_5b5a494c-a94c-48c2-90f6-af40761b0c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bad4bafc-e2d2-4f40-8c3e-2f42000bb5fc" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_5b5a494c-a94c-48c2-90f6-af40761b0c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_4e62e3fd-2674-4eb4-8dfc-78ce5e0908bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5b5a494c-a94c-48c2-90f6-af40761b0c0d" xlink:to="loc_us-gaap_RestructuringCharges_4e62e3fd-2674-4eb4-8dfc-78ce5e0908bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_2793cfc5-7e51-450d-a418-a219202e7eff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5b5a494c-a94c-48c2-90f6-af40761b0c0d" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_2793cfc5-7e51-450d-a418-a219202e7eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5ee6a2ae-22a8-46ba-9228-dfc094323eef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5b5a494c-a94c-48c2-90f6-af40761b0c0d" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5ee6a2ae-22a8-46ba-9228-dfc094323eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#RESTRUCTURINGNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bc953abc-3337-4adc-87a3-211699bdccd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d34de9c5-c334-4497-a71a-33685b2d8e31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bc953abc-3337-4adc-87a3-211699bdccd0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d34de9c5-c334-4497-a71a-33685b2d8e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_9c34183c-cb9d-482d-bb2e-5d5978a61f40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d34de9c5-c334-4497-a71a-33685b2d8e31" xlink:to="loc_us-gaap_RestructuringPlanAxis_9c34183c-cb9d-482d-bb2e-5d5978a61f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_904bc911-4696-4058-8cf8-4ba4e3f92106" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_9c34183c-cb9d-482d-bb2e-5d5978a61f40" xlink:to="loc_us-gaap_RestructuringPlanDomain_904bc911-4696-4058-8cf8-4ba4e3f92106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SanDiegoOfficeMember_8e85c8a2-8e33-477b-8f15-31d26848b25c" xlink:href="pacb-20241231.xsd#pacb_SanDiegoOfficeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_904bc911-4696-4058-8cf8-4ba4e3f92106" xlink:to="loc_pacb_SanDiegoOfficeMember_8e85c8a2-8e33-477b-8f15-31d26848b25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_85cb0e18-7094-419d-aff4-49cad4daf637" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d34de9c5-c334-4497-a71a-33685b2d8e31" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_85cb0e18-7094-419d-aff4-49cad4daf637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_0951f41b-2999-4fe2-9ec4-490a096b8a86" xlink:href="pacb-20241231.xsd#pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_85cb0e18-7094-419d-aff4-49cad4daf637" xlink:to="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_0951f41b-2999-4fe2-9ec4-490a096b8a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_c4249307-5ff6-4aa7-a151-58e883d58135" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_85cb0e18-7094-419d-aff4-49cad4daf637" xlink:to="loc_us-gaap_SeveranceCosts1_c4249307-5ff6-4aa7-a151-58e883d58135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_a9aa651d-5cbb-437d-9548-f21c7abafb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_85cb0e18-7094-419d-aff4-49cad4daf637" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_a9aa651d-5cbb-437d-9548-f21c7abafb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_6d43e000-6ead-4c55-8b9b-b50008a20fea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_85cb0e18-7094-419d-aff4-49cad4daf637" xlink:to="loc_us-gaap_InventoryWriteDown_6d43e000-6ead-4c55-8b9b-b50008a20fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_810b0a56-58e6-40c8-a703-ecaa20bc0afc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_85cb0e18-7094-419d-aff4-49cad4daf637" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_810b0a56-58e6-40c8-a703-ecaa20bc0afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1f7c5fab-0fbd-4bfb-b676-b45479f59b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_85cb0e18-7094-419d-aff4-49cad4daf637" xlink:to="loc_us-gaap_OperatingLeaseLiability_1f7c5fab-0fbd-4bfb-b676-b45479f59b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_69822b9d-8a4f-4408-90ad-37e85972498d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4c12c786-de0c-42f4-abc3-31de379779ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_69822b9d-8a4f-4408-90ad-37e85972498d" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4c12c786-de0c-42f4-abc3-31de379779ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1f7bc0ab-e363-4d21-85f8-080c878d54b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4c12c786-de0c-42f4-abc3-31de379779ac" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1f7bc0ab-e363-4d21-85f8-080c878d54b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1140224b-fe46-4d52-a3a0-e56146ce1fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1f7bc0ab-e363-4d21-85f8-080c878d54b8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1140224b-fe46-4d52-a3a0-e56146ce1fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeSeparationCostsMember_400510dc-f074-4569-a1f8-5fdf536595a3" xlink:href="pacb-20241231.xsd#pacb_EmployeeSeparationCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1140224b-fe46-4d52-a3a0-e56146ce1fd8" xlink:to="loc_pacb_EmployeeSeparationCostsMember_400510dc-f074-4569-a1f8-5fdf536595a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_fcf11f71-aa9b-4445-964b-78fb3e7c6ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1140224b-fe46-4d52-a3a0-e56146ce1fd8" xlink:to="loc_us-gaap_OtherRestructuringMember_fcf11f71-aa9b-4445-964b-78fb3e7c6ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8e0ea90c-f509-43d8-9e9b-1d3c22ffee0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4c12c786-de0c-42f4-abc3-31de379779ac" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_8e0ea90c-f509-43d8-9e9b-1d3c22ffee0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_927ae0df-eb36-4de7-a853-7fc859d29936" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e0ea90c-f509-43d8-9e9b-1d3c22ffee0b" xlink:to="loc_us-gaap_RestructuringCharges_927ae0df-eb36-4de7-a853-7fc859d29936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_7dbf090f-b7b2-44b1-b285-de10fa5cae71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e0ea90c-f509-43d8-9e9b-1d3c22ffee0b" xlink:to="loc_us-gaap_PaymentsForRestructuring_7dbf090f-b7b2-44b1-b285-de10fa5cae71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_badb6960-0b8e-4370-91c0-011acc5df858" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e0ea90c-f509-43d8-9e9b-1d3c22ffee0b" xlink:to="loc_us-gaap_RestructuringReserve_badb6960-0b8e-4370-91c0-011acc5df858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_9e0158a9-00c5-4b05-933d-e3d9727a4f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e0ea90c-f509-43d8-9e9b-1d3c22ffee0b" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_9e0158a9-00c5-4b05-933d-e3d9727a4f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5301a981-0736-4e8a-a669-a762c77a1fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_847b9f30-bad6-4e2a-a008-1709d14f06f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5301a981-0736-4e8a-a669-a762c77a1fb6" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_847b9f30-bad6-4e2a-a008-1709d14f06f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_863dbfd4-17c4-422b-9457-6f00f0b431e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_847b9f30-bad6-4e2a-a008-1709d14f06f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_863dbfd4-17c4-422b-9457-6f00f0b431e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_014e24a0-33de-493c-a00c-7e275936b03d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_847b9f30-bad6-4e2a-a008-1709d14f06f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_014e24a0-33de-493c-a00c-7e275936b03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6b30e90f-d9b2-4819-ad94-4be58ee58867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_847b9f30-bad6-4e2a-a008-1709d14f06f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6b30e90f-d9b2-4819-ad94-4be58ee58867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_31aa1669-5d30-4928-bf62-1fc3edd9ad66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_847b9f30-bad6-4e2a-a008-1709d14f06f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_31aa1669-5d30-4928-bf62-1fc3edd9ad66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a5d6b523-a8f2-45a5-b802-b924d78cabf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_847b9f30-bad6-4e2a-a008-1709d14f06f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a5d6b523-a8f2-45a5-b802-b924d78cabf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_f08b9c9b-7213-4153-abfa-8145b85f832c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_847b9f30-bad6-4e2a-a008-1709d14f06f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_f08b9c9b-7213-4153-abfa-8145b85f832c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5720a1e8-90aa-480b-a1c5-adaadfadaf42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_847b9f30-bad6-4e2a-a008-1709d14f06f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5720a1e8-90aa-480b-a1c5-adaadfadaf42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6e351356-370c-414c-872e-28342c809d96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_847b9f30-bad6-4e2a-a008-1709d14f06f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6e351356-370c-414c-872e-28342c809d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_55023c35-a5d1-4e51-b85c-ab6ef0df2a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_847b9f30-bad6-4e2a-a008-1709d14f06f0" xlink:to="loc_us-gaap_OperatingLeaseLiability_55023c35-a5d1-4e51-b85c-ab6ef0df2a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BalanceSheetClassificationAbstract_c29afa95-4aa4-43e9-aa43-9cb368811141" xlink:href="pacb-20241231.xsd#pacb_BalanceSheetClassificationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5301a981-0736-4e8a-a669-a762c77a1fb6" xlink:to="loc_pacb_BalanceSheetClassificationAbstract_c29afa95-4aa4-43e9-aa43-9cb368811141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8cb56b30-b051-4b59-b7dc-88f53f471dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetClassificationAbstract_c29afa95-4aa4-43e9-aa43-9cb368811141" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8cb56b30-b051-4b59-b7dc-88f53f471dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b519b6da-fc61-47ce-b57b-8a071407c9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetClassificationAbstract_c29afa95-4aa4-43e9-aa43-9cb368811141" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b519b6da-fc61-47ce-b57b-8a071407c9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_881ef2d8-fb28-4d8d-af95-ffab8f817afd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetClassificationAbstract_c29afa95-4aa4-43e9-aa43-9cb368811141" xlink:to="loc_us-gaap_OperatingLeaseLiability_881ef2d8-fb28-4d8d-af95-ffab8f817afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_eda105bb-c44f-4992-87b0-cdf7f73c70fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommitmentsAndContingenciesTable_29804910-acd6-48a0-988d-68b1e5a74336" xlink:href="pacb-20241231.xsd#pacb_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_eda105bb-c44f-4992-87b0-cdf7f73c70fb" xlink:to="loc_pacb_CommitmentsAndContingenciesTable_29804910-acd6-48a0-988d-68b1e5a74336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b6ab77bd-3c71-44eb-b85f-dc8758a5eb89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesTable_29804910-acd6-48a0-988d-68b1e5a74336" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b6ab77bd-3c71-44eb-b85f-dc8758a5eb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8301f108-23cf-4c31-9f23-5dfa79293ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b6ab77bd-3c71-44eb-b85f-dc8758a5eb89" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8301f108-23cf-4c31-9f23-5dfa79293ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_32cb2e72-25aa-44af-9867-e16ed7cecd7b" xlink:href="pacb-20241231.xsd#pacb_OmniomeIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8301f108-23cf-4c31-9f23-5dfa79293ad2" xlink:to="loc_pacb_OmniomeIncMember_32cb2e72-25aa-44af-9867-e16ed7cecd7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:href="pacb-20241231.xsd#pacb_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesTable_29804910-acd6-48a0-988d-68b1e5a74336" xlink:to="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d73dd2e4-a8de-4b1c-861a-b450712e4f94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d73dd2e4-a8de-4b1c-861a-b450712e4f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_565c561e-b6bd-44ac-8d43-8b43dbac5501" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_565c561e-b6bd-44ac-8d43-8b43dbac5501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRent_a79a230c-8c4e-4a47-9494-9fb0efc1916e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_PaymentsForRent_a79a230c-8c4e-4a47-9494-9fb0efc1916e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_25932e06-0257-4ce6-b5f8-73523e618120" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_OperatingLeaseCost_25932e06-0257-4ce6-b5f8-73523e618120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_b6bd4906-7af9-4903-82b4-19f60d188a91" xlink:href="pacb-20241231.xsd#pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_b6bd4906-7af9-4903-82b4-19f60d188a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_0f1cc9b7-49ff-4b81-b4a8-7437fc3cc385" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_PurchaseObligation_0f1cc9b7-49ff-4b81-b4a8-7437fc3cc385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_f3180233-b8e6-4d8c-a42e-ad909676573e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_f3180233-b8e6-4d8c-a42e-ad909676573e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDeposits_f16ca1d2-b1f6-4fca-8f38-ae4767eb75ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForDeposits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_PaymentsForDeposits_f16ca1d2-b1f6-4fca-8f38-ae4767eb75ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RefundFromDeposits_e078d14e-342e-489c-aea8-5be54a407e87" xlink:href="pacb-20241231.xsd#pacb_RefundFromDeposits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_pacb_RefundFromDeposits_e078d14e-342e-489c-aea8-5be54a407e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_5a962e4a-3db3-432a-98bc-dd9f9ff24009" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_DepositsAssetsCurrent_5a962e4a-3db3-432a-98bc-dd9f9ff24009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_a5b5c647-78fb-4079-b36f-79ec8f5ad1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_bd5e39a7-c629-4198-89fd-ad45e54f9482" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_a5b5c647-78fb-4079-b36f-79ec8f5ad1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f5b0f3c3-0d08-4089-8e6a-69ea3fc4daaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeTaxesTable_75035856-440b-4f68-92ae-da074118102d" xlink:href="pacb-20241231.xsd#pacb_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f5b0f3c3-0d08-4089-8e6a-69ea3fc4daaa" xlink:to="loc_pacb_IncomeTaxesTable_75035856-440b-4f68-92ae-da074118102d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6403539a-26d7-4086-ac67-48f4430f33ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesTable_75035856-440b-4f68-92ae-da074118102d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6403539a-26d7-4086-ac67-48f4430f33ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_dd93ab3a-c8e1-4a70-893f-e01c363f8dde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6403539a-26d7-4086-ac67-48f4430f33ae" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_dd93ab3a-c8e1-4a70-893f-e01c363f8dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_8fc145f2-650e-4a2e-b52a-3161705edc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_dd93ab3a-c8e1-4a70-893f-e01c363f8dde" xlink:to="loc_us-gaap_DomesticCountryMember_8fc145f2-650e-4a2e-b52a-3161705edc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_6ea67e03-9d27-450d-b07b-0639b7a5b76d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_dd93ab3a-c8e1-4a70-893f-e01c363f8dde" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_6ea67e03-9d27-450d-b07b-0639b7a5b76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:href="pacb-20241231.xsd#pacb_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesTable_75035856-440b-4f68-92ae-da074118102d" xlink:to="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition_c38313f9-9218-4b86-81d2-28a43defe265" xlink:href="pacb-20241231.xsd#pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition_c38313f9-9218-4b86-81d2-28a43defe265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_925d10ed-7342-468c-bfb3-b329c37acea3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_925d10ed-7342-468c-bfb3-b329c37acea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_24cc3630-5b49-4406-9989-f566e0e327e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_24cc3630-5b49-4406-9989-f566e0e327e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c50c81b7-42ea-4186-b057-5154837bbbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c50c81b7-42ea-4186-b057-5154837bbbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_8a6ead11-4569-404a-a315-66a2df51dabf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_8a6ead11-4569-404a-a315-66a2df51dabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_2a0aae5a-8389-4084-beb3-22d2f47b78a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_2a0aae5a-8389-4084-beb3-22d2f47b78a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration_ad2d08aa-7a8b-4b2e-a285-7d843965eae4" xlink:href="pacb-20241231.xsd#pacb_OperatingLossCarryforwardsAmountSubjectToExpiration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration_ad2d08aa-7a8b-4b2e-a285-7d843965eae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c773ebf6-afde-4a39-9693-d371ddc1ad07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c773ebf6-afde-4a39-9693-d371ddc1ad07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_dcb15790-b025-4935-b110-6b1aa7f8fd99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_1733acf4-a749-49f3-b4de-d43fac5704c4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_dcb15790-b025-4935-b110-6b1aa7f8fd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_64031341-50ac-472c-9264-c5c313c24e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ab473e73-a280-4361-a3d4-6873b25ca171" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64031341-50ac-472c-9264-c5c313c24e1e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ab473e73-a280-4361-a3d4-6873b25ca171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ad1fca4f-f773-4b18-b4de-2357584d3f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64031341-50ac-472c-9264-c5c313c24e1e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ad1fca4f-f773-4b18-b4de-2357584d3f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0785cf22-8fad-4dcc-961f-91068bfcee0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ad1fca4f-f773-4b18-b4de-2357584d3f5f" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0785cf22-8fad-4dcc-961f-91068bfcee0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e803fdb6-4950-433a-8ee2-51ba444e1aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ad1fca4f-f773-4b18-b4de-2357584d3f5f" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e803fdb6-4950-433a-8ee2-51ba444e1aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_7cf2e050-786c-45a4-a782-1d3f14552049" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ad1fca4f-f773-4b18-b4de-2357584d3f5f" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_7cf2e050-786c-45a4-a782-1d3f14552049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_af4e4a9a-6a0f-4e24-a41e-242b55a404be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ad1fca4f-f773-4b18-b4de-2357584d3f5f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_af4e4a9a-6a0f-4e24-a41e-242b55a404be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1f0e5194-7b28-43a8-82ab-3d23ffe91967" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64031341-50ac-472c-9264-c5c313c24e1e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1f0e5194-7b28-43a8-82ab-3d23ffe91967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_34f8bdd1-f39c-4ab7-8973-04d80a52a67e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_042a3d6a-4466-470b-a987-4cdcd50067a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34f8bdd1-f39c-4ab7-8973-04d80a52a67e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_042a3d6a-4466-470b-a987-4cdcd50067a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_74acb1fb-6218-4bc0-989e-c8c1317de9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34f8bdd1-f39c-4ab7-8973-04d80a52a67e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_74acb1fb-6218-4bc0-989e-c8c1317de9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_06b7b96e-95b0-4f79-9e15-badb00bf6f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34f8bdd1-f39c-4ab7-8973-04d80a52a67e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_06b7b96e-95b0-4f79-9e15-badb00bf6f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_cc0607c2-bae1-4361-8a4b-92f71ef40bd3" xlink:href="pacb-20241231.xsd#pacb_EffectiveIncomeTaxRateReconciliationTaxCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34f8bdd1-f39c-4ab7-8973-04d80a52a67e" xlink:to="loc_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_cc0607c2-bae1-4361-8a4b-92f71ef40bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_9c19f53a-a4c2-4932-a5ba-cfe659a539b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34f8bdd1-f39c-4ab7-8973-04d80a52a67e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_9c19f53a-a4c2-4932-a5ba-cfe659a539b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_a82a37c8-3cba-44f3-b6d4-057e54e8435a" xlink:href="pacb-20241231.xsd#pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34f8bdd1-f39c-4ab7-8973-04d80a52a67e" xlink:to="loc_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_a82a37c8-3cba-44f3-b6d4-057e54e8435a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_92b47fd0-39cc-4a64-9d5c-6c3dd3028d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34f8bdd1-f39c-4ab7-8973-04d80a52a67e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_92b47fd0-39cc-4a64-9d5c-6c3dd3028d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_b2796717-37ed-4e43-9e6d-ad5fc9fb75cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34f8bdd1-f39c-4ab7-8973-04d80a52a67e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_b2796717-37ed-4e43-9e6d-ad5fc9fb75cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_79df115a-4d37-431d-916b-ad0c3c5b2f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34f8bdd1-f39c-4ab7-8973-04d80a52a67e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_79df115a-4d37-431d-916b-ad0c3c5b2f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e4fed6b3-c42b-4432-857d-8a10686d03f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_c21dc8ea-236e-4c0c-aa9b-3b9d5b139f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e4fed6b3-c42b-4432-857d-8a10686d03f3" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_c21dc8ea-236e-4c0c-aa9b-3b9d5b139f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_157ade04-e21c-464b-b3e9-a8911aab856e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c21dc8ea-236e-4c0c-aa9b-3b9d5b139f2e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_157ade04-e21c-464b-b3e9-a8911aab856e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1061279f-7748-4cd0-b94d-882e14c0c86d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c21dc8ea-236e-4c0c-aa9b-3b9d5b139f2e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1061279f-7748-4cd0-b94d-882e14c0c86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_1ac445a2-956d-44e0-aec8-20d0dddcfa4d" xlink:href="pacb-20241231.xsd#pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c21dc8ea-236e-4c0c-aa9b-3b9d5b139f2e" xlink:to="loc_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_1ac445a2-956d-44e0-aec8-20d0dddcfa4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_816afdd3-754c-4808-9951-c8cba18f5a84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c21dc8ea-236e-4c0c-aa9b-3b9d5b139f2e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_816afdd3-754c-4808-9951-c8cba18f5a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense_a2787cc2-1919-486f-a93c-544f1395e291" xlink:href="pacb-20241231.xsd#pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c21dc8ea-236e-4c0c-aa9b-3b9d5b139f2e" xlink:to="loc_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense_a2787cc2-1919-486f-a93c-544f1395e291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_58c50fdb-04d6-4a93-ac4a-0e7db0f6380a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c21dc8ea-236e-4c0c-aa9b-3b9d5b139f2e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_58c50fdb-04d6-4a93-ac4a-0e7db0f6380a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetsOperatingLeaseLiabilities_d43dcbd2-ae2a-44ee-a4d0-2051f9b2a7a9" xlink:href="pacb-20241231.xsd#pacb_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c21dc8ea-236e-4c0c-aa9b-3b9d5b139f2e" xlink:to="loc_pacb_DeferredTaxAssetsOperatingLeaseLiabilities_d43dcbd2-ae2a-44ee-a4d0-2051f9b2a7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5531d4b5-c585-4b68-b852-43fe0cde8a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c21dc8ea-236e-4c0c-aa9b-3b9d5b139f2e" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_5531d4b5-c585-4b68-b852-43fe0cde8a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6dd91546-73a0-46cd-a4aa-5643a76e4e92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c21dc8ea-236e-4c0c-aa9b-3b9d5b139f2e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6dd91546-73a0-46cd-a4aa-5643a76e4e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_3d8ea34e-3fa0-4d6d-acb2-02a3e52f73e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c21dc8ea-236e-4c0c-aa9b-3b9d5b139f2e" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_3d8ea34e-3fa0-4d6d-acb2-02a3e52f73e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_aadfd050-2a3c-4029-a751-aa158bf60248" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e4fed6b3-c42b-4432-857d-8a10686d03f3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_aadfd050-2a3c-4029-a751-aa158bf60248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_16deade4-bc62-4020-8eef-bb4889b07284" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e4fed6b3-c42b-4432-857d-8a10686d03f3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_16deade4-bc62-4020-8eef-bb4889b07284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxLiabilitiesRightOfUseAssets_a6d39006-2f39-4271-a3e0-76973faf08d2" xlink:href="pacb-20241231.xsd#pacb_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e4fed6b3-c42b-4432-857d-8a10686d03f3" xlink:to="loc_pacb_DeferredTaxLiabilitiesRightOfUseAssets_a6d39006-2f39-4271-a3e0-76973faf08d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3bfa5f54-1718-4c0a-9dee-c72d82085501" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e4fed6b3-c42b-4432-857d-8a10686d03f3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_3bfa5f54-1718-4c0a-9dee-c72d82085501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_1a3f4d3c-26a9-433d-9a5b-f4478197f517" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e4fed6b3-c42b-4432-857d-8a10686d03f3" xlink:to="loc_us-gaap_DeferredTaxLiabilities_1a3f4d3c-26a9-433d-9a5b-f4478197f517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofUnrecognizedTaxBenefitAccountsDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#INCOMETAXESScheduleofReconciliationofUnrecognizedTaxBenefitAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofUnrecognizedTaxBenefitAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_47c12372-d255-482a-b71f-b7b978c54556" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_64c17506-0023-4e8c-ba0b-a370b4a81b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_47c12372-d255-482a-b71f-b7b978c54556" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_64c17506-0023-4e8c-ba0b-a370b4a81b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7733c411-28c3-4b03-a5bc-eba54f9181b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_64c17506-0023-4e8c-ba0b-a370b4a81b5e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7733c411-28c3-4b03-a5bc-eba54f9181b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_450326dd-0920-485a-93ae-e27d8e589928" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_64c17506-0023-4e8c-ba0b-a370b4a81b5e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_450326dd-0920-485a-93ae-e27d8e589928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_55951c4e-33e6-4e87-ab91-42d686502367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_64c17506-0023-4e8c-ba0b-a370b4a81b5e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_55951c4e-33e6-4e87-ab91-42d686502367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_33280065-6f30-4ac3-bf04-835f9a4c0be5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_64c17506-0023-4e8c-ba0b-a370b4a81b5e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_33280065-6f30-4ac3-bf04-835f9a4c0be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_80e9c53a-a060-4f1f-a373-b9fe0b5c42da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_64c17506-0023-4e8c-ba0b-a370b4a81b5e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_80e9c53a-a060-4f1f-a373-b9fe0b5c42da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5c2b03f5-1b76-4ebe-9777-7317364628f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockholdersEquityTable_c6160fae-8564-4630-a366-efe7e3379338" xlink:href="pacb-20241231.xsd#pacb_StockholdersEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5c2b03f5-1b76-4ebe-9777-7317364628f9" xlink:to="loc_pacb_StockholdersEquityTable_c6160fae-8564-4630-a366-efe7e3379338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_db644013-e2ac-4646-8bd2-63857dde66f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityTable_c6160fae-8564-4630-a366-efe7e3379338" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_db644013-e2ac-4646-8bd2-63857dde66f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f38b5566-f9aa-4cbc-aea2-d791373b824d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_db644013-e2ac-4646-8bd2-63857dde66f9" xlink:to="loc_us-gaap_EquityComponentDomain_f38b5566-f9aa-4cbc-aea2-d791373b824d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d1fd9dc3-6ee4-4305-b1d0-2f91986e538d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f38b5566-f9aa-4cbc-aea2-d791373b824d" xlink:to="loc_us-gaap_CommonStockMember_d1fd9dc3-6ee4-4305-b1d0-2f91986e538d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_b7b75e62-2af9-4db9-bcaa-efcf15a70057" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityTable_c6160fae-8564-4630-a366-efe7e3379338" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_b7b75e62-2af9-4db9-bcaa-efcf15a70057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_ded931a2-b3f5-4e2b-81d7-824ce0e56204" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_b7b75e62-2af9-4db9-bcaa-efcf15a70057" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_ded931a2-b3f5-4e2b-81d7-824ce0e56204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EquityIncentivePlan2020Member_1080ddd5-5f38-41cf-9dcf-5ab7234a3613" xlink:href="pacb-20241231.xsd#pacb_EquityIncentivePlan2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_ded931a2-b3f5-4e2b-81d7-824ce0e56204" xlink:to="loc_pacb_EquityIncentivePlan2020Member_1080ddd5-5f38-41cf-9dcf-5ab7234a3613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_a2ccd617-bc32-4b24-8150-63cfe28f38db" xlink:href="pacb-20241231.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_ded931a2-b3f5-4e2b-81d7-824ce0e56204" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_a2ccd617-bc32-4b24-8150-63cfe28f38db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c007b5c7-f5da-49c8-8601-a9140976dd17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityTable_c6160fae-8564-4630-a366-efe7e3379338" xlink:to="loc_us-gaap_AwardTypeAxis_c007b5c7-f5da-49c8-8601-a9140976dd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67833b2b-05d9-42b9-8144-34831eaa9626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c007b5c7-f5da-49c8-8601-a9140976dd17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67833b2b-05d9-42b9-8144-34831eaa9626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember_43f6762a-4b55-48c4-9594-9ee1b700f72c" xlink:href="pacb-20241231.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67833b2b-05d9-42b9-8144-34831eaa9626" xlink:to="loc_pacb_OptionsToPurchaseCommonStockMember_43f6762a-4b55-48c4-9594-9ee1b700f72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedAndPerformanceBasedOptionsMember_89439990-e45b-49bf-b466-0fdbb78bf684" xlink:href="pacb-20241231.xsd#pacb_TimeBasedAndPerformanceBasedOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67833b2b-05d9-42b9-8144-34831eaa9626" xlink:to="loc_pacb_TimeBasedAndPerformanceBasedOptionsMember_89439990-e45b-49bf-b466-0fdbb78bf684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_052ef6a7-4b84-45c6-8278-7053070a2ec8" xlink:href="pacb-20241231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67833b2b-05d9-42b9-8144-34831eaa9626" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_052ef6a7-4b84-45c6-8278-7053070a2ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_1b3334e6-7073-47d3-9ec1-96b981737982" xlink:href="pacb-20241231.xsd#pacb_TimeBasedRestrictedStockUnitsPSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67833b2b-05d9-42b9-8144-34831eaa9626" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_1b3334e6-7073-47d3-9ec1-96b981737982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cecba661-1192-42e7-8d3a-214ceac90b92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityTable_c6160fae-8564-4630-a366-efe7e3379338" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cecba661-1192-42e7-8d3a-214ceac90b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1cd4b0af-ac47-401e-900f-50552b718184" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cecba661-1192-42e7-8d3a-214ceac90b92" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1cd4b0af-ac47-401e-900f-50552b718184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShelfOfferingMember_7c9ce1cf-c434-41eb-bd5c-b197a0781b33" xlink:href="pacb-20241231.xsd#pacb_ShelfOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1cd4b0af-ac47-401e-900f-50552b718184" xlink:to="loc_pacb_ShelfOfferingMember_7c9ce1cf-c434-41eb-bd5c-b197a0781b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_24eb2db7-6eed-46d1-9fd7-d4c8f46ab11c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityTable_c6160fae-8564-4630-a366-efe7e3379338" xlink:to="loc_us-gaap_PlanNameAxis_24eb2db7-6eed-46d1-9fd7-d4c8f46ab11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a8eae2fb-d03d-47f6-98cc-6b913688b09e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_24eb2db7-6eed-46d1-9fd7-d4c8f46ab11c" xlink:to="loc_us-gaap_PlanNameDomain_a8eae2fb-d03d-47f6-98cc-6b913688b09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_3920d829-bbf9-4885-be76-6200da21c47c" xlink:href="pacb-20241231.xsd#pacb_A2020PlanInducementPlanAndTheOmniomePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a8eae2fb-d03d-47f6-98cc-6b913688b09e" xlink:to="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_3920d829-bbf9-4885-be76-6200da21c47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:href="pacb-20241231.xsd#pacb_StockholdersEquityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityTable_c6160fae-8564-4630-a366-efe7e3379338" xlink:to="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7b8d1251-0ddf-43f5-85f4-8bbe847fca77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7b8d1251-0ddf-43f5-85f4-8bbe847fca77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a1badd3b-c8e0-49d1-aa70-34d0b44debc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a1badd3b-c8e0-49d1-aa70-34d0b44debc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_381a646a-d940-4cb9-a7e7-35a460d48a70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_381a646a-d940-4cb9-a7e7-35a460d48a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_014f63b7-678c-4cc7-9d91-9cf3cc1250ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_014f63b7-678c-4cc7-9d91-9cf3cc1250ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_408f60b4-27b9-495f-ba38-a58fee6e84d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_PreferredStockSharesIssued_408f60b4-27b9-495f-ba38-a58fee6e84d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_eb2a3a21-5f14-4c95-9fe0-671acb069f36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_eb2a3a21-5f14-4c95-9fe0-671acb069f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_772ead8a-54f4-4c03-a865-154c2d453f33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_772ead8a-54f4-4c03-a865-154c2d453f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockVotingRights_85e76b8e-4932-4c72-a1a5-ec8f8a38d2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_CommonStockVotingRights_85e76b8e-4932-4c72-a1a5-ec8f8a38d2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_9569051c-1291-43f8-b19a-2e7fa6756224" xlink:href="pacb-20241231.xsd#pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_9569051c-1291-43f8-b19a-2e7fa6756224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingShares_78e190e1-48a9-428e-b0fb-cb5aa9126686" xlink:href="pacb-20241231.xsd#pacb_PublicOfferingShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_PublicOfferingShares_78e190e1-48a9-428e-b0fb-cb5aa9126686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OfferingShareAmountMaximum_2b3e203f-2ac1-4dca-92a3-8e192c12b811" xlink:href="pacb-20241231.xsd#pacb_OfferingShareAmountMaximum"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_OfferingShareAmountMaximum_2b3e203f-2ac1-4dca-92a3-8e192c12b811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_dbfe8968-30ce-4483-b0f6-8c3ec03eceb8" xlink:href="pacb-20241231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_dbfe8968-30ce-4483-b0f6-8c3ec03eceb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_36d20c05-25cc-4ee9-92cf-9f75c73768e0" xlink:href="pacb-20241231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_36d20c05-25cc-4ee9-92cf-9f75c73768e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7e54938f-0d5b-44e3-a975-2fb83e0417a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7e54938f-0d5b-44e3-a975-2fb83e0417a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_6b471f4e-1b7e-4400-8f0b-237921b02c46" xlink:href="pacb-20241231.xsd#pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_6b471f4e-1b7e-4400-8f0b-237921b02c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_79f89a9c-29d5-45d9-aeb0-392fff7c3a3c" xlink:href="pacb-20241231.xsd#pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_79f89a9c-29d5-45d9-aeb0-392fff7c3a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_39bb7962-05fb-4a7d-96be-51d25e669b36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_39bb7962-05fb-4a7d-96be-51d25e669b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1043a286-cd28-477c-b151-70c5c6a3942e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1043a286-cd28-477c-b151-70c5c6a3942e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_56aa45cb-2305-410d-9842-f623645f4adc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_56aa45cb-2305-410d-9842-f623645f4adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4c62e178-88ba-45e5-970a-b22175764b52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4c62e178-88ba-45e5-970a-b22175764b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e4fb5bab-b277-4898-9e5d-b049ff39bc03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e4fb5bab-b277-4898-9e5d-b049ff39bc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_249da8fd-a52e-49bb-9f08-029ceef1cca7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_SharePrice_249da8fd-a52e-49bb-9f08-029ceef1cca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_135185bd-6dc2-4110-8875-bd098348d49f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_135185bd-6dc2-4110-8875-bd098348d49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_718df4e0-2511-47f8-a972-9f35c40520dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_718df4e0-2511-47f8-a972-9f35c40520dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_42237a89-9d45-446a-86da-21f044adbac9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_42237a89-9d45-446a-86da-21f044adbac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_eb5267f5-cd4b-4340-b9d9-69f1891e0527" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_eb5267f5-cd4b-4340-b9d9-69f1891e0527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_aa1dc330-12fd-450c-b70e-69db4e702dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_aa1dc330-12fd-450c-b70e-69db4e702dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7d1e1bb2-9872-4cfa-8900-8ad3104c3a61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7d1e1bb2-9872-4cfa-8900-8ad3104c3a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_db7f81fa-5fa2-467a-9ce1-8e4c2441f301" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_db7f81fa-5fa2-467a-9ce1-8e4c2441f301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9f14fd8d-2129-4623-af71-f5597ce48c67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9f14fd8d-2129-4623-af71-f5597ce48c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_712beaab-ecfa-46d7-a7cd-7e707a62bf18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_712beaab-ecfa-46d7-a7cd-7e707a62bf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareInstrumentNumberOfSharesConversionRatio_5350c994-4874-4429-8fd9-479318759c32" xlink:href="pacb-20241231.xsd#pacb_ShareInstrumentNumberOfSharesConversionRatio"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_ShareInstrumentNumberOfSharesConversionRatio_5350c994-4874-4429-8fd9-479318759c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_838bf6a7-9d67-4701-a1c5-f79ce93b99e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_838bf6a7-9d67-4701-a1c5-f79ce93b99e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_8d744f93-5eda-45f2-b621-b6594047e7d6" xlink:href="pacb-20241231.xsd#pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_8d744f93-5eda-45f2-b621-b6594047e7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_e158822f-05c8-44d6-b425-569d025deda4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_e158822f-05c8-44d6-b425-569d025deda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6fe5aee4-d582-4106-ae9f-ae5797ba97d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6fe5aee4-d582-4106-ae9f-ae5797ba97d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b1b3c05b-d444-48fe-8ec1-3fd47567d296" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b1b3c05b-d444-48fe-8ec1-3fd47567d296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_NumberOfPurchasePeriods_8c425b56-a383-4064-b26f-72f35c182085" xlink:href="pacb-20241231.xsd#pacb_NumberOfPurchasePeriods"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_NumberOfPurchasePeriods_8c425b56-a383-4064-b26f-72f35c182085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PurchasePeriodOfEmployeeStockPurchasePlan_db06dd73-bfe6-4573-9242-1de8a8e171c5" xlink:href="pacb-20241231.xsd#pacb_PurchasePeriodOfEmployeeStockPurchasePlan"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_PurchasePeriodOfEmployeeStockPurchasePlan_db06dd73-bfe6-4573-9242-1de8a8e171c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_87cbc54e-ddff-4ec3-b742-a9e26fab794c" xlink:href="pacb-20241231.xsd#pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_87cbc54e-ddff-4ec3-b742-a9e26fab794c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_efa99ea8-ede0-4ba1-849d-2189deda340e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_efa99ea8-ede0-4ba1-849d-2189deda340e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_67bace9f-5209-42e5-b32b-d76ee2311df5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_CommonStockSharesIssued_67bace9f-5209-42e5-b32b-d76ee2311df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_61bb77f0-f089-4ef0-a944-91a8ed07446e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_61bb77f0-f089-4ef0-a944-91a8ed07446e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_3d3ae0f1-5c90-417f-b413-72e19b45ff38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_3d3ae0f1-5c90-417f-b413-72e19b45ff38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_73648a49-c01f-4009-987c-e9be9048928c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_73648a49-c01f-4009-987c-e9be9048928c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e16ab560-882d-4671-b41a-527915ea440b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e16ab560-882d-4671-b41a-527915ea440b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_955f9433-efe3-4ca3-b593-2690d80fc2be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_501e7700-4287-4ba4-ac5d-172919d50f59" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_955f9433-efe3-4ca3-b593-2690d80fc2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70a36cb6-1b41-4607-a928-8c1febc03b72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_8a7dd50a-e507-45fb-8eaa-6e56d154e542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70a36cb6-1b41-4607-a928-8c1febc03b72" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_8a7dd50a-e507-45fb-8eaa-6e56d154e542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c2c23d63-5c02-4b23-b936-071d85c6a022" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_8a7dd50a-e507-45fb-8eaa-6e56d154e542" xlink:to="loc_us-gaap_AwardTypeAxis_c2c23d63-5c02-4b23-b936-071d85c6a022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af78ccef-5219-4738-83a0-a1a72be65793" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c2c23d63-5c02-4b23-b936-071d85c6a022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af78ccef-5219-4738-83a0-a1a72be65793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedStockOptionMember_b7586421-92e5-46ca-ae1a-ecb08f503a1c" xlink:href="pacb-20241231.xsd#pacb_TimeBasedStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af78ccef-5219-4738-83a0-a1a72be65793" xlink:to="loc_pacb_TimeBasedStockOptionMember_b7586421-92e5-46ca-ae1a-ecb08f503a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_de133da7-1b55-46c6-91bd-43901ad7cc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_8a7dd50a-e507-45fb-8eaa-6e56d154e542" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_de133da7-1b55-46c6-91bd-43901ad7cc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_311e744d-56f7-40a2-9b7c-32dca6df0991" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_de133da7-1b55-46c6-91bd-43901ad7cc2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_311e744d-56f7-40a2-9b7c-32dca6df0991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_eacaa3f5-6de0-4adb-82c4-2c0584c3f6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_311e744d-56f7-40a2-9b7c-32dca6df0991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_eacaa3f5-6de0-4adb-82c4-2c0584c3f6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a6bfcb6d-330d-49b9-a0cc-32f89f2e39c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_311e744d-56f7-40a2-9b7c-32dca6df0991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a6bfcb6d-330d-49b9-a0cc-32f89f2e39c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d316e94a-6d52-4509-878d-cd4173838f91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_311e744d-56f7-40a2-9b7c-32dca6df0991" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d316e94a-6d52-4509-878d-cd4173838f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f90c8e2a-124e-450b-83d6-f20f83f7e2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_311e744d-56f7-40a2-9b7c-32dca6df0991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f90c8e2a-124e-450b-83d6-f20f83f7e2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_872e462f-d2cb-40e9-a85e-f9548816a898" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_311e744d-56f7-40a2-9b7c-32dca6df0991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_872e462f-d2cb-40e9-a85e-f9548816a898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_89e69228-fee1-4bc6-ae46-c7b20c7adecd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_311e744d-56f7-40a2-9b7c-32dca6df0991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_89e69228-fee1-4bc6-ae46-c7b20c7adecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cc4bb716-f909-4702-81aa-07594af93b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_de133da7-1b55-46c6-91bd-43901ad7cc2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cc4bb716-f909-4702-81aa-07594af93b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c66779b6-c2ef-49ea-8bdc-19a12c443516" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cc4bb716-f909-4702-81aa-07594af93b1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c66779b6-c2ef-49ea-8bdc-19a12c443516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f4250667-ba16-4c4e-9430-f342da382707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cc4bb716-f909-4702-81aa-07594af93b1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f4250667-ba16-4c4e-9430-f342da382707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e3149392-2a90-46da-855d-1d037bb72dec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cc4bb716-f909-4702-81aa-07594af93b1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e3149392-2a90-46da-855d-1d037bb72dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c7d0d014-dbac-432b-9c8f-12921a570442" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cc4bb716-f909-4702-81aa-07594af93b1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c7d0d014-dbac-432b-9c8f-12921a570442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_101f49d8-8c05-4577-a61a-52e83d065d67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cc4bb716-f909-4702-81aa-07594af93b1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_101f49d8-8c05-4577-a61a-52e83d065d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_df9b8768-5bda-4191-ab35-7c62a6ad98bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cc4bb716-f909-4702-81aa-07594af93b1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_df9b8768-5bda-4191-ab35-7c62a6ad98bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce3b1ff5-a312-4948-b1a4-b0eb1e562239" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6dc1cf9-67c1-4dc5-b153-aa298ca16406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce3b1ff5-a312-4948-b1a4-b0eb1e562239" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6dc1cf9-67c1-4dc5-b153-aa298ca16406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_80f49a77-a6a8-47c2-95c7-94870dd45d39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6dc1cf9-67c1-4dc5-b153-aa298ca16406" xlink:to="loc_us-gaap_AwardTypeAxis_80f49a77-a6a8-47c2-95c7-94870dd45d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cba438f-08d6-49e7-9890-19b2081309a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_80f49a77-a6a8-47c2-95c7-94870dd45d39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cba438f-08d6-49e7-9890-19b2081309a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_9b466413-199a-4a30-a778-c257e7462308" xlink:href="pacb-20241231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cba438f-08d6-49e7-9890-19b2081309a3" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_9b466413-199a-4a30-a778-c257e7462308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_9fc8eccd-611b-4cba-8ba9-e1a565aac3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cba438f-08d6-49e7-9890-19b2081309a3" xlink:to="loc_us-gaap_PerformanceSharesMember_9fc8eccd-611b-4cba-8ba9-e1a565aac3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c17d620d-952f-4185-8e4c-9d47d1b6ac46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6dc1cf9-67c1-4dc5-b153-aa298ca16406" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c17d620d-952f-4185-8e4c-9d47d1b6ac46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e30680ad-1a36-4ff0-8d10-26df3863038b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c17d620d-952f-4185-8e4c-9d47d1b6ac46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e30680ad-1a36-4ff0-8d10-26df3863038b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_327b9058-e9c1-4b20-82a5-7c527e962377" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e30680ad-1a36-4ff0-8d10-26df3863038b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_327b9058-e9c1-4b20-82a5-7c527e962377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e892d054-9222-45fe-bd1d-8ff4d4ca052d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e30680ad-1a36-4ff0-8d10-26df3863038b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e892d054-9222-45fe-bd1d-8ff4d4ca052d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_56ef6faa-207d-485d-9a27-61ca7464e771" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e30680ad-1a36-4ff0-8d10-26df3863038b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_56ef6faa-207d-485d-9a27-61ca7464e771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0091912e-43b0-4eb8-a2db-d9b6fcb981c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e30680ad-1a36-4ff0-8d10-26df3863038b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0091912e-43b0-4eb8-a2db-d9b6fcb981c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_20ecc7e3-fc52-4107-b8ed-d739e2f770f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e30680ad-1a36-4ff0-8d10-26df3863038b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_20ecc7e3-fc52-4107-b8ed-d739e2f770f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_74a1e6d3-b1d8-4b3e-96df-a1d11b608bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c17d620d-952f-4185-8e4c-9d47d1b6ac46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_74a1e6d3-b1d8-4b3e-96df-a1d11b608bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1b855264-7d0a-487e-bd00-c568066facd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_74a1e6d3-b1d8-4b3e-96df-a1d11b608bc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1b855264-7d0a-487e-bd00-c568066facd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93442a11-475f-49ac-9807-40b66593567f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_74a1e6d3-b1d8-4b3e-96df-a1d11b608bc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93442a11-475f-49ac-9807-40b66593567f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a2feea30-718b-491a-b9da-0ce973df6d84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_74a1e6d3-b1d8-4b3e-96df-a1d11b608bc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a2feea30-718b-491a-b9da-0ce973df6d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8a3740c3-d688-474f-b2a2-d10ebfd7d0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_74a1e6d3-b1d8-4b3e-96df-a1d11b608bc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8a3740c3-d688-474f-b2a2-d10ebfd7d0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_43edb9cd-5a96-447d-a736-0ea5e4831773" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_74a1e6d3-b1d8-4b3e-96df-a1d11b608bc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_43edb9cd-5a96-447d-a736-0ea5e4831773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ff09014d-02ae-4a19-9ccd-bae8743e20bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d53fb934-96fc-47e9-9433-af3247e75f52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ff09014d-02ae-4a19-9ccd-bae8743e20bc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d53fb934-96fc-47e9-9433-af3247e75f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e2f8c598-3420-4d3f-bcb4-d18e93c345bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d53fb934-96fc-47e9-9433-af3247e75f52" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e2f8c598-3420-4d3f-bcb4-d18e93c345bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4af18d48-e22c-4280-b194-374bc1e82c32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e2f8c598-3420-4d3f-bcb4-d18e93c345bc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4af18d48-e22c-4280-b194-374bc1e82c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_a1c3f0f0-2aea-4ea5-91e5-446003288237" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4af18d48-e22c-4280-b194-374bc1e82c32" xlink:to="loc_us-gaap_CostOfSalesMember_a1c3f0f0-2aea-4ea5-91e5-446003288237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_aa3ae6ae-732e-4570-a8e5-0e3fb111e3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4af18d48-e22c-4280-b194-374bc1e82c32" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_aa3ae6ae-732e-4570-a8e5-0e3fb111e3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_73c8bfd9-3094-45ec-9412-16c4d2a642be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4af18d48-e22c-4280-b194-374bc1e82c32" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_73c8bfd9-3094-45ec-9412-16c4d2a642be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationMember_ea2ebc42-73ad-4409-aab0-07fdf3ace766" xlink:href="pacb-20241231.xsd#pacb_StockBasedCompensationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4af18d48-e22c-4280-b194-374bc1e82c32" xlink:to="loc_pacb_StockBasedCompensationMember_ea2ebc42-73ad-4409-aab0-07fdf3ace766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_59b7bbd1-0687-4e24-9972-d58d95474e43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d53fb934-96fc-47e9-9433-af3247e75f52" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_59b7bbd1-0687-4e24-9972-d58d95474e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_22560a5c-c874-4f79-ad24-9e713a72adb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_59b7bbd1-0687-4e24-9972-d58d95474e43" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_22560a5c-c874-4f79-ad24-9e713a72adb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39143553-fd50-431a-b314-f9ce31fbe689" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2665382a-a433-4952-8cc7-c94d99502565" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39143553-fd50-431a-b314-f9ce31fbe689" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2665382a-a433-4952-8cc7-c94d99502565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f4a3ec53-0c22-428d-9781-3c8df0ce932b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2665382a-a433-4952-8cc7-c94d99502565" xlink:to="loc_us-gaap_AwardTypeAxis_f4a3ec53-0c22-428d-9781-3c8df0ce932b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4b24a6ea-f344-45ef-a5a4-48c4e87443d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f4a3ec53-0c22-428d-9781-3c8df0ce932b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4b24a6ea-f344-45ef-a5a4-48c4e87443d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember_21eb0592-36e6-4aa4-b4ba-1cc97a54a0a8" xlink:href="pacb-20241231.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4b24a6ea-f344-45ef-a5a4-48c4e87443d1" xlink:to="loc_pacb_OptionsToPurchaseCommonStockMember_21eb0592-36e6-4aa4-b4ba-1cc97a54a0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2665382a-a433-4952-8cc7-c94d99502565" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_55363a67-d669-4457-878e-f17921ebc2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_55363a67-d669-4457-878e-f17921ebc2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_fc67a2ae-c161-4dcd-a9b4-2008ffaf3b53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_fc67a2ae-c161-4dcd-a9b4-2008ffaf3b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5aa07a40-d77c-441a-9253-7f7e6bd3c822" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5aa07a40-d77c-441a-9253-7f7e6bd3c822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_77775409-a8dc-4a29-acd1-9207de40561d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_77775409-a8dc-4a29-acd1-9207de40561d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_22b01ae0-6e7d-4a82-9cbb-f17932b0fe1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_22b01ae0-6e7d-4a82-9cbb-f17932b0fe1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_31127536-a637-425c-8c70-752704dc130f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_31127536-a637-425c-8c70-752704dc130f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b00e6194-f920-4e12-aecf-fdc50e1b398a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16bef3e-3068-4075-a8b0-560c5fd15bbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b00e6194-f920-4e12-aecf-fdc50e1b398a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaf0a8e6-a7d5-4aae-9206-06833fd7efb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5146c76c-20e2-4eed-8997-b5d1a298d99e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaf0a8e6-a7d5-4aae-9206-06833fd7efb5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5146c76c-20e2-4eed-8997-b5d1a298d99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1b2e4ff-46d5-484b-b650-ca629f8c146c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5146c76c-20e2-4eed-8997-b5d1a298d99e" xlink:to="loc_srt_RangeAxis_b1b2e4ff-46d5-484b-b650-ca629f8c146c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_48303685-08dc-41e8-aad0-d1868e2656e5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b1b2e4ff-46d5-484b-b650-ca629f8c146c" xlink:to="loc_srt_RangeMember_48303685-08dc-41e8-aad0-d1868e2656e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_000b8af1-a426-48de-a279-7136fd04c4e6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_48303685-08dc-41e8-aad0-d1868e2656e5" xlink:to="loc_srt_MinimumMember_000b8af1-a426-48de-a279-7136fd04c4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_19225955-2c06-4466-8d8a-2cee2fd96237" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_48303685-08dc-41e8-aad0-d1868e2656e5" xlink:to="loc_srt_MaximumMember_19225955-2c06-4466-8d8a-2cee2fd96237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2b7b0959-efcc-4e86-b782-ddaa9e2ad335" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5146c76c-20e2-4eed-8997-b5d1a298d99e" xlink:to="loc_us-gaap_PlanNameAxis_2b7b0959-efcc-4e86-b782-ddaa9e2ad335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ec81109f-033d-406b-bffe-241a65c13d92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2b7b0959-efcc-4e86-b782-ddaa9e2ad335" xlink:to="loc_us-gaap_PlanNameDomain_ec81109f-033d-406b-bffe-241a65c13d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_44f53df3-fafb-427f-92e1-5295372e549e" xlink:href="pacb-20241231.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ec81109f-033d-406b-bffe-241a65c13d92" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_44f53df3-fafb-427f-92e1-5295372e549e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5146c76c-20e2-4eed-8997-b5d1a298d99e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2f5e5673-a376-43a3-830f-f4ee0a5cc803" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2f5e5673-a376-43a3-830f-f4ee0a5cc803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_f5917b75-28e1-49fa-aa5b-d71512527a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_f5917b75-28e1-49fa-aa5b-d71512527a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7f3a1bb8-94fb-4291-b530-c23ef32bf371" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7f3a1bb8-94fb-4291-b530-c23ef32bf371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_08e89613-0a65-49fc-a2c8-653c81db3c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_08e89613-0a65-49fc-a2c8-653c81db3c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d243e31c-6237-4254-9e27-bea48db2e135" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d243e31c-6237-4254-9e27-bea48db2e135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bfaa0c86-3606-421b-a04f-42f87d84434e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bfaa0c86-3606-421b-a04f-42f87d84434e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_482917fc-2ea3-4614-8792-c068d86f7b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0cc892ea-d9ba-44e3-b9c6-ca7f2b9a7749" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_482917fc-2ea3-4614-8792-c068d86f7b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0174b737-e7ed-4ac8-961b-284865a44296" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_d4f34220-acb1-48c1-887e-bbb78fc7f4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0174b737-e7ed-4ac8-961b-284865a44296" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_d4f34220-acb1-48c1-887e-bbb78fc7f4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_61bb9b2d-3bd9-4491-8ab5-37023acd6587" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_d4f34220-acb1-48c1-887e-bbb78fc7f4c1" xlink:to="loc_us-gaap_DebtInstrumentAxis_61bb9b2d-3bd9-4491-8ab5-37023acd6587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d7f0fe8f-b0e4-4530-b626-82d5fe086f62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_61bb9b2d-3bd9-4491-8ab5-37023acd6587" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d7f0fe8f-b0e4-4530-b626-82d5fe086f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_48a7667f-e601-42bd-b7bf-00ad9192fb77" xlink:href="pacb-20241231.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7f0fe8f-b0e4-4530-b626-82d5fe086f62" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_48a7667f-e601-42bd-b7bf-00ad9192fb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2029ConvertibleSeniorNotesMember_240debd1-47f8-4d70-b162-37080f399f36" xlink:href="pacb-20241231.xsd#pacb_A2029ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7f0fe8f-b0e4-4530-b626-82d5fe086f62" xlink:to="loc_pacb_A2029ConvertibleSeniorNotesMember_240debd1-47f8-4d70-b162-37080f399f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_fecb6de3-c3ef-471c-b08e-ac4d6d991fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_d4f34220-acb1-48c1-887e-bbb78fc7f4c1" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_fecb6de3-c3ef-471c-b08e-ac4d6d991fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_31cc9b92-3f31-449b-9d7e-cbd92db358f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageRateOfTimeDepositsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_fecb6de3-c3ef-471c-b08e-ac4d6d991fa3" xlink:to="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_31cc9b92-3f31-449b-9d7e-cbd92db358f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_31d6e02f-590f-4828-9578-a329a3de78e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_31cc9b92-3f31-449b-9d7e-cbd92db358f3" xlink:to="loc_us-gaap_NetIncomeLossAbstract_31d6e02f-590f-4828-9578-a329a3de78e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_50c24eca-f8d8-4ca2-9514-30cebc09332d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_31d6e02f-590f-4828-9578-a329a3de78e4" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_50c24eca-f8d8-4ca2-9514-30cebc09332d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_135df2a0-6661-4351-8c3e-799a959a9d91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_50c24eca-f8d8-4ca2-9514-30cebc09332d" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_135df2a0-6661-4351-8c3e-799a959a9d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_d9f9f744-8545-4d1e-be6c-052a07faf5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_31d6e02f-590f-4828-9578-a329a3de78e4" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_d9f9f744-8545-4d1e-be6c-052a07faf5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3965f220-4a0b-45bd-a6f4-930423b357d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_d9f9f744-8545-4d1e-be6c-052a07faf5b4" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3965f220-4a0b-45bd-a6f4-930423b357d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_84c9fe54-054a-41b9-b462-cf22ae74591b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_d9f9f744-8545-4d1e-be6c-052a07faf5b4" xlink:to="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_84c9fe54-054a-41b9-b462-cf22ae74591b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_a64ed2ac-7547-4e1b-983c-a6571b5cd4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_d9f9f744-8545-4d1e-be6c-052a07faf5b4" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_a64ed2ac-7547-4e1b-983c-a6571b5cd4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_82c7247e-7cbc-48e7-8c4c-5df2a989b71b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_d9f9f744-8545-4d1e-be6c-052a07faf5b4" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_82c7247e-7cbc-48e7-8c4c-5df2a989b71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4c3aa752-0d96-4c96-865f-9a918518f506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_31cc9b92-3f31-449b-9d7e-cbd92db358f3" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4c3aa752-0d96-4c96-865f-9a918518f506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_18e53717-2386-485e-9244-85c02379e0df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4c3aa752-0d96-4c96-865f-9a918518f506" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_18e53717-2386-485e-9244-85c02379e0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28aea69b-e89f-4335-951f-01186a102533" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_18e53717-2386-485e-9244-85c02379e0df" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28aea69b-e89f-4335-951f-01186a102533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f2db238f-3169-41d1-8e02-95337c6bea53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_18e53717-2386-485e-9244-85c02379e0df" xlink:to="loc_us-gaap_EarningsPerShareBasic_f2db238f-3169-41d1-8e02-95337c6bea53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_21f30f60-aeee-424c-ac74-4825ebf375b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_4c3aa752-0d96-4c96-865f-9a918518f506" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_21f30f60-aeee-424c-ac74-4825ebf375b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d9bca92e-b01c-4b06-9e10-5c43f36aac86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_21f30f60-aeee-424c-ac74-4825ebf375b0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d9bca92e-b01c-4b06-9e10-5c43f36aac86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_79196abb-6c91-4f48-89fc-cf2dd81a476d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_21f30f60-aeee-424c-ac74-4825ebf375b0" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_79196abb-6c91-4f48-89fc-cf2dd81a476d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d0d5b7f9-6688-4710-bee4-a2357ae21a11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_21f30f60-aeee-424c-ac74-4825ebf375b0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d0d5b7f9-6688-4710-bee4-a2357ae21a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e1ab9d54-dd02-4e0a-b77a-e846ea69eb49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_21f30f60-aeee-424c-ac74-4825ebf375b0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e1ab9d54-dd02-4e0a-b77a-e846ea69eb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f7cbc9d7-76e7-46fb-96a0-97cea1c501d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e9e113a4-c17c-43db-a5b4-eac71314cbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f7cbc9d7-76e7-46fb-96a0-97cea1c501d5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e9e113a4-c17c-43db-a5b4-eac71314cbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_45f36d09-d672-4b07-a1d2-9f708361c37b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e9e113a4-c17c-43db-a5b4-eac71314cbd5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_45f36d09-d672-4b07-a1d2-9f708361c37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_142b104c-24e1-47b1-a815-22d9429de16b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_45f36d09-d672-4b07-a1d2-9f708361c37b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_142b104c-24e1-47b1-a815-22d9429de16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_278c43e0-d9a0-4c79-8622-98fe7c586f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_142b104c-24e1-47b1-a815-22d9429de16b" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_278c43e0-d9a0-4c79-8622-98fe7c586f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_968b08e6-569c-4aa2-85eb-12dfcf49cf14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_142b104c-24e1-47b1-a815-22d9429de16b" xlink:to="loc_us-gaap_StockCompensationPlanMember_968b08e6-569c-4aa2-85eb-12dfcf49cf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cbe488ce-3471-4968-a3ca-b06527b2e158" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e9e113a4-c17c-43db-a5b4-eac71314cbd5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cbe488ce-3471-4968-a3ca-b06527b2e158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8296c722-3bc4-4a3d-a6ee-e03c107a0ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cbe488ce-3471-4968-a3ca-b06527b2e158" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8296c722-3bc4-4a3d-a6ee-e03c107a0ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_fb6a075a-6cdf-4f06-b137-408f17314cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_1cca3f1a-ae15-49ed-be8c-2ae699b2d2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fb6a075a-6cdf-4f06-b137-408f17314cb6" xlink:to="loc_us-gaap_NumberOfReportableSegments_1cca3f1a-ae15-49ed-be8c-2ae699b2d2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d93bb0dd-12b9-440b-ab5e-7a281085e521" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8740cb6-b3f3-4f49-befe-546964c5776b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d93bb0dd-12b9-440b-ab5e-7a281085e521" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8740cb6-b3f3-4f49-befe-546964c5776b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9fb38cb2-25d7-4e22-97c3-779bf3fdb1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8740cb6-b3f3-4f49-befe-546964c5776b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9fb38cb2-25d7-4e22-97c3-779bf3fdb1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_aaabd6a7-b3cd-481c-b3be-f8a512578f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9fb38cb2-25d7-4e22-97c3-779bf3fdb1ec" xlink:to="loc_us-gaap_SegmentDomain_aaabd6a7-b3cd-481c-b3be-f8a512578f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ReportableSegmentMember_58761a78-5baa-4a52-9966-3ca4ddc69853" xlink:href="pacb-20241231.xsd#pacb_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_aaabd6a7-b3cd-481c-b3be-f8a512578f7a" xlink:to="loc_pacb_ReportableSegmentMember_58761a78-5baa-4a52-9966-3ca4ddc69853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7255cdb4-71ec-4794-97c3-12fbf7cda34a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8740cb6-b3f3-4f49-befe-546964c5776b" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_7255cdb4-71ec-4794-97c3-12fbf7cda34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_47d2ff6b-edde-46fd-8703-861179179ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7255cdb4-71ec-4794-97c3-12fbf7cda34a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_47d2ff6b-edde-46fd-8703-861179179ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7255cdb4-71ec-4794-97c3-12fbf7cda34a" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_77dd2a1e-a531-4ff4-9bc9-34b7dfa3af96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_CostOfRevenue_77dd2a1e-a531-4ff4-9bc9-34b7dfa3af96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3b166a82-fa62-472c-909e-3f1f4af69be4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3b166a82-fa62-472c-909e-3f1f4af69be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_0da537e8-7356-4141-8e92-f28018929534" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_SellingAndMarketingExpense_0da537e8-7356-4141-8e92-f28018929534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_dff8a682-9988-4865-a763-d39975494a83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_dff8a682-9988-4865-a763-d39975494a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_6e3952b3-f750-401b-ac02-653bf0ec2c35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_6e3952b3-f750-401b-ac02-653bf0ec2c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_6430e09d-a5d9-48d4-a8c8-d9745421207c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_6430e09d-a5d9-48d4-a8c8-d9745421207c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_37185622-ed52-4d75-9a65-b8d4964eb52c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_37185622-ed52-4d75-9a65-b8d4964eb52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f0f3671a-f948-4c33-917e-67b932dee7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f0f3671a-f948-4c33-917e-67b932dee7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b09422a3-bf99-42a5-8a2b-7468ee4d54ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b09422a3-bf99-42a5-8a2b-7468ee4d54ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_4f6df34f-6f64-49c2-b51d-a9baecbcfcd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f56ea9d0-d299-4d7c-a451-33fedb93d205" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_4f6df34f-6f64-49c2-b51d-a9baecbcfcd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4e28681c-dfe7-4e6d-8943-b391df068082" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7255cdb4-71ec-4794-97c3-12fbf7cda34a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4e28681c-dfe7-4e6d-8943-b391df068082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8e8d3da4-9ef5-4156-a85b-277eab1dd0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7255cdb4-71ec-4794-97c3-12fbf7cda34a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8e8d3da4-9ef5-4156-a85b-277eab1dd0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a4d49ff1-f801-404d-9396-7e53a2708879" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7255cdb4-71ec-4794-97c3-12fbf7cda34a" xlink:to="loc_us-gaap_NetIncomeLoss_a4d49ff1-f801-404d-9396-7e53a2708879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_89a63c28-2af6-43df-95a0-969ad1b7467f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_aec59ea6-2db5-48da-a7fc-6c769e56628b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_89a63c28-2af6-43df-95a0-969ad1b7467f" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_aec59ea6-2db5-48da-a7fc-6c769e56628b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dd7ffa3a-a75c-48e9-ba85-15f1803785dd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_aec59ea6-2db5-48da-a7fc-6c769e56628b" xlink:to="loc_srt_StatementGeographicalAxis_dd7ffa3a-a75c-48e9-ba85-15f1803785dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f6c32c79-9bc5-409f-923b-1d5317c22dc3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_dd7ffa3a-a75c-48e9-ba85-15f1803785dd" xlink:to="loc_srt_SegmentGeographicalDomain_f6c32c79-9bc5-409f-923b-1d5317c22dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember_c2d4c00e-b082-4464-a268-e750217edde2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AmericasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f6c32c79-9bc5-409f-923b-1d5317c22dc3" xlink:to="loc_srt_AmericasMember_c2d4c00e-b082-4464-a268-e750217edde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_f4c4abb2-f991-42b4-9c17-e3552cfefbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f6c32c79-9bc5-409f-923b-1d5317c22dc3" xlink:to="loc_us-gaap_EMEAMember_f4c4abb2-f991-42b4-9c17-e3552cfefbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_b85adb4a-dc89-4ffa-90b4-1dc4a4a1de70" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f6c32c79-9bc5-409f-923b-1d5317c22dc3" xlink:to="loc_srt_AsiaPacificMember_b85adb4a-dc89-4ffa-90b4-1dc4a4a1de70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_72cf957f-b804-48fd-a4d4-ebc409cbf49a" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f6c32c79-9bc5-409f-923b-1d5317c22dc3" xlink:to="loc_country_US_72cf957f-b804-48fd-a4d4-ebc409cbf49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0c727c04-24b0-4efd-a45c-888afa607868" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_aec59ea6-2db5-48da-a7fc-6c769e56628b" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0c727c04-24b0-4efd-a45c-888afa607868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c8ad4f61-86c1-44a7-b172-3dbe457150b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0c727c04-24b0-4efd-a45c-888afa607868" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c8ad4f61-86c1-44a7-b172-3dbe457150b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_77349b8e-ca70-4eb3-8a3d-b140998fb014" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4affe986-90d6-42d0-9535-b99ad29763fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_77349b8e-ca70-4eb3-8a3d-b140998fb014" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4affe986-90d6-42d0-9535-b99ad29763fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bea23cc8-7ec3-48c9-af36-4fe9896f533f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4affe986-90d6-42d0-9535-b99ad29763fb" xlink:to="loc_srt_ProductOrServiceAxis_bea23cc8-7ec3-48c9-af36-4fe9896f533f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_02ba0bf8-41b7-43a9-9694-c8a1c3148d2a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bea23cc8-7ec3-48c9-af36-4fe9896f533f" xlink:to="loc_srt_ProductsAndServicesDomain_02ba0bf8-41b7-43a9-9694-c8a1c3148d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d0ecda9c-dd82-44d1-96fe-505ffb43ecca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_02ba0bf8-41b7-43a9-9694-c8a1c3148d2a" xlink:to="loc_us-gaap_ProductMember_d0ecda9c-dd82-44d1-96fe-505ffb43ecca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InstrumentMember_c5c5db01-2d90-4282-933b-2387c987fe90" xlink:href="pacb-20241231.xsd#pacb_InstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_d0ecda9c-dd82-44d1-96fe-505ffb43ecca" xlink:to="loc_pacb_InstrumentMember_c5c5db01-2d90-4282-933b-2387c987fe90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConsumableMember_13d235ae-ca33-4cca-a6fa-528dbc1a87e3" xlink:href="pacb-20241231.xsd#pacb_ConsumableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_d0ecda9c-dd82-44d1-96fe-505ffb43ecca" xlink:to="loc_pacb_ConsumableMember_13d235ae-ca33-4cca-a6fa-528dbc1a87e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_255405a6-9a56-427c-b781-c8cc1083dc30" xlink:href="pacb-20241231.xsd#pacb_ServiceAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_02ba0bf8-41b7-43a9-9694-c8a1c3148d2a" xlink:to="loc_pacb_ServiceAndOtherMember_255405a6-9a56-427c-b781-c8cc1083dc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f9c48fca-3e74-49c3-a71a-44980e0b8dae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_4affe986-90d6-42d0-9535-b99ad29763fb" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f9c48fca-3e74-49c3-a71a-44980e0b8dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0c16ef7d-0779-4f53-a9d2-e2c5debb1954" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f9c48fca-3e74-49c3-a71a-44980e0b8dae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0c16ef7d-0779-4f53-a9d2-e2c5debb1954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="pacb-20241231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_e95db99e-abec-45ec-80f4-204f8fb95b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_063c0b9b-bb90-4036-a6d1-06cfb19556d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_e95db99e-abec-45ec-80f4-204f8fb95b9d" xlink:to="loc_us-gaap_SubsequentEventTable_063c0b9b-bb90-4036-a6d1-06cfb19556d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4d65a0be-91c7-4770-90d6-e59396a2490b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_063c0b9b-bb90-4036-a6d1-06cfb19556d3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4d65a0be-91c7-4770-90d6-e59396a2490b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7130a8dc-a2dd-4b60-ad73-79cde21953da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4d65a0be-91c7-4770-90d6-e59396a2490b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7130a8dc-a2dd-4b60-ad73-79cde21953da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7e504c23-dfab-4b49-bb7b-aec111822798" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7130a8dc-a2dd-4b60-ad73-79cde21953da" xlink:to="loc_us-gaap_SubsequentEventMember_7e504c23-dfab-4b49-bb7b-aec111822798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_62fc034b-16a3-4c2c-b542-0dfc8b4f069f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_063c0b9b-bb90-4036-a6d1-06cfb19556d3" xlink:to="loc_us-gaap_SubsequentEventLineItems_62fc034b-16a3-4c2c-b542-0dfc8b4f069f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OperatingLeaseExpectedBaseRentExpense_563198e5-2406-48ef-b916-f2c2ebae8596" xlink:href="pacb-20241231.xsd#pacb_OperatingLeaseExpectedBaseRentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_62fc034b-16a3-4c2c-b542-0dfc8b4f069f" xlink:to="loc_pacb_OperatingLeaseExpectedBaseRentExpense_563198e5-2406-48ef-b916-f2c2ebae8596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount_5ba7942f-6721-4fda-85c6-07a63ed37d80" xlink:href="pacb-20241231.xsd#pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_62fc034b-16a3-4c2c-b542-0dfc8b4f069f" xlink:to="loc_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount_5ba7942f-6721-4fda-85c6-07a63ed37d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_eac11e97-1b40-4f45-8acb-bbe6f49d180e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TenantImprovements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_62fc034b-16a3-4c2c-b542-0dfc8b4f069f" xlink:to="loc_us-gaap_TenantImprovements_eac11e97-1b40-4f45-8acb-bbe6f49d180e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_ffe94d24-7ef3-41ba-899a-3994ed3df373" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_62fc034b-16a3-4c2c-b542-0dfc8b4f069f" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_ffe94d24-7ef3-41ba-899a-3994ed3df373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>box.jpg
<TEXT>
begin 644 box.jpg
M_]C_X  02D9)1@ ! 0$!] 'T  #_X0 Z17AI9@  34T *@    @  U$0  $
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M_P I3?'W_9*M1_\ 3OH]?T_5_,#_ ,&5/_*4WQ]_V2K4?_3OH]?T_4 %%%%
M!1110 4444 ?S _\&5/_ "E-\??]DJU'_P!.^CT4?\&5/_*4WQ]_V2K4?_3O
MH]% '8?'[_@R@^-%K\9?$*_"WXE?"^^^'INR^A2^*K^^M-96W8!A'<I;V,L)
MDC)*>9&P$@02;(M_E)Q__$%3^U-_T/W[/_\ X/-7_P#E9110 ?\ $%3^U-_T
M/W[/_P#X/-7_ /E91_Q!4_M3?]#]^S__ .#S5_\ Y6444 '_ !!4_M3?]#]^
MS_\ ^#S5_P#Y64?\05/[4W_0_?L__P#@\U?_ .5E%% !_P 05/[4W_0_?L__
M /@\U?\ ^5E'_$%3^U-_T/W[/_\ X/-7_P#E9110!^I__!OU_P &_5O_ ,$C
M-.UWQQXXUW3_ !5\:/%5I+H]Q<:/<3G1M%TOSTE%M;B1(WGDE>"&62:6-2I1
,(XU4+))<%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !] CH# 2(  A$! Q$!_\0
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MT5Q">#Z@CJ".A!Y%= !DU\^TT[/1GX]*$J<G":LUHT]T^J:[CZ***!!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C
M_P ;?VB]*^">H:7:ZAI%[J;:A')(IM70!0A .=Q]Z\V_X;Z\-X_Y%;5_^_L7
M^-<C^WWQXF\(X'_+K<?^AI7RK7T6&P=&I1C*2U?^9_17"_!.3YKD]#&XF,G.
M:=[2:6DFMODC[9_X;[\-_P#0JZO_ -_8O\:/^&^_#?\ T*NK_P#?V+_&OB>B
MNGZCA^WYGU7_ !#C(/Y)?^!,^V/^&^_#?_0JZO\ ]_8O\:/^&^_#?_0JZO\
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MOL#]ASX6WMK-?^.;^$PV\\)L]/#K@NI8%Y![?*H![_-7=^#?V+? ?AF\2ZU
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M!J/_ "$;K_KL_P#,U6JSJ/\ R$;K_KL_\S5:OTU']R0^%'H?[.O_ "7?X?\
M_8;M?_1BU^T@K\6_V=?^2[_#_P#[#=K_ .C%K]I!7R6<_P 2'I^I_/?B7_O^
M'_P/_P!*8M%%%?/GX^%%%% 'QK_P4<^%=MKGP]LO'-O&J:EHDR6US*J\RVTK
M;0"?]F1E(_WFK\X0.:_6[]MZ^@L?V8O&8FP3,MM#&#_>-S%C^6:_)$G<*^SR
MF;EA[/HW]VA_2_AW7JULG<)NZA-I>ED[?)M@!\HKZC_X)V>(YM)_:!_LQ6_T
M?5=-GB=/]I,2*?PVM_WU7RZ!GBOH3]@N)Y?VG?#3+_!#=L?I]GD']:[<:D\-
M4OV9]9Q)3A4R;%J>W)+[TKK\4C]8,8]A2=,T9.2/RK!\:>,M)\ ^&M1U_6[R
M.QTVPB,LTTG8=@/4DX '<U\ DV[+=G\>QC*I)0BKMZ)=6WLD:.K:K9Z%IEQJ
M&H745C8VR&2:YG<+'$HZDD\ 5\<_&3_@HYH^A3SZ;X TLZ_.C%?[6O"8[7([
MHGWW'N=H^M?+_P"TE^U)X@^/NM20L\NE>$X)/]$TE&QOQTDF(^\_MT';U/AP
M*\YY]J^HPN5124J^K[=%ZG[YP]X?T80CB,W]Z3^PG9+_ !-:M^2=O4]E\9_M
M??%KQR["\\875A;MTM]+1;15'IE '/XDUYW<?$/Q5<2>9+XFUF63^\^H3$_J
MU<^..])]XU[L:-.FK1BD?K&'RS X6/+0HQCZ12_)':Z'\:/'WAFZ2XTWQIKD
M#+_"+^5D_%68J?Q%>[?#G_@HE\1/"]U%%XECM/%VG@C?OC6UN .^)$4+^:FO
ME/'Y4I);CK45,-1JJTXW_/[]SCQN197CXN.(P\7?K9)_)JS_ !/V&^"O[3_@
MCXZ0"'1+YK76%3?+H][A+A .K <AU]U)]\5\A>*O^"B/Q%T3Q1K&FP:7H!@M
M+V:WC:2"0DJCLHSB3KQ7R%I>K7FA:E;ZAI]W-8W]LXD@N('*21L.A!'(IE_>
MSZG>W%[=2--=7,C32R-U=V)+'CU)KSJ664:=23:NGMY'QV!X#RW"8FK*K'VE
M.27*I;Q=W?56NFK>9]5_\/*/B4#_ ,@GP]_X#R__ !RO6OV6_P!L[QI\:?B[
M9^%];T_1[?3YK6>8R64,BR91<CDN1C\*_/$@'FOI/_@GP#_PTII7_8/O/_1=
M/%8.A&A.486:3+SWAC)\+E>)KT,.E*,&T]='T>Y^JM%%%?&'\R$9'KUI=N!T
M_"H9YX[6)I)6"1HI9G8X"@=237YW_M7_ +<%YXJN;SPI\.[Y[+0HR8KK6H&V
MRWAZ%83U2/\ VQR?8?>Z\-AZF*ERP^_L>_DN28O/,1[#"K1;M[)=W^BW9]*_
M&S]M/P#\'I9]/6=_$OB&)BCZ=IK#$+#M+(?E7W RWM7QQX[_ ."A'Q0\4RNF
MC367A2R/ 2U@6>7\9) ?T KYD9RS9;DGM32 3Z5]91RVA16JYGW?^1_0^5<$
MY3ET4ZD/:SZN6U_);6];OS.TUGXT>/?$$S2ZAXSURX9NJ_;Y%3_OD, *RX_'
M_BB)MR>)=8C;U74)0?\ T*N?/TQ0!FO15.*T43[:&#PU*/)"E%+LDDOR/4?"
MG[4'Q4\%NITSQOJA4?\ +.^E^UK^4H:OHGX8_P#!2O6+&6.U\=:!#JL!X:_T
MG]S,ON8F^5OP*U\38_\ UTF/3FL*N#H5?BC\^IX6.X9RG,(N-;#QN^L5RO[U
M:_SNC]K?AA\7O"GQ?T/^T_"VLPZG$@7S81\LMNQ'21#@J?T/:NW+8(]*_#WP
M-X]U_P"'/B&UUSPWJ<^EZG ?EEB/RD=U=3PZGN#Q7Z=_LK_M7Z7\>]+_ +*U
M)(M,\9VD>ZXLU;]W=*.LT.><>JGD>XY/R^,RZ6&]^&L?Q7J?A'$W!M?)D\3A
MGST?_)H^O=>:^:/HNBBBO&/S<^*?V_?^1G\(_P#7K<?^AI7RK7U5^W[_ ,C/
MX1_Z];C_ -#2OE6OK<%_ A\_S/[(X%_Y)S">DO\ TN05^B7['7_)!-#_ .NU
MS_Z/>OSMK]$OV.O^2":'_P!=KG_T>]<^9?P5ZK\F?.>)_P#R):?_ %\C_P"D
MR/;J***^:/Y:"BBB@"-^A!Z5^7'QK\/VWA7XL^*]+LPJ6L-^YB1>B!L/C\-V
M*_3+Q)XCL/">AWVKZG.MM8641EFE;HJC^O8"ORR\;^*)O&WC'6M>G'ER:C=/
M/L/\"D_*/P&T5[F6)\TGT_4_<_"JC7^MXFNE^[Y5%OIS7NOFE?TOYF+2-]UJ
M6I+6SFU&Z@L[=&>>XD6%$'4LQ"@?F:]\_H^4E"/-)V2U;/U#^"4SS_"#P;)+
M_K&TFV)_[]K7;'!.*S/#.C)X>\-Z7I:?<LK:.W&/]E0O]*TQQCWKX:;4IMKJ
MV?P-BIJK7J5([.3?R;;/,OVA?B-J?PI^&USX@TF&WFO(YX8@ERI9,,P!Z$&O
MEK_ANCQ[_P! [1?^_4G_ ,57OG[: Q\#+_\ Z_+;_P!&"OSXKW<#0I5*5Y1N
M[O\ 0_>N >'<JS7*98C&T%.2G)7=]DHV6C\V?11_;G\>_P#0/T7_ +]2?_%5
M].?LX?%'5?BW\/6US6(;:"[^V2V^VU5@A5<8.#DYYK\V*^^OV'O^2,2?]A.X
M_P#9:K'4*5.C>,;/0UX]X<RK*LG^L8+#J$^>*NK[.]UOY'T(O6ESCWI#T]ZH
MZOJMMH6EW>H7DBPVEK$TTKMT5%!)/Y"OG]S^>$G)I):L\5_:H^.S?"OPTFE:
M/,H\3ZHA\EN#]FBSAI2/T7W^E?GU)*\\CRRR,[NQ=GD;)8GDDD]373_$OQ_>
M?$_QQJ?B*\W*;N7]S&S?ZF%>$0?0=??=7+U]=A:"P]-+[3W_ *\C^RN$>'J?
M#^7QIR7[V:3F^M^U^T=O6[ZBT445V'W 4444 %%%% !1110 F*] ^"7Q>U#X
M.>,8-3@$EQI4["+4+)?NRQ9^\!TWKU!_#^*N I*B4543C)73.+&8.AF&'GA<
M1'FA---?ULUNGT>I^MVAZU9^(])LM3T^=;JQNXEFAF3E74C(-7^/[WZ5\B?L
M-?%)YDOO M]+O\I3>:;GLN?WJ?@2K#_>:OKS)]:^.Q%/ZO4<)?(_BC/\GJ9'
MF-7 U->5Z/O%ZI_=H_-,_"/4?^0C=?\ 79_YFJU6=1_Y"-U_UV?^9JM7Z,C^
MQ8?"CT3]G49^/'P_Y_YC=I_Z,6OVAR,5^'OP\\7?\(%X\T#Q&UM]M&E7T-Y]
MFW[#+L8-MS@XSCKBOM/_ (>B0X(_X5W)G_L+C_XS7SN9X6MB*D94HZ)'XWQQ
MD&99QC*-7!4^:,8M-WBK/F;ZOL?>&ZC=7P=_P]'C_P"B>2_^#8?_ !FC_AZ/
M'_T3R7_P;#_XS7C_ -G8G^7\4?F_^I.?_P#0/_Y-'_,^\!TYXH!KX-E_X*B*
M8F$?P[;?VSJ_'_HFO(_BK^WK\1/B)82Z;IHM_".FR@K(-/8O<,#U F/(_P"
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M>PKZIR4$V]$C]^J5(4H2J5':*3;;V26K;,6"WENYXX((Y)YI&")#&I9W)Z
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MJC<)TWLK?B?O_AKC*E3#U\')WC!J2\N:]_E=7*=?2?\ P3X_Y.3TK_L'W?\
MZ!7S97TG_P $^/\ DY/2_P#L'W?_ *!7KXW_ ':IZ,_1.)?^1-B_\$C]4^HK
MY<_X*(^,9/#WP".F0-A]<U"&S<_],UW2M^L:C_@5?46?SKX?_P""H-TZ>%_
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ME^<59->[4?-%][[KY._RMW):***\P^'(]HQSS[4H[>M!Y&*X?XQ_%/2?@WX
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MX1_Z])__ $-*^5:^KP7\"'S_ #/[%X%_Y)S">DO_ $N05^B7['7_ "030_\
MKM<_^CWK\[:_1+]CK_D@FA_]=KG_ -'O7/F7\%>J_)GSGB?_ ,B6G_U\C_Z3
M(]NHHHKYH_EH**** &<'Z5X_^UEX<M_$/P+\0O,O[[3T2]@;T=''\P6'XU[
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ME]<V5Y$8;JWD:&:,\%'!PP/XBH:^R/[>C)3BI1=T]4UL%%%%!84444 %%%%
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MY_VF'R(/J<^QK\Y/CQ^T-XE_: \1)?:PRVFG6Q(L=*MV)BMP>ISQO<CJQ_#
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MIR;;?=L_"/4?^0E=_P#79_YFJ@XK]19?^"=?PKGEDD9]:+.23_IOK_P&HO\
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M?YG] \-<>93E&4T,#B(SYX7O:*:^)O1W7<^"**^]_P#AASX>?\]=6_\  O\
M^M1_PPY\//\ GKJW_@7_ /6KI_M+#^9]1_Q$[(_Y:G_@*_\ DCX(HK[W_P"&
M'/AY_P ]=6_\"_\ ZU'_  PY\//^>NK?^!?_ -:C^TL/YA_Q$[(_Y:G_ ("O
M_DCX(HK[W_X8<^'G_/75O_ O_P"M1_PPY\//^>NK?^!?_P!:C^TL/YA_Q$[(
M_P"6I_X"O_DCX'HW+T]>E?H'8_L6?#6Q;S)K2_OO]F>^D _\=(KT/PM\$_ W
M@>17T7PU86=P.?M'EF27_OMR6_6HEF5-?"FS@Q7BEE<(/ZM0G-^=HK[[O\CX
M8^%'[+WC'XFRQ7$ML^@Z&6!DOKY"KLI_YYQG#-]3@>]?='PL^$^@_"70%TS1
M+7:SX-Q=R<RW#_WF/\@.!7;#VXH8]!7DXC%U*^CT78_&N(.+LQXA]RN^6E?2
M"V\FWNWZZ+HD24445PGQ1X/^VAG_ (49J'_7Y;?^C!7Y[5^J7Q*^'>E?%/PQ
M-H&L><ME))'(3;OL;*MD<UY*/V'?AX<'S-7P?^GO_P"M7LX3&4L/2Y9[ZG[;
MP9QCEN09;+"8M3YG-R]U)JS44MVM=&? ]??7[#W_ "1A^>/[3N/_ &6F']A[
MX>?\]=6_\"__ *U>K_#+X9Z1\)O#PT+1#.;,RO<9N)-[;FQGGTXHQ>,I5J7+
M#?0KC+C++<_RWZIA%/FYHR]Y)*R3ZW>NIV=%%%>,?B VJ6JZ7::U83V5[;QW
M=I.A22&90R.IZ@@\&K>23@T[%,$W%W6C1\7?&G]BZYL)9]6\ @W5O\SOHLKX
M:(?],7)^8?[+<^A-?+6H:?=:1?2V5];2V=Y$<26]RACD0^X(!K]=!@C..M<Q
MXV^&7A?XBVH@\1:-;:F%X1Y%(D3_ '7&&'X&O6HYC*&E577?J?LF0>)&,P,(
MT,RC[:"VE>TTO.^DOG9]VS\J:6OM7Q;^PGX;N$GN]%U^_P!(3!<6TT0N8UQV
M&2K?F37RSXP^';>$]3FM#J*W?E'&_P"S[,_AN->U2Q-*M\+_  /V_*.*\KSO
MW<+-\RW3BTU^:^YLX^BKT.EF9]IFP/\ =_\ KU[5\(/V7T^*$0GG\2-I\?\
M<BL0YX]S)C]*VG4C35Y/0];,<WP654G6Q<^6*\F_R/!Z[;X;_!OQ9\5KP1:%
MIK-; XDU"<[+:/U^8]3[+DU]I^!OV/?A]X2*37=G+XBNU(82ZDY* ^T:X3\P
M:]ML[&'3[>.VMHDM[:)=J0Q*%51Z #I7DU<Q4=*:N^[/QS./%"E&+I932;E_
M-/9>:BGK\VO0\D^!_P"S=H'P>MTO1_Q-_$+KB34I5(V9ZI&N3M'OU/<U[$<\
L4?=P*!S]/2O#J3E4?-)W9^#8W'XG,Z\L3BZCG-[M_EY)=$M$24445D<1_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_01a.jpg
<TEXT>
begin 644 image_01a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MP  +" *U!,4! 1$ _\0 '  !  $% 0$               4! P0&!P((_\0
M6A   0,# @,%!08"!0D$!P,- 0(#!  %$08A$C%!!Q-187$4(H&1\!4RH;'!
MT2-"%C-2X?$(%R0V-V)R=;,E-$.2-413<X*BLB9%5&-D=)-55L(G1H.4TI7_
MV@ ( 0$  #\ [_2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*IQ
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M\9S .,N#GN1T]#4,OM$U$N*ET0DMH(R5ALD?S?L*R57?6L]UON&9"6R=SW0
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MC\ZS(_9O9VE)6XM]U2<'WE;'&/VK/9T)IUA7$F"%*SG*ED]"/U-9K&F;)&2
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MIR.,8JHSCSZ[53GX?+/I3F!R&3\J9\M^G[4Y 8'/EOCI51MU\LU3!\/F.=/
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MV/1=X:G-6YY<5QAD!IQ:LI4K<Y)Y;["L;0NMIVGX,NVM07Y[BE<4=IO<(/\
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MASK7-9W:59[*VY$6&G7WT,!Y8R&@H_>(\JYR]>;KIY_4<IJX-RI8?C(7("0
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MY42!M\_"M;U'#5Q,W-!P6!PNCJI!'[_E6&G*PE0&4J&4^->AX$'GR\:H4;C
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M\OB_B,/]WPX&Q/#C/QJ_9V-2NL2.]D.1BA?"VB8V'>)./%)'7QS6>)M^B?\
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M<^Z</$A7SW'PJOM-SC?UL-,A(_G97@_^4U5-YBI #P=CJY<+R2#^M92)D9P
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MR"4CC2?EOCUJ*.F=/RE*<@CV9Y1_K8;A0H'X;?.LJWVZ[P)7"[=S-AX.4O-
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MPDGJ@[].E3<;M@N<:,IJ;;VGI 7[JP> 8SU'C4U;.U^VON)1.@O1.( %8/&
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M'48VS5>$%!SBO7%L K? Y9_6B@0O Y^'*H?24ZVJU%=GGI3")7>EM*5G"@D
M ;^HY9K1NTQ<6X:C4(I2N5W_ '2@G=1 0CAZ^)-="@/0>SS2C2KBK^.Z0>!
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MH+Z.)MGN^#&"1N/A66Q8K1&6\MBV0VU/?UA2RD<7KM62(D<.(<##7&V.%"N
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MSZU!Z<U!?M,Z52+I"/V8<H;(.'@5'; \,GKXU,0;=<-<VUJ-._T&T174I$<
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M**T7G;?(D07$R_=++AX#ZI.W*MEM<2YQ XF?<&YB3]Q09[LCUP<5*4KG/:)
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M20G)]W)&.7C6'/L9E6Q$4H9=4G (6-MU G\!^->8EAM46VE,N%&;0AQQ8)2
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MOIP-ACXU#ZFT5,LU]^S87'.RT71W;9*DI)QN!63V5O.L:Y8925)#B%I6G)Y
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MXTEU(X'RWCB(',)\SL:W!)SG8CUJI.#6KZKU<G2<=$I^U3)<<X278W"<*40
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M+KJT2&E=X<K1&V;23D<7GQ9^"2/"MBM\.-(]G BR7(R@XTE+RN'/ D <7+;
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M[A$BS(96)*G(BB.)&Q;X>(85G'4UM^DW[O(TU!>OP:%S=;"W4,I*0G.X&#U
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MO6X6>RSTZ?DK8@LK;96X6F75J2HG)S@CIGD"/E5CLVES[F;A$?6]&DL*"BX
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M*?DM1FFWWL!UU*<*7@9W/6LL>A]353G&U8LB)'D.-.O,H6MDDMJ4,E*B,;?
MD?&L*#IRRVUN2B#;(D<2OZX-M !WR/B-ZNVJT6VRL&/:X,>&RM7&6V4!(*CG
M? J0.W^/6K<AAF3'<9?:2ZTM)2M"AD*'@1UK!F62V7!N.U-MT:0W'(+2'&P0
MWC8<.?A595HMTV6Q(EPH[[S']4XML*4V>F#CXU(#/0X\OWKCO^4?_J3:_P#F
M(_Z:ZZ-H3_9YIK_E47_I)K8*4I2E*4I2E*4I2E*4I2E*4I5I]L.L.-JY*20:
MX1KJ8%QX>GW5MLR("U!>![JP0.$C%6I]P?U0Q:M,V=@N-L-H0MS! 4K8DXZ#
M;PKN-GA?9MGB0R<EAI*"K'4#!_*N;R=./Z]U==5W&2XU!MZ^Y82@=>O/ZY5J
MFJ;'#T5J*W^Q/JD\" XZV58)W/4#8$56+J]N6I<.X6]*6W0D#=1X3XX\Q@;=
M *FDL65<U3;"%+:6A7\%;*@HN$# !SN=AMX'SJ0BK;$]<E$<=XE0=5WB1A..
M-)VSY# S@5Z8GW%-K<CB*&VRHK2I(3DE*\JQOOC! \3CE4>Q+G&.DR&&>%Q@
MLE2U#B!"5'8CES /IX[#"=F36'W$I+94G(XD(3_#!SQ$>]LLG('H,5D,7A;T
M7O\ *RZE300I2P.)22>() S_ "D#^^KZ7S)"%37^Y>=0A*$EY22I9RM1SX;_
M *5:?DQEN*?4"[.6MT)*&"H!/W,XY$@#?R JRIZ8L!ES@0L!)4/9E'W3XCH$
M C;QJ_*A(;EF,VE2QP()&$IYI4"3GEL,^6YJTPWF(Z^E8CD)#P=XQ@+0D)P!
M@CBRK'EC;QK*M=FE.3%Q9/<H *I"0EPGBX@0.$?V0,Y)\1SK&FI89@%I0XDN
M!*$(CI*L[%*03UY$GKG'PP927"\L-I]E6&N!QP-@(0#X')W)\.AYU@IG-H0X
M"HNJ<2"L+=P<D'O-@,#88ZX_+,9F+C-_:+3,4,]^I"4!LKQQ $E.>9 P/+XU
MEFXK;:;<;$EV.&D*)"DC+G/!/-(RK)ZG \:L3Y[]H#C[3[P4A7NLJ<"E).$[
MG;_>5\<>%;3H[4MU1INX.S;8X&(K1=;< X>/)R1DXSZU,=G3[$^P.3T14,R'
MW>%TI2=RG &_IO6EZTT&_;X<Z^.SV7LNAU0X2",G&!N?$5J=OG.0Y]KFW!#R
M8Z'2O(_FP1DCY#Y5]!6>\0;W 3+@/I=; P<=#CJ*U35VN+;8;HAA"GC-0 '%
M( *4I/17C];U[MUVF:LAI<M%Z8:QNZT6\N)WY<]@>>=_6I(R=2PA[.+>U*2G
M[KX>&<;;$'&^>M>XR)-L==N=P#;BGT_QRV2>[ )Q@>&#BO4^[V%3;:I3:'4N
M*"0%M;X.=\'I7A[1]@DI"T14M!>^6E$).<[XY>E<ME:5M[M\N5NM;TAQI@)4
MX_D%+1XL$''@,_*MSMVC+C9("&(+L62R%=XH.)&%G!'+X^/2M,NVA[JN<Z8D
M0QO<X7$-GB!\\))(!\*LRM-VV-9U(?:E,7!#:UEU0QQJR.!(!WP1G?%1FGK?
M*O4A%O7.7 C=V5.+<=5A8]#MR_*I.=!F:%N$*X6>6IU+C0XBH#!)S[A'H/K%
M9C>JM8:;=:FSBJ1'DJ0\0Z 00OH#S3G!V\JB]0:OFW64Y+9B]W&6$H7A)PHC
M. =\=?RKQIJ[%Z]6N,6&G,2BI]<A(4D!6.61D$ ?AM7;8D"V6"%->CK2A#@+
MCBE+R#@<_P *Y;IBYVN4A[[<G+,,+<46GG24<. !PIQD9XCRKSJ/1D.WW"%+
MLTUL1)62A!43L1XC?!Y?&LC^D;UNL+/L%R,)Z*A+GLQ;!,APJ)6<_P!GH*WE
MK6@8@1G)MNE=ZIA+T@,)*DL)/(J.W3)K8@(LYI*\(<!PH*QN.7X[_C4#)TGA
M"F(<A AX&&'VN\"<#W4C/3.]<ID:7NZKGW-VB>RLETK4\&_=].(9QDX %>-1
MV#V5IH^RAN0%=VGNM@X=CT\,@;8-9]CU5J%EE.G(24M.K' @O A2,D;@GGSK
MP](NFAM0L2I4S[2CRVSWR2LD.#EN#D\^1ZUVV ZE^W1W$,EA*VP4M*3@IR,X
M(Z5R*]6C5EB=F.MGO8RUJ=#[&?X7O<6 //(!V(Y56P7UIFUMR;PR$I6[P]^$
M*!4<[D#'"<=>5;-I'3-KE/7"[KBL.1IBREA);P.!/-7">62*UNTI=CZSO3<>
M0TX\7"V&2ZC)2#@8XP2=NF1RJ$U[)<%UA(+33<EC*U.LL]T3RP2H'?Y"H^/+
MU%>XKBC)G.6\+"7SWJB@ C)!YUN4D:?^Q7+>MAC@;1DI]I>5W7@LC@VY]16K
M2[+W<"UQ[:M+\SB4HN,NK*E G8@$#A KK%ZDWN!HU]PIBLN-1QQ++A41@;]!
MOM7,V](JNK!E.:BB/2E#8N.J()_LY/,U[MVCM7SK,J6U-<;2CB"&2\I*U8VV
M_2M=9G3_ &DQ)<]V.M"\E3BU9SG!!_&I56I+O!4U'BW-X\1"PZPM2TD]1A7K
M7C0DJ3([38;\HJ5(6\LN*(YJ*59Y5]$]!C\N569,AN(PMYTD-IYD9)W\JB&I
M\:YMRY$9P+:6TDA6,;A1'7S%3J?N#;&W*O5*5K>K95YAZ?<=L?<(F!0_BO@<
M#*.JB.N!T%>=#WE_4>C;;=)7!WTALEPH3A)()3D#H#C.#XU)WF<NUV2;.;CN
M/JCLJ6EIH94H@9  -?/=Y[3+;([0[;JJ*AY1;MJFRP4Y6E[<!)'+F17?].3I
M=RTY!FSHRXTIYD+<:<&%)4?$#EX_&I?Y\ZTJ?>;Y%[4;39SW(LLZ,ZH>Z"X7
M$)R=\Y Y533E\OD[6^I;5=$MICPNZ7#0E SP*XMU$9SGAY5%R-1ZJA=IL2TO
MKAN6R8\M#<5I 6^VR$Y[U:ALD$^-;7JM^\1M.R7K&Y&;G(P0Y*(#2$Y]]1R>
M@R?A6NZ7OFI;YHJ[3N^C/S42'4P)*6.[:?0D#A5@GEG.YK&BZNO4CL>1JAZ;
M$C36VU./K<8XD'A41PA(/,G K9](O7R3I&%(OI8%T?;+BN[1PA/%]W(\=QFM
M>TG==67F[W]$F9 >ML(JBQ7VF"@*?&,D[Y*4YP?&H%&M]3QM+:HO;LJ'(CPW
MDQ+<^S'X4+<"^%:B,[IR:V?1=]O4N_7FT7N3%D.0VV'F7(C7"CA<3G!\\UE=
MHMROEBT=+NMA>CM28RDN.!Y'$"WN" /')!^=:WK+7%^LEUM4>V1_:&G[8Y+>
M2AM/%E('O DXP.H%6+MKZ\.S+@JV38K$:+86[DVIYH9=<5Z]/*IW4^J[A T'
M;+G%6VU-EKB(=6M&0SWO#Q%0Z<]C6LWG7FH+;!N;+$AN0]'OC<%E;;0RZTM&
M2E)SCC']HUF676%TN>B%R)=R:BW(7%Z*VVO"''>#=+05]WC/4\JVKLYODG4.
MB(-QGN!R<>-+Z@CARM*E#&/( 5MQ.2-JY)H_4UZ7KD6Z]353$W%4DPE1I*'&
M6TMDGWDIW2<8 SUJ;TM)E/:OU(]]JS7[';U)CH]J>"D]\!Q.$;<AD#<^-:7V
MBZNU#!UTV85S4Q9HD9J6EIE81[4@D<21G[Y/AX5;UCJZ_,]HZ';?<I4:!',/
MBA\8''WGWL-\U['F.5;==8<R7VPVZ+$N5T;CHBF?-;$DAKA!X6TI3C;)!R*Z
M6D )]WE5:Q9CJ&8CSCA6$MME:B@94 !OCSKDVB[\TU?]4H%XFSK$F&B8T]WA
M<4SG(6.60ORJWH]^ZW>-K&RV>_27CEMVVS77"X&DJ!/"5XV5XCI4MV;ZIO*Y
M\K2VH$R';C$6X$2EI&%H04XSUW"A@GGOX5T\8SMTV]*KGY^%15[N*H=KFJBM
MJD3FHZW6HS:0I:R!M@==\5R^PZEU%/T=K)V9=51I[$A*(\A]LM(C%0&0 1[N
M"3XULW99=+A.M%RA7.:]/EP9BFES%+#B'<@$<"@,$"M_JS(4EJ*ZM:U(0E!4
MI2>:0!TKA$:\7)S1^L[EI>YSC'2IH1TRG2Z^VGB(==/]D$;CK@<JBEW[43>E
M&K2U?W5K-V(1=DN%+"D=WGA"U#89/7K79NSJXR[OV?VB7/6ZY+6SPNK=&%+(
M)'%G]:T;_*._U)M?_,1U_P#R:ZZ-H3_9YIK_ )5%_P"DFM@I2E*4I2E*4I2E
M*4I2E*4I2E:]K.?(@:9DKB*X9+A2TT?-1 _6N.:@MD6%KF%:F60_Q%I#_>**
MBM:^9)Y]:6"._:^U-,."DA"):D% '%A&>O/;!-?0(QXCGD&N2W[4<K3\FZMV
M>6V93DTK6T494 4I&1T\:W6ULVB[^Q7F0F,[<E1DI6OBSP[9(P>6Y-:CVK6Z
M,N!%N,1#8DM/AI:T#)P02 1XUSN'>I4>X8E27V6SN"E._& .'8],@5N"V6XE
MP96Y$<=2\YP)2"3QC*,DY.#UY]3GI4LXIZ3"#K9C-R.Z<> XN+A&^_/E@[>M
M49B36[9*C28T<)7#0LH2,?Q25 ;^N,GRK!46C&CIE(AHE..E:DH;"N- /WB>
M@X1D"HI:V&HJ7?:$H<:94VXA+>"0D#(V&=R0#XC-2$:Y153?;)LMY2&2L@)1
MPE1PE(2D8Z>\?(5Y>27TL!DRT\(0A!1_+WKG$1YX 'GOX5[6"TAYV0S(?=;;
M=+9<7L5%S">1'@,>)/E556YQ3L!V;&*5!KB4E3FZD<.3Q[[^\0,'?&U6IGM#
M68K"(K260LJ2ZI. I:LD;=3D#TSYUD*<FRFN_5=6D%2D16U-JP2G?B.>> ,'
M.>E>TQ;.(SS;/>K98E--MA*B2T.($JSXDE0KW(6U:W9"H<<=\ML=VOB20TT,
M#."<E6>N^2=J@IK#$R1,=9#C/=(2MM:E<T9/%UQQ**B-O UC0;6^?8R'6$L%
MY09:+N?=XB%'&<</*L]4982RL/0FV2APO ##9PKW !U4>?PZ5ES;O$MEBEM.
MR&$R$O)4AIG"E.$8SQ?[HQ@>.*VR+JZS7K3+;27N%]U*6U1B/?5DX.!_-G?E
M6RZ=M+=EL<6"RUW00C)3G^8[G.WC4/KL,28%OMSZREN9-;;6!L2DDG]*C+GH
MVS2;BN%'@MI#-O44X. %*/NDG//8UJ/96B=&U1( 2][*VVH.''N9'X9K:9^E
M[3*TU<KO,@A4R2ER0E2U;I.3PXP>NQK0M,1W=.]HK4!25K6%I:7W8.V<'Y;]
M:Z'VD72Y,1XENLZGDR)"N)Q36Q">6YZ9SSKEZ+K?M.7*,]*E/*X5'O&E/]XE
M0SN.9Z?I6_7W6]J7I>-[!%9<F2V_X;/=9X!G"L^'6M0TS?'W;K'L][F2F8BR
M6\!6-SR!STK?4W?1.CICT%D<+SJ>%]:0I?+(WY[^585HO%Y<A/NVJZ0Y,..H
M)07E8X1XKXMQMCEM4]&B\+*;C EM2[FDA3O=.@I7RX@1G?;EX;5-.7*))0J.
MVV)$E8W9X=QD<R.@J"M.G[9!:^S[C&:#^2I+X/"'.(YQD==_RJY(TA8I"U-1
M)/<.IPKA0X"0=\'?)J!N]@G0&THNC@FV\J2A+*%96<9"?O>&>>U8&LW(UFTA
M#M\.W.Q6U2$N*SA7'CKD'??%8&D],(CW5?M;(*7&F%A+Z.?$058R.A!'QK:K
MU8F;A COLI'L#4L*<;2KA*TD@''A49J"SV!R'<X@[IM<2*%Q6E$(*5DG.,<\
MGAK4W9+$*S-VJ,ALOJ2E3O'E1SL4E)'D?QK";G(:>(0&FWW%<*D]V0<9!QA6
MV/V%3:;PIJ"J(B7(2IX)46E$.)=0D# \03C&-JMV:9>&+\Y)1<.X>]L2TY%X
MOO))P<#D0!MGH!71HG:)8G''T2'BUW;I;XRG*2,XSD9YG->/Z;VB7J'[)*FY
M4=X)2VMO"P2>8/U^54U1I5<BQ26[,C_25@#A=62.'.2$Y.V>OIO7+[9I;4<B
M6C"'V/9W .)XE)2>H!YC8$[=#6?:+A(GZ]8;O/"N&D$E3Z0 A*!D;\@,I'UF
MNHR=4B),<;3!DNQ4A"6WH[?$%\0V(QT%8O\ 3B.I*2FTW$-YPKB8.P&1\:UJ
MX_9&N)<:![#<82DJ)95W7 @9W.?WJ<@VY>G+T_*ESA%M$2*F-&XW $*]1XYZ
MUR1E^(=<*D7-U,N,I\K=6SDI5G)_.N]REV5-JR^W'[E,4J""D9#>.@J#T._I
MN58V6[>&0I!*5H<QWF<Y&?&M'[08MPL^JWKA;V7_ &=UH=X>#+1VQ@],<JL=
MF;L>9J5EJ<^MXH:46T.K/"A04,8!\L[>5;Y#<NUROMYMMT;D*M:FE\'>-!+8
MWVPH>7G7/[_(]E=:@6R%!,A;2FG%0PE97[PWP"<';RYFLYC44_2EF@OR%RVI
M+F2N+(0>%T!7,9Y''XBM,O\ >$WB\RIK,?N&)#H6H$=<<S^=6YEYEN0E05=V
MZP%$]XEOGDC)&VVR1]9J9[/H'?:XAR8[B/9VEG)><2E9/">0YGF>5?04A.[9
M#Y: 7D@'[WE7MUI#[*FW$<:%#=*MP:UZW03;79\3W>$-=XD ;#B<6:V5'W!Z
M5ZI2H._Z>8O\)MAV1*C+9<#C4B,Z4+0H;9\#MT(Q5RPV*'IRSMVR$%]RV5**
MG%<2E%1))5ZDGE4H0,[^O/YUH[O93IEW62=2^R%+Z5!?LX">Y*_[93X_KO6\
MIQP[GEY4R.?/P(%8,FUPI5UAW)UH*EQ L,.$GW>(85MZ5CR;! ??G2>%QN3-
M;;;?=:=*%<*">'!'+&3RJ,CZ%M475+FHF79C<YX@N_QR4+P, $'IY5+WJRP=
M0VEVV7!LO17<<: LHXL'."1^56[)8+?IVVIMMN0XB.-PA;JEXVQMQ$D#R&U6
M3I.R*T\+"J"/LL*"A'XE8V5Q;[^-9#UG;?O4&X]^^A4)M;:64+PA84,>\/+I
MUJY;;1!M$146"R&6G'5NJ )RI:B2I6?$YK&CZ9L\;3RK"U!;^S5A251SN%!1
MR2?$YR:I8-,VG34=UJUQ.X#J@IU:EE:ED;#*E'.W^%24^#$N<!^#-92_&>3P
M.-KY*!Z&HR[:7LE]:89N-N:>3''"R#Q#@&.0((VVY<CM7FX:/L%U7&7.M,=]
M45'=LY&.% Y)VQD;<CM7A>D[2_/N4J4S[0+@RVP\RO=LI1G&!X[_ ("K@TAI
M\67['^RHWV>5<?<\.0%>(///GFJJTI8391:?LF+]GA7'W/!L%?VL\\^?.I"%
M BVR*W#@QVX\=L82VTD) ]!^M9A!R#49%L-H@3W9D.UQ&)3I/&\VTE*U9Y[C
M>O9A1/9Y4=++"$2RLO!"0./B&"3CF<<R:QQ9K,S%AQGH<1;<5(;C=^VDEO'0
M$\CRY5E/0K<]*9DO18JY2=FGG&TE:?('G\JO8CB2" T)"DX"L#C(Y^I%9*?N
M\\TSC_"O*O[L'D:L-18S(5[/':;XS[P0D)"CYXYU2-'C1 41F6F4J))#:4IR
M>I.*N!AI#JG0VE+A&%+  *AYGG5T<\^/E53CD<;U:+2"OO VGO<</'C?'AGG
MBK/=PW$O,]TPKO-WF^$;Y_M#]ZM6PVSV7@M1BB*@E(3%X> 'KCA_&I#\-ZHK
M!00>6.M1,V[66R.-MSIT""MX90AYU+95X\^8WKQ)F6!E;-LEOVY*I'O,Q72C
M^)N<$)//UJ60AMM ;0D)0!@( P .FU<>_P H_P#U)M?_ #$?]-==&T)_L\TU
M_P JB_\ 236P4I2E*4I2E*4I2E*4I2E*4I2M3UW)MWV [#F.\+[W_=T)05J*
MP<@@#GOBN$?T@DJU0F\RDI7)0L+X>0RD8%=([+;0S.5*U))>[R6IY2>$#9.>
M9/SKJQ4 %*R, $G!^O"N*7 VMS6#CZ[7(D,H2I3K2FBG[RLA649S\?"MFMUZ
MTPVRB/%>]E; )[IT<20<].+?.:IH>T-MWN\W!;[<B.\L+:&<@>\KF.61CQJ-
M[1WX5[=8B6U+#TB&M*WW00 D$X"<]<GY8Z5A_:*'[8VTVR,J6K9:B3CB2G)(
MSN>+)\/A6.0;>0N.VS(#J5;H4HEMO[RDG.V<#X#-2$2[2I-M?XW&%(+1=PA!
M(PVYLD XV/B>0%>78CS+WM+*@7T/E<9(:'"XI6.)7/<@[#']GI4/[;%B=Z)4
MIXR<JXG%E)!/?#?A&<XW..OPK*CWAAF:EQ(D([M:Y#+K@0" HX'/QR2?0>%>
M)<QQR3!?C\?\52G7.Z6.,'[JMCU(P ?4U;9E=W)3'?<;8#*0E:RZ5$!/O  )
MP-@0!C!W/PRI<X=PV'Y49Y+J2XTOB4DA/'G&=\*.$CRWK'N#<::7OL]D=[-D
M\/N,X^Z,\(XNA(R?7?PJW=H:.ZCI@ L@M\1)X4IRG!*O^'P.=_&JLLEMH-2Y
M+">+@<([XJ/&4X0=L#/,^0_'P$VJ'#<;"H\F2ZE/"XXLDAK8;#^4G&1X"K[D
MR')BS6HZ(BFQ@H#3)/N@CW,] 3DYY^E8C3K1DK?"7N/O5\"6HR00O;A Z XW
MVY9'G4<Y[T,J2I:<K3QE;H/&HISL ,G)_2MCLVAUZO>D3Y,E+3*>)L*2"5%P
M$8R".6]75Z"FZ:O]B<@S?:'G9 "B&\<(&Y.,G;&:[(!PC<#;P]/PKEO:Q)#D
MRWP4.%+C:5/)(5C"LC!/R56-HZ\7#44Q^.[)6&GTH:4ZA0[T(0"<;>.>?K73
M[;;H=K@IB1&4-LI&,#&_J>I_>M)N2I*H4^!:U>U!N4VS&0K8<05WBDY)W  _
M"M!B:@NNF-9O3KQ S*>5_%[Q.#P\O=^0KJ\M7M-P>XW4,,OLMNLN*64%P#.4
MY!V V/QK0M2VF7<6%Q(T5N3)6OOUNAT$H2"4IW.Y!&/E49IFW2+%>%R[C$=8
MX4D(4IDN)&2-P1R//>LGM+=M<SV:=!FH?DJ60I*1@I3@8!'/GGGXUG:1TC8]
M0P5NR7WIDIS!=>0X1W:E#<;\SM419]$^T:NN=J7,>;MT9>%J:6"I8)]P;?6U
M9:M 76).$G35T"FR5!#H<X%#'3;GRJ[I?7%RL,R?"OSJG"TA?!W@RH.#<)SX
M&L>1JG5[EI<D3X/?P9*^(%U@@('@",8]?QK:M$SK-J>WN0V8:8,Z.05< XLY
MQE0)Z[?"IB^"(P'8+Q6YWS&4$K"UIW_LD[@G'(UR_7EP>;[BV+E(6EEO)0D[
M(!X=L9]T[<LGE4KH.:\RU[=<YBT-#"6>_6??P@X SZ[8ZUMFL9RM,:+98:0T
MX7UE&'$A0]X$YQD;UJ=J[-G;]IY5Q7<5B8OBX>-)(5CH>O/:H[0UFE2[VA<I
M!0S;E$ *3C*\XQGR._PKH-VT];;RVKVJ*@N9&%I]U0/J*TF7H.Z6]Y2[=)2^
MSC'=K5PJ(SL/A\*U_B:B+4S,86Q**%(<#C?%Q;G<'.VQ&_E63;FI]UAO6.U.
MQ$1'/])X7E<*E$8&,_IRJ+A2YEKN;TQMQ<=YI10E;" I/'O@ [C%=7TKK.XA
MI$74,60'W'DLIDA&$\1 *0KP._XBMH1,87,F-L)1,CND AE:3A6,$'<8VK#>
MTS;Y#<IZ3';C)5%,9!)!*$DY)SRSG-:]JC43EFL=OB6::F2I/"T T I2D@8W
M_NK4GM3:IM;$>Z2PM,>8HJ:63Q;9R2 <X'+PVKJ.C]4,ZEMI?X4MNI7PE/4C
MGG'QK4M=6RY:FOD=A#@CVECW52%GW>\.<[9\OQK)T7;;'IFVO,W.X6QR4X\5
MH<XTD<(V&":MSQIVZ:^]MFW-#L1$3A2"1W2CR*>+/7.<8K%O%JT1;I4&?"DM
MLK1+;4MMMW.1Q>?ASK<)>K-.2HKD43V'^]3W1;2>(D';&WK7)?Z+PX]M?E-R
M9B)[(+C8+8",IR2D$$GHK>NHRY5QE=G3!3Q)N,J,E .=\E.2<^.,_$UK.G].
MP](3HMZE^T\)C*4O*0OW]B2.'IC//%>M1ZST1>3%7*9>G.1U90 @I &=SOY#
ME5F^N:5E:6<GVU38CAP(,8)X2H[9X1SSCX5.7"W6&W]FBU1&FA$6RE:7%@<2
MB3S)\:XK8+@JTZ@@SFV^\4PX"$ ;J'+'QKZA4H*$4JVXE#8CG[M91.YSN,;U
M%K0?M*<?&.V-SX%52J?NCTJM*5J>M[M?+3:XZK!#$J6Y("% HXRA',D)R"H^
ME9>D[TG46FH=S0X'%.!25J[LM^\"0H<)Y'(\Z]IU/;#>5VDN.)EID>S\/ <%
M?=A>WEPFE\U;8=,J91>;FU#4]NV',GB V/(&HW_.-IGCDE=P+;;#B6N]4VHI
M65)X\IQG( QDXVK;1A0XAR(SD=:U%=^NS/:6BQ/M1DVU^ N0RI!/>*4DX/$>
M0J*UGJ.[V*^P9$.XQ/L[VJ.Q)C!M*BE+BB"MQ1.4CD$X'C41#UW>W>T=V))=
M[JSINB[8EM+23Q*""0?[8)QG/*NMC8[&M;UM,%NTI*D*O M+:"CCE!/$I*>(
M A(_M'D#XFM)7<M2.]E41U=]C1;E(FAIJ7(D)0KN23PI4M.4I<( S6SZ!U(S
M=-)Q%ONN)DJ==82)#X<4\IO[Q0K;C3YBM8TUJ)U7::N*Q?95S@2XKKA"E<?
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M7CT.U;8C6=UU>7;+!:8CON!3@DE1]Q"59 (\>7SK779TMIC^D<BZ1UW1IWN
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MU1&%8(9("$]0!G\J^AU+#4<N*!PA&2,>'ZUS;4$Z#J"\XEVN\NM1T#NV4,<
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M^?X5#:2MLAB;>+G+:+3DR1[H6?>X$[#]:UVV"'[9JG41=0[,:=<:;3Q \(
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M%( Y@ 8Y?7]U<TC6V:SV@O3KDAI$>4]PMKXP4\*<^Z? [ X\16SIAV>YB?\
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M#F<"I^/*M^I[4F%$;]J:?)2MPH(#2>O/)!\*A^T!BR0$V)B4G"6#P-#N^+*
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MJ%K@VCV<3[G,3&;>DIXFVAPE140-R<)J!.J=33-%KF15P&+E#E2(\Q9;+J7
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M$^F!7JL:5+CQ4H,AY#8<6&T<7\RCR \ZYDFXZI5VRPO;84YFUK;D,M-I(+7
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M7":ARY/$<JD,J7E"2.6!BN^Z7DP86D;<M4EEM#C065*<VXU;JQGS)K84J2I
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MH4V E16%( !\1OUQSK"U/IH7K[0FKGO-N,E02T&24KZ@$YQG>MBTZZ[HW0$
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MIK4A9[IP%/NLM(QC;<E59MJLLB=K/4TB+-N,1B*V8;96\M:5O+'$IP ]$Y
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M_&#BD)?2Z&^(#;."?*H>TZ>U-$O#*[H]+0W(=4D-M2$J/W2KJ?+PK9+A;[M
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M/?MA9X>AVS\N7PJ(NNM;):;PU;)<@AY8R2!E*,\N+'+/Y5F7G4UJL,1F1.D
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M?X;;?W0/HUF5'"3;3<DL%Z(9Z$82CB3WH3UP.8'E6/'58C=Y*8PMWVF1_'X
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M7NSRV7X3'>P< ND)RH'.^?#;'2M0O\V%J&;"%A@.HF=X5K6EOA(SCP_,UUM
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M;6B1Q*2F,D#"D@!>_GD;YKK>=S@<CRQ]>-:-VEZ=O>H[$&;5-<1W*DN^RMI
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M*ZPM""%I((*<@9VY?6:X'?HC.B]5Q&(=P=DF,X'71P;(41X9WVKHNGY]BO\
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MTA:U,.)5P1T-JQC(4$@$?A4]MML!M@9\*L/-\4AA2<#"R5$>A%8UE^[+V/\
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MDUL%*4I2E*4I2E*4I2E*4I2E0=Z>FNNL6Z"ONGGR2M[ )0@8R1Y[@?.N>]I
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MHY5Z'9E=E _Z5$ V.,J_050=FMR2I 1)845;9&< ^9QXBL@=F%R4VD>VQ\Y
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M=6I'(J'C6T#ED?';G51]>=4.<Y'0>%:W(T99I&H&[R\V\I]#H?[M3ZNZ+@&
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MSC*I+RG2H)0@$#^4'&=]SL,5>U3KBY6-FWS(%LBR[;(0VM3RY.%.*6H -M)
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M@+QOPY(SS\^M>^U"\,79%N*.[*FRO*FG.,$$)Y;\MSTK-[.K-9'[:]/N92Z
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MMLT"$\7VPLCG_P!U=_\ ]:B;AVH]EEWD,/W!:93T97$TIVWN**#_ .7\*/\
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M \(>/UJG^>-LC#>C=4*('2&/WH.V GW4Z&U21C8>QC]Z\L]J_<,AMC0.J&T
M;)3!  _&O8[7)1XL:!U4<<O]#J@[6YA/N=G^J3ZQ#7K_ #IW0JPCL]U*1GF8
MV*'M/O&<)[.]18Y[L8KU_G*OYW3V=7\^J *\GM#U6K9OLYNPZ#B6$BG].=;K
M!#?9O*.3OQRT@?'(JX-8=HRMQV<IW\;F@?I3^E?:22<=G;/QNB/VH-5=IAY=
MGT9/K=$57^DW:<O8Z!AX\[FB@U%VGY.-#P$@[_\ I)->?Z0=J./]2K;_ /\
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M-\9J9]LC<)R^UD[;+%47,B@?]Y;VW/O?7A5I=UMZ?O36$D\_X@Y_6*\_;5L
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M'2MKNSC"]N$YY;^=4==CQVPIUQMM)(2%+P 2>0SRWKTZ['82%.J;0DD)!40
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M\ZO(2<@JP=ML#;I7L)'5*=_+G5"!P\AMY>5:!<.RV+/G/2'+F\E+KI<[L)
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M22HXWX0.+& ?[JF188]RG0YL8*:3;4]W%XT9XMM\@\QC'QS69]ERTM*0VVA
M(.R)BPD9\L>=8D;L^TZS&2AV%WKA&7%EU7O*QN3O64WHC3[*N)FW\"MR"'%
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MV%L8;2!Q8 ',;GUJY7D[J^%<YUQIK46H+Q#8@Q(HA-RF9(F%[A4@HQD.(_\
M$\O"KE^T_J2ZZPM[K,>$BWQ)[<QN4E?"H #"DK;_ )E= KI6/J/L[F_TFCZ@
MTJ^B!+]Y+R,X!*E<2E^>_,=<UT="2$CB(*\ *(Z_6]7-_6L269N&?8TLJ)=
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M[JW1QQ)*#A/\IZ?X5BR+'IBW,E<BW0D(&^5H'I6-:E:3ON?8HL%XM8206 ,
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M#2K%LF0WYTGO)/>\'=M,E:4GB"<\1VV)'RKJ%OTG"@2TRT/2''DY5E2AOGR
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MGO&FU?=&1@G&P.=_A6W,Z5TK?8D>0TVB4PTV64+2Z2"-\Y\\[YK(:T3IN$P
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MG($!:5)82#W3J<9'0X//%7)6H+?&CJ8LCL!^6@\/LZ' "<#D,=169IRX3[I
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M1 41@@)SX5MLV]62'H[[$7"GMH#'<AQ<3&#CGOCK7,+<]'M;ZF[I"<=B.*!
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M<6T\KB3G;<D5TF/88.I=(VM4F;-+:6 LE#^"HD;\1ZUS:5V?/RY4AV&LMP>
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M#4JV-IC26QA*0,)6-MCX>OG4]V>S+S,TZ[%FLML-PPJ,VXG[V4C'+&"!XYJ
M&C[RC4-JN<:Y!\A!4COT[(*4\L#Q\OQJ"O[5TOEU(DP >%2''BQQ+4L\(&Y
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MXSO6%_FQ@EKW9\H)3G;(JIT1;K%(C7!EZ0M:)#8]\@@@J QR\ZW9* @^Z@#
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M*3X]<;YJ>P2#OCKO5,85L,<.PVWZ?7^-$\((XB-A\J ['R\M\_XXKV0"=@"
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M:HT^S>5Q&+6PI5T<D/A7  !P!PX*STK9KS%O+&FK=I*V-MO2WHO#(=*L!M
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M(XN\CAX-_P!K;.!419M9QKIIZ1='F_90TX6U(SQ'.V#MZBHI[0MLNSCUPO\
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M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4JVZZVPVIQU:4(3S4HX
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MIM4?<64]]%< RI+@Q@>)'U\*D^I.WPZ5&W,$S+61L!))/_D54E@]#R\:P9^
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M*MNF/K1<'W4!94%MM)".9X<K./4;5S>^LKN&LU.MOEHNN<#:WVW4J:)'#A)
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M=<;1(_B*"B,IYCU\15%)E*<44^U(3G9/N8%7!;@DJ5WKQ*SQ*RYC?&/VJVJ
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8E*4I2E*4I2E*4I2E*4I2E*4I2E*4K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,I BT# 2(  A$! Q$!_\0
M'  !  (# 0$!              ,% 0($!@<(_\0 61   0," P0#" P+! @&
M P$! 0 " P01!1(A!A,Q02)1810C,C9Q<H&1%3-"4E-B<Y*QLK/1!Q8F-&65
MH:/!T^$D5&.3-59T@J+2XO 7&"5#590W1/&#PO_$ !H! 0$! 0$! 0
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M#?A<3_6E3_,5VB"D_%7#?A<3_6E3_,3\5<-^%Q/]:5/\Q7:(*3\5<-^%Q/\
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M#?A<3_6E3_,5VB"D_%7#?A<3_6E3_,3\5<-^%Q/]:5/\Q7:(*3\5<-^%Q/\
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M#?A<3_6E3_,5VB"D_%7#?A<3_6E3_,3\5<-^%Q/]:5/\Q7:(*3\5<-^%Q/\
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M;*>+D/RL_P!J]7:I-E/%R'Y6?[5Z"[1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M,IR"S*XNMPT!NTW"RPND1$!$1 1$04F(^->!^94_5:KM4F(^->!^94_5:KM
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M4CV#$9';P6W+1;,+#I%61D8TV<]H/:564A:,3>PM O"TMO;74\/^^:M,H/$
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M[A<]H'+FK7I6-PV_+5<U7O#1DO:S,US2"";@YAP0:25+V3/9O9GEIL[=TCG
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M=JDV4\7(?E9_M7H+M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MBSRC>,T?;PNP*1DL<E\CVNMQL;V055=A<LE8)X)8F.D>TG>1EV1X&CVV(UL
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M7"SFG4<>OL]"L\S>L>M1RN;N7ZCP3S0<F&4/<-,YKI ][R"XAM@ &AH '4
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MW\(7ZUN9RYVF<J^OPJ@%4U\='1-(XVC/#3C_ $4M?A]&::*U)1%V6WM9/,\
M?XKJQ"&H=41D,<07="\QXZ<--/*LXA!.:-O0>0!T[SD@:]5M>2B9<])0T5/3
M4X;2T;;3#E8:M-[EWIX<[+JEIZ2:NI'PP4<CPV0.:ZW#2W 'G]*P Z"EINZ"
M([S-RF24N%LIORTTOHI624SJFFR27=9][$]B(UI:"D,;Z2HH:8NC: YS6@AP
M/H!6T&&T#:VH:VAIP &6[T--%F..BD=5/D;&ZTNKW#6V4<U!15M!+4U+H)-W
M$"&VR.C!<-#I87\J#O9AU$PO+:2 9_"[V-5B6@HWQ@.HX'!AS-;NQQ"T;7TF
M]RB22P)&<AV2XL;7X<_V%9EKJ5K'$5&KM!8G0_P03]S4_P#=XOF!:BBI&FXI
M8 1P.["ADK:..,O,[G 6T:7$ZFW!;1UM*Z/VUS+G5LEVN'EZD&XHZ7>%W<L(
M<.>[&MUL:6F((-/$0=#T H&5M)("[N@@'@"X@K$=?1R$VEE:!>Q>'-!L2-+\
M>'[0@YZVFC94,W0BB+8V@7: WP^8MKHJV7V1I89'T[*>IJ"(P2R%KA:[KZ6O
M=7L+X:C%8G,?G#6C4$V!N5<[D>^?\\IENL/)X0ZJF?'+BM/'$ULA&3N4-!&0
MZWMUJ^C?A08!NH&VTMNOZ+O;&&WU=KUN)6D3,T-BY_$ZYC?B5&W*'84"2(X+
MGCWK^BC9'13U[#'!$YK8W7[WH#=O9Y58;D>^D^>5@L[\P9G6#3IF.O!0:"AI
M 212PZ\>]A8DHJ7(2:2%V74#=A3&,$WS/%^IQ6KF9(WN#G7#3:[B4&HHZ4@'
MN:'_ "PL"AI&BPI80/DPI&QC):[M>)S&Z;D>^D^>4'*RG@CQ%X9#&T&$$@-
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M@(B("(B".7P#Y1]*Y*G?M?F?)%NK/L,A!&FFMUU2^U&_6/I7+454+I-T''.
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M<"T@?P0>>91;RKGI75$A9 6AIRM!X=8'D7+B37/PL$N\%I;F$3>3B!KRX?\
M=U9PTS3/7]\ES.F+"[-K;*/O*J<0@!PJ(7:XQQE@+VESC9Q%[\.7-:<IVZX8
MR(J=A<6[R4-S;IK3X#CZ=1Q73-#+3M;)'.XN$C!9S6V(+@#RZB5P"GA%/3MF
M<UL+JAN?*71B^4Y>?'-;@NJII:4;AS)G[X3,,=ZAQUS"^E_>W1'%5QN]E:<
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MFN_@I%&[\XC\UW\$'B:_9&OQ7:RNQ1]124S6;ME))-0LJ7%H8TN(+ST.E?0
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MI=/>Y]^YQ)]:Y-I,,IL1=AYK:YU+2T\YDD#:AT!EO&]H:'M<TBQ(=QY*MV%
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M7O\ 9JDQFCHZB'&JTU<N_O#*XMS;O(RX.5K1X>?EPLNP8/AK<4?B8H*<U[P
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M3.:RSHG$D@W-R2=3?CZ4%5B\NU5+B-%'1UN'O@JZPP]+#I'&!F1[PYQ$MCX
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MZ(.'&Z>>LP.JIZ=\C9I([-,9LX]E[BU^'$<>*\]LL^4XU,*F2J9-)#(71R>
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MX?#:W*;EO:@X=EL7J\7I:N2KEHI'15!8WN1V8-&4.RN-R"X7L2W1>:HY]_\
MA1EIO9*JFEIG22.B=.U\,0<T@-#,]PZSAH&WL"3:ZO=B:FCJ<.K'4E545+6U
M-G.FC8P AK0,@9T<M@+65'A=2/\ Q4Q6EAJI"ZQ<Z"*6/<M.4:N#B7E_.S
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MG CO//YRVW=9_>(_\G_J4DA(>P.8"VXL;Z@^19S2_!L^?_1!%NZS^\1_Y/\
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MNGIZ+V'FK74C1-O1(Q@!?O&BV8B^F;LU7LE\SJZ+#I9*:2LIY9IGPL,9DM%
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MO9'R%K#F<_,Z[LI:"";@@MY+KVKK<'HL/IFXY215--/4B-HE:S*QV5SB\EQ
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ME-M.*VW\1-LX4>_AE;(UDK;M;J0>':@WWW^%)ZED2= NR/TY6U6IJ(6M),@
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MC@"'=$Z=:!O0R%SR'Y6#735:QU39"0V.6XX@LLMQ+&Z.^891Q6&RP-\%S1Y
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M^5_Z#_>I^5_Z#_>J_1!0?E?^@_WJ?E?^@_WJOT04'Y7_ *#_ 'J?E?\ H/\
M>J_1!0?E?^@_WJ?E?^@_WJOT04'Y7_H/]ZGY7_H/]ZK]$%!^5_Z#_>I^5_Z#
M_>J_1!0?E?\ H/\ >I^5_P"@_P!ZK]$%!^5_Z#_>I^5_Z#_>J_1!0?E?^@_W
MJ?E?^@_WJOT04'Y7_H/]ZGY7_H/]ZK]$%!^5_P"@_P!ZGY7_ *#_ 'JOT04'
MY7_H/]ZGY7_H/]ZK]$%!^5_Z#_>I^5_Z#_>J_1!0?E?^@_WJ?E?^@_WJOT04
M'Y7_ *#_ 'J?E?\ H/\ >J_1!0?E?^@_WJ?E?^@_WJOT04'Y7_H/]ZGY7_H/
E]ZK]$'G:;#\;J,<HZ[%),.$5*R0-;2A^9Q> -<W+1>B1$'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_2a.jpg
<TEXT>
begin 644 image_2a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,( B<# 2(  A$! Q$!_\0
M&P   @,! 0$               4#! 8" 0?_Q !<$  ! @0# @D'" 8'!0<#
M @<! @, ! 41!A(A$S$4%18B05%5E-)45F&3E='3(S(V4G&1DK(S-$)R@;,D
M4W1UH:.Q!T-B<^,E-41%8X+P9:+!%R:#X4;"P^+Q_\0 &@$! 0$! 0$!
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MEZQ2Y:HR96J6F6PXTI:2DJ2=QL==1K 7X((( @@@@"""" (((( @@@@""""
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MLK*R@09Q#*@Y-C:);+JFR5(MS"2G3?OZXC1CHS,D'&)!+;CI^24^^$H +2G
M2;?.YMLMM3N,/FZI1W*4*H[L&)5]>JWT)25J"B!?K-P;;XE;F:0ZZJ595)..
M9!,EI"4FXT(78"W2+'TQ<?4Q>>UB)ZOS7$N'GW9QJGHJ+6UFYY;8*6K-9[)!
MYH*C>U^H],4J7C2>4E]ZH,2JY&70VI<PRO*5-EY;9?"=>;S0; _QUT>,8BHU
M00)9*4J4IAM]J5=;2-JE2"M(2#I>PW=$6N+*55*2A"95*)292EPH:&RSI5SL
MJLMM#TIZ8F)]I2(O:<ULMTZ9<G:;+S3K!84^V'-D59B@'4 GKM:'6$O^Y7/[
M9,_SEPNO86 L - (883_ .Y5_P!LF?YRXX\1\CQ?:^8T:Y\N\5U-^BX8GJC+
MJ;2ZPE*@IP72+K2#?^!,+ZIC63DZS39*3,M/-SCK;:G69D'9YW V#H"#K?I&
MZ+3N():8K#U(33)R<:;>1+3,PAE*V6G%)"@E>MR+$7-B!<7CE%6PDVPMYN;I
M26I9T-%2$HLVLDV L-Y*3NWD>B/+$1CUA\&(Q'K#//\ ^TM<M)M33M*90AYG
M;MA4Z I:"Z&@$C+SE7N2!N !OK:)/_U("I:;>:I#A#+J4HS/ 9@5K1J+7"@6
MR;)"M#Z#$U0G,$5N=2)R=:(IJ6G1D=4AE25_*)T&BAS<QT^W2'$Q6<-2Z9KA
MKE/:;4]E=4Z$97E!"7+FU[V2L&YZ[[M8N(\-8CPBPUB.8KU4J;:VY=,HTU+/
M2RFW"I2DNMY[D$#3J,-:_P#1NJ?V1W\AB!RMT"3?FBY/R++DNA(?.9(*$W
M)Z@2!;HN.N.ZTZA["U1=:4%-KDG%)4-Q!02#$]V)^;LMX+^B$A]B_P ZH?P@
MP7]$)#[%_G5#^/6]X@@@@/(PV*W5L8TH#B)=V84E*[-,VS*^RY _QC=1A,73
M"I/%]&F4-*=<;:=*&TBY6JQRC^)L(Q:L6K-9]PZXWF_-ZK?<S\2#C>;\WJM]
MS/Q(2R5=K\FPB1FI1YR<80[<OL%2II8&9"$J;.1)((YVHTMOO:LG$.)7F91]
MUE" ZTZ"Q+R[G/6EQO+SC\PY5*T-QS3_  \GW?H_5K?+1\;S?F]5ON9^)!QO
M-^;U6^YGXD4E56JSN%GG&$."I3#@8;0Q+J0J7)MF'RAL2@9N=HDD"*R<0UAQ
MMEE<FXRZ&V,[:I=>=Q>T"'2%#FI";'36X-P;6O/N_1^IODVXWF_-ZK?<S\2#
MC>;\WJM]S/Q(JX5J-2J<[4WI\+0D!D-M%E;:6E65F1SOG$&P*AH8U4/N_1^I
MOEG^-YOS>JWW,_$@XWG/-^K?<S\2-!!#[OT?J;Y?,44"::E)ZGM2^($4J8:F
M&VY)*)8):+]RHE6>Z[%2BD'=?IBI-8,3.3STTJFUP;5XK6T4,%&526@4@;7I
MV*3?TG3='UF".\</6)SF4R^6-822V$@4JM$I*CFV<O<WFQ,[]I]9.7[(\:PK
M,RS:FY26KS"7)=++I#$HI2LNTR*25+.4C:'=U#=K?ZI!#D5\R9?-J%0GJ).,
MS2:76W7&E3"[*0P 2]L\W^])TV0MKTZQJ>-YOS>JWW,_$C001ROP>G><VRNZ
M6?XWF_-ZK?<S\2#C>;\WJM]S/Q(T$$9^[]'ZF^6?XWF_-ZK?<S\2#C>;\WJM
M]S/Q(T$$/N_1^IOEG^-YOS>JWW,_$@XWF_-ZK?<S\2-!!#[OT?J;Y9MVJS98
M<')^JCFGH9ZO^9""A/SW)ZF9:%4EIX(U92=C8\P:B[D;]_\ 5G?W#_I"[#/T
M4I']B9_((Z5X/3K&(;IK6IV9.K2LU6*8[(3%!JP9=*<V787YJ@JVKENB$M0P
M>FH"90*+6Y9B8=4ZXQ+B62W<H2C1.>VF0$'K)ZX^F5<SB:/.FG"\Z&%[ :?/
MRG+OTW]<9EFH5*6=D6J8Q4GI9PI*C/R[JG%J*@%I4I5MF$I)4"18FX&ZT=*\
M/6O;*SKVGNRW)&<<EIIA]G$CZ9I_;O*6)3,M5BD@D*U%C8 W RBVZ+*,-O,M
M(V-+KS;K;[#[;J>#%25-,AD:%=B"B][CITM#*=GL8.TEX+0I2G)4*M+R:T.(
M6II2[ YCJE2 FW3GZ-(:.35<FJ%*.Y'TS/"G4J+3*FE+:"' A2D'5-R$&QZ;
M1KDQYE.=;P6T>3FJ+1Y6F2U JZF)9&S07"P5$7)U^4],08C?G^3LZ%T*I-I*
M1SE;&PYPZG(WE,VW%,GPC/M]@C:9_G9LHO?TWA?B_P"BD_\ NI_,(QTVGG<U
MU%\8*%3-0*B>3]4U/_H_$BC49%ZJ+DE36'*FXF4?VZ6U)EU)6<BDV4"X;BRB
M?M CZ%&7KU4K,G.J1(,+4VEC.C+*+>VBKD*!*39.464!O5>PB1PM(G,+/$WF
M,,2,'N-N2BV:=7VN!JSL)3P;*VK.M=P,^FKA&G4GJB%&"'Q+,2[LMB-]ME9<
M2'."ZJ*TK*E65SE%21=1UL2+QKEU/%*Y;.PR!E944J7)JNZK:Y$J*2H%/,YY
M3O\ LB.:K.)V!.(:EE.J9402)!?0L!.0WLLK3=70$G0D;XZ<J/,L<V?!!.83
M<G)4L&E5YI*FYEIPH,M=;;[FT6DW6;658@C72-$AVH(;2@8>JEDI"1^AZ/\
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M2'"2P%)V;2&TE)"]]FTG6^OHTB2FTQ=.J@J1I-=?G27E.NNB7&U4[LP20E8
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M1):>89;;4N:=EU@KVB3D2X;I4+9@2@:]5X">1Q/AZ4D)>6XYEE;%I+>:Y%[
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M>;9F9],RTENH!!*0V$'4)YBK@*-@JX*AZ8GDU,"6J")FKX>$P^PW*MOLS:0
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MGD5CA;33U0H/"EI4&TJE%YU)_:L"[<CKM'37'2WG66:E0U/,A*7$(E5E2!O
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M4HPE3S2'" V+ D PMQ=)RJ<*SZDRS((2G4-CZPB5M6)$-I0W)49*$@!(3,N
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M+KL.N(>),8(,JD5>8+:7&W'K.I4LJL =2 ,FFJ>G->T3_P#[)V+C@I32P@I
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MEE+H06P2D*%[1=Y(8=[&D_5" =0G?^F5//\ ]/F?YC$<\D,.]C2?JA"A["U
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M9S<]*;E*S?4<Z^\VCRF-XIJ"VN&!]Z2"Y-YMU\(0I12X@K5E%BFZ<QRD:>F
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M7]2;[_,>./>.9CS?K'JVOB0<<S'F_6/5M?$@/.35+^I-]_F/'!R:I?U)OO\
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M[XW](<F1IJYQ;ZV:N1MU/MIXG<YA4XTX=<FNK5OL48YIDE3952E3,M6%DJ>
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M2'D,MZI/NA/ARG22I&:*I*7-JA-@7:3NVZ_1 7W*Y17&EHXXD1=)%Q,HN/\
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MV.^]HC;I>)92<8X+,N%LU(OS#CDX%!;2E() 3N R[06Z#:PUN T9Y4I%RJC
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M<(5-)NEM3C2[+%N>FR7!;HT^T6*M0I^:J$\^P&E(=<6M +P!-TRH ]'Z%?\
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MS$JA@):65-+*5;1%RF_3D4[H;_-'H$67I;%S;+P2\Y,N(65,*<2T"DCA"0=
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MKU8\EJ)Y#_GN>*#DM1/(?\]SQ0'.&I6KR<Y/BI-@-S2N%(4EXK"%J)S(UW6
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M4LH-+3,'FMA8OENGY12NC<%6N!'M#FJTK$;3<XJ9F9?8H2'<BVD9=DDEPI*
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M"ON;)7R*5R0LVBSED;M;;51N;G=KON%\<3*GV)-.**BI;X7LUBH@I4I*DI*
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MH\L7W;X:\I$]CUGN9A50,0):DYD<5596:=FE73*$C5Y9M]L T.'$I22:U60
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MWF^L-\8?12?_ '4_F$1\75+SDJ/J9?X45I^@3E1D791_$=2+3@ 5\E+]!O\
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MV92@SLOG"VEM8A5)44[1HX@8VCS1S*X&M+BCLBT38#YHS [M_P!L?6[0G?\
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M?3'U:/(LZ=9]F*\7JU[2^5&8I3\[,2[=9RJEFY8(?<EUG:6:<;5=( L;+O\
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MR8F'Y=I5YZ8E0AL"YR%83J38$E(N3IK''+"2X&MQ4F6G@ -FI2%<XN.M]!U
M+2CH=Q$=&F5-3CSAIF&RM^^U5LUW<N"#F.770G?UF(Y>C5"7;::;IF'<K!66
M<R7%%O,HJ4$DIT%R=! 3TC$(JM;;E$2K:);@SBRX<MUN)4V" D$E(&<C7?I:
M-/L6OZM'X1&8:E*U+S"YEF1P^V^M(2IU"7$J4!:P)";D:#[HM[?$_P!6C?B=
M]T \V+7]6C\(@V+7]6C\(A'M\3_5HWXG?=!M\3_5HWXG?= /-BU_5H_"(-BU
M_5H_"(1[?$_U:-^)WW0;?$_U:-^)WW0#S8M?U:/PB#8M?U:/PB$>WQ/]6C?B
M=]T&WQ/]6C?B=]T \V+7]6C\(@V+7]6C\(A'M\3_ %:-^)WW0;?$_P!6C?B=
M]T \V+7]6C\(@V+7]6C\(A'M\3_5HWXG?=!M\3_5HWXG?= /-BU_5H_"(-BU
M_5H_"(1[?$_U:-^)WW0;?$_U:-^)WW0#A]IK@SOR:/F']D=4+\,M-G"E');1
M^HL_LCZ@BLM>)UH4@BC64"/G.^Z*U.9Q-3J9*2*31UIEF4,A1+H*@E(%]WH@
M&5>G.*Z9PAEIDN*>:927=$(*UA&97H&:\*GL3(IKSS,_*)<1*H09F<9"4M!2
M@HI 225:Y;?:H"++R<13+"V7V:&ZTL95H675)4.H@C413=I=5>DC)JD* )<E
M!+;8=2DY%!200$[@1N@.9K&DC)-3#DS3UMAL$)S+;&9:5I0M)UYME+&IT(!,
M12^.6)DJ0BA3P="6N:M"4C:+4V WF)L#\JD[^OJU[GZ'4:DR\W,R-#N^I*G7
M&RZA:RG5)*@+FUAOO'4I2:I)-MI8I] 26T);2M6U4O*DW *BFYL0#]H@-#2Y
MJ7JM*EI]IC(B8;#@0M(NF_0;10Q>TV,*3Y#:/FI_9'UA$;)Q&RTEMINAMMI%
MDI270 /0+16JLKB6JTQ^1<51VTN@ J!=)%B#U>B U.Q:_JT?A$&Q:_JT?A$(
M]OB?ZM&_$[[H-OB?ZM&_$[[H!YL6OZM'X1!L6OZM'X1"/;XG^K1OQ.^Z#;XG
M^K1OQ.^Z >;%K^K1^$0;%K^K1^$0CV^)_JT;\3ON@V^)_JT;\3ON@/:\TV)N
MAV;1K4D_LC^J<AWL6OZM'X1&7G9;$D\[)+6JCI,K,!](!=.8A*DVW?\ %_A%
MS;XG^K1OQ.^Z >;%K^K1^$0;)K^K1^$0CV^)_JT;\3ON@V^)_JT;\3ON@+E#
MFD52AR4\MIH.3#"'%I0+A)*02/\ &&&Q:_JT?A$9J4EJW3VUMR4GA^70I692
M64N(!/60$[XL[?$_U:-^)WW0#S8M?U:/PB%#[3?+&0&S1;@$S^R/ZQB(MOB?
MZM&_$[[HHNMXA35&*@X[14%IEQ@)4MT YU(5>Y&_F?XP&JV+7]6C\(CE;*=F
M<B&PNQRDHN 81IF,2K0%)XD4DZ@A;I!_PCE<WB1LI"S1$YU94W6Z+GJ&F^ I
M2M9J($@J9:IRF)FH+E0ZVA2,Z E5E)22=ZD*Z=UM-83+_P!HK0I4S-H;D014
M$LLA9("6"E"BI?4NRCIUD=1AXY+51XLLO26&G#+\]E"TK);]*04Z?:(L*1B!
M8<"I>AJ"R%+!VIS$6L3S=3H/N$!H0TT0"&T'_P!HCW8M?U:/PB$7",3]5%_$
M[[H]V^)_JT;\3ON@8>TYIOE96QLT:-2W[(ZEP[V+7]6C\(C%R;V($8EK!_['
M2O9RV<J6X$[EVMI#5,UB12U(2JB%:?G)#CI(^T6T@'^Q:_JT?A$59X!F0?=:
M7+LJ;05;1YO,A(&I) ()%K],*#/XA00%.4$7-A=YP7/5NWP+<Q#,LN-+30G6
MS="TE3J@>L$6_P (+ME2E\134NE*ZO*R;:>*U3RDL).TN%#3*;VT4--=>F*%
M.QR)QV@2[B*>'I]YQN9+:B4)LIQ*0V?VB2C7T?:(:N-UAN:XP=E<.IF4(R<)
M4' M*>K-EN!KNOTQ,$8A 2!+T,!"RM(^5YJC>Y'-T.IU])@C1;)K^K1^$0;%
MK^K1^$0CVV)_JT;\3ON@V^)_JT;\3ON@'FQ:_JT?A$)\.--F0F[MH_[PF_V1
M_7KB/;XG^K1OQ.^Z%5!=Q'P*9V2:1;ATU?,IW?MEWZ-UX#0UN<;H]#G:B)9+
MIEF5.!L#YQ W1D9G&C\K*//F6E752*0J;9+1:<<*G"C*V,RK%-KDW4#?HA^X
MK$CK:FW&Z(I"A925%T@CJ.D5D2%6:V&SI^'4<'!#.5M8V8._+S=+]-H!:<63
MS,RY++8ISJY=25N+:!ROH46A9O4V4-KKOW#09M+E4QG)4RLS=-33EOJE4)4Z
MXE2  I67*FV_7.D#34W'1$K=/JS264MT[#J$RZBMD);6 VH[RGFZ$^B*3F&Y
MY^JO5)Z1HKLP\/E ZX\I"M +Y2+;@/N@'F'ZLW7%3;R&T"6&Q6Q=%E97&4.<
M[T\Z)\1--C#%6(;1^I/?L_\  87LHQ!*IRL2]";!L+(VJ=PL-R>@ #[!%6N.
MXC.'JF'DTC9<$=SY%.YK9#>UQO@&>"_HE(_8O\ZH?0AP9]$9#[%_G5#Z (((
M( C$XE6AK'>'EN+2A "[J4; ;^F-M'S_ !N]+2V)J2_.2Z9B7::<6MI2 H+W
MV%CIOM :SATEY;*^N3[X.'27ELKZY/OC.K<I:*2]-+PO([66G!*S#2$-E*#F
M S!12+CG [@=>B.43=#X]<IC^'I&6*'PV'7F4)"TFX"A=.I)   WWO?0B TG
M#I+RV5]<GWP<.DO+97UR??&6JLS(TN;G6EX5I2VI<L!+@(NO;+*$W2&B1:Q)
MM?HM?HMR#E G:\:4:)34O"62\5!I!YQ *D92D*T"TFY O?<+0#[ATEY;*^N3
M[X.'27ELKZY/OA%3)G"U2G$2;='E4OK05@\!&S) !RA12+FQ!M"]-7H:IPRG
M):3VX0H9=FW;;![9;+YN_P#:OU0&MX=)>6ROKD^^#ATEY;*^N3[XRZ:UA!;B
M,E%ERP$OE]_@2,DOLDI4K/IU+!TZXNTF8PK6GFFY&CR[A<;+A49%(2@!13SC
M:P-TFW7: =\.DO+97UR??!PZ2\ME?7)]\=<GJ+V/3^[(]T')ZB]CT_NR/= <
M\.DO+97UR??!PZ2\ME?7)]\=<GJ+V/3^[(]T')ZB]CT_NR/= <\.DO+97UR?
M?!PZ2\ME?7)]\=<GJ+V/3^[(]T')ZB]CT_NR/= <\.DO+97UR??!PZ2\ME?7
M)]\=<GJ+V/3^[(]T')ZB]CT_NR/= <\.DO+97UR??!PZ2\ME?7)]\=<GJ+V/
M3^[(]T')ZB]CT_NR/= <\.DO+97UR??!PZ2\ME?7)]\=<GJ+V/3^[(]T')ZB
M]CT_NR/= <\.DO+97UR??!PZ3\MEO7)]\<O8?HHEW"*/3[A!_P##(ZOLA?AR
MA4=S"])6NDR"E*DF2299!).0>B 9<.DO+97UR??!PZ2\ME?7)]\*JA)4V6J$
MK)2>':=,S#Z%NV6VAM*$(*0HDY3K=:0!;[HJIG\)K6E"*.RXMQU+;24TX$N9
MLUE)TU1S%<[T>D0#_ATEY;*^N3[X.'27ELKZY/OC/R]0PC,%HIH[24.I"TK7
M3@  J^2_-TS93EZ_XB_#52PDZI!%)E$H<EN$-DR2;J *A:V7><IL+W.NFD!H
M^'27ELKZY/O@X=)G=.RWKD^^%5%5A.OKFDT^FR+G!E!#A,FD#6]B#;4&Q^Z(
M\64.CM87GEMTJ12H)38B60".</1 .>'27ELKZY/O@X=)>6ROKD^^.N3U%['I
M_=D>Z#D]1>QZ?W9'N@.>'27ELKZY/O@X=)>6ROKD^^.N3U%['I_=D>Z#D]1>
MQZ?W9'N@.>'27ELKZY/O@X=)>6ROKD^^.N3U%['I_=D>Z#D]1>QZ?W9'N@.>
M'2?ELMZY/O@X=)>6ROKD^^$]<H5'1-40(I,@G-4$I5:61J-DYINAUR>HO8]/
M[LCW0'/#I+RV5]<GWP<.DO+97UR??'7)ZB]CT_NR/=!R>HG8]/[LCW0'/#I+
MRV5]<GWP<.DO+97UR??%2E4VB5.DRD\*)(-\)92Z$&70<N87M>T7>3U%['I_
M=D>Z YX=)>6ROKD^^%>(6Y6K4&;DVYJ24ZM%D;1Y-@J_^$-.3]%['I_=D>Z%
M+U#H_*V0;%*D,AD9E13P9%B=HSKN])^^),9C#5+36T6CO'J1UNG3D\N<8EJK
M*MRBT$-($V$(",E@WD&@Y_.S=6D>(DZD_7&GYBH20D6GVW4-*G<Y2$W%]>FQ
MUZXV?$%$[(I_=D>Z/>(*)V1(=V1[HSRXSEWKQ=XKC$>.S(OR3_#)C93<C\M.
MI?,XF;"70U=.9O=<: C0VM$2T5)V<GPBK)5+MS*0R@SFS+K9!6H!8N192D@'
MJ1:-/4Z72I"ES,VU0)&84RV5AH,-IS6%SJ1I$LG2*+-23$QQ-()VK:5Y>#(T
MN ;;O3#9!'$VCO$3_9@Y<5YUV<9>JRL^5 #W" A"@E0S!)W9E"]B/3>Q,7F9
M&KH9=SX@2I;C;J+F>22-&]G;2P-PNY &^-KQ!1>R*?W9'N@Y/T7L>G]V1[HD
M:>/=NW&VGM6(_LPSZ'9UJK2BWY%Z=4S(YB9@!&9.8DA1N3N_QBXP'Z?/3S\J
MY*(3.K'-X0VLH<6KG.YK Y4C7*2;G=:&<A1*2K%-9;-*D2VAN6RI,NBPN%WZ
M(<\047=Q/(7_ +,CW1K9&<N<<1-8VXC'_P _9BY*@(32D4Z;FZ6\VJ?V[CNU
M&8M:*-KW(4I21?7<3K'+,D_1J+5N!SC*7'BTB60W,)6M*4FQ42D"Y()O8%5A
MO)C;\GZ+V3(=V1[H.3]%O_W3(=V1[HG+CV:CB]3/Q>L3.9C^[Y\9:L5"6ED.
MS["6.#I0XV_. J4H*!NH'IN+CT6!C?\ #Y(W/#9;7_UD^^%5?EZ11*:J>Y/2
M#X2H!2=BE)M]H0?\;#K(AJF@4120H4B0((N")9'NBUI%6-;7MJXB8B(C/;ZO
M>'27ELKZY/O@X=)>6ROKD^^.N3U%['I_=D>Z#D]1>QZ?W9'NC3@YX=)>6ROK
MD^^%.'IV3$C- SDL#QA-G5Y(_P!\OTPXY/47L>G]V1[H48?H=(<D9HKI4BHB
M?FD@F60= \L ;H!KPZ2\ME?7)]\'#I+RV5]<GWQUR>HO8]/[LCW0JKDC2Z53
MC-M8?IK]G$)6%,H39*E 7^:;G7= ,^'27ELKZY/O@X=)>6ROKD^^$=9?PQ0Z
MA+24Q1)=UZ9%TI:E&CE%P+F]M->B]M2;"(Z/,8?KL^TB3H<B)9R7<<S.2R M
M*T.!!38 BVN\& T'#I+RV5]<GWPNKT[)G#=4"9R6),FZ  \DD\P^F&?)ZB]C
MT_NR/="ROT*CMX;JCC=*D4K3)NJ2I,L@$$(-B-(";!?T1D/L7^=4/X0X,^B4
MC]B_SJA] $$$$ 1@L8-*>Q;164RK,V'&W$%AY>1"P00038VT]$;V,+BUR81B
MZBJDV]I,AIW8HZUV(%_0#J?0# 3NT2:>DC)KP[)%@VS)%8>!4<V:Y(;N3FUN
M3>+#DA4'WFWGL.TYQQMT/)6JIK)"@  ?T74!INA$JCX@8E&Y9;,RI4FD)0]+
MO!U2T\(8<NDN6NH)#@YP_9MK?6Q-2N,)ZEN)4\^A\H0EL(2T@I):7==^A>;*
M#T DVZX!R[+U5^84^[0*>IU1;45&I+U+9*D?[KH))_C'"9.HHFTS2<.4P3"7
M5/!T5%6;.H$$WV5SH2+;ON$+5.XR3-.6,P9(,-9$[!HO%/R>=5[Y=K^DYI!3
MN_C8X)7ETRO-[2HN/.NMN2P=6V@EHI1G0A2?FJ-ECJ!((ZX"Q*TZ?DG6W9;#
ME-;6V24$5->ETA)_W74 (\-+G#-*F3ABE[8S/"ROC%5]KDR9_P!%ORZ13107
MWZLB=89FY*1EI1.SEU+475*S/9D#Y2P!S)O??I8BVE*7I5?V$@T6)Q.S6K@Z
M]MEV)VP5F6G.;#9W2$W58"W3 7V,/.RS266<+TY+22HY15'"#F0$*!NWJ"E*
M18Z<T=47Y&5JM.452U!DDKR!LK757%J*02H E39.]1^^-1T00"7AF(NQI#VB
MKX4'#,1=C2'M%7PH=00"7AF(NQI#VBKX4'#,1=C2'M%7PH=00"7AF(NQI#VB
MKX4'#,1=C2'M%7PH=00"7AF(NQI#VBKX4'#,1=C2'M%7PH=00"7AF(NQI#VB
MKX4'#,1=C2'M%7PH=00"7AF(NQI#VBKX4'#,1=C2'M%7PH=00")^<Q#P=R]&
MD+93?_M%75_RH7X=FZ\,,TH-TB14V)-G*HU!0)&06-MEI&H>_5W?W#_I"[#/
MT4I']A9_((!7/2E5J2F3-4&16MA14VM-4<0I)(L=4M V/2-QB.6I,Y*/[=C#
M5.2X'=JD\9N'*KG;KM:#GJT&G..D6L02K[]0IRURDU.2"-H'699W(0X<N19&
M9-P %C?H2#;J7RIQ9,3B6YA;S#)F4AY>S:YJ1M,P;WW;-FM5#-J?38)$TB;0
M]+NIPW3@J7;2TU:J.62E((3ILK$@*-B=1?2.&Z),-(2E&&*=S'4.@JJCA.=*
ME+"B2W<G,M1UWWUCF75BY#LDEY;ZU+80MU1:9R)40K:!5K&Z3DR@:'I)U(AE
M>6!4RZMMP..-)8=4X&KW+C@VMAH,HRJRZZ*MJ1 -)%BJTP.B4H,BTEQ69215
M'"D?8"U9(UW"PBGBJ;KRL,3P=I,DA!2FZDSZE$<X=&R$7\,KQ M4]QZH7#WR
M*0TE(2-;A*@><-VI%]_\+&+]<*3_ .ZG\P@.^&8B[&D/:*OA1YPS$78TA[15
M\*'4$ EX9B+L:0]HJ^%!PS$78TA[15\*'4$ EX9B+L:0]HJ^%!PS$78TA[15
M\*'4$!C:W-5U4S1L])DDD5!)2!/J-SLW-#\EITZPXX9B+L:0]HJ^%'E?_6Z'
M_>2?Y3D.X!+PS$78TA[15\*#AF(NQI#VBKX4.H(#,4V7JM)E>#25#DVV;W"%
M59Q83I:PS-FPTW#2+O#,1=C2'M%7PH,,.37$$FQ.RTRS,R[2&G>$6)6H)%U
M@FXOTPZ@$O#,1=C2'M%7PH4O35>Y62)-)DMH)&8 3Q@JQ&=FYOLOLZ.F-A"=
M^_+*GG_Z?,_S&(#GAF(NQI#VBKX4'#,1=C2'M%7PH=00&=F^.Y^4=E)FBR*F
M74E*TIJBTW!WBX:!@E#6Y&4:E9>BR*66DA*$FIK40!N%RT28J8IE:N]5*8[3
MVB^TUF46M<FUS(*2NRTV%@O7G6^J8\PG3:E(SU17-JF3++"$MF9T6XL%>99&
M=0N04BXR@V^:(!IPS$78TA[15\*#AF(NQI#VBKX4.H(#&2$U7AB>LE-)DBX6
MY?,DSZ@!HNUCLM8<\,Q%V-(>T5?"CRG?2VN?\J6_T7#N 2\,Q%V-(>T5?"@X
M9B+L:0]HJ^%#J" R\_+U>J,;&<HDFXV-2D55Q(.EB#E;%P0=0=#%Q,S7VTA"
M*)3TI2+ "HJ  ]5">LTFH36+99^77-*E,J=N#HV&PE86A)"QJJXN,A-P#<6A
MUAJGKIE&;:<0IMQQ2GEMJ65;,J-\@))T2"!OZ( X9B+L:0]HJ^%!PS$78TA[
M15\*'4$ EX9B+L:0]HJ^%"F@3==$E-;*DR2D\.FB2:@H:[9=Q^BZXV$)L-_J
M$W_>$W_/7 ><,Q%V-(>T5?"BI46*K5I0RL_AZFOL%046UU%5KC=_NHTL9BOT
MR:G*Y2IR4EG%N2RB"XI3>R2@D%=P><%V39*D[B==(!;4\/3]6J<M/S-&EMI+
M-[)*$U,A*D:W2?D;V-R#8BXT-Q%^1E)^F!/ \.4IC*"D%-05>RC<Z[+I.L)7
M6:WAS ;S$C+OM.";2EA(""^EFZ;EQ2 4YC97.L="+ZP4R2Q3/*09[A#DD#)N
MMJFBA*U*0X@K44C5)*0HE)&^PU@-5PS$78TA[15\*%M>FZ^K#M3#M)DD-F4=
M"E)J"E$#(;D#9"_WQK(5XC^B]6_L3WY# 5<&?1*1^Q?YU0^A#@OZ)2/V+_.J
M'T 0000!&$Q:S+3&,*&W."\MLW%.<XIL ";W!!Z(W<8#&32G\5T9D2KDT'$+
M2IE#@05@[Q<D#=OZQ<0 RY@XR4K,3;$S)KF HAE;KZE(RJ"3FRD@:J2-?K#K
MCMUS S*6U+=>RN-!Y-ES)YIS6W;CS%<TZ\TZ:1VBE[-U:V<(S+*7#^C:G&4(
M3JA7-2%6%RV@FW4>LQ(*>X-!A6=W@_KS71M/^/\ ]5?W^B X<1@II+JE..%+
M92"4.S"@JZ@D9+'G\X@<V]B=8]0S@_.C,5)0ZXVVRYPEXI65H2I.M[)N%BU[
M7O'+%*5+.(4C"]0(:4E3*%5!HI:(4%G*,^EU)!/61$2Z"A:I4G"L_>54VIL"
MH-;T)0E-^?U-(^[TF D<8PW+U6;DIF1F64RH3=U4TX2XI66P0V%E:@<UK@$7
M!'1 PWA)UV8!;<0RTD+0Z9IXAQ.S#BB.=I9)UOU1U/4V9J<\)V9P]5"^C5DI
MJ+8#"M+J;&?FDY1?^/68A>H8?E3+\EZBV@Z$M5)M*B,F0BX7>Q3OZ]^^ ]95
M@]UM+HEYI#:E.H3G7,!:E(6$$)1?,JY.EA_^;6Y23P?/3W I52W9@MAT!+[]
MBDA)T5>Q-EI-KWUBNY277 "<-U-*TN+<:6BHM!3*EJ"E9#GTU'^)ZXZ;IS[
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M(43R5WO3OBA/6ZG55S-&*\/S""FH)*09EGG'9N:?._\ EH<\;UCS:F>],^*
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MLPM:SE*B  KH2E1^P&*],XDK#^RDJI67 ILN-NF=F$H=2DA*BA1-E920#Z3
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M7#R" 1\I6^RJQW%<'*5OLJL=Q7#R" 1\I6^RJQW%<'*5OLJL=Q7#R" Q=:Q
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MX2TE)*LER1LK@_\ $8Y72J$\AYN8G)AQ"U&R>)WM1E= *^;SU@NWS:?-&G3
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M5SF5"0D7D7SH/_9%&O8EI;V':FTA<UF7*.I3>2> N4$;RBP@+V#/HE(_8O\
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M?0A8)4@D;0*+8L%:E02=V[2_3:)G'$NXMO-*O)2XSF2CFE27<RTALF^BB4$
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MN]$<NTNJ<);F7DX<X0E=VW5R2LP4>HY[W,(WY'$JUSCIKN9;C3>R0W.);;S
M(N#;4:A5RFQ(._<!9FI*K3\XEF:G)8R;3ZG$K$[JJ[F86%@4E*;I!O ,Y60J
M:Z<MF37AQ4D_FS(9DU%MR^BK@+L;[C'KM(JLPEYEY.'G0X4J<0N16<UA9)(S
MZV L/LA%+TJL24@B1E*FAE+4FEIMP5#FCY$)* FVB@Y=07U6'HBTJ2JS4TT4
MU-+\N@Y%)X?D=6@.O%!+EKZ)4W<=-COZ09FCU/.06\.;12DN'^@JN2G1*OG[
MQT'HB1B5K-.86W+NT"693=:DMRBT)%]Y("_1OA=6)*I35;759"I4]IQMHRK
M4KG!"D',K->PYY2<I2?T8UA95J96)Z24RS-(0R]*[%;#E4NO/\K8J<M=:1F3
M=)W_ ,(#6$8E&^<HP^V7<\<=9,3^54?NSOCA-B"E.52K"9EZBRVTEAE!0'D
M.%+X60JX)M;=8C6%J*9B%<N^A_$*B[G=<2M$X$#-LR&[6U",V4E)TTW;[AJ%
M*Q&A02J>HJ5*-@#+N G_ #([RXF\JI'=G?'&8G*'4)K9-+JZ5(9<6IMTSMG0
M,ZR@Y]]P% ?9I'2T5UY4TT:AF;9V.4)G-D7RJRG@E8W92  >HJ$!HT<I'6TK
M1.492%"X4F7<((_''63$_E-([L[XXR#E)KTM0V6:?5FDS;:)=I $\0VVE# "
MB$[C=P&]P;CHZ(L,TRJRM::6Q5BU(IGW7W$"="MHE;F8$A7[.4E.7KN1ON T
M;S>)]@Y>9H]LIO\ T9WJ_?BCAUO$?)FE;*9I(;X&SE"I=PFV06OS]\:)Z=E3
M+.?TECYA_P!X.J%^&IR63A6D S+((DF007!]00%2>D:Q--H$^O#[J$+"D;>4
M6H)5T$77O@:I588=6XV* VXIS:J4B16"5V(S$Y]^IU])CFO,HFZE3IM#4A4&
MF XA<N^\E(!7ELX+@@D92-U[*-H6RDG6%S23.5<!@325.Y)[5T#:74FWS$F[
M8R#ZI_B#/BFK[9MW9X?VC2-DVO@*[H1]4'/H-3H(Y;I%4:2AIM&'D!O*I"$R
M*QERDE) SZ6))'I)A7*R=:8>D0JLYPEA!>=5/YK+LK:#*1968E.4_LVW=!CE
M9&NI0PM=6:2X6TL.WG<RB@N.9EE72M*2@BVE[@6$ _EZ?7)1;JI8T)E3JL[A
M;DUI*SUFR]3"[%*,1##,[MIBE%O*G,$2[@/SA_QQ9PPB?D5SXK%51-*<=NV5
M/I4D#6^4;T@Z:'J^^QBZ;EE85GTIF&22E.@<'UA 3Y,4>4T?NSOC@R8H\IH_
M=G?'#3ALKY4SZP0<-E?*F?6" 5Y,4>4T?NSOC@R8H\IH_=G?'#3ALKY4SZP0
M<-E?*F?6" 5Y,4>4T?NSOC@R8H\IH_=G?'#3ALKY4SZP0<-E?*F?6" R=;1B
M(35&VDQ2B>,$Y,LNX+*V;F_G[K7AQDQ1Y31^[.^.(:]-RRIJAVF&3:HI)^4&
MGR3D.N&ROE3/K! *\F*/*:/W9WQQ[L\3^4T?NSOCAGPV5\J9]8(C>FY1;*T\
M)9.8$6VH%_X]$ CI]/K$FRM%.5A]AM2R5)EY-:4E6XWLO?I%S)BCRFC]V=\<
M4L)L\4TMR5F#)RS0<^0:0ZA2@C*D<]20D*-P=;7M:Y)C0\-E?*F?6" 5Y,4>
M4T?NSOCA4\C$?*N1!F:5M>!3&4\'<M;.S?3/OW?XQJ>&ROE3/K!"=^<E>6$@
MKA+-A(3(OM!_6,0$F3%'E-'[L[XX,F*/*:/W9WQPTX;*^5,^L$'#97RIGU@@
M$3]/K4Q,,.S!H+KS)*F5N2:RI!ZTDKN.C=',M)5B5>>;E',/LNN*VKJ6I1:5
M*4?VE +U/I,<55.?$M+J,JU*/<'0ZEUU4TE"@%)L$@:W%XXD&"SBZ;JA5+2[
M#[(#UYA#A=<L@ IT!0$A)!UL=#: 8Y,4>4T?NSOC@R8H\IH_=G?'#3ALKY4S
MZP0<-E?*F?6" R<@C$?*>L!,Q2MILY?.3+N6.B[6Y\.,F*/*:/W9WQQ!3YR5
M&+*VHS+-BU+6.T'4N'?#97RIGU@@%>3%'E-'[L[XX,F*/*:/W9WQPTX;*^5,
M^L$'#97RIGU@@$"J=679PS*^(%S63(73)+*\AOI?/>V_2/9.5K4O+["0>H#3
M+:B-FQ*K"4G>= NP,1RUY/$M3FV)>3$O,M, .<+2"XM*E9B1;31>G[G1>/,*
MRJ:0U/-N.R[$NX^5L,!]#BD CG$K %[G4 W(Z^@!?R8H\IH_=G?'!DQ1Y31^
M[.^.&G#97RIGU@@X;*^5,^L$ KR8H\IH_=G?'"F@(Q&9.:V4S2@.'35\TNX3
M?;+O^WNO&JX;*^5,^L$)\.3<JF1F[S+(O4)L_I!_7K@),F*/*:/W9WQQ6=EZ
MX)EIYQ^@B8L4-K7++SZ[P#GOUZ"'O#97RIGU@A%6VTS<]29B5,@M<I-!UQQU
M\)4E&4@A.AWWO;3= 59NC5"H2HI;ZZ&6D$.AAMAU!2;FR@$N C6\>4V1GFF0
MU3G,.A+02@[*66HBWS;G/?2W3U1.PTM.*Q5%BFM-.289>6W,W65Y@1IE%P+6
MN3_"%5(H<S3L0HG#4)-+&8J<+<VJZA\IS"W\TZK2<QU&6 T63%'E-'[L[XX7
MUUO$8P[4]K,THM\$=SA,NX"1D-[<_?&DX;*^5,^L$+,0SDJK#-6 F&23)O
M.#7F& XP9]$I'[%_G5#Z$."_HE(_8O\ .J'T 0000!'SW'3K+.(:9,3$LW--
M,2[SRF'$@I7E256-P>KJCZ%&#Q>RY,8NHC#;##ZG&W$%I]92A8((() )W7Z(
M#J6GL+.OOM.T&6:"7@TUGIX27#9J_-4D$&[HTZA?=$#%6PPXMY;N')=N5"P&
M5F11<HV6U+BAT(RZ]?HOI#5ZE55^>EYM5+I&U8?,RFTZY8N%O9YC\E]73[NJ
M(I.A3DBDIEZ!0F[J*B!-NG4IRG>UNRZ6ZM("+A.&G"XRSAMGAB$*6XRY)-@L
M@)!"E]23F3NN==VAM1E:IAY]FGK7AF50J9;4%L<#1M-L-D4H2-Q!#M[D[A#)
MO#TXR&4MT*BI#)44?TUZXS  W.SUW#?U#JCIVASKS1;70:&4[K"<=!&B!H0U
M<&S:/PB I+JF$$ .)H<J)=*D!;RI% 3=396$C2Y58;K?QB_.*PO36)%R=H$O
M+\,=#24+DFLR%$@<X#TD;KQZ:14%,EDT&A;(VNCA3EM$;,:;+ZIM]D<NT.?>
M:E&G:)15HE#F82J>>.0W!W[/74 Z]($!5<G,,-B7<&'9<HF2I+">!-YIBQ2$
MEL;B#GZ2-T-*%3*+5Z%)5!R@4YI<PT'"WP5'-OT;HI*P]-K0XVJ@40I4M2R#
M.NZ*4021\GS=4@Z6W0QE6J](RC4K+4NC-,,I"&VT3C@"0-P'R4!=Y-T+L6G=
MU1[H.3="[%IW=4>Z(=MB7R"D=]<^%!ML2^04COKGPH";DW0NQ:=W5'N@Y-T+
ML6G=U1[HAVV)?(*1WUSX4&VQ+Y!2.^N?"@)N3="[%IW=4>Z#DW0NQ:=W5'NB
M';8E\@I'?7/A0;;$OD%([ZY\* FY-T+L6G=U1[H.3="[%IW=4>Z(=MB7R"D=
M]<^%!ML2^04COKGPH";DW0NQ:=W5'N@Y-T+L6G=U1[HAVV)?(*1WUSX4&VQ+
MY!2.^N?"@)N3="[%IW=4>Z#DW0NQ:=W5'NB';8E\@I'?7/A0;;$OD%([ZY\*
M Z>PY0Q+N$4:G A!_P#"HZOLA?AS#]%<PQ25KI%/4M4DR5*5+())*!KNBT\]
MB78.7D:3;*;_ --<ZO\ E10PZ[B(89I(:DJ46^!LY2J<<!(R"UQLH#JI4^FR
M]1E9"2P[277YA#CI+S2$)2A!2#N2222L6%NN*:)W"CCK;3>'V5K<<2AE*9!O
MY4*S66G_ (>8K4VW;M1%^>D*O4@UPRCT=XLJSMDSKH*3Z"&K_;UQ%+T>HRKY
M>8H5$0X7=MF$X[<+YVH^2T^<K0:<X]<!48G\)S&R(P\A+;J4J"C3T6 5<MW
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M]E2_W'WP#V"$7(_#_94O]Q]\'(_#_94O]Q]\ ]@A%R/P_P!E2_W'WP<C\/\
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M>J^;4[WACQQY7_UNA_WDG^4Y#N 2<;U7S:G.\,>..556JK24\FYT7ZIE@?\
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M^GOWN%L].>_3NAGRC=[ K'J$>.%3U>6<52+O$M6N)*83DV";FZV=?G;M/\1
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M^8.7,; GY06&L7>4;O8%8]0CQPNJ\Z*S3E23U(K[+:E)45,-H2K0W&I4>D"
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MF1BN11Q]523)3!SW9N++9T_1VL;_ . @-C!T0EXBF_..K_>Q\*#B*;\XZO\
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M**DY6@DY0"H!6RL2 I-P#<7$24^6-4ER]*XBK9:O9*UMM("QT*3F:&9)ZQI
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MU35!_P#+)CJ_<A?AW$,HWAFE-F6J9*9)D$IIKY!L@;B$6,*&?]HBIEN52]3
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MV94+7R%)(4G7?>^\$ @QH8 @@@@"""" (((( @@@@"""" (((( @@@@""""
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.]<$$!-!!! $$$$!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_3a.jpg
<TEXT>
begin 644 image_3a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,* B<# 2(  A$! Q$!_\0
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M((( @@@@"""" (((( @@@@"""" (((( @@@@"""" (((( @@@@"""" ((((
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M2T#?\U&L;3"5(<HF&Y65F5!4\L*?G'!KG?<)6X;]/.)M]0$/H( @@@@""""
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MBJ:4E0G'&G&E(*%S"BG,IK9*<M^V4:7^LZ7,?=XOSW8E8Y8T)*@')Q;5V53
M+TNXV,B4YE'G)&Y(O;?$9QMAULW<J&S(<V:TN,K2I!LD\X%-T@!:+DV S"(*
MC@VCU">FW2XKA[LNI!2XZ5)0E3>R!*+@Y;#K&H)%C>%]-_)O*I8<=K4T[/5!
MR84ZM]*U"X*4)RG,5$BS2==_V0XFFBQO6<4.4Z?F).3I+T^J4E.&S90ZEL-M
M$JMEO\Y9RJ(&F[?$,KCZ@S?"5;=YAEDJLX\RI*7 EH.J*3;6R3>V\VTZ+^J[
MAJA8AG=G,S;TO-J;V"TRDX65NHU4$J /. YQ (W7Z(I36"Y"ILMRLM.!<LW/
M-/3H4<RBME"494@62@J2 E0M:VX"'$B*)CBDK#B7L323J+Y5TY:DW!!L7$'<
M=T)ZY7F:$F7+K:5<(4L)*WDM)&5.;52M+FUA]</*]^ELK_ .?XB(H3$A+3<S
M+3#[>=<LI2F@=0"I.4W'3I%\'Z3[.B9RD:>?\J",4THM-J6\ZVM;+3NR+*RH
M;0 H3H#=1O\ -&NAZC'',54=H%:YQ.R+:7$J2%**@<_ZH%Q;9JOU6-[1--TJ
MGN.NOOK6T[,/,J#J7<J@ZC1LHZCJ1]=X6#!,DN9=4^5%D)0F60V2%H "\RE*
M-\RE%U9)MU=,3M/7,XL3:++<_BRDR#$T\77'^#IS*##2EA7S38* RWLI)W[C
M$O*:C7=3PT9FR 4AM94259 $BUU'-S2!>QWQ&,.4I]$VTTX_L7@IMUAJ9.S"
MB$@G*- JR4^&L<3A&F-J=6A,REQ;@=VB7;*0L+SYDFUP<VNM^K=#M%\7T>4X
MG8=H3%38E'UJF9DRK$O<!2W,ZD:DZ)'-)N=PB!K&DBB>>D)]A^3FI<+,P,I<
M0WERZYTC4$+!!^^VD7&J-2%TL4EE94TAQ3Z,C]W4+VA)6E0U!"R1?H.D4I7"
ME/9D7G*9-./+>;=2VY,NEU"@XE*5!1%BL<P6N=+0[3,SB\)@_EIMF;#BF%A:
M6W%-*(!MG2;*'UV/2(987_GZU_%H_P !N%%)IS=)I,K3VEJ6B7;",ZMZSO*C
M]9))^V&^%_Y^M?Q:/\!N..8[CR?:E]WB_6#J<F4R4A,S:TE26&ENE(WD)!-O
MZH6S.):;(4>3JD\XN7EYII+J26U+R@I"N=E!M8'>8GJD_2FFQ3ZG/2TN9U*F
M4-NO)0IP*%B$W/UVA0[@&E3-.9D9J8JDS+M)*&TOS15D24A.47&@L!]8^^/)
M$1;B_/4Q%N*T_C"A2K[S+TZI*V7%M.68<("D J7J$V(2 22-!I?>(YRTP[9Q
M7&:+-M;51*%6*>;NTU(SHN!J,PO"W$>"DU26,K3IX24TX],/N+6I94H/)RN6
MRJ!RG30W&Z)Y7 U!86^RUM@ZN7#;B4O6(!"4Y[;P3LQOT^<+:F+:E;4V,9+$
MTA4*TFF2PF%.+E.%AQ3*DHR9\MKD#6XAW".DX7IU#=9=DDOI4RRM@ N$A25+
M+AN-U\Q-K6M>T/(S-K\&*K7X$/Y,_P!%#_US_=3&RZ(QOY,_T4/_ %S_ '4Q
MLNB/7#WQR=@@@BJ(Q'Y0WV9=%%<?=;:;$\FZG%!(^\QMXQ>/M]%YB5VG4D)4
M; G_ ,?OC-47BP:\HZ'VU3N](\8.4=#[:IW>D>,)I3%3++6RJ,DT9UM1,TW+
MMA(ED<S?F//_ )Q-BF^8&XZHC3C%C/,3#E/2B33D4T,J%+6A33CF:X587"!H
M=1TB/F_=E/F;UGO*.A]M4[O2/&#E'0^VJ=WI'C"Y_%4HB:=8EZ,[,[-W8J6V
M6@,Y<6VD:J&]2#KT=,>IO$;$L]27D4_:2,]*&84<J0ML%302;$Z_SFH%S#[L
MI\QK7^4=#[:IW>D>,'*.A]M4[O2/&$E1QE)L4Y:I&GI<FC*&90E>S"4I 7<J
MU&[)J!J;Z=,25K%;,G+D2,BT[,H<=2I#@2 0VLMJZ="2+B_1#[KI\QK-^4=#
M[:IW>D>,'*.A]M4[O2/&$",7*DVVS4*2EP(84Y,N-)0"A0;94 $W.:Y> T.G
MV&-#+U21=P^JL/22I=MME;KC+K0#B F]]/\ XFW7I#[LI\QK89C@,MBR;F5O
M8?G&9FHIGDU%^>;VK"0V$!M*=]Q8V-[6481-2E5I](9D)'$LDB71+RX6TBKI
M"MHEMU*P@YAE3F+1L"!S=QW'=-8VDWI)4T*(X&THSW*VK$%PMIRV)S9E)-K7
MB;EA3%9G!3'>#B72^AXI0 JZ&UY;7N"$NI.NF^/3&6MX^R:F+>15'A,N*Q?+
M%Y1>""BK)0FW!DALY0;#Y=).G03T&T62].IG4.JKDB\R9AY>R:K29?(I3B"A
MQ1%\P"0L9;'?N-]-+-8SI\E4GT.R:52R%I:&0)SY@XZA:K=*1LP=.O6-%3)A
MJI,O.BGAEMM]QE)6$':9%%)4+7L+I._6&[>OL7?-:09KC"4?JM=IJVV:@U-!
M"ZHEW9@,O(7ES*)U4M-M=W5NCZ%RBH?;5.[TCQAQP5CZ!O\  (."L?0M_@$<
ML3(QB3>9]EBJQ/RCH?;5.[TCQ@Y1T/MJG=Z1XPYX,Q] U^ 0<&8^@:_ (Y?=
ME/4UDW*.A]M4[O2/&#E'0^VJ=WI'C#G@S'T#7X!!P9CZ!K\ A]V4]363<HZ'
MVU3N](\8.4=#[:IW>D>,.>#,?0-?@$'!6/H&OP"'W93U-9-RBH?;5.[TCQC*
MT>M4E$BL*JLBDF:F38S*-Q>61T]4?0N#,?0-?@$*,,R[)HI)9;/\KFOU!].Y
M'6C(4T1,:F\/&FB;V9BJU2E3M&GI1JKT[:3$LXTG--(M=22!?7=K&/=I;;++
MJ)3$DF_MI:596N:J@SIV>TS!)'ZMU)L#<;]-T?5:U,KE)BGRLG+RB7YUU3:7
M'T70C*A2SH+$DY; 7'2>B*$QBB2EG7F33%O.(5L4%L( ><"D(4D7-P 7$ZJL
M"+_5?M1EM'*6ZLQJYP^9RLI.(7-N3%7I"GG)5J70L5M92<N7.LIW9U6.M[#0
M6-R8L)D%FF[-W$L@N9:DTLM$54I"E;=:E@D$6"FBE&:UQT;H^AJQ5*-*4':2
MXA*''$K5=LV2VX&UKWZV6;6WG?:(N5]/#R"]3ULM@.AQ*THSM*1EL%:\V^8"
MW6H=!UWL?7V9VWHS^%G:91*9,RSU6I:2[//S*$MSJ5A*5JN$W)N2-UX:3U;I
M"J;-I35I J+#@ $RC7FGZX>TJN2=6J\U((I;S1EASG7&@$%0("D ]8)^W6&5
M6EV!1IX[%O\ V=S]0?LF.4Y2)JU3+<9F8IM9C:97*0FD2*55:12H2S8(,RBX
M.4?7%3$<U3*S1C),UN0;6I]AS.)Q"2D(=2HD&YLJP-OKM&ZH<NP</TTEEO65
M:_4'[ B_P9CZ!O\  (1E(B;W-ZFUK/A\U3E@/-2.)9 I7/.327WJG\L;AK+F
M(T)LA8W=(UWQ7F)&;F$U/+5Z1+N3CZG$J17%J2TG*L("4G<0HA1.M^@"PC[Q
MP=CZ!O\ "(.#L?0-_A$=-C/7V<]MZ/B\U*-S"EO+KM/>6Y,I4XTJK%"5,[ (
MMH="'+KM;G=)C0X=G:92<-4VG/UFFJ>EI9#*RB:04DI%C;7='T?@S'T#?X!!
MP9CZ!O\  (S5E]46F6Z<QIF\0^=5VM4ERC.)15)%2BZQHF803_.H/7#)5>H^
M8_Z7D-_I*/&'.*9=D4!9#+8/")?]0?3HAUP9GZ!O\ C.YTVM=K>YO>S"S58H
M\Q)OL"K4PEUI2+.3""DW!&H!O;KC)T)1HTK-,.3])4U,I:EFFD5)+NQ2$*2I
M>T4D*R#3*@WMUQ]FX,Q] W^ 1PRS UV#?X!&J<M%,6NS5F9F;V?(Y*?5R99H
M$Y.4F7"I3@)FI6II7LTADIVEB!8W";#Z]^D<PXLT^K\(GJS0VI-N0;E$,2\T
MVK,I%K*!RI*4V!.4E6JC'T"@3CE17.,STM*LS3"P=@VW\Q"KY3FU"P;'G"VX
MBP(A]P9CZ!O\ BSEHM,7YIO$WB;,7Q[1^UY#O*/&*CU;I!K%%4*K(E*9E94>
M$HL!L'!KKUD1O^#,?0-_@$)ZM+LBK4$;%O6=7?F#T=V,X>5BBN*K\C%S$XE$
MT3'-G\5U:E3N'W&F*I3WBAYAU;(FD$NH0ZA:T[^E(,803DW.XFJ$NS5)<,H$
MR7)F9J"VVYC.^A2+"^4$-A21EN+#6U[1]SX*Q] U^ 1S@LO] U^ 1[9JN\-.
M#%,6N^9X=0U32XN<Q+2S,*IB9-,PF=2XI*TNO*"M;7 #B?NBA39!*#+-SV):
M>)5,RRY,,HK*UEW(TX%N9B005K4V<FX9(^CU:8,@](!J0EW6IB92PXM1L49M
MQ MK]XCHF/\ 6(4U<A+AA4JI]#P(*E%*DI(RVT^=UPU&R]7SK$,A*U*N3=0E
MZQ1G$K4E3:%5/8JN)=QJ^9&J;*6#IT"'V&JO391-03-UJ16Z7FTJ?7,(3MU(
M8:0IP"^XJ2K7ZHW?!9?Z!K\ @X++_0-?@$-23@WBUWSFMUJDN8HEG$5214@2
M"P5"900#M$:;X\<=4JWYTDN\(\8URF&.6[0V+=N+5FV0?2)AUP9GZ%O\(BZW
MTLMFYP,.*(B]GQS$,]*3*9%<M596[3KERAY!*%*:6A"P+_JJ4/OC(2?#:K3Y
MQ+52EY%"BA#*9BH+2I!2SES)S:V*R2;C?NZX_2?!F?H6_P (@X.S]"W^$1)J
MNM>;FJJ\Q[OBBMCQ55&&JU3VWIN>,RG+.!.9!*"4%0-TE021<;KQVD"7EJBQ
M,3M;DEM,M.!II-0S!I2G"0G4\\)0<MS'U<S!3B!NG*D6!+N2RWD/ ZDI4@$9
M;:#G[[P4V8,Y-5)A^189,H^&TY#GSI*$J!.@L>=NAJ:WWC?3[OBJJ<@3+3S%
M8I:'$K<LZ)_(6@J:+V8 ?.YNF4Z7,:2B56F-TM&:>E&<SKJTMJ?0"E*G%*%Q
M?30B/K/!V/H6_P  @X,Q]"W^ 0BJQ1G9IF\0^;<=4KM22[PCQBSAJN4AI^L;
M2JR*,TVDIS3*!<;%L::QOQ+,?0M_@$**3+L&LU\%EO2;;MS!Z.U&<3MQ9RS.
M9G,4:9BS%58RCV(IF?E*AAR<9G95F5=14)I)# ;6I5TI%\X.:^6Z=4C6%TY*
MO/S-24WBFG)X07?E>-3=X*=0IL%-[-;-"5)NG??ZS'U[@LO] U^ 0IKTPJET
MU,TQ*RB[/-H<+HM9*EA)(L-3K]4<]GZO#&';Q?+%4G93SDRU7:0Z2'V&RY5U
M!3<NJ9#B$[]3DS)UT&E[B+DK)$RTFQ/8GIKB$)DT/Y:I8K2TMXN:@@\Y*T#H
MO;7='T6:FBQ7J=)(EI14K-!T*6?GA2!>P%K6A-REX/B-Z0>I[3DJE[8YVT)"
MD76VA)()U%W.@?7%T>JSA^K!-4ZL!EL.XSII>3(&7#B:H  K9*1E.FMU%*LV
M_2^\:_0Y"JT&0D&95NL2&1I 3SIY*S]>JE$G7KC5\&E_H&OP"#@LO] U^ 1F
M<._BS.%?Q8_\E[B'<(YVUI6DS"K*2;@\U,;:,;^30 854  !MSN_Y$1LHZNP
M@@@@",5C\.%-%#(07#.I" Y?*3I:]M;1M8Q>/4Y^)46OFG4BU[7O]?1 2M4F
M?2EK84C#(2PX5M9 JS:^DBR-#H/NCK=/J3:G66Z7AM)<65.(25 J*@021DU)
M!5]A,+93#^(I-EAB4#4G+(<.R;;?"5-_,LMTI2 ]HE8L1<@BY)U'&L.8DM./
M!]+<XZH?+*FRLK*6G4Y@<O,25K39(W"_[H!NQ3*Q+-AN7I6'6D)M9+>=(%B2
M- CH))_>3 Y)U=QR52[3<.J<EAFEPI2R6@+:HYFEN;N^J*8HF(IYU3TW/3$K
MG=!#+$ZH!#9=<*TW %SLR@ ]!&FZ\6)FAU>8<HDSPM29N3EDMS"T/%.T67&2
MX#8<X%*'-_3;[ \.4>=R.%ZC87RN.!Q96E5E+U 4;HU/..OU_7$YI=6+[KYI
M&'"\\;N.'/F7^\Y+F$_$N):@98S+KCDNB;2DMN3!;YC3J,KBDVY^=*%*L>E8
M_>+C=$Q&RN5O./.Z!3RC/* 2K.HK%K<X*04I3NR$7'UA;=D*NXH%VF8=6I-U
M#.5FUTY2?F?L@#]PM$7%%3=D7V&Z?0DR\RP&%!EYU(+>M@,J=!SB=.N*:J%B
M?@@2[.&:<R!#Q1-%I;PSJ/-6$\S0I_?E/7%O#=%KE-JJ3/3JER+<DVRVPA8+
M:"E"!;+:]P4KUTN%?8 \2>'*C(2"Y)NFT-QA9NL3#CCA5K<7NC<#J!N$7!3Z
MR&\G%>'LF7)ENNV7*$VMDW90!;J $:B" R/$=0+:&^),-;-L@H3E59)!)T&3
M34G[S%YI.)6496Y6BI3<JLEUP"Y-R?F])),:"" 1Y\4_0T;VSOE@SXI^AHWM
MG?+#R" 1Y\4_0T;VSOE@SXI^AHWMG?+#R" 1Y\4_0T;VSOE@SXI^AHWMG?+#
MR" 1Y\4_0T;VSOE@SXI^AHWMG?+#R" 1YL4_0T;VSOEA1AU6).*5;%FD%'"I
MGYSKM[[==_U=U[QLX387_,A_BYK_ ##D!0GF*U.2Q14)+#[TN"%%,PM:D@]!
MU3:."G5@/N/BEX>#K@2%N KS*RVRW.36UA;JL(LXBIK\^J0>9E69YN6>*W)-
M]02ET%"D@Z@BZ2;ZCKZ;0J?HV(GYZ:2W-K8EEJ2$[*9*1L\[9RH2!S"E(<&8
M?.O]P7%T^LNK:6Y3,/K4TX76U**R4+)N5#F:$G6\>.+*JE&Q%*PV$FYR#/;Y
MP5>V3]H _O BL_1<0MO(5+3[RLTPZJZYQ5FAM 6R01SDAL$%'6;_ %B!%$Q2
M@)<1.#;-[5*-K,E16E:D@9S;>!G4 -+I3H+FP-FI2O,S3DTW3Z"B9= "W4J<
M"U@=9R7,<J:L3\53N=FCA&P7FLZ[>V4_T8[1J;6I/$,^].S[TQ)*3EET*6"D
M"XRZ;PH"X)Z;WUZ'56_,L]_#N?W3 (:,K$W$5/V;-(R<&;RYG7;VRBWZL7LV
M*?H:-[9WRQ<H7Z.TW^$:_N"&$ CSXI^AHWMG?+!GQ3]#1O;.^6'D$ CSXI^A
MHWMG?+!FQ3]#1O;.^6'D$!B\2JQ'Q(O;LTD(V['S77";[9%OU>NT.,^*?H:-
M[9WRP8K_ $?<_B)?_'1#R 1YL4_0T;VSOE@S8I^AHWMG?+#R" S$G)UJ1#G
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MR,PL"5%2CJ>@ =<97#DEC*:<D'YER<;2F8O.)G'U@*3E2"$H5O!&8[M%$VL
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MVDZE;\\L #*%7N'3T'=O'2!I%V;E\*2DDJ:S/NI! RHG7LQN$G<5]"5!7[C
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M !(Y1IZO/8@GY6HR[:)-E-FEI:6"L@@9LQ&4A0N; DBUH=5;\RS_ /#N?W3
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M-S%;;QQ-+FI:=XJX/LV-GE6U<+195@;YB5*O<:)2/K,)EFN-TYY+;M3?6S4
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MGBX[/[-A1;2%):("CM046T2E9&@^<D$WAL^Q-2LY+2CV*YE$Q,DAELR[%UD
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M\M4JI*R2F1F HN&POS@;:#6QU)W#I4FB4!"D*EJF\T4R:99/^C7[)(1E)"0
MFRM2003<W!!UCZO! ?&':++.U"6:<GU.R+,D)9,P91]+C9LOG)&6_P"N1:]B
M-YN!9HW2<.!G(J<<S!@L7%,?-DE+X(&8$V)?O:Y%T#[/J<$!\HQ(VQ54T-AA
MUAR6DFRAUM4B\V@FZ""E.0D 9.@WZ-Q,>C2:*E\*9JSK3*9),JEI-)="38)N
M5  !0)3<@BYS$7CZK! ?,:?)420J\C455%UQ<J%\Q-.F&T))4XKY-(T2/E2+
M$*W"-ERMH_TTQW-[R0\@@$?*VC_33'<WO)!RMH_TTQW-[R0\@@$?*VC_ $TQ
MW-[R0IP[BBDLTDH6\_?A4R=)1XZ%]9'ZO48V4)L+ZT4_Q<U_F'(!-5*Q39Y^
M3FY6?>EYJ4=4MM3E.?<00I)2H%-AT'>"-1"68E:+.3TR_,5!Q:'W M232WLR
M^>VM25DCG)^3LD6T"NFT:O$E1>D#(MIG$2#$P\4/3KJ04M (4H#G<T%1 %SI
MT;R(6O8R>:FYB39DV9AQI0;1=_*HJSMI"EI"3D0K: I.MP(!,_)4!QU*V9U;
M-WGG'"*4[FY[H<!0<HRK38)"M=.B(4TZCI:RIJ[[2T%S9%JEO -!93F N+FZ
M0I.I/S_J A^]C&:EG4AZGRX"GW6T@3)S.!MP-*"!EYRR3<)ZAOBLG'3@(?<E
M$;% =2\AM[.$*"DI1SLO.NI:4Z$CG?4;!'2#0J179ZIM3DPKA*2D(,E,70"0
M<M[6*1:PYH('3#FJ8JI"Z1.H2],74PL"\F]^R?Z$>J-B1^IUZ>ICTAL."BQ<
MVR22H$ \W> ;W!W$"'-6_,L]_#N?W3 (:-BFD-T.GMJ>F,R99L&TH\?U1_1B
M]RMH_P!-,=S>\D7*%^CU-_A6O[@AA (^5M'^FF.YO>2#E;1_IICN;WDAY! (
M^5M'^FF.YO>2#E;1_IICN;WDAY! 8O$N)Z2]0UH0\_FV[!UE'AN>03O3]4..
M5M&^FF.YO>2#%?Z/N?Q$O_CHAY (^5M'^FF.YO>2.'%M&M_/3'<WO)#V" Q%
M$J=,I3LVIR?=6V\L*0PU3GVVVK7N0D@V*KZVL--PUN[Y6T?Z:8[F]Y(]T*J(
MJ3<VA<PRY,R\V^TMM"AF;2EU:49AO%TI&_?#F 1\K:/]-,=S>\D*:IBBDKJE
M$4EY^S<XM2KRCPTV#H_9UU(C90GK'YWH'\:O_+O0$?*VC_33'<WO)!RMH_TT
MQW-[R0\@@,=5*W3Y^:IKK%06RF4F=NM*Z:^LN<U2; V&711UUZ(C8K$HBO\
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MJX5,FRIE T+[A'3U0$L\*I(2^VGL1TQABX25/2%@3T#5V+"9*NK2%IK4@0H
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M'P!-$! (,\FX(T.Z-I&)_*%M-G1MEDVG#4Y,X.6^EKVUM :14I*YC_)9??\
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MI^[6 U>W9^F:_&([MV?IVOQB(>3- [#IG=&_"#DS0.PZ9W1OP@$?Y,_T5/\
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M!QA5/5J?[Q+_ !("+DI0>S&_QK\8XK"5 6E254QHI4+$9UZC[XFXPJGJU/\
M>)?XD1O5>H2[#CSF&Y\-MI*U';RYL +G_>0'E.$J A"4)I;02D  !:] /MCO
M)2@]F-_C7XP2]9J$U+-3#.')]33J M!+\N+@BX_WD2\853U:G^\2_P 2 BY*
M4'LQO\:_&#DI0>S&_P :_&)>,*IZM3_>)?XD'&%4]6I_O$O\2 BY*4'LQO\
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M6>[#S0[&Z.P&*57SRR:>XFJ^E/6G)P87_G$Z_.W0YY2*[#K/=AYHXY^G3/\
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M*<[L[Y8"3B6<]8ZK^&7^%!Q+.>L=5_#+_"B/E=1/2G.[.^6#E=1/2G.[.^6
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M!! $8G\H+B&44=UU:4-HG4J4I1L$@6N28VT8S'GSZ'?TY/\ X@&2L3T#,?\
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MZ9B.AHJM<4JL2 2N:;*29A-E#8-C37K!C:94_LC[H3TA*>.L0:#_ &MOH_\
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M/*32Y($2[A!$NC]D_5$G"L1=DTWWBOX,4ZI,X@-)G0JETX)V"[D5!9(&4_\
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M%!L]5KC:IO8G37KBW0UX9Q%)+FZ=39532'-F2N52G6P((TU!!!^WKB)JD3;
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M(V4)L+_F0_Q<U_F'(#QQK6_5IWOC7C%::F:G.%DO88>)8=#S=IUH64+@'?\
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MB@_)(EJA+R3M?KB7)DE+2KIR%0!.7-L[ V!-OJ@)9QM^>FZ5P=ZHMJ:>!>=
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MGS,Y3GGYN>6F0<"VU&CO[8@;AM,M['];3G?5#JLU-V2J]*E&)V7;7,.V4PZ
M"XV+!2@HD6(N+  W) W7M7PI69NL[=4P\R\C8LO M(R[%:\Q4RK4W*+#?8\[
M40%[E13.J?\ =TQY(.5%,ZI_W=,>2'4$ EY44SJG_=TQY(4TO$=.15JXHB=L
MN:;(M(/DVV#8U&33=TQL(34C\]8@_BV_\NU <Y44SJG_ '=,>2%$Y4)29K#$
M^W4*DTEEI2$L\4.K2%&]U@ENX58@?N%NDQL8Q]?K-0IV)9%AA]K@RRV7&;H*
MLI6=JM0/.RA N"G0$'-T0$7":=QM,50S$^N:7+&7:_T2\G+<"Y44MW5JD6ON
MUMOC,4&A2DEP%=0GYXJDWTNH3+T^8(<RA(!62V-0$ "PT3I]<;24J\P<5U!A
M<TF8DTR^W:2R4D, !.C@RY@I1*BGG$$7T%H0TS\HLS49BGH7(L(1/3&R0$.J
M*TI(391! W*401TA-QH08#14ZMTJG4R4D4&HK1+,H92I5.F+D) %S\G]46N5
M%,ZI_P!W3'DBQ0IA^;P_39F8)4^]*M..*(M=10"=.C6&4!C?R9F^%2>M\G_\
MA$;*,=^33]%U?]<_W$1L8 @@@@",5C\+4*,EMS9N&=2$K*<V4Z:VZ?W1M8Q7
MY0'4,)HSKJPAM$ZE2E'<D"US >WYIV3ET3#^+9%IHI0I*S)(L4J"LA'.W$)5
M;]Q@?#K4J]./8GIP9S!IQPR*""K0A/SM3N-H12TEAN7X*@8B;#3:9<.Y)AP*
M66T/)5E5FND*VHT&E@1TQ+PF0EI@KDJ[2$ML3AFI5"TK(%V]F4*L=P238C<0
M/K@-0W3:T\TAQO$$NI"D@I4*>FQ&\?K0&BUD@@UN6-U9C_HU&IZ_G;XSE=F:
M959EB:E\4RLH^AD!>3-E4ZF^16_< MS0WO=/5"V9E*6],U-:,2T]+,ULPRV4
MJLWD/-*@#99 TUO?I^H-FBEU5]"\E=E'$%9"[4]!!4#K?G;P1]XB15(K:P0J
MNRZ@=X-.2;__ )48M,E0T3<JZW7Y%MJ7GG9D-LE;85G<2O,;'YXL4]13IUWW
M QAAZWYWEOQ0$7$U;O?CR7O:U^+D[OQ1U-'K:4A*:Y+@)W 4Y.G_ .5$O*_#
MW:\K^*#E?A[M>5_% 1<3UO.5\>L9R+%7%R;_ -Z(S0:LIQESCB6SL$EHBG)Y
MA(L2.=U:19Y7X>[7E?Q0<K\/=KROXH#G%N(/6%KN"?-!Q;B#UA:[@GS1WE?A
M[M>5_%!ROP]VO*_B@.<6X@]86NX)\T'%N(/6%KN"?-'>5^'NUY7\4'*_#W:\
MK^* YQ;B#UA:[@GS0<6X@]86NX)\T=Y7X>[7E?Q0<K\/=KROXH#G%N(/6%KN
M"?-!Q;B#UA:[@GS1WE?A[M>5_%!ROP]VO*_B@.<6X@]86NX)\T'%N(/6%KN"
M?-'>5^'NUY7\4'*_#W:\K^* YQ;B#UA:[@GS0IP]3ZVNDDM5UM">%3.AD4G7
M;KN?G=)UAOROP]VO*_BA1AW%5"9I!0Y59=*N%3*K%707UD?U& ;<6X@]86NX
M)\T4Z@*E39<3$_B>69:SA*5N2"?G'<!SM\7>5^'NUY7\4*:U5\.UEJ4976V&
MTLS*'U97%)4H)!T"DD$'7># 2AF=+3TX,22>S2<KKO%Z-"+:*.;ZQ'F0X9.S
M,TS)8HDW'V5D/I:D49DJN0;\[K!%^L&%1G*8J1J\@<04X2LXZ765647$$D$A
M5SKNCU09ND4FL3LZ[B"26V^7,J$%9)"G5. G,2!;,19( -R8#2\6X@]86NX)
M\T4ZE3J\*3.%=?;4D,+N. )U&4_THN\K\/=KROXHIU/%N'UTF=0FK2Q4IA8
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M0"?K(3>&49J6IU8EWWWY5R@MNO*N\XU(+"G#<_.(<U-[[XM;+$_IM([FY\6
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M E+=^@Q>Y32?H=6]VO\ EA?5IZEUEEAF;DJHMEE]+Q;52GE)7EOH04;M?ZH
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M>PQ3VF*<TXNOO"1<+C952E!1.;-\X-72+Z'*1<:&\+9REHG\15&?>>JR)2<
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M9DO:B'4$ EY78=[9DO:B#E=AWMF2]J(=00"7E=AWMF2]J(.5V'>V9+VHAU!
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M#>8<<H*+VO(=Y1XP%?@N(>V*?[N5\:%-5E:\*K1 JJR)49Q>0BGJ&4[!W?\
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MV"?"*G^LWH5([X[\*#_6;T*D=\=^% 6^+Y'T&5]@GPA32I&2-7KP,G+$";;
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M&_"#DQA_L*F=T;\(!IM$?MI^^#:(_;3]\*^3&'^PJ9W1OP@Y,8?["IG=&_"
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M-Q<B5GDJJ#JW5;+8(;=0AO0G0&^9(M8*M;=<7Z;<W+TN615B,)T=9D E8.5
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M;FE@E>T6*D_E:R@DYKKTT!B=J4P[,(?+$S..EAO:.)34)FZ4VOK=>A^HQ0%
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M""" (((( @@@@"""" (((( @@@@"""" (((( @@@@"""" (((( @@@@""""
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M)IQ;#!95=TA+P4;K*T[B5$W,>&\(TYI$NAIV<1L'TOI4)A68E*<J0HG>D)T
MC100"Z0I;%/>F7D*><>F% K<><*U6%\J03N2+FP^L]<,8(( @@@@"""" (((
M( @@@@"""" (((( @@@@"""" (((( @@@@"""" (((( @@@@"""" (((( @@
M@@"""" (((( @@@@"""" (((( @@@@"""" (((( @@@@"""" (03^%J74*:]
M(/M+V#DPJ97D64DK45$F_5SC^[[!#^" Q*?R>21K$Y.OS3CC;ZLZ&P@!3:@+
M A1)W)N-PO?6]A;0NT5ARIRT_MII#DLWLD(0\0@IO>Q3TWL/N$-8(!$O#%-<
MG79I2'2I;FTR[4Y4*S)42D=!44))Z_M,6UTAA=7;J3BWEO- AM"G3D;)%B0G
/=<C2&4$ 0000!!!! ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image_4a.jpg
<TEXT>
begin 644 image_4a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &V AT# 2(  A$! Q$!_\0
M&P   @,! 0$               4#! 8" 0?_Q !8$  ! @0"! L$!0@'!@,(
M P$! @, ! 41$B$&$Q8Q%!4B05%459.4T=)68973!R,R<8$S0E)TD9*CLB0U
M-G.AL[0T0U-B<L$E=;%$1F-D@H2BX1<F1?'_Q  : 0$! 0$! 0$
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M+$$ 0000!!!! $$$$ 0000!!!! $$$$ 0000!!!! $$$$ 0000!!!! $$$$
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M"G8Z@=0_CN>J#8Z@=0_CN>J'M+3[2;#;:.A]LT[Q2/.#:.A]LT[Q2/.%.QU
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M5]R5CJU'/!!SP1^8=A!!!$!!!! $$$$ 0000!!!! $$$$ 0000!!!! $$$$
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M*F M+*;EO#;5M):'.=X1?\8T%XK%HB)Y,C7O[6RO_E[G^8B(^>)*]_:V5_\
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MZ"5T8J\BQJ929H[#145%#<BM(N=YL'-\<5&C5Y%+G%*J%,*0PNX$HX+C"?\
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M;;_T[4!+QS5_9N8\6QZHI5-V>J\H96<T;G"R5)40W4&VS<&XS2L'?8_A#Z"
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MI$P^MPLAE<Z]BUO)(1DLC$4K"A8VL%&^1M?I<C3:J)G@\U6DF7>+*PNHO;P
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M8M]7GDH19V=?]H:SWC7RX!3]&G]E5?WY_D3&SC&?1F+:*D7)L^<S_P!"(V<
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M7^F8@-$HZY6<8749M0?4VH'BA])5@6XKZTI +A.L()N/LB/I%-G!/TR6G D
M/M)<L 1O%^< _M BY 9J1K])D9%B42N<*6&DMI(I\QN2 .=!/-TF+>U=)_2G
M/ /^B'4$ EVKI/Z4YX!_T0;5TG]*<\ _Z(=00"7:ND_I3G@'_1!M72?TISP#
M_HAU! )=JZ3^E.> ?]$&U=)_2G/ /^B'4$ EVKI/Z4YX!_T0;5TG]*<\ _Z(
M=00"7:ND_I3G@'_1!M72?TISP#_HAU! )=JZ3^E.> ?]$*-'=):6S2%(6J;O
MPJ9.4B^<B^LC<CWQL83:+_U(?UN:_P!0Y >;5TG]*<\ _P"B%]5K-*JE-=E=
M=.M*44K0X*<^K M*@I)L49@*2,N>-5"G2&<F)"AS,U*E*7$!/UBDE0;25 *6
M0-X2DE7X0&0<;D)B;;G)BJ3JYIN:$X%HI+Z4!T)2A/)PGDA"5)L3^>3>X%KV
MC[]'T?<G"U/568;FEI6$OR#Q*"!8YAL7)WDF*JM):DF8:;EJBB;E3-%A<Z&
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M<7SS[)[3BM(6IL:4*+!IBWA-<'9PX-8GW6MSWAJMN?;0TMS2QQ*'U)2T3*L
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MUJ?XIOSCWCND#?5J?XI'G##BRG]1ENY3Y0GT9ITBJBDJDI8GA<UO:3_QW/=
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M_%-^<''E([7I_BF_.&/%E/ZC+=RGRCSBRG]1ENY3Y0"_CRD=KT_Q3?G&<J'
M7IZHS,K6:6T9@2P $VE"EI;4HK25)-TX@0+B--369&H2SCQILLW@F'F0-6DW
MU;BD7W<^&\7>+*?U&6[E/E$FL3U;IJ6I/+^\WS-4D^VS."7TBI7"9H-E3ZJB
M0I.%*A8;]Q*<^< PS6U*<7.MJK5)6Z:@)W"9M&!P @X5??8G<<[1N.+)"_\
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M>4CM>G^*;\X./*1VO3_%-^<,>+*?U&6[E/E%"KR\O(TB;FY:F23KK+2G AQ
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M:9O!/N.MLN)FEI#:-<3B43BU9U>2"@<^8N!%^7>T3F&"\*A,MMAIIU2W*J^
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M:.4Y%4H:09ZRYQ:3>H/G_<.G+EY;N: V$$)=F*;TS_Q&8]<&S%-Z9_XC,>N
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M#)]6JGPQ_P!$!YQ .V:UXT^4'$ [9K7C3Y1[M#)]6JGPQ_T0;0R?5JI\,?\
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MBA/2^3G_ -"(V< 1B]/OM43]>3_VC:1B?I"2M3='2VYJUF=2$KP@X3EG8Y&
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M>F-+! 9K:JA]?'<N>F#:JA]?'<N>F-+! 9K:JA]?'<N>F#:JA]?'<N>F-+!
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M&E%=D\C/,9<H9BVZ/9W2YRE:0U&3F&4O2[* M ;<&M39E3AY&\I.$C%?(D"
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MM2F?#U_.@X-I'VI3/AZ_G0OF=+%R]-ITYQ:XHS3#DPXUK!B:2VC$H"U\2N8
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M+B_M*$RV"K[S?..#6=%U(*%5.D%) !29AJQ -QS].<46-)I!R2J,TNG+:3)
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MD\C(9Y[LH#1&N:-%84JJTDJ2DH!,PW<).\;]WN@17-&FTI2BJTE*4@!($PV
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M0LIPE-[9$*Z<C>*C.F\KJ)<S-$?0^N3,V\&4)<0TFRRFZ]V>K5]UQ> TFTU
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M2*<VXIUN0E4.J"4E:64@D)MA%[<V%-NBPZ(\V@HO:\AXE'G!M!1>UY#Q*/.
MZ=I-.?;8;>D99Q$N<3*5M)(;/2G+(_=$9HE.54IBH.2K3DT^V&EK<0%'  1A
M%]P(.8YXZV@HO:\AXE'G!M!1>UY#Q*/. ]%&I@X/:G2@X*;R]F$_59WY.7)S
MSRCQVC4QYM"':?*+0@A24J920D@6!&7,,ON@V@HO:\AXE'G!M!1>UY#Q*/.
MD=ILC,3/"7I-AU_5EO6+:258#>Z;VO;,Y>^/7Z=)32Y=<Q*,/+ESB94XV%%L
MY9ION.0W1%M!1>UY#Q*/.#:"B]KR'B4><!R_0Z;,U$3[LFTJ9#:FBLH%UH4
M"E7Z0L-Q@;H-(:PEJF22"$%L%,N@62;W3NW&YN/>8ZV@HO:\AXE'G!M!1>UY
M#Q*/. E739%TOER387PD!+^)L'6@;@K+.WOB,4FG<'5+&1EN#J2$%K4IPE(-
MP+6M8$FWWQYM!1>UY#Q*/.#:"B]KR'B4><!.9*64$),NT0TD)0, Y(!! '0+
MI2?P'1$:*136[:N0E46=UXPLI%G/T]WVO?OCC:"B]KR'B4><&T%%[7D/$H\X
M#MRET]_$7I*6<Q*Q*QM)-S>]S<;[QX*13@\'Q(2H>2LN!P,IQ!9WJO;>><QS
MM!1>UY#Q*/.#:"B]KR'B4><!VQ2Y"5EU,2\C+-,*6'"VVTE*2H6L; 6OD,_<
M(X<H]->* [3Y18;4%("F$G"0  1ED0 !]P$&T%%[7D/$H\X-H*+VO(>)1YP'
M9ILD25&48)*2@DM)W%6(C=N*LS[\XB-"I"FW6C39(M.KUCB#+HPK5^D1;,YG
M/WQUQ_1NUY#Q*/.#:"B]KR'B4><!ZBCTYI3A;D)5!=(4YA92,9&XG+,BY_;'
MDO2I*4?>?:ET!QYT.J40,E! ;%NBR1;+FO!M!1>UY#Q*/.#:"B]KR'B4><!9
M>EF'S=UEMPA*DC&D')61'W'GB%=)I[BD+<D99:D**D%3*24D[R,MYCC:"B]K
MR'B4><&T%%[7D/$H\X#IJDTUE;*VI"5;6P"EE264@M@[PG++\([53Y15RJ69
M5<DF[8-R2%'FYR ?O ,1;047M>0\2CS@V@HO:\AXE'G "*+2TM(;1391+;:B
MI" PD!)(L2!;(D9&.FZ7(--!EN2ED-@!(0EI(%@<0%K;@<_OCG:"B]KR'B4>
M<&T%%[7D/$H\X#D4*DI8X.*9)AFY(;X.C#<V)RM;\U/[!T1*[2Z>^_KW9*76
M\$%O6*:258"""F]KVL3E[XXV@HO:\AXE'G!M!1>UY#Q*/. F3(RB9M4V)9D3
M*D8%/!L8RGHOOM[H@11*4TEM+=.DT);<UJ EA(P+_2&62LAG[H]V@HO:\AXE
M'G!M!1>UY#Q*/. &Z+2V5,ENG2B"RHK:*6$C5J.\IRR)]T#5&I;(<#5.E$!P
ME2PEE(Q$[R<L[P;047M>0\2CS@V@HO:\AXE'G =<44[&'#(2I6EPNA6I3<+.
M]5[;SSF/9>F2$K+EB7DY=E@K#A;;:2E.(6(58"U\AG[A'&T%%[7D/$H\X-H*
M+VO(>)1YP';-,D)9Q3C,HPVM3FN4I#:02L@@J-AOL3G[S$BY&4<>4ZN694XH
M@J46P2=W/_\ 2G]T=$0;047M>0\2CS@V@HO:\AXE'G 2JITFMY;SDHPIU8 6
MM38*E  @7-L\B1^)Z8&I"4EYA<RS*LMOK2$J<0V I0&X$C,@1%M!1>UY#Q*/
M.#:"B]KR'B4><!85*,..%QQAM2^3RE(!/))*<_<22.B\0BD4[&VH2$K= (0=
M2GD@@ VRYP /N$<[047M>0\2CS@V@HO:\AXE'G 6964EY.63+RK#;#"/LMM)
M"4I^X"(D4V1;M@E)=%K6PM)%K6MS<V%/[HZ(CV@HO:\AXE'G!M!1>UY#Q*/.
M D:IDBRVXTU*2[;;B\:T(:2 I6^Y%LSD,_=$?$M,Q)/%TIR,03]0GDA5\5LL
MKW-^FY@V@HO:\AXE'G!M!1>UY#Q*/. L(E)=MTNH8;2X;W6E !SM?/WX4_L'
M1%04&EMF7U4DPRF7?X0VAIL(2',)3BL!F;$QWM!1>UY#Q*/.#:"B]KR'B4><
M!G_HT_LNK^_/\B(V,8WZ-,]%E$9@OG^1$;* (QFGB4J50TJ2%),\D$$7!&4;
M.,=IW^5H7Z^C_P!1 :7BNG]1ENY3Y0<5T_J,MW*?*)I=]J9:UC+B'&[E.)!N
M+@V(_ @C\(\1,,K=+2'4%8)!2#GE:^7NN/VB BXKI_49;N4^4'%=/ZC+=RGR
MBY$;;B'FTN-+2M"A=*DFX(]Q@*_%=/ZC+=RGR@XKI_49;N4^47(@7,LLO,LN
M.)2X^HI;2=ZB 2;?@"8"+BNG]1ENY3Y0<5T_J,MW*?*)UNMM!)<6E.)02,1M
M<G</OCF7F69IK6L.)<;Q*3B2<KI)!_801 1<5T_J,MW*?*#BNG]1ENY3Y1<@
M@*?%=/ZC+=RGR@XKI_49;N4^43ZQ!<4V%IUB0%%-\P#>QM^!_88]<=;:"2XH
M)"E!(OSD[A 5^*Z?U&6[E/E!Q73^HRW<I\HD7,L-/LL..)2Z_?5H.]5A<V^X
M18@*?%=/ZC+=RGR@XKI_49;N4^43K=0R 5K2D$A(*C:Y)L!]Y,2P%/BNG]1E
MNY3Y0<5T_J,MW*?*+D0&99$VF5+B=>I!<#=\RD$ G[KD0$7%=/ZC+=RGR@XK
MI_49;N4^43I<075-!:2M(!4D', WL3]]C^R.7)AEE]EIQQ*7'R0VD[U$"YM^
M @(N*Z?U&6[E/E!Q73^HRW<I\HEE9EF;9#S#@<;)("D[B02#_B#$$S5)"3FF
M)69FVFGY@V9;6JRE[AD.?>/VP'7%=/ZC+=RGR@XKI_49;N4^46&W$.M)<;4%
M(4 I*AN(//%6;JLA(.LM3DVPPX\K"TEQ825GW?X?M@.N*Z?U&6[E/E!Q73^H
MRW<I\HL+<2VVIQ:@E"05*)Y@(Y9>;F6&WF5!;;B0M"AN((N# 0\5T_J,MW*?
M*#BNG]1ENY3Y1<BJ]/2LNP\^\^VAIF^M659(MT_M'[8#GBNG]1ENY3Y0<5T_
MJ,MW*?*)=>UJEO%U(;05!2B;!-C8W/NL8G@*?%=/ZC+=RGR@XKI_49;N4^42
MR\RS--!V7<2XWB4G$G=<$@_X@B)X"GQ73^HRW<I\H.*Z?U&6[E/E%R" S6E-
M.D44!93)2P/")?,-)_XR/=#KBRG]1ENY3Y0NTK_L^Y^L2_\ GHAY 4^*Z?U&
M6[E/E!Q73^HRW<I\HN00%/BNG]1ENY3Y0<5T_J,MW*?*+D$!3XKI_49;N4^4
M'%=/ZC+=RGRBY! 4^*Z?U&6[E/E!Q73^HRW<I\HN00%/BNG]1ENY3Y0<5T_J
M,MW*?*+D$!3XKI_49;N4^4'%=/ZC+=RGRBY! 4^*Z?U&6[E/E!Q73^HRW<I\
MHN00%/BNG]1ENY3Y0<5T_J,MW*?*+D$!3XKI_49;N4^4'%=/ZC+=RGRBY! 4
M^*Z?U&6[E/E!Q73^HRW<I\HN00%/BNG]1ENY3Y0<5T_J,MW*?*+D$!3XKI_4
M9;N4^4'%=/ZC+=RGRBY! 4^*Z?U&6[E/E!Q73^HRW<I\HN00%/BNG]1ENY3Y
M0<5T_J,MW*?*+D$!COHT_LNK^_/\B(V,8[Z-/[+J_OS_ "(C8P!&+T^<U7$K
MI4E(1.I45*-DIM;,GF'OC:0NJ5'D:PTVW/,:U+2L:++4DI-B-Z2#N)$!A6J/
M2%"71-5ZF+2@2S2P)T *;;NMP 7_ #W#<](&?1$3E.E>%.37'-">?<0E"E.3
MUKH,PMQQN^9"5(4A.7Z%K6,;#8G1[J!\0YZH-B='NH'Q#GJ@,<Q1I!N6E@O2
M*E:]AM"$J$Y=*;!Q2@ 5;E+< S_,3;W1>H#,A2'TJ15J(PVU3T2K0:G YA<
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M8D60TT5E9&(J)4=Y))),7H @@@@"""" (((( @@@@"""" (((( @@@@""""
M(((( @@@@"""" (((( @@@@"""" (((( @@@@"""" (((( @@@@"""" ((((
M @@@@"""" (((( @@@@"""" (((( @@@@"""" (((( @@@@"""" (((( @@@
#@/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image_5a.jpg
<TEXT>
begin 644 image_5a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" D/#R # 2(  A$! Q$!_\0
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MG$KP3PB>21:?L48TORL?DOY/<C.3D>JTJ3+;?5)2SB7G"62[24=I:",C*S[
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MI*DV&981$7BF1V:0'^F@$T"24VGQY18-CS27/%.TM)6BD
M
M
M
M
M
M
M
M
M
M
M
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MN3C:VN3-,0LK%)C-VE;_ +I#5'-II#32&VTDE"4DE)%ZB+F'0
M
M
M
M
M
M
M
M
M
M
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M*JKO4/DK4JI'0A;L9DUH2YY)G]8#< ?E)F=FFW0/T
M                                #QGY0.3G*'E-3&8="KB:6FU922,E
M?RR3(B)-I:2+ROMM'LP >,_)UR&1R"Y.G3RE%*DONF](>)&"6%81$22Y["(B
MY^?2>BVP>S
M
M
M
M
M
M
M
M
M
M
M
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MU<J(9+A2LCJ*4XHGB*TG&3,C4VHO61V?L,![ N<C+V#]#\I+FMY[!^@
M
M
M
M
M
M
M
M
M
M
M
M
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M4*2S)CN%:AUE9+0HOJ,M!BD
M
M
M
M
M
M
M
M
M
M
M
M
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MH#6APXM/BMQ8<9F-';*Q#3+9(0DOJ(M!"D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                              8W*69(I_)Z5*BN
M8MYO!P58)'9:LB/0>CF,>&9Y2\J9",-EYYQ%MF$B,DRM]FA(]IRR]$I__![Z
M1X7DC(?3RF@,)><)E3CAJ;)1X)GBU<Y?L+]P#H]RJY2QU$E^4XTHRM(EQT),
MR_:D<O#&OZ__ (+=T.3K,BJ)???24O$(:(\<A;RRPE'H2DC+GTVF?-^\:T:C
MQ6N4-6A)@J5XS915NM*<:;,RPC)6"9&1';81_5^\,WPIY1Y)E66'B,9BL/$M
MV8=F%9Y//9I'Y3ROY0K6E"9QJ4HR))$P@S,SYB\D7TBGL/TI^+*6V:FJRLFV
MB,R0\XED[$87J2?M]A6>L>>@I6GE!"2ZC%N%.:):,&S!/&%:5GJL :?A7REP
MG$Y4O":(S<+)T6HL.P[?%T:1^/#&OZ__ (+=T;%05%G1*[4VC)J4RRY&E-)_
MI&2RP%E]I)_A]0DJM&*/R8J#JXB$28S3+B%LM+(M)^-XQF9+L([3,M!& B\,
M:_K_ /@MW0\,:_K_ /@MW1K5)-*BN5U!4EA1TY++K9X:BPS41<^GFTEH+GTC
M^YJIY56LJ;C(4;#3"VH^ IPB)1$:SP2,C/\ ?H 9'AC7]?\ \%NZ'AC7]?\
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MD>@K4D9V?4 L\,:_K_\ @MW0\,:_K_\ @MW1A  W?#&OZ_\ X+=T/#&OZ_\
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MG[E#\@-WPQK^O_X+=T/#&OZ__@MW1A  W?#&OZ__ (+=T/#&OZ__ (+=T80
M-WPQK^O_ ."W=#PQK^O_ ."W=&$ #=\,:_K_ /@MW0\,:_K_ /@MW1A  W?#
M&OZ__@MW0\,:_K_^"W=&$ #=\,:_K_\ @MW0\,:_K_\ @MW1A  W?#&OZ_\
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M^O\ ^"W=#PQK^O\ ^"W=&$ #=\,:_K_^"W=#PQK^O_X+=T80 -T^65?L^?\
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M>P0@-WPQK^O_ ."W=#PQK^O_ ."W=&$ #=\,:_K_ /@MW0\,:_K_ /@MW1A
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MK_\ @MW0\,:_K_\ @MW1A  W?#&OZ_\ X+=T/#&OZ_\ X+=T80 -WPQK^O\
M^"W=#PQK^O\ ^"W=&$ #=\,:_K_^"W=#PQK^O_X+=T80 -WPQK^O_P""W=#P
MQK^O_P""W=&$ #=\,:_K_P#@MW0\,:_K_P#@MW1A  W?#&OZ_P#X+=T?WPPK
MV+-67Z<(B^1;^O\ W1@C]?\ I'^D7W& V_#&OZ__ (+=T/#&OZ__ (+=T80
M-WPQK^O_ ."W=#PQK^O_ ."W=&$ #=\,:_K_ /@MW0\,:_K_ /@MW1A  W?#
M&OZ__@MW0\,:_K_^"W=&$ #=\,:_K_\ @MW0\,:_K_\ @MW1A  W?#&OZ_\
MX+=T/#&OZ_\ X+=T80 -WPQK^O\ ^"W=#PQK^O\ ^"W=&$ #T'A7RCPB3E:\
M(T89%DZ+339;;Y/-81G;]0_'AC7]?_P6[H[%,BOX#;SK:'(M/_F[A6>/A1\%
M31G[<([2^O"+UC^+.F,*1AHC.1C<:;9-!EAXM2#)Q2R+22B,R,K=-I:- #EX
M8U_7_P#!;NAX8U_7_P#!;NC,J!-(E$PR;:D,-I:-QOF=41>,OZ[5&=GU$0E
M;OAC7]?_ ,%NZ'AC7]?_ ,%NZ,( &[X8U_7_ /!;NAX8U_7_ /!;NC" !N^&
M-?U__!;NAX8U_7_\%NZ,( &[X8U_7_\ !;NAX8U_7_\ !;NC" !N^&-?U_\
MP6[H>&-?U_\ P6[HP@ ;OAC7]?\ \%NZ'AC7]?\ \%NZ,( &\WRPKRG$$<_0
M:B(_Y%OV_HC^%RRK]GS_ /P6[HQ6OEF_TR^\<RYB ;WAC7]?_P %NZ'AC7]?
M_P %NZ,( &[X8U_7_P#!;NAX8U_7_P#!;NC" !N^&-?U_P#P6[H>&-?U_P#P
M6[HP@ ;OAC7]?_P6[H>&-?U__!;NC" !N^&-?U__  6[H>&-?U__  6[HP@
M;OAC7]?_ ,%NZ'AC7]?_ ,%NZ,( &[X8U_7_ /!;NAX8U_7_ /!;NC"'\/F,
M!Z1?*;E0VR3RWW4M'89+5&023MYM."./AC7]?_P6[H_KAFUE$HYC.3NT]+1-
M(>2I2UXE*2+ ([2,E:;3LLL%<I-)QC.**'@DZ9,&:RL,L4K!PR+39AX%IJL/
MG]5H"/PQK^O_ ."W=#PQK^O_ ."W=&94"LE?^AAX"<,HYD:"59ILLT6^VS1;
MS"4!N^&-?U__  6[H>&-?U__  6[HP@ ;OAC7]?_ ,%NZ'AC7]?_ ,%NZ,(
M&[X8U_7_ /!;NAX8U_7_ /!;NC" !N^&-?U__!;NAX8U_7_\%NZ,( &[X8U_
M7_\ !;NAX8U_7_\ !;NC" !N^&-?U_\ P6[H>&-?U_\ P6[HP@ ;OAC7]?\
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M_K_^"W=&$ #=\,:_K_\ @MW0\,:_K_\ @MW1A  W?#&OZ_\ X+=T/#&OZ_\
MX+=T80 -WPQK^O\ ^"W=#PQK^O\ ^"W=&$ #=\,:_K_^"W=#PQK^O_X+=T80
M -WPQK^O_P""W=#PQK^O_P""W=&$ #=\,:_K_P#@MW1^D<L*^:R(Y_\ @MW1
M@#]-_*%^W[@&WX8U_7_\%NZ'AC7]?_P6[HPO4 #=\,:_K_\ @MW0\,:_K_\
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MZ+*E.8QYS#PE8)%;8LR+06CF(;(P.1?HE!__ )GQ%#?       !@\LO1*?\
M\'OI'RE"UMK):%*2HN923L,A]6Y9>B4__@]](^3@/TVXXUA8M:D82<%6"=EI
M>S[!T3,DH,S1(>2:DDDS)9E:1:"+[!Q !^B<6E))2M1))6&1$>@E>W[?K W%
MFYC#6HUVVX5NFWVVC\@ _6,66'XZO'\K3Y7V^T?HY#QIP3><-.!@6&H[,'V?
M9]0Y@ _:GG5&LU.+,W"(EVJ/QK.:WVC^D^Z3Q/$ZLG"YEX1VE^T<P ?I:UN+
M-:U*4H^=2CM,Q^0
M      !^S,TJ09&9&22,C+U: <>==LQCBUV<V$HSL'\7SI_1+[A^0'13[JFR
M;4ZLT$5A)-1V6>RP$OO)=QJ75DYTR4=O[QS !T*0^2B43SEI)P"/"/0GV?8/
MXEYU+B7$N+):?)42CM+[!^  ?HW%JP[5J/#\JT_*^WVC^*4I:L)2C4?M,[1_
M         'Z,S)+9EH,K3+]X_(_2O(1]A_> _;LA]]25//..*3S&M1F9?O#*
MI&$I6/=M69&H\,_&,N8S'( 'Z4M:_*4I6DSTG;S@MQ;JL)Q:EJ(K+5';H'Y
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MN'(;0M:VC)*$(6H[2YEV8/[[1V.$V<!3[<C#=0E*W&R1H22E8)%A6Z5:;;+
M$F ?M3VB# /VI[1"F? 53U,(6M*EN-8:B3_0.TR-/VE9I^L2 /T;:N;Q>T0_
M2DF:K2-/,7](O8/RY\JO](_O%E)IJJM-.,EU+:L6I9&HK2.SU (\ _:GM$&
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M"#MP,$D'8?UGA\WJ^VTB#A@'[4]H@Q:K+?%[1#\C]'\DG])7W) , _:GM$&
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M&96E]6@?@!^L6K_=[1!@'[4]H@7Y7_"G[B'6#&RVH1XN'@8YQ+>%9;@VG9:
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M %!^;I&U%;C_ % /! />_FZ1M16X_P!0?FZ1M16X_P!0#P0#WOYND;45N/\
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M/]0#P0#WOYND;45N/]0?FZ1M16X_U /! />_FZ1M16X_U!^;I&U%;C_4 \$
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M'^H!X(![W\W2-J*W'^H/S=(VHK<?Z@'@@'O?S=(VHK<?Z@_-TC:BMQ_J >"
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M1%0VO."EXQQ+5F*LLPCP;>?U6BC\W2-J*W'^H!Y&!4U04H(F4N$G&:%<UJL
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M\><=<;&XP\' 4=IVI]NDRY[/JM*T>O\ S=(VHK<?Z@_-TC:BMQ_J >"'Z_\
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M&T:D9-8R2FU-(;<L-& G!(K3(S,K"T\QV\QD/0_FZ1M16X_U!^;I&U%;C_4
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M45N/]0#S"*O':>_DH1H9)M2$IQI&I!J5A&9*-.CV<W-Z_6/[)K9/R6WBCFG
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MM>TD:2,BMT:>?U6?L&U!Y#HF*EEG!2,1(4S\E;A6$1V\_P!8L_-TC:BMQ_J
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M$M!D>G25@U:328="I<>FT]E+$1A."V@OO,_69GI,STF9@-$
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M\AQCW3=_>8_F&[:?CN6^O28^OC.C^?IWZAC[W 'S+&/=-W]YAC'NF[^\Q]>
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M&- 9]3\J%UM'W&-           !GT3S.Q_Q>\8T!GT3S.Q_Q>\8T
M!G?UB_NG^<:(SOZQ?W3_ #@-$         &?5?)A];;^\: SZKY,/K;?WC0
M   $L_S;+_4K^XQSHWF.G]6;]TATG^;9?ZE?W&.=&\QT_JS?ND N   9U%\U
M-_IN>^H:(SJ+YJ;_ $W/?4-$        9RO2)OJB_?2-$9RO2)OJB_?2 T0
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M;YD[UN1\98T!GT;YD[UN1\98T        !GL^D4OJC/ONC0&>SZ12^J,^^Z
MT          9]8\WIZPQ\5 T!GUCS>GK#'Q4#0           9](^;/];?\
MB*&@,^D?-G^MO_$4-     !D,^E\OJ#/Q'1KC(9]+Y?4&?B.@-<9R/2)_JC?
MOK&B,Y'I$_U1OWU@-$         &?6O-BOUK7Q$C0&?6O-BOUK7Q$C0
M      9U)^1E=;>]XQHC.I/R,KK;WO&-$        9R?2)SJB??4-$9R?2)S
MJB??4 T0         9U9\U._I(]\ARY2>87_ --OXB1UK/FIW])'OD.7*3S"
M_P#IM_$2 U@         9]*\F9UMS[QH#/I7DS.MN?>-         9_]8O[I
M_G&@,_\ K%_=/\X#0         !G5KS/(^PO>(:(SJUYGD?87O$-$
M   !GTORIW6U_<0T!GTORIW6U_<0T &10_E*KU]SW4C7&10_E*KU]SW4C7
M   9Q^D2>J*]\AHC./TB3U17OD T0         9U;\R2_P!6-$9U;\R2_P!6
M-$          !G4SY:I=;/W$#1&=3/EJEUL_<0-$        9R_2)CJCGOH&
MB,Y?I$QU1SWT -$      9-?^:1.OQOBI&L,FO\ S2)U^-\5(U@&?6_,4[]0
MK[AH#/K?F*=^H5]PT           &=3?G53ZW_VVQHC.IOSJI];_ .VV-$
M      9[OI%$ZH][[0T!GN^D43JCWOM -          &?7?1^H]6<]TQH#/K
MOH_4>K.>Z8T           &1R=\V/=>F?_9<&N,CD[YL>Z],_P#LN#7
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M]PM !%FBF;.B;A/<&:*9LZ)N$]PM !%FBF;.B;A/<&:*9LZ)N$]PM !@PZ9
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M?J,;<I[A6 "3-E/U&-N4]P@3 A9[=;R2/@%&0HDXHK+<)6FRSZAM#.1Z1/\
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MG5D1<WJ(B(7YLI^HQMRGN'*C?,G>MR/C+&@ DS93]1C;E/<&;*?J,;<I[A6
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MI^HQMRGN%8 ),V4_48VY3W#*;@Q#Y3R63C,XLH32B1BRP2,UN$9V>W07[AZ
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M4_48VY3W"L $F;*?J,;<I[@S93]1C;E/<*P 29LI^HQMRGN#-E/U&-N4]PK
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MH-J ]&0T25H6IQ"R4D[;"/!,\!>C2@])6E[0&YELC9<OM-7PRV1LN7VFKXM
M!%ELC9<OM-7PRV1LN7VFKXM !%ELC9<OM-7PRV1LN7VFKXM !%ELC9<OM-7P
MRV1LN7VFKXM !%ELC9<OM-7PRV1LN7VFKXM !%ELC9<OM-7QFPI;Y56I**GR
M3-2V[4DINU/B%S^/9^ZT;XRZ?YYJWZ;7PR =\MD;+E]IJ^&6R-ER^TU?'C5?
ME.B1V)3\FDS&&B94_#4I2?YTVE9(,RTV(.TRT'ZM(K3R];S9"F'375JEO*;9
M9CO-R%N)2DS4I.*-1&9:"LT<X#T^6R-ER^TU?#+9&RY?::OCQ[_Y1T0H3JIU
M%EQJ@V\EG)%NMX/C(PR,W;<%/B\Y'8=NBSUBA?Y08"84><B%*<C.P,N,TD2E
MI(S,DHP4VVF9D?-H*RT!ZC+9&RY?::OAELC9<OM-7QY)_P#*-&;71VFZ<XM^
MIQRD(0N2TT2"-5A)M6HB-5OJ+2/<),S01FG!,RTD?J 29;(V7+[35\,MD;+E
M]IJ^+0 19;(V7+[35\,MD;+E]IJ^+0 19;(V7+[35\,MD;+E]IJ^+0 8$.6^
M57J2BI\DS4;=J24W:GQ?7X]G[K1I9;(V7+[35\<8/GNJ_:U[@\X]^46%#J4E
MJ7!?:I[:W6F9Q.-J2^ZT5JTDDCM+V$9\Y^P!ZG+9&RY?::OAELC9<OM-7QY&
M+^46._17*BNF2&U(?;:)"74.)5AE;:3B#--I$1FHN<K+!33.7T65'F2)T"33
MVF8^5M*<-*B?9,["4FSUF>C!/3I(!Z7+9&RY?::OAELC9<OM-7QYIGE]$72J
M//=B.H3467'S:(\)QI"/]TBM49G85A%SB9W\H\1NC4NH)@.8506XE#+TAI@T
M8'/A&X:2+[/: ]=ELC9<OM-7PRV1LN7VFKXZQG5/1FW5MFVI:24:#42L&WU6
MEH/]@H 19;(V7+[35\,MD;+E]IJ^+0 19;(V7+[35\,MD;+E]IJ^+0 19;(V
M7+[35\9N5O>$.'F^3A9)9@83=OE\_EV6?M&^,O\ K074C]\!WRV1LN7VFKX9
M;(V7+[35\>=F<MX\2ONT\J?(=AQW$L2)J%HP6WE$9I1@F>$>@N<N81\G_P I
M,7E%)CQHE-?2^Z^:#2IU%B6B(S-S0?U68-EMN@!Z[+9&RY?::OAELC9<OM-7
MQ: "++9&RY?::OAELC9<OM-7Q: "++9&RY?::OAELC9<OM-7Q: "++9&RY?:
M:OAELC9<OM-7Q: "++9&RY?::OAELC9<OM-7Q: #STV2\NLTI2H4A!I6[8E2
MF[5^(?-8HR_?8-;*W]G2>TW?$E1\_47]-[X9C6 8U1D.J1%MA2$626S*U3>G
M3S:%"[*W]G2>TW?'&J_)Q.MM>\-$!)E;^SI/:;OAE;^SI/:;OBL $F5O[.D]
MIN^&5O[.D]IN^*P 296_LZ3VF[XY/RGCBND<"25J#TFIO1H_3&@.,KYJ]^K5
M]P""GR7DTR(DH,A1$R@B42F[#\4M.E0JRM_9TGM-WPI?FF'^H1[I"L!)E;^S
MI/:;OAE;^SI/:;OBL $F5O[.D]IN^&5O[.D]IN^*P 296_LZ3VF[X@CR'2JT
MU10I!F;;5J24W:7E<_C6#:&?&\^3_P!4S_G =<K?V=)[3=\,K?V=)[3=\5@
MDRM_9TGM-WPRM_9TGM-WQ6 "3*W]G2>TW?#*W]G2>TW?%8 ,6I2'E,Q[84A%
MDEH[34WI\<M&A7K%^5O[.D]IN^.56^0C];9]\AH ),K?V=)[3=\,K?V=)[3=
M\5@ \C$37Z;4:LY'HS,AF;,RA!N32;4DL6A%AD25%SH/U^L=XM7G%R@*'.H+
M3$EZ*IY+C$I+JE)0I*;#M2G1:Y[?V#9JLAR+2)<AD['&VE*29E;89$/FB^4%
M357X\HY!8],-ULE8M/DFMLS*RRSU$ ^G96_LZ3VF[X_#LM[%+_\ Q\DO%/\
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M38XG1H5Z^87Y6_LZ3VF[XY5CYJSUN/\ %2- !)E;^SI/:;OAE;^SI/:;OBL
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M96_LZ3VF[XK !)E;^SI/:;OAE;^SI/:;OBL $F5O[.D]IN^&5O[.D]IN^*P
M8U2D/*9CVPI"+)+1^,IO3XQ:-"A=E;^SI/:;OCE5OD8W6V??(: "3*W]G2>T
MW?#*W]G2>TW?%8 ),K?V=)[3=\,K?V=)[3=\5@ DRM_9TGM-WPRM_9TGM-WQ
M6 #&I4EU-/(BA2%EC7=*5-V?**]JA=E;^SI/:;OCE1O-I?KG?B*&@ DRM_9T
MGM-WPRM_9TGM-WQ6 "3*W]G2>TW?#*W]G2>TW?%8 ),K?V=)[3=\93DATN4T
M9>2/DHH3Q$W:C",L-O3Y5EA6>VW2/0#(=]+HG4'OB- +,K?V=)[3=\,K?V=)
M[3=\5@ DRM_9TGM-WPRM_9TGM-WQ6 "3*W]G2>TW?#*W]G2>TW?%8 ,6IR'E
M1V2.%(19)9.U2F]/\HG1H5ZQ?E;^SI/:;OCE5_FS'6V/B)&@ DRM_9TGM-WP
MRM_9TGM-WQ6 "3*W]G2>TW?#*W]G2>TW?%8 ),K?V=)[3=\,K?V=)[3=\5@
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M96_LZ3VF[XK !)E;^SI/:;OAE;^SI/:;OBL $F5O[.D]IN^&5O[.D]IN^*P
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M_9TGM-WQ6 #&I\AU*IMD*0JV2HSL4WHT%HTJ%V5O[.D]IN^.5+\J=UM?W$-
M!Y^CONH54<&(^NV8LSP31XIV)T':HM/V:!JY6_LZ3VF[XCH?RE5Z^Y[J1K@)
M,K?V=)[3=\,K?V=)[3=\5@ DRM_9TGM-WQ"<E[/:%Y#(MR918&$W;Y1:?*L_
MB-D9Q^D2>J*]\@';*W]G2>TW?#*W]G2>TW?%8 ),K?V=)[3=\,K?V=)[3=\5
M@ DRM_9TGM-WPRM_9TGM-WQ6 #%J\AY=)E)5"D((T:5*4W87[E&8ORM_9TGM
M-WQQK?F27^K&B DRM_9TGM-WPRM_9TGM-WQ6 "3*W]G2>TW?#*W]G2>TW?%8
M ),K?V=)[3=\,K?V=)[3=\5@ Q:?(=2].LA2%6R3,[%-^+XJ=!VJ^X7Y6_LZ
M3VF[XXTSY:I=;/W$#1 296_LZ3VF[X96_LZ3VF[XK !)E;^SI/:;OAE;^SI/
M:;OBL $F5O[.D]IN^(%27L]LJR*1:4998&$W:?C(T^59_'UC:&<OTB8ZHY[Z
M ';*W]G2>TW?#*W]G2>TW?%8 ),K?V=)[3=\,K?V=)[3=\5@ \_67W5Q(V'%
M?19-CF1J-'.3J=&A1Z3YO9]@U<K?V=)[3=\25_YI$Z_&^*D:P#%K$AY=&F)5
M"D(2;*B-2E-V%HY]"C,7Y6_LZ3VF[XY5OS%._4*^X: "3*W]G2>TW?#*W]G2
M>TW?%8 ),K?V=)[3=\,K?V=)[3=\5@ DRM_9TGM-WPRM_9TGM-WQ6 #%@2'2
MD5 RA2%84FTR)3?B_P FC0=JON]HORM_9TGM-WQQIOSJI];_ .VV-$!)E;^S
MI/:;OAE;^SI/:;OBL $F5O[.D]IN^&5O[.D]IN^*P 296_LZ3VF[X@7)>SW&
M5D,BTHSI8&$W:?C-Z?*L_CZQM#/=](HG5'O?: =<K?V=)[3=\,K?V=)[3=\5
M@ DRM_9TGM-WPRM_9TGM-WQ6 "3*W]G2>TW?#*W]G2>TW?%8 ,6L27ET6<A4
M*0A)QW"-:E-V)\4])V*,_P!Q"_*W]G2>TW?'*N^C]1ZLY[IC0 296_LZ3VF[
MX96_LZ3VF[XK !)E;^SI/:;OAE;^SI/:;OBL $F5O[.D]IN^&5O[.D]IN^*P
M 8_)SS6X?K.;+,R]ELAS1]I<PV!D<G?-CW7IG_V7!K@    ))3#KR48F0;*D
MJPK<'"2K096*+UEI]I<Q"L &!+A(I] C1T+-9)F1C-1E9:9R$&>CU%:9Z/4-
M\9-?(U4M*24:3.7&(E%SE_+MZ2M%.12-J2^RU< 6CQB:<TW#BQ)U)<E.16B:
M)PH^&G1[#]@]-D4C:DOLM7 R*1M27V6K@#,I$4LL9<:B+BQXS+C26UMX&E:D
MGH+V>*?[Q),Y$4RK<J)U4JT.+.9?CQVFF7FL+%FVIPS/3H,CPDZ/J&]D4C:D
MOLM7 R*1M27V6K@#Q]9Y!/U)B<;<YLGG*NFJL$M*R3:E@FB;4:5$HN8_&2=I
M:-!\P\VG\G-6*8_0VI,<H#]+0S+E+BJ,CPY3[JTM&:CL4G"(BPC/G(STEI^J
M9%(VI+[+5P,BD;4E]EJX QZKR2@UKE%"GU*+#FQ(L-UC)Y3"7"PU*;,ED2B,
MM!(47[1@U#\G\V17TNP)L*+2"G0YYQBC'AH5'2E!-HL,DD@TI+U:#*RRP>VR
M*1M27V6K@9%(VI+[+5P!Y;DGR(?Y.-5(G9K;RID.+&+ 098!M,$T9_7:96B1
MS\F%.3R&>HT5F&Q5'X#<1ZHDSXR\$TF9^VPS3;9;[/8/:9%(VI+[+5P,BD;4
ME]EJX ^;2_R6U274);SM89-I:)J&L(G5JLD$K^B:L!&"9EH0DL+29Z1Z)?(I
MY?+1BNY:WBVIAR39P#M,CBI8LMM]J;1Z?(I&U)?9:N!D4C:DOLM7 'B.3WY.
MI5&JD&:Y4FW<G7'4I"6C*W%Q5,'IM]9JM^P>9>Y&5RF5!FD0V79,>4=.*1)*
M,E2+(YIPE)6:RQ=A).U)DHS/F\H\'Z[D4C:DOLM7 R*1M27V6K@#S]8Y%M<H
MJX_,JDN2J)D)PV(T:2XS@81F;BE&E186%XA6'HL25I&/*T/D+7$UF<Q+F,'#
M0] -R0N,9KD9.VV:3;4:M%IE8HSMYCL\K1]*R*1M27V6K@9%(VI+[+5P!\RY
M-<@JO)I-(D5)YB,Y$88;89R8T.)04A#RR<M,_&_DR(K+/69EIT:--_)U5*2M
M"8E5AXF0Q&;FF]#)Q1&QY)M81V%;Z\(CLYRTGH]YD4C:DOLM7 R*1M27V6K@
M#YM!_)E6X;:U'5HKKR6XZ&L/'+)1L/$XA2C4HS*TL(L%-A%HL'[C_DMG1HK]
M/35HZX4_!1.);"C62$/K=3BCPK",\/!.TM'E%[!]&R*1M27V6K@9%(VI+[+5
MP!Y?D_R+?HKU'4N8AW-ZIIJL098>/<2HK/LLTCVHBR*1M27V6K@9%(VI+[+5
MP!: BR*1M27V6K@9%(VI+[+5P!: BR*1M27V6K@9%(VI+[+5P!: BR*1M27V
M6K@9%(VI+[+5P!: BR*1M27V6K@9%(VI+[+5P!: BR*1M27V6K@9%(VI+[+5
MP!: BR*1M27V6K@9%(VI+[+5P!: BR*1M27V6K@9%(VI+[+5P!: BR*1M27V
M6K@9%(VI+[+5P!: BR*1M27V6K@9%(VI+[+5P!G1H2:E1*M <4I")+TIE2D\
MY$I2BM+]XQN1?(N3R:F/.R7H3A)C-PV<EC&R:VT&9DMS29&L[?V6#8I,1Y3,
MK!GR6[)3Q&24MZ?'/3I0>DQI9%(VI+[+5P!: BR*1M27V6K@9%(VI+[+5P!:
M BR*1M27V6K@9%(VI+[+5P!: BR*1M27V6K@9%(VI+[+5P!: BR*1M27V6K@
M9%(VI+[+5P!: BR*1M27V6K@9%(VI+[+5P!:,J$DEU>L)45J36V1E_\ RR%&
M12-J2^RU<&;"B/G5:DDJA)(TK;M426[5>(7/XEG[K 'EV_R?U6S%.U>&MB&R
MIBG(7")Q. :R4>.2K0KF).BSFMMM'\IG(&M4Z;,J+51A,39#;KB"99/$LON&
M1&:4GIP20E-FGG]0]WD4C:DOLM7 R*1M27V6K@#YVG\FM1S6RT])I4B1'D'*
M/'1G%MS7%%8HY!&HS4?LLT%S6#<Y.\BG:- J#+\AEUZ3%3$;=;2HB0@D&5F"
M9Z"M,SL(>HR*1M27V6K@9%(VI+[+5P!X6I_D\GS*-"I3<VG*83#3#D+?@DIU
M"25A&II=MI&?-@G:7K'T",PF-%9CI,S2TA*",^<R(K!QR*1M27V6K@9%(VI+
M[+5P!: BR*1M27V6K@9%(VI+[+5P!: BR*1M27V6K@9%(VI+[+5P!: BR*1M
M27V6K@9%(VI+[+5P!Q@^>ZK]K7N#Q$K\F3E07)I\F:PFB&X_(CMH:5CDNN\^
M$9JL,DGI*PM-OJ'JX<1\ZO4DE4))&DV[5$ENU7B^OQ+/W6#2R*1M27V6K@#P
M,#\FLI,Q+M0F1,498*VH#2F4F26L6A6"9J(U:3,S^\=8OY.),I*6J[53>:B,
MH8@G%1@+)*#-1*69VD:K3YBT:![G(I&U)?9:N!D4C:DOLM7 'E^2/(R3R<FM
MO2YJ)B68F3LJ5::TVK-:CM/F+3S$(I7(.I%18L.),IKCK)/(64R"3B32Z9^,
ME7EI41'ZCL/UCVN12-J2^RU<#(I&U)?9:N .5#I3=#H<.EM.+<;BM);):SM-
M5GK&D(LBD;4E]EJX&12-J2^RU< 6@(LBD;4E]EJX&12-J2^RU< 6@(LBD;4E
M]EJX&12-J2^RU< 6C+_K074C]\=\BD;4E]EJX,W)'O"' SA)PLDMP\%NWR^;
MR++/V ,63R(DKY2NR69<?-,J:W4)4=UDU.FZ@K"))VV8)Z#TEHL&?6_R=3ZC
M,?EPY\:&M<G^3;:2M"&V=!VD23(L/"M5I(R,[![S(I&U)?9:N!D4C:DOLM7
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M%':5WC\N<G*0EI9E!1:23,M)]X_>4Q=O?XC-T?AR3&Q2_P#\[;XIZ,8SI_\
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M< 5@),D?VC)[+=P,D?VC)[+=P!6 DR1_:,GLMW R1_:,GLMW '*D?-G^MO\
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MNX&2/[1D]ENX K 29(_M&3V6[@9(_M&3V6[@"L!)DC^T9/9;N!DC^T9/9;N
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MD1"YD=*DLH(R-U)&1X)?6*LYT_7HV^3W@*P$F<Z?KT;?)[PSG3]>C;Y/> K
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MT_7HV^3W@*P$F<Z?KT;?)[PSG3]>C;Y/> K&<WZ0R>J,^^X.V<Z?KT;?)[Q
MW/AE6Y#ARX^ <9I)*QA6&9*<M*VWZR_> V@$F<Z?KT;?)[PSG3]>C;Y/> K
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MZ?KT;?)[P%8SB](5=43[YCMG.GZ]&WR>\0E/A9\4YE<? R8DX6,*RW"/1;:
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M#1&+59\-R&VE$N.LRDQU&1.$>@G4&9\_J(C,7YSI^O1M\GO 1\J?1&M=0?\
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M4VT_3HBW,<\IPE22)9.GI,_&\FWVZ 'O0
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M_P!0CW2%8DI?FF'^H1[I"L        9\;SY/_5,_YQH#/C>?)_ZIG_. T
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M$9S?I#)ZHS[[@#1         !GU+YS3>M_\ ;6- 9]2^<TWK?_;6-
M  9')?T6IG5D?<-<9')?T6IG5D?< [T/S%!_4I^X: SZ'YB@_J4_<-
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MOJ&B,ZB^:F_TW/?4-$        9RO2)OJB_?2-$9RO2)OJB_?2 T0
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MD[UN1\98T!GT;YD[UN1\98T        !GL^D4OJC/ONC0&>SZ12^J,^^Z T
M         9]8\WIZPQ\5 T!GUCS>GK#'Q4#0           9](^;/];?^(H:
M SZ1\V?ZV_\ $4-     !D,^E\OJ#/Q'1KC(9]+Y?4&?B.@-<9R/2)_JC?OK
M&B,Y'I$_U1OWU@-$         &?6O-BOUK7Q$C0&?6O-BOUK7Q$C0
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M?I$GJBO?(:(SC](D]45[Y -$         &=6_,DO]6-$9U;\R2_U8T0
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M4B<4K\,>*9_*E"=FF94NIE3SBM2&GCC'ANFXZ;:,%/L581D?KM/FL%C/Y3*
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MSY:I=;/W$#1 28RH:M&XA5P,94-6C<0JX*P 28RH:M&XA5P,94-6C<0JX*P
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M*JY8$V3*6RIZ8ZI"#)-IR%$H]/JP321E]FGV#UF:X_TDOC';P9KC_22^,=O
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M6TF9DDB25IVGH^L=!%FN/])+XQV\&:X_TDOC';P"T!%FN/\ 22^,=O!FN/\
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M$RNF15&N1:IE!G9(<(O)+U$K0*\@8Z<GBG+P"L!)D#'3D\4Y>#(&.G)XIR\
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M>*<O!D#'3D\4Y>#55MWV+8?-_P UE0VC%[*@_-94-HQ>RH?2,@8Z<GBG+P9
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MRH1S2;B&_%2KG4HDE_$R';\UE0VC%[*A[FJ0VFX:%$J1\X8+2^X?.Z@O6?\
M'U"_(&.G)XIR\&JK;OL6P^;_ )K*AM&+V5!^:RH;1B]E0^D9 QTY/%.7@R!C
MIR>*<O!JJV[[%L/F_P":RH;1B]E0?FLJ&T8O94/I&0,=.3Q3EX,@8Z<GBG+P
M:JMN^Q;#YO\ FLJ&T8O94'YK*AM&+V5#Z1D#'3D\4Y>#(&.G)XIR\&JK;OL6
MP^81/R;39<-F2W4(Y(>02TDI*K2(RMTCO^:RH;1B]E0]U1X33E$A+4N01JCM
MF>#(<27DES$1V%^P79 QTY/%.7@U5;=]BV'S?\UE0VC%[*@_-94-HQ>RH?2,
M@8Z<GBG+P9 QTY/%.7@U5;=]BV'S?\UE0VC%[*@_-94-HQ>RH?2,@8Z<GBG+
MP9 QTY/%.7@U5;=]BV'S?\UE0VC%[*AQ3^36:J8Y%*H1\-#:7#/!598HU$7N
MF/IV0,=.3Q3EX0MPVCK<A&%(L*,T?SARW2ISUVV^KF#55MWV+8>%_-94-HQ>
MRH/S65#:,7LJ'TC(&.G)XIR\/P[%BQV7'G7I"&VTFI2CE.6$1:3/R@U5;=]B
MV'SK\UE0VC%[*@_-94-HQ>RH?0(2(-1A-2XK\EQAY)*0HI+NDNUH%&0,=.3Q
M3EX-56W%L/F_YK*AM&+V5!^:RH;1B]E0^D9 QTY/%.7@R!CIR>*<O!JJV[[%
ML/F#WY-IK"V$+J$<S><Q:;$JT'@FK3^Q)CO^:RH;1B]E0]S.AM)DP")<CQI-
MAVON'_Z:ST6GHYN<A?D#'3D\4Y>#55MWV+8?-_S65#:,7LJ#\UE0VC%[*A](
MR!CIR>*<O!D#'3D\4Y>#55MWV+8?-_S65#:,7LJ#\UE0VC%[*A](R!CIR>*<
MO!D#'3D\4Y>#55MWV+8?-_S65#:,7LJ$T'\G,N? 9F,SV$MOH):26@R,B/VC
MZCD#'3D\4Y>&7R=B-O<FZ>XI3Y*5'09DA]:2YO41'87[ U5;=]BV'A(OY-9L
MR(U);J$<D.I)224E5MACO^:RH;1B]E0]U1X;3E'AK4N01J:2?BON)+F]A'80
MNR!CIR>*<O!JJV[[%L/F_P":RH;1B]E0?FLJ&T8O94/I&0,=.3Q3EX,@8Z<G
MBG+P:JMN^Q;#YO\ FLJ&T8O94'YK*AM&+V5#Z1D#'3D\4Y>#(&.G)XIR\&JK
M;OL6P^;_ )K*AM&+V5#B7Y-9IS%1<X1\-+9.&>"JRPS,O^@^G9 QTY/%.7A"
MF&UGMU.%(L*,@_EW+?*5Z[;?V!JJV[[%L/"_FLJ&T8O94'YK*AM&+V5#Z1D#
M'3D\4Y>#(&.G)XIR\&JK;OL6P^;_ )K*AM&+V5!^:RH;1B]E0^D9 QTY/%.7
M@R!CIR>*<O!JJV[[%L/F_P":RH;1B]E0MHW("K4>JL3F*C#PV[2\=I2RL,O8
M1IM_>0]WD#/3D\4Y>#(&>G)XIR\,XNHJXHMG%Z?Z6V&/4&*X3L+"J-..V26#
M9 65AX*N?^6TB[)^4&TZ9_\ '.?CCG/AM)=A$2Y'C22([9#A_P!%7-:>C[2%
M^0,=.3Q3EX>2LN!.J1<I)%*FN1'D(AHDH<884T=JEJ29&1K5;Y/U#?'EFXC?
MA[(;PG\$J6T=N/7;\JYZ[;?V#>R!CIR>*<O *P$F0,=.3Q3EX,@8Z<GBG+P"
ML!)D#'3D\4Y>#(&.G)XIR\ XT3S-%_0&B,6D0FG*5&6I4@C-&G!D.)+]Q'8+
M\@8Z<GBG+P"L!)D#'3D\4Y>#(&.G)XIR\ K 29 QTY/%.7@R!CIR>*<O *QG
M%Z0JZHGWS';(&.G)XIR\("AM9[4G"D69,1_.'+?*/UVV_L ;0R"]+E]03\0Q
M9D#'3D\4Y>&6F&WX3K:PGL'(TJMQZ\*W#/UVVV?5S -\!)D#'3D\4Y>#(&.G
M)XIR\ K 29 QTY/%.7@R!CIR>*<O .53\J%UM'W&- 8M1AM(R2Q<CQI*".U]
MP_4?M/1]HOR!CIR>*<O *P$F0,=.3Q3EX,@8Z<GBG+P"L!)D#'3D\4Y>#(&.
MG)XIR\ K 29 QTY/%.7@R!CIR>*<O .5$\SL?\7O&- 8M(A-N4IE:ER+3PO)
MD.)+RC]1&+\@8Z<GBG+P"L!)D#'3D\4Y>#(&.G)XIR\ K 29 QTY/%.7@R!C
MIR>*<O *QG?UB_NG^<=L@8Z<GBG+P@R-K/9)PI%F36_.'+?*]MMO[ &T DR!
MCIR>*<O!D#'3D\4Y> 5@),@8Z<GBG+P9 QTY/%.7@%8"3(&.G)XIR\&0,=.3
MQ3EX!RJODP^MM_>- 8M1AM(1%L7(^<MD=LAP_7]9_P 1?D#'3D\4Y> 5@),@
M8Z<GBG+P9 QTY/%.7@']G^;9?ZE?W&.=&\QT_JS?ND.4V RF!)42Y%I-*,K9
M+AES'ZL(<J5!:<I$%9KD$:H[9G@R'"+R2YB)5A -@!)D#'3D\4Y>#(&.G)XI
MR\ XT7S4W^FY[ZAHC&I,-M=-;6I<@C-2_)D.$7EGZB,79 QTY/%.7@%8"3(&
M.G)XIR\&0,=.3Q3EX!6 DR!CIR>*<O!D#'3D\4Y> 5C.5Z1-]47[Z1VR!CIR
M>*<O"!4-K/;:<*18<91_.'+?*3Z[;?V -H!)D#'3D\4Y>#(&.G)XIR\ K 29
M QTY/%.7@R!CIR>*<O *P$F0,=.3Q3EX,@8Z<GBG+P#E5OD8W6V??(: Q:E#
M:0S',E2#MDM%ID.'SJ+VG_$7Y QTY/%.7@%8"3(&.G)XIR\&0,=.3Q3EX!6
MDR!CIR>*<O!D#'3D\4Y> 5@),@8Z<GBG+P9 QTY/%.7@'*C>;2_7._$4- 8M
M*AM.0"4:Y%N-=+Q9#A%H<47,1B_(&.G)XIR\ K 29 QTY/%.7@R!CIR>*<O
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M-VZ&=(_T<O@W;H"T!%G2/]'+X-VZ&=(_T<O@W;H"T!%G2/\ 1R^#=NAG2/\
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M82#1(,TL((\&.X9>27,9)L,3T"6TU3,%27S/*)!^*RM1:7EGSD5GK_9S /0
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M2F01JC.$6%'<27DGSF96%^T7Y>QT)/"N70%8"3+V.A)X5RZ&7L="3PKET!6
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M*2Q@DLVEDG!P2(CMPC29&9E@GA$8^Z@
M ,:FOM18%0D/+)#;4J0M:SYDI)9F9_N$O)[E= Y2K>;BL3&'6D)<P)+. :VU
M>2M.DR-)V']>CF'[9A9RH-8@8> 4EV4SAV6X.$:BML]?.,ODE0J["J"IE;*
ME;$)N P45:E8:4&HS<.TBLPC/R?5[0'M                 &73_/-6_3:^
M&0U!E0BPJO5R.W2MLM!V?^F0#!1^4>@JRLW$S6DLH4XTIR.994@E8!J:+G46
M%86DBY_8+(_+>C.QF'E+=84[)5%6R\24K86E)J5C"MT$1%:9VGSD/(R/R?\
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MS?ND)>3GFC^\R?CK :X      #.C^?IWZAC[W!HC.C^?IWZAC[W &B
M   #/K'S5GK<?XJ1H#/K'S5GK<?XJ1H        #^*\D_L']'\5Y)_8 @HGH
M_3NJM>Z0T!GT3T?IW56O=(:         SF/2&;U5CWWAHC.8](9O56/?> :(
M  #(D>EU-ZA*^)'&N,B1Z74WJ$KXD<:X    SZQ\Q;ZU'^,@: SZQ\Q;ZU'^
M,@:           #/H7H_3NK-^Z0T!GT+T?IW5F_=(:         SF_2&3U1G
MWW!HC.;](9/5&??< :(         ,^I?.:;UO_MK&@,^I?.:;UO_ +:QH
M     #(Y+^BU,ZLC[AKC(Y+^BU,ZLC[@'>A^8H/ZE/W#0&?0_,4']2G[AH
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MF4S_ .1<_ &4E^N^$ZSS=3\;D:?%R]>#9AGIMQ//]5G[0'JP&3E'*#9E,_\
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MRF?_ "+GX 91R@V93/\ Y%S\ !K ,G*.4&S*9_\ (N?@!E'*#9E,_P#D7/P
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MR@V93/\ Y%S\ ,HY0;,IG_R+GX #6 9.4<H-F4S_ .1<_ #*.4&S*9_\BY^
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MK6OB)&@,^M>;%?K6OB)&@           SJ3\C*ZV][QC1&=2?D976WO>,:(
M       SD^D3G5$^^H:(SD^D3G5$^^H!H@         SJSYJ=_21[Y#ERD\P
MO_IM_$2.M9\U._I(]\ARY2>87_TV_B) :P         ,^E>3,ZVY]XT!GTKR
M9G6W/O&@        ,_\ K%_=/\XT!G_UB_NG^<!H          SJUYGD?87O
M$-$9U:\SR/L+WB&B           SZ7Y4[K:_N(: SZ7Y4[K:_N(: #(H?RE5
MZ^Y[J1KC(H?RE5Z^Y[J1K@    ,X_2)/5%>^0T1G'Z1)ZHKWR :(
M ,ZM^9)?ZL:(SJWYDE_JQH@          ,ZF?+5+K9^X@:(SJ9\M4NMG[B!H
M@       #.7Z1,=4<]] T1G+](F.J.>^@!H@     #)K_P TB=?C?%2-89-?
M^:1.OQOBI&L SZWYBG?J%?<- 9];\Q3OU"ON&@           SJ;\ZJ?6_\
MMMC1&=3?G53ZW_VVQH@       #/=](HG5'O?:&@,]WTBB=4>]]H!H
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MV,;D:?&Q)X-F&>BS"Y_KM_8-\9!>ER^H)^(8"S%U#68W#JOABZAK,;AU7Q6
M"3%U#68W#JOABZAK,;AU7Q6 #&J*)I'$PY$<_P"<HP;&#*P[#_W](NQ=0UF-
MPZKXY5/RH76T?<8T $F+J&LQN'5?&"2)GAZHL>QC,UEXV).RS&GZL+_J/4CS
MY?[0U?V47Q3 :N+J&LQN'5?#%U#68W#JOBL $F+J&LQN'5?#%U#68W#JOBL
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M%U#68W#JOBL $F+J&LQN'5?#%U#68W#JOBL $F+J&LQN'5?#%U#68W#JOBL
M&-4T3":CX<B.992U9@L&6G"*S^F+L74-9C<.J^.56^1C=;9]\AH ),74-9C<
M.J^&+J&LQN'5?%8 ),74-9C<.J^&+J&LQN'5?%8 ),74-9C<.J^&+J&LQN'5
M?%8 ,6E(FYO+%/QTEC7="F#,[<8JW^F7K%^+J&LQN'5?'*C>;2_7._$4- !)
MBZAK,;AU7PQ=0UF-PZKXK !)BZAK,;AU7PQ=0UF-PZKXK !)BZAK,;AU7QE.
M(F>$\8C?9QN1O6*Q)X)%AMVE9A<_-IM_9[/0#(=]+HG4'OB- +,74-9C<.J^
M&+J&LQN'5?%8 ),74-9C<.J^&+J&LQN'5?%8 ),74-9C<.J^&+J&LQN'5?%8
M ,6IIFE&:QDB.HLI9\E@RTXQ-G],_6+\74-9C<.J^.57^;,=;8^(D: "3%U#
M68W#JOABZAK,;AU7Q6 "3%U#68W#JOABZAK,;AU7Q6 "3%U#68W#JOABZAK,
M;AU7Q6 #%I:)IP58M^.DL>]H4P9G;C56_P!,O7_^C%^+J&LQN'5?'*C>;U=8
M?^*L: "3%U#68W#JOABZAK,;AU7Q6 "3%U#68W#JOABZAK,;AU7Q6 "3%U#6
M8W#JOB!Q,W/<4CD1\9DSUAX@["+";MT8?V>OV_LVAG.^D43JC_OM .V+J&LQ
MN'5?#%U#68W#JOBL $F+J&LQN'5?#%U#68W#JOBL $F+J&LQN'5?#%U#68W#
MJOBL &)5$32AHQC\=193'L(F#+3C46?TS]=G_CG&ABZAK,;AU7QQK/S)OK<;
MXR!H@//\HT3"Y+U8WGV%M%#>PTH9-*C+ .TB,U'8?UV']@U<74-9C<.J^(^5
M/HC6NH/_  U#7 28NH:S&X=5\,74-9C<.J^*P 28NH:S&X=5\,74-9C<.J^*
MP 8M+1-.(YBWXZ2RE^TC8,].-7;_ $R]=O\ YYQ?BZAK,;AU7QRHWS)WK<CX
MRQH ),74-9C<.J^&+J&LQN'5?%8 ),74-9C<.J^&+GZS&X=5\5@ \KR*1,/D
M+R?-IYA+1TZ/@I4R:C(L6GG/#*W]PT&T3L]R2*1'QF3-6GB#L,L)RS1A_;Z_
M_/'D+_L_Y._V;'^&D:#/I%+ZHS[[H#KBZAK,;AU7PQ=0UF-PZKXK !)BZAK,
M;AU7PQ=0UF-PZKXK !)BZAK,;AU7PQ=0UF-PZKXK !BU1$PH)8Q^.HL>SH2P
M9';C4V?TS]8OQ=0UF-PZKXY5CS>GK#'Q4#0 28NH:S&X=5\,74-9C<.J^*P
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M8W#JOABZAK,;AU7Q6 "3%U#68W#JOB# FY[LRB/C,FY\0=EF%[,/_J-H9_\
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M6#.T\%/-X^@78NH:S&X=5\<:9\M4NMG[B!H@),74-9C<.J^&+J&LQN'5?%8
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MJS!\5W"PR+!T6$?,-&F\FJ72HDJ+#84AB2DD.(-Q1^*2<$B(S.TM XX_DH<
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MK+<+GLL ;("3-E/U&-N4]P9LI^HQMRGN 5@),V4_48VY3W!FRGZC&W*>X!6
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M)[3=\,K?V=)[3=\!Y7P&>UYO=GWAX#/:\WNS[QZK*W]G2>TW?#*W]G2>TW?
M>5\!GM>;W9]XX-\D'7)C\8IB"-I*%&>+/3A6_7]0]CE;^SI/:;OB"/(=*K35
M%"D&9MM6I)3=I>5S^-8 Q/ 9[7F]V?>'@,]KS>[/O'JLK?V=)[3=\,K?V=)[
M3=\!Y7P&>UYO=GWAX#/:\WNS[QZK*W]G2>TW?#*W]G2>TW? >5\!GM>;W9]X
M> SVO-[L^\>JRM_9TGM-WPRM_9TGM-WP'CI/(]V*AM2IB%8;J&]#9Z,)1%;S
M_6._@,]KS>[/O&W4I#RF8]L*0BR2T=IJ;T^.6C0KUB_*W]G2>TW? >5\!GM>
M;W9]X> SVO-[L^\>JRM_9TGM-WPRM_9TGM-WP'E? 9[7F]V?>'@,]KS>[/O'
MJLK?V=)[3=\,K?V=)[3=\!Y7P&>UYO=GWC^*Y$/)0I1SD:"M^3/O'J\K?V=)
M[3=\?AV6]BE__CY)>*?])N^ \E$Y'.RH;$@IJ$DZVE=AMGHM*WVCE3^2;E0B
M90F8A!8QQNPV^@M2+>?UX-H]12Y#R:3"24*0LB801*2INP_%+25JK1/07WD4
MO!3$?<+*)!X2319I>6=FE1'HYOV>L!E> SVO-[L^\/ 9[7F]V?>/596_LZ3V
MF[X96_LZ3VF[X#RO@,]KS>[/O#P&>UYO=GWCU65O[.D]IN^&5O[.D]IN^ \K
MX#/:\WNS[Q.CD>ZN:]&*8@C:0A9JQ9Z<(U?7_N_Q'LLK?V=)[3=\0,R'2K,P
MRA2#,V&2-)*;M+2YI\JS3_T 8*^0\@D*-$QHU6:"-!D1F/SR2C/P^4,IB2TI
MMU,<[4J_2+27M+ZQZ_*W]G2>TW?'XQ[F&2\V2,,BL)5K5MGL\L!< DRM_9TG
MM-WPRM_9TGM-WP%8"3*W]G2>TW?#*W]G2>TW? <JQ\U9ZW'^*D: Q:I(>5%:
M(X4A%DE@[34WIL<3HT*]?,+\K?V=)[3=\!6 DRM_9TGM-WPRM_9TGM-WP%8"
M3*W]G2>TW?#*W]G2>TW? 5C^*\D_L$N5O[.D]IN^/X<I[!/_ /'R>;I-WP'.
MB>C].ZJU[I#0&+1Y#R*+!2F%(611FR)25-V*\4M)6J(_WB_*W]G2>TW? 5@)
M,K?V=)[3=\,K?V=)[3=\!6 DRM_9TGM-WPRM_9TGM-WP%8SF/2&;U5CWWAVR
MM_9TGM-WQG-2'BKDI>1R#,XS)&WA-VE8IW3Y5FFWV^H_J ;@"3*W]G2>TW?#
M*W]G2>TW? 1R/2ZF]0E?$CC7'GG7W?">"O)'\(H4DB;,T82B-;&DO&LL*PN<
M[=)66Z;-;*W]G2>TW? 5@),K?V=)[3=\,K?V=)[3=\!RK'S%OK4?XR!H#%JL
MAU4)!'#D(_G+!VFIOU.H.S0KU\W[1?E;^SI/:;O@*P$F5O[.D]IN^&5O[.D]
MIN^ K 296_LZ3VF[X96_LZ3VF[X"L!)E;^SI/:;OAE;^SI/:;O@.5"]'Z=U9
MOW2&@,6C2'D42$E,*0LBCMD1I4W8KQ2TE:HC_>+\K?V=)[3=\!6 DRM_9TGM
M-WPRM_9TGM-WP%8"3*W]G2>TW?#*W]G2>TW? 5C.;](9/5&??<';*W]G2>TW
M?$")+V>Y"\AD&9QFBP,)NTO&<T^59_'U -H!)E;^SI/:;OAE;^SI/:;O@*P$
MF5O[.D]IN^&5O[.D]IN^ K 296_LZ3VF[X96_LZ3VF[X#E4OG--ZW_VUC0&+
M.D.G(IYG"D)P9-I$:F_&_DUZ"L5]_L%^5O[.D]IN^ K 296_LZ3VF[X96_LZ
M3VF[X"L!)E;^SI/:;OAE;^SI/:;O@*QD<E_1:F=61]PLRM_9TGM-WQE<G7W6
M^3E.0F(^XE,=!$M!HL5HYRM41_O(!H4/S%!_4I^X: Q:/)>11X:4PI"R)I)$
MI*F[#T?6HC%^5O[.D]IN^ K 296_LZ3VF[X96_LZ3VF[X"L!)E;^SI/:;OAE
M;^SI/:;O@*QG(](G^J-^^L=LK?V=)[3=\0)DO9[=7D,BTXR"P,)NTO&5I\JS
M^(#: 296_LZ3VF[X96_LZ3VF[X"L!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]
MIN^&5O[.D]IN^ XU/Y:G];+W5#1&+/D/&["MA2$V22,K5-^-XJM!6*^\7Y6_
MLZ3VF[X"L!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^ K 296
M_LZ3VF[X96_LZ3VF[X#C1/,T7] :(Q:1(>128R4PI"R)&A25-V'^]1&+\K?V
M=)[3=\!6 DRM_9TGM-WPRM_9TGM-WP%8"3*W]G2>TW?#*W]G2>TW? 5C.+TA
M5U1/OF.V5O[.D]IN^(2DO9[4O(9%N3$6!A-V^4>GRK/X@-D9!>ER^H)^(8LR
MM_9TGM-WQE)D.^$ZUY(_A9$DL7:C"LPST^599^VT!Z !)E;^SI/:;OAE;^SI
M/:;O@*P$F5O[.D]IN^&5O[.D]IN^ Y5/RH76T?<8T!C5"0ZK([84A-DE!E:I
MO3H/1H4+LK?V=)[3=\!6//E_M#5_91?%,:N5O[.D]IN^,$I#OAZI>1OX6:R+
M M1;\J>GRK/X@/4@),K?V=)[3=\,K?V=)[3=\!6 DRM_9TGM-WPRM_9TGM-W
MP'*B>9V/^+WC&@,6D2744IE*8,A9%A>,E3=A^,?M40ORM_9TGM-WP%8"3*W]
MG2>TW?#*W]G2>TW? 5@),K?V=)[3=\,K?V=)[3=\!6,[^L7]T_SCME;^SI/:
M;OB'*7L]DK(9%N368&$W;Y7/Y5G\0&R DRM_9TGM-WPRM_9TGM-WP%8"3*W]
MG2>TW?#*W]G2>TW? 5@),K?V=)[3=\,K?V=)[3=\!RJODP^MM_>- 8U2D.J1
M%MA2$V26S*U3>G3S:%"[*W]G2>TW? 92O]H;?]E+^*D>@'EE2'?#UM>1OX6:
MUE@6HM^53I\JS^(WLK?V=)[3=\!_9_FV7^I7]QCG1O,=/ZLW[I#E-DO*@22.
M#(21M*(S-3=A:#_WARI4AU-(@I*%(611VR)25-V'XI:2M5: V $F5O[.D]IN
M^&5O[.D]IN^ XT7S4W^FY[ZAHC&I,EU--;),*0LL)?C)4W9Y9^U0NRM_9TGM
M-WP%8"3*W]G2>TW?#*W]G2>TW? 5@),K?V=)[3=\,K?V=)[3=\!6,Y7I$WU1
M?OI';*W]G2>TW?$*I+V>VUY#(MR918&$W;Y2=/E6?Q ;("3*W]G2>TW?#*W]
MG2>TW? 5@),K?V=)[3=\,K?V=)[3=\!6 DRM_9TGM-WPRM_9TGM-WP'*K?(Q
MNML^^0T!C5*0\IF/;"D(LDM'XRF]/C%HT*%V5O[.D]IN^ K 296_LZ3VF[X9
M6_LZ3VF[X"L!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^ Y4;
MS:7ZYWXBAH#&I4EU-/(BA2%EC7=*5-V?**]JA=E;^SI/:;O@*P$F5O[.D]IN
M^&5O[.D]IN^ K 296_LZ3VF[X96_LZ3VF[X"L9#OI=$Z@]\1H696_LZ3VF[X
MRG)#I<IHR\D?)10GB)NU&$98;>GRK+"L]MND!Z !)E;^SI/:;OAE;^SI/:;O
M@*P$F5O[.D]IN^&5O[.D]IN^ K 296_LZ3VF[X96_LZ3VF[X#E5_FS'6V/B)
M&@,6IR'E1V2.%(19)9.U2F]/\HG1H5ZQ?E;^SI/:;O@*P$F5O[.D]IN^&5O[
M.D]IN^ K 296_LZ3VF[X96_LZ3VF[X"L!)E;^SI/:;OAE;^SI/:;O@.5&\WJ
MZP_\58T!BTJ2ZF$HBA2%ECWCM2INSY56C2KU<PORM_9TGM-WP%8"3*W]G2>T
MW?#*W]G2>TW? 5@),K?V=)[3=\,K?V=)[3=\!6,YWTBB=4?]]H=LK?V=)[3=
M\9[DA[/<5612"LC/$3>$W:?C-Z?*LT6>WUE]8#; 296_LZ3VF[X96_LZ3VF[
MX"L!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^ XUGYDWUN-\9
M T1B520\N&V1PY"/YS'.TU-^IU!V:%>OF_;ZAH96_LZ3VF[X"/E3Z(UKJ#_P
MU#7'GN4;[J^3%60J(\VE4)XC<6:,%)8!Z3L49V%]1&8ULK?V=)[3=\!6 DRM
M_9TGM-WPRM_9TGM-WP%8"3*W]G2>TW?#*W]G2>TW? <J-\R=ZW(^,L: Q:7(
M=3$<(H<A?\Y?.U*F_6ZO1I5ZN;]@ORM_9TGM-WP%8"3*W]G2>TW?#*W]G2>T
MW? 5@),K?V=)[3=\,J>V?)[3=\!E<A?]G_)W^S8_PTC09](I?5&??=&+R*DN
MHY"<GT)AON)*G1R):5(L5_)ITE:HC_@-!N2[GN2K(9!F<9HC1A-VEXSFGRK-
M-OM]0#: 296_LZ3VF[X96_LZ3VF[X"L!)E;^SI/:;OAE;^SI/:;O@*P$F5O[
M.D]IN^&5O[.D]IN^ Y5CS>GK#'Q4#0&+59+JH1$<)]!8]D[5*;L^53HT*]?,
M+\K?V=)[3=\!6 DRM_9TGM-WPRM_9TGM-WP%8"3*W]G2>TW?#*W]G2>TW? 5
M@),K?V=)[3=\,K?V=)[3=\!RI'S9_K;_ ,10T!BTR0\F.\10I"[9+QVI4WH_
ME%:-*O4+\K?V=)[3=\!6 DRM_9TGM-WPRM_9TGM-WP%8R&?2^7U!GXCHLRM_
M9TGM-WQE-ON^$TE>2/FHX31&W:C"(L-S3Y5EG[;= #T SD>D3_5&_?6.V5O[
M.D]IN^($27L]O*R&1:<9LL#";M+QEZ?*L_CZ@&T DRM_9TGM-WPRM_9TGM-W
MP%8"3*W]G2>TW?#*W]G2>TW? 5@),K?V=)[3=\,K?V=)[3=\!RK7FQ7ZUKXB
M1H#&JLEU5/,E0I""QC6E2F[/E$^Q0NRM_9TGM-WP%8"3*W]G2>TW?#*W]G2>
MTW? 5@),K?V=)[3=\,K?V=)[3=\!6 DRM_9TGM-WPRM_9TGM-WP'&D_(RNMO
M>\8T1C4V0\EJ39"D+MDNGXJF]'C'HTJ%V5O[.D]IN^ K 296_LZ3VF[X96_L
MZ3VF[X"L!)E;^SI/:;OAE;^SI/:;O@*QG)](G.J)]]0[96_LZ3VF[XA3)>SV
MM>0R+<F26!A-V^4>GRK/X@-D!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&
M5O[.D]IN^ K 296_LZ3VF[X96_LZ3VF[X#C6?-3OZ2/?(<N4GF%_]-OXB1^*
MM)=53'$JA2$%A(\92F[/*+V*'&OONN41Y*H;[9&MOQEFBPO'3[%&8#? 296_
MLZ3VF[X96_LZ3VF[X"L!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D
M]IN^ Y4KR9G6W/O&@,:G2'4IEV0I"K9+AG8IO1IYM*A=E;^SI/:;O@*P$F5O
M[.D]IN^&5O[.D]IN^ K 296_LZ3VF[X96_LZ3VF[X"L9_P#6+^Z?YQURM_9T
MGM-WQ#E+V>\/(9%N368&$W;Y7/Y5G\0&R DRM_9TGM-WPRM_9TGM-WP%8"3*
MW]G2>TW?#*W]G2>TW? 5@),K?V=)[3=\,K?V=)[3=\!QK7F>1]A>\0T1BU>0
M\NEOI5"D((R+QE*;L+27L49B_*W]G2>TW? 5@),K?V=)[3=\,K?V=)[3=\!6
M DRM_9TGM-WPRM_9TGM-WP%8"3*W]G2>TW?#*W]G2>TW? <J7Y4[K:_N(: Q
MJ?(=2J;9"D*MDJ,[%-Z-!:-*A=E;^SI/:;O@(Z'\I5>ON>ZD:X\_1WW4*J.#
M$?7;,69X)H\4[$Z#M46G[- U<K?V=)[3=\!6 DRM_9TGM-WPRM_9TGM-WP%8
MSC](D]45[Y#ME;^SI/:;OB$Y+V>T+R&1;DRBP,)NWRBT^59_$!L@),K?V=)[
M3=\,K?V=)[3=\!6 DRM_9TGM-WPRM_9TGM-WP%8"3*W]G2>TW?#*W]G2>TW?
M <:WYDE_JQHC%J\AY=)E)5"D((T:5*4W87[E&8ORM_9TGM-WP%8"3*W]G2>T
MW?#*W]G2>TW? 5@),K?V=)[3=\,K?V=)[3=\!6 DRM_9TGM-WPRM_9TGM-WP
M'&F?+5+K9^X@:(Q:?(=2].LA2%6R3,[%-^+XJ=!VJ^X7Y6_LZ3VF[X"L!)E;
M^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^ K&<OTB8ZHY[Z!VRM_9
MTGM-WQ J2]GME612+2C++ PF[3\9&GRK/X^L!M ),K?V=)[3=\,K?V=)[3=\
M!6 DRM_9TGM-WPRM_9TGM-WP$E?^:1.OQOBI&L//UE]U<2-AQ7T638YD:C1S
MDZG1H4>D^;V?8-7*W]G2>TW? <JWYBG?J%?<- 8M8D/+HTQ*H4A"3941J4IN
MPM'/H49B_*W]G2>TW? 5@),K?V=)[3=\,K?V=)[3=\!6 DRM_9TGM-WPRM_9
MTGM-WP%8"3*W]G2>TW?#*W]G2>TW? <:;\ZJ?6_^VV-$8L"0Z4BH&4*0K"DV
MF1*;\7^31H.U7W>T7Y6_LZ3VF[X"L!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D
M]IN^&5O[.D]IN^ K&>[Z11.J/>^T.N5O[.D]IN^(%R7L]QE9#(M*,Z6!A-VG
MXS>GRK/X^L!M ),K?V=)[3=\,K?V=)[3=\!6 DRM_9TGM-WPRM_9TGM-WP%8
M"3*W]G2>TW?#*W]G2>TW? <J[Z/U'JSGNF- 8M8DO+HLY"H4A"3CN$:U*;L3
MXIZ3L49_N(7Y6_LZ3VF[X"L!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5
MO[.D]IN^ K 296_LZ3VF[X96_LZ3VF[X"/D[YL>Z],_^RX-<8_)SS6X?K.;+
M,R]ELAS1]I<PV     &(U6GW*?.D%!5AL.J;2SA%;H21VJ/F+GT^SZQMB%NG
M-MM36R6JR4M2U'[#41%H_< DJCIOT2*\9$1N28BC(OK?;&R,>K-$Q1HS*3,R
M;E1$D9_4^V0V        !A4^OIG<J:S0RC&@Z8W'<-[#MQF-)1V66:+,'VG;
M:-T>0=Y+5>/ROJ%=I=;CQDU!+"7X[\ WK2:(R(B43B;+<(_4 GJOY3N3U/I=
M0F1)!SW8AE:RVA:<81NDT:D*--BDDH[#4FTK;"YS*WHQ^4>A'%D/SW'H>+F2
M(J4*CNK4K$GXZ["1:22*PS/F3;89D8\ZC\CC35/EP6JTI+2X^3QUG$(UH+'(
M=(UGAV+/^32GQ205G.5ND55'\EKL\W'#K:2>4[*4DU0S4A*7U$M98.,*TR7:
M:3M]A&2B(![&#RFI%3JSU,A3,?*9;)Q9(;7@$DR29'AV8)VDI)Z#YC'GZK^5
M"@PJ-,FT]XZC(CX.!&0AQ&-M<Q>$E1H/"02M!K21E;87.9$>SR=Y,M\G8TV,
MW)4ZU(<0I)8& :$I9;:(M&BVQNVTB+GT$5@\XC\FDE4>.Q)KQOMPX[46'_-"
M2;;2'VW;%F2O'4>*2FW01%IL,[;0]!-Y4HI+].14V$1T283\N0XEPU)CDT39
MJ+R2-1?RG/81Z.;3HB<_*)1#F4YB,X\Z4R4N,M9L.()C!:QAJ42DD=EAITZ"
ML,U6V$8IY4\DSY2D19;DUD&5#^2P_EL#QO*+FP.;UV\Y#/J_Y/RJTR4^JI8M
M,F23KB,1;_)G%R9:"/"+2:3,R5ZC]1@+F_RA\EW(F4E4S-LW4-)+)W24M2R,
MT8*<'"42L%5AD1D=F@S']I?+:E5NOMTRFJ6^AR$4Q$DD*)*BPU(-.E.@R-.F
MVS3HYR.SSM/_ "59 J&9U=M1QI45])HAFG#2P3A$D[7#\96,,S,K"T:$D-J@
M\BGJ#7BJ+532XTIIYIU@X]F$2WW'DF2L+0:<89<QV_4 D8_*$Y*Y2RJ4U2FS
M;CS%Q%J*<G'IP2.UU3.#:35I>5:?V"V#^4/D_(:IR),Q,:;-:87DY)6X2%/$
M6 @UDFS".W01V&9:;+!',Y 2JA6H\R57,=%CS%2V4.1"5(1::C)HG\*W%$:O
M)LYM%M@\R[R&Y20ZO IL%M;M*:E4]YZ2LV2;7DZ$I4LBPL8@S)!%@$2K3L/"
M(K2 >V8_*'R5DQWWVZM_)LLD^HUL.I,T&K!(TD:2-?C>+XMNG1SCC4ORC<GH
M-"=J34LY"L6^IIC%.)4I;1>,A98-K>DR*U1%SD,:3^2I$F) 8563(X=/3"0H
MHW.I+J72698?-XMF#]=MN@?A'Y*7(\:0<2M-1YDMB3&DNE!M;-MXR.Q",9:D
MRLLPE*49ES^JP/HL.1E<)B1@X.-;2O!MMLM*T4":%&R2#'C86'BFTHPK++;"
MLM%(                                  PX4MN!2:I,?MQ,>1)=785I
MX*5*,_X$(>3/*M^N2'(LVE.4Y\XZ)3*5/$X3C*[2(^8C)1&1VE8=GM,70X;5
M0I%4A/X6*D2)+2[#L/!4I1'9^PQ#R9Y,2Z'(<D3JNJH.Y,W$8_FY-$VTBTRM
M\8S4HS,S,[2^P@'J@                &73_/-6_3:^&0U!E0B)57JZ5$1D
M:VR,C]?\F0#QS_Y3U0XC\N70ELL*CJDPE'*2>/0E9(/"\6QOG(^<] [-_E*;
MS%&J;\)BQ]Q:4IBSDR")"$VJ4:DIL([<$L$^D"?R=2B3@*KYK;C,FS3TG#3_
M ""3<)?C^-8YS$6@DZ"')K\F"'GZBNJ5'*CG-NFZ;+.)3C7#*U9(M59824V:
M?4 _DK\ISD&"O+J,B-4$.MI4PY.2324+1AI4IW!\6TM%AIY]'UBX_P H31P6
MI;5(EO(73BG+;:\=Q%IF248)$?/89X6@B+2(W?R<29"VYDBLQWZFT\E:'7*<
M1LFA+>+)"FL.U5A:;<+GM^P:7)_D.FAPJC'5*0ZN5'3&;=2U@FA!(P>:VSG,
MSL*P!FSORG9*=$0BFQL;5(Q2;)%10PELC5@X)*4GQC_</H#9FMM*C(B,R(S(
MCM_B/"SOR=ORJ1&IB*TA$=,),&22X1+-ULE85J#PB-"NT7U#W$=A$:,TPW;@
M-()";>>PBL(!V         !F0?/=5^UKW!Y=_P#*,U%G2"?IZ44Y+C[$>9E)
M'CG6DVJ2:23XI'S$=I_8/40?/=5^UKW!Y5?Y.L9+=)-5)%/)Q]^/'1&+#9==
M+2K#-1DHB]1&GU\X#G!_*3EG)]VK*IL8TI?;90W%J2)!F:BM/"-*?%L(C.P^
M>P<W/RFN0Z:[)FT%U@U-MO1?YRDT.-+5@DM:K"Q9%SGH,B+UF.['Y/'':HB=
M5ZBW-6:30YBF#8*PF\6BQ.$K216G:9\YCC^;64[$0U*Y090N,EIN&;D%)H0A
MM1J(G$FH\89F>D[4_41 *X'Y18TZ)3WTT]\SE)?6MIJUU1);T6MDE/\ *$H]
M!'H$DS\IY1>3]*J>:V4+J"W$DS+GICDT2.DI2;+?J&AR2Y$GR;J3TMR:W)-;
M:DI)$8FB2I:\-9D1&>"1GS%:>CUF.2N0TUJEQHL&N-LN-)?;6MV$3B5H=MML
M+#(R,K>?",OJ >OAR%2H3,A2$(4X@EFE#A+25I>I1:#+ZQ4,^BTIBB46)3(Y
MJ-F,T3:349F>CUZ1H        #+_ *T%U(_?&H,O^M!=2/WP&?/Y5LP.4S%&
M<@230N.X^N6:<%M)(3A6)Z1V>SF&$U^466N.1KY./E(DI;<IS:9*3*0E:\%.
M$=A&V?K,K%:/68]-5*"BJU6',<D&A$=EYI31)TK)Q.">FW19]ACS#/Y.9J(R
M$.\HW''8C;;=/<R0B)A*%X189&HS</U'I3HYK '-W\J;49^"Q+I9LN.O+9DI
M5)(S:4A5BL B3_*6<_\ 1T#V5#J+]7I#,YV-DV/M4A!K-1X%OBJ.U)6&96'9
M9ZQ@)Y$N'0$TIZHI>-^8<J<^3. ;I*.U24%:> 1V$7.>@A1R-Y(KY*)J"3DM
M/E*>QB2:9-NPM.E5JCM4=NDRLYBT /5@            ,FH^?J+^F]\,QK#)
MJ/GZB_IO?#,:P#.JOR<3K;7O#1&=5?DXG6VO>&B     _AG85IC^@ ^;)_*(
M@^7JH1K_ /QEF()7^_;Y7J]>C[!]#E?-7OU:ON'BRY L)Y;*K"2;*,:3=2V9
M6D3WUEHT>L;[\>OY([A5*FGXAVV4YPK='ZX!H4OS3#_4(]TA6//TZ/73IL0T
M5*FDG$HL(Z>LS(L$O7CASJ$VMTK(G'I=/D-OS&8ZT(AK;58M1),R,W3TE;[
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M^,@: SZQ\Q;ZU'^,@:           #/H7H_3NK-^Z0T!GT+T?IW5F_=(:
M      SF_2&3U1GWW!HC.;](9/5&??< :(         ,^I?.:;UO_MK&@,^I
M?.:;UO\ [:QH        #(Y+^BU,ZLC[AKC(Y+^BU,ZLC[@'>A^8H/ZE/W#0
M&?0_,4']2G[AH        #.1Z1/]4;]]8T1G(](G^J-^^L!H@         SJ
MG\M3^ME[JAHC.J?RU/ZV7NJ&B           SJ)YFB_H#1&=1/,T7] :(
M     SB](5=43[YC1&<7I"KJB??,!HC(+TN7U!/Q#&N,@O2Y?4$_$,!K@
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M+]<[\10T!GT;S:7ZYWXBAH        #(=]+HG4'OB-#7&0[Z71.H/?$: :X
M        ,^K_ #9CK;'Q$C0&?5_FS'6V/B)&@           SZ-YO5UA_P"*
ML: SZ-YO5UA_XJQH        #.=](HG5'_?:&B,YWTBB=4?]]H!H@
M  SJS\R;ZW&^,@:(SJS\R;ZW&^,@:(#(Y4^B-:Z@_P##4-<9'*GT1K74'_AJ
M&N       #/HWS)WK<CXRQH#/HWS)WK<CXRQH        \_R%_V?\G?[-C_#
M2-!GTBE]49]]T9_(7_9_R=_LV/\ #2-!GTBE]49]]T!H          SZQYO3
MUACXJ!H#/K'F]/6&/BH&@           SZ1\V?ZV_P#$4- 9](^;/];?^(H:
M     #(9]+Y?4&?B.C7&0SZ7R^H,_$= :XSD>D3_ %1OWUC1&<CTB?ZHW[ZP
M&B         #/K7FQ7ZUKXB1H#/K7FQ7ZUKXB1H           ,ZD_(RNMO>
M\8T1G4GY&5UM[WC&B        ,Y/I$YU1/OJ&B,Y/I$YU1/OJ :(
M ,ZL^:G?TD>^0Y<I/,+_ .FW\1(ZUGS4[^DCWR'+E)YA?_3;^(D!K
M   SZ5Y,SK;GWC0&?2O)F=;<^\:         S_ZQ?W3_ #C0&?\ UB_NG^<!
MH          SJUYGD?87O$-$9U:\SR/L+WB&B           SZ7Y4[K:_N(:
M SZ7Y4[K:_N(: #(H?RE5Z^Y[J1KC(H?RE5Z^Y[J1K@    ,X_2)/5%>^0T1
MG'Z1)ZHKWR :(         ,ZM^9)?ZL:(SJWYDE_JQH@          ,ZF?+5
M+K9^X@:(SJ9\M4NMG[B!H@       #.7Z1,=4<]] T1G+](F.J.>^@!H@
M  #)K_S2)U^-\5(UADU_YI$Z_&^*D:P#/K?F*=^H5]PT!GUOS%._4*^X:
M        #.IOSJI];_[;8T1G4WYU4^M_]ML:(        SW?2*)U1[WVAH#/
M=](HG5'O?: :          ,^N^C]1ZLY[IC0&?7?1^H]6<]TQH
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MW R1_:,GLMW!6 #'Y.>:W"YS*;+(S]MDAS3]I\XV!D<G?-CW7IG_ -EP:X
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MHV^3WAG.GZ]&WR>\5@ DSG3]>C;Y/>&<Z?KT;?)[Q6 "3.=/UZ-OD]XY/U*
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M3<G/-']YD_'6%TF4/,9-R:_]KKXJ-^.&3<FO_:Z^*C?CCWP!G)E#P.3<FO\
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MIO\ 3<]]0T0$F<Z?KT;?)[PSG3]>C;Y/>*P 29SI^O1M\GO#.=/UZ-OD]XK
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M;2_7._$4- !)G.GZ]&WR>\,YT_7HV^3WBL $F<Z?KT;?)[PSG3]>C;Y/>*P
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M<)I)+QA8)F2W#,K?;I+]X] ,AGTOE]09^(Z LSG3]>C;Y/>($3X95QYPI<?
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M>MQ.%5^( M 18JIZW$X57X@8JIZW$X57X@"T!%BJGK<3A5?B!BJGK<3A5?B
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M8R&?2^7U!GXCHLQ=0UF-PZKXRVT3/">21/L8W(VK58D\$RPW+"LPN?GTV_L
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M\,74-9C<.J^ K&?_ %B_NG^<=<74-9C<.J^(,";GNS*(^,R;GQ!V687LP_\
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M.J^ Y5OS%._4*^X: Q:PB:5'FFY(CJ;)E6$26#(S*SVX9V?N%^+J&LQN'5?
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M"A1>3=%8I,);JH[%N";JB-1VF9G:9$7M&J
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M?\7O&- 9]$\SL?\ %[QC0        &=_6+^Z?YQHC._K%_=/\X#1
M !GU7R8?6V_O&@,^J^3#ZVW]XT 'GU?[0V_[*7\5(] //J_VAM_V4OXJ1Z !
M+/\ -LO]2O[C'.C>8Z?U9OW2'2?YME_J5_<8YT;S'3^K-^Z0"X  !G47S4W^
MFY[ZAHC.HOFIO]-SWU#1        &<KTB;ZHOWTC1&<KTB;ZHOWT@-$
M    &?5OD8W6V??(: SZM\C&ZVS[Y#0           9]&\VE^N=^(H: SZ-Y
MM+]<[\10T        !D.^ET3J#WQ&AKC(=]+HG4'OB- -<         &?5_F
MS'6V/B)&@,^K_-F.ML?$2-           !GT;S>KK#_Q5C0&?1O-ZNL/_%6-
M         9SOI%$ZH_[[0T1G.^D43JC_ +[0#1         !G5GYDWUN-\9
MT1G5GYDWUN-\9 T0&1RI]$:UU!_X:AKC(Y4^B-:Z@_\ #4-<       &?1OF
M3O6Y'QEC0&?1OF3O6Y'QEC0       !Y_D+_ +/^3O\ 9L?X:1H,^D4OJC/O
MNC/Y"_[/^3O]FQ_AI&@SZ12^J,^^Z T          9]8\WIZPQ\5 T!GUCS>
MGK#'Q4#0           9](^;/];?^(H: SZ1\V?ZV_\ $4-     !D,^E\OJ
M#/Q'1KC(9]+Y?4&?B.@-<9R/2)_JC?OK&B,Y'I$_U1OWU@-$         &?6
MO-BOUK7Q$C0&?6O-BOUK7Q$C0           9U)^1E=;>]XQHC.I/R,KK;WO
M&-$        9R?2)SJB??4-$9R?2)SJB??4 T0         9U9\U._I(]\AR
MY2>87_TV_B)'6L^:G?TD>^0Y<I/,+_Z;?Q$@-8         &?2O)F=;<^\:
MSZ5Y,SK;GWC0        &?\ UB_NG^<: S_ZQ?W3_. T          9U:\SR
M/L+WB&B,ZM>9Y'V%[Q#1           9]+\J=UM?W$- 9]+\J=UM?W$- !D4
M/Y2J]?<]U(UQD4/Y2J]?<]U(UP    &<?I$GJBO?(:(SC](D]45[Y -$
M     &=6_,DO]6-$9U;\R2_U8T0          &=3/EJEUL_<0-$9U,^6J76S
M]Q T0       !G+](F.J.>^@:(SE^D3'5'/?0 T0     !DU_P":1.OQOBI&
ML,FO_-(G7XWQ4C6 9];\Q3OU"ON&@,^M^8IWZA7W#0           9U-^=5/
MK?\ VVQHC.IOSJI];_[;8T0       !GN^D43JCWOM#0&>[Z11.J/>^T T
M        9]=]'ZCU9SW3&@,^N^C]1ZLY[IC0           9')WS8]UZ9_\
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M]PM !%FBF;.B;A/<&:*9LZ)N$]PM !%FBF;.B;A/<&:*9LZ)N$]PM !@PZ9
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ME*41H21X7,1E9H'NOR9U/*Z)(@E$;9*"[@&XAW#-U1FHU&OQ2L7:1F9:;+2
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MC1%:6"K0>@79LI^HQMRGN'&I_+4_K9>ZH:("3-E/U&-N4]P9LI^HQMRGN%8
M),V4_48VY3W!FRGZC&W*>X5@ DS93]1C;E/<&;*?J,;<I[A6 #&I$"$Y28RW
M(D=:E(M-2FB,S_@+LV4_48VY3W#C1/,T7] :("3-E/U&-N4]P9LI^HQMRGN%
M8 ),V4_48VY3W!FRGZC&W*>X5@ DS93]1C;E/<(2@0L]J;R2/@9,2L'%%9;A
M'ILL&R,XO2%75$^^8#MFRGZC&W*>X9908GA.MG)F<7D258&++!MPS*VSVC?&
M07I<OJ"?B& LS93]1C;E/<&;*?J,;<I[A6 "3-E/U&-N4]P9LI^HQMRGN%8
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M;*?J,;<I[A6 "3-E/U&-N4]P9LI^HQMRGN%8 ),V4_48VY3W"'((6>\7DD?
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ME/<*P 8M/@0EN3B7$CJ),DTIM:(["P4Z"T"_-E/U&-N4]PXTSY:I=;/W$#1
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ML &+59#JH2".'(1_.6#M-3?J=0=FA7KYOVB_*W]G2>TW?'*L?,6^M1_C(&@
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M5;Y&-UMGWR&@ DRM_9TGM-WPRM_9TGM-WQ6 "3*W]G2>TW?#*W]G2>TW?%8
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MFFWV^H<>0O\ L_Y._P!FQ_AI&@SZ12^J,^^Z ZY6_LZ3VF[X96_LZ3VF[XK
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MI/R,KK;WO&-$!)E;^SI/:;OAE;^SI/:;OBL $F5O[.D]IN^&5O[.D]IN^*P
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M#*W]G2>TW?%8 ),K?V=)[3=\,K?V=)[3=\5@ DRM_9TGM-WPRM_9TGM-WQ6
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MY(_M&3V6[@"L!)DC^T9/9;N!DC^T9/9;N *P$F2/[1D]ENX&2/[1D]ENX K
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M"L9')?T6IG5D?<+,D?VC)[+=P97)UAUSDY3EIEOMI5'09(02+$Z.8K4F?[S
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MLPST>399^RT!Z !)DC^T9/9;N!DC^T9/9;N *P$F2/[1D]ENX&2/[1D]ENX
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MT7Y(_M&3V6[@"L!)DC^T9/9;N!DC^T9/9;N *P$F2/[1D]ENX&2O;0D]ENX
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M5=]'ZCU9SW3&@,6L1GD46<M4V0M)1W#-"DMV*\4]!V)(_P!QB_)']HR>RW<
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MY<=9E(8583A'H)U!F?/ZB(S%^<Z?KT;?)[P%8"3.=/UZ-OD]X9SI^O1M\GO
M5@),YT_7HV^3WAG.GZ]&WR>\!6 DSG3]>C;Y/>&<Z?KT;?)[P'*A>C].ZLW[
MI#0&+1Y\-JB06W);"%ICH)25.$1D>"6@RM%^<Z?KT;?)[P%8"3.=/UZ-OD]X
M9SI^O1M\GO 5@),YT_7HV^3WAG.GZ]&WR>\!6,YOTAD]49]]P=LYT_7HV^3W
MB!N?#*MR'#EQ\ XS225C"L,R4Y:5MOUE^\!M ),YT_7HV^3WAG.GZ]&WR>\!
M6 DSG3]>C;Y/>&<Z?KT;?)[P%8"3.=/UZ-OD]X9SI^O1M\GO <JE\YIO6_\
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M3E)&JS,^HG47)Y5HFG74O.8E<8XQX:L7;@8!N%SX//9]0#ZR
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MO1I5H,O$L/ )9D=A6\X#[4 YMFM3:3<225F1&I)';8?LM'0
M 9-1\_47]-[X9C6&34?/U%_3>^&8U@&=5?DXG6VO>&B,ZJ_)Q.MM>\-$
M    <97S5[]6K[AV'&5\U>_5J^X!RI?FF'^H1[I"L24OS3#_ %"/=(5@
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MSF_2&3U1GWW!R\(87T%3_P#BY/X8A;KL,JY(7BJC8<9HK,VR+="G/5@6^OG
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M0NMH^XQH  \^7^T-7]E%\4QZ >?+_:&K^RB^*8#T       SZ)YG8_XO>,:
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M$C0&?5_FS'6V/B)&@           SZ-YO5UA_P"*L: SZ-YO5UA_XJQH
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MKXB1H#/K7FQ7ZUKXB1H           ,ZD_(RNMO>\8T1G4GY&5UM[WC&B
M     ,Y/I$YU1/OJ&B,Y/I$YU1/OJ :(         ,ZL^:G?TD>^0Y<I/,+_
M .FW\1(ZUGS4[^DCWR'+E)YA?_3;^(D!K          SZ5Y,SK;GWC0&?2O)
MF=;<^\:         S_ZQ?W3_ #C0&?\ UB_NG^<!H          SJUYGD?87
MO$-$9U:\SR/L+WB&B           SZ7Y4[K:_N(: SZ7Y4[K:_N(: #(H?RE
M5Z^Y[J1KC(H?RE5Z^Y[J1K@    ,X_2)/5%>^0T1G'Z1)ZHKWR :(
M  ,ZM^9)?ZL:(SJWYDE_JQH@          ,ZF?+5+K9^X@:(SJ9\M4NMG[B!
MH@       #.7Z1,=4<]] T1G+](F.J.>^@!H@     #)K_S2)U^-\5(UADU_
MYI$Z_&^*D:P#/K?F*=^H5]PT!GUOS%._4*^X:           #.IOSJI];_[;
M8T1G4WYU4^M_]ML:(        SW?2*)U1[WVAH#/=](HG5'O?: :
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M$A"OWF1%]8^C-+QC2%VI.U)':@[2/[#]9 )\;4]4B<4K\,,;4]4B<4K\,6@
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M?AU#5HW$*N#E1/1^G=5:]TAH ),.H:M&XA5P,.H:M&XA5P5@ DPZAJT;B%7
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M8N/'464O6X3YEIQBK?Z!^L7XRH:M&XA5P<J1\V?ZV_\ $4- !)C*AJT;B%7
MQE0U:-Q"K@K !)C*AJT;B%7!EMKF>$\DR88QN1M6IQQX)%AN6';@\_/HL_:-
M\9#/I?+Z@S\1T!9C*AJT;B%7! A<W/;QY/'QF3-VECSLLPE^O ^WU#:&<CTB
M?ZHW[ZP';&5#5HW$*N!C*AJT;B%7!6 "3&5#5HW$*N!C*AJT;B%7!6 "3&5#
M5HW$*N!C*AJT;B%7!6 #%JJYN;SQC$=*<8UI2^9G\HFS^@0OQE0U:-Q"K@Y5
MKS8K]:U\1(T $F,J&K1N(5<#&5#5HW$*N"L $F,J&K1N(5<#&5#5HW$*N"L
M$F,J&K1N(5<#&5#5HW$*N"L &-3%S":DX$>.?\Y=MPGS*P\([?Z NQE0U:-Q
M"K@XTGY&5UM[WC&B DQE0U:-Q"K@8RH:M&XA5P5@ DQE0U:-Q"K@8RH:M&XA
M5P5@ DQE0U:-Q"K@@2N;GM9Y/'QF3)T8\[+,(_7@?]!M#.3Z1.=43[Z@';&5
M#5HW$*N!C*AJT;B%7!6 "3&5#5HW$*N!C*AJT;B%7!6 "3&5#5HW$*N!C*AJ
MT;B%7!6 #%JJYITQPG(\=*<)%II?,S\HO5@$.-?7,.BO$ZPPE&&W::'C4?EI
MLT8)?>+ZSYJ=_21[Y#ERD\PO_IM_$2 KQE0U:-Q"K@8RH:M&XA5P5@ DQE0U
M:-Q"K@8RH:M&XA5P5@ DQE0U:-Q"K@8RH:M&XA5P5@ QJ:N:29>!'CG_ #ER
MVU\RL.W] 78RH:M&XA5P<J5Y,SK;GWC0 28RH:M&XA5P,94-6C<0JX*P 28R
MH:M&XA5P,94-6C<0JX*P 28RH:M&XA5P08<W/=N3Q\9DW-CSLLPO;@?]!M#/
M_K%_=/\ . ZXRH:M&XA5P,94-6C<0JX*P 28RH:M&XA5P,94-6C<0JX*P 28
MRH:M&XA5P,94-6C<0JX*P 8M67-.E/DXQ'2FPK32^9GSEZL A?C*AJT;B%7!
MQK7F>1]A>\0T0$F,J&K1N(5<#&5#5HW$*N"L $F,J&K1N(5<#&5#5HW$*N"L
M $F,J&K1N(5<#&5#5HW$*N"L &-3US"5,P(\<_YRK"M?,K#L+_<TB[&5#5HW
M$*N#E2_*G=;7]Q#0 8%'7,)=2Q;#"K9B\+">,K#L3H+Q3M+Z]'V#4QE0U:-Q
M"K@CH?RE5Z^Y[J1K@),94-6C<0JX&,J&K1N(5<%8 ),94-6C<0JX(#7-SV@\
MGCXS)E:,>=EF$7KP/^@VAG'Z1)ZHKWR =L94-6C<0JX&,J&K1N(5<%8 ),94
M-6C<0JX&,J&K1N(5<%8 ),94-6C<0JX&,J&K1N(5<%8 ,6K+FG2)1.1XZ48&
MDTOF9E^S (7XRH:M&XA5P<:WYDE_JQH@),94-6C<0JX&,J&K1N(5<%8 ),94
M-6C<0JX&,J&K1N(5<%8 ),94-6C<0JX&,J&K1N(5<%8 ,:GKF$[.P([!F<D\
M*U\RL/!3S>)I%V,J&K1N(5<'&F?+5+K9^X@:("3&5#5HW$*N!C*AJT;B%7!6
M "3&5#5HW$*N!C*AJT;B%7!6 "3&5#5HW$*N"!2YN>V3R>/C,F786/.RS"1Z
M\#[/4-H9R_2)CJCGOH =L94-6C<0JX&,J&K1N(5<%8 ),94-6C<0JX&,J&K1
MN(5<%8 //UI<PXL7&LL)++8_DNFJT\:FPO)+1;Z_5[#&KC*AJT;B%7!)7_FD
M3K\;XJ1K ,6L+FG1YI.1XZ6\2K"-+YF9%9[, K?WB_&5#5HW$*N#E6_,4[]0
MK[AH ),94-6C<0JX&,J&K1N(5<%8 ),94-6C<0JX&,J&K1N(5<%8 ),94-6C
M<0JX&,J&K1N(5<%8 ,6 N:4BH8$>.9G)\>U\RL/%HYO$TZ+/8+\94-6C<0JX
M.--^=5/K?_;;&B DQE0U:-Q"K@8RH:M&XA5P5@ DQE0U:-Q"K@8RH:M&XA5P
M5@ DQE0U:-Q"K@@<7-SW&,X\?&9,[86/.PRPF[=.!]GJ&T,]WTBB=4>]]H!U
MQE0U:-Q"K@8RH:M&XA5P5@ DQE0U:-Q"K@8RH:M&XA5P5@ DQE0U:-Q"K@8R
MH:M&XA5P5@ Q:NN:=%GDXPPELX[F$:7S,R+!/F+ *W]XOQE0U:-Q"K@Y5WT?
MJ/5G/=,: "3&5#5HW$*N!C*AJT;B%7!6 "3&5#5HW$*N!C*AJT;B%7!6 "3&
M5#5HW$*N!C*AJT;B%7!6 #&Y.Z:6[;:1Y;+M+V'E#EI?65OK^X;(R.3OFQ[K
MTS_[+@UP    &:=*:P'20^^VIU\WC4E1:%&5EEAE896>HR,:0 ,.HQ6X-$CQ
MFL+ 1,C:5':9F<A!F9G[3,S,;@R*^DETM"=-BI<8M!V'I?;YC+F^T38Z"9_R
M+=5?1ZG&GW5)/[#PP'H &+&3#D.&V><67.<DO274FK[/'TBW-<?Z27QCMX!:
M BS7'^DE\8[>#-<?Z27QCMX!:/%U;\G=(KLNM2JH65/U)"6FE+3;DB$HP2P+
M3Y\+"7;[3YM ]/FN/])+XQV\&:X_TDOC';P#Q:/R:J<<-$RO2'X;KKLB1'2P
ME&-==CJ8<5A<Y6X1J(O5:9:><J(GY.VF*8J&_47'S7(A/K6;))PLG2VDBLM_
MI$WI^T>LS7'^DE\8[>#-<?Z27QCMX!X^+^3A,?)L;6I4G(BCLPL:T@L3':>0
M[BSP;,(S-M)&KV$6CGM_#OY.)!5@ZA$Y0.,D4Q^<VPN(EQ"'W5&9KL,])DFQ
M)6\VDRL,Q[/-<?Z27QCMX,UQ_I)?&.W@'S]?Y)(BJC,F+JKAJDHE(6HXR#<5
MCTF2C4YY2L$S*RW01%S:3,5H_)H;;DF2U7I+4Z6ITI,AN.C^4;=2V3B22=N"
M9FV2B,N:T^<>US7'^DE\8[>#-<?Z27QCMX!Y='Y/8C34=EJ6XAB-4X]091@$
M>"3+"64MF=NDK$VVCK4N0[50KDB<53D-19KK#L^$2$+0^;)I-NPU$9I+Q4X5
MG.1%S#T>:X_TDOC';P9KC_22^,=O /,JY!,JY 2.2I5%TD/.J=RG%EA),WL;
MY-MG/H'![D-4YAIDO\JI2J@2'(Q241&D?S9PDX3>"166VIPB66DC/UD/6YKC
M_22^,=O!FN/])+XQV\ \A(_)O#=I*J<F0HXI3&Y*&5)L+!1')@FS5SV&1>41
M6Z>89?)CD%+E&^WRNA)DPVHK$6-&E.MO68LW#([4)+01.6$9^,?C&=EI$7T/
M-<?Z27QCMX,UQ_I)?&.W@'D'.0$B2BI0'^4#QT2>^^\] 1%;2?\ *&I5A.:5
M%@J,C+]'25AV" _R1P,E2@IS:'<>3J\73V$,N$2,!)*9(L!1EI,C,C\8S.SU
M#WV:X_TDOC';P9KC_22^,=O /%1?R:9"S&8CUR2AE"XJWVS80:7CCFG ^M-J
M4$1V>PCT:2/3Y1\B&^4-3?J&<'HKZX:(J#0VE6 :'B=2O3S^,1:/8/19KC_2
M2^,=O!FN/])+XQV\ \(O\DU/5*FO)F)2<A#^"HH+6,0MY)DH\818:DE:JQ)G
MHMLM,;DOD8B:Z\I4]U).3$2O$38I.#&Q%A';S_TK?48W\UQ_I)?&.W@S7'^D
ME\8[> 8'(_D2SR27.=;EJ?7+-&&E+*&6RP2LM)"-&$?K/UCU@BS7'^DE\8[>
M#-<?Z27QCMX!: BS7'^DE\8[>#-<?Z27QCMX!: BS7'^DE\8[>#-<?Z27QCM
MX!: BS7'^DE\8[>#-<?Z27QCMX!: BS7'^DE\8[>#-<?Z27QCMX!: BS7'^D
ME\8[>#-<?Z27QCMX!: BS7'^DE\8[>#-<?Z27QCMX!: BS7'^DE\8[>#-<?Z
M27QCMX!%!BM3J54X;Z34R_(DM.$1V6I4I1'_  ,1<F>2B^3[SSSU4DSUFRW&
M9QR23BF46X*='.=IF9GZQ128#+K,K"7)*R4\DL&2XGF6?L5S_6-+-<?Z27QC
MMX!: BS7'^DE\8[>#-<?Z27QCMX!: BS7'^DE\8[>#-<?Z27QCMX!: BS7'^
MDE\8[>#-<?Z27QCMX!: BS7'^DE\8[>#-<?Z27QCMX!: BS7'^DE\8[>#-<?
MZ27QCMX!:,J$1*K%7(R(R-;9&1^O^3(49KC_ $DOC';PSH,!E55J2#7)L0MN
MRR4X1^07.>%:?[0'GT_DS84EQM^LS766VS;@)P$$<0L,E^RQ>DB+27,5@LH'
M(9-%KKE7?J3DV2Z3BG+6B;)3BS\9=A'87BDE-A%ZAZ7-<?Z27QCMX,UQ_I)?
M&.W@'G*GR*SC37HA5$VS<G.S/'C(=;M6=N"IM=I*L]1^T=*%R*CT.GSHB).,
M*4RE@G#:)*D()&#ZN?UGZB^H;^:X_P!)+XQV\&:X_P!)+XQV\ \M+Y!+DT6-
M2FJ[-9A(C)BR622E2'T$=MI$?D*/FPB]0]@PRB/';8;*Q#:"0DC/U$5A#AFN
M/])+XQV\&:X_TDOC';P"T!%FN/\ 22^,=O!FN/\ 22^,=O +0$6:X_TDOC';
MP9KC_22^,=O +0$6:X_TDOC';P9KC_22^,=O .,'SW5?M:]P>9?_ ";0I4N2
MV_.?52W3><;@DVA)-..^4HED5I\V@CYOK&U#I[*JM4D&N38@V[+)+A'I3ZSP
MK3_:-+-<?Z27QCMX!Y6F\@40JY%JLNIN3GV#T8;*4$9)1@-V$DR*U)>NP[3/
MU#M*Y"MR6ZV2:@XVJJ2D23M90M*325F"I*K26D_61CTF:X_TDOC';P9KC_22
M^,=O //<EN1+/):4X\U,-])LXLDXDD$1FK"4K1HTGZBL(B')?(A]%'9@0:_,
MB8!.H<-""4AU#AG:1H/1:5N@_4/39KC_ $DOC';P9KC_ $DOC';P!2:9&HM)
MBTV&C!CQFR;07U$+1%FN/])+XQV\&:X_TDOC';P"T!%FN/\ 22^,=O!FN/\
M22^,=O +0$6:X_TDOC';P9KC_22^,=O +1E_UH+J1^^.^:X_TDOC';PS<@9\
M(B;PY.#DF%;E+EOE^W"ML^H!"[R)97RB54FISS49Z2B9(A$VE277D%8E6$=I
MI+VD7.,_E!^3=OE%*>F/51:)#L@EX>3(5@-$5A-EZR,M)X5MMICV&:X_TDOC
M';P9KC_22^,=O *6T$VVE!&HR21%:H[3/[3'019KC_22^,=O!FN/])+XQV\
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M<Z.+.:_B3921*QKUN%A*MT\_-9]0#UP#SF>.3^T9&^?[PSQR?VC(WS_> ]&
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M/&I$-Y1$M]:DVD@^<C,R,OJ/0-7(&.G)XIR\ K 29 QTY/%.7@R!CIR>*<O
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M,?0(B8<19N851?7_ $5/17#-/V6((=I+U-FI2F7"=?2A6$E+L!Q1$?M*U'.
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M)DY8[(R<P<8GR<,RMMM'TW+V.A)X5RZ,$I;?AZIS!?P<UD5F(7;\J?JLM_:
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MZ&7L="3PKET!6 DR]CH2>%<NAE['0D\*Y= 5C.3Z1.=43[ZAVR]CH2>%<NB
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M$MEA9$1MMN.J6@K"YM!D=GJM >I
M8U-?:BT^H2'UDVTU*D+<6?,E)*,S/]PBIO+BB5.-,DH=?8:B-90Z<B.MO^2.
MVQPK2\9)V'99I^H5T\WT4VI*BH2Y(*3(-I"SL2I6$=A&?J*T>%C<A^4-83,=
MK;R8=0D.-O/R6WB?1(P+<!K%X*<%M)V'SG:?/S /HM'JL:N4>)5(>'D\IHG6
M\,K%8)\UI#0'G^1M*G4/DG IU1>2[)8;P5&A)$2?8DK.>SVCT
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M, D2,6PTW(21XL])N&9ES&KG1;S:" ?60'-O#Q:<8:3<L+"-):+?78.@
M          R:CY^HOZ;WPS&L,FH^?J+^F]\,QK ,ZJ_)Q.MM>\-$9U5^3B=;
M:]X:(        XROFKWZM7W#L.,KYJ]^K5]P#E2_-,/]0CW2%8DI?FF'^H1[
MI"L 'AY?+&>Q-?91'C&EMPTD9DJW1^T>X'A8W)A^H5:6_+PV(N.49:+%.:?5
M["^L!^?#:HZO%[*N\/#:HZO%[*N\;7@92O;(WG_@/ RE=*1O"[@&+X;5'5XO
M95WC@CE;.;EO2"8C83J4I,C)5A8-MGK^L>A\#*5TI&\+N$C/)6G+J4J.9OX#
M2&U)\?3XV%;ZOJ(!!X;5'5XO95WAX;5'5XO95WC:\#*5TI&\+N#P,I72D;PN
MX!B^&U1U>+V5=X>&U1U>+V5=XVO RE=*1O"[@\#*5TI&\+N 8OAM4=7B]E7>
M'AM4=7B]E7>-KP,I72D;PNX/ RE=*1O"[@'G9'*V=*0A*V(Q$AQ+A6$KG29&
M7K^H4>&U1U>+V5=XOG<E*=&::4@W[5OMMG:OU*41'ZOK%?@92NE(WA=P#%\-
MJCJ\7LJ[P\-JCJ\7LJ[QM>!E*Z4C>%W!X&4KI2-X7< Q?#:HZO%[*N\/#:HZ
MO%[*N\;7@92NE(WA=P>!E*Z4C>%W ,7PVJ.KQ>RKO'\5RTJ"DFDX\6PRL\E7
M>-OP,I72D;PNX?E?(ZEI;4HCD6D1G\I_X 8,;E?/BQ68Z&(QI:0E!&9*M,B*
MSVC\0>54V!&Q#;,=2<8MRU1*MM6LU'Z_:H;4#DG39--BON&_ANLH6JQ>BTR(
MS]0XTCDQ3YU/Q[QO8>.>1XJ["L2XI)>KV$0"3PVJ.KQ>RKO#PVJ.KQ>RKO&U
MX&4KI2-X7<'@92NE(WA=P#%\-JCJ\7LJ[P\-JCJ\7LJ[QM>!E*Z4C>%W!X&4
MKI2-X7< Q?#:HZO%[*N\<$<K9R)CTDF(V&ZA"#*Q5A$DU6>O_>,>A\#*5TI&
M\+N$C7)6G+JDF,9OX#;3:T^/IM4:[?5_ND @\-JCJ\7LJ[P\-JCJ\7LJ[QM>
M!E*Z4C>%W!X&4KI2-X7< Q?#:HZO%[*N\/#:HZO%[*N\;7@92NE(WA=P>!E*
MZ4C>%W ,7PVJ.KQ>RKO#PVJ.KQ>RKO&UX&4KI2-X7<'@92NE(WA=P#STGE;.
ME-I0MB,1)<0X5A*YTJ)1>OZAW\-JCJ\7LJ[Q?/Y*TZ,PVMLW[5/M-G:OU*6E
M)^KV&*_ RE=*1O"[@&3&Y8SWIC#*F(Q)<=0@S(E6V&9%[1[@>&F<EGH%2BR8
M>$]&)]LU)/2MLL(M/UE]W\1[D    !_%>2?V#^C^*\D_L 043T?IW56O=(:
MSZ)Z/T[JK7ND-         9S'I#-ZJQ[[PT1G,>D,WJK'OO -$  !D2/2ZF]
M0E?$CC7&1(]+J;U"5\2.-<    9]8^8M]:C_ !D#0&?6/F+?6H_QD#0
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M1&<KTB;ZHOWT@-$         &?5OD8W6V??(: SZM\C&ZVS[Y#0
M  9]&\VE^N=^(H: SZ-YM+]<[\10T        !D.^ET3J#WQ&AKC(=]+HG4'
MOB- -<         &?5_FS'6V/B)&@,^K_-F.ML?$2-           !GT;S>K
MK#_Q5C0&?1O-ZNL/_%6-         9SOI%$ZH_[[0T1G.^D43JC_ +[0#1
M       !G5GYDWUN-\9 T1G5GYDWUN-\9 T0&1RI]$:UU!_X:AKC(Y4^B-:Z
M@_\ #4-<       &?1OF3O6Y'QEC0&?1OF3O6Y'QEC0       !Y_D+_ +/^
M3O\ 9L?X:1H,^D4OJC/ONC/Y"_[/^3O]FQ_AI&@SZ12^J,^^Z T
M 9]8\WIZPQ\5 T!GUCS>GK#'Q4#0           9](^;/];?^(H: SZ1\V?Z
MV_\ $4-     !D,^E\OJ#/Q'1KC(9]+Y?4&?B.@-<9R/2)_JC?OK&B,Y'I$_
MU1OWU@-$         &?6O-BOUK7Q$C0&?6O-BOUK7Q$C0           9U)^
M1E=;>]XQHC.I/R,KK;WO&-$        9R?2)SJB??4-$9R?2)SJB??4 T0
M       9U9\U._I(]\ARY2>87_TV_B)'6L^:G?TD>^0Y<I/,+_Z;?Q$@-8
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MOM#0&>[Z11.J/>^T T          9]=]'ZCU9SW3&@,^N^C]1ZLY[IC0
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M74-9C<.J^*P 28NH:S&X=5\,74-9C<.J^*P 28NH:S&X=5\,74-9C<.J^*P
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MI@S,BL]N&7W"_%U#68W#JOCE0_,4']2G[AH ),74-9C<.J^&+J&LQN'5?%8
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MV,;D:?&Q)X-F&>BS"Y_KM_8-\9!>ER^H)^(8"S%U#68W#JOABZAK,;AU7Q6
M"3%U#68W#JOABZAK,;AU7Q6 #&J*)I'$PY$<_P"<HP;&#*P[#_W](NQ=0UF-
MPZKXY5/RH76T?<8T $F+J&LQN'5?&"2)GAZHL>QC,UEXV).RS&GZL+_J/4CS
MY?[0U?V47Q3 :N+J&LQN'5?#%U#68W#JOBL $F+J&LQN'5?#%U#68W#JOBL
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M%U#68W#JOBL $F+J&LQN'5?#%U#68W#JOBL $F+J&LQN'5?#%U#68W#JOBL
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M9';C4V?TS]8OQ=0UF-PZKXY5CS>GK#'Q4#0 28NH:S&X=5\,74-9C<.J^*P
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M8W#JOABZAK,;AU7Q6 "3%U#68W#JOB# FY[LRB/C,FY\0=EF%[,/_J-H9_\
M6+^Z?YP'7%U#68W#JOABZAK,;AU7Q6 "3%U#68W#JOABZAK,;AU7Q6 "3%U#
M68W#JOABZAK,;AU7Q6 #%JR)I4I\W)$=2;"M)+!D?.7KPS%^+J&LQN'5?'&M
M>9Y'V%[Q#1 28NH:S&X=5\,74-9C<.J^*P 28NH:S&X=5\,74-9C<.J^*P 2
M8NH:S&X=5\,74-9C<.J^*P 8U/1,-4S D1RLDJPK6#.T["_W] NQ=0UF-PZK
MXY4ORIW6U_<0T &!1T3#74L6^PFR8O"PF3.T[$Z2\8K"^K3]HU,74-9C<.J^
M(Z'\I5>ON>ZD:X"3%U#68W#JOABZAK,;AU7Q6 "3%U#68W#JOB T3<]H+*(^
M,R96G$'99A%ZL/\ ZC:&<?I$GJBO?(!VQ=0UF-PZKX8NH:S&X=5\5@ DQ=0U
MF-PZKX8NH:S&X=5\5@ DQ=0UF-PZKX8NH:S&X=5\5@ Q:LB:5(E&Y(CJ1@:2
M2P9&?[<,Q?BZAK,;AU7QQK?F27^K&B DQ=0UF-PZKX8NH:S&X=5\5@ DQ=0U
MF-PZKX8NH:S&X=5\5@ DQ=0UF-PZKX8NH:S&X=5\5@ QJ>B8;L[ D,$923PK
M6#.T\%/-X^@78NH:S&X=5\<:9\M4NMG[B!H@),74-9C<.J^&+J&LQN'5?%8
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MH224)(B21<Q$0R7O!J,EI3^:FDNE:V;F+3A_9;SBQ-)IAD1E3X9D>DC)E/<
MN 19HIFSHFX3W!FBF;.B;A/< M 19HIFSHFX3W!FBF;.B;A/< M 19HIFSHF
MX3W!FBF;.B;A/< XP?/=5^UKW!DO<A*%(J,N7)9??3*2LEQG)"S82:_+4E%M
MA*585I_5ZA7#ID!57J2#A1C0@V\$C:38FU.FS1H%10J*N2N,F- 5(;22EM$V
M@U)(^8S+G(@&;2^1-*H\UB6RN8](:4HTKE2%/'I222*U5MA$DK"(K!TD\CJ-
M+34,-MY*ISZ9+KB'E)4EU)6)4DR/Q3(5(:Y/.QSD-MTQ;*58!N)2V:25;99;
MS6VCLFGT=2G$%#@FIJS#+%(M1;ITZ- "&A<DJ7R<D./P2?-QQLD*4\Z:S/3:
M9Z?69Z3,32N0=$E0H\7 DL8C#)#T>0IMS!6=JT&HCM-*O60U"B4,R:,H]/,G
MCL:\1'C_ */M_8.3_@Y&82\^5*:;69DE;F+2E1ESD1F THD5B##:BQ6DM,,H
M)"$)YDD7,0H&<W2Z2\VEQN#"6E16I4EE!D9?4=@Z9HIFSHFX3W +0$6:*9LZ
M)N$]P9HIFSHFX3W +0$6:*9LZ)N$]P9HIFSHFX3W +1E_P!:"ZD?OCOFBF;.
MB;A/<,[-L#PBQ60QL7DF%@8I-EN'SV6<X"V728<Z?&FR&S6['0M""M\4TK*Q
M1&7KT# 9_)QR<;CR6,3)4AXDDC"DK,XY)/"231V^(1'I*P;9Q*&4HHAQZ<4E
M2<(FC0C#,O;@\]@_*&.3[B2-#5-4E2\41I2V9&OH_;]0"-CD=2&*3&IA(=<C
M,2"DJ2XO#-YRVW"<,R\;3I%%!Y-0.3ARLB-X\I7AKQKAKP;+;$I]A%:?[Q=F
MBF;.B;A/<&:*9LZ)N$]P"T!%FBF;.B;A/<&:*9LZ)N$]P"T!%FBF;.B;A/<&
M:*9LZ)N$]P"T!%FBF;.B;A/<&:*9LZ)N$]P"T!%FBF;.B;A/<&:*9LZ)N$]P
M":H^?J+^F]\,QK#STZG0FJU2D-PXZ$.+=):4M)(E6(,RMT:=(ULV4_48VY3W
M .-5^3B=;:]X:(QJE AMHBX$2.G"DMI.QHBM(STES"[-E/U&-N4]P"L!)FRG
MZC&W*>X,V4_48VY3W *P$F;*?J,;<I[@S93]1C;E/< K'&5\U>_5J^X<LV4_
M48VY3W#D_38"8KIE"C$9(,R,FD^S[ '6E^:8?ZA'ND*QE4ZG05TR(M<..I2F
M4&9FTDS,\$OJ%6;*?J,;<I[@%8P.4')>%RA>A.R;25%=PRL+RD^M/U6^T:F;
M*?J,;<I[@S93]1C;E/< PN4Z:A2Z'4*G#K$MI3#6,;8)M@VTV6:-+>%9^T>H
M'S_EA4J0FB5>GLPB1*2TI!.)921$>CU\XT3Y1<G249'2SMMU=OO >O&?&\^3
M_P!4S_G&!X1<G=EGPS?>)FZ[1$SI#JZ>HV5I02$XA'BF5MNBW1;:7[@'N 'D
M/"+D[LL^&;[P\(N3NRSX9OO >O >0\(N3NRSX9OO#PBY.[+/AF^\!Z\!Y#PB
MY.[+/AF^\/"+D[LL^&;[P&_5OD(_6V??(: \/+KM$=;;)FGJ0I+J%*/$(*U)
M*(S+0?K(4^$7)W99\,WW@/7@/(>$7)W99\,WWAX1<G=EGPS?> ]> \AX1<G=
MEGPS?>'A%R=V6?#-]X#UXYN_(K_1,>4\(N3NRSX9OO'Y7RBY/&A1)I9D9EH/
M)V^\!Z2D>9('5F_=(2\G/-']YD_'6//PZ]0F8,=I^G*6\AM*5JQ"#PE$6D[3
M/3I'.FUNC1X>+E05.NXUQ6%B4*\4UJ-)6F?J29%^P![L!Y#PBY.[+/AF^\/"
M+D[LL^&;[P'KP'D/"+D[LL^&;[P\(N3NRSX9OO >O&='\_3OU#'WN#!\(N3N
MRSX9OO$S==HB9[[JJ>HV5MH2A&(1H,C5A'9;Z[4_N >X >0\(N3NRSX9OO#P
MBY.[+/AF^\!Z\!Y#PBY.[+/AF^\/"+D[LL^&;[P'KP'EX%5H51FMQ&*:27'+
M<$UL((M!&?J/ZANYLI^HQMRGN <JQ\U9ZW'^*D: Q:I A-QFC1%CH,Y+*3,F
MB+0;B2,N;UD+\V4_48VY3W *P$F;*?J,;<I[@S93]1C;E/< K 29LI^HQMRG
MN#-E/U&-N4]P"L?Q7DG]@ES93]1C;E/</X=,@8)_S&-S?1)[@'.B>C].ZJU[
MI#0&+2($)RBP''(<=:U1FU*4IHC,S-)6F9V"_-E/U&-N4]P"L!)FRGZC&W*>
MX,V4_48VY3W *P$F;*?J,;<I[@S93]1C;E/< K&<QZ0S>JL>^\.V;*?J,;<I
M[AGM0(1UV4V<2.:$QF5$C%%81FIVT[+/787[B ;8"3-E/U&-N4]P9LI^HQMR
MGN 1R/2ZF]0E?$CC7'GWH,0N4\%E,9DFU0Y*E(Q98)F2V"(S+VE:?[S]HU<V
M4_48VY3W *P$F;*?J,;<I[@S93]1C;E/< Y5CYBWUJ/\9 T!BU6!#;AH4W$C
MH,Y#";2:(M!NH(RYO61F0OS93]1C;E/< K 29LI^HQMRGN#-E/U&-N4]P"L!
M)FRGZC&W*>X,V4_48VY3W *P$F;*?J,;<I[@S93]1C;E/< Y4+T?IW5F_=(:
M Q:/ A.42"XY$86M4=!J4IHC,SP2TF=@OS93]1C;E/< K 29LI^HQMRGN#-E
M/U&-N4]P"L!)FRGZC&W*>X,V4_48VY3W *QG-^D,GJC/ON#MFRGZC&W*>X0-
MP(1UN0V<2/@%&:42<45A&:G+3LL^HOW -H!)FRGZC&W*>X,V4_48VY3W *P$
MF;*?J,;<I[@S93]1C;E/< K 29LI^HQMRGN#-E/U&-N4]P#E4OG--ZW_ -M8
MT!BSX$-,BG$B)'22Y."HB:(K2Q:SL/1[2+]POS93]1C;E/< K 29LI^HQMRG
MN#-E/U&-N4]P"L!)FRGZC&W*>X,V4_48VY3W *QD<E_1:F=61]PLS93]1C;E
M/<,KD[!B/\FZ<Z]&9<<7'0:EK;(S4=G.9@-"A^8H/ZE/W#0&-1X$)VCPW'(D
M=:U-)-2E-$9F=GV"[-E/U&-N4]P"L!)FRGZC&W*>X,V4_48VY3W *P$F;*?J
M,;<I[@S93]1C;E/< K&<CTB?ZHW[ZQVS93]1C;E/<($P(6>W6\DCX!1D*).*
M*RW"5ILL^H!M ),V4_48VY3W!FRGZC&W*>X!6 DS93]1C;E/<&;*?J,;<I[@
M%8"3-E/U&-N4]P9LI^HQMRGN <:G\M3^ME[JAHC&J$"$AV%@1(Z<*2256-$5
MI8*M!Z!=FRGZC&W*>X!6 DS93]1C;E/<&;*?J,;<I[@&54_3:@?J)?W-CT \
MK48,1/+&A-IBL$A3$LU))LK#L)NRTAOYLI^HQMRGN 5@),V4_48VY3W!FRGZ
MC&W*>X!QHGF:+^@-$8U(@0G*3&6Y$CK4I%IJ4T1F?\!=FRGZC&W*>X!6 DS9
M3]1C;E/<&;*?J,;<I[@%8"3-E/U&-N4]P9LI^HQMRGN 5C.+TA5U1/OF.V;*
M?J,;<I[A"4"%GM3>21\#)B5@XHK+<(]-E@#9&07I<OJ"?B&+,V4_48VY3W#+
M*#$\)ULY,SB\B2K Q98-N&96V>T!O@),V4_48VY3W!FRGZC&W*>X!6 DS93]
M1C;E/<&;*?J,;<I[@'*I^5"ZVC[C&@,:HP(2#B8$2.G"DH2JQHBM*P]',+LV
M4_48VY3W *QY\O\ :&K^RB^*8U<V4_48VY3W#!*#$\/5-9*QB\UDK Q966XT
M]-@#U("3-E/U&-N4]P9LI^HQMRGN 5@),V4_48VY3W!FRGZC&W*>X!RHGF=C
M_B]XQH#&I$"$[2V5N1(ZU'A6J4T1F?C']0NS93]1C;E/< K 29LI^HQMRGN#
M-E/U&-N4]P"L!)FRGZC&W*>X,V4_48VY3W *QG?UB_NG^<=LV4_48VY3W"'(
M(6>R;R2/@9-A8.**RW"Y[+ &R DS93]1C;E/<&;*?J,;<I[@%8"3-E/U&-N4
M]P9LI^HQMRGN 5@),V4_48VY3W!FRGZC&W*>X!RJODP^MM_>- 8U2@0FTQ<"
M)'3A26TG8T16D9\W,+LV4_48VY3W ,I7^T-O^RE_%2/0#RRH,/P];:R5C%YK
M6K Q966XU.FP;V;*?J,;<I[@']G^;9?ZE?W&.=&\QT_JS?ND.4VG040)*D0X
MZ5$THR,FDD9'8?U#E2J?"<H\):XD=2U1VS4I323,S-):3T -@!)FRGZC&W*>
MX,V4_48VY3W .-%\U-_IN>^H:(QJ3 A.4UM;D1A:C4O2IHC/RS^H79LI^HQM
MRGN 5@),V4_48VY3W!FRGZC&W*>X!6 DS93]1C;E/<&;*?J,;<I[@%8SE>D3
M?5%^^D=LV4_48VY3W"$X$+/;;>21\ XRE&G%%9;A)TV6 -D!)FRGZC&W*>X,
MV4_48VY3W *P$F;*?J,;<I[@S93]1C;E/< K 29LI^HQMRGN#-E/U&-N4]P#
ME5OD8W6V??(: Q:G AMM1S1$CI,Y+23L:(K2-16ES"_-E/U&-N4]P"L!)FRG
MZC&W*>X,V4_48VY3W *P$F;*?J,;<I[@S93]1C;E/< K 29LI^HQMRGN#-E/
MU&-N4]P#E1O-I?KG?B*&@,6E0(;D E.0V%JQKI6J:(SL)Q1%ZO8+\V4_48VY
M3W *P$F;*?J,;<I[@S93]1C;E/< K 29LI^HQMRGN#-E/U&-N4]P"L9#OI=$
MZ@]\1H69LI^HQMRGN&4Y!B%RGC,E%9Q:H3RC1BRP3,EMD1V>W2?[P'H $F;*
M?J,;<I[@S93]1C;E/< K 29LI^HQMRGN#-E/U&-N4]P"L!)FRGZC&W*>X,V4
M_48VY3W .57^;,=;8^(D: Q:I AMQVC1$CI,Y+*3,FB*TC<21ES>P7YLI^HQ
MMRGN 5@),V4_48VY3W!FRGZC&W*>X!6 DS93]1C;E/<&;*?J,;<I[@%8"3-E
M/U&-N4]P9LI^HQMRGN <J-YO5UA_XJQH#%I5/AN0E*7$CJ/'O%:IHC.PG5$1
M<WJ(K!?FRGZC&W*>X!6 DS93]1C;E/<&;*?J,;<I[@%8"3-E/U&-N4]P9LI^
MHQMRGN 5C.=](HG5'_?:';-E/U&-N4]P@<@0RK<9LHD<D*C/*-.**PS)3=AV
M6?6?[S ;0"3-E/U&-N4]P9LI^HQMRGN 5@),V4_48VY3W!FRGZC&W*>X!6 D
MS93]1C;E/<&;*?J,;<I[@'&L_,F^MQOC(&B,6JP(;<-LT1(Z#.3'29DT1:#=
M01ES>LC,A?FRGZC&W*>X!'RI]$:UU!_X:AKCS_*.#$9Y+U9YF*RVZW">4A:&
MR)23)!F1D9<QC5S93]1C;E/< K 29LI^HQMRGN#-E/U&-N4]P"L!)FRGZC&W
M*>X,V4_48VY3W .5&^9.];D?&6- 8M*@0W(CAKB1UF4A])&;1'H)U9$7-ZB(
MB%^;*?J,;<I[@%8"3-E/U&-N4]P9LI^HQMRGN 5@),V4_48VY3W!FR 1Z(,;
M=)[@&5R%_P!G_)W^S8_PTC09](I?5&??=&-R*@1'N0?)]QV*PMQ5.CFI2FR,
MS/%IYS%[<"$=;DMG$CX"8S2B3BBL(S4Y:=EGU%^X!M ),V4_48VY3W!FRGZC
M&W*>X!6 DS93]1C;E/<&;*?J,;<I[@%8"3-E/U&-N4]P9LI^HQMRGN <JQYO
M3UACXJ!H#%JL"&W")3<1A*L>R5J6B([#=21ES>P7YLI^HQMRGN 5@),V4_48
MVY3W!FRGZC&W*>X!6 DS93]1C;E/<&;*?J,;<I[@%8"3-E/U&-N4]P9LI^HQ
MMRGN <J1\V?ZV_\ $4- 8M,@0W([IKB1U&4EY)6M$=A$XHB+F]@OS93]1C;E
M/< K 29LI^HQMRGN#-E/U&-N4]P"L9#/I?+Z@S\1T69LI^HQMRGN&4W!B'RG
MDLG&9Q90FE$C%E@D9K<(SL]N@OW /0#.1Z1/]4;]]8[9LI^HQMRGN$"($+/;
MS91(^ 49M1)Q16$9J7ILL^H@&T DS93]1C;E/<&;*?J,;<I[@%8"3-E/U&-N
M4]P9LI^HQMRGN 5@),V4_48VY3W!FRGZC&W*>X!RK7FQ7ZUKXB1H#%JL"$W3
MS4W$CH5C&BM2T1'I<21^H7YLI^HQMRGN 5@),V4_48VY3W!FRGZC&W*>X!6
MDS93]1C;E/<&;*?J,;<I[@%8"3-E/U&-N4]P9LI^HQMRGN <:3\C*ZV][QC1
M&+38$-QJ2:XD==DEU)6M$=A$H["YA?FRGZC&W*>X!6 DS93]1C;E/<&;*?J,
M;<I[@%8"3-E/U&-N4]P9LI^HQMRGN 5C.3Z1.=43[ZAVS93]1C;E/<(2@0L]
MK;R2/@%&2K!Q166X1Z;+ &R DS93]1C;E/<&;*?J,;<I[@%8"3-E/U&-N4]P
M9LI^HQMRGN 5@),V4_48VY3W!FRGZC&W*>X!QK/FIW])'OD.7*3S"_\ IM_$
M2/Q5H$)JFN+;B,(42D6&EHB/RB^H<*_!B,45YQJ,PVLEMV*0V1&5JTD>D!Z
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MMRGN 5C.7Z1,=4<]] [9LI^HQMRGN$"H$//;+>21\ XRU&G%%89X2--EGUF
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M-E/U&-N4]P"L!)FRGZC&W*>X,V4_48VY3W *P$F;*?J,;<I[@S93]1C;E/<
MY5WT?J/5G/=,: Q:Q A-T2>XW$80M,=Q25):(C(R2>DCL%^;*?J,;<I[@%8"
M3-E/U&-N4]P9LI^HQMRGN 5@),V4_48VY3W!FRGZC&W*>X!6 DS93]1C;E/<
M&;*?J,;<I[@$?)WS8]UZ9_\ 9<&N,;DZ6#2W"+F3-EI(O812'"(OL(AL@
M">59D;^$TIU&+5A-H*U2RLYB^LQYV(VI1.RWZ>^V^M;98+;&B,DDJ)!H(R\<
MTVG:=G]+FL(>J !Y@F'8W)2 T\WBUHE12P3Y[,H19;[#LL,R]MH].,FOF::6
ME1)-1E+C&22YS_EV]!6BG+9&RY?::O@+0$66R-ER^TU?#+9&RY?::O@+1XDX
ME5E0*<J!6E06T1&T+:)A"[5$6D[3+["L^H>IRV1LN7VFKXSW84=YQ3CE#EFM
M1VF>-;+_ +@":G(?17*>W)D')>;@.I<>-))PCPV]-A:"'A>4+-)1RUY8IK5%
MDU!4V#&;@);I[CZG%DVLE$A:4F2%6FG3:7\!]*BD4)*DQZ/+02CM/^4;/[W!
M3ELC9<OM-7P'Q94)ABE<HJ56Z+)G\I9$**S%/(%R%F_D;2;2>))I+!<(S,\(
MN8S'J.5[&2SN0CM?CJG1HAO%/6F*J0DU&Q@D9H2DS.U7U#Z#ELC9<OM-7PRV
M1LN7VFKX#Y"VJ;3([SD-->I%!E39LF W BJ-6'@M$RDVS09H0M>.4E!DDCM*
MW0.[E0Y6/-3$3I%?:KYQ#1'A1(O\W4G(K3<PB2DB5CC/22C42L%)%I'U?+9&
MRY?::OAELC9<OM-7P'RN)5:URFY3)88J-:C4EUZ(WCFVULGHC/FZ1&I/K6E)
M&=G.6C388S4U3EQ&I3>!*JDI4ZG19,IU;:L*-:^I+AMX*#-)DV2;2))JLM59
M:0^S9;(V7+[35\,MD;+E]IJ^ ^.-3>5\Z&X;M2J[#<:E39<5YI*B-]33O\CA
M&I!&JU-O.E)J*PS(25*77:2]4V8)UAER9593ZL43B2PE-H4T1&EM1GA&:B))
M6$HRTF1)'V[+9&RY?::OAELC9<OM-7P'QFFNUY<ARIDU-<K3YQI:4NL'@*<S
M8]I(C*RW&>*9%S6$6@:$5ZO3GX4&+6>4IP')D5MZ1)8Q+R%FV^;Z",TD>#XK
M=MMI),]',/JV6R-ER^TU?#+9&RY?::O@,'\GTFJ2N1L1=8<?<FH<>;4N0C!6
MI*7%)2:M!6G@D6GU\X]6(LMD;+E]IJ^&6R-ER^TU? 6@(LMD;+E]IJ^&6R-E
MR^TU? 6@(LMD;+E]IJ^&6R-ER^TU? 6@(LMD;+E]IJ^&6R-ER^TU? 6@(LMD
M;+E]IJ^&6R-ER^TU? 6@(LMD;+E]IJ^&6R-ER^TU? 6@(LMD;+E]IJ^&6R-E
MR^TU? 6@(LMD;+E]IJ^&6R-ER^TU? 6@(LMD;+E]IJ^&6R-ER^TU? 6@(LMD
M;+E]IJ^&6R-ER^TU? 6@(LMD;+E]IJ^&6R-ER^TU? 6@(LMD;+E]IJ^&6R-E
MR^TU? 9K!M)H=65)2ZMDGI1N):MPU)PE6DFS3;9S6:1\WY-TRG5VD\HWVH<F
MF$[$2A%,98>9-+:"5@8;AI+&*4?.1&?J(?2*3+>2S*P8$ERV4\9FE3>CQST:
M5EI(:66R-ER^TU? 9W(UMQGD;2&G6U-N(BH)2%%8:3LYC(;PBRV1LN7VFKX9
M;(V7+[35\!: BRV1LN7VFKX9;(V7+[35\!: BRV1LN7VFKX9;(V7+[35\!:
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MP7Y6_LZ3VF[X"L!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^
MK&1R7]%J9U9'W"S*W]G2>TW?&5R=?=;Y.4Y"8C[B4QT$2T&BQ6CG*U1'^\@&
MA0_,4']2G[AH#%H\EY%'AI3"D+(FDD2DJ;L/1]:B,7Y6_LZ3VF[X"L!)E;^S
MI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^ K&<CTB?ZHW[ZQVRM_9TG
MM-WQ F2]GMU>0R+3C(+ PF[2\96GRK/X@-H!)E;^SI/:;OAE;^SI/:;O@*P$
MF5O[.D]IN^&5O[.D]IN^ K 296_LZ3VF[X96_LZ3VF[X#C4_EJ?ULO=4-$8L
M^0\;L*V%(39)(RM4WXWBJT%8K[Q?E;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN
M^ RJGZ;4#]1+^YL>@'E:C(=/EC0U'#?(R8EV(,T6JT-\WC6?O,;^5O[.D]IN
M^ K 296_LZ3VF[X96_LZ3VF[X#C1/,T7] :(Q:1(>128R4PI"R)&A25-V'^]
M1&+\K?V=)[3=\!6 DRM_9TGM-WPRM_9TGM-WP%8"3*W]G2>TW?#*W]G2>TW?
M 5C.+TA5U1/OF.V5O[.D]IN^(2DO9[4O(9%N3$6!A-V^4>GRK/X@-D9!>ER^
MH)^(8LRM_9TGM-WQE)D.^$ZUY(_A9$DL7:C"LPST^599^VT!Z !)E;^SI/:;
MOAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^ Y5/RH76T?<8T!C5"0ZK([84A
M-DE!E:IO3H/1H4+LK?V=)[3=\!6//E_M#5_91?%,:N5O[.D]IN^,$I#OAZI>
M1OX6:R+ M1;\J>GRK/X@/4@),K?V=)[3=\,K?V=)[3=\!6 DRM_9TGM-WPRM
M_9TGM-WP'*B>9V/^+WC&@,6D2744IE*8,A9%A>,E3=A^,?M40ORM_9TGM-WP
M%8"3*W]G2>TW?#*W]G2>TW? 5@),K?V=)[3=\,K?V=)[3=\!6,[^L7]T_P X
M[96_LZ3VF[XARE[/9*R&1;DUF!A-V^5S^59_$!L@),K?V=)[3=\,K?V=)[3=
M\!6 DRM_9TGM-WPRM_9TGM-WP%8"3*W]G2>TW?#*W]G2>TW? <JKY,/K;?WC
M0&-4I#JD1;84A-DELRM4WIT\VA0NRM_9TGM-WP&4K_:&W_92_BI'H!Y94AWP
M];7D;^%FM98%J+?E4Z?*L_B-[*W]G2>TW? ?V?YME_J5_<8YT;S'3^K-^Z0Y
M39+RH$DC@R$D;2B,S4W86@_]X<J5(=32(*2A2%D4=LB4E3=A^*6DK56@-@!)
ME;^SI/:;OAE;^SI/:;O@.-%\U-_IN>^H:(QJ3)=336R3"D++"7XR5-V>6?M4
M+LK?V=)[3=\!6 DRM_9TGM-WPRM_9TGM-WP%8"3*W]G2>TW?#*W]G2>TW? 5
MC.5Z1-]47[Z1VRM_9TGM-WQ"J2]GMM>0R+<F46!A-V^4G3Y5G\0&R DRM_9T
MGM-WPRM_9TGM-WP%8"3*W]G2>TW?#*W]G2>TW? 5@),K?V=)[3=\,K?V=)[3
M=\!RJWR,;K;/OD- 8U2D/*9CVPI"+)+1^,IO3XQ:-"A=E;^SI/:;O@*P$F5O
M[.D]IN^&5O[.D]IN^ K 296_LZ3VF[X96_LZ3VF[X"L!)E;^SI/:;OAE;^SI
M/:;O@.5&\VE^N=^(H: QJ5)=33R(H4A98UW2E3=GRBO:H796_LZ3VF[X"L!)
ME;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^ K&0[Z71.H/?$:%F5
MO[.D]IN^,IR0Z7*:,O)'R44)XB;M1A&6&WI\JRPK/;;I >@ 296_LZ3VF[X9
M6_LZ3VF[X"L!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^ Y5?
MYLQUMCXB1H#%J<AY4=DCA2$6263M4IO3_*)T:%>L7Y6_LZ3VF[X"L!)E;^SI
M/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^ K 296_LZ3VF[X96_LZ3VF
M[X#E1O-ZNL/_ !5C0&+2I+J82B*%(66/>.U*F[/E5:-*O5S"_*W]G2>TW? 5
M@),K?V=)[3=\,K?V=)[3=\!6 DRM_9TGM-WPRM_9TGM-WP%8SG?2*)U1_P!]
MH=LK?V=)[3=\9[DA[/<5612"LC/$3>$W:?C-Z?*LT6>WUE]8#; 296_LZ3VF
M[X96_LZ3VF[X"L!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^
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MMMLPGFSLM]?.-X>?EPTT[D_#B)4I9-28B,(_Z1X]%I_5]G,7,0]
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MR@=JD^=3IU+>IU0ADA:FEN)<2MM=N"I*TZ#+Q3+ZC(>?IWY1I-1HRJPW023
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MY#P#Y5>TN*_\A;A\QR.OAGRN_P#W.[1WAX9\KO\ ]SNT=XY> ?*KVEQ7_D/
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M4)7Q(XUQD2/2ZF]0E?$CC7    &?6/F+?6H_QD#0&?6/F+?6H_QD#0
M     9]"]'Z=U9OW2&@,^A>C].ZLW[I#0        &<WZ0R>J,^^X-$9S?I#
M)ZHS[[@#1         !GU+YS3>M_]M8T!GU+YS3>M_\ ;6-         9')?
MT6IG5D?<-<9')?T6IG5D?< [T/S%!_4I^X: SZ'YB@_J4_<-         9R/
M2)_JC?OK&B,Y'I$_U1OWU@-$         &=4_EJ?ULO=4-$9U3^6I_6R]U0T
M0   !Y^I^FU _42_N;'H!Y^I^FU _42_N;'H    !G43S-%_0&B,ZB>9HOZ
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M#_Q5C0&?1O-ZNL/_ !5C0        &<[Z11.J/\ OM#1&<[Z11.J/^^T T0
M        9U9^9-];C?&0-$9U9^9-];C?&0-$!D<J?1&M=0?^&H:XR.5/HC6N
MH/\ PU#7       !GT;YD[UN1\98T!GT;YD[UN1\98T        >?Y"_[/\
MD[_9L?X:1H,^D4OJC/ONC/Y"_P"S_D[_ &;'^&D:#/I%+ZHS[[H#0
M  !GUCS>GK#'Q4#0&?6/-Z>L,?%0-           !GTCYL_UM_XBAH#/I'S9
M_K;_ ,10T     &0SZ7R^H,_$=&N,AGTOE]09^(Z UQG(](G^J-^^L:(SD>D
M3_5&_?6 T0         9]:\V*_6M?$2- 9]:\V*_6M?$2-           !G4
MGY&5UM[WC&B,ZD_(RNMO>\8T0       !G)](G.J)]]0T1G)](G.J)]]0#1
M        !G5GS4[^DCWR'+E)YA?_ $V_B)'6L^:G?TD>^0Y<I/,+_P"FW\1(
M#6         !GTKR9G6W/O&@,^E>3,ZVY]XT        !G_UB_NG^<: S_ZQ
M?W3_ #@-          &=6O,\C["]XAHC.K7F>1]A>\0T0          &?2_*
MG=;7]Q#0&?2_*G=;7]Q#0 9%#^4JO7W/=2-<9%#^4JO7W/=2-<    !G'Z1)
MZHKWR&B,X_2)/5%>^0#1         !G5OS)+_5C1&=6_,DO]6-$
M !G4SY:I=;/W$#1&=3/EJEUL_<0-$        9R_2)CJCGOH&B,Y?I$QU1SW
MT -$      9-?^:1.OQOBI&L,FO_ #2)U^-\5(U@&?6_,4[]0K[AH#/K?F*=
M^H5]PT           &=3?G53ZW_VVQHC.IOSJI];_P"VV-$        9[OI%
M$ZH][[0T!GN^D43JCWOM -          &?7?1^H]6<]TQH#/KOH_4>K.>Z8T
M           &1R=\V/=>F?\ V7!KC(Y.^;'NO3/_ ++@UP     <)!D49TS=
MQ)$@[7-'B:.?3HT#RJ''G6B5%G*1%>D-I:*1)62UD25FI1F6E.&9%86CF]5M
M@#;KY&JEI22C29RXQ$HN<OY=O25HIR*1M27V6K@R')&5<FHKIH4BV;'*Q3AN
M6V24%:2CTF1V6E]1D/2 (LBD;4E]EJX&12-J2^RU<%H (LBD;4E]EJX&12-J
M2^RU<%H (LBD;4E]EJX&12-J2^RU<%H^;<I.558H?*>J-P&3F&;<!IJ.M1J)
MLUY0:EI;(R4XKQ"M2G29%;S) >\R*1M27V6K@9%(VI+[+5P?.8OY3I\FJ4E"
M8D$X$I#"''T*<41O.$HL C(OY,R45A)<(C5ITD/Y/_*=484:F$4!A<BH4N%)
M;P4K41/ON&BS!3:9I(B,["TF=A>L!]'R*1M27V6K@9%(VI+[+5P?/JKRQJ4[
M\D5?JS9+@5.$MR.I;1*18M#A)-225XR;2]2M)':7J&9RCFU6A5>118?*">_'
MD0XLE9N/83T99RVFSP5D16)6A2M!V\QGZP'U3(I&U)?9:N!D4C:DOLM7!Y6@
M/2Z=R\J5 *I3*E!3"9E&N4ZEQ<5U2E)Q9J(K;%)22B(_^H\AR8J/*5ZGPZ\;
M]67'8D2W)\F9+:.&MAO&D24HPL81VI25N"5EAGI+G#ZSD4C:DOLM7 R*1M27
MV6K@^94K\IU;J*2BE"IZ9LAZ(W&=63K;1$^EQ=JDJ\95A-'89686$7,%+Y>5
M,^5[L64Y'Q3Z6E+=0X;T1C ;6IQ+:TZ#6K!,R(ST8*K;3*PP^FY%(VI+[+5P
M,BD;4E]EJX/F4/\ *A6)$?%J@0TR9:XB(+BFW4-%CU+(C5A6&I)$C0I-A*M*
MP<Y_Y5JS#5B44R$[(CMR9,E+>-<0III]35B5)(\&W ,\-16<VC2 ^HY%(VI+
M[+5P,BD;4E]EJX.\=W*(S3V":<8@E8*N<K2YAV 19%(VI+[+5P,BD;4E]EJX
M+0 19%(VI+[+5P,BD;4E]EJX+0 19%(VI+[+5P,BD;4E]EJX+0 19%(VI+[+
M5P,BD;4E]EJX+0 19%(VI+[+5P,BD;4E]EJX+0 19%(VI+[+5P,BD;4E]EJX
M+0 19%(VI+[+5P,BD;4E]EJX+0 19%(VI+[+5P,BD;4E]EJX+0 19%(VI+[+
M5P,BD;4E]EJX+0 19%(VI+[+5P,BD;4E]EJX+0 19%(VI+[+5P,BD;4E]EJX
M+0 8%)B/*9E8,^2W9*>(R2EO3XYZ=*#TF-+(I&U)?9:N#).6Y!Y,UV8Q9C8Z
MY;J+2M\9)J,OXD,#D',EG4U1G*X_5&7Z:Q.4;SA*-IQ9J(R+UDDR(C(N8@'M
M<BD;4E]EJX&12-J2^RU<%H (LBD;4E]EJX&12-J2^RU<%H (LBD;4E]EJX&1
M2-J2^RU<%H (LBD;4E]EJX&12-J2^RU<%H (LBD;4E]EJX&12-J2^RU<%H (
MLBD;4E]EJX,V%$?.JU))5"21I6W:HDMVJ\0N?Q+/W6#?&5"/!J]859;8ML["
MYS_DR 49%(VI+[+5P,BD;4E]EJX/CDOE)7H4!B1$K,N8]58BG7D&XBV*O'$D
MC1:1I;*PS3S:#TC7H-8K4ZH,<GVYCZ)D28^M[*WC?\5"/%0;B;#<0:E:;2+F
ML ?3,BD;4E]EJX&12-J2^RU<'@G'N4J/R>5U2:V6<8TJ43LU35JB2DST-IML
M3["]A?6.DJ=7)SLM-,J#L<H%(;4XZZG#0;JTX9G9HPE8-EEIV%: ]SD4C:DO
MLM7 R*1M27V6K@^0U2N5M-)I%0SE-5$C4E,J<F/44,/+4;EEMBDJ-1V>JPB^
ML?8X;I/PF'4X>"XVE18?E:2MT_6 Y9%(VI+[+5P,BD;4E]EJX+0 19%(VI+[
M+5P,BD;4E]EJX+0 19%(VI+[+5P,BD;4E]EJX+0 8$.(^=7J22J$DC2;=JB2
MW:KQ?7XEG[K!I9%(VI+[+5P<8/GNJ_:U[@^557E37J<B97(LJ8MQZ5,C*@NF
M2FV6VB+!4E-A6&5MIG;IMT@/K>12-J2^RU<#(I&U)?9:N#Y71:K7_P"1H3\Z
MHMSI4J,LG''LH-+1HPUF3F"FPCT6IL\6WG,:U+F\I7D\M62K#:I<221,O*9,
MT,(Q=IDA&%S_ &GSZ3 >^R*1M27V6K@9%(VI+[+5P> I%4KU8C\GX<&<65)I
MBY4E]]9J(U*/!1AI(R-7K.P8[U2Y02^3%%::JDAV2DI;TI;503%=>2W;I*U*
MSL*SF))EZK2 ?5\BD;4E]EJX&12-J2^RU<$_)R>BI\FZ=.;*22'F$K+*?E.;
M^E]8U0$612-J2^RU<#(I&U)?9:N"T $612-J2^RU<#(I&U)?9:N"T $612-J
M2^RU<&;DCWA#@9PDX626X>"W;Y?-Y%EG[!OC+_K074C]\!WR*1M27V6K@9%(
MVI+[+5P?-YE7K#W*J?(C5*4TY%J;-/8@I4DFEH6DS-2DJ+2=NFW1S#,A5ZN<
MG:TB%REJ<Y]J/(-]\H[N,.TRT)-5A6-V>.:;=!%9I ?6\BD;4E]EJX&12-J2
M^RU<%*%I<;2XA1*0HB-)ES&1CH BR*1M27V6K@9%(VI+[+5P6@ BR*1M27V6
MK@9%(VI+[+5P6@ BR*1M27V6K@9%(VI+[+5P6@ BR*1M27V6K@9%(VI+[+5P
M6@ \]-C/(K-*2J;(6:ENV*4ENU'B'S6)(OWVC6R1_:,GLMW!)4?/U%_3>^&8
MU@&-48[J41;9LA=LELBM2WHT\^A(NR1_:,GLMW!QJOR<3K;7O#1 29(_M&3V
M6[@9(_M&3V6[@K !)DC^T9/9;N!DC^T9/9;N"L $F2/[1D]ENX.3\5XHKIG/
MDG8@]!I;TZ/T!H#C*^:O?JU?< @I\9Y5,B**=(21LH,DDENPO%+1I2*LD?VC
M)[+=P*7YIA_J$>Z0K 29(_M&3V6[@9(_M&3V6[@K !)DC^T)/9;N!DC^T9/9
M;N"L $F2/[1D]ENX((\9TZM-24V01DVU:HDMVGY7/XM@VAGQO/D_]4S_ )P'
M7)']HR>RW<#)']HR>RW<%8 ),D?VC)[+=P,D?VC)[+=P5@ DR1_:,GLMW R1
M_:,GLMW!6 #%J4=Y+,>V;(7;):*PTMZ/'+3H3ZA?DC^T9/9;N#E5OD(_6V??
M(: "3)']HR>RW<#)']HR>RW<%8 ),D?VC)[+=P,D?VC)[+=P5@ DR1_:,GLM
MW!^'8CV*7_\ D))^*?\ 1;N"X<W?D5_HF RZ7'>5282BFR$$;"#)*4MV%XI:
M"M3:)Z"P\NEX29;[991(+!22+-#RRMTI,]//^WU#3I'F2!U9OW2$O)SS1_>9
M/QU@+,D?VC)[+=P,D?VC)[+=P5@ DR1_:,GLMW R1_:,GLMW!6 "3)']HR>R
MW<$#,=TZS,(IL@C)ADS426[3TN:/)LT?]1M#.C^?IWZAC[W ';)']HR>RW<#
M)']HR>RW<%8 ),D?VC)[+=P?PXKQ%:=0DZ/]UNX+!YWEI+G0N2<Y^GH-3Q(L
M-23.U"3YU%9["]?JY_4 SN2<EFI5#E$J'4GE).H$LE(0GQBQ#*;3M3H.U*BL
MT>3S#U&2/[1D]ENX/GGY('YBH$]A;/\ ,R<)Q+UEEKAD1&7UZ"+[+"]H^G ,
M6J1WDQ6C.;(7;)8*PTMZ+7$Z="?5SB_)']HR>RW<'*L?-6>MQ_BI&@ DR1_:
M,GLMW R1_:,GLMW!6 "3)']HR>RW<#)']HR>RW<%8 ),D?VC)[+=P?PXCV"?
M_P"0D\W1;N"P?Q7DG]@#&H\=Y=%@FF;(01QFS(DI;L3XI:"M29_O%^2/[1D]
MENX.5$]'Z=U5KW2&@ DR1_:,GLMW R1_:,GLMW!6 "3)']HR>RW<#)']HR>R
MW<%8 ),D?VC)[+=P9S4=XZY*1ED@C*,R9N8+=IVJ=T>39HL]GK/ZAN#.8](9
MO56/?> =LD?VC)[+=P,D?VC)[+=P5@ \\ZP[X3P496_A'"DF3ADC"21+8T%X
MMEAVESE;H*RS3;K9(_M&3V6[@CD>EU-ZA*^)'&N DR1_:,GLMW R1_:,GLMW
M!6 #%JL=U,)!G,D+_G+!6&EOUNH*W0GU<_[!?DC^T9/9;N#E6/F+?6H_QD#0
M 29(_M&3V6[@9(_M&3V6[@K !)DC^T9/9;N!DC^T9/9;N"L $F2/[1D]ENX&
M2/[1D]ENX*P 8M&CO+HD)29LA!'';,B2ENQ/BEH*U)G^\7Y(_M&3V6[@Y4+T
M?IW5F_=(: "3)']HR>RW<#)']HR>RW<%8 ),D?VC)[+=P,D?VC)[+=P5@ DR
M1_:,GLMW! B,]GN0C+I%I1FCP\%NT_&<T>39_#UC:&<WZ0R>J,^^X [9(_M&
M3V6[@9(_M&3V6[@K !)DC^T9/9;N!DC^T9/9;N"L $F2/[1D]ENX&2/[1D]E
MNX*P 8LZ.Z4BGD<V0K"DV$9I;\7^37I*Q/W^T7Y(_M&3V6[@Y5+YS3>M_P#;
M6- !)DC^T9/9;N!DC^T9/9;N"L $F2/[1D]ENX&2/[1D]ENX*P 29(_M&3V6
M[@RN3K#KG)RG+3+?;2J.@R0@D6)T<Q6I,_WF/0#(Y+^BU,ZLC[@'XH\9Y='A
MJ3-D((VDF24I;L+1]:3,7Y(_M&3V6[@Y4/S%!_4I^X: "3)']HR>RW<#)']H
MR>RW<%8 ),D?VC)[+=P,D?VC)[+=P5@ DR1_:,GLMW! F,]GMU&72+2C(\?!
M;M/QE:/)L_@-H9R/2)_JC?OK =LD?VC)[+=P,D?VC)[+=P5@ DR1_:,GLMW
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M^7^T-7]E%\4P&KDC^T9/9;N!DC^T9/9;N"L $F2/[1D]ENX&2/[1D]ENX*P
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M-Y\G_JF?\X#KG.GZ]&WR>\,YT_7HV^3WBL $F<Z?KT;?)[PSG3]>C;Y/>*P
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MT_7HV^3WBL $F<Z?KT;?)[PSG3]>C;Y/>*P 29SI^O1M\GO#.=/UZ-OD]XK
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MT_7HV^3WBL $F<Z?KT;?)[PSG3]>C;Y/>*P 29SI^O1M\GO#.=/UZ-OD]XK
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M4Z/2%J3CUDW(0X@B4PJ.ILK5J<M\H_DR05EEMIVVCF?(FMPJ7$;33)#[#D>
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MF(YKQ;6$1OG87E66'@:?W -H!)C*AJT;B%7 QE0U:-Q"K@"L!)C*AJT;B%7
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MU<94-6C<0JX K 28RH:M&XA5P,94-6C<0JX K 28RH:M&XA5P,94-6C<0JX
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MY]%G[0&^,Y'I$_U1OWUCMC*AJT;B%7! A<W/;QY/'QF3-VECSLLPE^O ^WU
M-H!)C*AJT;B%7 QE0U:-Q"K@"L!)C*AJT;B%7 QE0U:-Q"K@"L!)C*AJT;B%
M7 QE0U:-Q"K@#E6O-BOUK7Q$C0&+55S<WGC&(Z4XQK2E\S/Y1-G] A?C*AJT
M;B%7 %8"3&5#5HW$*N!C*AJT;B%7 %8"3&5#5HW$*N!C*AJT;B%7 %8"3&5#
M5HW$*N!C*AJT;B%7 '&D_(RNMO>\8T1C4Q<PFI.!'CG_ #EVW"?,K#PCM_H"
M[&5#5HW$*N *P$F,J&K1N(5<#&5#5HW$*N *P$F,J&K1N(5<#&5#5HW$*N *
MQG)](G.J)]]0[8RH:M&XA5P0)7-SVL\GCXS)DZ,>=EF$?KP/^@#: 28RH:M&
MXA5P,94-6C<0JX K 28RH:M&XA5P,94-6C<0JX K 28RH:M&XA5P,94-6C<0
MJX XUGS4[^DCWR'+E)YA?_3;^(D<ZJN:=,<)R/'2G"1::7S,_*+U8!#C7US#
MHKQ.L,)1AMVFAXU'Y:;-&"7W@/0 ),94-6C<0JX&,J&K1N(5< 5@),94-6C<
M0JX&,J&K1N(5< 5@),94-6C<0JX&,J&K1N(5< <J5Y,SK;GWC0&-35S23+P(
M\<_YRY;:^96';^@+L94-6C<0JX K 28RH:M&XA5P,94-6C<0JX K 28RH:M&
MXA5P,94-6C<0JX K&?\ UB_NG^<=<94-6C<0JX(,.;GNW)X^,R;FQYV687MP
M/^@#: 28RH:M&XA5P,94-6C<0JX K 28RH:M&XA5P,94-6C<0JX K 28RH:M
M&XA5P,94-6C<0JX XUKS/(^PO>(:(Q:LN:=*?)QB.E-A6FE\S/G+U8!"_&5#
M5HW$*N *P$F,J&K1N(5<#&5#5HW$*N *P$F,J&K1N(5<#&5#5HW$*N *P$F,
MJ&K1N(5<#&5#5HW$*N .5+\J=UM?W$- 8U/7,)4S CQS_G*L*U\RL.PO]S2+
ML94-6C<0JX CH?RE5Z^Y[J1KC HZYA+J6+885;,7A83QE8=B=!>*=I?7H^P:
MF,J&K1N(5< 5@),94-6C<0JX&,J&K1N(5< 5C./TB3U17OD.V,J&K1N(5<$!
MKFY[0>3Q\9DRM&/.RS"+UX'_ $ ;0"3&5#5HW$*N!C*AJT;B%7 %8"3&5#5H
MW$*N!C*AJT;B%7 %8"3&5#5HW$*N!C*AJT;B%7 '&M^9)?ZL:(Q:LN:=(E$Y
M'CI1@:32^9F7[, A?C*AJT;B%7 %8"3&5#5HW$*N!C*AJT;B%7 %8"3&5#5H
MW$*N!C*AJT;B%7 %8"3&5#5HW$*N!C*AJT;B%7 '&F?+5+K9^X@:(QJ>N83L
M[ CL&9R3PK7S*P\%/-XFD78RH:M&XA5P!6 DQE0U:-Q"K@8RH:M&XA5P!6 D
MQE0U:-Q"K@8RH:M&XA5P!6,Y?I$QU1SWT#MC*AJT;B%7! I<W/;)Y/'QF3+L
M+'G99A(]>!]GJ ;0"3&5#5HW$*N!C*AJT;B%7 %8"3&5#5HW$*N!C*AJT;B%
M7 $E?^:1.OQOBI&L//UI<PXL7&LL)++8_DNFJT\:FPO)+1;Z_5[#&KC*AJT;
MB%7 '*M^8IWZA7W#0&+6%S3H\TG(\=+>)5A&E\S,BL]F 5O[Q?C*AJT;B%7
M%8"3&5#5HW$*N!C*AJT;B%7 %8"3&5#5HW$*N!C*AJT;B%7 %8"3&5#5HW$*
MN!C*AJT;B%7 '&F_.JGUO_MMC1&+ 7-*14,"/',SD^/:^96'BT<WB:=%GL%^
M,J&K1N(5< 5@),94-6C<0JX&,J&K1N(5< 5@),94-6C<0JX&,J&K1N(5< 5C
M/=](HG5'O?:'7&5#5HW$*N"!Q<W/<8SCQ\9DSMA8\[#+";MTX'V>H!M ),94
M-6C<0JX&,J&K1N(5< 5@),94-6C<0JX&,J&K1N(5< 5@),94-6C<0JX&,J&K
M1N(5< <J[Z/U'JSGNF- 8M77-.BSR<882V<=S"-+YF9%@GS%@%;^\7XRH:M&
MXA5P!6 DQE0U:-Q"K@8RH:M&XA5P!6 DQE0U:-Q"K@8RH:M&XA5P!6 DQE0U
M:-Q"K@8RH:M&XA5P!'R=\V/=>F?_ &7!KC&Y.Z:6[;:1Y;+M+V'E#EI?65OK
M^X;(    Y.FXEI9MI)3A),TI,[",_45HP<YS<GFK7*CI1#)*ER&V#4E1X)FI
M!%A:3(\'3;Z[++1O/-D^PXTI2DDM)I,TG896EZC]HSVJ'$9BG$);ZF+6S)M3
MEI)P%81$1>HC,M/M 2S#E*Y/Q53< I*I44W"05A$9R$:/V<PWQF5WS<WUR+\
M=L:8        \!4N4W*<^4U?@46-2W&*1'9?4B23A./X:5*P4J(["/Q3(K2]
M9#WX\C5.0T:I52J34U>JPSJC3;,QF*MHD.H0DTD5JFS46A1VV*+G 8">7/*.
M?#J]:I<6EG2:='9EG'DXQ+[C:HR'U)PTF:258HR(\&S07VC0Y4\NW*4UR<D0
MW8<:)5R6M<F<TM9-))O#3XJ%$=I\PHD?DZI[B)<:/5*K"ITM+2'X,5QM+:T(
M;2T2,(T&X230DB,B5ITC;E\FX<NJ4:>9NM+I!N'&;:,B0>&C ,E%9S$7-89
M/'4W\JC+- :F5R(I3CS[[<=RGMF;<IIHB-3R"<,C)/C$5AF9F?-:-&?^4FFH
MH$R; 2ZY(3C41DN(*QPTQCD)<LPB,VS01';H/QB*PC'\E_DPH[[>+CRYT-*7
MGG&4LXHTL)>L-QM"5(,DHM+"+1:E1VD9"A7Y-J"J4Y(24E"UTHZ583A'8V:2
M1AZ2,\9@D2<(SYB+0 DF?E)A)BUAJ&T\N=3(SCCCJF+6"<0DC-)V*PB\K1;8
M1V'89V"J1^4>D0W)*'XU02EDGR0]D]C<A;!&;J&S,])IL5SV$>"=AF.,O\F%
M)G5.3+D3JBLWF'6$EA-VM$XG!58K PC*SR4F9I3IL(M%G1_\G-.EN22?J%25
M%=*2;48W$$B.M^TG5H\2VTR49$2K2+"5HT@.<C\I]$AQW#DQ:DS(;>)HXCC*
M4NZ6\:2K#598:=)$9X1GHLMT#V4:0F5%:D(2XE+B"627$&A1$96Z4GI(_J,>
M2K'Y.J96)4Z2Y.G,.35MJ>)!MJ09(;Q=F M!I/Q=-JB,R/25@]12J>Q1Z3#I
MD7#R>(REEO#.T\%)6%:?MT +0
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M^J9_SC0&?&\^3_U3/^<!H          SZM\A'ZVS[Y#0&?5OD(_6V??(:
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M=6;]TAH#/H7H_3NK-^Z0T        !G-^D,GJC/ON#1&<WZ0R>J,^^X T0
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MH76T?<8T!GU/RH76T?<8T  >?+_:&K^RB^*8] //E_M#5_91?%,!Z
M9]$\SL?\7O&- 9]$\SL?\7O&-         9W]8O[I_G&B,[^L7]T_P X#1
M       !GU7R8?6V_O&@,^J^3#ZVW]XT 'GU?[0V_P"RE_%2/0#SZO\ :&W_
M &4OXJ1Z !+/\VR_U*_N,<Z-YCI_5F_=(=)_FV7^I7]QCG1O,=/ZLW[I +@
M &=1?-3?Z;GOJ&B,ZB^:F_TW/?4-$        9RO2)OJB_?2-$9RO2)OJB_?
M2 T0         9]6^1C=;9]\AH#/JWR,;K;/OD-           !GT;S:7ZYW
MXBAH#/HWFTOUSOQ%#0        &0[Z71.H/?$:&N,AWTNB=0>^(T UP
M    9]7^;,=;8^(D: SZO\V8ZVQ\1(T           &?1O-ZNL/_ !5C0&?1
MO-ZNL/\ Q5C0        &<[Z11.J/^^T-$9SOI%$ZH_[[0#1         !G5
MGYDWUN-\9 T1G5GYDWUN-\9 T0&1RI]$:UU!_P"&H:XR.5/HC6NH/_#4-<
M     &?1OF3O6Y'QEC0&?1OF3O6Y'QEC0       !Y_D+_L_Y._V;'^&D:#/
MI%+ZHS[[HS^0O^S_ )._V;'^&D:#/I%+ZHS[[H#0         !GUCS>GK#'Q
M4#0&?6/-Z>L,?%0-           !GTCYL_UM_P"(H: SZ1\V?ZV_\10T
M &0SZ7R^H,_$=&N,AGTOE]09^(Z UQG(](G^J-^^L:(SD>D3_5&_?6 T0
M      9]:\V*_6M?$2- 9]:\V*_6M?$2-           !G4GY&5UM[WC&B,Z
MD_(RNMO>\8T0       !G)](G.J)]]0T1G)](G.J)]]0#1         !G5GS
M4[^DCWR'+E)YA?\ TV_B)'6L^:G?TD>^0Y<I/,+_ .FW\1(#6         !G
MTKR9G6W/O&@,^E>3,ZVY]XT        !G_UB_NG^<: S_P"L7]T_S@-
M     &=6O,\C["]XAHC.K7F>1]A>\0T0          &?2_*G=;7]Q#0&?2_*
MG=;7]Q#0 9%#^4JO7W/=2-<9%#^4JO7W/=2-<    !G'Z1)ZHKWR&B,X_2)/
M5%>^0#1         !G5OS)+_ %8T1G5OS)+_ %8T0          &=3/EJEUL
M_<0-$9U,^6J76S]Q T0       !G+](F.J.>^@:(SE^D3'5'/?0 T0     !
MDU_YI$Z_&^*D:PR:_P#-(G7XWQ4C6 9];\Q3OU"ON&@,^M^8IWZA7W#0
M       9U-^=5/K?_;;&B,ZF_.JGUO\ [;8T0       !GN^D43JCWOM#0&>
M[Z11.J/>^T T          9]=]'ZCU9SW3&@,^N^C]1ZLY[IC0
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M.3Q3EX5@ Q:C#:1DEBY'C24$=K[A^H_:>C[1?D#'3D\4Y>'*I^5"ZVC[C&@
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M>#(&.G)XIR\*P 29 QTY/%.7@R!CIR>*<O"L $F0,=.3Q3EX,@8Z<GBG+PK
M!BTV&TMJ29KD%9)=+Q9#A<RC]A_Q%^0,=.3Q3EX<:3\C*ZV][QC1 29 QTY/
M%.7@R!CIR>*<O"L $F0,=.3Q3EX,@8Z<GBG+PK !)D#'3D\4Y>$!0VL]K3A2
M+,F2?SARWRC]=MO[!M#.3Z1.=43[Z@';(&.G)XIR\&0,=.3Q3EX5@ DR!CIR
M>*<O!D#'3D\4Y>%8 ),@8Z<GBG+P9 QTY/%.7A6 #%JL)MNFN*2N1:2D>5(<
M47E%ZC,<N4$-MJBOK2I\S);?EOK47EI]1G8+JSYJ=_21[Y#ERD\PO_IM_$2
MKR!CIR>*<O!D#'3D\4Y>%8 ),@8Z<GBG+P9 QTY/%.7A6 "3(&.G)XIR\&0,
M=.3Q3EX5@ Q:;#:6F5:N1HDN$5C[A>OZCT_:+\@8Z<GBG+PY4KR9G6W/O&@
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M8Z<GBG+P9 QTY/%.7A6 #&Y.:*4Y[$S9:2T>R0X7[3^OUC9&1R=\V/=>F?\
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M:&<CTB?ZHW[ZP';+V.A)X5RZ&7L="3PKET5@ DR]CH2>%<NAE['0D\*Y=%8
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M*Y=%8 ),O8Z$GA7+H9>QT)/"N716 "3+V.A)X5RZ&7L="3PKET5@ Q:K,:7
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MY=#+V.A)X5RZ*P 8W)S32G/8J;+46GVR'#_8?U>H;(R.3OFQ[KTS_P"RX-<
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MW,8Z43DG+CM554J)"B.O1$0XC,9Y3C+2$H,M!FDC+QC,^:T>LQ53UN)PJOQ
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M4-9C<.J^ K 28NH:S&X=5\,74-9C<.J^ Y5/RH76T?<8T!C5%$TCB8<B.?\
M.48-C!E8=A_[^D78NH:S&X=5\!6//E_M#5_91?%,:N+J&LQN'5?&"2)GAZHL
M>QC,UEXV).RS&GZL+_J ]2 DQ=0UF-PZKX8NH:S&X=5\!6 DQ=0UF-PZKX8N
MH:S&X=5\!RHGF=C_ (O>,: Q:2B:=*9-N1'2GQK"4P9GY1^O#(7XNH:S&X=5
M\!6 DQ=0UF-PZKX8NH:S&X=5\!6 DQ=0UF-PZKX8NH:S&X=5\!6,[^L7]T_S
MCMBZAK,;AU7Q#@3<]D641\9DW/B#LLPO9A_]0&R DQ=0UF-PZKX8NH:S&X=5
M\!6 DQ=0UF-PZKX8NH:S&X=5\!6 DQ=0UF-PZKX8NH:S&X=5\!RJODP^MM_>
M- 8U21-),7#D1S_G+=EC!E8=OZ8NQ=0UF-PZKX#*5_M#;_LI?Q4CT \LI$SP
M];+'L8S-:_&Q)V68U/JPO^HWL74-9C<.J^ _L_S;+_4K^XQSHWF.G]6;]TAR
MFHFY!)PI$<TXI5I$PHC,K#_WQRI2)ITB":)$=+>3MX)*849D6"7.>&5O[@&P
M DQ=0UF-PZKX8NH:S&X=5\!QHOFIO]-SWU#1&+2D33IK:FY#"4X2]"F#,_+/
MUX9"_%U#68W#JO@*P$F+J&LQN'5?#%U#68W#JO@*P$F+J&LQN'5?#%U#68W#
MJO@*QG*](F^J+]]([8NH:S&X=5\0&B;GMLLHCXS)E6'B#LLPD^K#_P"H#: 2
M8NH:S&X=5\,74-9C<.J^ K 28NH:S&X=5\,74-9C<.J^ K 28NH:S&X=5\,7
M4-9C<.J^ Y5;Y&-UMGWR&@,:IHF$U'PY$<RREJS!8,M.$5G],78NH:S&X=5\
M!6 DQ=0UF-PZKX8NH:S&X=5\!6 DQ=0UF-PZKX8NH:S&X=5\!6 DQ=0UF-PZ
MKX8NH:S&X=5\!RHWFTOUSOQ%#0&+2D3<WEBGXZ2QKNA3!F=N,5;_ $R]8OQ=
M0UF-PZKX"L!)BZAK,;AU7PQ=0UF-PZKX"L!)BZAK,;AU7PQ=0UF-PZKX"L9#
MOI=$Z@]\1H68NH:S&X=5\93B)GA/&(WV<;D;UBL2>"18;=I687/S:;?V>P/0
M ),74-9C<.J^&+J&LQN'5? 5@),74-9C<.J^&+J&LQN'5? 5@),74-9C<.J^
M&+J&LQN'5? <JO\ -F.ML?$2- 8M33-*,UC)$=192SY+!EIQB;/Z9^L7XNH:
MS&X=5\!6 DQ=0UF-PZKX8NH:S&X=5\!6 DQ=0UF-PZKX8NH:S&X=5\!6 DQ=
M0UF-PZKX8NH:S&X=5\!RHWF]76'_ (JQH#%I:)IP58M^.DL>]H4P9G;C56_T
MR]?_ .C%^+J&LQN'5? 5@),74-9C<.J^&+J&LQN'5? 5@),74-9C<.J^&+J&
MLQN'5? 5C.=](HG5'_?:';%U#68W#JOB!Q,W/<4CD1\9DSUAX@["+";MT8?V
M>OV_L#: 28NH:S&X=5\,74-9C<.J^ K 28NH:S&X=5\,74-9C<.J^ K 28NH
M:S&X=5\,74-9C<.J^ XUGYDWUN-\9 T1B51$TH:,8_'464Q[")@RTXU%G],_
M79_XYQH8NH:S&X=5\!'RI]$:UU!_X:AKCS_*-$PN2]6-Y]A;10WL-*&32HRP
M#M(C-1V']=A_8-7%U#68W#JO@*P$F+J&LQN'5?#%U#68W#JO@*P$F+J&LQN'
M5?#%U#68W#JO@.5&^9.];D?&6- 8M+1-.(YBWXZ2RE^TC8,].-7;_3+UV_\
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MR'Y--RX\I-,0ER/BL61.+)%K18+9FBW!4I):",R,R]0]*
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M'-WY%?Z)@)J1YD@=6;]TA+R<\T?WF3\=8JI'F2!U9OW2$O)SS1_>9/QU@-<
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M5\2.-<9$CTNIO4)7Q(XUP   !GUCYBWUJ/\ &0- 9]8^8M]:C_&0-
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M9RO2)OJB_?2 T0         9]6^1C=;9]\AH#/JWR,;K;/OD-
M!GT;S:7ZYWXBAH#/HWFTOUSOQ%#0        &0[Z71.H/?$:&N,AWTNB=0>^
M(T UP         9]7^;,=;8^(D: SZO\V8ZVQ\1(T           &?1O-ZNL
M/_%6- 9]&\WJZP_\58T        !G.^D43JC_OM#1&<[Z11.J/\ OM -$
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M5UM[WC&B,ZD_(RNMO>\8T0       !G)](G.J)]]0T1G)](G.J)]]0#1
M     !G5GS4[^DCWR'+E)YA?_3;^(D=:SYJ=_21[Y#ERD\PO_IM_$2 U@
M      9]*\F9UMS[QH#/I7DS.MN?>-         9_P#6+^Z?YQH#/_K%_=/\
MX#0         !G5KS/(^PO>(:(SJUYGD?87O$-$          !GTORIW6U_<
M0T!GTORIW6U_<0T &10_E*KU]SW4C7&10_E*KU]SW4C7     9Q^D2>J*]\A
MHC./TB3U17OD T0         9U;\R2_U8T1G5OS)+_5C1           9U,^
M6J76S]Q T1G4SY:I=;/W$#1        &<OTB8ZHY[Z!HC.7Z1,=4<]] #1
M    &37_ )I$Z_&^*D:PR:_\TB=?C?%2-8!GUOS%._4*^X: SZWYBG?J%?<-
M           !G4WYU4^M_P#;;&B,ZF_.JGUO_MMC1        &>[Z11.J/>^
MT- 9[OI%$ZH][[0#0         !GUWT?J/5G/=,: SZ[Z/U'JSGNF-
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M3<)[AFPJ9 75:FA4*,:6UMDE)M)L3:@C.S1H&^,J%;G>KX)D1X;=AF5O_ID
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M]1C;E/<&;*?J,;<I[A6 "3-E/U&-N4]P9LI^HQMRGN%8 ),V4_48VY3W""/
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MP<1;9:1'9;A?6*/ 16TRX?\ U /YX24/8Z=T@/"2A['3ND#^^ BMIEP_^H/
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MGZC&W*>X5@ DS93]1C;E/<&;*?J,;<I[A6 "3-E/U&-N4]P9LI^HQMRGN%8
M,6IP(;;4<T1(Z3.2TD[&B*TC45I<POS93]1C;E/<.56^1C=;9]\AH ),V4_4
M8VY3W!FRGZC&W*>X5@ DS93]1C;E/<&;*?J,;<I[A6 "3-E/U&-N4]P9LI^H
MQMRGN%8 ,6E0(;D E.0V%JQKI6J:(SL)Q1%ZO8+\V4_48VY3W#E1O-I?KG?B
M*&@ DS93]1C;E/<&;*?J,;<I[A6 "3-E/U&-N4]P9LI^HQMRGN%8 ),V4_48
MVY3W#*<@Q"Y3QF2BLXM4)Y1HQ98)F2VR([/;I/\ >/0#(=]+HG4'OB- +,V4
M_48VY3W!FRGZC&W*>X5@ DS93]1C;E/<&;*?J,;<I[A6 "3-E/U&-N4]P9LI
M^HQMRGN%8 ,6J0(;<=HT1(Z3.2RDS)HBM(W$D9<WL%^;*?J,;<I[ARJ_S9CK
M;'Q$C0 29LI^HQMRGN#-E/U&-N4]PK !)FRGZC&W*>X,V4_48VY3W"L $F;*
M?J,;<I[@S93]1C;E/<*P 8M*I\-R$I2XD=1X]XK5-$9V$ZHB+F]1%8+\V4_4
M8VY3W#E1O-ZNL/\ Q5C0 29LI^HQMRGN#-E/U&-N4]PK !)FRGZC&W*>X,V4
M_48VY3W"L $F;*?J,;<I[A Y AE6XS91(Y(5&>4:<45AF2F[#LL^L_WF-H9S
MOI%$ZH_[[0#MFRGZC&W*>X,V4_48VY3W"L $F;*?J,;<I[@S93]1C;E/<*P
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MMRGN%8 ,6F0(;D=TUQ(ZC*2\DK6B.PB<41%S>P7YLI^HQMRGN'*D?-G^MO\
MQ%#0 29LI^HQMRGN#-E/U&-N4]PK !)FRGZC&W*>X93<&(?*>2R<9G%E":42
M,66"1FMPC.SVZ"_</0#(9]+Y?4&?B.@+,V4_48VY3W"!$"%GMYLHD? *,VHD
MXHK",U+TV6?40VAG(](G^J-^^L!VS93]1C;E/<&;*?J,;<I[A6 "3-E/U&-N
M4]P9LI^HQMRGN%8 ),V4_48VY3W!FRGZC&W*>X5@ Q:K A-T\U-Q(Z%8QHK4
MM$1Z7$D?J%^;*?J,;<I[ARK7FQ7ZUKXB1H ),V4_48VY3W!FRGZC&W*>X5@
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MV4_48VY3W"L &-R=+!I;A%S)FRTD7L(I#A$7V$0V1D<G?-CW7IG_ -EP:X
M   .;BE);4I"#6HB,R21V81^S2,6/5Y;Y2&D,,8YAQ*'7,9_)MD9&:C.VPSL
MLLT<]I'[; HY0&HJ8DTD1JRN-81G81GCV[+3]0IQM3U2)Q2OPQF2Y9S^3T22
M;>+QDN*>#;;_ /M"-)?4?.7U&/0 (L;4]4B<4K\,,;4]4B<4K\,6@ BQM3U2
M)Q2OPQ&N MQ:EN4:EK6H[34IRTS/=#9 !F,-2HJ33'IE/9(])DV^:;?W-CMC
M:GJD3BE?ABT $6-J>J1.*5^&&-J>J1.*5^&+1X*N?E"=I/*:31V:2B0N,EA1
MI<FI9?DXP[/YNV:3QN#Z_&+3:0#V&-J>J1.*5^&&-J>J1.*5^&/,GRJKR>5+
M](5R>B$TPRF4M_.1VX@UK22L#%>5XAG@V^S2(.3_ .4=RL5BBPE4Z%@55A3R
M%0JD4E<;!22L%Y&+2:-!V6VGIL(![7&U/5(G%*_##&U/5(G%*_#'FY_*RK)J
MM4BT7DZJIM4M!92Z<PFC4X:27BVDDE6&K!41Z<'V>RWF]R[Q-/JBG:;@5&)/
M:@LP7)*4JD*=P,4=MGBX25VF1D=F"KGL >HQM3U2)Q2OPPQM3U2)Q2OPQ!R4
MK_A-0&ZH4<HY+==;Q>,P_(<4BVVPN?!MYO6/YR=Y0'7SJW\VQ!4^H/0OE,+#
MQ9V87,5EOLT_: T,;4]4B<4K\,,;4]4B<4K\,>&3^5(G.35=JS5'>4[3G&CC
MQE.&E4MAU9):=(\#Q<*T]%A^3]8I?_*.RZPV[28*)J7H\5YHUR<61K>?4S@*
ML2K!-)IT\_K*S0 ]AC:GJD3BE?AAC:GJD3BE?AC(H?*&9/JDZDU2EE3JA&0V
MZ242">;=:7:1*2K!29V&E1&5FBSG'E:5^5.54Z8Y42I=*0RW'??-DJRE4@B;
M2H[,5BR/2:2+GT$=ND!]!QM3U2)Q2OPPQM3U2)Q2OPQY+DMR^>K]8C4Z138<
M=4J"<UI4:HE(-*2-)8*TX"30?C%[>8QZ.;6,CY04RE$QAY<V^O&X=F!B\#19
M9IMP_:5E@"K&U/5(G%*_##&U/5(G%*_#'D97+R4WRCF4IB%2;(TE,?"F5E,=
MQPU)2=J6S;.TO&L*P])D/S _*!)GU5<9$&DH;3(=8L764E(,FU*(S)G%VF9X
M)F16\WK >PQM3U2)Q2OPPQM3U2)Q2OPQY6D\MJG+<HSM1H#<.!6"LC2F9Q/8
M*S0:TI<2:$X-I$KF,])6?6.]1Y655-;J%,HO)\ZCFYE*Y+KDK$$:E)PB;;+
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M*;?LLT#8 18VIZI$XI7X88VIZI$XI7X8M !%C:GJD3BE?AAC:GJD3BE?ABT
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MF,J&K1N(5<&7R=7,3R;IY,L,+;*.C!4MXTF96>LL$[/WF-\9')?T6IG5D?<
M_%'7-*D0R;8CJ;Q2;#4^9&96>S /[Q?C*AJT;B%7!RH?F*#^I3]PT $F,J&K
M1N(5<#&5#5HW$*N"L $F,J&K1N(5<#&5#5HW$*N"L $F,J&K1N(5<$"5S<]N
MGD\?&9,BTL>=EF$KUX'_ $&T,Y'I$_U1OWU@.V,J&K1N(5<#&5#5HW$*N"L
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MN"L $F,J&K1N(5<#&5#5HW$*N"L &+2US2@JQ;$=18][2I\R.W&JM_H'Z_\
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M5#5HW$*N!C*AJT;B%7!6 "3&5#5HW$*N!C*AJT;B%7!6 #&IZYA*F8$>.?\
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MXM'-XFG19[!?C*AJT;B%7!QIOSJI];_[;8T0$F,J&K1N(5<#&5#5HW$*N"L
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M,@8Z<GBG+P"L9Q>D*NJ)]\QVR!CIR>*<O" H;6>U)PI%F3$?SARWRC]=MO[
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M/B)&@,6IPVD1FC)4@_YRR6F0X?.XDO6?\1?D#'3D\4Y> 5@),@8Z<GBG+P9
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M4Y> 5C.3Z1.=43[ZAVR!CIR>*<O" H;6>UIPI%F3)/YPY;Y1^NVW]@#: 29
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M6E4@S3&<,L*0XHO)/G(SL/\ :+\@8Z<GBG+P"L!)D#'3D\4Y>#(&.G)XIR\
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M^#=N@+0$6=(_T<O@W;H9TC_1R^#=N@+0$6=(_P!'+X-VZ&=(_P!'+X-VZ M
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MOR]CH2>%<N@*P$F7L="3PKET,O8Z$GA7+H"L!)E['0D\*Y=#+V.A)X5RZ K
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M^J9_SC0&?&\^3_U3/^<!H          SZM\A'ZVS[Y#0&?5OD(_6V??(:
M      YN_(K_ $3'0<W?D5_HF FI'F2!U9OW2$O)SS1_>9/QUBJD>9('5F_=
M(2\G/-']YD_'6 UP      &='\_3OU#'WN#1&='\_3OU#'WN -$
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M')?T6IG5D?<-<9')?T6IG5D?< [T/S%!_4I^X: SZ'YB@_J4_<-
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M]](T1G*](F^J+]](#1         !GU;Y&-UMGWR&@,^K?(QNML^^0T
M     &?1O-I?KG?B*&@,^C>;2_7._$4-         9#OI=$Z@]\1H:XR'?2Z
M)U![XC0#7         !GU?YLQUMCXB1H#/J_S9CK;'Q$C0           9]&
M\WJZP_\ %6- 9]&\WJZP_P#%6-         9SOI%$ZH_[[0T1G.^D43JC_OM
M -$         &=6?F3?6XWQD#1&=6?F3?6XWQD#1 9'*GT1K74'_ (:AKC(Y
M4^B-:Z@_\-0UP       9]&^9.];D?&6- 9]&^9.];D?&6-        'G^0O
M^S_D[_9L?X:1H,^D4OJC/ONC/Y"_[/\ D[_9L?X:1H,^D4OJC/ON@-
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M$GJBO?(:(SC](D]45[Y -$         &=6_,DO\ 5C1&=6_,DO\ 5C1
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M/U8?_4;(SB](5=43[Y@.V+J&LQN'5?&62)GA.LL>QC<C3XV)/!LPST687/\
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MRD\PO_IM_$2 KQ=0UF-PZKX8NH:S&X=5\5@ DQ=0UF-PZKX8NH:S&X=5\5@
MDQ=0UF-PZKX8NH:S&X=5\5@ QJ:B::9>!(CE_.7+;6#.T[?TQ=BZAK,;AU7Q
MRI7DS.MN?>- !)BZAK,;AU7PQ=0UF-PZKXK !)BZAK,;AU7PQ=0UF-PZKXK
M!)BZAK,;AU7Q!@3<]V91'QF3<^(.RS"]F'_U&T,_^L7]T_S@.N+J&LQN'5?#
M%U#68W#JOBL $F+J&LQN'5?#%U#68W#JOBL $F+J&LQN'5?#%U#68W#JOBL
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MGZC&W*>X!RJODP^MM_>- 8U2@0FTQ<")'3A26TG8T16D9\W,+LV4_48VY3W
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MI[@S93]1C;E/< K 29LI^HQMRGN#-E/U&-N4]P#E1O-I?KG?B*&@,6E0(;D
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M?J,;<I[@S93]1C;E/< K 29LI^HQMRGN#-E/U&-N4]P#E2O)F=;<^\: QJ;
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MDQWB*%(7;)>.U*F]'\HK1I5ZA?E;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^
MK&0SZ7R^H,_$=%F5O[.D]IN^,IM]WPFDKR1\U'":(V[481%AN:?*LL_;;H >
M@&<CTB?ZHW[ZQVRM_9TGM-WQ B2]GMY60R+3C-E@83=I>,O3Y5G\?4 V@$F5
MO[.D]IN^&5O[.D]IN^ K 296_LZ3VF[X96_LZ3VF[X"L!)E;^SI/:;OAE;^S
MI/:;O@.5:\V*_6M?$2- 8U5DNJIYDJ%(06,:TJ4W9\HGV*%V5O[.D]IN^ K
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MX"L!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^ XTWYU4^M_\
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MA6)*7YIA_J$>Z0K        &?&\^3_U3/^<: SXWGR?^J9_S@-
M&?5OD(_6V??(: SZM\A'ZVS[Y#0        '-WY%?Z)CH.;OR*_T3 34CS)
MZLW[I"7DYYH_O,GXZQ52/,D#JS?ND)>3GFC^\R?CK :X      #.C^?IWZAC
M[W!HC.C^?IWZAC[W &B         #/K'S5GK<?XJ1H#/K'S5GK<?XJ1H
M    #^*\D_L']'\5Y)_8 @HGH_3NJM>Z0T!GT3T?IW56O=(:         SF/
M2&;U5CWWAHC.8](9O56/?> :(  #(D>EU-ZA*^)'&N,B1Z74WJ$KXD<:X
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M.7!\:,EY*EMJ5I;+ZC/G+^(#?JODP^MM_>- 9]5\F'UMO[QH //J_P!H;?\
M92_BI'H!Y]7^T-O^RE_%2/0 )9_FV7^I7]QCG1O,=/ZLW[I#I/\ -LO]2O[C
M'.C>8Z?U9OW2 7   ,ZB^:F_TW/?4-$9U%\U-_IN>^H:(        SE>D3?5
M%^^D:(SE>D3?5%^^D!H@         SZM\C&ZVS[Y#0&?5OD8W6V??(:
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M]G_)W^S8_P -(T&?2*7U1GWW1G\A?]G_ "=_LV/\-(T&?2*7U1GWW0&@
M     #/K'F]/6&/BH&@,^L>;T]88^*@:           #/I'S9_K;_P 10T!G
MTCYL_P!;?^(H:     #(9]+Y?4&?B.C7&0SZ7R^H,_$= :XSD>D3_5&_?6-$
M9R/2)_JC?OK :(         ,^M>;%?K6OB)&@,^M>;%?K6OB)&@
M  SJ3\C*ZV][QC1&=2?D976WO>,:(        SD^D3G5$^^H:(SD^D3G5$^^
MH!H@         SJSYJ=_21[Y#ERD\PO_ *;?Q$CK6?-3OZ2/?(<N4GF%_P#3
M;^(D!K          SZ5Y,SK;GWC0&?2O)F=;<^\:         S_ZQ?W3_.-
M9_\ 6+^Z?YP&@         #.K7F>1]A>\0T1G5KS/(^PO>(:(          #
M/I?E3NMK^XAH#/I?E3NMK^XAH ,BA_*57K[GNI&N,BA_*57K[GNI&N     S
MC](D]45[Y#1&<?I$GJBO?(!H@         SJWYDE_JQHC.K?F27^K&B
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M%(VI+[+5P6@ BR*1M27V6K@9%(VI+[+5P6@ BR*1M27V6K@9%(VI+[+5P6@
MBR*1M27V6K@9%(VI+[+5P6@ \]-C/(K-*2J;(6:ENV*4ENU'B'S6)(OWVC6R
M1_:,GLMW!)4?/U%_3>^&8U@&-48[J41;9LA=LELBM2WHT\^A(NR1_:,GLMW!
MQJOR<3K;7O#1 29(_M&3V6[@9(_M&3V6[@K !)DC^T9/9;N!DC^T9/9;N"L
M$F2/[1D]ENX.3\5XHKIG/DG8@]!I;TZ/T!H#C*^:O?JU?< @I\9Y5,B**=(2
M1LH,DDENPO%+1I2*LD?VC)[+=P*7YIA_J$>Z0K 29(_M&3V6[@9(_M&3V6[@
MK !)DC^T9/9;N!DC^T9/9;N"L $F2/[1D]ENX((\9TZM-24V01DVU:HDMVGY
M7/XM@VAGQO/D_P#5,_YP'7)']HR>RW<#)']HR>RW<%8 ),D?VC)[+=P,D?VC
M)[+=P5@ DR1_:,GLMW R1_:,GLMW!6 #%J4=Y+,>V;(7;):*PTMZ/'+3H3ZA
M?DC^T9/9;N#E5OD(_6V??(: "3)']HR>RW<#)']HR>RW<%8 ),D?VC)[+=P,
MD?VC)[+=P5@ DR1_:,GLMW!^'8CV*7_^0DGXI_T6[@N'-WY%?Z)@,NEQWE4F
M$HILA!&P@R2E+=A>*6@K4VB>@L/+I>$F6^V642"P4DBS0\LK=*3/3S_M]0TZ
M1YD@=6;]TA+R<\T?WF3\=8"S)']HR>RW<#)']HR>RW<%8 ),D?VC)[+=P,D?
MVC)[+=P5@ DR1_:,GLMW! S'=.LS"*;((R89,U$ENT]+FCR;-'_4;0SH_GZ=
M^H8^]P!VR1_:,GLMW R1_:,GLMW!6 "3)']HR>RW<#)']HR>RW<%8 ),D?VC
M)[+=P,D?VC)[+=P5@ Q:I'>3%:,YLA=LE@K#2WHM<3IT)]7.+\D?VC)[+=P<
MJQ\U9ZW'^*D: "3)']HR>RW<#)']HR>RW<%8 ),D?VC)[+=P,D?VC)[+=P5@
M DR1_:,GLMW!_#B/8)__ )"3S=%NX+!_%>2?V ,:CQWET6":9LA!'&;,B2EN
MQ/BEH*U)G^\7Y(_M&3V6[@Y43T?IW56O=(: "3)']HR>RW<#)']HR>RW<%8
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M9(_M&3V6[@SW([V>XJ<MD';&>,G,%NTO&;T>39IM]GJ+ZQMC.=](HG5'_?:
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MENSY5.G0GU<XOR1_:,GLMW!RK'F]/6&/BH&@ DR1_:,GLMW R1_:,GLMW!6
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M &+5I\-R&A+<N.LRD,*L)PCT$Z@S/G]1$9B_.=/UZ-OD]XY5CYBWUJ/\9 T
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MR>\5@ Q:G/AK:CDB7'4926E'@N$=A$HK3YQ?G.GZ]&WR>\<JM\C&ZVS[Y#0
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M Y4;S>KK#_Q5C0&+2US2@JQ;$=18][2I\R.W&JM_H'Z__P!$+\94-6C<0JX
MK 28RH:M&XA5P,94-6C<0JX K 28RH:M&XA5P,94-6C<0JX K&<[Z11.J/\
MOM#MC*AJT;B%7! XJ;GN*9QX^,R9ZPL>=AEA-VZ<#[/5[?VAM ),94-6C<0J
MX&,J&K1N(5< 5@),94-6C<0JX&,J&K1N(5< 5@),94-6C<0JX&,J&K1N(5<
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M@8RH:M&XA5P!6,_^L7]T_P XZXRH:M&XA5P08<W/=N3Q\9DW-CSLLPO;@?\
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M!)C*AJT;B%7 QE0U:-Q"K@"L!)C*AJT;B%7 QE0U:-Q"K@"L!)C*AJT;B%7
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M2$V-.+)"--IJM;M,[+"*SUJ*STPRZA26ZA4J5-6ZM"Z>^IY"2+0LU-K;L/\
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M"0A*E<Y(0GQ4)_W2 >A
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M?$CC7&1(]+J;U"5\2.-<    9]8^8M]:C_&0- 9]8^8M]:C_ !D#0
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MT1G*](F^J+]](#1         !GU;Y&-UMGWR&@,^K?(QNML^^0T
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M_P"3O]FQ_AI&@SZ12^J,^^Z,_D+_ +/^3O\ 9L?X:1H,^D4OJC/ON@-
M     &?6/-Z>L,?%0- 9]8\WIZPQ\5 T           &?2/FS_6W_B*&@,^D
M?-G^MO\ Q%#0     9#/I?+Z@S\1T:XR&?2^7U!GXCH#7&<CTB?ZHW[ZQHC.
M1Z1/]4;]]8#1         !GUKS8K]:U\1(T!GUKS8K]:U\1(T
M&=2?D976WO>,:(SJ3\C*ZV][QC1        &<GTB<ZHGWU#1&<GTB<ZHGWU
M-$         &=6?-3OZ2/?(<N4GF%_\ 3;^(D=:SYJ=_21[Y#ERD\PO_ *;?
MQ$@-8         &?2O)F=;<^\: SZ5Y,SK;GWC0        &?_6+^Z?YQH#/
M_K%_=/\ . T          9U:\SR/L+WB&B,ZM>9Y'V%[Q#1           9]
M+\J=UM?W$- 9]+\J=UM?W$- !D4/Y2J]?<]U(UQD4/Y2J]?<]U(UP    &<?
MI$GJBO?(:(SC](D]45[Y -$         &=6_,DO]6-$9U;\R2_U8T0
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M4Y>%8 ),@8Z<GBG+P9 QTY/%.7A6 #%I4-IR 2C7(MQKI>+(<(M#BBYB,7Y
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M@R!CIR>*<O"L $F0,=.3Q3EX,@8Z<GBG+PK !)D#'3D\4Y>#(&.G)XIR\*P
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MD;6>\'"D69-;\X<M\KVVV_L&T,_^L7]T_P X#KD#'3D\4Y>#(&.G)XIR\*P
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M>#(&.G)XIR\*P 29 QTY/%.7@R!CIR>*<O"L $F0,=.3Q3EX,@8Z<GBG+PK
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MKOH_4>K.>Z8T $F0,=.3Q3EX,@8Z<GBG+PK !)D#'3D\4Y>#(&.G)XIR\*P
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M)D&9(TX,=Q1?O(K!?E['0D\*Y='&B>9HOZ T0$F7L="3PKET,O8Z$GA7+HK
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MAE['0D\*Y=%8 ),O8Z$GA7+H9>QT)/"N716 "3+V.A)X5RZ&7L="3PKET5@
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MX96,.'Z_J+1]@OR]CH2>%<NCE2O)F=;<^\: "3+V.A)X5RZ&7L="3PKET5@
MDR]CH2>%<NAE['0D\*Y=%8 ),O8Z$GA7+H@RQK/>%@R+,FL^;N6^5[++?VC:
M&?\ UB_NG^<!UR]CH2>%<NAE['0D\*Y=%8 ),O8Z$GA7+H9>QT)/"N716 "3
M+V.A)X5RZ&7L="3PKET5@ Q:M-:<I<A*4R",R+RH[B2YR]9E8+\O8Z$GA7+H
MXUKS/(^PO>(:("3+V.A)X5RZ&7L="3PKET5@ DR]CH2>%<NAE['0D\*Y=%8
M),O8Z$GA7+H9>QT)/"N716 #%I\QI"IEJ)'C2%&5C#A^HO86C[!?E['0D\*Y
M='*E^5.ZVO[B&@ P*/,;;74<)+QX4Q:BP6%JT6)Y["T']1Z1J9>QT)/"N71'
M0_E*KU]SW4C7 29>QT)/"N70R]CH2>%<NBL $F7L="3PKET0',:SVA6#(LR9
M1?-W+?*+U66_M&T,X_2)/5%>^0#ME['0D\*Y=#+V.A)X5RZ*P 29>QT)/"N7
M0R]CH2>%<NBL $F7L="3PKET,O8Z$GA7+HK !BU>:TY292$ID$9HT84=Q)?O
M,K!?E['0D\*Y='&M^9)?ZL:("3+V.A)X5RZ&7L="3PKET5@ DR]CH2>%<NAE
M['0D\*Y=%8 ),O8Z$GA7+H9>QT)/"N716 #%I\QI+LXS1(\:29E9'</^BGGL
M+1]AB_+V.A)X5RZ.-,^6J76S]Q T0$F7L="3PKET,O8Z$GA7+HK !)E['0D\
M*Y=#+V.A)X5RZ*P 29>QT)/"N71 J8UGME6#(L*,LOF[EOE(]5EO[1M#.7Z1
M,=4<]] #ME['0D\*Y=#+V.A)X5RZ*P 29>QT)/"N70R]CH2>%<NBL 'GZU+;
M<BQ22E\K)D=1X3*TZ"=2?K+G^KG,:N7L="3PKET25_YI$Z_&^*D:P#%J\QIR
MC3$)1((U,J+QH[B2YO:96$+\O8Z$GA7+HY5OS%._4*^X: "3+V.A)X5RZ&7L
M="3PKET5@ DR]CH2>%<NAE['0D\*Y=%8 ),O8Z$GA7+H9>QT)/"N716 #%@3
M&DR:@9HD>-)M*QAP_P#TT%IL+1S<QB_+V.A)X5RZ.--^=5/K?_;;&B DR]CH
M2>%<NAE['0D\*Y=%8 ),O8Z$GA7+H9>QT)/"N716 "3+V.A)X5RZ(')C1UN,
MO!D6)C.E\@Y;I4WZK+?5S]XVAGN^D43JCWOM .N7L="3PKET,O8Z$GA7+HK
M!)E['0D\*Y=#+V.A)X5RZ*P 29>QT)/"N70R]CH2>%<NBL &+6)K3E$G(2F0
M1JC.$6%'<27DGSF96%^T7Y>QT)/"N71RKOH_4>K.>Z8T $F7L="3PKET,O8Z
M$GA7+HK !)E['0D\*Y=#+V.A)X5RZ*P 29>QT)/"N70R]CH2>%<NBL &-R<T
MTISV*FRU%I]LAP_V']7J&R,CD[YL>Z],_P#LN#7    '"2P4B*ZP:UH)Q!H-
M2#L45I66D?M&$5$GQ8\IF#-)*7GD6&JQ)DVEM*3(C2G0H\&RTN8B+UVF/2
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MFG2(QMR(Z48&@E,&9E^W#(7XNH:S&X=5\!6 DQ=0UF-PZKX8NH:S&X=5\!6
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MJ&LQN'5?$!HFY[0641\9DRM.(.RS"+U8?_4!M ),74-9C<.J^&+J&LQN'5?
M5@),74-9C<.J^&+J&LQN'5? 5@),74-9C<.J^&+J&LQN'5? <:WYDE_JQHC%
MJR)I4B4;DB.I&!I)+!D9_MPS%^+J&LQN'5? 5@),74-9C<.J^&+J&LQN'5?
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MXD<:XR)'I=3>H2OB1QK@   #/K'S%OK4?XR!H#/K'S%OK4?XR!H
M  ,^A>C].ZLW[I#0&?0O1^G=6;]TAH        #.;](9/5&??<&B,YOTAD]4
M9]]P!H@         SZE\YIO6_P#MK&@,^I?.:;UO_MK&@        ,CDOZ+4
MSJR/N&N,CDOZ+4SJR/N =Z'YB@_J4_<- 9]#\Q0?U*?N&@        ,Y'I$_
MU1OWUC1&<CTB?ZHW[ZP&B         #.J?RU/ZV7NJ&B,ZI_+4_K9>ZH:(
M  \_4_3:@?J)?W-CT \_4_3:@?J)?W-CT     SJ)YFB_H#1&=1/,T7] :(
M       SB](5=43[YC1&<7I"KJB??,!HC(+TN7U!/Q#&N,@O2Y?4$_$,!K@
M    #/J?E0NMH^XQH#/J?E0NMH^XQH  \^7^T-7]E%\4QZ >?+_:&K^RB^*8
M#T       SJ+YG8_XO>,?#:ZM;M7G,N+4II,A6"@U'86GU$/N5%\T,?\7O&/
M)ROR9QI<QZ2NI.DIU9K,B:*PK?VCVZ?'@P8\\<9QDSBB7S'+99%84IZPO_WA
MAETO6G]X8^D?FKB;4?W1=X?FKB;4?W1=X[-30V\,VR^;Y=+UI_>&&72]:?WA
MCZ1^:N)M1_=%WA^:N)M1_=%WAJ>GV\%LOF^72]:?WAAETO6G]X8^D?FKB;4?
MW1=XX?FUB9?DN<7_ )+&86++VV66!J>GV\%LOGV72]:?WAAETO6G]X8^D?FK
MB;4?W1=X?FKB;4?W1=X:GI]O!;+YOETO6G]X89=+UI_>&/I'YJXFU']T7>'Y
MJXFU']T7>&IZ?;P6R^;Y=+UI_>&-WD?*D.\KJ>AQ]U:<,]"EF9<P]7^:N)M1
M_=%WBB!^3AFGSF94>KR6W6E6DI+2+?V81&7\#&*M>CBP3&&/7_HMEZJJ>3#Z
MVW]XT1YNI4R8E$6VO5%5LELBM;CZ-//H:%V:9W_N*I[N-^".!Z)5?[0V_P"R
ME_%2/0#RD:,]&Y?)2].D2S52U&2GTMD:?Y5.@L!*2_?:/5@)9_FV7^I7]QCG
M1O,=/ZLW[I#I/\VR_P!2O[C'.C>8Z?U9OW2 7   ,ZB^:F_TW/?4-$9U%\U-
M_IN>^H:(        SE>D3?5%^^D:(SE>D3?5%^^D!H@         SZM\C&ZV
MS[Y#0&?5OD8W6V??(:           #/HWFTOUSOQ%#0&?1O-I?KG?B*&@
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M_P -(T&?2*7U1GWW0&@         #/K'F]/6&/BH&@,^L>;T]88^*@:
M      #/I'S9_K;_ ,10T!GTCYL_UM_XBAH     ,AGTOE]09^(Z-<9#/I?+
MZ@S\1T!KC.1Z1/\ 5&_?6-$9R/2)_JC?OK :(         ,^M>;%?K6OB)&@
M,^M>;%?K6OB)&@           SJ3\C*ZV][QC1&=2?D976WO>,:(
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MYDE_JQHC.K?F27^K&B           SJ9\M4NMG[B!HC.IGRU2ZV?N(&B
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M.B;A/</"?DOD<H73J3=5<J#L1*&<4N=C#5CK%$ZDC<0E6@R3:5AI([2(Q](
M19HIFSHFX3W!FBF;.B;A/<+0 19HIFSHFX3W!FBF;.B;A/<+0 19HIFSHFX3
MW!FBF;.B;A/<+0 19HIFSHFX3W!FBF;.B;A/<+0 19HIFSHFX3W!FBF;.B;A
M/<+0 19HIFSHFX3W!FBF;.B;A/<+0 19HIFSHFX3W!FBF;.B;A/<+0 19HIF
MSHFX3W!FBF;.B;A/<+0 19HIFSHFX3W!FBF;.B;A/<+0 19HIFSHFX3W!FBF
M;.B;A/<+0 19HIFSHFX3W!FBF;.B;A/<+0 19HIFSHFX3W!FBF;.B;A/<+0
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MR=5.5R=@*J;#4>:;"<<TTFQ*%6<Q%ZOL&J BS13-G1-PGN#-%,V=$W">X6@
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MS93]1C;E/<&;*?J,;<I[A6 "3-E/U&-N4]P_ATR!@G_,8W-]$GN%@_BO)/[
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M?J,;<I[A6 "3-E/U&-N4]P9LI^HQMRGN%8 ),V4_48VY3W!FRGZC&W*>X5@
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MI%T<RY0U8I"I!3#QJD$@U8M&DB,S(N;ZS ?1,K?V=)[3=\,K?V=)[3=\?/\
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ML<H:M&92TU,-*$\Q8M!_]!T\*:UKQ[I%T!] RM_9TGM-WPRM_9TGM-WQ\_\
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M/"FM:\>Z1= ?0,K?V=)[3=\,K?V=)[3=\?/_  IK6O'ND70\*:UKQ[I%T!]
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MC,K++.=)?N ?1LK?V=)[3=\,K?V=)[3=\?/_  IK6O'ND70\*:UKQ[I%T!]
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MRM_9TGM-WQ6 "3*W]G2>TW?#*W]G2>TW?%8 ),K?V=)[3=\,K?V=)[3=\5@
MQ8$ATI%0,H4A6%)M,B4WXO\ )HT':K[O:+\K?V=)[3=\<:;\ZJ?6_P#MMC1
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M%(VI+[+5P!: BR*1M27V6K@9%(VI+[+5P!: BR*1M27V6K@9%(VI+[+5P!:
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M6%A^45OV?Q'ZAQ'SJ]2250DD:3;M426[5>+Z_$L_=8-+(I&U)?9:N /(43D
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M8+"EJ1::C05IB[,5)V?'[!":D1GETF,I,V0@C1H2E+=A?O29B_)']HR>RW<
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M';-D*MDH(K4MZ-!Z="1=DC^T9/9;N ..8J3L^/V"&&5*I_ATJ/D3&)S82\#
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MV6[@9(_M&3V6[@"/D[YL>Z],_P#LN#7&/R<\UN%SF4V61G[;)#FG[3YQL
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MV?68#QG(BLSU5BE094N3*;J5 8GJ4^Z:\6ZGQ%&5NDL(L$^?G)1\YF/I0\S
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MSX3=-;0Y+80HE+T*<(C\L_K%V<Z?KT;?)[P%8"3.=/UZ-OD]X9SI^O1M\GO
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MG.GZ]&WR>\!6 DSG3]>C;Y/>&<Z?KT;?)[P%8"3.=/UZ-OD]X9SI^O1M\GO
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M_*+ZQPK\Z(]17FVI+#BS6W8E#A&9V+29Z 'H $F<Z?KT;?)[PSG3]>C;Y/>
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MER<))FX1818M!6EI]I'^X7YSI^O1M\GO 5@),YT_7HV^3WAG.GZ]&WR>\!6
MDSG3]>C;Y/>&<Z?KT;?)[P%8SW?2*)U1[WVAUSG3]>C;Y/>(')\,ZW&<*7'P
M"C.I-6,*PC-3=A6V_4?[@&T DSG3]>C;Y/>&<Z?KT;?)[P%8"3.=/UZ-OD]X
M9SI^O1M\GO 5@),YT_7HV^3WAG.GZ]&WR>\!RKOH_4>K.>Z8T!BUB?"<HD]M
MN6PM:H[B4I2X1F9FD]!%:+\YT_7HV^3W@*P$F<Z?KT;?)[PSG3]>C;Y/> K
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M.?1)QR79"G2/&*TF:%*P5'@KP5%989$1%;]M
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M9('5F_=(2\G/-']YD_'6 UP      &='\_3OU#'WN#1&='\_3OU#'WN -$
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M+XICT \^7^T-7]E%\4P'H      !GT3S.Q_Q>\8T!GT3S.Q_Q>\8T
M !G?UB_NG^<:(SOZQ?W3_. T0         9]5\F'UMO[QH#/JODP^MM_>- !
MY]7^T-O^RE_%2/0#SZO]H;?]E+^*D>@ 2S_-LO\ 4K^XQSHWF.G]6;]TATG^
M;9?ZE?W&.=&\QT_JS?ND N   9U%\U-_IN>^H:(SJ+YJ;_3<]]0T0
M!G*](F^J+]](T1G*](F^J+]](#1         !GU;Y&-UMGWR&@,^K?(QNML^
M^0T           &?1O-I?KG?B*&@,^C>;2_7._$4-         9#OI=$Z@]\
M1H:XR'?2Z)U![XC0#7         !GU?YLQUMCXB1H#/J_P V8ZVQ\1(T
M       &?1O-ZNL/_%6- 9]&\WJZP_\ %6-         9SOI%$ZH_P"^T-$9
MSOI%$ZH_[[0#1         !G5GYDWUN-\9 T1G5GYDWUN-\9 T0&1RI]$:UU
M!_X:AKC(Y4^B-:Z@_P##4-<       &?1OF3O6Y'QEC0&?1OF3O6Y'QEC0
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M?_6+^Z?YQH#/_K%_=/\ . T          9U:\SR/L+WB&B,ZM>9Y'V%[Q#1
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M1.*5^&+0 18VIZI$XI7X88VIZI$XI7X8M !%C:GJD3BE?AAC:GJD3BE?ABT
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M;4#]1+^YL>@ 28RH:M&XA5P,94-6C<0JX*P 8M)7-*D1B;CQU(P-!J?,C/\
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MAC&9K+Q<<=EF-/UX/_0>I'GR_P!H:O[*+XI@-7&5#5HW$*N!C*AJT;B%7!6
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M5@ DQE0U:-Q"K@8RH:M&XA5P5@ Q*HJ:<-&,8CI+*8]AD^9Z<:BS^@7KL_\
M/,-#&5#5HW$*N#C6?F3?6XWQD#1 >?Y1KF'R7JQ/,,(:.&]AJ0\:E$6 =ID1
MI*T_JM+[1JXRH:M&XA5P1\J?1&M=0?\ AJ&N DQE0U:-Q"K@8RH:M&XA5P5@
M DQE0U:-Q"K@8RH:M&XA5P5@ Q:6N:41S%L1U%E+]IF^9:<:NW^@?KM_\<PO
MQE0U:-Q"K@Y4;YD[UN1\98T $F,J&K1N(5<#&5#5HW$*N"L $F,J&K1N(5<#
M&3]6C<0JX*P >5Y%+F%R%Y/DTRPIHJ='P5*>-)F6+3SE@'9^\:#:YV>Y)E'C
MXS)FK2QYV$6$Y9IP/M]7_CCR%_V?\G?[-C_#2-!GTBE]49]]T!UQE0U:-Q"K
M@8RH:M&XA5P5@ DQE0U:-Q"K@8RH:M&XA5P5@ DQE0U:-Q"K@8RH:M&XA5P5
M@ Q:HN9D)8QB.DL>SI2^9G;C4V?T"]8OQE0U:-Q"K@Y5CS>GK#'Q4#0 28RH
M:M&XA5P,94-6C<0JX*P 28RH:M&XA5P,94-6C<0JX*P 28RH:M&XA5P,94-6
MC<0JX*P 8M,5-R9[%QXZBREZW"?,M.,5;_0/UB_&5#5HW$*N#E2/FS_6W_B*
M&@ DQE0U:-Q"K@8RH:M&XA5P5@ DQE0U:-Q"K@RVUS/">29,,8W(VK4XX\$B
MPW+#MP>?GT6?M&^,AGTOE]09^(Z LQE0U:-Q"K@@0N;GMX\GCXS)F[2QYV68
M2_7@?;ZAM#.1Z1/]4;]]8#MC*AJT;B%7 QE0U:-Q"K@K !)C*AJT;B%7 QE0
MU:-Q"K@K !)C*AJT;B%7 QE0U:-Q"K@K !BU5<W-YXQB.E.,:TI?,S^439_0
M(7XRH:M&XA5P<JUYL5^M:^(D: "3&5#5HW$*N!C*AJT;B%7!6 "3&5#5HW$*
MN!C*AJT;B%7!6 "3&5#5HW$*N!C*AJT;B%7!6 #&IBYA-2<"/'/^<NVX3YE8
M>$=O] 78RH:M&XA5P<:3\C*ZV][QC1 28RH:M&XA5P,94-6C<0JX*P 28RH:
MM&XA5P,94-6C<0JX*P 28RH:M&XA5P0)7-SVL\GCXS)DZ,>=EF$?KP/^@VAG
M)](G.J)]]0#MC*AJT;B%7 QE0U:-Q"K@K !)C*AJT;B%7 QE0U:-Q"K@K !)
MC*AJT;B%7 QE0U:-Q"K@K !BU5<TZ8X3D>.E.$BTTOF9^47JP"'&OKF'17B=
M882C#;M-#QJ/RTV:,$OO%]9\U._I(]\ARY2>87_TV_B) 5XRH:M&XA5P,94-
M6C<0JX*P 28RH:M&XA5P,94-6C<0JX*P 28RH:M&XA5P,94-6C<0JX*P 8U-
M7-),O CQS_G+EMKYE8=OZ NQE0U:-Q"K@Y4KR9G6W/O&@ DQE0U:-Q"K@8RH
M:M&XA5P5@ DQE0U:-Q"K@8RH:M&XA5P5@ DQE0U:-Q"K@@PYN>[<GCXS)N;'
MG99A>W _Z#:&?_6+^Z?YP'7&5#5HW$*N!C*AJT;B%7!6 "3&5#5HW$*N!C*A
MJT;B%7!6 "3&5#5HW$*N!C*AJT;B%7!6 #%JRYITI\G&(Z4V%::7S,^<O5@$
M+\94-6C<0JX.-:\SR/L+WB&B DQE0U:-Q"K@8RH:M&XA5P5@ DQE0U:-Q"K@
M8RH:M&XA5P5@ DQE0U:-Q"K@8RH:M&XA5P5@ QJ>N82IF!'CG_.585KYE8=A
M?[FD78RH:M&XA5P<J7Y4[K:_N(: # HZYA+J6+885;,7A83QE8=B=!>*=I?7
MH^P:F,J&K1N(5<$=#^4JO7W/=2-<!)C*AJT;B%7 QE0U:-Q"K@K !)C*AJT;
MB%7! :YN>T'D\?&9,K1CSLLPB]>!_P!!M#./TB3U17OD [8RH:M&XA5P,94-
M6C<0JX*P 28RH:M&XA5P,94-6C<0JX*P 28RH:M&XA5P,94-6C<0JX*P 8M6
M7-.D2B<CQTHP-)I?,S+]F 0OQE0U:-Q"K@XUOS)+_5C1 28RH:M&XA5P,94-
M6C<0JX*P 28RH:M&XA5P,94-6C<0JX*P 28RH:M&XA5P,94-6C<0JX*P 8U/
M7,)V=@1V#,Y)X5KYE8>"GF\32+L94-6C<0JX.-,^6J76S]Q T0$F,J&K1N(5
M<#&5#5HW$*N"L $F,J&K1N(5<#&5#5HW$*N"L $F,J&K1N(5<$"ES<]LGD\?
M&9,NPL>=EF$CUX'V>H;0SE^D3'5'/?0 [8RH:M&XA5P,94-6C<0JX*P 28RH
M:M&XA5P,94-6C<0JX*P >?K2YAQ8N-98266Q_)=-5IXU-A>26BWU^KV&-7&5
M#5HW$*N"2O\ S2)U^-\5(U@&+6%S3H\TG(\=+>)5A&E\S,BL]F 5O[Q?C*AJ
MT;B%7!RK?F*=^H5]PT $F,J&K1N(5<#&5#5HW$*N"L $F,J&K1N(5<#&5#5H
MW$*N"L $F,J&K1N(5<#&5#5HW$*N"L &+ 7-*14,"/',SD^/:^96'BT<WB:=
M%GL%^,J&K1N(5<'&F_.JGUO_ +;8T0$F,J&K1N(5<#&5#5HW$*N"L $F,J&K
M1N(5<#&5#5HW$*N"L $F,J&K1N(5<$#BYN>XQG'CXS)G;"QYV&6$W;IP/L]0
MVAGN^D43JCWOM .N,J&K1N(5<#&5#5HW$*N"L $F,J&K1N(5<#&5#5HW$*N"
ML $F,J&K1N(5<#&5#5HW$*N"L &+5US3HL\G&&$MG'<PC2^9F18)\Q8!6_O%
M^,J&K1N(5<'*N^C]1ZLY[IC0 28RH:M&XA5P,94-6C<0JX*P 28RH:M&XA5P
M,94-6C<0JX*P 28RH:M&XA5P,94-6C<0JX*P 8W)W32W;;2/+9=I>P\H<M+Z
MRM]?W#9&1R=\V/=>F?\ V7!K@   #\*2E:32HB4DRL,C*TC&>JD0S-TTH4VI
MQTGB4A6":%$@D$:;.;1ZOK/VC3'(WVDDHU.((D'8HS,O%/1S_O+]X#(J49J%
M1F([-I(3,BF5IVF9G(09F9^LS.TQN#(KZ272T)TV*EQBT'8>E]OF,N;[15FN
M/])+XQV\ M 19KC_ $DOC';P9KC_ $DOC';P"T8+=-GQV&V&TQ7&VDDA"EN*
M(S(M!6E@F-'-<?Z27QCMX,UQ_I)?&.W@$L.G/HJ")LG%)6VTII"&E&HK%&DS
M.TR+HA"H<:#7ZG6FW7CD5%#*'DJ,L!)-$HDX)66EY1VVF?[!5FN/])+XQV\&
M:X_TDOC';P#SR^0-/(UN1YLZ/*SF[4VY32F\8RZZ1DM*;4&6 9'989']=H\S
M4/R7RD3FXU'=89I+C<5$HW)"TNO&TZ;BE.))!DXH_49*;TJ.TCT#Z/FN/])+
MXQV\&:X_TDOC';P#R4G\E]&E4V%!5+G)1#RG%J(VE*,GU83A>,V9%["4DB41
M>L7T_D-3*:Q#9:D2U)B2FI:#6M-IK;CE'(CL26C *T[+-/L+0-[-<?Z27QCM
MX,UQ_I)?&.W@'E:9^3.C4IDVF)504DU15>.XBVV.LUHYD%SF9V_5S6#NK\GM
M)55%U%4F;CENDZ:<-&#:4DY/1YL,S+]'Z](]'FN/])+XQV\&:X_TDOC';P#Y
M_P IOR=5&9)>70Y;;29C,EF4X])6VNQYTW#*Q*%$M!&M1DGQ3]JS(S(>U30V
MDUB#4,:NV'$7&:9L+!+#-!J5;SV^(DN<5YKC_22^,=O!FN/])+XQV\ XQ*.Q
M"J=2GM..F]/<0MTE&6"DTH2@L'1[$ESVZ1F4'D?"Y/2TR(4R:JR-DRFW5(-*
MRQBG"4=B2/"(UJ(M-EA\Q\XV<UQ_I)?&.W@S7'^DE\8[> 11.3T6'0I5(;<?
M./)4^I:E&6&1NJ4I5AV6:#4=FCV<X\TQ^2BBQY45UN=4?YLIE:",V3M4TV3:
M;58O"LP2\FW!TG81#V6:X_TDOC';P9KC_22^,=O ,VD\EH-&D1WXSLA2H]/:
MIZ"<4DR-MLU&1G81>-XQV^KZAOB+-<?Z27QCMX,UQ_I)?&.W@%H"+-<?Z27Q
MCMX,UQ_I)?&.W@%H"+-<?Z27QCMX,UQ_I)?&.W@%H"+-<?Z27QCMX,UQ_I)?
M&.W@%H"+-<?Z27QCMX,UQ_I)?&.W@%H"+-<?Z27QCMX,UQ_I)?&.W@%H"+-<
M?Z27QCMX,UQ_I)?&.W@%H"+-<?Z27QCMX,UQ_I)?&.W@%H"+-<?Z27QCMX,U
MQ_I)?&.W@%H"+-<?Z27QCMX,UQ_I)?&.W@%H"+-<?Z27QCMX,UQ_I)?&.W@'
M&B?(2^NO^^8SX7)*/3*)'I<&H5&.TS)RDW6W4XQTS4:E)69IL-)F>DK"^T=*
M3 9=9E82Y)62GDE@R7$\RS]BN?ZQI9KC_22^,=O ,:D<C8=(JY5(I]1EO-LJ
M883+=2M++:E81I38DC/3TC,]!#TPBS7'^DE\8[>#-<?Z27QCMX!: BS7'^DE
M\8[>#-<?Z27QCMX!: BS7'^DE\8[>#-<?Z27QCMX!: BS7'^DE\8[>#-<?Z2
M7QCMX!: BS7'^DE\8[>#-<?Z27QCMX!:,NG^>:M^FU\,AWS7'^DE\8[>&=!@
M,JJM20:Y-B%MV62G"/R"YSPK3_: RF_R=4UI3QIJ-5L-LVXW\NG^:)->&9-G
M@V\_2-6C0/PW^3F VY-=54JBN1,9<;=E&M!/6K.U2B,DDFTRL3Y/,0]3FN/]
M)+XQV\&:X_TDOC';P#S$7\G4&-1VJ2=7JCL)E]M]MI2F4DDT':1>(VG09\_M
M&VW0&4R*P\X^XM54L2X=B2-"21@$E.CV>VT69KC_ $DOC';P9KC_ $DOC';P
M#S<K\GM/E0(T'.54:BLQRBN--O)P9#9*PK%D:3_>G!/ZQZQIE#+*&FTX*$))
M*4EZB+F$^:X_TDOC';P9KC_22^,=O +0$6:X_P!)+XQV\&:X_P!)+XQV\ M
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M 5@),@8Z<GBG+P9 QTY/%.7@'*I?.:;UO_MK&@,6=#:3)@$2Y'C2;#M?</\
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M@8Z<GBG+P#E1/,['_%[QC0&+2(3;E*96I<BT\+R9#B2\H_41B_(&.G)XIR\
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M;9]\AH#%J4-I#,<R5(.V2T6F0X?.HO:?\1?D#'3D\4Y> 5@),@8Z<GBG+P9
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MR\ K 29 QTY/%.7@R!CIR>*<O *P$F0,=.3Q3EX,@8Z<GBG+P#E1O-ZNL/\
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M"^M)?)IYB(["&@W#:.MRD84BPHS1D>/<MTJ<]=MOJYN\!M ),@8Z<GBG+P9
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M^(OR!CIR>*<O *P$F0,=.3Q3EX,@8Z<GBG+P"L!)D#'3D\4Y>#(&.G)XIR\
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MF0,=.3Q3EX,@8Z<GBG+P#C6_,DO]6-$8M7A--TF4M*I!F2-&%(<47[C.P7Y
MQTY/%.7@%8"3(&.G)XIR\&0,=.3Q3EX!6 DR!CIR>*<O!D#'3D\4Y> 5@),@
M8Z<GBG+P9 QTY/%.7@'&F?+5+K9^X@:(Q:?#:4[.(UR/%DF162'"_HIY[#T_
M:8OR!CIR>*<O *P$F0,=.3Q3EX,@8Z<GBG+P"L!)D#'3D\4Y>#(&.G)XIR\
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M%BHSIVX]RW0IOUVV^OF[@&T DR!CIR>*<O!D#'3D\4Y> 5@),@8Z<GBG+P9
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M:0OR]CH2>%<N@*P$F7L="3PKET,O8Z$GA7+H"L!)E['0D\*Y=#+V.A)X5RZ
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MR]CH2>%<N@*QG?UB_NG^<=LO8Z$GA7+H@RQK/9*P9%F36?-W+?*]EEO[0&T
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M*<]5EOKY^X!M ),O8Z$GA7+H9>QT)/"N70%8"3+V.A)X5RZ&7L="3PKET!6
MDR]CH2>%<NAE['0D\*Y= <JQYO3UACXJ!H#%JDQIR"221(MQ[)^-'<(M#J3]
M9"_+V.A)X5RZ K 29>QT)/"N70R]CH2>%<N@*P$F7L="3PKET,O8Z$GA7+H"
ML!)E['0D\*Y=#+V.A)X5RZ Y4CYL_P!;?^(H: Q:9,:1'>(TR#_G+QZ([A\[
MBC]1?P%^7L="3PKET!6 DR]CH2>%<NAE['0D\*Y= 5C(9]+Y?4&?B.BS+V.A
M)X5RZ,IN6VGE/)=P7L$X;22+$+PK26YZK+;-//S?N >@&<CTB?ZHW[ZQVR]C
MH2>%<NB!$QK/;R\&18<9LOF[EOE+]5EOKYP&T DR]CH2>%<NAE['0D\*Y= 5
M@),O8Z$GA7+H9>QT)/"N70%8"3+V.A)X5RZ&7L="3PKET!RK7FQ7ZUKXB1H#
M%JLQI< TI1(MQC1^-'<(M#B?69"_+V.A)X5RZ K 29>QT)/"N70R]CH2>%<N
M@*P$F7L="3PKET,O8Z$GA7+H"L!)E['0D\*Y=#+V.A)X5RZ XTGY&5UM[WC&
MB,6FS&D-22-,@_YRZ?BQW#YU'["_@+\O8Z$GA7+H"L!)E['0D\*Y=#+V.A)X
M5RZ K 29>QT)/"N70R]CH2>%<N@*QG)](G.J)]]0[9>QT)/"N71 4QK/:U8,
MBS)DE\W<M\H_59;^T!M ),O8Z$GA7+H9>QT)/"N70%8"3+V.A)X5RZ&7L="3
MPKET!6 DR]CH2>%<NAE['0D\*Y= <:SYJ=_21[Y#ERD\PO\ Z;?Q$CG59K;E
M-<0E$BTU(\J.XDO*+UF0Y<H)C;M%?0E+Y&:V_+86DO+3ZS*P!O@),O8Z$GA7
M+H9>QT)/"N70%8"3+V.A)X5RZ&7L="3PKET!6 DR]CH2>%<NAE['0D\*Y= <
MJ5Y,SK;GWC0&+39C2$RB-$C3)<,K&'#]?U%H^P7Y>QT)/"N70%8"3+V.A)X5
MRZ&7L="3PKET!6 DR]CH2>%<NAE['0D\*Y= 5C/_ *Q?W3_..N7L="3PKET0
M98UGO"P9%F36?-W+?*]EEO[0&T DR]CH2>%<NAE['0D\*Y= 5@),O8Z$GA7+
MH9>QT)/"N70%8"3+V.A)X5RZ&7L="3PKET!QK7F>1]A>\0T1BU::TY2Y"4ID
M$9D7E1W$ESEZS*P7Y>QT)/"N70%8"3+V.A)X5RZ&7L="3PKET!6 DR]CH2>%
M<NAE['0D\*Y= 5@),O8Z$GA7+H9>QT)/"N70'*E^5.ZVO[B&@,6GS&D*F6HD
M>-(496,.'ZB]A:/L%^7L="3PKET!'0_E*KU]SW4C7&!1YC;:ZCA)>/"F+46"
MPM6BQ//86@_J/2-3+V.A)X5RZ K 29>QT)/"N70R]CH2>%<N@*QG'Z1)ZHKW
MR';+V.A)X5RZ(#F-9[0K!D69,HOF[EOE%ZK+?V@-H!)E['0D\*Y=#+V.A)X5
MRZ K 29>QT)/"N70R]CH2>%<N@*P$F7L="3PKET,O8Z$GA7+H#C6_,DO]6-$
M8M7FM.4F4A*9!&:-&%'<27[S*P7Y>QT)/"N70%8"3+V.A)X5RZ&7L="3PKET
M!6 DR]CH2>%<NAE['0D\*Y= 5@),O8Z$GA7+H9>QT)/"N70'&F?+5+K9^X@:
M(Q:?,:2[.,T2/&DF961W#_HIY["T?88OR]CH2>%<N@*P$F7L="3PKET,O8Z$
MGA7+H"L!)E['0D\*Y=#+V.A)X5RZ K&<OTB8ZHY[Z!VR]CH2>%<NB!4QK/;*
ML&18499?-W+?*1ZK+?V@-H!)E['0D\*Y=#+V.A)X5RZ K 29>QT)/"N70R]C
MH2>%<N@)*_\ -(G7XWQ4C6'GZU+;<BQ22E\K)D=1X3*TZ"=2?K+G^KG,:N7L
M="3PKET!RK?F*=^H5]PT!BU>8TY1IB$HD$:F5%XT=Q)<WM,K"%^7L="3PKET
M!6 DR]CH2>%<NAE['0D\*Y= 5@),O8Z$GA7+H9>QT)/"N70%8"3+V.A)X5RZ
M&7L="3PKET!QIOSJI];_ .VV-$8L"8TF34#-$CQI-I6,.'_Z:"TV%HYN8Q?E
M['0D\*Y= 5@),O8Z$GA7+H9>QT)/"N70%8"3+V.A)X5RZ&7L="3PKET!6,]W
MTBB=4>]]H=<O8Z$GA7+H@<F-'6XR\&18F,Z7R#ENE3?JLM]7/W@-H!)E['0D
M\*Y=#+V.A)X5RZ K 29>QT)/"N70R]CH2>%<N@*P$F7L="3PKET,O8Z$GA7+
MH#E7?1^H]6<]TQH#%K$UIRB3D)3((U1G"+"CN)+R3YS,K"_:+\O8Z$GA7+H"
ML!)E['0D\*Y=#+V.A)X5RZ K 29>QT)/"N70R]CH2>%<N@*P$F7L="3PKET,
MO8Z$GA7+H"/D[YL>Z],_^RX-<8W)S32G/8J;+46GVR'#_8?U>H;(    YNNI
M9:6ZL[$(2:E'["(9+5=)Z,VZU%4I;RTMM-DX@S4HR-1D=A^+81&9V^P:<AI3
M\9UI*\ UH-)*P2.RTK+;#T']AC%31)*7BEE(8*4VIO%$EK!;,D)6G21'ZR<5
MS<VCV .E0E-S:&Q(01IPID8C2KG2HI"",C^LC(R_8-T8$V)D5 CL&O&**;'4
MM>#9A*5)0I1V>K29C?        &(]RFID2I3X<V2B&4%IEUZ1)6EMJQTUDDB
M49\]J#Y[.<N<;8^?<J>1-1K=6F3XKD3QU0ULDM]QE:5,X[",EH(\!7\J5BK%
M<QD9 /7%7:.J7&C)JL$Y$EK',-%(1A.MV&>$DK;5)L(SM+1H'\<KU(:8Q[E6
M@H9Q"9&&J2@DXI1V$Y;;Y)GH)7,/G4/\F-9C5.C/JFTZR(F-E+S:32:\62TF
MG%8)H4>"K!2X6 I.D])C@O\ )IREELQDR9E/95!@18;!1I#I$^3#N&6,/ (T
MX5O]&VPTD>D!]035Z8NF%4D5&(JGF5I2B?2;1Z;/+MLY]'/SCBWRBHCK3#S=
M9IZVI*\!A:92#)U5I%8D[=)VJ25A>LR]H\!7N2%1@?D=K-)0P4FH2Y1/J:BF
M[(TJD(4>E7C+L3I,["YC.P5L\@*A-JI5*HKI\5QPY3AIA81Y.MUEEI"T&9%:
MHB;4HS,BTJ >S3RDH3D25*16J<J/%,DR'4RD&ADS.PB6=MB=.C2!<HZ&:FB*
MLTXS=PL612D>/@VVV:=-F"JW]$_8/E]1Y#5FEPX%4>;9>D4I,*.PS36UNI?0
MTM2C<>0225IM2?B$LTV6D1^KM0^0M7J4.74ULPX+\NGRXS#$F(98E;DEQPCQ
M:B/!0:5$5AVF5O,=@#Z-X5\G,CROP@I62X9HQ^6-X&$5AF6%;9;I+1]8_1<J
M.3^+>=S[3,6PHD.JRMNQM1D9D2CMT'81Z#]ACP%,_)I66:ZU4)\F(XV3QN+;
M5(<?59DRF2+"4@K=."?,16:"(K"(=T_DUG)\'TDN ENGHI^4)3A6.+8-XUF1
M8.FTW4V&?L.VP![)?*RAXE;L6IPYRT*:(VHTII:R)Q:4I.S"+09J+UZ?5;H(
M4M\I*&ZJ0EJM4Y:HR#<?),I!FTDN<U:?%+ZS'@(?Y-*E%B4UHI$##C8PG%$:
MBPB5-:D%9XOJ0A1?:9>K2.58Y S8/)-M*&V9$B,Q()PH[!O+>4N4R\@L [,-
M/B*PBMML,["5S /I4*K4RHQG)4&HQ94=ORW6'TK0G02M)D=A:#(_L,9,;ESR
M=DOSTIJD5,>%BR<FKD-E'4:R,R)*\*PST&1\VD><Y+T:I5GDKRM9FQLUN5F6
M]BC)A;16*:0C#P%V+L,R/RB29\]A6B=OD)RB35#K!HHB)3<AIUN$VXYDRR0P
MIKQO$M(])&5A'9I+ZP'OEUZD-R(L==5@H>EI)49M4A!*>(^8T%;:HOL'2GUB
MF58G#IU1B3,4>"YDSZ7, _8>"9V&/G5)_)M5J*M#4>32Y3,A$<I1S&C<Q!MK
M4LR909&1D>$9%::33SD-GD%R/J')B3/=G+C&V^TRTVVR\M[!P,(M"EI)24Z2
ML1:HDV:# >[                                 8U-D-1:?4)+ZR0TU
M*D.+4?\ 122C,S_<)N3O*R%RC6ZAB+.BNH;0\E$MHDFXTNW!6DR,RL.P]%I&
M5FDB'[8AE4:%6(!J-!27I3)J+3@X1J*W^(SN2W)^M4^H*EUMZ XMJ&U"CE%P
MC,T(,S-:C416&9JYBYO:8#V                 #+I_GFK?IM?#(:@RH1$J
MKU=)VV&MLM!V?^F0#SZ?RDT?^7-V-4&4I;4ZP:HY?SM)+P+6B(S,_&L(L(DV
MVV\P[JY?TMFG(ERXL^(I3JFC8?:22TX*34:M"C2:;"YTJ/G(>9E?DXJ]3B%!
MJ$NG+BP&%,P,%*SQMKA*M>2?-H(DF1&?M'YC?DPGO,3V9DB)#COH?4S%@FHV
MX[KAE9@6I*Q-B4GH+G,P'HD_E'I>1I<<@5)J2IY#)0G4-I>/"3A)5I7@X)EI
MMPA5/Y<TRE-(74HTZ*1P\K63C:3-LK;"0=BC\<S+016_:/,R.0=;F.*J,R/R
M?ES<:V1Q9&,6RMM#> FU9IM)5ND_%,M-GUC5Y-\BI=&I]19E/1EO/0TPV#;4
MK 0@D':5AEXI81F=A6Z %B^7\#"I;;%/J,EZHQRD---(;PDH,[/&PED5O/H(
MSYAZU*L)!*L--I6V'SD/F%5_)Q4IU(I\%)4AY;4%,-;\A*L9',EX1N,J)-MM
MGJ.S[1]*C,Y/%98PS7BT)1A'SJL*RT!W         !F0?/=5^UKW!BN<OJ3'
MJ4F+);EQVF%.(*4XA),NK;*U:$'A81F5OL(AM0?/=5^UKW!X*=^3.=4"D4MZ
M3%*C8V1)CN$I64$ZZ6@E%9@V)/UD>GV /1(Y>T_-*Z@] J,9"7&VR:=:1AKP
M])*+!49666F>FTK-)"0ORG44H+TIV%4V202%--N,))4A*U8*5-GA6&1F7K,C
M]I#'IGY-9Z7\&4J!!AJ\N-35*)LU):P$N8)H(C49F9G]YC^JY!\H9<)#5070
MI1PVF6([3J%J;?0A1J,W+4^*9VEY)'9[3 >J<Y9P(K$1V=%EPDR2<5_+XLC;
M0@B,UJL6>@[2LLM,_8)C_*#33H].J+$*H2$5!2TL-MMH)?B\YF2ED1%^T0<C
MN1,V@53*Y^08*&5I8;BX5C*EKPE)3:16)+01>WV$(IOY/ZD[1(40F:)-=8*0
ME2)R%&A.,,[%I5@F>$5O-9^T!]$8<4\RAQ32VC6DC-#A%A)^H[#,K1W&90::
MJC4"#35/K?5&92V;BSM-1D7M&F        ,O^M!=2/WQJ#+_ *T%U(_? 9<K
MEO38E<<IKT>9@M+2V[,0T2F&W%$9D@SMPK3(NC9]8FHOY1*379+$:'%G8Y]X
MVT(6V@O%(C/&>5Y%A?;]0A?Y%U(^4LAUMV"ND2Z@U4)!.J7CB6@K,!)$6#89
MV:3/]@BJWY/ZLNI.S:$_!IJU/V-HC..1R0UH,U&;9>,LU:3(RL/F,P'TP!S;
M)26TI6K#61$2E666G[;!T              &34?/U%_3>^&8UADU'S]1?TWO
MAF-8!G57Y.)UMKWAHC.JOR<3K;7O#1        '&5\U>_5J^X=AQE?-7OU:O
MN <J7YIA_J$>Z0K$E+\TP_U"/=(5@       #/C>?)_ZIG_.- 9\;SY/_5,_
MYP&@         #/JWR$?K;/OD- 9]6^0C];9]\AH        #F[\BO\ 1,=!
MS=^17^B8"6D>9('5F_=(3<G/-']YD_'6*J1YD@=6;]TA+R<\T?WF3\=8#7
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M;4#]1+^YL>@'GZGZ;4#]1+^YL>@    &=1/,T7] :(SJ)YFB_H#1
M&<7I"KJB??,:(SB](5=43[Y@-$9!>ER^H)^(8UQD%Z7+Z@GXA@-<      9]
M3\J%UM'W&- 9]3\J%UM'W&-  'GR_P!H:O[*+XICT \^7^T-7]E%\4P'H
M   !GT3S.Q_Q>\8T!GT3S.Q_Q>\8T        !G?UB_NG^<:(SOZQ?W3_. T
M0         9]5\F'UMO[QH#/JODP^MM_>- !Y]7^T-O^RE_%2/0#SZO]H;?]
ME+^*D>@ 2S_-LO\ 4K^XQSHWF.G]6;]TATG^;9?ZE?W&.=&\QT_JS?ND N
M 9U%\U-_IN>^H:(SJ+YJ;_3<]]0T0       !G*](F^J+]](T1G*](F^J+]]
M(#1         !GU;Y&-UMGWR&@,^K?(QNML^^0T           &?1O-I?KG?
MB*&@,^C>;2_7._$4-         9#OI=$Z@]\1H:XR'?2Z)U![XC0#7
M   !GU?YLQUMCXB1H#/J_P V8ZVQ\1(T           &?1O-ZNL/_%6- 9]&
M\WJZP_\ %6-         9SOI%$ZH_P"^T-$9SOI%$ZH_[[0#1         !G
M5GYDWUN-\9 T1G5GYDWUN-\9 T0&1RI]$:UU!_X:AKC(Y4^B-:Z@_P##4-<
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M=6?-3OZ2/?(<N4GF%_\ 3;^(D=:SYJ=_21[Y#ERD\PO_ *;?Q$@-8
M  &?2O)F=;<^\: SZ5Y,SK;GWC0        &?_6+^Z?YQH#/_K%_=/\ . T
M         9U:\SR/L+WB&B,ZM>9Y'V%[Q#1           9]+\J=UM?W$- 9
M]+\J=UM?W$- !D4/Y2J]?<]U(UQD4/Y2J]?<]U(UP    &<?I$GJBO?(:(SC
M](D]45[Y -$         &=6_,DO]6-$9U;\R2_U8T0          &=3/EJEU
ML_<0-$9U,^6J76S]Q T0       !G+](F.J.>^@:(SE^D3'5'/?0 T0
M!DU_YI$Z_&^*D:PR:_\ -(G7XWQ4C6 9];\Q3OU"ON&@,^M^8IWZA7W#0
M        9U-^=5/K?_;;&B,ZF_.JGUO_ +;8T0       !GN^D43JCWOM#0&
M>[Z11.J/>^T T          9]=]'ZCU9SW3&@,^N^C]1ZLY[IC0
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M:O?JU?< @I\9Y5,B**=(21LH,DDENPO%+1I2*LD?VC)[+=P*7YIA_J$>Z0K
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M]MHRZ1;DRCP\%NWRDZ/)L_@-D9RO2)OJB_?2 [9(_M&3V6[@9(_M&3V6[@K
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M2WH_E$Z="?4+\D?VC)[+=P<JO\V8ZVQ\1(T $F2/[1D]ENX&2/[1D]ENX*P
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M']HR>RW<#)7MH2>RW<%8 /*\BHSJ^0G)]:9K[:3IT<R0E*+$_P FG05J3/\
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MK0I+=GRB?8D79(_M&3V6[@Y5KS8K]:U\1(T $F2/[1D]ENX&2/[1D]ENX*P
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M9(_M&3V6[@K !)DC^T9/9;N!DC^T9/9;N"L $F2/[1D]ENX&2/[1D]ENX*P
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MS:,3?I[Q: "+.],VC$WZ>\,[TS:,3?I[Q: "+.],VC$WZ>\,[TS:,3?I[Q:
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MNK,CY_61D8OSG3]>C;Y/>.5&^9.];D?&6- !)G.GZ]&WR>\,YT_7HV^3WBL
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MI^O1M\GO%8 ),YT_7HV^3WAG.GZ]&WR>\5@ DSG3]>C;Y/>&<Z?KT;?)[Q6
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M?DKML:,18!VV2%>S] !UI?FF'^H1[I"L95.7-*FQ"1'CFG$HL,WU$9E@EZL
M58RH:M&XA5P!6 DQE0U:-Q"K@8RH:M&XA5P!6 DQE0U:-Q"K@8RH:M&XA5P!
M6,^-Y\G_ *IG_..N,J&K1N(5<$$=<W.TTR8CFO%M81&^=A>598>!I_< V@$F
M,J&K1N(5<#&5#5HW$*N *P$F,J&K1N(5<#&5#5HW$*N *P$F,J&K1N(5<#&5
M#5HW$*N .56^0C];9]\AH#%J2YN(CXR/'(LI:LP7S/3AE9_0(7XRH:M&XA5P
M!6 DQE0U:-Q"K@8RH:M&XA5P!6 DQE0U:-Q"K@8RH:M&XA5P!6.;OR*_T3'#
M&5#5HW$*N#\.N3\4NV-&LP3_ /VA5P!_:1YD@=6;]TA+R<\T?WF3\=8_E+7-
M*D0R1'84C$(P34^HC,L$N<L [!/05S"I=C3#"DY1(M-3QI.W'+MT8)^NW_QS
M /0 ),94-6C<0JX&,J&K1N(5< 5@),94-6C<0JX&,J&K1N(5< 5C.C^?IWZA
MC[W!VQE0U:-Q"K@@97-*LS+&(^,Q#.$1OG816N6:<#[?4 V@$F,J&K1N(5<#
M&5#5HW$*N *P$F,J&K1N(5<#&5#5HW$*N *P$F,J&K1N(5<#&5#5HW$*N .-
M7^:L];C_ !4C.Y;I4OD=44I(S4I!$1$6DSM(=ZFN:<5K&1XZ2REFS!?,].,3
M9_0+U_\ Z,:&,J&K1N(5< E_G_(9>JO[LPR&7JK^[,??\.H:M&XA5P,.H:M&
MXA5P=NNQ^(8M?!&(LEJ2RZN,^2$.)4H\4H["([3]0^Y1*Y!EU!,%LY*)"FE.
MI;?B.LX2$FDE&6&DB.PUIYO:,ZH5&N%785+@IIS*WXS\A2GB6Z5C:VDV%9@V
M?*?7S>H&*;7CY0,52>[3GC8BNQD(82XU\HIM1F9GA<V*+V<XYZM6:N+.6HC)
MZ8?Q7DG]@EQE0U:-Q"K@_AN5#!/^;1N;6%7!Y*YT3T?IW56O=(: Q:0N:5%@
M$W'CJ;*,W@FI\R,RP2LM+ .S]XOQE0U:-Q"K@"L!)C*AJT;B%7 QE0U:-Q"K
M@"L!)C*AJT;B%7 QE0U:-Q"K@"L9S'I#-ZJQ[[P[8RH:M&XA5P9[2YN?)9DQ
M'QF3,VECSL(L)VS3@?;ZO47/;H#; 28RH:M&XA5P,94-6C<0JX CD>EU-ZA*
M^)'&N///JF>$\ \2R3I0Y."G&G@F6&Q:9G@Z#YM%FFT])6:=;&5#5HW$*N *
MP$F,J&K1N(5<#&5#5HW$*N .58^8M]:C_&0- 8M47-R-&-8CI+*6-*7S/3C4
M6?T"]=G_ )YA?C*AJT;B%7 %8"3&5#5HW$*N!C*AJT;B%7 %8"3&5#5HW$*N
M!C*AJT;B%7 %8"3&5#5HW$*N!C*AJT;B%7 '*A>C].ZLW[I#0&+1US2HL FV
M&%-E'1@FI\R,RP2YRP#L_>+\94-6C<0JX K 28RH:M&XA5P,94-6C<0JX K
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M-Q"K@8RH:M&XA5P!6 DQE0U:-Q"K@8RH:M&XA5P!QK/FIW])'OD.7*3S"_\
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ME..1B:>W!LQ6#;@K6K"YSY\.RSZN<>K
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MB,YOTAD]49]]P!H@         SZE\YIO6_\ MK&@,^I?.:;UO_MK&@
M  ,CDOZ+4SJR/N&N,CDOZ+4SJR/N =Z'YB@_J4_<- 9]#\Q0?U*?N&@
M   ,Y'I$_P!4;]]8T1G(](G^J-^^L!H@         SJG\M3^ME[JAHC.J?RU
M/ZV7NJ&B    //U/TVH'ZB7]S8] //U/TVH'ZB7]S8]     ,ZB>9HOZ T1G
M43S-%_0&B        ,XO2%75$^^8T1G%Z0JZHGWS :(R"]+E]03\0QKC(+TN
M7U!/Q# :X      SZGY4+K:/N,: SZGY4+K:/N,:  //E_M#5_91?%,>@'GR
M_P!H:O[*+XI@/0      #/HGF=C_ (O>,: SZ)YG8_XO>,:         SOZQ
M?W3_ #C1&=_6+^Z?YP&B         #/JODP^MM_>- 9]5\F'UMO[QH //J_V
MAM_V4OXJ1Z >?5_M#;_LI?Q4CT "6?YME_J5_<8YT;S'3^K-^Z0Z3_-LO]2O
M[C'.C>8Z?U9OW2 7   ,ZB^:F_TW/?4-$9U%\U-_IN>^H:(        SE>D3
M?5%^^D:(SE>D3?5%^^D!H@         SZM\C&ZVS[Y#0&?5OD8W6V??(:
M        #/HWFTOUSOQ%#0&?1O-I?KG?B*&@        ,AWTNB=0>^(T-<9#
MOI=$Z@]\1H!K@         SZO\V8ZVQ\1(T!GU?YLQUMCXB1H
M,^C>;U=8?^*L: SZ-YO5UA_XJQH        #.=](HG5'_?:&B,YWTBB=4?\
M?: :(         ,ZL_,F^MQOC(&B,ZL_,F^MQOC(&B R.5/HC6NH/_#4-<9'
M*GT1K74'_AJ&N       #/HWS)WK<CXRQH#/HWS)WK<CXRQH        \_R%
M_P!G_)W^S8_PTC09](I?5&??=&?R%_V?\G?[-C_#2-!GTBE]49]]T!H
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M5[Y#1&<?I$GJBO?(!H@         SJWYDE_JQHC.K?F27^K&B
MSJ9\M4NMG[B!HC.IGRU2ZV?N(&B        ,Y?I$QU1SWT#1&<OTB8ZHY[Z
M&B      ,FO_ #2)U^-\5(UADU_YI$Z_&^*D:P#/K?F*=^H5]PT!GUOS%._4
M*^X:           #.IOSJI];_P"VV-$9U-^=5/K?_;;&B        ,]WTBB=
M4>]]H: SW?2*)U1[WV@&@         #/KOH_4>K.>Z8T!GUWT?J/5G/=,:
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M $DOC';PM !%FN/])+XQV\&:X_TDOC';PM !%FN/])+XQV\&:X_TDOC';PM
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M#(&.G)XIR\*P 29 QTY/%.7A F&UGMU&%(L*,@_G#EOE*]=MO[!M#.1Z1/\
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M9 QTY/%.7A6 "3(&.G)XIR\(,C:SV2<*19DUOSARWRO;;;^P;0SOZQ?W3_.
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ME5OD8W6V??(: "3(&.G)XIR\&0,=.3Q3EX5@ DR!CIR>*<O!D#'3D\4Y>%8
M),@8Z<GBG+P9 QTY/%.7A6 #%I4-IR 2C7(MQKI>+(<(M#BBYB,7Y QTY/%.
M7ARHWFTOUSOQ%#0 29 QTY/%.7@R!CIR>*<O"L $F0,=.3Q3EX,@8Z<GBG+P
MK !)D#'3D\4Y>&4Y$;3RGC-83V"<-Y1GCUX5I+;]=MMFGFYOW#T R'?2Z)U!
M[XC0"S(&.G)XIR\&0,=.3Q3EX5@ DR!CIR>*<O!D#'3D\4Y>%8 ),@8Z<GBG
M+P9 QTY/%.7A6 #%J<-I$9HR5(/^<LEID.'SN)+UG_$7Y QTY/%.7ARJ_P V
M8ZVQ\1(T $F0,=.3Q3EX,@8Z<GBG+PK !)D#'3D\4Y>#(&.G)XIR\*P 29 Q
MTY/%.7@R!CIR>*<O"L &-2H;3D%2C7(MQ[Q>+(<(M#JB]1B[(&.G)XIR\.5&
M\WJZP_\ %6- !)D#'3D\4Y>#(&.G)XIR\*P 29 QTY/%.7@R!CIR>*<O"L $
MF0,=.3Q3EX0.0VBK<5&%(L.,\9_R[ENA3?KMM]?-]GL(;0SG?2*)U1_WV@';
M(&.G)XIR\&0,=.3Q3EX5@ DR!CIR>*<O!D#'3D\4Y>%8 ),@8Z<GBG+P9 QT
MY/%.7A6 #%JD-IN&@R5(,\I8+2^X?.Z@O6?\?4+\@8Z<GBG+PXUGYDWUN-\9
M T0'G^4<1MGDO5G4J>-2(;RB);ZU)M)!\Y&9D9?4>@:N0,=.3Q3EX1\J?1&M
M=0?^&H:X"3(&.G)XIR\&0,=.3Q3EX5@ DR!CIR>*<O!D#'3D\4Y>%8 ,6EPV
MG(CAFN1\Y?+Q7W"YG5EZC_CZQ?D#'3D\4Y>'*C?,G>MR/C+&@ DR!CIR>*<O
M!D#'3D\4Y>%8 ),@8Z<GBG+P9O9MMPY/$N7A6 #RO(J&V[R$H#BEODI5.CF>
M"^M)?)IYB(["&@W#:.MRD84BPHS1D>/<MTJ<]=MOJYN\<>0O^S_D[_9L?X:1
MH,^D4OJC/ON@.N0,=.3Q3EX,@8Z<GBG+PK !)D#'3D\4Y>#(&.G)XIR\*P 2
M9 QTY/%.7@R!CIR>*<O"L &+5(;3<$E$N1;CV2\:0X9:74EZS%^0,=.3Q3EX
M<JQYO3UACXJ!H ),@8Z<GBG+P9 QTY/%.7A6 "3(&.G)XIR\&0,=.3Q3EX5@
M DR!CIR>*<O!D#'3D\4Y>%8 ,6F0VEQWC-<@OYR\6B0X7,XHO4?\1?D#'3D\
M4Y>'*D?-G^MO_$4- !)D#'3D\4Y>#(&.G)XIR\*P 29 QTY/%.7AE-Q&SY3R
M6L)[!*&THCQZ\*TUN>NVVS1S<W[QZ 9#/I?+Z@S\1T!9D#'3D\4Y>$"(;6>W
MD84BPHS9VY0Y;Y2_7;;ZN8;0SD>D3_5&_?6 [9 QTY/%.7@R!CIR>*<O"L $
MF0,=.3Q3EX,@8Z<GBG+PK !)D#'3D\4Y>#(&.G)XIR\*P 8M5AM(@&I*Y%N,
M:+QI#AEI<3ZC,7Y QTY/%.7ARK7FQ7ZUKXB1H ),@8Z<GBG+P9 QTY/%.7A6
M "3(&.G)XIR\&0,=.3Q3EX5@ DR!CIR>*<O!D#'3D\4Y>%8 ,6FPVEM23-<@
MK)+I>+(<+F4?L/\ B+\@8Z<GBG+PXTGY&5UM[WC&B DR!CIR>*<O!D#'3D\4
MY>%8 ),@8Z<GBG+P9 QTY/%.7A6 "3(&.G)XIR\("AM9[6G"D69,D_G#EOE'
MZ[;?V#:&<GTB<ZHGWU .V0,=.3Q3EX,@8Z<GBG+PK !)D#'3D\4Y>#(&.G)X
MIR\*P 29 QTY/%.7@R!CIR>*<O"L &+583;=-<4E<BTE(\J0XHO*+U&8Y<H(
M;;5%?6E3YF2V_+?6HO+3ZC.P75GS4[^DCWR'+E)YA?\ TV_B) 5Y QTY/%.7
M@R!CIR>*<O"L $F0,=.3Q3EX,@8Z<GBG+PK !)D#'3D\4Y>#(&.G)XIR\*P
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M1XZ,(B)1:?4.4KEU1X=5>@OE.24=]$=Z24-Q4=IQ6#@DITBP4VX:2TG_ $B
M7TPZ=1Z9&IT-B8B-&;2TVDXCQG816:3P=)_6+<Z1_HY?!NW1/1Z[ KL$I<![
M#:-2TV*+!46"M2#,R/39:E6GZA<F3'-I#I/MFVLR)*R65BC/F(C]8#CG2/\
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MY=#+V.A)X5RZ*P 29>QT)/"N71R?GLG%=(D2=*#YXSA>K]$: XROFKWZM7W
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M0R]CH2>%<NBL $F7L="3PKET,O8Z$GA7+HK !)E['0D\*Y=#+V.A)X5RZ*P
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MC\6.X9:75'ZB%V7L="3PKET<J-YO5UA_XJQH ),O8Z$GA7+H9>QT)/"N716
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M),74-9C<.J^&+J&LQN'5? 5@),74-9C<.J^&+J&LQN'5? <JQ\U9ZW'^*D:
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M:S&X=5\!6,Y'I$_U1OWUCMBZAK,;AU7Q E$W/;I91'QF3(M/$'99A*]6'_U
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M$F+J&LQN'5?#%U#68W#JO@*P$F+J&LQN'5?#%U#68W#JO@.57^;,=;8^(D:
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M_2&3U1GWW!HC.;](9/5&??< :(         ,^I?.:;UO_MK&@,^I?.:;UO\
M[:QH        #(Y+^BU,ZLC[AKC(Y+^BU,ZLC[@'>A^8H/ZE/W#0&?0_,4']
M2G[AH        #.1Z1/]4;]]8T1G(](G^J-^^L!H@         SJG\M3^ME[
MJAHC.J?RU/ZV7NJ&B    //U/TVH'ZB7]S8] //U/TVH'ZB7]S8]     ,ZB
M>9HOZ T1G43S-%_0&B        ,XO2%75$^^8T1G%Z0JZHGWS :(R"]+E]03
M\0QKC(+TN7U!/Q# :X      SZGY4+K:/N,: SZGY4+K:/N,:  //E_M#5_9
M1?%,>@'GR_VAJ_LHOBF ]       ,^B>9V/^+WC&@,^B>9V/^+WC&@
M  ,[^L7]T_SC1&=_6+^Z?YP&B         #/JODP^MM_>- 9]5\F'UMO[QH
M//J_VAM_V4OXJ1Z >?5_M#;_ +*7\5(]  EG^;9?ZE?W&.=&\QT_JS?ND.D_
MS;+_ %*_N,<Z-YCI_5F_=(!<   SJ+YJ;_3<]]0T1G47S4W^FY[ZAH@
M  #.5Z1-]47[Z1HC.5Z1-]47[Z0&B         #/JWR,;K;/OD- 9]6^1C=;
M9]\AH           ,^C>;2_7._$4- 9]&\VE^N=^(H:         R'?2Z)U!
M[XC0UQD.^ET3J#WQ&@&N         #/J_P V8ZVQ\1(T!GU?YLQUMCXB1H
M         ,^C>;U=8?\ BK&@,^C>;U=8?^*L:         SG?2*)U1_WVAHC
M.=](HG5'_?: :(         ,ZL_,F^MQOC(&B,ZL_,F^MQOC(&B R.5/HC6N
MH/\ PU#7&1RI]$:UU!_X:AK@       SZ-\R=ZW(^,L: SZ-\R=ZW(^,L:
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ML7]T_P XT!G_ -8O[I_G :          ,ZM>9Y'V%[Q#1&=6O,\C["]XAH@
M         ,^E^5.ZVO[B&@,^E^5.ZVO[B&@ R*'\I5>ON>ZD:XR*'\I5>ON>
MZD:X    #./TB3U17OD-$9Q^D2>J*]\@&B         #.K?F27^K&B,ZM^9)
M?ZL:(          #.IGRU2ZV?N(&B,ZF?+5+K9^X@:(        SE^D3'5'/
M?0-$9R_2)CJCGOH :(      R:_\TB=?C?%2-89-?^:1.OQOBI&L SZWYBG?
MJ%?<- 9];\Q3OU"ON&@           SJ;\ZJ?6_^VV-$9U-^=5/K?_;;&B
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M[;;R2/@'&4HTXHK+<).FRP;(SE>D3?5%^^D!VS93]1C;E/<&;*?J,;<I[A6
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MI^HQMRGN%8 ),V4_48VY3W!FRGZC&W*>X5@ DS93]1C;E/<&;*?J,;<I[A6
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M&XW@MJ)1)PC1A86#:9>KUCW"5$I)*([2,K2,!)ELC9<OM-7PRV1LN7VFKXM
M!%ELC9<OM-7PRV1LN7VFKXM !%ELC9<OM-7PRV1LN7VFKXM !%ELC9<OM-7P
MRV1LN7VFKXM !%ELC9<OM-7PRV1LN7VFKXM !%ELC9<OM-7PRV1LN7VFKXM
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MAE;^SI/:;OBL $F5O[.D]IN^&5O[.D]IN^*P 296_LZ3VF[X96_LZ3VF[XK
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M+QE*;L+27L49B_*W]G2>TW?'&M>9Y'V%[Q#1 296_LZ3VF[X96_LZ3VF[XK
M!)E;^SI/:;OAE;^SI/:;OBL $F5O[.D]IN^&5O[.D]IN^*P 8U/D.I5-LA2%
M6R5&=BF]&@M&E0NRM_9TGM-WQRI?E3NMK^XAH //T=]U"JC@Q'UVS%F>":/%
M.Q.@[5%I^S0-7*W]G2>TW?$=#^4JO7W/=2-<!)E;^SI/:;OAE;^SI/:;OBL
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MQ)U*=D\JJ15$N-DU"8DMK0=N$HW#:LL^HL [?V"[(I&U)?9:N!D4C:DOLM7
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M/+1-IZHSV 2#E1#4_!P;+51W$F1D9V6V'HM'L\BD;4E]EJX&12-J2^RU< >
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M?VC)[+=P01XSIU::DIL@C)MJU1);M/RN?Q; &T DR1_:,GLMW R1_:,GLMW
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M-3H[JDR[)LA-DEPCL2WIT\^E(NR1_:,GLMW %8"3)']HR>RW<#)']HR>RW<
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M]ENX&2/[1D]ENX CY.^;'NO3/_LN#7&/R<\UN%SF4V61G[;)#FG[3YQL
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MU1\_47]-[X9C6'GIU1A.UJE+;F1UH;6Z:U)=29)M09%;IT:1K9SI^O1M\GO
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M4_$\%LOE #ZOX$\D-=_YM(F1R/Y+'4'F52+&$--J0O*2TJ,UDHK>;01)_?\
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M2GGAQFL@E8>%B%XY2G%.*-PK+4V'A8"R4GQ2 ?Z# ?E!&22)1VJ(M)C]
M                                  RJ,9)C3%*,B(ICYF9^KQS'\I'*
M&CU\GLUU!B7B58+A-*TI/[/9]?,8CR5V?R;KD-A1)>D+EM-FH[")2C416_M,
M8?(B%4"JRI4NBNTI$:G,P32HTV/.(-1J,K.=)6D1'ZP'O@
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M&$3JC*S2JQ2BL1IP2589D5H#[, YMFLVTFX1$LR+"(CM(C'0
M  9-1\_47]-[X9C6&34?/U%_3>^&8U@&=5?DXG6VO>&B,ZJ_)Q.MM>\-$
M     <97S5[]6K[AV'&5\U>_5J^X!RI?FF'^H1[I"L24OS3#_4(]TA6
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M@,^L?,6^M1_C(&@           SZ%Z/T[JS?ND- 9]"]'Z=U9OW2&@
M  ,YOTAD]49]]P:(SF_2&3U1GWW &B         #/J7SFF];_P"VL: SZE\Y
MIO6_^VL:         R.2_HM3.K(^X:XR.2_HM3.K(^X!WH?F*#^I3]PT!GT/
MS%!_4I^X:         SD>D3_ %1OWUC1&<CTB?ZHW[ZP&B         #.J?R
MU/ZV7NJ&B,ZI_+4_K9>ZH:(    \_4_3:@?J)?W-CT \_4_3:@?J)?W-CT
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M *Q?W3_.- 9_]8O[I_G :          ,ZM>9Y'V%[Q#1&=6O,\C["]XAH@
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M?7?1^H]6<]TQH           ,CD[YL>Z],_^RX-<9')WS8]UZ9_]EP:X
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M=*>*,\B0^IMZ0Z1)4I*#LP4D1*LM5;:9 /5XVIZI$XI7X88VIZI$XI7X8\C
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M7X84R3EM,C2L:R[C6R7AL*,VU6E_1,]-@M 18VIZI$XI7X88VIZI$XI7X8M
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M\JRP\#3^X;0SXWGR?^J9_P X#KC*AJT;B%7 QE0U:-Q"K@K !)C*AJT;B%7
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MM&XA5P5@ \K4%R_#*AFIA@EDQ+P2)XS(]#=MIX.C]PW\94-6C<0JX,JI^FU
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M.=](HG5'_?: =L94-6C<0JX&,J&K1N(5<%8 ),94-6C<0JX&,J&K1N(5<%8
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M*N"L &+3%3<F>Q<>.HLI>MPGS+3C%6_T#]8OQE0U:-Q"K@Y4CYL_UM_XBAH
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M8Z<GBG+P@CPVCJTU!K?L0VT962'+=.%SG;:8#: 29 QTY/%.7@R!CIR>*<O
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M-<BQ+#)E9(<MTFYZ[;3Y@&T DR!CIR>*<O!D#'3D\4Y> 5@),@8Z<GBG+P9
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MY/%.7@%8SD>D3_5&_?6.V0,=.3Q3EX0)AM9[=1A2+"C(/YPY;Y2O7;;^P!M
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M/%.7@R!CIR>*<O .56^1C=;9]\AH#%J4-I#,<R5(.V2T6F0X?.HO:?\ $7Y
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MGO!PI%F36_.'+?*]MMO[ &T DR!CIR>*<O!D#'3D\4Y> 5@),@8Z<GBG+P9
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M(&.G)XIR\(#AM9[0G"D69,H_G#EOE%Z[;?V -H!)D#'3D\4Y>#(&.G)XIR\
MK 29 QTY/%.7@R!CIR>*<O *P$F0,=.3Q3EX,@8Z<GBG+P#C6_,DO]6-$8M7
MA--TF4M*I!F2-&%(<47[C.P7Y QTY/%.7@%8"3(&.G)XIR\&0,=.3Q3EX!6
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MPQ/0);35,P5)?,\HD'XK*U%I>6?.16>O]G, ]  DR]CH2>%<NAE['0D\*Y=
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M*P7Y>QT)/"N70%8"3+V.A)X5RZ&7L="3PKET!6 DR]CH2>%<NAE['0D\*Y=
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M*VRPM-@#ZV1VI(_:0_0
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M-8!G57Y.)UMKWAHC.JOR<3K;7O#1        '&5\U>_5J^X=AQE?-7OU:ON
M<J7YIA_J$>Z0K$E+\TP_U"/=(5@       #/C>?)_P"J9_SC0&?&\^3_ -4S
M_G :          ,^K?(1^ML^^0T!GU;Y"/UMGWR&@        .;OR*_T3'0<
MW?D5_HF FI'F2!U9OW2$O)SS1_>9/QUBJD>9('5F_=(2\G/-']YD_'6 UP
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M'YB@_J4_<- 9]#\Q0?U*?N&@        ,Y'I$_U1OWUC1&<CTB?ZHW[ZP&B
M        #.J?RU/ZV7NJ&B,ZI_+4_K9>ZH:(    \_4_3:@?J)?W-CT \_4_
M3:@?J)?W-CT     SJ)YFB_H#1&=1/,T7] :(        SB](5=43[YC1&<7
MI"KJB??,!HC(+TN7U!/Q#&N,@O2Y?4$_$,!K@     #/J?E0NMH^XQH#/J?E
M0NMH^XQH  \^7^T-7]E%\4QZ >?+_:&K^RB^*8#T       SZ)YG8_XO>,:
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M$C0&?5_FS'6V/B)&@           SZ-YO5UA_P"*L: SZ-YO5UA_XJQH
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MKXB1H#/K7FQ7ZUKXB1H           ,ZD_(RNMO>\8T1G4GY&5UM[WC&B
M     ,Y/I$YU1/OJ&B,Y/I$YU1/OJ :(         ,ZL^:G?TD>^0Y<I/,+_
M .FW\1(ZUGS4[^DCWR'+E)YA?_3;^(D!K          SZ5Y,SK;GWC0&?2O)
MF=;<^\:         S_ZQ?W3_ #C0&?\ UB_NG^<!H          SJUYGD?87
MO$-$9U:\SR/L+WB&B           SZ7Y4[K:_N(: SZ7Y4[K:_N(: #(H?RE
M5Z^Y[J1KC(H?RE5Z^Y[J1K@    ,X_2)/5%>^0T1G'Z1)ZHKWR :(
M  ,ZM^9)?ZL:(SJWYDE_JQH@          ,ZF?+5+K9^X@:(SJ9\M4NMG[B!
MH@       #.7Z1,=4<]] T1G+](F.J.>^@!H@     #)K_S2)U^-\5(UADU_
MYI$Z_&^*D:P#/K?F*=^H5]PT!GUOS%._4*^X:           #.IOSJI];_[;
M8T1G4WYU4^M_]ML:(        SW?2*)U1[WVAH#/=](HG5'O?: :
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MAK,;AU7Q6 "3%U#68W#JOABZAK,;AU7Q6 #&J*)I'$PY$<_YRC!L8,K#L/\
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M?YLQUMCXB1H ),74-9C<.J^&+J&LQN'5?%8 ),74-9C<.J^&+J&LQN'5?%8
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M9R?2)SJB??4 [8NH:S&X=5\,74-9C<.J^*P 28NH:S&X=5\,74-9C<.J^*P
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MHIFSHFX3W +0$6:*9LZ)N$]P9HIFSHFX3W +0$6:*9LZ)N$]P9HIFSHFX3W
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M$FC%G:YT"_WOJYP&RA"6T)0A))2DK"(BL(B'[$6:*9LZ)N$]P9HIFSHFX3W
M+0$6:*9LZ)N$]P9HIFSHFX3W +0$6:*9LZ)N$]P9HIFSHFX3W +0$6:*9LZ)
MN$]P9HIFSHFX3W +0$6:*9LZ)N$]P9HIFSHFX3W )JCY^HOZ;WPS&L//3J="
M:K5*0W#CH0XMTEI2TDB58@S*W1ITC6S93]1C;E/< XU7Y.)UMKWAHC&J4"&V
MB+@1(Z<*2VD[&B*TC/27,+LV4_48VY3W *P$F;*?J,;<I[@S93]1C;E/< K
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MGN <JQ\U9ZW'^*D: Q:I A-QFC1%CH,Y+*3,FB+0;B2,N;UD+\V4_48VY3W
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M:8XW$CH6EE1I4EHB,CL^P79LI^HQMRGN 5@),V4_48VY3W!FRGZC&W*>X!6
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M;(V7+[35\!: BRV1LN7VFKX9;(V7+[35\!: BRV1LN7VFKX9;(V7+[35\!:
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M=\,K?V=)[3=\!6 DRM_9TGM-WPRM_9TGM-WP%8"3*W]G2>TW?#*W]G2>TW?
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M6 DRM_9TGM-WPRM_9TGM-WP%8"3*W]G2>TW?#*W]G2>TW? <J7Y4[K:_N(:
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M%AC1&%R3Y/\ @QR?;I>4Y3@.NN8W%X%N&XI=EEI\V%9S^H;H
M                         ,JCJ)$::H^8ICYG9I_IF/'RORIL1Z+4JB=)
M?:R.H(@(:E.DP:U*3A82K2\0K+=!VCV5$^0E]=?]\QYY?(F0A52>B55#4B75
M$U%M3L,G4-F2<' -)J\8OK(TG[ &]R>JKE<HK-0<:8:-VVQ,>4F0BRW09+3H
M,:PPN2] \&J(BGY3E"\-;KCI-DV2EK4:E6)*W!*T]!6F-T
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MXT!GQO/D_P#5,_YP&@         #/JWR$?K;/OD- 9]6^0C];9]\AH
M  #F[\BO]$QT'-WY%?Z)@)J1YD@=6;]TA+R<\T?WF3\=8JI'F2!U9OW2$O)S
MS1_>9/QU@-<      !G1_/T[]0Q][@T1G1_/T[]0Q][@#1         !GUCY
MJSUN/\5(T!GUCYJSUN/\5(T        !_%>2?V#^C^*\D_L 043T?IW56O=(
M: SZ)Z/T[JK7ND-         9S'I#-ZJQ[[PT1G,>D,WJK'OO -$  !D2/2Z
MF]0E?$CC7&1(]+J;U"5\2.-<    9]8^8M]:C_&0- 9]8^8M]:C_ !D#0
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M3\0P&N      ,^I^5"ZVC[C&@,^I^5"ZVC[C&@ #SY?[0U?V47Q3'H!Y\O\
M:&K^RB^*8#T       SZ)YG8_P"+WC&@,^B>9V/^+WC&@        ,[^L7]T
M_P XT1G?UB_NG^<!H@         SZKY,/K;?WC0&?5?)A];;^\: #SZO]H;?
M]E+^*D>@'GU?[0V_[*7\5(]  EG^;9?ZE?W&.=&\QT_JS?ND.D_S;+_4K^XQ
MSHWF.G]6;]T@%P  #.HOFIO]-SWU#1&=1?-3?Z;GOJ&B        ,Y7I$WU1
M?OI&B,Y7I$WU1?OI :(         ,^K?(QNML^^0T!GU;Y&-UMGWR&@
M      SZ-YM+]<[\10T!GT;S:7ZYWXBAH        #(=]+HG4'OB-#7&0[Z7
M1.H/?$: :X         ,^K_-F.ML?$2- 9]7^;,=;8^(D:           #/H
MWF]76'_BK&@,^C>;U=8?^*L:         SG?2*)U1_WVAHC.=](HG5'_ 'V@
M&B         #.K/S)OK<;XR!HC.K/S)OK<;XR!H@,CE3Z(UKJ#_PU#7&1RI]
M$:UU!_X:AK@       SZ-\R=ZW(^,L: SZ-\R=ZW(^,L:        //\A?\
M9_R=_LV/\-(T&?2*7U1GWW1G\A?]G_)W^S8_PTC09](I?5&??= :
M  ,^L>;T]88^*@: SZQYO3UACXJ!H           ,^D?-G^MO_$4- 9](^;/
M];?^(H:     #(9]+Y?4&?B.C7&0SZ7R^H,_$= :XSD>D3_5&_?6-$9R/2)_
MJC?OK :(         ,^M>;%?K6OB)&@,^M>;%?K6OB)&@           SJ3\
MC*ZV][QC1&=2?D976WO>,:(        SD^D3G5$^^H:(SD^D3G5$^^H!H@
M       SJSYJ=_21[Y#ERD\PO_IM_$2.M9\U._I(]\ARY2>87_TV_B) :P
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M?:&@,]WTBB=4>]]H!H          SZ[Z/U'JSGNF- 9]=]'ZCU9SW3&@
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MV)\4M!6I,_WB_)']HR>RW<'*A>C].ZLW[I#0 29(_M&3V6[@9(_M&3V6[@K
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M-\R=ZW(^,L: "3)']HR>RW<#)']HR>RW<%8 ),D?VC)[+=P,E>VA)[+=P5@
M\KR*C.KY"<GUIFOMI.G1S)"4HL3_ ":=!6I,_P"(T&XSN>Y*<ND$91FC->"W
M:?C.:/)LT6>SUCCR%_V?\G?[-C_#2-!GTBE]49]]T!UR1_:,GLMW R1_:,GL
MMW!6 "3)']HR>RW<#)']HR>RW<%8 ),D?VC)[+=P,D?VC)[+=P5@ Q:K&=3"
M(SFOK+'LE8I+=GRJ=.A/JYQ?DC^T9/9;N#E6/-Z>L,?%0- !)DC^T9/9;N!D
MC^T9/9;N"L $F2/[1D]ENX&2/[1D]ENX*P 29(_M&3V6[@9(_M&3V6[@K !B
MTR.\J.\939"+)+Q6)2WI_E%:=*?6+\D?VC)[+=P<J1\V?ZV_\10T $F2/[1D
M]ENX&2/[1D]ENX*P 29(_M&3V6[@RFV'?":2C*WR44)HS<L1A&6&YH\FRS]E
MND>@&0SZ7R^H,_$= 69(_M&3V6[@@1&>SV\G+I%I1FSP\%NT_&7H\FS^'K&T
M,Y'I$_U1OWU@.V2/[1D]ENX&2/[1D]ENX*P 29(_M&3V6[@9(_M&3V6[@K !
M)DC^T9/9;N!DC^T9/9;N"L &-58SJ:>9JFR%EC&M"DMV?*)]B1=DC^T9/9;N
M#E6O-BOUK7Q$C0 29(_M&3V6[@9(_M&3V6[@K !)DC^T9/9;N!DC^T9/9;N"
ML $F2/[1D]ENX&2/[1D]ENX*P 8U-CO*:DV39"+)+I>*EO3XQZ=*1=DC^T9/
M9;N#C2?D976WO>,:("3)']HR>RW<#)']HR>RW<%8 ),D?VC)[+=P,D?VC)[+
M=P5@ DR1_:,GLMW!"F,]GM:,ND6Y,D\/!;M\H]'DV?P&R,Y/I$YU1/OJ =LD
M?VC)[+=P,D?VC)[+=P5@ DR1_:,GLMW R1_:,GLMW!6 "3)']HR>RW<#)']H
MR>RW<%8 ,:K1G44QPU39"RPD>*I+=GE%[$CC7V'6Z(\I4Q]PB6WXJR18?CI]
MB2,75GS4[^DCWR'+E)YA?_3;^(D!7DC^T9/9;N!DC^T9/9;N"L $F2/[1D]E
MNX&2/[1D]ENX*P 29(_M&3V6[@9(_M&3V6[@K !C4Z.ZI,NR;(39)<([$MZ=
M//I2+LD?VC)[+=P<J5Y,SK;GWC0 29(_M&3V6[@9(_M&3V6[@K !)DC^T9/9
M;N!DC^T9/9;N"L $F2/[1D]ENX(<F>SW@9=(MR:W#P6[?*YO)L_@-D9_]8O[
MI_G =<D?VC)[+=P,D?VC)[+=P5@ DR1_:,GLMW R1_:,GLMW!6 "3)']HR>R
MW<#)']HR>RW<%8 ,6KQWD4M]2ITA9$1>*I+=AZ2]B2,7Y(_M&3V6[@XUKS/(
M^PO>(:("3)']HR>RW<#)']HR>RW<%8 ),D?VC)[+=P,D?VC)[+=P5@ DR1_:
M,GLMW R1_:,GLMW!6 #&I\=U2IMDV0FR2HCL2WIT%ITI%V2/[1D]ENX.5+\J
M=UM?W$- !Y^CQW5JJ.#+?19,61X)(\8[$Z3M2>G[- U<D?VC)[+=P1T/Y2J]
M?<]U(UP$F2/[1D]ENX&2/[1D]ENX*P 29(_M&3V6[@A.,]GM",ND6Y,H\/!;
MM\HM'DV?P&R,X_2)/5%>^0#MDC^T9/9;N!DC^T9/9;N"L $F2/[1D]ENX&2/
M[1D]ENX*P 29(_M&3V6[@9(_M&3V6[@K !BU>.\BDRE*G2%D2-*5);L/]R2,
M7Y(_M&3V6[@XUOS)+_5C1 29(_M&3V6[@9(_M&3V6[@K !)DC^T9/9;N!DC^
MT9/9;N"L $F2/[1D]ENX&2/[1D]ENX*P 8M/C.J>G639";))D=B6_&\5.D[4
M_<+\D?VC)[+=P<:9\M4NMG[B!H@),D?VC)[+=P,D?VC)[+=P5@ DR1_:,GLM
MW R1_:,GLMW!6 "3)']HR>RW<$"HSV>V4Y;(M.,L\/!;M+QD:/)L_AZAM#.7
MZ1,=4<]] #MDC^T9/9;N!DC^T9/9;N"L $F2/[1D]ENX&2/[1D]ENX*P >?K
M+#J(D;#E/KMFQR(E$CG-U.G0DM)<_L^T:N2/[1D]ENX)*_\ -(G7XWQ4C6 8
MM8CO(HTQ2ILA:2949I4ENP]'-H21B_)']HR>RW<'*M^8IWZA7W#0 29(_M&3
MV6[@9(_M&3V6[@K !)DC^T9/9;N!DC^T9/9;N"L $F2/[1D]ENX&2/[1D]EN
MX*P 8L".Z<BH$4V0G!DV&9);\;^31I.U/W>P7Y(_M&3V6[@XTWYU4^M_]ML:
M("3)']HR>RW<#)']HR>RW<%8 ),D?VC)[+=P,D?VC)[+=P5@ DR1_:,GLMW!
M N,]GN,C+I%IQG3P\%NTO&;T>39_#U#:&>[Z11.J/>^T ZY(_M&3V6[@9(_M
M&3V6[@K !)DC^T9/9;N!DC^T9/9;N"L $F2/[1D]ENX&2/[1D]ENX*P 8M8C
M/(HLY:ILA:2CN&:%);L5XIZ#L21_N,7Y(_M&3V6[@Y5WT?J/5G/=,: "3)']
MHR>RW<#)']HR>RW<%8 ),D?VC)[+=P,D?VC)[+=P5@ DR1_:,GLMW R1_:,G
MLMW!6 #'Y.>:W"YS*;+(S]MDAS3]I\XV!D<G?-CW7IG_ -EP:X    #D33:2
M,B0DL)6$=A<Y^W[1_5N);0IQ:B2A)&I2C/01$,XJY#-HU?RQ*,TDAM31DI>%
M;@X)>NVP_P!QVV /Y7UI;IB%J,DI3+C*4HSL(B)]NTS%.=Z9M&)OT]XBJDEF
M918\AA>&TY+BFE7-_P"NV-H!%G>F;1B;]/>&=Z9M&)OT]XM !%G>F;1B;]/>
M&=Z9M&)OT]XM !%G>F;1B;]/>&=Z9M&)OT]XM !%G>F;1B;]/>,V8QR5J$QJ
M7-:HTF4T9&AYY+2UH,M)&2CTE8-\>9J/+F@4JIJI\QZ8F45OB(I\APE6$1G8
M:6S)5F$FVPSLM(!H*ET0Y"Y&4T\WW&R:4X;B,)2",S))GSF5IGH^LQ'/C<F*
MA2<V/KIV2I:4RTA*FRQ*30:/Y/HG@F9%8-*JU>%1*6[4:B\;$1HTDMS 4JS"
M422T$1GSJ(N81UCE12>3[L1FHONH=F86(;:C.O*7@V&K0VE1E9A%S@)ETWD<
M\W$1(CT:1D;:6HZI!-NJ:2GF(E*M,K/M%ZI5#.8B8J13SE-H-M#QK1AI2>DT
MDKG(CL+1]0[4FJPJ[36I]/D)?BNVX#B2,N8[#(R/21D9&1D8ZQ9T68]*:CO)
M6Y%=Q+Y%_07@DJS]RB/]H#S4KDYR$EL26CA41DY*30ZY'2TTXI)G:98:;%:?
M7I'9VB\A9+[C[],Y.NO.&:EN.,,*4LSYS,S*TS/ZQM5:KP*)379]2E(C1F[+
M5J(STGS$1%I,S]A:1PH_**EU\G\VR#<6PHDO-K:6TMLS*TL)"R)16E]0#E,+
MDU4\64[-,HFB/%X_%N8!'9;9;S>27[B]@_,IODQ/)TIJ:1))U"4.8XFEX:4G
M:DCMYR(S,R+U#> !Y=VE\DEQ8\5HJ9&BQI2):&8RVVD8U'DF9)LYCL/]A"V6
M?)R>IPYATF0;J4MN&]BUX:4JPDI.WG(E:2+U'I'[F\HZ33JDW3I<LVI;B$NH
M;-M1VI4XEHCM(K/+6DN?U^P; #S4BF\C)I?SN%07RQBG/Y5EE7CJ\I6DN<["
MM/UV"F 7)NEI--.S5#3@DBR/BVRP2,S(O%LT6J4=GM,_:+Y-2APYD.+(?2V_
M-6IMA!D=KBDI-1D7V$1F,6I<O.3E(J,JGSISC4B*2#D61'E(:)1$:<):4&DK
M2,N<P%3)T%F14'BF0UJGJ)4@EO(42K$$BRSV8*2T?:(DT3D(AMQM%,Y.);=L
MQB2CL$2[-)6E9I'[F<O.3E/G/1)=06RIA:6W7%1G<4VI5AD2G<' +0I/.?K'
MI2,E$1D9&1Z2,@'F,S<ABBY-FWD[D^'C,5B&,#"LLPK+++;"(K051N0RV665
MTWD\IIFW%(-A@TMVG:>"5FBT].@>I !F9;1<E.+E4#)S3BS:QB,#!LLP;.:R
MSU#.9@\CH\-Z$Q$H341\[7F$-LI0X?M4DBL/]H]( #SRXG)%QJ,TMBAJ;B_-
MT&AHR9_0+^C^P?M]ODO)BN19"*0]'<<-Y;3A-J0I9G::C(]!JM]?.-X &)#/
MDY3U&J$=*C*-"6S-C%H,T)\E.CU%:=A>H79WIFT8F_3WBT $6=Z9M&)OT]X9
MWIFT8F_3WBT $6=Z9M&)OT]X9WIFT8F_3WBT $6=Z9M&)OT]X9WIFT8F_3WB
MT $6=Z9M&)OT]X9WIFT8F_3WBT $6=Z9M&)OT]X9WIFT8F_3WBT &#2:G :9
ME$Y.C(-4MY183J2M(UG8?/S#^O-\EY#,EE]%'=:DJQC[:R:4EU7241^4?UF*
MJ)\A+ZZ_[YB!7+;DZB',EYS;6Q#D%%>4TA2_Y4[+$)))&:ST_P!&T!;%F42#
M%;BPY-.CQVRP4-,N(0A)>PB+00HSO3-HQ-^GO'\I=4A5BG-3H$E+\=PK4K3:
M7[#(])']1Z1< BSO3-HQ-^GO#.],VC$WZ>\6@ BSO3-HQ-^GO#.],VC$WZ>\
M6@ BSO3-HQ-^GO#.],VC$WZ>\6@ BSO3-HQ-^GO#.],VC$WZ>\6@ BSO3-HQ
M-^GO&;"J<!%5J:U38Q)6MLTJ-U-BK$$1V:=(WQET_P \U;]-KX9 )6V>2K3D
MMQ#=&0N85DE24M$;Y?[Y_P!+]H[HDT-N44E$J"EXFB9):7DE8@CM)//S6F(&
MN77)R0J4EB>IU44C-PFX[JK2)6"9HL3XY$>@S3;8.T3EA0IZ"7&G'8<C)?Y1
MEQL\;89X-BDD?,1Z>8@'207)F9$<B2LTOQG5FXXR[BU(6L])J,CT&?UC^Q?!
MR$A]$9=-91(^52A:")>BRPR]EFBP<'>6?)YJEE4<Y)7$4^J.A;+:W#6XD[#)
M*4D9JLLYR(R'17*Z@MH:<74FTMN1CF)4I*B3BB.PU&=EA:=%AZ;0'X>B\DI&
M3$^Q17<ELR?#0TK$V:2P+?)_8-3.],VC$WZ>\93W+6@,IA&J<M1S6L='2W&=
M6I:+;,*Q*3,BM]M@] E1+02BYC*TK2L 29WIFT8F_3WAG>F;1B;]/>+0 19W
MIFT8F_3WAG>F;1B;]/>+0 19WIFT8F_3WAG>F;1B;]/>+0 8,.IP$U>I+.;&
M)"S;P3-U-BK$Z;-.D$HY+E/=GDBD%,>2:')%C6,6D^<C5SF7U&*X/GNJ_:U[
M@B\+J&51ET],Q:I48E&ZA,=Q5F#I41&2;%&5NDB,S ?R%%Y*4U:%P$4B(ILU
M&G)\6V1&HK#.Q-FDQ_"A<D$QI,=,:ADS)5AOMDVS@NJ]JBYE']H_#7+KDX\Q
M(>34%)1'6AMW&1G4&E2O)*Q22.TQS1^4'DNJ+(D9U+%L&G#M9<)2L([$X"<&
MU9&>@C21V@+(*>35,6I<%5,C&:$M_P BI""P4\R2(N8B]@YR8O)*9%;C26**
M_':4:T-.H:4A"CYS(CT$?UCNQRIHDAB(\S.0MN4:R:42%6%@%:O"T>)@ESX5
ME@G<Y:T!NG1*AEREQIBE)CK:CN.&X:>>PDI,[/KL ::*I2FT$A$^&E*2L(B>
M21$7[Q^L[TS:,3?I[QVCO(D,-O(-1I6DE)PDFD[#^H])?M'<!%G>F;1B;]/>
M&=Z9M&)OT]XM !%G>F;1B;]/>&=Z9M&)OT]XM !%G>F;1B;]/>,[.4#PBQN7
M1L7DF#AXU-EN'S6V\XWAE_UH+J1^^ X.>#3M2147,TKG(+!1*5BS=27L)?.7
M[QP?B<DY1**2BDODI_*3QIMK_E>EI]>@=7>5=#BUO,[T]+<VPO$4VK!*TK2(
MUV8)'87,9VCG!Y:<GZFMM$*?CENOG'0E++EIK(K>;!YK-.%S?6 U,[TS:,3?
MI[PSO3-HQ-^GO%H (L[TS:,3?I[PSO3-HQ-^GO%H (L[TS:,3?I[PSO3-HQ-
M^GO%H (L[TS:,3?I[PSO3-HQ-^GO%H (L[TS:,3?I[PSO3-HQ-^GO%H //3J
MC"=K5*6W,CK0VMTUJ2ZDR3:@R*W3HTC6SG3]>C;Y/>)*CY^HOZ;WPS&L QJE
M/AN(BX$N.K!DMJ.QPCL(CTGSB[.=/UZ-OD]XXU7Y.)UMKWAH@),YT_7HV^3W
MAG.GZ]&WR>\5@ DSG3]>C;Y/>&<Z?KT;?)[Q6 "3.=/UZ-OD]XY/U* J*ZDI
ML8S-!D1$ZGV?:- <97S5[]6K[@$%.J,%%,B(7,CI4EE!&1NI(R/!+ZQ5G.GZ
M]&WR>\*7YIA_J$>Z0K 29SI^O1M\GO#.=/UZ-OD]XK !)G.GZ]&WR>\,YT_7
MHV^3WBL $F<Z?KT;?)[Q!'GPRJ\U9RV"0IMHDJ-PK#LPK;-/UC:&?&\^3_U3
M/^<!USG3]>C;Y/>&<Z?KT;?)[Q6 "3.=/UZ-OD]X9SI^O1M\GO%8 ),YT_7H
MV^3WAG.GZ]&WR>\5@ Q:G/AN,QR1+CJ,I+2CL<([")96GSB_.=/UZ-OD]XY5
M;Y"/UMGWR&@ DSG3]>C;Y/>&<Z?KT;?)[Q6 "3.=/UZ-OD]X9SI^O1M\GO%8
M ),YT_7HV^3WC\.5. ;2R*=&,S2?_JI[Q<.;OR*_T3 9=+J$)ND0T+F1TK2P
M@E)4ZDC(\$M!Z1/0)T1FEFAV2PVK*)!X*G"([#>69'^TC(QITCS) ZLW[I"7
MDYYH_O,GXZP%F<Z?KT;?)[PSG3]>C;Y/>*P 29SI^O1M\GO#.=/UZ-OD]XK
M!)G.GZ]&WR>\0,SX95J8X<N.2%,,DE1N%89D;ENFWZR_>-H9T?S]._4,?>X
M[9SI^O1M\GO#.=/UZ-OD]XK !)G.GZ]&WR>\,YT_7HV^3WBL $F<Z?KT;?)[
MPSG3]>C;Y/>*P 8M4GPW(S1(E1UF4EE1D3A'H)Q)F?/ZB%^<Z?KT;?)[QRK'
MS5GK<?XJ1H ),YT_7HV^3WAG.GZ]&WR>\5@ DSG3]>C;Y/>&<Z?KT;?)[Q6
M"3.=/UZ-OD]X_AU.!@G_ #Z-S?2I[Q8/XKR3^P!C4B?";HL!MR9'0M$9M*DJ
M=(C(R25I&5HOSG3]>C;Y/>.5$]'Z=U5KW2&@ DSG3]>C;Y/>&<Z?KT;?)[Q6
M "3.=/UZ-OD]X9SI^O1M\GO%8 ),YT_7HV^3WC/:GPRKLIPY<<D*C,I)>,*P
MS)3MI6V^JTOWD-L9S'I#-ZJQ[[P#MG.GZ]&WR>\,YT_7HV^3WBL 'GWIT0^4
M\%Y,EDVTPY*5+QA8)&:V#(C/VG8?[C]@U<YT_7HV^3WB.1Z74WJ$KXD<:X"3
M.=/UZ-OD]X9SI^O1M\GO%8 ,6K3X;D-"6Y<=9E(8583A'H)U!F?/ZB(S%^<Z
M?KT;?)[QRK'S%OK4?XR!H ),YT_7HV^3WAG.GZ]&WR>\5@ DSG3]>C;Y/>&<
MZ?KT;?)[Q6 "3.=/UZ-OD]X9SI^O1M\GO%8 ,6CSX;5$@MN2V$+3'02DJ<(C
M(\$M!E:+\YT_7HV^3WCE0O1^G=6;]TAH ),YT_7HV^3WAG.GZ]&WR>\5@ \1
MRSAT&5R=KE0+)':@5/>4VX3I&K"2V>#85OU"UN@\D#;2:V(&$9%;_*^O]XQ/
MR@\J\F@U6@)C?RC\139NVVE@+09'HT6'89V<XYQ/RH-MQ6D2:>I;R4D2U-JP
M4V_41VG_ !'IAIU)C/##.</09AY'?04_??\ D2HHG)4ZH^@X\#)R80:3QA68
M1J7A:;?82= S_P ZD39;^]+N'!/Y2HB:@[*S<_X[2&\'#+1@FH[;?^+^ UVZ
MOB3/"]#F'D=]!3]]_P"0S#R.^@I^^_\ (Q?SJ1-EO[TNX/SJ1-EO[TNX.W5\
M29X6UF'D=]!3]]_Y#,/([Z"G[[_R,7\ZD39;^]+N#\ZD39;^]+N#MU?$F>%M
M9AY'?04_??\ D,P\COH*?OO_ ",7\ZD39;^]+N#\ZD39;^]+N#MU?$F>%HRJ
M'R50]$)EB#@J>L=L61^+@*/3IT:2+2*<P\COH*?OO_(\](_*5$D.QEYO?3B'
M<99AD>%XJDV?_P 7\!W_ #J1-EO[TNX.W5\29X6UF'D=]!3]]_Y#,/([Z"G[
M[_R,7\ZD39;^]+N#\ZD39;^]+N#MU?$F>%M9AY'?04_??^0S#R.^@I^^_P#(
MQD_E2BK6E!4MZU1DDK72YS_8/H"3PDD?M*T8Q1CPSEB]%C*7F,P\COH*?OO_
M "(J/1>3#U&AN38\(I2FDFZ2UDD\*S3:5N@>V&1R7]%J9U9'W#-TF4,2G4/D
MJY36%RH\ GU-D;F$LDG;Z]%N@4YAY'?04_??^1LT/S%!_4I^X: 7290\MF'D
M=]!3]]_Y&-RGI/)B+0''X;$/&I?CVXM6&K!QR,*PB,S/Q;>8?0AY_EGZ-*ZW
M$_\ L-AG)E#RM97R,/D[56:?3$JF.Q729,Z8Z:L8:#)-BE(T:;/60]Q#J,),
M*.E<V.2B;21D;J;2.S[1I (J3.=/UZ-OD]XA3/A9\=<RN/@'&0DE8PK+<)6B
MVWZQLC.1Z1/]4;]]8#MG.GZ]&WR>\,YT_7HV^3WBL $F<Z?KT;?)[PSG3]>C
M;Y/>*P 29SI^O1M\GO#.=/UZ-OD]XK !C5"?#6["P)<=6#))2K'".PL%6D](
MNSG3]>C;Y/>.-3^6I_6R]U0T0$F<Z?KT;?)[PSG3]>C;Y/>*P >5J,Z(KEC0
MG$RV#0EB62E$X5A6DW9:8W\YT_7HV^3WC*J?IM0/U$O[FQZ !)G.GZ]&WR>\
M,YT_7HV^3WBL &-2)\-NDQD.2XZ%)18:5.$1E_$79SI^O1M\GO'&B>9HOZ T
M0$F<Z?KT;?)[PSG3]>C;Y/>*P 29SI^O1M\GO#.=/UZ-OD]XK !)G.GZ]&WR
M>\0E/A9\4YE<? R8DX6,*RW"/1;:-D9Q>D*NJ)]\P';.=/UZ-OD]XRRG1/"=
M;V4LXO(DIP\86#;AF=EOM&^,@O2Y?4$_$,!9G.GZ]&WR>\,YT_7HV^3WBL $
MF<Z?KT;?)[PSG3]>C;Y/>*P 8U1GPUG#P)<=6#)0I5CA'85AZ><79SI^O1M\
MGO'*I^5"ZVC[C&@ DSG3]>C;Y/>,$I\/P]4[E3&+S62</&%9;C3T6CU(\^7^
MT-7]E%\4P&KG.GZ]&WR>\,YT_7HV^3WBL $F<Z?KT;?)[PSG3]>C;Y/>*P 8
MU(GPVJ6RAR7'0HL*U*G"(R\8_K%V<Z?KT;?)[QRHGF=C_B]XQH ),YT_7HV^
M3WAG.GZ]&WR>\5@ DSG3]>C;Y/>&<Z?KT;?)[Q6 "3.=/UZ-OD]XAR^%GPG,
MKCX&38.%C"LMPN:VT;(SOZQ?W3_. [9SI^O1M\GO#.=/UZ-OD]XK !)G.GZ]
M&WR>\,YT_7HV^3WBL $F<Z?KT;?)[PSG3]>C;Y/>*P 8U2GPG$Q<"7'5@R6U
M'8X1V$1\_.+LYT_7HV^3WCE5?)A];;^\: #RRI\/P];=RIC%YK6G#QA66XU.
MBT;V<Z?KT;?)[QE*_P!H;?\ 92_BI'H &9-J,%<"2E$R.I1M*(B)U)F9V']8
MY4JH0FZ/"0N7'2M,=LE)4ZDC(R26@](NG^;9?ZE?W&.=&\QT_JS?ND _><Z?
MKT;?)[PSG3]>C;Y/>*P 8U)GPFZ:VAR6PA1*7H4X1'Y9_6+LYT_7HV^3WCC1
M?-3?Z;GOJ&B DSG3]>C;Y/>&<Z?KT;?)[Q6 "3.=/UZ-OD]X9SI^O1M\GO%8
M ),YT_7HV^3WB$Y\//;;F5Q\ HRDFK&%9;A)T6VC9&<KTB;ZHOWT@.V<Z?KT
M;?)[PSG3]>C;Y/>*P 29SI^O1M\GO#.=/UZ-OD]XK !)G.GZ]&WR>\,YT_7H
MV^3WBL &+4Y\-;4<D2XZC*2TH\%PCL(E%:?.+\YT_7HV^3WCE5OD8W6V??(:
M "3.=/UZ-OD]X9SI^O1M\GO%8 ),YT_7HV^3WAG.GZ]&WR>\5@ DSG3]>C;Y
M/>&<Z?KT;?)[Q6 #&I,^&W )+DMA"L:Z=BG"([#<49>OV"[.=/UZ-OD]XY4;
MS:7ZYWXBAH ),YT_7HV^3WAG.GZ]&WR>\5@ DSG3]>C;Y/>&<Z?KT;?)[Q6
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M&1$1%SF-7.=/UZ-OD]XCY4^B-:Z@_P##4-<!)G.GZ]&WR>\,YT_7HV^3WBL
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MH/FT6:;3TE9IUL94-6C<0JX K 28RH:M&XA5P,94-6C<0JX Y5CYBWUJ/\9
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M&XA5P!6//E_M#5_91?%,:N,J&K1N(5<&"2YGAZH\0QC,UEXN..RS&GZ\'_H
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M,J&K1N(5< 1\G?-CW7IG_P!EP:XQN3NFENVVD>6R[2]AY0Y:7UE;Z_N&R
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MY!TZDS($G+JA-536<3"1+=2I$=)D23-!)26FPK+3M'K0
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MIG_.- 9\;SY/_5,_YP&@         #/JWR$?K;/OD- 9]6^0C];9]\AH
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M5"ZVC[C&@,^I^5"ZVC[C&@ #SY?[0U?V47Q3'H!Y\O\ :&K^RB^*8#T
M  SZ)YG8_P"+WC&@,^B>9V/^+WC&@        ,[^L7]T_P XT1G?UB_NG^<!
MH@         SZKY,/K;?WC0&?5?)A];;^\: #SZO]H;?]E+^*D>@'GU?[0V_
M[*7\5(]  EG^;9?ZE?W&.=&\QT_JS?ND.D_S;+_4K^XQSHWF.G]6;]T@%P
M#.HOFIO]-SWU#1&=1?-3?Z;GOJ&B        ,Y7I$WU1?OI&B,Y7I$WU1?OI
M :(         ,^K?(QNML^^0T!GU;Y&-UMGWR&@           SZ-YM+]<[\
M10T!GT;S:7ZYWXBAH        #(=]+HG4'OB-#7&0[Z71.H/?$: :X
M   ,^K_-F.ML?$2- 9]7^;,=;8^(D:           #/HWF]76'_BK&@,^C>;
MU=8?^*L:         SG?2*)U1_WVAHC.=](HG5'_ 'V@&B         #.K/S
M)OK<;XR!HC.K/S)OK<;XR!H@,CE3Z(UKJ#_PU#7&1RI]$:UU!_X:AK@
M  SZ-\R=ZW(^,L: SZ-\R=ZW(^,L:        //\A?\ 9_R=_LV/\-(T&?2*
M7U1GWW1G\A?]G_)W^S8_PTC09](I?5&??= :          ,^L>;T]88^*@:
MSZQYO3UACXJ!H           ,^D?-G^MO_$4- 9](^;/];?^(H:     #(9]
M+Y?4&?B.C7&0SZ7R^H,_$= :XSD>D3_5&_?6-$9R/2)_JC?OK :(
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MMRGN%8 ,:D0(3M+96Y$CK4>%:I31&9^,?U"[-E/U&-N4]PY43S.Q_P 7O&-
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MY3EQ9JT,N)9=F-H0;+;BB-1(/QL*VPNC9]8CH_Y1*;79,>/!ARSD/OXLFW,
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M-WQ6 #%IDAY,=XBA2%VR7CM2IO1_**T:5>H7Y6_LZ3VF[XY4CYL_UM_XBAH
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MOBI&L Q:Q(>71IB50I"$FRHC4I3=A:.?0HS%^5O[.D]IN^.5;\Q3OU"ON&@
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MAE;^SI/:;OBL &/R<\UN'ZSFRS,O9;(<T?:7,-@9')WS8]UZ9_\ 9<&N
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M Y5CYJSUN/\ %2- 8M4CO)BM&<V0NV2P5AI;T6N)TZ$^KG%^2/[1D]ENX K
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MR1_:,GLMW %8"3)']HR>RW<#)']HR>RW< 5@),D?VC)[+=P,D?VC)[+=P!6
MDR1_:,GLMW R1_:,GLMW '*C>;2_7._$4- 8U*C.JIY&4V0@L:[H2ENSY17M
M2+LD?VC)[+=P!6 DR1_:,GLMW R1_:,GLMW %8"3)']HR>RW<#)']HR>RW<
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M[1D]ENX XUKS/(^PO>(:(Q:O'>12WU*G2%D1%XJDMV'I+V)(Q?DC^T9/9;N
M*P$F2/[1D]ENX&2/[1D]ENX K 29(_M&3V6[@9(_M&3V6[@"L!)DC^T9/9;N
M!DC^T9/9;N .5+\J=UM?W$- 8U/CNJ5-LFR$V25$=B6].@M.E(NR1_:,GLMW
M $=#^4JO7W/=2-<>?H\=U:JC@RWT63%D>"2/&.Q.D[4GI^S0-7)']HR>RW<
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M/9;N"!<9[/<9&72+3C.GAX+=I>,WH\FS^'J ;0"3)']HR>RW<#)']HR>RW<
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MZI*DK22DJ)25%:1D=I&0_8@35:6E))34(9)(K"(GDV%_$?K.],VC$WZ>\!:
MBSO3-HQ-^GO#.],VC$WZ>\!: BSO3-HQ-^GO#.],VC$WZ>\!: BSO3-HQ-^G
MO#.],VC$WZ>\!: BSO3-HQ-^GO#.],VC$WZ>\!-4?/U%_3>^&8UAYZ=483M:
MI2VYD=:&UNFM274F2;4&16Z=&D:V<Z?KT;?)[P'&J_)Q.MM>\-$8U2GPW$1<
M"7'5@R6U'8X1V$1Z3YQ=G.GZ]&WR>\!6 DSG3]>C;Y/>&<Z?KT;?)[P%8"3.
M=/UZ-OD]X9SI^O1M\GO 5CC*^:O?JU?<.6<Z?KT;?)[QR?J4!45U)38QF:#(
MB)U/L^T!UI?FF'^H1[I"L95.J,%%,B(7,CI4EE!&1NI(R/!+ZQ5G.GZ]&WR>
M\!6 DSG3]>C;Y/>&<Z?KT;?)[P%8"3.=/UZ-OD]X9SI^O1M\GO 5C/C>?)_Z
MIG_..N<Z?KT;?)[Q!'GPRJ\U9RV"0IMHDJ-PK#LPK;-/U@-H!)G.GZ]&WR>\
M,YT_7HV^3W@*P$F<Z?KT;?)[PSG3]>C;Y/> K 29SI^O1M\GO#.=/UZ-OD]X
M#E5OD(_6V??(: Q:G/AN,QR1+CJ,I+2CL<([")96GSB_.=/UZ-OD]X"L!)G.
MGZ]&WR>\,YT_7HV^3W@*P$F<Z?KT;?)[PSG3]>C;Y/> K'-WY%?Z)CAG.GZ]
M&WR>\?ARIP#:613HQF:3_P#53W@/[2/,D#JS?ND)>3GFC^\R?CK'\I=0A-TB
M&A<R.E:6$$I*G4D9'@EH/2)Z!.B,TLT.R6&U91(/!4X1'8;RS(_VD9& ]  D
MSG3]>C;Y/>&<Z?KT;?)[P%8"3.=/UZ-OD]X9SI^O1M\GO 5C.C^?IWZAC[W!
MVSG3]>C;Y/>(&9\,JU,<.7')"F&22HW"L,R-RW3;]9?O ;0"3.=/UZ-OD]X9
MSI^O1M\GO 5@),YT_7HV^3WAG.GZ]&WR>\!6 DSG3]>C;Y/>&<Z?KT;?)[P'
M*L?-6>MQ_BI&@,6J3X;D9HD2HZS*2RHR)PCT$XDS/G]1"_.=/UZ-OD]X"L!)
MG.GZ]&WR>\,YT_7HV^3W@*P$F<Z?KT;?)[PSG3]>C;Y/> K'\5Y)_8)<YT_7
MHV^3WC^'4X&"?\^C<WTJ>\!SHGH_3NJM>Z0T!BTB?";HL!MR9'0M$9M*DJ=(
MC(R25I&5HOSG3]>C;Y/> K 29SI^O1M\GO#.=/UZ-OD]X"L!)G.GZ]&WR>\,
MYT_7HV^3W@*QG,>D,WJK'OO#MG.GZ]&WR>\9[4^&5=E.'+CDA49E)+QA6&9*
M=M*VWU6E^\@&V DSG3]>C;Y/>&<Z?KT;?)[P$<CTNIO4)7Q(XUQY]Z=$/E/!
M>3)9-M,.2E2\86"1FM@R(S]IV'^X_8-7.=/UZ-OD]X"L!)G.GZ]&WR>\,YT_
M7HV^3W@.58^8M]:C_&0- 8M6GPW(:$MRXZS*0PJPG"/03J#,^?U$1F+\YT_7
MHV^3W@*P$F<Z?KT;?)[PSG3]>C;Y/> K 29SI^O1M\GO#.=/UZ-OD]X"L!)G
M.GZ]&WR>\,YT_7HV^3W@.5"]'Z=U9OW2&@,6CSX;5$@MN2V$+3'02DJ<(C(\
M$M!E:+\YT_7HV^3W@*P$F<Z?KT;?)[PSG3]>C;Y/> K 29SI^O1M\GO#.=/U
MZ-OD]X"L9S?I#)ZHS[[@[9SI^O1M\GO$#<^&5;D.'+CX!QFDDK&%89DIRTK;
M?K+]X#: 29SI^O1M\GO#.=/UZ-OD]X"L!)G.GZ]&WR>\,YT_7HV^3W@*P$F<
MZ?KT;?)[PSG3]>C;Y/> Y5+YS3>M_P#;6- 8L^?#5(IQHEQU$B3A*,G".PL6
MLK3T^TR_>+\YT_7HV^3W@*P$F<Z?KT;?)[PSG3]>C;Y/> K 29SI^O1M\GO#
M.=/UZ-OD]X"L9')?T6IG5D?<+,YT_7HV^3WC*Y.SHC')NG-/266W$1T$I"W"
M(TG9S&0#0H?F*#^I3]PT!C4>?#:H\-MR7'0M+224E3A$9'9]HNSG3]>C;Y/>
M K 29SI^O1M\GO'\SG3]>C;Y/> ^3_E&<7X3O,X:B:6PC"02CL5H]9#S!391
M$1%)>(BT$6,,?7JMR?Y-UN>J;,G)-U223XDE)$1$(? KDAKO_-I'91ZBE@P1
MAQ8<Y_TQ.&7R_+I>M/[PPRZ7K3^\,?4/ KDAKO\ S:1.7(_DL=06R<G^0)I*
MB7E):5&9D96\W,1?O'IJJ&WB/_J6R^;Y=+UI_>&&72]:?WACZAX%<D-=_P";
M2'@5R0UW_FTAJJ&WB/\ Z6R^7Y=+UI_>&/9?DU?>>Y1/DZZXY9'T82C.S2-[
MP*Y(:[_S:11!Y,<F:>^;T>H.H4:<$\"H&W;^U!D?\1Y5J]+'@G#APY3_ *6,
M,YO9@/*4"9&C5:NQE5$UQVWVL1E$M3MA&R@SP5+49V6F?K'H,YT_7HV^3WCD
M;<:G\M3^ME[JAHC&J$^&MV%@2XZL&22E6.$=A8*M)Z1=G.GZ]&WR>\!6 DSG
M3]>C;Y/>&<Z?KT;?)[P&54_3:@?J)?W-CT \K49T17+&A.)EL&A+$LE*)PK"
MM)NRTQOYSI^O1M\GO 5@),YT_7HV^3WAG.GZ]&WR>\!QHGF:+^@-$8U(GPVZ
M3&0Y+CH4E%AI4X1&7\1=G.GZ]&WR>\!6 DSG3]>C;Y/>&<Z?KT;?)[P%8"3.
M=/UZ-OD]X9SI^O1M\GO 5C.+TA5U1/OF.V<Z?KT;?)[Q"4^%GQ3F5Q\#)B3A
M8PK+<(]%MH#9&07I<OJ"?B&+,YT_7HV^3WC+*=$\)UO92SB\B2G#QA8-N&9V
M6^T!O@),YT_7HV^3WAG.GZ]&WR>\!6 DSG3]>C;Y/>&<Z?KT;?)[P'*I^5"Z
MVC[C&@,:HSX:SAX$N.K!DH4JQPCL*P]/.+LYT_7HV^3W@*QY\O\ :&K^RB^*
M8U<YT_7HV^3WC!*?#\/5.Y4QB\UDG#QA66XT]%H#U("3.=/UZ-OD]X9SI^O1
MM\GO 5@),YT_7HV^3WAG.GZ]&WR>\!RHGF=C_B]XQH#&I$^&U2V4.2XZ%%A6
MI4X1&7C']8NSG3]>C;Y/> K 29SI^O1M\GO#.=/UZ-OD]X"L!)G.GZ]&WR>\
M,YT_7HV^3W@*QG?UB_NG^<=LYT_7HV^3WB'+X6?"<RN/@9-@X6,*RW"YK;0&
MR DSG3]>C;Y/>&<Z?KT;?)[P%8"3.=/UZ-OD]X9SI^O1M\GO 5@),YT_7HV^
M3WAG.GZ]&WR>\!RJODP^MM_>- 8U2GPG$Q<"7'5@R6U'8X1V$1\_.+LYT_7H
MV^3W@,I7^T-O^RE_%2/0#RRI\/P];=RIC%YK6G#QA66XU.BT;V<Z?KT;?)[P
M']G^;9?ZE?W&.=&\QT_JS?ND.4VHP5P)*43(ZE&THB(G4F9G8?UCE2JA";H\
M)"Y<=*TQVR4E3J2,C)):#T@-@!)G.GZ]&WR>\,YT_7HV^3W@.-%\U-_IN>^H
M:(QJ3/A-TUM#DMA"B4O0IPB/RS^L79SI^O1M\GO 5@),YT_7HV^3WAG.GZ]&
MWR>\!6 DSG3]>C;Y/>&<Z?KT;?)[P%8SE>D3?5%^^D=LYT_7HV^3WB$Y\//;
M;F5Q\ HRDFK&%9;A)T6V@-D!)G.GZ]&WR>\,YT_7HV^3W@*P$F<Z?KT;?)[P
MSG3]>C;Y/> K 29SI^O1M\GO#.=/UZ-OD]X#E5OD8W6V??(: Q:G/AK:CDB7
M'4926E'@N$=A$HK3YQ?G.GZ]&WR>\!6 DSG3]>C;Y/>&<Z?KT;?)[P%8"3.=
M/UZ-OD]X9SI^O1M\GO 5@),YT_7HV^3WAG.GZ]&WR>\!RHWFTOUSOQ%#0&-2
M9\-N 27);"%8UT[%.$1V&XHR]?L%V<Z?KT;?)[P%8"3.=/UZ-OD]X9SI^O1M
M\GO 5@),YT_7HV^3WAG.GZ]&WR>\!6,AWTNB=0>^(T+,YT_7HV^3WC*<G1#Y
M3QGBE,XM,)Y)KQA8)&:VS(K?;H/]P#T "3.=/UZ-OD]X9SI^O1M\GO 5@),Y
MT_7HV^3WAG.GZ]&WR>\!6 DSG3]>C;Y/>&<Z?KT;?)[P'*K_ #9CK;'Q$C0&
M+5*A#<CM$B7'49265'8X1V$3B3,^?V"_.=/UZ-OD]X"L!)G.GZ]&WR>\,YT_
M7HV^3W@*P$F<Z?KT;?)[PSG3]>C;Y/> K 29SI^O1M\GO#.=/UZ-OD]X#E1O
M-ZNL/_%6- 8M*J$-N$I*Y<=)X]X[%.$1V&ZHR/G]9':+\YT_7HV^3W@*P$F<
MZ?KT;?)[PSG3]>C;Y/> K 29SI^O1M\GO#.=/UZ-OD]X"L9SOI%$ZH_[[0[9
MSI^O1M\GO$#D^&=<C.%+CFA,9Y)JQA6$9J;L*VWZC_<8#: 29SI^O1M\GO#.
M=/UZ-OD]X"L!)G.GZ]&WR>\,YT_7HV^3W@*P$F<Z?KT;?)[PSG3]>C;Y/> X
MUGYDWUN-\9 T1BU6?#<AMI1+CK,I,=1D3A'H)U!F?/ZB(S%^<Z?KT;?)[P$?
M*GT1K74'_AJ&N//\HYT1[DO5F693+CKD)Y*$(<(U*,T&1$1%SF-7.=/UZ-OD
M]X"L!)G.GZ]&WR>\,YT_7HV^3W@*P$F<Z?KT;?)[PSG3]>C;Y/> Y4;YD[UN
M1\98T!BTJ?#;B.$N7'09R'U$1N$6@W5F1\_K(R,7YSI^O1M\GO 5@),YT_7H
MV^3WAG.GZ]&WR>\!6 DSG3]>C;Y/>&<X!G84Z-O4]X#*Y"_[/^3O]FQ_AI&@
MSZ12^J,^^Z,;D5/B,\@^3[;LIA#B:=')25.$1D>+3SD+VY\,JW)6<N/@*C-)
M)6,*PS)3EI6V_67[P&T DSG3]>C;Y/>&<Z?KT;?)[P%8"3.=/UZ-OD]X9SI^
MO1M\GO 5@),YT_7HV^3WAG.GZ]&WR>\!RK'F]/6&/BH&@,6JSX;D(DMRV%*Q
M[)V)<(SL)U)F?/[!?G.GZ]&WR>\!6 DSG3]>C;Y/>&<Z?KT;?)[P%8"3.=/U
MZ-OD]X9SI^O1M\GO 5@),YT_7HV^3WAG.GZ]&WR>\!RI'S9_K;_Q%#0&+2Y\
M-N.Z2Y<=)G)>45KA%:1N*,CY_8+\YT_7HV^3W@*P$F<Z?KT;?)[PSG3]>C;Y
M/> K&0SZ7R^H,_$=%F<Z?KT;?)[QE-SHA<IY+QR6<6<)I)+QA8)F2W#,K?;I
M+]X#T SD>D3_ %1OWUCMG.GZ]&WR>\0(GPRKCSA2X^ <9M)*QA6&9*7HMM^L
M@&T DSG3]>C;Y/>&<Z?KT;?)[P%8"3.=/UZ-OD]X9SI^O1M\GO 5@),YT_7H
MV^3WAG.GZ]&WR>\!RK7FQ7ZUKXB1H#%JT^&Y3S2W+CK5C6CL2X1GH<29^L7Y
MSI^O1M\GO 5@),YT_7HV^3WAG.GZ]&WR>\!6 DSG3]>C;Y/>&<Z?KT;?)[P%
M8"3.=/UZ-OD]X9SI^O1M\GO <:3\C*ZV][QC1&-3)\-MJ22Y<=%LEU183A%:
M1J.P^<79SI^O1M\GO 5@),YT_7HV^3WAG.GZ]&WR>\!6 DSG3]>C;Y/>&<Z?
MKT;?)[P%8SD^D3G5$^^H=LYT_7HV^3WB$I\+/BW,KCX!QDIPL85EN$>BVT!L
M@),YT_7HV^3WAG.GZ]&WR>\!6 DSG3]>C;Y/>&<Z?KT;?)[P%8"3.=/UZ-OD
M]X9SI^O1M\GO <:SYJ=_21[Y#ERD\PO_ *;?Q$C\5:?"=IKB&Y;"U&I%A)<(
MS\HOK'"OSHCU%>;:DL.+-;=B4.$9G8M)GH >@ 29SI^O1M\GO#.=/UZ-OD]X
M"L!)G.GZ]&WR>\,YT_7HV^3W@*P$F<Z?KT;?)[PSG3]>C;Y/> Y4KR9G6W/O
M&@,:FSX3:96'+CIPI+BBM<(K2MY^<79SI^O1M\GO 5@),YT_7HV^3WAG.GZ]
M&WR>\!6 DSG3]>C;Y/>&<Z?KT;?)[P%8S_ZQ?W3_ #CKG.GZ]&WR>\0YPA9\
MQF5Q\#)L'"QA66X7-;: V0$F<Z?KT;?)[PSG3]>C;Y/> K 29SI^O1M\GO#.
M=/UZ-OD]X"L!)G.GZ]&WR>\,YT_7HV^3W@.-:\SR/L+WB&B,:KSX;E+?0W+C
MK49%8E+A&9Z2^L79SI^O1M\GO 5@),YT_7HV^3WAG.GZ]&WR>\!6 DSG3]>C
M;Y/>&<Z?KT;?)[P%8"3.=/UZ-OD]X9SI^O1M\GO <J7Y4[K:_N(: QJ=/AH5
M-PY<=.%)4I-KA%:5A:><79SI^O1M\GO 1T/Y2J]?<]U(UQ@4>=#:74<9)91A
MS5J3A.$6$5B=)?4-3.=/UZ-OD]X"L!)G.GZ]&WR>\,YT_7HV^3W@*QG'Z1)Z
MHKWR';.=/UZ-OD]XA.?#SXAS*X^!DRDX6,*RW"+1;: V0$F<Z?KT;?)[PSG3
M]>C;Y/> K 29SI^O1M\GO#.=/UZ-OD]X"L!)G.GZ]&WR>\,YT_7HV^3W@.-;
M\R2_U8T1C5>?#<I,I#<N.M2D6$E+A&9_Q%V<Z?KT;?)[P%8"3.=/UZ-OD]X9
MSI^O1M\GO 5@),YT_7HV^3WAG.GZ]&WR>\!6 DSG3]>C;Y/>&<Z?KT;?)[P'
M&F?+5+K9^X@:(Q:?/AH=G&N7'22I)J3:X16E@ITEI%^<Z?KT;?)[P%8"3.=/
MUZ-OD]X9SI^O1M\GO 5@),YT_7HV^3WAG.GZ]&WR>\!6,Y?I$QU1SWT#MG.G
MZ]&WR>\0*GP\]LN97'P"C+2:L85A'A(T6V_48#: 29SI^O1M\GO#.=/UZ-OD
M]X"L!)G.GZ]&WR>\,YT_7HV^3W@)*_\ -(G7XWQ4C6'GZU.B.Q8R6Y+"S3-C
MJ,DN$=A$ZDS/["(:N<Z?KT;?)[P'*M^8IWZA7W#0&-6)\-VC3&VY<=:U,J)*
M4N$9F=GVB[.=/UZ-OD]X"L!)G.GZ]&WR>\,YT_7HV^3W@*P$F<Z?KT;?)[PS
MG3]>C;Y/> K 29SI^O1M\GO#.=/UZ-OD]X#C3?G53ZW_ -ML:(Q8$^&B1437
M+CI)<G"29N$6$6+05I:?:1_N%^<Z?KT;?)[P%8"3.=/UZ-OD]X9SI^O1M\GO
M 5@),YT_7HV^3WAG.GZ]&WR>\!6,]WTBB=4>]]H=<YT_7HV^3WB!R?#.MQG"
MEQ\ HSJ35C"L(S4W85MOU'^X!M ),YT_7HV^3WAG.GZ]&WR>\!6 DSG3]>C;
MY/>&<Z?KT;?)[P%8"3.=/UZ-OD]X9SI^O1M\GO <J[Z/U'JSGNF- 8M8GPG*
M)/;;EL+6J.XE*4N$9F9I/016B_.=/UZ-OD]X"L!)G.GZ]&WR>\,YT_7HV^3W
M@*P$F<Z?KT;?)[PSG3]>C;Y/> K 29SI^O1M\GO#.=/UZ-OD]X"/D[YL>Z],
M_P#LN#7&-R=\:EN&7,J;+41^TCD.&1_89#9    '-QQ++2W%G8A"34H_81"'
M/%/,EF4DO$-)*+!.VU5MA666F9V'S>P:0P6(TN/2\:Y%-R6^\MZ02%EC$81&
M18!F=EJ4X*2T\Q .]7>;?I+#S2R6VN5$4E1'H,C?;&N/-*CO1.2\./(227$2
MHQ&DC(["RA%A&9<YV66GZSM'I0       !@S^6')RE5'-]0K4&)+L(S:?>)!
MD1E:5MN@AO#Y?5VIT'E5RR4KD[/J;-6A1F(J6FB4TXM*%I,EJ,R))6J*T_45
MI@/8RN6/)R#5SI4NMP8\\C21L.O$A5JB(RY_:1E9]HJK'**C\GVFG:O48\)#
MIFE"GEX)*,N>P?+DTRK4ODWRCY.2*!/J,N=$C1F7&FB4PIPH;3>&;BS(B)*T
MF=I\V"/25SD_67ZGR&98DR$O02>3)J#2"<Q2LGP<(\,C(\(]&GV@/:4ZJ0:O
M#1,ITMB7&7Y+K+A+2?M*TO7]0[2I+,*(_+D.):88;4XXM7,E*2M,S^PB'P^7
MR=Y41*>J/B:NA],V6_4),-M2\KDKP#9>0EIQJQ-G-9:2%%XQ>L;<JG<NT(DQ
M%R:@I&;7*BJ0TZO#5*.-BLG+!58G^5PG22CQ2.RSU /J4B?$B4]R?(D-MQ6V
M\8MY1^*2>>VWV"DC(R(RTD?,/C$R)RT17:XJ*BM+QT*227#6M!-G@)Q1-F2C
M2O27BD1)6DU*PC/U]*A!Y4IF5)<)KE W4,"H*DO8]9L/-&2\F2R6$989'@&6
M"1**Q5O. ^R@/BO*&C\IH:ZG"IQUU5.1+;>C8+KSYK4J/:JU1.$Y9C?&(R,R
M2HK3*P?6*$<P^3]..H-N-S<F;QZ'%DM25X)81&HM!G;ZP&D
M                              RJ,9)C3%*,B(ICYF9^KQS'ZIU>I%7<
M<;IE5@S7&K,8F-(0X:+?:23.SF,0(:=?Y/5EEEM;CSCDI*$H62%*49J(B)1V
MD1_6?,/._DXBU2$X]$6S6H]*8C--MLU8D&I+VG#)M1$1FBS!TV8-O, ^B
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MS+S4AE+S+B'&EEA)6A1&E1>TC+G'89M"*HE0815=:%U'$IRA2$V$:[-.@:0
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M\XT!GQO/D_\ 5,_YP&@         #/JWR$?K;/OD- 9]6^0C];9]\AH
M   #F[\BO]$QT'-WY%?Z)@)J1YD@=6;]TA+R<\T?WF3\=8JI'F2!U9OW2$O)
MSS1_>9/QU@-<      !G1_/T[]0Q][@T1G1_/T[]0Q][@#1         !GUC
MYJSUN/\ %2- 9]8^:L];C_%2-         ?Q7DG]@_H_BO)/[ $%$]'Z=U5K
MW2&@,^B>C].ZJU[I#0        &<QZ0S>JL>^\-$9S'I#-ZJQ[[P#1   9$C
MTNIO4)7Q(XUQD2/2ZF]0E?$CC7    &?6/F+?6H_QD#0&?6/F+?6H_QD#0
M         9]"]'Z=U9OW2&@,^A>C].ZLW[I#0        &<WZ0R>J,^^X-$9
MS?I#)ZHS[[@#1         !GU+YS3>M_]M8T!GU+YS3>M_\ ;6-
M9')?T6IG5D?<-<9')?T6IG5D?< [T/S%!_4I^X: SZ'YB@_J4_<-
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M5?)A];;^\: SZKY,/K;?WC0 >?5_M#;_ +*7\5(] //J_P!H;?\ 92_BI'H
M$L_S;+_4K^XQSHWF.G]6;]TATG^;9?ZE?W&.=&\QT_JS?ND N   9U%\U-_I
MN>^H:(SJ+YJ;_3<]]0T0       !G*](F^J+]](T1G*](F^J+]](#1
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MD4/Y2J]?<]U(UQD4/Y2J]?<]U(UP    &<?I$GJBO?(:(SC](D]45[Y -$
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M,<8/GNJ_:U[@\B]^41V/.>6NG,N4M3K\>*\U(,W'76DVF1I--A$>DBTF>CF
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M@K !)C*AJT;B%7 QE0U:-Q"K@K !BU-<TXK6,CQTEE+-F"^9Z<8FS^@7K_\
MT8OQE0U:-Q"K@Y5CYJSUN/\ %2- !)C*AJT;B%7 QE0U:-Q"K@K !)C*AJT;
MB%7 QE0U:-Q"K@K !)C*AJT;B%7!_#<J&"?\VC<VL*N"P?Q7DG]@#&I"YI46
M 3<>.ILHS>":GS(S+!*RTL [/WB_&5#5HW$*N#E1/1^G=5:]TAH ),94-6C<
M0JX&,J&K1N(5<%8 ),94-6C<0JX&,J&K1N(5<%8 ),94-6C<0JX,]I<W/DLR
M8CXS)F;2QYV$6$[9IP/M]7J+GMT;8SF/2&;U5CWW@';&5#5HW$*N!C*AJT;B
M%7!6 #SSZIGA/ /$LDZ4.3@IQIX)EAL6F9X.@^;19IM/25FG6QE0U:-Q"K@C
MD>EU-ZA*^)'&N DQE0U:-Q"K@8RH:M&XA5P5@ Q:HN;D:,:Q'264L:4OF>G&
MHL_H%Z[/_/,+\94-6C<0JX.58^8M]:C_ !D#0 28RH:M&XA5P,94-6C<0JX*
MP 28RH:M&XA5P,94-6C<0JX*P 28RH:M&XA5P,94-6C<0JX*P 8M'7-*BP";
M884V4=&":GS(S+!+G+ .S]XOQE0U:-Q"K@Y4+T?IW5F_=(: "3&5#5HW$*N!
MC*AJT;B%7!6 "3&5#5HW$*N!C*AJT;B%7!6 "3&5#5HW$*N"!M<W/<@RCQ\9
MDS5I8\[+,)RS3@?;ZAM#.;](9/5&??< =L94-6C<0JX&,J&K1N(5<%8 ),94
M-6C<0JX&,J&K1N(5<%8 ),94-6C<0JX&,J&K1N(5<%8 ,6>N:<BGX<>.1E)\
M2Q\SM/%KY_$T:+?:+\94-6C<0JX.52^<TWK?_;6- !)C*AJT;B%7 QE0U:-Q
M"K@K !)C*AJT;B%7 QE0U:-Q"K@K !)C*AJT;B%7!E\G5S$\FZ>3+#"VRCHP
M5+>-)F5GK+!.S]YC?&1R7]%J9U9'W /Q1US2I$,FV(ZF\4FPU/F1F5GLP#^\
M7XRH:M&XA5P<J'YB@_J4_<- !)C*AJT;B%7 QE0U:-Q"K@K !)C*AJT;B%7
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M,CMQBK?Z!^L7XRH:M&XA5P<J-YM+]<[\10T $F,J&K1N(5<#&5#5HW$*N"L
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MGRU2ZV?N(&B DQE0U:-Q"K@8RH:M&XA5P5@ DQE0U:-Q"K@8RH:M&XA5P5@
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MXQV\&:X_TDOC';P"EM& VE!*4>"1%:H[3/[1T$6:X_TDOC';P9KC_22^,=O
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M 5@),@8Z<GBG+P9 QTY/%.7@'*I?.:;UO_MK&@,6=#:3)@$2Y'C2;#M?</\
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M6Z5.>NVWU<W> V@$F0,=.3Q3EX,@8Z<GBG+P"L!)D#'3D\4Y>#(&.G)XIR\
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M-9X+"C6R6;EV-J,[3-/B:#MTVD/RMBA.R3DN4@EOFHEFZJF+-6$7KMP+;?K
M8M4;16ORCMT6:ZO(8]).4AAMY;9K<6Z:#7:DR\E*+"]F&?M'D(\<X% Y/RX[
M\LGI7*DXSRERG%X;2'9"4HL4HRLL(B^NPK;1]&?9I[U:AU8TSVY<5"VDJ1$<
M(EMKLM0KQ-)6I29<UAE]9VT&[3<4ALH;J4H6;J+(#GB+.T\,BP+"5:9G;]9@
M,[D,I\J Y#><<=3 F2833KGE+;:=4A%NC29)(BM]=@]2,"BMTZA4B/38;4[%
M,ILPEQ'34LS.U2E'@:5&9F9G[3,:6=(_T<O@W;H"T!%G2/\ 1R^#=NAG2/\
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MFY9SN3=.E'$=B8V.E6(=6:U(T<QF>D_M,:XA*I1B(B)J61%S$4-VZ/[G2/\
M1R^#=N@+0$6=(_T<O@W;H9TC_1R^#=N@+0$6=(_T<O@W;H9TC_1R^#=N@+1E
M_P!:"ZD?OCOG2/\ 1R^#=NC-R]GPB)S DX.28-F3.6^7[,&VSZP'@:A/E/<M
M9IG.D1ZLW4V(D*.<I2$JCJ2>$HF[<%1>LSL/FYQC,U"7R0K28]<GO52+#F8U
MPF9)J(WC+1Y:B.TB/"-%AZ=!#["I^GJE)EKAO')0DTI>. YAI(^<B5@6D0Y.
MIHTA)I>I9N)-W'F2Z:LRQG3TH\KZ^<!K-N)=:2M-N"LB45I6:#'019TC_1R^
M#=NAG2/]'+X-VZ M 19TC_1R^#=NAG2/]'+X-VZ M 19TC_1R^#=NAG2/]'+
MX-VZ M 19TC_ $<O@W;H9TC_ $<O@W;H"T!%G2/]'+X-VZ&=(_T<O@W;H":H
M^?J+^F]\,QK#STV<RY6:4M*)!$VMTSPH[B3.U!EH(TVG^P:V7L="3PKET!QJ
MOR<3K;7O#1&+4IC2T1;$2-$ELSMCN%Z_K+^ OR]CH2>%<N@*P$F7L="3PKET
M,O8Z$GA7+H"L!)E['0D\*Y=#+V.A)X5RZ K'&5\U>_5J^X<LO8Z$GA7+HY/S
MV3BND2).E!\\9PO5^B ZTOS3#_4(]TA6,FG3644R*DT2+4LH([([AEY)>LDZ
M17E['0D\*Y= 5@),O8Z$GA7+H9>QT)/"N70%8"3+V.A)X5RZ&7L="3PKET!6
M,^-Y\G_JF?\ ..N7L="3PKET01YC15::LT/V+;:(K([ENC"YRLM(!M ),O8Z
M$GA7+H9>QT)/"N70%8"3+V.A)X5RZ&7L="3PKET!6 DR]CH2>%<NAE['0D\*
MY= <JM\A'ZVS[Y#0&+4IC2V(Y$F07\Y:/3'<+F67M+^ OR]CH2>%<N@*P$F7
ML="3PKET,O8Z$GA7+H"L!)E['0D\*Y=#+V.A)X5RZ K'-WY%?Z)CAE['0D\*
MY='X=GLFTLL"3Y)__LSET!_:1YD@=6;]TA+R<\T?WF3\=8_E+G-(I,)!HD&:
M6$$>#'<,O)+F,DV&)Z!+::IF"I+YGE$@_%96HM+RSYR*SU_LY@'H $F7L="3
MPKET,O8Z$GA7+H"L!)E['0D\*Y=#+V.A)X5RZ K&='\_3OU#'WN#ME['0D\*
MY=$#,QHJS,6:)%BF&2*R.Y;H-SU66ES@-H!)E['0D\*Y=#+V.A)X5RZ K 29
M>QT)/"N70R]CH2>%<N@*P$F7L="3PKET,O8Z$GA7+H#E6/FK/6X_Q4C0&+5)
MC3D5HB3(^<LGI8<+F<2?K+^'K%^7L="3PKET!6 DR]CH2>%<NAE['0D\*Y=
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M>%<N@.-)^1E=;>]XQHC%ILQI#4DC3(/^<NGXL=P^=1^POX"_+V.A)X5RZ K
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M*!JNTN0Z48R9<A.+D,.H(FB8;2E:+%-8PR,TJ(B2LDF2M)%Z_LH
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M)*7YIA_J$>Z0K        &?&\^3_ -4S_G&@,^-Y\G_JF?\ . T
M 9]6^0C];9]\AH#/JWR$?K;/OD-         <W?D5_HF.@YN_(K_ $3 34CS
M) ZLW[I"7DYYH_O,GXZQ52/,D#JS?ND)>3GFC^\R?CK :X      #.C^?IWZ
MAC[W!HC.C^?IWZAC[W &B         #/K'S5GK<?XJ1H#/K'S5GK<?XJ1H
M      #^*\D_L']'\5Y)_8 @HGH_3NJM>Z0T!GT3T?IW56O=(:         S
MF/2&;U5CWWAHC.8](9O56/?> :(  #(D>EU-ZA*^)'&N,B1Z74WJ$KXD<:X
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M)&@           SZ-YO5UA_XJQH#/HWF]76'_BK&@        ,YWTBB=4?\
M?:&B,YWTBB=4?]]H!H@         SJS\R;ZW&^,@:(SJS\R;ZW&^,@:(#(Y4
M^B-:Z@_\-0UQD<J?1&M=0?\ AJ&N       #/HWS)WK<CXRQH#/HWS)WK<CX
MRQH        \_P A?]G_ "=_LV/\-(T&?2*7U1GWW1G\A?\ 9_R=_LV/\-(T
M&?2*7U1GWW0&@         #/K'F]/6&/BH&@,^L>;T]88^*@:
M#/I'S9_K;_Q%#0&?2/FS_6W_ (BAH     ,AGTOE]09^(Z-<9#/I?+Z@S\1T
M!KC.1Z1/]4;]]8T1G(](G^J-^^L!H@         SZUYL5^M:^(D: SZUYL5^
MM:^(D:           #.I/R,KK;WO&-$9U)^1E=;>]XQH@       #.3Z1.=4
M3[ZAHC.3Z1.=43[Z@&B         #.K/FIW])'OD.7*3S"_^FW\1(ZUGS4[^
MDCWR'+E)YA?_ $V_B) :P         ,^E>3,ZVY]XT!GTKR9G6W/O&@
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M/6XG"J_$#%5/6XG"J_$%H (L54];B<*K\0,54];B<*K\06@ BQ53UN)PJOQ
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MD\@Z-1YK4UE4UZ4AQ"\=(D*<4HT-K;21V^HD.**SZB]8_*OR><GC99:5'?\
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M-N4]P#E6O-BOUK7Q$C0&+58$)NGFIN)'0K&-%:EHB/2XDC]0OS93]1C;E/<
MK 29LI^HQMRGN#-E/U&-N4]P"L!)FRGZC&W*>X,V4_48VY3W *P$F;*?J,;<
MI[@S93]1C;E/< XTGY&5UM[WC&B,6FP(;C4DUQ(Z[)+J2M:([")1V%S"_-E/
MU&-N4]P"L!)FRGZC&W*>X,V4_48VY3W *P$F;*?J,;<I[@S93]1C;E/< K&<
MGTB<ZHGWU#MFRGZC&W*>X0E A9[6WDD? *,E6#BBLMPCTV6 -D!)FRGZC&W*
M>X,V4_48VY3W *P$F;*?J,;<I[@S93]1C;E/< K 29LI^HQMRGN#-E/U&-N4
M]P#C6?-3OZ2/?(<N4GF%_P#3;^(D?BK0(35-<6W$80HE(L-+1$?E%]0X5^#$
M8HKSC49AM9+;L4ALB,K5I(](#T "3-E/U&-N4]P9LI^HQMRGN 5@),V4_48V
MY3W!FRGZC&W*>X!6 DS93]1C;E/<&;*?J,;<I[@'*E>3,ZVY]XT!C4V!"<*7
MAQ(ZL&2XDK6B.PK>;F%V;*?J,;<I[@%8"3-E/U&-N4]P9LI^HQMRGN 5@),V
M4_48VY3W!FRGZC&W*>X!6,_^L7]T_P XZYLI^HQMRGN$.00L]XO)(^!DV%@X
MHK+<+GLL ;("3-E/U&-N4]P9LI^HQMRGN 5@),V4_48VY3W!FRGZC&W*>X!6
M DS93]1C;E/<&;*?J,;<I[@'&M>9Y'V%[Q#1&-5X$)NE/K;B1T*(BL4EHB,M
M)?4+LV4_48VY3W *P$F;*?J,;<I[@S93]1C;E/< K 29LI^HQMRGN#-E/U&-
MN4]P"L!)FRGZC&W*>X,V4_48VY3W .5+\J=UM?W$- 8U.@0EJFX<2.K!DJ2F
MUHCL*PM',+LV4_48VY3W (Z'\I5>ON>ZD:XP*/!ANKJ.,C,KP)JTIPFR/!*Q
M.@OJ&IFRGZC&W*>X!6 DS93]1C;E/<&;*?J,;<I[@%8SC](D]45[Y#MFRGZC
M&W*>X0G A9\0WDD? R92L'%%9;A%ILL ;("3-E/U&-N4]P9LI^HQMRGN 5@)
M,V4_48VY3W!FRGZC&W*>X!6 DS93]1C;E/<&;*?J,;<I[@'&M^9)?ZL:(QJO
M A-TF4MN)'0I*+24EHB,OX"[-E/U&-N4]P"L!)FRGZC&W*>X,V4_48VY3W *
MP$F;*?J,;<I[@S93]1C;E/< K 29LI^HQMRGN#-E/U&-N4]P#C3/EJEUL_<0
M-$8M/@0EN3B7$CJ),DTIM:(["P4Z"T"_-E/U&-N4]P"L!)FRGZC&W*>X,V4_
M48VY3W *P$F;*?J,;<I[@S93]1C;E/< K&<OTB8ZHY[Z!VS93]1C;E/<(%0(
M>>V6\DCX!QEJ-.**PSPD:;+/K,!M ),V4_48VY3W!FRGZC&W*>X!6 DS93]1
MC;E/<&;*?J,;<I[@$E?^:1.OQOBI&L//UJ#$:BQC;C,(-4V.DS2V16D;J2,O
ML,AJYLI^HQMRGN <JWYBG?J%?<- 8U8@0VJ-,<;B1T+2RHTJ2T1&1V?8+LV4
M_48VY3W *P$F;*?J,;<I[@S93]1C;E/< K 29LI^HQMRGN#-E/U&-N4]P"L!
M)FRGZC&W*>X,V4_48VY3W .--^=5/K?_ &VQHC%@0(:I%1)<2.HD2<%)&T1X
M)8M!V%H]IG^\7YLI^HQMRGN 5@),V4_48VY3W!FRGZC&W*>X!6 DS93]1C;E
M/<&;*?J,;<I[@%8SW?2*)U1[WVAUS93]1C;E/<('($(JW&;*)'P#C.J-.**P
MS)3=AV6?6?[P&T DS93]1C;E/<&;*?J,;<I[@%8"3-E/U&-N4]P9LI^HQMRG
MN 5@),V4_48VY3W!FRGZC&W*>X!RKOH_4>K.>Z8T!BUB!";HD]QN(PA:8[BD
MJ2T1&1DD])'8+\V4_48VY3W *P$F;*?J,;<I[@S93]1C;E/< K 29LI^HQMR
MGN#-E/U&-N4]P"L!)FRGZC&W*>X,V4_48VY3W (^3OFQ[KTS_P"RX-<8W)TL
M&EN$7,F;+21>PBD.$1?81#9    'Y,B41D9$9'H,C'EU07U0(\M;#K;[TTI#
MYH;PG&D$2L B3Z["P2LL/G,[+1ZH 'F"8=C<E8+3S9MK1+C%@GSV92BPS]AF
M5AF7J,>G&37S--+2HDFHREQC))<Y_P NWH*T4Y;(V7+[35\!: BRV1LN7VFK
MX9;(V7+[35\!: BRV1LN7VFKX9;(V7+[35\!: BRV1LN7VFKX9;(V7+[35\!
M:/B?+Z"WX55=_-[\B7(3'0Q$E0'7FY^"23_F\ANQ3"DG;:5O.5IZ#.SZ_ELC
M9<OM-7PRV1LN7VFKX#QKG)ZG_G J,E%&C$94AIY#A1DZ'S=>,U$=GE\VGGYA
MX[DY1I/)^I\D*S56&&Z<W2W'2?@TXVW6W<21FB296FLL E&1\YJ(_%YA]CRV
M1LN7VFKXXO/KDM+9>I$EQIPC0M"S9-*DGH,C(UZ2,!\TJ+_)YRM<HIM?H+U4
M156&5TAS)''<J:-DB)EHR29M+PR,S\D[5$?JM'230Z@7*(^328+C5'K<B/4Y
M!8!NH:)M-K[:W#/2:EMLZ?7C%&/I2)3S:$I12924I*PDDIDB(NV/WELC9<OM
M-7P'S_D%RDI]"Y&*BU94J*_$<E/ODN$]8A&.6JVTD6'H,CT&./)[E&QR<8Y7
M)D1Y:IJJM-DQF2B/&3Y<Z+%$DR\:RSG'T!]TY;"F9%&?>:7H4VYB5)/[2-8[
M9:^16%2Y?::O@/AM2H'*"B<FJM2JA3W'D5R.Q)<Q$E4@U2D/-XXS_DTX*EI4
M1V:2\0[#,7RH-6CS)L*MQI$QFGMTUG*EM*=RN.F6I9*,K-)D@[%%ITI/GM'V
M/+9&RY?::OAELC9<OM-7P'A.3\ZBTKE)5JE!AO4RA3%18;2CAN--R)9FLC-M
MNPC25AH2:L$B,RY] CY<9RIG+L^4U-AR93U.IC2,2T1V/)<6^DT_78O$J,O8
M1CZ"\ZJ1@8ZC/N8M1+1AXD\%1<QE:O0?UCMELC9<OM-7P'PFFT21376(U1-#
M:69-00J3-H[DY"U8;-AD@K-*K#,E>RT>B+DRYRCGS(T)JD''728[!295(4A*
M;5/)4IEHS+%J+2=GV&/J>6R-F2^TU?#+9&S)?::O@K$-,5CDC4Z!#DO2Y%-@
M'%<-:5&LU&S:FT[/&,R,CT6\X^=U&6U4?R4<G*2PU).9 <@G+;=I[JTM$G0H
MU)-)$LB]:2/2/K+;JFG7G&Z/(0MU1*<4DV2-9D1$1F>'I.PB+3ZB(=\MD;+E
M]IJ^"/C%5A-K10EQW(+L9NHO&^^UR9<:9:M8(BPX]MKGU*M]9>P6(:HS'*6D
M2JK#8G4A-+DMFIF@N-LFZ;Q'83&"HTG9;I]?/ZQ];RV1LN7VFKX9;(V7+[35
M\!\V:IE6:_(HB([3YBS2Z3BH"C,WE1,>2L59SD>+L+!T&1:/J$\R72TH?F\D
M:1.I\52XS%1J,"(XT9,EAX9(;P2(S18FU9),R)1^P?4<MD;+E]IJ^&6R-ER^
MTU? ?))-9Y3%'-1U*OH2EEXZ.ZW!M5,<QJR03R<46DT$C09%H,U<X[R9?*1J
M1EDVK5F/37JI(:D.L,X>2(;-6*)*209F2E'89F2B.Q)>O3]4RV1LN7VFKX9;
M(V7+[35\!YK\G4@F^2%-ISA/HEL16U.)=86C0JVS29$1GHTD6DO78/9"++9&
MRY?::OAELC9<OM-7P%H"++9&RY?::OAELC9<OM-7P%H"++9&RY?::OAELC9<
MOM-7P%H"++9&RY?::OAELC9<OM-7P%H"++9&RY?::OAELC9<OM-7P%H"++9&
MRY?::OAELC9<OM-7P&;'-A-$JQR2<6P3THW4MVX1IPE6D5FFVSV:1\>33:74
MJ9*EH9ET>*N1&PHD:DK>R=AO#P5/89$2S,_*/Q[-%I&/L-)EO)9E8,"2Y;*>
M,S2IO1XYZ-*RTD-++9&RY?::O@,'\GYR%<CXQR(S3!FXYBR;BE')QO"/!6;9
M:$FHK#/07/S$/5B++9&RY?::OAELC9<OM-7P%H"++9&RY?::OAELC9<OM-7P
M%H"++9&RY?::OAELC9<OM-7P%H"++9&RY?::OAELC9<OM-7P%H"++9&RY?::
MOAELC9<OM-7P%HRH6%G:L8-F%AMV6\UN+(49;(V7+[35\9L*6^55J2BI\DS4
MMNU)*;M3XA<_CV?NM ?'WZ4N3 =C0*7-8EQX2V:PLHBU$IPWDJ(S39_*F16J
MLTZ#%-$:2J.Y$G,3)5&BKE5 U165L%*0KQ$8#)6*;M/#*POMM'VG+9&RY?::
MOAELC9<OM-7P'R:!28=:Y#<I5%%=AKD)Q^;8;+S"6TH18A"CL(G%'81JLYS]
MHVE4H^4)U<WDN(9A4IJ&UB34AQ2L7AJ*TM-EIDDR+GLL'O\ +9&RY?::OAEL
MC9<OM-7P'Q>KT]UJE<GI63RLXQZ6AJ)$>I!267W37Y!J5;@*LY[22=FDE#[;
M$QAPV3=0EMPVTX:$\R3LTD0Y9;(V7+[35\,MD;+E]IJ^ M 19;(V7+[35\,M
MD;+E]IJ^ M 19;(V7+[35\,MD;+E]IJ^ M 19;(V7+[35\,MD;+E]IJ^ XP?
M/=5^UKW!\?G4N9*JDN(U'>8KI29KT^3%AF2E1EI\2Q9I(EVEH(L+VCZI#EOE
M5ZDHJ?),U&W:DE-VI\7U^/9^ZT:66R-ER^TU? ?$J%#>ES51UPV2I#[K2WFH
M;#K"%$PU:LR)1)-2SM(C,OZ1:!WI3$R<BI.<F*6<+*VDQU0L2MIQN*1F9K4X
MLB);JN;G,R(_6/LV6R-ER^TU?#+9&RY?::O@/E_(^F/UIBDTJ8S*@1Z73G"-
M"%&2\)Q9I+^4LM(\ O5I&9.IF(Y'T-$I$N.U$.5B252BF(-9F9(2LE81D:M!
M$9I.VWG(?8\MD;+E]IJ^&6R-ER^TU? 3<G#FJY.4\ZC%:BRS83C6&DV);.SF
M(O5]GJ&L(LMD;+E]IJ^&6R-ER^TU? 6@(LMD;+E]IJ^&6R-ER^TU? 6@(LMD
M;+E]IJ^&6R-ER^TU? 6C+_K074C]\=\MD;+E]IJ^,W*WO"'#S?)PLDLP,)NW
MR^?R[+/V@/G]3@./<NID63$<SM*J3#D*5DJEX,,DF2['"*Q)%:9&5I:3(8J8
M3O(BLF]3X;E2C1)IM(6\P9$M\R]1)2?C$D\$E&9$9Z3'VS+9&RY?::OAELC9
M<OM-7P%+:C6TE:DF@S(C-)\Y?4.@BRV1LN7VFKX9;(V7+[35\!: BRV1LN7V
MFKX9;(V7+[35\!: BRV1LN7VFKX9;(V7+[35\!: BRV1LN7VFKX9;(V7+[35
M\!: BRV1LN7VFKX9;(V7+[35\!-4?/U%_3>^&8UAYZ;)>76:4I4*0@TK=L2I
M3=J_$/FL49?OL&ME;^SI/:;O@.-5^3B=;:]X:(QJC(=4B+;"D(LDMF5JF].G
MFT*%V5O[.D]IN^ K 296_LZ3VF[X96_LZ3VF[X"L!)E;^SI/:;OAE;^SI/:;
MO@*QQE?-7OU:ON'+*W]G2>TW?')^4\<5TC@22M0>DU-Z-'Z8#K2_-,/]0CW2
M%8RJ?)>33(B2@R%$3*")1*;L/Q2TZ5"K*W]G2>TW? 5@),K?V=)[3=\,K?V=
M)[3=\!6 DRM_9TGM-WPRM_9TGM-WP%8SXWGR?^J9_P XZY6_LZ3VF[X@CR'2
MJTU10I!F;;5J24W:7E<_C6 -H!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^
M&5O[.D]IN^ K 296_LZ3VF[X96_LZ3VF[X#E5OD(_6V??(: Q:E(>4S'MA2$
M626CM-3>GQRT:%>L7Y6_LZ3VF[X"L!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D
M]IN^&5O[.D]IN^ K'-WY%?Z)CAE;^SI/:;OC\.RWL4O_ /'R2\4_Z3=\!_:1
MYD@=6;]TA+R<\T?WF3\=8_E+D/)I,))0I"R)A!$I*F[#\4M)6JM$]!?>12\%
M,1]PLHD'A)-%FEY9V:5$>CF_9ZP'H $F5O[.D]IN^&5O[.D]IN^ K 296_LZ
M3VF[X96_LZ3VF[X"L9T?S]._4,?>X.V5O[.D]IN^(&9#I5F890I!F;#)&DE-
MVEI<T^59I_Z -H!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^
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M>GRK+"L]MND!Z !)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^
MK 296_LZ3VF[X96_LZ3VF[X#E5_FS'6V/B)&@,6IR'E1V2.%(19)9.U2F]/\
MHG1H5ZQ?E;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^ K 296_LZ3VF[X96_LZ
M3VF[X"L!)E;^SI/:;OAE;^SI/:;O@.5&\WJZP_\ %6- 8M*DNIA*(H4A98]X
M[4J;L^55HTJ]7,+\K?V=)[3=\!6 DRM_9TGM-WPRM_9TGM-WP%8"3*W]G2>T
MW?#*W]G2>TW? 5C.=](HG5'_ 'VAVRM_9TGM-WQGN2'L]Q59%(*R,\1-X3=I
M^,WI\JS19[?67U@-L!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D]I
MN^ K 296_LZ3VF[X96_LZ3VF[X#C6?F3?6XWQD#1&)5)#RX;9'#D(_G,<[34
MWZG4'9H5Z^;]OJ&AE;^SI/:;O@(^5/HC6NH/_#4-<>>Y1ONKY,59"HCS:50G
MB-Q9HP4E@'I.Q1G87U$9C6RM_9TGM-WP%8"3*W]G2>TW?#*W]G2>TW? 5@),
MK?V=)[3=\,K?V=)[3=\!RHWS)WK<CXRQH#%I<AU,1PBAR%_SE\[4J;];J]&E
M7JYOV"_*W]G2>TW? 5@),K?V=)[3=\,K?V=)[3=\!6 DRM_9TGM-WPRI[9\G
MM-WP&5R%_P!G_)W^S8_PTC09](I?5&??=&+R*DNHY"<GT)AON)*G1R):5(L5
M_)ITE:HC_@-!N2[GN2K(9!F<9HC1A-VEXSFGRK--OM]0#: 296_LZ3VF[X96
M_LZ3VF[X"L!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^ Y5CS
M>GK#'Q4#0&+59+JH1$<)]!8]D[5*;L^53HT*]?,+\K?V=)[3=\!6 DRM_9TG
MM-WPRM_9TGM-WP%8"3*W]G2>TW?#*W]G2>TW? 5@),K?V=)[3=\,K?V=)[3=
M\!RI'S9_K;_Q%#0&+3)#R8[Q%"D+MDO':E3>C^45HTJ]0ORM_9TGM-WP%8"3
M*W]G2>TW?#*W]G2>TW? 5C(9]+Y?4&?B.BS*W]G2>TW?&4V^[X325Y(^:CA-
M$;=J,(BPW-/E66?MMT /0#.1Z1/]4;]]8[96_LZ3VF[X@1)>SV\K(9%IQFRP
M,)NTO&7I\JS^/J ;0"3*W]G2>TW?#*W]G2>TW? 5@),K?V=)[3=\,K?V=)[3
M=\!6 DRM_9TGM-WPRM_9TGM-WP'*M>;%?K6OB)&@,:JR754\R5"D(+&-:5*;
ML^43[%"[*W]G2>TW? 5@),K?V=)[3=\,K?V=)[3=\!6 DRM_9TGM-WPRM_9T
MGM-WP%8"3*W]G2>TW?#*W]G2>TW? <:3\C*ZV][QC1&-39#R6I-D*0NV2Z?B
MJ;T>,>C2H796_LZ3VF[X"L!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O
M[.D]IN^ K&<GTB<ZHGWU#ME;^SI/:;OB%,E[/:UY#(MR9)8&$W;Y1Z?*L_B
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M;8:9*$GI]>DCTC?&!,AHI] C1D*-1(F1CPC*RTSD(,SL+FTF>@;X
M   /'U?E96:=RC;I$?DL[+.0E:XSI3FD$ZE!(PSL/R;#61:><>P&-,I"Y/*>
ME58G4I1"8D-*;LTJ-S%V6?9@'^\!CUC\H="IL*HNQY+<V5 4@GHK:[%Z74MG
M89E8>"I6FRVSF.RT5<H^5,BBU*DTZ%2'*E+J1.FVVE]+1))LDF=IJT?TOX#Q
M/YGY2([L1NLM&PWA9*MQMQ2SPWT.GC"-9HT$BSQ4EA6VGS#T4_D*_&JM*J7)
MV4U'>@KD.*34%O24N*=0A-MIKM(BP.8C(@%D/\H5#734R:B]FN03[D9Z+(/"
M6TZV9$LC--I8)6D>%S6*(SLM'Z;_ "@<GL?4T2)AQBI\S(UFX@_Y1>#A'@D1
M&9EY79MYK!YBH?DKJ4IA6+KR%2)>5'/6MIQM+BW[+5I2VX1G@DE*20HS3HM^
MH_U*_)I67C1D]:8:2EU#AIP'$FLSCMLKPE(4E5A&V2B21D1\R@'LJQRGB4JB
MQJBPE<_+5MM06HQD9R7%E:@B4>@B,B,S49V$1&8E;Y9,Q8LMSE%"D4-4=U#5
MLCQVW345J<4M.A>@CM(M)6';8)'.1<ISD11:.52)%1HRV'HTG%F:#6T5A$I)
M&1FDTF9&5MNGG/U\'^2G*67)CUF36X9UF+*QT=C$.'#;1BE-FC!PR5:>$:C7
M;SZ++ &TOEKR:3.8A9XBG(D8O$I2K")9+\@R46BP_4=H_4?ECR=E+=3'JT=U
M33J&E8!F?C+5@)LT:2-6BTM%H\O2OR9.4B'-CM5!MQ,A,'3BC38IA[&K.PC.
MS",SL(N8<(OY-*I%RQ358CIM6T[&82RM+*G$/$Z2UHPK$&=F"9-DDM-MGJ ;
M-6_*/2*/54Q7$..LX"C6^W_06F0EA2<&RT[#,SM]B=%MI#55RRY.H?EL+JK"
M7(9&;Y*M(D$1DE6FRP[#,B.SFMTV#RB_R<U=<@IZJK!R^QQP[(ZR:QJIB)/-
MA6X/B8-EMNGG$4O\E56F'.;77&3;?1)0A2FW#58\I*_)-> @DFDBL0DK><^>
MP!ZO\X% >G4J+"EY6=3DN1D+:([&U(1A'A6Z2YTV:/Z5O,/[4^6#\6KS:;2Z
M#,JRZ<TEV:;*T(Q>$6$E*"4=KBS3IL+ZM-IV"21R*F+Y5QZXQ.92;,Y,G%+;
M,[49,EE16D?/XIF7VCI5.3%;37:I4>3]5C13JS3;<HI3*W#94A."3C6"HBPL
M&S0?K21V^H!RD<OI++E0?:Y-37Z73E)*5*2ZE+C1&VE9F;*K%>*2BM+U6'[!
M[5IU#S2'6U$I"TDI)EZR,>$?Y&5TVJM3XM:BHIM44G*778RG)1HQ2&UV*PB3
MA*)'.9'Y1F/<QV$18S;#96-MI)";3]1 .P
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M9_SC0&?&\^3_ -4S_G :          ,^K?(1^ML^^0T!GU;Y"/UMGWR&@
M     .;OR*_T3'0<W?D5_HF FI'F2!U9OW2$O)SS1_>9/QUBJD>9('5F_=(2
M\G/-']YD_'6 UP      &='\_3OU#'WN#1&='\_3OU#'WN -$         &?
M6/FK/6X_Q4C0&?6/FK/6X_Q4C0        '\5Y)_8/Z/XKR3^P!!1/1^G=5:
M]TAH#/HGH_3NJM>Z0T        !G,>D,WJK'OO#1&<QZ0S>JL>^\ T0  &1(
M]+J;U"5\2.-<9$CTNIO4)7Q(XUP   !GUCYBWUJ/\9 T!GUCYBWUJ/\ &0-
M          !GT+T?IW5F_=(: SZ%Z/T[JS?ND-         9S?I#)ZHS[[@T
M1G-^D,GJC/ON -$         &?4OG--ZW_VUC0&?4OG--ZW_ -M8T
M !D<E_1:F=61]PUQD<E_1:F=61]P#O0_,4']2G[AH#/H?F*#^I3]PT
M  !G(](G^J-^^L:(SD>D3_5&_?6 T0         9U3^6I_6R]U0T1G5/Y:G]
M;+W5#1     3RUJ;AOK0=BDMJ-)^PR(4">6A3D-]""M4IM1)+VF9"?P/AU2Y
M75FHRH;STHR.,\2T)06"6$5MAF7MTF7[1I_G%Y1?3L;DA'.Y#UJ&Y#)YME)R
M9),M_P J1VJ,E&7\",6?FZY1?0,;XA]&--_/_MY^KFQR^KT9A#+3K"6T%8DL
M41V#I^<7E%].QN2'-CD#7I+"'FFF%-K*U)XTBM'3\W7*+Z!C?$-?I?S,]3\X
MO*+Z=C<D'YQ>47T[&Y(/S=<HOH&-\0?FZY1?0,;X@_2_F9ZGYQ>47T[&Y(/S
MB\HOIV-R0?FZY1?0,;X@_-URB^@8WQ!^E_,SU/SB\HOIV-R0Y^'U>R@Y&-8Q
MIHP,+%%S6VV#I^;KE%] QOB'/P!KV4''Q3&-)&'@XTN:VRT/TOYF>KI^<7E%
M].QN2'#P[K>5G*QC&/-O%FK%%Y-MMEG-SCO^;KE%] QOB'#P$K>5G%Q;&/)O
M&&G&EY-MEMO-SA^E_,SU=_SB\HOIV-R0?G%Y1?3L;D@_-URB^@8WQ!^;KE%]
M QOB#]+^9GJ?G%Y1?3L;D@_.+RB^G8W)!^;KE%] QOB#\W7*+Z!C?$'Z7\S/
M5S=Y?5Y[%XQUA6+62T_R1:#+UCI^<7E%].QN2'-WD#7F<7C&F$XQ9(3_ "I:
M3/U#I^;KE%] QOB#]+^9GJ?G%Y1?3L;DA)X<5K/!S\:SE!QL3A8HK,'"MYOM
M%?YNN47T#&^(2> ]:SP<#%,Y04;'8.-*S!PK.?[1)TO\?^SU5_G%Y1?3L;D@
M_.+RB^G8W)!^;KE%] QOB#\W7*+Z!C?$+^E_,SU/SB\HOIV-R0?G%Y1?3L;D
M@_-URB^@8WQ!^;KE%] QOB#]+^9GJYL<OJ]&92TTZPE">8L41CI^<7E%].QN
M2'-CD#7I+*76FF%(5S'C2(=/S=<HOH&-\0?I?S,]3\XO*+Z=C<D'YQ>47T[&
MY(/S=<HOH&-\0?FZY1?0,;X@_2_F9ZGYQ>47T[&Y(>ZY#5N=7:;)?G.)6M#N
M G!022(K/J'A?S=<HOH&-\0]UR&HDZA4V2Q.;2A:W<-."LE$96?4.?J.Q;';
M_?-8SS>L&=_6+^Z?YQHC._K%_=/\XY6VB      //<E_E*[_ &J][J!Z$>>Y
M+_*5W^U7O=0/0@,^J^3#ZVW]XT!GU7R8?6V_O&@ \^K_ &AM_P!E+^*D>@'G
MU?[0V_[*7\5(]  EG^;9?ZE?W&.=&\QT_JS?ND.D_P VR_U*_N,<Z-YCI_5F
M_=(!<   SJ+YJ;_3<]]0T1G47S4W^FY[ZAH@       #.5Z1-]47[Z1HC.5Z
M1-]47[Z0&B         #/JWR,;K;/OD- 9]6^1C=;9]\AH           ,^C
M>;2_7._$4- 9]&\VE^N=^(H:         R'?2Z)U![XC0UQD.^ET3J#WQ&@&
MN         #/J_S9CK;'Q$C0&?5_FS'6V/B)&@           SZ-YO5UA_XJ
MQH#/HWF]76'_ (JQH        #.=](HG5'_?:&B,YWTBB=4?]]H!H@
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M;WO&-$9U)^1E=;>]XQH@       #.3Z1.=43[ZAHC.3Z1.=43[Z@&B
M   #.K/FIW])'OD.7*3S"_\ IM_$2.M9\U._I(]\ARY2>87_ --OXB0&L
M      #/I7DS.MN?>- 9]*\F9UMS[QH        #/_K%_=/\XT!G_P!8O[I_
MG :          ,ZM>9Y'V%[Q#1&=6O,\C["]XAH@          ,^E^5.ZVO[
MB&@,^E^5.ZVO[B&@ R*'\I5>ON>ZD:XR*'\I5>ON>ZD:X    #./TB3U17OD
M-$9Q^D2>J*]\@&B         #.K?F27^K&B,ZM^9)?ZL:(          #.IG
MRU2ZV?N(&B,ZF?+5+K9^X@:(        SE^D3'5'/?0-$9R_2)CJCGOH :(
M     R:_\TB=?C?%2-89-?\ FD3K\;XJ1K ,^M^8IWZA7W#0&?6_,4[]0K[A
MH           ,ZF_.JGUO_MMC1&=3?G53ZW_ -ML:(        SW?2*)U1[W
MVAH#/=](HG5'O?: :          ,^N^C]1ZLY[IC0&?7?1^H]6<]TQH
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M12-J2^RU<%H (LBD;4E]EJX&12-J2^RU<%H (LBD;4E]EJX&12-J2^RU<%H
M(LBD;4E]EJX&12-J2^RU<%H (LBD;4E]EJX&12-J2^RU<%H (LBD;4E]EJX&
M12-J2^RU<%H (LBD;4E]EJX&12-J2^RU<%H (LBD;4E]EJX&12-J2^RU<%H
M,"DQ'E,RL&?);LE/$9)2WI\<].E!Z3&ED4C:DOLM7!!!->:ZB;;Z(ZRDR;'E
MIM2V>$KQC*TK2+GYR'SF).K*VTH1RDJ2J).FQXC=2?(D..J-*S<4S:FU*%&E
M)%I/UV /JN12-J2^RU<#(I&U)?9:N#$Y"SI50Y-X<N7EBV9+S"9!D5KJ$+-*
M5'9H,S(N<>H 19%(VI+[+5P,BD;4E]EJX+0 19%(VI+[+5P,BD;4E]EJX+0
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MAND_"8=3AX+C:5%A^5I*W3]8#ED4C:DOLM7 R*1M27V6K@M !%D4C:DOLM7
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M3H\FS^ WLD?VC)[+=P92O]H;?]E+^*D>@ 9DV,\F!),YTA1$THS(TMV'H/\
MW1RI4=U5(@J*;(01QVS)*4MV%XI:"M3:+I_FV7^I7]QCG1O,=/ZLW[I /WDC
M^T9/9;N!DC^T9/9;N"L &-28SJJ:V:9LA!82_%2ENSRS]J1=DC^T9/9;N#C1
M?-3?Z;GOJ&B DR1_:,GLMW R1_:,GLMW!6 "3)']HR>RW<#)']HR>RW<%8 )
M,D?VC)[+=P0JC/9[;1ETBW)E'AX+=OE)T>39_ ;(SE>D3?5%^^D!VR1_:,GL
MMW R1_:,GLMW!6 "3)']HR>RW<#)']HR>RW<%8 ),D?VC)[+=P,D?VC)[+=P
M5@ QJE'>2S'MFR%VR6B\9+>CQBTZ$B[)']HR>RW<'*K?(QNML^^0T $F2/[1
MD]ENX&2/[1D]ENX*P 29(_M&3V6[@9(_M&3V6[@K !)DC^T9/9;N!DC^T9/9
M;N"L &-2HSJJ>1E-D(+&NZ$I;L^45[4B[)']HR>RW<'*C>;2_7._$4- !)DC
M^T9/9;N!DC^T9/9;N"L $F2/[1D]ENX&2/[1D]ENX*P 29(_M&3V6[@RG([O
MA-&1E;YJ.$\9.6(PB+#;T>398=OLMT#T R'?2Z)U![XC0"S)']HR>RW<#)']
MHR>RW<%8 ),D?VC)[+=P,D?VC)[+=P5@ DR1_:,GLMW R1_:,GLMW!6 #%J<
M=Y,=DSFR%VR62L4EO1_*)TZ$^H7Y(_M&3V6[@Y5?YLQUMCXB1H ),D?VC)[+
M=P,D?VC)[+=P5@ DR1_:,GLMW R1_:,GLMW!6 "3)']HR>RW<#)']HR>RW<%
M8 ,6E1G50E&4V0@L>\5B4MV?*JTZ4^OG%^2/[1D]ENX.5&\WJZP_\58T $F2
M/[1D]ENX&2/[1D]ENX*P 29(_M&3V6[@9(_M&3V6[@K !)DC^T9/9;N#/<CO
M9[BIRV0=L9XR<P6[2\9O1Y-FFWV>HOK&V,YWTBB=4?\ ?: =LD?VC)[+=P,D
M?VC)[+=P5@ DR1_:,GLMW R1_:,GLMW!6 "3)']HR>RW<#)']HR>RW<%8 ,2
MJ1WD0VS.9(7_ #F.5AI;];J"MT)]7/\ L]8T,D?VC)[+=P<:S\R;ZW&^,@:(
M#SW*-AU')BK+5+><2F$\9MK)&"HL ]!V)([#^HR,:V2/[1D]ENX(^5/HC6NH
M/_#4-<!)DC^T9/9;N!DC^T9/9;N"L $F2/[1D]ENX&2/[1D]ENX*P 8M+CNJ
MB.&4R0C^<OE8E+?J=7ITI]?/^T7Y(_M&3V6[@Y4;YD[UN1\98T $F2/[1D]E
MNX&2/[1D]ENX*P 29(_M&3V6[@9*]M"3V6[@K !Y7D5&=7R$Y/K3-?;2=.CF
M2$I18G^33H*U)G_$:#<9W/<E.72",HS1FO!;M/QG-'DV:+/9ZQQY"_[/^3O]
MFQ_AI&@SZ12^J,^^Z ZY(_M&3V6[@9(_M&3V6[@K !)DC^T9/9;N!DC^T9/9
M;N"L $F2/[1D]ENX&2/[1D]ENX*P 8M5C.IA$9S7UECV2L4ENSY5.G0GU<XO
MR1_:,GLMW!RK'F]/6&/BH&@ DR1_:,GLMW R1_:,GLMW!6 "3)']HR>RW<#)
M']HR>RW<%8 ),D?VC)[+=P,D?VC)[+=P5@ Q:9'>5'>,ILA%DEXK$I;T_P H
MK3I3ZQ?DC^T9/9;N#E2/FS_6W_B*&@ DR1_:,GLMW R1_:,GLMW!6 "3)']H
MR>RW<&4VP[X32496^2BA-&;EB,(RPW-'DV6?LMTCT R&?2^7U!GXCH"S)']H
MR>RW<$"(SV>WDY=(M*,V>'@MVGXR]'DV?P]8VAG(](G^J-^^L!VR1_:,GLMW
M R1_:,GLMW!6 "3)']HR>RW<#)']HR>RW<%8 ),D?VC)[+=P,D?VC)[+=P5@
M QJK&=33S-4V0LL8UH4ENSY1/L2+LD?VC)[+=P<JUYL5^M:^(D: "3)']HR>
MRW<#)']HR>RW<%8 ),D?VC)[+=P,D?VC)[+=P5@ DR1_:,GLMW R1_:,GLMW
M!6 #&IL=Y34FR;(19)=+Q4MZ?&/3I2+LD?VC)[+=P<:3\C*ZV][QC1 29(_M
M&3V6[@9(_M&3V6[@K !)DC^T9/9;N!DC^T9/9;N"L $F2/[1D]ENX(4QGL]K
M1ETBW)DGAX+=OE'H\FS^ V1G)](G.J)]]0#MDC^T9/9;N!DC^T9/9;N"L $F
M2/[1D]ENX&2/[1D]ENX*P 29(_M&3V6[@9(_M&3V6[@K !C5:,ZBF.&J;(66
M$CQ5);L\HO8D<:^PZW1'E*F/N$2V_%62+#\=/L21BZL^:G?TD>^0Y<I/,+_Z
M;?Q$@*\D?VC)[+=P,D?VC)[+=P5@ DR1_:,GLMW R1_:,GLMW!6 "3)']HR>
MRW<#)']HR>RW<%8 ,:G1W5)EV39";)+A'8EO3IY]*1=DC^T9/9;N#E2O)F=;
M<^\: "3)']HR>RW<#)']HR>RW<%8 ),D?VC)[+=P,D?VC)[+=P5@ DR1_:,G
MLMW!#DSV>\#+I%N36X>"W;Y7-Y-G\!LC/_K%_=/\X#KDC^T9/9;N!DC^T9/9
M;N"L $F2/[1D]ENX&2/[1D]ENX*P 29(_M&3V6[@9(_M&3V6[@K !BU>.\BE
MOJ5.D+(B+Q5);L/27L21B_)']HR>RW<'&M>9Y'V%[Q#1 29(_M&3V6[@9(_M
M&3V6[@K !)DC^T9/9;N!DC^T9/9;N"L $F2/[1D]ENX&2/[1D]ENX*P 8U/C
MNJ5-LFR$V25$=B6].@M.E(NR1_:,GLMW!RI?E3NMK^XAH //T>.ZM51P9;Z+
M)BR/!)'C'8G2=J3T_9H&KDC^T9/9;N".A_*57K[GNI&N DR1_:,GLMW R1_:
M,GLMW!6 "3)']HR>RW<$)QGL]H1ETBW)E'AX+=OE%H\FS^ V1G'Z1)ZHKWR
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M\GO%8 ,6J3X;D9HD2HZS*2RHR)PCT$XDS/G]1"_.=/UZ-OD]XY5CYJSUN/\
M%2- !)G.GZ]&WR>\,YT_7HV^3WBL $F<Z?KT;?)[PSG3]>C;Y/>*P 29SI^O
M1M\GO'\.IP,$_P"?1N;Z5/>+!_%>2?V ,:D3X3=%@-N3(Z%HC-I4E3I$9&22
MM(RM%^<Z?KT;?)[QRHGH_3NJM>Z0T $F<Z?KT;?)[PSG3]>C;Y/>*P 29SI^
MO1M\GO#.=/UZ-OD]XK !)G.GZ]&WR>\9[4^&5=E.'+CDA49E)+QA6&9*=M*V
MWU6E^\AMC.8](9O56/?> =LYT_7HV^3WAG.GZ]&WR>\5@ \^].B'RG@O)DLF
MVF')2I>,+!(S6P9$9^T[#_<?L&KG.GZ]&WR>\1R/2ZF]0E?$CC7 29SI^O1M
M\GO#.=/UZ-OD]XK !BU:?#<AH2W+CK,I#"K"<(]!.H,SY_41&8OSG3]>C;Y/
M>.58^8M]:C_&0- !)G.GZ]&WR>\,YT_7HV^3WBL $F<Z?KT;?)[PSG3]>C;Y
M/>*P 29SI^O1M\GO#.=/UZ-OD]XK !BT>?#:HD%MR6PA:8Z"4E3A$9'@EH,K
M1?G.GZ]&WR>\<J%Z/T[JS?ND- !)G.GZ]&WR>\,YT_7HV^3WBL $F<Z?KT;?
M)[PSG3]>C;Y/>*P 29SI^O1M\GO$#<^&5;D.'+CX!QFDDK&%89DIRTK;?K+]
MXVAG-^D,GJC/ON .V<Z?KT;?)[PSG3]>C;Y/>*P 29SI^O1M\GO#.=/UZ-OD
M]XK !)G.GZ]&WR>\,YT_7HV^3WBL &+/GPU2*<:)<=1(DX2C)PCL+%K*T]/M
M,OWB_.=/UZ-OD]XY5+YS3>M_]M8T $F<Z?KT;?)[PSG3]>C;Y/>*P 29SI^O
M1M\GO#.=/UZ-OD]XK !)G.GZ]&WR>\97)V=$8Y-TYIZ2RVXB.@E(6X1&D[.8
MR'H!D<E_1:F=61]P#\T>?#:H\-MR7'0M+224E3A$9'9]HNSG3]>C;Y/>.5#\
MQ0?U*?N&@ DSG3]>C;Y/>&<Z?KT;?)[Q6 "3.=/UZ-OD]X9SI^O1M\GO%8 )
M,YT_7HV^3WB%,^%GQUS*X^ <9"25C"LMPE:+;?K&R,Y'I$_U1OWU@.V<Z?KT
M;?)[PSG3]>C;Y/>*P 29SI^O1M\GO#.=/UZ-OD]XK !)G.GZ]&WR>\,YT_7H
MV^3WBL &-4)\-;L+ EQU8,DE*L<(["P5:3TB[.=/UZ-OD]XXU/Y:G];+W5#1
M 29SI^O1M\GO#.=/UZ-OD]XK !'G.GZ]&WR>\?AZ=3WF5M*GQR2M)I,R>3;I
M%XXONXB.Z[@X6 DU66V6V$)_'J/F]7Y*<FHSU+*-)PR>G);>/*2.Q!H69GHY
MM)%I&IX%<D-=_P";2//5G\H"JA,IBF()H9B2DR%DM5JC,B45A?58H;'YU(FR
MW]Z7<.BVO[\L_P")"Y'\EGX33K\G%NJ3:I.4D5A_88H\"N2&N_\ -I$$+\I4
M2)":CYN?7BTV86&16CO^=2)LM_>EW"V]1[_4_P 5'@5R0UW_ )M(>!7)#7?^
M;2)_SJ1-EO[TNX/SJ1-EO[TNX2WJ/?ZG^*CP*Y(:[_S:0\"N2&N_\VD3_G4B
M;+?WI=P?G4B;+?WI=P6]1[_4_P 5'@5R0UW_ )M(G+D?R6R\V<H_D":)1+RD
MO*M,K+>;F#\ZD39;^]+N' ORE1,O.5FY_2T3>#AE[3.VW]HMO4>_U/\ %?X%
M<D-=_P";2)"Y(\F<[*CX_P#FI,$LG,I+R\(RLMYN;U#]_G4B;+?WI=PD+\H\
M0JLJ=F]_2P3.!AEZE&=MO[0MZCW^LG^+3\"N2&N_\VD/ KDAKO\ S:1/^=2)
MLM_>EW!^=2)LM_>EW"6]1[_4_P 5'@5R0UW_ )M(>!7)#7?^;2.U'_* Q6*J
MS ;@.-J=M\=3A6%_ >T&,6.KAG*9GZR1$2^>R>1_)9HV<3(P\-TDK_G)'@IT
MVF*/ KDAKO\ S:1ZJI^5"ZVC[C&@)W*FZ?K*Y0\+X%<D-=_YM(S"Y*<FO"DX
MF4?S3(2=P\I+R\8966\W-ZA]-& 7^T-7]E%\4P[F/=/UDRAB>!7)#7?^;2'@
M5R0UW_FTCW0!W*FZ?K)E#PO@5R0UW_FTAX%<D-=_YM(]T =RINGZR90^>PN1
M_)9^&AQ^1BW56X2<I(K-/L,4>!7)#7?^;2/543S0Q_Q>\8T [E3=/UDRAX7P
M*Y(:[_S:0\"N2&N_\VD>Z .Y4W3]9,H>%\"N2&N_\VD;5%B4.@1W&(4]K%N*
MPC)R0D](]  SBQXL7[S,_P"S*$F<Z?KT;?)[Q%E\+/A.97'P,FP<+&%9;A<U
MMHV1G?UB_NG^<17;.=/UZ-OD]X9SI^O1M\GO%8 ),YT_7HV^3WAG.GZ]&WR>
M\5@ \MR;GPVUUO&2F$854=4G"<(K2P4:2&]G.GZ]&WR>\9/)?Y2N_P!JO>Z@
M>A 8U2GPG$Q<"7'5@R6U'8X1V$1\_.+LYT_7HV^3WCE5?)A];;^\: #RRI\/
MP];=RIC%YK6G#QA66XU.BT;V<Z?KT;?)[QE*_P!H;?\ 92_BI'H &9-J,%<"
M2E$R.I1M*(B)U)F9V']8Y4JH0FZ/"0N7'2M,=LE)4ZDC(R26@](NG^;9?ZE?
MW&.=&\QT_JS?ND _><Z?KT;?)[PSG3]>C;Y/>*P 8U)GPFZ:VAR6PA1*7H4X
M1'Y9_6+LYT_7HV^3WCC1?-3?Z;GOJ&B DSG3]>C;Y/>&<Z?KT;?)[Q6 "3.=
M/UZ-OD]X9SI^O1M\GO%8 ),YT_7HV^3WB$Y\//;;F5Q\ HRDFK&%9;A)T6VC
M9&<KTB;ZHOWT@.V<Z?KT;?)[PSG3]>C;Y/>*P 29SI^O1M\GO#.=/UZ-OD]X
MK !)G.GZ]&WR>\,YT_7HV^3WBL &+4Y\-;4<D2XZC*2TH\%PCL(E%:?.+\YT
M_7HV^3WCE5OD8W6V??(: "3.=/UZ-OD]X9SI^O1M\GO%8 ),YT_7HV^3WAG.
MGZ]&WR>\5@ DSG3]>C;Y/>&<Z?KT;?)[Q6 #&I,^&W )+DMA"L:Z=BG"([#<
M49>OV"[.=/UZ-OD]XY4;S:7ZYWXBAH ),YT_7HV^3WAG.GZ]&WR>\5@ DSG3
M]>C;Y/>&<Z?KT;?)[Q6 "3.=/UZ-OD]XRG)T0^4\9XI3.+3">2:\86"1FMLR
M*WVZ#_</0#(=]+HG4'OB- +,YT_7HV^3WAG.GZ]&WR>\5@ DSG3]>C;Y/>&<
MZ?KT;?)[Q6 "3.=/UZ-OD]X9SI^O1M\GO%8 ,6J5"&Y':)$N.HRDLJ.QPCL(
MG$F9\_L%^<Z?KT;?)[QRJ_S9CK;'Q$C0 29SI^O1M\GO#.=/UZ-OD]XK !)G
M.GZ]&WR>\,YT_7HV^3WBL $F<Z?KT;?)[PSG3]>C;Y/>*P 8M*J$-N$I*Y<=
M)X]X[%.$1V&ZHR/G]9':+\YT_7HV^3WCE1O-ZNL/_%6- !)G.GZ]&WR>\,YT
M_7HV^3WBL $F<Z?KT;?)[PSG3]>C;Y/>*P 29SI^O1M\GO$#D^&=<C.%+CFA
M,9Y)JQA6$9J;L*VWZC_<8VAG.^D43JC_ +[0#MG.GZ]&WR>\,YT_7HV^3WBL
M $F<Z?KT;?)[PSG3]>C;Y/>*P 29SI^O1M\GO#.=/UZ-OD]XK !BU6?#<AMI
M1+CK,I,=1D3A'H)U!F?/ZB(S%^<Z?KT;?)[QQK/S)OK<;XR!H@//\HYT1[DO
M5F693+CKD)Y*$(<(U*,T&1$1%SF-7.=/UZ-OD]XCY4^B-:Z@_P##4-<!)G.G
MZ]&WR>\,YT_7HV^3WBL $F<Z?KT;?)[PSG3]>C;Y/>*P 8M*GPVXCA+EQT&<
MA]1$;A%H-U9D?/ZR,C%^<Z?KT;?)[QRHWS)WK<CXRQH ),YT_7HV^3WAG.GZ
M]&WR>\5@ DSG3]>C;Y/>&<X!G84Z-O4]XK !Y;D5/B,\@^3[;LIA#B:=')25
M.$1D>+3SD+VY\,JW)6<N/@*C-))6,*PS)3EI6V_67[QQY"_[/^3O]FQ_AI&@
MSZ12^J,^^Z ZYSI^O1M\GO#.=/UZ-OD]XK !)G.GZ]&WR>\,YT_7HV^3WBL
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M_(RNMO>\8T0$F<Z?KT;?)[PSG3]>C;Y/>*P 29SI^O1M\GO#.=/UZ-OD]XK
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M!22#L]NC[1C:GJD3BE?AAC:GJD3BE?A@/CT7DC6406)A4F>A]B33FR94[_\
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M"4>#I_1L&SC:GJD3BE?AAC:GJD3BE?A@+0$6-J>J1.*5^&&-J>J1.*5^& M
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MBPB([2(_6.@BQM3U2)Q2OPPQM3U2)Q2OPP%H"+&U/5(G%*_##&U/5(G%*_#
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M0JX Y5OS%._4*^X: Q:PN:='FDY'CI;Q*L(TOF9D5GLP"M_>+\94-6C<0JX
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M+F,C'0?AM"6FTMI\E)$1#]@
MPHTU-.HE6G+(U(C/2GE)+G,DJ4=G\!F\EN458J<Y<*LQ(D=UR*W-CJBJ498M
M9F6"JW^D1ES\Q^P:M/C,S*;4HLA.&T])D-N(M,K4FHR,M'U&).37))GDVZ\Z
MFHS9JU-(CM'*41XIE%N"@K"*VRT])Z3 >E                 94(R36*N9
MF1$2VS,S]7\F0U1EP2(ZO5R,K2-;=I?_ ,L@'@G_ ,H]9AQ<JF4^ 3$UA3]/
M6EU6"VDG"1_+*]EADHS(B+U#O3_RB5"II*#!@19M4:F.1G#BN83#R4(PC6A1
MF5A&9IYS/U\XU6/R=PXZWU)J]3L-DV(I&XC^:(4K"4E!X.DC/18JW1H'.%^3
M:#!*0I-2GY0^PMI<AO ;6E2S\9222G!3H(DD1)T$0#/5^4.;!I%6*>S!?JT1
MW$QFX;AXMYS%X9I\8[;4%;A6'9HY](M?Y95,DI.% 8FN-TI,U]EM6"HEJMP2
MM4=A)(B,SMM/FL%+'Y-Z,BD%3):WI\9M"D1TR&F"-C"*Q2DFVVFU1\]JK=(O
MI'(^!1HDZ+'-S%2VDL<R2-#:48!$1D7LTZ?6 \M-_*//CMT52FX,9$R 4R3(
M?:>6VU:K!L_DR/!+_>5H'TAE9.L-N$I*B6DE$I)Z#M+G+ZAY&;^3Z)*I\:GH
MJM38AMQTQ7F4+092&B5A6*M3H.WUIL.P>N9:0PRVRVG!0VDDI+V$6@@'4
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M 9\;SY/_ %3/^<!H          SZM\A'ZVS[Y#0&?5OD(_6V??(:
M YN_(K_1,=!S=^17^B8":D>9('5F_=(2\G/-']YD_'6*J1YD@=6;]TA+R<\T
M?WF3\=8#7       9T?S]._4,?>X-$9T?S]._4,?>X T0         9]8^:L
M];C_ !4C0&?6/FK/6X_Q4C0        '\5Y)_8/Z/XKR3^P!!1/1^G=5:]TA
MH#/HGH_3NJM>Z0T        !G,>D,WJK'OO#1&<QZ0S>JL>^\ T0  &1(]+J
M;U"5\2.-<9$CTNIO4)7Q(XUP   !GUCYBWUJ/\9 T!GUCYBWUJ/\9 T
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M(F^J+]](T1G*](F^J+]](#1         !GU;Y&-UMGWR&@,^K?(QNML^^0T
M          &?1O-I?KG?B*&@,^C>;2_7._$4-         9#OI=$Z@]\1H:X
MR'?2Z)U![XC0#7         !GU?YLQUMCXB1H#/J_P V8ZVQ\1(T
M   &?1O-ZNL/_%6- 9]&\WJZP_\ %6-         9SOI%$ZH_P"^T-$9SOI%
M$ZH_[[0#1         !G5GYDWUN-\9 T1G5GYDWUN-\9 T0&1RI]$:UU!_X:
MAKC(Y4^B-:Z@_P##4-<       &?1OF3O6Y'QEC0&?1OF3O6Y'QEC0
M !Y_D+_L_P"3O]FQ_AI&@SZ12^J,^^Z,_D+_ +/^3O\ 9L?X:1H,^D4OJC/O
MN@-          &?6/-Z>L,?%0- 9]8\WIZPQ\5 T           &?2/FS_6W
M_B*&@,^D?-G^MO\ Q%#0     9#/I?+Z@S\1T:XR&?2^7U!GXCH#7&<CTB?Z
MHW[ZQHC.1Z1/]4;]]8#1         !GUKS8K]:U\1(T!GUKS8K]:U\1(T
M        &=2?D976WO>,:(SJ3\C*ZV][QC1        &<GTB<ZHGWU#1&<GT
MB<ZHGWU -$         &=6?-3OZ2/?(<N4GF%_\ 3;^(D=:SYJ=_21[Y#ERD
M\PO_ *;?Q$@-8         &?2O)F=;<^\: SZ5Y,SK;GWC0        &?_6+
M^Z?YQH#/_K%_=/\ . T          9U:\SR/L+WB&B,ZM>9Y'V%[Q#1
M      9]+\J=UM?W$- 9]+\J=UM?W$- !D4/Y2J]?<]U(UQD4/Y2J]?<]U(U
MP    &<?I$GJBO?(:(SC](D]45[Y -$         &=6_,DO]6-$9U;\R2_U8
MT0          &=3/EJEUL_<0-$9U,^6J76S]Q T0       !G+](F.J.>^@:
M(SE^D3'5'/?0 T0     !DU_YI$Z_&^*D:PR:_\ -(G7XWQ4C6 9];\Q3OU"
MON&@,^M^8IWZA7W#0           9U-^=5/K?_;;&B,ZF_.JGUO_ +;8T0
M     !GN^D43JCWOM#0&>[Z11.J/>^T T          9]=]'ZCU9SW3&@,^N
M^C]1ZLY[IC0           9')WS8]UZ9_P#9<&N,CD[YL>Z],_\ LN#7
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MX,@8Z<GBG+PK !)D#'3D\4Y>#(&.G)XIR\*P 29 QTY/%.7@R!CIR>*<O"L
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M<GBG+PK !)D#'3D\4Y>#(&.G)XIR\*P 8M-AM+:DF:Y!6272\60X7,H_8?\
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MA>#(L.,T7S=RW0ISU66^OG&T,YOTAD]49]]P!VR]CH2>%<NAE['0D\*Y=%8
M),O8Z$GA7+H9>QT)/"N716 "3+V.A)X5RZ&7L="3PKET5@ Q9TQI4F 9(D>+
M)M.UAPO_ $UEHM+3S\Q"_+V.A)X5RZ.52^<TWK?_ &UC0 29>QT)/"N70R]C
MH2>%<NBL $F7L="3PKET,O8Z$GA7+HK !)E['0D\*Y=&7R=EML\FZ>VI+YJ3
M'01FAA:BYO49%8?[!OC(Y+^BU,ZLC[@'XH\QINCPT*1(,TM)(\&.XHN;VD5A
MB_+V.A)X5RZ.5#\Q0?U*?N&@ DR]CH2>%<NAE['0D\*Y=%8 ),O8Z$GA7+H9
M>QT)/"N716 "3+V.A)X5RZ($S&L]NKP9%AQD%\W<M\I7JLM_:-H9R/2)_JC?
MOK =LO8Z$GA7+H9>QT)/"N716 "3+V.A)X5RZ&7L="3PKET5@ DR]CH2>%<N
MAE['0D\*Y=%8 ,6?,:4[",D2/%DD9VQW"_HJYK2T_80OR]CH2>%<NCC4_EJ?
MULO=4-$!)E['0D\*Y=#+V.A)X5RZ*P 29>QT)/"N70R]CH2>%<NBL $F7L="
M3PKET,O8Z$GA7+HK !BTB:TW2HR%)D&9(TX,=Q1?O(K!?E['0D\*Y='&B>9H
MOZ T0$F7L="3PKET,O8Z$GA7+HK !)E['0D\*Y=#+V.A)X5RZ*P 29>QT)/"
MN71 4QK/:E8,BS)B+YNY;Y1^JRW]HVAG%Z0JZHGWS =LO8Z$GA7+HRTS&_"=
M;N"]@Y&E-F(7A6X9^JRVSZ^8;XR"]+E]03\0P%F7L="3PKET,O8Z$GA7+HK
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M*Y=#+V.A)X5RZ*P 29>QT)/"N71 Y,:.MQ5X,BPHSQ'_ "#ENE3?JLM]7/\
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MGXT=PBT.I/UD+\O8Z$GA7+HY5CS>GK#'Q4#0 29>QT)/"N70R]CH2>%<NBL
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M)/"N716 #%JLQI< TI1(MQC1^-'<(M#B?69"_+V.A)X5RZ.5:\V*_6M?$2-
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M.5*\F9UMS[QH ),O8Z$GA7+H9>QT)/"N716 "3+V.A)X5RZ&7L="3PKET5@
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M+V.A)X5RZ*P 8M7FM.4F4A*9!&:-&%'<27[S*P7Y>QT)/"N71QK?F27^K&B
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M:&>[Z11.J/>^T ZY>QT)/"N70R]CH2>%<NBL $F7L="3PKET,O8Z$GA7+HK
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M4FE0SI*VR:-:DD<\X^38TRL/Q,67K,SM4?./H^*J>MQ.%5^(&*J>MQ.%5^(
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MOQ %H"+%5/6XG"J_$#%5/6XG"J_$ 6@(L54];B<*K\0,54];B<*K\0!:,O\
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MB)GA/&(WV<;D;UBL2>"18;=I687/S:;?V>P/0 ),74-9C<.J^&+J&LQN'5?
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ME"4N+(DDRM3C?K]2U*/Z[=-H#982M#"$N.*=61$2EJLM,_;H(B_<0[
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M*<Q(5(;?92LGEH)!KT<YI+01_4-0<(\=F)&;CL-I;:;22$(3S)(N8AW
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M4_<- 9]#\Q0?U*?N&@        ,Y'I$_U1OWUC1&<CTB?ZHW[ZP&B
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M+5.+L*Q5G]$>JY%2U3>24!Q48F,!LFR3981DG1:7_P"N>T4\H:'"K],.--/
M0A1.$YHM19S\_JLYQCU"9R75 =6S7V6UMQS2TF/6%MI*Q)X-B4N$5O[-(#V(
MSE>D3?5%^^D?CD^XZ_R;I;KZU+>7#94M2SM-2C05IG]=H_:O2)OJB_?2 T0
M        9]6^1C=;9]\AH#/JWR,;K;/OD-           !GT;S:7ZYWXBAH#
M/HWFTOUSOQ%#0        &0[Z71.H/?$:&N,AWTNB=0>^(T UP         9
M]7^;,=;8^(D: SZO\V8ZVQ\1(T           &?1O-ZNL/\ Q5C0&?1O-ZNL
M/_%6-         9SOI%$ZH_[[0T1G.^D43JC_OM -$         &=6?F3?6X
MWQD#1&=6?F3?6XWQD#1 9'*GT1K74'_AJ&N,CE3Z(UKJ#_PU#7       !GT
M;YD[UN1\98T!GT;YD[UN1\98T        >?Y"_[/^3O]FQ_AI&@SZ12^J,^^
MZ,_D+_L_Y._V;'^&D:#/I%+ZHS[[H#0         !GUCS>GK#'Q4#0&?6/-Z
M>L,?%0-           !GTCYL_P!;?^(H: SZ1\V?ZV_\10T     &0SZ7R^H
M,_$=&N,AGTOE]09^(Z UQG(](G^J-^^L:(SD>D3_ %1OWU@-$         &?
M6O-BOUK7Q$C0&?6O-BOUK7Q$C0           9U)^1E=;>]XQHC.I/R,KK;W
MO&-$        9R?2)SJB??4-$9R?2)SJB??4 T0         9U9\U._I(]\A
MRY2>87_TV_B)'6L^:G?TD>^0Y<I/,+_Z;?Q$@-8         &?2O)F=;<^\:
M SZ5Y,SK;GWC0        &?_ %B_NG^<: S_ .L7]T_S@-          &=6O
M,\C["]XAHC.K7F>1]A>\0T0          &?2_*G=;7]Q#0&?2_*G=;7]Q#0
M9%#^4JO7W/=2-<9%#^4JO7W/=2-<    !G'Z1)ZHKWR&B,X_2)/5%>^0#1
M       !G5OS)+_5C1&=6_,DO]6-$          !G4SY:I=;/W$#1&=3/EJE
MUL_<0-$        9R_2)CJCGOH&B,Y?I$QU1SWT -$      9-?^:1.OQOBI
M&L,FO_-(G7XWQ4C6 9];\Q3OU"ON&@,^M^8IWZA7W#0           9U-^=5
M/K?_ &VQHC.IOSJI];_[;8T0       !GN^D43JCWOM#0&>[Z11.J/>^T T
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ME/!93&9)M4.2I2,66"9DM@B,R]I6G^\_:-7-E/U&-N4]PCD>EU-ZA*^)'&N
MDS93]1C;E/<&;*?J,;<I[A6 #%JL"&W#0IN)'09R&$VDT1:#=01ES>LC,A?F
MRGZC&W*>X<JQ\Q;ZU'^,@: "3-E/U&-N4]P9LI^HQMRGN%8 ),V4_48VY3W!
MFRGZC&W*>X5@ DS93]1C;E/<&;*?J,;<I[A6 #%H\"$Y1(+CD1A:U1T&I2FB
M,S/!+29V"_-E/U&-N4]PY4+T?IW5F_=(: "3-E/U&-N4]P9LI^HQMRGN%8 )
M,V4_48VY3W!FRGZC&W*>X5@ DS93]1C;E/<(&X$(ZW(;.)'P"C-*).**PC-3
MEIV6?47[AM#.;](9/5&??< =LV4_48VY3W!FRGZC&W*>X5@ DS93]1C;E/<&
M;*?J,;<I[A6 "3-E/U&-N4]P9LI^HQMRGN%8 ,6? AID4XD1(Z27)P5$31%:
M6+6=AZ/:1?N%^;*?J,;<I[ARJ7SFF];_ .VL: "3-E/U&-N4]P9LI^HQMRGN
M%8 ),V4_48VY3W!FRGZC&W*>X5@ DS93]1C;E/<,KD[!B/\ )NG.O1F7'%QT
M&I:VR,U'9SF8] ,CDOZ+4SJR/N ?FCP(3M'AN.1(ZUJ:2:E*:(S,[/L%V;*?
MJ,;<I[ARH?F*#^I3]PT $F;*?J,;<I[@S93]1C;E/<*P 29LI^HQMRGN#-E/
MU&-N4]PK !)FRGZC&W*>X0)@0L]NMY)'P"C(42<45EN$K399]0VAG(](G^J-
M^^L!VS93]1C;E/<&;*?J,;<I[A6 "3-E/U&-N4]P9LI^HQMRGN%8 ),V4_48
MVY3W!FRGZC&W*>X5@ QJA A(=A8$2.G"DDE5C1%:6"K0>@79LI^HQMRGN'&I
M_+4_K9>ZH:("3-E/U&-N4]P9LI^HQMRGN%8 ),V4_48VY3W!FRGZC&W*>X5@
M DS93]1C;E/<&;*?J,;<I[A6 #&I$"$Y28RW(D=:E(M-2FB,S_@+LV4_48VY
M3W#C1/,T7] :("3-E/U&-N4]P9LI^HQMRGN%8 ),V4_48VY3W!FRGZC&W*>X
M5@ DS93]1C;E/<(2@0L]J;R2/@9,2L'%%9;A'ILL&R,XO2%75$^^8#MFRGZC
M&W*>X9908GA.MG)F<7D258&++!MPS*VSVC?&07I<OJ"?B& LS93]1C;E/<&;
M*?J,;<I[A6 "3-E/U&-N4]P9LI^HQMRGN%8 ,:HP(2#B8$2.G"DH2JQHBM*P
M]',+LV4_48VY3W#E4_*A=;1]QC0 29LI^HQMRGN&"4&)X>J:R5C%YK)6!BRL
MMQIZ;!ZD>?+_ &AJ_LHOBF U<V4_48VY3W!FRGZC&W*>X5@ DS93]1C;E/<&
M;*?J,;<I[A6 #&I$"$[2V5N1(ZU'A6J4T1F?C']0NS93]1C;E/<.5$\SL?\
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MA_\ 4'@(K:9</_J ?SPDH>QT[I >$E#V.G=(']\!%;3+A_\ 4'@(K:9</_J
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MTMS"Q'-@F@K+,+_?_@ H\)*'L=.Z0'A)0]CIW2!_? 16TRX?_4'@(K:9</\
MZ@'\\)*'L=.Z0'A)0]CIW2!_? 16TRX?_4'@(K:9</\ Z@'\\)*'L=.Z0'A)
M0]CIW2!_? 16TRX?_4'@(K:9</\ Z@$TNO4AYDDM4PFU$ZVHU$VC2DEI-1?M
M(C+]HH\)*'L=.Z0)Y?(]41A+F<"7A.MMV8BSRUI3;Y7JPK?V"GP$5M,N'_U
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M:O?JU?< @I\EY-,B)*#(41,H(E$INP_%+3I4*LK?V=)[3=\*7YIA_J$>Z0K
M296_LZ3VF[X96_LZ3VF[XK !)E;^SI/:;OAE;^SI/:;OBL $F5O[.D]IN^((
M\ATJM-44*09FVU:DE-VEY7/XU@VAGQO/D_\ 5,_YP'7*W]G2>TW?#*W]G2>T
MW?%8 ),K?V=)[3=\,K?V=)[3=\5@ DRM_9TGM-WPRM_9TGM-WQ6 #%J4AY3,
M>V%(19):.TU-Z?'+1H5ZQ?E;^SI/:;OCE5OD(_6V??(: "3*W]G2>TW?#*W]
MG2>TW?%8 ),K?V=)[3=\,K?V=)[3=\5@ DRM_9TGM-WQ^'9;V*7_ /CY)>*?
M])N^+AS=^17^B8#+I<AY-)A)*%(61,((E)4W8?BEI*U5HGH+[R*7@IB/N%E$
M@\))HLTO+.S2HCT<W[/6-.D>9('5F_=(2\G/-']YD_'6 LRM_9TGM-WPRM_9
MTGM-WQ6 "3*W]G2>TW?#*W]G2>TW?%8 ),K?V=)[3=\0,R'2K,PRA2#,V&2-
M)*;M+2YI\JS3_P!!M#.C^?IWZAC[W ';*W]G2>TW?#*W]G2>TW?%8 ),K?V=
M)[3=\,K?V=)[3=\5@ DRM_9TGM-WPRM_9TGM-WQ6 #%JDAY45HCA2$626#M-
M3>FQQ.C0KU\PORM_9TGM-WQRK'S5GK<?XJ1H ),K?V=)[3=\,K?V=)[3=\5@
M DRM_9TGM-WPRM_9TGM-WQ6 "3*W]G2>TW?'\.4]@G_^/D\W2;OBP?Q7DG]@
M#&H\AY%%@I3"D+(HS9$I*F[%>*6DK5$?[Q?E;^SI/:;OCE1/1^G=5:]TAH )
M,K?V=)[3=\,K?V=)[3=\5@ DRM_9TGM-WPRM_9TGM-WQ6 "3*W]G2>TW?&<U
M(>*N2EY'(,SC,D;>$W:5BG=/E6:;?;ZC^H;@SF/2&;U5CWW@';*W]G2>TW?#
M*W]G2>TW?%8 //.ON^$\%>2/X10I)$V9HPE$:V-)>-985A<YVZ2LMTV:V5O[
M.D]IN^(Y'I=3>H2OB1QK@),K?V=)[3=\,K?V=)[3=\5@ Q:K(=5"01PY"/YR
MP=IJ;]3J#LT*]?-^T7Y6_LZ3VF[XY5CYBWUJ/\9 T $F5O[.D]IN^&5O[.D]
MIN^*P 296_LZ3VF[X96_LZ3VF[XK !)E;^SI/:;OAE;^SI/:;OBL &+1I#R*
M)"2F%(611VR(TJ;L5XI:2M41_O%^5O[.D]IN^.5"]'Z=U9OW2&@ DRM_9TGM
M-WPRM_9TGM-WQ6 "3*W]G2>TW?#*W]G2>TW?%8 ),K?V=)[3=\0(DO9[D+R&
M09G&:+ PF[2\9S3Y5G\?4-H9S?I#)ZHS[[@#ME;^SI/:;OAE;^SI/:;OBL $
MF5O[.D]IN^&5O[.D]IN^*P 296_LZ3VF[X96_LZ3VF[XK !BSI#IR*>9PI"<
M&3:1&IOQOY->@K%??[!?E;^SI/:;OCE4OG--ZW_VUC0 296_LZ3VF[X96_LZ
M3VF[XK !)E;^SI/:;OAE;^SI/:;OBL $F5O[.D]IN^,KDZ^ZWR<IR$Q'W$IC
MH(EH-%BM'.5JB/\ >0] ,CDOZ+4SJR/N ?BCR7D4>&E,*0LB:21*2INP]'UJ
M(Q?E;^SI/:;OCE0_,4']2G[AH ),K?V=)[3=\,K?V=)[3=\5@ DRM_9TGM-W
MPRM_9TGM-WQ6 "3*W]G2>TW?$"9+V>W5Y#(M.,@L#";M+QE:?*L_B-H9R/2)
M_JC?OK =LK?V=)[3=\,K?V=)[3=\5@ DRM_9TGM-WPRM_9TGM-WQ6 "3*W]G
M2>TW?#*W]G2>TW?%8 ,6?(>-V%;"D)LDD96J;\;Q5:"L5]XORM_9TGM-WQQJ
M?RU/ZV7NJ&B DRM_9TGM-WPRM_9TGM-WQ6 "3*W]G2>TW?#*W]G2>TW?%8 )
M,K?V=)[3=\,K?V=)[3=\5@ Q:1(>128R4PI"R)&A25-V'^]1&+\K?V=)[3=\
M<:)YFB_H#1 296_LZ3VF[X96_LZ3VF[XK !)E;^SI/:;OAE;^SI/:;OBL $F
M5O[.D]IN^(2DO9[4O(9%N3$6!A-V^4>GRK/XC9&<7I"KJB??,!VRM_9TGM-W
MQE)D.^$ZUY(_A9$DL7:C"LPST^599^VT>@&07I<OJ"?B& LRM_9TGM-WPRM_
M9TGM-WQ6 "3*W]G2>TW?#*W]G2>TW?%8 ,:H2'59';"D)LDH,K5-Z=!Z-"A=
ME;^SI/:;OCE4_*A=;1]QC0 296_LZ3VF[XP2D.^'JEY&_A9K(L"U%ORIZ?*L
M_B/4CSY?[0U?V47Q3 :N5O[.D]IN^&5O[.D]IN^*P 296_LZ3VF[X96_LZ3V
MF[XK !BTB2ZBE,I3!D+(L+QDJ;L/QC]JB%^5O[.D]IN^.5$\SL?\7O&- !)E
M;^SI/:;OAE;^SI/:;OBL $F5O[.D]IN^&5O[.D]IN^*P 296_LZ3VF[XARE[
M/9*R&1;DUF!A-V^5S^59_$;(SOZQ?W3_ #@.V5O[.D]IN^&5O[.D]IN^*P 2
M96_LZ3VF[X96_LZ3VF[XK !)E;^SI/:;OAE;^SI/:;OBL &-4I#JD1;84A-D
MELRM4WIT\VA0NRM_9TGM-WQRJODP^MM_>- !Y94AWP];7D;^%FM98%J+?E4Z
M?*L_B-[*W]G2>TW?&4K_ &AM_P!E+^*D>@ 9DV2\J!)(X,A)&THC,U-V%H/_
M 'ARI4AU-(@I*%(611VR)25-V'XI:2M5:+I_FV7^I7]QCG1O,=/ZLW[I /WE
M;^SI/:;OAE;^SI/:;OBL &-29+J::V284A982_&2INSRS]JA=E;^SI/:;OCC
M1?-3?Z;GOJ&B DRM_9TGM-WPRM_9TGM-WQ6 #(J#[A4N;_\ CWT83*\)5K?1
M/2=BA-R;D/)Y+TA)0I"R*$R1*2INP_$+VJM'G_RG<H2IM'336'7$2I6G":<-
M)H27/S>WV#?Y%OQGN2-/R1YQUMMHFS-Q1J42B+27.=A>PO45@#6RM_9TGM-W
MQ"J2]GMM>0R+<F46!A-V^4G3Y5G\1LC.5Z1-]47[Z0';*W]G2>TW?#*W]G2>
MTW?%8 ),K?V=)[3=\,K?V=)[3=\5@ DRM_9TGM-WPRM_9TGM-WQ6 #&J4AY3
M,>V%(19):/QE-Z?&+1H4+LK?V=)[3=\<JM\C&ZVS[Y#0 296_LZ3VF[X96_L
MZ3VF[XK !)E;^SI/:;OAE;^SI/:;OBL $F5O[.D]IN^&5O[.D]IN^*P 8U*D
MNIIY$4*0LL:[I2INSY17M4+LK?V=)[3=\<J-YM+]<[\10T $F5O[.D]IN^&5
MO[.D]IN^*P 296_LZ3VF[X96_LZ3VF[XK !)E;^SI/:;OC*<D.ERFC+R1\E%
M">(F[481EAMZ?*LL*SVVZ1Z 9#OI=$Z@]\1H!9E;^SI/:;OAE;^SI/:;OBL
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M,\1-X3=I^,WI\JS19[?67UC;&<[Z11.J/^^T [96_LZ3VF[X96_LZ3VF[XK
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M/:UY#(MR9)8&$W;Y1Z?*L_B-D9R?2)SJB??4 [96_LZ3VF[X96_LZ3VF[XK
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MH3IL5+C%H.P]+[?,9<WVBK-<?Z27QCMX!: BS7'^DE\8[>#-<?Z27QCMX!:
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MMI%I/06@]%O,0U<@8Z<GBG+P"L!)D#'3D\4Y>#(&.G)XIR\ Y5CYBWUJ/\9
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MZ<GBG+P9 QTY/%.7@'*I^5"ZVC[C&@,6HPVD9)8N1XTE!':^X?J/VGH^T7Y
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M3;6,D=PG,K5H5AMV%A85I6E;HMTV?4 ]0 R<92=H_P#/KO!C*3M'_GUW@&L
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M3EX,@8Z<GBG+P"/D[YL>Z],_^RX-<8W)S12G/8F;+26CV2'"_:?U^L;(
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M$DAY2J>X9N)+01*\327U&.,-FATYO A4HHR, V\%FF+06"9VX-A(YK3,[/K
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MZ5&9_98,Z=R,K](JSD_DK3LF)#V*CH3(;6:6^<UGC;;$F9F6"1VDG05@#ZV
MYMX>+3C,'&6%A6<UOKL'0              9-1\_47]-[X9C6&34?/U%_3>^
M&8U@&=5?DXG6VO>&B,ZJ_)Q.MM>\-$        <97S5[]6K[AV'&5\U>_5J^
MX!RI?FF'^H1[I"L24OS3#_4(]TA6        ,^-Y\G_JF?\ .- 9\;SY/_5,
M_P"<!H          SZM\A'ZVS[Y#0&?5OD(_6V??(:         YN_(K_1,=
M!S=^17^B8":D>9('5F_=(2\G/-']YD_'6*J1YD@=6;]TA+R<\T?WF3\=8#7
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MHC.1Z1/]4;]]8#1         !G5/Y:G];+W5#1&=4_EJ?ULO=4-$
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M%--+>4RI.$3:G#(\!Q1EXJ%>H;@#/HWF]76'_BK&@,^C>;U=8?\ BK&@
M    ,YWTBB=4?]]H:(SG?2*)U1_WV@&B         #.K/S)OK<;XR!HC.K/S
M)OK<;XR!H@,CE3Z(UKJ#_P -0UQD<J?1&M=0?^&H:X       ,^C?,G>MR/C
M+&@,^C?,G>MR/C+&@       #S_(7_9_R=_LV/\ #2-!GTBE]49]]T9_(7_9
M_P G?[-C_#2-!GTBE]49]]T!H          SZQYO3UACXJ!H#/K'F]/6&/BH
M&@           SZ1\V?ZV_\ $4- 9](^;/\ 6W_B*&@     R&?2^7U!GXCH
MUQD,^E\OJ#/Q'0&N,Y'I$_U1OWUC1&<CTB?ZHW[ZP&B         #/K7FQ7Z
MUKXB1H#/K7FQ7ZUKXB1H           ,ZD_(RNMO>\8T1G4GY&5UM[WC&B
M      ,Y/I$YU1/OJ&B,Y/I$YU1/OJ :(         ,ZL^:G?TD>^0Y<I/,+
M_P"FW\1(ZUGS4[^DCWR'+E)YA?\ TV_B) :P         ,^E>3,ZVY]XT!GT
MKR9G6W/O&@        ,_^L7]T_SC0&?_ %B_NG^<!H          SJUYGD?8
M7O$-$9U:\SR/L+WB&B           SZ7Y4[K:_N(: SZ7Y4[K:_N(: #(H?R
ME5Z^Y[J1KC(H?RE5Z^Y[J1K@    ,X_2)/5%>^0T1G'Z1)ZHKWR :(
M   ,ZM^9)?ZL:(SJWYDE_JQH@          ,ZF?+5+K9^X@:(SJ9\M4NMG[B
M!H@       #.7Z1,=4<]] T1G+](F.J.>^@!H@     #)K_S2)U^-\5(UADU
M_P":1.OQOBI&L SZWYBG?J%?<- 9];\Q3OU"ON&@           SJ;\ZJ?6_
M^VV-$9U-^=5/K?\ VVQH@       #/=](HG5'O?:&@,]WTBB=4>]]H!H
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M*K\0>67^4FF,K4IZG5)N*AQ,=<A;;9)0^IO&$RI.'ADNP\$[4V$K09D.,/\
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MC;TVH)ETU!HC5!MXDR"M3@J,U66&:BYSL^LK!L9HIFSHFX3W!FBF;.B;A/<
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M13-G1-PGN 6@(LT4S9T3<)[@S13-G1-PGN 6@(LT4S9T3<)[@S13-G1-PGN
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M_9_R=_LV/\-(T&?2*7U1GWW1C<BH$1[D'R?<=BL+<53HYJ4ILC,SQ:><Q>W
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MQ166X1Z;+ &R DS93]1C;E/<&;*?J,;<I[@%8"3-E/U&-N4]P9LI^HQMRGN
M5@),V4_48VY3W!FRGZC&W*>X!QK/FIW])'OD.7*3S"_^FW\1(_%6@0FJ:XMN
M(PA1*18:6B(_*+ZAPK\&(Q17G&HS#:R6W8I#9$96K21Z0'H $F;*?J,;<I[@
MS93]1C;E/< K 29LI^HQMRGN#-E/U&-N4]P"L!)FRGZC&W*>X,V4_48VY3W
M.5*\F9UMS[QH#&IL"$X4O#B1U8,EQ)6M$=A6\W,+LV4_48VY3W *P$F;*?J,
M;<I[@S93]1C;E/< K 29LI^HQMRGN#-E/U&-N4]P"L9_]8O[I_G'7-E/U&-N
M4]PAR"%GO%Y)'P,FPL'%%9;A<]E@#9 29LI^HQMRGN#-E/U&-N4]P"L!)FRG
MZC&W*>X,V4_48VY3W *P$F;*?J,;<I[@S93]1C;E/< XUKS/(^PO>(:(QJO
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M!)E;^SI/:;OAE;^SI/:;O@*P$F5O[.D]IN^&5O[.D]IN^ Y5WT?J/5G/=,:
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M"&DT]JD4B'36#4;45E#*#4=IV)*PK?W"X
M             !E491)C3%*.PBF/F9_\9CSS/Y2*;+@394&%/E8B<F PVALD
MKDNJ3A%@DHRL3SZ56:"M'HZ)\A+ZZ_[YCRSO(NJM.U29!FQ4S'JNFIQB<2K
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M- 9\;SY/_5,_YP&@         #/JWR$?K;/OD- 9]6^0C];9]\AH
M#F[\BO\ 1,=!S=^17^B8":D>9('5F_=(2\G/-']YD_'6*J1YD@=6;]TA+R<\
MT?WF3\=8#7       9T?S]._4,?>X-$9T?S]._4,?>X T0         9]8^:
ML];C_%2- 9]8^:L];C_%2-         ?Q7DG]@_H_BO)/[ $%$]'Z=U5KW2&
M@,^B>C].ZJU[I#0        &<QZ0S>JL>^\-$9S'I#-ZJQ[[P#1   9$CTNI
MO4)7Q(XUQD2/2ZF]0E?$CC7    &?6/F+?6H_P 9 T!GUCYBWUJ/\9 T
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M@,^K_-F.ML?$2-           !GT;S>KK#_Q5C0&?1O-ZNL/_%6-
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M#/I%+ZHS[[HY6V@         #/K'F]/6&/BH&@,^L>;T]88^*@:
M  #/I'S9_K;_ ,10T!GTCYL_UM_XBAH     ,AGTOE]09^(Z-<9#/I?+Z@S\
M1T!KC.1Z1/\ 5&_?6-$9R/2)_JC?OK :(         ,^M>;%?K6OB)&@,^M>
M;%?K6OB)&@           SJ3\C*ZV][QC1&=2?D976WO>,:(        SD^D
M3G5$^^H:(SD^D3G5$^^H!H@         SJSYJ=_21[Y#ERD\PO\ Z;?Q$CK6
M?-3OZ2/?(<N4GF%_]-OXB0&L         #/I7DS.MN?>- 9]*\F9UMS[QH
M      #/_K%_=/\ .- 9_P#6+^Z?YP&@         #.K7F>1]A>\0T1G5KS/
M(^PO>(:(          #/I?E3NMK^XAH#/I?E3NMK^XAH ,BA_*57K[GNI&N,
MBA_*57K[GNI&N     SC](D]45[Y#1&<?I$GJBO?(!H@         SJWYDE_
MJQHC.K?F27^K&B           SJ9\M4NMG[B!HC.IGRU2ZV?N(&B
M,Y?I$QU1SWT#1&<OTB8ZHY[Z &B      ,FO_-(G7XWQ4C6&37_FD3K\;XJ1
MK ,^M^8IWZA7W#0&?6_,4[]0K[AH           ,ZF_.JGUO_MMC1&=3?G53
MZW_VVQH@       #/=](HG5'O?:&@,]WTBB=4>]]H!H          SZ[Z/U'
MJSGNF- 9]=]'ZCU9SW3&@           R.3OFQ[KTS_[+@UQD<G?-CW7IG_V
M7!K@     FG+<;I\E3"D)>2THT*6=B258=AG]5H\W$D2''W8JI,A"4I94A+K
MR<-QPR7:@EE;82L$C^PM&@R :]?(U4M*24:3.7&(E%SE_+MZ2M%.12-J2^RU
M<&-E"Y7)2"ZZHUNG*C)6I166J*0@C^W27/Z^<>F 19%(VI+[+5P,BD;4E]EJ
MX+0 19%(VI+[+5P,BD;4E]EJX+0 19%(VI+[+5P,BD;4E]EJX+1\CY257E&[
MRVY10*7*KRG(D:.J S3&V5-)=6A1_P MC"/Q341>OFP@'T_(I&U)?9:N!D4C
M:DOLM7!\[=_*C.CRZDR=(2XU!.1'6_8\E*I##"W5F1XLT8!J0I)%AX?KLLYN
MZN7O*4K<'D_3S4AJ(ZXT<]9++*G%-M)+^3LM(\#"/F+39;Z@][D4C:DOLM7
MR*1M27V6K@^9SN6U??F(;B-M1Z@@T1W6<HPHQK3/3'696MX7C<UOJ2H]%I$9
M[/*KE7-H7*U+$=EZ3_\ B\:4<G/Y-2U2&V\+!2A2S,B49^+:9D5A%:=H#V>1
M2-J2^RU<#(I&U)?9:N#YXU^5*2MZEVTF.F-(6E$F1CW<%M2I"F;/DBP#\7#_
M )3 MTIYR'[+\J,A')Z'57::P@WX#TI;:G\$DJ0^VT181ES>/:>@ST6$1F ^
M@9%(VI+[+5P,BD;4E]EJX/G#7Y3JO*9<1#HT54IA4Q+Q//.MI_D$-+,R)39+
M*TG#+!-):;--@K;_ "FON4]VLII<8J,PA*73<FDA_&G&Q]B4J21*+22+".WG
M.RP@'O,BD;4E]EJX&12-J2^RU<'FN1?*^7RF?FQIU+7!>C-M/$>"ZE*T.85E
MA.(0=I8)D9D1D?.1CV0"+(I&U)?9:N!D4C:DOLM7!: "+(I&U)?9:N!D4C:D
MOLM7!: "+(I&U)?9:N!D4C:DOLM7!: "+(I&U)?9:N!D4C:DOLM7!: "+(I&
MU)?9:N!D4C:DOLM7!: "+(I&U)?9:N!D4C:DOLM7!: "+(I&U)?9:N!D4C:D
MOLM7!: "+(I&U)?9:N!D4C:DOLM7!: "+(I&U)?9:N!D4C:DOLM7!: "+(I&
MU)?9:N!D4C:DOLM7!: "+(I&U)?9:N!D4C:DOLM7!: "+(I&U)?9:N!D4C:D
MOLM7!: # I,1Y3,K!GR6[)3Q&24MZ?'/3I0>DQI9%(VI+[+5P929BZ=R<K<Y
MLDJ<C.2WDI5S&:349$?[AB\BYU5<J"XTZLG5&Y%/9GDLTH+%+6:B-)8-GB^+
M:1>KV@/7Y%(VI+[+5P,BD;4E]EJX+0 19%(VI+[+5P,BD;4E]EJX+0 19%(V
MI+[+5P,BD;4E]EJX+0 19%(VI+[+5P,BD;4E]EJX+0 19%(VI+[+5P,BD;4E
M]EJX+0 19%(VI+[+5P9L*(^=5J22J$DC2MNU1);M5XA<_B6?NL&^,NG^>:M^
MFU\,@'?(I&U)?9:N!D4C:DOLM7!X(ZQ7#KG*Z'4:U&I[4-AAQI]M'B1D*TF9
M81':HR]9ESGH(<:16>4TI5,A(F&:I+[\F*NH)P'W(J$V(QI((B\92B]5MA>T
M!]#R*1M27V6K@9%(VI+[+5P>%?G\J4?D_K#S=4C9SBRI*'99LG8E"#/0VBWG
M]16G]8Z3*O7Y;TE-)EDT<"DMN.KD-VM&\M.$:M&E2B389%:16GI >VR*1M27
MV6K@9%(VI+[+5P?*:I7^4.:J-4SJ$XZ>Q34R:B<&1';?-1KLPC2LC,RL]1)(
MC]H^MQ'4O0V'D&HTN-I41K\HR,K=/U@.612-J2^RU<#(I&U)?9:N"T $612-
MJ2^RU<#(I&U)?9:N"T $612-J2^RU<#(I&U)?9:N"T &!#B/G5ZDDJA)(TFW
M:HDMVJ\7U^)9^ZP:612-J2^RU<'&#Y[JOVM>X/-RIE?3RSG0E5*''C*IRWHO
M\F9I9L59AN6GI/U^HB^L!ZK(I&U)?9:N!D4C:DOLM7!\UIU;K,AAF/%K,Z3&
MGU!IF#.E,MDMY"2M>6C!27\F9E81F7,>@74NL<JY#/+)M<Z&N="DX+!J;/$L
M(P+?%(M*C+ZSTF ]YD4C:DOLM7 R*1M27V6K@\+3*URAJ\>@1X$E*IBJ<N7)
M>?L)"U&>"C#))6V6VG85@QWZURFG<F:.IN?(5(+*79JX<IAAUQ"+?)2X2CL*
MSU)/[0'U+(I&U)?9:N!D4C:DOLM7!/R?GM57D_!GL./K;?92M*I!$3AZ/Z5A
M$5O[!J@(LBD;4E]EJX&12-J2^RU<%H (LBD;4E]EJX&12-J2^RU<%H (LBD;
M4E]EJX,W)'O"' SA)PLDMP\%NWR^;R++/V#?&7_6@NI'[X#OD4C:DOLM7 R*
M1M27V6K@^?2^4%;=Y35%^).>2W#J3--;@$V@VUDM)VK5HPK;;#MMYBYAEP>5
M'*&B5A$+E74)#;;,C'/J:0EP[#([$VH39B_Z6FPR+G ?5<BD;4E]EJX&12-J
M2^RU<%2%I<02T*)25%:1D=I&0_8"+(I&U)?9:N!D4C:DOLM7!: "+(I&U)?9
M:N!D4C:DOLM7!: "+(I&U)?9:N!D4C:DOLM7!: "+(I&U)?9:N!D4C:DOLM7
M!: #STV,\BLTI*ILA9J6[8I26[4>(?-8DB_?:-;)']HR>RW<$E1\_47]-[X9
MC6 8U1CNI1%MFR%VR6R*U+>C3SZ$B[)']HR>RW<'&J_)Q.MM>\-$!)DC^T9/
M9;N!DC^T9/9;N"L $F2/[1D]ENX&2/[1D]ENX*P 29(_M&3V6[@Y/Q7BBNF<
M^2=B#T&EO3H_0&@.,KYJ]^K5]P""GQGE4R(HITA)&R@R226["\4M&E(JR1_:
M,GLMW I?FF'^H1[I"L!)DC^T9/9;N!DC^T9/9;N"L $F2/[1D]ENX&2/[1D]
MENX*P 29(_M&3V6[@@CQG3JTU)39!&3;5JB2W:?E<_BV#:&?&\^3_P!4S_G
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M"]'Z=U9OW2&@ DR1_:,GLMW R1_:,GLMW!6 "3)']HR>RW<#)']HR>RW<%8
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MJM\C&ZVS[Y#0 29(_M&3V6[@9(_M&3V6[@K !)DC^T9/9;N!DC^T9/9;N"L
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MC.3Z1.=43[Z@';)']HR>RW<#)']HR>RW<%8 ),D?VC)[+=P,D?VC)[+=P5@
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MTI%V2/[1D]ENX.5+\J=UM?W$- !Y^CQW5JJ.#+?19,61X)(\8[$Z3M2>G[-
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M,N8U6:?XCCC:GJD3BE?AAC:GJD3BE?A@+0$6-J>J1.*5^&&-J>J1.*5^& M
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M&XA5P01US<[33)B.:\6UA$;YV%Y5EAX&G]P#: 28RH:M&XA5P,94-6C<0JX
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M&XA5P,94-6C<0JX \UX"IVB>Y_U!X"IVB>Y_U#TN,J&K1N(5<#&5#5HW$*N
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M1/<_Z@\!4[1/<_ZAZ7&5#5HW$*N!C*AJT;B%7 'FO 5.T3W/^H/ 5.T3W/\
MJ'I<94-6C<0JX&,J&K1N(5< >1A<CREL*<RXTX+SC=F*M\A:DV\_KLM%/@*G
M:)[G_4-:EKFE$<Q;$=192_:9OF6G&KM_H'Z[?_',+\94-6C<0JX \UX"IVB>
MY_U!X"IVB>Y_U#TN,J&K1N(5<#&5#5HW$*N /-> J=HGN?\ 4">0R4J(\X'H
M.WY'_P CTN,J&K1N(5<#&3]6C<0JX \'R7Y)%4>25&FY:;>/@LN8&*MP;4$=
MEMHN3R/)50=BY<?\FRAS"Q7/A&LK++?]W^(OY%+F%R%Y/DTRPIHJ='P5*>-)
MF6+3SE@'9^\:#:YV>Y)E'CXS)FK2QYV$6$Y9IP/M]7_@,GP%3M$]S_J#P%3M
M$]S_ *AZ7&5#5HW$*N!C*AJT;B%7 'FO 5.T3W/^H/ 5.T3W/^H>EQE0U:-Q
M"K@8RH:M&XA5P!YKP%3M$]S_ *@\!4[1/<_ZAZ7&5#5HW$*N!C*AJT;B%7 '
MD9G(\HD<G<O-=KC:+,59Y2R3;S_6*? 5.T3W/^H:U47,R$L8Q'26/9TI?,SM
MQJ;/Z!>L7XRH:M&XA5P!YKP%3M$]S_J#P%3M$]S_ *AZ7&5#5HW$*N!C*AJT
M;B%7 'FO 5.T3W/^H/ 5.T3W/^H>EQE0U:-Q"K@8RH:M&XA5P!YKP%3M$]S_
M *@\!4[1/<_ZAZ7&5#5HW$*N!C*AJT;B%7 'D8?(\I33B\N-. \XW9BK;<%1
MIMY_J%/@*G:)[G_4-:F*FY,]BX\=192];A/F6G&*M_H'ZQ?C*AJT;B%7 'FO
M 5.T3W/^H/ 5.T3W/^H>EQE0U:-Q"K@8RH:M&XA5P!YKP%3M$]S_ *A&GDF2
MJN[!RX[&XZ'L/%<^$I1666_[O\1['&5#5HW$*N#+;7,\)Y)DPQC<C:M3CCP2
M+#<L.W!Y^?19^T!G> J=HGN?]0F3R.(Z@Y%R\_$:2YA8KGM-16<_^Z/78RH:
MM&XA5P0(7-SV\>3Q\9DS=I8\[+,)?KP/M]0#)\!4[1/<_P"H/ 5.T3W/^H>E
MQE0U:-Q"K@8RH:M&XA5P!YKP%3M$]S_J#P%3M$]S_J'I<94-6C<0JX&,J&K1
MN(5< >:\!4[1/<_Z@\!4[1/<_P"H>EQE0U:-Q"K@8RH:M&XA5P!Y&;R/*'%-
M[+S78M";,59Y2B3[?K%/@*G:)[G_ %#6JJYN;SQC$=*<8UI2^9G\HFS^@0OQ
ME0U:-Q"K@#S7@*G:)[G_ %!X"IVB>Y_U#TN,J&K1N(5<#&5#5HW$*N /-> J
M=HGN?]0> J=HGN?]0]+C*AJT;B%7 QE0U:-Q"K@#S7@*G:)[G_4'@*G:)[G_
M %#TN,J&K1N(5<#&5#5HW$*N /(Q.2!2D.JR\TXMY;?R5MN"=EO.*? 5.T3W
M/^H:],7,)J3@1XY_SEVW"?,K#PCM_H"[&5#5HW$*N /-> J=HGN?]0> J=HG
MN?\ 4/2XRH:M&XA5P,94-6C<0JX \UX"IVB>Y_U!X"IVB>Y_U#TN,J&K1N(5
M<#&5#5HW$*N /-> J=HGN?\ 4)BY'$=05$R\]#1.86*]IF5G/]0]=C*AJT;B
M%7! E<W/:SR>/C,F3HQYV681^O _Z ,GP%3M$]S_ *@\!4[1/<_ZAZ7&5#5H
MW$*N!C*AJT;B%7 'FO 5.T3W/^H/ 5.T3W/^H>EQE0U:-Q"K@8RH:M&XA5P!
MYKP%3M$]S_J#P%3M$]S_ *AZ7&5#5HW$*N!C*AJT;B%7 'D9O(XHD13^7FO!
M-)68JSG,B]OUCG4N214ZGN2BFFY@*26#BK+;5$7M^L>CJJYITQPG(\=*<)%I
MI?,S\HO5@$.-?7,.BO$ZPPE&&W::'C4?EILT8)?> S_ 5.T3W/\ J#P%3M$]
MS_J'I<94-6C<0JX&,J&K1N(5< >:\!4[1/<_Z@\!4[1/<_ZAZ7&5#5HW$*N!
MC*AJT;B%7 'FO 5.T3W/^H/ 5.T3W/\ J'I<94-6C<0JX&,J&K1N(5< >1B<
MCBDD]_/C3BWE-_)6VV>OG%/@*G:)[G_4->FKFDF7@1XY_P Y<MM?,K#M_0%V
M,J&K1N(5< >:\!4[1/<_Z@\!4[1/<_ZAZ7&5#5HW$*N!C*AJT;B%7 'FO 5.
MT3W/^H/ 5.T3W/\ J'I<94-6C<0JX&,J&K1N(5< >:\!4[1/<_ZA-X'%G#)<
MO/Y+&86*^NRSG'KL94-6C<0JX(,.;GNW)X^,R;FQYV687MP/^@#)\!4[1/<_
MZ@\!4[1/<_ZAZ7&5#5HW$*N!C*AJT;B%7 'FO 5.T3W/^H/ 5.T3W/\ J'I<
M94-6C<0JX&,J&K1N(5< >:\!4[1/<_Z@\!4[1/<_ZAZ7&5#5HW$*N!C*AJT;
MB%7 'D9O(\HD-R1EYKP+/%Q5ENFSVBGP%3M$]S_J&M5ES3I3Y.,1TIL*TTOF
M9\Y>K (7XRH:M&XA5P!YKP%3M$]S_J#P%3M$]S_J'I<94-6C<0JX&,J&K1N(
M5< >:\!4[1/<_P"H/ 5.T3W/^H>EQE0U:-Q"K@8RH:M&XA5P!YKP%3M$]S_J
M#P%3M$]S_J'I<94-6C<0JX&,J&K1N(5< >1B\CBDG(++C3BGC;^2MML(M//]
M8I\!4[1/<_ZAKT]<PE3,"/'/^<JPK7S*P["_W-(NQE0U:-Q"K@#QT'DD4Q4L
MLM-&(D*9^2MPK"([>?ZQ9X"IVB>Y_P!0T:.N82ZEBV&%6S%X6$\96'8G07BG
M:7UZ/L&IC*AJT;B%7 'FO 5.T3W/^H/ 5.T3W/\ J'I<94-6C<0JX&,J&K1N
M(5< >:\!4[1/<_ZA,?(XBJ"8F7GI:-S"Q7L,BLY_K'KL94-6C<0JX(#7-SV@
M\GCXS)E:,>=EF$7KP/\ H R? 5.T3W/^H/ 5.T3W/^H>EQE0U:-Q"K@8RH:M
M&XA5P!YKP%3M$]S_ *@\!4[1/<_ZAZ7&5#5HW$*N!C*AJT;B%7 'FO 5.T3W
M/^H/ 5.T3W/^H>EQE0U:-Q"K@8RH:M&XA5P!Y&;R.*'!>D%.->+3;@XJRW^(
MI\!4[1/<_P"H:U67-.D2B<CQTHP-)I?,S+]F 0OQE0U:-Q"K@#S7@*G:)[G_
M %!X"IVB>Y_U#TN,J&K1N(5<#&5#5HW$*N /-> J=HGN?]0> J=HGN?]0]+C
M*AJT;B%7 QE0U:-Q"K@#S7@*G:)[G_4'@*G:)[G_ %#TN,J&K1N(5<#&5#5H
MW$*N /(Q>1Y2%R4Y<:<2\;?R5MN@CMY_K%/@*G:)[G_4->GKF$[.P([!F<D\
M*U\RL/!3S>)I%V,J&K1N(5< >:\!4[1/<_Z@\!4[1/<_ZAZ7&5#5HW$*N!C*
MAJT;B%7 'FO 5.T3W/\ J#P%3M$]S_J'I<94-6C<0JX&,J&K1N(5< >:\!4[
M1/<_ZA,KD>15!$7+S\9E3F%BN:PTE99;]8]=C*AJT;B%7! I<W/;)Y/'QF3+
ML+'G99A(]>!]GJ 9/@*G:)[G_4'@*G:)[G_4/2XRH:M&XA5P,94-6C<0JX \
MUX"IVB>Y_P!0> J=HGN?]0]+C*AJT;B%7 QE0U:-Q"K@#QU1Y)E!99<*:I>,
MD-,V8JRS#62;>?U6BSP%3M$]S_J&A6ES#BQ<:RPDLMC^2Z:K3QJ;"\DM%OK]
M7L,:N,J&K1N(5< >1G<CRA0'Y)3C7BD&O!Q5EMG[13X"IVB>Y_U#6K"YIT>:
M3D>.EO$JPC2^9F16>S *W]XOQE0U:-Q"K@#S7@*G:)[G_4'@*G:)[G_4/2XR
MH:M&XA5P,94-6C<0JX \UX"IVB>Y_P!0> J=HGN?]0]+C*AJT;B%7 QE0U:-
MQ"K@#S7@*G:)[G_4'@*G:)[G_4/2XRH:M&XA5P,94-6C<0JX \C&Y'E(=E(R
MXTXA[%VXJW"\5*K>?_>%/@*G:)[G_4-: N:4BH8$>.9G)\>U\RL/%HYO$TZ+
M/8+\94-6C<0JX \UX"IVB>Y_U!X"IVB>Y_U#TN,J&K1N(5<#&5#5HW$*N /+
MKY#&3:C;J%J[/%)35A&?[Q_.2421!K,V/*:-MU+*=!\QE;SD?K(>IQE0U:-Q
M"K@8<^VW)HMO6%7 %8SW?2*)U1[WVAUQE0U:-Q"K@@<7-SW&,X\?&9,[86/.
MPRPF[=.!]GJ ;0"3&5#5HW$*N!C*AJT;B%7 %8"3&5#5HW$*N!C*AJT;B%7
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MG+:='D8;2L:V2L)A>$@[2_HF9%:7[!8(J53(U&I4:FPT8$>,V3;9?40M
M    &7_6@NI'[XU!E_UH+J1^^ \U-Y<RH]=DL,T]AVFQ)2(3[QR#2[CED9E@
MIP;+.8M)^L0\GORBS:W+9BO08\-Q<DR6XXM9(2R6BS21?RF%XMG-;[1M/<B&
M5\HEU-J>\U%=D(F2(1-I4EUY!6)5A&1F1>TBYQ!7?R<-5^4_+D51Q,IV02R<
M*.@\!HBL)LO61EI/"MMMT@/> .;:";;2@C49)(BM4=IG]ICH
M  ,FH^?J+^F]\,QK#)J/GZB_IO?#,:P#.JOR<3K;7O#1&=5?DXG6VO>&B
M     .,KYJ]^K5]P[#C*^:O?JU?< Y4OS3#_ %"/=(5B2E^:8?ZA'ND*P
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M><BYM ]V EG^;9?ZE?W&.=&\QT_JS?ND.D_S;+_4K^XQSHWF.G]6;]T@%P
M#.HOFIO]-SWU#1&=1?-3?Z;GOJ&B        ,Y7I$WU1?OI&B,Y7I$WU1?OI
M :(         ,^K?(QNML^^0T!GU;Y&-UMGWR&@           SZ-YM+]<[\
M10T!GT;S:7ZYWXBAH        #(=]+HG4'OB-#7&0[Z71.H/?$: :X
M   ,^K_-F.ML?$2- 9]7^;,=;8^(D:           #/HWF]76'_BK&@,^C>;
MU=8?^*L:         SG?2*)U1_WVAHC.=](HG5'_ 'V@&B         #.K/S
M)OK<;XR!HC.K/S)OK<;XR!H@,CE3Z(UKJ#_PU#7&1RI]$:UU!_X:AK@
M  SZ-\R=ZW(^,L: SZ-\R=ZW(^,L:        //\A?\ 9_R=_LV/\-(T&?2*
M7U1GWW1G\A?]G_)W^S8_PTC09](I?5&??= :          ,^L>;T]88^*@:
MSZQYO3UACXJ!H           ,^D?-G^MO_$4- 9](^;/];?^(H:     #(9]
M+Y?4&?B.C7&0SZ7R^H,_$= :XSD>D3_5&_?6-$9R/2)_JC?OK :(
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M5IJ#6_8AMHRLD.6Z<+G.VTQM#/C>?)_ZIG_. ZY QTY/%.7@R!CIR>*<O"L
M$F0,=.3Q3EX,@8Z<GBG+PK !)D#'3D\4Y>#(&.G)XIR\*P 8M2AM(8CF2I!_
MSEHM,AP^=9>T_P"(OR!CIR>*<O#E5OD(_6V??(: "3(&.G)XIR\&0,=.3Q3E
MX5@ DR!CIR>*<O!D#'3D\4Y>%8 ),@8Z<GBG+P_#L!DFEGAR?)/_ /:7+PN'
M-WY%?Z)@,NEP6ETF$LUR"-3"#/!D.$7DES$2K"$] B-.TS"4I\CRB07BO+26
MAY9<Q'9ZOV\XTZ1YD@=6;]TA+R<\T?WF3\=8"S(&.G)XIR\&0,=.3Q3EX5@
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M!D#'3D\4Y>%8 ),@8Z<GBG+P9 QTY/%.7A6 "3(&.G)XIR\&0,=.3Q3EX5@
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M:&<CTB?ZHW[ZP';(&.G)XIR\&0,=.3Q3EX5@ DR!CIR>*<O!D#'3D\4Y>%8
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M&0,=.3Q3EX5@ DR!CIR>*<O"#(VL]X.%(LR:WYPY;Y7MMM_8-H9_]8O[I_G
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M5RZ*P 29>QT)/"N71 W,:*MR%X,BPXS1?-W+="G/59;Z^<;0SF_2&3U1GWW
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M)PJOQ %H"+%5/6XG"J_$#%5/6XG"J_$ 6@(L54];B<*K\0,54];B<*K\0!:
MBQ53UN)PJOQ Q53UN)PJOQ %H"+%5/6XG"J_$#%5/6XG"J_$ 35'S]1?TWOA
MF-8>>G(FE6J43LB.I9K=P#2PHB+Q#MM+#.W1]@UL74-9C<.J^ XU7Y.)UMKW
MAHC&J2)A(C8<B.?\Y;LL8,K#MT?TQ=BZAK,;AU7P%8"3%U#68W#JOABZAK,;
MAU7P%8"3%U#68W#JOABZAK,;AU7P%8XROFKWZM7W#EBZAK,;AU7QR?;GY*[;
M)C&6 =MD=7L_3 =:7YIA_J$>Z0K&53D33IL0T2(Y)Q*+"-A1F18)>O#%6+J&
MLQN'5? 5@),74-9C<.J^&+J&LQN'5? 5@),74-9C<.J^&+J&LQN'5? 5C/C>
M?)_ZIG_..N+J&LQN'5?$$=$W.TTB?CDLFVL(S8.P_*LL+#T?O ;0"3%U#68W
M#JOABZAK,;AU7P%8"3%U#68W#JOABZAK,;AU7P%8"3%U#68W#JOABZAK,;AU
M7P'*K?(1^ML^^0T!BU)$W$1\9(CF64M68+!EIPRL_IF+\74-9C<.J^ K 28N
MH:S&X=5\,74-9C<.J^ K 28NH:S&X=5\,74-9C<.J^ K'-WY%?Z)CABZAK,;
MAU7Q^'6Y^*7;)C68)_\ [.J^ _M(\R0.K-^Z0EY.>:/[S)^.L?REHFG2(9HD
M,)1B$8)*849D6"7.>&5HGH*)ATNUI]A*<HD6DIDU';CEVZ<(O7;_ .><!Z !
M)BZAK,;AU7PQ=0UF-PZKX"L!)BZAK,;AU7PQ=0UF-PZKX"L9T?S]._4,?>X.
MV+J&LQN'5?$#*)N>9EDB/C,0SA&;!V&5KEFC#^WU@-H!)BZAK,;AU7PQ=0UF
M-PZKX"L!)BZAK,;AU7PQ=0UF-PZKX"L!)BZAK,;AU7PQ=0UF-PZKX#E6/FK/
M6X_Q4C0&+4T32BM8R1'464LV8+!EIQB;/Z9^O_\ 1"_%U#68W#JO@*P$F+J&
MLQN'5?#%U#68W#JO@*P$F+J&LQN'5?#%U#68W#JO@*Q_%>2?V"7%U#68W#JO
MC^&W4,$_YS&YM75? <Z)Z/T[JK7ND- 8M(1-.BP#;D1TMG&;P24P9F18)66G
MAE;^X7XNH:S&X=5\!6 DQ=0UF-PZKX8NH:S&X=5\!6 DQ=0UF-PZKX8NH:S&
MX=5\!6,YCTAF]58]]X=L74-9C<.J^,]I$W/DLB?CXS)F;3Q!V&6$[9HP_M]?
MK+FLTAM@),74-9C<.J^&+J&LQN'5? 1R/2ZF]0E?$CC7'GGTS/"> 6.9-TX<
MG!5BCP2+#8M(RPM)\VFW18>@[=&MBZAK,;AU7P%8"3%U#68W#JOABZAK,;AU
M7P'*L?,6^M1_C(&@,6J(FE#1C7XZBREC0E@RTXU%G],_79_XYQ?BZAK,;AU7
MP%8"3%U#68W#JOABZAK,;AU7P%8"3%U#68W#JOABZAK,;AU7P%8"3%U#68W#
MJOABZAK,;AU7P'*A>C].ZLW[I#0&+1T33HL VY#"6SCHP24P9F18)<YX96_N
M%^+J&LQN'5? 5@),74-9C<.J^&+J&LQN'5? 5@),74-9C<.J^&+J&LQN'5?
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MO@,CP,I72D;PNX/ RE=*1O"[AKXNH:S&X=5\,74-9C<.J^ R/ RE=*1O"[A
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M/Z9B_%U#68W#JO@,CP,I72D;PNX/ RE=*1O"[AKXNH:S&X=5\,74-9C<.J^
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M4G"1:26#(_*+UX9CC7T3"HKQNOL*1AMVDADTGY:;-.$?W /SX&4KVR-Y_P"
M\#*5TI&\+N&OBZAK,;AU7PQ=0UF-PZKX#(\#*5TI&\+N#P,I72D;PNX:^+J&
MLQN'5?#%U#68W#JO@,CP,I72D;PNX/ RE=*1O"[AKXNH:S&X=5\,74-9C<.J
M^ \["Y*4Z04C#-_^3?6VFQ?J+F]0K\#*5TI&\+N%--1--,O D1R_G+EMK!G:
M=OZ8NQ=0UF-PZKX#(\#*5TI&\+N#P,I72D;PNX:^+J&LQN'5?#%U#68W#JO@
M,CP,I72D;PNX/ RE=*1O"[AKXNH:S&X=5\,74-9C<.J^ R/ RE=*1O"[A)X*
M4[.V36OXO$8SR]-N%9[!Z+%U#68W#JOB# FY[LRB/C,FY\0=EF%[,/\ Z@)_
M RE=*1O"[@\#*5TI&\+N&OBZAK,;AU7PQ=0UF-PZKX#(\#*5TI&\+N#P,I72
MD;PNX:^+J&LQN'5?#%U#68W#JO@,CP,I72D;PNX/ RE=*1O"[AKXNH:S&X=5
M\,74-9C<.J^ \[4>2E.B4]U]LW\-)%9:O1SD7L%?@92O;(WG_@459$TJ4^;D
MB.I-A6DE@R/G+UX9B_%U#68W#JO@,CP,I72D;PNX/ RE=*1O"[AKXNH:S&X=
M5\,74-9C<.J^ R/ RE=*1O"[@\#*5TI&\+N&OBZAK,;AU7PQ=0UF-PZKX#(\
M#*5TI&\+N#P,I72D;PNX:^+J&LQN'5?#%U#68W#JO@/.PN2M.D'*)9O_ ,D^
MIM-B_41%]7UBOP,I72D;PNX4T]$PU3,"1'*R2K"M8,[3L+_?T"[%U#68W#JO
M@/,T[DQ E+G$X;UC,I32+%_T2(CTZ/K%_@92NE(WA=P_='1,-=2Q;[";)B\+
M"9,[3L3I+QBL+ZM/VC4Q=0UF-PZKX#(\#*5TI&\+N#P,I72D;PNX:^+J&LQN
M'5?#%U#68W#JO@,CP,I72D;PNX2'R4IQ59,:U_%FP;GEZ;241>SZQZ+%U#68
MW#JOB T3<]H+*(^,R96G$'99A%ZL/_J G\#*5TI&\+N#P,I72D;PNX:^+J&L
MQN'5?#%U#68W#JO@,CP,I72D;PNX/ RE=*1O"[AKXNH:S&X=5\,74-9C<.J^
M R/ RE=*1O"[@\#*5TI&\+N&OBZAK,;AU7PQ=0UF-PZKX#SM1Y*4Z+3GWVS?
MPT)M*U>C[A7X&4KVR-Y_X%%61-*D2C<D1U(P-))8,C/]N&8OQ=0UF-PZKX#(
M\#*5TI&\+N#P,I72D;PNX:^+J&LQN'5?#%U#68W#JO@,CP,I72D;PNX/ RE=
M*1O"[AKXNH:S&X=5\,74-9C<.J^ R/ RE=*1O"[@\#*5TI&\+N&OBZAK,;AU
M7PQ=0UF-PZKX#SL/DK3GW):5F_8T^;:;%^K!2?L^LQ7X&4KI2-X7<*:>B8;L
M[ D,$923PK6#.T\%/-X^@78NH:S&X=5\!D>!E*Z4C>%W!X&4KI2-X7<-?%U#
M68W#JOABZAK,;AU7P&1X&4KI2-X7<'@92NE(WA=PU\74-9C<.J^&+J&LQN'5
M? 9'@92NE(WA=PD5R5IQ59N-:_BU,+</Q]-I*21>KZS'HL74-9C<.J^(%(FY
M[9+*(^,R9=AX@[+,)'JP_L]8"?P,I72D;PNX/ RE=*1O"[AKXNH:S&X=5\,7
M4-9C<.J^ R/ RE=*1O"[@\#*5TI&\+N&OBZAK,;AU7PQ=0UF-PZKX#S-4Y,0
M(3#"VC>M<E,M'A+M\53A)/U>PQ?X&4KI2-X7</U6D3"BQ<:\PHLMC^2T:;#Q
MJ;#\H]%OJ]?M(:N+J&LQN'5? >=J7)6G1:9)D-F_AMMJ4FU>BTB^P5^!E*]L
MC>?^!16$32H\TW)$=39,JPB2P9&96>W#.S]POQ=0UF-PZKX#(\#*5TI&\+N#
MP,I72D;PNX:^+J&LQN'5?#%U#68W#JO@,CP,I72D;PNX/ RE=*1O"[AKXNH:
MS&X=5\,74-9C<.J^ R/ RE=*1O"[@\#*5TI&\+N&OBZAK,;AU7PQ=0UF-PZK
MX#SL/DK3GWIJ%F_8R_BTV+]6 D_9[5&*_ RE=*1O"[A1 1-.14,"1'(RD^/:
MP9VGBT<WCZ-%GM%^+J&LQN'5? 9'@92NE(WA=P>!E*Z4C>%W#7Q=0UF-PZKX
M8NH:S&X=5\!BKY%TQ2%$AR0E1EH5AD=G\!PY-TB92:Q,;?1:@VRP'4EXJRM_
M@?U?_P!QZ'%U#68W#JOABZAK,;AU7P%8SW?2*)U1[WVAUQ=0UF-PZKX@<1-S
MW&(Y$?&9,[8>(.PBPF[=&']GK ;0"3%U#68W#JOABZAK,;AU7P%8"3%U#68W
M#JOABZAK,;AU7P%8"3%U#68W#JOABZAK,;AU7P'*N^C]1ZLY[IC0&+5T32HL
M\W)#"FRCN81)8,C,L$^8\,[/W"_%U#68W#JO@*P$F+J&LQN'5?#%U#68W#JO
M@*P$F+J&LQN'5?#%U#68W#JO@*P$F+J&LQN'5?#%U#68W#JO@(^3OFQ[KTS_
M .RX-<8W)W12W;;3/+9=I^T\H<M/ZBM]7WC9    $TQ;K<)]R.@EO(;4IM)G
M82E$6@C_ &CS*:K4B7DB5OK<4I@B4M@D/'A$X:R21E@Z, [#,K+"/2>@>L4E
M+B%(6DE)45AD96D9"!-'@(9-I,?0:B7;A'A$9%81DJVTK"T%I 9KDIR;R9AO
MO&1NG*C$NPK+%%(01D9>TC+3]?,/2#'JS#4:CL,LH)#:)<4DI+U?R[8V
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MD90MQ+YI,]!%@:-&!85F"8#U1&1E:1VD8_HYH0EMM+:")*$D1)(N8B(=
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MX: SZ'YB@_J4_<-         9R/2)_JC?OK&B,Y'I$_U1OWU@-$
M&=4_EJ?ULO=4-$9U3^6I_6R]U0T0          &=1/,T7] :(SJ)YFB_H#1
M       &<7I"KJB??,:(SB](5=43[Y@-$9!>ER^H)^(8UQD%Z7+Z@GXA@-<
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M0O\ L_Y._P!FQ_AI%[/I%+ZJS[[H#YED[_T+O8,,G?\ H7>P8^O  ^0Y._\
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MG?\ H7>P89._]"[V#'UX 'R')W_H7>P89._]"[V#'UX 'R')W_H7>P89._\
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M?^A=[!AB'L*S%.VV6V8)\P^O#.7Z1,=4<]] #YED[_T+O8,,G?\ H7>P8^O
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M 5I(C+&&=A:;+YU;Y4QWI%,IAU=ZH1'ZF?\ *L+,E(L,X_C&G!7HTI(K;;+
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M21\#)B5@XHK+<(]-E@V1G%Z0JZHGWS =LV4_48VY3W#+*#$\)ULY,SB\B2K
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M )1(^4 &AI^9X+I?5_#7DAJ7_*)#PUY(:E_RB1\H -#3\SP72^K^&O)#4O\
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M&GYG@NE]/F<L.2SS"4L1\6LG6U&>3$5J26DU%H]J2,OVBCPUY(:E_P HD?*
M#0T_,\%TOI=4Y7<F95)F1XC.)E.L+0RYDQ)P%FDR2=I:2L.S20L\->2&I?\
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MOX:\D-2_Y1(>&O)#4O\ E$CY0 :&GYG@NE]7\->2&I?\HD/#7DAJ7_*)'R@
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M>"Z7U?PUY(:E_P HD/#7DAJ7_*)'R@ T-/S/!=+ZOX:\D-2_Y1(>&O)#4O\
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MR8BL/U':6D4>&O)#4O\ E$CY0 :&GYG@NE]7\->2&I?\HD/#7DAJ7_*)'R@
MT-/S/!=+ZOX:\D-2_P"42'AKR0U+_E$CY0 :&GYG@NE]7\->2&I?\HD/#7DA
MJ7_*)'R@ T-/S/!=+Z?&Y8<EFW92G8^$EQW";+)B/!3@I*SZM)&?[11X:\D-
M2_Y1(^4 &AI^9X+I?5_#7DAJ7_*)#PUY(:E_RB1\H -#3\SP72^K^&O)#4O^
M42-BASZ%R@;>7!@MX+*B2HW(Z4Z3]@^(#Z?^2GS=4OUR?='/U'3X:>&Z)E8F
M9E[?-E/U&-N4]PA<@0BK<9LHD? .,ZHTXHK#,E-V'99]9_O&T,]WTBB=4>]]
MH<C;KFRGZC&W*>X,V4_48VY3W"L $F;*?J,;<I[@S93]1C;E/<*P 29LI^HQ
MMRGN#-E/U&-N4]PK !BUB!";HD]QN(PA:8[BDJ2T1&1DD])'8+\V4_48VY3W
M#E7?1^H]6<]TQH ),V4_48VY3W!FRGZC&W*>X5@ DS93]1C;E/<&;*?J,;<I
M[A6 "3-E/U&-N4]P9LI^HQMRGN%8 ,;DZ6#2W"+F3-EI(O812'"(OL(ALC(Y
M.^;'NO3/_LN#7     !D2*P4:I.,.L+2RU&<D*=/^E@8%N"7K*Q?/[='M' J
MW)PTQEPT)G.&W@-D[:C!62U$9JL]1-KMT>K1S@**^9II:5$DU&4N,9)+G/\
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M^4T6F9GH]9F/,Q_RF07*A3(3].DL.27WHDJU1+*$^VI*,%9IM(R-2TD2B/\
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MELC9<OM-7Q: "++9&RY?::OAELC9<OM-7Q: "++9&RY?::OAELC9<OM-7Q:
M"++9&RY?::OC-A2WRJM245/DF:EMVI)3=J?$+G\>S]UHWQET_P \U;]-KX9
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M);,K5-Z=/-H4+LK?V=)[3=\<:K\G$ZVU[PT0$F5O[.D]IN^&5O[.D]IN^*P
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M-Z;'$Z-"O7S"_*W]G2>TW?'*L?-6>MQ_BI&@ DRM_9TGM-WPRM_9TGM-WQ6
M"3*W]G2>TW?#*W]G2>TW?%8 ),K?V=)[3=\?PY3V"?\ ^/D\W2;OBP?Q7DG]
M@#&H\AY%%@I3"D+(HS9$I*F[%>*6DK5$?[Q?E;^SI/:;OCE1/1^G=5:]TAH
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MW?'&B>9HOZ T0$F5O[.D]IN^&5O[.D]IN^*P 296_LZ3VF[X96_LZ3VF[XK
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M7BZ%>OF]@MR:+L'_  V;P[5;Y&-UMGWR&@ R<FB[!_PV;P9-%V#_ (;-X:P
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MQW4HBVS9"[9+9%:EO1IY]"1=DC^T9/9;N *P$F2/[1D]ENX&2/[1D]ENX K
M29(_M&3V6[@9(_M&3V6[@"L<97S5[]6K[ARR1_:,GLMW!R?BO%%=,Y\D[$'H
M-+>G1^@ ZTOS3#_4(]TA6,JGQGE4R(HITA)&R@R226["\4M&E(JR1_:,GLMW
M %8"3)']HR>RW<#)']HR>RW< 5@),D?VC)[+=P,D?VC)[+=P!6,^-Y\G_JF?
M\XZY(_M&3V6[@@CQG3JTU)39!&3;5JB2W:?E<_BV -H!)DC^T9/9;N!DC^T9
M/9;N *P$F2/[1D]ENX&2/[1D]ENX K 29(_M&3V6[@9(_M&3V6[@#E5OD(_6
MV??(: Q:E'>2S'MFR%VR6BL-+>CQRTZ$^H7Y(_M&3V6[@"L!)DC^T9/9;N!D
MC^T9/9;N *P$F2/[1D]ENX&2/[1D]ENX K'-WY%?Z)CADC^T9/9;N#\.Q'L4
MO_\ (23\4_Z+=P!_:1YD@=6;]TA+R<\T?WF3\=8_E+CO*I,)139""-A!DE*6
M["\4M!6IM$]!8>72\),M]LLHD%@I)%FAY96Z4F>GG_;Z@'H $F2/[1D]ENX&
M2/[1D]ENX K 29(_M&3V6[@9(_M&3V6[@"L9T?S]._4,?>X.V2/[1D]ENX(&
M8[IUF8139!&3#)FHDMVGI<T>39H_Z@-H!)DC^T9/9;N!DC^T9/9;N *P$F2/
M[1D]ENX&2/[1D]ENX K 29(_M&3V6[@9(_M&3V6[@#E6/FK/6X_Q4C0&+5([
MR8K1G-D+MDL%8:6]%KB=.A/JYQ?DC^T9/9;N *P$F2/[1D]ENX&2/[1D]ENX
M K 29(_M&3V6[@9(_M&3V6[@"L?Q7DG]@ER1_:,GLMW!_#B/8)__ )"3S=%N
MX YT3T?IW56O=(: Q:/'>718)IFR$$<9LR)*6[$^*6@K4F?[Q?DC^T9/9;N
M*P$F2/[1D]ENX&2/[1D]ENX K 29(_M&3V6[@9(_M&3V6[@"L9S'I#-ZJQ[[
MP[9(_M&3V6[@SFH[QUR4C+)!&49DS<P6[3M4[H\FS19[/6?U -P!)DC^T9/9
M;N!DC^T9/9;N (Y'I=3>H2OB1QKCSSK#OA/!1E;^$<*29.&2,))$MC07BV6'
M:7.5N@K+--NMDC^T9/9;N *P$F2/[1D]ENX&2/[1D]ENX Y5CYBWUJ/\9 T!
MBU6.ZF$@SF2%_P Y8*PTM^MU!6Z$^KG_ &"_)']HR>RW< 5@),D?VC)[+=P,
MD?VC)[+=P!6 DR1_:,GLMW R1_:,GLMW %8"3)']HR>RW<#)']HR>RW< <J%
MZ/T[JS?ND- 8M&CO+HD)29LA!'';,B2ENQ/BEH*U)G^\7Y(_M&3V6[@"L!)D
MC^T9/9;N!DC^T9/9;N *P$F2/[1D]ENX&2/[1D]ENX K&<WZ0R>J,^^X.V2/
M[1D]ENX($1GL]R$9=(M*,T>'@MVGXSFCR;/X>L!M ),D?VC)[+=P,D?VC)[+
M=P!6 DR1_:,GLMW R1_:,GLMW %8"3)']HR>RW<#)']HR>RW< <JE\YIO6_^
MVL: Q9T=TI%/(YLA6%)L(S2WXO\ )KTE8G[_ &B_)']HR>RW< 5@),D?VC)[
M+=P,D?VC)[+=P!6 DR1_:,GLMW R1_:,GLMW %8R.2_HM3.K(^X69(_M&3V6
M[@RN3K#KG)RG+3+?;2J.@R0@D6)T<Q6I,_WF T*'YB@_J4_<- 8M'C/+H\-2
M9LA!&TDR2E+=A:/K29B_)']HR>RW< 5@),D?VC)[+=P,D?VC)[+=P!6 DR1_
M:,GLMW R1_:,GLMW %8SD>D3_5&_?6.V2/[1D]ENX($QGL]NHRZ1:49'CX+=
MI^,K1Y-G\ &T DR1_:,GLMW R1_:,GLMW %8"3)']HR>RW<#)']HR>RW< 5@
M),D?VC)[+=P,D?VC)[+=P!QJ?RU/ZV7NJ&B,6?'>)V%;-D*MDD16I;\7Q5:2
ML3]XOR1_:,GLMW %8"3)']HR>RW<#)']HR>RW< 5@),D?VC)[+=P,D?VC)[+
M=P!6 DR1_:,GLMW R1_:,GLMW '&B>9HOZ T1BTB,\NDQE)FR$$:-"4I;L+]
MZ3,7Y(_M&3V6[@"L!)DC^T9/9;N!DC^T9/9;N *P$F2/[1D]ENX&2/[1D]EN
MX K&<7I"KJB??,=LD?VC)[+=P0E&>SVI&72+<F(\/!;M\H]'DV?P ;(R"]+E
M]03\0Q9DC^T9/9;N#*3'=\)UHRM_"R))XRQ&%9AGH\FRS]EH#T "3)']HR>R
MW<#)']HR>RW< 5@),D?VC)[+=P,D?VC)[+=P!RJ?E0NMH^XQH#&J$=U.1VS9
M"K9*"*U+>C0>G0D79(_M&3V6[@"L!)DC^T9/9;N!DC^T9/9;N *P$F2/[1D]
MENX&2/[1D]ENX K 29(_M&3V6[@9(_M&3V6[@#E1/,['_%[QC0&+2(SJZ4RI
M,Z0@CPO%2ENPO&/VI,7Y(_M&3V6[@"L!)DC^T9/9;N!DC^T9/9;N *P$F2/[
M1D]ENX&2/[1D]ENX K&=_6+^Z?YQVR1_:,GLMW!#DSV>R1ETBW)K</!;M\KF
M\FS^ #9 29(_M&3V6[@9(_M&3V6[@"L!)DC^T9/9;N!DC^T9/9;N *P$F2/[
M1D]ENX&2/[1D]ENX Y57R8?6V_O&@,:I1W4HBVS9"K9+9%:EO1IY]"1=DC^T
M9/9;N *P$F2/[1D]ENX&2/[1D]ENX _L_P VR_U*_N,<Z-YCI_5F_=(<IL9Y
M,"29SI"B)I1F1I;L/0?^Z.5*CNJI$%139""..V9)2ENPO%+05J;0&P DR1_:
M,GLMW R1_:,GLMW '&B^:F_TW/?4-$8U)C.JIK9IFR$%A+\5*6[/+/VI%V2/
M[1D]ENX K 29(_M&3V6[@9(_M&3V6[@"L!)DC^T9/9;N!DC^T9/9;N *QG*]
M(F^J+]]([9(_M&3V6[@A5&>SVVC+I%N3*/#P6[?*3H\FS^ #9 29(_M&3V6[
M@9(_M&3V6[@"L!)DC^T9/9;N!DC^T9/9;N *P$F2/[1D]ENX&2/[1D]ENX Y
M5;Y&-UMGWR&@,:I1WDLQ[9LA=LEHO&2WH\8M.A(NR1_:,GLMW %8"3)']HR>
MRW<#)']HR>RW< 5@),D?VC)[+=P,D?VC)[+=P!6 DR1_:,GLMW R1_:,GLMW
M '*C>;2_7._$4- 8U*C.JIY&4V0@L:[H2ENSY17M2+LD?VC)[+=P!6 DR1_:
M,GLMW R1_:,GLMW %8"3)']HR>RW<#)']HR>RW< 5C(=]+HG4'OB-"S)']HR
M>RW<&4Y'=\)HR,K?-1PGC)RQ&$18;>CR;+#M]EN@!Z !)DC^T9/9;N!DC^T9
M/9;N *P$F2/[1D]ENX&2/[1D]ENX K 29(_M&3V6[@9(_M&3V6[@#E5_FS'6
MV/B)&@,6IQWDQV3.;(7;)9*Q26]'\HG3H3ZA?DC^T9/9;N *P$F2/[1D]ENX
M&2/[1D]ENX K 29(_M&3V6[@9(_M&3V6[@"L!)DC^T9/9;N!DC^T9/9;N .5
M&\WJZP_\58T!BTJ,ZJ$HRFR$%CWBL2ENSY56G2GU\XOR1_:,GLMW %8"3)']
MHR>RW<#)']HR>RW< 5@),D?VC)[+=P,D?VC)[+=P!6,YWTBB=4?]]H=LD?VC
M)[+=P9[D=[/<5.6R#MC/&3F"W:7C-Z/)LTV^SU%]8#; 29(_M&3V6[@9(_M&
M3V6[@"L!)DC^T9/9;N!DC^T9/9;N *P$F2/[1D]ENX&2/[1D]ENX XUGYDWU
MN-\9 T1B52.\B&V9S)"_YS'*PTM^MU!6Z$^KG_9ZQH9(_M&3V6[@"/E3Z(UK
MJ#_PU#7'GN4;#J.3%66J6\XE,)XS;62,%18!Z#L21V']1D8ULD?VC)[+=P!6
M DR1_:,GLMW R1_:,GLMW %8"3)']HR>RW<#)']HR>RW< <J-\R=ZW(^,L:
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M5(<01K5816JLYSL(BM/V$.1KY.JBY*:J6<?&8W%&;>!AX6%A6<V%A:;>>W2
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MKPT+F1;#L,O_ -H1ZCYAM#S\IG)N3T5G)\1@2XQ8O#P[/YPC3;ZS/G_:/0
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MI$1:42)S;9KC'++#(R+%%SJ,[-!?:/-O<D\/D96Z45)8-2I,EV"Q8C!+",\
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M\2.-<9$CTNIO4)7Q(XUP   !GUCYBWUJ/\9 T!GUCYBWUJ/\9 T
M  &?0O1^G=6;]TAH#/H7H_3NK-^Z0T        !G-^D,GJC/ON#1&<WZ0R>J
M,^^X T0         9]2^<TWK?_;6- 9]2^<TWK?_ &UC0        &1R7]%J
M9U9'W#7&1R7]%J9U9'W .]#\Q0?U*?N&@,^A^8H/ZE/W#0        &<CTB?
MZHW[ZQHC.1Z1/]4;]]8#1         !G5/Y:G];+W5#1&=4_EJ?ULO=4-$
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M6V??(: SZM\C&ZVS[Y#0           9]&\VE^N=^(H: SZ-YM+]<[\10T
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M4>K.>Z8T           &1R=\V/=>F?\ V7!KC(Y.^;'NO3/_ ++@UP
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MF,J&K1N(5<#&5#5HW$*N"L $F,J&K1N(5<'X=R]QI;>3QBPDF5N4*T6_\ N
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MR-4($,X^*CN?RKCF$;ZB\M:EV>1ZL*S]@UP 28RH:M&XA5P,94-6C<0JX*P
M28RH:M&XA5P,94-6C<0JX*P 28RH:M&XA5P3(:GHG/R<1&/&MH1@X]6C!-6F
MW _WOX#4 !)C*AJT;B%7 QE0U:-Q"K@K !)C*AJT;B%7 QE0U:-Q"K@K !)C
M*AJT;B%7 QE0U:-Q"K@K !ES&I\II+>)C(P76W+<>H[<%9*L\CUV6"G&5#5H
MW$*N"L $F,J&K1N(5<#&5#5HW$*N"L $F,J&K1N(5<#&5#5HW$*N"L $F,J&
MK1N(5< UU RLR:-Q"K@K !EP6JA#@1HV(C+Q+26\+'J*VPB*VS ^H4XRH:M&
MXA5P5@ DQE0U:-Q"K@8RH:M&XA5P5@ DQE0U:-Q"K@8RH:M&XA5P5@ DQE0U
M:-Q"K@E0S/147I>)C'C6FV\''JT8)K.VW ]>'_ :H ),94-6C<0JX&,J&K1N
M(5<%8 ,AR-/<J\>=B8Q8EAUG QZM.&IL[;<#U8O^/U"S&5#5HW$*N"L $F,J
M&K1N(5<#&5#5HW$*N"L &7,9GRF$MXB,BQUMRW'J/R%I59Y'KP;!3C*AJT;B
M%7!6 "3&5#5HW$*N!C*AJT;B%7!6 "3&5#5HW$*N!C*AJT;B%7!6 "3&5#5H
MW$*N!C*AJT;B%7!6 #+@LSX=/CQ<1&7B6TMX6/45MA66V8 IQE0U:-Q"K@K
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MU*,[;<#ZQK  DQE0U:-Q"K@8RH:M&XA5P5@ DQE0U:-Q"K@8RH:M&XA5P5@
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MC\E9*L\CUV6"G#J&K1N(5<%8 ),.H:M&XA5P,.H:M&XA5P5@ DPZAJT;B%7
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MJT;B%7 PZAJT;B%7!6 #+B,SXJ'2Q$96,=6Y\NHK,([;/(%.'4-6C<0JX*P
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),*S]@T  !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>line1.jpg
<TEXT>
begin 644 line1.jpg
M_]C_X  02D9)1@ ! 0$!] 'T  #_X0 Z17AI9@  34T *@    @  U$0  $
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'^BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>pacb-20221231x10kg0011a.jpg
<TEXT>
begin 644 pacb-20221231x10kg0011a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  T .\# 2(  A$! Q$!_\0
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M;OA3]J#X7^,KI;:P\76<-RV (M05[0DGHH,JJK'V!-?E?17LO)Z%K*3O\O\
M(_3:GAKE3IVA5J*7>\7^'*OS1^T2L&4,IR#R"*6OS1_9\_:HU_X/ZA;:=J4T
M^M>$F94DLI7+O:K_ 'H"3\N.NS[IYZ$YK](-#UJQ\2:/9ZKIEREYI]Y$L\%Q
M']UT89!_^L>17SV+P=3"2M+5/9GXUQ#PWB^'JRC6]Z$OADMGY/L_+[FS\8OV
MNO\ DY;XB_\ 86D_D*^]/^"8_P#R;K?_ /8P7/\ Z)@KX+_:Z_Y.6^(O_86D
M_D*X;P[\3/&'@^Q:QT'Q7K>B632&5K;3M1FMXRY !8JC 9( &?85]!4H/$8:
M,$[;'[#C,JGG&2T,+"7*[0=WY(_>2OF#_@H-\4]#\'_ +6_#EQ=POKWB 16U
MI8Y#/L$JN\K+U"A48!O[Q4?3\SO^%[?$K_HH?BK_ ,'=S_\ %UR6J:M?Z]?/
M=ZC>7.HWDGWI[J5I9&^K,237'1RUTYJ<I;'S>6\#RPN*IXBO634&G9+=K5?(
M-'TFYU[5['3+*/S;R]G2V@C_ +TCL%4?B2*_:/\ :&^-NG?LW_"2;7+@+>:@
MJK9:99NV/M-P5.W/?: I9CZ#'4BODG]@G]CW5K?Q)9?$KQOITNFV]E^]T;3;
MI-LLLI! N'0\JJ]5! ).&Z ;N;_X*C>,Y]2^*WAGPR';['I>E_:RN[@RSR,"
M<>RQ)^9IUW#%XF%):J.YIFLL/Q%G>'R^#YH4N9R:Z[77X)/U?8^4?B+\2O$G
MQ7\477B'Q1JDVJ:E<'[TA^2)<Y"1KT1!V4<5T7AK]FWXH^,-%75]'\!ZY>Z:
MZ>9'<+:,JRKZQ[L;Q_NYKWS_ ()Q_ ?2OB5XXU?Q=K]LM[8>&S"+6UE7,<MU
M)N(9AW"!,X/=E/:OU# "@ # J\3CEAY>RIQV-\\XKCDM=8#!TDW!*]]$O))>
M1^!\T>O> ]=N;69-1\/:S;AK>X@D62VN(PRX:-U.& *L05/4'GK69;?\?$7^
M^/YU^M?[=WP%TCXG_!W6?$D5G#!XH\.6SZA#?I&!)+!$I:6!VZLNS<P!Z,HQ
MU.?R4MO^/B+_ 'Q_.NW"XA8F',E9]3ZC(LXIYUAG7C'EDM)+_@]C^@2OS&_;
M>_;,U;QEXDU3P#X-OY-/\,6,KVM_>6[;9-0E4E74,#_J0<C ^]C)R,"ONO\
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MI[94XR.:^9]0_P""9_P]U;XA:IKL^K:E;:'=SFXAT#3T2".#/+(),,=F[.%
M7 P,\9KZ2^&/PK\,_!WPNOA[PGI[:9I0E:?R6GDF)D8 ,VYV8\[1QTKGQM:A
M72E#XCQ>*,SRG-8PK81/VVEW:RM;9]VNZOZ['Y8?%'_DIGB[_L+WG_HYZ^H_
MV;?VK/ WPL^$NF>'=;;41J-O+.[_ &>UWIAY688.X=B*^7/BC_R4SQ=_V%[S
M_P!'/72>"?V;_B+\1O#L&N^'O#O]H:5.SI'<?;K:+<58JWRO(K<$'M7T]>G1
MJT(QKNRTZVZ'[SFV!RW,,KHTLTJ<E/W7=R4=>5V5WY7T/L__ (;P^&'][6/_
M  !'_P 57A7[4/[6^F?%CPJOA7PO97<.FRS+->7E\JHTFPY5$0$\9PQ).> ,
M5P?_  QM\8?^A0_\J=G_ /'JY;QW\ _B!\--/^W^(_#-S86(8*UTDD<\2$]-
MS1LP7)XYQS7'0PN!A44H33?35'S659!PKA<93K87$1G43]U>TB]>FBW?8WOV
M6?AG>_$CXOZ((HF_LW2KB/4+V?!VJD;!E7/JS *![D]J_46OS/\ V8/VC;GX
M+>(%T[4 DWA/4)P;U1$#+ Q&T3(1R<<94YR <#-?I;%*D\221NLD;@,KJ<A@
M>00>XKR\W]I[9<R]WH?!>(WUQYE!UXVI<MH-=?YK^=^G:Q^,U]_Q^W'_ %T;
M^9K];OA!_P DE\$_]@2Q_P#1"5^2-]_Q^W'_ %T;^9K]6O!<TMO^S[H,L"EI
MT\+P-&H[L+12!^==V<*\*:\SZSQ)CSX;"1[R?Y(_.;]H3XES_%3XK:WK#2^9
M8Q2M:6"]EMXV(3'^]RQ]V->;T45[]."IQ4([(_7L+AJ>#H0PU%6C!)+Y!111
M5G4%?<7_  3[^),^H:3KG@F[E\P6&+^Q#')6-VVRJ/\ 9#E&^LC5\.U]$_L(
M231_'=%C!*/IEPLOLN4/_H06O.S"FJF&G?IJ?&<8X2GB\CQ"FOA7,O)QU_*Z
M^9\W?M=?\G+?$7_L+2?R%?5'[!W[-?PV^+GP5N];\6^%X=9U2/6)[9;B2XFC
M(C6.%@N$=1P6;MGFOE?]KK_DY;XB_P#86D_D*^]/^"8__)NM_P#]C!<_^B8*
M\O%2E#"1<7;8_/L^Q%;#<.T:E";C*T-4VGMY'H/_  PW\#O^A!MO_ VZ_P#C
MM=3X+_9G^%OP]OX[[0? ^DV=]$08[J2$SRQD=U>0L5/N#7IM%?.NM5DK.3^\
M_&*F9XZK%PJ5YM/HY-_J%?EQ_P %/O#LVF_';1]6*'[+J6BQ!9,<&2.6177\
M%,9_X%7ZCU\[?MN?L[S_ !\^%J-HT*R>*]"=[O3E/!N$*XEMP3P"X5",_P 4
M:C(!)KHP554:R<MMCV>%\PIY=FE.K5=HN\6^U^OWVOY'SC_P2S^(VGZ=KGB_
MP5=RK#?:DL.H6 ;CS?*#K,F<\L%9&  Z*Y[5^B]?@397VK^"_$27%K->:)K>
MFW'RR(6@N+:9#@CLRL"",=17U/X;_P""FOQ4T714LK[3_#^N7,:!5O[NUD25
MB!U<1R*I/3HJUZF,P,ZM3VE/J?>\2<)XG,,6\;@FGSVNF[:I6NNEK'W5^U[\
M1M,^&_[/OC&XU">-)]3L)M*LH6/S33SQM& !WP"S'V4U^,%M_P ?$7^^/YUW
M7Q@^.GC/XYZXNI>+=7DO?*+?9K*,>7;6H/41QC@=!DG+' R3BN%MO^/B+_?'
M\Z[\'AGAH6;U9];PWDLLEPDJ=25YR=W;;R2/VB_; \+7'C+]FGQ_IMK&9IQI
M_P!K6-026\B1)R !U.(C@>M?CQ\/?%'_  @_C[PUXC\HS_V/J=MJ'E#J_E2K
M)CJ.NVOWFFB2XB>*5%DC=2K(XR&!X(([BOR"_;#_ &5]2_9_\93:CI\#W/@?
M5+AFT^[4$BV9LM]FD]&49VD_>49ZA@/,RVK&TJ,NI\+P/F%'DJY96=N=W7G=
M6:];)?B?K9X7\3:;XR\-Z9KNCW*WFEZE;I=6TZ\;XW4$''8X/(/(.0:U*_%K
MX'?M9?$/X 0R6GAW4(;S1Y&+G2-5C::U#GJR@,K(3GG8PSWS@5WWQ$_X*+?%
M?QYH4^DVS:5X6@N%*2W&C02+<,I!!4222/LSGJH##L:REEE7GM%JQY]?@7'Q
MQ#A1E%T[Z-OIYJV_H?H#??MA?"32?'>K>$=2\76VFZOILWV>9KJ-UMS)@;E$
MV"@*D[6W$8(/H:]8T77M-\2:=%J&D:C:ZK82C,=U93K-$_T920:_"GX?_#[Q
M#\5O%UGX>\.6$NIZM>-PJ@X1<_-([?PJ,Y+&OV@^ /P=L?@3\+-'\)6;K<2V
MZF6\NU7'VBX<YD?Z=%&?X54=JSQF%I8=+EEJ<?$F0X'):=-4JK=1[IVVZORU
MV6OX'YC_ !1_Y*9XN_["]Y_Z.>OT&_8F_P"3>="_Z^+K_P!'O7Y\_%'_ )*9
MXN_["]Y_Z.>NN\!?M.?$#X:>&;?0- U2"UTRW9WCCDLXI""S%F^9E)ZDU]'B
M\//%8>,(;Z?D?MG$62XG/LFHX7"M*2<9>\VE91:Z)]S]3JQ/'$.E7'@W7(]=
M\O\ L9K*87GFXVB'8=Y.?;-?G;_PVS\6?^@[:_\ @N@_^)KEO'W[27Q$^)>D
M-I6N>('DTUR#):VT,<"28[/L4%A[$XX''%>-#**_,G*22_KR/S/"^'&:QK0E
M5JPC%-7:<FUZ>ZM>VIYE7ZO_ +.]Y<7_ ,#?!$UUDS?V5"F6.255=JG_ +Y
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5]%%?#-N3NS^3YU)U).<W=O=O<__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>pacb-20221231x10kg0012a.jpg
<TEXT>
begin 644 pacb-20221231x10kg0012a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  T .\# 2(  A$! Q$!_\0
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M;OA3]J#X7^,KI;:P\76<-RV (M05[0DGHH,JJK'V!-?E?17LO)Z%K*3O\O\
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M>_;,U;QEXDU3P#X-OY-/\,6,KVM_>6[;9-0E4E74,#_J0<C ^]C)R,"ONO\
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MI[94XR.:^9]0_P""9_P]U;XA:IKL^K:E;:'=SFXAT#3T2".#/+(),,=F[.%
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M5JPC%-7:<FUZ>ZM>VIYE7ZO_ +.]Y<7_ ,#?!$UUDS?V5"F6.255=JG_ +Y
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5]%%?#-N3NS^3YU)U).<W=O=O<__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>pacb-20221231x10kg001a.jpg
<TEXT>
begin 644 pacb-20221231x10kg001a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  T .\# 2(  A$! Q$!_\0
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M;OA3]J#X7^,KI;:P\76<-RV (M05[0DGHH,JJK'V!-?E?17LO)Z%K*3O\O\
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M>_;,U;QEXDU3P#X-OY-/\,6,KVM_>6[;9-0E4E74,#_J0<C ^]C)R,"ONO\
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MI[94XR.:^9]0_P""9_P]U;XA:IKL^K:E;:'=SFXAT#3T2".#/+(),,=F[.%
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M5JPC%-7:<FUZ>ZM>VIYE7ZO_ +.]Y<7_ ,#?!$UUDS?V5"F6.255=JG_ +Y
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5]%%?#-N3NS^3YU)U).<W=O=O<__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>pacb-20241231_g1.jpg
<TEXT>
begin 644 pacb-20241231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  T .\# 2(  A$! Q$!_\0
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M;OA3]J#X7^,KI;:P\76<-RV (M05[0DGHH,JJK'V!-?E?17LO)Z%K*3O\O\
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M>_;,U;QEXDU3P#X-OY-/\,6,KVM_>6[;9-0E4E74,#_J0<C ^]C)R,"ONO\
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MI[94XR.:^9]0_P""9_P]U;XA:IKL^K:E;:'=SFXAT#3T2".#/+(),,=F[.%
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M5JPC%-7:<FUZ>ZM>VIYE7ZO_ +.]Y<7_ ,#?!$UUDS?V5"F6.255=JG_ +Y
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5]%%?#-N3NS^3YU)U).<W=O=O<__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>pacb-20241231_g2.jpg
<TEXT>
begin 644 pacb-20241231_g2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "J!LH# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 445XA^T7^U5HW[.5]H=KJNBWVK-J
ML<LD;6;HH01E00=Q[[A^5;T:%3$35.DKR9A6KT\/!U*KM%'M]%5-'U)-8TFQ
MOXT:-+J!)U1NJAE# '\ZMUBU9V9LG=704444AA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%>,?&S]L;X0?L]7_\ 9OC?QE:Z?K'EB0:5
M;1275UM(RI:.)6* CD%]H- 'L]%?"EW_ ,%CO@E'J7V.QT#QUK!8X22QTNVP
MY] 'N5;_ ,=JU:_\%?O@E]H$&IZ/XVT&3KMU'2(@0/7"3L<4KH=F?<-%>0_
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M10 4456NM4L[%L7-W!;GTED5?YFGOL+;<LT5!:ZA;7P)M[F&X Z^4X;^53T
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M[>)&44,+6I9A0C9U+J5NK6J?J];^ATM%%%?/GXL%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7R-^V?^T1\2O@9XM\*3:%IMK#X3:02RWC#S?M\@!WVTF5_=#;DC&2>"
M#\I ^N:YSXA?#_0_BCX1U#PUXALUO-,O4VNO1T;^%T/\+J>0?:N[!UJ5"NIU
MH<T>J.'&4:M>@X49\LNC,[X/_%K0OC5X%L?$^@RDV\XV36\A'F6TP WQ./49
M^A!!'!%?%O\ P5&_Y&+X??\ 7K>?^AQ5XOI?COQ)^RCX\\9:!X*\5QZ@6F>R
M>YAC62V(0_+)L<$&9<D<95?F&7SQQWB7XC>,?'%X+O7O$VK:K.F=C7-V[+'D
MY(1<X4>P %?;X')WAL8L53E>GT[ZH_/LRX@A6PCPM2/[SKM:Z9^PG@?_ )$K
MP_\ ]@^W_P#1:U\J_MD?MA:C\-O$.G>#/A_<13>)(IXYM2F$0F$8R"EJ%[L_
M&['(4@#EN/F+X?\ [7'Q1^&^Z*'Q'<ZS8&,Q_9=78W(C^7"M&SY92O4#.W@9
M4CBO8?V"_@78>-O%6J?%+7]3CUVZL;YA90R-NE^U,-[7,ZY.&&[Y1S\V6!.U
M2?.65PRZ4\5C+2BMEW;[GJ4\Z>:QAA<'>,GNWT2['W%X!U36]<\%Z-J'B32H
M]#UVYMDEO-/BE,JP2$<KN('/3(YP21EL9._117QLGS2;2L?<Q3C%)NX4445)
M04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !45W,UO:S2I&9FC1F$:]6(&<#ZU+1
M0!^,EW_P6E^,SW4S6OA+P+#;%R8XYK.]D=5SP&872ACCN ,^@J-?^"T?QLW#
M=X6\ D9Y T^]'_MY7S[^VW\ ;_\ 9V_:'\4:#):20Z'>W,FI:+/MPDMG*Q9%
M4]S&28S[H>Q%>#5G=FED?JWX3_X+/)J7PS\4RZWX%6R\;V-EYNF?89S)I]U*
MSI&/,#$/&%,@8J"VX*1N4XKRO_@GC\9OACXT^,FL6WQO\)6'BGQYXPU7S[#Q
M=KD"7D8GD 5;9HG!6++?<=1U8+\H5<?!GAVU>^U![57VK+#(7]PBF3'YH*]%
M\):9+8W5M=6S-%<02++'(O!5E.01]"!5).0M$?T?:+X=TGPW;M;Z1I=GI<#'
M)BLK=(5)]<* *K>+?"OAWQ9I$MKXGT?2]9TM59I(=6MHYX N.25D!7&.M2>$
M?$$'BWPKHVN6S*UOJ5E#>1E>A61 X_0UY9^V;XI_X1']E_XB78E\F6YTM].C
M(.&+7!$''OB0GCIC/:IZV*/R(_:8_:2\!>$?VF/#WC+]G7PA9^"H_"LTBR:E
M9Q?9[?66W8;_ $9"%6 H'7C#.LAR%P /H'XV?\%F]3L_[/M/AMX*LXIY+&WN
M+N]\1L\RQRRQ*[11Q1,F0F[&]F^8@_(!U_/_ ,1:"$#?+7"Z] UIK5[;._F&
MVE:W#'T0[!^BBJ=XD[GW3'_P6@^-R1JI\,^ G(&"S:=>Y/N<7>*[CX(?\%=/
MBW\0OC'X(\*ZQX3\'/INNZS::7/_ &;:W<5PJSS+%N1GN74$;\\J<XQQUK\S
MZ^T/^"5/P$U#XI?M*:;XMFM&/AGP9G4+FY9?D:Z*LMM$#_>WGS/I$>F12NPL
MC]RJ***L@**** "BBB@ HHKR?XW_ +57PM_9QNM)MOB)XH_X1Z;5DDDLU_L^
MZNO-6,J'.8(GVX+K]['7BDY)6NQI-['K%%>!?#?]O3X"?%KQ-;>'O#/Q&L;G
M6+E@EO;7MK<V/G.3@(C7$4:NY)P%!)/85W^M_'?P-X=^+NA?##4-<^S^.=<M
M6O=/TK[).WG0J)26\U4,:\0R\,P/R].1FK/3SV)OOY;^1WU%%>??&CX_> OV
M>?#MGKGQ!\0)X>TR\NA903-;37!DF*L^T)"CM]U6.<8&.3R*3:6Y23>QZ#14
M5K>0WUI#=6\JS6\R++'+&<JZD9# ]P0:\Y^#G[27PW^/TVMP^ O$\6O3Z+*L
M.H0_9I[>2!FW!?EF1"02K#<H(R#S3ZN/4F]X\W0]+HKSGQ)^T/\ #[PC\3[3
MX=ZMX@^R>,;O3I-6ATW[%</NM461WD\Q8S&,+#(=I;=\O3D9\?\ ^'H'[,O_
M $4O_P H.I__ "-4\R[_ -:K\TU\F5ROL?4U%>+?!C]LKX/?M">*+CPYX \7
M_P!OZS;VC7TMM_9EY;;85=$9]TT**<-(@P#GGIP:]IJK-6;ZDW6P4444AA11
M10 4444 %%%% !1110 4444 %%%% !1110 5\M?M;?M-ZOX%U:T^'W@)!-XS
MU",--=;0WV*-AQC/&\C)R>%'-?4M?F;X9U1?$/QR^+7BK5"#<6VH31JQY\N(
M22# ^BPJ/PKW\IP].I.=:JKJ"O;NV[*_D>OEN'C7JMS5TNGY&+JWP7BU"%]:
M^(GC2]O+Z0EI)Y+D8#'G:&D!+?0 ?2O.O&NAVUCI:P:#XPFU_0[=Q))H\]P\
M90#^)4.%?W*C(ZXQS3O$WB:\\<:Q/J%[(VTDB&'=E8D[*/Z^IKE=2A50:^]P
M\ZG,E.7RLK'['+AN5+"JM4EKVTLCUC2OB-\.O#>B6LFE^&EN+]XQYD30AFC;
MNK2ODG\,BL34OBOX>UI7CO\ X?Z?)$W5HIA'*![.L8/ZBO,M)C\R:=.PP?YU
MHR6N!6TJ-.G-W;;]6<N$R6G7H*K9MZ]7T9T47BZ^\)+/=?#OQ;KWAR*0[Y]+
MCOI+=^.X:-@LBCT/S8['DCU_X:_M'?'#1]+BUC2?$D?CC3T(^TZ7J($UQ'@\
M@YQ)D]BK'.>E?-MU#C-5+.XEL;U'@ED@DS\KQL58'U!%=$\-2Q$+2BF_-)_\
M$\#&97",^626O='ZM?L]_M>>&OC@_P#9%U"WASQ=&,2:5<MD2D?>,3'&[!S\
MI (KWJOQ$N_%VJ?;[35#<NFLVCK)#J4;;9P5Z;F'WB/4\]LD<5]J^#?^"CET
M_A73;>Z\!:AX@UZ"()>W%I.(XI&'&\ (Y&1R0>^:^)S'()Q:J8-73W5]OF^A
M\ACLIJ49VI*_EV/N:BOF3X;_ +?'@7QAK,>C^(+&^\%:C(P1/[2PT!8] 9!@
MKV^\H'/6OIF.1)HTDC=9(W 964Y!!Z$'TKY;$86OA9<M:+1X=6C4HOEJ1L.H
MHHKD,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HJ.YN8K.WEN+B5(((D,DDLC!510,EB3P !
MWK\_?VGOV_[O49KSPQ\,+EK.S1C'<>)%XEFQP1;@_<7_ *:?>/\ #CJ?1P6!
MK8^IR4EZOHCSL;CJ.!I\]5^BZL^J_C-^U)\/_@?&\.NZM]JUD+N31]. FNCQ
MQN&0$!]7(]LU\6_$K_@I)XZ\122P>$--LO"=D<A)Y%%W=$>N7&P?38<>IKY&
MN+F6\N)9[B5YYY6+R2R,69V)R22>22>]1U^AX3(<)ATG47/+SV^[_.Y^>8O/
ML7B':F^2/EO]_P#E8[;Q5\;OB!XVD=M;\9:WJ"MUADOI!$/I&"%'X"N*9F=B
MS$LQY)/)-)17T,*<*:M!67D?/3J3J.\W=^8^&:2WD62*1HI%.0Z$@CZ$5W_A
M']H;XE^!I$;1?&^M6R)T@DNVGA_[]R;D_2O/:*4Z<*BM.*:\QPJ3IN\)-/R/
MM/X8_P#!2_Q)I,D5MXYT&VUZTSAK[3<6UR!ZE#E'/L-GUK[5^$OQ\\#_ !LT
M\W'A76XKJX1=TVGS?NKJ'_>C/./]H97WK\5ZNZ)KFH^&M6M=4TF^N--U&U<2
M075K(8Y(V'=6'(KYS&</X7$)NC[DO+;[O\CZ/!\08K#M*M[\?/?[_P#,_=VB
MOBG]EC]O6'Q9<6/A+XD2Q6>L28BM=>XCAN6Z!9AT1SV884]]IZ_:U?G>+P=;
M!5/9UE;\GZ'Z)A,91QM/VE%W_->H4445Q':%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9_B+1
M8?$GA_4](N#BWO[66UD(&?E="I_0U^1OB?P[?>$?$6HZ+J41AOK"=[>9"/XE
M.,CU!Z@]P0:_8*O _P!I+]ERS^,B_P!MZ1-'IGBJ&,)YD@_<W:CHLF.0PZ!@
M#QP01C'L9=BHX>;C/9GZ?P-Q'1R3$SH8MVI5+:_RM;-^3OK\C\YJ*[KQ5\#/
M'W@N[>#5/"FIH%.//@MVGA;Z2)E3^='A7X&>/O&EVD&E^%-3<,<>?/;M!"OU
MD?"C\Z^K]M3MS<RMZG])?VE@O9>W]O'D[\RM]]SF/#'AV^\7>(M.T738C-?7
M\Z6\* ?Q,<9/H!U)[ $U^N7AW18?#?A_3-(MSFWL+6*UC)&/E1 H_05XG^S;
M^RY9_!M?[;U>:/4_%4T93S(Q^YM%/58\\ECT+$#C@ #.??*^4S'%1Q$U&&R/
MYLXYXCHYWB84,([TJ=]?YF]VO)6T^84445XY^8A1110 4444 %%%% !117@_
M[97[4G_#)/POT[QA_P (S_PE?VS5XM+^Q_;_ +'LWQ2OYF_RI,X\K&W;_%UX
MY.J7=I?-NR_$J,7)V7]6U/>**HWVI_8M#N-1\O?Y-NUQY>[&<*6QG'ZXKY&T
M#_@H?_;G[&WB'X\_\(!Y']DZH--_X1_^V=WFYE@CW_:/LXV_Z[./+/W>O/$N
M23DG]FS?S=E^),?>46OM;?=?\C['HKD=%\??VO\ "6P\;?8/*^U:''K/V'SM
MVW=;B;R]^WG&=N[;[X[5\S6/_!0_[9^QGJ'Q\_X0#9]DU0:;_P (_P#VSG=F
M9(M_VC[/Q]_./+[8SWJI_NY3A+>-K_-\J_'0(^_&,X[2O;Y*_P"1]CT5XY^R
M=^TCIW[5/P=L?'-CIO\ 8D[W,UG>:6;G[0;2:-ONF38F[*&-\[1P^.U>1?M%
M_P#!1#3O@1^T5X=^$]IX0_X2>]U%K-+V_&J_918O<R[53R_)?>0A5_O+PP'O
M52BXU(TGO+1?F2FG"51;1U?RT/L"BL+QYXRT[X=^"=>\4:O+Y.EZ-8S7]R__
M $SC0NV/? P/<UX;^Q3^V=IO[8WA7Q#J,.@?\(MJNBWB07&EM??;#Y3INBFW
M^7'PQ61<;>-G7FIC[SE%;I7?HW;\RI>ZE)[-V^9]'T5\G?'/_@H'H7P _:<\
M.?"OQ+X=\K1=4M;>XG\5'4=JV7G/(B[X/*Y0,B[F\P8#$X^7!]%_:[_:4'[*
M_P '7\=CP]_PE(6^@LQ8B^^R9\S=\_F>7)TV]-O.>M0YQ4%4>U[?.]OS*Y7S
M^SZVO\K7_(]LHJAX?U7^W=!TW4O*\C[9;1W'E;MVS>@;;G SC/7%7ZVE%PDX
MRW1G&2G%2CLPHHHJ"@HHHH **** "BBB@ HHHH **** .%USX[?#KPSK%SI6
MK>-]!TW4K5MD]K=7\<<D;8!PRDY!P17EO[1/[4GA/1_@QXFG\&>--'U3Q))
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M=C)@[NWS4ZE+ JO"-.HW![NVJ)IU<<Z$Y5*:4ULKZ,N_\-,?"?\ Z*)X;_\
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M^N*<;>R@NO+'_P!)6_FNOGT0Y7]I-]+O\W^';R"BBBD 4444 %%%% !1110
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M@CH0>000>16EG9OM^'JNA-U=+N;M%?*GP+_X* >'/CC^TMXO^$MGHGV :/\
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M&K3>C"BBBL#<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW^K6>J3Q75V'LY6<2RJX9PS $[B<D FKY6INF]U*,?\ P)V3%&THJ:ZJ3_\
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MU?=-I;GY]5J0I1YJDDEYNQT_Q^_Y':W_ .O*/_T-ZTM>_P"*)^%MOIX^2\O
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M6+X7JV'097:258MNR ,X-U(0G%?%'F?DKV^=WM\RY6A*<9/X9<J\W:_Y;_\
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M_MVTTT']U:3-'$2L:]ABYV_2-!V%?-O_  3OU2?X#>/OA5X[><CPK\0KJ_\
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MBJ>[%.UM$_*_;RMM?77H?>]%%%( HHHH **** "BBB@ HHHH **** "BBB@
MILL23QO'(BR1N"K(PR&!Z@CN*=10!YE>?LO?!K4+J6YNOA)X%N;F9B\DTWAJ
MR=W8]228LDU9T/\ 9Q^$WA?4X=2T;X7^#-)U&$YBN['P_:0RQGU5UC!'X&O1
M** "BBFR2+#&SNRHB@LS,<  =230 ZBOD7]H3XQ77B[3=8T_2;B2VT2WMY=K
M1DJUPP4_.3UVYZ#\3SC%_P#9)_::G\6M#X+\6WGFZPJXT[4)C\UTH'^J<]Y
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M@VY_NX*D+A98QTC&>O\ VO/^4;?[-'_7WH__ *0S5^@?[1W[-O@_]J/X?_\
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MW;.[;T4]:^W***TO[MC.VMPHHHJ1A1110 4444 %%%% !1110 4444 %%%%
M'Y"?'&3'QJ^('_8P:A_Z4R5R^@2?\3[3?^OF/_T,5N_'23'QM^(0_P"IAU#_
M -*9*Y?P_)_Q/M-_Z^8__0Q7Z]2A^YCZ+\C^@J&(_P!F@O[J_(^_O^"D3;?A
M[X2_["C_ /HEJ_/WS/:OOW_@I4VWX=^$?^PJ_P#Z):OSW\VO(R.-\#%^;_,\
M/ANMR9=!>;_,M^9[4>9[54\VCS:]_D/I_K!;\SVK] O^";K;OA[XM_["B?\
MHI:_/+S:_0C_ ()JMN^'?B[_ +"J?^B5KP,\C; R?FOS/F.)*W/ETUYK\SX1
M\02?\3[4O^OF3_T(UU'P.D_XO5\/_P#L8=/_ /2F.N,\02?\3[4O^OF7_P!#
M-=3\"Y,_&[X?#_J8=/\ _2F.O7JP_<R]/T/<KXC_ &::_NO\C]A:***_(3^?
M0HHHH **** "OCO_ (*B?##Q+XZ^ >DZ]X5LY-2U+P9KD&OR64*EGD@C1U=E
M4<DKN5B!_"K>E?8E%3)-V<79IIKU3NOQ146DWS*Z::?HU9GYS?M(_';]DO\
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MBK3O$]_X;TB]\2Z:ABLM9N+"*2\M4.[*Q3%=Z [FX4C[Q]:FDO9^SO\ 9?\
MY*E)17RYG\BZK]HJB_FC;YOEYG\^5?.Y\0?L^V::C_P4Z_:6M)/]7/HD,38]
M&2T!_G7.?L'?&SPK^R#8^._@=\7=8@\$^(-%UV>^LKC4U:*VOK61(U5XY,;>
M=FX9(RKC&<-C] M-^'_A?1O%.I>)M/\ #>D6/B34D$=]K%M811WETHVX6695
M#N!M7AB?NCTJKXV^%7@KXEK;#Q?X/T'Q4+;/D#6],@O/*SUV^:K;<^U*G>E"
M$8](<K\[/F3^3%*U2<Y2ZRYEY:6?W_Y'SM\#?VO_ !/^T9\:/B+;> ] T_6/
MA-X;T\KI^O2Q3VTVI:EM0K LCG:$)\SGR\A0A/WAGQ]_CE^RW^UEH.IGX^^%
MM%^'7Q$TN>2TO]/U:66VU&#RR0FV[2.)Y,#/[LYVD$%2,$_H%H6@:7X7TFVT
MO1M-M-(TRV79!96,"P0Q+Z*B@*H^@KF_&/P5^'OQ$U&/4/%?@/PSXFOXU")=
M:QH]O=RJHZ -(A('M1**T6ZM;7>][W_2W:UO-J6[V=^G:UK?K?N?('_!*'6M
M9O/#'Q.TJRU'5-9^%&DZZ;?P;J&KAA(\&Z7>JY PNT0,5  #.W )(K[RJMI>
MEV6B:?;V&G6<%A8VZ".&UM8ECBB4=%55   ]!5FM92YK>22];*UWZF45:[[M
MOR5^B"BBBH+"BBB@ HHHH **** /.?$'[1?PT\*:Y>:-K'C32M-U2T?RY[6X
MFVO&V <'CT(KYQ_;@^-'@;XA?!FUT_PSXJTO6[Z/5X)WM[*X61UC$<JEB!V!
M91GW%=C\4/V ?"?Q2\>:SXJOO$FM6E[JD_GR0VXA\M#@ !<H3T ZFO&_C9^P
M3I7PF^%?B3Q1H&NZGK%Y8P)(]I=0ICRA*AD<%0#\J@MZ8!KZS+X9;"M2FJLN
M>ZTMI?[CX[-)9E4PU:FZ4>2SUOK;[^Q\\^ 9_P!]-_NC^==IJUUC2)^>R_\
MH0KS#P7JB6MYL<[5D7:&/KVKMM:NO^)//SV7_P!"%?<5(_O$?BM6CS4VO4YS
M4+K*GFM'X(S;OCU\/!_U,-A_Z4)7*WMWE3S7>_LG^%[KQI^T=X,@MTREC>#4
MYY,$K''!^\R<=,LJJ/=A5XAJ&'J2ELD_R.C*,.WB*<8K6Z_,_33P?\>OA]X_
MUX:+X=\5Z?JVJE&<6MNY+[5^\>G:KEY\8O!>G^.8_!MSXBLX?%$C(B:6S'SB
M64.HQCNI!KROX+_L5^%?@C\0%\6Z3KFL7UZL,L/D7AB,>)!R?E0'(^M;>M?L
MK>'M<^/EK\5Y=6U./6K>6&5;)#']G)CB$8!RF[D#/7K7Y=.G@55DH3ER\NFF
MO-V]#]]A4QSI1<H1YN;773E[^IU?C+X_?#SX?:Y)H_B/Q;I^D:I&BR-:W#D.
M%894].XIGA']H3X<^/=>@T7P]XNT[5M5G#-%:V[DNX52S8X[ $_A7F_QK_8D
M\*?'+QY<>*M6UW6;"]FACA:&R,0C 1=H(W(3G\:A^#?[#?A+X*_$'3_%VE:]
MK5]?622HD%XT/EMYD;1G.U >C'O6GL\N]AS>TE[2VUM+_=M<S]IF/M^7V<?9
MWWOK;[]SVOQ1\2_"_@K6-&TK7-:M=,U'6)?)T^WG8AKE]RKM7CKN=1^(I/'?
MQ,\+?#&QMKSQ5K=KH=K<R>3#+=,0'?&=HP.N!7)_%C]GW1?BYXT\%>)-2U&_
ML[OPK=?:[6*U*;)6\R.3#[E)QF(#@CJ:3]H#]GO1?VB-!TS2M;U&_P!-AL+D
MW4;V!0,S%"N#O5N,&N2G'"MT^>32=^;R[6.NI+%)5.2*;5N7S[W*_P#PUI\'
M_P#HH&C_ /?QO\*]-T+7+#Q-HUEJVE74=]IMY$L]O<Q'*R(PR&'L17R/_P .
MQ? /_0T^)/\ OJW_ /C5?4_P_P#!MK\//!.B>&;*::YM-)M([2*:XQYCJ@P"
MV !GZ"ML93P,(IX6;D^MT8X.ICIR?UJ"BNEF;]%%%>4>J%%%% "21K+&R.H9
M&&"IZ$'M7YW?#'3OBG_P3P\5>,?"5K\+/$'Q9^$FN:F^J:-?>%8C=7EDSJ%:
M*6!06^ZL:DG:N4W G<5'Z)45-FI<T7TL_-;_ )K0=[QY7WO\_P"F?!O[-W@?
MXC_%;]M;6OCUKWPXO_AEX3?0CI%KI^NR!+Z=QL4-Y.T,G"DG< !D %N<>9?L
MW?$KQY^RO\3OCG_:7P%^)_BBU\3>*9[VRN]$\.SO$8EGN,-N9 &#"12"N017
MZ?T4TN5KET237WR4G^(/WKN6[:?W1Y5^!\1?';XK>*?VI/V/_C!I5A\'/B!X
M3UBWMK..TTW7=%ECN=1+7",WV>,*6DV",EL XR*Z)OV6Q\>/V / OP]U^SGT
M#Q38>'K&;3Y+Z!H;C3=1BA 7>K ,G.4<8SM9N^*^NZ*4HJ2E';FY?DXWU7S=
MQQDXN+[7_&VGX?B?FW_P3?\ @/XXN?#?[1'A[XM^'-?T2?Q:8[.ZN]7LI(&O
M3(EVD\L4CJ%EYDW;E)'S YY%:'P3^(WQO_8<\&S?";Q'\$/$OQ/TS2IIW\/>
M(?!\;W,%Q#)(7"3;4<Q#<SG+88 XV$ ,?T4HJY-M\R=M%%_+9^37ZM:DZ6LU
MU;7E?<^,/V3_ ("^/K?Q!\7/C7\4-+31O'/CR!X;3P_ XE?3[-4^2-BN<NP6
M)=O4",9PS%5\(^"_[+?B_P 7?\$S/%/A74_#&M>'O'>EZ_<>(=$LM0L)K:\^
MT0)$R&.-U#DR*)8U('5N.E?J-14<O*I*&GNQBO+E?,FO.^OJ5S/FC*6KYG)^
M=U9KTMH?FMX,^!?Q!N_V#_CKXM\5^'-8NOBW\2Y9+ZYTK^SY1?\ EQS*L,(M
M]N]?^6KA,<*R^E9_[1WPB\=:Y_P3S_9\\.:;X*\1:AXATN_T][_2;72IY;NT
M5;><,98E0N@!8 E@,$CUK].:*TNN?F2M\&G_ %[;M]]]2(W2UU^/_P GM?[K
M:'R'^VS\"?'.N^+?AG\9OA?I\>N>-? -R6ET&201G4;-B"Z(S$#</G&.I$C8
MRP"GS[XG?'?]H']J30M/\ ?#?X1>.?@]J-Y<PR:MXO\ $#2Z:EA"K NL$FU&
MDR>I7YBH("'=D??M%9QBDN5ZQOS6\^OR;6J_S*N]U\5K7\NGS5]#Y)^-FJ_M
M ? 7X@>%/$W@ZSU+XN_"^TTB/3]9\+P>4=4%PB[#>*_EF:5F^5L ME@X( (8
M>+^*M(^('[:7[3OPD\4Z7\%_$/PHTKP5J$=_JOB?Q7:?8;RZC66.00(A :0#
MRV"XW &5L[1G=^CU%7%M3526K3NO7?[M=/+38EI<CA'2ZL_2UOO_ .'W"BBB
MD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRO]HOQ)-HO@9;.
MW8I)J4P@=A_SS +,/QP!]":Z2X^+WA"SU6YTV?6XH+RVE,$T<D<BA''4%BN/
MQSBLSXM^&H_B3X!=M(FBOI[=Q=6S6[AUE(!#("/4$_B!7!BI>UH5(4I7E;H>
M9BJBK8>I&A).5NC^\^-O$W_(MZM_UZ3?^@&O!;&^N--O;>\M96M[JWD66*:,
MX9'4@JP/J" :]Y\4*5\.:L",$6LH(/\ N&O'/ _@S4_B#XJT[P_I$)FOKV4(
MOHB]6=O15 )/L*^6P-VFEW/P7.X3J8BE"FKR>UM[W/U+^&?BIO''P]\.Z^ZA
M)M0L8IY5 X$A4;P/;=FNEKE[&;0/A7X3TG2+G4;>QL]/M([:'SW"O(J*%R%Z
MDG&3C-2>&OB-X=\8:A/9:/J2WMU!&)9$6*1=JDX!RR@=?Z^E?9JI%-0<ES']
M 4:BA"%.M-<]E?7=VU.DHHHK4[0HHHH *X/XU?'+P9^S[X)F\5^.=832-)1Q
M#'\C22W$I!*Q11J"78X)XX !)( )'>5\%?MD6,'CC]OK]F;PCK>VY\.H;G4C
M93#,<DZEG7<O0Y,$8P?<=ZG652%).W,[7[=7^"^\K2,)U'JHIO\ KYG>^#_^
M"G/PG\1>)-'TG6M(\8^ 8=8(&G:KXLTA;6RNB2 NV5)7PIW+\Q 4 @DBO1/V
MFOVP/"7[*]QX3M_$NB>)-=N?$TLT.GV_ARTAN)"\9B!4J\T9RQF0*%W9Y]L^
M5?MW?''X7Z?H.J>!?BS\*OB-XD\)6YM;V77]#TE?[.BD)'E[+MIX]K@G81Q]
MXKSFO$?V^/%B_P!I?L8^)?!^C7VN)]LCU#1]'O;@1W=V,Z<\$$DI+@2-\JEL
MM@DGFB,E/EM_.HM[Z._3OH]M_(?+:5G_ "R?;5*_W;>A]$^%_P#@HAX?\5>)
MM)T6+X/_ !>L)=1NXK1;J^\,QQV\)D<('D?[0=J#.2<' !KL_#7[:GP]\2?M
M):S\$0FJ:;XPTTNBS7\,26=Y(J*YCA=92Q;8Q;#(N0C>V<CX2?M$?&GQQ\0-
M*T3Q7^SAJ'@30+HR?:?$$WB:&[2UVQLRYB6%2VYE5.",;L]J^#/'WP(UWXR_
MME?M(ZKX,O+BQ^('@N>U\0: ]NV#+/%Y9:+'3<P'R_[04'@FCF4:L(R^%J3?
MHK?EJ[=27&].3B];Q2[7=_S=EY'Z4_'+]IKPO^S_ .(O .C>(;#5[RZ\::F-
M*T]],ABD2*4O&NZ8O(A5<RKRH8\'CU=^T-^U)\/?V8M!M-1\;:I)%<WS,EAI
M-C%Y][>L,9$<8(X&1EF*J"0,Y(!_/_X^_M$Z=^TW8?LB>+K8);:NOC);/6=/
M7K:7J36?F)CJ%.0ZY_A<=\UZ_I-G!\1/^"OGB&/Q! MW%X.\)13:+'<#<D<A
M2W/F*#W!NYB".AYZCBE&4I*G?7FEK_=C%2NO6^GK<+KEY[?93MYN;CKZ=?0]
ME^#'_!0/X8?&7QY%X*^S^(O!'BRX -GI/C#3A92W>1N'EE7=<D= Q!;^$&KO
M[1/[=7P]_9B^(?AWPAXPL=>>[UJ!+F.^T^W@>UMXVE,6Z5GF1@ 5).U6X]3Q
M7C/_  5ZTNVT_P"!_@[QK:H+?Q/X?\3VK:=J,?$T.Y)&90W7!:*-L>J UY;^
MWI\-X_CU^V5\)O"%UMCN-?\ !%XD#8X2[\F\D@/T$RIGVS4<^B:6TFFN]H<R
MMYO;U-/9J*?,]X\R?;WE%W_,_3]9$:,2!E,9&X,#QCUS7SO^S_\ MU?#S]I3
MXH>(O _A"RUT7VB037,FH7UO EG<1QS+%NB9)F8ABX8;E7Y>N#Q7SU:_M@7]
MM_P3-EU-I9E^(ULO_" _9LG[2-2_U(;'7S!!^]_W@17(?\$^_A1#\#_V[/'O
M@>,?Z1I/@>RCO&SD-=NEA)<,/]DRN^/;%;PBI8F5.]XI.S[^[S+\.5_]O(P;
M:HJ35I=?+WE%K[V__ 6?<7[//[37A?\ :5L?%%UX9L-7L(_#NJ/I-V-7ABC+
MRJ,EH_+D?*^YP?:O)O&W_!3;X2^%_%&K:+H^F>+O'_\ 9&?[2U+PCI*W=G:;
M20V^5Y$RHP?F4%3C@FOF#]EGQ!?^%?V.?VO=4TQY(K^#5-3\J6(D/&6@*[P1
MR"H8G/M7UW_P3=\*Z7X7_8U^'K:;;Q1/J5M+J%Y+&H#33O*^YG/<@*J\] @'
M:N>GS5(J5]H0?JYJ_P!VC_ TG:$G&V\IKT47;[]5^)ZC\-?VBOAY\6/A=/\
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MCNI1E'_MU-6?R=O0UJ-59\TMG&2?G=K7\+^I\+_M>?MW?"CQY^SEKWA7X?\
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M;=;^I]9_M'>&=&U'P0GC/07VIK@:V>V &#,\4C;O]DY1@P]>?6I/AGX3T?\
M9O\ A59^(8S'J/C3Q):1R1S.O$,;JK[%']Q<KD]6;'08QY-#\1$\3?#7^R;=
MFDMUU*.]\MCS PBE1E(]]RX[<&J7Q/\ BTT5OIEM_K+VSTZWLH+<G*PK'$JE
MF^K MCW]*Y%7Y7)TXVG*WR>MW_7<UJYA@XUGF5E?E7*^S>[7GV_X<3XA?$9[
M&26\O[A]1UBY^95E8DG_ &F]%'8#TP.Y'T-^Q/X4N[/P#J7BO4RS7_B"YRC.
M,'[/%E4P.PW&3VQBODSX-_![7_CMXTC0+.-+$H?4M59?DB3J5!Z%R.%4>W0
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M[7_@EKH=WJ7QJ\8>(DB,>GVNC-;2E1\HDGN(W1/RAD/_  &OT.^)W_(IS?\
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MN>&](UG5-'D\[3;[4+"*>>RDRIWPNZEHVRJG*D'*CTK>HHZW **** "BBB@
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M6]M;WV^1RXC,OK%-T^6Q^''B*3_BH-4_Z^I?_0S75_ *3/QV^'/_ &,FF_\
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MZ,O\CZBOVM\5>!O#OCBS^R^(=#T_6K?& E];)+CZ;AQ^%<##^R;\((+GSU\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>pacb-20241231_g3.gif
<TEXT>
begin 644 pacb-20241231_g3.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MF;J_\^MZHC:4T[NRTJN'D[>]-JB[\Q:=R(>V+)J)<B:H)]EC\ZARRX<_H0,
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MR'#&0^.X*4/8!D,(!%A8A=)$B"WP"2[8!D"(A4.H!B[8@K*.@5A8A6U8!2Y
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MZL8N[;HN>@R$TNCJPZ %MI))9>P-W*5+UC!2M)4D+_I'"SV2;WE*3$+B@ZA
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M#8.^Y^?PR.N$C* %)KO+S6N%7LP_T>MPVMFU_>L_^^\W0,0XH/\"QH$8*@[
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M!)(KL?Y:"EFINE)J+*O<LJO%%X?\"R_ YJ+16;1,3?<B#HPXP@@T;D-S.-#
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MW0".-_+*W&<*]J77X$N#H@&-!!^#L()UZ5YR"N'B @="AR7N2M]IR'?F\Z=
M;8I2N%-/Z>X3.YJ-IW0HHUE+/$4QVYU,(B__PU"H;C8J^)0L4Z<+V:<>M9SI
M]"Q5J>(.] S"D$S9JB4,D9KT, :UJ"%(C!6J24S(9[*;>+$E:!Q:31B"-16A
MCTERX1;88-0MM.#E?F])49+$E34]ELU'-#+7C.BAMO19ZT=B\^.-@H1 !'+
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MGB@6%68:NY034Y>2ULJ,AZ'Z5$2$M4L/ 5&+,%C>1KX)/3:V4YU>K%5*P!J
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M<!SLR"E(,M)/,X<HQ8-RB*:5MGAJ.;K1J#\[)=YXIJ$*\$#E*.GT*2F[/&#
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MR/EQHS/E$MS[%,.:,!$#37:!AH[(5Y@*9I*3G308#@PV35@]4R!AV)W+ @
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M"99;/]Z4W97+],(J?+W:/ -!=Y2\@[1'H&FNLUS;$J:F"Y9 &"8VZ$T9#U5
M>#YAG_$R.U%!<<L0%<C8O)*I ^"IG>*5C'WH/_NBH\FKBPBJB*:/W'N/]RB*
M7LFKB0: 7BEI@N II\!8D_\. ,:E"[+;!]@-*3RM(/[CC6L.6C9E.)T.AVN5
MS,KEIR@&QBFV7_>A9IV>FZ*VYJ%69F"TXJ$68"\\S9 K#'NZBV]&GQ!35Z<,
M-E>AS;@5VW@.U2MK,B"MQ*V\0RQC.91QU#LY59H[7LMK0QD@P5%-.H(FV%-1
MVW^&RU%ALML;TG%#L)C D*?X">L2Z80FZ8Q&:00K&I'N%<(>")..#P3+O9M
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MX-.5&^;?BB]7Z/EI>P\SC(L)RDZ6GI)HY#VB@HE\1K6RFL!D8R,YBDFG0G<
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M]7>?=XZC]TTG9Z#B[LI-=];8;A>JJ%]O^HZ'>I$+K]N0_XNYW9QE,9BNFFE
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MV0$ 2F,86&$@ %2I*Y16!1#CJE.I4:EF??J5Z=0#*L8RC1JU*MFG6,O"0!O
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$'!  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>pacb-20241231_g4.jpg
<TEXT>
begin 644 pacb-20241231_g4.jpg
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MM^*/@WI'B"TMM OHK6]7Q!90P.SR(7!012R C YR17M5?&W[0O[8O@'X<?\
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M/FVN7D>=//:4S?,TLASOR-W!&!@ ^/O^#?C_ ),$\8_]E$U/_P!-FGU\X?\
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M&.BJB@ #J?<DGO6G0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !4-GIVGZ=Y@T^PA@\V0O+Y,07>QZL<#D^]344 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%0WFH6&GQ^;?WL4*_P!Z
M60*/UH&DY.R)J*YG7OB_X \.Q&;4==C"CJ<A1_WTQ _6N(U[]LKX5:02EMJ"
M3D=/+<OG_OVK#]:VAAZ]3X8L]+#9+FV,_@T92^1Z[17SKJO[>NB1EDTS0YY/
M[K"V 'YM(/Y5SU[^WEXD9B;+P^^.P::-?_:;5TQRW%R^R>W2X'XCJK^%;U:1
M]5T5\A3_ +<OQ!D.8])1>>]R/Z(*XS]J?_@I#\5/V>_@GHGQ<TCP_;ZC-JOB
M1M-ELKF\=$1!%))N!4?>^3'3'-:T\GQE2:A&UWHM3T<)X;<2XS%T\-3C'GJ/
MEBN9:NS>^RT3/O"BOR4T_P#X."?B[ V;_P""-C*,](M?*?\ H5NU=1X?_P"#
MA.1I5?Q+\#=1A7/S+:ZU!./UMXC^M=DN&,XBO@3^:_S/HZ_@/XE45?ZK&7I4
M@_PYKGZAT5\!^$?^"_'[.>KRQQ>(_"_B+2ATE>YT='4?1H;AS_XY^%>Q_#[_
M (*U?L5?$"98;7XPZ39E@,+J5P]D<^A^U)$OY,:XJN39I1UE2?W7/E\P\,^/
M,L3E7R^K9=5%M?>KH^F:*Y3PE\;?AAXXL(]3\->+;2Z@E^Y-!,LD?_?Q"R?K
M736E[9W\(N+&[BFC/1X9 P_,5YTH3@[25CXROA<3AI.-6#BUW31+1114F 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 455U76=+T2W^U:I>I"G;<>6^@Z
MG\*\9^*?[9GA3PLTNF>&1]KN5R/W1#$'W/W5_P#'C["MJ.'JUW:"N>EEV49A
MFM3DPU-R_)>K/:KW4+'383<:A=QPH/XI' %>?^/?VG/AKX&+07&J)),!Q'N.
M3_P$ M^8 ]Z^4O'G[0OQ)\=W+O<:S):0OD>5;2$-CT+_ 'OP&![5P[LSL7=B
M6)R23R37KT<H2UJOY(_2<K\-X)*>.J?]NQ_S/?O&_P"W/X@OV>W\):6T:'A9
M)3Y8_)26/_?0^E>6^(_CC\3O$TK27GB>: .>5M#Y?_CP^8_B:Y*BO3IX7#TO
MAB?>8'A_)LO5J-&-^[5W^))=7=U>S&XO;F2:1OO22N68_B:CHHKH/8225D%%
M%% PKS'_ (*5#/[&'A)O3X@L/_)2>O3J\R_X*3C/[%?A8^GQ$(_\D[BNC!_[
M[2]?T9ZO#W_)3X#_ *^K_P!)D? E%%%?:']/A1110!H^&O%_BSP7J(U?P=XG
MU'2;M?NW6F7LD$@_X$A!KW?X3_\ !4S]L[X43PF+XF_V_!#C;!XCMA<,?7]\
MI6?G_KI7SO16%;#8?$*U6"EZH\K,\BR7.:;ACL/"JO[T4W\FU=?(_3_X%_\
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M&:UA)=T_TW75)FA1117GGQX4444 %%%% !1110 4444 %%%% !1110 4444
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MT^)J#_R0N:]+KS7_ (*.\_L.Z"?3XGQC_P I]U6^$_WRE_B/4R#_ )*7 ?\
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MBB@ HHHH **** "BBN)^.GQE\._!GP5=>(]:O1&T<1*  %N> %'=B>%'KR>
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MP/Z<\9..1@X/%<K6T9*:NCV*%>GB:?/!_P":?5-=&NJ"BBBJ-@HHHH ****
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MWCK![/\ 1G\ ^*WAIBN \U]I1O+"5&^27;^Y+S7XK5=4NHHHHKPC\E"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHH) &2: */B3Q!8>&-'FUG4)55(
ME) 9L;CZ9[?7L,FOS8_:P_:&U'XY>.Y4LKYVT6QF86:C(6=^AF(],<*#T7T+
M-7M7_!0W]I-F'_"I/"6H8:>/_B821/\ <@/\/'>3_P! '3YZ^/J^LR7 >RA[
M>:U>WH?T/X8<(K X99KBH_O)KW$^D>_J^GEZH****^@/V$[SX)_'+5_A1?R:
M=>V_]HZ!?';J6E2X(((P73/ ;';HP&#V(]0\8>"-'GT6+XB?#>^_M#P]=\AD
MR7M&[HXZ@ \<\CH>Q/SG79?!WXS^(OA#K37%D@O-,N_EU/2IC^[N$Z'KD*V.
MAQ['(XKCKX=M^TI[]N__  ?,^;S;)ISJ/%X/2I]J.RFO/M+M+Y/3;KJ*Z_Q)
MX3\.^)?#J_$_X4W!NM&FYN[/'[VP?^)67D@#/X<')4@UR%<L9*2/$H8B&(A=
M:-:-/1I]4UT844451N;WPP\#77Q*\?Z5X'M)_*;4+H(\N,^7& 6=@.Y"*QQ[
M5[;X]\9_LV?!'Q6?A9!\#+;6DLEC34]4NI5:9690QVET8NV""<,@SP,8KS7]
ME?7-/\/?'SP[?ZG,L<3W$MOO8X >6%XT_P#'G4?C79?%W33\.OVD=;\0>,OA
M+)XHT[5EWZ?;N[QQNSB,[U94;+*59-N._P!,^?B/?Q/)*]N6Z2=KN_R/C,X;
MQ6>K"U>9TU2<XQC/DYI\UGKS1NTM4F[+<Y3XZ^"_A-IOQ T__A5'BNTFT?5@
MAECANO-^P.7 8$DY"X(8!CG[P[5[Q)\(_A';^+V^"DGP/0:7'H/VJ?Q<[XDC
M;D9,I7.<J3][J#\NT5S/Q@^ WPXU#XJ_#[P?HWAZ+0K;7%NGU)+;*LPC1)-F
M3T;AE!QU;I77>(]9T_XK7?B/]EZ2VU'P_/8VR+HEZ)9&6ZB2-?OD\LI[@D[E
M.<[A7%5K.I3IJ,GLVWU2O:^F]CYC'YG/%X+"*E5J6C"4I2;M*,>?D51\K7.X
MV>FNFK/CR^AM[>^F@M+CS8DE98I<8WJ#@-^(YKZ=^!O[//P[U3X*6EGXUTJT
M_M_Q3:W-QIES.F984V 1E/HNV3_@=<3\6?@AX)MOC3X5^"_@&P\JZGM81KL\
M=Q))N=CEWP[':1&K/@8&&%>Q_$"W\ 0_%KPYK[_';0]"'A"/R5T"8Q[MK#$B
MEC,I3=%M4?*<8!YZ5MB\3[2G!0;5]?/3;;NST^(<\>.PF'IX6<Z?.I5+I/FM
M%-034;Z3E;RLOD?&^J:;>Z-J=QI&HP&*XM)WAGC;JCJQ5A^!!J"O7_VT_ 4?
MA7XM'Q-81C[%XAMQ=QLGW?.&%D ]<_*__;2O(*]*C55:E&:ZGW&5XZ&9Y=2Q
M4?MI/T?5?)W05YI_P46_Y,9TC_LJL/\ Z;;JO2Z\T_X**_\ )C&D_P#95H?_
M $VW-=F$_P!\I_XD?1Y!_P E)@?^OL?R9\!4445]J?U %%%% !1110 4444
M%%%% !1110 4444 %%%% !7VG_P2,_;ZOOV>_B);_!+X@ZR1X5UVZVZ9-<2?
M)IUVY'RDG[L4IP#V5]K< N:^+*.G2N7&82CCL/*C46C_  \SP>)>'<NXJR6K
MEN-C>$UOUB^DEYI_?L]&S^FW3=1M-6L8M1LI-\4JY4_T/N.E3U\(_P#!&O\
M;MD^-_P];X+?$;6?,\3>'843SIY,O>VO"17'/)8<1R'GGRV)RYK[NK\AQV#J
MX#%2HU-U^/F?YN<6<-8_A'/:V68M>]!Z/I)=)+R:U"BBBN,^<"BBB@ HHHH
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M KIPO^^4_P#$CVL@=N(\#_U]C^I^?]%%%?:G]0!1110 4444 %%%% !1110
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M7YE_\$#OVD3<:1K?[.FNWY+Z;-]NTA';_EVF8"15'HD^T_6Y-?II7X[FV">
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M"85MAO\ >Z?^)'?DSMG^!_Z_4_S/SOHHHK[8_J4**** "BBB@ HHHH ****
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M\\>*-!U^-Z+^H+&*&#JS=-S=/X9KWDTFW);**LW?1W/E/_@J=^S;^S+\'O\
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M?G?$.,HO+\FI8K%.K"CA85*E5R]Z,:E6-JF'3E&4JU)0<&W=QC]ERNC\\?\
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MFOI^'H:5)>B/W;P9PRY,77?]V/YO]!M%%%?2G[D%%%% !1110 4444 %%%%
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M5^(L5E VO:=J9MK2WN3)+"8[<%A)\NT']XO0MWSBO6?!2JO_  4>\8$*!N\
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M;\QJ***^X/ZM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMVJF@6ILM#L[0C!CMD5OKM&:MU^(S?--L_RNQ$_:8B<^[;_$****DQ"BBB@
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M@K+\?OVG/"?PZDM#-92:DMUJR[<C[)!^]E4^FX+Y8]W%?T*>'=+71=#MM,
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M* "BBB@ K&^+GPF^%W[1O@8_#;XTZ(;JU0,=+U>WPMYI<A&/,B<@\<#*D%6
M (8 "MFBG&4H24HNS74NE5K8>M&M1DX3B[QDG9I]T_ZOL]#\N/VL/V-?BC^R
M?XE6V\2QC4_#U]*1HGBBRB(M[L8)"L,GRI< DQDGH2I8#=7D5?M)JEAX<\6>
M%[WP#X_\.VVM>']3B,=_I=ZFY'&<AE[JX(!##!! (((!'Y]?ML?\$ZO$?P&C
MG^*OP?DN=?\  <C%IFV[KO13_<N /O1^DH''1P/E9_K<MSF.(:I5])='T?\
MD_+[NQ_1' _B91S9PR_-FH8AZ1GM&I^D9O\ EVD_AWY5\P4445[Q^NA1110
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M2Q#O'I+MZ^7G]Y^P\$>*,\N4<#G4^:CM&J]90\JG5Q_O;K[5UJOR^HK7\=^
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M:5)WU^3?[0_[-GQ5_9B\</X'^*&A^2TFY].U*W)>UU"($#S(9,#<.1E2 RY
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>pacb-20241231_g5.jpg
<TEXT>
begin 644 pacb-20241231_g5.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ?H"80# 2(  A$! Q$!_\0
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH \FUK_ )#-_P#]?$G_ *$:*-:_Y#-_
M_P!?$G_H1HH [/X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#R;6O^0S?_ /7Q)_Z$:*-:_P"0S?\ _7Q)_P"A
M&B@#L_A__P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_ $%:Z:@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH \FUK_D,W_\ U\2?^A&BC6O^0S?_ /7Q)_Z$:* .S^'_ /R!
MIO\ KX;_ -!6NFKF?A__ ,@:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH \FUK_D,W__ %\2?^A&BC6O^0S?_P#7Q)_Z$:* .S^'_P#R!IO^OAO_ $%:
MZ:N9^'__ "!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=%?CS\+_ (/>*/C'J=Y8>%K*.]NK2$3S+).D0"%@N<L1GDUZ1_PPS\7_ /H
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MV=_AC/\ &OXQ:7I5T)+BQ\TW^J2DDGR$(9\GU=B$SZO0!^M-%?'?_!1V-(?
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M_P#HI: -RBODO_@HY_R2[PS_ -AD?^B)*Y7_ ()I?\U&_P"X;_[=4 ?;U%?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?/'/_8.;_P!"6OA#]B?QY_PA/QZTB"6399ZW&^ERYZ;GPT7X^8B#_@1K[O\
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MHS]$-?=M?D9\"_'$7PO^-WAW6H[K?IUO?^1-/@J'MI"8W<@_[#%L'N!7ZYT
M?F=^WM_R<'=_]@ZU_P#037VO^R?_ ,F[^!_^O)O_ $:]?%'[>W_)P=W_ -@Z
MU_\ 037VO^R?_P F[^!_^O)O_1KT 3_M2?\ )OGCG_L'-_Z$M?#?["/_ "<1
MI7_7E=?^BC7W)^U)_P F^>.?^P<W_H2U\-_L(_\ )Q&E?]>5U_Z*- 'T[^W]
MX'_X23X,PZW%'NN= O4G9@,GR9/W;C_OHQ'_ (#7E'_!.'QD;;Q)XL\+2/\
M)=VT>HPJ>S1ML?'N1(G_ 'Q7VGX]\*P>.O!.N^'KC BU.REM2Q'W2Z$!OJ"0
M?PK\P_V8?$4_PY_:+\,?; ;<M?-I5U&W&#+F'#?1V4_\!H ^M_\ @H1XP_L7
MX.V&AQOB;6M1177/WH8AYC?D_E5Y[_P3A\#^9?>*_&$T?$2)I=L^.[$22_B
M(?\ OHUQ_P#P4,\8'6OBYIF@QR;H-%T]=R9^[-,=[?F@AKZV_9-\#_\ "!?
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MLTBC 8H@4D?7%>$?M[?\F^7?_81M?_0C0!X5_P $X?\ DHGBO_L%+_Z.6OT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9[TJ46ZGP578#SL52W)ZECV )Z;4/^";>N1W.+'QII\]ON/S7%G)&X'.. S
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M?90?0T 4?^"<OP_NX7\3>-+B)HK6:-=,M&92/-^8/*1[ K&,COD=J;_P4?\
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M $$8(/>ODWXJ?\$^_#OBK5+G4_"6KMX7DF;>VGR0>=:ACUV88-&"><?,!T
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MM/%5_P")(-:-G#*L%O'9F(K(Z[-^2YZ*SC&.]?4U 'Y*_M%?!.3X#^/D\/\
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MS,V=N3CKZT <Y^U)_P F^>.?^P<W_H2U\-_L(_\ )Q&E?]>5U_Z*-?H7\5_
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M/02*1QUZKGCJ: /0_CE^V5X+\'^#;^+PKK=OX@\274316BV#>9' Q&/-=QP
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M.2YSTKZ(H _++]LGP;=>$?C]XCDFC86NJNNHVTI7 D5U&['T<.OX5]??L_\
M[5_@+5_AGH-EKGB&TT'6].LXK.Y@U!_*#F- OF(QX(8 'KD9(Q7IOQF^!OAC
MXY>'X].U^!TN+<LUGJ%N0L]LQQG:3P0<#*D$' [@$?*&L_\ !-S68[I_[)\:
M6,]MGY/MEH\3@9Z':6!('Y^U &#^W'\??#OQ0GT'P_X7O%U2RTUY+FYOHU(C
M>1E 54)QG W9/3Y@.QKUK_@G7X-NM'^'?B'Q#<1M%'K-ZD5N&7&^.!6&\>H+
MR.OU0UC> _\ @G+86.HQ7/B[Q.VIVT;!C8:; 81( >C2$DX/?: ?0BOL'1M'
ML?#VDVFF:;:Q66GVD2PP6\*[4C0#  % 'PG_ ,%(O^1V\'?]@Z;_ -&U[1^P
M%_R0%?\ L*W/\DJY^TU^RS=?M :[HNH6_B&'11I]L\!CDM3-OW-NSD.,5W'[
M//P?F^!_P]'AJ?4X]7<7<MS]HCA,0^?;QM)/3'K0!XC_ ,%&/!\5]X \.^)8
MX5-UI]^;.211\WE2HS<GT#1KCTWGU-9/_!.#QFTVD^+O"DLG%O-%J5NA/9QY
M<OX I%_WU7TI\<OA<GQD^&>K>%3=KI\MV8GBNVC\P1.DBOG;D9R%*]?XJ\>_
M9W_9 U7X$_$+_A(O^$MM]3MI+22SGM$LFB+JQ5A\Q<]&13T[4 ?-G[>W_)P=
MW_V#K7_T$U]\_ S_ )(G\/O^Q>T__P!)HZ\5_:"_8TO?C;\1IO$\'BF#28Y+
M:*#[-)9-*1L!&=P<=<^E?0G@+PTW@SP+X<\/O.+I])TVVL&G5=HD,42IN R<
M9VYQGO0!^<_[9GP=?X3?%9M8TN-K?1-<9KVT:+*B"<$&6,$=,,0XQT#@#I7-
M_LA_\G'>"?\ KXE_]$25^BWQX^#EC\</A[=>';J9;.Y$BW%G?%-YMYE_BQD9
M!4LI&>C>N*\+^#?[#-]\*_B9H7BJ7Q?;ZC'ILCR&U2Q:,R;HV3&[><?>ST[4
M ?7%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'DVM?\AF_P#^OB3_ -"-%&M?\AF__P"OB3_T(T4
M=G\/_P#D#3?]?#?^@K735S/P_P#^0--_U\-_Z"M=-0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 >3:U_P AF_\ ^OB3_P!"-%&M?\AF_P#^OB3_ -"-% '9_#__ ) T
MW_7PW_H*UTU<S\/_ /D#3?\ 7PW_ *"M=-0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCI]]XKT2SOP2IM;C484E!'4;"V<_A0!TM%-219$5T8.C#(93D$>M.H ****
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MQCX+^*$GPC^*LOVG4RWEZ?JTC%FD<C*(SX_>(X^ZY^;/RG)/R_7% !17Q?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!Y-K7_ "&;_P#Z^)/_ $(T4:U_R&;_ /Z^
M)/\ T(T4 =G\/_\ D#3?]?#?^@K735S/P_\ ^0--_P!?#?\ H*UTU !1110
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M;I7Q!_99O?#VMP-<Z7?:E<)/$DC1E@#&P^92".5'2O'_  #\ O!>O?M<>+?
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M2D3 _DP'X5]*7-Y!9H'N)HX$)P&D<*"?3F@"522H)&TXZ>E<M\5O^27>,?\
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M%;V6S[8LMT8?,^[O$EMMS[9Q3?V??^3ZOB=_USU#_P!*H:G_ &_O^1W^$O\
MU\7'_HVVH ]$M/V)_"GB"SN+_P >7^I>*?%^H#S+W5OM;1!)#C(A08 1>@#
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MT,K ?]<Z\F^!&C_&?QQXD\5?$OP%_9UO=:I>36UU<WQC/+,LS(@=3\HRG3T
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M^'O^P=;_ /HI:^4O"7_*1;Q1_P!>9_\ 2."@"C_P4.DNHO%'PN>R -ZLET8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHY8'*Y*AE+;AC(S@B/7/A?\ %S]J;Q-H7_"P=&M? _@O3)1.UE%,'GG) W8
M9CN(^7+;0H)P"<@_8M% #8XUAC6-%"(H"JJC  '05@?$/3;G6/A_XFL+.(SW
MEUIEU!#$" 7=HF55YXY)%=#10!\%?!73?VB_@3X;O-%T#X<V%W:W5V;QWU)E
M=PY1$P"ER@QA!V]>:Z'Q5X1_:9^/EHNA>(;/3?!OAVX8&Y$,T:(Z@]&59))6
M Z[3@' SZU]J44 </\+?A;I_PB^&MGX5TIFN%MXG,MPZA6N)FR7<CMDG@9.
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M%']H7POI-MH%]\*8=<U2WB\A-62_18IMJX5WPV,G&3\RY]!7U+10!\Z?LN_
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M,%:^KJ* /CSQMI/QU_:;M+;PQJOABU^'GA1Y4EO[B:8222A6R!MW;FP1N"@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /)M:_Y#-_\ ]?$G_H1HHUK_ )#-_P#]?$G_ *$:* .S^'__ "!IO^OA
MO_05KIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BJ;:UIZW8M6OK9;H_\L3,
MN_KC[N<]2/SJY0 4444 %%%% !1110 4444 %%5;S5++3V1;J[@MBYPHFE5-
MWTR>:LJP90RD$$9!'>@!:*** "BBB@ HHI P.0#G'!H 6BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#R;6O\ D,W_ /U\2?\ H1HHUK_D,W__ %\2?^A&B@#L_A__
M ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*Y9OBMX)6_P#L+>,- %[G
M'V8ZG!YG7'W=V>O%<3^TS\-?&OQ:\%VOASPCJ]CHUO<7&[4Y+R:2-I80.(UV
M(V02<D$C.T#H36%<?L0_"I_";Z1%HLD=\8/+75S=2M<"3'$I&[:3GG;MV]L4
M >^ Y&1R*S8_$^CS:U)H\>K6+ZO&-SV"W*&=1@')CSN'!!Z=#7S5^P#XVU36
M_ ?B'PUJ=T]V?#UXD5N9#N,<4@;" ]P&1\>@..F*\L\5>']?\6?MV>*=%\/:
MS_PC]U?Q+!<:D@S+#;_8X3*8_1RH(!XP3G(ZT ?;EQ\0/"]GJQTN?Q)I$&IA
MMILI+Z)9L\<;"V<\CMWK?KY'^,'[$G@#0?A'X@U+0X]0@US2;":^2]GNVE-P
M8D+LKJ?E^8*P^4+@MGMBO0OV*_&VH^-O@/IDFJ7#75UIUQ+I_GR$EW1,%-Q/
M4A7"_110![+KGB32?"]G]KUG5++2;3.WS[ZX2%,XSC<Q Z _E7C_ .U!XBTK
MQ-^S'XTO='U.SU:S:WB N+&X2:,_OXOXE)%> ?#WPF/VT/CEXK\0>*+RYG\'
M:&_DV5C!*55HV9A$BD?=!5"[%>22.1FM_P#::_9FTSX5?#+7/$7P\FN=$L&B
M2#6='DNY)8+JW,B[6&\EMZ/M/)Z9QCH0#VG]C?\ Y-K\%_\ 7.Y_]*IJ]DN+
MB*TMY9YY4A@B4O))(P544#)))Z #O7C?[&__ ";7X+_ZYW/_ *535ZYK&DVV
MO:1?:9>(9+.\@>VF0,5+(ZE6&1R.": /FCQ#^TK=V?[56@>&+/Q3I)\!7%KY
MEU,KP-$)/)E;F?\ A^94XS[=Z^C+/Q!I?B31[NYTC4K/5+90\;364Z3(&"Y*
MDJ2,X(./<5\'>)OV?_!6F_MB>&_ %OITR^&+VS\Z:V-U(69O(F?._.X<HO?M
M7VE\/_A3X<^#_A/4-&\+VDEE83RR7;QR3O*3(T:H3EB3T1>/:@#YQ_X)QRI!
MX$\9R2.L<:7\3,[' 4"(Y)/85]4:-XZ\->(KQK72?$.E:I=+]Z&SO8IG'&>5
M5B>E? ?['OPAO/C-H>OZ1J>M7%AX'MKN*XOM.L6V37\Y4^6KOCB-0I)'<D=P
M".E_:R_9_P!!^ .C^&?''P_-UH5W;ZBEK(JW4DAWF-G2568D@_NV!&<'<.!0
M!]YUB^(/&OA[PEY?]N:]IFC>8,I_:%Y'!N&<9&]AGD@5ROB[XJ#PM\"[CQ[+
M%&95T>._CA.0C32(OEIZX+NH_&OGW]G']G#1?C'X3;XC_$T7/BK6M?EEEBCN
M+F2-(HU<H#B,KR2K8&=H7: !B@#Z[TS5K'6K-;K3KRWO[5ONSVLJR(?HRDBK
M=?%6O:$?V/?VA/"!\,W5TG@3Q=+]GN=(EF:1(W#+&Q&[KL\V-U8G=]Y2<5]J
MT ?,_P#P4&_Y(/;_ /89M_\ T7+7&_L)_%Z[L?.^%WB0O;WD,0O]'\\X9H70
M2M$/4;6$J_[+-V KLO\ @H-_R0>W_P"PS;_^BY:\\^-_POU"T^#WPQ^+?A3=
M;^(O#>BZ:UVT(Y>!84*R$=]A.#ZHQSPM 'VW7QM_P3;_ .16\;?]?MO_ .@/
M7TG\&_BA8?&'X>Z5XFL-L9N$V7-N#DV]PO$D9^AY'JI4]Z^;/^";?_(K>-O^
MOVW_ /0'H ^PKZ\@TVSN+NYD6&VMXVEED;HJJ,DGZ 5^7Z^*-?3QU%\?V1QI
MC^+3;F/!W!-@?R\^GDDQ_A7VA^VI\0/^$%^!&KPPR;+[7&72H>>=K@F4X]/+
M5Q]6%<K>? K;^P^/"WV?_B;1:6-9VX^?[5G[05_WL$Q_2@#Z;M+J&^M8;FWD
M66"9%DCD7HRD9!'U!KY._;2^)7B=O&'@_P"%OA74'TFY\0F,W-Q"YC=Q+,88
MDWCE4W*Y;'48'3(/HW[&?C__ (3SX#Z(LLGF7VC%M*GYYQ&!Y?\ Y":/\0:Y
MG]KW]G_Q!\1KC0O&?@MU/BG00 +;<%>9%?S$,9/R[T?)P>NX\Y ! ,N+_@G;
MX$.C&&XU[7IM59<M?++$$WXZ^68S\N>Q8G_:K*_9EUCQY\*_C-JWPG\2R7^M
M:!&)!8:C-'(T<3*GF(4=LA4>/.4R<-C'?,?A?]O*]\+74>B_%+P5J&C:G%\L
MMU:1%"W;<8)-I [Y5CUX%?3'P[^*OA7XK:2VH>%M9@U2&/ EC7*RPD] \; ,
MO?J,'!QF@#Y;_P""D_\ R _ G_7Q>?\ H,5:\/\ P3I\'R6L4T7BG7HIV4.K
M?N2%;&<\(/YUD?\ !2?_ ) ?@3_KXO/_ $&*OLFQ_P"/&W_ZYK_(4 ?#?B33
M?BE^Q-J%AJ]IX@E\:> 9I_)FM;HL%1CD[2A+>4Q X=3@D?,.@/VCX,\7:;X]
M\*Z7XATB7SM.U&!9X6(P0#U4CLP.01V(-<E^T;H4'B+X$^.[2=!(JZ1<7*J?
M[\*&5#_WTBUY;_P3[UJ;5/@3/:2R,ZZ;J]Q;1*>BHR1RX'MND<_B: /2?VE_
MB!_PK7X)^)]7CD\N]DMS96A!PWG2_(K#W4,7_P" 5\F?LC+J?P3^-VA:)K+>
M59^-]!BNX 00 7!DA)_VODD3ZO7H?[9U_+\1_BA\-_A-92';>7:7M]L/W5=C
M&K>VU!.WT(JU^W9X:E\,Z3X#\?Z)$L%WX9U!(%\L8"H2'BS_ +*O%C_MI0!]
M;5\L?M7_ !U\26?BK2/A9\/)&C\4ZL4%S=P-MEMPY^2-&_@8C+,_\*X(ZY'T
MGX7\16OB[PUI6MV+;K/4;6.[A.<_*ZA@#[\U\:_ _P#XK+]O3Q_J5V?.ETO^
MT/)9OX?*ECM%_)&(H Z[0?\ @GOX8N+(W/B_Q-KFMZ_< M<W5M,D<>\XY&]'
M9B.?F8\^@KA/'G@;QG^Q%J>G^)_!^OWFN^!9KGR;K2K]OE1FZ+(J_+E@#B55
M4@C!'.&^ZZ\S_:8T2+Q!\ _'=M,@=8]*FNQGLT(\U3^!04 =EX+\7:?X]\)Z
M5XATJ0RZ?J-NMQ$6X8 CE3Z$'((]0:VJ^;?V =9EU3X!"VD<NNG:K<VL8/\
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M'2[^'5K2WMO,^WV[!H[EY&,CR(03E2S'')XQ7S5^R+_R=%\9/^OB\_\ 2TT
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M-%U1=,U#Q-H]CJ3':MG<W\4<Q.,X",P/0CM7RO\ M-L&_;"^#)!R#)8D$?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^,NJ>//A9IL/B#1=8+O>Z,S %"YW.I4L"5W_ #*R'*YP1C[R?$KPE\;OVAO
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M6)QG@YP2,4 >\^(O"^C^+M.>PUO2[/5K)^L%Y LJ?7# X/O7P_=^$;?]G?\
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M'I^N:9.+>]B@SY3DC*N@))4'!&"3@J>: /'_ -F?4(?@7\;/BK\/-2E^S:3
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M=QC% '=4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >3:U_P AF_\ ^OB3
M_P!"-%&M?\AF_P#^OB3_ -"-% '9_#__ ) TW_7PW_H*UTU<S\/_ /D#3?\
M7PW_ *"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $=Q;Q74$D$\:30
MR*4>.10RLI&""#U!':OD_P 1?L5^(/#.O7FH_"CX@7OA*VNW+R:9)/+'&F3T
M#QGYE'8,I(P.3UKZTHH Y?X9:%K?AGP'H^E^(]4_MK6[:(I=7^]G\YMQ.<L
M3P0.?2NHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "ODSQ%\+_B7\$?CEK_Q!\ Z/#XQT/Q S2:AI33+
M'.A=P[ 9(_BR590V Q!7C)^LZ* /FB_^-WQP\5V$^G^'_@Q-X>U&7,2ZEJFI
M*\4&>"X5DCW8Z@Y(XZ'I6Y\%_@OK?[.OP;\0?V>L/B3QS>*]\\0)\F6<)B.%
M6.TE1S\QQDL>E>]T4 ?(7AOX,_%#XW?&31?&GQ9TVST+1=#VR6FD02JXD*MN
M50JN^!NP7+G)"@ 8Z?7M%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 >3:U_R&;__ *^)/_0C11K7
M_(9O_P#KXD_]"-% '9_#_P#Y TW_ %\-_P"@K735S/P__P"0--_U\-_Z"M=-
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 >3:U_R&;_ /Z^)/\ T(T4:U_R&;__ *^)
M/_0C10!V?P__ .0--_U\-_Z"M=-7,_#_ /Y TW_7PW_H*UTU !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!Y-K7_ "&;_P#Z^)/_ $(T4:U_R&;_ /Z^)/\ T(T4 =G\
M/_\ D#3?]?#?^@K735S/P_\ ^0--_P!?#?\ H*UTU !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!Y-K7_(9O_P#KXD_]"-%&M?\ (9O_ /KXD_\ 0C10!V?P_P#^0--_
MU\-_Z"M=-7,_#_\ Y TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y-K
M7_(9O_\ KXD_]"-%&M?\AF__ .OB3_T(T4 =G\/_ /D#3?\ 7PW_ *"M=-7,
M_#__ ) TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y-K7_(9O\ _KXD
M_P#0C11K7_(9O_\ KXD_]"-% '9_#_\ Y TW_7PW_H*UTU<S\/\ _D#3?]?#
M?^@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'DVM?\ (9O_ /KXD_\ 0C11K7_(
M9O\ _KXD_P#0C10!V?P__P"0--_U\-_Z"M=-7,_#_P#Y TW_ %\-_P"@K734
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_ /Q]O[KX6^,_!'@WPEK6M>(?$NK7\D<T< \JV@N0%R2I)\P G@X49!W'&*
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M%% !1110!Y-K7_(9O_\ KXD_]"-%&M?\AF__ .OB3_T(T4 =G\/_ /D#3?\
M7PW_ *"M=-7,_#__ ) TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7"?"#X7
M_P#"J=%UC3_[3_M3^T-7N=5\S[/Y/E^<0?+QN;.,?>XSZ"N[HH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \FUK_ )#-
M_P#]?$G_ *$:*-:_Y#-__P!?$G_H1HH [/X?_P#(&F_Z^&_]!6NFKF?A_P#\
M@:;_ *^&_P#05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R;6O^0S?_ /7Q)_Z$
M:*-:_P"0S?\ _7Q)_P"A&B@#L_A__P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_
M $%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH \FUK_D,W_\ U\2?^A&BC6O^0S?_
M /7Q)_Z$:* .S^'_ /R!IO\ KX;_ -!6NFKF?A__ ,@:;_KX;_T%:Z:@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH \FUK_D,W__ %\2?^A&BC6O^0S?_P#7Q)_Z$:*
M.S^'_P#R!IO^OAO_ $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#R;6O\ D,W_ /U\2?\ H1HHUK_D,W__ %\2?^A&B@#L_A__ ,@:
M;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS1;2UW#)\W4(3M]CM8_I39/V)?BRN[&AVKXZ;=1@Y^F6I>QRW:Z_\"_X)/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=C=Q+/!/&<K)&P!5A[$$5\K^%?VN_B/X^L;C4/"_PA?6],BN'M_M5OJ!V[E
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M[>\A66,_\!8$5Z]'.*L=*JO^#/T;+?$C'T+1QU-5%W7NR_R_!'Y#^$_&^O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0!S/_"-ZO_T&Y/R/^-'_  C>K_\ 0;D_(_XUTU% ',_\(WJ__0;D_(_XT?\
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M_C1_PC>K_P#0;D_(_P"-=-10!S/_  C>K_\ 0;D_(_XT?\(WJ_\ T&Y/R/\
MC7344 <S_P (WJ__ $&Y/R/^-'_"-ZO_ -!N3\C_ (UTU% ',_\ "-ZO_P!!
MN3\C_C1_PC>K_P#0;D_(_P"-=-10!S/_  C>K_\ 0;D_(_XT?\(WJ_\ T&Y/
MR/\ C7344 <S_P (WJ__ $&Y/R/^-'_"-ZO_ -!N3\C_ (UTU% ',_\ "-ZO
M_P!!N3\C_C1_PC>K_P#0;D_(_P"-=-10!S/_  C>K_\ 0;D_(_XT?\(WJ_\
MT&Y/R/\ C7344 <S_P (WJ__ $&Y/R/^-'_"-ZO_ -!N3\C_ (UTU% ',_\
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M (UTU% ',_\ "-ZO_P!!N3\C_C1_PC>K_P#0;D_(_P"-=-10!S/_  C>K_\
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M_C1_PC>K_P#0;D_(_P"-=-10!S/_  C>K_\ 0;D_(_XT?\(WJ_\ T&Y/R/\
MC7344 <S_P (WJ__ $&Y/R/^-'_"-ZO_ -!N3\C_ (UTU% ',_\ "-ZO_P!!
MN3\C_C1_PC>K_P#0;D_(_P"-=-10!S/_  C>K_\ 0;D_(_XT?\(WJ_\ T&Y/
MR/\ C7344 <S_P (WJ__ $&Y/R/^-'_"-ZO_ -!N3\C_ (UTU% ',_\ "-ZO
M_P!!N3\C_C1_PC>K_P#0;D_(_P"-=-10!S/_  C>K_\ 0;D_(_XT?\(WJ_\
MT&Y/R/\ C7344 <S_P (WJ__ $&Y/R/^-'_"-ZO_ -!N3\C_ (UTU% ',_\
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M (UTU% ',_\ "-ZO_P!!N3\C_C1_PC>K_P#0;D_(_P"-=-10!S/_  C>K_\
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M "!IO^OAO_05KIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M>\$^ M&^'MA>V>B6[VT%Y>RZA,KRM)NFD(+MEB< X''2NAHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \FUK_ )#-_P#]?$G_ *$:*-:_Y#-__P!?$G_H1HH [/X?
M_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>7?R@OZU>NR/:?V*?V>?^$7TN+Q]X@ML:O?1?\2RWE7FV@8?ZTCL[CIZ*?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *^$?VW_CX?$.K/\/M#N,Z982 ZI-&W$]PIR(N.JH>O^U_N\_0
MO[4WQR3X,^ 76QE7_A)=5#0:>G!,7'SSD>B C'JQ7MFOS)9IKRX))>>>5\DG
M+,[$_F237T>583F?UB>RV_S/VOP_X=]M/^U\5'W8_ GU?67RV7GZ'4_"OX:Z
MI\6O&^G^&]*7$MPVZ:X*Y6WA'WY&]@/S) ZFOU8\#^"]+^'GA33?#VC0>1I]
MC$(T!^\YZL['NS$DD^IKR[]E3X$Q_!OP,MSJ$(_X2C5E6:^9ADP+U2 ?[N?F
M]6)Z@"O;ZY,QQGUBIR1^%?CYGSO&O$?]LXOZMAW^YIO3^\^LOT7EKU"BBBO'
M/S8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .$^+GP9\-_&?P^=-
MUVVQ/&";74(0!/;,>ZGN#QE3P<>H!'YO?&CX$^)/@CKGV35H?M&FS,19ZK"I
M\FX'I_LOCJAY],CD_JY63XI\*Z3XVT.ZT?7+"'4M-N5VR03+D'T(/4$=01R#
MTKU,'CYX5\KUCV_R/O>&N+<5D,U2E[]![Q[><>S\MGZZGY7?"'XT^)/@OX@&
MHZ%<YMY2!=Z?,28+E1V8=B.<,.1]"0?TB^#/QT\-_&W0OMFCS>1J$*C[9I<[
M#SK<G_T)2>C#@^QR!\1_M&?LFZM\(II];T3SM8\(LV3+C=-99/"R@=5]'''K
MCC/BGA3Q9J_@?7K76=#OYM-U*V;='/"<'W!'0J>A!X(ZU[]?#4<PA[6D]>_Z
M,_8<UR/*^,\(L=@9I5.DO_;9K?\ 5>:T/V,HKP#]G7]K#2/C!##HVL^3HWBY
M5Q]GW8AO,#EH2>_JAY],C./?Z^2JT9T)N%169_.>89=BLKQ$L-BX<LE^/FGU
M7F%%%%8GFA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DVM?\
M(9O_ /KXD_\ 0C11K7_(9O\ _KXD_P#0C10!V?P__P"0--_U\-_Z"M=-7,_#
M_P#Y TW_ %\-_P"@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !69XF\2:?X0\/ZAK6JW"VN
MG6,+3SRMV4#L.Y/0#N2!6G7PI^W1\<O[;U=?A]H]QFQL'$NJ21GB6<<K%GN$
MZG_:..J5V87#O$U5!;=?0^DX?R:IGN/AA(:1WD^T5O\ /HO-GS_\9OBIJ'QB
M\?:AXBOMT<4A\JSM2<BWMU)V(/?DDGNS$U[K^Q!\!_\ A*->'CS6K?.DZ9+M
MTZ.0<3W(_P"6GNL?_H6/[I%>#_![X8:A\7O'VF^'+#<BS-YEU< 9%O I&^0_
M0<#U) [U^K7A?PWI_@[P]I^B:3;K:Z=8PK!#$O90.I/<GJ3W))KZ+,<0L-26
M'I:-_@C]IXTSJGDF AD^ ]V4HVT^S#;[Y;>EWO8U****^1/YR"BBB@ HHHH
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M-> _B%I'Q&T^_O=&>9X+*^FTZ8S1E#YT1 < =QR.: .EHHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M &I9_P#/W!_W\7_&C^U+/_G[@_[^+_C0!:HJK_:EG_S]P?\ ?Q?\:/[4L_\
MG[@_[^+_ (T 6J*J_P!J6?\ S]P?]_%_QH_M2S_Y^X/^_B_XT 6J*J_VI9_\
M_<'_ '\7_&C^U+/_ )^X/^_B_P"- %JBJO\ :EG_ ,_<'_?Q?\:/[4L_^?N#
M_OXO^- %JBJO]J6?_/W!_P!_%_QH_M2S_P"?N#_OXO\ C0!:HJK_ &I9_P#/
MW!_W\7_&C^U+/_G[@_[^+_C0!:HJK_:EG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_
M (T 6J*J_P!J6?\ S]P?]_%_QH_M2S_Y^X/^_B_XT 6J*J_VI9_\_<'_ '\7
M_&C^U+/_ )^X/^_B_P"- %JBJO\ :EG_ ,_<'_?Q?\:/[4L_^?N#_OXO^- %
MJBJO]J6?_/W!_P!_%_QH_M2S_P"?N#_OXO\ C0!:KY,_;J^-W_"/Z#'X!TFX
MQJ.IH)=2>,\Q6V?EC]BY'/\ LCT:OH?XA?$K1OASX-U7Q%?W43P6,)<0I(-T
MS]$C7W9B!^.:_*'QEXLU'QUXHU/7]6F\[4-0G:>5NPST5?15& !V %>YE>%]
MM4]K+:/YGZMP#D/]H8SZ_77[ND]/.?3_ ,!W];">#_">H^.O%&F:!I,/GZAJ
M$RP1+V&>K'T4#))[ $U^L7PQ^'NG?"WP/I7AO3%S!9Q /-C#32'EY&]V;)]N
M!VKYM_88^$=KX;T.;QYK#0QZEJ2&'3HY6 :&WS\TF#T+D<?[(]&KZQ_M2S_Y
M^X/^_B_XT9IBO:U/91VC^?\ P!\?9_\ VAB_[/H/]W2>OG/K_P" [>MRU157
M^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&O#/R@M455_M2S_Y^X/\ OXO^-']J
M6?\ S]P?]_%_QH M455_M2S_ .?N#_OXO^-']J6?_/W!_P!_%_QH M455_M2
MS_Y^X/\ OXO^-']J6?\ S]P?]_%_QH M455_M2S_ .?N#_OXO^-']J6?_/W!
M_P!_%_QH M455_M2S_Y^X/\ OXO^-']J6?\ S]P?]_%_QH M455_M2S_ .?N
M#_OXO^-']J6?_/W!_P!_%_QH M455_M2S_Y^X/\ OXO^-']J6?\ S]P?]_%_
MQH M455_M2S_ .?N#_OXO^-']J6?_/W!_P!_%_QH M455_M2S_Y^X/\ OXO^
M-']J6?\ S]P?]_%_QH M455_M2S_ .?N#_OXO^-']J6?_/W!_P!_%_QH M45
M5_M2S_Y^X/\ OXO^-']J6?\ S]P?]_%_QH M455_M2S_ .?N#_OXO^-']J6?
M_/W!_P!_%_QH M455_M2S_Y^X/\ OXO^-']J6?\ S]P?]_%_QH M455_M2S_
M .?N#_OXO^-']J6?_/W!_P!_%_QH M455_M2S_Y^X/\ OXO^-']J6?\ S]P?
M]_%_QH M455_M2S_ .?N#_OXO^-']J6?_/W!_P!_%_QH M455_M2S_Y^X/\
MOXO^-']J6?\ S]P?]_%_QH M455_M2S_ .?N#_OXO^-']J6?_/W!_P!_%_QH
M M455_M2S_Y^X/\ OXO^-']J6?\ S]P?]_%_QH M455_M2S_ .?N#_OXO^-'
M]J6?_/W!_P!_%_QH M455_M2S_Y^X/\ OXO^-']J6?\ S]P?]_%_QH M455_
MM2S_ .?N#_OXO^-']J6?_/W!_P!_%_QH M455_M2S_Y^X/\ OXO^-']J6?\
MS]P?]_%_QH M455_M2S_ .?N#_OXO^-']J6?_/W!_P!_%_QH M4R2-)HWCD1
M9(W!5E89!!Z@CTJ#^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@#X__:+_ &)T
MNOM7B/X=6ZQ3<R7&@+@*WJ;?T/\ TS/']W'"GXKN+>>PNI()XI+:YA<H\<BE
M71@<$$'D$&OV4_M2S_Y^X/\ OXO^->+?'K]F_P '_&FWDOH[JUT7Q0J_N]3A
M*XEP.%F4'YQVW?>'') P?H<'FCIVIU]5W/V;AGCR>%4<)FK<H;*>[7^+NO/=
M>?3Y^_9[_;7O_"OV;0/'LDVJ:.,1PZMR]S;#H!)WD7W^\/\ :X ^VX_&F@3>
M'X-<76M/&C3J'COVN46%@?1R<?\ ZJ_)WXA?#?7OA?K\FDZ]:"&9<F*>)M\,
MZ_WXW'##]1T(!XKG6O)Y+6.V:>1K:-F=(2Y**S8R0.@)P,_05Z%;+:.):J4G
M:_;9GV&:<#Y9GDXXW U%34M7RI.,EW2NK/\ #RN?KYH/Q$\*>*+@V^B^)]&U
M>X_YY6%_%.WY*Q-=#7XP6]Q+:SQS02/#-&P=)(V*LK Y!!'0BOO7]CG]I2[\
M>0W/A/Q;?_:-;M8_.L[Z<@-<PC 9'/=UX.>K G/()/E8O*Y8>'M(.Z6Y\!Q%
MP'5RC#/&86I[2$?B35FEW\UWVL?55%5?[4L_^?N#_OXO^-']J6?_ #]P?]_%
M_P :\,_*"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X
M/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\
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M/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\
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M/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\
M&@"U14$5];SOLCN(I&_NJX)J>@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH \FUK_D,W_P#U\2?^A&BC6O\ D,W_ /U\2?\ H1HH [/X?_\ (&F_
MZ^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "BBB@ HHHH **** "BBB@
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M^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\
M/!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_
M #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_
M  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1
M_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?X
MUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \
M&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\
M/!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\
M"%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_
M  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6
M[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;
M_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \
M&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (
M7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\
M"%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M
M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^
M_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;
M_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>
MD_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (
M7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4
M 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^
M-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^
M_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3
M_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>
MD_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!
MA?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW
M^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^
M-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_
M #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3
M_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%
M_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?X
MT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW
M^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\
M/!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_
M #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_
M  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1
M_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?X
MUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \
M&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\
M/!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!EZ?X
M;L-+N!/;Q,L@!&2Y/6M2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^A&B@#L_A_\ \@:;_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH ****
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MI]?R/W/CC-*>2Y9#*,'[KFK:=(+3\=O-7-NBBBOD3^< HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK;35<<I #\\G_ V& ?1#V:OKFJFDZ5::%I=GIMA MM8V<*000I]U(U 55'T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N2^*WQ$LOA7
MX!U?Q+?89;.(^3"3S-,>(XQ]6(^@R>U=;7P'^W;\7O\ A*/&-MX*TZXWZ;HI
M\R\V'Y9+LC&#Z[%./J[CM7=@\.\364.G7T/JN&<FEGF94\,U[BUE_A6_W[+U
M/FCQ!KU[XHUR_P!7U*8W%_?3O<3RG^)V))/L,GIVK] /V(?@_P#\(-\/V\4:
MA!LUCQ JR1[AS%:#F,>V\_.?4%/2OD#]F_X2M\8?BEIVE31L=(MO],U%U_YX
MH1\F?5V*K_P(GM7ZGQQI#&D<:+'&@"JJC  '0 >E>WFV(48K#P^?IT/U3Q$S
MF.'HPR?#Z7LY6Z17PQ^=K^B7<?1117RQ^ A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG\/_ /D#3?\ 7PW_ *"M=-7,_#__ ) TW_7PW_H*UTU !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% '!?'+XH0?"'X:ZMXAD*-
M=QIY-C"__+6X?A!CN!RQ_P!E37Y0:A?W&J7US>W<S7%W<R----(<L[L268^Y
M))KZ)_;<^+W_  G7Q&'AJPEW:1X=+0L5;Y9;HX\UO^ X"#T(;UKE/V4_A#_P
MMKXJ6D=Y!YN@Z4!>ZAN'RN ?DB/^^V./[H?TK[' TXX/#.M4W>ORZ(_I?A/
MTN&LDGF6+5I37.^_+]F/J_S=NA]C_L>?"$_#'X6PWM]#Y>N:]MO;G(^:.+'[
MF(_126([%V':O=Z2EKY2M5E6J.I+=G\\YCCJN98NIC*WQ3=_\EZ):(****Q/
M."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DVM?\AF_P#^OB3_
M -"-%&M?\AF__P"OB3_T(T4 =G\/_P#D#3?]?#?^@K735S/P_P#^0--_U\-_
MZ"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7AG[4/[.EM\:O#GV_38XX/%VGQG
M[),<*+E.I@<^AY*D]"?0FO<Z*UI59T9J<'JCT,OQ^(RS$PQ>&E:<?ZL_)]3\
M9+ZQN=)OI[.[@DM;RWD:*6&52KQNIP5(/0@BOO;]C_\ :9'CNQA\%^)[K/B.
MUCQ97<S<WT2C[I)ZRJ/^^@,]026_M@_LS?\ "<V,_C3PO:9\16L>;VSA7F^B
M4?>4#K(H_%@,=0 ?@NPO[G2;ZWO+.>2UN[>198IHF*O&ZG(8$=""*^P_=9I0
M[/\ )_Y'])_[!Q[E'\M2/WPE^L7^*\UI^S=%>&_LO_M%6WQJ\-_8=1>.W\6Z
M?&!=PC"BX3H)T'H>-P'W2?0BO<J^/JTIT9N$UJC^;,?@,1EF)GA,3&TX_P!7
M7D^@4445D>>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >3:U_R&;_
M /Z^)/\ T(T4:U_R&;__ *^)/_0C10!V?P__ .0--_U\-_Z"M=-7,_#_ /Y
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MTW^[/_WP/\:/^$\TW^[/_P!\#_&@#HZ*YS_A/--_NS_]\#_&C_A/--_NS_\
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MQ@JP(P003R*ZL-B)X6HIQ^?F?09'G6(R+&1Q5#5;2722[?Y/HS\F_!_B[5?
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M[L__ 'P/\:/^$\TW^[/_ -\#_&@#HZ*YS_A/--_NS_\ ? _QH_X3S3?[L_\
MWP/\: .CHKG/^$\TW^[/_P!\#_&C_A/--_NS_P#? _QH Z.BN<_X3S3?[L__
M 'P/\:/^$\TW^[/_ -\#_&@#HZ*YS_A/--_NS_\ ? _QH_X3S3?[L_\ WP/\
M: .CHKG/^$\TW^[/_P!\#_&C_A/--_NS_P#? _QH Z.BN<_X3S3?[L__ 'P/
M\:/^$\TW^[/_ -\#_&@#HZ*YS_A/--_NS_\ ? _QH_X3S3?[L_\ WP/\: .C
MHKG/^$\TW^[/_P!\#_&C_A/--_NS_P#? _QH Z.BN<_X3S3?[L__ 'P/\:/^
M$\TW^[/_ -\#_&@#HZ*YS_A/--_NS_\ ? _QH_X3S3?[L_\ WP/\: .CHKG/
M^$\TW^[/_P!\#_&C_A/--_NS_P#? _QH Z.BN<_X3S3?[L__ 'P/\:/^$\TW
M^[/_ -\#_&@#HZ*YS_A/--_NS_\ ? _QH_X3S3?[L_\ WP/\: .CHKG/^$\T
MW^[/_P!\#_&C_A/--_NS_P#? _QH Z.BN<_X3S3?[L__ 'P/\:/^$\TW^[/_
M -\#_&@#HZ*YS_A/--_NS_\ ? _QH_X3S3?[L_\ WP/\: .CHKG/^$\TW^[/
M_P!\#_&C_A/--_NS_P#? _QH Z.BN<_X3S3?[L__ 'P/\:/^$\TW^[/_ -\#
M_&@#HZ*YS_A/--_NS_\ ? _QH_X3S3?[L_\ WP/\: .CHKG/^$\TW^[/_P!\
M#_&C_A/--_NS_P#? _QH Z.BN<_X3S3?[L__ 'P/\:/^$\TW^[/_ -\#_&@#
MHZ*YS_A/--_NS_\ ? _QH_X3S3?[L_\ WP/\: .CHKG/^$\TW^[/_P!\#_&C
M_A/--_NS_P#? _QH Z.BN<_X3S3?[L__ 'P/\:/^$\TW^[/_ -\#_&@#HZ*Y
MS_A/--_NS_\ ? _QH_X3S3?[L_\ WP/\: .CHKG/^$\TW^[/_P!\#_&C_A/-
M-_NS_P#? _QH Z.BN<_X3S3?[L__ 'P/\:/^$\TW^[/_ -\#_&@#HZ*YS_A/
M--_NS_\ ? _QH_X3S3?[L_\ WP/\: .CHKG/^$\TW^[/_P!\#_&C_A/--_NS
M_P#? _QH Z.BN<_X3S3?[L__ 'P/\:/^$\TW^[/_ -\#_&@#HZ*YS_A/--_N
MS_\ ? _QH_X3S3?[L_\ WP/\: .CHKG/^$\TW^[/_P!\#_&C_A/--_NS_P#?
M _QH Z.BN<_X3S3?[L__ 'P/\:/^$\TW^[/_ -\#_&@#HZ*YS_A/--_NS_\
M? _QH_X3S3?[L_\ WP/\: .CHKG/^$\TW^[/_P!\#_&C_A/--_NS_P#? _QH
M Z.BN<_X3S3?[L__ 'P/\:/^$\TW^[/_ -\#_&@#HZ*YS_A/--_NS_\ ? _Q
MH_X3S3?[L_\ WP/\: .CHKG/^$\TW^[/_P!\#_&C_A/--_NS_P#? _QH Z.B
MN<_X3S3?[L__ 'P/\:/^$\TW^[/_ -\#_&@#HZ*YS_A/--_NS_\ ? _QH_X3
MS3?[L_\ WP/\: .CHKG/^$\TW^[/_P!\#_&C_A/--_NS_P#? _QH Z.BN<_X
M3S3?[L__ 'P/\:/^$\TW^[/_ -\#_&@#HZ*YS_A/--_NS_\ ? _QH_X3S3?[
ML_\ WP/\: .CHKG/^$\TW^[/_P!\#_&C_A/--_NS_P#? _QH Z.BN<_X3S3?
M[L__ 'P/\:/^$\TW^[/_ -\#_&@#HZ*YS_A/--_NS_\ ? _QH_X3S3?[L_\
MWP/\: .CHKG/^$\TW^[/_P!\#_&C_A/--_NS_P#? _QH Z.BN<_X3S3?[L__
M 'P/\:/^$\TW^[/_ -\#_&@#HZ*YS_A/--_NS_\ ? _QH_X3S3?[L_\ WP/\
M: .CHKG/^$\TW^[/_P!\#_&C_A/--_NS_P#? _QH Z.BL?3/%-EJUT+> 2^8
M03\R@#C\:V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R;6O\
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ME(_(C_YYK_WR*/(C_P">:_\ ?(J2B@"/R(_^>:_]\BCR(_\ GFO_ 'R*DHH
MC\B/_GFO_?(H\B/_ )YK_P!\BI** (_(C_YYK_WR*/(C_P">:_\ ?(J2B@"/
MR(_^>:_]\BCR(_\ GFO_ 'R*DHH C\B/_GFO_?(H\B/_ )YK_P!\BI** (_(
MC_YYK_WR*/(C_P">:_\ ?(J2B@"/R(_^>:_]\BCR(_\ GFO_ 'R*DHH C\B/
M_GFO_?(H\B/_ )YK_P!\BI** (_(C_YYK_WR*/(C_P">:_\ ?(J2B@"/R(_^
M>:_]\BCR(_\ GFO_ 'R*DHH C\B/_GFO_?(H\B/_ )YK_P!\BI** (_(C_YY
MK_WR*/(C_P">:_\ ?(J2B@"/R(_^>:_]\BCR(_\ GFO_ 'R*DHH C\B/_GFO
M_?(H\B/_ )YK_P!\BI** (_(C_YYK_WR*/(C_P">:_\ ?(J2B@"/R(_^>:_]
M\BCR(_\ GFO_ 'R*DHH C\B/_GFO_?(H\B/_ )YK_P!\BI** (_(C_YYK_WR
M*/(C_P">:_\ ?(J2B@"/R(_^>:_]\BCR(_\ GFO_ 'R*DHH C\B/_GFO_?(H
M\B/_ )YK_P!\BI** (_(C_YYK_WR*/(C_P">:_\ ?(J2B@"/R(_^>:_]\BCR
M(_\ GFO_ 'R*DHH C\B/_GFO_?(H\B/_ )YK_P!\BI** (_(C_YYK_WR*/(C
M_P">:_\ ?(J2B@"/R(_^>:_]\BCR(_\ GFO_ 'R*DHH C\B/_GFO_?(H\B/_
M )YK_P!\BI** (_(C_YYK_WR*/(C_P">:_\ ?(J2B@"/R(_^>:_]\BCR(_\
MGFO_ 'R*DHH C\B/_GFO_?(H\B/_ )YK_P!\BI** (_(C_YYK_WR*/(C_P">
M:_\ ?(J2B@"/R(_^>:_]\BCR(_\ GFO_ 'R*DHH C\B/_GFO_?(H\B/_ )YK
M_P!\BI** (_(C_YYK_WR*/(C_P">:_\ ?(J2B@"/R(_^>:_]\BCR(_\ GFO_
M 'R*DHH C\B/_GFO_?(H\B/_ )YK_P!\BI** (_(C_YYK_WR*/(C_P">:_\
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M .>:_P#?(H\B/_GFO_?(J2B@"/R(_P#GFO\ WR*/(C_YYK_WR*DHH C\B/\
MYYK_ -\BCR(_^>:_]\BI** (_(C_ .>:_P#?(H\B/_GFO_?(J2B@"/R(_P#G
MFO\ WR*/(C_YYK_WR*DHH C\B/\ YYK_ -\BCR(_^>:_]\BI** (_(C_ .>:
M_P#?(H\B/_GFO_?(J2B@"/R(_P#GFO\ WR*/(C_YYK_WR*DHH C\B/\ YYK_
M -\BCR(_^>:_]\BI** (_(C_ .>:_P#?(H\B/_GFO_?(J2B@"/R(_P#GFO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >3:U_P AF_\ ^OB3_P!"-%&M?\AF
M_P#^OB3_ -"-% '9_#__ ) TW_7PW_H*UTU<S\/_ /D#3?\ 7PW_ *"M=-0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'DVM?\AF_P#^OB3_ -"-%&M?\AF__P"OB3_T(T4 =G\/_P#D
M#3?]?#?^@K735S/P_P#^0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME-MOU84445!S!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[C'A:625_K.&5Z$WI_=?\K\NS^737L:***\<_-@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#R;6O^0S?_ /7Q)_Z$:*-:_P"0S?\ _7Q)_P"A&B@#L_A__P @:;_KX;_T
M%:Z:N9^'_P#R!IO^OAO_ $%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML9A)86I9[/9GXUQ+P]6X?Q?LY:TY:QEW79^:Z_?U)J***X#Y$**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >3:U_R&;_ /Z^)/\ T(T4:U_R&;__ *^)/_0C10!V?P__ .0-
M-_U\-_Z"M=-7,_#_ /Y TW_7PW_H*UTU !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML_A__P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_ $%:Z:@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHI* /%/VM_BU_PJWX3W:6DWEZWK6ZPLMIPR C][*/\ =4\'LS+7
MYG6=G/J%Y!:VT33W,[K%%%&,L[,<!0/4DU[!^U=\6O\ A:WQ8O7M)O-T32<V
M%CM.5<*?GE'^\V<'^Z%]*[3]A?X2_P#"8?$&7Q7?0[]+\/X:'</EDNV'R?\
M? RWL=E?9X:*P&$=2>^_^2/Z<R/#T^$>'I8S$KWVN>7J_AC^2\FV?9?P-^&,
M'PC^&>C^'D"F[C3SKV5?^6EP_,ASW .%'LHKOJ**^/G-U).<MV?S9B<14Q=:
M>(K.\I-M^K"BBBH.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCJD)4Y.$U9H_FK%86M@:\L-B(\LXNS3_ *^[N%%%%0<@4444 %%%% !1110
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M[:VA0R233.%1% R68G@ #N: )J*\FA_:N^$MQJPTY/&^G_:"VT,RR+#G./\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCZU NV'4K.&\1<YPLB!P/R:M6N"^ 2LOP/\   8$'^P;(\_]<$Q7>T %%%%
M!117-RZIX@61PFEQL@) .[J/^^J .DHKF?[6\1?] J/_ +Z_^RH_M;Q%_P!
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MJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RH Z:BN9_M;Q%_T"H_^^O\
M[*C^UO$7_0*C_P"^O_LJ .FHKF?[6\1?] J/_OK_ .RH_M;Q%_T"H_\ OK_[
M*@#IJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RH Z:BN9_M;Q%_T"H_^
M^O\ [*C^UO$7_0*C_P"^O_LJ .FHKF?[6\1?] J/_OK_ .RH_M;Q%_T"H_\
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M_M;Q%_T"H_\ OK_[*@#IJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RH
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MO$7_ $"H_P#OK_[*@#IJ*YG^UO$7_0*C_P"^O_LJ/[6\1?\ 0*C_ .^O_LJ
M.FHKF?[6\1?] J/_ +Z_^RH_M;Q%_P! J/\ [Z_^RH Z:BN9_M;Q%_T"H_\
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MO_LJ/[6\1?\ 0*C_ .^O_LJ .FHKF?[6\1?] J/_ +Z_^RH_M;Q%_P! J/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y-K7_(9O\
M_KXD_P#0C11K7_(9O_\ KXD_]"-% '9_#_\ Y TW_7PW_H*UTU<S\/\ _D#3
M?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBOGC\;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,7DN(>&Q<;/H^C7=/^FNH4445SGBA1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ?P]Z\VU[_@N-I<2NNB_".\NB1A9+_74AP<=2JP/GGMD9'<4 ?J+17XZZ_\
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M#:<E",$G*D_SZ5V'PK^+_C'X(^*AXD\#:]<^'=:$+VQNK8*VZ-\;D96!5@2
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M+'EW-]:"^G0CN);@NX/OG->SV]M#9V\<%O$D$,8VI'&H55'H .@KB/F#\#O
M7_!+;]HKQT$DD\'0^&;5^EQKVH0P?G&I>4?BE?1W@/\ X(@ZU/Y4OC3XGV%B
M1S):Z#ISW.?82RM'CZ^6?I7ZT44 ?$O@/_@D'\ /"9CDU>TU[QE*O+#5M3:*
M,M[+;"(X]B3[YKZ-\!_LR?"7X8^6?"_PY\-:1.G2ZATV)KC\9F!<_BU>FT4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'DVM?\ (9O_ /KXD_\ 0C11K7_(9O\ _KXD_P#0C10!V?P__P"0--_U\-_Z
M"M=-7,_#_P#Y TW_ %\-_P"@K734 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M HHHH **** "BBB@ HHHH \FUK_D,W__ %\2?^A&BC6O^0S?_P#7Q)_Z$:*
M.S^'_P#R!IO^OAO_ $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB@ HHHH ****
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M>Y21Q)^2FO?/!?\ P1/^)FJ>6_BCQSX:\/QMU2P2>_E0>X*Q+GZ,?K7[(T4
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MLLQ<>!O&FC^)/EWM;V=ROVB,>KPMB1/^!**] H **** "BBB@ HHHH ****
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MQ^->W>"_V&/B1XEV2:I'8^&K9N2;Z<22X]DCW<^S%:[/JF!PNM2U_-_I_P
M^F7#W"F0+FQCBY+_ )^2N_\ P%:/_P !/&O%WQ&\4>/KCSO$6O7^KMG*K=3L
MR)_NI]U?P K"L[.XU&ZCMK2"2YN)#M2&%"[L?0 <FOOWP/\ L!^"M#\N;Q'J
M5]XFG7DQ*?LEN?\ @*DO_P"/_A7O_A+X?>&O =K]G\/:%8:.A&&-K J._P#O
M-C<WXDUG4S:A27+1C?\ !?U\CBQGB'E6!A['+J+G;;3DC^5__)4?G1X%_8]^
M)OC;RY6T4:!9OS]HUE_(/_?O!D_\=KZ/^'_[ /A71?+N/%>JW7B*X')M;?\
MT6W^AP2[?4,OTKZIHKQZV9XBKHGRKR/S?,>/,YQ]XTYJE'^YH_\ P)W?W6,'
MPEX#\.> [+[)X>T2QT>$C#"TA5&?'=FZL?<DUO445Y3DY.[9^?U*DZTG.I)M
MOJ]6%%%%(S"BBB@ HHJGJVLZ?X?T^:_U2^MM-L81NDNKN98HD'JS,0!^- %R
MBOE?XJ?\%-?V??A89X3XR'BS4(L_Z'X7A-[NQZ39$/\ Y$KXX^*G_!;7Q!?+
M-;?#KX?V.DIT34/$5PUU(1ZB&+8JGZNXH _6^O*_BG^U-\)/@KYR>,_B!HFC
M7<.=]@;D37@Q_P!.\>Z3_P =K\'OBK^W!\<?C+YL?B/XBZN+&3(.GZ7(+"V*
M_P!UHX @<?[^X^]>&,Q9B2<D\DF@#]D/BC_P6I^'7A_SK?P+X/UKQ=<+D+=:
MA(FG6Q/9AQ)(1[%%_#K7Q_\ %/\ X*U?'KXA":WT?4M,\"6$GR^7H5F#,5]#
M-,78'W397S[\+OV8_BO\:6C;P7X!US7;:0X6^CM3':9]#<2;8Q^+5]@_"S_@
MBW\3?$@AN/'/BG1?!ELV"UM:!M1NU]00I2,?42-0!\'^,OB#XH^(VJ'4?%7B
M/5?$E_S_ *3JU[)<R#/8%V) ]A69H^BZCXAU"*PTJPNM3OI3B.ULX6EE<^@5
M02:_<;X6_P#!(_X$> ?)GURSU7QY?IAB^LWAC@W>JPP[!C_9<O7UEX)^&WA+
MX:Z?]@\)>&=(\,V> ##I-C%;*V/4(HR?<T ?@W\,?^":O[0GQ0\J6'P+-X:L
M9,9N_$TJV 7/K$W[[\HS7UK\,O\ @B&O[J?XA_$DG_GI8>&;/'UQ<3?_ !JO
MU3HH ^7?AO\ \$T?V>?AKY4L?@.'Q)>IC-UXDG>^WX]8F/D_E'7TAH'AO2?"
MFFQZ?HFEV6CV$?W+73[=((E^B( !^5:5% !1110 R6))HWCD19(W!5D89# ]
M01Z57L=)L=+W_8K*WM/,QO\ (B5-V,XS@<]3^=6Z* "BBB@ HHHH **** "B
MBB@ KR#XO?LN>"/B\L]U<V7]CZZX)&JZ>H21F]9%^[)[Y^;'1A7K]%:4ZDZ4
MN:#LSMP>.Q.7U57PM1PDNJ_K5>3T/RU^,G[-'C'X,S27%]:_VGH6[":O8J6B
MQGCS!UC/3KQG@$UYUX;\4:OX.UB'5=$U&XTO4(3\EQ:R%&]P<=0>X/![U^QD
MT,=Q"\4J++%(I5T< JP(P00>HKY@^-7[#F@>,/M&J>"WB\-ZNV7-BP/V*9O0
M <Q'_=!7_9'6OI<-FL9KDQ"^?3YG[EDGB#0Q45A<YBE?3F2O%_XH]/E=>21S
MOP5_;QM;[R-*^(D"V=P<(NM6<9\ICZRQCE?]Y<CG[JBOKK2]5LM<T^"_TZ[A
MOK*X7?%<6T@DCD7U5AP17Y%>._ASXC^&>M-I?B32I],NADIY@S'*H_B1Q\KC
MW!-=%\(?CYXM^"^H>9HE[YNG2-NGTNZR]O+ZG;GY6_VEP?7(XJL1E=.LO:8=
MV_(VSK@/!YA3^N9+)1;UM>\)>CZ?BO0_5VBO(/@G^TYX2^-$$=M;S?V1XAVY
MDTB\<;VXY,3<"0=>F#QR!7K]?,5*<Z4N2:LS\'QF"Q.7UGA\5!PFNC_K5>:T
M"BBBLSB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \F
MUK_D,W__ %\2?^A&BC6O^0S?_P#7Q)_Z$:* .S^'_P#R!IO^OAO_ $%:Z:N9
M^'__ "!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "OC']OCXP;([+X>:;/RVV\U7:>W6&(_^
MAD>R5]5?$;QU8?#7P3J_B34F'V:P@,@CS@ROT2,>[,0H^M?DMXL\3W_C3Q-J
M>NZG+YU_J$[W$S=LL<X'H , #L !7NY3AO:5/:RVC^?_  #]:\/<C^NXQYC6
M7N4MO.?_ -JM?6QK?"KX>7WQ4\?:1X:L0RO>3 33 9$,(YDD/T4$^YP.]?K/
MX?T&R\+Z%I^CZ="+>PL8$MX(Q_"BJ /J>.O>OFS]A;X._P#")^#)O&FHP;=4
MUQ=MH'7YHK0'((_ZZ,-WN%0]Z^HZC-,3[:K[..T?S./CS//[2S#ZI2?[NCIZ
MR^T_ELO1]PHHHKQ3\Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHK'\1^,-!\'VHN=>UO3=$MSTFU*[CMT
M_-R!0!L45\\^,O\ @H-^SQX'#_;_ (J:)>,H^[HQDU+<?0&W5Q^N*\,\8?\
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MJAV1F$89I< J>2G/49KZ2\&_\$1?'-]L/BKXD:!HP/++I-G/?D>W[SR/\^M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (K
MJUAO;>6WN(8YX)5*212J&5U/4$'@BOF3XP_\$VO@)\8_/GN/!T?A;59<G^TO
M"[BQ<,>K&( PL<\Y:,GWY-?4%% 'X^_&#_@BKXST/S[OX;^,=/\ $]L/F73M
M90V5T!_=61=T;GW;RQ_7XC^+'[-?Q1^!LS)XY\#:QX?A5MOVR:#S+1CG&%N(
M]T3'Z,>HK^EZH[BWBO+>2">))H9%*/'(H964C!!!Z@T ?RQ6-]<Z7>0W=G<2
MVEU"P>*>!RCHPZ%6'(/N*^H_@_\ \%-/CY\(?(M_^$L_X3'2X^/L/BJ,WF1_
MUVR)AQT_>8]J_6+XP_\ !-_X"?&3SY[OP9%X9U67).I>%V%A(">K&-086)/.
M6C)_,U\.?&#_ ((J>+]%\^\^&WC/3_$MN/F73=;C-E<@?W5D7=&Y]V\L?U /
M8_@]_P %I/ /B+R+3XB^%-3\'W385M0TUOM]G[LRX65![*LA]Z^WOA;\>_AU
M\;+$77@;QGH_B5=@=X;.Y4W$0/\ STA.)(_HRBOYW_BU^S9\4/@7.R>.O!&K
M^'X0VP7LT'F6CMG&%N$W1,?HQZBO/=/U"ZTF^AO+&YFL[R!@\5Q;R&.2-AT*
ML#D'W% ']4%%?@)\'_\ @IS\?/A'Y%NWBI?&>EQ\?8?%49O#C_KOE9NG3,A
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MRO.6V'_<VU[O10 BJ$4*H"J!@ =!2T44 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH \FUK_D,W_P#U\2?^A&BC6O\ D,W_ /U\2?\ H1HH
M [/X?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO&_\^F3_ &EA/^?B/JRBOE/_ (>0?#3_ * ?BO\ \!+;_P"2*/\ AY!\-/\
MH!^*_P#P$MO_ )(H_LO&_P#/IA_:6$_Y^(^K**^4_P#AY!\-/^@'XK_\!+;_
M .2*/^'D'PT_Z ?BO_P$MO\ Y(H_LO&_\^F']I83_GXCZLHKY3_X>0?#3_H!
M^*__  $MO_DBC_AY!\-/^@'XK_\  2V_^2*/[+QO_/IA_:6$_P"?B/JRBOE/
M_AY!\-/^@'XK_P# 2V_^2*/^'D'PT_Z ?BO_ ,!+;_Y(H_LO&_\ /IA_:6$_
MY^(^K**^6K7_ (*+_#"X#;].\2VV.GFV<)S]-LQJ?_AX?\+/^??Q!_X Q_\
MQVE_9N,_Y],?]HX3_GXCZ>HKYA_X>'_"S_GW\0?^ ,?_ ,=JY#_P4"^$TD:L
MUQK$3$<H]@<CZX8C]:7]FXS_ )]/[A_VAA/^?B^\^DJ*^;_^&_OA+_S^:M_X
M+V_QJ['^WA\'GC5CKMXA(R5;39\CV.%Q4_V?BU_RZE]S*^O87_GXOO/H.BO
M(?VZO@W)(JMXCN8E)Y=],N<#ZX0G]*N?\-N?!7_H=/\ RE7O_P 9J?J.+7_+
MJ7W,?UW"_P#/V/WH]SHKQ.U_;0^#-YNV>-H5V]?-L;J/\MT0S5A?VPO@ZS #
MQQ9Y)QS;S@?^BZGZGB?^?4ON97UO#_\ /R/WH]DHKRG_ (:J^$O_ $/>D_\
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M&#DJ1@DY!/3C<HKX*'M&U*/ET.?!YK1QDO9I6EYGM5%%%>&>R%%%% !1110
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M\/:_-)]VUL]1B:X^ABW;P?8J* /0J*** "BBB@ HHHH **** "BBB@ HHHH
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MJYGX?_\ (&F_Z^&_]!6NFH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MACX7T^>+[EU_9<4MP/\ MLX9_P#QZNWO_&_A?P^BQ7NOZ1IJH JI<7D40 [
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MX+\/VLHDAT+3(9%Z/'9QJ1^(6K:Z'IJL&73[4$'((A7C]*C_ %DCTI?C_P
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MO<_!3X>7C!KCP%X9G8# :31[=B!Z<I52Y_9_^&-U&$?X>^&%&<_N](@0_FJ
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M_9_$/B:(YY,L]N^?RA%9]U_P36\(LR_9_%VM1+CD2Q0N3^2BO"_M3*Y;Q_\
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MG'^SMX"\I[7X:Z?JMPGWIM<EEU#>?4I,[1_@% KWKPOX)\.^![/[)X<T#2]
MM/\ GAI=G';)_P!\HH% '\_'P]_X)]_M!?$KRGTWX9:QI]M)S]HUQ5TU O\
M>Q.48C_=!SVKZ9^'O_!$WX@ZMY<OC/QYH/AN)L$PZ7!+J$P'H=WE*#]&85^Q
M-% 'PG\-_P#@CK\$/"/E3>)+G7_'%RO+QWEY]DMC]$@"N/QD-?4_PY_9U^&'
MPD6(^#_ /A_0)X_NW=K81BY/UF(,A_%C7HM% !1110 4444 %%5KG4K2S<)<
M74,#D9"R2!21Z\FL^X\9>'[23RY]<TV&3&=LEW&I_(FJ49/9$N26[-FBN7F^
M*7@NVE:.;Q?H,4B]4?4X01^!:J$GQR^&\,C1R?$'PM&ZG#*VM6P(/H1OK14:
MCVB_N(=6FMY+[SMZ*\X?]H[X6HS*?B!X>)4X.W4(R/S!YK/;]JOX2*I)\=Z5
MQZ.Q_P#9:M86N]J;^YD/$45O-?>CU>BO&)/VQO@Y%&SGQO;$*,G;:W#'\ (\
MFJ$W[<'P7CC9E\8-*PZ(FEWF3^<('ZUHL%BGM2E]S,WC,,MZD?O1[M17SU<?
MMY?!^&,LFM7T[?W(]-F!/YJ!^M9]Q_P4$^$\$89)=9N#G&V.PP?K\S 5:R_%
MO_EU+[B'C\*O^7B^\^E:*^6[G_@HM\+X$#)I_B2X.<;8[*$$>_S3"J5Q_P %
M(OATL9,&@>*)).RR6]L@_,3G^5:+*\:_^73(_M+"+_EXCZQHKY!F_P""D_@M
M8V,7A77GD[*Y@4'\0Y_E5*3_ (*6>'!&Q3P7JC/CY5:ZC )[9.#C\JM93CG_
M ,NW^'^9/]J8-?\ +S\S[+HKXG/_  4RTW''@&ZS_P!A-?\ XU5'_AYQ_P!4
MV_\ *[_]S5?]C8]_\N_Q7^9']K8+_GY^#_R/N:BO@^X_X*:7S2$P_#ZWCC[+
M)JS,?S$(_E4?_#S+4_\ H0;3_P &;?\ QJJ_L7'?R?BO\R?[8P7\_P"#_P C
M[THKX G_ ."EOB%I6,/@K3(X^RR7DC$?B /Y5C^*O^"BOC'7O#FHZ;8Z!IVC
M75U"T*7\$TCR0;A@L@/&X#.#V.#5QR/&MJ\4OFB'G.#2TE?Y,^D/C1^VUX(^
M$NJ2:/:)+XJUJ$E9[?3Y%6&W8<%7E.1NSV4,1@YQ7G7A?_@I5H.H:C'#K_@R
M]T:T9@IN;.^6[*9[E3'&<#VR?8U\ LQ9B2<D\DFDKZJGD6#C#EDFWWN_^&/F
M9YUBY3YHM)=K?TS]L_"?B_1?'6@VVLZ!J5OJNEW S'<V[94^H/=6'=3@CN*V
M*_)/X#_M.>*?@ FIV^CPVFI:=?E9'LM0#F-)!QYB;6&"1P?4 >@KUO\ X>3>
M./\ H6/#_P"4_P#\<KYRMD.)C4:I:QZ:GT%'.\/*"=72770_1&BOSLD_X*2^
M.S&PC\,^'5?'RLRSD ^X\T9_.J?_  \@^)?_ $ _"G_@)<__ "167]A8WLOO
M-?[:P?=_<?H_17YP?\/(/B7_ - /PI_X"7/_ ,D4?\/(/B7_ - /PI_X"7/_
M ,D4?V#C>R^\7]M83N_N/T?HK\X/^'D'Q+_Z ?A3_P !+G_Y(H_X>0?$O_H!
M^%/_  $N?_DBC^P<;V7WA_;6$[O[C]'Z*_.#_AY!\2_^@'X4_P# 2Y_^2*/^
M'D'Q+_Z ?A3_ ,!+G_Y(H_L'&]E]X?VUA.[^X_1^BOS@_P"'D'Q+_P"@'X4_
M\!+G_P"2*/\ AY!\2_\ H!^%/_ 2Y_\ DBC^P<;V7WA_;6$[O[C]'Z*_.#_A
MY!\2_P#H!^%/_ 2Y_P#DBC_AY!\2_P#H!^%/_ 2Y_P#DBC^P<;V7WA_;6$[O
M[C]'Z*_.#_AY!\2_^@'X4_\  2Y_^2*/^'D'Q+_Z ?A3_P !+G_Y(H_L'&]E
M]X?VUA.[^X_1^BOS@_X>0?$O_H!^%/\ P$N?_DBC_AY!\2_^@'X4_P# 2Y_^
M2*/[!QO9?>']M83N_N/OKQ_\.?#WQ.T"71_$>FQZA:-RA;B2%O[\;CE6]Q]#
MD<5^?GQ\_9)\0_"%I]5TOS-?\*@Y^UQI^^M1Z3*.W^V./7;D"K<7_!2'XD+(
MIDT'PL\>?F5;:Y4GZ'SSC\JMO_P4C\;2(R/X6\/,K#!5EG((]/\ 65WX7+\Q
MPK]U)KM<^PR#Q"ED,_W4G*F]X.]OEV?FOFF?/_A_Q%J?A76+;5='OI]-U&W;
M=%<V[E74_7T/0CH1P:^Z_P!GS]M33O&C6V@^.&@T?7&PD6I#"6MT>P;M&Y_[
MY)Z;>!7P=X[^(EOXRUZ;5+7PYIWAUICNEM=,+BW+=V5&)VY] 0/0"N<_MJ7^
MXGZU[&(RWZW#]Y&S_%'Z;FW'7!7$.&2QCG&I;1\CYHOM=:->6WHS]NJ6ORX^
M%?[;OC_X7Z&NC*MCK^G1 "W35!([VZC^%'5@=OL<XQQ@5VW_  \F\<?]"QX?
M_*?_ ..5\S+(<9&344FO4_"\1FV7TZLHTJG/%;/E:O\ )['Z(T5^>EM_P4H\
M8K(3<>%-#E3'"QO,AS]2Q_E5G_AY9XF_Z$W2?_ F6H_L/'?RK[T8_P!LX/\
MF_!GZ!45^?O_  \L\3?]";I/_@3+1_P\L\3?]";I/_@3+2_L/'?R_B@_MG!_
MS?@S] J*_/W_ (>6>)O^A-TG_P "9:GM?^"E^N*&^T>!]/E/\/E7SICZY0YH
M_L3'?R?B@_MC!_S?@S[[HKX+_P"'F6I_]"#:?^#-O_C5'_#S+4_^A!M/_!FW
M_P :J?[$QW\GXK_,K^V,%_/^#_R/O2BO@O\ X>9:G_T(-I_X,V_^-4?\/,M3
M_P"A!M/_  9M_P#&J/[$QW\GXK_,/[8P7\_X/_(^]**^"_\ AYEJ?_0@VO\
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M1[!U;'MBNTKX&<)4Y.$MUH?<0FJD5..S"BBBH+"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \FUK_D,W_\ U\2?^A&BC6O^0S?_ /7Q)_Z$:* .S^'_ /R!IO\
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MK$\#<H!/&<D"@#WZBBB@ HHHH *AO+R#3K.>[NI4@MH(VEEED.%1%&68GL
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?TK*NOV ?A)<>9LLM5MMW3RM08[/IN!_7-5_;V"E\47]R_S(_L3&1VDOO?\
MD?GM:_&KXAV2LMOX\\30!CDB+6+A<_D]6KSX]?$35+06NH>,=6U.U&,V]_<&
MXC; Q\RR9#?C7W5=?\$Z?AA<*H34?$MMCJ8KR$Y_[ZA-95U_P3:\",S_ &?Q
M-XBB4CY!*T#D''?$0SS]*/[6RV7Q1_\ )0_LO,([2_\ )C\YM6TO2=<:1KOP
M]H#229WR1Z+:1.2<Y.Y(P<\]>M<M-\(?"$Q<MHD0W')V22+^6&X_"OTPE_X)
MI^'6C81^--423'RLUI&P'U&1G\ZI'_@F;IN./'UUG_L&+_\ ':/K^4/>*_\
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M_P!#]=_^"Q?_ ([5X?\ !-/PUCGQGJN?^O:*C^T,I6R7_@/_   ^HYH]V_\
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MIV'\<FI3 G\F _2KT'[#_P %X8E1O"#S,.LDFJ7@)_*4#]*7]OX..T9?<O\
M,/[#Q<MY+[W_ )'Y5T5^LD/[&_P;AC5%\$6Q51@;[NY8_B3)DU?C_92^$D<:
MH/ FED*,#<KD_B2V34OB+#=(2_#_ #*60XCK)?C_ )'Y&45^P:_LW?"Q<8\
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MW^2/RCHKW+6?V*/C#H^H26R^%/[113\MS9WD#1N/49<,/H0#[5[3\ _^"?\
MJ4>L6NM?$EX;:UMI%E30K>19FG((.)G&5"9X*J23SR._TE7,L)2ASNHGZ.[/
MGJ678JK/D4&O561]$?L<^%[SPG^SKX2M;Z-HKFXCEO3&XP5265Y$_-&4_C7M
M%(JA5"J % P .@I:_+JU5UJLJK^TV_O/TJC35&G&FNB2"BBBL34**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M![>\6+A3+&Q4L!VW !L=MV.U0?M2?\F^>.?^P<W_ *$M &5^QO\ \FU^"_\
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MY^+7\A_\31Y'BC_GXM?R'_Q- '345S/D>*/^?BU_(?\ Q-'D>*/^?BU_(?\
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MY^+7\A_\31Y'BC_GXM?R'_Q- '345S/D>*/^?BU_(?\ Q-'D>*/^?BU_(?\
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MY^+7\A_\31Y'BC_GXM?R'_Q- '345S/D>*/^?BU_(?\ Q-'D>*/^?BU_(?\
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M:BN9\CQ1_P _%K^0_P#B:/(\4?\ /Q:_D/\ XFN<W.FHKF?(\4?\_%K^0_\
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M_P")H Z:BN9\CQ1_S\6OY#_XFCR/%'_/Q:_D/_B: .FHKF?(\4?\_%K^0_\
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M.1&!G/;M6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >3:U_R&
M;_\ Z^)/_0C11K7_ "&;_P#Z^)/_ $(T4 =G\/\ _D#3?]?#?^@K735S/P__
M .0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!\C^)?A_\1?V?_CAKOCKP%X?
M/C'PSXD=I]1TF*3;,DC,78#J1\Y9E8*P 8J1T)\R^'GCCXF^*_ASXN\#>#/A
M_>[M?UF^:\UJZ9DAM%FPLL&XJJB11P26R,_=SBOT%KD_AO\ #73/A?I>I6&E
M3W=Q#?ZC/J<K7CJS"64@L%VJORC' .3[F@#+^ _PM7X-_"_1_#!N%N[JW#2W
M5P@PKS.Q9]O^R,[1[**\0^/7Q4^(WB[0_&?@:Q^#.MRV5P\VGP:U%.[I+&LA
M"S+'Y'(8*& W=^IKZOHH ^2/V;_B)\1? ?AWP?X O_@]K<=C#<?9I]=FE>-(
MDEG9VE:,PG 4/TW\[>HKT7]K+X&W_P 9O!-C+H+K'XGT.<W5@'8()00-\08_
M=)VH03QE #@'(]RHH ^0[[]H;XV:MX1?PU#\'M;M?%LT)LWUOR9%M0Y&#,H,
M80'J1F3:#@Y(XKUS]EWX)2? WX:)IE\\<NN7TQO+]HCE4<J%6-3W"J!SZEB.
M#7L%% 'R-X\\ ^._@%\=M3^)?@3P]+XOT#7E;^T]'M 3.KL0SX"AFY<;PZJ<
M98$8Y./XQTOXD_MA>*-!T?5?!.H?#[P-IMQ]IO'U162:5L8)7>B$MM+*H52!
MN))[#[1HH BMK>*SMXK>"-8H8D")&HP%4#  _"I:** "O+_VB_@C9_'CX;W>
MA.T=MJT)^U:7>29 AN%! #$9.Q@2K<' .X E5KU"BM*=25*:J0=FB)PC4BX2
M5TS\6OB%\-_$GPK\0R:+XHTF?2KY?F02 &.9?[\;CY77W4G!R#@@@9?AOPWJ
MOC#7+71]#TZXU75+IML-I:1F21L<DX'0 <DG@ $D@"OVPU+3;/6+.2SO[2"^
MM),;[>YC$D;8((RI!!Y /X5%H^@Z;X>MFMM*TZUTRW9S(T-G L2%B "Q"@#.
M !GV%?7+B.?)9T_>]=/N_P""?+OA^GSW51\O:VOW_P# /"_V0/V;7^!7A&XO
MM<2!_&&KA3=F(AQ:0CE+=7Z$Y.YRO!; RP16/T%117RE:M/$5'5J.[9]-2I0
MHP5."LD%%%%8&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO_Q-'_"O]/\ ^>UU_P!]+_\ $T =-17,_P#"O]/_ .>UU_WTO_Q-'_"O]/\
M^>UU_P!]+_\ $T =-17,_P#"O]/_ .>UU_WTO_Q-'_"O]/\ ^>UU_P!]+_\
M$T =-17,_P#"O]/_ .>UU_WTO_Q-'_"O]/\ ^>UU_P!]+_\ $T =-17,_P#"
MO]/_ .>UU_WTO_Q-'_"O]/\ ^>UU_P!]+_\ $T =-17,_P#"O]/_ .>UU_WT
MO_Q-'_"O]/\ ^>UU_P!]+_\ $T =-17,_P#"O]/_ .>UU_WTO_Q-'_"O]/\
M^>UU_P!]+_\ $T =-17,_P#"O]/_ .>UU_WTO_Q-'_"O]/\ ^>UU_P!]+_\
M$T =-17,_P#"O]/_ .>UU_WTO_Q-'_"O]/\ ^>UU_P!]+_\ $T =-17,_P#"
MO]/_ .>UU_WTO_Q-'_"O]/\ ^>UU_P!]+_\ $T =-17,_P#"O]/_ .>UU_WT
MO_Q-'_"O]/\ ^>UU_P!]+_\ $T =-17,_P#"O]/_ .>UU_WTO_Q-'_"O]/\
M^>UU_P!]+_\ $T =-17,_P#"O]/_ .>UU_WTO_Q-'_"O]/\ ^>UU_P!]+_\
M$T =-17,_P#"O]/_ .>UU_WTO_Q-'_"O]/\ ^>UU_P!]+_\ $T =-17,_P#"
MO]/_ .>UU_WTO_Q-'_"O]/\ ^>UU_P!]+_\ $T =-17,_P#"O]/_ .>UU_WT
MO_Q-'_"O]/\ ^>UU_P!]+_\ $T =-17,_P#"O]/_ .>UU_WTO_Q-'_"O]/\
M^>UU_P!]+_\ $T =-17,_P#"O]/_ .>UU_WTO_Q-'_"O]/\ ^>UU_P!]+_\
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MT?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\
MGM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T
M =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T_
M_GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$
MT?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\
MGM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T
M =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T_
M_GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$
MT?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\
MGM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T
M =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T_
M_GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$
MT?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\
MGM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T
M =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T_
M_GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$
MUCZYX7M=,O-.BBDF9;F78^]@2!E1QQ[T =]17,_\*_T__GM=?]]+_P#$T?\
M"O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?
M]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-1
M7,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=
M?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\
M"O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?
M]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-1
M7,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=
M?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\
M"O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?
M]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-1
M7,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=
M?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\
M"O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?
M]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-1
M7,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=
M?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\
M"O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$UC^&?"]KK5G-+/),
MK)*4'EL ,8![@^M '?45S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__
M !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\
MPK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]
M]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_
M /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__
M !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\
MPK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]
M]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_
M /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__
M !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\
MPK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]
M]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_
M /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__
M !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K \2V-Q>7^D/#$TBQ3;G*_P (RO/Z&M^B
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K \&V-
MQ86%PEQ$T3-,6 ;N,#FM^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@# \16-Q=:IHTD,32)#-ND8?PC<G)_(UOT44 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'DVM?\AF_P#^OB3_ -"-%&M?\AF_
M_P"OB3_T(T4 =G\/_P#D#3?]?#?^@K735S/P_P#^0--_U\-_Z"M=-0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44C,%4DG '))I
M$D61%=&#HPR&4Y!'K0 ZBBL_4O$&EZ/=6=M?ZE9V-Q>OY=K#<SI&\[9 VH"0
M6.648'J/6@#0HHHH ***;)(L:[G8(OJQP* '4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 44WS$$@CW+YA!8+GD@8R<?B/SIU !116?H_B#2_$4,LNE:E9
MZG%$_ER26<Z2JC8SM)4G!Y''O0!H44V21(@"[*@)"@L<9). /KFG4 %%%-$B
M-(R!E+J 67/(!S@D?@?RH =1110 4444 %%%% !1110 4444 %%%% !1110
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MCWKY@&XKGG'KCTI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-CD29 \;*
MZ'HRG(- #J**S]8\0:7X?CBDU34K/38YG\N-KR=(@[?W06(R?84 :%%%-61&
M=D5E++]Y0>1GUH =1136=8U9F(55&2Q. !ZT .HI <C(Y%+0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !136D175&90S?=4GDX]*=0 445GZ;X@TO6;B\M]/U
M*SOI[-_+N8K:=)&@;)&UPI)4Y5N#Z'TH T**;)(D*%Y&5$'5F. *=0 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-):;*DM)-YCDC<(\\L.FXJO!^[* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OECXH_$WXK_
M !/UKQ#X*\"^%KCPUI%G//9WWBR]+*KQ(2KF%BH S@_<+MR,;>M?4]4==_Y
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M87:01EL !0RLZ-N4#()!'&3]H:AJ%MI-C<7M[<1VEG;QM+-/,X5(T R68G@
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M7^; .  <D8[UQOP=^.7A+XY^#;;6Y!I]AJ-NS"YTN[G266R<$@'+*N590"&
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M?_XNNH^'?[,?@#X5ZY-J_AO3;FQU"6V>T:9KV63$;D$X#,<'Y1S0!Y=\"/\
MBZW[4'Q)^(,G[[3M%QH>F-U3@[6=#_NQL?\ MO7T5XT\::-\/?#=YKVOWT>G
MZ9:+NDE?J3T"J.K,3P .36?\-?A=X<^$GA^31O#-DUE827#7+J\K2LTC!06+
M,2>BJ/PI_P 2/AIH'Q8\-G0O$EK)>:;YRS^7',T1WKG!W*0>YH ^4K34;O\
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M]B:*;7M0:>+<N"\**$5OH6\S'M@]Z^GJBM;6"PM8;:VACM[:%!'%#$H5$4#
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MT9SR#D?Q4 >\T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'DVM?\AF_P#^OB3_ -"-%&M?\AF__P"O
MB3_T(T4 =G\/_P#D#3?]?#?^@K735S/P_P#^0--_U\-_Z"M=-0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >3:U_P AF_\ ^OB3_P!"-%&M?\AF_P#^OB3_ -"-% '9
M_#__ ) TW_7PW_H*UTU<S\/_ /D#3?\ 7PW_ *"M=-0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >3:U_R&;_\ Z^)/_0C11K7_ "&;_P#Z^)/_ $(T4 =G\/\ _D#3
M?]?#?^@K735S/P__ .0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >3
M:U_R&;__ *^)/_0C11K7_(9O_P#KXD_]"-% '9_#_P#Y TW_ %\-_P"@K735
MS/P__P"0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >3:U_R&;_ /Z^
M)/\ T(T4:U_R&;__ *^)/_0C10!V?P__ .0--_U\-_Z"M=-7,_#_ /Y TW_7
MPW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!Y-K7_ "&;_P#Z^)/_ $(T4:U_
MR&;_ /Z^)/\ T(T4 =G\/_\ D#3?]?#?^@K735S/P_\ ^0--_P!?#?\ H*UT
MU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!Y-K7_(9O_P#KXD_]"-%&M?\ (9O_ /KX
MD_\ 0C10!V?P_P#^0--_U\-_Z"M=-7,_#_\ Y TW_7PW_H*UTU !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!Y-K7_(9O_\ KXD_]"-%&M?\AF__ .OB3_T(T4 =G\/_
M /D#3?\ 7PW_ *"M=-7,_#__ ) TW_7PW_H*UTU !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!Y-K7_(9O\ _KXD_P#0C11K7_(9O_\ KXD_]"-% '9_#_\ Y TW_7PW
M_H*UTU<S\/\ _D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444
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MVJV]ESD#:ZG)[,*QM)^.'P_U[7ET73O&6C7FJ,_EI;0WB,9&Y^5#G#'CH":
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MAKX4_91_9OT3XZ?#O4=>U[Q#XDM+RWU62Q1-.O42,HL,+@D/&YW9D;OC '%
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M-"[Y:-@=HSY?..X]: /I>BN5\$_$[PM\0!)%H'B'3M:N;>-7N$LIUD,>> 6
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M(((/O67=>.O#UCXJM?#5QK-E%X@NH_-@TUIE$\B88[@G4C",?^ F@#=HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /)M:_Y#-_\ ]?$G_H1HHUK_ )#-_P#]?$G_ *$:* .S^'__
M "!IO^OAO_05KIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S_$
M.M0>&] U/5[H,;;3[66[E"?>*(A9L>^ :_.OQ/\ MO\ Q1UC5IKC2]4MM LF
M8^59V]E#*%7L"TJ,2??CJ>!TK]'KVS@U&SGM+F)9[:>-HI8G&5=6&"#[$$U\
MAZ]_P3KTV\U:XFTCQK/INGNVZ*UN-.%P\8]/,$J9'_ <_6O7R^IA:?-]87I=
M7/TC@_&9#A'5><P3;MRN47-6UNK)/7SL>#_\-D_&'_H;_P#RF6?_ ,9H_P"&
MR?C#_P!#?_Y3+/\ ^,U[1_P[C_ZJ'_Y1/_NBC_AW'_U4/_RB?_=%>S]8RWLO
M_ ?^ ?IG]M<#_P E/_P2_P#Y \7_ .&R?C#_ -#?_P"4RS_^,USWCK]HKXB?
M$K06T7Q'XC>_TQI%E:W6U@@#,O3<8T4D \X)QD ]0*^B?^'<?_50_P#RB?\
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M-\S=)R=^MVH._P!YXO\ \-D_&'_H;_\ RF6?_P 9H_X;)^,/_0W_ /E,L_\
MXS7M'_#N/_JH?_E$_P#NBC_AW'_U4/\ \HG_ -T5E]8RWLO_  '_ (!P_P!M
M<#_R4_\ P2__ ) \K\-_MO?%/1]4AN-1U6VUZT5@9+2YLH8@R]P&B12#[\]N
M#TK]$_#&O0>*O#6DZU:JR6VI6D-Y$K_>"2('4'WPPKY-T;_@G386VI02ZIXW
MGO[%6!EM[?3! \@] YE?;]=IKZ]T_3[?2=/MK&SA6WM+:)888DZ(B@!5'L
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M022-*A(]#N8?53Z4 <'X^\.VG[,7[3W@/5O"B_V5X<\72?8+_2H<^1GS$1V
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MG@WPSJ.C^&_%5W#%-XC<VMG:75I)+#=-N52C$(4'+J/G('S"@#QR3X2_ O\
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MWGFP 947S8C&S8RW+ GG ).?&_\ AQC_ -5L_P#+4_\ NV@#Y5_X>C?M._\
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M?AG\ _CQ\/WT7P=%H-C?209AGM8534K5N#N=21(V,<[B0>>:]'\0^%;CP/\
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M(RCD+MRH]2W&<&NW_9I^'MS\,?@KX;T.^B,.I+$US=QD\I+*Y<J?=0P7_@-
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M6!&PO1=R3LIQQBNC_P""??\ R!/B#_V&1_Z":/VU_P#DJ/P(_P"PS-_Z/LJ
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MMU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0!\^>#_V&_AGX4UM-4N(]4\27$;B1$UNY26,,.Y5$0-]&R/:O9O''@^R\?\
M@_5O#FH23P6.I6[6TTEJRK(JGJ5+ @'Z@UNT4 <Q\-/A]IWPK\#Z9X6TF:ZN
M-/T]76*2\=6E.^1I#N*JHZN>@'&*\R\:?LA^%/$OBJZ\1Z/JVN>"]6O"3=R>
M'[L0).3RQ*X."3@G! )R2,G->Z44 >6?"/\ 9Q\)_!V^N]4T_P"VZOX@NU*S
MZQJTPFN&!.6 ( "@GK@9.!DG%;WQ6^#_ (9^,WA]=)\2V;31Q/YEO<P/LGMW
MQ@LC8XSW!!!P,@X%=K10!\ZP_L6Z->1V]EK_ ([\9>(]#MY%DCT>]U/_ $8D
M=F7'3K]W:>>M>^Z9HMAHNDV^EV-G#::=;Q""*UB0"-(P,!0O3&*NT4 ?/6L?
ML4^$9-:O-0\.:]XC\%I>DFXL]#O1% V3G 4J2!R>,D#L!7HOPA^!GA3X)Z7<
M6OARUE,]T0;K4+R3S;FX(Z;FP  ,GA0!R3C)KT"B@#SN\^!VA7WQFL?B9)=Z
MB->L[8VL=NLD?V4J8W3)79NSB0_Q=0*V/B9\+_#OQ<\,R:'XEL1=V;,)(W4[
M989!T>-OX3^A!(.1Q7644 ?.*?L3:+=V\&G:SX\\::WX?MV5HM'NM2'V<;2,
M KMQCC^$*?0BO=[/PKIFE^%U\/:?:II^DQVQM(H+8!1'&5(POOSU.>>M:]%
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M_$/["7@RZU:?4?#>M:YX/EF.6ATZX!A7V4$;@.O&['/&.E=)\*_V0_!/PO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#R;6O^0S?_P#7Q)_Z$:*-:_Y#-_\
M]?$G_H1HH [/X?\ _(&F_P"OAO\ T%:Z:N9^'_\ R!IO^OAO_05KIJ "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#R;6O^0S?_\ 7Q)_Z$:*-:_Y#-__ -?$G_H1HH [
M/X?_ /(&F_Z^&_\ 05KIJYGX?_\ (&F_Z^&_]!6NFH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /)M:_P"0S?\ _7Q)_P"A&BC6O^0S?_\ 7Q)_Z$:* .S^'_\ R!IO
M^OAO_05KIJYGX?\ _(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\FUK_D,W_P#U\2?^A&BC6O\ D,W_ /U\2?\ H1HH [/X?_\ (&F_Z^&_]!6N
MFKF?A_\ \@:;_KX;_P!!6NFH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)M:_Y#-__
M -?$G_H1HHUK_D,W_P#U\2?^A&B@#L_A_P#\@:;_ *^&_P#05KIJYGX?_P#(
M&F_Z^&_]!6NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /)M:_Y#-__P!?$G_H1HHU
MK_D,W_\ U\2?^A&B@#L_A_\ \@:;_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \FUK_ )#-_P#]?$G_ *$:*-:_Y#-__P!?
M$G_H1HH [/X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#R;6O^0S?_ /7Q)_Z$:*-:_P"0S?\ _7Q)_P"A&B@#
ML_A__P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_ $%:Z:@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \FUK_D,W_\ U\2?^A&BC6O^0S?_ /7Q)_Z$:* .S^'_ /R!IO\
MKX;_ -!6NFKF?A__ ,@:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \F
MUK_D,W__ %\2?^A&BC6O^0S?_P#7Q)_Z$:* .S^'_P#R!IO^OAO_ $%:Z:N9
M^'__ "!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R;6O\ D,W_ /U\
M2?\ H1HHUK_D,W__ %\2?^A&B@#L_A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\
MKX;_ -!6NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBH+Z^MM-LYKN\N(K2UA4O+/.X1$4=2S'@#W- $]%1P3QW4,<T
M,BRPR*'22-@RLI&001U!%24 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DVM?\ (9O_ /KXD_\
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M))%.)FVN!RK21QQ)_>(=A\O- 'Z:WU];Z78W%Y=RK!:V\;32RN<*B*"68^P
M)KX:_9E_:IUG2?V8?BM^T+\3-6U'4O#UQK]Y-H.E.1^ZM%D$4%O#QQNFD,63
MG&P$G@UZU_P43^*!^%?[(7CZ\@E\O4=6M1H5FH^\SW3>4^WW$1E8?[M=1\%_
MV=O#?AW]E_P/\,/%?AW3==T^PTJW6^T[5+5+B%KLCS)GV.",^<\C ]03P: /
ME?X>^(/VW_VF/"<'Q(\->*_!_P ,_#FI@W.D>'[NQ25[B#^!F9[>5PK8X8L"
MVXL%52M>N?L3?M?^(_C5XD\8_#'XFZ);^'OBMX.=OMT5GQ!=PK((VE1=QVE6
M9 <$J1(C*<' Z/\ :8_;"\#?L6Z/H&AW'A;6=4>73G.F:;X?M8Q;VT$ 5$61
MF=?*C'"C"M@ \<5\[?\ !,G3&^,OQF^*7[16M:UHH\0^(@]C'X9TV\$T^G6[
MRHVZ=<Y0$6\2ID?,%<\=* /T%\6>+M$\">'[W7?$>K6>AZ-9)YEQ?7\RQ0Q+
MTY9CCDX '<D 5^>_AW_@I%J?QU_;K\ ^ _AS?-9_"]Y[BUO99K./S=9<02OY
MG[Q"\,:LB[0I5CR6ZA5^M_VE/V5?"G[5%KX7T[QG>:DNB:)>O?/I^GS>2+QR
MFP+(^"0H&?NX;G@BOC+XF_#_ ,.?"_\ X*K?LZ^&O">C6F@:%8^%E2"QLH]B
M+\^JY)[LQ/)8DDDDDDT ?IK7R3^VK\4O%EC\4_@/\+/ NNW6A:SXN\1_:-3N
M=/8"9=,@ \]3D'Y2KNWUAKZVKX@^'/\ Q>[_ (*??$+Q.?\ 2=%^%OA^'P_9
MR+]U+RXW&0_4;KQ#_NCVH ^L_B=\5O"/P:\)W/B7QKK]GX>T6WX:YO'QO;!(
M2-1EI'.#A%!8XX%?$/[*/[?7B;]JC]MC7-!TR5M+^%MOH=Q+I^D36T/G2R12
M1*+F63:7#,';Y VT# P2"Q^C_CU^QCX"_:5^(GACQ-X].H:I9>'[5X+?0HK@
MPVLS.X8O*5^<] ,*5SCG(XKY7^#&AZ=X9_X+&?$S2=(L+;2]+L_"EO!;65G$
ML4,,:V&F *B* % '84 ?H/XX\9Z1\._!^M>*->NELM%T>TDO;NX89V1HI9L#
MN<#  Y)( K\^_AS\;_VN/VVVU3Q7\*K_ ,.?"+X=P7+6UA/JULEU/>%?O#+P
MR[R,@,P5%!^4%BK5]/?\% /#^J>)_P!C?XIV&CK+)??V6+C9"NYVCBFCEE '
M?,:./QKF/^"9?CKPWXN_8]\#V&@W4+76AP26&IV:L/,M[GS7=BZ]M^[>#T(;
MV. #EOV?/VL/B1X9^/0^ O[0FFZ7:>-+NW^U:#XCT?Y;/5XP&.". "WER;2%
M3)0J45L9^TJ_+3_@HU\5](_X;D_9]T_0KR*7Q#X7U*UEU&2W<,T7G7L)C@?L
M&VH[%3VE&>M?J70!\^^,K7X]M^UYX-G\/WD*? A=-(URV867F-=[+G!!9?M'
MWC:_<8#C_>KZ"KX6^+7Q7\9:3_P54^$W@>R\3:I:^#]1\/M<7>AQ7++:3R>5
MJ)WO'G!.8H^?]@>E>1?$7XU?'O5O^"B7Q(^$GPU\530+JUO;V=F=3F:6RT&+
M[):SSW<<)!4. LBC@\RGN00 ?J-17Y@_M"_!?]I/]CKP+<?%K0?VC?$'Q M]
M)G@DU;2=<24P>6\H3<D4D\J%-SHI0!2%)(/R\?H#\!?B@OQI^#/@SQRML+-]
M=TR&]EMUSMBE9?WB#/4!PP![@"@#O:**_.?Q9X^^*7[7_P"V)X^^$/ASXK77
MP<\*>"XBGEZ.I74M3D4A7D5@R.1ECT<*JA"%);=0!^C%?-'[<G[6=_\ LJ>#
M_#%SH^AV^L:QXCU,:;;R7DA6"UX!:1E7E^#@*"OKGC!\5N/AS^U!^RK\7/ \
MWA[QWXD^//P[U6]%OK.GZM!YUU8P;E#.9'=B#L)97#J"R$,I!Y\F_P""OOPQ
MU^Q\5>#O%4WCW5;O1M<UB.UL?#<BG[+I,B01JTT)W\LY!8_*.6/- 'ZM45\G
M^+/%FK?\$_/V6O%?B#QCX]U?XN:Y]O9M*NM<1ED>>:...&U/[QB(E:-Y&.X<
M%\<XSXQ\+?V;_P!I?]I;P7IWQ(\:?M&>(OAW>ZY$M_IWA_P[!)'#;0.H:$RQ
MQS1+RI!\LACC&YBQ( !^B]%?!_[+O[1GQ0^&?[2E[^S?\=-2@\0ZQ);-=^&_
M%,495[] K2!7. &!C63#$;E>)T)?((T/VSOVE/B1??&_PG^SO\$+J#2_&^N0
MB[U3Q!,@<:=;D,P5<A@A\N-W9MI(4H$^9N #[@KYW_;^^*_BKX)_LJ^+O&'@
MO5/[&\1V$MBMM>_9XI]@DO(8W^25&0Y1V'*G&<CFOG+XH?LN_M)?L_\ @&_^
M(G@S]H_Q9X\\0:)";^]T#6(Y)[:[B0$RB&*265<A<D)MRV."#BMO]LWXF:K\
M8/\ @EOJWBS7?#M[X3UR_73OMVD7UO) \$Z:E"CX60!MC%2RD_PLO)H ^LOV
M;?%VK>/OV>_AMXEUZ[^WZWJ_AZPOKVZ\M(_-FD@1W?:@"KEB3A0 .PKTBOS_
M +K]LZU_9X_9!^"/A/PG8_\ "6_%[Q!X2TJ'1?#ULAF:,O;1JL\R+SMS]U.K
MD8& &8>[_L=_!GXF?#WPI+KWQ>\?ZUXN\;ZROFSZ;<7S26&E*QW>3%&#L+YQ
MN<#:,;4^4$N ?1-%%?F_-\6/C)^WY\>?&/A+X4^.I_A9\)O!\PMKKQ%80-]L
MO9<LH*L&5CN9)"JAT 0!FRQ H _2"BOS3^+EO^T1_P $[XM)\?K\5-2^-GPU
M^U1VFM:;XF21KFW$C8#"1Y)& )&U9 X 9T4HP->\_MT?&J]B_8.UCXD?#OQ!
M?:1)?V^E7VFZK8R-!.L,]U;]QRI*.01[D4 ?6=%?E_\ "7X;?M7?M;^#_"_Q
M0M_C-<?#S166W@TO1[>\G!N;:'$4MS/L&V220I(_[T/N)YVKBOT^1=JJN2V!
MC<W4T ?/_P"T=:_'NX^)WPG?X2WD-MX.CU+/C*.461,EIY]OPOGJ7_U?VC_5
M$'GUQ7T%7PM_P4 ^*_C+X?\ [1G[,.D>&_$VJ:'I>O>(/L^J6=C<M%'>Q_;+
M%=DJ@X8;9'&#V8^M<!^VK\?OC#\/?V]/!'A'X9ZO<32ZUX=AMK30;JX8:<;R
MXDNX5N98ONMY?R29(Q^Z&<@8H _2BBOS=^,'[*O[3GPI^'NN?$S2OVGO$7B/
MQ-H]E)JE]H;I+#8R)&OF2K#&9GBRJJQ"F$!\8PN<5].?LA?M-'XW_LK:9\3?
M%7D:==V4%TNM2PH5A5K8MYDJCG **'QV)('2@#Z&KXO_ ."@G[0OQ ^!_C[X
M"Z;X*U_^Q;+Q/KLMGJT7V.WG^TPB6T4+F6-BG$LG*%3\W7@8\:^$MS\?/^"C
MVL>(_&]E\5-7^"WPOL+]['1[#P\'2YN"H!^9XY(R^ R%G9V7<2JJ!G'C/[77
MAOXP_#7X[? OP-\3?%:_$+1+'7X[[P]XKEMC#=7"2W-LL\$_S'+1M&AZL<2@
M[B"%4 _9NBOG/]NC]JI_V4_@^FKZ59PZIXPUFZ73=#L9U9HVF(RTCA2"51>P
M(RS(.,DCQ70/V-?VE?&?AVW\3>*_VG_$GAOQQ<I]J_L;2HF.FVCL-WDNB2HC
MXX!PFU>0-PY(!][45\;?L5_M*^-/'GC#Q[\"_C%Y ^)O@Y#NU+3RT(U.SRJ&
M<%=NUQYD3!U";EF0A5*M7FOPR^,WQ _9#_;(O/A/\7_%^J>*O /C(J_A;Q)K
MER93 Q8B)6D;IDGR9!V?RWX5LD _1.BOSN@^,7C[]N;]KM_#OPS\6:QX3^"G
M@5]NLZWHER]NVKR;N461>HD*%4YX17DZL%K]$%7:H49P!CDY- "U%=>;]EF\
MCB;8VSI][''7WJ6JVI2-'IMVZ$JZQ.0PZ@[30!X7^QK:_':U^'>KK^T!>0WO
MBLZJYLG@%F +/R8MH_T553/F>;U&[\,5[[7YG?L<?'+X@^,O^">/Q\\6ZYXR
MUK5O$^D?VK_9^K7=X\ES:^7IL,B>6Y.5VNQ88Z$DU@_LJ:3^TE^V]\'=-FN?
MC/JWPX\(:&\M@-7T\R3:MK=UYC2/)),)(W"(LB1C#X^3&T\F@#]3Z*_-WX._
M$KXT_LH_MG^'/@;\3/'5Q\3O"7BRT$FEZQJ 9[E"5D$;[G9G4^9$R.C.XP58
M'GGV3]OS]JCQ7\&U\&?#GX7P1W'Q1\=77V73YI(UD%C$76,2[6RI=G<!2P*@
M)(2. " ?7U>;_M)>+M6\ _L]_$GQ+H-W]@UO2/#U_?65UY:2>5-' [H^UP5;
M# '# @]Q7R-JO[$_[2NA^$9_$^F?M1>*-4^(<$)NQHSO+_94\P ;R$5Y2F"1
M@,T6#P"J@FNETGXW>+OCO_P3;^*6M^//#=]X;\5VGAG5K&]6\L9+1+TK9EEN
M8E=1\KJXSMX#*X&!@4 >J?L _%?Q5\;/V5?"/C#QIJG]L^([^6^6YO?L\4&\
M1WDT:?)$BH,(BCA1G&3S7T17Y9>"O'/B'X;_ /!%VU\0>%M9O= UNUO'$&H:
M?,T4T8?7"C;6'(RK,#[$U]^?LM:]J/BG]FOX6ZSK%[/J6JW_ (9T^YNKRY<O
M+/*]NC.[,>2Q)))]Z /4:*^%O"OQ7\977_!6+QEX$F\3:I+X-MO#\=Q#H37+
M&TCD-G:,7$>< [G8Y]6--_;&_:*^)?BC]H+PS^S?\$]2CT#Q-J< N];\1LFY
M["%D9]BG!\O$2^86 W'?&JE23D ^L_CIXDU'P;\$?B%K^CW'V/5M*\/:A?6=
MQL5_*FBMI'C?:P*MAE!P00<<@UXU_P $^/C!XS^.W[+&F^+/&6K_ -M^)KB[
MO83>?9H;?(20K&-D2*@P,=OK7SG\?/V=OVA?V<?@?XQ\2:5\=-9^+FBMI%U:
M>(O#_B>WE?-G-"T4UQ;L\TA5HP_F;05P$)RP!1O5O^"4LC1_L-Z2Z$JZWVI$
M,.H/G-0!ZM^QK:_':U^'>KK^T!>0WOBLZJYLG@%F +/R8MH_T553/F>;U&[\
M,5[[7YG?L<?'+X@^,O\ @GC\?/%NN>,M:U;Q/I']J_V?JUW>/)<VOEZ;#(GE
MN3E=KL6&.A)-8/[*FD_M)?MO?!W39KGXSZM\./"&AO+8#5]/,DVK:W=>8TCR
M23"2-PB+(D8P^/DQM/)H _4^BOS=^#OQ*^-/[*/[9_ASX&_$SQU<?$[PEXLM
M!)I>L:@&>Y0E9!&^YV9U/F1,CHSN,%6!YY]9_;X_:B\:?#C6O!'PB^$JQ?\
M"S_',RI!>2HK_8+=G\L2!6! 9F#?.P(58Y#C." #[)HKX"NOV2_VG_A)X;E\
M:^&_VC]:\<>,K"'[;/X5UJ&:?3;\J-SVT>^9L9 *J0B%CCF/.18_X)2_''QI
M\=-)^+&K^,=<U#5GCUJ%K2UO;EYDL8Y%E8PQ;C\JC@8_V10!]ZT45^:?[;_Q
M^^,'P_\ VYO"?@SX9ZU=FXU_PS!9V.C2W)%BM[<S74*W3QG*ED 5LL,9C4G(
M&* /TLHKXH^#?PU^+/['MOX\^)7QJ^-=]\0O!]EH+W3Z8UQ/-Y=V&5CY:S9"
M\+Y:;"H8R\J,"O./@YX/_:+_ &\O#LWQ-USXPZI\'/!NI2R)H6@^$5>.1HHW
M*^8[K(C;=RD99F+X/"+M! /T>KY]\96OQ[;]KSP;/X?O(4^!"Z:1KELPLO,:
M[V7.""R_:/O&U^XP''^]7@7P^^,WQ:_9%_:8\*_!SXR>+5^(O@SQH?*\.^+Y
MX#'=QW!81I%)R2<R%%96+D>;&P?&Y:UOBU\5_&6D_P#!53X3>![+Q-JEKX/U
M'P^UQ=Z'%<LMI/)Y6HG>\><$YBCY_P!@>E 'W317Y<_$7XU?'O5O^"B7Q(^$
MGPU\530+JUO;V=F=3F:6RT&+[):SSW<<)!4. LBC@\RGN018_:%^"_[2?['7
M@6X^+6@_M&^(/B!;Z3/!)JVDZXDI@\MY0FY(I)Y4*;G12@"D*20?EX /T^HK
MY$^.7CKQA\=O^"?B?$KX?ZOJ?A'Q6=&M_$B#1[EX7S$NZZ@RIRR;?.VCN50U
MZ3^Q/\;&^/\ ^S-X)\675S]IUDVGV#578Y<WD!\N1F]"^T2?204 >Y45\%Z!
M\:/%/Q@_X*,>,+6P\6ZEI/PB^%FDR?VO:VUR\=G=W4:LK^<J_>(E>7KU6T_"
MN2^''B7XZ?\ !1KQ'XE\2^'?B/?_  8^#FEWTNFZ8-#C9=1U!A@[F<.K!MC(
M6;<%4L%520S4 ?I#17YR^)/B'\9O^"=?Q(\'_P#"P_B'<?%SX+^)+Q=/GU;6
M(&&H:5)U+%BS,2%)?EF#K&XVH0">Z_;X_: \=Z'\4_A;\%_ 7B>V^']QXWDW
M7OBZX4$V\1<QK'$Q& Q.3E2&)\L!EW$D ^X*X+X\?%6/X'_!WQ9X\ETYM670
M;%[S["DHB,Q! "[\':"2.<''H:^,?B?^RK^TM\#_  A<>,?AK^T-XR^(?B&P
M99I?#FLQ-<K>@N PA22251@'/E[>0&PP.!6]^V_X;\>?%[]A^V\::SK>K?#7
M5M)T&2[\1^$;9#Y.HS/Y*M#+^\X171V7.XX?GF@#Z3_91^+VI_'K]G_PCX^U
MBTM;#4=;BGGDM;(-Y406XEC51N))PJ+DD\G)XZ5ZU7P7_P $Q?A#XH\-? OP
M]X_NOB;K>K^'M4T&\M[/P9<*19:;)]K)$T1WGYAY3_PC_7-^/SU^QCXJ_:4_
M;,\!ZMX.LOBIJGA+0-)OVN]5\;R2R7.J3M*B+%90MO1D51')(2KKR_)Y (!^
MO-%?DUXG^)W[1O["O[0MI\+HO'-U\:D\:V,:>'Y?$\TKM%=3R-#"Y,CR.ICD
M7YDW['5L_*3\O9?M!?L[_M,_ [X8ZO\ %^']IK7]?\0:-&NHZGH:K)!IVT,O
MF"",RF%E3D[6A4,H/ ^Z0#],Z*^?OA+^U)9ZY^QGI'QO\6HMI%'HDE_J26HX
M>:%GBD6,=B\D9"KV+ 9[U\Q?!SP?^T7^WEX=F^)NN?&'5/@YX-U*61-"T'PB
MKQR-%&Y7S'=9$;;N4C+,Q?!X1=H(!^CU%? 'P^^,WQ:_9%_:8\*_!SXR>+5^
M(O@SQH?*\.^+YX#'=QW!81I%)R2<R%%96+D>;&P?&Y:Y;]M7X_?&'X>_MZ>"
M/"/PSU>XFEUKP[#;6F@W5PPTXWEQ)=PK<RQ?=;R_DDR1C]T,Y Q0!^E%%?F[
M\8/V5?VG/A3\/=<^)FE?M/>(O$?B;1[*35+[0W26&QD2-?,E6&,S/%E55B%,
M(#XQA<XKWGX!_$?Q+^V]^Q9::C%XDNOA_P",M2!L;K7=$C(>VN+>X4M)$N\8
M$B(,C<,>8PZ"@#2_9#_:SO\ ]J#QA\6;:30[?0]'\):G!IMC&LAEGFR9Q))*
MW Y,2D*H^7D9;K7TO7Y#_P#!,WX'^+/%GQ0^(6J:;\5]>\.V?A7Q5:/JFG6:
M$Q^(0D\S,MQ^\& XC=3PW$K?C^O% !17(?%[XGZ1\%_AEXD\<:[YATO0[-[N
M6.$9>0CA8U_VF8JHSQEAGBO@3X,>!?VD/V\/#LGQ/U_XU:O\(/"FH32+HFA^
M%(Y(F:%'92Y*2QG;N! 9V=GP3\J[<@'Z55\J_P#!1O\ :>\0_LN_ FVU;PC'
M&/$^MZDFE6=Y-&LJ6>8WD>78P(=@(]H4C&6R<XP?'/A_\;?B_P#L>_M->&/@
M_P#&CQ6/B)X(\9.(M \7SP%+J.9F$:(YR3_K"BNC,^WS48/C(/F7_!7SX2^)
M-'_L?QI=?$;6-3T#6O$,%M9>$IE/V/2W6T(,L1WG+$QL?NC_ %AH ^O/V3?A
M;^T7X+UZXU7XT?%&R\8:9=Z6$BT2UMT5K2[,B-N,@A3=M0.O!P2YX. :^GJ\
M>_9S^"?BOX+:7K5KXJ^*FN_%*:_FCD@N-<0JUHJJ043,C\,2">G2O4M>URR\
M,Z'J.L:E.MKIVGVTEW<SMTCBC4N['Z*"?PH OU\7_P#!03]H7X@? _Q]\!=-
M\%:__8MEXGUV6SU:+[';S_:81+:*%S+&Q3B63E"I^;KP,>-?"6Y^/G_!1[6/
M$?C>R^*FK_!;X7V%^]CH]AX>#I<W!4 _,\<D9? 9"SL[+N)55 SCQG]KKPW\
M8?AK\=O@7X&^)OBM?B%HECK\=]X>\5RVQANKA);FV6>"?YCEHVC0]6.)0=Q!
M"J ?H]^V5:_':Z^'>D+^S_>0V7BL:JAO7G%F0;/R9=P_TI63/F>5T&[\,U[Q
M:^;]EA\_F;8N_I]['/3WKXD_X*V?%3QA\)?@)X5U3P7XEU/POJ5QXFBMI;K2
M[EH)'B-K<L4)4\KN53CU K%_:+^+7C;]G3]MKX->(KWQ5JLGPI\:PQZ9J&DS
MW3-96]UM$+R;"=J >;;RYZDK)[T ??5>!?ME6OQVNOAWI"_L_P!Y#9>*QJJ&
M]><69!L_)EW#_2E9,^9Y70;OPS7<_M#_ !9MO@7\$?&?CNY*9T73I)X$D^[)
M<$;((S_O2M&O_ J_+WXE?%#XV?#C_@G;X!^(&H?$OQ2GB[Q?XO\ M*WC:E*)
MHM/-K<"*$'/".8A-@==Z^@P ?L#:^;]EA\_F;8N_I]['/3WJ6OBW]NO]JCQK
M\,_^%>?"SX5B-OBAX\>.."]E02&QA9EC$@5@5W.Y;YF!"K'(2,X(Y6\_95_:
M<^"_AF;QUX<_:*UKX@>+=-B^WW/A/7()IM.U':-TEM%OF;;E=RKA$+'&#&3D
M '6?\$Q?VA?B!^T-X!\=ZE\0-?\ [?O=,UW[':2_8[>V\N'RE;;B&- >2>2"
M?>OM"OSE_P""*,QN/A#\2)67:TGB-7*^F;=#BK=]\6OC#^W5\??&/@KX3>-F
M^&'PJ\%W M=0\3V,)>]OY\LF$.0<%DDVA60!5W,22JT ?H?17YO_ !9M_C__
M ,$\;;3/B /BIJ7QK^&:WD=IK>D^)U9KNV21@%=)6=VY/RAMP 9E!1@<CK?^
M"FW[06N>&?V8/AOX\^&OBG4M%M]=UNSN(K[3+A[:2YLY;*>958CG#80X/<#T
MH ^\Z*_/K2_V;_VF/VE?#5I\1]>_:"U;X7ZEK$*ZAI?A'PY%-'9V,#@/%',T
M<\>]MN,[E<C/);D5TO\ P3G_ &B_B+XX\0?$KX2?%B[75O&/@.[\G^U0!OG0
M2R12*[  /M9%*O@%E?GID@'W!7@_[<_Q,\2_!W]E7QYXP\(:E_9'B/3(K5K2
M]\B*?RR]Y!&WR2JR'*.PY4]?6OFWXT_&CXM?M2_M6ZO\!/@WXK;X?>&_#$)?
MQ'XKM8RUQYBE1(J,"&&UW$:HK(699"6VCCRG]M[X+_';]G/]G;Q##=_%O4OC
M!\-]<^SV&L1>(X7:]TMQ<1RPSQRM)(Q4R1B,Y8#]XHVG(90#]"/V4/'&M_$K
M]F_X=^*?$E[_ &EKVK:/#=7MWY21>;*PY;8BJJ_10!7K%?('PI^+%Q\#/^"9
M/AGQW:6*ZE>:)X/AN+>UD#;'E.%3?MYV!F!;&. >1UKQWX#? 7XV?M5?"S2?
MBGJ?[57B;1=2UQ))X-,\-[DLK)MVWRY(XIHT+ +RFT;2>IY) /TAHKY2_8GU
MKX_:7K?CKP-\;;2YUFVT.X T/QD]NL2:C'N967<,;QCRW5BN[EPQ.!CZMH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<[DC([8W>M>Y_ WX5V'P0^$/A+P)IK+);:%I\=HTRKM\Z4#,LN.Q>0NY]V-
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M_8:^,7[+/Q2BAT#XL6=]\'O[1EO;GP]<0L+BY5HRB[AL*K(/W9+(X#&,9'8
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ML8&7(/?GM_"?[&O[4WP&TZ3PC\)?CQHJ> UE9K2'Q%IPDN;%&)8B,-!,O4]
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M.5)4,O6OH[]K+]GR?]H+]G/6_AEH-[9>'6O/L:VTTL),$"07$4@4(G0;8]H
MZ<4 3?L8VD5C^R7\((X5V(WA;3Y2/]IX$9C^)8G\:]FKB?@CX!N/A3\'?!'@
MR[NH[ZZ\/Z-::9+=0J525H8EC+*#R 2N>:[:@#\ZO^"E_P#R=-^R)_V,W_M]
MIU1_'*WCNO\ @L?\%$E0.H\-[P#_ 'ECU-E/X$ _A7OO[57[)>K_ +0GQ>^"
MWC#3M>LM)MO 6K?VC<VUU$[O=+]HMI=J%> <6Y'/]X4>//V2]7\7?MQ> _CK
M#KUE;Z3X<THZ=+I+Q.9YF*7:[E8?*!_I*]?[IH ]<_:$_P"2!?$O_L6=3_\
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MVEX!^#GQVB\-?"SX@^)5\->--4D:Y\*W<:L+F.XR(\QG&QPQ*AHRP+<8P0K
M ^E-4U.TT73;O4+^XCM+&TA>>>XF;:D4:J69F/8  DGVK\[/^"-^I6VLZ?\
M&_4+)/+L[KQ##/"F,;8V$S*/R(KII/V#_BYJVCOX=^*'[3FKZU\*+&,&\L(+
M3[-<7MJ@RT<\[2$HN%Y+-*, _6N=_P""+>B+;_#'XH:O:Q.FEWGB)+:U9LX*
MQ0AL#/.0)E_.@#]&:_.3XZVD5]_P6.^"<<R[T7PX)0/]I$U-E/X%0?PK]&Z^
M8_'G[)>K^+OVXO ?QUAUZRM])\.:4=.ETEXG,\S%+M=RL/E _P!)7K_=- #_
M /@I/I=]JW[$?Q0AT_=YZ6EM</L&28H[R"27\-B/GVS7RA^R3^QMXU^+W[/'
M@SQ1X;_:D\?>&-+N[5D&AZ3=W M]/D1V1X5"W2@ ,IXVCKG'-?I[JVEV>NZ7
M>:;J-M%>Z?>0O;W%M,H:.6-U*NC ]002"/>OA'2OV"OC-^SKKVK']G+XQV^@
M>%-2E^T/X;\66WVF&*0C!*OY<@)P%^<(K$*H8MMR0#A_'7[$.D>%OBO\-5^)
MW[6>OZQXECU..Y\.:;XF5[J6659HB5A\RX?87=8EXQN(4<D8K<^-7_*9+X*_
M]BRW_HG5*](^!?[!>OZ?\:8OC'\<?'Q^)GQ M!C3HH8/*L; C.UT7"@E<L55
M415+%L%L$=CX\_9+U?Q=^W%X#^.L.O65OI/AS2CITNDO$YGF8I=KN5A\H'^D
MKU_NF@#P+X,V\<W_  66^,CN@9H?#:O&3_"WD:8N1^#$?C7T)_P4A_Y,E^*7
M_7E;_P#I7!4'@/\ 9+U?PC^W%X\^.LVO65QI/B/2AIT6DI$XGA8):+N9C\I'
M^C-T_O"O2/VHO@]>?'[X">+O &GZA!I5YK<$<,=Y<HSQQE9HY,D+R>$(_&@#
MC_V"[>.Z_8O^%<$T:RPR:&J/&XRK*6<$$=P17QW^SO\ %"/]@?QQ^U#\,-8?
M;I?A^WE\6>&HIV.V=6")%&"3RTBS6:G'>-_3C] /V<?A7=_!'X'>#? M]?0Z
ME=Z%8K:27=NA6.4AB<J#R!SWKYQ_;F_X)WR?M:_$+PQXJTCQ):^&+JULSINK
M&:!G:ZMUE$D6S;QN7=+][KE/[M '!_L;_!'6=$_X)Y_%/Q-/YLGCGXF:/J^J
MM<,N9G5K:9+4'UW$O*#_ --Z\1_X)^_LL^*_CM\!SK'A?]HSQI\/8K34[BTN
M?#N@W4R002#:P?:EP@!=64YV\\\G%?KCH&AV/A?0=-T;3+=;33=.MH[2UMT^
M['%&H1%'L% 'X5\3>)/^"?\ X[^%?Q0UKQQ^S9\3H_AZ^N.TVI>&]6MA/ISN
M7+80;'4(-S;08RR9.U@#@ 'E7[0?[!MCH/AG3(_C/^V#XG;0;F^5;*'Q6TMS
M ;D(V&5)+I@&"%_FQP&/(SS]#_M,_!?X&_M!CP1\(/'_ (KCM?B-'9*VA7-K
M(L6ILHB)=PA5E,<@@8E6X)0A2&&:XWPK^P#X]^*'Q8T7Q_\ M)?$JW^(,NA.
M)--\.:3;&'3T8$,-WRQC;N525$8+[5W,0,'TW]L+]BNV_:8O?#?BK0?$UQX%
M^)'AELZ7X@MD+Y4-O6-P&5AM?+*RG*[FX;.* /EOQ?\ LI_M0_L<^%]7\5_"
M_P".$WBWPMH-K)?W&AZQO!%O&I:0);S&6(X0'.UD8@?+S@5ZKXT_: G_ &H/
M^"6_C?QU<Z='INJW&C7-M?V=J6:))H9@K,F>=K* ^#G;NQDXR:?B/]D_]K?X
MO>&Y_!OQ"^/V@0>$+M!!?'0])'VJ\A(PZ.1##P1D$!\,#\V>E?2&D_LK>#_#
M_P"S'=_ _2S<V?AJYTF?3'N\JURSS!B]PQQ@R%V+],9P,  "@#A?^">G_)B'
MPY_[!EW_ .E,]>(_\$3H57]G7QK,!\[>*I$)]A9VQ'_H1KO_ -CC]DKXU_LV
MZE+H'B#XHZ;XE^&$%E=6]AH<,+AXI97#K*-R90 [R4#D?O&^M=S^P;^RCJW[
M(?PMUSPKK&NV?B"XU#67U-;BQB>-$5H(8]I#<YS$3^(H \ _;04-_P %*/V8
M0P!&8CS[73U]0?MU?\F?_%O_ +%^X_E7,?'3]DO5_BU^U/\ ";XK6FO65AI_
M@O9]HT^:)VEN<3-)\C#@<-CFO6OVA/AG=?&;X)^,_ ]E>PZ==Z]ILMC'=3J6
M2)F'#,!R1]* /@FRTN^U;_@B"8=/W>>FG27#[!DF*/6VDE_#8CY]LUG_ +)/
M[&WC7XO?L\>#/%'AO]J3Q]X8TN[M60:'I-W<"WT^1'9'A4+=*  RGC:.N<<U
M]R?LS_ (_!7]FOP]\*_$-Q9^(TL;6[M+R1(B+>ZCGGFD92C?PE9=I!Z\U\U:
M5^P5\9OV==>U8_LY?&.WT#PIJ4OVA_#?BRV^TPQ2$8)5_+D!. OSA%8A5#%M
MN2 </XZ_8ATCPM\5_AJOQ._:SU_6/$L>IQW/AS3?$RO=2RRK-$2L/F7#["[K
M$O&-Q"CDC%;'QRMX[K_@L?\ !1)4#J/#>\ _WECU-E/X$ _A7IGP+_8+U_3_
M (TQ?&/XX^/C\3/B!:#&G10P>58V!&=KHN%!*Y8JJHBJ6+8+8(['QY^R7J_B
M[]N+P'\=8=>LK?2?#FE'3I=)>)S/,Q2[7<K#Y0/])7K_ '30!ZY^T)_R0+XE
M_P#8LZG_ .DLE?-7_!(;_DS;3O\ L-7_ /Z&M?6/Q*\*R^.OASXJ\-P3I:SZ
MQI5UIT<\@)6-I87C#$#J 6S^%>5_L5_LZ:C^RW\#K7P+JNKVNN7<-]<79N[.
M-HXR)&! PW.1B@#YD_X)*JT?BS]H]64JR^)X@588(/F7?%?HG7P7H7[!?Q;^
M#_[1FO\ C/X4?%:ST/P5XCUJ/5M7T.^A8R31^>97M\!&5A\\BJX*L%?&>I/W
MI0!\N?\ !3?3+[5OV(?B5'I[/YD<5G<2J@Y:*.]@>0>P"J6/LM=1^P;KVF^(
M?V/?A1<:4\;P0Z%!9R^4<[9X08I@?0^8CY^M>W:UH]CXBT>^TK4[6*^TV^@>
MVN;69=R31.I5T8=P02#]:^%-*_82^-W[.^J:O!^SK\9K70_"&I3_ &C_ (1W
MQ9:"Y2V<@@E',4HR./F"(6 4,6VY(!R?_!5[4X=8^,'[-GA;2F$WBIM<>YAB
MA.9HDDN+6.(X]'D1L>\1K:_X+/?\D7^''_8VQ_\ I--7H?[/?[!>J^&?C WQ
MC^-/CEOB=\2U'^ALL/EV5@<%0R*0-Q )V (BIDD*3AAV/[='[*.K?M:>!?"^
M@Z1KMGH,VD:RNIO->Q/(LBB)TV@+T.7!_"@#Z6KRO]JO1[_7_P!F3XKZ;I:O
M)J%UX6U.*&*,9:1C:R?(/=ON_C7JE(RAU*L RD8(/0T ?%__  2,US3M4_8U
MT>SLY(VN]-U6^M[U%;++(TIE7<.V8Y(_PKSO_@JMK&G'XJ?LSZ5YD;ZLOB8W
M7EAOGCA,]HN2.P9AP>^P^E=-K7[ OQ+^#7Q.UOQ;^S/\3++P)I^O2>9J'AC6
M[;SK%&SG]W^[D! );:"@9 2 ^#@<]XF_X)F>/OB#XT\)?$'QK\6T\5_$*QUB
MWO-1O+JU,=HMG"ZO':VL2 !/F$C$X5<MPH.XL 3?\%L/^3;?!O\ V-L/_I'=
M5ZO_ ,%%O@D?C3^Q[K'V.#S=<\,PQ^(+#:/F/D(?.48Y.86EP!U8+6[^WE^R
MCJW[7GPMT/PKH^NV?A^XT_64U-KB^B>1'58)H]H"\YS*#^!KZ-ALD&FQV<ZI
M/'Y0B=67*N-N""#U!H _*;X]?'J__;,^"/[,GPFT:]9O$7CVYAE\1O&<O"+1
MS;R2./[I=)Y\'M"#7I'_  6.T&Q\*_LG?#K1=+MUM-,TWQ':V=K;ITCBCL+E
M$4>P50/PKN/V2_\ @FS#^S7^T+KOQ!N-?M=:TM(KJW\.Z>D+B6P2:7@NS'!9
M8BT?'!\QC7IG[>7[*.K?M>?"W0_"NCZ[9^'[C3]934VN+Z)Y$=5@FCV@+SG,
MH/X&@#YF_:.E7PI_P50_9XU[7&6/1+S1+6RM;B8[8Q,6O(U3/J))XF_[:"OT
MHOKZWTNQN+R\GCMK2WC::::5@J1HH)9F)Z  $D^U>%_M5?L@^&_VJOASIVA:
MO>2Z+K^CL)M(\06B;I;.7 #?+D;XVVKE<CE5(((!KPBW_8__ &G_ ![H<7@7
MXF?M VEU\-R%MKV/0[(+JFHV@P##).T*,-RC:27?.X[M_2@#"_X(VW5O?_#?
MXL7%BODVLWBEI(%Q]U#"I4?@"*^:?V ?V:?%OQB;XE:3IGQT\6_"O7M!U98M
M2TK0+B6/[43O7SI%2>/)#QNN2#CCGFOT,_89_9'OOV1?"OC#1+O6K368=8U?
M[?:_98W7R(@@14;=U( ZUQGQM_8)UVZ^,]U\8?@;\0I?AAX_U L=3BE@$UA>
MD@;F9,$#<RJSJZR*S?-@,,D \G^-G[ ^H>'_ (=:C<?%/]L+QJ/!3/%'=Q^(
M99Y[21C(IC5HWNF#'>%(&#@KGMFN2_X*0^$]-\"_\$]O@GH&C>(5\5Z/8:O9
MQ6.M*@1;RW^PW1BD4 D;2A7&">,5ZMJ?[!?QF_:(\3:--^T=\7K+Q#X3TF87
M$?AOPO;&WAN&''SL(X@I(R"^UF 9@I7.:]<_;@_8_N_VHO@WX8\">&=5T_PI
M#HFJ0WD7VB!FA6&.WEA6)%3I@2+CMA: /I#0;>.TT/3H(4$<,5M&B(O15"@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"3E3G(% 'T5'&L4:HBA$4855& !Z"G5XO\#?VKO"7Q_\??$;PCX>T[6K/4O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^:'CR
MT@OO^"UW@>"YACN(6T:3='*@93C2;PC(/N*_2^OR0_:V^#<'[0'_  55T/P#
M<ZS>>'X=6T9-VHV !FA\JPN)AMSZF+:?9C0!^K/_  B>A_\ 0&T__P !8_\
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M6M^#9_#FM>!/'^BQ&>\\.Z[%MD$895<HV 259U!5E5OF! (SB3]J3]N3P?\
MLRZOI/AAM*U3QKX^U=5:Q\,:&F^=E8E4:0\[0S JH4,Q/1<<UYK^RK^U'^SY
M^T]\;IO$>F^%F\*?&R2T,+?VN@%Q<Q)&5=8)%8K)MC7D%5?:N<$*2/-?V,[5
M/B)_P4K_ &D/%>O1I=:OH%S<Z;IS3#YH8EN3;*R#M^YMU7/HY]30!W]A_P %
M-;WP;XDT>Q^-/P0\5?"'2-7E$-KK=[*UU;ACCF3=#$0 #E@NYE'\/I]1_&?X
M\>#O@+\,;OQ[XKU+RM A5/*:T FDNW?_ %<<(!P[-VY QDD@ D3_ !J^"?A+
M]H'P#<^#O&NGMJ.AW$T-PT<<K12*\;AU*NO*DX*DC!VLP[UXW^UCX)_9\\"_
ML]^'M.^,%M*W@3PNT%OHMB;^[:X>:.$QQ1QA) \S^6&'SD@#<3@ F@#RW_AY
M'\2-<T>+Q!X4_93\<Z[X6FC-Q%JDL\D/FPXSYB*EK(&&,G(8@XZU[[^R?^UY
MX0_:X\)ZCJ?AVWO-)U729$AU71M0 \ZT=]VP[APR-L?#<'Y3D C%>#Z/_P %
M(O$OCRRB7X3?LT>//%.GL@2TO+F,6-F%X"'S$CEC5<=MW;KW'E?_  3 OM:O
MOVPOVC9_$&CQ^&];N9I9]1T:"598[.Y-](9(@RDJP1F900<4 =7_ ,$T/^3I
MOVN_^QF_]OM1K]%:_.K_ ()H?\G3?M=_]C-_[?:C7Z*T ?.OC;]L2S^'G[67
MA7X*:[X7GM(O$ULLVF^)OMBF&1V60+&8MF0QEC,?WCRRGH:]^UC5[/P_I%]J
MFH3I:V%E ]S<3R'"QQHI9V/L "?PKX<_X*U_#&^OOA'X7^+/AX-#XE^'>KPW
MBW,8^=+>21!N]]DR6[>PWFH?VZ_VIH=>_8.\/:AX89FUCXK06NG6=K;DM(J2
MJ&NXP.^ &@/O)0!ZO\$?V[O#?Q.^ _BGXP>)M&E^'W@C1;YK-+N_NOM#W>T)
M\R(B Y+2(@4;B6R.U>86?_!2_P 5^*;!_$?@[]FGQYXF\!*[_P#%01ED:2-2
M1YB1)"X<#!SB3"XP37SS_P %!_ =S\!?V=?V9/@M8V<^I6C7$T^IV-G(4&H7
MT?D;U# 'EY;N?;P<;AUQ7T!I?[<OQPT73;33[#]BSQ79V%I"EO;VT&I2I'%&
MBA515%A@    #L* /IK]F[]ISP/^U+X';Q'X,O)6-NZPZAIMXGEW5C,1D)(N
M2#D9PRDJ<'!R"!Y'\9?^"A>B^!?BM>?#/P%X"\1_%SQQIZDW]CX?C_=6K#&Y
M&D"N25R-Q"%5) +9R!X1^Q+H_P 3X_VZ/'OCC4_@_P"(OA;X,\::;-)<Z;>1
MR/:0W@,+AS*8XPS,ZSL/E&//8<]:Z>]_:@_9Z_91^-'CC1?A5X"\1^._B+KE
MVTOB!?#(EOP;A7=G4RS2,VX/*VY8E*AC@X*X !L:3_P5"N/"GC72-"^-/P5\
M3?!ZTU9]EKJU_.UQ!G.-S[X(3L!(R5W$9!(Q7O'[77[5%E^R;X)\/>)+[09-
M?@U;68M(\N.[6V$.^*23S2Q5@0!$>..O6OSN_P""C'[0/Q1^.'P+TG_A)?@/
MJOPR\(VNO6\L.KZ_=_Z7)<FWG"Q"!HXW4%3(2<,/D&2,@5ZG_P %6Y&F_8=^
M#LCL7=M4TUF9N22=,N,F@#U+PK_P4_LOB%\<-%\'>$_A;K^N>$=6UA=%MO&2
MS>7#)(6VF18S%M,8 9SF4-M&=N>*^X:Y/X2^#;'X>?"_PIX:TZWBM;/2],M[
M5(X5"K\L:AC@=R<DGN23764 <M\3OB=X:^#?@;5?%_B_5(]'T#38Q)<74@+=
M2%55502S,Q"A0"22*^.[/_@I?XK\4V#^(_!W[-/CSQ-X"5W_ .*@C+(TD:DC
MS$B2%PX&#G$F%Q@FN%_X+.>)-0_LOX,^$8+2ZU+3]8UBZNKC3;>0Q_;)(?LZ
M1Q9 /S'[2X'!P3G%=II?[<OQPT73;33[#]BSQ79V%I"EO;VT&I2I'%&BA515
M%A@    #L* /IK]F[]ISP/\ M2^!V\1^#+R5C;NL.H:;>)Y=U8S$9"2+D@Y&
M<,I*G!P<@@?.UW_P50\+6/B;Q]X7;P+K>H>+M UY] TC0='D^UW6MRI),CR(
MJH/+1?)!/WC^\  .#7FO[$NC_$^/]NCQ[XXU/X/^(OA;X,\::;-)<Z;>1R/:
M0W@,+AS*8XPS,ZSL/E&//8<]:A_X)P>#[#4OVV_VH?$D]O%+?Z3K5W:6TCKE
MHA<:A=%ROH2( ,]<''<T >A^'/\ @J6NA^/-(\-?&3X-^)O@XNK2>7:ZCJDC
MRPX.T;W#P0ML!8!F0-MR,]\?:OC+QGHGP]\)ZKXF\1:C#I6A:7;M=7=[.3LC
MC49)XY)[  $DD  DBOB;_@LSIMK=?LIZ3=RV\;W5KXFM?)F*_/'N@N P!]",
M9'0X'H*Y7_@J+XPU'2?V"OAQI]O-(L>NWFE07SY.)8TLI)MK>N9(XV_X!0!U
M6F_\%0->\;37FK> /V<_'7C3P':R-&_B*U#*S;?O%8DAD4D=2/,R!C.,UY/^
MS+\8/#WQZ_X*L>(/'7A:6>31=5\*JT:W41BFB=+2TCDC=>S(Z,IP2#MR"003
M^C7P;\&Z9\/?A/X0\-Z-#'!IFF:5;6T*Q?=($:Y;/<L<L3U))/>O@WX8^"=+
M\"_\%CO&]OI$$5K:7_A^74V@AX"S30V[S''8M(7?_@= 'T/X\_:"\)>'?VXO
M ?PKO/AW9:CXLUG2C>6OC%Q#Y]E'LNV\I<QE\8@D'#@?O3QUSRWQ,_X*6^#?
MA'\;O'WPZ\1^'-16X\,VT#V<]C,)Y]8NIEMVCMH8-HVL1.3DMC$9]0*\O^-7
M_*9+X*_]BRW_ *)U2L+X=^#[#Q5_P6B^(]U?6\5P=#TM=3MQ*NX+,+*QA5A[
M@3D@]NO6@#M;O_@JEJW@/6-/;XI_L]^-/ASX9OYUBM]:O#(Y(.>3');Q#(4;
MBBNS8!P#QG[GTWQ5H^K^%;7Q+::C;RZ!<V:ZA%J)<+"UNR"02[CC"[#NR>U?
M._\ P4NTVUU+]B7XE_:K>.<V\%K/$77)CD6[APRGL>2..Q(Z$U\^>/O%>J>&
M_P#@C!I5S82R)<7.@V&G23+DE();Q(I!]#&2G_ J .VNO^"H-QXR\4:K8_!O
MX(>+OBYHFE2^5=ZYI_F01=_F1%@E)R!E0Y1F&>!6KX0_X*B>$?'7Q-^'O@;3
M/"&KV^O>(]0?2]4LM4?[+<Z%<JX79+&4/F Y)!!'0@@$$#U?]@?PAI7@W]C_
M .%MOI,,44=[HL&IW#1CF2XN%\V5F/<[G*^P4#H!7RA^UQX+TG0/^"HW[/VN
MV$$=O?Z[):O?^7P99(IGC61O<IM7/I&* /TNKYU_X*'?\F6_%7_L&+_Z/BKZ
M*KYU_P""AW_)EOQ5_P"P8O\ Z/BH YG_ ()J^'=*OOV(_AE/<:99W$S0WNZ2
M6W1F/^GW(Y)%=Q^TU^Q[\/\ ]H[X=:KHU_X?TVPU\P,=+URVMDBN;2X ^0[U
M&6C) #(<@C/0@$<O_P $R_\ DQSX8?\ 7&^_]+[FOIZ21(8VDD941069F.
M.I)H ^"O^"0OQDUOQI\'?$_P^\13R7.I> K^.T@>9R[QVDHD\N$MSD(\,RCG
M 7:HX KU3]H+]OCPS\&_B)!\.?#/AC6OBC\2),&7P[X=C+-; IO'F.%;#%2&
MVJK84Y;:,9^;_P#@D&/[<^(G[1/BRT#?V-?ZI;"V9 =K[IKR7@>RNG_?=>'?
ML+_M%_$/P;XH^*/CW0/@/KGQ@U_Q-J>Z^UNRO'C>R!9I6MR1;RGYF<,>1G8G
M'RB@#[8\#_\ !2*SM_'FE>$/C)\,/$?P2U35V\O3[O6]TUC.^Y5 \XQ1D#+
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MUD\^?3UDC/H1N(K[Y^.&AZ>?V??'VD+9P1Z8/#%_;+:)&%B6(6KJ$"XP !@
M=L4 ?.WB;_@IGX:U;3M"B^#W@7Q%\9?$VI6"ZE/HNBQ.ATR(L5*W4B1R^7(&
M!&T*PZ'=AE+=%^RE^WYHO[2'C?5_ >L^#]4^''Q TV)IY-"U:3>75=H=59DC
M82*6R49 <<C/./-O^"-/ANPTO]EG5-7@MT74-4\0W'VFXV_.ZQ1Q+&A/HN7(
M'J[>M<YXIC2S_P""TW@]H$6%KOPU(TY08,I%A= %O4X1!_P$>E '+?M@?%#P
M_P#!?_@JA\,/&OBJZ>ST'1_"337,L<32/S'J2(JJ.2S.RJ.V6&2!S7I>J?\
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MEMQA,D:LT9/<J25S[5X+_P %1_\ DQ/XF_\ <,_].EI0!W_[%/\ R:/\(?\
ML6;'_P!%+7M=>*?L4_\ )H_PA_[%FQ_]%+7M= !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'DVM?\AF__ .OB3_T(T4:U_P AF_\ ^OB3_P!"-% '9_#_ /Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 >3:U_R&;_ /Z^)/\ T(T4:U_R&;__ *^)/_0C10!V?P__
M .0--_U\-_Z"M=-7,_#_ /Y TW_7PW_H*UTU !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!Y-K7_ "&;_P#Z^)/_ $(T4:U_R&;_ /Z^)/\ T(T4 =G\/_\ D#3?]?#?
M^@K735S/P_\ ^0--_P!?#?\ H*UTU !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y-K7
M_(9O_P#KXD_]"-%&M?\ (9O_ /KXD_\ 0C10!V?P_P#^0--_U\-_Z"M=-7,_
M#_\ Y TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y-K7_(9O_\ KXD_
M]"-%&M?\AF__ .OB3_T(T4 =G\/_ /D#3?\ 7PW_ *"M=-7,_#__ ) TW_7P
MW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!Y-K7_(9O\ _KXD_P#0C11K7_(9
MO_\ KXD_]"-% '9_#_\ Y TW_7PW_H*UTU<S\/\ _D#3?]?#?^@K734 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'DVM?\ (9O_ /KXD_\ 0C11K7_(9O\ _KXD_P#0
MC10!V?P__P"0--_U\-_Z"M=-7,_#_P#Y TW_ %\-_P"@K734 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'DVM?\AF__ .OB3_T(T4:U_P AF_\ ^OB3_P!"-% '9_#_
M /Y TW_7PW_H*UTU<S\/_P#D#3?]?#?^@K734 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% 'DVM?\AF__P"OB3_T(T4:U_R&;_\ Z^)/_0C10!V?P_\ ^0--_P!?#?\
MH*UTU<S\/_\ D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DVM?\AF
M_P#^OB3_ -"-%&M?\AF__P"OB3_T(T4 =G\/_P#D#3?]?#?^@K735S/P_P#^
M0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 >3:U_P AF_\ ^OB3_P!"
M-%&M?\AF_P#^OB3_ -"-% '9_#__ ) TW_7PW_H*UTU<S\/_ /D#3?\ 7PW_
M *"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 >3:U_R&;_\ Z^)/_0C11K7_ "&;
M_P#Z^)/_ $(T4 =G\/\ _D#3?]?#?^@K735S/P__ .0--_U\-_Z"M=-0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 >3:U_R&;__ *^)/_0C11K7_(9O_P#KXD_]"-%
M'9_#_P#Y TW_ %\-_P"@K735S/P__P"0--_U\-_Z"M=-0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >3:U_R&;_ /Z^)/\ T(T4:U_R&;__ *^)/_0C10!V?P__ .0-
M-_U\-_Z"M=-7,_#_ /Y TW_7PW_H*UTU !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y
M-K7_ "&;_P#Z^)/_ $(T4:U_R&;_ /Z^)/\ T(T4 =G\/_\ D#3?]?#?^@K7
M35S/P_\ ^0--_P!?#?\ H*UTU !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y-K7_(9O
M_P#KXD_]"-%&M?\ (9O_ /KXD_\ 0C10!V?P_P#^0--_U\-_Z"M=-7,_#_\
MY TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y-K7_(9O_\ KXD_]"-%
M&M?\AF__ .OB3_T(T4 =G\/_ /D#3?\ 7PW_ *"M=-7,_#__ ) TW_7PW_H*
MUTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!Y-K7_(9O\ _KXD_P#0C11K7_(9O_\
MKXD_]"-% &YX9\36VA6,MO<13&0REOD4<< 8Y(YXK7_X6!I__/&Z_P"^5_\
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M7_XJC_A8&G_\\;K_ +Y7_P"*HHH /^%@:?\ \\;K_OE?_BJ/^%@:?_SQNO\
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M5_\ BJ** #_A8&G_ //&Z_[Y7_XJC_A8&G_\\;K_ +Y7_P"*HHH /^%@:?\
M\\;K_OE?_BJ/^%@:?_SQNO\ OE?_ (JBB@ _X6!I_P#SQNO^^5_^*H_X6!I_
M_/&Z_P"^5_\ BJ** #_A8&G_ //&Z_[Y7_XJC_A8&G_\\;K_ +Y7_P"*HHH
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M^%@:?_SQNO\ OE?_ (JBB@ _X6!I_P#SQNO^^5_^*H_X6!I__/&Z_P"^5_\
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M7_XJC_A8&G_\\;K_ +Y7_P"*HHH /^%@:?\ \\;K_OE?_BJ/^%@:?_SQNO\
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M5_\ BJ** #_A8&G_ //&Z_[Y7_XJC_A8&G_\\;K_ +Y7_P"*HHH /^%@:?\
M\\;K_OE?_BJ/^%@:?_SQNO\ OE?_ (JBB@ _X6!I_P#SQNO^^5_^*H_X6!I_
M_/&Z_P"^5_\ BJ** #_A8&G_ //&Z_[Y7_XJC_A8&G_\\;K_ +Y7_P"*HHH
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M^%@:?_SQNO\ OE?_ (JBB@ _X6!I_P#SQNO^^5_^*H_X6!I__/&Z_P"^5_\
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M7_XJC_A8&G_\\;K_ +Y7_P"*HHH /^%@:?\ \\;K_OE?_BJ/^%@:?_SQNO\
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M5_\ BJ** #_A8&G_ //&Z_[Y7_XJC_A8&G_\\;K_ +Y7_P"*HHH /^%@:?\
M\\;K_OE?_BJ/^%@:?_SQNO\ OE?_ (JBB@ _X6!I_P#SQNO^^5_^*H_X6!I_
M_/&Z_P"^5_\ BJ** #_A8&G_ //&Z_[Y7_XJC_A8&G_\\;K_ +Y7_P"*HHH
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M^%@:?_SQNO\ OE?_ (JBB@ _X6!I_P#SQNO^^5_^*H_X6!I__/&Z_P"^5_\
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# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>pacb-20241231_g6.jpg
<TEXT>
begin 644 pacb-20241231_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC]'K_DXT/^O53\D?"U%%%?IY_>84444 %%%% !1110 4444 %%%% !7[&?\
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M_LF>N_\ I!-71A?]ZI_XE^9['#W_ "/\)_U]I_\ I:/YW****_;#_4P****
M"BBB@ HHHH **** "BBB@ KU']A[_D]#X1_]E,T+_P!+X:\NKU']A[_D]#X1
M_P#93-"_]+X:PQ7^ZU/\+_(\CB#_ )$.+_Z]5/\ TAG]$=%%%?B1_ED%%%%
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M/(X@_P"1#B_^O53_ -(9_1'1117XD?Y9!1110 4444 %?CI_P<$_\GH>'?\
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M6%%%% !1110 5Y=^W#_R9?\ %S_LF>N_^D$U>HUY=^W#_P F7_%S_LF>N_\
MI!-71A?]ZI_XE^9['#W_ "/\)_U]I_\ I:/YW****_;#_4P**** "BBB@ HH
MHH **** "BBB@ KU']A[_D]#X1_]E,T+_P!+X:\NKU']A[_D]#X1_P#93-"_
M]+X:PQ7^ZU/\+_(\CB#_ )$.+_Z]5/\ TAG]$=%%%?B1_ED%%%% !1110 5^
M.G_!P3_R>AX=_P"R9V7_ *7ZA7[%U^.G_!P3_P GH>'?^R9V7_I?J%?2\*?\
MC=?X6?N/T>O^3C0_Z]5/R1\+4445^GG]YA1110 4444 %%%% !1110 4444
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MZI_XE^9['#W_ "/\)_U]I_\ I:/YW****_;#_4P**** "BBB@ HHHH ****
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M&G<VL4OA>1F2,L=JD[N2!@$U!_P@/_!03_HO_@3_ ,)23_XJ@#W2O+OVX?\
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M_P#)M'_#B_0?^?#P)_W]US_Y-H_UQRS^2?W1_P#D@_XF5X%_Z!L3_P" 4O\
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M?\(#_P %!/\ HO\ X$_\)23_ .*H ]THKPO_ (0'_@H)_P!%_P# G_A*2?\
MQ5'_  @/_!03_HO_ ($_\)23_P"*H ]TK\=/^#@G_D]#P[_V3.R_]+]0K]%_
M^$!_X*"?]%_\"?\ A*2?_%5XY^T%_P $Q/B;^U/XTMOB'\>/$W@37=8M-,33
M[>\^Q:G:[+9)))%39;W,:G#RR')&?FQG &/7R3'T<MQRK54VK-:6OKZM'Z-X
M6<7Y;P1Q7',\="<J:A.-H*+E>5K:2E%6[ZGXQ45^L?\ PXOT'_GP\"?]_=<_
M^3:/^'%^@_\ /AX$_P"_NN?_ ";7V7^N.6?R3^Z/_P D?TS_ ,3*\"_] V)_
M\ I?_+C\G**_6/\ X<7Z#_SX>!/^_NN?_)M'_#B_0?\ GP\"?]_=<_\ DVC_
M %QRS^2?W1_^2#_B97@7_H&Q/_@%+_Y<?DY17ZQ_\.+]!_Y\/ G_ ']US_Y-
MH_X<7Z#_ ,^'@3_O[KG_ ,FT?ZXY9_)/[H__ "0?\3*\"_\ 0-B?_ *7_P N
M/R<HK]8_^'%^@_\ /AX$_P"_NN?_ ";1_P .+]!_Y\/ G_?W7/\ Y-H_UQRS
M^2?W1_\ D@_XF5X%_P"@;$_^ 4O_ )<?DY17ZQ_\.+]!_P"?#P)_W]US_P"3
M:/\ AQ?H/_/AX$_[^ZY_\FT?ZXY9_)/[H_\ R0?\3*\"_P#0-B?_  "E_P#+
MC\G**_6/_AQ?H/\ SX>!/^_NN?\ R;1_PXOT'_GP\"?]_=<_^3:/]<<L_DG]
MT?\ Y(/^)E>!?^@;$_\ @%+_ .7'Y.5^QG_!OM_R9?XB_P"RF7O_ *0:?7+?
M\.+]!_Y\/ G_ ']US_Y-KV+]GW]BS]IG]ECP7<_#SX#_ !+\":%H]WJ;ZA<6
M?]C7MUON7CCC9]]Q-(PRD48P#CY<XR3GR,[XAP698%T:49)W3U2MIZ-GYSXI
M^,W"_&_"<LLP-&M&HYPE><8*-HMWUC4D[]M#ZOHKPO\ X0'_ (*"?]%_\"?^
M$I)_\51_P@/_  4$_P"B_P#@3_PE)/\ XJOC3^9CW2BO"_\ A ?^"@G_ $7_
M ,"?^$I)_P#%44 >Z4444 %%%% !1110 445RWQC^.'P9_9X\"W'Q.^/7Q7\
M.>"_#EHZI<:YXIUF"PM4=L[4\V9E7>V#A<Y8\ &@#J:*\Z_9Y_:\_98_:UTB
M]UW]F']HGP9X_M=-D6/4G\)>([>^-FS9VB98G9HBV"1N R!D9%9W[0O[=7[&
M'[)FJV&@_M-_M4> / >H:I%YNGZ?XJ\56ME<7$62/-6*5PYCR"-^-H(QG- '
MJU%9G@WQKX-^(OA6P\=_#[Q;IFNZ'JELMSIFLZ-?QW5I>0MRLD4T;,DB'LRD
M@UY)X=_X*6_\$\O%WQ;3X#>%OVX/A3J/C*2\^QP^&[/QY8274MSG;]G1%E.^
M;/'EKE\@C&0: /;J**Y#3_V@?@7J_P :K_\ 9NTKXP^&;GX@Z7HPU;4O!,&M
MP/JMI8%HU%U):AO-2(F:(;RH'[U.?F&0#KZ*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBO$_'O_  4H_P"">WPL^*K? [XD_MN?"O0?%\=R+>X\.ZMX
M[L(+JWF)P(I4>4&*0G&$?#'(XY&0#VRBJ6L^(_#WASP_=>+/$.O65AI5E:/=
M7FIWMTD5O! JEFE>1B%1 H+%B0 !G->7? C_ (* ?L-_M0^,+OX>_LY_M=_#
MCQQKME$TMQH_A?QA9WMR(E.&E6.*0L\8/5U!49'/(H ]>HK@?V@?VJOV9_V4
M?#EMXN_:9^/OA#P#IM[,8;&[\6^(;>P6ZD&"4B\YU,K $$JN2!R>*O?!#]H/
MX$_M+^"$^)7[/'QC\,>./#\DS0C6/"FN07]NLJ@%HV>%F"N 1E#AAD9 H ["
MBO%_BG_P4<_8!^!_Q.'P7^,?[:?PO\+^+-Z)+X>UWQQ8VMW S@%!+')*#$6!
M! ?;G(QFO9;6ZMKVVCO;*X2:&9 \4L3AE=2,A@1P01SF@!]%%% !1110 444
M4 %%%% !1110 4444 %%%% !7R]^U'_P3'\&?MB?MP_##]J'X^^,[/Q)X%^%
MOA^_BTCX/:UX:6ZT^YUNY;']K2R/-Y;M'$(U2)X'PT8<.#Q7U#7Y]?\ !=O_
M (+ Z5_P3P\)>%?V=?AWXZTKPS\3_BRTEOH_C/Q):2R:5X,TP.([C6;A8XW:
M=X]Q$4"(Y9QEE(4)( <-X?\ A;\([S_@Y5T&\_8=\&:1H-M\.O@KJ$/[2%SX
M1L8[33YIKUB-)T^Y6$+&UZ&$=Q@C>8X5R?W6%?\ \$?O@?\ !C]L;]I+]M3]
MKK]HWX5^'O&WB:7]IO7OA]IMSXLT:#4?L&@:/#;Q6UI"LZL(D:.8!PH ?RUW
M9VBM+_@D[^W=_P $-OV>/#?AS]C/]E+]M>Q\9^/?''B#SM;\0:GH^IG5_&OB
M*Z.9KVZGFM@#)(^=H9]J+A<G!)X/]D#]LW]G?_@C%^UK^U7^S#^W_P"-)OAU
MIOCWXXZK\5/AGXHU;1[N33_$.FZM'$TL-O-!$X:6W:%(VC.&+$@ E30!2_X)
M_P#[,GB[XK_!K]OW_@DA\"/C;=_#+PYHGQJN].\":U:::U^/#&E:JJ3W-C;P
M>?"?),<<T2J)5VFX=\DY#;7_  6F_8D_X)\?LE_\$</^&9_!/[._A0>-K]=(
M\+_!:'0O#L$>OZOXI::%(9K>5%\]YV(DEF<N2ZEU8L7 ;5_X)=?&K1/V?/V>
M_P!KS_@LS^T/X4U_POX ^)OQ2U#Q?X6L;[2734KSPU:1B"PN1;MAE>Y9V5%;
M"_=;=L8/7S]^Q#_P5K_X)B_'']I*7_@J-_P4R_;3\,67Q&2.>Q^#WPG73-3N
M['X8:,Y*D[TM3'/JEPN&FN%SM!V*5'R1@'Z5?M%_M;7O_!-;_@G-HWQ6_: F
MF\6>/=)\*Z1H%AHUG(9+KQ=XNEMXX(K.# +2//=!F)4,1&)'P=I%?GQ_P2D_
M9B^+_P"S-_P<-:R_[2OC:7Q!\5OB'^QU<>-?BEJ'F[H(];OO%-F'M+8 D);V
MT,-O;(%.W%OE< A1]0?M3?L8_$#_ (*U_$WX'_\ !0W]BS_@I-IGA3P=X(TJ
M?4?AY8WGP?3Q!97&J3/-%)K&R[O+8>:(PD48DA8PM$TB,&<X^6?AW^SA_P %
M'-*_X.25\%>*?^"E^E:MXTL_V6[;5M9\<)\#+"WCU+P\OB6!9-#%BMX4@=Y/
MWGVT.77[HC(YH _:>BBB@ HHHH **** "BBB@ HHHH **** "BBB@##^)WAS
MQ1XP^&OB'PEX'\:-X;UK5-#N[/1_$26?V@Z7=2PND5T(MZ>:8G99-FY=VW&X
M9R/SW^*G_!.3_@FM_P $OO\ @C+XW\#_ +4/@KP=XNM],\%Z@WBSQ_K7A:"+
M5_%6NW(D\J9))&EG6[DN9(T@ F9HR$VL N1^BOBOQ1H7@CPOJ7C3Q3?BTTS2
M+":]U&Z9&80P1(9)'PH).%4G !)QP*_#GP/_ ,%A_P#@F?\ \%%/VS(_VMO^
M"AO[5^D>$OA=\*M>?_A0WP,U/2K^X:[OH^/^$GUA8+>2)YSS]GM]S"$9)YRT
MP!T_[2?@#X_^"?\ @A/^PQ^P?^TKJFJVVH_%WXW>!? _Q$LKBYDCN5T&[NKF
MZCTZ4Y#*T4,=C$R$Y4P%3TKVC_@N[^SI\ ?V/O@W\"?VP_V:?@QX8\">,/A3
M\>?"T&BZGX1T*#3Y)-+N)7M[G39# B^9;R(5#1MD8!'1V!L_\%9/C3\._P#@
MH%^P+\-OV_/^"?\ JL_Q8T?]GW]H[P]X\U"V\-:9<?:;ZWTF1Q>P0PS1H[M&
MEU'*<+C9&QSP:X7_ (*,?M^?LN?\%H-.^!_[!_\ P3S\=W/Q%UKQ-\8O#_B3
MQQ<:;H5Y%#X3\.6$C375U?//$@AD!**L9Y8AEX)0. ?9NH_\$L/AM\1?^"D'
MB7_@H)^T=X@TOXC12^#;#P]\./ GB3PI'-:^#(XOFNIX7EFD2::XE+OO$,;1
MB1D#,"37S?\ \$O?A_X U/\ X++?M<_%+]B32[+0/@I;Z%H_AC6I/#=JD6CZ
MAXXA >ZFLXD A9[9#(DI48,DY;GS,G'_ ."YG_!7WX?_  S^-ND?\$K_  Y^
MTO#\'+KQ7IL=Y\7/C%>65S))X7T&52?LFFI!&[RZC<QY59 -D*N#N#'=%[9_
MP33_ &]?^"/'_"$^'_\ @GY_P2[^.GAO4]1T3P[=/X9\+Q:7J,+73Q1M++<W
M$\UL@DD=R9)9"=S%F('04 >&?&'P9_P0K_X(T?LS>(OV2?VSM;T3Q]X]\8:%
MJ?B76[GQCX0&I^+/'$E_=7:QRF>.W;$AE1X8VWH(VB\PE26D/U+_ ,$+/@[^
MT!\ _P#@DU\%?A1^T[),/%^F>&96N;6YN!++96<MY/-8VKL"1NALY+>(K_!L
MV?PU\YZ9_P %TO\ @GG\2OV<?$/PM_X*[_#?3? 7Q:TD7^D>//@7XA\&WFH3
MW;"65(([ / PO([B,QF-U8#<Y.X+MD/MO_!O;\)/V@?@C_P25^%G@#]I+1]6
MTK78H-0N-.T'7F<WNDZ5-?3RV-K,'^966W>,B-L&-66,A2FT 'VG1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %5]1TG2M7C2'5M,M[I(Y!)&MQ"
MKA7'1@"#@CUJQ10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %5[+2=*TR2:;3M,M[=[F3S+AH(50RO_ 'F('S'W-6** "BBB@"M
M<Z/I%Y?0ZI=Z7;2W-MG[/<20*TD6>NUB,KGVJS110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBEQ!P1Q!2P.!I4I0E2C-N<9MW<YQ^S.*M:*Z7O?4_;/_ (>Z?\$\_P#HX/\
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MC\0-+T6]UU-0T/0;S3";BUFU=O[*B%GN?,*Q.Z2LTA3"YR/KS_@M'^TM\?\
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37$O(X+;N^:^[Z** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>pacb-20241231_g7.jpg
<TEXT>
begin 644 pacb-20241231_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSY: /YQ?VM/A'XW/_! B_P#^"B/QCM2?'/[4_P"U]%X@U"Y92#_9D%AX@\A
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MK_H)PW_@=7_Y2?NO17X4?\/DO^"D7_1QO_EH:/\ _(E'_#Y+_@I%_P!'&_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5^.G_!P3_P GH>'?^R9V7_I?J%?L77XZ?\'!/_)Z'AW_ +)G9?\ I?J%?2\*
M?\C=?X6?N/T>O^3C0_Z]5/R1\+4445^GG]YA1110 4444 %%%% !1110 444
M4 %?L9_P;[?\F7^(O^RF7O\ Z0:?7XYU^QG_  ;[?\F7^(O^RF7O_I!I]?-\
M5_\ (H?^)'X?](3_ )-S/_K[3_-GW11117Y>?P6%%%% !1110 4444 %%%%
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M.-#_ *]5/R1\+4445^GG]YA1110 4444 %%%% !1110 4444 %?L9_P;[?\
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M2-<\,^&[J*== L+XS/<-YD;/%YIDEC,:(\BQ+;)EV9V"?K/10!^!?@_]C/\
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MI>%/^1NO\+/W'Z/7_)QH?]>JGY(^%J***_3S^\PHHHH **** "BBB@ HHHH
M**** "OV,_X-]O\ DR_Q%_V4R]_](-/K\<Z_8S_@WV_Y,O\ $7_93+W_ -(-
M/KYOBO\ Y%#_ ,2/P_Z0G_)N9_\ 7VG^;/NBBBBOR\_@L**** "BBB@ KR[]
MN'_DR_XN?]DSUW_T@FKU&O+OVX?^3+_BY_V3/7?_ $@FKHPO^]4_\2_,]CA[
M_D?X3_K[3_\ 2T?SN4445^V'^I@4444 %%%% !1110 4444 %%%% !7J/[#W
M_)Z'PC_[*9H7_I?#7EU>H_L/?\GH?"/_ +*9H7_I?#6&*_W6I_A?Y'D<0?\
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M+\SV.'O^1_A/^OM/_P!+1_.Y1117[8?ZF!1110 4444 %%%% !1110 4444
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M_9EV]#SLX\:_#+%91B*-+'WE*$TE[*MJW%I+6G;?N?L-17A?_#6'QL_Z,?\
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M !1110 4444 %%%% !1110 4444 %%%% !7SQ^V9_P $I?V"_P#@H'XV\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!^%'_  63_P"4D7Q'_P"X/_Z9[*OF*OIW_@LG_P I(OB/
M_P!P?_TSV5?,5?LV5_\ (LH?X(_^DH_TXX!_Y(7*O^P:A_Z:B%?NO_P1L_Y1
MN_#C_N,?^GB]K\**_=?_ ((V?\HW?AQ_W&/_ $\7M>%QC_R+(?XU_P"DR/R;
MZ2O_ "0N&_["8?\ IJL>._\ !5+XK_%+P+_P5'_8)\#^"?B5K^CZ+XJ\?>*8
M/$^CZ5K,]O:ZQ%%86;1QW44;!+A49F*K(&"EB1C->A?'W_@M?^R)\ /VD/&/
M['UWX/\ B;XO^*7@^WTZ8^!/A[X!N-9U'5TO+472M9QP$[UBA*M*\AC2,NHW
M$L ?'O\ @KW_ ,I;_P#@G7_V4;Q=_P"FZRJ7]B>RLI/^#CG]M?49+2)KB+X?
M^ (XIS&"Z(^F1%E#=0"40D="47/05^;'\0'TO^P[_P %,/V9_P!O?P'XM\9?
M"^3Q#X9OOA]JCZ?\0/"?Q#T5M'U?PU.J,^+V"1B(E*HYW!BO[MP2"C >%2_\
M'&7["<,*^/YOAC\;E^$[ZQ_9J?'QOA->?\(6TOG>1O%]GS#'YN4W^3C<,5Y;
M^SE>?";0O^"MW_!4>;XW7#VG@*/P1X$G\:/;P3/LTW_A%;EKR39;JTC$1-*W
MR*7.3@$FO.9/#?[4O_!/?_@EZWQA_9N_:!^#/[5_[&&D>%/[3MOA]\7?!OV#
M4Y?#,DV\V<-V@,%U*K.1LO+<,&!C\H.JQT >Q_\ !5S_ (+*?$S]D_\ :N^
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MS6= ^&>K7TUEX?GUO1'34-9N4N9;9(;2TC+RS/++#((U R51G(5 6%+]EO\
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D%[>.YDW2)$Q1"45@IVC(X%?O[110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>pacb-20241231_g8.jpg
<TEXT>
begin 644 pacb-20241231_g8.jpg
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)"?D3=7Z$_M'_L[^"?VDOV8_&O[+/B)!I^@^-/!E]X<F:RA4?8H+BV> /$G
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M2-9U.*QC9($N+JRBGD$:LS%4#.0 6) QDGK7>4 %%%% !1110 4444 %%%%
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M_P B4?\ #Y+_ ()N_P#1QO\ Y:&L?_(E']EYG_SXG_X#+_(/]0>.O^A5B?\
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MHK\Q?^(CG_JS?_S(?_WOH_XB.?\ JS?_ ,R'_P#>^C_5K._^?7_DT?\ ,/\
MB!OBE_T+_P#RK0_^6GZ=45^8O_$1S_U9O_YD/_[WT?\ $1S_ -6;_P#F0_\
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M110 4444 %%%% !1110 4444 %>H_L/?\GH?"/\ [*9H7_I?#7EU>H_L/?\
M)Z'PC_[*9H7_ *7PUABO]UJ?X7^1Y'$'_(AQ?_7JI_Z0S^B.BBBOQ(_RR"BB
MB@ HHHH *_'3_@X)_P"3T/#O_9,[+_TOU"OV+K\=/^#@G_D]#P[_ -DSLO\
MTOU"OI>%/^1NO\+/W'Z/7_)QH?\ 7JI^2/A:BBBOT\_O,**** "BBB@ HHHH
M **** "BBB@ K]C/^#?;_DR_Q%_V4R]_](-/K\<Z_8S_ (-]O^3+_$7_ &4R
M]_\ 2#3Z^;XK_P"10_\ $C\/^D)_R;F?_7VG^;/NBBBBOR\_@L**** "BBB@
M KR[]N'_ ),O^+G_ &3/7?\ T@FKU&O+OVX?^3+_ (N?]DSUW_T@FKHPO^]4
M_P#$OS/8X>_Y'^$_Z^T__2T?SN4445^V'^I@4444 %%%% !1110 4444 %%%
M% !7J/[#W_)Z'PC_ .RF:%_Z7PUY=7J/[#W_ ">A\(_^RF:%_P"E\-88K_=:
MG^%_D>1Q!_R(<7_UZJ?^D,_HCHHHK\2/\L@HHHH **** "OQT_X."?\ D]#P
M[_V3.R_]+]0K]BZ_'3_@X)_Y/0\._P#9,[+_ -+]0KZ7A3_D;K_"S]Q^CU_R
M<:'_ %ZJ?DCX6HHHK]//[S"BBB@ HHHH **** "BBB@ HHHH *_8S_@WV_Y,
MO\1?]E,O?_2#3Z_'.OV,_P"#?;_DR_Q%_P!E,O?_ $@T^OF^*_\ D4/_ !(_
M#_I"?\FYG_U]I_FS[HHHHK\O/X+"BBB@ HHHH *\N_;A_P"3+_BY_P!DSUW_
M -()J]1KR[]N'_DR_P"+G_9,]=_]()JZ,+_O5/\ Q+\SV.'O^1_A/^OM/_TM
M'\[E%%%?MA_J8%%%% !1110 4444 %%%% !1110 5ZC^P]_R>A\(_P#LIFA?
M^E\->75ZC^P]_P GH?"/_LIFA?\ I?#6&*_W6I_A?Y'D<0?\B'%_]>JG_I#/
MZ(Z***_$C_+(**** "BBB@ K\=/^#@G_ )/0\._]DSLO_2_4*_8NOQT_X."?
M^3T/#O\ V3.R_P#2_4*^EX4_Y&Z_PL_<?H]?\G&A_P!>JGY(^%J***_3S^\P
MHHHH **** "BBB@ HHHH **** "OV,_X-]O^3+_$7_93+W_T@T^OQSK]C/\
M@WV_Y,O\1?\ 93+W_P!(-/KYOBO_ )%#_P 2/P_Z0G_)N9_]?:?YL^Z****_
M+S^"PHHHH **** "O+OVX?\ DR_XN?\ 9,]=_P#2":O4:\N_;A_Y,O\ BY_V
M3/7?_2":NC"_[U3_ ,2_,]CA[_D?X3_K[3_]+1_.Y1117[8?ZF!1110 4444
M %%%% !1110 4444 %>H_L/?\GH?"/\ [*9H7_I?#7EU>H_L/?\ )Z'PC_[*
M9H7_ *7PUABO]UJ?X7^1Y'$'_(AQ?_7JI_Z0S^B.BBBOQ(_RR"BBB@ HHHH
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MC_+(**** "BBB@ K\=/^#@G_ )/0\._]DSLO_2_4*_8NOQT_X."?^3T/#O\
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M^$-;?_+*C_ASM\;/^@/X[_\ "&MO_EE1_K+DG_/W_P EE_D'_$<O"W_H8?\
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M_P"!5M_\51_PUA\;/^C'_'?_ (%6W_Q5?EQ_ I[I17A?_#6'QL_Z,?\ '?\
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M^$-;?_+*C_ASM\;/^@/X[_\ "&MO_EE1_K+DG_/W_P EE_D'_$<O"W_H8?\
ME*O_ /*CXYHK[&_X<[?&S_H#^.__  AK;_Y94?\ #G;XV?\ 0'\=_P#A#6W_
M ,LJ/]9<D_Y^_P#DLO\ (/\ B.7A;_T,/_*5?_Y4?'-%?8W_  YV^-G_ $!_
M'?\ X0UM_P#+*C_ASM\;/^@/X[_\(:V_^65'^LN2?\_?_)9?Y!_Q'+PM_P"A
MA_Y2K_\ RH^.:*^QO^'.WQL_Z _CO_PAK;_Y94?\.=OC9_T!_'?_ (0UM_\
M+*C_ %ER3_G[_P"2R_R#_B.7A;_T,/\ RE7_ /E1\<U^QG_!OM_R9?XB_P"R
MF7O_ *0:?7QS_P .=OC9_P! ?QW_ .$-;?\ RRK[%_X)]>'/C9^PG\%]1^$/
M_#-/COQ3]O\ $T^K_P!H_8+:Q\OS+>WA\KR_M$N<>1NW;AG?C'&3XG$&=9;C
MLN=*A4O*ZTM)?FD?E?C'XG<#\5<%RP&5XOVE5S@^7V=6.B;N[SA%?B?=-%>%
M_P##6'QL_P"C'_'?_@5;?_%4?\-8?&S_ *,?\=_^!5M_\57P9_)![I17A?\
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MH]I&B*LH5V$@,A5USFOU4Z=:_-;XZ>+_ !G_ ,%U_CIJW[&_P&\1WFE_LI>
M=;6V^-_Q)TJ=HV^(.I0.KGPUI<R];1&"FZN4.&X53M*F8 X+XI_\%+/VU_&W
M_!"?]FKX@Z3XJ/A3XV_M,>-_#GPZ@\806"I+8R:A=7,1U>*( (DDUM:"12H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>[FVU?Q5<&?Q=%X8\9ZOHUGK\ISN>\M+"ZA@N'8DEW9-SDG>6R:]KUG]D?\
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M:I=:C/-+%!N"DQ1LJDJI()4$>\T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
B444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Pacific Biosciences of California, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">16-1590339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1305 O&#8217;Brien Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Menlo Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">521-8000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PACB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,852,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive Proxy Statement relating to its 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001299130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Mateo, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 55,370<span></span>
</td>
<td class="nump">$ 179,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="nump">334,561<span></span>
</td>
<td class="nump">451,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">27,524<span></span>
</td>
<td class="nump">36,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">58,755<span></span>
</td>
<td class="nump">56,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">18,781<span></span>
</td>
<td class="nump">17,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">495,681<span></span>
</td>
<td class="nump">742,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">30,505<span></span>
</td>
<td class="nump">36,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">16,091<span></span>
</td>
<td class="nump">32,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">2,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">389,572<span></span>
</td>
<td class="nump">456,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">317,761<span></span>
</td>
<td class="nump">462,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">9,305<span></span>
</td>
<td class="nump">13,274<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,260,447<span></span>
</td>
<td class="nump">1,746,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">16,590<span></span>
</td>
<td class="nump">15,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">22,595<span></span>
</td>
<td class="nump">45,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">13,864<span></span>
</td>
<td class="nump">16,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">10,026<span></span>
</td>
<td class="nump">9,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities, current</a></td>
<td class="nump">3,224<span></span>
</td>
<td class="nump">8,326<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">66,299<span></span>
</td>
<td class="nump">95,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">5,900<span></span>
</td>
<td class="nump">5,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration liability, non-current</a></td>
<td class="nump">18,700<span></span>
</td>
<td class="nump">19,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">14,914<span></span>
</td>
<td class="nump">31,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible senior notes, net, non-current</a></td>
<td class="nump">647,494<span></span>
</td>
<td class="nump">892,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities, non-current</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">751<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">753,853<span></span>
</td>
<td class="nump">1,044,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,654,804<span></span>
</td>
<td class="nump">2,539,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,148,926)<span></span>
</td>
<td class="num">(1,839,075)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">506,594<span></span>
</td>
<td class="nump">701,304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,260,447<span></span>
</td>
<td class="nump">$ 1,746,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2010</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">294,418,000<span></span>
</td>
<td class="nump">267,744,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">294,418,000<span></span>
</td>
<td class="nump">267,744,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 154,014<span></span>
</td>
<td class="nump">$ 200,521<span></span>
</td>
<td class="nump">$ 128,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">9,393<span></span>
</td>
<td class="nump">1,983<span></span>
</td>
<td class="nump">733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LossOnPurchaseCommitment', window );">Loss on purchase commitment</a></td>
<td class="nump">998<span></span>
</td>
<td class="nump">3,436<span></span>
</td>
<td class="nump">3,705<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenue</a></td>
<td class="nump">116,732<span></span>
</td>
<td class="nump">147,741<span></span>
</td>
<td class="nump">79,269<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">37,282<span></span>
</td>
<td class="nump">52,780<span></span>
</td>
<td class="nump">49,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">134,922<span></span>
</td>
<td class="nump">187,170<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general and administrative</a></td>
<td class="nump">175,017<span></span>
</td>
<td class="nump">169,818<span></span>
</td>
<td class="nump">160,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment charges</a></td>
<td class="nump">184,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Merger-related expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,042<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(850)<span></span>
</td>
<td class="nump">15,060<span></span>
</td>
<td class="nump">2,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AmortizationOfAcquiredIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">18,006<span></span>
</td>
<td class="nump">6,157<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">511,595<span></span>
</td>
<td class="nump">387,247<span></span>
</td>
<td class="nump">356,231<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(474,313)<span></span>
</td>
<td class="num">(334,467)<span></span>
</td>
<td class="num">(307,196)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,033)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Gain on debt restructuring</a></td>
<td class="nump">154,407<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(13,412)<span></span>
</td>
<td class="num">(14,343)<span></span>
</td>
<td class="num">(14,690)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">23,783<span></span>
</td>
<td class="nump">32,684<span></span>
</td>
<td class="nump">7,638<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(309,535)<span></span>
</td>
<td class="num">(318,159)<span></span>
</td>
<td class="num">(314,248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="nump">316<span></span>
</td>
<td class="num">(11,424)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(309,851)<span></span>
</td>
<td class="num">(306,735)<span></span>
</td>
<td class="num">(314,248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">4,984<span></span>
</td>
<td class="num">(3,678)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (309,648)<span></span>
</td>
<td class="num">$ (301,751)<span></span>
</td>
<td class="num">$ (317,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IncomeLossPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="num">$ (1.13)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in usd per share)</a></td>
<td class="num">$ (1.59)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average shares outstanding used in calculating &#8206;net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">274,488<span></span>
</td>
<td class="nump">253,629<span></span>
</td>
<td class="nump">224,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">288,366<span></span>
</td>
<td class="nump">253,629<span></span>
</td>
<td class="nump">224,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 136,149<span></span>
</td>
<td class="nump">$ 183,872<span></span>
</td>
<td class="nump">$ 108,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of revenue</a></td>
<td class="nump">92,284<span></span>
</td>
<td class="nump">127,568<span></span>
</td>
<td class="nump">60,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember', window );">Service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">17,865<span></span>
</td>
<td class="nump">16,649<span></span>
</td>
<td class="nump">19,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of revenue</a></td>
<td class="nump">$ 14,057<span></span>
</td>
<td class="nump">$ 14,754<span></span>
</td>
<td class="nump">$ 13,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AmortizationOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AmortizationOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IncomeLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Loss per Share Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IncomeLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_LossOnPurchaseCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss On Purchase Commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_LossOnPurchaseCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 60<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481408/470-60-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,978,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 790,987<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">$ 2,009,945<span></span>
</td>
<td class="num">$ (1,087)<span></span>
</td>
<td class="num">$ (1,218,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Basic net loss</a></td>
<td class="num">(314,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(314,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="num">(3,678)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,678)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans</a></td>
<td class="nump">11,230<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">11,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">78,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">562,904<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
<td class="nump">2,099,782<span></span>
</td>
<td class="num">(4,765)<span></span>
</td>
<td class="num">(1,532,340)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Basic net loss</a></td>
<td class="num">(306,735)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(306,735)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="nump">$ 4,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock following milestone achievement (in shares)</a></td>
<td class="nump">8,988,391<span></span>
</td>
<td class="nump">8,988,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock following milestone achievement</a></td>
<td class="nump">$ 84,761<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">84,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in acquisition of Apton (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in acquisition of Apton</a></td>
<td class="nump">76,642<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">76,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan', window );">Issuance of common stock in connection with Apton liquidity event bonus plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan', window );">Issuance of common stock in connection with Apton liquidity event bonus plan</a></td>
<td class="nump">2,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs</a></td>
<td class="nump">189,200<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">189,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,836,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans</a></td>
<td class="nump">15,319<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">15,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">72,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 701,304<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
<td class="nump">2,539,892<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="num">(1,839,075)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">267,744,000<span></span>
</td>
<td class="nump">267,744,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Basic net loss</a></td>
<td class="num">$ (309,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(309,851)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans</a></td>
<td class="nump">7,703<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">7,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock in conjunction with convertible notes exchange (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,452,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock in conjunction with convertible notes exchange</a></td>
<td class="nump">36,199<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">36,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">71,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 506,594<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
<td class="nump">$ 2,654,804<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="num">$ (2,148,926)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">294,418,000<span></span>
</td>
<td class="nump">294,418,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Acquisitions, Liquidity Bonus Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Acquisitions, Liquidity Bonus Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (309,851)<span></span>
</td>
<td class="num">$ (306,735)<span></span>
</td>
<td class="num">$ (314,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">13,774<span></span>
</td>
<td class="nump">11,463<span></span>
</td>
<td class="nump">9,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">27,412<span></span>
</td>
<td class="nump">8,261<span></span>
</td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">12,165<span></span>
</td>
<td class="nump">6,810<span></span>
</td>
<td class="nump">6,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">71,036<span></span>
</td>
<td class="nump">72,118<span></span>
</td>
<td class="nump">78,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment charges</a></td>
<td class="nump">184,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashMergerRelatedCosts', window );">Merger-related compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,395<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,033<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Gain on debt restructuring</a></td>
<td class="num">(154,407)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Accretion of discount and amortization of premium on marketable securities, net</a></td>
<td class="num">(13,044)<span></span>
</td>
<td class="num">(12,840)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in the estimated fair value of contingent consideration</a></td>
<td class="num">(850)<span></span>
</td>
<td class="nump">15,060<span></span>
</td>
<td class="nump">2,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory provision</a></td>
<td class="nump">4,618<span></span>
</td>
<td class="nump">10,584<span></span>
</td>
<td class="nump">6,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(205)<span></span>
</td>
<td class="num">(11,424)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(628)<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">9,091<span></span>
</td>
<td class="num">(17,829)<span></span>
</td>
<td class="nump">5,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="num">(8,320)<span></span>
</td>
<td class="num">(13,841)<span></span>
</td>
<td class="num">(33,906)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">2,228<span></span>
</td>
<td class="num">(8,984)<span></span>
</td>
<td class="num">(12,324)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,405<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(26,342)<span></span>
</td>
<td class="nump">13,103<span></span>
</td>
<td class="num">(3,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(2,108)<span></span>
</td>
<td class="num">(10,420)<span></span>
</td>
<td class="num">(3,734)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(11,920)<span></span>
</td>
<td class="num">(8,759)<span></span>
</td>
<td class="num">(7,724)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(14,882)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(4,612)<span></span>
</td>
<td class="nump">2,449<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(206,058)<span></span>
</td>
<td class="num">(259,173)<span></span>
</td>
<td class="num">(263,211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(6,188)<span></span>
</td>
<td class="num">(8,843)<span></span>
</td>
<td class="num">(16,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for purchases of acquired entities, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="num">(498,635)<span></span>
</td>
<td class="num">(756,567)<span></span>
</td>
<td class="num">(442,788)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="nump">34,856<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">593,971<span></span>
</td>
<td class="nump">769,521<span></span>
</td>
<td class="nump">575,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">124,004<span></span>
</td>
<td class="nump">4,604<span></span>
</td>
<td class="nump">116,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under equity offerings, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">189,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock from equity plans</a></td>
<td class="nump">7,703<span></span>
</td>
<td class="nump">15,319<span></span>
</td>
<td class="nump">11,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,375)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(86,411)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PaymentsInConjunctionWithNotesExchange', window );">Payments made in conjunction with convertible notes exchange</a></td>
<td class="nump">50,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Notes payable principal payoff</a></td>
<td class="num">(490)<span></span>
</td>
<td class="num">(1,842)<span></span>
</td>
<td class="num">(1,608)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(42,987)<span></span>
</td>
<td class="nump">108,891<span></span>
</td>
<td class="nump">9,622<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(125,041)<span></span>
</td>
<td class="num">(145,678)<span></span>
</td>
<td class="num">(137,506)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">182,633<span></span>
</td>
<td class="nump">328,311<span></span>
</td>
<td class="nump">465,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">57,592<span></span>
</td>
<td class="nump">182,633<span></span>
</td>
<td class="nump">328,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">55,370<span></span>
</td>
<td class="nump">179,911<span></span>
</td>
<td class="nump">325,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash at end of period</a></td>
<td class="nump">2,222<span></span>
</td>
<td class="nump">2,722<span></span>
</td>
<td class="nump">3,222<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">57,592<span></span>
</td>
<td class="nump">182,633<span></span>
</td>
<td class="nump">328,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">14,805<span></span>
</td>
<td class="nump">15,687<span></span>
</td>
<td class="nump">14,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Convertible notes exchange</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">441,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_NoteExchangeMember', window );">Note Exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock</a></td>
<td class="nump">36,199<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_LiquidityBonusEventMember', window );">Liquidity Bonus Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,111<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_MilestoneAchievementMember', window );">Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">84,761<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonAndOmniomeMember', window );">Apton And Omniome</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_TransferOfInventoryToPropertyAndEquipment', window );">Inventory transferred to property and equipment</a></td>
<td class="nump">4,194<span></span>
</td>
<td class="nump">3,984<span></span>
</td>
<td class="nump">2,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges', window );">Property and equipment transferred to inventory</a></td>
<td class="num">(2,572)<span></span>
</td>
<td class="num">(7,022)<span></span>
</td>
<td class="num">(715)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset and liability additions and modifications</a></td>
<td class="nump">18,253<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonAndOmniomeMember', window );">Apton And Omniome | Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 76,642<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PaymentsInConjunctionWithNotesExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments In Conjunction With Notes Exchange</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PaymentsInConjunctionWithNotesExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_TransferOfInventoryToPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer of Inventory to Property and Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_TransferOfInventoryToPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 60<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481408/470-60-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of physical assets used in the normal conduct of business and not intended for resale, from reclassification, impairment, donation, or changes classified as other. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTransfersAndChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_NoteExchangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pacb_NoteExchangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_LiquidityBonusEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pacb_LiquidityBonusEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pacb_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonAndOmniomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_AptonAndOmniomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_BusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pacb_BusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 1.  ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Overview</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing technology and our Sequencing by Binding (SBB) short-read sequencing technology. Our products address solutions across a broad set of applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Long-read sequencing was recognized by the journal Nature Methods as its &#8220;method of the year&#8221; for 2022 for its contributions to biological understanding and future potential. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-read sequencing</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been applied to produce telomere-to-telomere genomes of humans, pangenome references, and has been recognized for its ability to provide more complete views of human variation</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus is on creating some of the world's most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to &#8220;PacBio,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; and &#8220;our&#8221; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates, including those relating to the valuation of inventory, fair value of contingent consideration, valuation of acquired intangible assets, useful lives assigned to finite-lived assets, asset impairment assessments, computation of provisions for income taxes, and valuations related to our convertible senior notes. While the extent of the potential impact of current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of December&#160;31, 2024. Actual results could differ materially from these estimates. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Functional Currency</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. dollar is the functional currency of our international operations. We remeasure foreign subsidiaries monetary assets and liabilities to the U.S. dollar and record net gains or losses from remeasurement in other income, net, on our consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#8217; securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive income (loss) in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net. We have the ability to hold, and do not intend to sell investments in unrealized loss positions before the recovery of their amortized cost bases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities, and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash includes cash that is not readily available for use in the Company&#8217;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Concentration and Other Risks</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist principally of interest-bearing investments and trade receivables. We maintain cash, cash equivalents, and investments with various major financial institutions. The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing. At December&#160;31, 2024, most of our cash was deposited with U.S. financial institutions. Our investment policy generally restricts the amount of credit exposure to any one issuer. There is no limit to the percentage of the portfolio that may be maintained in securities issued by the U.S. Treasury and U.S. Government Agencies, or other securities fully backed by U.S. Treasury or Government agencies. We have not experienced significant credit losses from financial institutions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trade receivables are derived from revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers&#8217; financial condition and, generally, require no collateral from our customers. The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review our trade receivables including consideration of factors such as historical experience, the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. We have not experienced any significant credit losses to date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, and 2023, no customer accounted for 10% or more of our total revenue. For the year ended December&#160;31, 2022, one customer exceeded 10% of our total revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, 36% and 49% of our accounts receivable were from domestic customers, respectively. As of December&#160;31, 2024, no customer represented 10% or more of our net accounts receivable. As of December&#160;31, 2023, one customer represented 10% of our net accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently purchase several key parts and components used in the manufacture of our products from a limited number of suppliers. Generally, we have been able to obtain an adequate supply of such parts and components but in certain instances have incurred additional costs to secure a supply of constrained material. An extended interruption in the supply of parts and components currently obtained from our suppliers could adversely affect our business and consolidated financial statements. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inventory, Net</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value on a first-in, first-out (&#8220;FIFO&#8221;) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs. Determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Property and Equipment, Net</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, reviewed regularly for impairment, and depreciated over the estimated useful lives of the assets, using the straight-line method. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred. Transfers of assets between property and equipment, net, and inventory are transferred at standard cost and recognized at carrying value.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated useful lives of the major classes of property and equipment are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Operating Leases</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have various operating lease agreements for office, research and development, manufacturing and distribution facilities, including our headquarters location in Menlo Park, California. As of December 31, 2024, these leases had remaining lease terms that expire between 2025 and 2027. We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. Operating lease expense is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period incurred. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Combinations</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, contingent consideration can be earned by the sellers upon completion of certain future performance milestones. In these cases, a liability is recorded on the acquisition date for an estimate of the acquisition date fair value of the contingent consideration. These estimates require significant management judgment, including probabilities of achieving certain future milestones. Changes in the fair value of the contingent consideration subsequent to the acquisition date are recognized in operating expense on our consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded on our consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets with Indefinite Lives</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and capitalized in-process research and development (&#8220;IPR&amp;D&#8221;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is assessed for impairment and then amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually. We perform annual impairment testing of goodwill as of the first day of the second quarter, or more frequently if indicators of impairment exist. We perform annual impairment testing of IPR&amp;D as of the first day of the third quarter, or more frequently if indicators of impairment exist. Events that would indicate impairment and trigger an interim impairment test include, but are not limited to, unexpected adverse business conditions, weak demand for a specific product line or business, economic factors, shifting focus to certain lines of business, unanticipated technological changes or competitive activities, loss of key personnel, changes in business strategy and acts by governments or courts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level. We have one reporting unit, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test. We generally perform our impairment test using a combination of an income and a market approach to determine the fair value of goodwill. The income approach utilizes estimated discounted cash flows, while the market approach utilizes comparable company information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the IPR&amp;D impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the IPR&amp;D is less than the carrying amount. The qualitative factors include, but are not limited to, macroeconomic conditions, industry-specific conditions, and company-specific conditions. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the IPR&amp;D is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the IPR&amp;D with the carrying value. If the carrying amount of the IPR&amp;D exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative impairment test.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intangible Assets and Other Finite-Lived Assets</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangibles assets include our acquired developed technology and customer relationships. We capitalize finite-lived intangibles assets and generally amortize them on a straight-line basis over the estimated useful lives. Intangible assets purchased as part of an acquisition are included in Intangible assets, net, on our consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review intangible assets with finite lives and other finite-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. We assess the recoverability of assets based on the estimated undiscounted future cash flows expected to result from the use and eventual disposition of the asset. If the undiscounted future cash flows are less than the carrying amount, the asset is impaired. In light of the changes in circumstances that led to the recoverability assessment, we also assess the remaining estimated useful life of the assets. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to net book value, significant changes in the ability of an asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to estimate the fair values of identifiable intangible assets with finite lives and other finite-lived assets, we estimate the present value of future cash flows from those assets. The key assumptions that we use in our cash flow model are the amount and timing of estimated future cash flows to be generated by the asset over an extended period of time and a rate of return that considers the relative risk of achieving the cash flows, the time value of money, and other factors that a willing market participant would consider. Management judgment is required to estimate the amount and timing of future cash flows and the relative risk of achieving those cash flows.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue Recognition</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables; service and other revenue consist primarily of revenue earned from product maintenance agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods are transferred to our customers, or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Invoicing typically occurs upon shipment, or delivery in the case of an instrument, and payment is typically due within 30 days from invoice. In instances where the right to payment or transfer of title is contingent upon customer acceptance of the product, revenue is deferred until the acceptance criteria has been met. Revenue from instrument service contracts is recognized as the services are rendered, typically evenly over the contract term. Revenue from development agreements generally includes upfront and milestone payments. Revenue for these agreements is recognized when each distinct performance obligation is satisfied.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into, or periodically modify, contracts with customers that include a combination of promised products and services, resulting in arrangements containing multiple performance obligations. We determine whether each product or service is distinct, in order to identify the performance obligations in the contract and allocate the contract transaction price among the distinct performance obligations. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Therefore, instrument revenue is recognized upon transfer of control of the asset to the customer, which is generally upon delivery for sales made to our non-distributor customers and upon shipment for sales made to our distributor customers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for contracts with multiple performance obligations is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using historical average selling prices combined with an assessment of current market conditions. If the standalone selling price is not directly observable, we rely on estimates by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices, and other observable inputs. We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts and sales taxes collected on behalf of governmental authorities. We update the transaction price for expected consideration, subject to constraint. Where we expect, at contract inception, the timing of payments to be consistent with the transfer of goods or services or the contract duration to be one year or less, we do not adjust the transaction price for the effects of a significant financing component </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically modify existing contracts with customers, which could change the scope or the price of the contract, or both. When a contract modification occurs, we exercise judgment to determine if the modification should be accounted for as: (i) a separate contract, (ii) the termination of the original contract and creation of a new contract, (iii) a cumulative catch-up adjustment to the original contract, or a combination thereof. Further, contract modifications require the identification and evaluation of the performance obligations of the modified contract, allocation of revenue to the remaining performance obligations and determination of the period of recognition for each identified performance obligation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our agreements provide options to customers which can be exercised at a future date, such as the option to purchase our product at discounted prices, among others. In accounting for customer options, we determine whether an option is a material right and this may require us to exercise judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right and, therefore, a performance obligation. If the contract gives the customer the option to acquire additional goods or services at their normal standalone selling prices, we would likely determine that the option is not a material right and, therefore, account for it when the customer exercises the option. If the standalone selling price of the option is not directly observable, an estimated standalone selling price is utilized which considers adjustments for discounts that the customer could receive without exercising the option and the likelihood that the option will be exercised. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we generally provide a one-year warranty on instruments. We accrue the cost of the assurance warranty when revenue of the instrument is recognized. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee sales commissions are generally recorded as selling, general, and administrative expense when incurred as the amortization period for such costs, if capitalized, would have been one year or less.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Revenue</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue reflects the direct cost of product components, third-party manufacturing services, and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain, and support our instruments, consumables, and services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing overhead is predominantly comprised of labor and facility costs. We capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support our installed customer base. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists primarily of expenses for personnel engaged in the development of our core technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, partner development costs, facilities costs, and other related overhead. We expense research and development costs during the period in which the costs are incurred. We defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Credit Losses</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade accounts receivable</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review the allowance by considering factors such as the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. Credit loss expense was immaterial for the years ended December&#160;31, 2024, 2023, and 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-sale debt securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities. We regularly assess whether our securities in an unrealized loss position are credit related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income. Unrealized losses that are not credit related are included in accumulated other comprehensive income (loss). The unrealized losses on our investments are mainly attributable to government securities, including U.S. government and U.S. agency bond securities, impacted by movements in market rates and not due to issuer credit risk. We have the ability to hold and do not intend to sell the investments in unrealized loss positions before the recovery of their amortized cost bases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruptions associated with epidemics or pandemics, or other customer-specific factors.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Income Taxes</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. The effect of a change in tax rates on the deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review our positions taken relative to income taxes. To the extent our tax positions are more likely than not going to result in additional taxes, we accrue the estimated amount of tax related to such uncertain positions. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share-Based Compensation</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize share-based compensation expense for share-based payments, including stock options, restricted stock units, performance stock units and stock issued under our employee stock purchase plan ("ESPP") based on the grant-date fair value. We estimate the fair value of stock options and ESPP using an option-pricing model. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_124" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 9. Stockholders&#8217; Equity</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information regarding share-based compensation.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Comprehensive Income (Loss)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss) is comprised of unrealized gains (losses) on our investment securities. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Shipping and Handling</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to shipping and handling are included in cost of revenues for all periods presented.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Earnings per Share</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing diluted net loss by the weighted-average number of shares of common stock outstanding and potentially dilutive shares outstanding during the period. We calculate the potential dilutive effect of outstanding stock options, restricted stock units, and common stock issuable pursuant to our ESPP, using the treasury stock method. Potentially dilutive common shares issuable upon conversion of convertible senior notes are determined using the if-converted method.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This ASU improves segment disclosure requirements, primarily through enhanced disclosure requirements for significant segment expenses on an annual and interim basis. The improved disclosure requirements apply to all public entities that are required to report segment information, including those with only one reportable segment. The standard was effective for us beginning in fiscal year 2024 and interim periods within fiscal year 2025. We adopted this ASU for our fiscal year ending December 31, 2024 and applied the amendments retrospectively to all prior periods presented in the consolidated financial statements. There was no impact on the Company&#8217;s reportable segments identified. Additional required disclosures have been included in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_130" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 11. Segment and Geographic Information</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Pending Adoption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-04, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt With Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard will be effective for us beginning in the first quarter of fiscal year 2026, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-04 on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to provide disaggregated disclosures, within the notes to the financial statements, of specified categories of expenses that are included in line items on the face of the income statement. The standard will be effective for us beginning in fiscal year 2027, and interim periods within fiscal year 2028, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard will be effective for us beginning in fiscal year 2025, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2023-09 on the consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">BUSINESS ACQUISITIONS</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 2.  BUSINESS ACQUISITIONS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Apton Biosystems</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2023, we acquired Apton Biosystems, Inc. (&#8220;Apton&#8221;), a California-based genomics company focused on developing a high throughput short-read sequencer using highly differentiated optics and image processing, paired with novel clustering and chemistry (the &#8220;Apton acquisition&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Apton acquisition, all outstanding equity securities of Apton were cancelled in exchange for shares of our common stock with a fair value of $76.6 million, cash of $0.2 million, and contingent consideration with an estimated fair value of $18.5 million. Excluded from consideration transferred was $1.3 million attributable to accelerated share-based compensation expense. The fair value of the 6,121,571 common shares issued was determined based on the closing market price of our common stock on the acquisition date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Apton acquisition, contingent consideration of $25.0&#160;million, which we may elect to pay in cash, shares of our common stock or a combination of cash and shares of our common stock, is due upon the achievement of a milestone, defined as the achievement of $50.0&#160;million in revenue associated with Apton's technology, provided that the milestone event occurs prior to the five-year anniversary of the closing date of the acquisition. At this time, the number of shares, if any, to be issued in connection with the achievement of the specified milestone is not known and will be calculated based on the daily volume-weighted average price of our common stock for the <span style="-sec-ix-hidden:f-527">twenty</span> trading days ending on and including the fifth trading day immediately prior to the occurrence of the specified milestone. Upon achievement of the milestone, we may pay cash in lieu of our common stock to ensure that the issuance of our common stock does not exceed 19.9% of our outstanding shares of common stock then outstanding.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized on our consolidated statements of operations and comprehensive loss. The fair value of the contingent consideration liability is calculated, with the assistance from a third-party valuation firm, using a Monte Carlo simulation to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was accounted for as a business combination and, accordingly, the total fair value of the consideration transferred was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values on the acquisition date. As of December 31, 2023, the major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,287&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets, current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,338)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,191)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,008&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have finalized the purchase price allocation for the </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apton acquisition. There</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were no material adjustments from those amounts disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred costs related to the Apton acquisition of approximately $9.0&#160;million during the year ended December 31, 2023, which are included in merger-related expenses on our consolidated statement of operations and comprehensive loss. Merger-related expenses include $2.8&#160;million relating to a liquidity event bonus plan that was treated as a separate transaction and included the issuance of 168,621 shares of common stock that were issued with a fair value of $2.1&#160;million based on the closing market price of our common stock on the acquisition date. As a result, the total shares issued in connection with the Apton acquisition were 6.3&#160;million shares of common stock. </span></div>The excess of the value of consideration paid over the aggregate fair value of those net assets has been recorded as goodwill. We recognized goodwill of $52.3&#160;million, which is primarily attributable to the synergies expected to occur from the integration of Apton and is not deductible for income tax purposes. We allocated $55.0 million of the purchase price to acquired IPR&amp;D. The fair value of the IPR&amp;D was determined, with the assistance of a third-party valuation firm, using an income approach based on a forecast of expected future cash flows. Expected future cash flows utilize significant assumptions such as revenue projections and discount rate.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 3.  FINANCIAL INSTRUMENTS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy established under GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 1: quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,370&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,370&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,739&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,739&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,370&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,370&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,739&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,911&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,905&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,905&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,579&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,579&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287,656&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287,656&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,979&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,979&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,561&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,561&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,505&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,505&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,592&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,561&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392,153&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,894&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">561,244&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634,138&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration - Apton acquisition</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,700&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,700&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities measured at fair value </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,700&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,700&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and our valuation techniques did not change compared to the prior year.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contingent Consideration - Apton</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify contingent consideration, which was incurred in connection with the acquisition of Apton, within Level 3 as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value. Estimates and assumptions used in the Monte Carlo simulation include risk-adjusted forecasted revenues for products and services leveraging Apton's technology and an estimated credit spread.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of the contingent consideration liability based on the simulated revenue of the Company through the five-year anniversary of the closing date of the acquisition. As of December&#160;31, 2024, the key input used in the determination of the fair value included projected revenues of the Company relating to the high-throughput short-read products and services leveraging Apton's technology. The assumptions used in our valuation are inherently subject to uncertainty. A decrease in the projected revenues would result in a decrease in the fair value of the liability. The discount rates used are the sum of the U.S. risk-free rate and the estimated subordinated credit spread for CCC+ credit rating, which ranges from 9.4% to 9.6%. Changes in our estimated subordinated credit spread can result in changes in the fair value of the contingent consideration liability, where a lower credit spread may result in an increased liability valuation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the contingent consideration liability related to the Apton acquisition for the year ended December&#160;31, 2024 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance as of December 31, 2023</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in estimated fair value</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(850)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance as of December 31, 2024</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,700&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the fair value are recorded as the change in fair value of contingent consideration on our consolidated statement of operations and comprehensive loss.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contingent Consideration - Omniome</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2023, we achieved the commercial milestone in connection with the 2021 acquisition of Omniome. Consequently, former Omniome securityholders were entitled to receive as milestone consideration, among other things, an aggregate of approximately $100.9&#160;million in cash and approximately 9.0&#160;million shares of our common stock, representing $95.9&#160;million divided by the volume-weighted average of the trading prices of our common stock for the <span style="-sec-ix-hidden:f-661">twenty</span> trading days ending with and including the trading day that was two days immediately prior to the achievement of the milestone. The $95.9&#160;million represents the $100.0&#160;million that was to be paid in shares of our common stock offset by $4.1&#160;million attributable to stock options issued by PacBio in replacement of Omniome&#8217;s unvested options as part of the transaction, pursuant to the terms of the Omniome merger agreement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the achievement of the commercial milestone, $101.3&#160;million of the contingent consideration, which includes certain payroll taxes, was paid during the year ended December 31, 2023. Additionally, 8,988,391 shares were issued at a value of $84.8&#160;million to the former Omniome securityholders.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash, cash equivalents, restricted cash, and investments:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized<br/>Cost </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,370&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,370&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,370&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,370&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,746&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,905&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287,393&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287,656&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,139&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,561&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and investments </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,509&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,931&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,786&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,739&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,958&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,911&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,579&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,029&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(528)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,979&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,239&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(585)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,505&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and investments </span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631,197&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631,416&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of December&#160;31, 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238,957&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through 5 years </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,604&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,561&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income included in other income, net on our consolidated statements of operations and comprehensive loss was $24.9&#160;million and $32.8&#160;million for the years ended December&#160;31, 2024 and 2023, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">BALANCE SHEET COMPONENTS</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOTE 4.  BALANCE SHEET COMPONENTS </span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Inventory, Net</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, net, consisted of the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchased materials</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,270&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,434&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,172&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,653&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,081&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory, gross</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,523&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,833&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory reserve</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,768)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,157)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory, net</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,755&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,676&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Property and Equipment, Net</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment and machinery </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,273&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,907&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,770&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,226&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,882&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,528&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,280&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,628&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,972&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,594&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,276&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,453&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,226&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81,948)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74,794)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,505&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,432&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress consists of capitalizable costs that have been incurred for the construction of finite-lived assets and is primarily comprised of amounts that will be classified as lab equipment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense during the years ended December&#160;31, 2024, 2023, and 2022 was $13.8 million, $11.5 million, and $9.5 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the interim impairment test of goodwill in the second and fourth quarter of 2024, we also performed a recoverability test for the definite-lived asset group, which includes property and equipment, noting no impairment.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Goodwill and Intangible Assets</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is reviewed for impairment at least annually as of the first day of the second quarter, or more frequently if an event occurs indicating impairment. We performed our annual assessment for goodwill impairment, noting no impairment. Based primarily on the sustained decrease in our stock price during the second quarter and overall market capitalization as of the end of the second quarter of 2024 as well as other factors, we concluded that there was an indicator that it was more likely than not that the fair value of the reporting unit was less than its carrying amount that required an interim impairment test be performed on goodwill. As a result of the interim impairment test performed as of June 30, 2024, we concluded that the carrying amount of the entity-level reporting unit exceeded fair value and recorded $93.2 million of goodwill impairment. The impairment charge is included on our consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decline in the fair value of the reporting unit below its carrying value as of June 30, 2024 resulted primarily from the decline in our stock price and changes in the timing of expected future cash flows as compared to our initial long-term plan, due to continued impact of longer than expected median sales cycles resulting from various factors. We performed our impairment test using a combination of an income and a market approach to determine the fair value of the reporting unit. The income approach utilized estimated discounted cash flows, while the market approach utilized comparable company information. Significant assumptions used in the income approach included revenue growth expectations and a selected discount rate of 12.0%. The discount rate was based on the weighted average cost of capital, determined using market, peer company, industry data, and related risk factors. The assessment is a level 3 fair value measurement due to its reliance on certain unobservable inputs and significant management judgment. The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. An increase of 100 basis points to the discount rate used in our assessment would have resulted in additional goodwill impairment of approximately $85&#160;million. The assessed fair value was deemed reasonable based on a market capitalization reconciliation and a supportable control premium. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the fourth quarter of 2024, we concluded that the significant increase in the carrying value of the reporting unit resulting primarily from the debt restructuring during the quarter and changes in the timing and amount of expected future cash flows due to macroeconomic headwinds, among other factors, indicated that it was more likely than not that the fair value of the reporting unit was less than its carrying amount that required an interim impairment test be performed on goodwill. As a result of the impairment test performed as of December 31, 2024, we concluded that the carrying amount of the entity-level reporting unit exceeded fair value and recorded $51.3&#160;million of goodwill impairment. The impairment charge is included on our consolidated statements of operations and comprehensive loss for the year ended December 31, 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed our impairment test consistent with the approach used to determine the fair value of the reporting unit in the second quarter of 2024. Significant assumptions used in the income approach included revenue growth expectations and a selected discount rate of 12.0%. The assessment is a Level 3 fair value measurement due to its reliance on certain unobservable inputs and significant management judgment. The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. An increase of 100 basis points to the discount rate used in our assessment would have resulted in additional goodwill impairment of approximately $95&#160;million. The assessed fair value was deemed reasonable based on a market capitalization reconciliation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the impairments, the carrying value of goodwill now approximates fair value. Changes in our future operating results, cash flows, share price, market capitalization or discount rates, among others, used when conducting future goodwill impairment tests could affect the estimated implied fair value of goodwill and may result in additional impairment charges in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to goodwill during the year ended December&#160;31, 2024 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462,261&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144,500)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317,761&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include developed technology, customer relationships, and acquired IPR&amp;D.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Apton acquisition in August 2023, we allocated $55.0 million of the purchase price to IPR&amp;D. As of December&#160;31, 2024, the research and development project had not been completed or abandoned and, therefore, the IPR&amp;D is not currently subject to amortization. During the year ended December 31, 2023, acquired IPR&amp;D of $400.0 million as a result of the Omniome acquisition in September 2021 was completed and became subject to amortization.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D is reviewed for impairment at least annually, or more frequently if an event occurs indicating the potential for impairment. Based on the interim impairment test of goodwill in the second quarter of 2024 and our annual IPR&amp;D impairment assessment in the third quarter of 2024, no impairment of IPR&amp;D was identified.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the fourth quarter of 2024, we concluded that due to significant macroeconomic uncertainties and the related changes in the timing and amount of expected future cash flows, among other factors, it was more likely than not that the fair value of the IPR&amp;D was less than its carrying amount that required an interim impairment test be performed on IPR&amp;D. We performed our impairment test by comparing the carrying value of the IPR&amp;D to its estimated fair value, which was determined by the income approach, using a discounted cash flow model. Significant estimates and assumptions used in the income approach, which represent a Level 3 fair value measurement, include revenue growth assumptions, a selected discount rate of 14.0%, and a selected obsolescence factor of 13 years. The discount rate was based primarily on the weighted average cost of capital, determined using market, peer company, industry data, and related risk factors. Based on our analysis, the carrying value of the IPR&amp;D exceeded its estimated fair value, and we recorded an impairment of $40.0 million in the fourth quarter of 2024. The impairment charge is included on our consolidated statements of operations and comprehensive loss for the year ended December 31, 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. An increase of 100 basis points to the discount rate used in our analysis would have resulted in additional IPR&amp;D impairment of approximately $5&#160;million. A decrease of one year to the obsolescence factor used in our analysis would have resulted in additional IPR&amp;D impairment of approximately $5&#160;million. We also performed a recoverability test for the definite-lived asset group, which includes developed technology, noting no impairment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the impairment, the carrying value of the IPR&amp;D now approximates fair value. Changes in macroeconomic conditions, industry-specific conditions and company-specific conditions may impact the estimates and assumptions used when conducting future IPR&amp;D impairment tests. These changes could affect the estimated fair value of the IPR&amp;D and may result in additional impairment charges in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to IPR&amp;D during the year ended December&#160;31, 2024 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-814">Impairment charge</span></span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to IPR&amp;D, we had the following acquired finite-lived intangible assets as of December&#160;31, 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated <br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,179&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,607)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,572&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,539&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,967)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,572&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense of intangibles was $27.4 million, $8.3 million and $0.9&#160;million for the years ended December&#160;31, 2024, 2023, and 2022, respectively. For the years ended December&#160;31, 2024, 2023, and 2022 amortization expense of intangibles in cost of revenue was $9.4&#160;million, $2.0 million, and $0.7&#160;million, respectively. For the years ended December&#160;31, 2024, 2023, and 2022, amortization expense of intangibles in operating expenses was $18.0 million, $6.3 million, and $0.2&#160;million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets is included within our cost of revenue if the costs and expenses related to the intangible assets are attributable to revenue generating activities. Amortization expense for intangible assets that are not directly related to sales generating activities are amortized to operating expenses. For developed technology intangible assets that are utilized in both revenue generating activities and in research and development activities, we allocate the amortization expense between cost of revenue and operating expenses. The finite-lived intangible assets are amortized using the straight-line method over their estimated useful lives.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of acquisition-related intangible assets with finite lives is estimated as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030 and thereafter</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,512&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,572&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Accrued Expenses</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,706&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,337&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,470&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchase commitments</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued product development costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued professional services and legal fees</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,641&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory accrual</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warranty accrual</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,100&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,681&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,147&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,595&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,708&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Warranties</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide a one-year warranty on instruments. In addition, we provide a limited warranty on consumables. At the time revenue is recognized, an accrual is established for estimated warranty costs based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranties are recorded as part of accrued expenses on our consolidated balance sheets and warranty expense is recorded as a component of cost of product revenue on our consolidated statements of operations and comprehensive loss. There were no material changes in estimates for the periods presented below. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,681&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,651&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions charged to cost of product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,144&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repairs and replacements</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,725)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,197)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,100&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,681&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Deferred Revenue</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had a total of $19.8 million of deferred revenue, $13.9 million of which was recorded as deferred revenue, current and $5.9 million of which was recorded as deferred revenue, non-current, which primarily relates to deferred service contract revenues and is scheduled to be recognized in the next five years. Revenue recorded in the year ended December&#160;31, 2024 includes $14.9 million that was included in deferred revenue, current as of December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly enter into contracts with multiple performance obligations. These contracts are believed to be firm as of the balance sheet date. However, we may allow customers to make product substitutions or certain modifications at our discretion. The timing of shipments depends on several factors, including agreed upon shipping schedules, which may span multiple quarters. Most performance obligations are generally satisfied within a year of the contract execution date. As of December&#160;31, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations was $58.6 million, of which approximately 62% is expected to be converted to revenue in 2025, approximately 30% in the following twelve months, and the remainder thereafter.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Liabilities, Current</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities, current, consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued Employee Stock Purchase Plan</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,715&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term loan</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,210&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities, current</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,224&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,326&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE SENIOR NOTES</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 5.  CONVERTIBLE SENIOR NOTES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2029 Convertible Senior Notes</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 7, 2024, we entered into an exchange agreement with SB Northstar LP (&#8220;SBN&#8221;), a subsidiary of SoftBank Group Corp., pursuant to which we have agreed to exchange the remaining approximately $459.0&#160;million in aggregate principal amount of 2028 Notes outstanding for (i) $200.0&#160;million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 (the &#8220;2029 Notes&#8221;), (ii) 20,451,570 shares of common stock (the &#8220;Exchange Shares&#8221;) and (iii) $50.0&#160;million of cash (the &#8220;2024 Exchange Transaction&#8221;). The Exchange Shares were issued on November 21, 2024 (the &#8220;Closing Date&#8221;). The 2029 Notes, the Exchange Shares, and shares of common stock issuable upon conversion of the 2029 Notes are subject to certain lock-up restrictions for a six-month period (the &#8220;Lock-Up Period&#8221;) beginning on the Closing Date of the 2024 Exchange Transaction; the lock-up restrictions will terminate immediately prior to the consummation of any change in control of the Company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any conversion of the 2029 Notes, SBN will not be entitled to be issued a number of shares of the Company&#8217;s common stock which would cause SBN's beneficial ownership of common stock to exceed either 9.9% of the total number of issued and outstanding shares of common stock or 9.9% of the combined voting power of all of the securities of the Company, in each case, following such conversion.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are governed by an indenture (the &#8220;2029 Indenture&#8221;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2029 Notes bear interest at a rate of 1.50% per annum. Interest on the 2029 Notes is payable semi-annually in arrears on February 15 and August 15 and commencing on February 15, 2025. The 2029 Notes will mature on August 15, 2029, subject to earlier conversion, redemption or repurchase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are convertible at the option of the holder at any time from the expiration of the Lock-Up Period until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2029 Notes are convertible into shares of our common stock based on an initial conversion rate of 204.5157 shares of common stock per $1,000 principal amount of the 2029 Notes (which is equal to an initial conversion price of approximately $4.89 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2029 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after August 20, 2027, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2029 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2029 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a Fundamental Change (as defined in the 2029 Indenture), the holders of the 2029 Notes may require that we repurchase all or part of the principal amount of the 2029 Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are subject to certain debt and lien covenants as well as springing guarantees, in each case, the terms of which are set forth in a second letter agreement between the Company and SBN entered into in connection with the Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the 2029 Notes under the 2029 Indenture. The 2029 Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2029 Notes at a rate equal to (i) 0.25% per annum of the principal amount of the 2029 Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the 2029 Notes outstanding for each day from, and including, the 181</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day to, and including, the 360</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2029 Indenture). On the 361</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day), the 2029 Notes shall be subject to acceleration as provided for in the 2029 Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2029 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2029 Notes were not issued at a substantial premium; therefore, the 2029 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the 2029 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exchange qualified as a troubled debt restructuring under ASC 470-60 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Troubled Debt Restructurings by Debtors</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Since the undiscounted cash flows of the 2029 Notes were less than the carrying amount of the exchanged 2028 Notes, the carrying value of the 2029 Notes was determined based on the total undiscounted cash flows. As a result, no interest expense will be recognized for the 2029 Notes. The Company recorded a gain on debt restructuring of $154.4&#160;million, which resulted in a decrease of basic net loss per share of $0.56, during the year ended December&#160;31, 2024 on our consolidated statements of operations and comprehensive loss. The gain was calculated as the difference between the carrying amount of the old debt and the carrying amount of the new debt, adjusted for debt issuance costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2029 Notes of approximately $3.1&#160;million, including $0.2&#160;million of lender fees, which were recorded as a reduction to the gain on debt restructuring on our consolidated statements of operations and comprehensive loss. We also paid accrued but unpaid interest of $1.8&#160;million on the 2028 Notes in connection with the 2024 Exchange Transaction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not receive any cash proceeds from the 2024 Exchange Transaction. In exchange for issuing the 2029 Notes, Exchange Shares and paying $50.0&#160;million of cash pursuant to the 2024 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. Following the closing of the 2024 Exchange Transaction, no amounts were outstanding on the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the liability for the 2029 Notes as of December&#160;31, 2024 is $214.2&#160;million, of which $212.0&#160;million is included as convertible senior notes, net, non-current, and $2.2&#160;million is included as accrued expenses on our consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the estimated fair value (Level 2) of the 2029 Notes was $175.0&#160;million. The fair value of the 2029 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2030 Convertible Senior Notes</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we entered into a privately negotiated exchange agreement with a holder of our outstanding 1.50% Convertible Senior Notes due 2028 (the &#8220;2028 Notes&#8221;), pursuant to which we issued $441.0&#160;million in aggregate principal amount of our 1.375% Convertible Senior Notes due 2030 (the &#8220;2030 Notes&#8221; and together with the 2029 Notes, the &#8220;Notes&#8221;) in exchange for $441.0&#160;million principal amount of the 2028 Notes (the &#8220;2023 Exchange Transaction&#8221;), pursuant to exemptions from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder. The 2030 Notes were issued on June&#160;30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are governed by an indenture (the &#8220;2030 Indenture&#8221;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2030 Notes bear interest at a rate of 1.375% per annum. Interest on the 2030 Notes is payable semi-annually in arrears on June 15 and December 15, commencing on December 15, 2023. The 2030 Notes will mature on December&#160;15, 2030, subject to earlier conversion, redemption or repurchase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2030 Notes are convertible into shares of our common stock based on an initial conversion rate of 46.5116 shares of common stock per $1,000 principal amount of the 2030 Notes (which is equal to an initial conversion price of approximately $21.50 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2030 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after June 20, 2028, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2030 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2030 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a Fundamental Change (as defined in the 2030 Indenture), the holders of the 2030 Notes may require that we repurchase all or part of the principal amount of the 2030 Notes at a purchase price equal to 100% of the principal amount of the notes to be repurchased, plus any accrued and unpaid interest up to, but excluding, the fundamental change repurchase date, and all unpaid interest from the fundamental change repurchase date thereon, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the 2030 Notes under the 2030 Indenture. The 2030 Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2030 Notes at a rate equal to (i) 0.25% per annum of the principal amount of the 2030 Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the 2030 Notes outstanding for each day from, and including, the 181st calendar day to, and including, the 360th calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2030 Indenture). On the 361st day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361st day), the 2030 Notes shall be subject to acceleration as provided for in the 2030 Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2030 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2030 Notes were not issued at a substantial premium; therefore, the 2030 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the 2030 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Exchange Transaction was accounted for as an extinguishment driven by the change in fair value of the embedded conversion option. We recorded a loss on extinguishment of debt of approximately $2.0 million in connection with the 2023 Exchange Transaction during the year ended December 31, 2023, which represents the difference between the fair value and the principal amount of the 2030 Notes of the debt at the modification date, plus unamortized debt issuance costs of $1.5 million related to the respective portion of the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2030 Notes of approximately $7.3 million, which were recorded as debt issuance costs and are presented as a reduction to the 2030 Notes on our consolidated balance sheets. The debt issuance costs are amortized to interest expense using the effective interest method over the term of the 2030 Notes, resulting in an effective interest rate of 1.6%. We also paid accrued but unpaid interest of $2.5 million on the 2028 Notes in connection with the 2023 Exchange Transaction on June 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not receive any cash proceeds from the 2023 Exchange Transaction. In exchange for issuing the 2030 Notes pursuant to the 2023 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. Following the closing of the 2023 Exchange Transaction, $459.0 million in aggregate principal amount of 2028 Notes remained outstanding with terms unchanged.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current on our consolidated balance sheets as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">441,000&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">441,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt premium</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,959)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,907)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435,494&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434,617&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2030 Notes for the years ended December&#160;31, 2024, 2023, and 2022 was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,081&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,032&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,031&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,495&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the estimated fair value (Level 2) of the 2030 Notes was $293.9 million. The fair value of the 2030 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2028 Convertible Senior Notes</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;9, 2021, we entered into an investment agreement with SBN relating to the issuance and sale to SBN of $900.0 million in aggregate principal amount of the 2028 Notes. The 2028 Notes were issued on February&#160;16, 2021 and bore interest at a rate of 1.50% per annum. As discussed above, in June 2023 we completed an exchange of $441.0 million in aggregate principal amount of our 2028 Notes for $441.0 million aggregate principal amount of the 2030 Notes, leaving approximately $459.0 million in aggregate principal amount of 2028 Notes outstanding. Also as discussed above, in November 2024 we completed an exchange of the remaining $459.0&#160;million in aggregate principal amount of the 2028 Notes outstanding for (i) $200.0&#160;million aggregate principal amount of the 2029 Notes, (ii) the Exchange Shares and (iii) $50.0&#160;million of cash. As of December&#160;31, 2024 no amounts were outstanding on the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2028 Notes of approximately $4.5 million, which were recorded as debt issuance costs and are presented as a reduction to the 2028 Notes on our consolidated balance sheets. The debt issuance costs were amortized to interest expense using the effective interest method over the term of the 2028 Notes, resulting in an effective interest rate of 1.6%. In connection with the 2024 Exchange Transaction, the remaining unamortized debt issuance costs related to the 2028 Notes of $1.1 million were extinguished by offsetting the carrying amount of the convertible senior notes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2028 Notes is included as convertible senior notes, net, non-current on our consolidated balance sheets as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,374)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">457,626&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2028 Notes was as follows for the years ended December&#160;31, 2024, 2023, and 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,139&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,133&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,500&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,428&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,605&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,117&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 6.  RESTRUCTURING</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, we implemented an expense reduction initiative that included workforce reductions, the closing of our San Diego office, and other actions to reduce annualized run-rate operating expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the pre-tax restructuring charges are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended</span></div><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative amount incurred to date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee separation costs</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,008&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,008&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,214&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,214&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="-sec-ix-hidden:f-1008"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restructuring charges</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,222&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,222&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> For the year ended December&#160;31, 2024, cumulative charges incurred to date include $14.9 million in sales, general and administrative expense; $5.9 million in research and development expense; and $4.4 million in cost of revenue.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative charges incurred to date include employee separation costs comprised of approximately $5.5&#160;million related to salaries, wages and other employee benefits paid to terminated employees pursuant to the Worker Adjustment and Retraining Notification (WARN) Act and approximately $4.5&#160;million of severance costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other costs in the year ended December&#160;31, 2024 are primarily related to accelerated amortization and depreciation of $8.1&#160;million for the right-of-use asset, leasehold improvements, and furniture and fixtures relating to the abandonment of the San Diego office. We also incurred cumulative charges to date for excess inventory of $3.6&#160;million primarily relating to a decrease in internal demand resulting from the expense reduction initiatives which were recognized in cost of product revenues. The accelerated amortization and depreciation, which was recognized in sales, general and administrative expense, was determined as a result of the Company's change in estimate pertaining to its remaining useful life of the San Diego office utilizing the estimated date on which it planned to abandon the San Diego office. The lease liability pertaining to the San Diego office was also remeasured during the year ended December&#160;31, 2024 resulting in a reduction in the operating lease liability balance of $4.4&#160;million, which was offset against the right-of-use asset on our consolidated balance sheets. We exited our San Diego office in September 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the liabilities related to the restructuring is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Separation Costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expense recorded in YTD 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,008&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,816&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,824&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid during YTD 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,008)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,646)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,654)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount recorded in current liabilities as of December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated total restructuring costs to still be incurred</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above excludes noncash activities and amounts incurred relating to the San Diego office lease liability. The ending balance of the San Diego office lease liability as of December&#160;31, 2024 is $2.6&#160;million, and is included in operating lease liabilities, current on our consolidated balance sheets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other restructuring costs are expected to be incurred and paid by the end of 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 7.  COMMITMENTS AND CONTINGENCIES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Leases</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. All of our leases are operating leases. Lease payments comprise the base rent per the term of the lease. Lease expense for these leases is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period those payments are incurred.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often have options to renew lease terms for buildings. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the maturities of our operating lease liabilities were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,481&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,780&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,371&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,431)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of operating lease liabilities </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,940&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,026&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,914&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,940&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our incremental borrowing rate to determine the present value of lease payments, as the implicit rates in our leases are not readily determinable. The weighted-average discount rate used to measure our operating lease liabilities was 7.7%. The weighted-average remaining lease term for our operating leases as of December&#160;31, 2024 was 2.7 years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the present value of operating lease liabilities was $14.2 million and $12.1&#160;million for the years ended December&#160;31, 2024 and 2023, respectively, and were included in operating cash flows.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease Costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs were $14.5 million and $10.4 million for the years ended December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Contingencies</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see subsection titled </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_31" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Legal Proceedings</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Part I, Item 3 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnification</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification obligations has been recorded as of December&#160;31, 2024.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Purchase Commitments</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we enter into agreements to purchase goods or services or license intellectual property, certain of which are not cancellable without penalty. For those agreements with variable terms, we do not estimate the total obligation beyond any minimum quantities or pricing as of the reporting date. Licensing agreements under which we commit to ongoing minimum royalty payments, some of which are subject to adjustment, may be terminated under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our purchase orders and contractual obligations are approximately $57.6 million as of December&#160;31, 2024, which consist of open purchase orders and contractual obligations in the ordinary course of business, including commitments with contract manufacturers and suppliers for which we have not received the goods or services. A majority of these purchase obligations are due within a year. Although open purchase orders are considered enforceable and legally binding, the terms generally allow us the option to cancel, reschedule and adjust our requirements based on our business needs prior to the delivery of goods or performance of services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a loss on purchase commitment of $1.0 million for the year ended December&#160;31, 2024, which was recorded as part of accrued expenses on our consolidated balance sheet and is included in the aforementioned purchase orders and contractual obligations amount. The purchase commitment loss is based on an estimate of future excess inventory related to supply agreements with third-party vendors, for which we do not expect to have related sales.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a long-term supply agreement, which was most recently amended in September 2024 (the &#8220;Supply Agreement&#8221;), for the purchase of certain products with a semiconductor manufacturer (&#8220;Supplier&#8221;). The Supply Agreement provides for minimum purchase commitments through 2027 in exchange for guaranteed capacity at Supplier. We are responsible for providing certain materials to allow our Supplier to perform its obligations under the contract.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid our Supplier a deposit of $9.0 million in November 2022 and an additional deposit of $6.0 million in 2023, for a total of $15.0 million (the &#8220;Deposit&#8221;). The Deposit is fully refundable to us, in accordance with the Supply Agreement, if we meet the minimum volume purchase commitment for the applicable year. $3.0 million was refunded to us during the year ended December&#160;31, 2024. As of December&#160;31, 2024, $4.0 million related to the Deposit was included in prepaid expenses and other current assets on our consolidated balance sheets and $8.0 million related to the Deposit was included in other long-term assets on our consolidated balance sheets, as we believe it is probable the minimum volume purchase commitment level will be achieved.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450-20/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450-30/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 8.  INCOME TAXES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes both in the United States and certain foreign jurisdictions in which we operate, and we use estimates in determining our provisions for income taxes. Significant management judgement is required in determining our provision for income taxes, deferred tax assets and liabilities, and valuation allowances recorded against net deferred tax assets in accordance with U.S. GAAP. These estimates and judgements occur in the calculation of tax credits, benefits, and deductions, and in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes, as well as the interest and penalties related to uncertain tax positions. Significant changes to these estimates may result in an increase or decrease to our tax provision in the current or subsequent period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether the factors underlying the sustainability assertion have changed and the amount of the recognized tax benefit is still appropriate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for Global Intangible Low-taxed Income as a period cost.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024, 2023, and 2022 income/(loss) before taxes from U.S. operations were ($311.0) million, ($318.9) million, and ($315.7) million, respectively, and income/(loss) before taxes from foreign operations was $1.5 million, $0.7 million, and $1.8 million, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Income Tax Provision (Benefit)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision (benefit) consists of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,956)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,468)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,424)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,424)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of 21% to pretax loss as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Statutory tax rate </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State tax rate, net of federal benefit</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger Expenses</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairment</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets for federal and state income taxes are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434,122&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435,488&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,416&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and experimental expenses</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,281&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,196&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,506&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancellation of indebtedness income and interest expense</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,424&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,907&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,195&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,584&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,618&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,510&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">653,562&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642,479&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(558,794)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(525,703)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets:</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,768&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,776&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91,504)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109,488)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(548)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,549)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,491)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95,314)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117,527)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(546)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(751)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, we maintained a valuation allowance against our net deferred tax assets which totaled $558.8 million, including net operating loss carryforwards and research and development credits of $434.1 million and $91.4 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. We regularly assess the need for a valuation allowance against our deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that our deferred income tax assets will be realized. In evaluating our ability to recover our deferred income tax assets within the jurisdiction from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. We maintain a valuation allowance on the net deferred tax assets of our U.S. entities as we have concluded that it is more likely than not that we will not realize our deferred tax assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, the Company's valuation allowance increased to $558.8 million, primarily because of an increase in our credits and capitalized research &amp; experimental expenses that were fully offset by a valuation allowance. For the year ended December&#160;31, 2023, the Company's valuation allowance increased to $525.7 million, primarily because of an increase in our net operating losses, credits, and capitalized research and experimental expenses that were fully offset by a valuation allowance. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had a net operating loss carryforward for federal income tax purposes of approximately $1,704.2 million, of which $783.2 million is subject to expiration beginning in 2025. We had a total state net operating loss carryforward of approximately $1,170.6 million, which is subject to annual expirations. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have federal credits of approximately $64.4 million, a portion of which will begin to expire in 2025 if not utilized and state research credits of approximately $54.6 million, which have no expiration date. These tax credits are subject to the same limitations discussed above.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, our total unrecognized tax benefit was $17.7 million. A reconciliation of the beginning and ending unrecognized tax benefit balance is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,335&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in balance related to tax positions taken in prior year </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,085&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,410&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken in prior year </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,044&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,554&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in balance related to tax positions taken in prior year </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,128&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2024</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,676&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December&#160;31, 2024 and 2023, we had no accrued interest or penalties due to our net operating losses available to offset any tax adjustment. If total unrecognized tax benefits were realized in the future, it would not result in any tax benefit as we currently have a full valuation allowance. We file U.S. federal and various state income tax returns. For U.S. federal and state income tax purposes, the statute of limitations currently remains open for the years ending December 31, 2021 to present and December 31, 2020 to present, respectively. In addition, all of the net operating losses and research and development credit carryforwards that may be utilized in future years may be subject to examination. We are not currently under examination by income tax authorities in any jurisdiction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 9.  STOCKHOLDERS' EQUITY</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Common and Preferred Stock</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Certificate of Incorporation, as amended and restated in October 2010 in connection with the closing of our initial public offering, authorizes us to issue 1,000,000,000 shares of $0.001 par value common stock and 50,000,000 shares of $0.001 par value preferred stock. As of December&#160;31, 2024 and 2023, there were no shares of preferred stock issued or outstanding.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stockholders are entitled to dividends when and if declared by our board of directors. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Underwritten Public Equity Offerings</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we entered into an underwriting agreement, relating to the public offering of 17.5&#160;million shares of our common stock, $0.001 par value per share, at a price to the public of $10.00 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 2.6&#160;million shares of our common stock, which was subsequently exercised in full, and the offering, including the sale of shares of common stock subject to the underwriters' option, closed in January 2023. In total, we sold 20.1&#160;million shares of our common stock. We paid a commission equal to 5.75% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $189.7&#160;million, excluding approximately $0.5&#160;million of offering expenses.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Equity Plans</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), the 2020 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), and the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#8220;Omniome Plan&#8221;) allow for the issuance of stock options, restric</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ted units and awards, and performance-based awards. The 2010 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) allows eligible employees to acquire common stock at a discounted price through payroll deductions during designated offering periods.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 25, 2022, stockholders approved an amendment to the 2020 Plan, and we reserved an additional 18.0&#160;million shares of our common stock for issuance pursuant to equity awards granted under the 2020 Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2024, stockholders approved an amendment to the 2020 Plan, and we reserved an additional 20.0&#160;million shares of our common stock for issuance pursuant to equity awards granted under the 2020 Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had 28.4&#160;million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan. Shares remaining and available for future issuance reflect shares that may become eligible to vest upon the achievement of maximum targets for certain equity awards.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Stock Options</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for time-based awards:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(shares in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average<br/>exercise price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,011</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.63&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(515)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.15&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,153)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.89&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(327)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.81&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,509</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.09&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of the outstanding options presented in the table above as of December&#160;31, 2024, totaled $0.1 million, and had a weighted-average remaining contractual life of 5.4 years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of outstanding options represents the total pre-tax intrinsic value (i.e. the difference between $1.83, our closing stock price on the last trading day of our fourth quarter of 2024, and the option exercise price multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December&#160;31, 2024. The aggregate intrinsic value changes at each reporting date based on the fair market value of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vested and exercisable options as of December&#160;31, 2024, totaled 9,429,082 shares, had an aggregate intrinsic value that was not significant, a weighted-average exercise price per share of $11.26, and a weighted-average remaining contractual life of 5.1 years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vested and expected to vest options as of December&#160;31, 2024, totaled 10,957,644 shares, had an aggregate intrinsic value of $0.1 million, a weighted-average exercise price per share of $11.13, and a weighted-average remaining contractual life of 5.4 years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during the years ended December&#160;31, 2024, 2023, and 2022 was $0.8 million, $8.8 million, and $5.0 million, respectively. The total intrinsic value of options exercised represents the difference between our closing stock price on the exercise date and the option exercise price, multiplied by the number of in-the-money options exercised.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of all options granted was $1.40 in 2024, $7.32 in 2023, and $5.93 in 2022, each determined by the Black-Scholes option valuation method.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restricted Stock Units ("RSU") and Performance Stock Units ("PSU")</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have awarded both Restricted Stock Units (RSUs) and Performance Stock Units (PSUs). Each RSU represents the right to receive one share of our common stock upon meeting the required service-based vesting conditions. RSUs typically vest over four years, with equal annual installments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, PSUs were granted and are based on performance against predefined revenue targets and require continued employment throughout the vesting period. These shares become issuable after the third year of the performance period. Achieving the maximum revenue goal allows up to 200% of the target PSU shares to become eligible for vesting, while failing to meet the minimum revenue goal results in no shares vesting.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the time-based RSU and PSU activity: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(shares in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units (RSUs)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Stock Units (PSUs)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RSU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PSU</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,308</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.06&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,722</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.02&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,801)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.43&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,018)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.90&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,211</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.41&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of shares vested related to RSUs during the years ended December&#160;31, 2024, 2023, and 2022 was $47.2 million, $39.3 million, and $39.2 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of all RSUs granted was $5.02 in 2024, $9.65 in 2023, and $10.15 in 2022. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, a total of 33.5&#160;million shares of our common stock have been reserved for issuance under the ESPP, which allows eligible employees to acquire common stock at a discounted price through payroll deductions during designated offering periods. Each offering period typically consists of four purchase periods, each lasting approximately six months. Shares are purchased at the lower of 85% of the fair market value of the common stock at either the beginning of the offering period or the end of the purchase period. If the stock price at the end of a purchase period is lower than at the start of the offering period, the existing offering period will be reset, and a new offering period will begin. The ESPP provides for an annual increase to the shares available for issuance at the beginning of each fiscal year equal to the lesser of 2% of the common shares then outstanding, 4,000,000 shares, or an amount determined by the ESPP&#8217;s administrator.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023, and 2022, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,906,529</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares, 1,735,058 shares, and 1,878,168 shares of common stock were purchased under the ESPP, respectivel</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y. As of December&#160;31, 2024, 14.3&#160;million sh</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares of our common stock remain available for issuance under our ESPP.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Share-based Compensation</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,691&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,399&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,802&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,172&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,435&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,676&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,173&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,036&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,118&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,613&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, $0.6 million and $0.6 million of share-based compensation cost was capitalized in inventory, net, on our consolidated balance sheets, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate forfeitures related to our share-based compensation plans. The estimated forfeiture rate is based on historical data, trends, and other relevant factors, such as employee turnover rates and expectations about future forfeitures. The estimated forfeiture rate is reviewed periodically and adjusted as necessary to reflect changes in these factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit of share-based compensation expense was immaterial for the years ended December&#160;31, 2024, 2023, and 2022 due to a valuation allowance on the net deferred tax assets of our U.S. entities, for which we have concluded that it is more likely than not that we will not realize our deferred tax assets.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Determining Fair Value</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of share options granted using the Black-Scholes valuation method and a single option award approach. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSU awards granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting period. For shares purchased under the ESPP, we estimate the grant-date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Term &#8211; The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, considering the contractual terms of the stock options and vesting schedules.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Volatility &#8211; The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Dividend &#8211; We have never paid dividends on our shares and, accordingly, the dividend yield percentage is zero for all periods.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Risk-Free Interest Rate &#8211; The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference observable market prices of similar or identical instruments in active markets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81% - 93%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77% - 78%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70% - 76%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.48% &#8211; 4.32%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.73% &#8211; 4.60%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.41% &#8211; 3.66%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.40&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from option exercises for the years ended December&#160;31, 2024, 2023, and 2022 was $1.6 million, $6.5 million and $3.4 million, respectively. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESPP</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares to be issued under the ESPP was estimated using the following assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81% - 118%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79% - 97%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70% - 97%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9% - 5.3%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9% - 5.5%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6% - 3.5%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.53&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received through the ESPP for the years ended December&#160;31, 2024, 2023, and 2022 was $6.1 million, $8.8 million, and $7.8 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, $80.1 million of total unrecognized compensation expense related to stock options, restricted stock, and ESPP shares was expected to be recognized over a weighted-average period of 2.2 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 10.  NET LOSS PER SHARE</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of the basic and diluted net loss per share amounts presented on our consolidated statements of operations and comprehensive loss: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net loss</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,851)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(306,735)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314,248)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net loss</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,851)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(306,735)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314,248)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Interest charges applicable to convertible notes (2028 Notes)</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,428&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Gain on debt restructuring (2029 Notes)</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154,407)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net loss</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(457,830)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(306,735)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314,248)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in computing basic net loss per share</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274,488&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,629&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,550&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net loss per share</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.13)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.21)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.40)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in computing basic net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274,488</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,629</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,550</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Weighted average shares issuable upon conversion of convertible notes (2028 Notes)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,395</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Weighted average shares issuable upon conversion of convertible notes (2029 Notes)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,483</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in computing diluted net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,366</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,629</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,550</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net loss per share</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.59)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.21)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.40)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares issuable upon conversion of the convertible senior notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible senior notes</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,512</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,063</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,690</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity awards</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,136</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,246</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,291</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_97" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2. Business Acquisitions</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for detailed information on contingently issuable shares that would be due upon achievement of a milestone. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_124" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note </a><a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_124" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">9</a><a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_124" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">. Stockholders&#8217; Equity</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for detailed information on equity awards.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT AND GEOGRAPHIC INFORMATION</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 11.  SEGMENT AND GEOGRAPHIC INFORMATION</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are organized as, and operate in, one reportable segment: the development, manufacturing, and marketing of integrated platforms for genetic analysis. Our chief operating decision-maker (CODM) is our Chief Executive Officer. Our CODM reviews financial information presented on a consolidated basis for the purposes of evaluating financial performance and allocating resources.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a regular basis, our CODM reviews:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">total revenues by category</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">total expenses and expenses by function, including sales and marketing and general and administrative, which include depreciation and share-based compensation</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">net loss per share</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assets are primarily located in the United States of America and not allocated to any specific region, and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the segment profit or loss, including significant segment expenses is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,014&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,521&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,304&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,732&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,741&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134,922&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,170&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,244&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,465&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,773&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,531&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,389&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,500&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger-related expenses</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,042&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(850)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,060&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,006&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,157&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on debt restructuring</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154,407)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,371&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,341&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,052)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,424)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net loss</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,851)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(306,735)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314,248)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by geographic location is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Americas </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,711&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,410&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East, and Africa</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,594&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,658&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,598&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia-Pacific</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,709&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,453&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,014&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,521&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,304&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes United States revenue of $75.3 million, $100.5 million, and $66.8 million for the years ended December 31, 2024, 2023, and 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by category is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instrument revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,776&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,451&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,719&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumable revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,373&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,421&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136,149&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,872&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,699&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,865&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,649&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,605&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,014&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,521&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,304&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 12.  SUBSEQUENT EVENTS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 7, 2025, we entered into an amendment to our existing lease for our corporate headquarters, research and development facilities, and manufacturing and distribution centers in Menlo Park, California. The lease amendment extends the term from the prior expiration on October 31, 2027 to its new expiration on April 30, 2034. We will pay approximately $97.7 million in base rent over the life of the amended lease, and receive base rent abatement of approximately $11.6&#160;million for the period beginning on March 1, 2025 and ending on July 31, 2026. We are also entitled to a tenant improvement allowance of $7.2&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 7, 2025, we entered into an agreement to acquire certain technology and related intellectual property from the Chinese University of Hong Kong for $9.7&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Basic net loss</a></td>
<td class="num">$ (309,851)<span></span>
</td>
<td class="num">$ (306,735)<span></span>
</td>
<td class="num">$ (314,248)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes. We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct periodic risk assessments to identify cybersecurity threats, as well as assessments in the event of a material change in our business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following these risk assessments, we evaluate whether and how to re-design, implement, and maintain reasonable safeguards to minimize identified risks; reasonably address any identified gaps in existing safeguards; and regularly monitor the effectiveness of our safeguards. We devote resources and designate high-level personnel, including our Vice President and Head of Information Technology who reports to our Chief Operating Officer, to manage the risk assessment and mitigation process. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our overall risk management system, we monitor and test our safeguards, including through annual third-party vulnerability assessments. We train our employees on these safeguards, in collaboration with human resources, IT, and departmental management. Personnel at all levels and departments are made aware of our cybersecurity policies through training. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage assessors, consultants, auditors, or other third parties in connection with our risk assessment processes. These service providers assist us in designing and implement our cybersecurity policies and procedures, as well as to monitor and test our safeguards.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established procedures to evaluate and respond to cybersecurity incidents, including cybersecurity incidents at third-party service providers which have a potential to impact our data and systems. Our cybersecurity risk management is intended to address such risks, as well as other risks related to third parties. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not previously experienced a cybersecurity incident that was determined to be material. For additional information regarding whether any risks from cybersecurity threats are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to Item 1A, &#8220;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_19" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risk Factors</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; in this Annual Report on Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes. We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct periodic risk assessments to identify cybersecurity threats, as well as assessments in the event of a material change in our business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following these risk assessments, we evaluate whether and how to re-design, implement, and maintain reasonable safeguards to minimize identified risks; reasonably address any identified gaps in existing safeguards; and regularly monitor the effectiveness of our safeguards. We devote resources and designate high-level personnel, including our Vice President and Head of Information Technology who reports to our Chief Operating Officer, to manage the risk assessment and mitigation process. </span></div>As part of our overall risk management system, we monitor and test our safeguards, including through annual third-party vulnerability assessments. We train our employees on these safeguards, in collaboration with human resources, IT, and departmental management. Personnel at all levels and departments are made aware of our cybersecurity policies through training.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">One of the key functions of our board of directors is to provide oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through the audit committee.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Vice President and Head of Information Technology and our cyber committee, which includes Facilities, HR, IT, Legal, and Management, are primarily responsible to assess and manage our material risks from cybersecurity threats.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our audit committee provides regular updates to the board of directors on such reports.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Vice President and Head of Information Technology and our management committee on cybersecurity oversee our cybersecurity policies and processes, including those described in &#8220;Risk Management and Strategy&#8221; above. Our Vice President and Head of Information Technology is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents by leading cybersecurity risk management and working directly with our IT team. Our Vice President and Head of Information Technology also provides appropriate information and updates to our management committee on cybersecurity.</span></div>Our Vice President and Head of Information Technology and representatives from our management committee on cybersecurity provide annual briefings to the audit committee regarding our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Our Vice President and Head of Information Technology and our cyber committee, which includes Facilities, HR, IT, Legal, and Management, are primarily responsible to assess and manage our material risks from cybersecurity threats.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our Vice President and Head of Information Technology has years of cybersecurity experience and expertise including holding numerous applicable cybersecurity certifications, such as ISC2 Certified Information Systems Security Professional (CISSP).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">Our Vice President and Head of Information Technology is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents by leading cybersecurity risk management and working directly with our IT team. Our Vice President and Head of Information Technology also provides appropriate information and updates to our management committee on cybersecurity.Our Vice President and Head of Information Technology and representatives from our management committee on cybersecurity provide annual briefings to the audit committee regarding our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like. Our audit committee provides regular updates to the board of directors on such reports.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div></td></tr></table></div>The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates, including those relating to the valuation of inventory, fair value of contingent consideration, valuation of acquired intangible assets, useful lives assigned to finite-lived assets, asset impairment assessments, computation of provisions for income taxes, and valuations related to our convertible senior notes. While the extent of the potential impact of current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of December&#160;31, 2024. Actual results could differ materially from these estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional Currency</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Functional Currency</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. dollar is the functional currency of our international operations. We remeasure foreign subsidiaries monetary assets and liabilities to the U.S. dollar and record net gains or losses from remeasurement in other income, net, on our consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents, Restricted Cash, and Investments</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#8217; securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive income (loss) in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net. We have the ability to hold, and do not intend to sell investments in unrealized loss positions before the recovery of their amortized cost bases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities, and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash includes cash that is not readily available for use in the Company&#8217;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration and Other Risks</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Concentration and Other Risks</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist principally of interest-bearing investments and trade receivables. We maintain cash, cash equivalents, and investments with various major financial institutions. The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing. At December&#160;31, 2024, most of our cash was deposited with U.S. financial institutions. Our investment policy generally restricts the amount of credit exposure to any one issuer. There is no limit to the percentage of the portfolio that may be maintained in securities issued by the U.S. Treasury and U.S. Government Agencies, or other securities fully backed by U.S. Treasury or Government agencies. We have not experienced significant credit losses from financial institutions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trade receivables are derived from revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers&#8217; financial condition and, generally, require no collateral from our customers. The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review our trade receivables including consideration of factors such as historical experience, the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. We have not experienced any significant credit losses to date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, and 2023, no customer accounted for 10% or more of our total revenue. For the year ended December&#160;31, 2022, one customer exceeded 10% of our total revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, 36% and 49% of our accounts receivable were from domestic customers, respectively. As of December&#160;31, 2024, no customer represented 10% or more of our net accounts receivable. As of December&#160;31, 2023, one customer represented 10% of our net accounts receivable.</span></div>We currently purchase several key parts and components used in the manufacture of our products from a limited number of suppliers. Generally, we have been able to obtain an adequate supply of such parts and components but in certain instances have incurred additional costs to secure a supply of constrained material. An extended interruption in the supply of parts and components currently obtained from our suppliers could adversely affect our business and consolidated financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Net</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inventory, Net</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value on a first-in, first-out (&#8220;FIFO&#8221;) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs. Determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Property and Equipment, Net</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, reviewed regularly for impairment, and depreciated over the estimated useful lives of the assets, using the straight-line method. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred. Transfers of assets between property and equipment, net, and inventory are transferred at standard cost and recognized at carrying value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating Leases</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Operating Leases</span></div></td></tr></table></div>We have various operating lease agreements for office, research and development, manufacturing and distribution facilities, including our headquarters location in Menlo Park, California. As of December 31, 2024, these leases had remaining lease terms that expire between 2025 and 2027. We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. Operating lease expense is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Combinations</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, contingent consideration can be earned by the sellers upon completion of certain future performance milestones. In these cases, a liability is recorded on the acquisition date for an estimate of the acquisition date fair value of the contingent consideration. These estimates require significant management judgment, including probabilities of achieving certain future milestones. Changes in the fair value of the contingent consideration subsequent to the acquisition date are recognized in operating expense on our consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded on our consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets with Indefinite Lives</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets with Indefinite Lives</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and capitalized in-process research and development (&#8220;IPR&amp;D&#8221;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is assessed for impairment and then amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually. We perform annual impairment testing of goodwill as of the first day of the second quarter, or more frequently if indicators of impairment exist. We perform annual impairment testing of IPR&amp;D as of the first day of the third quarter, or more frequently if indicators of impairment exist. Events that would indicate impairment and trigger an interim impairment test include, but are not limited to, unexpected adverse business conditions, weak demand for a specific product line or business, economic factors, shifting focus to certain lines of business, unanticipated technological changes or competitive activities, loss of key personnel, changes in business strategy and acts by governments or courts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level. We have one reporting unit, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test. We generally perform our impairment test using a combination of an income and a market approach to determine the fair value of goodwill. The income approach utilizes estimated discounted cash flows, while the market approach utilizes comparable company information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the IPR&amp;D impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the IPR&amp;D is less than the carrying amount. The qualitative factors include, but are not limited to, macroeconomic conditions, industry-specific conditions, and company-specific conditions. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the IPR&amp;D is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the IPR&amp;D with the carrying value. If the carrying amount of the IPR&amp;D exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative impairment test.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets and Other Finite-Lived Assets</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intangible Assets and Other Finite-Lived Assets</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangibles assets include our acquired developed technology and customer relationships. We capitalize finite-lived intangibles assets and generally amortize them on a straight-line basis over the estimated useful lives. Intangible assets purchased as part of an acquisition are included in Intangible assets, net, on our consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review intangible assets with finite lives and other finite-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. We assess the recoverability of assets based on the estimated undiscounted future cash flows expected to result from the use and eventual disposition of the asset. If the undiscounted future cash flows are less than the carrying amount, the asset is impaired. In light of the changes in circumstances that led to the recoverability assessment, we also assess the remaining estimated useful life of the assets. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to net book value, significant changes in the ability of an asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to estimate the fair values of identifiable intangible assets with finite lives and other finite-lived assets, we estimate the present value of future cash flows from those assets. The key assumptions that we use in our cash flow model are the amount and timing of estimated future cash flows to be generated by the asset over an extended period of time and a rate of return that considers the relative risk of achieving the cash flows, the time value of money, and other factors that a willing market participant would consider. Management judgment is required to estimate the amount and timing of future cash flows and the relative risk of achieving those cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue Recognition</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables; service and other revenue consist primarily of revenue earned from product maintenance agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods are transferred to our customers, or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Invoicing typically occurs upon shipment, or delivery in the case of an instrument, and payment is typically due within 30 days from invoice. In instances where the right to payment or transfer of title is contingent upon customer acceptance of the product, revenue is deferred until the acceptance criteria has been met. Revenue from instrument service contracts is recognized as the services are rendered, typically evenly over the contract term. Revenue from development agreements generally includes upfront and milestone payments. Revenue for these agreements is recognized when each distinct performance obligation is satisfied.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into, or periodically modify, contracts with customers that include a combination of promised products and services, resulting in arrangements containing multiple performance obligations. We determine whether each product or service is distinct, in order to identify the performance obligations in the contract and allocate the contract transaction price among the distinct performance obligations. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Therefore, instrument revenue is recognized upon transfer of control of the asset to the customer, which is generally upon delivery for sales made to our non-distributor customers and upon shipment for sales made to our distributor customers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for contracts with multiple performance obligations is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using historical average selling prices combined with an assessment of current market conditions. If the standalone selling price is not directly observable, we rely on estimates by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices, and other observable inputs. We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts and sales taxes collected on behalf of governmental authorities. We update the transaction price for expected consideration, subject to constraint. Where we expect, at contract inception, the timing of payments to be consistent with the transfer of goods or services or the contract duration to be one year or less, we do not adjust the transaction price for the effects of a significant financing component </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically modify existing contracts with customers, which could change the scope or the price of the contract, or both. When a contract modification occurs, we exercise judgment to determine if the modification should be accounted for as: (i) a separate contract, (ii) the termination of the original contract and creation of a new contract, (iii) a cumulative catch-up adjustment to the original contract, or a combination thereof. Further, contract modifications require the identification and evaluation of the performance obligations of the modified contract, allocation of revenue to the remaining performance obligations and determination of the period of recognition for each identified performance obligation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our agreements provide options to customers which can be exercised at a future date, such as the option to purchase our product at discounted prices, among others. In accounting for customer options, we determine whether an option is a material right and this may require us to exercise judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right and, therefore, a performance obligation. If the contract gives the customer the option to acquire additional goods or services at their normal standalone selling prices, we would likely determine that the option is not a material right and, therefore, account for it when the customer exercises the option. If the standalone selling price of the option is not directly observable, an estimated standalone selling price is utilized which considers adjustments for discounts that the customer could receive without exercising the option and the likelihood that the option will be exercised. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we generally provide a one-year warranty on instruments. We accrue the cost of the assurance warranty when revenue of the instrument is recognized. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee sales commissions are generally recorded as selling, general, and administrative expense when incurred as the amortization period for such costs, if capitalized, would have been one year or less.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenue and Shipping and Handling</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Revenue</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue reflects the direct cost of product components, third-party manufacturing services, and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain, and support our instruments, consumables, and services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing overhead is predominantly comprised of labor and facility costs. We capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support our installed customer base. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Shipping and Handling</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to shipping and handling are included in cost of revenues for all periods presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists primarily of expenses for personnel engaged in the development of our core technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, partner development costs, facilities costs, and other related overhead. We expense research and development costs during the period in which the costs are incurred. We defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Credit Losses</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Credit Losses</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade accounts receivable</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review the allowance by considering factors such as the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. Credit loss expense was immaterial for the years ended December&#160;31, 2024, 2023, and 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-sale debt securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities. We regularly assess whether our securities in an unrealized loss position are credit related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income. Unrealized losses that are not credit related are included in accumulated other comprehensive income (loss). The unrealized losses on our investments are mainly attributable to government securities, including U.S. government and U.S. agency bond securities, impacted by movements in market rates and not due to issuer credit risk. We have the ability to hold and do not intend to sell the investments in unrealized loss positions before the recovery of their amortized cost bases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruptions associated with epidemics or pandemics, or other customer-specific factors.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Income Taxes</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. The effect of a change in tax rates on the deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized. </span></div>We regularly review our positions taken relative to income taxes. To the extent our tax positions are more likely than not going to result in additional taxes, we accrue the estimated amount of tax related to such uncertain positions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share-Based Compensation</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize share-based compensation expense for share-based payments, including stock options, restricted stock units, performance stock units and stock issued under our employee stock purchase plan ("ESPP") based on the grant-date fair value. We estimate the fair value of stock options and ESPP using an option-pricing model. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_124" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 9. Stockholders&#8217; Equity</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information regarding share-based compensation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Comprehensive Income (Loss)</span></div></td></tr></table></div>Other comprehensive income (loss) is comprised of unrealized gains (losses) on our investment securities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Earnings per Share</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing diluted net loss by the weighted-average number of shares of common stock outstanding and potentially dilutive shares outstanding during the period. We calculate the potential dilutive effect of outstanding stock options, restricted stock units, and common stock issuable pursuant to our ESPP, using the treasury stock method. Potentially dilutive common shares issuable upon conversion of convertible senior notes are determined using the if-converted method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This ASU improves segment disclosure requirements, primarily through enhanced disclosure requirements for significant segment expenses on an annual and interim basis. The improved disclosure requirements apply to all public entities that are required to report segment information, including those with only one reportable segment. The standard was effective for us beginning in fiscal year 2024 and interim periods within fiscal year 2025. We adopted this ASU for our fiscal year ending December 31, 2024 and applied the amendments retrospectively to all prior periods presented in the consolidated financial statements. There was no impact on the Company&#8217;s reportable segments identified. Additional required disclosures have been included in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_130" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 11. Segment and Geographic Information</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Pending Adoption</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Pending Adoption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-04, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt With Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard will be effective for us beginning in the first quarter of fiscal year 2026, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-04 on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to provide disaggregated disclosures, within the notes to the financial statements, of specified categories of expenses that are included in line items on the face of the income statement. The standard will be effective for us beginning in fiscal year 2027, and interim periods within fiscal year 2028, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard will be effective for us beginning in fiscal year 2025, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2023-09 on the consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. </span></div>The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently Adopted Accounting Standards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.2.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483530/326-20-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479391/326-20-30-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479366/326-20-35-8A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3D<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479175/326-30-30-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3D<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 13A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479148/326-30-35-13A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479391/326-20-30-4A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479148/326-30-35-7A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-21<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Estimated Useful Lives of The Major Classes of Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated useful lives of the major classes of property and equipment are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment and machinery </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,273&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,907&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,770&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,226&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,882&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,528&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,280&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,628&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,972&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,594&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,276&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,453&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,226&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81,948)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74,794)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,505&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,432&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Combination</a></td>
<td class="text">As of December 31, 2023, the major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,287&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets, current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,338)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,191)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,008&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,370&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,370&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,739&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,739&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,370&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,370&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,739&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,911&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,905&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,905&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,579&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,579&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287,656&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287,656&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,979&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,979&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,561&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,561&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,505&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,505&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,592&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,561&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392,153&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,894&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">561,244&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634,138&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration - Apton acquisition</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,700&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,700&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities measured at fair value </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,700&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,700&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in the Estimated Fair Value of Contingent Consideration Liability</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the contingent consideration liability related to the Apton acquisition for the year ended December&#160;31, 2024 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance as of December 31, 2023</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in estimated fair value</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(850)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance as of December 31, 2024</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,700&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Investments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash, cash equivalents, restricted cash, and investments:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized<br/>Cost </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,370&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,370&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,370&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,370&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,746&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,905&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287,393&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287,656&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,139&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,561&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and investments </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,509&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,931&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,786&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,739&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,958&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,911&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,579&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,029&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(528)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,979&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,239&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(585)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,505&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and investments </span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631,197&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631,416&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of December&#160;31, 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238,957&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through 5 years </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,604&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,561&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, net, consisted of the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchased materials</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,270&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,434&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,172&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,653&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,081&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory, gross</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,523&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,833&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory reserve</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,768)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,157)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory, net</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,755&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,676&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated useful lives of the major classes of property and equipment are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment and machinery </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,273&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,907&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,770&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,226&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,882&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,528&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,280&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,628&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,972&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,594&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,276&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,453&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,226&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81,948)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74,794)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,505&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,432&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to goodwill during the year ended December&#160;31, 2024 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462,261&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144,500)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317,761&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock', window );">Schedule of Impaired Intangible Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to IPR&amp;D during the year ended December&#160;31, 2024 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-814">Impairment charge</span></span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets From Business Acquisitions</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to IPR&amp;D, we had the following acquired finite-lived intangible assets as of December&#160;31, 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated <br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,179&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,607)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,572&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,539&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,967)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,572&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Finite Lives</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of acquisition-related intangible assets with finite lives is estimated as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030 and thereafter</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,512&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,572&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,706&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,337&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,470&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchase commitments</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued product development costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued professional services and legal fees</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,641&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory accrual</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warranty accrual</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,100&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,681&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,147&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,595&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,708&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock', window );">Schedule of Changes in Reserve for Product Warranties</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,681&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,651&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions charged to cost of product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,144&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repairs and replacements</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,725)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,197)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,100&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,681&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Liabilities, Current</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities, current, consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued Employee Stock Purchase Plan</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,715&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term loan</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,210&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities, current</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,224&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,326&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Net Carrying Amount</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current on our consolidated balance sheets as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">441,000&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">441,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt premium</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,959)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,907)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435,494&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434,617&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2028 Notes is included as convertible senior notes, net, non-current on our consolidated balance sheets as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,374)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">457,626&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfInterestExpenseTableTextBlock', window );">Schedule of Interest Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2030 Notes for the years ended December&#160;31, 2024, 2023, and 2022 was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,081&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,032&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,031&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,495&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2028 Notes was as follows for the years ended December&#160;31, 2024, 2023, and 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,139&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,133&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,500&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,428&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,605&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,117&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ScheduleOfInterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Interest Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ScheduleOfInterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Pre-Tax Restructuring Charges</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the pre-tax restructuring charges are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended</span></div><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative amount incurred to date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee separation costs</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,008&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,008&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,214&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,214&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="-sec-ix-hidden:f-1008"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restructuring charges</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,222&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,222&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> For the year ended December&#160;31, 2024, cumulative charges incurred to date include $14.9 million in sales, general and administrative expense; $5.9 million in research and development expense; and $4.4 million in cost of revenue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the liabilities related to the restructuring is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Separation Costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expense recorded in YTD 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,008&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,816&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,824&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid during YTD 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,008)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,646)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,654)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount recorded in current liabilities as of December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated total restructuring costs to still be incurred</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LesseeOperatingLeaseDescriptionTableTextBlock', window );">Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the maturities of our operating lease liabilities were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,481&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,780&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,371&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,431)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of operating lease liabilities </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,940&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,026&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,914&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,940&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_LesseeOperatingLeaseDescriptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Description [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_LesseeOperatingLeaseDescriptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Provision (Benefit)</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision (benefit) consists of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,956)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,468)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,424)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,424)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Federal Income Tax Rate</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of 21% to pretax loss as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Statutory tax rate </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State tax rate, net of federal benefit</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger Expenses</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairment</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Reconciliation of Deferred Tax Assets and Liabilities</a></td>
<td class="text">Significant components of our deferred tax assets for federal and state income taxes are as follows:<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434,122&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435,488&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,416&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and experimental expenses</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,281&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,196&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,506&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancellation of indebtedness income and interest expense</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,424&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,907&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,195&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,584&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,618&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,510&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">653,562&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642,479&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(558,794)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(525,703)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets:</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,768&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,776&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91,504)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109,488)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(548)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,549)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,491)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95,314)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117,527)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(546)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(751)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of Unrecognized Tax Benefit Accounts</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, our total unrecognized tax benefit was $17.7 million. A reconciliation of the beginning and ending unrecognized tax benefit balance is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,335&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in balance related to tax positions taken in prior year </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,085&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,410&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken in prior year </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,044&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,554&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in balance related to tax positions taken in prior year </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,128&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2024</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,676&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for time-based awards:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(shares in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average<br/>exercise price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,011</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.63&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(515)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.15&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,153)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.89&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(327)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.81&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,509</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.09&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Time-Based RSUs Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the time-based RSU and PSU activity: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(shares in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units (RSUs)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Stock Units (PSUs)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RSU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PSU</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,308</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.06&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,722</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.02&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,801)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.43&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,018)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.90&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,211</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.41&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,691&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,399&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,802&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,172&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,435&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,676&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,173&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,036&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,118&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,613&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81% - 93%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77% - 78%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70% - 76%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.48% &#8211; 4.32%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.73% &#8211; 4.60%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.41% &#8211; 3.66%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.40&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Stock Purchase Plan</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares to be issued under the ESPP was estimated using the following assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81% - 118%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79% - 97%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70% - 97%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9% - 5.3%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9% - 5.5%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6% - 3.5%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.53&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of the basic and diluted net loss per share amounts presented on our consolidated statements of operations and comprehensive loss: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net loss</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,851)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(306,735)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314,248)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net loss</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,851)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(306,735)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314,248)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Interest charges applicable to convertible notes (2028 Notes)</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,428&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Gain on debt restructuring (2029 Notes)</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154,407)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net loss</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(457,830)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(306,735)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314,248)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in computing basic net loss per share</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274,488&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,629&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,550&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net loss per share</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.13)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.21)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.40)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in computing basic net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274,488</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,629</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,550</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Weighted average shares issuable upon conversion of convertible notes (2028 Notes)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,395</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Weighted average shares issuable upon conversion of convertible notes (2029 Notes)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,483</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in computing diluted net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,366</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,629</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,550</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net loss per share</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.59)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.21)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.40)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares issuable upon conversion of the convertible senior notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible senior notes</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,512</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,063</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,690</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity awards</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,136</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,246</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,291</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Profit or Loss</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the segment profit or loss, including significant segment expenses is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,014&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,521&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,304&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,732&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,741&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134,922&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,170&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,244&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,465&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,773&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,531&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,389&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,500&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger-related expenses</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,042&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(850)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,060&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,006&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,157&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on debt restructuring</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154,407)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,371&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,341&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,052)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,424)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net loss</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,851)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(306,735)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314,248)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue by Geographic Location</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by geographic location is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Americas </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,711&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,410&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East, and Africa</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,594&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,658&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,598&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia-Pacific</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,709&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,453&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,014&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,521&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,304&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes United States revenue of $75.3 million, $100.5 million, and $66.8 million for the years ended December 31, 2024, 2023, and 2022, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Revenue by Category</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by category is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instrument revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,776&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,451&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,719&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumable revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,373&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,421&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136,149&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,872&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,699&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,865&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,649&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,605&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,014&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,521&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,304&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES- Narrative (Details)<br></strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>unit</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>segment</div>
</th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StandardProductWarrantyPeriod', window );">Product warranty period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net | Customer One | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer One | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Domestic Customers | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StandardProductWarrantyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Standard Product Warranty, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StandardProductWarrantyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pacb_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pacb_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pacb_DomesticCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pacb_DomesticCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of The Major Classes of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 02, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan', window );">Issuance of common stock in connection with Apton liquidity event bonus plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan', window );">Issuance of common stock in connection with liquidity event bonus plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of share consideration</a></td>
<td class="nump">$ 76,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">18,500<span></span>
</td>
<td class="nump">$ 19,550<span></span>
</td>
<td class="nump">$ 18,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred', window );">Less: Share-based compensation expense excluded from consideration transferred</a></td>
<td class="num">$ (1,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in acquisition (in shares)</a></td>
<td class="nump">6,121,571<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone', window );">Milestone revenue</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod', window );">Anniversary</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition', window );">Average trading period</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Merger related transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Merger-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan', window );">Issuance of common stock in connection with Apton liquidity event bonus plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, acquired during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan', window );">Issuance of common stock in connection with liquidity event bonus plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger', window );">Percentage of outstanding shares of common to be issued in merger</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton | Achievement of Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Closing Date Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares of common to be issued in merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense excluded from consideration transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Average Trading Period, Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Acquisitions, Liquidity Bonus Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Acquisitions, Liquidity Bonus Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_AptonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=pacb_AchievementOfMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=pacb_AchievementOfMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS - Schedule of Business Acquisition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 317,761<span></span>
</td>
<td class="nump">$ 462,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other assets, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,338)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_AptonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-term restricted cash</a></td>
<td class="nump">$ 690<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long-term restricted cash</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">2,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">392,153<span></span>
</td>
<td class="nump">634,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">18,700<span></span>
</td>
<td class="nump">19,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">55,370<span></span>
</td>
<td class="nump">179,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember', window );">Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">334,561<span></span>
</td>
<td class="nump">451,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">18,700<span></span>
</td>
<td class="nump">19,550<span></span>
</td>
<td class="nump">$ 18,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=pacb_CashAndMoneyMarketFundsMember', window );">Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">55,370<span></span>
</td>
<td class="nump">70,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">109,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">46,905<span></span>
</td>
<td class="nump">88,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember', window );">U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">287,656<span></span>
</td>
<td class="nump">352,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-term restricted cash</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long-term restricted cash</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">2,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">57,592<span></span>
</td>
<td class="nump">72,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cash and cash equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">55,370<span></span>
</td>
<td class="nump">70,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">55,370<span></span>
</td>
<td class="nump">70,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">334,561<span></span>
</td>
<td class="nump">561,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Cash and cash equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">109,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">334,561<span></span>
</td>
<td class="nump">451,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">109,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">46,905<span></span>
</td>
<td class="nump">88,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">287,656<span></span>
</td>
<td class="nump">352,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">18,700<span></span>
</td>
<td class="nump">19,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">18,700<span></span>
</td>
<td class="nump">19,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Cash and cash equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">18,700<span></span>
</td>
<td class="nump">19,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_LongTermRestrictedCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Restricted Cash Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_LongTermRestrictedCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ShortTermRestrictedCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Term Restricted Cash Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ShortTermRestrictedCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_AptonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=pacb_CashAndMoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=pacb_CashAndMoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 20, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 02, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in acquisition of Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock following milestone achievement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,988,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock following milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,900<span></span>
</td>
<td class="nump">32,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid</a></td>
<td class="nump">$ 100,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in acquisition (in shares) | shares</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in acquisition of Apton</a></td>
<td class="nump">$ 95,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone', window );">Milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in acquisition of Apton</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in acquisition of Apton</a></td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod', window );">Business acquisition, anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,121,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition', window );">Average trading period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeMember', window );">Omniome</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition', window );">Average trading period</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Valuation, Income Approach | Measurement Input, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Valuation, Income Approach | Measurement Input, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Liability, Measurement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_FinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_FinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Contingent Consideration, Revenue Achievement Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Average Trading Period, Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_AptonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">$ (850)<span></span>
</td>
<td class="nump">$ 15,060<span></span>
</td>
<td class="nump">$ 2,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance as of December 31, 2023</a></td>
<td class="nump">19,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance as of December 31, 2024</a></td>
<td class="nump">$ 18,700<span></span>
</td>
<td class="nump">$ 19,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">$ 690<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">2,422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pacb_CashCashEquivalentsAndInvestmentsMember', window );">Total cash, cash equivalents, and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">389,509<span></span>
</td>
<td class="nump">631,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">389,931<span></span>
</td>
<td class="nump">631,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">55,370<span></span>
</td>
<td class="nump">179,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">55,370<span></span>
</td>
<td class="nump">179,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pacb_CashAndMoneyMarketFundsMember', window );">Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">55,370<span></span>
</td>
<td class="nump">70,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">55,370<span></span>
</td>
<td class="nump">70,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">109,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">109,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember', window );">Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">334,139<span></span>
</td>
<td class="nump">451,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(585)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">334,561<span></span>
</td>
<td class="nump">451,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">46,746<span></span>
</td>
<td class="nump">88,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">46,905<span></span>
</td>
<td class="nump">88,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember', window );">U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">287,393<span></span>
</td>
<td class="nump">353,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(155)<span></span>
</td>
<td class="num">(528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">$ 287,656<span></span>
</td>
<td class="nump">$ 352,979<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pacb_CashCashEquivalentsAndInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pacb_CashCashEquivalentsAndInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pacb_CashAndMoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pacb_CashAndMoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue', window );">Due in one year or less</a></td>
<td class="nump">$ 238,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Due after one year through five years</a></td>
<td class="nump">95,604<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 334,561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Purchased materials</a></td>
<td class="nump">$ 45,270<span></span>
</td>
<td class="nump">$ 32,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">22,172<span></span>
</td>
<td class="nump">27,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">14,081<span></span>
</td>
<td class="nump">15,746<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, gross</a></td>
<td class="nump">81,523<span></span>
</td>
<td class="nump">75,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserve</a></td>
<td class="num">(22,768)<span></span>
</td>
<td class="num">(19,157)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 58,755<span></span>
</td>
<td class="nump">$ 56,676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 112,453<span></span>
</td>
<td class="nump">$ 111,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(81,948)<span></span>
</td>
<td class="num">(74,794)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">30,505<span></span>
</td>
<td class="nump">36,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pacb_LaboratoryEquipmentAndMachineryMember', window );">Laboratory equipment and machinery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">47,273<span></span>
</td>
<td class="nump">44,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">33,770<span></span>
</td>
<td class="nump">35,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">18,882<span></span>
</td>
<td class="nump">19,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7,280<span></span>
</td>
<td class="nump">6,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,972<span></span>
</td>
<td class="nump">3,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,276<span></span>
</td>
<td class="nump">$ 1,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pacb_LaboratoryEquipmentAndMachineryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pacb_LaboratoryEquipmentAndMachineryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,774<span></span>
</td>
<td class="nump">$ 11,463<span></span>
</td>
<td class="nump">$ 9,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges</a></td>
<td class="nump">$ 51,300<span></span>
</td>
<td class="nump">$ 93,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 144,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate', window );">Goodwill impairment, discount rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate', window );">Increase in basis point discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate', window );">Additional goodwill impairment</a></td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate', window );">Intangible asset impairment, increase in basis point discount rate</a></td>
<td class="nump">0.0100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate', window );">Intangible asset impairment, discounted cash flow model, discount rate</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm', window );">Intangible asset impairment, discounted cash flow model, term (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate', window );">Additional intangible asset impairment, change in discount rate</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm', window );">Intangible asset impairment, increase in term (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm', window );">Additional intangible asset impairment, change in term</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,400<span></span>
</td>
<td class="nump">8,300<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,412<span></span>
</td>
<td class="nump">8,261<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">13,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,864<span></span>
</td>
<td class="nump">16,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="nump">5,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 58,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="nump">62.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pacb_CostOfRevenueMember', window );">Cost Of Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets, finite-lived</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets, finite-lived</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember', window );">In-Process Research and Development Indefinite Lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets, indefinite-lived (excluding goodwill)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc | In-Process Research and Development Indefinite Lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets include acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="nump">19,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod', window );">Deferred service revenue, noncurrent, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Goodwill Impairment, Change In Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AdditionalGoodwillImpairmentChangeInDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Intangible Asset Impairment, Change In Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Intangible Asset Impairment, Change In Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AdditionalIntangibleAssetImpairmentChangeInTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BalanceSheetComponentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance Sheet Components [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BalanceSheetComponentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Noncurrent, Recognition Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill Impairment, Discounted Cash Flow Model, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill Impairment, Increase In Basis Point Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset Impairment, Discounted Cash Flow Model, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset Impairment, Discounted Cash Flow Model, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset Impairment, Increase In Basis Point Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset Impairment, Increase In Obsolescence Factor, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pacb_CostOfRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pacb_CostOfRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_AptonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of December&#160;31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 462,261<span></span>
</td>
<td class="nump">$ 462,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges</a></td>
<td class="num">$ (51,300)<span></span>
</td>
<td class="num">$ (93,200)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(144,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of December&#160;31, 2024</a></td>
<td class="nump">$ 317,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 317,761<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-Lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Balance as of December&#160;31, 2023</a></td>
<td class="nump">$ 456,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Balance as of December&#160;31, 2024</a></td>
<td class="nump">$ 389,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Impairment charges<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-Lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Balance as of December&#160;31, 2023</a></td>
<td class="nump">$ 55,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment charge</a></td>
<td class="num">(40,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Balance as of December&#160;31, 2024</a></td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of intangible asset. Includes, but is not limited to, finite-lived and indefinite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 411,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(36,967)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 374,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 411,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(36,607)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 374,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(360)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Finite Lives (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 27,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">27,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">27,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">27,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">27,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">2030 and thereafter</a></td>
<td class="nump">237,512<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 374,572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Salaries and benefits</a></td>
<td class="nump">$ 11,706<span></span>
</td>
<td class="nump">$ 29,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AccruedTenantImprovementsCurrent', window );">Accrued interest payable</a></td>
<td class="nump">2,470<span></span>
</td>
<td class="nump">2,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Accrued purchase commitments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AccruedProductDevelopmentCostsCurrent', window );">Accrued product development costs</a></td>
<td class="nump">1,111<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services and legal fees</a></td>
<td class="nump">824<span></span>
</td>
<td class="nump">2,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProductLiabilityNet', window );">Inventory accrual</a></td>
<td class="nump">1,237<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Warranty accrual</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">4,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">2,147<span></span>
</td>
<td class="nump">2,216<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 22,595<span></span>
</td>
<td class="nump">$ 45,708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AccruedProductDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Product Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AccruedProductDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AccruedTenantImprovementsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Tenant Improvements, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AccruedTenantImprovementsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProductLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of the estimated aggregate accrual for damages arising from third-party use of the entity's product(s) or process(es) as of the balance sheet date (if the accrual qualifies for discounting).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProductLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward', window );"><strong>Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Balance at beginning of period</a></td>
<td class="nump">$ 4,681<span></span>
</td>
<td class="nump">$ 1,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualWarrantiesIssued', window );">Additions charged to cost of product revenue</a></td>
<td class="nump">6,144<span></span>
</td>
<td class="nump">8,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualPayments', window );">Repairs and replacements</a></td>
<td class="num">(7,725)<span></span>
</td>
<td class="num">(5,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Balance at end of period</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 4,681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualWarrantiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the standard and extended product warranty accrual from warranties issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualWarrantiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Other Liabilities, Current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent', window );">Accrued Employee Stock Purchase Plan</a></td>
<td class="nump">$ 2,014<span></span>
</td>
<td class="nump">$ 3,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,210<span></span>
</td>
<td class="nump">4,121<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities, current</a></td>
<td class="nump">$ 3,224<span></span>
</td>
<td class="nump">$ 8,326<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Employee Stock Purchase Plan Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 21, 2024 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 07, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PaymentsInConjunctionWithNotesExchange', window );">Payments made in conjunction with convertible notes exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares', window );">Lock-up period restriction</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Gain on debt restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,407,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RestructuringOfDebtPricePerShare', window );">Restructuring of debt (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible senior notes, net, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 647,494,000<span></span>
</td>
<td class="nump">892,243,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,595,000<span></span>
</td>
<td class="nump">45,708,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,033,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">459,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">457,626,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,000<span></span>
</td>
<td class="nump">472,000<span></span>
</td>
<td class="nump">617,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 459,000,000<span></span>
</td>
<td class="nump">$ 459,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 441,000,000.0<span></span>
</td>
<td class="nump">$ 900,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PaymentsInConjunctionWithNotesExchange', window );">Payments made in conjunction with convertible notes exchange</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of stock price trigger</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate outstanding balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 459,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtIssuanceCostLenderFees', window );">Debt issuance cost, lender fees</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible senior notes, net, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of notes</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, shares issued (in shares) | shares</a></td>
<td class="nump">20,451,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of stock price trigger</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2045157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | d</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | d</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Notes | Convertible Debt | Debt Conversion Terms One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentInterestInTheEventOfDefault', window );">Debt instrument, interest in the event of default</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Notes | Convertible Debt | Debt Conversion Terms Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">361 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentAdditionalInterestInEventOfDefault', window );">Additional interest in the event of default</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Notes | Convertible Debt | Debt Conversion Terms Two | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">181 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Notes | Convertible Debt | Debt Conversion Terms Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,000,000<span></span>
</td>
<td class="nump">441,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,494,000<span></span>
</td>
<td class="nump">434,617,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,000<span></span>
</td>
<td class="nump">463,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 441,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0465116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentInterestInTheEventOfDefault', window );">Debt instrument, interest in the event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentAdditionalInterestInEventOfDefault', window );">Additional interest in the event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 293,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice', window );">Debt redemption, percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPriceTradingDays', window );">Debt redemption, trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays', window );">Debt redemption, consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Convertible Debt | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">181 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Convertible Debt | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Convertible Debt | Debt Conversion Terms One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Convertible Debt | Debt Conversion Terms Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">361 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ExchangeTransactionMember', window );">Exchange Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ExchangeTransactionMember', window );">Exchange Transaction | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Paid accrued but unpaid interest</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentAdditionalInterestInEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Interest in the Event of Default</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentAdditionalInterestInEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentDebtDefaultCalendarDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Default, Calendar Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentDebtDefaultCalendarDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentInterestInTheEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest in the Event of Default</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentInterestInTheEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPriceTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPriceTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtIssuanceCostLenderFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Cost, Lender Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtIssuanceCostLenderFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Holding Period For Transfer, Assignment Or Sale Of Founder Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PaymentsInConjunctionWithNotesExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments In Conjunction With Notes Exchange</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PaymentsInConjunctionWithNotesExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RestructuringOfDebtPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Of Debt Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RestructuringOfDebtPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 60<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481408/470-60-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_ExchangeTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_ExchangeTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 441,000<span></span>
</td>
<td class="nump">$ 441,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Unamortized debt premium</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="num">(5,959)<span></span>
</td>
<td class="num">(6,907)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">435,494<span></span>
</td>
<td class="nump">434,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">459,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,374)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 457,626<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">$ 6,081<span></span>
</td>
<td class="nump">$ 3,032<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">950<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">7,031<span></span>
</td>
<td class="nump">3,495<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">6,139<span></span>
</td>
<td class="nump">10,133<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 6,428<span></span>
</td>
<td class="nump">$ 10,605<span></span>
</td>
<td class="nump">$ 14,117<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 12,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Cost of revenue<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_SanDiegoOfficeMember', window );">San Diego Office</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 25,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">25,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Sales, general and administrative | San Diego Office</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">14,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | San Diego Office</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">5,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue | San Diego Office</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember', window );">Employee separation costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">10,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember', window );">Employee separation costs | San Diego Office</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">10,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">10,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">2,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other costs | San Diego Office</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">15,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">$ 15,214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_SanDiegoOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_SanDiegoOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits', window );">WARN act and other employee benefits</a></td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory provision</a></td>
<td class="nump">4,618<span></span>
</td>
<td class="nump">$ 10,584<span></span>
</td>
<td class="nump">$ 6,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Decrease in operating lease liability</a></td>
<td class="nump">11,920<span></span>
</td>
<td class="nump">$ 8,759<span></span>
</td>
<td class="nump">$ 7,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">24,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_SanDiegoOfficeMember', window );">San Diego Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation</a></td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory provision</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Decrease in operating lease liability</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Worker Adjustment and Retraining Notification (WARN) Act and Other Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_SanDiegoOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_SanDiegoOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense recorded in YTD 2024</a></td>
<td class="nump">$ 12,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash paid during YTD 2024</a></td>
<td class="num">(12,654)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Amount recorded in current liabilities as of December 31, 2024</a></td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Estimated total restructuring costs to still be incurred</a></td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember', window );">Employee separation costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense recorded in YTD 2024</a></td>
<td class="nump">10,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash paid during YTD 2024</a></td>
<td class="num">(10,008)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Amount recorded in current liabilities as of December 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Estimated total restructuring costs to still be incurred</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense recorded in YTD 2024</a></td>
<td class="nump">2,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash paid during YTD 2024</a></td>
<td class="num">(2,646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Amount recorded in current liabilities as of December 31, 2024</a></td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Estimated total restructuring costs to still be incurred</a></td>
<td class="nump">$ 946<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected cost remaining for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 11,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">8,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">7,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">27,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(2,431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">24,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetClassificationAbstract', window );"><strong>Balance Sheet Classification</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">10,026<span></span>
</td>
<td class="nump">$ 9,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">14,914<span></span>
</td>
<td class="nump">$ 31,606<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 24,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BalanceSheetClassificationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance Sheet Classification [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BalanceSheetClassificationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">14 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,200,000<span></span>
</td>
<td class="nump">$ 12,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,500,000<span></span>
</td>
<td class="nump">10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations', window );">Additional liability associated with indemnification obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFirmPurchaseCommitmentLoss', window );">Loss on purchase commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForDeposits', window );">Payments for deposits to supplier</a></td>
<td class="nump">$ 9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RefundFromDeposits', window );">Refund from deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Liability Associated With Indemnification Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RefundFromDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refund From Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RefundFromDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFirmPurchaseCommitmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss recognized on firm purchase commitment for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 330<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFirmPurchaseCommitmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for deposits on goods and services during the period; excludes time deposits and deposits with other institutions, which pertain to financial service entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition', window );">Probability of benefit realized upon settlement uncertain tax position</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">(Loss) income before taxes from U.S. operations</a></td>
<td class="num">$ (311,000)<span></span>
</td>
<td class="num">$ (318,900)<span></span>
</td>
<td class="num">$ (315,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Income before taxes from foreign operations</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">558,794<span></span>
</td>
<td class="nump">525,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">434,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development credit carryforward</a></td>
<td class="nump">91,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">17,676<span></span>
</td>
<td class="nump">14,554<span></span>
</td>
<td class="nump">$ 10,410<span></span>
</td>
<td class="nump">$ 8,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">1,704,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development credit carryforward</a></td>
<td class="nump">64,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration', window );">Operating loss carryforwards, subject to expiration</a></td>
<td class="nump">783,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">1,170,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development credit carryforward</a></td>
<td class="nump">$ 54,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Amount Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_OperatingLossCarryforwardsAmountSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Probability of benefit Realized Upon Settlement Uncertain Tax Position</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Components of Income Tax Provision (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">$ 521<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(9,956)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(197)<span></span>
</td>
<td class="num">(1,468)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(205)<span></span>
</td>
<td class="num">(11,424)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="nump">$ 316<span></span>
</td>
<td class="num">$ (11,424)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Reconciliation of Federal Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal benefit</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(10.80%)<span></span>
</td>
<td class="num">(20.00%)<span></span>
</td>
<td class="num">(25.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit', window );">Tax credits</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="num">(3.70%)<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent', window );">Merger Expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.001)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Goodwill impairment</a></td>
<td class="num">(9.80%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Merger Expense, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Credit,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_EffectiveIncomeTaxRateReconciliationTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Reconciliation of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 434,122<span></span>
</td>
<td class="nump">$ 435,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">91,416<span></span>
</td>
<td class="nump">83,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Capitalized research and experimental expenses</a></td>
<td class="nump">73,281<span></span>
</td>
<td class="nump">63,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">Accruals and reserves</a></td>
<td class="nump">10,506<span></span>
</td>
<td class="nump">16,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense', window );">Cancellation of indebtedness income and interest expense</a></td>
<td class="nump">20,424<span></span>
</td>
<td class="nump">14,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">18,195<span></span>
</td>
<td class="nump">18,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liability</a></td>
<td class="nump">5,618<span></span>
</td>
<td class="nump">9,510<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">653,562<span></span>
</td>
<td class="nump">642,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(558,794)<span></span>
</td>
<td class="num">(525,703)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets:</a></td>
<td class="nump">94,768<span></span>
</td>
<td class="nump">116,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangibles</a></td>
<td class="num">(91,504)<span></span>
</td>
<td class="num">(109,488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(261)<span></span>
</td>
<td class="num">(548)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DeferredTaxLiabilitiesRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(3,549)<span></span>
</td>
<td class="num">(7,491)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(95,314)<span></span>
</td>
<td class="num">(117,527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="num">$ (546)<span></span>
</td>
<td class="num">$ (751)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Cancellation Of Indebtedness Income And Interest Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Deferred Expense, Capitalized Research and Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right-of-use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Reconciliation of Unrecognized Tax Benefit Accounts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 14,554<span></span>
</td>
<td class="nump">$ 10,410<span></span>
</td>
<td class="nump">$ 8,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decrease in balance related to tax positions taken in prior year</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase in balance related to tax positions taken in prior year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase in balance related to tax positions taken during current year</a></td>
<td class="nump">3,128<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">2,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 17,676<span></span>
</td>
<td class="nump">$ 14,554<span></span>
</td>
<td class="nump">$ 10,410<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 18, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 22, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>period </div>
<div>$ / shares </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2010 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Voting right of common stock share holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned', window );">Voting right of common stock share holders, number of votes | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PublicOfferingShares', window );">Public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_OfferingShareAmountMaximum', window );">Common stock offering price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod', window );">Public offering, option to purchase additional shares, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares', window );">Public offering, option to purchase additional shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering', window );">Commissions, percentage of gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Proceeds from issuance of common stock from underwritten public equity offerings, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of offering expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, aggregate intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, weighted average exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ 7.32<span></span>
</td>
<td class="nump">$ 5.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,418,000<span></span>
</td>
<td class="nump">267,744,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation cost capitalized in inventory | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pacb_A2020PlanInducementPlanAndTheOmniomePlanMember', window );">2020 Plan, Inducement Plan, And The Omniome Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remain available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_ShelfOfferingMember', window );">Shelf Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ 7.32<span></span>
</td>
<td class="nump">$ 5.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedAndPerformanceBasedOptionsMember', window );">Time-Based and Performance-Based Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, exercisable, number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,429,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options expired, weighted average exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,957,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShareInstrumentNumberOfSharesConversionRatio', window );">Ratio of number of shares into which the share instrument may be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of shares vested related to RSUs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.2<span></span>
</td>
<td class="nump">$ 39.3<span></span>
</td>
<td class="nump">$ 39.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="nump">$ 9.65<span></span>
</td>
<td class="nump">$ 10.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsPSUMember', window );">Time Based Restricted Stock Units PSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal', window );">Amount eligible to vest upon achievement of goal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional common stock reserved for issuance (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remain available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_NumberOfPurchasePeriods', window );">Number of purchase periods | period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PurchasePeriodOfEmployeeStockPurchasePlan', window );">Purchase period of ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased', window );">Percentage of fair market value at which stock can be purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding common stock used to determine annual plan increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Common stock purchased under plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,906,529<span></span>
</td>
<td class="nump">1,735,058<span></span>
</td>
<td class="nump">1,878,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Options To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Voting Rights, Number Of Votes Per Share Owned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:positiveIntegerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_NumberOfPurchasePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of purchase periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_NumberOfPurchasePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_OfferingShareAmountMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering Share Amount Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_OfferingShareAmountMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair market value at which stock can be purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering, Option to Purchase Additional Shares, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering, Option to Purchase Additional Shares, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PublicOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PublicOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PurchasePeriodOfEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase period of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PurchasePeriodOfEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ShareInstrumentNumberOfSharesConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares into which the share instrument may be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ShareInstrumentNumberOfSharesConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480637/718-40-25-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pacb_A2020PlanInducementPlanAndTheOmniomePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pacb_A2020PlanInducementPlanAndTheOmniomePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_ShelfOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pacb_ShelfOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedAndPerformanceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedAndPerformanceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsPSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsPSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Stock Option Activity (Details) - Time-Based Stock Option<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">13,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(2,153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(327)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">10,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 10.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">1.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">3.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">8.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in usd per share) | $ / shares</a></td>
<td class="nump">5.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 11.09<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Time-Based RSUs Activity (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning (in shares)</a></td>
<td class="nump">11,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">12,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(3,801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(6,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending (in shares)</a></td>
<td class="nump">14,211<span></span>
</td>
<td class="nump">11,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning, outstanding (in dollars per share)</a></td>
<td class="nump">$ 12.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in usd per share)</a></td>
<td class="nump">5.02<span></span>
</td>
<td class="nump">$ 9.65<span></span>
</td>
<td class="nump">$ 10.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">12.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">7.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending, outstanding (in dollars per share)</a></td>
<td class="nump">$ 7.41<span></span>
</td>
<td class="nump">$ 12.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units (PSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning (in shares)</a></td>
<td class="nump">541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending (in shares)</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning, outstanding (in dollars per share)</a></td>
<td class="nump">$ 9.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">9.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending, outstanding (in dollars per share)</a></td>
<td class="nump">$ 9.43<span></span>
</td>
<td class="nump">$ 9.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 5,691<span></span>
</td>
<td class="nump">$ 5,399<span></span>
</td>
<td class="nump">$ 4,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">19,172<span></span>
</td>
<td class="nump">22,435<span></span>
</td>
<td class="nump">30,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Sales, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">46,173<span></span>
</td>
<td class="nump">44,284<span></span>
</td>
<td class="nump">43,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pacb_StockBasedCompensationMember', window );">Total share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 71,036<span></span>
</td>
<td class="nump">$ 72,118<span></span>
</td>
<td class="nump">$ 78,613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pacb_StockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pacb_StockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Fair Value of Employee Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ 7.32<span></span>
</td>
<td class="nump">$ 5.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.48%<span></span>
</td>
<td class="nump">3.73%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.32%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">3.66%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ 7.32<span></span>
</td>
<td class="nump">$ 5.93<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pacb_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">118.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in usd per share)</a></td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="nump">$ 5.34<span></span>
</td>
<td class="nump">$ 4.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pacb_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pacb_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Basic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Basic net loss</a></td>
<td class="num">$ (309,851)<span></span>
</td>
<td class="num">$ (306,735)<span></span>
</td>
<td class="num">$ (314,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Basic net loss</a></td>
<td class="num">(309,851)<span></span>
</td>
<td class="num">(306,735)<span></span>
</td>
<td class="num">(314,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Less: Gain on debt restructuring (2029 Notes)</a></td>
<td class="num">(154,407)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Diluted net loss</a></td>
<td class="num">$ (457,830)<span></span>
</td>
<td class="num">$ (306,735)<span></span>
</td>
<td class="num">$ (314,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing basic net (loss) income per share (in shares)</a></td>
<td class="nump">274,488,000<span></span>
</td>
<td class="nump">253,629,000<span></span>
</td>
<td class="nump">224,550,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share (in usd per share)</a></td>
<td class="num">$ (1.13)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing basic net (loss) income per share (in shares)</a></td>
<td class="nump">274,488,000<span></span>
</td>
<td class="nump">253,629,000<span></span>
</td>
<td class="nump">224,550,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing diluted net (loss) income per share (in shares)</a></td>
<td class="nump">288,366,000<span></span>
</td>
<td class="nump">253,629,000<span></span>
</td>
<td class="nump">224,550,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share (in usd per share)</a></td>
<td class="num">$ (1.59)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.40)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Add: Interest charges applicable to convertible notes (2028 Notes)</a></td>
<td class="nump">$ 6,428<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Add: Weighted average shares issuable upon conversion of convertible notes (in shares)</a></td>
<td class="nump">9,395,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029ConvertibleSeniorNotesMember', window );">2029 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Less: Gain on debt restructuring (2029 Notes)</a></td>
<td class="num">$ (154,407)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Add: Weighted average shares issuable upon conversion of convertible notes (in shares)</a></td>
<td class="nump">4,483,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 60<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481408/470-60-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestOnConvertibleDebtNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestOnConvertibleDebtNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2029ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2029ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Shares issuable upon conversion of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="nump">20,512<span></span>
</td>
<td class="nump">31,063<span></span>
</td>
<td class="nump">20,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="nump">34,136<span></span>
</td>
<td class="nump">27,246<span></span>
</td>
<td class="nump">27,291<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details) - 12 months ended Dec. 31, 2024<br></strong></div></th>
<th class="th"><div>unit</div></th>
<th class="th"><div>segment</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 154,014<span></span>
</td>
<td class="nump">$ 200,521<span></span>
</td>
<td class="nump">$ 128,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">116,732<span></span>
</td>
<td class="nump">147,741<span></span>
</td>
<td class="nump">79,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">134,922<span></span>
</td>
<td class="nump">187,170<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment charges</a></td>
<td class="nump">184,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Merger-related expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,042<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(850)<span></span>
</td>
<td class="nump">15,060<span></span>
</td>
<td class="nump">2,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">27,412<span></span>
</td>
<td class="nump">8,261<span></span>
</td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,033<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Gain on debt restructuring</a></td>
<td class="num">(154,407)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">23,783<span></span>
</td>
<td class="nump">32,684<span></span>
</td>
<td class="nump">7,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="nump">316<span></span>
</td>
<td class="num">(11,424)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(309,851)<span></span>
</td>
<td class="num">(306,735)<span></span>
</td>
<td class="num">(314,248)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pacb_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">154,014<span></span>
</td>
<td class="nump">200,521<span></span>
</td>
<td class="nump">128,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">116,732<span></span>
</td>
<td class="nump">147,741<span></span>
</td>
<td class="nump">79,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">134,922<span></span>
</td>
<td class="nump">187,170<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">87,244<span></span>
</td>
<td class="nump">79,287<span></span>
</td>
<td class="nump">84,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">87,773<span></span>
</td>
<td class="nump">90,531<span></span>
</td>
<td class="nump">76,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment charges</a></td>
<td class="nump">184,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Merger-related expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,042<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(850)<span></span>
</td>
<td class="nump">15,060<span></span>
</td>
<td class="nump">2,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">18,006<span></span>
</td>
<td class="nump">6,157<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,033<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Gain on debt restructuring</a></td>
<td class="num">(154,407)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">10,371<span></span>
</td>
<td class="nump">18,341<span></span>
</td>
<td class="num">(7,052)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="nump">316<span></span>
</td>
<td class="num">(11,424)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (309,851)<span></span>
</td>
<td class="num">$ (306,735)<span></span>
</td>
<td class="num">$ (314,248)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 60<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481408/470-60-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pacb_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pacb_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 154,014<span></span>
</td>
<td class="nump">$ 200,521<span></span>
</td>
<td class="nump">$ 128,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AmericasMember', window );">Americas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">78,711<span></span>
</td>
<td class="nump">105,410<span></span>
</td>
<td class="nump">69,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">Europe, Middle East, and Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">34,594<span></span>
</td>
<td class="nump">40,658<span></span>
</td>
<td class="nump">22,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia-Pacific</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">40,709<span></span>
</td>
<td class="nump">54,453<span></span>
</td>
<td class="nump">36,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 75,300<span></span>
</td>
<td class="nump">$ 100,500<span></span>
</td>
<td class="nump">$ 66,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AmericasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AmericasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 154,014<span></span>
</td>
<td class="nump">$ 200,521<span></span>
</td>
<td class="nump">$ 128,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">136,149<span></span>
</td>
<td class="nump">183,872<span></span>
</td>
<td class="nump">108,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_InstrumentMember', window );">Instrument revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">65,776<span></span>
</td>
<td class="nump">120,451<span></span>
</td>
<td class="nump">48,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ConsumableMember', window );">Consumable revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">70,373<span></span>
</td>
<td class="nump">63,421<span></span>
</td>
<td class="nump">59,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember', window );">Service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 17,865<span></span>
</td>
<td class="nump">$ 16,649<span></span>
</td>
<td class="nump">$ 19,605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_InstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_InstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ConsumableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ConsumableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 07, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments to acquire intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_OperatingLeaseExpectedBaseRentExpense', window );">Operating lease, base rent expense</a></td>
<td class="nump">$ 97,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount', window );">Lease base rent abatement</a></td>
<td class="nump">11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="nump">7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments to acquire intangible assets</a></td>
<td class="nump">$ 9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Base Rent Abatement, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_OperatingLeaseExpectedBaseRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Expected Base Rent, Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_OperatingLeaseExpectedBaseRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>124
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  !$<5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    (  !$<5H@^?1N]    "L"   1
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MY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @  $1Q6G9!#D$H"   (S$  !@
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M@)TL?FFO^%JC'8;>,QBY&7Q7/M.B4DDPQJLC53M%=)D<*AN<=9XX[)0346+
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M: %7 7\DFQN4+:@C_5P2L.0_V*2QG9X"W!7C),S$HH(01^DG?,E [ AT\X#
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MJOZZE/%,%@H _Y_G>?7^H'[@<&%X]%]02P,$%     @  $1Q6JZG)IFA"
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M0S%LJ@'(+_AU&TKX<0O\90>_\,"V53NNX"A& &91U;=P6JXN@OOK"*/Y=EW
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M?]S2546Y Z HW7CT(YQNC[SQDG[@&TM@P+U?*,YW!:^?L#M'8-S%:J19=]U
M&-2<6/H&EK-PKN5MPN)A7#XF1+8&"*!WYT-WKK^%*@*NF(X!P5^U0BL@C!%C
M"?*XB#BZ@8YNIUIX1%29\-8#2FX1Q15G"V0E:9[BMNH]<V]&)L+^P@=$_R5L
M:V"> *L08((FT=3_%F#4,,PSD /27; K0#QG@8U\8N^'#0U%0\2%$:(1P<DJ
M<4:!2UF _&C#LO>[@?_&I]W.RWU>>YI"J;%:5K4#K*3'U\"9^A8Y@V%<\&@8
M_,#'7^)J8  28(,+@QX[RAT/9]=4BP[6U_4>UR#'LX0185(XL7$!.%UL7-7
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MORZEY05X/S?&=S=\P/I3V\6_ 5!+ P04    "   1'%:DU>L.I@-  #3*0
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M"C8PN)P)WPLGH?B05S(1O@]7@+%]WV>>7N.VQ^(RBNJT3B2I,%;P\4A+)O8
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M8/I"W0"*6+?IZ ,63Q"Q%-=9+1.XABR;W*$+7(CEK3MAE60UXPF02G.$X[H
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M$M=ZDP$:1)(*2(E.?&?\MZ;\:VU\E\$F(@HJ#A .E7"/,FN,T@D *4RWW9%
M($!8&WXP&O]@7;UWC?+8BM._3?I[;J0ICU#FWA@PU8%87JOUV)K.J,.#F57A
MY/8H[:)^ .HB=J5GDX3!AP!0GUH'(:8ZM4M3TC.Y)^S:-$4!@J?S/=9O*?Y
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M]=,W=G&=&(.M5">C.5_+U.<*]?U&N=FETVO#JKWQ9%O;S#O._4E'=O/9@.S
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MEVM^5/F.OX5%@XJ@YT/:DZ@*N@'7UWE>N1^T0/-Q]+/_!5!+ P04    "
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MZ&CA,:)X*HWW  -1-2VUK[&HB-QBM,-XRY-$>F0MNU%P!9]+5()5B7YO. F
M]!/\NEGC(&?!D.PS0Z60P5E3(9X::.I%D"6>JJ9B)6?+-&IGB#1T1)59CB./
ME ;'7A20.VI)%-UD<O12$'3+0>M)61!!'=8.(U]"APC/6W/?X&P B;^F3@J7
M+4/1#M&0PZ'_4BK&V.R3=D+J:<]JA/&<P*2;2L[VA8[D(L!;3X\,$B-J$ 2
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M.QQ&_>4"IW]A: '>IUJ[^H8V:/Z?</X_4$L#!!0    (  !$<5I_HPL([ P
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M[*#!!QV"208NK9[:TD8R+]+0-5[EK@ZNM(6.ID!.E;K.C>(8#@HXHW19"M&
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M,AA,O7#N]W+5#:K!//+&/A_O3[TH0&ZZ.;#6IM!3XF5"568PC4#_RO3!'D!
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M'_A-(+WYMR[H\"W[Z<Y[I7/PVOMJJ5/*$-O8P"^_.G==S3T8?O4\>]S44J0
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M[G<]4'4/6D^,7+N^;R$-=9%NF%/;CLJ^0/M+2>XV$WO [H_ ^&]02P,$%
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M*?C^#/X](GP2P+4 % />R*^B!&X8\*8$5 O-K0#9,%"-P+FE"O-E)<#T13\
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M;PI-!OA\I93=+BC >((]_@=02P,$%     @  $1Q6O6'CX:B P  Q <  !D
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MK>Z>J(NN,[\>[]XW! &)<$CR J:]='22D.W>C&[B31/[]-QX=/TX#'7%-AS
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M&BAO8\=WC@L[4I3*++A)5.,"'D']K+="S]R!DI$*F"2<(0%Y[*S\Y7IAXFW
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MV97%MX.:2JPSE3MM<F'5Y+AW.OQT-OQ(!_B.W[5:N-9G0:J,C;FC+Q?Q<6]
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MFEMXU-@/MZ[&%".*4H]:TU'8KFYGC:,NT$56CU%8T666VX^N!]#5*D2.P3N
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M*;,WG>M=,\@7[2I[635%LZR*.GM'7SI"UZ'/_O?EHA\ZPK?_,P<BV<"3^0V
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M'7PZ#>$-4?\K-\RIA9\S/K./9O&R\ZR$W0,D(3Y,AP0+915##B9V%]^6>#+
M\$D,=*3U54VN?[7CD#T$6[DX^_'E]<O7_.?YCU]YZ_62#5/5.V%EE^/2*0<7
M?::RK>)W,JEF5\]![RI?8#]V4!E*$1U.?;4EHW#/%-TNR-9V0^"YIV0PB%]
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M:^4M >\XQ^Y.L[^R)V%OX26QJ4$\G<%]QKY1-I$TWD 0DL>A3S<]SPI^ ^,
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M<I "\!Q;W1^:]I88C*BQ[-WSOK7I46VNF?/H0K2VN P3MMN[J65Q"$22JX)
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M%0 ?4%)(,DRCR5G^%#]FF_:6]M+E09_SEO84!@/;L !&,T)/3IU>_&7\_ #
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M@!*+;#YA7M(LHA/PAC"U57):C./$,@+8-P/GB\M>M33A]_3WS!MQ7O ;<21
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M -L+<)O<^151A>S<]V@-+M1-Y3H$'Y#TO"Q0K#A8"UM^P/P?BZ+YX!,3<'Q
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M2N. Z[D0>C\Q"0[O_/A?4$L#!!0    (  !$<5HS OIB&P,  (<&   9
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M3D)+.9QGF'9XBQ8O>0 O3N"#DK8P\$IFF/T+$!*YGF&R9[A(CB*^Q/0,AO$
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M52W+3->&)H@OLT?35L]GSWOW]K^0.K8H)+-:V[-A:92?K.$UO(?R8RC?-XW
MF;KQF\;SG1@!XB-.O*C/0G3B3"8>@81#;T(66\L ?>(2J!8OW[".YTP16KX3
M3@, ETAX=7-"-O&WDC8 P3(BU/$#G]P)S7)"*4(5P4@IM9QN,.PCF25)7=2Y
M%47*(< D8Q;L"&$X#4R4Q8$33X/C(4>81. ZH6M"SH^0$;RAD(NZD(L.#KG?
MD#DV69[WQ=<@2G]\7:Q9N8(MH;-5BTS26AK=&!49Y1%N3K_GTK%:V? 78?5"
M4-O3B=G0?#G?2B>">R)*KHN*9=+* 3E6&D)'%+H*7?=G,(&Q-(V1".F0J>/.
MU/'AQY-EA:U?EQI6RE!&D!DRC59]QA_$_:GQK^>W[UA1??K\?[1^&#JNZ[XV
M/CD*7--SB.EI@S%@^4EG^<G!EC?GI.;O35;NL3ZYDJ(@Y[4" B)\EB $56:"
MM=<Q@\N^54@0EJ86\IES'%B=K%GZ(L,RP\ (9=GPSBWO;,>;-;S?,.,+USF$
M/R:\TDW:/]X[K'ZS9<%^IL)!"[P'W$DJ/&F>K$N1B]43_&+""QF.QE.TCI",
M(A<5 H(%:2Q$WKRP-3EH2)[;3*?6685\B;SEFO%P_[M?)A[U/K5YL\$+_2W>
M-'J&-R"!:2>!Z<$2V.WZJK:I?U8(J;._FJ1\^8C;G+(#]]S__I8W9GDMF4VF
MUZVLFL.^3RF#[/J5<@<A\([JLJ'*]JGR'56V1U6V5%^KQ%)ME-16.YG:6V,@
MY"$FXW84FP'N+GB*]MKQ7GNRUY[NVKYKCS2(&_?BI3FF/3]V0O1M%7" LZF[
MN[&Y![L;HI8U=M<ZMM<]PW#]_MGBMEY0?V^AM$!^E!E0C=GN><F7F3:W L1)
M[$;&%5/']^-N=W V3*LTJ=B3N96B.@E0''DH\(-N4-5>- R?(M--&;4-1<^)
MJ+\;*D6*F@<%BTT!30X7"N,1^!0W"\?UGXU>(F%"??"EL4^6M-1SOL*K)<?C
MQ.S-B0*Z=^%@!L!43@[T@%+.)]^9E*S4NR[?H3@& B?"?>:;$1! :!";\HM&
MY)47?C47HW :-C>HV)T,*FKO&P ]6%';PQ6^NVTO3$M<%N:MR=H=9&](;7"=
MX=/<BH5WMS2SZ-9/FV[1U\?W/VV1?_GZM']3?=WIK*&]55:61L3F$H3;J4B-
M::T[($=</BF9M2>::H_YU!QM1BWMQ<DRE%!267,4WJB_R 0%<@SSF0*A48KD
M58Y]-Z(\0MGEA:B,0X=.X^-]0JA:GE%I]+&E-.1L;^=L[V!G-Y*[R=A]EF?&
MO@[.-RG!LM>[@\#]WFU6R/=72)H5_N;+5Y<)BRH73YR3A1;)C^[S YG#QB9^
M')?:VM>)<=8OUCAQWB.Y%"07Z-^FBV#JMK9![%(3H-3;!FC?7BR@9RN[B>-[
M_1\,QGM?Z5! K.RW2)-9ZU(W'^RZM]WWSEGSE6\WO/E8^@5"S*#(G"\QU?T0
MAR,BF^^/S8,6E?WF=R\TJA7;7'.6<FD&H'\IA-X^F 6ZK\!G_P502P,$%
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MC6HRTRA>K8%5.<Q1,(,Y3"TSN.&HX9_IDJR(*O\>*X$_(#U^@)7/M:Y9AN.
M]*%1/6,P^?@A'D8W)\)/N_#34^B31Y)CW@@$N8('A9\6[ 4.4YH53*U1'PO\
M-/1T*TF+;0H$"O^3(7QU@)]Y?& *@6E824&*UM=PSBORDHVFFNH+^(%,>1(
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MHL"BS:LI: .%5>7F?W,%RIH6\TUIH6D4D*"Q9H]&]F;9DLE,'<.A,M>M(*]
MS\1"L2I37?AM48ZXA,^V<'AVQ!ZYQ#X -PNM-+(8NTP#IIY;QE7Z*1#J>(3
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M-N#[C4#OFHDQT/X5F/\%4$L#!!0    (  !$<5KLYPQ">@4  $T,   9
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M#%XX&%RHJL( G GKF"^MR9P  *LU*6*(.4N3',(05SE,K!+OKD5);8FV,EX
M\2:)($)^QLFFH^SUO62O[R9[?3\AUZ:^S6&)?6D5I?S68>9M'R,,V5Z6[$<X
MB>L:H\-@+^!\/WE>DZM[:;J?;S]AZ(SOK$\^<O+'R%&H_#-:JU/ &-7!2OHK
M2_VTOX-3:<^I]/]PZA3/M]#FZ34B[01\?=CM8E>Y,?6+*#5MJ5'X]K(U@BQ*
ML..F/JD<\T_IC8EKA:_DKJ&;3"^>49N(((VPY@-("E;DG"9JA>WG>9YX!A78
M3"*69S@G>,[2HL );.Y5*7W&M.]%O4;&<IP+.(=2TBM8RI-_C;3=1'PMV^,7
M5[R&Q@)=9"TV]*YUZ]M>_[6_*T_65\1G\?5%^P*'CFHMU'*.JGP_PX9AUI?7
M]<+IE;\PSK3#ZZ=_7>)]7QH2P/VYUFZ[( /]/XCC?P!02P,$%     @  $1Q
M6J"(O8)[!   _Q\  !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&ULO9EM
M;^HV%,>_BI5)TR9U#0E/;0=(E#PLTKV H'>3-NV%"0:L)C&S#=Q*^_"SDQ (
M"EFY]ZAO2NSD_SLQ_G..:_<.C+^*#2$2?8VC1/2-C93;)],4X8;$6-RS+4G4
MG17C,9:JR=>FV'*"EZDHCDR[T>B8,::),>BE?5,^Z+&=C&A"IAR)71QC_O9,
M(G;H&Y9Q[)C1]4;J#G/0V^(UF1/Y93OEJF46E"6-22(H2Q GJ[XQM)Y\JZ4%
MZ1._4W(09]=(#V7!V*MN!,N^T=!O1"(22HW ZF-/1B2*-$F]QS\YU"AB:N'Y
M]9'NI8-7@UE@048L^H,NY:9O/!AH259X%\D9._Q&\@&U-2]DD4C_HD/V;%=%
M#'="LC@7JW9,D^P3?\V_B#.!U;DBL'.!?2EH71$T<T'S4O!X1=#*!:T+@6U?
M$;1S0?N]K]3)!9WW"KJYH)M.5O;MIE/C8(D'/<X.B.NG%4U?I/.;JM6,T$1;
M<2ZYNDN53@XF,W\X#OX<O@23,1J.'30/_''@!:/A^ 4-1Z/)E_%+,/;1=/(I
M& 7N_!<TQIQC[1_TDT,DII'XN6=*]2H::(9YV.<LK'TEK&6CSRR1&X'<9$F6
M98"IQE ,Q#X.Y-FN)3HDO$=-ZP[9#;M5\4*C[Y,[-\C1+J&R@N'>PA!DK7[Q
M51CO_9AFA=Q_O]RNF9=F8;!FRFM>X<VS'(<F*S2GZX2N:(@3B89AR':)I,D:
M35E$0TH$^NN3TJ) DEC\766I+%"K.I#.V4]BBT/2-U12%H3OB3'X\0>KT_BU
MR@Z0, <2YD+"/$B8#P0K^:A5^*A51Q^,=_&"<,16J@!N&9=X$9'CCT14N:46
M=ZM;(&%.!NND,+U4V ^LGKD_M\#_/N%!OI /!"O-:[N8UW;MO$XY6^Y"B0ZZ
MK"3R#6T)IVQ9-:/U( N]$<RK)J]6=^OD0<)<2)@'"?.!8"5+= I+=&IG<HXC
M50UF9$^2';E#8[4@_Q>-TK60R@ 352/.FB.6A"H%Z"6)6MG.J'BMLDYMP%N3
M 23,@82YD# /$N8#P4I^ZA9^ZG[4$J0+Z2-(F ,)<R%A'B3,!X*5?/10^.BA
M-B^54PU7J>9.5RO=I_YKK[)++>]6NT#"'$B8"PGS(&%^!K,:9RNIQOUI+56R
MP6-A@\=:&^1Y0U>HD-!]NA#]WOI4&_%6HT#"'$B8"PGS(&$^$*QD**MQVH1I
M?%2%RB,!60F4YH#27%":!TKSH6AE/YUMZEG E:H>>+-M(&D.*,T%I7DY[6J%
MR>T %+-L!_MD!_L;*I:CZI.0-"QJE;B];M4'OMDVD#0'E.:"TCQ0F@]%*]OK
MM,-K?=@6KP6ZQPM*<T!I+BC- Z7Y4+2RGTX[O5;]5N\W5"_0S=Z<=I'3FYUR
M4G= @[J@-*]Z"*W'R[H$NO-KGAU#JA*R3D^8!4JS0':05_1FI]C/^A1;'V->
M] ^MIV%ZIFN>,-G1^&?,US01*"(KA6S<=]N&,DAZVIPU)-NFAYT+)E4=2R\W
M!"\)UP^H^RO&Y+&A Q1G_H/_ %!+ P04    "   1'%:GQ':L; #  #*%
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M>(%1! G,E*&@^NL)QI DADGK^+DB]:K?-,#-\9K]O%R\7LP#E3#FR6<6J?G
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MYJ1C%T(>"/%#,S"7!MUWI68"J[PWM)OO:\(WA*O)%F&IDG>>J7%1Q@1,R"8
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MODH'>'5GK2J2Y>4M[I%)=2<LBXFZYP/7'=3S'6/RN:(OALT_!\'_4$L#!!0
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M;)A>G&ORG(HS(RHV:&.CA:QW$!2246KR<R Y).>ND)Q#(1FJQE!JLFD<DG/
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M >_I+J:'WY-BG(8HSU?HQ;DFS\F[H,G;[G60%K/>1=#C<I2:;"0G^L*UH;N
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M.2< /'ZV9& P7-(@AFF6YIR\P.":V9*\"%_S]BYV^B16CL'D1B8+Y.\\@3+
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MDQBHT0:E$2B:.8]66VULM]H'(VLOU[8;@-)\4!J!HID*U#8<NR?(4AC2]<Y
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MP2BT-"TDS)3"GI?IDU((1L'$V^]Y/FQ[GK==SV-5 LES5@*2ED%I#$KC4)J
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M#"V80VD"2I,HFBDN;>J/?]!)S#3766A0@[^G^?'^ .5RY(?CP[.8H>5R*$U
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M7OEZE%QO)%MDT]B8237;9<NY&K^!ZP!U?\I4@><;/> 5 WWK'U!+ P04
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MJ]?/[']DXI68#1&P8/%?42CW4V-DH!"V)(WE SO]"86@@>8+6"RR7W0JL-A
M02HD2XI@E4$2T?R?/!5&5 (LKR/ +@+L>H#;$> 4 <YK ]PBP,V<R:5D/OA$
MDMF$LQ/B&JW8]$5F9A:MY$=4K_M:<G4W4G%RMKB[_;I\>%S-/RW1>GF[NGM
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M4IU',=<=U/,Y8_*MH4\\U0EW\!]02P,$%     @  $1Q6HW)^+![!   8Q8
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M-P-3 'E_3JG8+M0#JDD\^ =02P,$%     @  $1Q6O;!O4_+ P  RPT  !D
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M+3>"TF(HC:)HNK94R'YD#]E_:"9\5\ZGPKG9SOB6H[RF^3-*#!J,A])"*(U
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MW^W/G"]%71?+YML%2W@3*Q+PW]\51;W]013P6)1?FVI?_Q]02P,$%     @
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M%[=?IW]^^OK9F\T7[][T3>Q^1+-O=]>W?Z-SM)"K+-C$@.@2+03U'\XG4N(
M36DBUQTG6>9FC^H>T'L/!(EB_D$ZWBT\]/[M!_0612FZ#>F&DS3@0UW(B-5S
M=;^(;I)'9YZ(#IOH"TU%R-$L#2"H ^B2:LG7?.([,5L1/? OD(7/D&F8=D-
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MC;G^C[:%K6.A^9H+FA1@Z4%"TOP3OQ2!. )X[1J 5P"\<P%^ ?"K@* &$!0
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M(>Z_=14W=JBO-K]--K\MMJ+Y^_85O[!_?;Z*FXGL6N3X:*1_##(UPCPX1(N
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M*X0&#!NP1J^1W<PVD$0N6B!MC;A;/PS[P$AGBZA$JB1EI_^^1TI1+4<V,D#
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MSDW#"AP2UUT&]0Y)_O9-/(B^'#/YG\C^,)[VQM/7V//YMEZA!K5V7>FMLY5
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M:E?B2M.@@+U:'7CN1V/&BB=N]O&I;@9:LFQ1J8"QWI?UAE,UI]0B<,)%M>N
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M<8#;!$"@UA)!FP$$-$R[6E,+!?R64C!^@9DU;6TA0$;.)+N*Q;UF2_:5K3F
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MNZ:0>:O1S;#(\2;/T7XE1VB#"4W%BH-1&N&H2F#*@LNJ[7W5-W8C8X##*^#
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MY!2PO &6GPBZSEI"SU3(=9<=KC"*,%,!\OZ"4K$_40.4;<C^_U!+ P04
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MFT<;R#"_H#D0^69%68:%;+*US7,&.-:B++4]QQG:&4Z(%8SULVL6C&DATH3
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M7"<"KQ."G0C$3DAV(C [(=J)0.V$;"<"MQ/"G0CD3DAW(K [(=Z)0&]!O85
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MPP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @  $1Q6IE<G",0!@
MG"<  !,              ( !Y@$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    "   1'%:=D$.02@(   C,0  &               @($G"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @  $1Q6K =$V,\ @
MO04  !@              ("!A1   'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    (  !$<5HS%JQ6CP8  &$=   8              " @?<2
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "   1'%:A%\Q
MA6P#  #M#P  &               @(&\&0  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @  $1Q6H#N!(1["   /"P  !@
M ("!7AT  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (  !$
M<5JNIR:9H0@  /Q    8              " @0\F  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    "   1'%:E4@$UYH,  #)2   &
M        @('F+@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @  $1Q6I2T=DXQ*0  OX4  !@              ("!MCL  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (  !$<5JT&C<SZ0<  '83   8
M              " @1UE  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    "   1'%:DU>L.I@-  #3*0  &0              @($\;0  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (  !$<5IO 6U&!Q(
M "@]   9              " @0M[  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @  $1Q6E93].XI$P  P%0  !D              ("!
M28T  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "   1'%:
M@8@P0&,&  !;$   &0              @(&IH   >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    (  !$<5I_HPL([ P  +$B   9
M      " @4.G  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @  $1Q6AE5*#P'#0  )"4  !D              ("!9K0  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "   1'%:WT&4(VT1   P-
M&0              @(&DP0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    (  !$<5J/:+'&L 0  !0,   9              " @4C3  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @  $1Q6GB<<O.\
M!@  S0X  !D              ("!+]@  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    "   1'%:]8>/AJ(#  #$!P  &0
M@($BWP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (  !$
M<5K2;(6(8@(  (@&   9              " @?OB  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @  $1Q6BQU:+Y# @  B@8  !D
M         ("!E.4  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    "   1'%:/*4S.!$"  #=!   &0              @($.Z   >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (  !$<5I(4^_^90H  "\L
M   9              " @5;J  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @  $1Q6AY+4<RH)P  2XL  !D              ("!\O0
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "   1'%:K-]Z
MB:D#  #S!P  &0              @('1' $ >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    (  !$<5HS OIB&P,  (<&   9
M  " @;$@ 0!X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
M $1Q6E!DDV(_!@  $A4  !D              ("! R0! 'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    "   1'%:8<C=9:P'   1%@  &0
M            @(%Y*@$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    (  !$<5IT/F&$UP,  (L*   9              " @5PR 0!X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @  $1Q6F%&+FK% P
M^0@  !D              ("!:C8! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    "   1'%:;:&6&S8#  #U!@  &0              @(%F
M.@$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (  !$<5II
M*@JI408  -<0   9              " @=,] 0!X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @  $1Q6B.XL;9U!0  ! \  !D
M     ("!6T0! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  !$<5I6.VB(5@8  .DH   9              "
M@0E= 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @  $1Q
M6@8XG6JF P  11   !D              ("!EF,! 'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    "   1'%:8&HSY]H-  !^GP  &0
M        @(%S9P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   (  !$<5HX,"/BFP8  &HV   9              " @81U 0!X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @  $1Q6DTO2)R) P  < T
M !D              ("!5GP! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    "   1'%:P Y8DP@'  #A+P  &0              @($6@ $
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (  !$<5J\C4(=
MB@(  (H%   9              " @56' 0!X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @  $1Q6FAU[M;I @  .P@  !D
M ("!%HH! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "
M1'%:)EV[P$($  "S%@  &0              @($VC0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (  !$<5H@,N/3%PP  -:,   9
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M970U,2YX;6Q02P$"% ,4    "   1'%:E/Q+#& #  !0"@  &0
M    @($EJP$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (
M  !$<5I)L4"+,@,  # (   9              " @;RN 0!X;"]W;W)K<VAE
M971S+W-H965T-3,N>&UL4$L! A0#%     @  $1Q6@ZB[N>X @  $P<  !D
M             ("!);(! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"
M% ,4    "   1'%:MJC(W 42   "]   &0              @($4M0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (  !$<5I#PO/O.P,
M -P+   9              " @5#' 0!X;"]W;W)K<VAE971S+W-H965T-38N
M>&UL4$L! A0#%     @  $1Q6HA<HCBA P  D@X  !D              ("!
MPLH! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "   1'%:
MM@LTO5T$   .%P  &0              @(&:S@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4X+GAM;%!+ 0(4 Q0    (  !$<5JZZSA!ZP,  . 1   9
M      " @2[3 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%
M  @  $1Q6KF; )B< P  '@X  !D              ("!4-<! 'AL+W=O<FMS
M:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    "   1'%:E0R<WKL#  #M#@
M&0              @($CVP$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+
M 0(4 Q0    (  !$<5J-R?BP>P0  &,6   9              " @17? 0!X
M;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @  $1Q6F""/($Z
M!0  BQX  !D              ("!Q^,! 'AL+W=O<FMS:&5E=',O<VAE970V
M,RYX;6Q02P$"% ,4    "   1'%: .;_^UD#  "5"P  &0
M@($XZ0$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (  !$
M<5KVP;U/RP,  ,L-   9              " @<CL 0!X;"]W;W)K<VAE971S
M+W-H965T-C4N>&UL4$L! A0#%     @  $1Q6B.1E&A9!   R0X  !D
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M=#<P+GAM;%!+ 0(4 Q0    (  !$<5I13XHJ^P,  %L3   9
M  " @3X3 @!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @
M $1Q6F0#1^PS!   WA   !D              ("!<!<" 'AL+W=O<FMS:&5E
M=',O<VAE970W,BYX;6Q02P$"% ,4    "   1'%:Y$W%BGT$   J%@  &0
M            @(':&P( >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4
M Q0    (  !$<5JFY$U[6P4  %H=   9              " @8X@ @!X;"]W
M;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @  $1Q6E]T6TM3 P
M;0P  !D              ("!("8" 'AL+W=O<FMS:&5E=',O<VAE970W-2YX
M;6Q02P$"% ,4    "   1'%:V;Y\]3T"   3!0  &0              @(&J
M*0( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    (  !$<5K"
M3UFAC08  !T@   9              " @1XL @!X;"]W;W)K<VAE971S+W-H
M965T-S<N>&UL4$L! A0#%     @  $1Q6KUG2=0>!   DA0  !D
M     ("!XC(" 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4
M"   1'%:,C+O8PH$  "5%   &0              @($W-P( >&PO=V]R:W-H
M965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    (  !$<5IMG!_*?P,  ',0   9
M              " @7@[ @!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L!
M A0#%     @  $1Q6ID1Z+!Q P  7Q@   T              ( !+C\" 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "   1'%:EXJ[',     3 @  "P
M        @ '*0@( 7W)E;',O+G)E;'-02P$"% ,4    "   1'%:YHV#TL8%
M  #V-   #P              @ &S0P( >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @  $1Q6K3%"JYH @  1R\  !H              ( !IDD" 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @  $1Q6BP!9SL; @
M#BX  !,              ( !1DP" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     %@ 6  ?&   DDX"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>346</ContextCount>
  <ElementCount>510</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>98</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - BUSINESS ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONS</Role>
      <ShortName>BUSINESS ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - BALANCE SHEET COMPONENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS</Role>
      <ShortName>BALANCE SHEET COMPONENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - CONVERTIBLE SENIOR NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - RESTRUCTURING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/RESTRUCTURING</Role>
      <ShortName>RESTRUCTURING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHARE</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - BUSINESS ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTables</Role>
      <ShortName>BUSINESS ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONS</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables</Role>
      <ShortName>BALANCE SHEET COMPONENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - CONVERTIBLE SENIOR NOTES (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - RESTRUCTURING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/RESTRUCTURINGTables</Role>
      <ShortName>RESTRUCTURING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/RESTRUCTURING</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/INCOMETAXES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/NETLOSSPERSHARE</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES- Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES- Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of The Major Classes of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of The Major Classes of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - BUSINESS ACQUISITIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails</Role>
      <ShortName>BUSINESS ACQUISITIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - BUSINESS ACQUISITIONS - Schedule of Business Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails</Role>
      <ShortName>BUSINESS ACQUISITIONS - Schedule of Business Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofGoodwillDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Finite Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Finite Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Other Liabilities, Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Other Liabilities, Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - CONVERTIBLE SENIOR NOTES - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails</Role>
      <ShortName>RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - RESTRUCTURING - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails</Role>
      <ShortName>RESTRUCTURING - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails</Role>
      <ShortName>RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - INCOME TAXES - Schedule of Components of Income Tax Provision (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Components of Income Tax Provision (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Federal Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Reconciliation of Federal Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Reconciliation of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Unrecognized Tax Benefit Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofUnrecognizedTaxBenefitAccountsDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Reconciliation of Unrecognized Tax Benefit Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - STOCKHOLDERS??? EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Time-Based RSUs Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Time-Based RSUs Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Fair Value of Employee Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Fair Value of Employee Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="pacb-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>80</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="pacb-20241231.htm">pacb-20241231.htm</File>
    <File>pacb-20241231.xsd</File>
    <File>pacb-20241231_cal.xml</File>
    <File>pacb-20241231_def.xml</File>
    <File>pacb-20241231_lab.xml</File>
    <File>pacb-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pacb-20241231_g1.jpg</File>
    <File>pacb-20241231_g2.jpg</File>
    <File>pacb-20241231_g3.gif</File>
    <File>pacb-20241231_g4.jpg</File>
    <File>pacb-20241231_g5.jpg</File>
    <File>pacb-20241231_g6.jpg</File>
    <File>pacb-20241231_g7.jpg</File>
    <File>pacb-20241231_g8.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1282">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>131
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pacb-20241231.htm": {
   "nsprefix": "pacb",
   "nsuri": "http://www.pacificbiosciences.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "pacb-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "pacb-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "pacb-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pacb-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pacb-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pacb-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 442,
   "keyCustom": 68,
   "axisStandard": 31,
   "axisCustom": 1,
   "memberStandard": 50,
   "memberCustom": 40,
   "hidden": {
    "total": 10,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 4,
    "http://www.pacificbiosciences.com/20241231": 2
   },
   "contextCount": 346,
   "entityCount": 1,
   "segmentCount": 98,
   "elementCount": 871,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1282,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.pacificbiosciences.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.pacificbiosciences.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "longName": "9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSoldAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "9952154 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-16",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-16",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "9952156 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONS",
     "longName": "9952157 - Disclosure - BUSINESS ACQUISITIONS",
     "shortName": "BUSINESS ACQUISITIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS",
     "longName": "9952158 - Disclosure - FINANCIAL INSTRUMENTS",
     "shortName": "FINANCIAL INSTRUMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS",
     "longName": "9952159 - Disclosure - BALANCE SHEET COMPONENTS",
     "shortName": "BALANCE SHEET COMPONENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES",
     "longName": "9952160 - Disclosure - CONVERTIBLE SENIOR NOTES",
     "shortName": "CONVERTIBLE SENIOR NOTES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.pacificbiosciences.com/role/RESTRUCTURING",
     "longName": "9952161 - Disclosure - RESTRUCTURING",
     "shortName": "RESTRUCTURING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "9952162 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.pacificbiosciences.com/role/INCOMETAXES",
     "longName": "9952163 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITY",
     "longName": "9952164 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHARE",
     "longName": "9952165 - Disclosure - NET LOSS PER SHARE",
     "shortName": "NET LOSS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION",
     "longName": "9952166 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTS",
     "longName": "9952167 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9955511 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9955512 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R26": {
     "role": "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTables",
     "longName": "9955513 - Disclosure - BUSINESS ACQUISITIONS (Tables)",
     "shortName": "BUSINESS ACQUISITIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables",
     "longName": "9955514 - Disclosure - FINANCIAL INSTRUMENTS (Tables)",
     "shortName": "FINANCIAL INSTRUMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables",
     "longName": "9955515 - Disclosure - BALANCE SHEET COMPONENTS (Tables)",
     "shortName": "BALANCE SHEET COMPONENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables",
     "longName": "9955516 - Disclosure - CONVERTIBLE SENIOR NOTES (Tables)",
     "shortName": "CONVERTIBLE SENIOR NOTES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.pacificbiosciences.com/role/RESTRUCTURINGTables",
     "longName": "9955517 - Disclosure - RESTRUCTURING (Tables)",
     "shortName": "RESTRUCTURING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables",
     "longName": "9955518 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "pacb:LesseeOperatingLeaseDescriptionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "pacb:LesseeOperatingLeaseDescriptionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.pacificbiosciences.com/role/INCOMETAXESTables",
     "longName": "9955519 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables",
     "longName": "9955520 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables",
     "longName": "9955521 - Disclosure - NET LOSS PER SHARE (Tables)",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables",
     "longName": "9955522 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "longName": "9955523 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES- Narrative (Details)",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES- Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "unit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "pacb:StandardProductWarrantyPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails",
     "longName": "9955524 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of The Major Classes of Property and Equipment (Details)",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of The Major Classes of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-71",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-71",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
     "longName": "9955525 - Disclosure - BUSINESS ACQUISITIONS - Narrative (Details)",
     "shortName": "BUSINESS ACQUISITIONS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails",
     "longName": "9955526 - Disclosure - BUSINESS ACQUISITIONS - Schedule of Business Acquisition (Details)",
     "shortName": "BUSINESS ACQUISITIONS - Schedule of Business Acquisition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-78",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "9955527 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "pacb:ShortTermRestrictedCashFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "pacb:ShortTermRestrictedCashFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
     "longName": "9955528 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentIncomeNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails",
     "longName": "9955529 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-160",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails",
     "longName": "9955530 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RestrictedCashCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-171",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails",
     "longName": "9955531 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails",
     "longName": "9955532 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Inventory (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails",
     "longName": "9955533 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Property and Equipment, Net (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
     "longName": "9955534 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "pacb:GoodwillImpairmentDiscountedCashFlowModelDiscountRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofGoodwillDetails",
     "longName": "9955535 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Goodwill (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails",
     "longName": "9955536 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-196",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
     "longName": "9955537 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails",
     "longName": "9955538 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Finite Lives (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Finite Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails",
     "longName": "9955539 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Accrued Expenses (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails",
     "longName": "9955540 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ProductWarrantyAccrual",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-29",
      "name": "us-gaap:ProductWarrantyAccrual",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails",
     "longName": "9955541 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Other Liabilities, Current (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Other Liabilities, Current (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
     "longName": "9955542 - Disclosure - CONVERTIBLE SENIOR NOTES - Narrative (Details)",
     "shortName": "CONVERTIBLE SENIOR NOTES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "pacb:PaymentsInConjunctionWithNotesExchange",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-213",
      "name": "pacb:HoldingPeriodForTransferAssignmentOrSaleOfFounderShares",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails",
     "longName": "9955543 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)",
     "shortName": "CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-233",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-233",
      "name": "us-gaap:DebtInstrumentUnamortizedPremium",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
     "longName": "9955544 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)",
     "shortName": "CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-235",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-235",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
     "longName": "9955545 - Disclosure - RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details)",
     "shortName": "RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-251",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
     "longName": "9955546 - Disclosure - RESTRUCTURING - Narrative (Details)",
     "shortName": "RESTRUCTURING - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails",
     "longName": "9955547 - Disclosure - RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)",
     "shortName": "RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsForRestructuring",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails",
     "longName": "9955548 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:LesseeOperatingLeaseDescriptionTableTextBlock",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:LesseeOperatingLeaseDescriptionTableTextBlock",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "longName": "9955549 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails",
     "longName": "9955550 - Disclosure - INCOME TAXES - Narrative (Details)",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "pacb:ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "pacb:ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails",
     "longName": "9955551 - Disclosure - INCOME TAXES - Schedule of Components of Income Tax Provision (Benefit) (Details)",
     "shortName": "INCOME TAXES - Schedule of Components of Income Tax Provision (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails",
     "longName": "9955552 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Federal Income Tax Rate (Details)",
     "shortName": "INCOME TAXES - Schedule of Reconciliation of Federal Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9955553 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "INCOME TAXES - Schedule of Reconciliation of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofUnrecognizedTaxBenefitAccountsDetails",
     "longName": "9955554 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Unrecognized Tax Benefit Accounts (Details)",
     "shortName": "INCOME TAXES - Schedule of Reconciliation of Unrecognized Tax Benefit Accounts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "longName": "9955555 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails",
     "longName": "9955556 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Stock Option Activity (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-271",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-271",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails",
     "longName": "9955557 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Time-Based RSUs Activity (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Time-Based RSUs Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-279",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-277",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails",
     "longName": "9955558 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-290",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-290",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
     "longName": "9955559 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Fair Value of Employee Stock Options (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Fair Value of Employee Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-302",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails",
     "longName": "9955560 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-311",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails",
     "longName": "9955561 - Disclosure - NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails",
     "longName": "9955562 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details)",
     "shortName": "NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-318",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-318",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails",
     "longName": "9955563 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "unit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R77": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails",
     "longName": "9955564 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-324",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails",
     "longName": "9955565 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-327",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails",
     "longName": "9955566 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-339",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTSDetails",
     "longName": "9955567 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-345",
      "name": "pacb:OperatingLeaseExpectedBaseRentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "pacb_A2020PlanInducementPlanAndTheOmniomePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "A2020PlanInducementPlanAndTheOmniomePlanMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Plan, Inducement Plan, And The Omniome Plan",
        "label": "2020 Plan, Inducement Plan, And The Omniome Plan [Member]",
        "documentation": "2020 Plan, Inducement Plan, And The Omniome Plan"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_A2028ConvertibleSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "A2028ConvertibleSeniorNotesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028 Convertible Senior Notes",
        "label": "2028 Convertible Senior Notes [Member]",
        "documentation": "Convertible Senior Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_A2029ConvertibleSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "A2029ConvertibleSeniorNotesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029 Convertible Senior Notes",
        "label": "2029 Convertible Senior Notes [Member]",
        "documentation": "2029 Convertible Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_A2029NotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "A2029NotesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029 Notes",
        "label": "2029 Notes [Member]",
        "documentation": "2029 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_A2030ConvertibleSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "A2030ConvertibleSeniorNotesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030 Convertible Senior Notes",
        "label": "2030 Convertible Senior Notes [Member]",
        "documentation": "2030 Convertible Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r916"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "AccruedEmployeeStockPurchasePlanLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Employee Stock Purchase Plan",
        "label": "Accrued Employee Stock Purchase Plan Liability, Current",
        "documentation": "Accrued Employee Stock Purchase Plan Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "pacb_AccruedProductDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "AccruedProductDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued product development costs",
        "label": "Accrued Product Development Costs, Current",
        "documentation": "Accrued Product Development Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional services and legal fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "pacb_AccruedTenantImprovementsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "AccruedTenantImprovementsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest payable",
        "label": "Accrued Tenant Improvements, Current",
        "documentation": "Accrued Tenant Improvements, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r183",
      "r726"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r99",
      "r188",
      "r722",
      "r762",
      "r763"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13",
      "r23",
      "r589",
      "r592",
      "r638",
      "r758",
      "r759",
      "r1085",
      "r1086",
      "r1087",
      "r1101",
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "pacb_AchievementOfMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "AchievementOfMilestoneMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of Milestone",
        "label": "Achievement Of Milestone [Member]",
        "documentation": "Upon achievement of a milestone."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "pacb_AdditionalGoodwillImpairmentChangeInDiscountRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "AdditionalGoodwillImpairmentChangeInDiscountRate",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional goodwill impairment",
        "label": "Additional Goodwill Impairment, Change In Discount Rate",
        "documentation": "Additional Goodwill Impairment, Change In Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "AdditionalIntangibleAssetImpairmentChangeInDiscountRate",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional intangible asset impairment, change in discount rate",
        "label": "Additional Intangible Asset Impairment, Change In Discount Rate",
        "documentation": "Additional Intangible Asset Impairment, Change In Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_AdditionalIntangibleAssetImpairmentChangeInTerm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "AdditionalIntangibleAssetImpairmentChangeInTerm",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional intangible asset impairment, change in term",
        "label": "Additional Intangible Asset Impairment, Change In Term",
        "documentation": "Additional Intangible Asset Impairment, Change In Term"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "AdditionalLiabilityAssociatedWithIndemnificationObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional liability associated with indemnification obligations",
        "label": "Additional Liability Associated With Indemnification Obligations",
        "documentation": "Additional Liability Associated With Indemnification Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r916",
      "r1265"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r773",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1203",
      "r1266"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_AdjustmentForAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentForAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Amortization",
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r492"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r968",
      "r979",
      "r989",
      "r1022"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r971",
      "r982",
      "r992",
      "r1025"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r983",
      "r993",
      "r1017",
      "r1026",
      "r1030",
      "r1038"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r530"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "srt_AmericasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "AmericasMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Americas",
        "label": "Americas [Member]"
       }
      }
     },
     "auth_ref": [
      "r1268",
      "r1269",
      "r1270",
      "r1271"
     ]
    },
    "pacb_AmortizationOfAcquiredIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "AmortizationOfAcquiredIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of acquired intangible assets",
        "label": "Amortization Of Acquired Intangible Assets",
        "documentation": "Amortization Of Acquired Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r452",
      "r1094",
      "r1216"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization of intangible assets",
        "terseLabel": "Amortization of acquired intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r366",
      "r373",
      "r880"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from the computation of earnings per share",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "pacb_AptonAndOmniomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "AptonAndOmniomeMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Apton And Omniome",
        "label": "Apton And Omniome [Member]",
        "documentation": "Apton And Omniome"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_AptonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "AptonMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Apton",
        "label": "Apton [Member]",
        "documentation": "Apton"
       }
      }
     },
     "auth_ref": []
    },
    "srt_AsiaPacificMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "AsiaPacificMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asia-Pacific",
        "label": "Asia Pacific [Member]"
       }
      }
     },
     "auth_ref": [
      "r1268",
      "r1269",
      "r1270",
      "r1271"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r159",
      "r187",
      "r213",
      "r253",
      "r259",
      "r277",
      "r281",
      "r322",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r584",
      "r586",
      "r616",
      "r717",
      "r800",
      "r872",
      "r873",
      "r916",
      "r946",
      "r1161",
      "r1162",
      "r1218"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r191",
      "r213",
      "r322",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r584",
      "r586",
      "r616",
      "r916",
      "r1161",
      "r1162",
      "r1218"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets measured at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r601",
      "r903"
     ]
    },
    "pacb_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.pacificbiosciences.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r952",
      "r975"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.pacificbiosciences.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r952",
      "r975"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.pacificbiosciences.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r952",
      "r975"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value",
        "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r1115",
      "r1116",
      "r1228"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r495",
      "r496",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "pacb_BalanceSheetClassificationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "BalanceSheetClassificationAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Classification",
        "label": "Balance Sheet Classification [Abstract]",
        "documentation": "Balance Sheet Classification [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_BalanceSheetComponentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "BalanceSheetComponentsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Components [Line Items]",
        "label": "Balance Sheet Components [Line Items]",
        "documentation": "Balance Sheet Components [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Consolidation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r577",
      "r897",
      "r898"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r68",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r577",
      "r897",
      "r898"
     ]
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger related transaction costs",
        "label": "Business Acquisition, Transaction Costs",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger-related expenses",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of share consideration",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1"
     ]
    },
    "pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "BusinessCombinationConsiderationTransferredRevenueAchievementMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone revenue",
        "label": "Business Combination, Consideration Transferred, Revenue Achievement Milestone",
        "documentation": "Milestone Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of contingent consideration",
        "verboseLabel": "Change in the estimated fair value of contingent consideration",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r1093"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of contingent consideration",
        "verboseLabel": "Contingent consideration",
        "periodStartLabel": "Beginning balance as of December 31, 2023",
        "periodEndLabel": "Ending balance as of December 31, 2024",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r140",
      "r580",
      "r602",
      "r603",
      "r604"
     ]
    },
    "pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anniversary",
        "label": "Business Combination, Contingent Consideration, Liability, Closing Date Period",
        "documentation": "Business Combination, Contingent Consideration, Liability, Closing Date Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rates",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "documentation": "Value of input used to measure contingent consideration liability from business combination."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r603",
      "r604"
     ]
    },
    "pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition, anniversary",
        "label": "Business Combination, Contingent Consideration Liability, Measurement Period",
        "documentation": "Business Combination, Contingent Consideration Liability, Measurement Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration liability, non-current",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r140"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BUSINESS ACQUISITIONS",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r578"
     ]
    },
    "pacb_BusinessCombinationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "BusinessCombinationMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination",
        "label": "Business Combination [Member]",
        "documentation": "Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets, current",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred income tax liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process research and development",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total consideration transferred",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger-related expenses",
        "label": "Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized",
        "documentation": "The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r138"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents at end of period",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r181",
      "r860"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1205",
      "r1206"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents:",
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash, and Investments",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "pacb_CashAndMoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "CashAndMoneyMarketFundsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and money market funds",
        "label": "Cash And Money Market Funds [Member]",
        "documentation": "Cash and money market funds."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_CashCashEquivalentsAndInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "CashCashEquivalentsAndInvestmentsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash, cash equivalents, and investments",
        "label": "Cash Cash Equivalents And Investments [Member]",
        "documentation": "Cash, Cash Equivalents and Investments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r112",
      "r210"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r112"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r420",
      "r940",
      "r941",
      "r942",
      "r943"
     ]
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r1166"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r149",
      "r718",
      "r787"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies [Line Items]",
        "label": "Commitments and Contingencies [Line Items]",
        "documentation": "Commitments and Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies [Table]",
        "label": "Commitments and Contingencies [Table]",
        "documentation": "Commitments and Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, dividends declared (in usd per share)",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r936",
      "r937",
      "r938",
      "r940",
      "r941",
      "r942",
      "r943",
      "r1101",
      "r1102",
      "r1104",
      "r1203",
      "r1264",
      "r1266"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r788"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r90",
      "r788",
      "r806",
      "r1266",
      "r1267"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r721",
      "r916"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting right of common stock share holders",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned": {
     "xbrltype": "positiveIntegerItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "CommonStockVotingRightsNumberOfVotesPerShareOwned",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting right of common stock share holders, number of votes",
        "label": "Common Stock, Voting Rights, Number Of Votes Per Share Owned",
        "documentation": "Common Stock, Voting Rights, Number Of Votes Per Share Owned"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r193",
      "r195",
      "r200",
      "r713",
      "r732",
      "r733"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income (Loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software",
        "verboseLabel": "Software",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r855",
      "r859",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1143",
      "r1144",
      "r1147",
      "r1148"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r72",
      "r73",
      "r288",
      "r843"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r72",
      "r73",
      "r288",
      "r765",
      "r843"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r72",
      "r73",
      "r288",
      "r843",
      "r1064"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration and Other Risks",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r165"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r72",
      "r73",
      "r288"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r72",
      "r73",
      "r288",
      "r843"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ConsumableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "ConsumableMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consumable revenue",
        "label": "Consumable [Member]",
        "documentation": "Consumable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration by Type [Axis]",
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration Type [Domain]",
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477",
      "r480"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, current",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477",
      "r480"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, non-current",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477",
      "r480"
     ]
    },
    "pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "ContractWithCustomerLiabilityNoncurrentRecognitionPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred service revenue, noncurrent, recognition period",
        "label": "Contract with Customer, Liability, Noncurrent, Recognition Period",
        "documentation": "Contract with Customer, Liability, Noncurrent, Recognition Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued purchase commitments",
        "label": "Contractual Obligation, to be Paid, Year One",
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of convertible debt",
        "label": "Convertible Debt, Fair Value Disclosures",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r431",
      "r432",
      "r442",
      "r443",
      "r444",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable upon conversion of convertible senior notes",
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r1166"
     ]
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible senior notes, net, non-current",
        "label": "Convertible Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes payable",
        "label": "Convertible Notes Payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r148",
      "r1232"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r896",
      "r903",
      "r917",
      "r934",
      "r1261"
     ]
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization."
       }
      }
     },
     "auth_ref": [
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of acquired intangible assets",
        "label": "Cost, Amortization",
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cost of revenue",
        "terseLabel": "Cost of revenue",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r213",
      "r322",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r616",
      "r872",
      "r1161"
     ]
    },
    "us-gaap_CostOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenueAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Revenue:",
        "label": "Cost of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_CostOfRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "CostOfRevenueMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost Of Revenue",
        "label": "Cost Of Revenue [Member]",
        "documentation": "Cost Of Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Revenue and Shipping and Handling",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Losses",
        "label": "Credit Loss, Financial Instrument [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r1098"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r288"
     ]
    },
    "pacb_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer One",
        "label": "Customer One [Member]",
        "documentation": "Customer One"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1143",
      "r1144",
      "r1147",
      "r1148"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r1049"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r1049"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r1051"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r1051"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r1053"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r1051"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r1044"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r1045"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r1045"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r954",
      "r1043"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r954",
      "r1043"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r954",
      "r1043"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r957",
      "r1046"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r1048"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r1048"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r1049"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r1052"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r961",
      "r1050"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r1047"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt conversion, shares issued (in shares)",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33"
     ]
    },
    "pacb_DebtConversionTermsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "DebtConversionTermsOneMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Conversion Terms One",
        "label": "Debt Conversion Terms One [Member]",
        "documentation": "Debt Conversion Terms One"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DebtConversionTermsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "DebtConversionTermsTwoMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Conversion Terms Two",
        "label": "Debt Conversion Terms Two [Member]",
        "documentation": "Debt Conversion Terms Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONVERTIBLE SENIOR NOTES",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r211",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r419",
      "r420",
      "r430",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r446",
      "r453",
      "r454",
      "r456",
      "r625"
     ]
    },
    "pacb_DebtInstrumentAdditionalInterestInEventOfDefault": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "DebtInstrumentAdditionalInterestInEventOfDefault",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional interest in the event of default",
        "label": "Debt Instrument, Additional Interest in the Event of Default",
        "documentation": "Debt Instrument, Additional Interest in the Event of Default"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r78",
      "r79",
      "r145",
      "r148",
      "r216",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r914",
      "r1096",
      "r1151",
      "r1152",
      "r1153",
      "r1215",
      "r1217"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Principal amount",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r148",
      "r457"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price per share (in dollars per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r433"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, convertible, conversion ratio",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r82",
      "r129",
      "r130",
      "r433"
     ]
    },
    "pacb_DebtInstrumentConvertibleTermsOfConversionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "DebtInstrumentConvertibleTermsOfConversionAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Convertible Terms Of Conversion [Axis]",
        "label": "Debt Instrument, Convertible Terms Of Conversion [Axis]",
        "documentation": "Debt Instrument, Convertible Terms Of Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DebtInstrumentConvertibleTermsOfConversionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "DebtInstrumentConvertibleTermsOfConversionDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Convertible Terms Of Conversion [Domain]",
        "label": "Debt Instrument, Convertible Terms Of Conversion [Domain]",
        "documentation": "Debt Instrument, Convertible Terms Of Conversion [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold consecutive trading days",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold percentage of stock price trigger",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold trading days",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DebtInstrumentDebtDefaultCalendarDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "DebtInstrumentDebtDefaultCalendarDays",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, debt default, calendar days",
        "label": "Debt Instrument, Debt Default, Calendar Days",
        "documentation": "Debt Instrument, Debt Default, Calendar Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount of notes",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r625",
      "r626",
      "r886",
      "r887",
      "r914"
     ]
    },
    "pacb_DebtInstrumentInterestInTheEventOfDefault": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "DebtInstrumentInterestInTheEventOfDefault",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest in the event of default",
        "label": "Debt Instrument, Interest in the Event of Default",
        "documentation": "Debt Instrument, Interest in the Event of Default"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r459",
      "r625",
      "r626",
      "r914"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, stated interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r432"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r455",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r914",
      "r1096",
      "r1215",
      "r1217"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r216",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r914",
      "r1096",
      "r1151",
      "r1152",
      "r1153",
      "r1215",
      "r1217"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid accrued but unpaid interest",
        "label": "Debt Instrument, Periodic Payment, Interest",
        "documentation": "Amount of the required periodic payments applied to interest."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "DebtInstrumentRedemptionPriceConsecutiveTradingDays",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt redemption, consecutive trading days",
        "label": "Debt Instrument, Redemption Price, Consecutive Trading Days",
        "documentation": "Debt Instrument, Redemption Price, Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption price, percentage",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "DebtInstrumentRedemptionPricePercentageOfConversionPrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt redemption, percentage of conversion price",
        "label": "Debt Instrument, Redemption Price, Percentage of Conversion Price",
        "documentation": "Debt Instrument, Redemption Price, Percentage of Conversion Price"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DebtInstrumentRedemptionPriceTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "DebtInstrumentRedemptionPriceTradingDays",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt redemption, trading days",
        "label": "Debt Instrument, Redemption Price, Trading Days",
        "documentation": "Debt Instrument, Redemption Price, Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r57",
      "r58",
      "r74",
      "r128",
      "r130",
      "r216",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r455",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r914",
      "r1096",
      "r1215",
      "r1217"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized debt premium",
        "label": "Debt Instrument, Unamortized Premium",
        "documentation": "Amount, after accumulated amortization, of debt premium."
       }
      }
     },
     "auth_ref": [
      "r1164",
      "r1214",
      "r1215",
      "r1217"
     ]
    },
    "pacb_DebtIssuanceCostLenderFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "DebtIssuanceCostLenderFees",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance cost, lender fees",
        "label": "Debt Issuance Cost, Lender Fees",
        "documentation": "Debt Issuance Cost, Lender Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1124"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1124"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]",
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]",
        "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1098",
      "r1201",
      "r1202"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1215",
      "r1217"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1098",
      "r1201"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r173",
      "r1098"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r146",
      "r555"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1098",
      "r1201",
      "r1202"
     ]
    },
    "pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancellation of indebtedness income and interest expense",
        "label": "Deferred Tax Asset, Cancellation Of Indebtedness Income And Interest Expense",
        "documentation": "Deferred Tax Asset, Cancellation Of Indebtedness Income And Interest Expense"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and experimental expenses",
        "label": "Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Costs",
        "documentation": "Deferred Tax Assets Deferred Expense, Capitalized Research and Development Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets:",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Deferred Tax Assets, Operating Lease Liabilities",
        "documentation": "Deferred Tax Assets, Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1199"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1199"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accruals and reserves",
        "label": "Deferred Tax Assets, Tax Deferred Expense",
        "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances."
       }
      }
     },
     "auth_ref": [
      "r1199"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1199"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "negatedLabel": "Less: Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred tax liabilities, net",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangibles",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r1199"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fixed assets",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1199"
     ]
    },
    "pacb_DeferredTaxLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease right-of-use assets",
        "label": "Deferred Tax Liabilities, Right-of-use Assets",
        "documentation": "Deferred Tax Liabilities, Right-of-use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits, current",
        "label": "Deposits Assets, Current",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits",
        "label": "Deposits Assets, Noncurrent",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r48"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed technology",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1143",
      "r1144",
      "r1147",
      "r1148"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r952",
      "r975"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r952",
      "r975",
      "r1018"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "pacb_DomesticCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "DomesticCustomersMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Customers",
        "label": "Domestic Customers [Member]",
        "documentation": "Domestic Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_EMEAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EMEAMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe, Middle East, and Africa",
        "label": "EMEA [Member]",
        "documentation": "Regions of Europe, Middle East and Africa."
       }
      }
     },
     "auth_ref": [
      "r1268",
      "r1269",
      "r1270",
      "r1271"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in usd per share)",
        "verboseLabel": "Basic net (loss) income per share (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r232",
      "r235",
      "r245",
      "r246",
      "r247",
      "r252",
      "r575",
      "r583",
      "r597",
      "r598",
      "r714",
      "r734",
      "r865"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r245"
     ]
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding used in calculating \u200enet loss per share",
        "verboseLabel": "Denominator:",
        "label": "Earnings Per Share, Basic, Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in usd per share)",
        "verboseLabel": "Diluted net (loss) income per share (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r235",
      "r245",
      "r246",
      "r247",
      "r252",
      "r575",
      "r583",
      "r597",
      "r598",
      "r714",
      "r734",
      "r865"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Earnings Per Share, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r249"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET LOSS PER SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r248",
      "r250",
      "r251"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r902"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r540",
      "r566",
      "r902"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r902",
      "r1099",
      "r1194"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r1099",
      "r1194",
      "r1196"
     ]
    },
    "pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Expenses",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Merger Expense, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Merger Expense, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r1099",
      "r1194",
      "r1196"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r1099",
      "r1194",
      "r1195"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State tax rate, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r902",
      "r1099",
      "r1194"
     ]
    },
    "pacb_EffectiveIncomeTaxRateReconciliationTaxCredit": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit",
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Credit,"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Salaries and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "pacb_EmployeeSeparationCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "EmployeeSeparationCostsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee separation costs",
        "label": "Employee Separation Costs [Member]",
        "documentation": "Employee Separation Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation cost capitalized in inventory",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1193"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]",
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]",
        "documentation": "Deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r175",
      "r197",
      "r198",
      "r199",
      "r217",
      "r218",
      "r219",
      "r221",
      "r226",
      "r228",
      "r230",
      "r254",
      "r323",
      "r324",
      "r381",
      "r475",
      "r564",
      "r565",
      "r572",
      "r573",
      "r574",
      "r576",
      "r582",
      "r583",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r596",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r627",
      "r628",
      "r638",
      "r730",
      "r758",
      "r759",
      "r760",
      "r773",
      "r826"
     ]
    },
    "pacb_EquityIncentivePlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "EquityIncentivePlan2020Member",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Equity Incentive Plan",
        "label": "Equity Incentive Plan2020 [Member]",
        "documentation": "2020 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r968",
      "r979",
      "r989",
      "r1022"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r965",
      "r976",
      "r986",
      "r1019"
     ]
    },
    "pacb_ExchangeTransactionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "ExchangeTransactionMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange Transaction",
        "label": "Exchange Transaction [Member]",
        "documentation": "Exchange Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r601",
      "r612",
      "r903"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r601",
      "r612",
      "r903"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r903",
      "r1205",
      "r1206",
      "r1211"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r613",
      "r905"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r613",
      "r905"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r599",
      "r601",
      "r602",
      "r603",
      "r604",
      "r611",
      "r612",
      "r614",
      "r645",
      "r646",
      "r647",
      "r886",
      "r887",
      "r894",
      "r895",
      "r896",
      "r903",
      "r907"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r483",
      "r488",
      "r601",
      "r612",
      "r645",
      "r894",
      "r895",
      "r896",
      "r903"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r483",
      "r488",
      "r601",
      "r602",
      "r612",
      "r646",
      "r886",
      "r887",
      "r894",
      "r895",
      "r896",
      "r903"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r601",
      "r602",
      "r603",
      "r604",
      "r612",
      "r647",
      "r886",
      "r887",
      "r894",
      "r895",
      "r896",
      "r903",
      "r907"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in the Estimated Fair Value of Contingent Consideration Liability",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r610",
      "r613"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r599",
      "r601",
      "r602",
      "r603",
      "r604",
      "r611",
      "r612",
      "r614",
      "r645",
      "r646",
      "r647",
      "r886",
      "r887",
      "r894",
      "r895",
      "r896",
      "r903",
      "r907"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r329",
      "r330",
      "r331",
      "r332",
      "r337",
      "r345",
      "r346",
      "r347",
      "r455",
      "r473",
      "r594",
      "r615",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r731",
      "r878",
      "r903",
      "r905",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r917",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1204",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1212"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL INSTRUMENTS",
        "label": "Financial Instruments Disclosure [Text Block]",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_FinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "FinancialInstrumentsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Line Items]",
        "label": "Financial Instruments [Line Items]",
        "documentation": "Financial Instruments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_FinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "FinancialInstrumentsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Table]",
        "label": "Financial Instruments [Table]",
        "documentation": "Financial Instruments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Life (in years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r352",
      "r372",
      "r880"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030 and thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1145",
      "r1272"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r855",
      "r880"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r855",
      "r880"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r855",
      "r880"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r855",
      "r880"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r855",
      "r880"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r376",
      "r377",
      "r680",
      "r681",
      "r855"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r372",
      "r681",
      "r880"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r372",
      "r376",
      "r377",
      "r380",
      "r680",
      "r855",
      "r880"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r376",
      "r377",
      "r855"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithFiniteLivesDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r680",
      "r1144"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Roll Forward]",
        "label": "Finite-Lived Intangible Assets [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Functional Currency",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r983",
      "r993",
      "r1026"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r983",
      "r993",
      "r1026"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r983",
      "r993",
      "r1026"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r983",
      "r993",
      "r1026"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r983",
      "r993",
      "r1026"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on extinguishment of debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r55",
      "r56"
     ]
    },
    "us-gaap_GainsLossesOnRestructuringOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnRestructuringOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on debt restructuring",
        "negatedLabel": "Gain on debt restructuring",
        "negatedTerseLabel": "Less: Gain on debt restructuring (2029 Notes)",
        "label": "Gains (Losses) on Restructuring of Debt",
        "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r810"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofGoodwillDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Balance as of December\u00a031, 2023",
        "periodEndLabel": "Balance as of December\u00a031, 2024",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r353",
      "r712",
      "r873",
      "r879",
      "r904",
      "r916",
      "r1127",
      "r1134"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, acquired during period",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r879"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges",
        "label": "Goodwill and Intangible Asset Impairment",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets with Indefinite Lives",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1125",
      "r1137"
     ]
    },
    "pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "GoodwillImpairmentDiscountedCashFlowModelDiscountRate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment, discount rate",
        "label": "Goodwill Impairment, Discounted Cash Flow Model, Discount Rate",
        "documentation": "Goodwill Impairment, Discounted Cash Flow Model, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "GoodwillImpairmentIncreaseInBasisPointDiscountRate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in basis point discount rate",
        "label": "Goodwill Impairment, Increase In Basis Point Discount Rate",
        "documentation": "Goodwill Impairment, Increase In Basis Point Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges",
        "negatedTerseLabel": "Impairment charges",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r354",
      "r360",
      "r364",
      "r879",
      "r904"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r102",
      "r158",
      "r213",
      "r322",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r616",
      "r867",
      "r872",
      "r1107",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1161"
     ]
    },
    "pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "HoldingPeriodForTransferAssignmentOrSaleOfFounderShares",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lock-up period restriction",
        "label": "Holding Period For Transfer, Assignment Or Sale Of Founder Shares",
        "documentation": "Holding Period For Transfer, Assignment Or Sale Of Founder Shares"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r952",
      "r975"
     ]
    },
    "us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of intangible asset. Includes, but is not limited to, finite-lived and indefinite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairment charge",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r366",
      "r378"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets, finite-lived",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r1094",
      "r1150"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets, indefinite-lived (excluding goodwill)",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r1094",
      "r1146",
      "r1150"
     ]
    },
    "pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "InProcessResearchAndDevelopmentIndefiniteLivedMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-Process Research and Development Indefinite Lived",
        "label": "In Process Research And Development Indefinite Lived [Member]",
        "documentation": "In-process research and development indefinite lived"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In Process Research and Development",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1146",
      "r1147",
      "r1148"
     ]
    },
    "us-gaap_IncomeApproachValuationTechniqueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeApproachValuationTechniqueMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation, Income Approach",
        "label": "Valuation, Income Approach [Member]",
        "documentation": "Valuation approach converting future amounts to single current discounted amount."
       }
      }
     },
     "auth_ref": [
      "r1207",
      "r1208",
      "r1209"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Loss) income before taxes from U.S. operations",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r539"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r153",
      "r158",
      "r715",
      "r728",
      "r867",
      "r872",
      "r1107",
      "r1109",
      "r1110",
      "r1111",
      "r1112"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income before taxes from foreign operations",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r539"
     ]
    },
    "pacb_IncomeLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "IncomeLossPerShareAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share:",
        "label": "Income Loss per Share Abstrct",
        "documentation": "Income Loss per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r389",
      "r394",
      "r606",
      "r610",
      "r613",
      "r755",
      "r757",
      "r811",
      "r855",
      "r906",
      "r1234"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r394",
      "r606",
      "r610",
      "r613",
      "r755",
      "r757",
      "r811",
      "r855",
      "r906",
      "r1234"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r540",
      "r541",
      "r549",
      "r560",
      "r902",
      "r1198"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r540",
      "r541",
      "r549",
      "r560",
      "r902",
      "r1198"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r534",
      "r540",
      "r545",
      "r546",
      "r547",
      "r553",
      "r559",
      "r567",
      "r569",
      "r570",
      "r571",
      "r772",
      "r902"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxProvisionBenefitDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax provision (benefit)",
        "totalLabel": "Income tax provision (benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r174",
      "r229",
      "r230",
      "r253",
      "r267",
      "r281",
      "r538",
      "r540",
      "r568",
      "r735",
      "r902"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r536",
      "r537",
      "r553",
      "r554",
      "r558",
      "r562",
      "r769"
     ]
    },
    "pacb_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "documentation": "Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "documentation": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "pacb_IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration liability",
        "label": "Increase (Decrease) In Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability",
        "documentation": "Increase (Decrease) In Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r674",
      "r1093"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory, net",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities",
        "negatedTerseLabel": "Decrease in operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1093"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "calculation": {
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Add: Weighted average shares issuable upon conversion of convertible notes (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r247"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r370",
      "r375",
      "r880"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r375",
      "r380",
      "r880"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets include acquired IPR&amp;D",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r375",
      "r880"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r370",
      "r375",
      "r880"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r983",
      "r993",
      "r1017",
      "r1026",
      "r1030",
      "r1038"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r953",
      "r1042"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r953",
      "r1042"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r953",
      "r1042"
     ]
    },
    "pacb_InstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "InstrumentMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Instrument revenue",
        "label": "Instrument [Member]",
        "documentation": "Instrument [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset impairment, discounted cash flow model, discount rate",
        "label": "Intangible Asset Impairment, Discounted Cash Flow Model, Discount Rate",
        "documentation": "Intangible Asset Impairment, Discounted Cash Flow Model, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "IntangibleAssetImpairmentDiscountedCashFlowModelTerm",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset impairment, discounted cash flow model, term (in years)",
        "label": "Intangible Asset Impairment, Discounted Cash Flow Model, Term",
        "documentation": "Intangible Asset Impairment, Discounted Cash Flow Model, Term"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset impairment, increase in basis point discount rate",
        "label": "Intangible Asset Impairment, Increase In Basis Point Discount Rate",
        "documentation": "Intangible Asset Impairment, Increase In Basis Point Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset impairment, increase in term (in years)",
        "label": "Intangible Asset Impairment, Increase In Obsolescence Factor, Term",
        "documentation": "Intangible Asset Impairment, Increase In Obsolescence Factor, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets and Other Finite-Lived Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r678",
      "r680",
      "r862",
      "r1137"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "periodStartLabel": "Balance as of December\u00a031, 2023",
        "periodEndLabel": "Balance as of December\u00a031, 2024",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r1144",
      "r1146"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r450",
      "r460",
      "r888",
      "r889"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual interest expense",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r451",
      "r888",
      "r889"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r1089"
     ]
    },
    "us-gaap_InterestOnConvertibleDebtNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestOnConvertibleDebtNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Add: Interest charges applicable to convertible notes (2028 Notes)",
        "label": "Interest on Convertible Debt, Net of Tax",
        "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r238",
      "r247"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r207",
      "r208"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_InventoryFirmPurchaseCommitmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFirmPurchaseCommitmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on purchase commitment",
        "label": "Inventory, Firm Purchase Commitment, Loss",
        "documentation": "Amount of loss recognized on firm purchase commitment for inventory."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryGross",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventory, gross",
        "label": "Inventory, Gross",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory, net",
        "totalLabel": "Inventory, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r861",
      "r916"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Net",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r180",
      "r189",
      "r348",
      "r349",
      "r351",
      "r675",
      "r863"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventory reserve",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r1082"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in process",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory provision",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment income, net",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of discount and amortization of premium on marketable securities, net",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, All Other Investments [Abstract]",
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total investments",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1205",
      "r1206",
      "r1210"
     ]
    },
    "us-gaap_InvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments:",
        "label": "Investments [Member]",
        "documentation": "Assets held for their financial return, rather than for the entity's operations."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_LaboratoryEquipmentAndMachineryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "LaboratoryEquipmentAndMachineryMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment and machinery",
        "label": "Laboratory Equipment And Machinery [Member]",
        "documentation": "Laboratory Equipment And Machinery [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r637"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "pacb_LesseeOperatingLeaseDescriptionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "LesseeOperatingLeaseDescriptionTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases",
        "label": "Lessee, Operating Lease, Description [Table Text Block]",
        "documentation": "Lessee, Operating Lease, Description [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "LesseeOperatingLeaseLiabilityBaseRentAbatementAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease base rent abatement",
        "label": "Lessee, Operating Lease, Liability, Base Rent Abatement, Amount",
        "documentation": "Lessee, Operating Lease, Liability, Base Rent Abatement, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted operating lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r78",
      "r79",
      "r80",
      "r83",
      "r84",
      "r85",
      "r88",
      "r213",
      "r322",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r585",
      "r586",
      "r587",
      "r616",
      "r786",
      "r866",
      "r946",
      "r1161",
      "r1218",
      "r1219"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r150",
      "r724",
      "r916",
      "r1097",
      "r1123",
      "r1213"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r179",
      "r213",
      "r322",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r585",
      "r586",
      "r587",
      "r616",
      "r916",
      "r1161",
      "r1218",
      "r1219"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities measured at fair value",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r1205"
     ]
    },
    "pacb_LiquidityBonusEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "LiquidityBonusEventMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity Bonus Event",
        "label": "Liquidity Bonus Event [Member]",
        "documentation": "Liquidity Bonus Event"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate outstanding balance",
        "totalLabel": "Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r148",
      "r443",
      "r458",
      "r886",
      "r887",
      "r914",
      "r1232"
     ]
    },
    "pacb_LongTermRestrictedCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "LongTermRestrictedCashFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term restricted cash",
        "label": "Long Term Restricted Cash Fair Value Disclosure",
        "documentation": "Long-Term Restricted Cash Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r1151",
      "r1152",
      "r1153"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r54",
      "r1151",
      "r1152",
      "r1153"
     ]
    },
    "us-gaap_LossContingencyAccrualProductLiabilityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualProductLiabilityNet",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory accrual",
        "label": "Loss Contingency Accrual, Product Liability, Net",
        "documentation": "Present value of the estimated aggregate accrual for damages arising from third-party use of the entity's product(s) or process(es) as of the balance sheet date (if the accrual qualifies for discounting)."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r1156"
     ]
    },
    "us-gaap_LossContingencyDisclosures": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDisclosures",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r406",
      "r409",
      "r410",
      "r411",
      "r412",
      "r531"
     ]
    },
    "pacb_LossOnPurchaseCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "LossOnPurchaseCommitment",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on purchase commitment",
        "label": "Loss On Purchase Commitment",
        "documentation": "Loss On Purchase Commitment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r893",
      "r927",
      "r932",
      "r1165",
      "r1233",
      "r1235",
      "r1236",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1262",
      "r1263"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r405",
      "r407",
      "r409",
      "r410",
      "r489",
      "r531",
      "r604",
      "r673",
      "r754",
      "r756",
      "r764",
      "r778",
      "r779",
      "r831",
      "r833",
      "r835",
      "r836",
      "r838",
      "r853",
      "r854",
      "r877",
      "r890",
      "r899",
      "r907",
      "r908",
      "r912",
      "r913",
      "r928",
      "r1163",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Risk Free Interest Rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1207",
      "r1208",
      "r1209"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r603",
      "r604",
      "r907"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r603",
      "r604",
      "r907"
     ]
    },
    "pacb_MilestoneAchievementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "MilestoneAchievementMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Achievement",
        "label": "Milestone Achievement [Member]",
        "documentation": "Milestone Achievement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r405",
      "r407",
      "r409",
      "r410",
      "r489",
      "r531",
      "r604",
      "r673",
      "r754",
      "r756",
      "r764",
      "r778",
      "r779",
      "r831",
      "r833",
      "r835",
      "r836",
      "r838",
      "r853",
      "r854",
      "r877",
      "r890",
      "r899",
      "r907",
      "r908",
      "r912",
      "r928",
      "r1163",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]",
        "label": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r893",
      "r927",
      "r932",
      "r1165",
      "r1233",
      "r1235",
      "r1236",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1262",
      "r1263"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Basic net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r114",
      "r154",
      "r177",
      "r192",
      "r194",
      "r199",
      "r213",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r229",
      "r230",
      "r243",
      "r322",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r575",
      "r583",
      "r598",
      "r616",
      "r729",
      "r808",
      "r824",
      "r825",
      "r944",
      "r1161"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net loss",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r222",
      "r223",
      "r224",
      "r225",
      "r232",
      "r233",
      "r244",
      "r247",
      "r583"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Diluted net loss",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r234",
      "r237",
      "r238",
      "r239",
      "r240",
      "r244",
      "r247"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Pronouncements Pending Adoption",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r983",
      "r993",
      "r1017",
      "r1026"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "us-gaap_NoncashMergerRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashMergerRelatedCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger-related compensation expense",
        "label": "Noncash Merger Related Costs",
        "documentation": "Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "pacb_NoteExchangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "NoteExchangeMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note Exchange",
        "label": "Note Exchange [Member]",
        "documentation": "Note Exchange"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes exchange",
        "label": "Notes Issued",
        "documentation": "The fair value of notes issued in noncash investing and financing activities."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "pacb_NumberOfPurchasePeriods": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "NumberOfPurchasePeriods",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of purchase periods",
        "label": "Number Of Purchase Periods",
        "documentation": "Number of purchase periods."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r868",
      "r876",
      "r1108"
     ]
    },
    "pacb_OfferingShareAmountMaximum": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "OfferingShareAmountMaximum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock offering price (in usd per share)",
        "label": "Offering Share Amount Maximum",
        "documentation": "Offering Share Amount Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_OmniomeIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "OmniomeIncMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Omniome, Inc",
        "label": "Omniome Inc [Member]",
        "documentation": "Omniome, Inc. (\u201cOmniome\u201d), a San Diego-based company developing a highly differentiated, proprietary short-read DNA sequencing platform capable of delivering high accuracy."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_OmniomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "OmniomeMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Omniome",
        "label": "Omniome [Member]",
        "documentation": "Omniome"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expense",
        "label": "Operating Expense [Member]",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expense",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expense:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r867",
      "r1107",
      "r1109",
      "r1110",
      "r1111",
      "r1112"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r915"
     ]
    },
    "pacb_OperatingLeaseExpectedBaseRentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "OperatingLeaseExpectedBaseRentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, base rent expense",
        "label": "Operating Lease, Expected Base Rent, Expense",
        "documentation": "Operating Lease, Expected Base Rent, Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity of Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, liability",
        "verboseLabel": "Present value of operating lease liabilities",
        "totalLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r915"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r915"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "pacb_OperatingLossCarryforwardsAmountSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "OperatingLossCarryforwardsAmountSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, subject to expiration",
        "label": "Operating Loss Carryforwards, Amount Subject To Expiration",
        "documentation": "Operating Loss Carryforwards, Amount Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_OptionsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "OptionsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options To Purchase Common Stock",
        "label": "Options To Purchase Common Stock [Member]",
        "documentation": "Options to purchase common stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r141",
      "r766",
      "r767"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on investments",
        "verboseLabel": "Other comprehensive (loss) income",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r13",
      "r142"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Liabilities, Current",
        "label": "Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities, current",
        "totalLabel": "Other liabilities, current",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r916"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities, non-current",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "verboseLabel": "Other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_OtherRestructuringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherRestructuringMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other costs",
        "label": "Other Restructuring [Member]",
        "documentation": "Restructuring and related activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r881",
      "r882",
      "r883",
      "r884"
     ]
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherSundryLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Sundry Liabilities, Current",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r79"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r981",
      "r991",
      "r1024"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r973",
      "r984",
      "r994",
      "r1027"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r973",
      "r984",
      "r994",
      "r1027"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of contingent consideration",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "PaymentsForContingentConsiderationRevenueAchievementMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone revenue",
        "label": "Payments For Contingent Consideration, Revenue Achievement Milestone",
        "documentation": "Payments For Contingent Consideration, Revenue Achievement Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForDeposits",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for deposits to supplier",
        "label": "Payments for Deposits",
        "documentation": "The amount of cash paid for deposits on goods and services during the period; excludes time deposits and deposits with other institutions, which pertain to financial service entities."
       }
      }
     },
     "auth_ref": [
      "r1090",
      "r1091"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent payments",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash paid during YTD 2024",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r1092"
     ]
    },
    "pacb_PaymentsInConjunctionWithNotesExchange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "PaymentsInConjunctionWithNotesExchange",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments made in conjunction with convertible notes exchange",
        "label": "Payments In Conjunction With Notes Exchange",
        "documentation": "Payments In Conjunction With Notes Exchange"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments of offering expense",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash paid",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r579"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash paid for purchases of acquired entities, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of intangible assets",
        "terseLabel": "Payments to acquire intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of investments",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commissions, percentage of gross proceeds",
        "label": "Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering",
        "documentation": "Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "PercentageOfFairMarketValueAtWhichStockCanBePurchased",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of fair market value at which stock can be purchased",
        "label": "Percentage Of Fair Market Value At Which Stock Can Be Purchased",
        "documentation": "Percentage of fair market value at which stock can be purchased."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding shares of common to be issued in merger",
        "label": "Percentage of outstanding shares of common to be issued in merger",
        "documentation": "Percentage of outstanding shares of common to be issued in merger."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Stock Units (PSUs)",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r462"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r788"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in share)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r462"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r788",
      "r806",
      "r1266",
      "r1267"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r720",
      "r916"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1084"
     ]
    },
    "pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability of benefit realized upon settlement uncertain tax position",
        "label": "Probability Of Benefit Realized Upon Settlement Uncertain Tax Position",
        "documentation": "Probability of benefit Realized Upon Settlement Uncertain Tax Position"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of common stock under equity offerings, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock from underwritten public equity offerings, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock, Net of Issuance Costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity, net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock from equity plans",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r17"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of investments",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r1114"
     ]
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of investments",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r203",
      "r290",
      "r321"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from stock options exercised",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r17"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product revenue",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r284",
      "r679",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r857",
      "r891",
      "r926",
      "r928",
      "r929",
      "r933",
      "r935",
      "r1157",
      "r1158",
      "r1165",
      "r1233",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1262",
      "r1263"
     ]
    },
    "us-gaap_ProductWarrantyAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyAccrual",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Standard and Extended Product Warranty Accrual",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r413",
      "r415",
      "r418"
     ]
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warranty accrual",
        "label": "Product Warranty Accrual, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r1159",
      "r1160"
     ]
    },
    "us-gaap_ProductWarrantyAccrualPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyAccrualPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repairs and replacements",
        "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments",
        "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ProductWarrantyAccrualWarrantiesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyAccrualWarrantiesIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions charged to cost of product revenue",
        "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued",
        "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r284",
      "r679",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r857",
      "r891",
      "r926",
      "r928",
      "r929",
      "r933",
      "r935",
      "r1157",
      "r1158",
      "r1165",
      "r1233",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1262",
      "r1263"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r637"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r182",
      "r727"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r637",
      "r716",
      "r727",
      "r916"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r166",
      "r172",
      "r725"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Lives of The Major Classes of Property and Equipment",
        "verboseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTransfersAndChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTransfersAndChanges",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment transferred to inventory",
        "label": "Property, Plant and Equipment, Transfers and Changes",
        "documentation": "Amount of increase (decrease) of physical assets used in the normal conduct of business and not intended for resale, from reclassification, impairment, donation, or changes classified as other. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r637"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "PublicOfferingOptionToPurchaseAdditionalSharesPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering, option to purchase additional shares, period",
        "label": "Public Offering, Option to Purchase Additional Shares, Period",
        "documentation": "Public Offering, Option to Purchase Additional Shares, Period"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "PublicOfferingOptionToPurchaseAdditionalSharesShares",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering, option to purchase additional shares (in shares)",
        "label": "Public Offering, Option to Purchase Additional Shares, Shares",
        "documentation": "Public Offering, Option to Purchase Additional Shares, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_PublicOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "PublicOfferingShares",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering (in shares)",
        "label": "Public Offering, Shares",
        "documentation": "Public Offering, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase obligation",
        "label": "Purchase Obligation",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_PurchasePeriodOfEmployeeStockPurchasePlan": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "PurchasePeriodOfEmployeeStockPurchasePlan",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase period of ESPP",
        "label": "Purchase Period Of Employee Stock Purchase Plan",
        "documentation": "Purchase period of employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r405",
      "r407",
      "r409",
      "r410",
      "r482",
      "r489",
      "r519",
      "r520",
      "r521",
      "r531",
      "r604",
      "r648",
      "r657",
      "r673",
      "r754",
      "r756",
      "r764",
      "r778",
      "r779",
      "r831",
      "r833",
      "r835",
      "r836",
      "r838",
      "r853",
      "r854",
      "r877",
      "r890",
      "r899",
      "r907",
      "r908",
      "r912",
      "r913",
      "r928",
      "r938",
      "r1154",
      "r1163",
      "r1208",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r405",
      "r407",
      "r409",
      "r410",
      "r482",
      "r489",
      "r519",
      "r520",
      "r521",
      "r531",
      "r604",
      "r648",
      "r657",
      "r673",
      "r754",
      "r756",
      "r764",
      "r778",
      "r779",
      "r831",
      "r833",
      "r835",
      "r836",
      "r838",
      "r853",
      "r854",
      "r877",
      "r890",
      "r899",
      "r907",
      "r908",
      "r912",
      "r913",
      "r928",
      "r938",
      "r1154",
      "r1163",
      "r1208",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225"
     ]
    },
    "pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "RecentlyAdoptedAccountingStandardsPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Standards",
        "label": "Recently Adopted Accounting Standards [Policy Text Block]",
        "documentation": "Recently Adopted Accounting Standards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationFromSegmentTotalsToConsolidatedAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less:",
        "label": "Segment Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofUnrecognizedTaxBenefitAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Tax Benefits [Roll Forward]",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r965",
      "r976",
      "r986",
      "r1019"
     ]
    },
    "pacb_RefundFromDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "RefundFromDeposits",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refund from deposits",
        "label": "Refund From Deposits",
        "documentation": "Refund From Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Notes payable principal payoff",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "pacb_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r855",
      "r872",
      "r1226"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r977",
      "r987",
      "r1020"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r967",
      "r978",
      "r988",
      "r1021"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r974",
      "r985",
      "r995",
      "r1028"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash at end of period",
        "label": "Restricted Cash and Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r143",
      "r181",
      "r210",
      "r719"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term restricted cash",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r161",
      "r210"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1077",
      "r1095"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURING"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESTRUCTURING",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r393",
      "r396",
      "r401"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedCostRemaining1",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated total restructuring costs to still be incurred",
        "label": "Restructuring and Related Cost, Expected Cost Remaining",
        "documentation": "Amount of expected cost remaining for the specified restructuring cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative amount incurred to date",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r395",
      "r398",
      "r400"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restructuring charges",
        "terseLabel": "Expense recorded in YTD 2024",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r397",
      "r398",
      "r1155"
     ]
    },
    "pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WARN act and other employee benefits",
        "label": "Restructuring Charges, Worker Adjustment and Retraining Notification (WARN) Act and Other Employee Benefits",
        "documentation": "Restructuring Charges, Worker Adjustment and Retraining Notification (WARN) Act and Other Employee Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r393",
      "r398",
      "r399"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r395",
      "r398",
      "r399",
      "r400"
     ]
    },
    "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges."
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1061"
     ]
    },
    "pacb_RestructuringOfDebtPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "RestructuringOfDebtPricePerShare",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring of debt (in dollar per share)",
        "label": "Restructuring Of Debt Price Per Share",
        "documentation": "Restructuring Of Debt Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount recorded in current liabilities as of December 31, 2024",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r399"
     ]
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated depreciation",
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r131",
      "r723",
      "r761",
      "r763",
      "r771",
      "r789",
      "r916"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r217",
      "r218",
      "r219",
      "r221",
      "r226",
      "r228",
      "r230",
      "r323",
      "r324",
      "r381",
      "r564",
      "r565",
      "r572",
      "r573",
      "r574",
      "r576",
      "r582",
      "r583",
      "r588",
      "r590",
      "r591",
      "r593",
      "r596",
      "r627",
      "r628",
      "r758",
      "r760",
      "r773",
      "r1266"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r253",
      "r260",
      "r261",
      "r275",
      "r281",
      "r284",
      "r286",
      "r288",
      "r478",
      "r479",
      "r679"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Geographic Location",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r809",
      "r856",
      "r864"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, amount",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, percentage",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset and liability additions and modifications",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r915"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Revenue, Net",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r1063"
     ]
    },
    "pacb_SanDiegoOfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "SanDiegoOfficeMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "San Diego Office",
        "label": "San Diego Office [Member]",
        "documentation": "San Diego Office"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule Of Accrued Expenses And Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued expenses and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302"
     ]
    },
    "pacb_ScheduleOfBalanceSheetComponentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "ScheduleOfBalanceSheetComponentsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balance Sheet Components [Table]",
        "label": "Schedule of Balance Sheet Components [Table]",
        "documentation": "Schedule of Balance Sheet Components [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r68",
      "r577"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Combination",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r68"
     ]
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash, Cash Equivalents and Investments",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Provision (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1200"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Carrying Amount",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r57",
      "r58",
      "r74",
      "r128",
      "r130",
      "r886",
      "r888",
      "r1100",
      "r1215"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Reconciliation of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r37",
      "r235",
      "r236",
      "r245"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Reconciliation of Federal Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r902",
      "r1194"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Category",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136"
     ]
    },
    "us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfImpairedIntangibleAssetsTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Impaired Intangible Assets",
        "label": "Schedule of Impaired Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported."
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Indefinite-Lived [Table]",
        "label": "Intangible Asset, Indefinite-Lived [Table]",
        "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r375",
      "r380",
      "r880"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets From Business Acquisitions",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r1125",
      "r1137"
     ]
    },
    "pacb_ScheduleOfInterestExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "ScheduleOfInterestExpenseTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Interest Expense",
        "label": "Schedule of Interest Expense [Table Text Block]",
        "documentation": "Schedule of Interest Expense [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r96",
      "r97",
      "r98"
     ]
    },
    "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Reserve for Product Warranties",
        "label": "Schedule of Product Warranty Liability [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r637"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r395",
      "r398",
      "r399",
      "r400"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Pre-Tax Restructuring Charges",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r120",
      "r121"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r122"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r100"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Profit or Loss",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Time-Based RSUs Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r132"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Employee Stock Purchase Plan",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Employee Stock Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Reconciliation of Unrecognized Tax Benefit Accounts",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r901"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Finite Lives",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r880",
      "r1145"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r159",
      "r253",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r288",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r380",
      "r395",
      "r400",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r869",
      "r872",
      "r873",
      "r879",
      "r931",
      "r1233",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1262",
      "r1263"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment, Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r775",
      "r776",
      "r777",
      "r832",
      "r834",
      "r837",
      "r839",
      "r842",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r858",
      "r892",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r930",
      "r938",
      "r1165",
      "r1233",
      "r1235",
      "r1236",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1262",
      "r1263"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SEGMENT AND GEOGRAPHIC INFORMATION",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r271",
      "r273",
      "r274",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r868",
      "r870",
      "r871",
      "r872",
      "r874",
      "r875",
      "r876"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and marketing",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ServiceAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "ServiceAndOtherMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service and other revenue",
        "label": "Service And Other [Member]",
        "documentation": "Service and Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance costs",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount eligible to vest upon achievement of goal",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning (in shares)",
        "periodEndLabel": "Outstanding, ending (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning, outstanding (in dollars per share)",
        "periodEndLabel": "Ending, outstanding (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of shares vested related to RSUs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional common stock reserved for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock remain available for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, exercisable, number (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r499"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in usd per share)",
        "periodEndLabel": "Ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r499"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, outstanding (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, weighted average exercise price (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding common stock used to determine annual plan increase",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r495",
      "r496",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options expired, weighted average exercise price (in usd per share)",
        "verboseLabel": "Expired (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canceled (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r497",
      "r516",
      "r517",
      "r518",
      "r519",
      "r522",
      "r526",
      "r527",
      "r528",
      "r529"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ShareInstrumentNumberOfSharesConversionRatio": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "ShareInstrumentNumberOfSharesConversionRatio",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ratio of number of shares into which the share instrument may be converted",
        "label": "Share Instrument, Number of Shares, Conversion Ratio",
        "documentation": "Number of shares into which the share instrument may be converted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price (in usd per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "pacb_ShelfOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "ShelfOfferingMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shelf Offering",
        "label": "Shelf Offering [Member]",
        "documentation": "Shelf Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofOtherLiabilitiesCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term loan",
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r145",
      "r916",
      "r1231"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r1083"
     ]
    },
    "pacb_ShortTermRestrictedCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "ShortTermRestrictedCashFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term restricted cash",
        "label": "Short-Term Restricted Cash Fair Value Disclosure",
        "documentation": "Short-Term Restricted Cash Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_StandardProductWarrantyPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "StandardProductWarrantyPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product warranty period",
        "label": "Standard Product Warranty, Period",
        "documentation": "Standard Product Warranty, Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r159",
      "r176",
      "r253",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r288",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r380",
      "r383",
      "r395",
      "r400",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r869",
      "r872",
      "r873",
      "r879",
      "r931",
      "r1233",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1262",
      "r1263"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r90",
      "r93",
      "r94",
      "r175",
      "r197",
      "r198",
      "r199",
      "r217",
      "r218",
      "r219",
      "r221",
      "r226",
      "r228",
      "r230",
      "r254",
      "r323",
      "r324",
      "r381",
      "r475",
      "r564",
      "r565",
      "r572",
      "r573",
      "r574",
      "r576",
      "r582",
      "r583",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r596",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r627",
      "r628",
      "r638",
      "r730",
      "r758",
      "r759",
      "r760",
      "r773",
      "r826"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r775",
      "r776",
      "r777",
      "r832",
      "r834",
      "r837",
      "r839",
      "r842",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r858",
      "r892",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r930",
      "r938",
      "r1165",
      "r1233",
      "r1235",
      "r1236",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1262",
      "r1263"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r254",
      "r628",
      "r679",
      "r768",
      "r774",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r788",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r807",
      "r809",
      "r810",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r826",
      "r939"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r254",
      "r289",
      "r628",
      "r679",
      "r768",
      "r774",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r788",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r807",
      "r809",
      "r810",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r826",
      "r939"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r980",
      "r990",
      "r1023"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "StockBasedCompensationExpenseExcludedFromConsiderationTransferred",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Share-based compensation expense excluded from consideration transferred",
        "label": "Stock-based compensation expense excluded from consideration transferred",
        "documentation": "Stock-based compensation expense excluded from consideration transferred."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_StockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "StockBasedCompensationMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation",
        "label": "Stock Based Compensation [Member]",
        "documentation": "Stock-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity awards",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "StockIssuedDuringPeriodAverageTradingPeriodAcquisition",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average trading period",
        "label": "Stock Issued During Period, Average Trading Period, Acquisition",
        "documentation": "Stock Issued During Period, Average Trading Period, Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock in acquisition of Apton (in shares)",
        "terseLabel": "Issuance of common stock in acquisition (in shares)",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r131"
     ]
    },
    "pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock in connection with Apton liquidity event bonus plan (in shares)",
        "terseLabel": "Issuance of common stock in connection with liquidity event bonus plan (in shares)",
        "label": "Stock Issued During Period, Shares, Acquisitions, Liquidity Bonus Plan",
        "documentation": "Stock Issued During Period, Shares, Acquisitions, Liquidity Bonus Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock purchased under plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan",
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r64",
      "r89",
      "r90",
      "r131"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock following milestone achievement (in shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r89",
      "r90",
      "r131",
      "r770",
      "r826",
      "r840"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in conjunction with convertible notes exchange (in shares)",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in conjunction with equity plans (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r89",
      "r90",
      "r131"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r89",
      "r90",
      "r131",
      "r503"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in acquisition of Apton",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r90",
      "r93",
      "r94",
      "r131"
     ]
    },
    "pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with Apton liquidity event bonus plan",
        "label": "Stock Issued During Period, Value, Acquisitions, Liquidity Bonus Plan",
        "documentation": "Stock Issued During Period, Value, Acquisitions, Liquidity Bonus Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock following milestone achievement",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r89",
      "r90",
      "r131",
      "r773",
      "r826",
      "r840",
      "r945"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in conjunction with convertible notes exchange",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in conjunction with equity plans",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r89",
      "r90",
      "r131"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r93",
      "r94",
      "r117",
      "r790",
      "r806",
      "r827",
      "r828",
      "r916",
      "r946",
      "r1097",
      "r1123",
      "r1213",
      "r1266"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_StockholdersEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "StockholdersEquityLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity [Line Items]",
        "label": "Stockholders' Equity [Line Items]",
        "documentation": "Stockholders' Equity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r212",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r475",
      "r595",
      "r829",
      "r830",
      "r841"
     ]
    },
    "pacb_StockholdersEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "StockholdersEquityTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity [Table]",
        "label": "Stockholders' Equity [Table]",
        "documentation": "Stockholders' Equity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r640"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r640"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r640"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r640"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r640"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r641"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_SupplementalBalanceSheetComponentsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "SupplementalBalanceSheetComponentsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Components [Abstract]",
        "label": "Balance Sheet Components [Abstract]",
        "documentation": "Supplemental Balance Sheet Components Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BALANCE SHEET COMPONENTS",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credit carryforward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed technology",
        "label": "Technology-Based Intangible Assets [Member]",
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1143",
      "r1144",
      "r1147",
      "r1148"
     ]
    },
    "us-gaap_TenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TenantImprovements",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenant improvement allowance",
        "label": "Tenant Improvements",
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants."
       }
      }
     },
     "auth_ref": [
      "r1229",
      "r1230"
     ]
    },
    "pacb_TimeBasedAndPerformanceBasedOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "TimeBasedAndPerformanceBasedOptionsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time-Based and Performance-Based Options",
        "label": "Time Based And Performance Based Options [Member]",
        "documentation": "Time-based and performance-based options"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_TimeBasedRestrictedStockUnitsPSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "TimeBasedRestrictedStockUnitsPSUMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time Based Restricted Stock Units PSU",
        "label": "Time Based Restricted Stock Units PSU [Member]",
        "documentation": "Time Based Restricted Stock Units PSU"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_TimeBasedRestrictedStockUnitsRsusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "TimeBasedRestrictedStockUnitsRsusMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofTimeBasedRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Time Based Restricted Stock Units Rsus [Member]",
        "documentation": "Time-Based Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_TimeBasedStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "TimeBasedStockOptionMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time-Based Stock Option",
        "label": "Time Based Stock Option [Member]",
        "documentation": "Time-based stock option"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_TransferOfInventoryToPropertyAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "TransferOfInventoryToPropertyAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory transferred to property and equipment",
        "label": "Transfer of Inventory to Property and Equipment",
        "documentation": "Transfer of Inventory to Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Option, Eligible Item or Group [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r455",
      "r473",
      "r594",
      "r615",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r731",
      "r903",
      "r905",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r917",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1204",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1212"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r393",
      "r398",
      "r399"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government &amp; agency securities",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r1227"
     ]
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unamortized debt issuance costs",
        "label": "Unamortized Debt Issuance Expense",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofUnrecognizedTaxBenefitAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r550",
      "r901"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofUnrecognizedTaxBenefitAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in balance related to tax positions taken in prior year",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r901"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest or penalties",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r901"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofUnrecognizedTaxBenefitAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase in balance related to tax positions taken during current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r901"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESScheduleofReconciliationofUnrecognizedTaxBenefitAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in balance related to tax positions taken in prior year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r901"
     ]
    },
    "pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20241231",
     "localname": "UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government &amp; agency securities",
        "label": "Us Government Corporations And Agencies Securities Not Included With Cash And Cash Equivalents [Member]",
        "documentation": "US Government Corporations and Agencies Securities, , Not Included with Cash and Cash Equivalents [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r163",
      "r164",
      "r167",
      "r168"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Axis]",
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r603",
      "r907",
      "r1209"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Domain]",
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r603",
      "r907",
      "r1209"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average shares used in computing diluted net (loss) income per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r247"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average shares used in computing basic net (loss) income per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r247"
     ]
    },
    "us-gaap_WeightedAverageRateOfTimeDepositsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageRateOfTimeDepositsAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share:",
        "label": "Weighted Average Rate of Time Deposits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "60",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481408/470-60-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-13"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-10"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480637/718-40-25-10"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "330",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-5"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-4A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-5A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479366/326-20-35-8A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-5"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-17"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.M.2.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483530/326-20-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479175/326-30-30-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-13A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-7A"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3C"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3D"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450-20/tableOfContent"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450-30/tableOfContent"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>132
<FILENAME>0001299130-25-000061-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001299130-25-000061-xbrl.zip
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M9K+URIU"UH"8$(-!JH@D3^T8O8ZV-F#3"3U*B)< [4GY9$E&^?- 5R#[!/B
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M902N \$0@1LS/XF!I%$,YCU:\#+NL";DNFVD-,<2M!@[.96@3#IJT'][:(R
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M)%@'DTYHS1/NXF#49K-3UGB%B@]IV.?<F,/' @W#"I1@(ZZR^]*<G#?$T;8
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M(?EEP<C!]?OP^026>9)GI4ALW.ZXF[R]=MNC1$/O8.]O124.JDJ;HHRZHPB
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M/SHRB806!J18GP*JTC8F(R_/8AE0TQR XA4%P">AZ">HZ=%CR(I*!U*?J$W
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M[6] Z*4MSVX/%_!)&$^MP"($QWR)2R3DJ1K#"354('6JBW*6L3F,9B)!2"V
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M1?)(!7EBR6&IPUF%?6T/,ZKN4MV9K]ZKJ9CX/G,P48B3376K[*>,=J/X,Q4
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MQ "A9^@92FJ;*^S \#1=D"_.CJ*B#U. -8##H?<D.KO9-@[H0+_O!-\H;62
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M- JTME6I0WF*(RHM!/C^ANI &V&")'E)?/KRU'G#7R;&S2PLK1)$RVVJ+_C
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M1QYDZ0]N16Z>G"#_0%<+M0?#3:?>#^-W)PMJGO>[-39@45J4>\+.BA*72BD
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M#J5 !@^8WC&@DB<&4 :/1RT.-__Z 7Z]UL\C"Z=,W1>+[Z^BAW MW7+R*,G
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M!]='$6RE\9MJF_D(7259$3+IC;DJJQUOG%JFT\C#^ <[=B8ILA@T7]E.*BR
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M=".]DSTT1_Y,NG67[>4][8C ]PL/'J;I*%1U9D\N>L!!8P@AL-<HVTZ]>Y.
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M1V(UBC3H2<3B6DKGUBM5&M""8)#;#(_&8@A2<%<>?VX$EKXW#C8)$JB]X3Y
MW_@%4&N;U-KYFZV%BB<;2,X<,$!#M0("P4&X4>BUUT<P: Y_(1DXN5&!CLC5
M9<GM7ONJCSW0B YK*E@0Y4%RB_22<4$&]0(6GB,9N#AG_X!.! _<U+HP<HD2
MLW;&FLD4^%L3\\1KIHBBZ'?EN"C"##LM4]QXT^+71V#87SL\?V?U+P*UB^G]
MIZ8G^T;^074:JAH$2Q*W)NJ.MH([]7;G[+2^UD>RV#?N&5X2X4/U2<>;RE$\
ML'[HNV;37^/0RT94E]WF6*\X\T0<62(!$]=-6/!"145FR4^Z#QBA8D0?\DZH
M$'DD@H!RHI@.:B-Q:#E.#(-!UIEJ5"BT@HY/;-N&3BP</VSMC U(A0/S0_[8
M1UV$\*2<ZI ,'?-QY>V0?G"!SZ)#)6R<R9V@#?9KA[?WXY5]4A.D9G/Y-4BC
M1'H10EI[;N5-+#G+2*$.3=;/+S>G(2*9F.SA[&-E_#CQB'D5Q\]0DYDKI>_
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MY$1.BM FAO6"G<:*E$4Z2JDWH>%LG":F==S(ZK^V7Z '=W>*=+<VH3#,V$E
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M%5Z,M*F4/16:WDWNW1CH6"$#JB?1VDWFS"YX17BT0QP6U<20*K9"P8&6FI5
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M5V(V?KMCMC>AN!:-WZB'I__*R'*D(2VJ!_G%M_2#P9:$>H36;E\#@ZA7X"B
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MR3 $0F M*M=Q+QUJXYKRW9+-=NI\C^BF%(@;'Z_L25FGO?EY77T+('@!!"^
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M^H^OF7]('FU\]?C%:GK]X2%3-+Q$2_!.8!]S4\U4,[WD4DL>M R<&_](G=H
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MD.(P=-$U#[T611TLYT!YA>/,A;,BHZ]+9[4VU*TSU':SY4P W3I^^_8-*2_
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M%?5/^K=JF\N6CC*I?A>0.8M__CLO/4&*RJDZI^MM7\1$4_^V">-(-8'?, <
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M*P:*GNJERCXI^O2KYR\30ZT2T7.;=;5??5L1A/7[(1X]^H7GWWZ?OD!33H\
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M3<@UM:F".9A(THB3;=<01._HNP7_(CV2$";6->"QQ%#!UMF(%D5P)GMTI!0
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M=LC#F\&K@M+_R25-'5N>Y/];_^^J]2*Y+AU?-BT+?9^^7/6G)MZ+BJOVJ\O
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MRAD9Z1G^-C5>RZ3\UH[?2*=.](W1&JI !9VDQ57XO5R%&6=M;-<0R#)<A%R
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M@04"D'P6#73NPOM Q5GS\.9<-RX>5;W"LRN5TXWG/U$]:35R="E?3\@*NNO
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M^CE.A$;N,!J(^X@QG===@K1$>%-2^H-ZIIAM+)[#EE\E0''"BU&Z86/ G]W
M.3P>'Z 64]/46;Q=%R S0"H;! 5A@Y@<SK\]_S,NS+TSUVTM *)->;#>=IT)
M<X.JAGEX[9L*BR!5D^XRT%;<D)VJ-0'GFV!W80LHI7M15S2X[*!%VW:6?!%
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ME-@#=4E\5JP7DB#\FGU+SFQRB<I:\*1=R@ \F+#A1V-]B0OG (6![6P#D?N
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MP'>UFQA5GK=>^.]HS4#07F:5;M]5<)#8LK7=C&%[N$W%/_)F%$FK^N36;UH
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MC):T6*4?L).KL5-E!/CRWXE]\D*0D$*&(#U=V2:QM8%B9[E%K\YH\#4SV([
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M*2$7T4C/D2._TN4]+H"$.*+3(4F+YQPV,C8")7?,<#01M8S4B0MU]4..4(/
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M.*E1C-I@M(C@V4-WJ7&JQ\(<K\TT=IC0<=/5*TF8<AW?>"KVV96*Y_%4>K'
MT4G9V8+M@B],E=%K7)^'BA'$#.S&Q]%G?+$;/X\L;KG/L.0WI4L5^16DY:!T
M&W1*]22=AD(LIT-W7JSJ:NG4_L,^Q".0.M!<R,'@2Q7B%4R!R%W1NLP38U%G
M- Y^&Q'NFNG; D<0J"E2PX.5,0J'%+O<&0$[PWEXH+9C4@M!&G)>4J&=C^7'
MI":<LDNE^_.X?3.S29PJ=^-Q4?D)LHY7<3Q"3@'\U4B-0Y28O6EX39$7*KQR
M_D >2\/[W=DB>+QYLQ8'XYP4]Q9GP=3Z*!@9M0;5L0(TL,)DF,^P5-1)_0ZE
MG29I$/B2OGKTHY<=.;(Q,'Z4C,@[O-WU0[E:$YWR;*;[0F&%K291<+M:P@T1
MW^  *WNU^<QCALP-Z6W5V/>,+M.#-N6+_U$A[\<:U.9!\%;S\,TO7\#F\"CT
MO?MSZ;Z0>31*;=WP;HRC<H[B1S(4P&']BB0IIZ>^=XK-0@XV;<4[SA-R3IRN
MQ&5R%6+IUPIW\]YJIBDP*NS$-$FFX?4+[W:; 4>NM?&_4];3KJ)CW G'XG?E
M D1=B].JU>53'DTXF6YOZN<ZBUKLJR6\QBW5N*4:MU3CEFK<4HU;6H=;ZMT=
MM[1YK]1>^TT-=GI!8*>ZM>TK;VU[?G+QQZ?+"^_LHW?V]>3\Z/+T[,O%D_2V
M_8&6]-$V=6Y#DN,@G#++G/%6QR:-LH;>B9-384JAM>P&,X3/X)?@A;M5"XK!
M@N=9A\Y6K0.2RC-T '/&&'MM>$<E*;,X&0HO<T:B*@FA!4S'?U,) #_#0E=#
M&;9JZ9])!"M7IKU-*^-;,$,\(Q)E:3]\2T1QD&>ZK&R,HT9A_<'SNE/@Z<TO
M'(YL>)^#*&#&2]/0\H,]@B@H1U$P7:0AG3C+6P@&&\=*Z3N5&9.M:@HL5]9V
M;\J2A-UWN-L34=V!T8K',LFR>?KSW_]^<W/32-6P<15?_SW\_O^.XN%__OTH
M&4ZP)\_?U>@J2/X.%D_P=QAXJWUXV.HTG7]M=W%"O>[?=8"D@P&2QB0#X]KQ
M^JLCM,]V'U3@>+?E>MBJB],'*Q=-88,=O$"H+3-'4PY( RV.X]DL-)F=9UC+
MCVJ0Y$&RX+5L'W#V>[O6DM$!(0'!XV2.!Q/6%C$?(>&+39=L@:K"&E^#*T*>
M_3A1%#?@]+].GUV<')M;[$8-TC C=)1SHKE*GGP7>:/YXCO\&A[;!C@N/]54
MS,])Q?QPY_P)F)M);(^M4RO^R3_)W3A94T9!0N?JLGM&)G9%L+K=1N>QLA_M
M1O/@;E2_J__>;3Y.HJ@>U)T&]2"RY+6)C\--$A],#GX7UO<[7WF'&_';52D*
M!*9MP/)XQ_3/$WUMPZUZ!-[].^_ P=V= MJ3=P3/B7-XZ"CUJ: 4;K$YXNPG
MU&ACAF"?]*=-F#B7#"G5'[?'ARN9LIKKKL>[2VVK<] 9[C^ZU+IVX^U,9FLF
M>1N+V8]9I2<ZVX7;_2G3N%LSX[?>,?DZKVO6?ZN:]1;KQ?*LUE+S__RT6NYQ
M;J57_)Z[R9E'_SS<2H'[*H0#NOBJ+'BW"9L[U:;W" ?KP9=G]3S?/FAB[\M8
MG"V84:NS[[>ZA^S@/F1V6D(WGN6=#EK%D7@4.7FB\[!*3AY/')YHX*V#CG_0
M;Z\5AWK77]JNO^OV_7Z[L^05_? --U]K5]Z"E9N_-8O8WG_8L=D2*?[;3P\P
MAK?92+E82:R[TDYNWVXG/[Y\/M5-W_</]GO;?M'OL@9H[?O[MYA2]4)NM)!^
MN_5 95JO(ZQC_V5<2 ^]CSK]K;R/+N/,:;_\D#MHLUCK=M].O:[?;'7O=SUM
M'&O^L7KB1V[+$\EHN]GT>^W6^FVI5__)_+)]O]?LK_++MG3A=V=YVYV7<4$^
MQ&/;POD<(_EM//;J-,;SO><%)RNT>,UO25J\R"C 8=MO']S3S*IOE8TLV7;?
M[^T?U.[KP^_G3@^%M0Y+/\S(>: H;HG6?K%A:7T=K>[[]BHNIA;X_[WU :OZ
M8GKH"O=[ZZ_^>B$W4JG[ARM]\GH%-UK!]7FH^DYZYHD=;=PKXU7<38=^YW!]
MJ*B^FAZ8\#L\>& LKEY'3/CYW5:S7L<'KV.G_T [:4OT^(-3IUMZ/U'G+.PL
M)?U-D)MH%E+?F]=Q(1VN=^KKZ^AAQ]_O=FK\R6/$GF A#VI7Z4%KV%^??=^9
MJ^C!OM)6PWB&$L6KX3QLT+?V_7YG?1U!#>=YAA!@W^]W:SC/<^6S6GZS>5C#
M>9[*VJAO2I[5?G<K;\I"4_97?D%V^G[[H+X?MTR%]-I^_V!] *U>_"?3WZV>
MWSU<Z2YNZ<+OSO*V'UB:M"6WR$M#NYZ9=JTGW%R]QKO6>-?'98-)59 ,)]RO
M55VK:4S=MU\)KJC3]0_;][2TZIME,]*(OM_JUWG'Q\#%M/UVMXZ8UXC7EXPN
MN@BFV$WZ2D5@^4RYZ?EH%D9AFB74)?*5W$S]GM]LU9#7)V5D./0/6G4MQB-$
M1OS684UM\0AQOY=Q-;W0F^G4]N?F3@2O ]_:.NCZO>8M<<_Z)GK($E,?B_;[
M6H/^$&&M5W);9/+EW V?%=P'R1YULE<C3W&P]G5<$)M(2GU!/+#&I-G=%M[5
M75['=[20=03M89G89O-)5K#V41ZA7IQ;TH61-P9?Q;L.ICFW3H-?PA3(=XFC
M-!Q)W\Y7<4&].^BME-CZ8GH@,Y_?W*_-[<?!MQRVGD:QOJ)%;-8TVUM]/]6U
MXZ5PA=^\163K"^I!*[SOMVXACJG7<;.:'?^@IB]_C(4\?* COR6:_&43;\<&
M=RFAO-=>DM #!= [O&>'B"U%9[\ 6'SGH.^WN[? 1.K5?RI=WN[ZG>XM; O;
MN?H[L\:WU F_ANMR"Z=CZQ*F6+;WRB_'=]T^*(+6RAYI]<7X#.74G:[?W=^U
M]@@O8>5;G4/P%?=W;.5W9GT?F@C>DAOD3A?B*$SGTV#Q<Q1':O5.O\9OO9S0
ML*9M@X'!B/,PG1#4,AY[(S5X'<QM-9+FZ6^GMM_LU,UL'];W"Y>P#@4_"I+F
M9=SE+S5=^5L01G@GX0WD)2K-DGR8Y0F,_E7<1]AWL=NLB]!V'&;].E9R$V&M
M5W);9/+EW!&G4:;P:GB43.'.7 WO6AV_VUH)I:YOA0>N+B:6:C?E8443G0=2
M/M:K2/V,:A=EFZ^?,^H&%T;#>*9\+U*OA+FIW?'[MW2%J>^@!R;>_?U;FL'6
M"[E9^8E_V&S5=_G#PK8/=.RV1%O_&'[*47C]PS,W S6.$R47D9<%WYWJ9QK/
M:\6&=)J'?J_3J[$AVZ-,.JT#O]7;-:[]%[#R!_Y^^Y;^\MNY]CNSPN]>"(?4
M"^-Q/C77(K8XN Y3K'][-U"1&H?9DAYZD1Y;IU47NCUIR+#E=]O=VLUX8)5;
MOUN7LS\*M*&^B+;68?NB,L+M5SMH&SHF//B?.[!YHSC'PFTRTQY@I=YURY_H
MHGI[3T_M80NRC5<V^:X'O96QJR==D:=5KD5WX_EE^8E.^DI9?G:1?3+_IXG-
M)5>'6VK)K"7SF233;[5NJXK98KG<97/TA?1^7#9%_YX%("3:@H/_HT<B/^SV
MX,GS. V1<.=GHB<-K]7[FW"43>2I[J]$_)KV)\$ A"W/EG\""XBO+LDO+, T
MF*?J9_TO[W7!2AC1A.A'[V=!<A5&6MIQC*75I<7GC^V;&TU^N]C?\F;YN $?
M_7WY[X<'C<-F]4?-1NMO#A2MM'(PJ#>KCD?QL#HG<C1N'1[VEKM/%?;JQZ[;
MX6&CTSVXZ[(=-#J=_;6KMNF3VMU&OW7X*(_J=AH'O>ZC/*IUT-@_K/Y)22PV
M4Y&%4R0?[:':^+G;8$D*9U=>F@SQT^%@K]UL=UOM3NM_KEJ-O^97;[Q@FMF/
MVOC1]U;SVU6S*9\7A;/5G'^_CS!T#^;?:6[5&;E[.[*S<#2:JC6.K!R,S34B
MS' 3E?@Q3&$4'BZG]S%.9EZKN?>/6_*.]V[_=H_%T(\HWXG5]\93K=+^?L62
M5-P?[O^=)';Z5VIOD*C@VUXPSE3R<S"]"18IKI<SPQF(HGOI+-\7*R[*\?A1
M)]SJ_8TW:*2&,9.<_@P.JDKP6S"4X+F'X$T2-?[/-_\K' X.>H-Q1QT$S6&W
M-^@$AZUQ)PAZS</6X; W[OU/_\TOEW17Q&/O&%ZH(J3%"WXI;6;YZA>]@,9B
M";+V5YYFX7CQYL7=W9M?U"/X5[5\4]\C8%>QW/NKEOM1SGJK)'?]LMRUN:'C
MM8IRM=F!7YZ&=4#>UW*T@1Q)Y.WQY:A@1-Q%L.X<"[0*C1[T<YC!6X8;B!I3
MI=U7X):VU/FL)#"#:3S\MB0>\5S$HM.N>,0FQW*53;;OV&2][F&_USOH@/_8
M7C+##MOWL\-:_;9KB%4/N]5;M^N__#^#Y.^W7065ZS@+ON]IZ<=U>X]7=^$/
MRRO]9M.'K]RD_8/UF[1^M@]UL&^_M!V)3EBB/;B^P>I)X9B_[>XW>AZ\9PIW
MN>_%B=?N_,WWLMA[V^IU&TW]D3>&C[*)\A8J2#P%=_[(^Z"&:C90"8<@.BV?
MK%7?"U+0-+-Y@.RW^* VG(3>G1_4:11%X.$7TY.M[<2N*!+4SY-XE \SL]J)
M2O,IZM1Y$L+0X;W>.(EG7F!_!7;06UCNOEFE$/\_5N42580\R?=@4;,PF,(3
MXO$X59DW6'@!?M4^)YC#^[_#BS(%7WN[WSAT'XH<^?F,[C9YZ,XL\X5*KL.A
MHL:9,=4&Z 76TQ^5)]]J=,SD2:3[SFIL+-%+ MW:;^P_6)YK&[>V3>YCFYQ:
MM; %!DJKL8_AM$<S4/H5!DI[_V#90.EU'L5 V7+#HK/?W7+#XG3IEG*M"_=.
M(^NBVQ/K8K_7.'@,XP)&<1_CPG<NXQ&,&1Z%OTL##DH<]O%PA;&7+M),S5+X
M#G)C;'A?N -L]3OW?]3=[XR[F]9W?4Y]^;SBR^?8F(_I=MP^O?W.:@6YTH!:
M=?L<5-P^G7;_R6Z?.P[[$;WC?OM'7F*]-9=8>PLN,5>L;W4J'(^*KK162ZZT
M?M-Q-QYPI>UW&MU[N!<>^J'&$RSZ>GBOI=X-O&GIVIO .H OQ7?4T%D(]+.F
MX2 )D@7\2L'XN+D-/RO(LB0<Y'P;R.UYE<0WV01?C?_%3W2\6/Q7\%UA!@,8
MX0IG%JT'W"!\RH7Z5ZZFWNDIC>7T5!7'!\L&PA+/5))Z60+;3XE]' R]NN']
MJ8BZ9)@MS4XFD<5VP>!Q&2V@.TB:4@I/FH3PHQOS//AAJM3FHY7W<20 ;W\*
M .#[=+# 3L#'OV/!8>KET1#.51!&V8+&Q\L,^P"OSKR;23B<X%]2L\$@-'I(
MFYD.-9JB1E/4:(H:35&C*6HTQ2_[_1I-4:,I:F?_-: ICN.4*,C/=6KIMP3)
M+KXF\3C,?#)A^2^?:=SW15UL2_)(3[><FW-BE9V>==\X$WH CMT=_#C7B=O(
M97.=L03L[0@]H*R43;0C38?@<:$_.HBO.0TVC6^((@N^D<7@I@4C7%QTML!G
M^7"'.*./ODT":N@J@D4=W9)3[#KI+_BT\OW.W,B=X&51WX<J30MNG/UUR3L:
M!VF&I0&3(-ICMPN>X?A;(S6C5.#8>EY_+_N(Z./:@<   GFLAX_US&.38#9'
M.F3KMW*TEISJU&X(N%CHFE5YK@4296\X ?FGV<%X6/3T1F*NMVL]?!]7>IJC
M>@$9;$@IN;.\^E$HB;)^=LW$B0\*(A,B<6<43/42L3^'LL""J?D\059AP)P9
M!C>.?+Z[A;H;WG%I=CP9%"&W(6XY6K"Z.RXMSZ$3 ,$)O&T[2 38N<R#<^;*
M%;N_5RK2S9L"F-<US&EY/NDMN5YX'9\(V%"4#EB3Z6+-/%/8'K![2(>@!H"5
MY3GK5:;<OI/:IPGUG!D^R@!W)8N/0:JI-,28YPD(=XI'=C8+26]0C.IMR]EN
M6JY5$;%[;B8.HNKE-+ P]7@WZ>4>'&M2?+B/XQR.MUH^A:XDYO,YZ(7@*E&*
M%"%?(1RK 24[BKTHSIPXTB2XMJ),<KPS>\D&PIQ,!O<F;?7*F*+#OU%DL]._
M7X2T$![MM>^1.>PTQ)SA)20Q:W?_=M]!7+G/ L%H[V_^*(G4&H5=&97=T KP
MJZ\=MM]*E_C;OG.(X)'!QAW+JT.U:XT/=['QG_#Q-(V] 3QR/.8[=[ PUM@L
M_.[#EZ)\'.B9J/$X'(8J@O^%]]\$21)@%)0NTW"&5#/Z>,'Y2<#U]%(%4X-?
MPEH.E3>>XJ+0Y/ (\L'5[YL&>32<X(-AP:(K'0EV#!&57.MEQ%?2M90$-QYJ
M@@168K-#6OM5K\ZO.@?9">!F(='Y *=V&L_I;CEA<V#7':G"_$;._+2Y8^\!
M.."HK-O+3A4!-SK=^X#Q2I=!ZZ!O7_!8*MCX8D6S>JZ2-(XB\#2,40TOD'FG
M6G,7%;*U0RG/=P,Z2F>:G)25=4Q3]GW<A<UB,E%4,@2](_J:<EN@W/,$%Z+:
M]6"[T\E55GMDL_DT7BA4GR;#)^Q==W4%;A6-VVUF''/KT-E1MO[;SV$MU\K[
MU2GO"S2_?>\W\B.G?/T?C6;@'<,!(_?XI:AQF2E[S*S0@N)$G4/KZO.2.C?%
M OW>_8H%2L#JP_O9]@7HPRIMOEI-MKH/TY,4B\-W[^E?L-%X%_VY!@]1<0/I
M6\<%.3":(4_0\,>CB6.$O7W;=.Y9BF#, MAHM+'%M5VZ06CPV22)\ZL)#JZW
M%$(**&X$7PJ^*?(F^ HHBI5_BUQM%D#A+>KNEV^%;M=Q)NM;H;X5GNI6. 4-
M%29DR1RSTMAU[8_&XPCF$XY#\O='L"'@^=))"^UL2XI0CG\*PX8?#L$?U^%X
MBG/'.::"X^$W\<#QD,'/OX$B&P9S@IA*L,'5^=C78Q#'W[SK8(II**W%4PTC
M&X+KO\!7TQ=PA(2!4G.,7L"?\TCGJ[0O+S\,9G$.0\1/0,WA5^&W)N(O$8%A
MD$Z\\32^,?;[+!@FL1K&43P+A]Y$!:,;6" TWV<Q/@/!61(9 '4,=]2,0R:P
M$S-W\3)UUQM KK'R(]))?(-KY:X%SXWV"Y?]*HY'A/W"48&<@3-!$<IDE47^
M[LWIU_/_"&;S]Q_>_$3Q3(7C&L.;>9WA8CF">TUR,B8]E(PHOG?0=3#W19EQ
MLQ4;SOI"V=9BCYO\7XENKCH6/PH.\%B#VAP@T&H>OOGE2YSA,@<O82[=%S*/
MQDO9D%^#:1"!SK^8*.K3]"(F=0S75!R5T30_\)K&F^PK. 7>Z:GOG69JYAWP
M_1>FWE$4Y<11@/<@IJH,K(U4[SA/J$1VI+(@7!>MK@' -0"X!@#7 . : %P#
M@'_9/Z@!P#4 N(YJO8:HUF<%?GJR=RX!:\EK['QH2Z:UE)UE6&%S5<"X%*+P
M+# 6X:0A8__>=HN1=,K@<B1<8N9!$J:%\CX"U=@L[]$\PPS#6Q?"A!#/*MQ@
M1;'@-(2GC<)LX2$<" -G49YZ</0TMT^D>#0W84:5@?Q"=Q0<N2HPX\  ;@4Q
M5@PF& [55"4F<2NEBIZ"=V&]XDV0C-*-QT6)# >!?.<1ZH!385B$%<5\$&+N
MRB#4.3P0'C4((REL98*A&MI3:\Q*U7)4 LP=:<#<J07,'1%@;M>5:'FFM\"U
MP4DJX77=9-UCI.:,&J87%I"+^OS? 6)N$.2H%4;PI6%63/:N@9/7RJ%6#I4%
M1I1\PNON(R91_ELGJ] >AYE2\A!%>"17TZZK"#M?FS1B4\;,=^C.]XY8B$3-
M,7D59:FD^V8J2/-$,9'$; X'4J<"V918\U[EY7.I[0F&DU Q<EC_')9$I? $
MU?!V!7?_E&O?N=/:G\VB$-M_$E!J_3Y,PV 03M$RO'5+K.9W=^?2>9_Y,QEW
M\H@1LW#,,S;A-^80K;7UJ]/6GZ0"Z>0["BOX(!,M?Q_4(-MUW:QGIY9F-X+9
MD<G6WM@5OD4[4,E4A7<X"L=CE2A,"@H>HZBK\"_M9J?I85Z:$71,AQ-&PW".
MV+'0HM@TZNPF"3.U%X_'^@EY)+8@E8;"W,(TS2D3*54;_&K"BHC/3N]M'\A[
MV4%47-1%:G6$^&R$XNEOTW-G\8@P+QNH4V\%>5^M?&KEPV5S&"4!,4)5@Z!Y
MB[S<=<6C9T9'IH@I)3^QUUT-Y+^;07@54%'<DMHYD5/L7=K8G"_5E__*86D(
M\88V@Y<EU(=N5#5:BL*#@S]$F!7^X0)\R!$%M(Y=3?#NS='%\9N?O&Z_N;??
M]'E+]^#E\NCE+4X1U8M_CI.TX5V$J*M8D\%1IM=A@,NBTD0)1>H&%^)0U!9I
MK"E"O*B.O0(;IG]HU9K5>OX:8)W[$EBFD<I4,H.-'MFB6"I>(3[Y%8-F6XVV
M")\!AW.8LV\MI2_.Y3!0V8U2:Z<03V6/]"6QXGNX1O@]7TH1$= 6)U7W0HTY
M>WH$3:O]<C!G.)?>"YD'4AE$=&FB?7&AP*%*^,"_8)13;7"]9H/K%-'9< F_
ME.(M,Y]R[NMV:G*FUW#I-(H%6-U[$#1TZ&(N5EWA4Y.0#(8QH^-QO&(\D+:I
M#VM]6*N$^XPT^FD$$J1\[XO:^6A,N3T0]ZX)98)8_[*J8-$R;#"OAOQ(5ZKP
MQV1V<]V'^=Z X=@U[+>&_=:PWQKV6\-^:]CO6MCO80W[K6&_M7G]&LQK-JR]
MR^ [<OU>ARF%L7]E)HN?=MW6_M,I4V;Z.YQL!I.=F\EB)N)>G5H:WA$8\F.5
M,*K,/%IH0#C%T;I/[Q8?22<=_!F#(*::N0__$X/TPJ4Z!<.?8MD<W98!X4@$
MW^9P" JB5F<_"]_6B(Q0W06FBTF1! \%HO(H2*?G3TD8NRXJY5F-IUQQ'S-%
M *)"T!IFOLL,_L%\P5C*/A>P2"K$>[-YHB8J2A$)0HGF.U#"@"@@SPE!DH/*
MY9-H!'I@5:LHM?5_-"X:'G(ET#H1AQ=S=L)$A,&$DL@A)AF\68R)F? ;\B13
M:@8AAI)DYO8L^ >X+*<@U?3\BE=7N&WAZ#_?W'XC]'I5#9LVZK;T6C1^,/QV
ME<1PW>X5%>T3MW/K'C9,1[TP0NZ-G_?X;]4*<DS_\P3 E]/_\\?IA]/+?WI'
M7SYXQT=?3R^//GGG)Q=G?YP?GUSLNOX_@P/%D90%^-QY,N3*#U,WX4OTA8XF
MGKY)/!U15A;A<T$Z\3F>@C4,H#*$8+007($_3 KQF@&G+YDLB5I(Z5RC =PD
MNB@B5<,\$3K ++Y2-!C2MB9[RFI45&$1>HPNC*>^![/YE)A2O/\*HARGRG<(
MIFO!W\G3E*%P=7[S*7-I[>[+R6_B7 Y?R#P:W@62$.'!5DGZ'__KH-WJO_=.
MZ/P]78;S3I-]\\MM9_,I=..]TJS$_(,*C0SJ$08RR;(.KJX2=26TZ.VFWVKW
M?!@UEVD9VPEY2[&PBEBAR X;QVA^[1'Y^P#6"JGN%$%NT+2S3[W2U.+(3)16
M]*!H-YT",;+VR"B#V61Q@A<U?$D3I+(*MRQYC%%F(YF^XSOZ%NU, 21* 0B:
MB%=,7N< <UPUC18KL\4'O)*#( T+=KAS?]"*HK<^8KJI;]1[T!)[UYK[:;5$
MKTTLQOF4;?PSLX7/A7\0)G?B2BQQ;B%Q>J*HD,FE=!0^-?RF&#G46P6,BTP)
M#QO*[16<+[>S!Q/7W] W!GF*Q&V[TVP 3CBI@&O11"%:07B@$'JF2T\U:?S"
MG/A;^YP8YK7TML8HAK'R)DZ^@;H:.E]$COE@J+WI47P#3NN_R7S#744OF#!T
M\W"NJ'\-F8:6CPWF=94$LSHI7D?MJBM^R#7!_TN63,$U.;57RZZ[;T<IEV!4
M0X I\(+-8 X.G3I\C%QMZKB5VBR[L;H@NP]5?+GH%,R2_4;+8FMP2+FX8U4N
MW9U T+JIA\OMVVLZE;9((Q\LV,B8!2/=!/JO/"J%]88. C BK*^&"1<X#>#G
M7[#/AE13=6OM5&NG%>W35P!*'Z2.?G#H"+P>-4@PGL+'[I!.78OTCB($&]62
MQYQ8,%@;T^F)C]?%KS#W))ND&9SF3U^]=^B!MIOO+W[]0O_6>O\3*"8OS0=I
M. HQ>(,-[.)Q]FL0?<.V.?G<.XZ3><-?XMPV<25RQ +6./!<YC9!>2^T]S&^
ME*FI<O#R: +:@@#6<4Y9U TW(">W+RXO3&N?5^91;>7V9K;R,]CGL-H46X-5
ML]K07$I1O+1N<9ZE6"X"6[<SUO5IY/U7'BG;#+(H\2A#U^QY@R\<HTE,Y#IR
M:93.0.!Q]$4+FK,@A2J4>9Z@1)-/;AJDB=2][79;=Q=H4T^(SH >'4862H^K
M>D*Q,M!'0O]KNJU+S2][AYN/RYEXQ:$[+>%BW?%C#>*";TPU"_<XKD Q#2](
M$N+1B&7/6CUI-B3UA_#?U# &QH+OC=Q/7)O&>1UEIF"&2(F]_(-.TT>%]9>$
M3^#ETU E8D6D5&$%HJ)F\TRWA4B4;J]70Q!K"&(-0:PAB#4$L88@KEFE?K.&
M(+Y*".*6&+^%.$>ER[?*V 4';(4E2U_4;<\ENL)\.M)_Z2&6Y=AU.UP[$ZW=
M=^%/&(IR/<+USRI6?OOP 'A"N^EW>RV_UW?3>H64WCO\G3BXIO+^@KZKG5TR
M3>%Q.**>.R !7+ I:A<70W;BYZ;><!I+S?F2YU5X]S%\#^?^ >:G7VQ\VD.W
MZ+TT2HX1KI@=C0.%F[B*K+5;42J/9'*.A:SS$5-XS!XX]$0N$$K++$IT>FGX
M?0]>!0(T!Z&-1X7Y?,+?_3'WOM)'9BD'"DY-)$8]?MV=MQY5%0/">Z%JJ1@-
M6?Y<XX\/"<%O&(4LD" H"+>+=<@PS6<S2PD8+:3ACD09LR2>ZC%@YP3X0GD+
M8 )!8JL!D83/2V3HK4:O^3=<"TJASJJ<(_.8#9TC';70#M)1?@7:1?]7T45R
MODORU5L:>\E%,@^CKQ_>P4':U#_:,B5YN2SQ;A@YR)BK8>X2[4@8 #<:Q"4+
M9\HR=:CO\]"2Q^)?BE+O(?/&E#Y(L1T3'-/A1(URI-7(DH!TW2@H22GM#P*M
M$%[J2\8.OUF!;PW</1DLU@IN>;9T*:S!.K@-Y#F%.'452&* $V![MWK]51H(
MC\/;%@$K;M?:WCN^>>!T**0Z\72H<NGUW)]K&5/1;1P<TCMI..71_$20,Q4,
M":Q6U'<@D#&![N .#/=&(?CCF@N4 7=.<W WR5W@#?X.VTK08GR0DX=(&]X?
MMVE@DRU74QE3JK(,%42.XW5^.8 C%.CTQNHME'P2Z6J7)%A3$5?O.RD6O-5V
MZU1;&JY[GNHM.*LKY_!(9[6[#T>UM?^@HVK&^."CVL;[<L?.JIY]?5;OB8 A
MG+#9@:&:"_*$[-- FV-"!"KFF$P;3XHGQ1/C /:<969I46 S!EC D$K%AGX=
M?ZK-=#&F!6.I=YA%VX4LZ<(':^Y@^06.PR78JSXO8/GK XUVHGF .1'P"&\^
MS5-0/O,@'%F[$DS<+/:]08X$&:)4_&65LS/[3ETAJ68 =^T*/*$DTJ !UT81
M=JQ"%H002\Z9%P>#V@>D4A$4(-I,G SQ7GD3Z=3K;IHEMO_"<A8$@+G32CRN
M9ORI;M:L_QLD(HTK1CJ$>48!CA(=IF7$@L:N9HOY[FSED8%N8/54E5_KKRK%
M<JL*RK:/<QV2&&!2N!"_(/,:E"R2VIGPQ7+0HNHY.HH!1]FGK4B1>0*C%RE_
MCAX[WA3C<3A%SS$EO8"G%@O8,J2'OV\8HCP>?(_)G(>K_6Z+US5"1*I(>[[N
M@P4AGE:^0,/'-76Q;;%M,3@HR@-0EXBFY$L%/- ,E:A"Y>S>PP4O4=CY1(OC
M'8C+"[LM)ZZ\7ZZ)Y/R.=VZ.'GQA7G:LI ^]M_W>YK$EJE/AUL!V;JZ\',.G
M\+Z/%O/XCD#,#'-<,8.?&J\$,G!J05I^]=G3DLA\B%J\BN&3:I$G!_HJ#\#F
MRI1BB.FBN%%Q(M!W:N8N9Z+XC3Q#:F[#L*@MN2$8!%QSJO'!H,Z19[(LQ[<.
M$ZLC$7P?911)BJ_Q=8$=>&FNYA1:F\^]2:Q2V!E57S-,U@R3-</DJV&8K-$L
M-9JE1K/4:)8:S5*C67[IMVHTRZM$L]3%+Z^N^,6&]+QC*<L]Y_#WBRC)^Q-;
M-$RQO1:'T#!CH+Z'*16F;%AXQ]B) 8;JI$"78DCC'%-.Q-@2_R4<4;9&CK(S
MNLS9KB?#9W1LD?F;OF=>J^T1FB9U.A!)X@[#DHR_W\3@WY )[,P,-"*" AV_
MQEZ\$;6HQ?9#,$F>D2K47+N1//-%6@VL+.:%Y9F[JT#%R2!K'$0_AX%%F4-L
MH.RO;2JO:@4K.RM1#3H&].&^,>-3/V_<$J]@@G6J!;?(?M0Z6%7A]?!;N?JD
M4HIC__T/=T"+B]/J-KIDP1)7D<YJD=[4M&=1E@3##*74C88M)X%[_<:^C:RO
MKYVE*+'3RQKD,KK3ZR6FNR946!3KV2PTIS^;F,>"C$7Y&)^?Z#>F^7R.>"D^
MVP8^27P>S)8V5.&UXNS651R/*,)INC5[1_#,OV(G$8590C,S9PJ8+4!.#AP0
ML9'@08??3[,)D3=5KPG#":B3(=8\153Y3]<Y#GZJK@AZ-@@CFV=$/)WN'XL?
M$N><EZ<NF +3%9C/F5*G6X%+<(DOY=])8Q0TGP$JN+I$]$\!63$"A0T7*2V'
M62_00S#RF4XAW:G9=7W"[W7"CTJT+D0.R)&DFN7ER2.1!R\H.@QSZ;^0>7A[
MF/,QEP,J/-,C&4S#'8L1PSV5@@)$3AKO N^QA9NPE;LL0%[0E"\RRH<%,[8N
MR_UJ\:)FN)N^$XU-:J\EB\("8P#I9T"]7TN>3+#D7!W0,:R$\!]]N.>*?2TK
MAJN8-B+PWKJ5""-%T>D-VUZV_0J>"OT(K%3?+Q8Y<,4Q@< PY\P@0AY:U51=
MHD6\9O5LM'W1\-YVG!?@VH-XYC14>$E^-\J-AG<ZQF7!:(S@(V9A%,[RF7<=
M3_.9LR_6XM%OH-PH;N.0K 5\F6^GAYN+^#]DEIWRX!(E;+6F7VG">"G=B)07
M$<X@(FMBKO>@.Q\<(K9E>+@6SU^UT>")C?$FTNR1@F'O^_S-D"@IIU-9MU+-
MBK06T6/ZP&.B%Q>FQBN&&"0D(RFNF6SO1BM&I@LO!YE/B8K'OMA&6*K@H)ST
MK"GK3F %EKA1, L(LQ8G[I\1FX2='%W+J+:&GM;?P1:> 1P84A$N 9;KW#*1
M=J=;)/DQ##AO6P=]A_1&5$C#^W,2@LS<J"JB/Y270A^=U2/AY_4*:)MH@L)A
M>:K=&(C63+[QGO"-Q6?B;\@?QQ:5F1I.(EC_*T9.V-_;H:]?II2IW. R)BHQ
M&3 Z@"Z_T2UJNJO9"?E2TL-@+&_(4-[Z,#S982 JKSC/A$LR3BK#/')?EH5=
MSL%!XZ#B%%3*/V'!4/R9+JOB3?#WL<GM],H_1HV-MH]UWG6<"1Z" L.@T'L1
M"];2<W?'DH!ZA98!XYS0P=PSP+" H6 YU*9J*2*R@O6LZW.'7_S56[ =#4^:
M&*C8Y\#""4T DM'CA,:6&,MR@+;NO?OT?E:S>2C.;ZO] MQ&FD[CI4SD)00D
M:"(7^2!5_\K1>CBY+N=*M]]UKX!WZ> J*TKRTMGL<K'T\)W/9)SUI5*XONB>
M[*+[JB\RYZ8#*<>6,(4\5Y D6)<D^2T.NU#@GB+L4_(F^7<.?T.JBRO"9$21
M$8)7HRFF@PY!1EAM'*74UQC;O>']8=#)'.XWN0?[ E/I-C#7+L]ACO4U\2*8
MTCM-8#_!NIS<*9)&EC_I8$&#=]T%&*CVJ\VC9.[JFH,+5U2)D+!KHN=/77&P
M*@([""E=D*/MAQ5?HB<47[>P9H8%:E<L,NX#IG%&^ =M(V **PF#:7UX?NSA
M<5HYB24F%6&U07;_^W( /SP<=$?M?DMU>W![MCK=PV:W=7C0W>_LCX/_:>XU
M]UKX_[H'S4Z7!:75?K_UAL"=)V8B^1D&]2EG2@]_)LM %S4.%#76J;[PYS%J
M>:R[GE<<&(XT,M;"/3L/HD+^P1V11+=7PFETU6@PPDKTX4*[\<$UK _=FQ@$
M%@C/2&'$ !=MAJ%:C 3$B9OWKP$C3ZC/:5ML(6*:#X<J3<?Y5&+I*AF&W%?.
M"1O:S(FT;\EU*!W+JD>C!#$$7'5+\4DU2M_7>_AD>TA)ND H'4:65T-@<':G
M2IL=#Z2P]<9L%L7L8$>^J2Q]7Y^[)]XS;-!!E9-CN1)61.AU)X^J391F(HH:
MPF'<=&2?HW^W9B?K$J.ZQ*@N,:I+C.H2H[K$Z)=^NRXQ>I4E1K41]QC.$_BO
M< 0J\MEBA%/W)BS-<'$@5:!R'5O--%/9TJ\8G895'F%T'4^O&?<W3]0\2 @Q
MS@4J/KX:,7 9_0>V!6> %V79"77.Y'B9FB)O&J8UX!=S4%0+"5&_Q^_6CL"3
M.@*P(*K$\ZRBJT#3X&*N(=8M02F]@(F%2)<Z4 @)J=<H"*6A$HH ^B:W$&Z(
MRM^&\-+IV$/"QW@6#E&0,6$0!E/?J0E!! +-5J)%X/8BOQ\6L 3C,0)52D=S
M;5D8U9H5JYELBD7^/G(<9GP8'T*!C2(;I8!2"5T)EU_$7%%.OW"92'1%>)IA
M$&'^ EZ@$T,4/''B8O"1C9>!#A@'UR $U!,.4T.T"!ANF4XU0A.3(F:X*!EY
MI'O()4&85G;[O)DH!..F(;6T+1:4V15BVC;12V9'$,TC%5^R6.5M4"/.!Y!W
M&Z;?9+_P[?@S&&:=*7AP0+TU/&@W]P_&@VZ[VQV,ND&WV1YW6_W>87/05]W.
M__0.#EK]%G<[E;R9[0S/'OPUQ_=P&_%C*I-R"BOIZ[JQL!&QBE2=R5KBCNL^
M]>;P(<7;'@&L=4EC_-R-<G4T'^/X5$H31H3;Q3'5K0GKZNQ5C5.]CWAX+I"]
M/ED\O"?A3@A+O]4X[*P7EHWC*NU&\V!]7&7SOW>;CQ."HD%U'B_84PH4'&X2
M*!@2+&CEH7@,S7AXFY"39/R3.AZ<+.&\C:P;*;]].>YZ]!]CE@<;13S>D>$5
MY_"(4?I386XKU%TP_'8%9E\TVI.1J?ZX/3Y\+X<6C[03Z,4Q/^INMSH'G>'^
MH^\V!L8VF?VMD[PE1/:#5NF)S@2BX1\@_Q[^LX=QWA]Z$LISJSX)Q[>UE2Z+
MQ^,<B*;W",KAP8>B>DG>/M&4WY>CO%LPUW?@0OC-WL&2#GPTO>?=:>ZW!ME=
M17,GY?(H$O=$AW"EQ/T P7JB*;UK]P[]5K^S4K">3'Y>FG(6PN,1]BKAPJOU
M"MK,N7V[]7+K =D6/=5J=_UFL\N%17?553].(U6L_>,O\1,)6]??OV6!ZY-9
M/)GOQ&[ZJ7!&3<#WM9W1=]VV?WC0O[,I41_/C31@\\ _.&S5!W2SY?JBL$H$
MVV>DG$ZKI!?T!#='_1,4]W"ZIR4L@;@.14)S#.N1-?-ZW:&'+<A6*KA6N^<W
MNZW[.DL/6I$?Z4H]ORP_CZ/UC"+[5&Y8J]OS]_NK_?MGDLR-\R1W 28\ #JR
M,CM;G0JRE*U'RS;>EK/P$E=H$E)CM#R5]I-X+ZX( %I.).*-*C#12#50H=I
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MMF!B95B8O_<5.S4%3+4AO-I%DF]E'K#PO4D\'<':)K,IO9%R*TA!S1UNPMF
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M 4+T7\#]O.:>N.1DH0%,>M%RW0W#9)C/,/(PQ GQ>AD9X3U&UY<^@6&&'!.
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MIGGVB3#K9Y04SI$AEE)>9J9;!]@ EK)C(;O'LS]$O!QF8#%(F*A1L.-".IL
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MY_2 F4WJV;97L,(6,PM3*]"&BDO!X8ISBELX:WSU-C(/G8K/UL+3?718OQH
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M<3Y:%A;4A,DW#K-2Y[Q/GAU=1I_ZEEZ0&C')?#<<"8!_I-8D18\?N$_T>*(
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M'#ON97\Q=B,_@',/Q\DZ1Z75TY3E)9B'R?Y^$%KZN<2@K<V7+;/(#J:XMZ3
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MP(OV;/\D&\0W2@AXLD6B\WS0$*<(2MHV 8IE>I#&_I&6X\+O-*8?!_Y9UP@
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M9/J#>>!S!\D+(,R8KCM2L=[J*5!6QJ.?YRS.ZJ$%3#V+7<G@$JTB-K\Z$X>
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M(3 I1+X0/3LXF1-H&2-X$]>S/-M%QY:\@/V%[:5ZD QML@=J(#7F?H@IILO
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MO%L&Q4$"Q#**[1)=958,AW%-=7)-M0'/%163T>JIHJ869V%SQ=0(Q50OMDW
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M$#9L]6Y8QUA7@="N:? Z?<Z!#8;D?F9;LSE0/0D'GKT)N+)Q<^)/I_XK.;Q
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M"I$O1,\.,"^2LQ4Y8V'B>I9GN]:4'(*\@$F.=L)-RZ3)GJ?IY ?G?H@IC,O
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M'?)7-WJ&%_"8H%0\/W)"P?EA/\.:PP\1XJQC,A/NE8PA/83ED3&(_TT@? -
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M]EU&0<;O7O 'R!@CC$QN4>&;EZY1Y4,N["1\IKT,#$T7SV+J"% I#A+!JB@
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MSDV$!N*&\AO>*KPP0JP([(HG$@F40D)?KY?,O8-_<S3^DL4((:1OB2X."8$
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M04TGKS*_M\E@T9*;0$O 9;M8=L*30- @X@$&,J^PI$KZ'E1.@<;(G).(;V
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MP'"4CEZZH^GB*7#GWV,QR@C-6!9B(/6OQ+UC(CD[\W9"]<!?1<4]!\WI.T:
M,5&OA*(1B.V++!@U456^E!&J*H4I8QJ,RH<@_(%_RD5IT[L<_S'%SG\PC;"D
MXT%9R"LO)<D5(P 8;62T\$1US-D"*!5W3X6KM.",RU8B7)-Q1_#PES*:F7_O
MA8$O<RIY*<P')J!$%/R56 +D#&<-]I@6*<B5PU2N+O[R3+C/0>"EXRV9FPNH
MI5O ''1DP(8&;JXJ)U; E"&TN8U1;"R;2L$$$3JPY8(% PJ*E%Q A6%GFYE
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M'1>5"8%4Y<WN,Z-3V1Q@&8:HKAA!-EK&7VZ+N1M6+)E#/\KV1;$?S!F^>1#
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MW&E].0L[+JMTH:M9!9EI+0]!B'G(!+K3/'^\TK:=N15%OQ0V<ZB_8$F-[K3
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M'"&Z$ZW!EINTU2U>KVG].W6O81$U? OAX!)?H/MX<4#9>Y"0UPBV7>)#=\L
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M1B8QBTX *D;,&[K$/%O"QXI7:5ND3(+=VO'<0TB&_J4R.U+UH9G=0.(-)-Y
MX@TDWD#B#22^)B1^6!\2CY-'5^1NK^X80=<&1W^9./K]/=GO$/K!HN@F[:F9
MZKXE_NM1"4Y^M#=.OMU_[?B,0H>P=G?4G0V.@,O(WE?C9OG6\X\\'T-L;Z[X
M8^5B3+0R.SA^X_.7[Q^L3M.RWOWQ[?;SAV_?K.N;_^^/VV^WWV^_?/YV%##?
M:R&VUP<&NE['8)^]\X)H$Z&SZ]*QH%]\ZSJYPT[<'5EDD\J3B,AW?KDV^C":
MUB_H?.VTWM+7]/?VV[]C[](;6 H8Z+[GB%SM.T8ETR+E4Y@'LT04&1 %?PAW
M:2U@4A+XL08;.UH$(=93=+#J']9(G+%0P CQT65:'2GF%=?0R)]QH]A;(? 3
M#'<JTX8M"+$IDJS*Y@?P6FNVA$7SNJL$JERP%78EW%B_H/&MKX_O!C=LY5HO
MIZW4+4$V?383+4-%7_?"RJB[= :2RJ@D@%X;$QT5]+L'A%O,$)M#'9VPNMY/
M48Q)E;E0Q:DR>%6:@),K&O$?0J7X&(HN\(AV)84BB=Q&3L,8]AI .3,XXV7T
M_S:N^GLH'#>BR"[]X[OH: _TP(L>W(KBFM$M>1BQTHU O(*@ ^$$8P]2_63<
MF P'S8%TJ\@I3RPXLB7M(Y4Y/?2JOHIJ(=^#:\Z;<IDL^C4,HJADJIU68])J
M=K;,E*.)*=S.:\=KVR1.2N^/^Y1#ZS_FT,3$,L?W299?*UMQNS$!$[U?N>2F
M]>&G"%G,PV"56W&<4@9AB0YR@*(]+=!^H;*2B##)*7V$&551:MEB.[#89K=R
MK842K,X,V!6'1E#YCFHUW$.:/7 4&Y4[PEE^^Z:T"@6G<%LXU[TG,#WOUTM)
M%M%U*INB3 ??-WZRN@)%XTJ,K/:FE>Y-MS$9V.U.V^X/V\4=*N+;Q8EKB/5,
M*1PT5ZA<#2\MJ[I,%\2;>%Z3J[P6W,N[+2KE1FW1,#B":-B'7#16ZC4FG7ZS
M5: 47H5<R4M>Z/&!43E:AA7@1;ES6=W:WG;U(;0#/Y&K(/0&WA54MJGR=S8&
M%;!\,:5?<.I:>(R'E7@=1)@@2.G IPZE<R)?63X^^^CA)%J-6U:TL;U.I_*;
MG&_M@^HW)OW6KH/"TY#-9O,E>8F2_V>4:2JC*C&J.HIJ0RT<!K9N!CI0)("J
M(J*UU0TRW&>WMM+P#1<Y[V'J-;J8=P:-R=R[KVAC[O@^MJ^E]IRRDX&0;%3F
M2S4:4'S>M*YCC@,&)8#Q:&P^H8IZ<(-J;XO F9"G7KDHR5$D?I0"#M)]Q^AD
M$%L__."!!PIE(%#E5^5$M.L@<OP^6,)BKV02F"63P*HEMJQ?FI&RN+U7WL^K
MA>>ZS'^#&SML3.('F/1&B'+4%G@:F+.))!HZ#6HJB#<"+>:X]O1Q[(' 7"1*
M:G>OT131&15\W;(W3>N/-4GCPD9J<D (*91-)&,(H<&2TBW ,*_/ZVY+!J"<
M+[]BR]R 1:*T]XS!S"J%"J>4@EP9ZG*EFV$4('5,/8$C^S+_DMHB7"/X,K^A
M:7P/WC&N-=SZO['P#E\A1,55)V6%$>A'X^:X("O^)A>5R;\KSPV,L2V]]MS%
M7.3?>02Y_(KVHA+(H5;8&(@@5?U$+%U64A=9C\RADL<2H"5JXFKE=$6-A4P4
M6XM=XQ&LQ7PBF=:H8;PPI;-*":U<5[H"S!I5@L+6I$^$[<EXWQ<T )Q,=_&T
M4N_<"U<R>]*Q?D/ZM6Z<<!E8D4>=$\A>"+*5$$'X.+'80;S2R64"G\S22K/8
M<2"3"!\ET[^$'H&]0")-!*H66U0<V8L4,EHL1-YKQ-_B857JF0L4V#F13L%W
M,%)+DOTJ8#Y7CHLDRMRTS41X4)VUZ),6KMY3]/G1-''4\$OH?BHNYXQN!GMN
MT\-4?G I6L_%08Q]:\HH<HL=B66?9SH8!@CPC@"[ K^F_BF*/4OO6Z&>-PB]
M5>[B@ZFD\XDJ#9#MZDJQ%/!LP=QD"5)8JBZZ.?9NH_VK&,/IC(LQG,ZX&,.Y
M)C&0SR 2F*^5\Q<V9EHZD:AS7E'$&[94J>64FZ/M]N-.#'U;#D*]L5IW9/U"
MX,D@ 4ITH[^_*>)I]J@-T]E6&^:RHPBC?G/8'AT&7=%IMD:=0Z KZL8;#G$Q
MC_>*J=](@X^D-KI8@2PS6<0"=U I.]EPWIF/,Z&5EG6 !8LXX:$7_!]/6IB^
M($) G,&*:MG0HXP-W=W#N?&[TJ%N15HB<O0U23_A^T4?]:=4!E[S:P%)"[[X
MD-*44HN[2C9C*AWB.DKMYZ<<%4;_:AW92^#F6ZQD35&FRE86^3U5Z^QLB=GO
MR^.&);:SQ*U/_C O9I^PM>RM4K7X;_=S/VG, Y=XOV\#)1D&.@SA_!H$+GIV
M#)?4Y!*Y<;5)N ,DW+$[(W,''.A4>2(LMTYLB?4W]/R<BA _ _XD'4\9(W0;
MDW:_&#XU7/ H6GA?;&V6NN->!3?\<J[L((_FN_-3^[+VQ=$#?FG;W>ZHP#)_
M-]Q2DU8^%9UZAD>>DT>>PAC]QJ1CM\=%G,F9\P4-W\_#ML^$0[Z3W[;22UMW
M9[-(Y2XAE1/TKN+\Y;>40)!FY>$W+];+=I -.4<1<P821MIFI9+F,XMK2YA!
M8S+NV:U6\>I]G+9ZB,-_M'PJMB>HS$:N6Z[JN0*-LH,\9FGSA@-4^U?UV"/P
MB8A+>:*S+&%.3I_Y7T#RB>)Y95-YKNWD(3@_L#"R'F+2.X]0BQ),&+?GI1-E
ML%LDOW/0$:(.KGG!1UY !F.B*LE3[;TL8@@_*D0@+P;E\2=55DG(\)KE2_.7
M C<IDKI>A\%/PBTL-S4Q@:/]P)I:?!A;!GR92]GX >MF;@@=R%]''07JX@"[
M0Y"(.V& 6H'N;:<M<9WYBC8K@A9=R1W5:XI6(UOV!+;\5C&V>'_-0QG71M!^
M8VLGI/-/+S3M4")9_ BO,&J:DCY6^ZQ&H!\WJZXN>58<(<-[)R,4":C%12 -
MQU]. S^)>*]2@J@AJ@(+FL<<Z>I8D5@/UQ'%GJ50/"&1=51;323[J%6*9$_1
M_?O V#_)9;W#]6 ;Y;K ]NX8K/#!R!YT2F#ME1@VW#$6*F3F 7)P*BANVW;\
M%[[I$+N1DE:OA:15W(DL:1T6R6]=([WQ]MXZ*"B;3% !?BV*8SJ7NED5._C]
MP&D5VGZW&Y-!2<I)=K_+R;!&LWE3A,84H3%%:$P1&E.$QA2AF8Q'IB_K"Z\G
M<[[V=65+2JQ(0_AR3(&)(HDJ5MITUG&-=0VM %B-JY2R4&L!EHP^#>QG):#.
M"R?BG08PK2)TN:US)YR+5%U0R[>0GQ],E\\C3:0%KZN4M15(0I_LTB"E0>Y%
M6D^0?#8S)4=M?+"C,8BFUVZD)"KI)F*4U'"7YJ8*%=QW98H9[&LRX_6ST3>D
MQ:_720BZ)(MX(4<%*S]VXOOQT&[%\^@BH*W$D:*2R 5AYWR9E$TNDA1NO_[^
MG\YJ_?9]5;J.>B"78EV>ED,)K7LDY?CRI,B;A=E(RLYS\"#9S.$])Q5IS),X
MH;(5T<*:([2_236>R[^S$LSD^3?+M)>A4*VH>!\EZ#**5*(I3.(O;NYE$W9D
M+LV.IK+[UTUKMP:J<%JMG(Z/LH:H5G%_6RFN7DG+ZM[^+:M-*2Y3BJNT%%>W
M:5D?;S]??[ZYO?YDW7[^]OWW/W[[\/F[*<5E2G'5(::/>-/\E[QIE'0K:RAR
MJ=6Y/J:7J<<+.J@Z2^(B)M^N[","EQ[#FY^R2=ER2;W/\.['VA.DA*+B)% 4
MF8Q?C_JD$0UA7R[-B3YE\0/JH-)AZB"9>+ %F(LGJB509U$>_A#)AA<2/\LI
M+ L/-'90=#:8UPL4XD4+[%V*YH_UZ_7U5ZU&NL\[P%&-])7STUNAKH";D43<
MGSR%*=V3[/'\=2(2%[%K3/[)Q"\^^X!IYWQ;4=E)I\AUK!C,,&8M,<F$3 _Q
M*R(&S/J?TN!TVN)L]%4ZF?S&-WL?5N:2Z98?7_:*:8^J+IBG>PO*90+59QN\
M/7E@/;LY[5ZS1YZU3WA$5ON-]:\DB*F6/#!M1-S&:\=SKN)]A7@7.G0)"?L/
M/M,R7=^:<SKR.77>2$X*"-,/_.1;X@C3IB<IM]H6\^A!%V3"#.O[D_TH_V4K
M&V&?TX] ,"R=L/SL[=P067+9]6L*9HM7J66@Z<NG8>/C?,6Z(,FN%9\!&X@J
ML 1A" ?!"XE--_I#XI* 2\#ABTJF:-:)_M)4#"6!:PDM0%5LII3645H:>C\R
MO7??E%X^ZO2C9(WX&7[*<# Q)P,"YM Y$_W(<A?ISS2+6?8:*C@%2H\]A[NI
M9]W"*T@9_#(O,W1YO\34MNV7V+;]O6W;<]!=_DR+&)">IXL4%#I41<D7KC1-
MHXL4!$JIAJD>* I=D6,F2N9PBAYJ=?.0EV#E)\V++.GMIU L\58LJ@FG:+T;
M^'<!?B/Z[8IF@-1)Y8%9]QY[X*Z<'=.G_JY(7'/XP9Z+X=%Y(3&ER!/Y623S
MN J-DE6@=>ZQ,%969@D)SYVWWHH8P%D%*8)@Y?R !36M/_D4T1D%XX)LM E3
M  1\M68A;0NZM[#@"KV<V$4!#[ D24C^+BKW)@^6(PGTAH-9;B+M+U,A!)OO
MBE0TT%-5WYK+4<F1K+'H![R8[PVZY%Q&07VA1 -I;.3VST$[5SV_Y%TM9$RI
M9C]E,P<U;WA@0U1!#[C"K3AU_!_PGR6>%4DG<>_J<!'N#\Y,T@.JEOA$H%VA
M3F2Z/2KOI#:4+#[,+]^")*;WN&"U$>'*]V$194$W^FLS6]#=M@47@VZ\+J_X
M(DP:-UNFBG=:XIODJ>;17DAV6LA MF5P0&#Z8*$CLJ'X=G..!.;;?G]IQF[3
M^I)PE2N*,O7LU #2G\VMY@0U-/$N/BZ?6\7PJ;4)HL.YXY^1N?F#67\E[EU:
M'4I=!',0BP$(<-F*2[ZH*!UKX''.C"RJ@G)T?_/"9TX8;HBY"" LV474?HJ$
MGX2K\.N0D6=$0C!MP8WBHE#25/UX[6SX+^&3,-'!FRDK9U1W=>5HN%O]R+&V
MIRK7167/$?@L:F[OCAP8()4!4AD@E0%2&2"5 5)M!5*-#9#JA0.IJA0C"MJ7
MA/([E0Z.O=+MGDZP-%!9I]V*YCNI0:!GT/^F&01Z4!"1(+]C]Q(*HKQ##\0A
M'$P"B9-!X,@I?/'5"^&!SX$?RG_2Z^DD2Y 6@POR.U',C&)'Y(_@>HSP8@LX
M3];=AZIWVK^VJHRG2E)1YAV=G]H_[D%ZLZ?M>BF!_TZ[V1YN+WFY[U##YGB\
M7<?=__->ZS!ZGYF3F9.9T^GG-&H.^]M'JF78Y)3B3KM>29J<NHP%_EEXTE(1
M!75"U*S*9@+W*FOPU-^8@Z[_R356]EM_-[/^,RZR--JI/U:4'\J4\M[CM'=5
MT-A=(^,L"5_$28Z[ 3OLZ1>]M1VSM<?:VJ[9VL-O+57;>NKM5W"-'WLSCG0M
MUI".3R:G%[!1>\DZLU%[2J[7O5%%.73&6NA^2^+>PO.\M(Y_Z9F9'7QF!Q,$
MYCU/?,_%RZ;*9D1OGB*OGIO#S.\/R0^O^+$+XN\=S<9*(+.FW]A+[#<V:F^O
M:"QZA.$?6I\P%=I.RP'4K5'<&U)KI.[P7%HC'4!H&I9X$2S1.0I+S+V?S+WZ
M-PN#,FX8\92O=N>M80?##F?%#MUG8(>Q80?##N?)#KUG4ICZK8M0F+90_L$)
M_$A64!6!'XZ.CS3Q6G3<?RXZ;C<FPY;='G;JT;$AUU=-KH/3:R']SB.U$$.J
MKYI4A\] JEU#JH94ZY/JCGYFQU,">L^C!%R^ASY8K5A(B3%K9\W"@EL^Q1:_
MH#:@M6AZ_ SBM_\"_16OGI+&K6>@I(&AI!=(2<>)LFVGI*&AI!=(2<\0G.I?
M2'!J3X(Y/%V<@28_?H8H3?^Q41IS_ <__N-$);8>_Z!ECO]<CO\XSOSMQ]\V
MQW\NQ_\,SO'!<SG'+]Z%\T?S6].ZPP*Q/E5HI%Y'EG-'Y7(C+%]"%4Z,8R=/
MY<_@5Q\\UJ]NC*ASIJ3CN+VW4U+/4-(+I*1G<#8/C+/Y!5(2_.(92.E"O,VO
M6;EOMY[!>3QXK//8G/_AS_\X+M_=0?K!J#%IM\;VL#LV1/#<1/ ,_MV!\>^>
MS_D_%^Q\V'HF(7#Q?AZJ3<(SY<M2YI^$W-FO:LL+4HZ?"ZT^;!\XZV+O>COG
M;H6].A)\!B?[\+%.=D-^+X[\GL'[/3RX]]N0WZ62WW,AQ8>]"[^ ]Z6T$Q+4
M61@TQ_&<[T%0_<>E'ABZ.0NZ:1_'3;X'W0P>:0@;PCD/PGD&-_KPT1AL0S-G
M03//Y7H?HNM].+;'[?:Y$,X%^>/*BU?>ILV/3;G*E_][\]BNQRZ(HTTR[&-O
ML!UQ0TTH/E'5>8DENPS]M'?$'0]&/Z/'9I,8^CEK^MD1N#L<_3PV'<70SUG3
MSXZHV^'HY^"A-H.".3PU[ B"'8X:SK^>TNLY]!VAISJ'OMOS,NHU)F-[W!N:
M<W_N<]\1(3H<LS\VH<(<^L$/O;,CO'-@9A\\"[._ ,=+N Y")V9P5M-82UHU
M'I@B1>^(.QU.C)F"/R^2?G;$H XL$4>-26]@CUM]0T,OB(9.Y04>&2_PBZ2?
M WJ!=\N@<>LB9-#KUM-/Y=<=FS)#YW/H!W3&[B$&.HW):&3WAR;[]-D/_E1^
MU['QNY[/H9_4[SKN/0^W7[POQI03>RQ]G\J_/#8%>UXB_71/ZJH>#QJ3SFAH
M#_H#0T0OB(A.Y1T>&^_PBZ2?DWJ'QZ/+$$*O6F_OGLK9.S;U@<[GT$_IH1VT
M6HU)M]^QQ\8W\_PG?R)/[*!E/+'G<^BG],0.6IUG8O>+=\[P&F!>>AJFZE<=
M*C^1VWG0,H5N#,T)FCNEUWO0ZH%D[?;L_J!NGK<AO)=&>"=R1P]:!W='&YJ[
M4)KKG=*%/6@-+EW8F3(IY61T(B?VH&7JZ5PVH9S26SUH(9:YW[;[M8&$AEK.
M@EI.Y,@>M!Z-6C:$<A:$<E+G=[MU=F)%^,GDB^1.]H%(GE@TZ+FK.)G?FRI8
MI@K65E'Y;1&$\57,PI45@I@+O5G,>+L)@_DKW!05P;*U,YN^H8W\#OOXN]I&
MK.Q8>F44;X5V8S(8'ZI(]87Y35XHL50$V6H3R]Z*:/M"BM 80JI'2!5QK",2
MDNE;_ ()J<+,.<#EU3O_R^M5XSUZ%5') QQ]OS'IMFH>O3GAPY]P1?COB'?$
M8YO_FM,_^.GW*P)Q1SQ]T^'W7$[_4-IA\8Q'SR#;+]Z?\BGP[XP[Y>GN%-S'
M1TBM/1SPX\:D;?>[=1LX&=/FG$EIF[/ED:2T]0+LF(+C+Y*.MMVF1Z$C4WC\
M!=+1-E?+T2ZV3N<2+K;7K*IO=\0<CS"ZC4G'[G5J$H8Y_].Z:8YRO?2,G7XN
MA[_52W.4PS>5R<_E\(^@5NXA]P?/(O<OWH7#TRZ=*&)Q9*V8@WOO6DYLS>%,
MK'L\E$(BYA%S0^KNRI'TW_\XTI(O7=>O=&-)_.@U$=(A^'G8F/2'=G]\* W_
MK#.O#$>]7H[:49_@<!PUNO2<,L-2AJ6>XMBLR5+;[8V#E^\WW&2XZ0RY:4?"
MT,&NIRX6RAIW[':_>Z$,M8UO3L<>1[(3*]GC!%QP!CZ-2F_VX?F@W9@,._9H
MW#N7E#E#[:^/VG=46#D<M7? S!^T[4[/D+LA]W.+5AS28.@^.L_$4+JA]..&
M9@XOUC%+IMNSP7XY%V)_AL1_;3%=F+$;)-,ERZ[FN7+BS=2>9VK[SL"\Z!0O
MNJ#H[; <@.\Y4V^YO6O1^538,+\W%4I,A9(=[>+]&&:(W<E <XL\$&4.:757
MUO4ZAC^=V;\2+_+PLZ=@7%^4)_Y%^=O;_1TE(M\E$;P@BFZ"U=3SB3I2JKG1
MB4;>#ILZ9NI+[,!F..-E<,:.FIA'YHS')H$;SC"<<6S.Z!Z9,_9P^0P;D_;(
M'M9-HC;<8;CCV-RQ \-P"NX8701W;&&"2_?POR@_?KN_ X=]9%7H_-L9&JH]
M1ZK=@74^+M7V'EO&P%#MZZ;:'5'3$Z@/O3:H#V.[WS_;ZG.&<L^/<H<[,(NG
M(-S.\Q#NQ0<">%[F,HWO'3@YDR^I$")]O3C^IVW(Q=O(NQ([M4CSTW!PO6,U
M$'W2 9ZI@\DPJV'61^2,'HY9'UM2Q3"K85;#K'MEH]9AUCT4[OZ!'<V&80W#
MOBJ&W1$L.C"[#EXTN^[.)7E^YGN>3)-GY+$S\$SM3*<]G ;[Q#[(AI&>FZX,
M(STE4_=PC#0RC&08Z>4RTJX<X /K?>/'Q44,,QEF.G]F.JG' QCWHEB)0I/_
MB!UX%?SI>O<3.>_/R0J.9C;Y)WPH9[ERPCO/Y_/H9#GAKR2*O?GF0%30;NTB
M@PZ2P<<@M.(%LS;,"2WFN\RUWK,96TU9R'>[V[:M3JO3L_&QD%D/^!\_L.(0
MWCIG861-6?S F&]]8O=L:<'C_"\=VX*Q^=^[LB(M?*+'0$.V#L*X$ /%O"CX
M;I:$(9R,-74B+[(<W[6"A#_"<ZAB-EOXWK\2&,B%T_2#V)HM'/^. ?FNU@[&
M5N. 5K<./7@SKK&IJ(=.JOQDQC4.QIVWQ^/^4PZFD H*!\-?#TP2\(#]FP2.
M)L2G,CEE-V4Y9?NL<' &I/<GG-,2Z )>3/*F+$_.MAX6WFQA/3B1Y?E($'"H
MGH\/^8P+K@<O7M A:ZET5C#G>V'3UYZOT2$0VBP.@&Z3B!.(BU\%:QJ#P3Z
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M..4,U1RD0D-SO_B_2__6.W1O_:%Y%DAU@Z\#?P:_HLE]A]>\6P:S'ZD:UVN
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MEP9G[?6:W4/I@0AGW:X'[O]YKW48E=E,JM:D^H=3XW,J8*?],B"^V]$P9XP
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M';M7M]#"68>232KG:54_S'-OM^L'(DP,=DL,-HK>6->S6;)*EE1NWF7K$(Z
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M1'KZH[G ?6M 8R9PO<.52P1A<4;R^6;4AHNOD0#3DIKR9+/>!N?I\])5_(:
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MZ(U:>=<QLKD0NYS"YJ25:]DXGVD1:U."<QIR!M2<P ?BV]28A5#S[ZQ?2U)
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MU-X< JDFO8I00"W7VS9>0-<3-17)2)Q*M?DZ;R#PAKC0Y8F>C J*J?D:!>7
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M+*V)@!F1-YUEC\-H8S?O<-MQA%E B0R44S.="RMQ-O[E=]2W4\J=A&4=F+5
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MY_P3 /2&_!\'Z(VO*18X'12@M\;G=-X >QM]EEUQ.#K#F@/L)?7Z_@![QJ$
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MJ9NYF(R/#N3PJ]ZN4^LBU=NUCRG=!ZUZA!#PO4&S;Z0OVLZILRO9:Y-S0T7
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MP^_1K^T<-@$)@D/PHFREA7Q,^>7$"%]>Z"&_14,=!K]A>:^'CPR+RO@EG4!
MFH83?^&DB87IQHVNX+G<\CW#-YZ R7RZ98"5E@1%2F0UC412\PMEA&AM=[/?
M^3N_,F"R?[/IMY5CWX<%P]\D=<#Q^B)VF8F/U.\TQKUTZNL7T!\_L-2"-D=0
M5>(]6K#"/<B>J*A&6>8ZJ:@Z>=DY)5,2V-C50W6K.3*N+?'B7;2=XUFS:6B!
M**\5X62]S!EEVZB2F?<%\9N=Q:O,SJX?)CS.I0.@ZSNN0::R2C9VF+P$*+SJ
MQA7*\X6CY=Q,]2@K%PL.STHC3#C %ZKO/Q; 3 OMUO:!$'35]J?S<H56=:IQ
MIQUUMBF'D6/#UMEL]4,R1[\9HJ0I;G8$4HDAE.'?WN&-^:]P]N@N"?^*C"<9
M?@'K@UQ+^#'O]KNZ0/T*/V5'3UCA@%<9'$PC@*W=A6__G9871EG,^P _ ,DG
MF9GN;F/<T;.*(GZ5R>YFV9VD$O%'VDH/MP)QTZ:MX)&6W$[O1-OIXW9Z&4AU
ML>VDT::VL:KT]./<6C%HV Z$^,17E4F' 1;MY&,BE;PSVW8]7/'BAXUQ.^,(
MDPRY)S\>= .([M8:;MB  G&J2U%\=5GSHHV*Y!, "V%3K8B8W@DO]-=B>952
MF<-[491Y-[MQEN!T8BA]-PL9^2,/1<4"*'F9D5@<M MF$.O@MMQ&45@4E+X3
MSN>OLGPXK%.?.9C(0-[9RR\["T'L#5MZUZCF&L]HM8>;K_&*_[[;KN;&L[Z+
MVGQW6NK"<^VR#&W;]MNR"?6G'!4A/EL!_B,CDM @B$BW!]43!W]8'H^!CUNC
MM)@3P$.G7FI>6:&[B+*SC/8[_[UAWK//'V/%(KO?NLGBTY,.2:4#20G&THI*
M!:ADG(O>*#,_8\?Q3I<[#>.MS[O0-\^[$&6J.4Y]UF2+@=X8]XSZ#Y@M[@^5
M4FB5R,"!5$"N#!R!U0^TI3UR3:5YO?@@\H&QZR!RQ>Z*W:MB]][1V+U3.W;/
MF9W:K6!VZK8);07K3D_[L;-W9S^(&J#W^\2[]3B+2SFR3VR*_?X7,9SRW5X^
M>,Z5IN1Y0<@R3GFW,4[?&AU]MOT. F%D,G@U9W\@/B]W]BFG=,_#+SF(<-!K
MC$?-42^-G)+''8H)CNVI[7+T6SRV_HX>V\6/H:5J;67"]C5A1,9K>_JG,REG
MR+#\9)11A*-,V?F9LF),4-:@(?9"L]LO[NXH5CB502O/ %O,VDB9M1UC,UYS
M=A&&K<+KD= SX^2K@(6'[5US:<K2U>4BX0!<H9](L:G#WSE8J^[P=[U-NGBK
MQFL>9+OH/L9MC]NPNIB]@\9S)4*X80?+:](=!*5#N#I<EF;QT!%9Y2S#OJHB
MO6$705":72,]"#N7EQ3+G)$)K<)V]NIZ-5W0JM+C![6TKIN[(7;4YJ)5H4-]
M. $V/A#1+[< <3^"U-$1J3#^+N-V4 -G^IIKK[K$O0[GF&5<IQ>KTQ1YG5!Z
MSLHWJ\PG&^SJDRE1.C5G79PH5>FS5N&K#O?S58\N05E8DXD.XIT;BC_2-&WK
M.6J+_VKZ["N#!TQH/"+0)*^C>#AZ.QW%\2F,CH0.B(-%<)PPCB41H>1X"#N]
M"F+S+B/0'1R@27-#XI!28L2(H?]"DQE<AK^E@22F)]J8O:)-S*ICN<BC5,>R
MZEBNM&-YU[)UU?-[$=VLJN?W GM^[T-C'UKY"[\$VP?K,>7S%_%2KWU1M1N>
M1>+#F9B/HS8P8Q8(7*UZ:(]Y;+\4T%[JKB6/B;NGX6)])RX^(K,>Z'@4L^[#
MK+W3,*NAF/6M>#Q13J-)</$X.Y4SA,0)ONPRUT.Y.MG5W,S+%K@.(EFFP6%5
MC6M]5/'^?D,YENAF#WM4!:YG:(3+G7P/)UZFKPQ5=>NF0[WA@YLM.VMTREZ!
M_MG8N/S+\&)&+N<VO B#<^K?VK)8#3[$9YG^71[&M3R+;)[O@P%L9V YJU;&
M(]=-%+1^I^25 68GLZ8"**MX3)98-XNG9(DAL$2OE<;9.Q1+G+VY?(@&>5V$
M;:S6--)\HV)E&3]OB,K9;#O*'A^APK[Z./];#%\UG !+ P6FHKTZ'/@6LU;5
M@>-]0,M005ZYA.;<=-G5H^FQ*15U,=LC6E^$"3MA>/?9L<5XS\<%$S6==!:_
MXU'<Q$[BQO%R&-[ ?);"JJFK-U]A@%<%MV!;[!']><44AP[QJF"*;K;-5$%>
MSGG_Q=PGYFJ"VBK0*WS15]C)R^)J3G7QCR_,Q9*^K9T/"3[?N4U7V<PZV<P#
M<%$6M_1QC*,RE?6*&FNA1P9O"RHG;X;D@5C@#\>9TAQO:[DR+7<9GQ04S8U\
MJW9TKVBS6[FK>!N> 4Z/S;XYU]O#QGBD+A'KJB.[:RQR*,XHHR)/A9&I.&2K
M%:T'A^B[0E#6U(@>[_#O_#ES+R+F/&%FEHA\/<5V;63P;+NHZQ@B%$^<*+M8
MJSBR>GXPRO&#.O:Z9U>+'7L'C[TX%LT)L-T(**)^IHR@4RMH%JT>+><B3>"-
M(]$_[D+PCVR.[Y;+C=4+X>R\>TIKP.LUB6IVZ1PISN(]O%<OB^17&W8^FZ[3
MM\O.Q_5;BC-VR7N-"^/I G!CZ_^.@52)!W<14FKE>!92]CWA:\%Y14A2OR3A
MP@1MV]%7S$>@9."GOW(FL%>C86O4SO[3&@+3&N5Z&V;G)CDQQF[3F3X:]=+X
M,8FS/"[=1J-6ISLL2[9AJ].I!@++Z+8&^JB21W4[K6%O,YI686"N8:L_VHP*
M5@J(*B%%XD]7&-N\[[8X)UG+)\US)_S*\ J!G'2CH__/D][ZY^JIH9D+/_J3
M@7_ZJ;=_/+7;XN])YH0HZN<NS- =KG[2WK*OMW9./BZMZ73!-MS@"<$HKC&W
M PKR04X6&A8-R:E]<MPEQ)=7_W?+)=[.LXEW((9\Q+JUR;8KAZ*2CD#0*9ID
M&9C8_\[=:/]/[.K19>:/*W/F,_>]N7@Q7STD6!P6$7@Q;G72!B/'DLYFE>Y8
M[_W"3PA<&(?['^\AWF,N?@J68IYZ"=K<13_K?UF3QV'O<=9A0[,]Z?8>.^9(
MGW5,L]<>Z:-);];[GP&V\:"Q<&8:NE68^/D_?S/':X=)_PNN@,#,Y*VQL@6E
M;V H+O[$IM=^^&NCUE"ALE,L!MS)/ THMP"?D[ ]$>P"H2\8N:$>$HEC>-I3
MT?FD34S7?9TY[HOI3OD??+9<P9&XKP)+E-D3>.PC\U\8L^FQ]!W$#Y7@HO!<
MDWK5Z $+RWRT%N <,80*=;6999OVQ (EY#)XLH_?7 4N.%!,O#&&4QI@73M^
M*X9&*C_<TG:%CTTUU6$C>K3,'.1871^D^0)^B6]* LK> Q-8,]!PMD]%^8[-
M!%V<P WG#=%F!*&(, *$!&G@$4Y)XB1-ER715M=]VSB+YS W7^T; &<=Z*U1
M9[.7>OXXJ)V#X:".S@H&=5_HTU-<" _ESN@Y[RT?WC$IDGJP4*DZ 3QTZJ4"
M^ZS02@&W7C0D:>=<)*)82N=#VCB^/ZP4%(QE]N:C9&[CG,_H,X*F\50E^&[D
M0B;\QGUJ*-[4B*8W-6JIX%#;T*>^DQR")68W<?XH.S5&UX>-<;?3;>I&R?;@
M&I3M%*W9J(ELY_'XFQK6,C@A*X^0E7O-[C!=E*V*)S<=\%?F,=.=S"D^GK)G
MMG!66-DC05LN ]'LD!H[Q&=(L+BD>VE6-]J-\4AO=BL;JJ>*[DZM"*OF$+TQ
M'G::H[)F_>)UX8VYHHS"OR%0<N-ZD?T$4V6A6C07] _5Y5Q<,5)O8HKGY2]$
MZT2,])+OK^WIA\@>8;-^>;_ ,!KC0:=I#-/E'4I9UEI9GI1K.HUQO]/41R5-
M[,4KT.O)Q W@($EIH@9UGY6>K,*!7./[\AS=1=C;9J^MG,8STX,'Y8H><$6_
M.1PH1[&LHVA/V&+!+X&=F6;94_;HLZG-/$]>+Z,*M/!"@WF^]!F5*MS#98P3
M_6YV&R,YK_L%RW\KZ+VS0/3Q\B=SCK92D[56DR?C&)R\WFV.VFG 0:5"%<)F
M+;S%..8=L+R8D>YM L4K*P5#D((A!$P*8OK,]&:]V&A$;-0;JIDT)1$PHK(!
M!B<1%H>^*FVZ3XXRNJ!$JL9*64MS=J?=&/>:?;WD[:32CZ?6CP=G#+TQ'C5[
M^I$1^<]>XQ%00F;-MQJU?3#7\@_7\79@<:,Q[O<ZS5Z_JC*C _78[JL7WT"+
M]B$]RAVY!^]BND:S.R@[M?1@3'+VRO-/YGGOM;^GQQ=>A+N8#T-0@8K,FB-6
MEN.[X"OVALW!J#B"DG(4C\<29?5>%2S1 Y8P>LU!NU-G4*T>]IC74-_E.HOY
M/1#*6=Q7$WYFY1- G3Y$0]WFH%]5G*P\Q7/T%'=BG0'A"S0'@]T@JI2?F#[C
M6]LW[2<$.+Z,(IX#>8:Q_)"$^N<WCX*XG.G7_UU> H94&-YK*[?QO-W&8_$+
MWK:T1YD],_5P*FNH$C\AB+OP'I5.K$0G?G&QZ]5__;(P;1\8_>._ HN*=[.8
MMHOS:_L5 *TJ#5</#5?N]'6(@[M*7>U\,4S[O7)F5X''E!;;[XXXQL1?\55W
MLV_>KK:XBT-KF[UN.L>M%%MM%=M!&:+3& ^:W='QQNV][7Q?#"[MPG-^AW#H
M0N#E?4HANEV(7WO-CEY!_*KR?G56G(=A'VQFT0?-GE%B]GM-<G]U'DGR(4>-
M-A'X\A3C+=X4EE$E!+D4,[.N(3*40!\#Q/0-P'G,8=D% :DV$G4@]9,K42<7
MG#,RL 4$9P#Q1J_F0S#6)QA$TRCBJ+QU1I.^]C4)N\HO)3MZDU#CF]H+TY:F
M9?OP7\PP:\_I\BS-?(*_>C[A'2/L=%;]Z\O<FLPU'T,@^,-_[*Z&>SM5M@C6
MZL=8:TCU3!GCDC4@[ )^:&+/[") QJ!M;4)!#*$%-H)6.;-*=[X)J2QCPP1&
MULT8*2,W3.NN<H&9"$+7A/:=M<(>84AE3.B+3@1(O.)3=1:OK20*=HW%*U-J
M+,1KGZ!*FH)T,%NS?/S=TG&Q4^8';%#SY[!&VT% =]/'KVJ."VIKR33"4N==
MWHB@'DI<##E="AZ.<,=G/#)XGTFH)"WM._[C*5B8+KP&/PD,S5'C!03[=DG?
M\,['5^03SP)MB^("%)QK?&;.,^] M]D3C=K1V#-\")],PW=093A(#!SGN)4>
M6Q9!&T]L^M:&]_%=P:KPZZ(?"=^*9P'Z??M3_;G%H?#_&;B6-[6XE,Q<9RF5
MW)P!3>%OC-2GI 2=G_EL6@O"7-],C[CN\024/2H86*&'2"9P[EF+3 1"*]?Y
M)\@*'FC@!RY]@E[-O]#$?U^M%J9MTUM\T"7LB;XIE%FPX#H+2(-:S D'5A'_
M2+.0PRJ.'8XAR+(' A[_6^N^I<'#^<0 TT."S<UGHAKN'[^$9[V-%^!K(:.+
M \^#WS\;M?$)Q!!)^ I&!6B$M,BSTO@Q[',T[=?_]+*UC0U&B-J:@==K8'Y[
M^G;SNW+AK2[0$\1X8N+=$ Z;L,.]P ]TR-*\TFB+++"T_VTN5[]EPZ5)]@'&
MF@4+>)4SF\$N4(5E\G5+*WHLG<,>R^ PQV)026\KG:PJ?RQIGPEUBSBL9OYI
MY4+;E3^K<Q'U:U*(&WSPN8G.]Q8O-#%8)&.&"IW3"LS"3SA 'Y5H*8XS^L;N
M_FB1M&F<#SN-L=X<M+L98[HC3H3]<)-;S3[HYBQ_$]QQO0\>T:H^.!]_KBQN
M#S,WT(7(==C9L'PT:!Y_& H_"Q\'8@6\2489) E8H$?VEK, 15 :GQBSC1WV
M/>[.\8X;L^1-?=#.F.0:'3<_ZR39P'L)N(JP0N?DFP\^T+]#&"1RF(6CG!Z[
MDT'$_!%)H'G2[UY82U!B]&YM&C#\"[[J?_^OH6&T?YN G_+$=>*+#=[;W%K1
M7_3?T$%[MCSZGE@>X;[8\,ROX.G9 5J/*:U='PW[?-'P,O#:Q>*C)[2T!YRD
ME%[1TGP5OIPF_-88I\&3L[1TC (X_6F&;E<0$?5L/*COPIF4IQZ+PP^I!\N&
MO7WL)=P8]IKQ@(^+@0AOGO!0A?9@4E]HUHP\87YFF+<)V3VTLE718HN2*$N+
M 6;*"V@!.E<[H3:GL'X2 X^;O= M3$HMBH ':TS*K>5- @_],/,1PL U#M^8
MRU.S9-4L635+5LV25;-DU2Q9+/50LV0O=Y:L$78@EAY3^LW&#/23C?X:.$T2
MQ^PK6*E/W&O*FU3:&ZZ/)*VQ2[XYTX%I(Q[A!C%RD#?WR FBO9A>I?G+'+IG
M.J?8FC38D!MK:==TCV!/P.\.(RQT.*.0GK);-B7V<_?X:"[D%5%B"&RAJ.M<
MIKH.>^"N#*L;H&I4X6.<HN+D:--#W]YPPM^%H)@)K:()A:(7&6]VAD5&M2\6
M*I5!:&\N%LK5SR4+<?OMQGC8['1*8L&>HN)V5$MN!.D*KW>D@8K=VM-%@\AE
M>/"O'UC18.-ED>/RN[("'0YOL]Y<[^W$XI+@.'(K6&!Z]I/K++\@0;_ HAW\
M[!=)\4R6U[&5NLZM.C5E]5N[-*M/ RIUF02NB[42;X[AC\#ODNI)?K_A%,WB
M^+(6 *(SH]D>UMH"U% :-CM91I'&M?-O,"KETHR.Y-)T:'Q2MRQ,;[WZB]Z,
M"7B[WDXIY;^E:Z:4\L]U=LI*2I=4?[?6"/YO3!R41W0@H:C0(^JA6,!VZBP6
M-92&S1Y11WE$)1O"*G.(^C3VJM<K.RCM5 Y1*;B4?4W#@5IJCY$7NC"H'_U$
M^:)!8UQ!D[*2F1JY4^<O.8<7G(.[64.$T=*-NHQ9JDC :BA7FQVSKL(%4;@@
M!X><K\R9I6J39K\T<GC=P$-RP!&B(JDZURO=!2[XJDAW7H\C.H7I>*-!VJ8]
M_1NXLRMFFPOJ9(T9\U@C%AP_? %G<<=_*]K;6MJFVBBJ&^)=A:(=K,)FP7R[
MR &POLA]Q4837T\F;L"F";8&(D^0M5^ ESP6]46U(ZX>M/<1MI.N7&^,;2<E
MB^EB,),_/^*.!&>(#J&\!LE8ASA^BC<XFO8K;V">H@Q@5V1+NYUMJ93S>*>D
M;'^7W3^\%[R)'=4O3K"8BI9IV2 D7R5+T7A+MO Z%Z^\[\*D_LOLELOO\ H+
M5D^=W?%VJV<3'*G $WTH,?YW&:P(.YBPLS;UM=3'93<C;Z_%/P<^U6W&^SFB
M!;L,&]4])+1-#9*R=]>397BILB&D_ H;96R2[-0'VK$/K$%2(,8 JDN?M^T@
M8L,L[(//;+/: AJRUH%&';#8TO7(HNX>.#;1X<_W)?Z>:"X$E6CSYBT\(6R)
MP7./R$1%L_'/85=M'/X@\.>.R]OT!9O$\0\*-<R@)&TOQ=6-;B-6:ENBEM9W
M)C_FS@(VXB%>L__ZV?'9!\N; +F!.AFELP.#ZQM8)YM>^_*7^.Q"%;5Z+\]$
MG44)9O&6G>*Q@G#0=HT5\CV!9*_':!WD59">_\H";K;]]U?\8]D>PXS^4\9C
MT-<\AD&FQ_#Y[N&C-FIIVOW#W<W__:^[/S]\_'K_G]K'_^_;[<,_BC4'E'2'
M+H774KU@X$&CD[7>#+8#SU74)+*50XAN-\YR*="6OK@2H(2TUT'8X\C>\@U2
M>09TYE8973$PV+PWHXG^!"AM0LT0UL\G1QELRMW$=]#*&FV]C?\&Q6PS[B$B
MZ@Z9453E!-[#X6,L\!PM<!16$,> @0!WB1"'FM)<_1NL54!.N^5YX'CE>IX>
MCHOWTMVM"??S]O.G=9O#CY+.CB;.>]?RQ=-B 5_<P23, S@7^=^T:\F7N15'
M[ MS:35;]I,*76.[^6*Z=^X]G0TBA[#HD1D+!X.-.B$#66QENN0F(J /,;V'
M#Z>CK_PL0EFJZ#APNN'ISB*YFU+'T2]P'*M0\=")% X^$9F+\<BBY 'N<GQW
M@0_Z@=STY/G-<.#-U;^9ZV128+ AR*QN=;>H4Z:E%C8LO;#!<18V.LK"=CS/
M8;M8Z%T@.(^D=DT"N(688K#N1*L\&ZB+FYAZ%3$017F$K;;@F2A8/:++33V.
M-XA";2&.W&1A(AD@X$.;^N@([)BIY8+Y=5R.+>(*+(U'!E_=1>'IQ4WI![E0
M^:P/8HVEF"8[7Q.C0KASI(T$C] X]9  S(2PG!@&_Y4P8):7H&RY0#6VT[\[
MF ^@N1Q>;.F=#=+X#$%M4=H2HE'.ZV"QH.CO9O [%A+Z[L4NGQD;&HVQ8[-<
MZ9-I7@V77@R4:Z1BG</$.D<,<[YA2NG%M6#=MO:%>^@\+Z/="4<].?7DK$*=
M6UO[;],.3/<U2LLSROA2YA?1H7A2#2E C;]/+F-+D3)<\#R@@*-9"U]0VY3V
MCGL;,,TX\271[\432F)T#;O4_9S7/2%1S2(#2]",,:79W-51[A\B:!GVBGC)
M8 AH0Q!1^HC"Y.(UT/JI5;(O(XE"%S\K#I?TE_G36@;+S+U@W1MN)F,O<@<M
MC>215@Y<N@PQQ_*8%/@9%N9H3ZYITU56_+/D7FPV>\22N4QXM\+U/3A? G<R
M-SUV+9+FYH*S)R^[2%NB:>!.S=?8UL'5[[37+<T5?$9SZ!64JQ<OT8(5QVT+
M<_3FXI"2MFV3NTHB1!%&!D96<4$4$&(F0>EY[%\!OP1@/YD[L3QYI;!8<)1.
M//DHM1(!$W,D+0Z:$;TMX2>MX6[%^><_Q0$U*:G#WQG7J'270E=<Q(L>N&7E
MSVK+Q>>]B= ;I#ND.Q2/H&[M!V!^C[^L_#%!3&6T,_#6BYX37=6L3 MQ'_'W
M$*'@%^"X@&TCKS--#9OVLH5SNTG&A9-'M-4G=A.^Z6[VA^MX. MSPMC4N[,Y
MN6(*EU3*-:@F]P?S)=>'M+@R(F*,((3KM09IZ_&+U$-/^"Y$-*27<4#M; Y+
MTPG]=GX;BO=LX3. 1D'L2:%])6P=(,4TF/B2D1-J$.'@4.?R1,=>^'@;M858
M*):;(<?A#6J"OI^1JO(O-XY7M(PDQH4C; (>CC)02Q)LV 3AEW)]B/V&60'S
M%<V+)Z1NS[T9:,.W>23(,?+D)91PQGUE3CV*@O=3\'X*WD_!^REX/P7O-P:G
M3L'[72:\GR@+RJH6,G+K5E0:\_S3F")E^64!SSA@NC)=224*E Z<Q\30B6H:
MQ3YO;8P#<181[EA[%X.RIX_A;P6 _:^\!)-^?6M#,$69HP(/BGTX^3B9;: J
M3'/JK)!7[I:VA66(V<\%B?YB3K#@1/O=<KR)A>.3*$R\ 7)#0&%;9A._U$HL
M03XT_GY>QAH6B5HB-J'@D[(9/&'A4<VG#X&"9(<CIIV1(!B \>)1DZI".=U6
MS*7P"59\]4@C9?A?>71,134?EZN%\\H8+S;29%HJ?4 ?[[]\25+%TQ@PKX5:
MBXFG4'QM3N!4W/7R#LR5RA@:%B+2IG-@[Z>YMC)?7=!P,O[F8Q,H.ILR#P2$
MZH'"B&U%B<#SF=IT9VM_F:^:T>/H.,VU*UD,K9^I^(G709$0B.Q8*%_\0%\X
M6K\K/[Y'RG*8",K[J308?NUWY!F<5@0!,A\4Y+HXN@)7^/MK]!$1P5\C<\FD
MV7IBLVS933RFQRJH82L/DF![UHSD-Y3=5>#B3[P*FBL0+A9A7CL(T^(A_<^)
MV?X[L)FF#R6";AVX;71&W-:E'*WBMLJF5)7EED%[2XI^7VX1/"+;:B"X_0//
MHCRK(%C*,&-,2R:K\+83"?@<-?70B"[>K!%R309/-+4U'RGRC>*>2TN[+_\Z
M")H6>"<C5AIK*:%NC]#. P\_8_M2L!*S',W)W&+/?$W "$M^(:GYP*4XTA'?
M-0%_'6=")IB_$(.K4.G\0R7N5O);SZVQTHXX^=GZ@-XL7GR-S5C ?7EX^:/^
M&>'EH^_. >#IHHK+0K#$ 8Q8W!Z/2S13;)Q',-8R&0>\-?SX@=X:=3:+7"G\
M^,U)[.*_[[:KR??3HCJG +7?E&/<#4B*GE,"V5Z8IFR ^SU2[A.JT#HJ>%:V
MIN3.R?]Y=/\V#J^V=T'P/U\*?*=_L.F5"6LQGQC10A:@\(Q!VH*<,VA<K/8=
M$R3%4>-2/L)VC(:SPHO+"PRV@/GL'!@(-R%V'I]%O4Q)A([1H#'6.\VVGB[Q
MV5&62YWS.8ZN. 9$S GP#G-K/)-,;!R0AZ4^O>;J]*/0I%]0D6;5C(Z&5#/:
M[[PQJ,0:PBS](7(_133\#KNL/892GH(W#JO@B>S>K<U+B:F4,5.+CQKC[B@M
M!E6<5I9NWQF0KR;<7!HT[*S!O_(UN[&?9O=*<6])[6ZTVZ#=6Z.10AP\,.]\
M#$OFW[AVSP>PW56]R_I?-OU U[^<TT5G1"R?%Y(X0WL;;;TQ[NGI$N B\_"4
M^E;J^U#J6S+M[AK<:(P[K0S.5AJ\6O:YP4NQA5+@1_?//SGNC%EX-QD*2=D4
MC-'NT 2+7MI]5P9 &8!3&H ,[BYM KJ-\; UO%0G/N\:ZF">_,IRV;3P-9.R
M!17: B(^QVZ-;$&&NN^!4V2D6QF5LE?*_K3>?HI]2RO[/C9(#_.ZQ=^ZLC\>
M VVYATT-B2BS^XH@]L]*[O(L1J?FU[=&>T#C4WOMM(.ES(DR)YO,2:>FM[I&
M&V]U]58&2Y_0C.PR^R.W'/C(M9?FTY/+GO@( M^U;,^:"&PH 5L2 XN4_6%R
M-D T=($75)J/SO/Z;*+U*GI",8$OED/=&&P9DU$A1]Y*,A#"5D:AO-$>(2I'
M!JY6"#6"->K8*V!J+VM58+%"=MPB?A7!;A;6C,50T7( IP:I?<N&MWOF/H/$
M9)/ALV-CG3L(&=7)/N )Q/^.V"2?'?\?#%XD!VUP'P]B?/$K_)R>B5:%(QDB
MVN@$@]--(2/2X(:S:039*AA90N$R(18>%PF"ZX%?7>%XB?5GO+-:K$6?FUK8
M"8A-G=HC\U\0?70WN+5!-MQ:0D1R]:J.*#JM83K-V.0=00*6G)=C\W9'T32Q
M,#U? T8F6A L&6\BFL'_^'/M7X'I^AQNE"N $'"+UW0G*R*U)<ZG6RTL#M=*
M@T7(^<'O(X/,V=72L9D$/_-^Y>T=?-)+A-_J@O:QGJ.'B)?)OC&239Q=DOQU
M! \&W['<\&3A(]GJC+>>YG/*9([ZQT,WG+!6@44<EP,PX<=Y];J@X\R$-RX)
M:"K.9VM(4.<D05SIT($+RG*( D'58G:BM%N>L!3MZO,XX4;*>.5Q23,:XU&S
M:XR:[:&1A]_<Y"QJ;^ MSO= 1)QS@VW%-), @0TSK,Z:E(6@B;N#.PYZM<\X
MZ!WR%8TTD"#70M5:YW1+#V[O<3NK/6YGM;6=?Y6KO(D6^<#<92$#W44#K><8
MZ$+8Q;74+SBBBF-54T_?62N9OW-OS9Y^%-MZ</!7.V8$XA+1HXS J#=H]KOI
M1L_BRF>;VB@YY>[P!+N66]GNWNO]K>[]$11L]Z 1^':"E5:V U*V>I8'>0;*
MMC1!]M+!P[<2)/$@)T,[)/!D8HZU $))S"ADTUP%S9''Q706@]R=4GI'/ZS>
M215!46Q=0,50!B$]+CM2,>5V>6#UNNLVC3;=[V])E)3;ZA;XU9-M%<LT,V V
MHJTFQVAN%)ZTV*SE%C)R!ENB]- ^4>"Y,09OE@["HX6>E?)*&23",+DB"E$T
M'AY(E"N(@$ZVZJ)"<V(JM^P;R^KICQ]@?Y]@>TE>CIERP\!<4#>#F2U;Z.7=
M-GY8GZ:*G4/$.&AU,L)ROO-. 8V5N_L] ^8C[)Y"PXQ.(;%[H\FS6%.&\Q5
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M@<X7V2QN D)$HB2.KN9PI, 0$S/P)'SN[PMS\N/J?C)W%@BW&TKNDOES9RI
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M5'S&DWE^B?=G3\%&32;@;Z+O\<JA".6GM5>++2C"$\AYR"@E\?ST7@ZVY]Z
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M25!Z?0== SX]A&;(15B;'2),QG&N%R;2"JX)/?CRE01CX$H0IB@%&-/CE<_
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M'M@A71WQ#4L#0_B_29=8$Y4JGQ5Q2RP,<;&W-R&X"SW3IFG;[<^9;+8XK&#
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M=<WHNFUPM8)57Z2:VLQ;S$R(N=*(N:)9@ANU55$$9A\KGU/E79!T*P[U!?,
MMAMMUB1],0IKE=XKQ-TDVX(+NM!\P1KY/UG70O*N1UW:=\(%\@F)MTGB<7H^
MFB\Q,W_BE%S*MO+9I2H+9UR) 2VKE7+EJN=%,BS^(M<T9;%>PKZ@[&VL>Z$G
MMDRKO?Z@IFX;6"XDU[0"9ZKO;=(-L8#BYWPJV):2V%Z$\2NL9&T%2J/O*:KT
MEH9\1Z 1(S_D:2 %):/6TA<U^-QFRR*6\. @6AZ^.RVANR/?Z<AW6$%VL2S)
M2KX3['7Z[)7UD+HC>S50N==JBM8J/7LMZQXXUXXV5\^Y5%'ZSDM(?=<<)@7I
M@T^O7R?-<ML^-0/6%>^1SO>=T]1FQKYS\IRS]/B-Y[#I?%P7''MPI[H#LW[%
M<6O@_(WE1!>Y+(\27>16/4ITD3M(%[DB9MDJMGV<:!RW8O9OOB6::!R7A4J[
M-(X[?/?)K)D[J,N!%I+,K8A7Z_66GN'M'\<>3[R^8)4OG)_T(S+'N5J7ER@F
M/3.@O./S.WE%2\QBT&SI,2<OUN_)>/,?^^D"E_F<4%Z/3//H+;(TM75VV6S5
MFG)1@0EEL"7D N]"MLZ>D&[EUCG #BF%/Z-5@AV"<1J27M/DO,7CQ$X0.Z&P
MG6 <?R=HF'-IU/1&:3IREO@<G(T'.I'OC6F-?'-L>TA)QPS"&BN6W>ZCBBNB
M6.;W@2J58!]@^(M6TPW1&Z*T>*G*)> 3Y>Q2DVH-?=&1(B(\#\P.2@G8 =,W
M%8"- [/#R0O)=N"8YW>FY?0=2TC$!=962\#:&D.ZII2S=KR0B ?DDXW](0_
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M-DF P%'U8 ..4!6>!$OWIE-/16R@@N_$\V;%K<PP5L^PRA&[&/@%$'M&UY_
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M3\H=:V?KFU?,O&J']^AGER:_8VD#KM1G9)@/0*BM*?#HC]PP\\ :VQ(@WVM
MZO/,;C,3"0@:-A7I(^<*>..YC.9IML=,WT?#5Q)0H<@?D:\FM\!SSC?<5DON
MHR9V.9CAP^N0CH@FM9!Y[R=A N3A_+?M"^EINBBD=[H:C:[-ZS/XS3&TF2O0
M9J;%*<E]YVO[_C/6KP35IG/]]9;\\_O]]</GZRO4<A[(XZ_M1W)WSSJ?@/[S
M<-?A/YRZ[+GUPE18SP[;LK5A6ZX+C1<I><+ *0R<PL I#)S"P+G9P-G*;^ 4
MILH*F"IS)-?M2W6\:]^#]G=]O;6:I,M93B\SH-M<?IZ9U:+Q(G'"*<,)IU0V
M6UEBIYQ[.*QT[Q]JI/._G:OOC]?_ZI#NER_75YU[7C_\JGM_U[UO/W;(U^Z_
M.O=8NW^G<OUE.-A<SY3\Y9D>/^.R@0[6A:6LZJ'C3CHWVJSR$78"9,&"& ;%
MZPPRNUL<$OL38S"]E]=IJ-="M@5>SM*CXCK(WRB-B[;.9JWRO VL*)S*\7CH
M7+$/, R8![%!-A$FJ.8+L,9&0E:N)6L!YEWL+KHFD$L@U^&02P;DFL+55??;
M7>?V86>7DT"F"B)34R!3M9&I-%9CW@@;0.G^^O'?I/O[+6A0OU[?@39%0)EZ
M;%_?DD^=VPZH5MC[B/_.-*QO[=OV5]8_B7V\[]R MO69/#QVKW[[M7OSN7,/
MESP^PN4"W2J);DLBCS/"6T,2\";@[3#PIF)GJ1C(&$:ABPL [F$&M1[OVZ"*
M<?]7+6X0QX^8Y/KV<P<4M<\=<8(42+: 9*I LFHC6;F.D!J@V=W]]>W5]1UH
M8]..E>1+I\,1[:%S_Z_KJ^W;YL6+@'00X%5Q\-K4P%,$.(@ !Q'@( (<1("#
M"'#8+<#!$ $.(L#AF $._]I>2S*6:4DP&NL<)N:;5G@11".8\^M'<>X3Y[[]
MG/MTYCK\]?K3]2,_YGVYQI &-,D_/+8?N1G^X>K7SN?O-[NW3,_/MTIS%5WV
M=1I\9[X_>+VS6<+ 8;QAX+2Q4FG?PZ[$>"BT/2OBM8VPD L_#)H!Z[H-.,H*
ML,P<46?.IHX;>K5-1[Z+S#4_9L9K2!D6$BNU''8AY3W5K6,/NG!"F*R5<V6-
M>K.!9)@6@'N8E/DY0I&]"_) *:M]_X(FAJMT\>-E0XP[>+-4I1:W+N0V(9PN
M/RDGQ4_DP1I0&RO/'H6QVL,A"9(1,,#R6"EW>U))*AQ07C8-2V E!7IKDV]2
M]7,]/^X%.373.0&9KWV\F7OA.?!D5C\/4#'TJL6>:GG9L_,R<'K.D2 NZ9/
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MU*XB:BNST5=?AU[/',8VV^YX-L0J+M"%);DR%^')+PX$-I=J)I71IRN,S8;
MYBIBL[H4F[$%@^]8F(#&8?J[ZX2[@+3 Z%.?"08D"8PN-T;+D@#I4P3I5/TS
M0.=4_3-#E;A).8ZV[8Y<QQO1%4;D[!T7>.%*GPY9CO';BI*HEAVZ&G&\DTPR
MG5=BK1@LBTRRDX=E19W",OQGS$3RYE*"KUT[LCC*;M2':V\PBJU2*G,U3,X3
M>):-2N*S2$L[97S&\<K:M,&P-%6;8\OS#0T!$<@]ZKNPA-AOC(<.,RQ]I BO
M<_5TT+8Q;2K!?GJ(8/[D:YW\YHP([?>QA\1/K-PP#N,T^!:W15<.DJNE,E?#
MU#S!9#5ANDI!LDA^.SHD)RUX9$E67_"#X_$>.<ZLS?B*-\YQL!^9&_K>D*,E
M!>J;H-FFS,:@R!(Z*;>P4V]'T6ZG IM<I&4=?9/OVJ[!2.E=LC+)<-6+5+RN
M!CY\=& ENW7R*W7]UZ7JEZQ55_VJTI&X&IE=D^Y12J.29V*1W'5T;$XI8'JL
M@+U8U)NTYVYS(V$.!6PKK&6%:!FHGC*QR&=JQ7)"3GR_0N]\FWJGR+PZ^G;=
MD][9*E+O_&;Z/\B_$ JI2U,JYS]-ETG^5B+XA;Y9WJG4Y7T65"Z5OODA-'M#
MFC!AJGQO_"!-AS>-O<!A6Y)%?P [?WQV[' 0OR5]%Y_DA32]Q>P%WC *5]\R
M S1!-!K!@.$*-J[I8WW @G.@UM <!_0B^>.C[03CH?EZX;AL]NRFC_"$)\<]
MC\>"$YB7'[A2_.?IL.H2'UHLI>(WQS_7X:</B]\;K;HA+?\)F(A]'TN^.;+"
MH,Y6\54\V7CXP%D$*.C8Y!>[+QN&_G%!7YA9R,/2S3#JJM;*2[96754;:ZF6
M]4F*5F_*1B&/TM1Z2]<*>12(E(:Q_)8YMLBF$\[LE_BG<\28"ZW..<D9/9'
MMV*5%C55%'!_/,GU/\=/9\0<AM.?%";[9.G'$\A'_OLL<\K2^&4;9M!:XQ<V
MMX*KBX\<VQ[2-6I2O#&RPR?,,)M"&\ HF.)/F.5Z1LH5K/YO08SD$:E;?!S^
M<B&S+RK)JKR$)DND2_K?@3^=_Q,][_G4_'%N]D$#N#"'S^9K@ 1+37$$O)@6
M23FER0J9V^\72@Y9+TBY/NBX8NWZ%\?JM?1>7Z4M4[(TO:>:AMQ735.7#-FP
M]+[^1_/L\I&)%_3@P M!8UOFB9E7)6(H@5/;16.9SG=P:0]B6VMI>:56LZXV
MUH-ZUB?I\'ZU58S4VJB 9'U2H][4BA'*<K,NZ7H1XB^7/6#E(7I_1H%4R8 ]
M=M00IH$\EKQF8LDSL;*?NS^SY^Q1G[?>FAH,%6$P+)O!\ @ T?K[+RU%T3X*
MF"@;3+083+P,J1E0:C\E-D L!9H+!*@[],@=0L&=YX=].*E[Y/JZ1FYNKI)^
M?/^,AJ]QOQMT9 I *!$@S.FHL1:ICE><H?8(%8: BI)"A?'2=_P@9/D5\/]Q
M)!M^1=KQ=R&Z"_:#'A.50F%1FW)#($AY$.2@$#$7L"M0X9BHH$CQ.0,&Z;FV
MR5'A@7TX*"SP?M6R(6#AK<+"/A/&!"SDA 4Y,3_(JJ1[/0X+CP/'/P@J?$.C
M!VDRVX,X:KQ91-AGNI) A/T6V5=D2=4U5?]@RXK<E+1T,])K%VX/&5Y,D"/9
M^B9+]YZ$?,19M[4)HF1-.&<&T4_D%B!F (<>G]S<U2L7KB02QLL'R GGRM*!
M@N,/;P]65.$P.EU\3L62RH:2*KG4V$ON^#?'&M A)5],?P1/F\:28@5VN5G=
M0%*1-UXR:(Y;JE0R:4G99S4L@<7[UI45&;YJ@*YLM'1Y1E>>'JT13)-B=]^H
M_P1@"G_=4\]_,EWG_]BHB#GR *DSU\)KC[TAG,;;UE^1PR.=R97GCY?_\A#U
MXE-Z7(POK6H/3)\.O*'-!,;8IP$,V8S35/V?#HP@OA<4?*!.Y#OA:WR]/W/]
M[$& .1VGM7<J)B6$_EXZ(<&]W(?2W0\K(_:9?BQDQ!%DA#)QUR">.H#RDT:P
M*PPK,WA:FU??<]50I:8UP%]1Y^<6'6_+BB9E!K9*070U]/C#0O01S"L-85XY
M8;CF;0=426HH2@O;#JB:K!FLZX!A)%T'BK&M_)/V^Z3CV'28LJO,= Y%'XI
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M[?Y.VC<WY*YS_]"]?2"?_DT>?^T\=,C=/?Q[^_A0X]&^U,0 >.H'GDN>!U[
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M.0[NZF"6M3>5M/:6B+UJ[2VJFV=.#@JT\P[-;5EDP@Y71VV'FJNI]Q T*2E
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M+[+HF;WY[IUZU-@Q%F2)/__P_U!+ P04    "   1'%:,9/"^R$Q  !D\@$
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M5?:2>]V-3[ '!W5+I4*_>G(5RJTP7 5;')UBRDNPJ=0:H6K'(SI@3C*KLL7
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MSA%UNJ ^W1I]4;WV$@1IE_RLC6AOSRZX-PKU]@]N?'+@5&U?HP-@\O5N;K1
MWSF(13 =LV6)M:Z,W EPU\-[!TDY94DW@;6%G'4K SA'>DL6Y";HK+QL[?D^
MAZE7!PI[8]NF\WTWDES3M^_YX2&H'(J@#!0E")J@X"_8FID6TAOO2&WYUEYM
MLX$N>SM >#%FM9=ARQ8##YG%U7"2VV8QH669$Z!@"9HRQ4) ^LI',HK,R6":
M=W9:'UVK%.GYY+)Q"#WS,T[GWZHUGI/PJN"6C;@&WE#H$7R]EA;H#X\.@E0!
MD@HRE"B*:.^EK8WN1TB@[DJNQQ*HC677.E/V'=]5PR-<M:Y=JH?+=C4#75CD
M+$; K"PH"G7!UVFKA%PY;IC7S8LK-L'W(^1=.^=7*_EU$I;^%N:75VZ7@T56
MT)?69S2:G9;K&[IO)].S6S=T!TRC4"P$D++Z-TB>3G!(T(7(TENT'2BV%L#[
M=$"]+TKN7>#=:<-[';K0&N9XB< YJTHZ)8IR303K++?,6H?-2V6>!;5ABO;G
MU'L[2:H395<)_13%EY>J@N;:Y9# %R*WTL705QK!>2T"TSP*;'WC=U.,?6K)
M]P(JK+D8N]16W\<V1L8H\I<<:)FUWY U$'C,$#E:GV4FK[)U"YRG\&R8;OU9
M==1V\NDZHKZNY+ZQ<,&2T=%%*$P3HVVH$U H.!'%L:249-;MJ>CH 73=7YJG
MD"MJ+LE+CA*A+A=\RA%"84EH2_]WK8=N-;DT_]+Q\ZY4VOP2_":2:O8BW2S$
M'?CHDM=!01#5T\A20O FUUM@+&<FA"VMIP[>?'Z?\IA[8L76V]_F,/YXG*88
M9O@&5_\]'F_9)OJ9TI5!HHC=\^Q 1%D[NU8'0YL".G 7BB]>\/6.\_>%^ <(
M=UMQL;],:-ET[,[J+N?!OKD<F/C@7-@!,\GRJ.L$B% ;GN::9DH%O*(WE$*R
M()O;SNV0_@B!<VO5N0>9MG-7)^-$6_(;3C_B]-:<"&)\MMQY$+J>0DDG*=X2
MY$QSK9CSR03=>O3=HV!^@/BX-8G:"*9#/?503X7ORE0E*1VCL,O2!M0K]@&\
M%>1 1.XX2SKKW+K,84.(/T!U4O>*J9T0VW:<O63_[1Z"Q1.Y;3" %(V0EB1,
M3C%-3JF/U0NU-K;FU*-@UF&/_<GL6AO)M.]'\*YR^4/=Z--"*U^:TYO7-:]0
MLF*B=Y$!#[DV#Y1D8%5)%,:&8!3SPN7<FC\;8ER'5N[G4DJ=BK%#^[=\&[Z#
MOU2:RZL/1<2D0P3':_<N)JHC)Q,8IW@JK$3M6O-L WCK4,S_7!3K2G@-V?6%
MXM+)]-L_I[1A;R9?QP/EN8S".K J*%JODN H/"#1QUA(IX80VX\TN8MBK70H
M^]G(LI,L&N8_5\'BC?Z!%##2?P_IAT.* Y2M)V(V0T27:B]<6YND)U*+S$0G
ML6C5ND')<YC6XLL>1]?L)U':4$X=VJN#E*8+S#=UG>8L6^4*(+>EMID,$'4N
M8(R,7J3(L;3O[OD\KK58]).EVYO+JT,F76G("HD'KX.PK-9%9U"<\3I[K8#P
M6M*R6=:V=0NP)P&MQ9V7OJG;/7FV%5%3CV9U#G\]=N3V@,8WPUFJDSM)5[Z?
MXL5P<3%PWF)()H%03)*B5&[5]=:67)L[.:-"^YS1QC#78MC/E]+N5IS->'<;
MU;V*M6BQ#I!!0%4/,BV2=\_((,LDZ@1)GDWSO@-/(UJ+33]9:KNAC'ZX =6T
M1TR@$+535:F].M(RFPJ1*RPY!IM5ZYM:/1I0S7^RA'H?6=-M"%$17S>>\5HQ
M]-8#2Z%.U*X3Z73.8!S]-E.TRZK[0YX[H-:BH?VY:-A64NT:_T\F^>MP5*<J
MWU'RQQ>?PW"Z:KEGK9&Z9+ F,O). \7)M4=N\%:AMBQ9;#[*9 U<:]'H)\O$
M-Y=71Y.PM<28+//D4PKZPW,/'HNJS;"Y*!$QQY<?/?J3I="WET"71S"WCHZ^
MGUM[ZXRSP@++2)&'EQ9BJ;WS$&/0GJ$RW=NE1\"M54KZTZ74NY#<'AR=#YAP
M^&5I06T*T5J"DB2O1]PL@U>&0T#M;'3!*M^Z GD=7&O1Z6>K6&\NL/U-;HM>
M<1=<+:FIO1HQ, B&;"C+#(TIY*3)/DYN$R]]J;O32P^["JH9?1[N"#6PC)LD
MK 7O!(5_$8G*3GNPT@:E4G0NM=8]#R-9BRH_2?%Y0YGTHQ?7>YP.)_F^[KSL
M-';56>]#F.-1*9CF@UQ<YD5RR YIC=)2U"BR!:51B&"BTJ9U(<M^5[C'RWXA
M9LD+BV S%[2#LH KU65.)DC)LO+-?=)M+_O]P!W NN7X T%1%^)_B>Y.3GD4
MN+S%7R_A9L$@"EZ >:])=2:.IO4Y[K;=G7[@-F*]H.>NXN^:G@_UY&2F7@77
M 712H7::R! #!G#*D TW9-U-ZYX@V\YG>.$)*3\\/7<5_Y[FLKS^_>SXY.CL
M[.#P__Q^?'9\?GQZ<G:6/F%>C'!2K@Z&EET)9L/ZV#<X#\/1[#;,]<:U;/VL
MME-<VBRYT7"7!X[>*/B??!P/_YM8E&N3W3(,UZ?*5PVZ;N2X;U16T6<6%YB)
MD8,<R!X'[8C1B5/<5^^\I)S!$;=M5 E3:'WMK:.E=' DO@ZL!^%<:IZ;'34C
M*0B?(NVL00,JQ )>A #%9$N[KE64K3V.;E?4)R>Z#V_'&H?E+\6GYD>< YZ5
M3%$QT"%'4"E[,H2.@^2J#HHK5JG6?:ZOGMTG[[B/O-M*1ET6%FW/^L5T2O]@
M]<GE%99!45IYJ1*((FJQ%&<0F+: (NJ"6D39O"MOMROJDS/=1S;WB$^]?$>N
MKF.<AS]NELX77P3&C!!S[:[-'$40/B$XP7*=D:5('CU^3QY>5:^::_SL+TL#
M8O7RA3FF8*P,QR3<=\,O>+?R9S:H4[QD[:(7*;*O(;Z"B I!K::D,)5\ZU8S
M>UQ>GSJ+_.QO4$NF]?)5NJD7L,2LO*\E<KYN.ND%I^@KYYQ$[Z7(=@^%WBV6
MTJN^HC_[.[(MA?:4]7Q[?')P<GA\\.[XY.S\P^_+,<[?4X"K]85;Z_H-PVQ!
MJPWSMV$X78XZF8S#A]K;MU9;O ZSX6R'U&BW@-KF3_>X>8V2K"M,U\^NE[Q&
MDXIHP#PZ'0U%T DM<;/42>E"@?.)WIB((?'6:=)'P70S8^FA56<E7-'2@]*6
M[))-#!RKMDK1VYFDC['Y#<6UP?4I_=B&-^O-4=I53AU<>7T04U%)>1%J=_Q
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M[M^_'44_[13TX!)^6OL;Y6]D\6ND?(LP3@3[V[=)^OG?_\=//\TDY\=Q/!K
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MN>FSK,X/_<D?+[Z_P'?\,R[ZCY-O_5) 2(,03!.@'"5GHB*X2D$TB\)K0->
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M002>%+?&U"[M?SZ\?<"_>.*TW4:UC?JVC8;GTU'\8W[*>TN3HWC &ZHC&@L
M:%5[--7P&''<!A]D[?R?)1#[-Z(.K]L5C=H>KY@&)2JO+[X,1M\!.DAG7XIX
M%M%U9I35(9.,"R82C4I<ID-3Q*C$N-0\5*]C6@OF+^944E2#O:9D+W7"^0CQ
M\[#_7Y>S+=DGRKC*ED0MD=>II%1'APY&,C8IG3B'VE./5B,Y(I.^@J@;Y*PO
MHUIT*=@ 5R/[?!VFP]C8-?3V(!5V$/I>=H4Y/AN,B+K4U?%26Y42;G].!3ST
MG'"4,6U2[28X^R7# X;K/KFPC:R;E#3&T06<?/DR'OGX>1GEHEL3F)2MT(2#
MYT2*TO*)X?F8E-0&I'+Z;J"U0FGC)LCV;W74T>12L6-U-30P1&_,?NL:;5_Y
M=LY'59(YB ^BI/FD4 KQ(M'*24^!*^%KE\"LPW)$ID05<3<H@EJ%:]%9?0-D
MC<R)]:@.8U#4T=X&E-A!] T.E'L0QF"TB(R34L9/I+6(54M+=!0B!L&L%+7-
MBGV3X@'#8M^<V$;B>^#"A_[DCS=C@-/A%,8PF7[PT\7)1B5%K!*WVBA=B0XR
M@O+P)%+/%.=,!5E[PM;FZ/9O9-32Z0-4J:20VE?\CRC0N[&R]S#NCU+/,:VE
ML:R,;LE$*B@GKX@D)$<U,#R$S9W@QII+YAIH]L>@EO4Q>]=+ QMVMS5T;TT/
M+,V1)DI*63*1WCGBLD SW)H@)14"FB6@[@#[V7/P4"IL<#+.@]&3CZ-YPLAB
M33#Y=3R:3'K!<P%.*WPM0B0R.GQ+4BSW#BI;(PR$NT,"=Z;80YB.AC]5A=\@
MW::[/CB=3"XAO;HLK1)F.V=WE7$SUZ@ ]4XD[4C",QF!ADP<F)(7A!AM $IS
M[536C<$=#5W:J*-% L]JH+,>'3=Q&FTT>A3([\!9:<$HB!=:$L$S@+1 +:]]
M[[,IMF-GS6[*J'@S-&NXM1KDR5<\/S_!Q[%/U]^[QHPNB-8>C"(B)U?Z*F2"
M.V(B1G&(PFI-(]O(M'[<\Y\]1_8E^XJQOP[RXN!\,QJO,;@^P%<8%H)_[N-7
MY9=_ZP_0L1P-H>>C-TQE02(P220U:'*5'')-*<\4$HU:;\2:G6 <!WGVIXEE
M#NFF]LWL^[BN60-CF/12.399R@3M=5\8SX@3)?XA=8+ K(7JO9RW0_CL*;4'
MQ2S3R+0T=Y;!(ASF BT9..7RECM+O,.O$C4T2K32M U[M'E^.!)54,LRAVR]
MCKZS&]AW,.WED $)[8DNU3$RA]+J*Y:)F][(G*4TK%WO^"L81\.'746\K'6W
M]^Y9Y_$SI,L!C/++SR6Y<-(?OIY,^Q=^BFQ>= ?#'ZX^BBNWW*H#IGF?K@8R
MV[&YUX*1=1M71D%5Z5R)QI1-1!KMB?/&$YLX&/Q1DJ'VP5)U 3M/4JLV+\RB
MW1DEMX1'3]$35I*$E,J8:^F2R-(+4WWV6BWPK=N>'9Z[2Q/:#J+W0S=76UK]
MB^]77_ZSCYO7.'[^_A8]KD%WKR\H"SPF2E2FM+0-3<19IPD3T4I<8S*\=F/.
MS9 ]_^F"6[%F'7?K::_!)=$5M!NW5Y-EO/.\@$W -DJ]V@KH@<8%-M#X.E(U
M4]?!.::4$-%I02CEZ*UY:8@SF1+-#0/0AK'J]49/@%L/#?A[:M3:1DLM*=7=
MM$\Z"8AY5E&R#/U%$$1;,&50G"76>D&"M3DD"<'?[;=2CT#+< [8,[^^(M=1
M9D<M-$C!N8)V_]'?G?6_#T=A N.OY<B?I:P!6G01_]4L[\,/XN5@%O >#09O
M1N-2V=<SPF2#2RD-3M"NS;3<J0E&.)><0E)6I=KYZ,T7]=P'/%3Q-9X$8YY&
M5EK/:B6H*Q(L@PBD=IE8SPU1P?N8/?Y,UTZ9?1;C(IX862H,G]A&TP>=97*S
M]GH6]3L=GER,+H?3LW6!OJM5LIX#SX*E0(Q',TDR']!"BJ;,BT\Q1B]".EQ:
MY4Y+^^LE>/J,:MB\=)MW/4O)9=")Y,A%N1"3)(A8I*QCYB:68M.GLJL?Y@;&
M3S[?&17JA^G&M,AVURV;/GF?=RN/DD:EBY0%C+-\\A4?4O:/<K>+,,[+!M-M
M.M<&H,/3BT+D)$:FB03)2-!<$^2UT!J )U^]E=(V '=]VU]!F%Y_[-T'SH*6
M HR2@7G"$ZY<<I#$HQ-'4M3) ECF;.VW>P-8^[J\:,>7NP=,;5T\F6N'Y6OZ
MJSD+T@1#@G>AC$7,Y8*>$4:#42D)GW+MUE%KH!SJ8J&ZQN^ZH!4DW\ V_XCF
MT23#N'CGLZ0:/+;/\LJ"=/S(R>H?S>--FZRET15"S74<Z(:A!D%&3TR[3YVQ
MODS_34J3&$PD:#I'](RS0WXESJA@F;+:Y^G39^I#]Q5/G:C;*+5VH^H5]O3)
M+7MZ'D*'KMH:+,*S9?*TH20X*.-J@XX05#**/^1M;// _4<0#J?246-]-(C?
M%HB(ZP[21?O([)1C(9 R,[0T 6?$:BZ)9"E913-:LK7SFN[#L^?,TB8:O-NR
MLY;X6VPG".RWT1"^_^;'?\#TS>4P+9!)&_'AX(B7QA$I'"M=(04QB(Q&)1)B
MW7@36?N8_6\=]=1Q=RNH(\M&W7S16<'-[[U'KV711,,:QKRG)&5OYCE*(A47
MEN4LO 8E:A=:K@1R!!2H)^@&@=[?SW\=?87Q\*(+F(Z_C&;ATK+1G7P"/!-A
M<NV;+H:K"65=P%738#V13FKBJ/(D>YZ%X"PF6CMO^!$PCX@YK974H*)[^90,
M"<TH2Q6)*F@B-2"@C!N>X(9R;C)X5SO0<T!;=&\&Q&Z";K"CW-GFWHU*]<S@
M,D'Z5W_Z^=YWQ#+@F6E#;*8P:SGH' H#@N6)4T<EJYVD]WBT^]]?=E3U_<=1
M*STUL5AF6R#<CIS.P:&?ECS5>*"J8DX%1!BHY82#BY0')6BJG:AW+Z#GSY-:
MTJZXV73;Z^^3+8[%;?@=G'&,RT044%ZF)B#3C32$:9%! 7Y$E!MY-ZT0/E=.
M/1VU-3!Y[K_'.;D8C:?]_RX3'R;3U]_*DDKB88SC2TB++H8G&?][,AB,_O3#
M6/[ERS&D_O1M:>UD<N8N"WRU(JY)TJ"(BT$0:2R5+D1T(C>:OE[M G;7%1U@
M[,83N<7=*Q<:Q SOKN?.:F.\O"AI5Y"ZIF2_#\?@!V6YOZ*27D >C>&C_]9#
MKX<)JQ@1R:$5P=#SM;%,YC3,1/1=J$JULT"K #]FWNY?LPWLP\<NHKQ:UXLP
M23&I$#5U#)TR!X%8I@)120;P/HKL:D<YJ@#_BYXU-=O 0;[_;%AW'/3 .IG*
M! 5C%"72<K2TRZAK!A$H]5HR2?=Z_J]#>LP$W(/N&EBF'Q##N!_QO>@B4I?C
M,5K-O1 D>%FF*GMF2]0)7P,NT8 W/G FLD13NC*A5@(Y9K[L+OD&([5N@UIV
MI]Z-AG&.%(SVFG)/C#*BM&SW)&3E"2W=VI7T4M+:A0V;H_MQB%--1VO[*C9*
MB']Q\O;DW<O7Y_]\_?KCR[/?WI^]NYT$_GX\^@+CZ7<_3&5Q7TI,X!U,=TB$
MW_&)51/@:ZZ^4N+[XI%E=N3TY,9SKVFKE*4>,B=*AS*J*4OB78K()VTS<JUT
M&:_\SC^,:N>6>U=O[MIGS9MS>/12A,#7)U+<FX/2!%=,261!L\R%,K%=KO_]
MV/:5[%Z9(TMM]EJHXJFDN:]=THOO5R-S*%5E689XC4N2I:S+.YY)Y"XR \;G
M6#OPL0&L0Z6_MZ'#W<;YE=728K#"VM5?3]#9!&*C-/<-X!TF>[VZ:C>ESHYZ
M.1"%O.5.*' D!&:(-,$3)XPFRFH;&7"T2_=VNA]XIME38,XVZJB=XOG6AW+W
M-AI_OT)6LA1]_(SG_/C[_%;-1!NM-X90BN"DX))8&A+A*@00-'#J-KL,W>AQ
M^_?IJFMIU%3$#:YSWH*?P.?1()U>?!F/9BW7KY)3.;6.:TW*93Z1:-^1P'D@
MPG 5\=60]0=&W0/G>-A16_9M$H._7$YA?+7DQ35[#"YQCM87;H>X7%F&27.*
M)[6CF0;M4J[M(:V!<GQTJ"'S-CE]':SS49[^Z<=EZJ(??NJC5=XU6%JDN()A
M1EI.-+>A%*FB""10(F36C#H(U-3N7;41L..E23U]-+AU>',Y1CE?C@$%\*;_
MK7QUE9QL/7B.R]8I973ET*FSLB21<69M0C(;6GLH^WHTQT>/2I)O</50>K),
MQY>QR/=TB'+XA- 6V%B4H(VQN+5E@680P\735$Q)X[*04EM1^T+J/CS'QXMJ
MTJ\XGNG!M<\&&V8\ /'H\R0J6P;4E<$_BBF2 O/,1:L1WK[<UCW/E-Q36+:B
M EJDG%WG=KR"+V.(_?FPA2\#Z,0^3/.LNN[[:Q?3,R8 2HBB!X_VM(QE((AG
MGGC< 0WNA-Z:ZEEGE; ?'>4.HM1]QMW*Q)@$*FO.!,$W!+$Q@:9[SI9D%9B6
MS&M+:UO%]^$Y.A)5$_Y:OVFO=^/O_+CDPW^%ZG?@2Y^\A[ON^U>SXYWV;+*[
M'Y3\Z/// -/B%HV&<&L E(M*2^<]43RBYRP$1[.&)Y*3!ILE]U%L5JG^P(-V
MFV9Z=0>V^BGS"[ 4P:F<2)(FER&]D;C$* F ACM#JW"I-_2ZX:6;/*[U;7-U
M[=V>45I=HH>^89Z,IV6O2VB^GRVFT,VZWR@5;,;MC:D,1$K<1EV(FCB?N4TL
M2;U9Q@(^X,;A@G^[/EC6/7O?=\:M5#NJ*.**]L4-/->];."J*]8&H+:Y#-Y,
M_\M ]GOM6T='RPJO)."]:=\:39/QG$"902FEI<0J20F+,4N;7/!VHXN9IZ7U
M-3>V>U3Z-G)MX$K,T<QC,KBH'*1#+UM8! ->$">D)12/1$]M3#'5KOF[!6!_
MSD)%I=Q--WNT1!M.2[@Q%[WCL629,>,< 0H!_127\*#"TXIGRY40IDRWKJSH
M-5".[$BO*?B&?=9OPBI?CF$1[]T$8*.4KP?!'2;AJXHJ-Z#'[GIH.-%B/5!M
MG6/12Z(-P[?$"%6:<UCB/9.2"F]UKEVW>""B/)#>=1B>;"/^V@E=)U^FH^'\
MH',J&)U3"=5SBP==*GTKHR,T63PS\7M6;Y:V=>-#]Q\[K"SO405A5;0*.AQG
M%\/^Z ).AW'14L6 IRXR7 PJ1*J QH[%%2F?J/14@9&;A7GN?O)1J6\GL378
MF$^'<X'"V_[7KO3S9D;&Y,7WW_Q_CL8O!QZE478AP\!S[I%CPB0B1>G_Z"&B
M;<-TUE(Y*6IG46T)\4@MP9:*:M)([UZXUV#?^8O%2[4)Y$8VXR/@'L:*;$J#
M[2A738?[W]960@^*:J^](;K$8R0ULNS$FH!-ABDFHDBUG=DG0[L';-*GSKIM
M5%?;>NTRDB):"Q]@ OBQI>KY51G^.NJN<^\L9Y&UI)(PPEF2O59$^LB)1;N>
MQ P2F/7)A;R1L?28IQ^B#5MCG8[VJ9 & ;8WV[Q<P" )$0GGPJ,5X8$X@))?
M3P6#[*2IWH!J"WA':GZU4E"#9-5[H*X^LC> V\CLVA+JP>8,M5']YA2KIK<&
MIM:VL%U63"=CT-<M7:.3\B0XAOZS]%S@V2;JU^$\"9H]/"3H2;)L&W6UJ.:Z
MG$Q'%S#^ +.!N)//_2^+U&_<KBVCPA*A&5H(+)@R@4(130&TE#'%ZC/X[H%S
M@)'#+55Y-P>_DAX:V$X?(7X>C@:C3]]?^,D*42P&"S#NL]8D,.$0) LD""5(
M#CZ88&*.H79_[8V '3=MZNNF2; @(K7/IW[:I;R]+?]@<>O"M38Q:43ELR\M
M\#AQ(E/BHM&VE!-X7OM:ZAXX1VI<UU) @_J>-=#FK\8FX)I%+.\!=JC89"4U
M;D:/'72POTUD4?[F1/ V9F)<R=_A21#'8RCY_3Y3831SM4^? Q#DP2CB(?BQ
MC>BK3Z,;3:9G^0-\A>'E(I4+LC+4@D7SR)0I)-02JZ4G((WDUE JU8.5$NL^
M_!"1O6JR'U447 ,S\PS/2US;\-/K;U^0\ M4P67*./=X[G%%I&22>,T1GW/*
M9IF#@=IU4JN1'(/N*\JZP18_I^,'*.M#<.]AG$?CBV(2G85!_U.W^H*X]#_]
MV+_HQK>>XW<GV7?%RRBJ\?05BJO;\H(4S ,:2U;;DKUA==GM@%CCE70![25>
MFSEU5W"DUN@!U;Q,6KU[V_;K"M5>3%:HP!G1H0S@P!<&3UF'WE8,(K'@8_2U
M&UC<?/Z>Y]BUJ-+:6:P-3J;3BR^^/RY;\%F^ZV'/G/U!<?9[F3&IJ$_$^>+(
M!X<'J)>QZQ%'=8@:=.VF6!M".R)BM%!&@[/LU]$H_=D?#*[A=A-Z0'G)@V?$
MBC+7L?3><2Q0XEW.P'V.QM?.@5B-Y(@844'4M4?0+4-ZU9_$T>5PWKC]S6#T
MYV^C!(/%MS_@:=;30@2=?2#@;1D' 1S/M#*%)()/H+W@EF[DN3SJ\4? B#W)
MOF(ZWQK$:/F/2P? T^$+/^E/WH_ZUZOHX 9JC3,9"(\)I2.=(1YQDDPY:.LH
M$W>S^3>FRD///EZ>5)5ZQ<2#65YZ2IV8_6 9^,O/> PB[%M@I<N22O3?C2]!
M_^P<L8QYXC+3P#R7RIJ-*++MDX^%($TE7C&4/D_*NF4*;4'JJ""'H#4Q79,<
MB(HXJCV).@FK>!+XEPU3Y1X)X5@(LQ\=-/!A%_48*(W0'W8^UP>(HT_#,B3M
M-.$*^KGOK\SL>:U&.AFFM_CM_F V]6HRN;PH5Y#WIB+V8C3.Y1);5$F6W I*
M+,^6*,FHX(IFEFMGU^UQ>4= Y:=.BF7^F\;9[%?SVQ;G0$]R#>7.A,2RW4L'
M0+R(CK#$@[29&F%JMZ3<%N,1,;&I>I;I9%O&BZ[7TH4I5F!',]((SXG*&MU6
MJ1-B]XD(RCA+2JF@:N^/N^ ])IKM2VW+E'-M;+]-'%^KC-19H4''0R!2TTR\
M<HJ8*%T0(7M&TV[FWP\4>]B;)E9$+'<K-]X6^4<87_2XAP"> M'>E8&5(A,G
M@B,9/%>"2:8%;\*=\O0?E3-;2WX%5W;/QKEGKUS>''DP0#TS1(%"V5"E2& T
M$-"@M1.2"5D].V<;@$= I?:*64&CW8+DU_&5M:_ RC!+U$IPIU H7E-24E-(
M$ G*Z+=D@%$G^&:U?8\$< 1LV9O\5Y!FMUCY!C&6LS!!V4YBZ43[QD?\L&[+
MM-92R\JL%-TEMZ2 <D)>J,"-=-K(I<YXCX]SK89P+,39CPY64*=6!/U!OG=@
MF?$A9Z$)I2R6Q))(@A2*Y%A: 06'/]OL.F[+!Q\+35K*>P4Y=DY%/TG_>3F9
M%EAO1N.;#>9[@2:N+)Z+B8-'VD(D-J#)Q31'.TMZ):K?VJ\%<P3LJ"OP%538
M.2!^$\RR'=5+5$8=F22E1Q&:39J1D"1Z:IQE:B PK6IG%MZ/Z)A(44_T*YBQ
M<ZCXY6@X'>.!]J_^]/.B9F\1[_[>4T:%G$IW*4MC<>%QX3)RHH&"U$8(:V)E
M8MP+Z(AX44_P*VBQ<\CW7G0O+\?C,HXD&IO1K\HD&<&(M R]+8=_M2)%QW40
M(C<89/4@KA^%)(]1PPJN/#I6NQ'(=Z-AG.-T_S][[];=5I*CB?Z56?..[KA?
M9IWSH+2=69YQ6A[;677ZB2LN")M=,IE-4JYT__J#X$572B+%V.06S5XS6;YD
M:B. +R( !( /BQ<E2# A%% Z54P'!CQ+G:,K-K"R3[A<B_:S(.:9QEA33;A;
M<G9#(9?/LW-.))P,QWF0"=-:. 4L)5Q6I$2,D#1GNI24=-ZLMN.Y$AP!4O9G
M@36X:<#6^XC@5YT8JV?]@979*VLYN5>&Q#6Q0&#: G<Q4P!FG.2M(YWM)#P"
M0.W!-&N0M/-,\HW:=@:IMI\I'L"5F"ER"[6FPUJ(/ <AH@U*V\8 VDBP(\)-
M>T.L@<O. THWDI+^,)%BPA<<!&,\.J8@%:7HH,1YJT9]_4PL6^6\B*T'06PI
MXL\&H6<:9PV8=AZYMG/+X.(VY@,CD+'H.4B>:%=$$R DSP!-\,9Q*^Q=VK?#
M]X0N9?_9X-?:G&MPJ7M Y#BX(V!+*L<!/P29X]T5G>@<3W2.)SK'#8%RHG,\
MT3F>Z!Q/=(XG.L<3G>.)SO%$YWBB<SS1.9[H'$]TCB<ZQU[AY$3G^$+X $]T
MCB_:?"<ZQQ.=XXG.\43G>*)S/-$Y]@AV)SK''1KX3G2.)SK'$YWC<;M?)SK'
M$YUCSXCV3G2.+PIF)SK'$YWCR^7E.]$YGN@<3W2.)SK'$YWCB<[QX2C_1.=X
MHG/L&SY.=(XOB]+O1.=XHG/L)YWCB1GOQ(QW8L;KQ^C7$S/>B1GOQ(QW8L8[
M,>.=F/%.S'@G9KP3,]Z)&6^/@#DQXYV8\5X^E/L.BA,SWHD9[\2,MZ\DTHD9
M[\2,=V+&.S'CG9CQ^H*9$S/>B1GOQ(QW8L8[,>.=F/%Z=F.=F/%.S'C[T?>)
M&>\%HZ.MPD_,>$>5=CXQXYV8\=;AXL2,=V+&.S'CG9CQ3LQX)V:\$S/>B1GO
MY0)J#Z8Y,>.=F/%.S'@G9KR=('1BQCLQXYV8\5HSXZT&9XSOY;:6Q'*WY=V%
M*._I3^V!-V_+]>Y(H[=AR>#-X5G7D+8A>E^,!U^=*^700)320I;T 9L%FMPZ
MX'Z.G#O3\ER-;GGBZXL9+B$DS)P.>S^?11Z5H0B&1[ E\V2\YX*U[FK=3L*N
MR?WVAJE[;#_=&>K0!(#/T.E\(DA&&U4)!F20I,ZL)$0KR;65"C$(SY5WA]NB
MAYC&M ^P[#AU?ANC]63L]R8BGZ;.=PB#!O._GV/#GL O^)HI+!%<CAH4Q?+D
MUVI/8&$8E5=<F3WWE_1F)&K?4;>-Z3I!VZ-SSI<S<XQ1S(=HP6A5XR9!<9/&
M %P;'J5RUF/[ 88;"/8RAM!O9>)[D&IMG_T.GO\XOKCX=3SY5YCD 3I3LO41
M2G*5L#07<"8P("$]CR0ECZVK'3:3K'<P:A\;=&"B+B8GW1'M/<[N%Z%[%S4Y
MG &*9!845DZ'@!R$#IYKR91-S3O>-I"K5S-XGVW3>\=/8X-T<85MU<+ %"L1
MA0?#>3V,52T5%)4)EQGF?)'M)RKUM+=DGS#JS$0=\-)NA'D;4S2H&$A7)Q5'
MIR$PKT"+D+@40?#<^F%@^T-HE[UTYVM7 QJK >O$QO-)S?)/\&OUP[_CX@_?
MU&SLM/Y';T:7W^;C%\?D_PC'Z+;*P%D=@R,9JV.2.)"21''2!V=;O_%VL8XC
MWYD',OB#<X\.],KRB,Y_)0.M8?7L\B%F!VGV^E;32FN-GG,>$>?:G=9,UL2E
M U'$O 7?010&H7 4T@F=35#["T<Z>*Y9I_5??MSXW7+H?K#<,<8!O:D\>Y+"
MBA@]2*4BZL0\BZV/YVUEW->337/<//Q$TX%Q^O)(LPT+46#9U]G;0)%"!)6S
MA:BR!"&-E(QG*YL76/28AVX_,-F!E6X;<_6 )FP3<4^L=!V8?D>^L.?8K0=P
MTS*@+84!NCH4MJ""D*2$6)*6SK"HS1X]BMX\P?059=N8JQ,F@'D:'_,UO]7'
MX9>O5X16V4?%2@@0L1A21?#@+2,9N4(GBD:96G,</B%2KR+@W4UZCT*@G3TZ
MR(T_1IX7A(I!2 LZ^%S'^T0(L=#^L2X6&84KH76#\8LF,=P%)JWLL-?[ZH\I
MELN+=\." U1!,2<YR%S),1P3X+0PX%/*GAO%\>[4^ XOJ6NY>@6:-L%><W/L
M]^GVM\F<%H$KI=![8(7""Z5D J^B@(2N:&6SPN:SN)Z2Z:>"RC/,L%]/^"RE
MRV^7=!9BOC63(Q?#$6-](0FNCF=!"DGISG0VZY*,S"*UKAG97LJ?"THM3-7!
M@]LC$K_'V< *9FS!V@U;$EVE@I-T*H-CD?[&Z!)M:^?F<8E^+M!L:X('V4XZ
M>M!Y=?[^[V\^?G[[R[LWG]Z\?WO^\?WYYS>?WH=)?8SZCCL\SFSXDYL^M#QG
M-8T>35YCG+T=36>3RSDGTA6N9+%*UE8IRXT&Y>F("%DRL$ZSE%@(>'>N68,X
M=*THNT?<-W_L(G-JR2<7C Z[P-!35&?G@QH4E*A=Y";P8%J?+FO$V-<#1PL;
MWX^;=]-J7YXM;J]CGHTRB25,5@+]KP(E*F%Y,@5B<$8JQ:.SW4+_D(\0.]OU
M49QLK=].,G W);J1']A$KH[>#1Z2Z3 /!+O:[%$([*CP?0*""2VT2XS"KSIK
M,J$%YTR";')V22;D=X?!OC @/)'"WQ<.MM%S:Y[M,S*!>S4>?4>*C.BP^X2C
MX7CR?CS#57J/,R%1N C%L%#KFNI,8V1 QYYBJ-"ZO!F+WI.?VG^(T<8DX\[T
MV3#W=26=OR6,4QA\$>!=T+7#44+DGL1*TC%:K-=);VQ<?X2V?+:V.MBHDCT*
M+"F,*C6-P>1\F UGX TCG!4IM<O>J+NYIX=M^?BGCL2X#?79FAOWS5]I/O7Y
M\R2,IHMQ'DNIE R.6_(^HR,@JA R.&DS"*^*,\S3/>0WLO*#GS@&Z[;17T,.
MV]52WXU'7V8X^5:7_)G^FT7[I;(L\%RIVZ,!I;D'EUT!C8@RI1"*;_WHO4Z.
M8XFY=M9Q!^G>NS*MVJ\WD*JCF&N]1(>)N':WV!,0V$'='41<#TCG/<M96 LL
M97(J,-)I9QC%&DEDI4.D/VX]MV.?('@BVMH7!K;1<@>VO^%R5,&6MY+#K#4=
M<'31.5IGC.1C"I),&N%2,@YUD*UK6=8)LO^[OX65[L\,W5'%K>.NVS?<#?DJ
MI\?TO"S^I&Z313U@4H67R$#Y3/_0*D),BBZ_'&1!D0*+F]$-;O?=EW[_=ZWJ
MAN[@EJ*N*H0W$':]M[ S/@[A'71NS^?A9@=CM$X*;"VTT$RK7,=EZ#D%1 H0
MN)<@M&+"!B[4W;>=7B/G 9>BW\#9Q@9= .9:H(6$(UR%QBDJGY*'0E=D':A"
M=RZ60AM4\21-](SQC<'QT%?V/*&U6^O<Q4$3U7;A?-P1[/._QJN49DXA)>F@
M#A\ )3DMUQH+T>7@,"B6-DP /_:5G\GFSU-MPWT^G<P&'VON:W&L9<F5K1/P
M31U38M"!UU&#D#IKF8TE+WN3P()^ZHV@@GYW'5#<^N!+]R&?K[T'>_IW,.&J
MPGX#,;;)$FUBS/8[]VF';P?EWS7?#IKK8B]>)9]9'0.AZ32HK+"E#A25G$,.
MWB3MDD>^T3"P0QOP ;^KO?VV45ACN_U.FOIV^6V5/;!89]\$B%G3/>%J,6B.
M'&1TD@1B4HB-NAR?L-RMC^[OVMQ)[>,6.FOH],P%"7_=$"18+4RQC+PO)VM_
M9017WVWI>L; >=9>;]3.\93Q;G[T!1KOV3KKO"CI59A,?@Q'7\Z^58+M@38J
MA9SI3D^\GBQ>@<N)4ZR6R:M.411L/;SC,7D._6#ZKH.*UATTWD'#UFW9?@T)
MEW)YC%SH7"!ER\E]UY4.60D0WKAL-6=*MFX^?TB68T3!,S7=^7GP=C3#"4YG
M'\,,YS.[\@T>GF*3B25$2*IVH98B(6(J8#P:.K0$*[[U7.C-I3M&E#2S1@?O
M[K<C]&4NH/;[K(3_]#60[&^GTTO,?!!TEL7;"-YJ)*5$!<''"*0+A\FF$IM/
MZ]U.PN/!3T=6:?U(\R'\J )-WU8Q__-R-*\EJFR$\U*Q59W10&=G*<*1@"P;
M4 (Y^.+)\\I<"&%<$&ZS/-IFWWO9,.A*L0U3,',1_S:^R OFK>$X_SJ>S*O)
M"D[.IM/AE]%\3N3D4Z@3JWZE.Y(^N(#M@&$=<9X=",/)9?)^R8.K$WG4EB?F
MG-@(#,\4X C0L0_5WX>+;ARVW$@]DYVG7VE1UU?C>?DT&Z=_?I@,$WZ>#+]\
MJ3/M?8I!E0Q&5ZXV.O@@4.P%-DM)_A<7:+IMN=A:Y)>-M4/8[3[L3&>PN[YD
M/]:N=S[0SLA<IRED;NK^H*T1HU&0,-7&%B9T;#U'?F/ACAQ*.]GB/FCL'D S
MQS@):B.ZR@Q30@F@*C5W2$*#TT:A=AY#ZCC?\K!P/PUHGF&+^Z!QW5]P=%/7
MF_MU^#$=*,YS]MF#=/4)U$L'/LH,40:.-C&>4NNRQJT$/'+P[&R3^P#RW0.(
M_FR*Z;).?K@A-Q_P;.A*104\<P>J-F"ZR@03R.4S5DKA9+=#"[80]F<!5@M;
MK<D6-DX8?\2,W_Z<K0[16]FI$I21" Z9KK/K"M"&2)"L=<9[^AO>;:[P0=&.
M$4%M[+ &+RVK*.OO7B\J EY1@#G*83(_-]&;.K8.@9&[5DNXZ-Q414/,G@?K
M*+HT=U*#&Y5./O"YEVW^CM2ZQO*[M5FNSV._'7W^BF^^SVE EB(/.(_>,\N!
M:XN@I%-T81H+W JO&$N29_D,ZS_RR:-#0"OUKD%!RSK\LYSG>@X7UP+?D=9@
M0.=B?0$K'%01@<ZMQ $YZDS:2%%LUH.[[9>/#A.-E;T&&L_. *\T\!NI:?IN
M/)WB]'ST$:OD:78Y(5>GRA@)NT$7F[!.#M04D06;(13%R*O6Q@23;&:EL0_Q
ME$PO&R>=:'X--)Z=[9T#>8U *Z]FGHL>)":%%5I!TMJ#<EI"<+66AO[8)&VS
M$FZC4^*I+[UL:[=7YAI3-\BP%IQ,,/\Z'(51PE?CZ6I(;38%BZU1C@H9E,BZ
M=BH:P,BE3A0$A=*Z:_=!85XV$MKJ>@T*GITRO;ZYIM/+E4SOZOS)R:^(TT%0
M0D7K$'(,<[)C!TY0^*(C9A6]%H5MMM4?_L;+-FU+!:XQ;..TYN+5<9B63]0K
MUV1@F17!>@$NENJE"@6>KAY@'G.(RLEXMT&J<;;@ <%>-C:ZL\$:I.R<OZS]
MZI^7_>H##$I[I*_KZ"IQBR)7Q'A=&<F9\585Y[N8V+#Z_G'8_=D:75,NMCOA
MR'62<UZ'0O!;<(VI$GT)!C+/L0[\(B^SN$).)Z(42<JP6?W_\P8TW!3E.(S>
M0L]K[-]R/,<*E[?D8SJ*X$4"*T7M*:N-G+D2T#H?0TZHM/'=X6"=2$>'AYWU
MO@87.]>1GJ4TN<3\;ACB\(+TB]-7E^2CCNC$*H*5I"R$*'*EU:&K*44/B2F4
M1:*.NG7X_Z PQX&%-KI>@X*=I[?=F2SS:QA._AXN+O'U<%J'=E_6"C2KLT*C
M$*1W%*@4C>"*RI"S#SY)%W-SGV #L8X#&:WUOP8CNU6,;OC>=;,'??Y7@Y30
M:*D#!+KA0"$6B)X;<#Y1T$OACU?/>5W:7(*7#9#]*7\-9';+(SXJ]<W"#191
MD 8L:-)!;<22X&VN#Z4250XE"+OY>(Y-OGCLD'BN<M= X-GYQ:>E7%]B,<AU
MB$BD8TXQ7^>8\@).:U9Y<!2+DHEHGC/)9Z./'SLP&JA\#49V+MB\]1[RYJ\9
MR74YG'[]MGPNH^B9>48"6@O%5L(T9NNTD:*!T?GFR'$2G+6.4I\4ZF6#I1O=
MKT%'XQ3FS9Z\-Z5@JF"^47!C*)A"C!(<:D57'@55P2(YUG3O95F"5AV7]#XA
MX'&@ICN;K$'0SJG-F_1XYV7Q^D(XG[^_#+@J46>!D+PF-5# #9[%.M$!(Q/D
M/,G2FA7H,7F. Q_--+ZFZY$=@(#N4_J*^?("Q^4]WADAT)R2;H-O[8&D;ML5
M=TQ;1["P6JH"J1A;.0L3A. \:,*HRDG(H+NMD;X2I0O:.KI&G0E902)?'92I
M;)TQ%HKTF3%)2B-]M^]OO:"MV\;&F]#6;:/5'M/6%<]%\9I#T+R2CU,L%[*K
M)$U692U%<KEU'O:^%'T:?[>579^FK=M&O_MD*=M$KI^5MFXKFVU*5_8<A>^5
MQY E[[$.O)HG@'6HS7$R01'&J^0<RZ7;@Z!_M'6=X& ;/>^?#4N[7'G6)"2.
MF4X_F<$55VN'O5"%HXMW47 $;%A;F60[-JQM]-D%;=WCI'HF<G)[I &2D*3+
MO$!42)&8XDHKP:7P3X89+XZD<!=K-]3GOJ?_<>Z<JL,59&5C5Y5%T64E(3O4
M*>E8IVEW>K[W=?I?N\!@!XUW/OWOCU%89$TP?YC@M^'EMX'2OK!$GJX*LI+%
MU.F$,5L@_"?FN/(^=3LUY;Y,QXB*'37?P3EQ0Z*;Q<5O_OJ3?"4<!$/'EU )
M.,D"=-)K.L6, [0,?4@VV]0Z&_*X1,>!BH9:[XAI[ZJ<- 3CE&,%L-2R,55G
MR'D4((2+(4IF>&K](-;/ MU=[/ULC3XXB^] 2>G5 \P2J1VFI!_XTEX3TINL
MMN-TM/'"\Z 9>*POY@XYQ0L$/4> $T5:Z5S[WJB]I:.9=#IG$>ED$W5$-AUY
MT7D'DCO+&;=,YBZ&A?8L';V-C3=)1V^CU1ZGH[F*=?B])SUX6R>@%/#:)6"2
M="),,5EV^U;1MW3T5G9].AV]C7[WF7W<1*Z?-1V]E<TV34,^1^'[! 1BT=HG
M"4;4)G7#:T&'RQ 2+T%)7HS?B'RBMT#8/AW="0ZVT?/^T]'D%9-GS#5P*PU%
MR]Y#%)H#&AX\5XJ)(TQ';V62[=+1V^AS_^EH9P-&D3(($U(E3['@@XG BM3,
M9*:YWJR:_R6EHW>Q=D-]=G"VWXND(OTR75SF18KTJH1KD'12G%L-5D92078"
MHM$:@M6)&6VM:IYNV%2V0P.E3<#0B24Z2%D_6MA71'!"B$ *J+F8FB\-D=>!
MG-D+T@=+[N<LI=P%&<TTOI_S8R"D+"Z0#,%+.M)T='6$;Z4(I67SPH*5K0=Q
MKQ'C.&R_JWX?S$)WE*?\^.;3YX]_O/I,_\W[WZX3=A\F^#G\=6L4TJNO8?(%
MISMD*I_]K::YRC8K;I2MO/T].B#.1IG^#"??\1J/.NJ@O$J$'_J'(AB"9\7,
M!XQ9PR-+K/5DV$WDVO4H6NG^O-SZVOQ+%Y6Z:7Y@+C(V,6050TF (HM*),AH
M-TH$491@C,6H2^O\YA;B[2OOV1PM=T^OKDS2E^3H(PJ<9P.LRRQ7:DEDM;=.
MF R.<0Y68U8<C9.E=2O2$R(=*FW:&1+&W5FD W?I,_U[=U2P##$W$:RCY.J#
M0ATFN]K4A.,N];]7@&3I4!M- NH80=&V %\J8RDJF60Q*C9_==DS,)[(MAX&
M%]NHO77N]0UYP>,?B)_PSS"9AW_S4W*9.8K>IL)#@)(-7<S61XB")="> @Y-
M!Z53FU&Q/?J9_8=1C6PQ[D21'214SF=?<7)KN2N>ZNR,=,F"XY;N0>8,+9<%
MR)I@GE@,5K?V'AZ2Y:6CH*FN.TFC4#RY8)B=YP[J?U#56\^UX%)&GNI\L.Q
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MV2 DJW1UE58C* M>^3IS/S(LB7LZ/KO,QA_?*;.+ACO(NMX&Z&(VD/92(#/
MA+9TZ:*!6"L+K-1"HN&.B^8/L?>D.#:S[ZCGAHT3"VKBG.?J#!=7I==GT^FX
M-O1@_L=P]O7M*"/Y4*ONP?-X,?PR_U5UMF-6GN2VH?CEZ#D1%7!?#,O<N> W
MF]>W@Q#' H^]&J.#WHD/EY/TE0!]+=* %9Z2CX1H7\AGCXZ30Q0(UDK:DF1*
MTK7NW+POQ;'@HY&>'^R4:-!T]^MP\FTEWK4>WHVGTT&1W#$A)07CM;$GNP1!
M":05>^:--=K*UM[#!F(=&S9:6^(^6$Q#M_(U_CF>UH;SPDT*/ N(O#8?EQ3
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M'.E$ 2="33%K8='3)6)[PWV][>)>T/[H%J![HZ7:!5U]NF:VY-\:H/,B,ZW
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MVZ,/H.E3$^/&ZUP> D)$Q@,R,%@GK04GP*<8YZXDA?VL(._-F]*6:SMMCCZ
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M/-2Q@(*[PT:Q4&(>'\ETWV"UN%>>[E>(*B$2!?=8M@M]L[D2\YM?4<?D.9+
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MU 6(= #Y!<M6/QV@JT '2&GDT0%B%GOR=,!X^9XQ(O,AJGI?A1>'.0U^BHK
MU$K&RFNI+W#PT0&PS1NDA%"Y!I++<OVDY1^! ^.STAWW(@"KN=F"I*QR%=>C
MU( O_S,"R;L[@?>F&&_0F,<J=8!P5J9YI5$Q=I7Q(<SCA&C^0:&?O;U8?95]
MN3!7LIL%E)/J1Z[#53Z(\/4N-1:L7NV/,;CTXTA6!GSV8#=;6R,UQ_/SQEG2
M]LQ7=/+F\C?XQ.?9L>'U0_ZFAC9XW1FH'?G-HM%,_SJKAV3*TB/%57</!KF_
M@%#0[V:O_!F;=:_3$8NL=<?GYSI3W/=FM5P -(D[D4B_0K$JQ0'-SOFKS<3N
M:IW\$#%O\1BGN;0WFE*TUD^-#H:\#[QVGNV5_7JWO/NUFB+\S<?BR^<Z Z\9
M([%Q950,YGRS:H%=;S'9PT=A7G'E[E"4^TQ3+2H%R1;;.=H*(H?862?2 5A:
MGKCQ6,%[?2G1W]411[%[<E?!USU&OK31 @HEJIB]9937!^;JCVW[7_=Z3'S\
M/-6 LOZ3P^,HWTI(&0P@['0U'41?>;N39Y1X9!2T^,U]4C96FV,@L2=%&XE%
MX46('?K#N''EO OZBPG:9R@F&:6O5#KA6A'9!JF3Y<*KQ8B9@/-*EK+;$M4M
M^N&VEU+!H.XN&^ #W><0=B.N<X;2:.4\*O>/;I=G\8=/TEO^'-51M&D3N8+D
M!3I@BN]!0[26 W]GEF7_$T/]>47%[BUA:M$IT'PY\<).UW3)#%[ECM]ZQ;1&
M[_EB(>]LWO7&Z'FQT;T9<5^H)UF5=E;].8UWQ'N[F;D4'N$8?BFCX6)J#"XY
M6NC'F:4G?K=VLLC9/9>R[<HBK"$!H:VP_%W^K4_% M,IZ SG;4_0"N0DZ37T
MO$(X5?04DL.[*6UV\?%<X-HO0Q>U&=X^0L&:/_J/MV8FWLU23E&U%7LF8&MR
MBR6?9;C5GBL2%9DAYUX+#W ?+3CTU.LH+8A=4OSWB+[FA_<5^.5OW](NA8M?
M-Y"-YS6]V?L8 F"81X.1'CLSM!W3K+T.()N\W>\!_AY?G"[.MKKMXL)Q%QWP
M*0].!YS7R--G?E695-9K\*(U9J_ZVX::(&(?6K Q^)FF%#::QT%CZ29L-C5,
MU[W]GJH_\C)KC=B-?<L)M!:;42'".E%D:<G$9EWQ+_ [QE\).<D_#99,@Y[K
M5SU\"C2.%OW4JO>M,7T79[LM$;R:%M<K&V^;\Z97/-= LD4?FH^]+GQ51-+4
MOW\0]IVZ'18<-U@-C_:$I>C8'],!R\[U1.ONG1C1&\DS]L3TAE)00)31.M.=
M=?[+^@N@6%>WQ[^,%)=2>Y7?60^U9TN7W[(-!IZ$8NF.:M"*CD!10_*36+U8
M7?7SK\-U7ELC3PJ8$ [ZJDCO#P)6:7_E>;A1?2Z0<G!UZ1@TZ%ZL\:RT4NU3
M<\_9U$\[K,K4I%H:_PE;-*(:%/7R-B0^%_)^,:+FA5>].''IQ3MU?9T.M_'6
M,;(1<>\''2"DO.>+=? !E;]V&/'8"]O8 !X4:BT>YZ<=H+I>?"_PRDJ*JO-R
M,#=H_382(&1]X5: U^7$>Y-!5L*QA[_<.+"^K$TZ2\WU%/3/(RT@Y^,O>)EY
M*N* 0@?\.IXK:)4^3@?#;!"VOLY8A3<7NMPJ#&(J [;%HI:;F-\_U]=^[P0)
M+4%-CQW.*[#8,YM/C5M1\_*/KG(+Z M!IDV#J!.EIKJ\G8'_CM01H%WYXT24
MC-[7OK* FZ>-V]N>$3AT.)LW-+$$>T/5#,4"N3PUY(NYHH[:@QHRS] DU'[N
MLY1JMYU&/RH_F1T/A2F_P<4K=(#W.K?^)_AG_O;@%([9N=*UK\YO.SX^XA#F
MU%/<<IDLQ:XL:F<>(1E]1813N37X&SPMY5"[=35A)D?4I-^>H":B]8]!(%P>
MOS"F)5WVT3Q)YUQ@[L6C>YGFAW^PT%>Y.L3BZ5O%9'/S9SVB"!*>";2?3"C<
M0Y631O$#ORHWD 9(CT<M&0TDXM+.K\J#V14M1>S,#A\\SN3/\\GXB8F]XF8I
M%J)B-^2CB,$6@\K1,G;N(I"=C+P_+/?;>TON<5U\<E(:I]0Q,SQO:X8B;TL5
M@N);'-WWP;S& I#KBI0/NMI66KLV?V5O+KX$_ [=;357[-+G4N%_FK3R6QVG
MH3Y_E>=:XM\R#'0%%MB<5GMXXA!']<.8__0I!8Q/HY@A.\2I"B/-3G3 F4&J
M!/+I&&Z8UD.B ZJW,#RH%=ANT6^M"N\9J@-\:2,C,&/@NT)G:5?O%-)J]"!6
M)H%40I([OVBZ>W!X ^^[O-W]K+@Z.^P;*KF6@RR%)*UN>>. 26#"RV#@E,;'
MD9.0H$W-K:S8B&%(234)Z,V:)-GC^6:BO(&Z).DI9F J3+QGWM0+[WT W=7I
M*6@4X>O!3-,!K$^UO$D<(+R=\(O!201^)LC^37,+);@[<'MF)W%L3R6)R@/&
MYU7GYA/W:)SL>4_&3G\XP7(B?7X'N3Z)0T[K#/9@?FNU3@Z^**-MF[]N2$#M
M(<J)0V([W4J)PRVMAB=*B:3-NYCW-0@O5A(V!F9YBO!W_D0'/#8Y4+*=]W!=
MQ9\>=I_9SKQQ=2L_8:_V&1GOJ$O1/8G6N\H[KX"UUM%AW-/P.[0+(7.Z%<,D
MJB?:Y:*"O_P81*$W=.FR-:6_@V''4NK;:()D<RTT4[J$U<)>WWIWB'(JMIVX
M&E^[$QW&.M%L6MZ_M/Y")7[BX(28W%^\C4]"L''X.PI1>&A3TS!\ A;*N7%M
M#4B(\VR2P]WR+:X[F.%XM]XDW7#H2^AZ\M![T<W1TWE'7=<G#5,82.W+:'J7
M.S"S$@K41>00!VEG6?(1@.,2+74"JK-59+?6P6Q\'H?D%='WG H>O")/UJIZ
M<%U^9>\T(W=2!LL?I!=Z^D%8'QW  NUQ[L 0WD6VAO^RB=OYZO9K;N\P]V'.
MC;\SOU^,JG?=L@AQQ&C.[('2]B@Z]>B^"6K2TX)2.-*2-C?T?,ZH;U=GREND
M)^U[X,":D,\SI?C]+FAE,1^K6O]S-P'I+D/-:P6Q,F?_5851<_!?;.A L6WR
M:5A5+H:R&(]6VC\A-5@3>\2]7S[K,[G5QKN,KH7@#;#:P(6>-R4$MP3E4//.
ME)OUX\GK#7\&E%WU;:8?<'W]SIL9\9Q)H=(?PPM>R&OBZ(+$"&)BMYOM2R=G
M-U(/=V"\M4_?[$;^$%_]B,I#N],!D_U&Q[DT40ZN27CZGDW*"@G$"//U22ZU
M8J-\Y7C8>5I[<^.+VL/Z8D.OZ08YY?H,?'W/SQ6UYKX$0=24!$]NP_C<P>SA
M2'N3*BEMTGHPO="?0K$.^>Q1W9;_*[F[]*/"647J[6HJ XRR3@?, 7]_-W:<
MT+A/#00><:*:RR3Q%\!\Y99Z[$>Y]D%NNUFDO,D@G,3@RS =CRS;G%1#XH7Z
MO  ^B?L?;#\^1<+5SN6VZ^VC%%KKVG-!U@O/7<%)4(XS:F#"6YN_=$#5NA'O
MF?$.B]?U'A^6R&7F7>;9CF6H7\=WQL#ND*@75XN#2CQ%-8=D=_ 2<'FY%72"
MHS1/VI-'$";.6Z)CXV2W+CMP@K)[@#>+>=W8W]ZX,]M;RQ?TEFW* 1T1X6>H
MH.4\X9/UKZ&ENI@GN$D3R^LZ*JXXZL[7IK[5APG83-L*](6_>&G/^Y>E#1QY
M,8^))KS>REF-_F!6_S4XQ\>'$]20*7;/CT7X8@\6FH&37B@T,(S46QU3.<AK
M<=IP=K'L;E'._U-RP&43-@1DKS-^C#&L(?Z.\"][:%(_-*T;*F0@7C%C>6I5
M(HY3<=-!(:[9^R.<Q<C!J/-%5V[TH^$8JY4CEUBERTR1O=NW<[43$ -8"%DR
M+QH!(G+<(SYUE!N3;!RINU=WMR$$WJZI+_566BS[@J+C(.4FE;WZ^"."@R6J
MCMUDT2 <-+ESEU1:U94L<AO[K><W4B; XY&S%5>)Z3?MN?JSEKY?B]4M/KT;
M[Z-D/$=.,V)1,2I&#JKWB>,1H:4.][ZT><.00KV@U)>?&992'5CBM9!8='3]
M T?XAX=?ABK=4OMBO0[')8+:-&])IKZ$8*$J"$TZ(!Q.#L)B$FN!W#/P!HOO
M>0;-B<1+Z?/7OO(\NIVBWM;U8A7/2]%>Q]1:1]4. ,W&JFIC*GQHXU_MNJM^
M!5Y_M(W?,R\S.E7>KKRARO*]OC0KP/?WZV6S+'-[T%H_FC "9*4#U@K@,#K@
MM"(R(>A(I]H9QRX_838BCT6/;!=RW_+WP2ZFG?GI(E:J0D11->B =LQ?C4T@
MF9TWU(.PT_:6JDF0C\3&>;V17QA^NEACL Q0?L7'$"/L6B( 83:1QGJJZS18
M@5C,A=158C\5--G.KIW0S=TD"ZF"6(!4D0]/GB?US_$K.L ']@9Y >F>H]\&
MY0Z@ _ Y0C;V/Y4%LMJG)_6#GK;-7QKJ_%##);XM6>"\XZ>/*=M*)\&VA3/D
M5"VWLJ#(_;(CJ"XBF@Y@%C\N01A3M*AR?[RU&$-("B*;!Q5R+D;N5:)"]SC[
M_:42[P9<8H_U4SL/\=R%BH2-0WEKD>2K;A%AH"ER>2^1EE]:P:>!)@44!L?X
M5'&+&L1TZM@,/7M)W/8"NS=*F!?9)0W0 7896QAE9VHONHD.6 J+,X6":*/0
MNJ 8G7,(#;+O)SC$**(SCZ<9,63K3IIPYF05<-Z[^E;:D='PI;R%2TVV-.\R
M^ +5F.(8UI?+$8V#Q5(#L'FQCJ+5Z9>KX*[L5S7O,/G=*WM_-9$GL.V1JNK]
M<-,H+]N0E'<N!9#T8X5CE<J*IDQ]3+R+R%)5ACW2T0TS:MV&KBO! XGR%!S?
MUF8!]?*)KRZ_0';^9$OP]2^VFW]DZ/WK_J:RSRU3Z9]F&N/67; X8&W)EM%G
MN'47D L1DD^U)X>6>_IZ6 ]=33J?$^3Y6Z!!?_E*/%[O4K53<GCAY=)8/P\5
MK]X>Q_5I#!R\O5F0T5M.TU_3YMT%XXTI]^&TP466R+#3")[:$2CN8HMGP+D6
M+RMF?.T'R >.!J:+[4H7VEXRW-235US-E2%/4>Z$=>E($>I+B(5=@L N8)3@
M/O6%RWRE4XF^<U#Q_3X3?'5WK#7#A[<SKY_JW-:ST*8\__YU+ZAAM7@^8T,]
MY+N72ZBF'1V07C_?@WENW0&M0W?MQ)O2)J#G:#S4:^0(CO"GS>9%VK\R+JQ?
MS/@I8973D'?CAH_5I6O\Y_<S@XEQI/#C-#K 72%RGIN<O^C AT-%AEWZ9S_F
MCJ]W49=3D(L\>5'V(H_IRQ&],.^9ETZ[V8+2-&*7G/H'HX$2V,9BUA+:7D).
M4\5_)Q:TA.2D!A('3CC'AP[@V86)&_#S>QT<I8-%QRF,K0L2;1PK[_;T%4L8
MB#TFQL_S&GIZ\,@%2)L[&,OZH9\<@3,VP>@-\3Y.=./6#/\E]I87]H[W\)50
MD=T;HW2NO%"^D#TUFKNGZH=(O#?%/LV(</_(+/9PAL1!/BP_284,WBI GH$5
M,D:W)4]OXM6;R[#:SBDV4X"E;/SK2(#;,Q%0\G%>F"9\M0=8/]$#!6R^P,P@
M)+"E^=Z2$(HXU_'[ZOLT(N<].@!^3-+VL@_;-X-89:>N/TFEF@\-?#</$*S+
MLMH,Q).U!RO7"F)3PF.E/I[Z3\:A</P1Z8IAH(TX<D YX*N&JKZWNXTT*6Z[
M55M%8LS85!:!'WUO+1:>")\E1YB>Y#,Q^&.C7L$.7&ZEMR>DE[<[E>=WX5QG
M#,?Q+NAO:ZPL'UA>ZPX=P.1=35"(VD=Q>F"X40'G\*J0QL:H@;]/='/2^:Y<
M;W=^.:<4$3_1G<M;8S6518M8B92_G")MH>4G;66U=HO_"AH@OR74-G]MO%;:
MX,)ZT-Z4SO;WPN2W)[E.Y5E=6UXI'4 PH0,28%5D79K(QE>?YN$K'G^G;'9)
M7:WN@V5Z/N"II\\-]X!D*71W%-&UD:\#?^.^AYUR0<B!.:UITX,A++F<B[:G
M>J#K^\^;OAL-<B)":IOJYDC&\NVXE?7HN>G>99D\OV'&)!*D.!B)MV5?C:1I
MP/<@HXSBJU;?&AV.[=0?]@N%26T@!5MM]F)WWAW.TP$=NUY98^F93Y5\0WQ%
M:IV/2QX5[JN0]E>I7*KZK<VY*] XZQ6#G"(8.;G$S ^YC&Y!3%&4UCJZT74L
M'0[*"N_1,\\<FO;[?LR',.)C!L(6K?QJG/57)J*1"V]RV6I&<1D/R6F5&X%G
M;X6$@,YX.QPW=WLHT@&(B7DT*XV+#%F(/@D;R84641&^NW7]LHHN6?IJ<^*)
M?K]7&64[<P%K@*KVV __A\U7ZU5K*D]<EQW+*[3GX%1&IZATKB;LO$=#AJK&
MZ^&;(Y]OU]BG7U6Q<N7?8M 9.P)!+X1- ]D1NHN0Z0.2R^C?G;,;6=NOBC?,
M;Y0'>Y48^'JY1WGY9\Y9?)8^V[-ZZ5FHC#.RXD'#GD+OMKK]I!5Z%ST@>H[B
MBP@@BU',X)(=\^?(TI^0[6[$VYO6K]=3UX[82/YVEWI3KQOPN'FQ/6$K[5[I
M'O(:IEV>QMB<D!-SM)N1MQFRSO,96:ZP*8_VPO#2Z)T&W(^\[M;CD>?:FOKG
ME8]UQCO!\Q1ED.A.%6  P4IYJ!"/8#RI*DQD!Z+^/;+;(E"4C+Q-F&GS/Q$4
MW<DJF!UQU3];\Y\MKNTEQX@+ WU-/B2HMP6EGM130,I(PT:/\H9YV=SM_E5Q
M.@";-!1+Q1V7:0EB&CCPF:KMFB$9T/,(,*%E>6ZTNOJLBE',RSAQT<":Z6SD
MB+I^90@F'.F=X-\UW3FN"JU9[4HZWR62-H:9"8!PW*_F9E.0BG$R4+A\,_;C
MDQJI':@:K1_Y9:>3X\TT1PQ-BCR( W9"7XLJ$P-1_D'!Q>Y!%SS\E6_??O [
MGO&8E.KN<RI-K/)N65-JC9TX9F >M!V$%.\W(SWSUK8W6OY.Y6UU&\(0C-%Q
M&6!NL*N#ZKVQ$^>VLN5"V#<>]'?&+1%9Q5!'!7&Y6PG0;&B-1$^<#D#$G)1(
M.)A64>!8:Y7]1CB(4X;K*Y087G&2VN] AR5>P3>U=AYGAITESY!TC^NTC+!/
MXKITE,A!BZ'2,&A71J#?[!5HU<' 6'N9[MLO.0:/6?><)2N]3]QV@\:^40]D
M"I.%0W' B'UMF7X'H@2N-:]J?7?ZPW=;N<7;?5]ETN_LL7<D:A#MU T#=*J!
M<2FTA[-_S"!4.VKN:SW%2/4'*0?!&2A0?);7""1+?9 ;GF1([*'R.B]T-Q;.
MZ9:Y3Y>\RMT8Q^F8N3^).GYW?$:;W?C$ZX&$^>0BZGF"<KJ&95IV$H[RQ*VA
MX5XOM&;VV3T14#_2#3QEC@/_@)XHVZC:3;P"=)P&=+]Q0%B;E_!2?_(UML]&
M7CSV:K9\IZ]X1;$!4%V-WRGO(WKA,X:#:DKD7N@)KT" L"W0SHEZ&JCA6]:,
M?G7Z]CT<IPE;?'79Y5N7?+3\9#(4Y%A$&E/W#,9\!D=*0_J*=166&U)KY0(V
M0B.*X#"#/WT#3L53MO?_X*_;SQ0]U6<18"QAW$7ID+$4,\2UXVSQ/R,XA3=H
MK(BWC>'3Z$GYJN8_HG-TP,:5T&_SZ!"!09'-4>S/-PP+>-YDG (3.:AKA1'E
MKN%:_V@P[;C03:0G(]O-9U_M-PODECD(<UMZ)@U:?8BGL)WXY68S^R<XLO,(
MW,7QIBEM)Z8.S/=0A%=%,X0R<<-,%G2J,"9;[\,!EO7ADY337G]C6_6/8Y!/
M,G4XR/K=%S&<6I<_&I4[PC]OFH^XN%]J<L<+7.%B#BUQ%1!:%@$+'N&RO;<^
M-NWVT $&]H=5K:&<RT@/U>&=/60T[%)!K/2_/ EBIEGA_GN+U^))C3! V\-K
M%3)3@XN<Z$"%*TVM?VW6*(F1%'QJIG?O27R9Q[U+A, $-$%CH^-!NDRM>T^P
MIN#PITUC\\2M74P"IM[MC98E+@1]F@J,M/_I+#(1(\#X_.=5;8Q,*;C3ST2-
M=T\+.$T'G&MVJK E%Q >ZN-";.].IZ18_*(DO3< $'Y-+9)K'"9RO B2V+IL
MSCO"6<L+JT'$@?@:U<^?;C*N;QC#PQK\0W#EC?+[1ID*\L \Q4&(TR2'4U=8
M\NMBO7@'#5_#W(D-3$A>Z;*ZA.&07T>YQ$2Y5!?"J:^ZS3QBP**UE8U#A6WZ
MX?C2UKMK=(!7I?FT\[>D@<L905=:?II_PB@[#)9V.5>_#<^WTFK12MAAG\Z3
M6PECBT[Z6*E9VAYAZ;U]JK2'I\;!1\3K5]F 1I7^K)-V%!^SX#G[ "H=P*U#
MU%=)4.66I'0<CA>/-@ZXZ;6&+GG1QB%#_HYUP$!5M]7##Y8RI1V!OT^2&D?'
M*/D-KE%W$K85!Q!]5B+4*R[C5O\,"? :1S@1 _O;_'2BL0DWIJ8G#F!7Y[[H
M=7S^7*7*-;ODO_DPX\>Q%X4/VY#@X_W3?M-WY?3@I7>7(0NW4.":Y#/]V:F]
M5YN?W@Z0Z878=/<JC-KJ0"'*G2;PZ(*UI^0:G.Y!7,4TYN'(<TI7V^[*O7C_
M.[3%B"/.6Z@OR(5<L+ "PNB3)Y2C[L.GQF_#^13'#^*5&3<HX<V(W, :>>T/
MTZU"H[;!72%)5.XC]:+CHDH[X+[')P?E2=H*#P<57NF<F&]2#S55\0*AKB:!
M8OUF=43CTU2JCR)U>:R72Q:Q_[%3S-N-<"*W8/->03E48(+PIK]3[DV>I_T%
MM].M)5EYO/(RIV( (4MO&:ZX2# /R$7S-VJ*U12TBJ32SJHORBG=C.L^&MR:
M6V17Q3Z,/RD/KS_@8P[./<7X!=8IRG.&GW&^VI$<I<Y+4GB%@!50#0EA2;B\
M\]"KQ?D;X[T!'L]?OB1^^?E3*UR#,YB),YBW..<#GORBZO6<@_P*GG>WY >:
M+,42K:-&&YY7(!NY%82^=*<#/ 0#ZV&=Y9_YQ5DOV337376O #5=+')!2-+8
M\1<^DA8A*5IE@I!)?.QY%&%3"RH]CF]G<CF(6#;X_DFQ9[S&/_:UIVI1)>S#
M5ZK1LH_?IX:$G5UK:E*A%$JSGCR7OXEAJ-*1@3]-@.G2.C[8U<<8+&?>]55Z
M_WYAZY%%X;/ MW"U*K$%%-X_'V%X_-YZT>U-A3-!+U+0P2B(*<-UZ_:77W^>
MX93E?UDXW5Y*/WO=LWA;O<RC'YT!&7I/Z;N0.!SH"/.?7T-%<]/.:B[*&77L
MD3'WCC\@G$H1H->9D#=91+&<RNCY'.^[QHT IO0+//SJ3A%)M\B#E!=P?^S!
M5L]'JB<A-WY>]8]*W%I%04W*WM:%N[_$YX4/_9S^%,A8BP2S\$NH]HNZ+;4>
MUV),2QMU+%?)GON31[&QY T,J?DX?[L2EZLPQ6<!+WIP0KJLJ.'7.:@A5DD]
M.S-!7< S84ID,#8I.HQS8!'%38[3-;8#V=0MU\ Q2L%OL1\#O.,816:B0K7M
M1_3G,1'(E,=VG\9[H<LEAWEVIM#+9$G2X6@E3=9=%$!&$^+LR7?*R(F6#7]@
M/JATVN\-LYMG7&P6SQI=5^A',T\$#OE#'<WK8QWX42B%!R?ID.T_Q/3_R5KM
MCEM:P;V$&BP.#M7[I@A/ZG0G9HH]%IT>\A5_F1C?LP0M3^Z;L.+CT')P_U/R
M7=W7)L9)JJ_..'EO!]]">0A9'# [^*'#U:Q(=AR^<S$_Y!SRIYZEUD<QFJTT
MD'!%:8B-.H6%168-QOU%X\_QU=FHUB);WY8_<=8"A'HE5:&Q@S'[1N +[M,(
MO@,NF]X0_I#G;U\__<(B-H]^W([U6%C[K)P>1]P#"W;C/B_*:(R)HE.V$D"#
MKUJEZAJ"K33M4PIU'BHA>M;?@J+B($U99%N)YH1 :/]N8 [E>[QU(WFFQ[J5
MEUQ8W.YCXV'6QO_M55)O5!#S<<P"C=?[><L5B)!GKEA-4SB.]Z5X$M=LF?SY
MO>3NP,CUXT7[/A_%[UK"CHH+A-U*B;#Y%JZ5:U01(E-R^;6ZF.0#1T?]I3,5
M4"ZXI!6AJ2+C"R.C,&N!=V_>G;6PNDEWR2[DA7UVLU %&_LSWG.^;"G-CT 7
MIT^/J6.#!SS(0*O4GE;N,>4$0ZC..I][\E&:F%3/:!2PK\8O.R"])\.<]_TC
M7#E.^*%\8XK).GA7C>,LF=&.F/'^*.#+KIB:QXIW#,>GD+SBYPD$OLZ^HJAJ
MY[6K8*KQ\]:KQ-"&\#"1]1=6KY!<:.=E(W%QOOA$%_$ ,YO%Y*&L/R=2TMM<
MC^R/S='[3;*!B=]8,;C5BVCOW!Y\F!M<637X<36UQEZILZ[E](G.R(J8\KPQ
MX/VL&>_S^D6XFMBL%2V-4 ,=\S9;N"-2ZW.] $NJ%OT&2"9/E'H!)^F "X6$
MEH5O#:I$'"[$4O.]?OS7+UNJD<)'6:M4_7(O'2GB-#GDSBAS4OIKOGE3V_;T
MIV]9%WR33&W[S-"R$$GNN$[#YF??[*7M\"TI:D!N,M"4D'W-X,70]5]=UKU^
M<]I^S*%ME+.T">Z-/5N$,C$'F[4)RRC8\*^WNW]>KDBRK&=6F]A0-4L%+T+P
M<2*.WB#K4<$C>SWAP_@UU@?PGR(Q>)O @PM3L[I:%YJY.]L6TV_(_/RQQ*E_
M*6*^4?&]E'.IAF70&D5I_6NV*PAPHHI,'+QK]'=4>''(K^ >)^(,UKAR?Q%%
M%7_A=-&NR*M['7#HTE,4-_AIX<=SU%/43Y!IKFA1F85=(>DS;WY,B6#M?/Q)
M@/V8_==1]W]OH!\TZ; IG?/DT%+()X]J8UR"V04KW9IDLWE58/MP]A(=T%3!
MHK[TN!$ZX[R8-A'Q=P;*O!9D[%WF^2 3M?KF"]$^Q>*26+Z?$'@KB52.A=YH
MC69,_SQ$J@L,$=O_S8L]RW\$$GF/2:8JVCD$P4("#>>V0SV"3[@LP\3\8V^$
M]*<./I<LG('0GA R[41FLQ_CD$<7GR=1MJ$TF5;3/?<]KRG:[PXZX/*1'_9I
M)"C4-G27#E#:V"'#=KCI@*&:(B3&CPX@6B [D/ \6F2.&(V200?$HMXAIK6F
MD5.3R"7@$>I$9P]=IV .\ZS_4[>R"CI@X:/&T7WVB4CEJ8+M+[,&0F%N0;NH
M%.K)X]!_'I<@U-\>:ZUH/41F'DD3&DB]A*!.D=OL2F:QL',;J9S5E4NQI%UU
M&N\[9Y;CY0?P'DG>G30R9F5B#EH-[@&A^#T:',]-R&>MFHT\YK:!@%R6&IBD
M;T/,7E>!I\!;$PF)_9;\(7;V<G\.,WB?1;(Q\R7VHWZV2K4\_5[2\KTD[$#G
M4T$L:#7I9_M__\31>IX.".]SHPD@.V;"#J@2]>\'CT,<K.=5]B#X0XHR/(]4
M2E8O(D/:@XY,\DJGO=YZPN1KE*MO/[[G>ILA4?W\5E^S,S]+5B;HVPE^\.OD
M%@&IWH8IVOV]8W/H<<-@Y X339!\0[:UF])G4 K;)0DO'I!_@Y9@ #J@3RCL
M,G+R=]Z1N0L4-9W^06XUVJ>"ZYVQ7/F/BD[\[(,JB(@2]&K8(/A+)>8U'>"<
MQXW@(J<A2^9%?(YPRRAEUJ+DR[-7%#4RG>^TB%Z:!"4"5J\6F,)F["N<83<^
MY;0N.1N4=D>DI_O0C-)[:N%R$6&]&JPL8C3.&/#?5UY[JB?KXYT2/(+6'4 '
M#$^"UK\#IY"D;T,T43J@_?,(38$LUPJL1),L[$;'E=A=Y;2J!N4>W'W F6F:
M>8YA^-9+?2\BF,3[EM:!)N331#UO&""^SLR*0!X&16F^25]VS=+?_=.7WG;V
MHS"@4,L5Q47I2RO7]]B="AA&#*#O\EC71 I"X/[0AK:^5E*PPE8>SHMCRFUQ
MI06;8+7@D7N:_&J! A%=]S/Y(:[4X[7BJ/!1S78RL?^"]2\=^6%YJB/Z?)B:
M5WU%UFHG)C8NV'WX>$UY)MA*ZHKHE*LH3GFS*[2?8D-K;SKHV7F%.:>E7>!Y
MY)BZ"&.9[B@Q*GUH?-V^UW.\G'W4LU? ==;Y-L.#,[/G506GC@O1CX^A.+XH
M&A,\Y$?&"[T/10CU47Q)9H"M2T)Q0\Q=<-!R)Z7HRG43_,?4\894QYF\0Q=^
M%(&B>Y5F:IK4N_TX8SL8G"6')OJI%>^E^NV[+X,7RJ$\&??(YMBD2%)3955J
M*9P.L(X:QFUL!T2!O/B7[LBF:')RJ=:JR_K6ZGC]0@@MHJ*!-3M4GG-MO@@M
M8E!T'>84?+-CO%6HQ8'#(APOA[JD&S57M/L^TG7W(R#;;>#MT40K?)6D.*IS
M(VS2#*%+3L\ZW4*8,?J#KJF%G*]-&0 9WI23Z/06[#Z]FOG-=1U8(@"M7:5R
M9[3-:Y&#8,!V!8X3 D4')#W'Z\W3.BP3;]3%;\$RQ>'),_R:43S4GRWJ52_D
M1GS+))JK\&C0@=Q!R'S%6FF:KHQOB%X?Q=\#=+RNOSQ)A$Q_6/@=1[F);#.J
MQ9SR^E&97KZ@SB7/Z8)?L6AR_P1]_JPRD7R)8'R"OV<G06,64XU\T\I,U<OH
M(V<0-CLOWKC;=^A]!V*&$QC*M9%Y]_# ZDV2K-=V''@JJ><H&I^_D)>0-48'
M1%OUF! *U@6+<W)^X94<WW^R%>0<^EQKO\POVS?)LHQ_6$+EX:.Q'@10K!S=
M':\2'%92"\C#OT(3=[WM#!Z'[XZD?,A2FVON],E3D%GBWJUT,?N0H-;F^2%H
MWU)"JG^;#NB%ILAGCY9(:XNDM3['9=&:"C=1T73 [F4RC-96CSF2]GI1HZ7P
MR:B ['9OI.1),%[N<D-RH7C9DYM%\:^Z]8L])D*#I:VRTP?0OW#Y?((/XN8D
M#IEY3&V$_M49"5$'7-)T"#8H?)\RQVU'3$C/^SR%SO#UOF)H=^.'FIJ9!A=4
MC38-!NH J1;D.[ BN'4GJ>EWX<5RYOZ9'RFGN5XG&R'Z3E_?  O^S7L#_0)^
M29.";]H0K4HJR;$G&M;BP^\LD,&"S3O\N4AV5K7%1I4%:&W#5A"68^I$V_T*
MNS*DXN!SM(L[ IU.,LOBBQ=C\;MY[]VJ(@KA!T=5]9<M]]5)LO9/>Q37HF<1
M)O[FBD?%+FKZ4U.;H=X'N2($&A!C3%NC!<QO6'VOS?RV!7Y?I8K=H!U!#_3W
M4/K?&]B+C/\"?UE/6B*;P4Q=ELM%-+>,C72*Q5A>>#6>C"=0:-WG@,>B:3IU
MHG.C>:?UJ5!8-(9TS88.6/M;^1D\._B'IC<E.UL^L@_-/)(K#1O'G'E>3OD
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M=#32ZM[99OY0P[Y()9M3C7$EQ,C<EZ:BQB_.Z.7(WC*XCH?-J>U+^C(%_#Q
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M:$9N.>T')*30QBG@P^].>/^G+CUE!TFR(ZRRPX'I).-_@E\9IT@O\L,#T-.
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ME2\PMW8%WOQLGO^K+(#7(V9X%1EHFBT;?[#2TFR_]*ME:6F':0/[?3ZT0:+
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M5730^74>';'1]_HAI;96ND(KP_%UUB_-+RRX._!E-VC+H.-;N&&R.)L9=EX
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MOB\V,?V[AQZ' ] OQ,@W%&4BIX&];*>#T##<.+\T5K%B_/KSQC<&# PD@_P
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ME(74#K9/*IB:#+ ^+22_0T7,^W4;%*@WHF<*U@+J&/7>YFG.)+50$$\/V/3
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MW7\;2*I7Q+&TW++\ZF.8@7>[^VPQ@ZL_Z^;DTX=M*71;D<>S\89J6887C+@
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MK08^&C,R $5$.-.2W),G_W,VX_\%P FXVL.V0Y+!3J-^?6W8SP'%IQ8&57;
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MQCC/ORH3>OOZ(\4B<P/ 5UR'PE:]L!^KN/^MA2^EX*#HY(I)\'$LMS2RL_&
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M<A(R+&=S??$(R)/^!VD*90VU/C3"#?7O@40@F03=.!E46$/K<+5%#E3**D&
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MHJ8L+F'-^TSBV1W@_P4( (   #    D H %    ( @ A " , $0"@&@ &
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M D9"P&@(% "!@B!0" 0*@T"1$"@:@@! $" ( @)!P" () 2!AJ  $!0(@H)
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M(Y!H!!J- J!1(#0*@D;!T"@D&O6_8?\9[3^U_Z/\O[W_[_#_'RP/6!@ P!\
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ML8E,P87E]W#L6&K/%$Z#$V+%P+R=52$UVS=$J^1E,<__V"0LTO.]?A8_PS#
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MU&B9L<W>YX;.S?D/H+8W#[=^_,CM!;[91%'V[LHW?C\A=KU@<KXD3GO0*=+
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M__:>*!859AJ[E!-3EY+6RHR'H?I41(2U2P\!48LP6-Y&O@D]-K93G5ZL54K
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MO@]T6.G!S*[>C)#@,LT7;3$8L8_\)*C$,,R5-B-4L ,ZFJ-Y3B[CZ _PAL@
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M=\/4.@M1'\_;,]';,S-#--.;$=1+']F;O>WX60H!O1SA7"0#D T*D1Y3*&*
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MRM-0_,PWSN+H'<4$@09B<.2[J^1+SN1-[N1*GN1/+N53KKMA!\5&'<6\;<U
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MZW>.&O\O@]&4]IJF_U*B&"@S9O,=.OFV+>,9)EHB]=HS'VHIIJ.JRY- !SS
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MQ+VD=A<_MB0>BRA0?!JT/D]6YC'"O\)(:](!DJXL;OT4 _XG:JMG[F: Y>G
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MONG_WW.18T3:C48F^&#C=0A-XY.-X*W1*QS",%3+G+4+78PH+Q>NJ?N+SB=
M,.#F9,9/<S[5ET)][D()^A,?!XN5->@CZC^D)/L-DY'E \1J4A'$S"0<4H8(
MTYUN*XV"MHX/?<WPRNB^+[C7?N-F*V]W$B".A3==0(]F=$7G3+5 S\L5D\K4
M@*6-(<K:%WLAM$,[$-ES.2O./X.-MQ8^*5'??LH5< F89E+50:0O;$-<RDQ;
M0C:?"+F? RYU8G+LZTH.M4D]G\"'\%C_#I4KJY:G,RCIZ'L%.H=)*H/G@+A_
MJ-,@.^V2.?MDJW!?<O"]399=UK0LBW- DC4D!*YS<.VNIC'N=.-_]C4[7S!6
M,K3Q(6%9E>"S"!)SSK?5_ZSKH>DAM'/WC@_?']6=2_+YJGDY<VTZA1I1TF_R
M=IESIGVX478D]@M><9W<A\D<1UC->K1>WX+N['+,(E8_OT**Q;P>.K$]!]BQ
MP[:N>7?L9&.A"J0T\O4-((VO_*V))[LR?#K="UW^O9&0^AU]I?U[2!5D1[FO
M;<?R.BQ[IX&QXZ1X29B^/Z(:3?_-9,9E-6"7<A/8;/0OXZTU=O$_ +/+HH7\
MNJ\5F+FB*[&.Q+MJ"]H$)0R.J#983%G9 *+!:0Z6GJ$@KV_2;T60ML[^5)\#
MHH'43]+"SP&T2*)P@?Y)@*W':\#);Q5'O/^ED+.7H#HA3/U#'K6<WM-&FJ4;
MV#5O:B4"L(Z'-$XV2(MWT^V/(=(7^<K@_(X#*SMQ\O$8)7]_ 4Z=CG)^"ER1
MS=E$E^K#*DB)M4ZN<;R-MF<$#%KK\\^ R,!_-N%RZH.GP<9,RHD7>\UYD6U[
M*BI0/-XW6/=,:=.%*$9!\X6Q!/I%^@7$YX],(=FA65VF93.%MW3?WOC:?"I&
M1X 9F/"&Y^\ZWTGZ3MQL8Y[?9=]J<#MTL?XHR+1P0>!*7-MO'D#9G@H2-3W"
M'[.TPFUH#\0WW2.$6SF@2\ H:HEQD2E]!=.R>9.7HJ5\%ARBHDXR'YQHY73C
MUYDE5DOG/[4-M8PDO"P9K$+NR:V%']HB QI9QI]$].P'&X/53=>AZL<24 ?-
MG[>R:>$_G12.D)#P%K+;6ZZR[Z/S-J+*+RP..7.G:N_I,DC([TC(TH1#OVZA
MU)^,V^9:(A59^8\9QR5<Q1MFZS#W21LKBD7@7\,KP^[,]KJG!C<2*<[BGCQ[
MX'?KL:U:9F&RC&T-#8.<C$.F4]X8GKZ3Q^Z9UGW/5"]F]D-( F.M1;;O+D=B
MFEQOFI]I:*E)"<7=DJ#^:R,!X9-8B'\E@I,0)">=7>'\LAN354U-)Q'@U'99
M11&D]!2K$5#[!YE!F->M+?<#LX#_C%5%<24_-X74:@Q'RUB.O.G.NC\EO;7\
M^#";#^41:\\]7>ZA_R"Q4,:BT#W[9?_U,=6[60,OZF)UY'7\MP1DU:AV%948
M@GZ65[. J,U#.:OOAEF[\W1,WIE23N+V5KAA%YW)89,2M=K%O?Q@Q7%:EGSC
MQ_LE-I_]2$09/*),AP9<OB!% 9K-*N7H0'#YA)X#@F4(+ZTL4-]W]^Y;K2@+
M;&P'9#DI4*0CIZ:MQ(MER0_'QL;I*$VN.]/=+!Z^NLPY@:3[)[9N(:V1GE2\
M6U+O@VUOIZ%=NBN25&VU!+(LCE&MBIGMV^3;'@RDOGM*C9)Q*U:[O<\9N[N]
MNGZ<]ANK$B[6$^\D/7*2M\N*?*O4G0L#[CLTCHX5_CT-'\?-?R*:8SLPJ+FK
M!/_%GF)>V+"%B/&$L4KELD/F1/[5VZT"30$WKK)V(HNTM&!0I5/.E)?N^07Q
M4\XVF\7:4(NT-Q>$)4?O AN(M_OQS^+:4Z7J2=GU;W/22JU3S6-"B&V+60^8
MZ&,R?H?2-8NJSH*63/PAU^MA9T]]88.-]%X2EQW%;4O9_KR.K_KLRKU/[N:R
M %<WK823 ] 6\P%@!E):X^V->1HYGER_Y'&-TFCF@9@? '>SV8E$#_G)B?$>
MG++YT2O>WX''N01A@JS?^@)<WKG7"Q&"*',:(I%YWDY[#6]=0/)^D+<KQ\*E
MISH @-0_0JBW?]'IO\# *ZL0 I_PSM <[V!'V_P-ZS-DD6;D8%M]#].CKCT5
M(3169 ;6>G1VHV S,?E/FM //\Z-54.@YH9*M=SXNN-N[IGX')$3%]_(/[ #
MQ4NDBUC2Y3#.Z7)C91^XJ*1WXUE.?\8!^X#O)0NFB3'S]4)+J\:QW2):QTE-
M\SI$].JQAYS$Q1XS(3;_X1?:3?!M+R4R/3ILBC=(7Q!G9)([!1MC.%DY!W0P
M%/Y NI,^$^^+"[-OI8JF/M96*[W=\F+S44?>Z7VI<X#_&'-R:@\MOS>GAD\4
M^4_7MBG]Z//IT0TT8TS^J=L%J5J)6?^7'"T)?!Y@.Q_"R?=[^$WE3*U/T+.S
M/Q*0*^/51-NT OW]<%^EA>DW.-K@?;GOO[[[-L%<.D.X"F\M<\,5XS/6BE#W
MW7C#*KC&Q8=A4YNYEEM*9X\4W.2\O>&7#+R>H)CN<#*X;#SEQ?*2+]M:OL(9
MYRXZ3I[Z(5K&J:ZBIV,I>41 =KIQ>=24%.QN^X8A87"PUW3;1[DI=H\I> K-
M'_B8V[9+E,3' #7.!ER ;28V+<84BVCBCFU9AJ;BW)70T/IIWN\L#IX/7:-/
M\ 6%&O8'J@YCJ2'&D!OA^3JF(&W8S\T2M5E]N>DZ P-\9=0T219*"#P'W#QK
M PM5AL[.=?:X?VL)&S43^A6]4!8MX[L^5ND.9?6R&<;HYX0L0T*K7*V1]$U3
M5ZSV&I\"7.LO&WS2^.CZ-?(F#L'LJX/SC#SZ(6^#7Y.%#6/M[I<IAEVZRI['
M_1,KW?_>0#*M AKM:)?*.UR14!M+3[^E]O[L;]:[OZHFPYRCPE2:V:2+'5EH
M=XH,1=)7%HW&J<7^==%U$)U\:\PO_V1@FPN74X@]PWL,NB.H*QY:C#X,D,Z)
M\!@1G>%HXERW BK:0*BVR#S8_M8&,>U1HGFNE\/8*2X')9&L-&-H?*<M36RM
MB4(^1#U3OK /V<AE^S'$_Q&9$TKSN[2T1JQEF^4.(T\_KU3'/ALJVV8#R$8T
M^N7E *0N3OSAR9#?%S\^EOHAL:-4Z>>'#\M<RYL8@]:>A$E! X1PVW9A' RO
MM?K9,%M+R[-RQFBWUE;M"%I<*6_ADW\(G5*F$58S#Z8Q>$%O(Y)E>[:N(#'&
MRW+UG=OV7"F8TW8*'0J^YS7E9XKMQ>/%IEM>\DVSOEB$?9+Y>(24'R&+>:&U
M<<5),<:R4LB==W_-'K<T<X#M@J]%NS:$,&_K<A,VE])VS^9O3UNSOJ&W8828
M5[\H_LEO6"IX?%"=*,U]^L9//U>P"/FA<<WE'/#>3(?36*]&QCG"<U2JFU1;
M"#K1VVQ'YQ/%"%09VV#*#ZC:46&]>1-*G8DO)E0'ER&?:0DWCDH2W@=J$?RQ
M9^U)NE];\VV2?7?]2B5./NOO78VQ[\!R>2#YL+!VVKL$WI=^U^>FND^;Y[W*
M1XI[0Z/&00&4ZS_=^N6M+0D]R[)H=GT"?D_-6ZCH:^S8;,9]YM&$^$^_ @=C
MI/\X;^H\DE>>[S<^UG]@4R,DZB[P)&&^XAA9%+\T8GHX:>1>5A623Y!LE]F/
M\/59!EZU+7\N\=V>8TC!1G!0\1*_QJ\/*W<T7/O%0[#[&$9&!+6=G+S]DK4O
M+P)?]<6&2<9CP['&%.S!YASPZZ!];JE:_LH2*DQ.>LE(&Z/+B+=W+?1.LWEK
M:AKHLR_[])T*.&MDCIF 68+<LG(F."R_'!97XV-OJ& M3DOF<M" ?9U)ZX]\
MC1TJ5[7.76A<R/\Z'FG.K&!P;,\]-"9BH]$GU6"B4W)<TPF?0Y>A_-$V5&O8
M\?9B88U!HBK-%S 0%QSBX/DLJVI0H,Y"+^*#J CSNK66Y_C*_"[MF82O#NE;
MO1.9@I">?B+X<'VX$N1B//XZ]+9<YX>F&6D6K2M"3]^)F2!317")=<L-]D?[
MMV<>Q8E>??YLJO37'P:5]UW$/M=&,!;2.A])OEI->(N+: TKM$JB<'N&DX_\
M=;O\*4FS':KQZXL+%?_QWZ+N1A.&&]NW"E&Y)W"5[9E+[2>HZP.Y06W"UB%E
M:P%SM(6YB(;F,V0NR![='@Z:1=LA)K27F':0!?\8N,U!VW,W&Y-83<($E\X!
MNJI+; G K6R.2V?(42?/^Z>YQ#O:^.N-I$PR=S,NI.-4!'QGP*'U;:LSI[96
MG2(M%VDC4TIP\H>-BZ3_4:7K(YY';&T'QA"DH_:I,+!]1O[38MAZ25G"U9+D
MV9ZL1T=:C5'RNJBR5Z<]9,JN,\HNK&>3RG)NFQ^P!\<4^DLY^,9RZ^1;+*Y%
M846,HTQJ-W0DLA VSW ]*6?*FI'.>DQD-YJG)<9$RZ]K+1?954J8JB:^*7PS
M2Z8J)7O@'.F7"6AP\?>E^0;)C$WFXHSZV(%_36];_6?<]E]2^P<A%SNN0,A>
M9$-2VU:)],:U=#(J-%.4RJN8?>WDHANJ?2F0R:_X4G.6=0 )H]$7MY9]*;19
MLK[JV#'O/W>/P++\UHU&@X6S&V:6:U1[#BAZ[:W;P3;^264@FK*$$:UU#K""
M?&ID(2PN;$?1ZY1==_D>K@.0J0:"^.69/>0INU-IX/9$?0)T*2UP3O!'R]S#
M*H<;$B@%2K7/%&S!'^D&D*\1E^'3CWK-(G-[A"\@Q/)(^(ISRBV>Y@*=9+U0
M0=@!PAM>>&J(N1 @Z<?-_^Y-FAF\G4QW#OALNX!IS'UB;C$FE%7GUQ- #]:G
MS1F9@<PCO[BEB![HCPI6V(,%CYD\;U#?(*U;W,P\N(]6($JG3Q(L6_%@]N%V
MKM_ET7,7PLK]+A_IFK=TI8:^9@AB@+C=9NA8UJ35DENTZKD)) CZ8:;X,NKI
M__X//=O/8N!7V,KT]1S@(7@...ZB(8$T,M HID0Q?4E5TP^04(Q4W9,^?K78
M(O/)S*Z+V]@'_R<ZI,)7;+%8!<.:;#WE^\KS\:U%5Q2D-[4ESAI49BFE'1B?
M$BM(D&PI)^!*Y)C\,J:W/FIDT@5J#2.+VWX;/J"^^\'AE@KR??_+4]#"> N$
MTO<NEC%M 7C-*G&,49>QAUIBK$!1.6)0V5M>E7NEE">&>\A7B&"=2Z!255@)
M=-L^2*T3&[&LD>]?D&(8'8\(Q\@@8X5GB?T]4H'@_&^J YD/\XWQC;&V:I65
MNQGOG]^%T1W\MT(JC>W/GL'_--(3UA>M*W9?8IX/L*5_?\QAPGPKMYRV,YH6
ME36HKU4H(Z8=6*YB3,$1WE.JV?9^95FJ+B>FZQP0";Q.?(\UP=SQ\L0P1JTF
M.I89%]Q.NDEK1QKC&/DKWWSUK_MI,2YWP3(0_L3+QH^^3?^#EES$WQKF>Y\6
M_=D+;_5*[[A((?M-IFCQICAT4Y2I<EUEXO8+45,V'%!D!5OFWY*F?%8\/>"7
M:)2LC<$HZT,/(#G58C%.OBJJ[W$T2K=KW9*2#RYTO;#8!=\:@RC]6VX'/@<0
ME+##+:D K,JG2I,@"(4;C0]TI"*FBA"(@7EL.[O%A0X4Y.+NB8JY+<J5/:85
MG[5EK(6&B7=R8?TBV@]*>/R3;#)O97VD1@@LH<TAGVL1 ;Y 8 3\LJ\&>JQ"
MWF6.1;]?LT[QT;H1V?1;T\WB P$46UG:RZ.>%&W%83"7@=J3W]Q#4\Q[*TI_
MBSY'?CC%JH SQ;&$\"A80LKQ/B+9K^H$V.T])E@TA>2>5>'T,Q&-\W08??!P
M9QFN8ROL_I9]+!=[#M <WLEI0(T4"S7VG . F@9=B1'C]U.86HM5#ZLKP\39
MW@0;()XPF5(NW&Z02=LTNIZ5W!YDF3?[,#![N@GWV+JMC<6_7V&[7^DMIPPO
MF0Y*&XG#:Z1AKQ:9:;E8&QY8FY;JF#/G"QJ?@I,V+.:]A#7+1XK<5JO#35 %
MWWAB9)V@OM&MR4._!\4Y>*'C;H2HSTMSMX6XW4Q;5WE7I+;DS\+'L>Z[4?O!
M]I6%^-YDKGA7TNQ/^#=@D(77RS6#>1I"[%_7I,3[>W[=-4]FUH:AV6@1*)VQ
M<[PY7A_:=X!(:#R0?8'E3,_74\F;V6*L<OXS4<4D^J[;+TB)(D!\\FA2#K)Z
MO^?.7JRRXQ?AX_+-TS%\>N:LUW1KK=B&F/+\AY#N:B6NZV)!+!W$J^0$2+"0
MX(XX24VQ?GR,[+T[^B!U,7KL'9O(2AQIW[@]1-?#X12_FS<G4?MY)=D%=FQ?
M4%Y)WG4_X13$42R0BQ<%P5#Z29LQF<04?$ZX:M'#V14)+UV..EJDH;.AN8\)
MIL97?3'MBDVM(9EIX'";1G%-I(HJ;OW/I-8'G3^W;G[R6?[I;,QO',WJDJ^Q
M<U84QV#"%.A:,%Q>9C-5*+B;?7KMKJ81Q>__-9[$2/@3F&4[5;KQQ>[N[#O>
MI'91V:\;\OW;VOS*-W?:&SY*V6ADPSY$[M\D0'5Q#AF)K/9UCQ]=D3)<GOB8
M9G,JNQC2,BO<]-%%5K'8 Y8HM]-O[(/*)U)P.!"H%L>B%HSD[U4$L?I56RL>
M'E&1Y:&;1C1>$T4&Q7L=9@?LQZ$V%J)N>9O0@XN'I3HFZ;]K:/W7ZL(A HCR
MRWX"1@_:6-U<.QZ9WR*T^N;F<6$5]FBO5^;E9"WM1>1J9;/D-T\6)X-ODW(0
M[^0]FX_IO3(7=>H,IT0>G;Z3?H#>"SL'#+"E[25NFH@9Z<_JS719^MASBSU;
M-0]_(]#9FL?UE[82W@J]*BGRA(D.E!DI*K-"MP=J@UA!)WXL'K=3<H_:"8(Q
M!5=)LS/,=VB?JBX]/P>8UQR^-U'Q[V>WIU:9)UON^O(N96WR+;KZZ7;;(LY\
MT"7DW'4>A@T(,]HB)AQX79A'!A]]+$&'8HTJLM-4L5\NLMSN2!=?'SVLV%(L
M\OZU%S/CY#7S$!Q0')S\T^3-/NGCQ3WJN@7=A:EB UMX.Q#T%=";%09+M6AH
M!;((='#1%:-!;[I?TKGX41>.!7-^+NBWRIG/@%E.IETB\O/Z@^DVC#G-K=8,
MKB6N0J^J\8O*I&5* X/<X]TVG_OZKJQ+\HZ0+=K&4T'T,L-SZJBM6<RCWLN)
MW+<^I<;':VJ9_E,V N5"'J4LS%)/XC6?L@MC^%985R2I56GMKJON,9\#7L'$
MC-(P!B[ORNNN!'DJPG_1$:.<$R95YRA/ZVL-)RZ$JY%B.%_QK8'_(<\!W LW
M ?QX_#B3JV!#D2!WM%->(/>XRL)^$)P/YS>$<33CMO+F1O;%&'(&SBS 4$0(
M@6EQ_D8;BO4SR!D,-I=#+B$B-IOPXGT&#"_#]_IIQ?JQTG;ZCLE&25O>\__\
M"( UNH[[8V[H;16'6TZMH'/ 9-KPS"'29<!7/MO+H5-O4[?Y[J6:F#G7+>@)
M@[..IN+]3X F@%LVDK/J?K9G2<?:]U3GR#X!X\R*CSR_-9\S^*_^GV;IWG7O
MOV75^*!*(AD3\"K[Q=7HI^"04S?D#[(4HEE&CF%I6*(22X;N%+;WV%=%>MLA
MIB*"B*^1 ^/#(S -(%-H2_?AJMEDMU2@9&>ASRL.&% H9M2NOP=R4</EPIC]
M(+'NJ?5@\YJ*T)3Q*KZA^S&ZS-1I6"Z*&B0$.2&H_7RH,J\^1:M%.L2TI_.4
M,Q.+Y" 4GU'YLA.^F#>H<\K*=HG"A^W/\B4Y5^/?QYQMC1XRVY%I7PZBDB%F
M77+&K7T"WBE",.+@]!IZ@1C3=WIL,@%M>:"%&\M?YE^Z+B_4IG3C058Y9^9&
MZ#+YFL$YX YZX0>"CB@U9$0 O8T^O11[OSZR\-)F@R0_Y'7"!K!LOV76;-&D
MU6)83OV#X)%LSXEE740O;.(Z'9-++.64_P6+9"F9T96EA5&2XI%^M+E+G(^Z
M<$19[2WQ^%59Y1ZWU)+-;=N'=38?GU^POALG_TO.BC_NX43_8CG?.2!1+#-M
M%(&W.=@ZW&<RH$+2&+?Y*)J03T[0V=Y1[J_AFX?>SY AMN4W!5X(.CBD]52B
M8I7).U:J))#E"X+C$LE&DZ8DOMO@%QQ]W-E% JGP=7A\9  -9B"E>;9Z!=R<
MNT"A2U'?PQ;??$@^<J0F]\KTK4T>U1"SI7B,JN"!@B>[2!4LNAEXG6!_2:+1
MYWC9)JTGCA!G6"E2\;XJMW]9JO!1RR;%'R*Z%QM#Y<N-0X3SO@EH7M:.7'5I
M\HF.('PU1BTX3O8_&\ ;V\:L]4I/Y?*23S<@EPCC6=/ZTV];!'<%A_C&][*L
M[M(VO4E8'VT?S<\8!+)]<U9^'U7_[N3!*GI.(7>SBE7G=\5P\1WF#FS&,GA]
MY"PY-1P4X[HV[>+Y3_X'UW\OTO&_7@7Z(<&''&\2T4/OOOXH_-9D=@ZXS#XZ
MQ9\SAE%V#:PW^MYCXOL0N]LL:"F/J9$'.'5#P C]KGJ"?'[ZPU98@,(Y0/UU
M.DG,B,10@-25U]CRSI%)'4:7Y"89$L5P[C4GC^YH;M_M(;THT/:2Q3SV(UW>
M. ?4T#FN)A]M"8P)^&F.LA_<084C$">I3TZOHX"B5L=JY*/RF,U7K,H%'ZV3
M@,>+Z):&C'!D<4]I07\!XOY9/ZLZA4'\DN#]S9B,Z1IR@ASX%N[5RM4!H6 $
MFLYD/?QHB]_/QBC,^\CABTIB!Q:)88UE,ZB[%LZOW,6JFK272@N(&RK9-"EW
M#-AY(:F^1KH//).V.=07,!8HGYQH]UXS'4T'ZZR2Q"C4"-8+??P,[P9'NP]%
M2[G. 4WP_4T#W;&J*F?*1[N9813/HB[[$V[&AF.ZM693[5\>%<J.Q,&+_C&3
M_%^YF?\'Z\KYY/\'4$L#!!0    (  !$<5HF2T/L*LL"  I\!  4    <&%C
M8BTR,#(T,3(S,5]G-2YJ<&?LNW=4$]_?+CH(&.E%>HL*"HJ TGNPT$3$AB (
M45&*@!1%$$."(J!4 0$1(2 6%"&"%*FA(]*+5"$DH4I+J -I=_R]MQR_[UV_
M<\Y=ZUWWK'N=Q?Z#S#.9O6=_/L_G>?;.L(98$X#@*3-+,X -.DZQG0( UBAP
M F#?L>/W'W1P0'^<NS@Y.3@XN6&PG;MXN7EY>;AY>/CXA07Y^(7X>7@$Q02%
M=HN(BHKR"HA+B(E("(N(BOS^$C9VZ!H.3BY.3BX1/AX^D?_I@U4+".V"S7(]
M9F?;!^P08F,78F,U G  8.-D^]<!_.\'VPZHCSMAN[BX>2! B2"P@XV=?0<'
M^^]>0V=#H/, AQ"G\-ZCQW;N/G<-ML]/1/UA0O8N^>.%=:+G>R@*&M?]'W%Q
MBXE+2$KM/Z"H=/"0II:VCJZ>_HF3IF;F%I:G+ERTO61G?]G!Y<9-5S=WCUMW
M[@;<"PRZ'QSV.#PB\LG3J,2DY\DIJ2_27K[.>?/VW?O<#Q^+OA27E)9]+:^H
M;VAL:F[YUOJ]MZ__Q\#@T/ (D42>G)J>F9W[15U975O?V 2WMG^/BPU@9_L_
MCO_;<0E!X]K!P<'. ?L]+K8=@;\!0AR<>X_N%#YV#G;-;_<^]8>[1(XG9!?6
M<<EKG*>(7O?OX193T"3NI_X>VK]&]C\VL$?_CT;V?P[L_QK7",#+S@9-'KL0
M@  88A1"Q.(Z[>#MVS=?64TG;TG<J=73@V5Z(IFB3"P+,"K +[]E 21W$,,"
M]GC@YXGX-=&"EZ%Z6-!N&T/?J& !-:DLX&G.GW#/=Z__0OY"_D+^0OY"_D+^
M0OY"_D+^0OY"_D+^0OY"_D+^0OY"_D+^0OY"_@LAAB^I4WT^!?E9F1>C]"[#
MVLU/Q+P*)$5IX;9X"2Q@L!&[+?0ZU  1R0)6=J8S:Z19P#&'N;RT?RQU<BN]
M_MO^MO^29ICNP *>=;  !LJ2!61+*0W@)S6@\$,*8V;-HH %)IP%?)/RV09]
M&)R>[PK<B"R _O ="\!%L(#N2Q6W *7747_;W_9?TE:\/9DG=%C .E61^=@]
MYQ^1RO[E3YXLQ_[)H[G ZRBEO^UO^Z]H[*TE_VT1C_UO S6+O^N?-#F-_H-'
MLW9$*?UM?]M_21,X\$<-__^2V(SS()?&OGEI&J7U:ZF6#7Q)80$C>1NQR(=R
MXJ61UG'*>)%;Z2F=!\^<YX 'NSE/" ,R-V:*$I P$%.'%6$!MQ""5YQ/^E19
M&<I88T)T'1^@5HLU!//F"V$U2NSKMUILB_I3M0-3-D](M@OG4>?K\FRW$&3\
M,"3F,;5!KP>7%VYKSMMGV :$'%HX\C3^=)'VY R[ F )R SVXPM3%ZT_T(_W
M2]?)J96+!]?7]\YM)TT8?<]J.PG^(OK7589[K:B;&%>^+D)=)L4:U!E+]I<L
M.OAYO_>@:#6NR%6:S,+\SP"RK3OPZL;*S&ZF,>.UX=F[^4:X_+7*5L-H!+]'
M3*.% =>.566Y]X;\M=P X[B3<Q..[^/X:'KV@-"AY66Z7I?+EFT%O>8K(Y*I
MZC@[#<YJK^B_6W637;/6E>@\6LE!VV&-F/!9M";#'QDK1%L.NM7TT_5XL:Z5
MO6II,:4O= ^H_,Q1%6CM7MD%XP#0V'.VFOGG^Z[TJ6A)\SRN**Q\ZO8HJ/.2
MQ=".3T9/]N&5\+=LMG01,BQ@R!0*G2R!@2AE,@)4Q#4ME\U)I3:,'4=UW:R@
MG1X/KN^@#;70/IU@8XX&VPVB]U$YX\/ORII?[G\GMAT27OFS:R]3Q%2!<09V
M9HTMQQ2M33]+96PVP>&>SHK]Z@?Z57FCY?SWQ?C)N Q?/,04W=:C"6%:2T D
ML\(9,W>QF&VIWVX2OPAI D48&4O;5<9\5()_CVXFB"VMI3LA;;I?IQS,MGK!
MZQ##(Z^L='./N(2N)MMVDBG:'G60\0:%H<@W'6]F_F)NGBY)_U;3K67N\EGY
MV@_VU=UQP5?=<K6V,42&?U?CMA@V;VYE:T-\@SIV3'$S)X#W_8HF6[8I2HT%
M<,I09S)R0<>ZSZTKM?$?G90,;WNUB). 5.:VZ!2F4"=.NA8/UQQ53CDR,G^N
M]>UI7+."E^:5X*TG>2Q@!]27^Z:B%!VZ2#33W >&&=+W84B;P%$]R$06P(]Q
M13Z!BU;I,*J)^8>DQPPZ@CCB[XN<=O)+B+CZ(.IMGB/=FI%!M^8L^;F-?UQB
M:INR/VIFTW^/4=31.-/.8S)Q6=VP^7Q1,K:HI7FN1A>EZ61^SIX\J+E5TX*9
MBCD<(R+ZG#_,UPAV7+I4F0P?'66>X5]FU@W@M[FR!/JDE%LQ-UC E@Z&':*/
M),SL("X*RB',B$LC7K J( \,-.\OT&0!//97M%[=*_5RT?&*L7WS+,Y>#,;3
M#>AV6@/H9Q@?C]?S"RWG2L01JRU=3@R_/KWY)F=<NSOB&B9J4$Y&*K?/Z_RE
MZ XIK]2'MZOOD:5/N!3ZW*ZZB/Q2MJA%\@FK.5K46Y)__-=\?=$9%=PGM;17
MP[&CIQ.6IKC]3\7Q[Y+7W<.^MAUUBLY@?$1X&?DX4/>S@'"4T ?+-[,IZL7B
M4AG/PUVKGOF.7O$O#'NFC4V7[-PEPK;9-)Y_\_VWIP'W?;R6-R]YV%H%S'+-
M9-,_]GZ^R2$3]FT?7L50A29'MZ,.Q%7\=#@TVG37<+;S_=W/'4<,ET9:?+OR
M7/2ZJF_,,E5!+.UP4/=<L^,8_R]QX8ZW3MHTJS>=.MX<>1_JI/MG"G;M"T78
MYQ8(3&";JG7(=@TTN+#'_,9]A0/2E>JC+T<"FB<5OTX*/HB Q26OB/_G"'A%
M^!S9C &/&^^Q)/*9A;S4>6)_6#J^371"X@0+8(<KE@_/(7,T@7/(1#'$BG\*
M"]C0QC%3N!D^4!U0GNH:Y=EX5P&>*01MZKLDJ%H_C;V;YAI"(K1I7R_4)93+
M(^Y>G9@\"^M+#1S81AWP_$ J?1*0Z+:KIMI:?_R7]+?'GZUDJ)GQTCMA5-$M
MJXFN1W@1C'M;='[P"$_^-1ZO)/L?!:4YGYFB@7I>P:HF&[ET.\H@*7ZA[9/#
MK53E!\2Y ][/;KWT[IQ]8Y@1WDU6V'%/YZP QUG8O*SH*GXAGG8:T3PF-F,^
MB,JMNOS.#"=OMB-_P<AP(F?ILRXO3/*J&5NMV^(B"SBP%<@"KDDC&;NZ83UW
M[<A=]2P@;%P);/DP;A_D\-U@-,_BY.KAI#<F>Z^6MPEE6@>;TX]T-;& ;6"$
M!4Q\%V"JAB)L<G'2C"2F]#R!FRDX.FLL7V)E;:VF^*)%IDUII%$P\."^ZL10
M;N55EXUW8#DY'3XBW:3O'$9:%O08.&?MX^/C\O[7A0:IL@3!O>=D *M)6M)E
M^! +*&ZAKX$)+.!A*IYN^YLMD9+,E@I,LS(RRBZ>/$V]XXX?/O^$!92]_QID
MN*RM\E7XJ'3I<@O*M:8=FIZMF8T1T RM@-J?>K$HLGT I>^P+9BCHB#!V!8
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M]DM-B]V&\8?@XT>,.XK5Z-RA"(=9W$/\Q!ODBD&0 ;.N#S,[0H5##OZ+6J-
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MZ9!0(RF<^'[[Q_>\YXR]OWW&.&/O,<[^,7\Q6%EKWG->]W7-NTP(7LM@U/8
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M>05U;U#P+9D:HTNGO9>/%C_L/L?4I*B&HW0='B4J1GE7*DGW2V5T2+*]I!0
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MSK^.<_!*-?F:CM03RZD:J_QM+O#2^'9G'%U%0/4RZ.(7B9T3+!\CA2*TU>_
MR28?[VBIYXF7P34_.Q]!3-0R5!"I-8S_8TL6S+Y:VVB\O$,+&T%P\2I),#*-
MQ<F"4#' [,TJI1FK66+(I6D:9UQVMTI\!.@RG*KBQ_.01E*OJ+(W-!B<\VD
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M<JP%097>G-#SAOX8O^U\(NQ[,3#SG/X%G6X#KN1#"V'*#IAM&K!U!M"3+I?
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MWZ-H.EA\7Y6? 3$**3)] [^%IX)EU+^0'OHT_-+O]@"[Y@]32LXHMP=-$??
M;Z3!+VK29MN"B(XYB&XN9*"R=(8>,G_:8NRG==/Y-_E4.APR,>;^RNGW:(\6
M:@Y#@&W(6"]FJ(X.Q$" JE8%MP_%4'J\^$#U=N[A1F8$K77#4W"536".6<-7
M,ZLQ:W7ATO*W'^-O++77!_&_$<X[^:?$26UU=$077*05OBY(62U#.Y6SXEV7
M@Y]@:__=]E:9YT$B^V^,MFAH)SX_E8'3$<J.KA-&S480K&HN6#V&QS3/EKVI
MKG\]I2W^QIR.;5+5:4*(-4IL7?LDY4'/P^I.5N][9C<F%TII0= >WU7.S5>5
M?]=XO0G8O%@OL%VB8_<1Y76<3#H]3CR-X^AOZ9Q923 X_DK"FY[=L@5R&)7.
MT]-O^2@[4@Z?Q.[ #65:?"X&M<X\"^6&*34PK?0_-I6_KW;Y*.,/7(=HN6VN
MC!3XTJY*+]O(%"%IKP@?)CS"2.]4RZ8%4J\._&BB9_A6.&I'Y79J\C.(]0FU
M 9-Z9HHZX2+#!=6F6%=#$HL>CPT-BTV\8P1 !I!VX!\]4Y-H-)HB-M5NKYI@
M/0L-(RG@]()WPB_Y*(NX"L23 0-S.Z/PS"A!%CHW)4$#&'_KB]&A'7TJD])"
ML_$F5RJ7\TR?VGA<^HWH 5! =>_)LX""6_1>\0GTK=D>J7]E=LNS:Z?."G]%
M386/IXA-VS3-Z5?ETSJ26*Z]VH>@7^82"9.M**XQU7;\;K;@^4P(6+A!K<5Q
M=@*,9IN=ECE.@OOAD%BV_0C0V2E5G(V;"XIQ4M'_Z<2'\S?8,GH%W$QL0G3]
M?$X2BMILY/CWV82@[$%97L.&%^! KW!K4K>SC^?9UMX*HZ+KG78<XM6%HC*T
MV!K#/8_C]R@$+R'@J TD/Y1@C1\F;=F;RES^AJSU9I+7?,$" /;TKQ)W-L/2
M3A<SAD\SNS)::PE>(7GEK]=2C0S8<;^+>GH&_04=>9N"3QJWN/>$D(_;;JT4
M?X5]-U[V6MS->&XPN[S<4$B #.0RQW2>EFY=TZ<9\FH]*4!,,XCV.)7-H)*H
M9:IF+89FLVV)>4C5I<7R#BIOJHC=L1-7Y20X:AU_(@..8O<QZX*:WP@O,3#:
M(\'%9W]D'@]S#]Q9W==TX$'/)@:W6$BN,Q]IJRJKY"V5@D[AOK?7N8@_]TEG
M:G*_-@!B%+AB+,*I;._W^0[P%'R6Q.4,.4-DR"+8:="/C(3H] IP+T9'V*CO
MBVQQ\%+#R< L8T =$X*!:#.$$" *?R\9R9,+Z/Y"0&!O\?_HKMB;?\<FL7WJ
MG%&,E$EMP4DL4,:7QN)']Y**2W&MN9A02'#J>1\#RZ.W62Q:5TS:N;W=GC"7
M7P%83EN>)!D,^/1/&&O]'A_7P*6K=MGC?HE,,S[?;MJ1!EFT]H4KN7Y5NS^A
MOZK="[!_D7_NG_]_Y9^UF/>_9IQ"F*BTKUK4E2XV05B(^@27#.=:]H',X4W;
MX0&LIIWG[<(W#@9C#VE,[A-&^\_KG]9[G;<P2!3+L)B\&(*EN_(PFE')W$Y?
M8T%L,?(<7!1OG;!>@F7DZL[HX@_<D-"^D_.!U4Y^[--=UZFJ3;%S*;G+XU<H
ML76$*^K)E6VAM6P_E8J=O>2&Z)>'U;2>5/ 11PV?87O'E3"(Q%JNX$8+9(3)
M%#Q4DEDPWEG?/5_&QW^3DE.$5[%,:/H8!6*#H; BX0C.:8*W1H)AR4#!9]\Q
MP>CSM[/^6QI0$5L>!P[*]DR/TZKOH,.]K?'[D5GFU0[Y0:>95A:HGS->? Y)
M>"9EPQY(Y^]3OTP&G,G V#'I!L&M<5:S4E>I)5$\R$]QN</X";KX25-<A_'%
M*K8=X9J"DWQA(!D"*?Y<\$Y6@V#GX)&?A] ?0?2EZO!7+;"Q/.E%5M/XE6.K
M(&/!>WZU! W7O%622$VD(3ZK[F+\'JS#X:W.A2O<A+=V%1% #[ <NS&D3_.C
M[@+I/%$=E]#Z$J^!^=I4(/?C$J^&:N5[=?XS.=KS_@*!)N@ SF?;CFS=1,TA
MD#*BC^]"4@.>J%"&>Y[@)WIY]WCW4+X]CX>BOW3C?LK7YIU=%"HGG5&PCJ G
M^;KND8IA/=>ETFS?"R^?.9R3"L)B9I\VVV.\->?\]3A7S<&%O?Y>_UTI4CA)
M..$+TDE/?FS.RZXP #VO]4LH\NF)6^J=;$5O+"0 Z41+NDJ\/IBW2P;*ZEFV
M=2L^Z']A_JIP,47^ZIF\&Z7>CF%>^WJT$X_)  N))53OS8OSBO<^?YV8M'RL
M:"49]\>UI7+7[HY(%T=EUO&JSI,XCZ(BZ,V"U_*]OCJE\N$F(<QP3@\E*XMB
M[U-7/]J]W'\6)V3W--"AO5TP<7P Q'M"/V?P.NIX<.0#/FI<:T2'$)=$RL)^
M95.0Z!'/,19X^!,-L,>XK%1> 5#7CS.)$E\)$^C@D&)=EF[4KDZ[H)E$?YQ.
MM(PTYT,:53V1DA<.YRGFD$5IK[S2 ")=GZP*HF5GRF1JXV[I@$RA]2B+S%9F
MA/'+U>GJQ3U7@AZVEQJ.(*2@5E_(EG*IYZITF5LKOVFT'748^G62MMW.MLMV
MGF)^IGCQ]2Z4!TZ'5P_^:'[CX]>IS%-T]@X&\VZ"=EU,"L8BJ,>0L<&&P^!
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M?62TUO:C<]9MHPJ2C/57F)EH(FF+-&P>$I/(@(:EZ8CB?E@U&./]5B[_F>X
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M A/HCF2GX'\0-#"]3!9$?;Q)-,/D-5"3P],N>FHAV)B1&P>G(<30B8\AU(@
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M$8PQ,VQ-V!0N5V&7W/?V 3>%-&1$,TZICZBTKZKRN1P]M'8YH4Y@@AVF+,A
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M6F,%PU?)9W=<;X-92!UUO$1+;"&F:I.90-DB(_=C>_EMK8XYYX_W@AP&>5L
M+9#+F"1(V4NDQ.^15C'0,"(S>H;6Q6+T#5PG%]+!TU^OG.MT3=4J)C--ZA1,
MX7Z4-\]#?Q7+6=/F6'SN'G\-WLB$#-BG/BIEC^]/_JJ9X!1!<Z3TK4D9'38,
M#2 #105Q> U,6R!<;98,,#VV$38=?& -OAN$;G*V<V.B#J.>^W96GDG]WK/4
M["$0&Z*W"T,&QNI(;"-U5US"U4>@9<I"4D'F6M"HG<L@FQ<L%<LV<KC>V4<U
M1\++,C Z+"1(SB5<3"^.#'R7R[]V4=Q O;O<W^IKT7R1U$30^F?U*Y0B6-,
M)"8<(4&0; ;1U=5$-EG,]XZ5,(CZA+TQ-J<L\ THT([O,#%X-EZ)' ^O[3@R
MA;-6Q"'=1TWZ@]R2:D<R=B:SBKQT4GSW^@F%&*4D2885+O:FM'/=>V\E2Q2(
MI167XY+I[2] )?1%XR=BFK=#=LC A!AZNA#/WV@!JL' ;)"LL,?HR09ZP?W8
M/R9T7O-.R@A2S-#3")T%#OEJ0<=!>N.U0G"GZG!IJ'#&A0'%9W+] .)\V4R9
M9V5P($1]L)JM0++9QW8+U"SQG=XPBL*=TN?UJ:?L;K &E=5!L!T9>,5.!FAJ
M.157/0YL!$9$CEPGS:D_6J=K,*NT<XKT5?#F4/X@ [;/C\!O0=?&VJNN71I*
MO\8(J7LJ36!"*F[40>E>!^_!AOKK)21VOXJ,_I@BOAM-@GV:L3Z.(0-.$KYM
M%PX9%LI.G+^Y8:[Z!FU%?N;SZ?J=LXVZ+=X/M"N .8\XO&!;8MEZ13[,MQ%$
MW^>EHM2P5_9P\_Z(W)D :@&V'N,/,!._W!BS;VC;/IIA,,4#7V0 B"+BSOCL
M[:+.U+&7#-Y>EKJ#Z '/(TMNLV:3D7YQ:75%T2L4&G/4YO_:$E51\02N/7!3
M]_:8H8B3J )O74"E]A7*#T<T(>"ERRYD !Y)NA3Y#99!"C"IVV\G UBQK$_^
M-]/^[2M7_O3FRL>_S7^;_S;_;?[;_+?Y;_/?YK_-?YO_-O]M_E_2G%V[9 13
MQ8#TH1\AW#2KIU&I>VTR_,_S\[1[VAG028W<^*7?*QQ\I'=D>*1F6C$,[_U^
M ((DW]K"5WP/\]NXOB16]==K6_S&WQ>_-;A_XV^+WV,/?N-O"LJ.DG\K8!7^
M;QTU_5SO/X;)!<2?XNA?+L;U&_^\^"VT]AM_3_PFF[_QM\5?2S:_9*WL*38;
MZ#SPA?KQ&,C*J!3G"FBQ;UX42);:4 P!ROZ/7[Y_IEC6O$GC)!_4:XA_%)QM
MO<CO6#7T,>3NH>NCTV5Y7G36!B-*N6+OW=8S.;72H_Y5=#O9/F[\1@I7,39;
M03:U^U,+VP(98*US@IXB"IM&6HW8^=U15_]@][9 KU#?/<U45&5U'L*';+BE
MK/&5TQ:7^M;YD^K3"RL[QUGPY[;5E](><E5=0;M@Y5Y[;O1F=1),;W0/I/+%
MI9.&BB%B*R2M--AU\<?F;XSOQS2C*6R06-0X':8W8+\@%WLL<]-P\Q94?OPR
M7XO@9!.>[2!Z5C(D59(0>%T+*\G\F"M=!'1WD/DL&:CB:)1$4S\M63?L2"!6
MITT=(X*7?TK2/[#'_TPZN(5 D8%H\!\EJ(D)3&E2M./IDEQY.ZA33MW;Z"%2
MRNJ;6C(0$&:N(2Q>3>OA_N%H<"64F?A:E[@Z%\Z(0856W\T9UPO<3='BSQC_
MJ7-I=M3=RFZZ*EQ^[RZA)/?.PBUT5Z:5([L\DRKRJI"A-?A^_0!A9IH,8"*A
MQX88Y7/OOZ".$)_K1%C',W]]#$0VS XG49D%,QD:>T.$?R1^Z2,##>J2)JJ/
M<$*,_%ZZ]]^1'@D2<[O6D0_U0N6IE;LO#(RZ=VQ[G;DW8U<2N:P;NW>94%15
M^'&\5M%UR'9Q.?[SVM.I@CJ<)$&(##C@Y)NZ]<C Z3K2W;U\>=)9B2SM&;P4
M[L[4U\7\TD_?^6:FPU564?UD (H*YGHE:F/ADGA?Q<;7R),_1+-M!Q53HC<&
MQO;$5&7C'"9?<9*!.ZG<KV:*W:;3ND;*:YYA(D.),GF'=8$E*3?D5B\/OR[,
M'O6P8M9;4>!*HSQ*(]Z$K*31SA8WZ;H02R0/*OBS$+S'F;4<A RG0GQ6?-@D
M54W4N#3H_;NKW2\NYT^RC^ G+75YFUGH,PNE'!ZLG$&/SK*YPAQ;IR_B'-K2
MTE=?!$5>O2G<.8^=VCWKCN1:_!*K0;+NW50.<PR2M8#2O'7IU *W6&Z!'SJA
M>B"4I"E^9KA,!U_!'N)*,0];]>L[4GP#ZC2@-:[:$!S_^AB:\3Q'^LAL-2Y_
MPEVWTV?O8(=%H!?;^:GZZYB;<'QUF0UDN+?W&1]M3]%1UYBOYGY075 ,D3'S
MRE>N:S59L%B]B".M(0DOI:N@^9;D+G''7Y-^=A=D1\((YNKZ;C(F3B>QYX_
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M.J;_Z$6B_]WPIU\4*Y9,>36]PH]'!TG U0O&:"DM [['>6*[QB-9/*VZ$:+
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M*;4A<!3;@CA%PJ']/X1#3 "1DRDO;RMK3:YPO&< Q9-&Y$!:> E6P#_+@OA
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M32^6L)IO?+?Y'9(#OD0L>#=MSKZD/73U7'_):.SHA9KVM_Y_.:PKM)XE X%
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M:IXR.K)N^0]P%-^?$7_H\8)&<E.04!/M)D<P?5O+)^68V$+)0D3/>[#[31;
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M2N.J(Q=BJD\FE[]-@+PI&/S7Y#7N0<D#]:K7)QB '@NE^U#B%0PY TVEU3,
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MR@V$G'<C@86\-HK$GXW T3Z2H1++.T^?[Z18CF]#JI2'#$BF^&<AI/#Z<K#
M4+J;@_"1)RE<S&7K!9[?7P=^;Q6(X+RE9LN463,@+DN3]M<B$!27+8.RHJ?*
MOQ<&C9F"/_RJN\,  I##[3GE39C3)<_C=LNR!%R<MO2O1D'6E0W*:%%4?X\T
M'-ZT*\)KPUL<0"V+V==W:'Q^)&UE"SSF>HCT"MM5P4\VKO#CO5Y?557X]*W;
MCNSP\JG*YW=OVE6273M\(&\!X!+3+ /X.:A)A.$XPNG':L &2^:TM$-6D0NG
M>K\(#XG).FX6I-./'B&(^2M,Y1=$PQ02"[*.:K)"I!XUJLBK'6 %YXEE47KV
MKM63^)O)*;+$H=""&IYIE1?<I6(WKQ9?,D]_L7^K3,:_4,4P"_VTX*!%RQW#
M"MK1Q2D)TPX807L^%PZ;9Z13Y9&OOHN*S&JXE1QB?I6\^8G#GF+ZJ1T/"T:<
M["DXE=^"_CPR>CLKV_V- ?:>0_:_EMEP00\ON-[ZT5WX3 E2XTS*K[K$=(S.
M62M*]U:@49U)Z7_S/G_D-_?WY=8Q([K3S,C#=-Z)Q7O?L:-&"25]5HJ0NL<(
MN._9=O_K@DNWW6<-[4^,?_R@>L',\_P9DZ/K245TK,P,9%27H!E5.*U)1 3C
M]F0TK<@XHZL7JN:-%L[L("<DYL7V1=,&^]J-^HP2:YG.[=&[KUFW^Y]9R%__
M_)1I^,/;=-HR66Y.1D]\O+%=K*;O=G/"S[AG3UQUU%KE=AWV+E%Y0*P(_AM#
MW3Z(\P/D\<G5,[84VAB$"-Q%CCS#?&VZJ^3)?8-_&6N(U)D[DZ/*^Q9W+ A9
MXQ"G-H9NAL31RTR%8ARF!+E^3(AYBZMFGU<7<$E_RWW]&V#SB5N4>LX72B4Z
M[U$FITU+C)K1'>)EJQT2E!N;Z)VIR6T2M@7U-^_+;3]I\?R-A?;_9GWO\&_N
M-_=/RK&T(<N]7J\L(S@6ACSEY[:5F\!NT8]RSF0*[K*-(F]3SF,?4_VF/LH0
M%%Y[0-CM23YE"J0S/U$UD0/FR!'# R$5F Y(^"1 -24Z/(P6?-(\UZ<+$C8L
M>S"XCGF.GG(FF[(L*F'RVEPXR8CF:D@'/82XIMBHRM]NKZ.5%F,'*4$[RPUX
MJA)JH6188B\()71RSZ/#, XE6]@JTALZ]"OX.H_+J@[@&WW(9S \=1$LW'_^
M:V_>-0^QX;M<$X,7WXW. YV:7^S*?=6H9 5RG[&%:664J=_KRR+/E8/UO\NM
M/@S[PJM?-T\SY==*4> P8IZU42S]%:-G@5M:^S?:!':"_@-49CT7B&C'8P4Z
MY5,_16@[YPC4D*T^<4S<PM$VTS.U@#VL[L#5K7SP! . 5@63V_#,;\>NXWLU
MU5B% \2F2(HF'XQ=.^W&Z-I=TL>?:<"&GUAY8X-U;>C0JLG9+PD,@-4BA@&H
M\M/I"G_=T^Q_?1I<X6Z!]P3]N]\X=> W_YO_S?_F?_._^=_\/QX?GT5Q:M2M
M.#G:U'Z6^6FEFL.#/\W*IH.YPPOD*E]EDU&-YU&_M!Y9L?*B#!47H?F/_KY%
M0"<^7!))/M!Z$2N)M$=%A$RS-+4G//\E@:=)>*0D']@Q5]_YQ0!>?>W:2_47
M6X*.ZD\K4,4F0[#$J(6^Y2'X]7R.-H2MH^]M>G/Q5_]'4898U9+(BVL6 \\W
M1UGY?NVN/PU@U<^MYN36[G\'N_\>7ZG?!)W=+=[&LJ]KWDXN3KY1NIJ*"%_1
MW=S;2]G;.TWE9P!!;TB<#KL10L^"\&3CGXH[SRJ7N/Q>1<[1!EC6C.;'7TP>
MJCMC C]'\<B@N(XZ=''YE,=D,P#S%]]X00LI+$6OS#N]*<O000<E\3C<KV2#
MCS4;4A]ML>.X\9"TI0U?6ONG^YK<<VBA_](*BB'-=[R"&F+'N2W?:F<HAP$!
M(RTC75[#*X1 KXGU[FLN?8J8BY2=/3F*WS0B98B=YS;IZN6R28,WTJ:"7/>I
M=KL8JW[0X[32+$/WSUDLS[RF2#^3#WD37O2Y)"[1G&I20F9$FYR#4\Y1C A*
M[K 3CTH_]E)[OH-ML^X02>6DRU3<C0.$:@8PO$;^,$AG7=2UDTC(H1AZ=;8D
M=G8\W8KF0BSY1D5.LC C0N!W*:;[=W5X"F_\31);%OI(NX:+$/-@K]6!:2?<
MIAKK>:P<79'*1&+Y1O-;W@W@[Q3RA#P92+LA_ 'I@:V8\M#?XA48&L23W N)
M9+FXVNI=4(^QQ EKJGFPCZ<5<XY<GJ_N#XET\W+S:XAD;V&<LF@3C'W4(054
M%[7OX%<(*+_X/MXSE/-UE<W9:&:N'AVY?TVB!,W^$I^:):5;IN/RAF"]7G9<
M3XBBY?=MYL!=2V(6H>45*;"!Y&#"]F,+[R3^]%OBR!W7*,B[>=\PHDL%+QXF
M/:C& #JH,6\HT!-O'Y*_;L^K98RV6?BG=!%5E"^EU11/W?@'J##\9\>?I$+R
M2\YB7*)0O%?VY(^X,L-WLAN=YQI:PHX\ W]C,ER:<1[MFN8A@T/LI@2EX1;V
M9\T6[X2\+V>9B6  =8TBOJ+I1G>%PIL,'@[IC[6Z5B7\ *<<18_XUK4ZT==:
MON^H3!LU+6'#)T^4PDZ,.=VZ@+SRXS!DT7'HO.SN= R]3PJ3BGR,#42.F)1.
M-@G>/3[Z,ZZT=P#')G4F&D8Y^C&]S+@Z'XZ=@ARV!W%2+3.\W73UAJI>+QTM
M%#B[^&-R.2< ]Y./9D^$OI9E   %JDLDQX+BK;*^?<6EY$<53*Y(M8-<'1;<
MKBQQ:-[+&EJ'N$U']*;HQFE<JM\KL!]Q#^@CC7::C::%B<U Y_ZPU<1Y*&YO
MJ ZI+- KW2%.RE[9L7<E^DBP=B%+MG"V\%M?P]I3?2Y>F@VN61<45>1R'-P1
M3^D]Z&)P/A'ZT&$)JJ!/C&WZ4%XW&O<RIDG?*MU708NLQ/228DG2A5&T":$>
MG0?G&Z6IQ:9U=Q2DYMZ_\T/U"VFQ(4J6^-10H;+5^0H/2L-V&Q9E3@UN9#]]
M![VGCODQ.>)%-JFA:/A=K/ZD+;<=.(>L<5U_)*4J$E)UL@$[Y5/OG%=OE?X&
M]16#G6, S/10/$(\]6,OO;TSVH.OR-FNH&MO$JWG#AZEB)&*;U!&\>[]FUE[
M:LN/]L5,^["IS29D0G^X,'!9G:E[:9T%/]FDYX;W"G/TH!U<'K7X]J)M6*HC
M9$W[/ /@2G;?/1%P -,'?844E(5&"?'PD)E-%LOPA@S@CF?[:.4JI"8D66'J
MA3KWK-57CN,[^#RD\,;J53Q?@LB$V-'D;$@=&-I>O*/FM9FSKWIN&_?^J#[^
MD^!/LG_0<1B?=S64" J2@W+:%_D8\L'95$,J<9I"R[?NKVHB;E,V6A)#FJ!G
M[.N$!T >JZDJ=]J.B)V9S\8NY[Q,_WET-XF\3:DGM^])A%0]9P"59:,^.:><
M^&[(G-*>9U]7,U83FP,%0HZOTJ_!M7KA"HZ5YU.@TJL>H'W=2P M1;'D<@LN
M+16-B'%H#GW9%Z7T"GZQK)C9F$Z2KU+N^&; $&FR%S>(_&I3/[GLS[Z&VWU_
MIKK?(+]DP*7M.D>7*)4M^,"FQG#N4N*7SPN&B:?C;3)_7B\;E'_QF?,&VD/X
M'O=#?X#;J<[AA#GA2A7J"\7)(_'A#Y<MJ5AP7X^GKO4V0L%2\Y21%/X//5O3
M"/NU;."J37%->=1B+Y[O\N,$#9$PK:-?53DU'Z6]RB2LHGY@1^+)CRHH^AX2
M;U3E3L5;<"8P !_0M5V_DPV%BU:BZ4(?.13%"4@.^ED'Y/&:^W:8>1Y'!W\G
M'\$'#R&^"C""_AA"F)D)AC&*\]R-32;'O]!V<U"6=6V4#M9^(&GP:BI Q6@N
M?D5O[^H87*PFJ2F%/U@7S?IC)_I<G+_:&_RC+:F8AL*%[HV 2:-7N)SVGT:3
M&^OT<DBJHFZXW:_W#*#(S4&I].E$GWD&;8TF-H0L0ARBNO> %;W-8#]/..2,
M!IG2I$8EG.8JZ.M"+R9?U3,;91A-,X!&!A#*-]DH<<K$8??0J,FD:8KVPUB.
MB<@AROMM4&@],+0P](T!1%9)M*P=R<S*DBSO?WPT?M=-WF+B!N2AZHH3O8E3
MM0-Q (]6!?-00,>:QRZH1J<W6QK,ZU )>Y!K73-;DSW9:6&DKLX_>I#],^-/
MX-G-U(G!;Q91C*8$84WE/ZV+0W<D8SKZA(0C_!^A/K6NF#O"6?8\J19_J<)N
MD9\XVE>@L%!U>4-"'A2G6R05N%1X%UPP7>KUF+AVTE@C"Z:Q6&%S,<XG0;]1
M;E7<FLZ-G2S: MN2#M?Z$2)=&8!1?Z8"SW9?;=,ZFN I$K,L[>N)Z>;X&3*U
M/R&<G>08;>9[S2^'XKS2*H3O, S\@"O;V$#?T^^MNTY+HG.5MX#"3#QC99^[
MASMO=FH.T;U301?]S<,P5-:4@5VT@-UQ.P';PI:75W(B );K+!E^/F7GM,0X
M.-!9&EO0$S(?\/.-HHT+?DJFGXT:01\Q\_$NF_<UX844UC^ZU/XO>*CP;\K/
MP_Y[LB->VG,2*_I[DEW$^ <Q36!0L X5Y"%Z1;HSJU)5"_?E!F()M U5%)\!
M':=?<$ >535V(+ =GFZK"IF-%FV-\NZ:B,1Y0#Z<_8N7-$C3URT>DAW]"+E7
M%K;>]DL^S,'GO?2MUX\#..[#DI EV\O#7D0C4WIO;Z\IEM6B-=QG].I@@<_Z
M4TC*X"I+MMQ6Q?'G+B?(W-O4OU1_]0A<:)8M3H0,*^4GC_RK4U?  'RI0I3:
M-+@-,4)Y(HIN%AZZNOSTL75IO$"N;Q2^&M7$_@M[ <Q!-1ND'Z<TL+EIQ_BZ
M"(['E E7A:NF^PKAJP(I@;N!Q"Z"X1N2:8-ARMGN M51N^#A<T]4VWV G727
MX9!%22WUPS5PST-XZTY0$ ,PA"@0?IS^\G:(W+\O<_,,()8!B-% !K\\'M[7
M]-&>J_\'J)C^9\0?6N7]]X$ #TXBC!-^CN*0ZQU\(]*+ST=>$DLMK4!P6E4(
M%#( :SW$/7N>;;Z,K<Z5L4X7+S=A/=E>@>)J+F-4I4CBKBAYC%++ (X,-5GB
M<X]XV0D)BA_C=HXS34?)8:<46=58G4UF(=:0UQ!B6=T5$VT?EJ1/"]<M%OE#
MVJ9 T<+T/2O4:L@FIO!;7Q3'\:6'XTOK\Z@%Q,EOO?B\:)\X<1-]LS6LQ# J
MESI>!;*BX]"LT$90T->)28W9I43RZ&@R*E&Q<.\#JD?GB0J/Y4CM1'1<W8-2
M8\/L15U/I.HOQ<7*N&N9TN7-"LAUBS>V 6&7\J"*?_2>Q?_?WL4J31:"?7#C
MU(GYW=K/7B..,\\NK\SR&NI30Q=99SA9?Y789B;=G<]N>SB3Q?*LS&9V;H5_
M3VT1P@37_4!MGSP^42G/,^.JLO/ *OT519)7\%L[A8W4;D@!$6;Z';W&[7@.
M6?7+KOPTGNZ:$ PLT-'?$CR"Z</P>XO=HH3@PU>8S$I-:Y5)\E6;UFH:7Y:_
MK7-D8]K7HB"'/) !8,F8VU@VMZS.A*MR0(7NAXU=R>_':U&%S#3$,1X!1X4;
M90P 33VYJQNL&,+11-&Q]DF\FY&W1A[RH,T.3N2V;_'4TZ_UUGCAJP6];E;O
MAZSK$.G+1IBJK\O?9CA].1V>8:4ASV C5S:FXD/I[?!><^^[='5RN_5.A'@W
M] R=."U,>;G%!,I(-,RU*; KJPI&NPG.1O8[7%7@+)MYQ_K][*Y1U[1D=,./
M2>OE+IQB4HC#"[K8NZ7;L.-8[5]8P7;W?5&;P_W1(^N?$7_<2?5_#W#_0I<H
M-(?2.> 2_5L9UO2^#_XQ=R,8 '=C8,ETQ;UC:&N<[V85=8I6@I#@"$6?Y-?Z
MFH2(Q*^0OY10B\QLMKM6#QQ@V7N]C=%F"MEM?IK2;NB//O(4.VJ<?+G3(EEM
MP?<:6B$K8P\$T9.-UU<MJM:]&F$\'F7\(3D:ZI9(4Z&]IY] OV8 1Y\3:@+;
MAN1N2&"V.1)X0UI/, "7%ZQTDK,)98@,H6@A1.$/RVIJ CNZ-\^7EVL&&\RP
M;$N!<H^_&[\?A(@?RDTBR*>"C'9!GRBHCP['T\)'>M'T$2RLXB\[[<00O_X_
M9A[^TU"@0, UU/),LP2NEK ]4Q6CDK=O?6IUO 2Z^H:F_>+6FGDL]_WWJ1<N
M5<LZWZ@U$W\TF'[-6'-<K@?]E@&<K.-;@AVAPKSP-%>.:X2359?CP>9--S\6
MG5O- KUB%E+'V-*B&8!=%@7V11N/Y#*3\;Z["AV_.P<97I?::Z0G%.XU%NZ$
MP&E!I(TIIU@2KH$M:VRY9% \4"?+GM\G^ 9XR>O23P"5*O *]@$L3DS)G7(^
M ;/U'4@?MC=T]7%M8  ?SFX_D%07X%3'%#4.9B7<=U]T'J+VT*3>/_.^)M]^
M(: E8X5K.QZM@]OMF=_TI3?AKNCQZ?#GO:LXGI=U-K [< &*"858P48<]N1-
MH2'T*]4,0.-MZ&;X3A)-7RAN%4I$X]50[=T1_EB8V)O&KF/W&V#$N2G>7[JA
MWPM=&X8&G'EZ=;$[!1'[O3L+AO_1T](_&_[(0VC2PJ; ;/"[\83,D+Q%KH6%
M+$'(HZK>)KO+,=ZA+T&*9T35+C%AT\*>1G^^9*']J-NE,HI%].!+T%^=1YD.
MJ"2N%OY-@;M+<0N7 =X/.3.US^OQU3@5_+6JGVI[8//_=K<UZ(HXR1',"1?O
MESMC/9PWP62=F;UX\3$"F7;-=!%8@\5A5=<9P*EH%7_=D]1.OZR5-R1W^%U*
MAEQL!-TIY--J4=D5A/&%KK7/(,,#ZJN<0EL.9*E]M3H/OQ?^J#80\0:_7NX:
M![H:,[<M17]<2;XC5$I^I.SR#6]NO+J%3(-D4IR/Z :Y'IDFW>Z+GHM'KN*&
M8+7%R^AA%%Z!>@42I.P1U &V*/6G?\R>@3<8,9U ;Y^Z0M,0VEJ2O0\3?O Y
MI_.':?$.CC\\%]74WVSH]7[4>8YFNW]ESUS^Z'GQ_PAOFQ6-/653N#UQ;G3S
MYW1@\PC<9CE&X%+EW4P6<$CTYTW1[L1M93$3 QLM^Q>^Z=WM)$I$\<GC%GR&
MR<A<B&@_]6E=866O<U9Q=8"N:;L/WV7+V-LU3EF';JFQGJ\CTU#[LO=NNOH,
MG(?@ET>)&E0U-N\8F[R9OAKMVY9.WV524[^ +>-8WK_;CW1&T&6)M9EP30<A
MY^=X"^>T^]OOV8LN41\=]P!  <L2J^Y)2W[M2C.EU>7OK,-L/^2V++J>.=$=
M(+8,\4B\M\P 1.G:F^@]%J%94/L#"/S";C-=K--N3T'3VWD9NZ?YETN<_.G!
M$S797 5_;-X@F897/M+M*Z1P8%MG\WQM6QTX_W)/TNO!;/ISW)04[[.+WG?N
M."HR ",+Z%\>F[^;"_JCN^J?"'^<"P;WF*XV-R6_IV678H*W=V?)X5-8]N$C
M<\6%,>U^Q:&!)Y,#=.\ (IS<WKS/AQ*]A:=2:O]2Y$0_1WE%G#08M"1!0Z@:
M;D\2'=,2FE=J7,\?F,V9_<DB$L!Z5NB0_P%2,=F%=#>#= %\$2X]--T#-YV]
M8FYJ+J#I5GHC0N!$6\X70_Z[W:YBS?1#B%Z3N7I!?H.0YCJVZFKB2E?HM<B)
MVJSUK^:%,'E5*ZO'$:\J[\I$=+,,>L).R#533JM:^N-'*^ Z0N^'I&TC'<^W
M.<7>6J<6*;PT>Z&\HK8TAPIB $4#V[A.#OI)9'C51-UN6>K5X$E=PSW(L!6[
MT2]MC?(+KMPW7E:HSJ$*:A0(:BK-(VS!I9_-+ZPF^7-U,9,VK2'?R6?76<\.
MG2.A+2B!^]?-8=)%7&N,0UP8X',MKO>3;BEL+HPB)9QT&3OU6&#C.DB)\JSK
M$2UV?Q!S'/<^J3>$*>UB]DY@B;>$[TT,)'QD.G[\(*_ZU4^''ZCS B@-6G&=
MA .,@RJ:1O%JV"@M#Z5"71V?I)Q\\R34\?@]!G!,1OF2T[<R)0 E2U'(%PV%
MV,GV(Z1HV-N4]X4^RA?CW9Z=ZYN^(WG_V.J3N03YN8B8X&<M<DA[B4W,2/54
M; TFU'!QY'IMN7\^=*E4$Q#?7CYD;3GU"]L'U\\#A=YK)K_N9\8_CIXY'GO&
M?/'SS.'Q"AM1-;%>B!4V(GZ2!\Q3M.0F2S_;8[/'/?9#<N.:C$#DJM;#W?>B
MM7ZU<.0>&P-(A]^F]-GQKY:C'H3;KC0-70>UO911U3N=OV>!Z!YA ($B@ZLE
MF)"ZTU?C3SRJ8VL*'3TRPWVMUZG^\?6'BKRB2MB3=($)>C/?=DB-XY2_U8-*
M8NT 8<0^46\YM2GA4&%#T+EW,.:(W .M78(2RQQ[#. $U;SZW?:8[A?3-5',
M9*4250<2ZX4L=[\LL;R6(R,@ZU56D#+7P;1S\KK03N:B_&Y=D@/2[FS<X*)(
MRF46+:T#[^EGPXK-0-^,4Z:G4"\MM*[-W2AJ%V( %>KFL_]S1)AMIBCVI;U[
M]WKT_5N$^BCI$WMPV!P$K]J'K(;0B) 6% 4J.[G:Q0#@'/M<U)^!J_$C9U(J
ML$<0W)-01TAL@?WC83L\M*.@<>X]LJ)2B4[NF:A>^QL3S _42"-AFRJ."C,Z
M_$/+D>.6OO732GPHI#:&SCQF4Y4SE!6/IQ<:PZQSP4N!KK"5Y!]7TFJ5$9MU
MIA))U&O>'9*M'M*:7+)%W^OOG[).>/,-\%+"#$@,=^$?P,]1C#+FU[5R<WZ
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M*<WOGIA[5J<\5Q!H11\SV!V$9B,"6B2<7H\29HP2F,W09JBE@K :GPE[-J[
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M3+HBC)_'+)&IEQV1 G7R=7[>UJ)EVJ?",SFT^KM0&C?1+5#64H@T8VCR8R?
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M#'E98]H=42<2FI%WO2^TF/5Q>LH+KM5G&R?V4--W]5DT0QBP_.S-0$;5&>0
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M'=4V/I/!R2"\8>_KO0R)".9G'=QD/!O4#"T#[Y^UQL)&)*N7&J9P)^6VZ0L
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M!A%45/VI[Q+/LHT/MX@_:TWGR3E]6E?BW0318V;[6<1E]*8J<R<;U@.N8^&
MS(0#,;28T=PZ-!/P<C;-/:[30&2M6="]CTR,(=Q*&JL=[%Y(E]+/:JO'&*&+
M!6[J2.$OHW',G<0>8/T3M)Z1PFP8^3JDHL-(![#C>5CP& ZX606IO_?*]0A
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MSWS%U>F(FS?]:"M\#O^V:H#5R&+#X$> 9#;L/'(?=OPXB0V3,D/W6XRV+JN
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M?MVR7UJ2H>_\N6NV7.#EQQN?"7V<7Y+8(-T.KFD/YD[?SI\ GG:V8%P)D$_
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M!-<5ZY*H \->#R\= RW<D?M8BLG@WBQR[[,PS-F>@U>"OO3&?T68Q.-_?D(
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M^(%J\_Y(3 W=$(_T?U_G9^C232+% R/9^U>V-/IABH3'A"F3A>$318Y/(_G
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M>7"HU\!V+BJ&!IO:>=)?DNNAW+F[->D0904M=JYQFL]O?3\]I?:R*Q8H1#"
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M* M.K>9UV/"S"?F*OBAT[T=9TS=2/1>O*G(%*,B>_+_WQ> #OI,QIAB5T#/
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MNR3-[YS&^<@'FKHH\E-3$7T<*NRF"=AZ'26@BJX8V:K!QNK[W2Y5L8<7,]<
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M;)=EG7=!DC^SL HZY%8NJ!+2VI!)A8_T>(<UQY?. 2>5./WN1((AS'ED5]U
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M,!WHYG&=[2IBZ7,V\Q_O?5KG[$O5HU)+4^X^']!UX_;13%\UW66X,[^!+U&
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MD<87^>Z.KT/$K_<-Q5O#TL&!=1+-*ZF9QY?X1BZ/1QMQTSNQB^_RBEE:I+D
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M<@96 Q]6'55Y7B8(B"HH/;[5G_EZKPWB J)6)M-(&*")G$!9 ZA$,!M<@=P
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M<34IO<AG0R]<+4E)EAC]J,@Q4X_;@GW^NV/_0AUT4YEH(QW6,X ]PM ,9R7
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M7@7 BYAF%_C#/T"U]R#JC\;^R[>3H ;0%S%)X?UH!S$9*1Z:$'NOR_U8J@#
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MM81K?N_@(?R^[Z^[F>VSI>JD0FDX-60EP&M\=W")][*&H0!4'D!2KM%K,<)
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M9?ZSPL0#+L[F:\K+"."H->/Q4"X[?;04LE)]EW_AIK&T1(#ZHBD!K8L*KIY
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MF_K]R")7%ML3* Y;,<$?6T=1ND<YF<565H]87,8,Y9^!'>[4Y?7<<J"51J)
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M9KS=*_"KE"'*[&ASIVM^^UW P2QA0,F6Z8(^OT/NY?8V-EK>SJ6>NI_2['&
M4U!DI%JY_I9]X=AI1<X?^HL%#TCJLWPT!F6J?QZ\^+62LM8I(UH_HUU9,?/
M\IF;31;7^S3IV:&KNBJ'=/_X9SOA@>9%J!2ZE]"HUD"=[9$1G# (I8SWVT3
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M#G#Y@\G$UZD.!:1\5Z1/I*:\ZIL+-6_F!)%7PY7DW6)OQQ&ETFN^/8=$_40
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MU[YKW[7OVO]_92=M6?J*3MD?[),SDZ\@?UGR6 9+__G[$9R=F?\+4$L#!!0
M   (  !$<5J+:5_,-S@  .=)   4    <&%C8BTR,#(T,3(S,5]G-BYJ<&?M
MNWL\5'W;-[PD>S6R+;M)A+*9DETEDYSV29*0F$JR)Y6,&C,A^R1U1E%&(94T
MV6>3L5<AV3-BQHBRG1DTEF9FS;NZ[LU[/M=]W>]]/\_S>?]XWO=:/L=\,+/6
M[]A\C^/X'FM^BS_"IP%2]M9VUH# !@'@+/P#\)> S187PL[[ KX ? CPQP!+
M8(/ [^/WZX;?QT;!WZ]"&S<*;A06$A;^FXB(B<(B(BPL*B$J)O[[@'^3E!"7
M_/W'[XO\RZD;A 0%A<1%A$7$_Z</?B.P153@IH"[H, .8,,6 <$M OQ6  GK
M*/0W]02 ?ST$-@AN%!(6@=60@#]0*06K+R@(*RT$:PR_&PV_#VS<(B2MMM="
M6,;YG,B.<%F#F(RGHNI'2IOD3O0R-?:=OQPK)BZOL'6;XDY-+>U=NPV-C$U,
M]Q^P_,/*VL;6SM[EI.LI-W>/TSX7?"_Z^0<$7KD:<2T2&W4][E9\0F)2<LJ]
M^W\^R,QZ^"C[67Y!X?.B%R]?E9575%95OZNI;6YI;6OO^/#Q4U__P.#0\,@H
M99(^]6UZYON/V3G6\LKJ3_8:N/[KMUT"@*# OQW_T*XML%T;?L= Y+== ALB
M?W]@RT8AM;W"TA;.(N?"9788Q(C*'LEX6MHDIK[O!%/N_.5><7D-P\F=K-^F
M_<VR_YYAL?]+EOV[8?^W711 4E  #I[@%@ -\+C/4K2!?\K_JG '^$#L)*$)
MBT-P-HT$$4M)"]7A=)04U'<],W531^(J'Y#$GM<[H2+TN.#3VLM=37[5F^>E
M-=[(98PZ>[C?Q#_HQ6@1FO;Q =I;:AF2*UO,)@R;H[@&K/B9M$B:SDD^$)^1
M#S93="1*)).\*#-GR\R.C-_:9_#IC=L6TY!"#YM/$P9\(.X]?($G>%56Z%,^
M(%K4R$@SW\4TOO_J#9' 0OW!3'O7=ZM@TL.,\_ ;Y7*!F/Q^43.UJ>W(XI-N
ML3@[6/]LJ(T/2!#.)9%I^>8[0'(8JCFG6W&3I</0PN+XS(#9S*A<Q1XIY:^&
MQ+J]4J]OD\AG;726"0LY?$#$#M^$KF!TD"5Q&UE:S3TI:,E0LZAP9?.-+)%6
MO0T35,<AC0SVD5CW4 WM"^=?E<2IS@ ?3#^(S'K)T8E5L+T^;#5>C*%V)94R
MS\Y@4N,49\:+WO:10F]3TA;.WO66T!;\>O1IS(F/VP"F[2LJTXD :KLU8L!=
MZ8UC/10M=FC5<%:+?(-67:\:L57Q^NG."+W:UAX#Z[+]6XB&(=1*<+]K'N+J
ML_HQ=A.OJ%Z.HP!UY1KR7IFK^V<_+WP**OUQWV5@P=!VZD8-_8B ^ZTW29XS
MR*@_;PPG$YJTT;0R0CF"*\=IQN]EH196)HFR/]Q410="0BI+D&WLH5*OX)JT
M";$OGCT&#T?:#&+=57I-MC9M1WHZ8R3X0),KF4;F Z4,KC2:7I30L D7P31)
MXSJ0P*S#(1</.@E[C#JP=9SV/TV;X3AVF:ZH[H]='(=>EM_9QTYLZ5$,($OC
M!)YRK7I+BA)Z,+V+$4KNH8>E;919NJ_>R-[=*@S0,G)G;AIK/TL!_G=$AQ7$
MYO'^1-/RD4Q'%*B;E4R@5:)A$'>15>JW384A=J;?YB*+ZJI*"O,J*V(C4DP'
M9UJB4W9)8_-SS@:HW]OSSH]72&I#@-J;BKAR1$@TAN/+/0]#ZAE./,CI-K*<
M#]RF*QS@ XEFYZ;$JD#[&YT?#KLOYD9<V+#DF%%9^Z'AY+27C/\E@7DTTPZ-
M@-VVE4Q[T:#">VJ^&_I,%JMWG41NPYVI?-?'!_P)&X)4->IB9Q6.9WOX[GU]
M)2I(LBPZ3_?MPKF58MT+BV\4( FG*<P( Q)+Y@,;>Q,AT30. K<K.JR#N+4S
MH&$+&.FC6_OD9[U;-11<&]^Y/\K;^OY>SX2#J:]"UK>;CL!:VQ*:C.%,*D*7
M13 6/?B T!YPBMG27$50A?;,*I:LQ>"W!&17UGEL.F&GC[IW\-&]J0]I&K7^
MZA;L6%?!1QHG1I%:^'9,J1M7^1%'&S]LOI=7SPV =:EA$MK(J1.HC(^LHE9,
M,D6Y/& W[76JGTI#J?*E4,?2#2)+= O9&U*U;X4P($IKH82%@,2^\P%A%O0)
M4XI.B^@U+\P'H: >.9L0<]#-.7?3L5^V<HF;[W9&&P:V)(@J*0]_P3"C"'%<
M(QIR!$DS+Z5U:ZH8SS<39<[W<_>'7XQ!.E5!GY[<"M^RIF!<]5T0BD+ED<[Q
MZOC 612H3>+*5T-B"EHWT<'H6.\MH!UKK47U4$AD$Z347_GA3<7\B[SX2?>"
MFMB969\5^KO'?E$2&N'RXC5&*SUMC!$,)-$"NRJ?Y=2$&25!XI:<O5B7270S
M([ZVRZ3!E.5*3 [1?V/FH!%><,(LW'/\,VY437IWL&NR-]W:K_$D@'R*9+JD
MCRBQ#_ *^8 ?2@D:)B/1?N.(-HR4V5ZFDD=<2VW[N[)CV8&%\8-]AM>ZH,,9
M%S,>V_KH;][3(H@T@T'SA+"<9(=>* XB_-+\3+8D!Y$!D$@/6[C/0D]&WC2,
MB2K!)DY^KB[TSY0P#!=;*GJ;O?4\57VWYO<(KZXCM[_=W4_*(-/&$"-9[">\
MFV3:XS"F$KL*](5K*3$5T;K)Y82B&WOP 1_XI=L[IGLYJLK%44'39#TR=.LW
MR11@%0Y9&/=I)SN!#Y1%7.$#3SLPJ61FF%M2*)F62Z[*6OC(,IY9MC5'0B-D
MR0@,PMM.)V.CMWI_94Z=[:#%'!12DIUN^0HMQX&+MU XB&!YLG-A, 9R+X "
M3)-F\EBN/@L3I_7VBR&QVB*$79QP0<UL+-'V_LVH2&<&YB$?D"+3$LA5:^ED
MVE=2'+K<*JLYLI</!*!C<TW)+)&$59TPN8"/EV*_>S7<LWU&=B"6M3N^[U(X
MFYR@.JB@!IT&N//P<AWS:YCJCE2"/Q\ =[^?_IIEOJ4/,OU!%C>7ZU)^J%55
M7=:0'9"_VG7JU,I4;H26$<\1_XFP'$3>1%ZP@%=;35'D7N)5HFEQA"H--#/,
MII$XHL#V!7<J))MK_^ #,B%F/BP=N\36[)"B^Y'A18'/?E2V=7<=/WKVWASE
MR];Q:EW[SAJ+0!Z11ZQ'O0'5::A8,P5Z*K)L[KK-+<,Q/>NQ;K?EHI0ATV^.
M'^RKMME^NK?95..XB)>5['&!_QTY:>8X&2:)';8DMJ@:,*<32IZ/"RF<QA==
MS)(Z*A>G_^.K7+!!K('I=M5!_/],:6WX W;I(GZ(#RB1SS' G>EM*(H)^YJJ
M4VI%L:?$(=1)X^(]?0VCA##_M9RM<A?3-"]Z-;Z(CH\!8@56T?%PL4N/,S<$
MQ^BDT<X6U0/5=2Q2[%6.!$/VQZXP[7O-$S^]2B[X71!MME"Z*_<PK3[&JY"P
M'PV0SR' W59%"]7,#DAB)UQWVF$EXK!34Y'M9)6)608+T[2"C=VU.!US/M/2
MY_JP&_:=_!WY45I.QG>%)*L*OY].D+@72P:2\'H%(AI_A7%E?":K;^)V_^JY
MM62$3O;69_W\NL]A\N"#.PH.[NJH'5U\P)#VMNK)%2E.S3: <R>%6PISD6.$
M( S%C=W-2VW0QGGS7C88!4&FK"W@Q_ P^7R2]R/S;J"OXKN4Q=9F"RF_:UO:
M7]VLDS)PQ&$X[EP+%FDQ!DZ"45ZAN2S. =;^"UC']@;]:#HZHJM!2?@=/44C
M=H1-;YX$LN]Z5OZLN#$.#1X,[@P]I7'9%H 27Y#2R+0T:NG,2PZ*NXN%3*7#
MER!BB>QG7^HCK@1$Y&&+SPQ[.E>5WAF_:./@T3!V]?:;SR8AOC/;137"UXU@
M/F-,:#I/".A)0F_[B8PEO\UJ2U? >DYV-*&V>/X@2G$C:>E29P*H%//=]2G3
M]YT"%K_98&DIGV<W^ F[+TD(3K<."/ 4G,]@%J@O P_T+#!H>A@W<O;2$J/I
M^IEA-S>#1QK9UA7)C\8?WNNRT[C_4<N(^Q,N7Q_Y0)7;XG>F$B2A%>G#V0/!
M^215X;6O.5>@U\P:4OC"/1<=]OQMW-5RNYV/3[P^\5SA:M[+KREC90)YB-D=
M*6 1^W<"%V)-)HNX6W2\X-\SN 9#\D,8.=S>REJFMD?,/17/D\EJE<?VHS:N
M+$5LW>[Y\?'9J95B:),"R.'XX.QX)>8F.%->,<$?D>2MFV/!/):C>]HIK=[G
MQLM-YI$UG2$.C\Y8:?;)O178NGTU#S%1J_WLIOA?A7L/7I7)!S[2?B#9QX+A
M>E +D3V#EAW^UARTXO((H_MA,M W_^N7MRP?R*B%"2=:A=4/V>[B \.?"#GF
M<-[HK*Z !?^0IORL@T0/\0'-:!(?&+6NAR^D),[-( TQP.UKW$=LF&CY*J[P
M =M@G1F0!%DAN+:\U$;R.NH<'_">P]MR3J=HDSI[%L_^E;R3,O_&NJN^-Y%'
MU-G:@]!>Z L?*&\H8AULI+PI$DG$N4R^-Y^8<.\NH=O'+TG3DB@;YC*DKE?\
MT)FS;P*?,JLG>]I[$FO)S834!M%^,[O)DNL?2XR>(#S*/19):J$O?C3&?=BH
MFG?36E3X)CJ' 6H[Q:!]G,"=Y!9D IKIR@#5.A8_1M'&?3JN#Z9ZXU0J6:]/
M%TA[=(;H=194<2@^LM([FHS>#V>_6KZI:.)Z"DHL,3OWFFO)>W">Q0>2N.:_
MCCU]@S/W.L('[.^J#%UQ])DQTS*;WI:RTB/'[%F >[OP!QA<<'_TZQD+ZJ!6
M9!8Q42W7J;>^UWY9@J2P!X^_'PCM;ZZ6LM@^H/%(WP^[Q)V/DRU-_B-V^\/C
ME;_0KV:O'9C(NO)L[FY4U7 F0ZC5,X61-E L&2OZ0>ONE</(.V3FA35N?A8]
MC)?92>09!CP@3^H)0IN(O!("[2E:M5Z%E<7&]E4@4RGZ)3>0K=L@@\ R]].!
M67N_=JH,3N1JD?WC?/](L,W47)XP<8YMQ2="K7R Z40=58#$!IE3+J #1XFK
MP0=N'6RA?*ZB-!06\8$PS)QJQ)2EK";&X%?4$T*D9%"E.ZKS\85[N#'V( Q!
M#4+37CBL>0UH3"JZ@@\LM/F\ DF?[NBD2P<<J)S)BHI4!%Y5(_P,ST^);Q"^
MNV_W"]?M@+8@:QXFBU/(,9%&<GD65Q8YN<:5OF$U4.];,)N[J[0*E)/,CGW5
ML7,H/^IB6$G!.]^T-S(.[J&>X=,E9\>?-)ITH:N'F\F@-G(!KEX;;S!)"]$<
M6]CWQDXM3I)\H'DJKO4TM2V5L?4TE8K-:37P"!1]:7:\3JZ[SM3E@VOE<;N+
MNM0!MX5RCCK432TU:7; Q!#*.IKU=)IRY2L>%7F9''7S,>P" IYG6@>$[E0[
MN6WGQ<MRUI?R)-/''-A2O#]ABY^2Q8,A46@$(\X')E',]PEUF\L#GA-",0&0
MU^KQ;G&'&0\GR<0M7X_6.<@=7+;8+B7P 9YQ\)I0+U(>[AL"V"+V$Q"!;"%*
MVQ18!8@D3@V>8-J=D_3/K,:?EQ9Y(N5A_--KQ&@=PPG F3#3V\G@P?EF] ;\
M]I'HXI:)@Z#.2Y#@7;6U*S/+6V9HZJ[DJNE^D=)MI*]4":S?'TQ,PE6&"/9B
MYP(E]/ZY39G$D)E]Z\?_B%%W_.Q@+'?XH\;CRW8DU6'8BL?(TD28O(=$(R'Q
M76]PBBO0WA^*465].#B1Q>3AKBH\%'2">,$S)I!:\^Z10:_,RO>#-[<+KE-X
M.:L,B@*["+S/=($V/07K"KP^%N)4>04XBQ=8]HJ&943>R'WTGT7[)5;FICT:
M7-AUCC5MT35PCK"]2]:X"N60N*#&I=<!R+3*%^?39(%D9++^U''@QX876TF#
M&&%"$YK@PT@D5RG VH611'"RY65@]92*RE7R%FQ-A%)U4/'QJMD*S_KV"4V=
M(,# 1KHN^.##I9 !./G"0$T8A^<X6MPH,([CR 5 (U[,5'I*Y)I"@QE,$"9W
M#(22*[[GSBY-$S1GZ+;GQLWN@,E2FT8 ;0"X$2_K?%CHKX(_0&AJ0B]?5U6!
MZ:8?S%$+?\7CVX:GBKC*,G"E?3I)Y6A>P_S"O'#K8Q9QTX9!#TYZ[SQTS! ]
M/^CT$2GA;"7W*XHW(^ML!?R]R'&VP0[A$#YF@:G0)U\&=#?@)_@=4TIDAE5S
M'Q&2R O/O?G K# 18])&6-8FT&TFX9KKM&ZRCP^0X&0SCNZUDG6;_LYT=[:2
M!?Y%KJ 5S7<0FI^":#HIA0_ 4Q8%S;P-7EYSY8A0S(@5O%R1K$YJ957H:-J8
MY[;/"/L7UB[W;D=>=)T_T7+\0>"=WI20AH\Z[RM'9E^0NJE@TD&H1(D/H!@0
M+1_:L9D/%%OS@4X.'WBG,\8'3I63U^&&>M^&V]--IAM@P_B !77=OIH/Z*!M
M_XOSM?]Z>@NDK@73^578QW\6$Y;+5U-2N.-PT8TCS_62ER$^L"2.IF]G_*H(
MXY+)G-CTGT$'^0 1LVY(Z$+_?W3=V8;?=S4N$R;#<&>9I.9TT)>QP #MZFU\
M"Z/)D$S8P06J_Y,=*\;1R9&+U"=U6:;M-J<?,6>NB-;89Z9R8$:S[[2J/AB5
M3%(T9%7_F6UWXP"E:J&Z**2'#'=X%J+O2(IVWH;?0E9!TVC$]4,(6-O1?65P
MK^<=(9^?A[G"9C%8V2],!N_^010/-: SBW6!K.>YNKR.'[ 96HK(GW-%W]+C
M7SQ+X9E!*^)_SU%^"^\VS%"CR=\ZN58P9S!8@_%K^(M[A332 YJ,04?)K1BV
M"XJP&N=$RJ&3UV71+'68U!1H<7,>P32% M.4'S!-65X!=?^=FG2C0Q#K^Q@I
M1/:Q"!)/+?N]?GT'>S1K@0^45K<EL[_[M82$E^:^>YM=NX?,.,D'6LG[<I1B
MVBYB#SPT,XQZY9IZR[6OON#Q^3<4^\7":WU>'J",E0_<,SSXP#'DN@(?*+'A
M[B2NPIF60?@UR#G'9? !:9?5;'C.1$!>9\GK!2//8-H]J<L'BA#<5#XPE ])
M]_RZQ <^D'F!@I!&T2Q,;(\@N;5-A!6[TO_\V@,B7#NGOB#H%GH](I8/S-P_
MG](!-]]RZ#%Z&<4'3J>##NA9F,SMX ,_7R# >\2"89XH87E>B ]T:[;)I<,5
MVH]G2OB&@2J1S$Q"?R($NWC^.)*U$VU'^B7%!Z:'8 1E.Z;H(/^B(/HOBN>A
MZ?;X^YA5-1BBKV'M#'/D9HFE!&XNHIG,T::@H"Q+;Y._+',]<L&1'E:!'T6+
MT3CR)ER[+\/F?D>I+8ONY\GC@81XR.:4Q(^PU;N=>RM*'SY.SWRRR_HRP:.I
MSEK/_EBGU%B9XZ@F]0^"Q8"S%5Z#8!G_?V2%=<O"?T4OPTHJH!<>S9-_61A=
M3XN*7(3CI(EA78$^YL(\L$#&S5J!-T<$LV9N*,,T6IVKQ8N&R51A_OI7&,[L
M%M[1?Y@L/Y$C-R GRTDD[\]N.'0.DR1]DC,OD?QMU7P+G)M'OY!7&Q1;Y*!Y
M%RYJV>S.=AA&FU'0>QCD?=MX6WJMY, ,R./_S,;U3[?^TZW_=.L_W?I/M_[3
MK?]TZ_]OW>J]\Q56@;V:Y5*390LR:$DABI'&I0Z34=ON&70$WJ^[)RQ@),+=
MCF8>=_J%@C;"S/J$$[3[YJ&^^CHV?-W[*+"&#USH\8+=(%;\&";3(I X/,/
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M@:2 K?7\O3=#<D.?V9K%PP>2?YRW::)8X7&$IEWHBRB8E)2;<)6-7I/A"A2
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MT%E:/Z5Y;T_7:W_!>7$=^GL3-AUTY6S&=Q,%^( ?.9ZZJ4$?YP'&35$W>DZ
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M8"$7X?]OTN,#HGR JX&$&56R#5>-',1!9_@)5?^B5MF0(^_7+4F&=IA^7$&
MB4H029T/[/W.!W ZJUTB4M.REPQ??BYY["/+&PV]Y_24-]AL;H ->\#,Q<2U
M^=0$GGAJ+^W]J;PB_]C>>[7/^\L=O8R)UOCSPZNS,#-D;3;A>=M /CT0Z#8[
MB.,#,C-8W8X1GC?N:_UP;\EZ2*U7>CLW:BI7?LII@;$0;%/)]AXC?GT<TKU0
M@S=M7YN^X3TT_'1=G8,@-)FB?9'@;N3B08XGGH*L&$XPLREV1"^JOP1M6ES\
M)\P&5[$S_5<=/#T-+QMR7OSQJN/2B='M:H+;2):_[SU G9AR#%>F#A(M9<71
MAA=<F#[VS'AJZU@)JF5OAY]&__B\2>WSPI +[3-SD]_>U81O[+_K&[D]5'";
MT2\W*]PC[C)." Y:&6@1S>0#; 1X4"L>I_8R" ^ NUC%C=EPHPR1L7M[X^4;
M,_6"S]+S/-4]IUW3<(\\#INZ/TH7MZ6C Q$4$BV1*R_!OL][3+C(&%%O=V )
M6H/1+)(56,A"=U!4'G?8,\<3[MYW"//;V?F,1%F:>>!C>_>1K'JFZS;UU;ZG
M;_NO+NK+A#UWMPQ1LOW<VR1EI=NA.R+XTNS^Q$WT;O1YF+=KB_Q^D&'C(#C*
M.8?3X55P75[X8V0K>R@NK=ZH+V9FM4*#0T5T*F+",I2"9@=:*4471#F;!=ZD
M[WM7>MP!L3'1@<S4XBJM<%#<$)!\+D(A >?#\? G;C$_&/C%X^,!]Q\FN=O)
M[^\MNUKI^H@;_M02R=RZ\:[.FN-"<$&=XQ$'TVSLW==7*L[6[IH3F!-HY+Y<
ML=S4B@H+E_ZH]-+-YDR"2*SH(2L ?Y8XIL6^#@?F,5Q5X.'X(@_)]F:]SM5G
M9C5A$AL,6;DOZ4I>QMC5L<ZZ#R45#V])=Z7H2V[:V]DNKO-)(=S7U]L!$OL(
M!T2#E_W[K@BZS"2-X)M."62X\8&$1&9/&UK>X15.M_3+DN\P-^3EQ%RUB?$^
M=^M28N7. 6G/W6<V^ "^2<?%>(%55=7E,7HAVVV?I1WI4 Z4.[GYID"C;,?;
MM_=^&NW2?1J4]*7@RL.F")<!X3F!U3Q$%V.,01=I<8HG5'WGRE2A;N-A3#C0
M9(?J'4L"%=4JK,IZN4<HAGMG?YV:/[G\!TRAWO^Y(4^G;.^)R[8\DQ=+>GJA
M;(EB_^GE;](V,]M#WAS8TW/D4* ]L%X'B<.L3WL%A#G?)2+OH,<PW1</X8<Q
MY=^Y1C8+*W3D32HSBW"6#X1%WX<TR6<Y;AG?O%K"H>(NF)9IA4UL'<\-CV/!
M102NYVY7^$ F@@]$#H]=F@C+\@6WN9#,3WV;Z)Z]4*LU H6P4F^:5J>\R[Z#
MTFFY81^>O]6DYYCY\A/KP2+M]P65E974*RO7R+9D&A6Y7DQ<@^?]KVE(%B*=
MY]4#N:-Y5,SO9S7,?]\*93:C8:7:OO*!6\60-.DMH4MP >W+,:$09NOKUJ+S
M>8^#&;D'5KI6=-I]([1[7T8=]#CM$* UZ.G3Q.QO.68\"1DW^[# 8_9[V(_[
MV'].AP9>2>G;%S)>48&)@:>-G9P [!A;FID8"QFBFG+(LCBSK/;C 51YH_<&
M8DOZN)WYG]+AHD(HMU"J9[9M=]87=CTCM0E_'<MI)3.=D.D8IG/Z3;0TF1;/
M]'!D771*R70C*N(LF42[FK(O-C%)&96N0[$V*OEVJ*56B\3'?7YW9\R@CP/R
MBJ%/"EN'?ETD"E4$3X]N3]JN>[T4B#"O7&?QSN)WS;WDH*%N)-,932DEA_6
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M6E45JOISU1^WK[#%;YD/E,^<<?A JUI:)]7]^%=:RQ_]OP!02P,$%     @
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MT/!/IW3[)GIH.D?D^MMU.FJ,FA2F[,&*<V\>&K\O$.8$IRX&P%+A3)(&SU0
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M3[;*<U?VL]NEO2\?G'/4*#<4W>1^:9[\R9;3Q*).?^-NAJ(Y1:RD9JPBY'"
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M)J84D=Q8P7\!^NW%:W/W@8V^A!6?\)L&?LY[3VNV<+ 2OOTG'!.ZC(/ZO'S
M(!';=3=[)5'W3@U;_T(4Y3HC[,$?/.4RY,VY]@$\A5&?I*Q",#+ER!?MBH_S
M)#$<JM%"HX[S.E>:OJ8L=867Y^[V=?6TY.0KN>I *TL8EM+CFL-]&.EZ/5Q[
M TK<>DLK@W(ER]N!28Q?(C9?O,+.)@UKKE+JZ[TW_L7"7#[%W7Z3ZE6(TEAG
MK8IXZT&]P?'@5<UFGRE3N04&HS?MO^J[7[+T^2YKN>(9H>OQ-;"QDU+1U/!
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M_H!>9\R)W=S)535_N/?:8N;CC)%QK%'*R07Q-:A0&!& Y8$:HG(>0Y_14^]
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M]T.+*E(Z@"T;K:G-%K2S#FC38T":!!J;>-L$@R4YL)-YX]HPC2T6='%I?,N
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MUK7G9*,819'?4&HP:"5;PS/C/[9<VUYR*L+R>&:+,J>^<"RE,,\VX:GZP,K
MR9]G-SL+!_\E/O3JQADG\>:/2!LHBZP?)H]X6O!?@_[8&((D3X5=Q" _\IMT
MQ]TP+\NU\%1][5^VO>_4R^KZVH1.SLV[\1M3+3I&4T^HR/M[;N&GZ=-\,'$T
MR+EG6'IB/M5"J(!T&!J,;Q3E78;5F-)C6[BV P6W.PL=(Y\P3=/5HK.G;?WN
M]9?7,<&TH'EZ-!9RH \5<_SA2TQZ+$W&4NQDXX-)> 2OWL5T'TT.G&]+Z*TZ
MN'NV>'E+UK<=*3.:5[;F#FU+[K3 -V-A#2I/_AJ'!!<^YA'@,$B=_9LH\:$/
M-J2WJ9L,F 1AUKP!4SH^<'ZZ7_/%MKR)?B+6\O(QQ@Y%*PY\>YV'LH2*/4PB
MW^3TX.2W7*@5D0J".A$)#%0Y^2B3)0#* NDBA"9/=;Q<HVJ$)N/)@R>S67[7
M?VK:_A;R*39[I%71*CQ5ERQYVW:N2><$OPN.G\!*DDY 8G70J\X1Q]%?.#G_
M);<3U5[3;Y5'@O4U_'U32>?+LM.&0D[(&/UEU5R"C<=7%C438K&5R /N=AC;
M% Y%"-M G^"KG:VN=[HBU_:)6#H./RK;,)5QV/N9H9&2R%06P*OFOR))9;FR
M@M :!_,IX+D-&$9X$531TUS_LQ!*M8=SGWJ"+;CBP+4!-;2S6:ZU*38Y/_1\
MC-PKG_G>\SW_,R0J?H+&DR_F9+/G68ML>Z8C*],,%<7Y_E@EFE]2JB@L !CT
M9KZ?<] COZCQT2C?;^,+(Q85+4OA>:0<TZ?BXM@C07CHT/P0K@VL.'*=NQIU
M7,LMOM51ZK0D3S=OQG+3YQ#]RZ=NIMNFCQ"Z+@S>^QGG*O%VQ];D\@L4O4#D
M+0TZ0AV6YV@/F%"52$*P3V@P$RO;NEYU/I%GQ51C!9UX'6=T-W;>1/+)_0-%
M(@=*Y#=NJ%-YC'G?,]33GF/&KVC4)'>AU\<E+JV.*B:_07"#U:DI6]_M>X<H
MW@_(4=F%GY6;&'/_<K9BPYGM9EZ:US@G/N)#>A+QT-'44:\VB@1Y _*A49-M
M0FL_^6OU.5SR8!:54TV-^_3.H+"5J%A:]32+]#&$G-]]X>OUD2<T1_(&\EM"
M96T+,37'DO_44IVTH[+/(I*]QWB*/9AP[N4#^C'W=8=-6[NN&+16KU%[=WQ1
M0H8[M,IBB9.'YID+N16LP;2](1OS?&&[JSD&20ZJE\>W090DDSWB3@T5/;QK
MIQV>?-D[:! NK<_*CVU"_20F$\J5;UF*D-OH%:YS:5R[651D!STF@,VVQB]9
M//Q$U,$HFWU]OY)J^]T\Y,T,\A7C_%[%,GUVJIR8OH!U1P;4Q2!"*P7&I<ZY
M/(.%6\Q];UG631 21GS+]3.\-M0U5%;WZ?G4QCA$AZ3LVO!  2I,T?WQ"H2W
M+,W9G85:&47-R9H38ME%$5X,\>02'@%:M/TT7U;J]>EW%\&XE=2AXE)6\'[1
MB/_X3455;,&:R+*N3CS:BE#UITZ2Y#K ?<W88'9GJWWP47JS.9WSZ#TX7#ZS
MH\"L>*I3H]7LP7K_NHSU98;9=ENB+=>@$.%11I"$YO(7_C/*2901*-O LVR'
M,-^Z!TZG,M+&&CZU24 W#<9NKUI-"L@K:I]7(+=CH4/X6$N93PV23[^;#^13
M/1P*>2YU=4FM9HT;JZM]>W-?F_:^F?LZ]6I!/DC\OD9:C"W_\)^[TT5021#C
M2_*%NZF\,#B6NS.[U*L]DRD VN\IC6_O#[Y<>A$"N]K''XE^<OMBZ[C=4_/U
M+=\OG29CLP3( 1RZT4:I$+O#%8M(G1![])2G\S%X,FD_U)@+7MD=@+A7=FXW
M(QK4)_KH<WU/'8C>#0QI.8EW4RHSYT!NJ#_:2?2PG'9^;AAVN*_EF =/^S/*
MV_%2O,T#U49/(]+[0\[<&U\(NM9ULHWFE]V5^N&#B_?Q#U*EY)C!&^1WZ.4Q
M0X,<'#NEB*T[X=<JW<8^47ZF1AG9SL;?^KWATO$@DS-=@9ENMQ?M%=1B[BB<
M?W[HV<8,D6O=_TN^+00%P_\-4$L#!!0    (  !$<5I36R1-T(,! .8/#P 5
M    <&%C8BTR,#(T,3(S,5]L86(N>&ULU+UY;^0XLB_Z__D4?'V @V[ G-9"
M;7.6"U>5J^&+:MLHNV;NO,9#@JM+,^E,CZ1TE>?3/U)+IG)3DDQ*KGN ,^6V
M)4;$CV(P&(SEO_[7]Z<Y>.%%F2\7__V3_R?O)\ 7=,GRQ>-___3EX2-,?_I?
M__-O__9?_P^$_^?=YT_@PY*NGOBB N\+CBO.P+>\^@JJKQS\=5G\(W_!X&Z.
M*[$LGB#\G_JU]\OGUR)__%J!P NB[K'NK\6?21H&B'("41@G$*$P@%D21) S
M7_@^$8($R<7CGWW?RRA//>@+CB B.(!$( :I1SP_(($(:5@/.L\7__BS^A^"
M2PZD>(NR_L___NEK53W_^==?OWW[]J?OI)C_:5D\_AIX7OAK]_1/[>/?]Y[_
M%M9/^UF6_5K_=?UHF1]Z4 [K__I_?O]T3[_R)PSS15GA!54$ROS/9?W+3TN*
MJQKUDWR!HT^H_X+=8U#]"OH!#/T_?2_93__S;P T<!3+.?_,!5#_?OE\?91D
M]JMZXM<%?U1S>\>+?,GN*UQ4GS#A<\E]/5KU^LS_^Z<R?WJ>\^YW7PLN#@\[
M+XJM4167F>+2CQ67_WZ,V*]GL.^(WVJ?5P?,U>+>N.)Q"-,;9^P^2 W!QV>X
M1^9LEIL/ZFK!IOIVUZ3.9GU\CEU]%LL*SR?X+#9D>BS/U2\^R9]:,FJ@ 65:
MTVE5=X]5_KWB"\8;;;DU-,C9?_\D?YJM2OB(\?/LR_UO2[E5+M3^]WY9/"^+
M6H&7EPMV^2AWS9R7]YRNBKR2/_W.GP@O9HDGMR^4)C"3VQ1$3.YS:2"WN)@F
MC(F49)B16;7^[&=\ ;_<=QS6;)S-PT\&^%1'UGG!R^6JH,T.*?E2UD'#ZO]\
M^=/]G\#CFBGP'_CI^3\!5LR\@G+-RW_]NA%I'*CG/P* <S/L[L&&&]!G!^ %
M QU#8,,1^*/AZ?\[BN>2;E&?*S-C6>PBLJ0N$-FL[%)"4L,A<$EJ3-KA)38!
M^I7/J[+[#52_J9?W.1S\NO<171:=Y+B@)^:J?>)7NI16V7,%MZ9-%,LG9Q!5
M2V??7S.ADO6?P+)@O)#V^@$8]M;2[3-7-!:/G[@T$C_EF.3S>O0[_*JX*#^L
M^"4IJP+3:H9CGDBSFT$O##A$OC3),996I:"(2@W& A9Y)OK*A/C(BNIW7"E8
M7\%2@)H;T&/'3#T90:JGE\8"RDPA?>)ER?D%6'/3('6QANKU E1+0#BXPSF[
M !_SDN(Y^!O'!5CC^T?'IT,E90./(^UD1'I2M60#RJX^LAK#3!$]8TIF#_D3
M?R<IL,]<#I93:=;=5TOZCR^+O"H_EZMN%_=0'(LT13#*,BS/^=2'Q(\S2,(4
MXRB,/3_D.@K(A.C(BF=#'-3404T>_/SY_DOYBY[B,8)P6.&,!8R9HE$,@)H#
M< 0>Q<5I:\<>)=9ZLNKM=W*TMJ@;H08'46L^*H=6H@T C>)5;];:U \:A]2_
M&XTUB2:UD:[3H%;OVIEP]U]QP96+C[U?/CWS15E_-I=%(3\.KCZC=Z^;1UK%
M??D-%^SVN38N_R*9XTR:F%??GSFM3]3J5[>K2ODEE;/WKURY:.4STC:59[?/
M_ GG"_G[]\M%K?I7>/[ BR=_1@+L>3[GD 1> E&<^!"G$88AEV=;&L810IF)
M@?CCB#;R+M P6I_K>,NJ,J5>Y*\OP+>61X ;)D'1<0GHADTPSP4WLU1_''@U
M[> ?A^'Q-K]:@%:/]Z4$/3$!>07]YUI102VK,M!K:2] [[.ZZGU6?ZD_JY[4
M%Z"3&[2"@[7DH"<Z4+*[L]M_O.ET="KX@02;],SQ \E]Y$3S W)HM^O?R!G!
MY=??>?'(B\]\KESA[Y=E5<[\%'%!!((L0P@B1$*8L9C!F/B)"+/,#YC1)GR4
MTM@NF9H@+!J*<JOKZ4*U22Y*P^WN.&1ZNX\3(,PV@Y8D:&B"EBBHJ;K3PR<%
M<Z06C].95$N=%'=7:9Q^P6X-7[*_K\JJ=J0\+#]SQ7X^YS>\NE[(KYU_6I;R
M]^\EY;MB^9(SSMZ]?I%JZ7JQ]LM<TBI_J3TR&R>M(#X6ZG3E1S%$":,PQ5$$
M$Q9B$E#! VQTJ30&DR-KCA[+RMPI.J;!@E=@+AE6OU4_UVMKI2RH? &6:[<F
M7C-LIF!&F4\]W?36LV2FUG8F:,TOD R#AF/PL^+Y%_5GQ3;H^%:F[\]?FBG[
MI>>*WK _BHMY3'P=:==16)Q4,8\)\JY.'Y66V7; >#Y[K^[]UFM>T#05"?5@
ME";2A.,TA"EG*>3"3Q,>X8!@+1-N;^21%6]-2V?]G9!_6.>=)969HM(62%NA
M'&7^@!8H.?W3X_+E5_E.HP#D#YMUOS_2)(OUJ #="CO^@)V5U%P['KZ*>NU?
M1 GYQ:K+QH_Y"Y\%<2R\6*X>D:G(T<C'$,O?2(,HXFG@AS&EL8D99,7%R,OM
MX2LO.%8$S>P4.T3U#)'1<1KWSKI&L[FR5HRY,R#.PL61A6#'PZ0FP%DP[>[Q
MYPUF<8]]26FQXNSJZ7F^?.6\ONRYDU_F5TGX3GZ7:^+O5T4AB<\$\DF ,(&4
MQ00B$G"(O32%-$D8]D+N"1%I7VB;4A_[%-:P SI^VJO(CB.5"[ PN+HUQE;C
MIGM,Q Q/1!I@]756R]"8^!G<@8^)H]UEN&L\S:[$;?$8O!LW'G2Z2W);>;=N
MRZT'L3,KU=E._?_5/U?Y"YZKK6!S3:_^<+E@V[_H/=D$]<NC8J'VE ^\^5?^
M]WRE[@"NODNN%X_\,Z[XE1!<'FF2)$MQ2@/(8S^#"'D>S'!(89!BC!"A*.5X
M5JUCV4_:6=.R;[15'(G['W)S\PJPE@OEBE-^N8O&.\<W7%_4%YG%)K9%/6!F
M^4X\Z7HF\X\[E8:'Y7K6:F_=57_6>M%(S2-J&G=^N?U&(Q3HI (_=W+]<@'6
MHH%.-J"$ XUT[@SVMYD51Y;^Q,Q/>D1XFXG9/5N\$1=V>]WUXJY84GD:DAS)
M8PY5S'W@+WR^?%:F51OTR+V0\91PR-(T@4AX*K V8U"D81BSQ$<<&87W:U$=
M^1!RO0 M$Z#CHE8_/3[,=A ]*/44OW. S/2U!C8C9!09">U('>K1G%2+&<&P
MJWS,7K8,*Z5?.5O-^:VX7C N\D5>\4_YB[H"J>17E),YORQ+7I4/6/XX"_V,
MB##V(8VPM&^%(#"-0A]F?I#$!&69EX5&H9]&Y$?7(AU-4!-55DC'%*RY G_4
M?&C>>%ABK*=5QD/.5+V<#9IY1*&5[*ZB_LR(3QN99P7,7O2<W2BV1HNZB'W
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M9!X4&!%$?1HGH5;0GPG1D2W-C@NU 7=\@"N3<E-&"&H8BB/@8J8BAB!I0_B
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MD-BN,.1D1#O3\0,77)X\F>HKTC8$^OY>_G=>U:<JL2Q4E,ZZ?=DL\N*$I4+
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MBB,!"?<8C%'FIS$.,IYFLT7M#F</!ITPCY/46@-9LP;V")M<P]>Q'$L!F.0
MY"T+@"H>##ME#N"GY\@Y%X[S"G]+#!19T-%M2E\X#40X)9V[0(2CE*8.1#@E
M\H% A).O6&1+8[*:X^)37E;U/9)Q$8*C XQL++5T@2)\87H#>5SJT\<9)P*;
MK<2^K&UJM-M@3"VY[%*ECXXZ7;[T*<&VDJ9//FS9G0OG17WY>[UX7E7E)U5;
M/&QOMSTD3R]"8.@%,8:(B !FG&(843^(!4>89<*H,==Q6B,ORIH4" V[< U
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M,>B\8NDX%8+3:CVJ'%!UH%2%]1=4VGZ-?E'U*S<E*56)R"C)_,"#+/4RB$C
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MA0ZFA$C=D:;0]TB&682)B+%9XPYMVB;KP[H#:-WW<YU.^>>S<B@'8-33&Z-
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MCT <)0%D'(?RX.6CB!H%[APF,[8:;8F"YX:JH>(\C(RFSCM;7D-UU8G:$KP
M[UW'<@^+Y$K)'"8RK7X8%'1O:0\_;>&OWCEW73\]X[Q0_K4/>5G3XDS=S*N+
M^=^7C,^[7]>5U%$88)'B $:(JG,4\B#&G$(<>T' *4I#JA^Z< XG(Z_MGML
MUP4,\C5S%X"MV0-4Q3 (R2!X4AQN_F90?^S\6='P<D^%M9E>V:L3<=V#></9
M)E0$_-[ W/UMN!B]8Y@-W.%3P6WG&Q\9=C-7N0NH!OWF9Q&8SHGN H<MC[J3
M 4=JP%(>J^Z_3JY\SIMLH?)Z(>W4?,EVDBS;]$M^5^24SR(>1/)PGT#Y X4(
M$P;34 0P8"QD-.2"19[3?BR.!1AY.VN94G5'\H*S"_!M-W&?M]R 9\4.^#E?
M@%7)P+,J"J7D_,5Q3Q?7'T 8>")-< 3EL2*&R,<(IIGG0\8"[,6,>J$GS*I+
M_<B?@%6AJJMF\O_OFUN],]&//%^&@0 :51E*_;(,:ZF G/A&K@,%&CK90"W<
MA/U]1IJ6J=K]N&;_Q^K^,]+D&#<#&HN/LPOA'F3JOEK2?[2<'0A!*W<SCGT6
M)GZ:0$'4E201&)* )3!,DXB$F(3"URIL/PY[8\>,]1-8-SW(5 ;RNAF-XK?3
M:-9%=%W,E.9.]&;X&^XS_9*[Q[>2+?@O#H;&EE,5XG6(I_OZO"Z8>ZNRO0Z!
M':CFZY**>>KB9[6;U#>+A&&?\XC#E%%Y7!09EJ<%G\(PB(@OT@"'6"L&=VO4
ML16E<O*454[Q'/S.<;DJFO)<)K>VVR@,:S-KV0R5D)U81OF,>V*<D<NX&6NR
M/,8]]OLYC/M_-$^%N5DN/LL%ZGLD\J71]5 \+2KV<8X?=;->C@XP\IJX435'
MU ZF*$-_JVR=JKBE"M%PS7:TPT ,KQ5G&)BM'3WQP1^*"T?)*2>EM,I#.3[J
M9"DG)P7K9Y><?MBV6#)=/G'5*Z*YM%>QSZM\\=AFP\G-\!T72U6H63WW@+^K
M6_ZJP)*&G.OBM0Z-5F655.&YY7Q>5\QOZK/.(BQ(PK$/6<8"B#"/((G3$&:!
M\-(H#HG/D4E,\XB\CAP0K7@&I&8.Y#5WH%+LF99C'F^N],X9/\@,F%[YU8#_
MK-C^I4G\WG .-JQW$]0^7W/?5)';<+MN8^2R-O3HF#HK)ST>IQ-7H!X=\OVB
MU>.3M#+#[OCRAB\O7Q[KI WE#+M\J@RLL(/O3V"$W5W=@AOY_YTWN2:_X[RN
M"T(8V6*'T= RQ<X&PMP2.Q\#4TML4$A;0^SPH%/:88-B[9AAP\^Z#(^2NJ!0
MM0BN%[>DE,*4M$XBQE1.D3*V9UF:98A1#&E*I('%_!BFR$?0S]*$)A%-,Z+?
M%MZ:C;<,C,I;WM1%DZKY7E\UOG)<E)I7C&?.P+!FF Y74XMH(!JG8TO^ /J,
M@8:SB^$2ZB[!=1']Y!+D$4*?S@/;4=B3+D9V,4\G1_\! IYT$="+=M(>S;8K
MK^!%P9DT$KO"QCDO[XJE-"6KU[NY2F->,%6.XOFI+L/NASQ%C$#.8@Q1''D0
MI\R#02BPER6)CSP\6_!'Y;G1.X@;<J"UQK)FC?7YT%YB'_/O*K"H3NHT[<!K
MAJ7>,7D,?"R[\#:,J,,LZ+%R 3IFY$^*G3K%<<V0RT:\5D@X:\5K1GWB9KQ6
MT.RWX[4;QORP>+NJ2JGQ5)NESYPNY9GC]7K!;O"35A[S\ AC'Q@E"?USX("@
MIT^";F0T6^8]FJ CJFP+EK_D3'6]&93?Z QX6CRK4^# L).= T^+UC\):CQM
MM[W_MERR;_E\OK$GE-=HQA(B?#\*("$HA<@+*22"8<C2!"5^2#V>:9WUALF,
M?99;$P/T*RX>33W@1[ AB$4>CSW(5*=O%(8^S%B<0409I4+^G[1W.@OG81*(
MMJV9AQ\&*3W[Y?QOPTQ_=?0N>F>CX?[EQH;(L$B.[(TC1"8U*X8%W;4>3CQ]
M;K#BF6G"FS XJ?,8\Z,,1L23ZSK@,21>FD O\V.*XD3XC!H&VSMGTF1]V/5]
M[A<[WDKG5WR4H&,9?&SNN-9,JQ<^J(?EWVYXL[3J8/SZ1=OX1F>3JZ>4WG;"
MS!3:\9G:%%Y8SY8X,%L=SRIZOIFEB>(=76/K/.;1&8-O%/?H&N#CL8_.*3GK
M(:@,YL=%_B_.KIG<<G*1XW51KKJYDSS/=CN3/+SVSK5UD"9GJB1<XO, 2XI0
M9+$/$8Y\2#@-810D+$LBSFC&3:)+1N)SY,B2YLION^5@5>!%V7@%SNXSZ&2J
M]!3\#S !9EK^<&_"#<^@SW37EJQC^P)LK%[E?.OQ#EKF'1<.'!G?\;H:.N'R
MK?L=NH1:HQ.B4W+.%/\]?\:J3,7\=</?@])6F'9)5:J/5ZDXDC8J+S>/S3Q5
M,(UZ2M\3><B7VAT2E$3RS)^@,$Y1@I%1SI);]D9VG/S.BT=>P*+M=LA;1LY6
M[^=,B+56GPAF%\I\PVI?K_>9O>@:&I:-&J\9[CT\JOYV@.1X:OL<YMY:6SL
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MDS2U/LRL^3#[E/5-3OG[KZH.U5* ?)- CBU2Z$\#2#WL,]4F@*!4J>P PRQ
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MD2]@QF)?%2A.DXCZ0212DSMS?=(C7Z-+1IHR[\\M*RI&,^_8D.9[QX?9RC6
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MST4HQH3X28ZCD(%Z[I@2'CI.M&.C2K-I,_*__U<6!NE_-YH.&#0RQ=4PC#0
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MEYX.?A^G'X&:&H[^ALW,DX_XWH#7PLMSA[;90:W7?]-Z_;]6K[\ET\2KI?H
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M&<\%B7,?)4$2(^R' <JS,$*,Y0D-<X'#%+_K?1V>J^#X9OXN*27'+TK02(K
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MXSE/.*:9R'.(=]N YL!;ZNMR\8B^*A-*^T'W@DHVZ0XF&)KYEATC ]NBUJ"
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MF$9<BC $]=QSQ]K 6NFSVE-$J@>]Y4)X;[4Y47'A2<5&]1N@;G+X6LR4U_N
M#=-NFA-OQ]C$VS*-U!48:;8G7L/JF_K7>:6V=),UI1%_**Z5*;?YYZK=]<1K
MQ&E>WYUZ?8U(GI:I,NOV=*<[A>D><$<:U2%CHZI<]X >ZN0!*%@$%1X?5\T
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M55W56?\&6,X)Q-A,MPV''$R=5:!=MT#;LN+M>)G4U9*E5[/CMA@'CH+#(AT
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MA9A>9^@,O"/;Q3L_5DOV+_5]G:E+P$_W/_YNVE.P#RFS4]&!_+#MN2=Z17&
MN6@]4CDZ%L]1&?58[!'U\%CL^[C%[$YU?^7Z#OME3AZG(0_\""<YHH1@A!,_
M1YG %$D_]+-$QM1G1K'YHY6'C@5L:'F:&&!JYY[TW7ON(IF AZ"9.+!YG:=8
MMYO6N;?2>+,Z3PFP-ZGSY <LZ_6U6K]Z>2D$FU7>TN^Z54#YX^K[#W-7G/%B
M ^^.^HQJ,^#5''@_*1Z@)U8_-&9GEU-48/NK#Y !SC1C:5U5\_?2&[>NWU3\
MHPI_XP>MDGC+U9ULJG>;+V\4Q"%-@@AEDB4(^WH\I601BN,HQ#+G:1H8'8'G
M" P=<U,4O3OI-31!R:;'8'3O9!<BPC;N@716T;<38H)2:"\2US9CUNRE0M-B
MSXK2DP5[_-R82:]GN3[(<3W_.2<]?,IM,3DE89QA*5$2)"'">:2L9AP0E#,L
MLBSV(QZ!^G^<(S2TF7#0S*:T;V9W#BE#R\"!_$"#P$;T2_OX',DU3".?\GVJ
M[ON$[6GE<_QYRTU+JEZCVHKXMM9*0/VENCGK+&:=5/=0D$6IZ&C-3P-!J<A2
M1 )?(BPSB0A)U7_2/ P$)S(A(/<4A/C0F[MVULPJPO 1&%9P&N[V@4 ":@#2
M-"+6?$R\FI/J%S5P-3.ZB+?%CD/58 &"*W4!(3VN"K$ Y4BMV*QAFT!/5Y]G
M)9LORW4A6M-V8T&#C&,%?9HI\R"DB.0I1BR+(J)>AY")#\N;/TEGZ(O%W;=?
M;[X_W'[Z>N/]N/EV>_?=^W;W</,#FC%_&B,S5>% <IA6J.I==A0=C\PT%,M9
M-OQI*B,GP7>*>IS[WOUQNXVZ[>_YBR!ZW2J%:_O+O\U$H99\>ON\U.V\IHE,
MHS3/,I1QJ;:OK^Y$),LC%' 6YAG!0A .V;X@Z@-OZE87X2UA[_>:--#FAX%J
MMM\'@PJF!4ZBI(MDOEW]VH\66!U82>U(2<!HCZHZK& Y5"AVB\"S3?2D[U=1
MO-W)FZ+0#8QW6NRK85&[Z3+#?>\WU+49K.@O%V*Y+N=-_NMA(_3V*?G590DW
M% >KQ TC J/E<$#$;:=S@)ZS-W)WO;6_$";JK)RINB>3D"4Q8F&J_>8^0QDC
MZBH=!3@(,<XC;M3KHH_0T+D=Q6S!9B^ZI4M%3G_W%^839'MA,C=T+Q7>PM)M
MSP;31)UE7)G*Y=#4/4EF=%NW2]A3QF[GYRTB7%<OJ^6BB7+(/$DEPQ*% 9<(
MASY%-%)V;:IV;1KP4' 9FD]RWBT\=&Z'I@29<=P2V2!^92D(;'=51*P&-K>$
M@<QJMA/*+CK5_8* $YJ/&>\>SMSZ_(ASF8^YW!_)?.+?[8[;!\&>%LOY\O&M
MFG-QJ][-XG%&Y^*J+,5JDRP8)2'CL0P1D;$.0/$ 9;F($>5AP$A,F?!! 2@C
MJ@-O^\_B5<R7+\K,7&VY@9W!9MB9'<C.$8'ICQWY9K;0C@&OYF" E!60S(Y.
M;C.:HQ[C(!@.SW38PY;)UL62K]GJ-Z(; ZS>KA@KUF0^305/29H$*&1QCG 2
M)8C2+$=I%N8R#T(A>3Y]$<5LR7^L2+$R4PVGB4&^^8<DC3?!)S*O\H[)RJ/B
M<;:H!BDH\[Q>$)AV?1HSF>8\SS(?$1K'""ND4.;S5"E2[?*+HC0D<8/9S<*P
M :\KQ#8$;? 2"^X8*3.U>;GL,#VIOE4+K@M(M'?NYL^5DEL/8JNY\#9L> T?
M#C/6.^5TE;!^FLBX^>J=@AZEJW=_&IZM?K-8S=0ZG*OO0'F_+%=D_O_/7JZ7
M7+?7Q;GP989T!WVU=2E!1*0)"HAD/ LR$7-IFKI^GLS 1D]-V&LH3[R:MJ>(
M>YJZ>6)[!U#=.]>=^+"=:RLY* >^7S"KA/B.94?+CN\7K9TJ;_!I&V=#>S)Y
MV\ZY?7XALT+?+*^?=.^BV\6#*)ZG@F.69!%#L=##[Q+U4Y:*'$4L(WGD2V:8
M;F-#?&BGQ98;;[8SU8GFQYMM&9IXK&))IY4H(L\0QP 0:Q-/R' ( KTE._ .
M[SG>;0N\FAOU&>]A6/ @GI?A0+3TSK@%$^C.L4.CV^4#7'-$MY"=M/NN(\LU
M+-3U;B#9G;Q;KTIM.ZLK59T>=2=UD^#EXF'Y26Q2I7X1Q:,HIBDGH9091F&D
M!QFH_T$T)0(Q3GWNJW\3H5'_E$N8&#H*M.6JZA>RXZO)FM2_915KWFJI;J.;
MO$JEQY\K_@#*R/8U&&CT$<"%:?:_ JX 93\"OG9*_V*<_]/1 7 A0IT'@>W:
MXQT(%TJ_=S!<NI;% ?%570Z$.-.*1?LSORN&KBA956DT38!;9P&$.$M1)G3O
M(Z'."8(Y0YB%-&8LB")JWK'2AH.!CX:*!X_J_Q2Z7H1LJ -4DQ6P!OI^:+A@
MRK[F9N*=[Z0T\313GN;*V[(UZ<LZ<(0G0,\/C:N=DA\*7YB&OP2;3O5NM?!X
MNOT2N?<4^T4+V46,KDGYI =_J#]T2\M7,J\JKE;7I"ATTZ4J&7*:BE3&F1YF
MG@5*?_NYTN0DBU$8!CZE4<@%Y[ .@$9T(1O'JA^@)E\%")C^0>P8@05&S$",
M<C]AV(]1[.>9NBQQB0@/L1YYPC*9IFG(0"-=G4-H4PIR#L +0TUFB)I%GISC
M!#O[MA!5/[0XF&B,-DS42>7NPE @H1U%I<QHCAJD L%P&+."/6PY W;KR[F3
MARD!MPL]*'DQ6XGY[%7PFS_9?*T-_9^72_[';*YCU+%VOPB483T_R1=*HT18
M_8>J!QD3@DO0_*1+F!E8T>Q8TRKET)&N]M)LRQ^J&/1^$AL6O<>&1V"%ZT7O
MQDPWC84X3&7M@WV48#3Q=JRAKS786^Z\GWO!AL^U=8"2J[&WE[ R[E1<!Z =
M#<UUL2:\A.;Z:?%XN_BB*W-JCP=?/"K%_/?%:[GBVV[A/Q>+%;]=W!?%/PI@
MEWQK @-KO7\(4B!=QX'T3YO S&SAM>K0=$7.7C/ZGW6&1>W!NU>65^'I9TOO
MX4F9&Z007LME5-DE2DI1J@?,&\G:OX]NK3C:JX"IPU'?@N/Y 1?#:55#94]U
MM,*JBX%I5UM=OIA%NTZE7=5[_T:>U?T<"YSY)$!ARB.$8Y:CG F,:)P'%',B
MB1\;-^O<K3MT9D1-R=.D (TZ6W)WJY,+I($I""-!8"TZC]FV:]#96F>\]IS'
MS.\UYSSQSRXJ$*^72H46*VV1/"BPRJ?EG#>3TCZ3MW*:Y33$5#*4A5F,,$XH
MRE*U4RB6F#!.91P&]F6)/=0'WDI;DMZJF0W'%=%+"A7[T#2[WPR&$6R#'I4T
MMCB9>#OP-H/U/G>!=V&IHR$(@]0_]M%^QZ)(0UBZ*R5-%[%L(*8#K%7Q1KO<
MO36$\=/;[B/WY*URTFMKL+8,=VR6=ZLG42A3<''WHI<HORP+*6:KM6+Y-Z&[
MF@I^I00ACZ(R(S^3E=AV)IAB/_2EC',D&0T1ICA2&BT,49@',2$RIC@!=2'Y
M&&(-K" ;5IJ&9WPYGVMK_$44=1H$M/?9AX#,M*O:AV!V..5>,=\4P^WUH6B)
MZ-$WK_VY1LSZLC;97-U:HGJ5K-Y*">LUTDZ\EKP3;R.QUXA<W_@\+73K8NBP
M+]R'>HVN.LY]#*'&[67W,60^<Z!^,.XLHRH+W3AT6;Q])W_\HM8M9F1>3@/,
M?"E8@**<8X1#%J*<J)_\-$I"G$91(D ]/4]2&3H=5?W^J5)ASQN*P*#&26@,
MHQ67"@P,0VS(33Q%T-M2G"A5NRP=&NB=<KD*')RD,6Y$H$O,(U=_YX?MMN7/
M9+8HOZI7)\J[Q<V?.L=E/2N?ZGB"MN2G44RB-,8^RFBF;%N>IH@F0B>:9(&Z
MHL>,YZ MVDMQZ!1!1=I3IHC8(ZV]Q5P1A^W<?O3\(-0*+D<T\".$21PBZH<"
MA6D8D#0- AR+Z:*:#,\?Q@8QKT$\(O]!L333B$Z_7S#MJ$E[/VG:_Z%1N3E"
MY7,7*F =:2RI(WW93V]4W6DL_J$>-7\0'A?]1W&SX$W4X3#*</U:\'\4A[$(
M6%C4=OTQHJ(ZN<PP_G:M8W?JQRIZMW(7!K6&OS\*.@;R%D'0P4!W'/6\%#ZK
MH*<UT=%BGI?"T@YY7KR6115*U;O]Z&YZ\Z?^4=0))T+QM'R^5M?-&:_2J)=U
M6W<I"O5MG/I)$(1QSI'(L@SA2%)$?,G4?WQE8:I?$C\ 6$ANN!K)?!)E^5^-
M$XQ6-TC6=I:)FE]/- Q[^JNC/M)B6<>6-CP#2C(N?VO=^G+$EV _8NZO!CF@
M)&94Z.WJ8UR] E>UD,X@ZRR;N9S*>#4TSA#9*ZAQMZK%:76[8(6NX/DLZC]O
M%Y_6Y6RAU+!BALX6%2U%6%\)ZMCECH66O[4\\Y%M8= 49W&28*(3?WB"L+H-
M(Q+2&!&6XS (2)(D1MD_HW(]\!UA1_Y@-\\W# #4Z6AOTN"@^XCO!^K6K3GW
M?MK(\!^ZU\A&#*\E1Y6HL7F/>WRV@WOE^8^U*B _XOL&G+(?\;W;'<8?[?W#
MCNZQWT/G"3\:,^,9 F/CNV<OC$[\@I'D;8OF7FVPQK?$8I;Y-&$HRC-E#"1Y
MC'(6ZIAGEDL_E]Q/C5KR&- :^ AO7$ND<BU9#"8_ Y!ATHP;L>TS6;89*JTD
MEH%FD7>+Z7(*^1E*X\\?[Q;YY.3QGD>L&S:_B&+UIA=<72VJ)(H7_:[_7@JY
MGG^=23$-U,;E22B1"%*A;/P\07D49(@F,I$APS(+<UCQO0%5R)?<JO2^)J7,
M<6F8^P^!S&R/.X8!MM<WQ"=>1;YN4[QA8.(U\'SM@L>F-[&IP.X:%?=2'+MK
ML2D$)UH8&S\Z<H)QDV'5BJY\7\[G7Y:%_L=ICG&2DC1%64@IPFD0H\SW"9)"
M)F&4)*&A?V!8-@>V)G9C?.N^9R,E_':_&4-;Y-WQMC=C+!-RMRFW[8#A[YI[
MKV'?I1$T*+[OG2G;S>1?(_/5"&AGF:QFU"S[+>TJ5+XN%X^Z<>LW/5-.T2?J
M=].$$DD9)H@*'BM=S03*4AHB$N,L"M,L2H719"Y#>L-[83?4O5(L=!ET-4%O
MXBV$,G(6RP5BZT(WSP.V!^I!T4RO.L0&IB#;L%04O8;D1/UUT8<(O!>0F9RN
MN@#U4!NW_X^9Z$>=?PP?L\U./_0R73&F>[EMO[^Y8((&<8!8EOL(4\90)@..
M2()YZE.)0PS2 KT4!]8#&VK>2TT.FK+>AY?9?G>*PN4QC]G"V^)RWX.+14J[
MH:S.TMO[Z(V<ZFXH_G':N^F#MB7K+\MRMBKKGCD[;3^-HBS!4<01#0A'."(8
MY2F-$8O2V ]B&LD,5-5YCM# .WU#%EIZ?@85LXWM0E;8?MY0W';$&N+<[A/+
M68GX&3(C5X-W"WM<^-WS>;O]J3.UM]$;MIE3U4ROVL9OOHG5E$8TB;(H5\>S
MKWM:XPSE'*>(2![[$<]#EF>0#6M,>> =O"W\\4C/;+0+ 33;VX/  MOL5>%)
MBX?-T+C)=IQ<J\VRXL2=!@ +[T@EF-,=54> X3A4&O %X$495_R?#\M[L=1.
MAR^+!_'GZI.2X5^F-1=G'A_:0.?_7)>KR@/WL/3N;^[V''>Z\GVYTC=W\^*(
M<S!T[WI'",#VMZGPWN^:&:_BQE&A0H^L5G4(Y]8<K<R@1ZAV%4'?1^T.\5^6
MKY6#[W:QF0*JPS7-#-"#292'!G_;/1]&<>X'C" _33+=7Y>B+(@$"H(DQ32-
M:<J-!E@XYFM@7;#A4E]085-4=6/8XWNNH=M^T#=I9FN\P_N!::IW>C5@N\4Q
MD(ZL&E=<C6KS.(;RT")RO;Q%GOQWH5N&L-6Z4&9971-[7\R8N!=%%9^9QB&G
M>:X[7.E6 #A,&*)9S)!/LEQ*P1*:F,\1ZJ,VL'+=([^I76_UI *WI#*#L%O_
M.0<&IM7V,;FK*]>]BKBGJ-=Q8I=H -*N7:)BERY]&3JPY&93:3N3DGL7&2^9
MV%2>O21@XX>L(\"K@JCER?R.SF>/U;?A\UK<+KXI\_?A#S%_%;^HSSR5TR (
MTX3B $5,! @GNE U3R2B/)=QS)5MFD; 8+ AZ>'C084>,OC2=#.J)A#.JBL8
M=/2..9IF-N P&,$48HL';\?$I!G0>$]F?%+7U=\M7(Z, 4ON+F)L2GCLX#$0
MD!-Q9.@*=DIEY\)0!MG5\[)8S?ZG.=TR)M(P(7HH#$<X2R*4LY@B&D4BC:)
M1#ZH'N LI:%51HL43$6<Q\9,(SB1&.B1,A$6O,%[!7&TG\_3&77[]HI[N%O[
M'[#;G-^$NEZI$TYH]_/5*YG-=2#Y85D/:JV*"W2C8K4G/I%RQJ8Q2PB/LP3Y
M/,@1%I$Z]@/NHT!PFLD@SWE((5L62'_@C5S1T/E?WKRKB9\3),TV^(#XP+:]
M8L2K.=DT]MIRH\_^FA^OS5 UUG/&W.D(2RP<:0XH]5'UB24TAUK&=AF+L4G+
MYY>KROB8OVFC\=>Z)>LO@I3K0H C4X;+#:P^]A/*&W8JF]A[+?^S:=O<\ 28
M:&0(57_T:@"4H)<'<X &B&@!Y;<;+V1(8[QA0C"A]T8' 1^%JX%?R]7B\?/J
M9*^NJX4BN&O9!6L/"%YX8-7PJRA7]?2.O1;LY]O4Z<C)KW7_N8..=>:: XYN
MOPX9%%B8-G&(J>,>?]8@6:D<.+71E(\U$&TU9+^(I<.B2MN;D@0SCEF.LH +
MA D6B#"1(IK2-.64QZG/IZOEBLP-O1/5LB ]LUW<>$\\Z$>:P;- 5T0MM:'?
M 2P+T,G0+0#<O;#'KRM?0KWHN(Z#/4&.O 3[_VI9]U^7FY4/RRNFU&@ASA87
M3W&>8TS5GI!IQA .H@C1G":(1AR'6.*82G_3LM)LDY@3-_KR[7>FA&VES3B#
M:DY\PT5UA(@-"\#F .:XFFU"QUC9M0IH>- ^@(8+[Z!]P&2_?X##E@%@^5UU
M#C G/&X# 3 @1WT$X"O8*9GJ(K'):IV)=ET%R03SPPRCD(29CBPJ?1(R]5>9
MA\1/E%Z1$N)B/$]J8)N_OL[.=Y0OJ"KMP,M,6;A! :8<:@"^M@$8HA:E7S1'
M^[Z#T*C[O%_@PWUM\(1MQD"YNI-ZCGJIM,,/4;S.F-C.5_\L7@K!9G5H4;S,
M157EON![D:XLYCST98A(%*O]3M.\C@>FN=KP21S%- -% 2]G:7 W85D-P2C$
MJUATC&$;"G SA3$NC% _8HU@Q5UE7C3\3;PMAUZ;Q8FW9;(V1X:)8KK#S%GZ
MPL4,C9S6X K XW0'9RN/W$#I7JA-L%B11U'/;V_Z?E31F%_(G[/G]?,TB7*2
M9KE$)(YCA)GDB%**428Q"624R3 !S:8:DMF!M>N. ZTAEJT>/:R.49::%V^M
M._NH2PL7BL;S;"&46ECHI*87M9HW:]*)1^K$9/**S;3V1WEQ,'WNH"O3_FMO
MMV:J1/ :&3Y 9R8 TN_=G\F$U;]&ER8 Z,YZ-4%HPD-G7Q2&RX7X+IB.8[Q]
M7HN'Y:^SY;SB[D[^;?DLKG5SB.+M*_GCZGEE&CF#KCNP.F_8\3;\>'Q=)9QL
M6=+;73/E-5QYBJV)MN_6IG=L*S3[(V5# @E3K\-@"(J(V8)A%1 #$QLM'F8+
M0SL<9KV&[0U_F_ZN#.)=A?I,E%-&19!%489XJHQ-+(6R.'D6(R9S3$D848Y!
M1:@=M(9/W=E0KNZ'K$T;>D,_#YCIU=L)#- []3X"UT8(6%R1>V5S=O<]3VGD
M2VVOR,>WU?Y'7%Y#Z[:2BM3M0ILLLU>A'?[E_7(^8V_3)*9!0AE&?ARHVV4N
M&,H33!'#TH]D*M((L\MOEYT\#+S]VZ/GVCRYN/]U8WO)M<X98O:WM9.C &H&
M/*?Y>PZ0&/0VU<W!![@D&4%D=O<Q6\I2/[$GP==S=66ZT?73>O$Z)?F!_/F=
MK"JS1^G!>>VK>ZCRD[<IL+%(TX3$>KQ81)2B4MJ*X(@CEH>9Q!'S(Y["QA%<
MP@YD!UK-*=@PI\WW?4;T;[X(/=MEOLG:5PQ[FF.@2KOD=1CJMI$@!BJY%K9;
MO@ZQ/$3]]XJ[@12? YA<:<!+6!E7%3H [4@GNE@3[N]Y*+@Z9!\J9W4=IU"T
M3)TZ)Q\>V*9J4:M2=,V=,:=%[?>X7"PE3$4\%*1R,+=M'V.A0=Z33L&L7"2G
M5QS-#](I4-O9T?U!.Q-#IXI7F>)UNJ2R8UJ9$4UQ [];J'V\+G2?!?6!;\M%
ML?FK+GTJO\X6XG8EGLMI)#.1L\1'::PK(I,L1'D>4!0R'OB"43^5H,N14^Z&
M=LYND^XG3;?9RG708GA3S<,]M2&V/%>?:G-=E0J6WN^:<:_B'-B,R^T[-3-<
MWNU- ;V_[_&2P.;-(& ZLG?<\C:J 30(K(<6T3!$+)LD"\6#N'NIQEHN'K_J
M*/ZV>^HFO?7S6NBJGX<_EM,TH)1$,D2<"8&P3!)$XSA$"<<\SRGG5( &4 'I
M#ZR@U5<Y ?9(!N)GIBH'1 6F#&M&]!"GAA6OXF72;I-\U,I&<>2P;[(=%*ZZ
M)P.IC]M#V0Z:HT[*ELO8*9SO=1;G%R6-[DU8+,C\>EVNU'VP*#^]_2R6CP5Y
M>9JQ*YU0=. @84$6A#)@*,YTB9GO,Y1G48@R/R941DQ9E* ^[1?P,K2#?<]5
M57&I$WIV+'E?]<X!N]PO0=],=8V$*4R-;2#4>\C;L.5M^3J MF)M4.>4 Y <
M*;A+.!E5V3F [%#QN5CR@JG?MV6Y%OQSU9OP7A2S):_"!V7]^R_+HLFZ+:>A
MX"EF>8Q8BBG"7#"4L8RC$(>$8$IHQ$!Z#T9^8%6GZ1'U%="J;B_E5"[G\^4?
MVN9XGLV%^IU..F5/,]$T3M:=5NL!H(;]52W1-W3+#X8IT!%?85<3]&I.O)J5
M29T/6DXV_RJ7Q:80P&'&@AT0+D>3FQ,??UHY&)B3 \SAJ]B.N**KVX7NH5IE
M:?XY*Z<9S[)$)!+Y 8D0#B1!5.82Y3CR$W7]BY4R@@VW.B0QL+ZI>N[N*'J_
M:YI ]]D)7,RTQ&72PC0!4%"+F5;G9'$VS>J(P,ASK,X)>#S!ZNPG+;JH-T-K
M'Y:;DOI6/[&F\0SC+,WSC""?DUA9!$P@$C&&<.:GH1_[)"+$N(]Z/[V!MV3#
M0#6R9=-%H-TA#] PW "[[ITZ "*P;=L'1G_O'2M4 (W4W:)CUTI]@])JN=]Y
M>FL]NNM0!)2YLZ&ZP3+CM50WEVFOJ3K@L8L':VO%NG67?YZ5;+[4WO%R*L.
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M:&T?1E0];Q:[B'K5<Z'*CGHVP'K'QQ7 !M,2S(#5<TF=PV45EE?E+3U2 P[
MIP%2KN8K6$GNK&N3#LV96S<9P'#<O\GD80>3&ZY)W=37+$0F",<TAQ$/8HBB
M9G9F$4"*:"C/KT7*A%%CZ9-4O*?1#YK\:_9F'\=%3^LOEM9,RU\)"G[O23K-
ME(^(Y&/ P8[&VPTZ>"WFZ,"#HP_;J6,_)+N_"3'T*18\XEF6$)4V"W.(8A1!
MPJ229@'*Y+_D$8^,&BJ.$?.LG#UIN47WUYA8ZQO;-%,<14U/9UUA8::Z>QAV
MM[D.C@CN%%A'/D=Z/$IJ5G76$?JU5FL]8Z?<=RL5JEA7+_]85W\T933J:N8B
MXU@$29!#'.44HK00L,AQ*+4\QUF81FF"C4K73I/QK-"*5E>L1HUKU<X HZ>Y
MEXMKIK,[>E>@%[JC>05^KM8CLALK[;AHCM3U#)%9%75<T-<J.O%I,^6LJ\WB
MBTK/=O55$9='XE2USN"JX6(B]U>B\J4!2DA28)8$(M71QE?K^CX3*TK@]YNU
M.BIH=AQ\+?FXNET@CVF(4IYKZDU)\1+\RK&JW6X*,R:%TU:O,Z*,Z9-\9*!+
M\K>]'KU>;1;%.2-"KRGG_MGR;NPW7"Y5,N3#NE(59S><;+YR*C?&YGKNONMX
M8_[41'.\5!=\5;/Q=UP>655KPP7-BJ(@10Z3@J80%5D <X&E,\NC*(YQSO*<
MFM6 .>'+>]570QQL=]2!:H=G?+'6R2O0VU#G@]7*/BAVP)X?Z3KW_$))&RJ.
ME3N]GW?0OH ]GT Q>@5(PZKC&0<NH7-U^]<)3_->$G8)X]%=8J>+6V2#;X50
M^<Q^)(-<[8LDIRZMK6BY+)NHWL?UBG&F"NXEH[??52F9M.75 Z^Z7^2!A*HK
M]2QEA)"(0EHT0Z00@SEG&2PPXF&.8R$=%NW\L$O./#L\+4G0T=2TIN[A'[>H
M;PJJF57=<0GVW9R!8A0<<MI<F]WSVK^ *W#X0JY Q_%;O1B#[/%;O2"[?/+L
M+\HLQ>P#S-&DLU."\Z6A?>!TD)CV0L#R1DE7./A)J $DKX:07*_8U\=UM;GG
MU9,ZV'?S*EY5 (8DR%&4R"-#1#*(:)'"(BH09"B7IW/YQSPIC.Z#7<S2C,66
MBKVKH^$Z3:.> 7N&-TDN?R=ZIXEYD3;,G&D!Z[5^TQT\KJY[7,[0O+<[G %X
M=)G#W<H7E)H/"E+[-EJ")P%A D&*\A0BZ>;#G"0A3'">Q"@AN<B,IC6<H>/9
MPK7UTLMA"?G4S%,CE!AA-&8IAS0J.$2<Y%!-LI!G)!&%.$V(4#,MUAN\G ^E
M';4?!B4](^Y =C/+;'&_P*YT_KQ0+HOE3U"9OSS^O*@G"^)'/FYGSKK[;NJ2
MVPU_7M?EIEX4:1AQ'.20LBR'*$/2KTN+  9IDD<)$H2F6N&+$1J>S5A/$8AU
M!5A'4_6?J;?/S\N25V9Z>@HD/1V]4'0S_3R0NB?G3C5'9'&DEJ<HS*J2(R*^
M5L>QCUK$'U7 \Z[IYZ%65;_=<(&WR\U[Y=HP7-W@EWH1<GG(PF$,>=&4  9"
MGKTR#%F8H(R(# ="Z\2E3]*SHC9Y@W+'Q)545OD'UO(A=]6.$\ D*P91*STT
M->*$SC&R2*O<#>!I_G#3P],S 6Y\P&,0K7,.DUT8S@E<9J$U(\E'8V9Z*\T7
M##.2["#*9?:D9?B*/SPU706?Y7FO7#W<K9HJ;/5U^64WI)'3F&>B8# FH3R3
MY0F'1)5SX8BQ(*8<Q1$Q"E!I$/4=@FI9 #L>P( )BPF71GAJ!I<<HV1F,AT
M9!XO,I#8541(A^2\,1\#$(ZB.B;/VLQG>EJ5ZR<5=>_*JB@/:<C" @I6J%8
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MO?XL7_]'_-0.J2&L2%." AA2FJG!<ADLN,AAG%,2YQSS0!@5) T7][RY*U)
MT;(:]G. @IY^VLIFIH_:8ADKWRG^'2G;P=*S*M<IH5XKT\G/6![?-WC37&V^
M_==671O8#1EKOD=([GT100GD%!7RN![*X[J@!":$95F8Y'E(A-%Q?8R:9_5J
M21[.%317LW&\-$_AKE P4T1C ,P/UCJ"N3I(C]*:]^"L(_;105GK(>MF^EP^
M]"B/WS?\&U^NGQM"[=G[\UH>%E\611:C(D2J5+>9280)+$2"( J3"*,H0[0P
M.AIKT/2LX#T'331IP(/IT+QI[/34W#$B9LI^#HP^KG8%6@[ []W_>ZG_-X#
MW0R"28IS3Q_0A>#$W 'M1VUW?_F^[^IZR]E-,]V@K7WM6D^J.\>+A <!0XA
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M<:^9NB59;NI+&IZ; X;HN09XQ[;A$(U+WY&>#9H3>3,CI3@#BK5VA)?Z[>X
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M+T0@*"$Y,S%(I@QXMDCR*U>8&1MC!/6LC4]<S,Q-RXFJU>QX 0TS!].9-VM
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MS.,6:0[PS$S3JX'P5V#/#V@8:B\?]$AV/($;_T@:M OPC*A=$P$?R)JU%[@
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M$MCSM)MAW; %&KZZ>;I6/=UM7H">4^,95C/KZ0=18Z_H DP<^4PV',SJ45T
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MEMBO?0J]AV8NCO^X[BH!CRL%]QG$84T:S3'G+,(P31,LCPE%($\(6, @RI.
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MS=DB+QA%(N<P9O(_B @*<8YSF(9)'JE!-#PWZHL]0LM_@NNXC@WOJ#NL91O
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M%"(2"HB1:C&>A3@(A(@*;I1'U*;LV1;LR8%G16\_4KNYHL76RR6N:NM!V_H
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MI+T=7ZX>^D*/191SQN3N 8LDR"$J4 @+3 (8(IZHX0:882VGUI8!SU[OGC[
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MR'JV9^_^_O7NX^W7K^#Z_?_[^]W7N_N[3Q^_FKDEFO#I>2CN03$S<3U],&
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M@)>[*,UU7:]IJ8ZBZJ*6NN7^M"I%2=O[F619/C0_U0L:I#'A6, PD3861:F
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M$@S8!#L^YW\%!O,/YG\5=J,0]E_L+Q-?;+/9!F[E'QUSX(C4?!,/W&)S,/S
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M.IFNP$ JE55JY;H"O62@$PWTLK4Q8M_SF?R_%J^3GSRR_P/,E/+_<O2F5<W
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MMKEY<C+ZOK==_6;7 :Y_LPYBUE<E';?&A[/%KV.THN>$V.VA$X#LI@NVT;7
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M8#@PW%1AA\(VX57AB%]ZVG\+>%UG)62H*[MA8M->VUD)?G!U9_?6A95';^3
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M:(S+G+@8_B?HO!DM[78<.(6:W6$@ !;!U&RX,\$9J0*="$Y1F?0\<$;4_=/
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M7!]QM7#*K$'C<,K\A5-S:8SZ9_6O-R^&;]0?!3N(-R_^ U!+ P04    "
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M#CU4T)K9B#$/)[IVZ[E*I&\'QC]*<>(0^FS OFUB^^"+&T\*@^@>+-PDG:>
MX7@W82#^]]6BJ_C>0BRE8U;2"O=RP  >!/$4=S7!/YR3DEAJ2/5+^YY9&KA
M;@B8;KE5AL!, UOH$4G<C)OB6EA>QDTQ24HUCE?@G&40K N>*&VBK_]4<R,Y
MVT'WCU(@7$ON SH3W=WO]PU\W5KW9I?ZS")/24 PZ F);#QX8FU)@A)"(\G*
MWFM<L>%:??,:VV&B]?NMFH)LP*1<3QB[YN.-6XS#B%NFI18,E%,>X^PLP.<8
M0''B5 @D2%-[+NZCA QS E95\:RVO!L$S=OQY&I9>BH;GG7T":*A%D0HE0!E
M4R5'A.=&>L)K!ZT;2!FF]/LU@;.+S!N$3H?_SLU[.UZ$R6QQ-;]5J!)X=,:J
M#")QL7J[Y9S3H)1PCC!BN*I=\OTB K>S3W^4R_;^=-, \/Z1QA\_X88Y^)+F
M[F,ZN2H=QT[S@\[+*X.,TF,)';NRC1(:9%8FV*%KQP*5:*R))+1V]=B+"!PV
M-.P1*+/7TEJ[D%Q;]H<]P1DIDQ4S 6K+O7+7 H%PV@WW49QG84CM!-X+21SV
MQ=7@L*RBN3]N-_?SB]/#?__E]/W;H[/SH__X[?CBO^[RM%\']T<^_96ZMC_'
M5_T)F4],;\V)6\J%AXSX!*'*_5:2Z.]EPZS4.B57VR7:BK#*7=PY]42@OP*$
ME?$L,4EP99"9]II28X*GL7;I4DM=W.MCX9F>[B^1=P-'YPWU*XF4!-UL6M[(
MK/I69Y$<=P'#H81.,+>ZO'YU&!AI%H.BW)G:!4M/$M0(EG;0]";0["WV!C!T
MCX=U2V,;\'AF@8%76B(GI?Q3!@7!HU<@E$I4U/;\'R6D$<SLK^C[0>;>4F\
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M())L,@WXHUB[(_ 3Y#0*K5U5/^M'#PU ZD8TUUY><L$ISXM;A[X=L:Z,1Q#
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M-69<@AKWSQQ0>HV:;-[-?^#J8CV2Y]79V3H N/M'F]8'$5!9F\FX&^?J(YH
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M1I#:@8=!Z:23=PJR#OQJ/:I76H(N6D4KK(VF]?JK<8=!;;[2;L.%(Y<X*>%
MI,! ):T@YEP7:BN?95%!VN8[[%H1?QR3J;; X!@K1+97<P=>P0WCO_V\^>5_
MS<BP+-.WG^\I[#M;-Q9)QJ-(F9$P&:M#)^O4+V^ R^04L9>M:#VD<1AEQ[]N
M9 ?8/ 7>=CKL"9EWBI2KA_Q=MR1I+67R1@)C@ISQH"QX6Q@883FBL9PW?[:S
M%8&=X+0A0IX"87-U]83%=95\M9:8O.Y2RXY3*( 2C$-;E_,Y<"Y(B,Z5F!7&
M<'\<1SOD/22G$YRU!\%3<-M3(SV!J\GD\R29KJ//(:'+H*P)X(,-X+) 2W^5
M56R=.#K\0KNNI] WO- /CHB>CL/S/*^9_-=\$5>X_%$E?M5-C&DQ3_1_7;4_
MA;-T>795RUB<G;U=+.O#U%,K;;%D">H(&!)(8;5,*SD(H03#K)W.K1^BC,Y4
M)W;_\(!]ZNAT@9X.CM,N*P:<T9+Y*O&Z6$ 97\ %84''$%()]'>F]:N(HUL%
MT1G0&BR6V$;K.P/[^U5)[R(L+PX,[[N#"ZZRK._FK\X7E_.+DZ<2JS>RX:<>
M X^.(=A \9'B(5)HE&S=3YM32D'&/%V?\UZL=>)P'?DQ.ARZCO1.*4H)%4V&
MDH2LU5+RAV6J6C&I")OJ6_PCN5-&FXOW3SD,NVE]SSOES3QW4/0,JV_WMO2&
M>;Y3K1BOPCGTRX<M9^XDC\/6+DL,63.?@*LZ$Z1H#=[S D8%@<P(D[!U8>XP
MM<O?,5Y\KD;C:IO4#Q)TM1:UAX54<96FD&BUBCR R,+4E0X* F<6<C+9(3KN
M76NS/("LHZ@W;H.;^[:TM6HZ< H>Z:2Y61JB;+00@X]U/V>I/32\+@RR.F<9
M<FD]ON\)4J9%57.5W\]\-)!_!S#Z0G[TBKY<DTA7K7;D8)R41Q^8TX]</?Y7
MUQ6&4-<(9VT@19N ?)%$(6WQA)@L.).\,-[:NK6D?^(,1PM +3K1[M1O(!YQ
MA%[]X@A=UZYP/4(#';'C:A.+91 ]UL6UD>Z3J+/5XB5'<9L/3@NQZ>"P&%DW
M'5C2RA+Q<8^SS;S6XK7G,4+=_UD'K'-P1BA0/&>G64'1?&3@<_1,.%!B%.W?
MGY?;2A4]F#%BY,_%''_^&9;_P8NWE_.\X42Y1,2BAZ"L!R4]KV-8)5CBA"4M
M,_$VV'@]^9EI358[5=XW06WDVH/A69R?X[(:Z8_A.RXWTYR<Y3P$!KD$>UT0
ME]F 2;P4&0QJV?K5\J.$3)OO;@Z?=D+O #G_^OS'X@<NY^?KC.+R^^(JGU@-
M\JNO2/<^KFY#J,UZ.:F=CR0E%ET Y6O;+],!2A!%2L%39JT;7G8@<]K$\FBH
M&UMA'6#RH2<0,[F9CFE(.E*4;I 8*&28I;!,"%LPC+GY>DHK=C"':3^A=X":
M>^;XPZ*^ CN[S)C_/;OX]NQY=!Q%X<:"*PRO)N9Y3\+#Z$06S#/%6[<R[TYM
M-YG:76#R_!4ZELZZ0.>5J<9?DY+7S%#\G ,SY#3HZFY&XB@R)T"@3TQ$+5EN
MW='\+$'3>FRM,=9*\E.'@O]:;7'U;W.6HK>>"Y5!(Q-UE0R=*JLL<",+:J0?
MD>[M5G\BBAR+PFE]N39X[$>%'9C#3;WZI-POR]RR__ZF/=4[FQDF 2EQ$C>2
MOQR-J#%5D<8@N<NA^=*T;0B<UER.7>8:3U<= /%YX;TZ7RPO9O];]S&M+M[\
M7<]B[:5.:7F)>3,_^U6A?[\Z.UO\%>:I_I^OB8W9Q?LZA-&6(GR1=)\D.HR*
M10T^10G*.J9\3 F%:HS<<3F:>"W;>%#<JEW@H+C8_90L+L)9DU-RG_][TDGI
M\KRVOF%>CQ[]UWR)X:R*YX\PF_^&9;$D,_3WJ=.,2Z<YR.S)9>=:@4MU);3E
M-CD?F<ZMF]R;$#[Q4KB#8?[P6N[@ MB5Z7J,;YFV67.EB4OF.0?E,8+C.H+.
M*F((21;?.B7:A/!I'>O^H;V[EK>'MK^"]AR_5D(.X-T\=7&=HO,JU_U7UFH&
MR@D*BEUFP#$A8\$HKEK/EMF-TFG&+??FC3318P>F^!/1O)PE O\ZX7VYK$HX
MC5%A4(Q$%KBK26TZ=$)1K&U#%%P615%O8S ^2L@T@Y8/C[7]M= =E!YF33XL
MYNF:,[0F&"8"6&UE7:T4(!8=@-6M2EH%I5CK=V;#J9MF^O+4H&NFKZ.?Z+>8
MKSO?+\/9G^'B6N)7;SQ^?=]QHY]RI9^#O']I2-QAG\B,)=7#OJ)!FV/.SI(/
MZL@DHQ40<O1 M[[,6850F@^L/<PKFJ>-3?6#;E7V@>1=G]J1Y_/E+SS[@7^2
M8K_=3K\Y32DY5KNXR"J0J="F  FE#F]7.I<LG(ZMRVJM:.^FRML*@2]%9 =1
M<@>>R5"^KWG^/QB67_Y:?/FV7%Q^_?9V]@-O.5?%AI1=!A%(!\H'38I(&9 N
MW,)XL3:T;EMH1WTW)>:I =Y8T4<$\<_$]AE>__[G[^&".+52"D%,&N2%G#O,
MQ&F=+>H\X]Y&'=A4%OLAM=U4I:>&\)Z*;%;@&,U+_^W5>_(GWWS^KS=OOKP^
M^?/CR8=?/<HJ^#D=BI][.-M;?Z.QS[P?CWNZOE>+>2Z_DYPJ?,/9;^&L5LT^
M?T.\>+TX_[Z8K[WNV2J=+>ITAEM\L^0YH_L^JKJ6IQ"TO=,>@N:LSC9T*K"7
M1+_SUUMTNJYE^BG\1<<'E[-PMCI-**5R68*33M")D0&<LQ&LMY875[>:CO$\
M_@$A$SX1&AT*C[6_[J>)#B[>&R;^O5C^Y]W\XW)!)WQU*G.(6CD%V@>L3Q(L
M>!X$.!:\4+$X(UM?JH]3,F$+]72 VET7/2'J[6P^6]%5\,=BD5>GWCL7;<X@
MF66@ZAJTF$DP60?IM"@DI3'Z\1]2,N%JU^D0M;LN>D+4U99:Z90)A@@WT9"%
ME<9"B)D\1D_&-6=MK!D-2<.7 X^SL74Z!&TO^PZ:D&ZHKT'Q];J\.H^K+B93
M(D>I'41F*,8(C@+D1#)R)3%?7+:J^;*$IZF9<"/K=(C:3R?[-DM\:6^>ZO*H
M)!*31F4P@N)7"F(U^*@XZ$)'@R4EO&Y=&KS[_0E7KTX'I&WE?OS) W(-O^/R
MXF>8YUI^^EZE3E(8,97PPA</G%C8AO_)T@PV228M8=NXBFT;"-8A)S %T7+%
M58KR);5,EF:XK>-O9/V1/GSQZH[ KT?H!V6YI"B7)>9 16W((U ,$H^&%R&U
M3>,]M'B>MF-+1FP#F*=?7#345P>^_Y/<_/:S#AM:S[IB3%>.R!4UQ(VJ,WDI
M,BZ0A$_<H@TEM6X2'T!6+\\>6N)A,:YR>L9;96@SP\H)+S62TQ*YI7,: WAI
M#6AG7.(H#&+K7M<!9$V+M^90& JU'?4R]<-<^@GU(2=YKS><U-%"@<0\Q^7/
MZR>:-E'\$ZP%QH@9)84"QV(&H6-$R:)@?M@KVT&?ZQ1!NVIX,:JX.[!5[S&L
M\-OB++\[_[Y<_,"[SXV5H*A*& /U13HHBHT@"A%!6J$3'4.%JG4<^@PYTW9N
MC(6LUGKH %+5/[VD'W<CHLU;\11]%H)\ S+;)!Z*K'T2##)Z5E@T/I?67OX3
MI$S;03$VE%K(OR,8?5Z4B[](L.](1?.O,_(WU[NG-C.M**JQR@DPPL7ZPKRF
M@9"!5,5PYC$RVWK%UR#"IGTB="B(M=/-SH#[@<NX:#79_'(YGUW4<'J>W\[^
MKK^ZF67F @9!@C*YEBIB+<FK.K]%<$>1=BZ6^<8X>YJ::=\$C0VN1EKHPH2M
M9Q>GJIEU+?XKL;+AA2>%QEI'1KA(<A0Y"8OEZGA;7Z12QLG6Q:/GZ)GVR<_X
M!JN1)CI U9.R>G_S)DIKQP(6 =K$6F(MBJ+DG(!<1U>L"5$U?TG[,E6]S#.8
M(IFUFVIZ!MM5+;^03TG>9("D:Z=:LAZ\YAIRY('[Y R=G4,!;7A?Q>'S#SOJ
M?RB\ME=&%_[6G0$(OR.1D:Y6FM&OSW"MLGF^'GFS_O,GV3^U-B+)E ZIH.!8
M)8?@ @\0R#&PY" $9YN/>&E$>Z=IC3: G43!78S >)*5VFB041<CN 0ZD<0-
MEQ2)E^*@Z,B-XL$XUCIH?8Z>3M,A(]O,;15QK!T?'\*R3GO\@<T[.Q[\Y(-T
M<#S/SV2=&C(YLDV) ;F)&I3V&F)B$;PO:*7/0>EA*S$.V:EQ]<$;S_CQSUV[
MQ3FAUR5#5I9"[Q03^,P91*2XFU-@=F>AZ//\#?G<L;5=;*/]7XI*[84_8="P
M6EY4>YLISCY97JUYNJK:<JVC*V1BN2X(2I$I]S$9\*$(EWE69EB##WW@SF5'
MO[N]Z)[Z]I1(:J_;14-!]P&4VXU@N-GOY:QAV08!&%FI2P48.$T1.$^I*)=]
M#&Y0W7$86AX2, UDVNCT(4#V%' '.8AKZJ^S=22$$A49V"P=$8]!@I?* ?,A
M!.923KGU;-M?")@<'?LJ]'[7W\[2[0 :FU7EKQ*Y]:O96@OUS"A>.+?> S*,
MY-C[3/:4C*HH3F@I+1.E=0+T"5*F?'PXVOW34OR=HJC^<HF;VH-QWO,4%!A;
MYPI865= 6P<A<(H]97"FM!YZ]")1TZ8ZFZA^ )QVU\/4[7FOOE\LYM=FU>MH
M3<DU*ROJ.(Q<5Y8F#RP[LM#T9\X,:\*[\T/[T_\>NEHT$-S4"C\YG\\6Y_AN
MGC9;7BP&YA,GYDF92D=6W_$[T"$S%9A&JX;%S/=_\K1)XQ%5OY<(.[A)WLTS
MEME\=H'O9S_6(W'O]L6L?OOY9_B?Q?+U62#I56MI.08A N%9V@Q*UM6? 1/=
MQ=P4H[17LG5/W)8D3OG4?73_94QU]8_&6^8^A//-T8V:F6""!5,#3<6LJ@?.
M +ILN>8RR=S:<]Z!S*GG%(X(F^T@NK<.I[XT;V:4U!?<1$:=POL[_L"SQ;I*
M<X_]3<>.SM)*[Z"$FFX-28 C?Q-2087<!8IXRZ"+=9>O=XV]_?&P.*1R.C"2
M;[<YR,@Q2YE "!GHK@D('K%VXC/)L7AEFZ^2V8*\*6>*C'Y5CZ6FOA'XZ''V
M17.3K25WN.[;S3I ])Q<;!6$)/,FVS^DV)+$:4WD:% 9#LF]]=8!+%]?KBXH
M%EM^PK.K;9'?9M\W+;-T4!UGTH$TG&X4'BVX[#48AFB42CF5UGU_SY#3+=SV
MA\']/N9&.ND 7E\P?9LOSA9??_X65H^(;K-#GHM0C('(I2>F>(0HM8020[31
MII*:SU(?1-BT&9A#0JZ]GCH W[MYHF/TF32V[O1X7_^'309;&&-3-G6R>PEU
M?9$ +PL#GZQQM:LVB/8+#IXD9\JQ7@?(O[110[^(VKQ=\3(&EPI87\NJ(DOP
M@B)28UPH3%K#??M9J,\0-'4,VTCMP^"T@PZFSHK4!:\GY1.%VO/+36D>B[;,
MH:,+W2)%\<R!,RH *JN$LXRI^V/AGDAZ//+#N\3#+GI;-!1B!U;EY#O69M?Y
MUS=_?\?Y:L-%](5Q(0+97*%!*:X@&$'\>*]=425:;-U _C@E4Z_3:(V;AG+O
M #W7T/^$51[$S$=<EL7RO%[E)_%L]G4MK<IAW8#V979._\E)^4Q_NBIA_522
M1+N\J(L5UJ8Y*LD#TB7OS'JG@S/5*B,X&[3RD>YYT1IU;3F8<K+EZ+[4A,J>
M^K9\7*3O;U<$)FV4#P&T2 F4E (B$QE*-DC'5H0DA_7FO_"A0?BR1X:OYA+N
MP##>?8QVFK*3.@H.)BI;Y\=:\C@]Q:\IRLQC2"FT'NUP]_L3-J@WU>J#W<$[
MBK@#>+P[_QYFR^I2G)3[^8ZKU,M93;V<%LZ59B&##S6M$CTYDT&E]6PZ9F(R
M:)H/:AY&VH1=IV.":@S%=("WNE'AK]G9V2U[=0'\*>J@1 P<G*2 93T_Q_/(
M(/A24(22[/T=0WO#ZW%*)NP!&A--#<0^M>?SD(7Z.&UQ.;]>:?SV;/'7GXN,
M9YL__E2WI!DIHRDA @97%[2C("\/([B$(:,)4KAARZMV^OR$9>HQT'0@/?2'
M-(J^EW5JX;OY;V$U6WU<S&ZY7K,7F;/>%@21,DE3>5MG42,4)M#4A7SR?M/\
M8)B]].T)L^8'Q%A3#4P-L%<YKUN)P]E#1E]_HZN>V/R%.>6+8DH%L*&6G(KW
MX#@/X LWR(-0VME!\-KVRQ.F$48#UZC2GQI:]US%+0Y0TEAB- ;L>NX()@V>
MF0#)Y+KE*DOZS<!&PQU)F#"G,!K8#J./#AS[S4L)DEZ<S:\7%:7%U_GL?S&_
MR\3QK,S"30AS_8HBOYKG]_3'L[/UFEOZN\OS6GA_MO'S-"7K?:GU#)U5[61B
MX$1QH!5G4FA6>&G=FWA ]@8= W<TQZ!W@'1P=EY@Y\W?Z>PRS^9?-_?5J1(&
M:WT84KV6E$>$(),'GD54KC K;?MM;-O1. C%_NA0/*JJ>H#B,VFG6][7J:='
M>"4WV\H@ZAHQ1SZXR<1KJ'LSN>!9:QUU:[N\#[W#TM'L^#!Z*!UVZ^P.R4@X
M;94IFCQ8$2,HPPJ$.LS()N6CC"5PEO?S=ULEB/CQE$0.JY9CP]\77)Z?BH 1
M T,PP=,!T[* E]%#P2"TY(H;*4;!7?WZ,+P=3[7D,&KH_%Y^:,1%M,@"MZ!1
MDRB9UA YBX &C?%2<:F:]V!N0^ P&!Y?F64\+4V_O_=>[NS)0_=H"BT9+877
M),I@&-3V0X@R8YTYGBURYJ48]HIU1P*& >[(*C&'4$:W5^QM_NPDKNB#JU1'
MJKX-B7[8VL [YYCC=0>063<PYDAB)4SI**SRQJH'H_5VSV<^3L(PT!U9:>8P
M"ID:=EL<K35OW(98BC3 &$^UA3!!5%)#274(5/3T=\/*S%M^>!C$CK9 TU[X
M';ARK_+_7*XN*A=O%\N[,^%/(\M"._( LL! )P03N$B.*3>"O%$5M&S>!?,D
M,<.0=3S5F+;2[P%&=VA_Z&V>9J:225Q!G4Y%SJ7A$+.B.%KPPBQ&;G3K#O;G
M*1H&J..K:S340P>H>KV8K\=\_WMV\6WS GM3?_EYJJV.)=>99(ZEFIPA.:DD
MP"!#9:R4SJ;&H'J6H&&8.KXJ0SLM] ZIUY?+*NG39%VAJ+= MI*#<IQB84^_
M=3(G+TR4LHRP(NY%NH8U%Q]?B:"Y3GK'V8?%/%VSY;%X48($$T(!I5,]/H$!
MSU+GZ(H-K!P2:K>D#4/;\50#QM3,U!'B0)ZN6QS6*Y]P.5ODTTS'1PNG@*6$
MU]UD$2,DS9DN)26=A_59[4K!,)0=60W@(.KHW<C=O(O<M-6<6IF]LI:3]VF(
M.Q,+!*8M<!<SQ<7&2=XZHMR.PF%@/+Y*P(AZZ@"%@Q[@GJ;Z_%SQ *[$3 %U
MJ/U8UD+D.0@1;5#:-@;?(,*&8>YXB@'C:>58H$9_F*H.O^)I,,:C8PI248KL
M.:Z?PM7^@<2R5<Z+V'JDT98D#H/?\90%#J&I8P'B<T,'KAP.?FH$,A8]!\D3
M'<!H H3D&: )WCANA;W_1'_ZV1+7M ^#[O&4&R;5;3-,'WC+YF;^PJ)L.AF:
MK]M\^A,'V;LYD,,]%W!NP/<Q_*QM[W77U:N4EI?A;'6S;+'N_+6F(,@23*U)
M*(C!)C!."R-]$%JWW@#V##FM'G]_6IR=O5TL_PI+BK^,UU$'#\D&#8KN@KI)
M,@./&9GVW&G6FL-'R)AXEWHC!#SUZGM7>7=PZ]XT2Q452@K:@?&1D64E.7@I
M)63+>20. AGXD7 R+3CV5N(3H-A*HCLCX?OZ8ES/6QIS?H3*12?N/(2LB!?O
MZNO?:*&H*)3UQ>GFY8,]YD>,-B5N+*SL(>WI&Q<? -\)&Y.5!@3%PC4"3N 8
M.N#6)<*^<.7^2]?#FI+1]L^/9DJVD>B>IN3-//?@^MZO\X_H C_UJ0.[PH,X
M;N02GRR_AOEU3\7KQ7RU.)OEJU,RSQ_O\'I2WL[F%*7-PMG-:,Q;UTEHS-I8
M!LS7B%!Q,E.%)9 R2)-D%JA;%_J:$+[W$N&; 7DOO%:\FI070L+,M0:_WCL7
ME0$7>01;,D_&>RY8Z]%>VU$XK?]U>"P^6%L\GCX[\/"WW3"6T4958R&27 &5
ME81HI0,G%6(0GI,_TOIMRPA[!$?#ZYAHV7.GX#:JZQ^9CZZ?"+Z6D$L$EV-U
MI\@="DE[PA3#J+SBRASX97Y_2XM&A4V#G8+;Z+ +F#Z[N>YZGK<QBOD:I!FM
M:F9:! @: W!M>)3*68_M5WT,(*QK*.X/CP=P;*VK+@ X^#S?EFMLJ#DFX\'7
M9@?ET$"4TD*6] %+_I#)K9WS7>B<-I_3YUV^FQ([ .HSNZ3NID30F9*MCU"2
MP_I0K4Z&#PSH]'D>Z?CQV#K5/(RRKFUE X0,7SJXJ[HZ .%]5C[@Q<.GX=Y%
M3><U0)',@L*ZQC8@!Z&#YUHR95/S23H#Z.IV^^#.>'A@!1LKIYO"R7:C"9AB
M):+P8#BO/HZJ;^&$!"^98<X7V7X>=_L!$E/L)&P&Q-'4U4]!9M!ALS%%@XJ!
M='6/1W0: O,*M B)2Q$$SZV[I9I9PM$*.;U8PFV4T[3NT\(.WN/P)FE;#UQ=
MMG6RK&UF2_R&\Q5)^NH/W]0"QZK^3V_FE^?KS5D+"@F%8^3;9."L#I^6C-7!
MYAQ( *(XZ8.SK3N=Q^!CFG'UDUC5B91__#U_SVCI+:ET,^5U/;YUM7YH,V9M
M= ]J#EP^;26W/2NL5QNT+K^3["O<P]GC;;5U7M#98G6YQ)L*5EV?7(0GA,=H
M0.FZ8Q +_98KQYVP&-VP%0>[?+U=2?0Q0?_V\\[OKM>'!<L=8QS0FUR[B2EN
MC=&#5"JB3LRSV-JB;TOCA-NT1@?0TR70$?3705+@&>OPH!P26/9UARM0L!E!
MY6PA*A*FD$9*QK.5S=\/;$%>+\7/,7 R/#^UE]+ZQN.C-1$MZP+-P@!=7>]3
M4$%(4D(L24MG6-2F=1?WEB1VF[K:#RK#(;FWWCJ Y76IK"8ATK?YXFSQ]>>G
MV==OQ-Q5X2S[J%@) 2(6NF)R\. M(YZX0B>*1IE:=W:^0%*WL-L?#@^V8+;3
M30=0VSS:_H1G:W6MOLV^;U@)0D7R9BSHX'.='1PAQ$)GU;I89!2NA-:SM9XA
MI]M<:'.(M=))!_!Z1FRWQ3/-9*W:.B"_>3V+WT$4!J%P%-()G4TXX*W:74U\
M6A=O-S5U#;U_K;!<GKV?%3Q%%11SDH/,=8VQ8P+J@S/P*67/C>)X?V_FB-"[
MI:O;ZW1'- R&VXZJZ1INJS^6ZR6T7"F%W@,K=$B5D@F\B@(2NJ*5S0J;#ZM_
MB:9NK]2Q8;:#2OJ&V*N4+L\OSVKA\I=AK[D8CAAKY2JX.C,8Z5(@E]39K$LR
M,HO4NAUR>RJ[+3*.#L,6:MNWT#TV-#_@Q:D5S-B"=?!8S81:P8D?E<&Q2']C
M=(FV=23Q/$7=E@!'A]RVZMC=[BTNPED/I;PWJXO9>47ZV\N+FJB_<]#JK)/Y
MBOZ;.][T.NIZ*+>_9A??;L4Z9K%O5'H/7 X\G.PG+!AFKM$R$%CKXL$H\)EB
M?N16>^E#CHZ_!(G)"H;/W4T/=?6!A/SE+SS[@7\NYA??5J?,2^FS=$"_(!]=
MVP(AA)J7<#)FK704!_1I!U!\?,7$X>#:QN]HK-O.G>.'W/X?#,LO?RU.HY9.
M!E10-!>@>*CO50,'EC(KKJ24?.L&Y)T(G292.P;<[J+)XX0KX0]/30I>E"R!
MAR3)=9,,O'<.DA2&9>ZT+ZU?L>](ZC11W=% =FMM'B5HWRXNEZ?.Z#I$/P$F
MYD%%*^JT0 FF!*\HGK7!'["3XQE*IXD*CP6R6^OR.!%+_RT%R-HJ)M99E_H4
M6RH((JD:>S,1,LM.MAZ^L!NE@Q [SHS=8T#LMKH\.L2^*O3E&U9U5,98SR%*
M.I**N;I4.M17B)EIG:7FS<?#[4'N(.R.,V2W<^SNKM6^ 7R5>W1183# HXV@
MA _@T6O@Q0>C32SDP_>7"AYG 6!/,-Q6-\>?%U[/H,5\?>;&S.@^\:4#YV*'
M\#M9%C4Q&5/4""G4\-WI"%[7*><*BPZ2;FJ67E+#9%G4-P22Q4_$Z_3U9@'*
M#%<W.\8\:H-UQQA: \H4#3&1%RW(><9B4)C[VY#VMGHO$G5LN=!M('+?\+75
MT,ZV[P<NXZ+)XN:KL_P%YV%>]P4O%S^N)O%MV'$\<LVDA)08(V$E 5X5 4*@
MET9:YZ0<=)Y>^M*Q929W05%[D7?@IVU6-UV&L]OE#[]?XKOY@U* R$))'1TD
M5]<VZ6C <:Y 2J.,1)T5'VL?ZLO4'5N><1\S-I+.IEXR>'VT/BX7^3)=W!D4
M]GJQNCU?Q6@KA!10-$7SRF& 6+0!:<E"JT0LWJ_5/&_2GO_<L>4"][5K#87?
M@7&[9:K@:D5*"V=O\?:R-[*@)N,,(="14-$(B(('L(R%DH-7F)MOH'^6HF/+
MX^UCQ!KJI@.DU4T!U2S/YE\I'OMYO=CD^C3=KN:DZ#HEKZ.R ;BU)#.IB+'@
M/9B,A1599'"MWUH/)N[8<G'[X&\<C74 Q6L6_AV62W)1-XRM7R;-R@SSYH3Q
MZ#.=JWCUWE+58Q:CM"!B43[HF"7*QD <2-JQY>+V@>$8VNH A"<7WW!Y;>(?
M"[.#XS)FXN&JLYEY\*%PR$GK7"PR75HWW#Q/T2#(N7\&Y!KJI@.D/<V(PYQ%
MU@&<])Q<B(#@O6!UHYC&("02+^.X=SOBR_\S\-5&(\=?67C]+9!OL9K-Z_CK
MY0\LB^6OUGXV:KEAF\\?N :QLV2F*TRXPCEJ#5H*NGYU'8@N<GTH5G>O>L99
M,2\I;++"Q)_7.<IW\\\789[#,K^:YS?7HKSG@+R;IR6&%?Z.5__^91B==T)+
MAL!EW6','(. /-$_HI?&>IV;=W U(OWHBAQ;P.V^^9U"VQWX 8\[TJ=%Z"A5
M,>#KY$YEZ1_!*P\HDF59*G*G_4&BG&D?<T\"BD&ASE8:ZF; ]..\W-Y>[U8K
M<H%.<^*<9<[IX(H Q(@E7R?5W18EYES0R^8NZ##*IGWSW2\:]])@MU;P8_BY
MKE&>"B=,%*5 E+5KR$B$2!($G1&M16--;EW">YZB:1]]]XO#G336S[#S)TQ]
M]EYSIPT87O=C2%/J5"P'"2/3L6A>9.N'@GM<QJ,]_.X7=EMIZ)^QVW:=#7N8
MJQ@Q,'_ABP>.Q;?A?[+PVRK+Z.[50%=NC8>$(GL8);BH;68\QW+_O5L'X??=
MNOJF\^SSQ2+]Y^/E,GVCL_R1OG]3:=KDR+1,-LB$@/4HJZ("!&D,N$0',VAE
M5!GVD'S;+Q];C+P-)AYK=1A')1WX@)^_+987=)>?_[98+A=_S>9?5Z<HF;#,
M"V"VZ/J,NY:/? $FDQ0N)*9#:\?O$3*.K4MP%XBUTD('0%I?#9\OYWGY\Y%D
MOJ4P2&'VP'F@N#UQ.A4>'01NF O%FRQ:0^I9@HZM W ?<+733"\P>X2-P+G2
MF=@P(3M0G-<EN(*#3>AYM(@QM.Z6?X*48^L"W!M:>VJC_]K=ZY,/__WFTY=W
MO[U_\_G-AW<GGSZ<?'GS^4.-ABYF/W /[W_@3V[LY>_"SY[>_ 8POV.\> 2#
M H--2M:'X9PPZ*(%GXV'(C$SPU/0I?7U\#@E^X]ACQ2IT\^ZK*?P:LJN=24(
M%CP$AAY4M@*B"@I*U"YR$W@PK2?9/4+&M"6%!GI_.%5]/U%W<)G]RL)ZQ8%)
M+&&R$NC?"I3@&GPR!6)P1BK%H[.MBP /J9@>*WLI]EF@;"WE[G!R9V0\$UIH
MEQBP4H/-A!:<,PFRR=DEBD*Y:SW:YRE:>L+,]CI^%C(["GSR)S*D._=Z,?^!
MRXOZ:/LSSF>+Y8?%!6XV W F) H7H1@6ZGZ^VJR,C'S_H!@JM"X/6USVXJ=Z
M0L>NZER,)ML>D.)_(=XI#+X(\"YH4%%)B-P3&TDZ1L+Q.NG!P/#;XF"T4O(X
M.-A9<AVH7;)G02R%4:6.DF8R9B"CR< ;1I@N4FJ7O5'W9X$_C8/G/S5M;7<4
M8#24[=1(>?-W6G=A?EF&^8H<=U++-1=*!L=MJ W@!'I5IWTZ:3,(KXHSS--=
MZP<AY,E/3%M^;8^,-K+LP"M]OYA_I9]V7D7TA?Z?M=>5E66!9P[F:I4E]^"R
M*Z 14:840O&M\W"/T='3/;-_!+.WI#M$R_4Q\I[E+*RM0U?IEL1(Q\BP.A!!
M9*5#I#]N/3;O<4JF]5#WU_ +D-E!W!V YLX%6AFYMI,.L]9T>,CT.E-WYI*W
M)8@3:81+R3C4H?5CQ$<)Z0LRNVCXX:R(/<4]M:/RJ^6]PT\MKJY.RM6?U!?D
M5PM%DRJ\1 ;*9_J'5A%B4F24<Y %10HLYD'>RW;?[<G9W?UV&EO@QX.EZZ,G
M--,JJSKOGM7VRQ0HVO<2A%9,V,"%NI^[W1M-4]Y=H^M_-YSMH(P>D';+P!5'
M<]Q$!2DJGY*'0O:7S*\@@XZE#AU3/$D3/6/#>KR>^\I1(&@7S=['4!,Q=XB7
M+W\M-AFHG$)*TI'MQCJ!HC9T6&,IJ,S!85 L#<S=/?>5"9NS)L7+;F*>$"^K
MY<7IIYINN#*_67)EM05NF"51H .OHP8A==8R&TNNXQ#/F7[J':^9?G?K,?_R
MP9YR-[L[.KO+L ?%WR276'#6ZMJG7[=+*P-.<@XY>).T2QZ'#>0;HOHI[Y0]
ME'5?W3M(;F*%_SF;S\XOSS>!F\4431V[EC59/U=W]N7(048GB0$FA1@T-_L%
ME?_RT8F5OHO*%BWD-[7BP]]W" ]6"U,L(U_&23)R.8*K12BZL#!PGK77@YY.
MO:3XNQ^=QB-HIOB=Y==!ENS7>^[]S3I06:R2T02PW)!$?'! ]I"!=>0()18"
MRG%[B6Y(F696X6$:BG:3=W>P>1V6RY^S^==7YXO+^HS%J!1J!Z]*O%Z<7H'+
MB5.@GBDL2E$4;#UY\#EZ>NH?V5'ASX)H#^E/.EG\<6[>AH37G'B,7.A<(&7+
M*0+3B<Z9$B"\<=EJSI1LO;OC*5IZJ@F.@:$=I=Z=)7HWIY^,JXM/X0(_7]2W
MYA]QF:JNON)IL:DN%8F05(EU&;6$B*F \6CH5A:L^-;[BH93UU->?PR$-=-,
M)YB[3>Y<IY'JCIL-LY^_D=2O)WOPTZ"S+-Y&\%8C"3$J"#Y&(-DY3#:5&,=X
MH3"<PIY2+>VP-Y*&ID[@;B9VO*ML_<_E?-T%]._9Q;=U@]BF0^A49V<-4@B"
M+!M0 CGXXBFDR5P(85P0;E@J=]CW>O+2]X/06$*>&C?_M3C+Y"5^7,_$>+M8
MKGO(B(Q7J]7LZ[QR>[+\',[PI+PE/X#T=75$3AEB5#X[$(:34^G].MIAH!.%
MN98GYMRP/0@[$C#-K/#1D'4(-71R13Y>:2&,K+Z1$&ZO_Y-R-1IA.4OX93G[
M^A67I\:G&%3)8'3*H,A 0U Y@\U2DG_*!9IQ7Z=L3?(TP\0/&&:.JL.>(7OK
M2'RJ^N2GVAF9"^.0N:EGD8YAC$9!PE2?#3&A8^NIXH.)FV; ^"0PW$LOQP&X
M]7DBQFQ$%V2!$DH %3%"2$*#TT:A=AY#&CFC]C1QTTP<GQAP.^BE9\#=&'3R
M1JIW\GOXN3I5G.?LLP?I:I>"EPY\E!FB#!QM8CREUJVR6Q$X+*_+_A'(VUM!
M1X$^^K,5ILLZ2.(.G_R49T-^ RK@F3M0]4VND])"()_86"F%D^-.0=B"V&&H
M/.9RPTB*ZPZAGS#C^?>+C;7_)5U9PGI"JD-6QVO1!4"'+T&RUAGOZ6_XN(GD
M)TD;AKXC+E2T4<K4N9A?>5H/.,$2+L\N7E/D7P>UKNT[>H,J* 1&_FQM*W5U
MPZN&F#T/UE'8;X8MJ1[TN6'0.8H*Q$@R[@LUFX+*N_F7;_CF1TT<E6L.3SF/
MWC/+@6N+H*2K<[F,!6Z%5XPER?.P=<R#/SD,/4=10QA1UGTAZ%7.LXOU0LQ;
M_NXQ9S"@<[&6@ L'540@\YHX($>=27@IBF%/M+?]\C \'4]!853)=^ Z_1%F
M\U5==8FKD[IMB1A-%Y=+\@0K2Y&.2="ECO #9S6%RL%F"$4QBEBT,<$DFUEI
M[#.]1-,PC!U%:6$4-4QMK1ZA?^/TK8LB=7F<L$(K2%K[NCQ.0G"UZY+^V"1M
MLQ)ND'5ZZ4O#D'(4R?WVDNW ^OQ^_=FWLWD=7+I>)?['DH[!:38%BZW!IPH9
ME,BZ/FDV@)%+G2@V#:7UC( GB1F&HB/+S;<0_-2&9BV9U>IRP\+[.JYT6;>$
MGP8E5+0.(<<ZDRD9!TY05*DC9A6]%H4-,S%/?V,8+(XB@]Y2FEV8E;NBN2K9
MS])U;\C&<SNUS(I@O0 72PT A )/MRLPCSE$Y62\_\BV<3;H"<*&]:P><7Z\
MA4(Z0%D=QO'E>AC'*0:E/1*Q.KH(*BORU(S78+1BQEM5G!]CILWF^\,P<U39
MZYW%VP$T[N3:UXUGA/3U"Q2G2O0E&,@\QSH?D!SXX@KY\XA2)"G#L-=YNTVQ
MN4O*,, <5<*YA=#[PL[F"/S"#M-1!"\26"GJ*Z8ZM"#3U:R<CR$G5-JT7ECZ
M DG#L'04&>@QE- !II[>N(Y%L)*4A1 %N?L%Z?9-T4-B"F61J*-NG=YYDIAA
M.#J*7'1;P7> H'MCPMZ&V?*_P]DEW@[X7YU:G14:A2"]H_BQ: 175(:<??!)
MNIB;^T #R!J&JJ/(2(^EC"[B^)=+Q7?GO*S_ZC0E-%KJNFXM"%"(!:+G!IQ/
MV12*2KW:I=(ZG()AX#J*5/3A--$UW.XV:K&(@@1F09/(ZKM<"=[FVI\@4>50
M@K##QW -^>(P.!U/OGH427<-G\<[JDYS'2X6R1JKNMU/!5[ :<U %*%8E$Q$
ML\N8P$$?'P:JHTA?'T3^'7A;OY0#W_Q]06Q<SE;?SJ\KS?'BE'E&_%@+Q3).
M7-DZA:QH8&2&'?F5@K/6F807B1H&M*-(B(^CB Z0]?3C[C>E8*KGYDYOGJ$8
M%[$N!D2MZ%:G6#=8I)B%KO8L2]!JY/<++Q X[/']$:?*6RJH _2].E]0V/*_
M:PV=E*OB(QVI=?GQE*L2=18(R6N2&BH-GL4Z?PLC$^1;RM)Z=-%S] S#UE&E
MU)N)OQF4#KR_\W:K_0>\-W^G^4;/ =\ZR([/;7D>=^LGBT(0R@J05U_3$C*#
MYY*"11,%7:3&R3C&^^##;/VD^]Z9D!4D"F9 D7$&%V,!Z9DQ24HC_;@5Y7ZW
M?FZC]R%;/[<1=0<7W[TVTCJFM'@NBM<<@N81E*7@-V17MQ9:E;44R>76F?>'
M5$R/E;T4^_+6SVVDW!U.[JR>,BQYCW6JY3J=JT-]K"H3%&&\2LZQ7,9%2\=;
M/[?2\="MG]L(?.J,U,N+Y[3+=36EA,0QTZDB\^N*JZWI7JC"T<7[\!EUJ=_A
MMWYNI<[MEOIM(]L.D/+"#E,3N0Q:&B".B)O,Z8Y62$&&XDHKP:7P+SK$#??#
M'GXOZ#Y(:2C;[BZCVQ"4@D&KI2J0BK%D;T6"$)P'39&IRDD0C^,^Z[XAI2<(
MM79?=I-W=["Y-^66<^=4'28D8]W.4?<DNZPD9(<Z)1WKTI51L7,,,X:W4O@V
M,X:WD7Z',X;_-0]7&2S,'Y=X/KL\/U7:%Y;HO*D@Z^J[.C4Y9@MDI!-S7'F?
MQITW]I"FGHS2&)C:4PL=6*@['-Q]]/#F[^\X7^%I,'0_"Y6 $^U ;HVF:]HX
M0,O0AV2S3:WOM^<IZG/&\#Z(:JB![?'DK_ TQZ]UG/&7<1X$A&"<<JP EMHA
MJNJ06H\"A' Q1,D,3ZT+M%L_"#AX*^4^D-E9NKL;G,5%..NA6+&I EX?CQ%+
M%4]\Z<"%BB'\CENFD!$SJYNC6&"J#H=($ 6%^&@5,UKFP.P8A>_#E"F8=#IG
M$8D;45?=D)V-SCN0W%G.N&4RCS'7_!C*%-OH?4B98AM1=^ 8/9)<Y2K6A5@4
MQB9OZRBP EZ36)@LT@I33);CUK3Z+%-LI=B7RQ3;2+D[G-Q)GB$6K7V28$0=
M4V%X;45Q&4+B)2C)B_&#MI#]$\L46^EX:)EB&X%WD'Q^(95.7AMY;EP#M])0
M,.D]F5_- 0T/GBO%Q#^\3+&5.K<K4VPCVPZ0\D(JW=F 4:0,PH14U_59\,%$
M8$5J9C+37 ][^7&L98I]D-)0MMU=1K?!IO'"\Z 9>*P]WPXY.*2(TU&<*<CD
M2N?:CY YDC)%._=E-WEW )L'06:D7Z:SRWR5+K]IE#Q-.BG.K08K(YVT[ 1$
MHS4$JQ,%!=:JYIF<H;3U=(OM"(3% ;32 =J>;;TM(C@A1""!U;18S9R'R.M\
M\.P%R8\EUUWG\\$+&/N@JIGT.T#2(R?D5$A97"":@Y=T8^OHZBJ#0(>!Q,0+
M"U:V7FSR"!E]EBD:6Z.M9-U_ZOG3F\]?/OWK]1?Z?S[\<9N!_;C$+^'O7\8-
MOOX6EE]QM4?R>>=O-4X_M^&Y40+ZE^^]FN=/>%:K4J_J2Y_UP(B;W&2(+@8F
M+;BZYU"QZ,%G=*!#0>88>7+8^I /)FY?H[;1PDEYXI-K4WWEN\:050PE 8HL
MZKYW1F=9(HBBZ "Q&'5IG;[>@KQI7;)QT'3?+(ZEK0YNUU^//[&Q9FJ%RQ^X
M3N)9EUGF/@"R^II8F R.<0Y68U8<C9.E=6'H!9*F!=QH4%B,IY<.8/:%_KM[
M(KO.ZV3I4!M-C.@809&4P)>Z$!Z53+(8%9O76YXDIB-;MJ_*%V/(?^HTZ1OR
MNA8_$3\C272ME_5INT[C16]3X2% R88<5>LC1,$2:$\NL:8#Y]2P!;#/?F9:
MC#32XV(4H79@9TXNON'R%_%<\Q&R,](ENOZY)5O,G"'QL !9TY%*+ :K6]]C
M3]$R;;JA+8*:RKT#_+R;4]2$GTD=N(ZJZ_]0%5/M;W I(T]U!F)VH#@S% B+
M]8-QIF61(K/6@RB?(6=:%!W*#6JECWZA=7WX9(Q9:B,@(8E&!</!BY)!I" L
MRUI)W]H^/4O0M-=<,[4/@],..N@ 4)_QC/[JZQ\XQV4XHZ/W*I_/YK,:[]:I
M*=<YO,U%;J7 F$0&$UVFBYP;B#8@Z&@Q6,:92*VS*5L1V"7@=@'&_=S!:%KJ
M ((U/"$"OA%;O^,//%M\K]*[YFGC 42B640&)J=Z7FL?1K8! K=T6HU1TK4.
M\ :0->WU.1[<6FND Y!55^*D? YG-Z>$ EV4AB'P4/>G:W(JG:1PF&/$%*VS
MVK?>:_J B&F+/^,!:#]I=P"77QS2CV?ARFM(RBGT7H$UJ3Y%9AH"T0V9Y?H4
M.7BGPYAYS TAT\)FDNSE3CKH$4B;!_.!2R&M!&9"/5TY0O0D'1:$=SS[$OWH
M4.K!26^@Y)=@LX/$I\Y1?B:J9_AU<5+*+&UN7$,"8;710DDM07DFP3G)@4G,
MF8Z7S7K88.7'?GIG*-A%9XN6 NS-=/R:RG]_TZBAHP[*JP2A_D.Y),"S8M9[
M+JWAD276VHL90M>T+RD[J*_MIJ'N4'?5RG&JT B4U?DSMDY,C0I<)IE9EU C
M\\S%UH.T'J.C(R/51-O/PFD'T7<Q?>*9(T<!1UWDLO[UJ;!>II(T6-2<(@*6
MZT@?!T%P3VA B\V'LPTD;=JP_K P:Z2@W@S7749N MR3<A7QGBQ?+\Z)S&\X
M7\U^X-4?OJF=::OZMN/-_/(<KXJ8IQK1!$&^AQ!U J>)@8)@X8!.(/.*?!/$
M44':B(]I \;#(GH*U?<_VOF7]LT/87F5.&[5E_K@!X[9?/H\]0?O,(W):QEB
M BFEK3%* F>#!,$Y!1PQIY1;OT/HLL,T2Y71TW61I"1'17D+P?) 8C%.1Y$=
M-N_!^@=VF&Z#IGTZ3+?15F^7^TV:R"=)#HE,D*+/=&>(##$*!)VUMRX83G='
M-_G8+KI)MU+[H'SL-CKH$4C7F2;/%!T]3GZN\084TPY<*G3OQU!72WK!6>OQ
M94>4C]U*R0/SL=M(O,M\K$.GDPL"Z-!(4-9&<(5KD#R+.F@KBH&OZ8\G'[N5
MSE[,QVXCP-Y,QU-A#'$4&5*4;"E(J&5Q"II+H5_Y%')=RF?D 9\Z;)>/[:+1
MK]D-U4)#4]N=QS*"_UXL_X/+5_E_+E<7ZS$YE4=R'F=S^F\^+"YJ$+76[+]?
M??I 'B;]_;JQ=M.B_1O.L<PN5J?,:[+;G"R2]_YJF;+'5 7! O,FNN#,(/LU
M)I4=V<$F@%KTJ-T.C.MG_('+.LUT;0KX:5)"><DLZ%+JX)U 9H!K#IHN#2>S
M=ERVGHEUCX0CR +O@KP6 N\ +[_(9_/ *24\J^F[.A^7"$NSJTQ>\"$8S3.0
MN"(H:3-XK1P4P9,-,90HXYAW\O/D'4%N=A^<C:6H#C#X;OZ#)+Q8_OSW<G:!
MOR_^FI^:K"0RQL!@H$ I:0TNUN=.ZU=.0;""K=MZ'E(Q;?%]=$3M*?8N@).6
M&.IHC*M_OYN??%^7'>9?W]??OY^%.#N;7?P\=9Q%%K2I9K@&7,F1-\PD8 K$
M54PL-'^V/YBX03#31PRS,934S^#UI[CAQ29=0IU<%^DLQ4+'R%@#46EE?=$^
MJN:/'/< F#E:@+50P)$5'F_GQCSF%L2?]5WIHE1AMY^8,_2+AYF;LQ/_!Z]M
M&N^$J"E?%U0!I9@#"A\S2(M.>TL1@QNUN["7VJ9*7"3K#&1D"92@$QYBDC53
MB=)Z:WWX_]-SFJ)IG]KF-MKJP!M\:60'W0?5AXB TM2QHX*#T\4!<^1I6)>U
MBJU'LKY TO'4.[>"PI;3<[;12P<P>WIF ^>*":$B%%3DOV8M(,C  +7ARB3D
M);<&V)%.S]E*Y8.GYVPC_ZDK$L\/>E&,:<YR@L)JL[(V'@(G^>B2BY9&>QWD
M2^[;\4[/V4J/PZ?G;"/4#NS,DU-<2BJ<#A"'$'P=#:,T>$/2LJY$B3:9$%MW
MZQS;])Q=$-14[AW@9UC<C0R#IRN]:.9!U2$>'HD[GF42HA1$-FI*_^C+[",Y
M1KMIJ#O47;^]\<(&9+D QKK](Z.%X+0$6Q(%+%EX+T=M"CN>9T];:7O(LZ=M
M1-\!?#Z&G[5:OWJ[^-4$G]H<"_.L0+11D/&-'*)PFHX=9R7H%-"V[HI^BI9C
M*&CO :,F*N@G/?]8@K ^5HW&&P8L.JP%4@:>)_HMYR$EG8O3HZ8"KNDXAI)U
M*X.TB^@[,$C/> !UCD^Z_O4G/+]J+>*G'AG7+GA@+&E0D9&;*&6F4#=[2]98
M%7/ ]YB/$WD,E>U6P&NNM/YK1:]/_OSSW9<_WWSX\OG5A]]?GWSX\N[#'V_^
M7WMONN16CJP)_I^GF!= 7^R+6=N816K)TK12H1N*S)KZ1<,:8A>#5)$,9:J?
M?APD8R<9AR0. 8:RK$JE]0#N_CG@[O#ETYL/#^?<GEU/;L;SR^$U,,".P^_P
MB>D<^#'_,4EO[.SK^]'DSUD6WN/WM4-F,!QE7\7'!1^;EX5>I]Y,KJ^'B]S'
M&:C F\DX+PO$#6'9Y[-G!</$&DT07@SHB]HB*W.$1$GP;Y0ER94VT7?:8#^O
M]+#4K;GS]N:>&9HK9Q+#""ZKS P*S,!8(Z*P"80G+%/Q",L.^ZOKQ_2'JVX/
M^P5DUH!=\3'.9C%N2%UX0-\G. TN_XRC[_$WX/17N!<E SL\<" L9R%3ZI#A
M0B$@#R?L.".QM*+NN]>Z..T//9,*HCPAR/XKVNGEGY,!)L!';C$"0PHL_3RP
M"GCJD8I4"<.DPZQTTL..6ZSKR3<'T'T$=VJX!*#%@70,QQS)""9',G2>IQ9R
MWIF+0D?XGY:E4_-VWF3=V$";V-Q9>">&SO>3F^F $6M)-I%$ )9R0S5R25)$
MDL_]]0SPN-8%?[O'NN&#)K&YL^A.#9K#[W%@19!.4(:L3J!ZP@KD-*;(&<J#
MTMZZXG[1KGNLFTS?)C1W%=T)0?,LP9IW1":LG?'&(44)0YP((-<EBS3)DU)%
MTHR63B_=:Z-U$_*; ^G^0CPAI Z$HMB2N,C5M6"W8(<L\0*,%VM#@A_3TXEH
M1P-G)SRJGP:/.XFJV)3EGB#X^S@,9SZ'IV-X]Y>'O[H,5@]D9((P(1%3.7.%
M\-PABT9$->/4:V"G.:J=N6FCG<"I7S<XBPCQT#?Y7JOEA,"4>9;[TP<"K!,$
M[!/AX>B7,>&0J%6E"WX/J98S)X^W$H*HVB=YD?'[BQWEW@M?OL8X?S.RL]E=
M7X\[)GEJ;+)&Y%X,''$6#8*?,&2\8U)K0@COUN[_Y;7JQA/[?YCI@^4-F' ;
M5.%-;G\+9ZSV3N2@$W(X]V]VPB"G<C])G01+7)$02AMNVW=4YUVE%^%W.Y3V
MD42[N/HT6796!H*<(,;)8%'R$@A2/B(G<OLVBQ7A6'EC^7&@=;^I.H=8173M
M*8]V 38 /L1$@T;)48UXT+F:'GB6DG4Z::)L*OWR=H@Q5?P5HR*8=N)],=^Q
M1B99B>;GNWS^>'E=1VF,OINU%H,E.$\"]SR7?!M#P<]S&/F05%+,*YQ*U^D<
M)3UKH:E;5EH6V5"C,3<$(^NSGP.G,3(:%$MJ1Z*PBK.G]2,;3/B75CJES*I=
M(/'(@"_*[@9NP5]N9L-Q#HGX_]P,9\.[V=1.6J>4"PAX 9<YCRY[L@D%KY70
M5D2G2X^(W["5B@9[66%/RG.^40#EGTYC7-63:G"6$\$:4>9!USPCR"3*D C)
M*D,-L\5=P!<W5?>L*B+Z#G#:7PZU*_S/K\?#R74>C7,[NI=Z1Z.BB(K\JL!M
M DV3"D4B8P!7PP?E.MUB3[_<'A(.D-JD% MKRW_+R?OQKLK%!1&9L0IY24WN
M>Z:1-@E<AL!%%#P9KNFAELW'NE75_5U#_;"Y@0OIL6_YSSB\^IH[0>5&PU?Q
M[>HEZ,+.X^<X]3EN$10+@4:.K,X9FXYXI"6QN=4=5@3^ "CLU>%_>8]MVD![
M0F1K+*"PO%K'XUT5W>(/+^/TF@R$%%Y($I&3N?4BMT!?X QIQUEPU@N!2U=K
M[[K'-@_#(^#Q4'DU@,=')>J@3F!%6,HP;-KS/-Z:*V2XX6!E.!R3)P;,@\)P
M>[*%BG'.WM%T"+<; ,MC95A.9!6&T8@EPE0H,$BC1"ZW'U-,4!8ET83V6]_7
M>3IN\23J&@?0SCRO;;J?A;#P8^SH+JY_-IM-<GO]&/XYG'_], X1?)/;!X5S
M-QI>+7Z6'6 7N $ZE4TF3PF!4Y0ZCHA)$@>BM37=T@T.V$2=).A^H754P31P
M;'V^F?JOH#SW) QP(MX;!]IC$OC13A,P&"VH$&<J>>8]TZ5GN3S?19W<Y2/=
M=(?QO '4W,UT>#^<7M^2<\^WCY/9;) 8T9@RAMRBS7[0'EE.8ZZBPD8J*10K
M;2UUV%:='.3CX*JT5!H V@.C\&W\-IGE45F)2&])H,B1//HH>8MT8AK9R)54
MT2GA2N=PKME&G7SAHYOB>W&]MF%U$=/-.+P'KMUM/V*E P%'@F6T<VT ]Q$.
M6.& &99C%;7J9"\]_W:=3-XCF$$'LK&!X^-VWV"]Q?GL-K]/6"-IY!:QX!CB
MC%IDM/,H!)/@^J4<X](OMFLWTBU6B4\+.>58WQQ^'F3P6>&$EUPMNO(BP+U!
MCLF$E(E>)V$#B:4CX9OVT@U%)QKR+B* ]CNI??CTYORW=Y=G_U^9?+=MGRN<
MW]9YYX7RV3Z,8>EX:?]:DZJ4A,.)>89PP!HPH0T"(]<B::)ER?-@;?EI?ANW
M<Y %<_?=VX=+)3 36L@\AP7PGJ1&AMJ(@L6*$Z()IJ&3_?+TRW5?]4N)\Y'=
M<A#S&KAU[O9_=C/_.IGFZ%/.>9$<J("#%%$95.:'1-9+^)E.G#-@%;/E'>IU
M.ZGXQGJ8:)^/##R4STVB994/ S85LXY9Y'4DB%N%X=YE"45,/),LZ1#ZQTL+
M260EY/PB=/9@>@/@@5W'V7SHW^34@>F/5?Z33IYPD2B2 N>G-YKK4\!49T02
MA44,'I=&SMJ-M :;?63\U* ]F.$-H.8+""&"P?\1_N;H_[V9#F=AZ+-85N3(
M:*6*F"$3*.B3P $YK!S"DAFGP'17LG1AT M;JELRVPN22@JA=L#NP;5^[S<2
M!2>PSY-.%,\O:8DAQP-<[9PEZX7"W/-=3=Z/#20I%K%ARK"MMMP_3R=N]<!Z
MGGZ)XYB&\XMH1\/_$\/OWR;C+W$^'\4<7[CK=0W4?IXL\W\'GFE&6#+ +J+S
MJYE$.H>HJ;:<!:"'2M$)(8?MHPU[>$\$3.J(HX%;;,F[_"J60]S+X-7-<'RU
MRBJ9C&>_Q#29Q@<\OKV]!X:*0' ,2#%.$9?:(Y<<\)E1XYFR/CZ=G%?(MMYK
MNVT<=H<!]-A2.TV OH=?#J_& \I]-B P$BYSF&.)C-$&)2%EQ)%1%4M7$NV_
MVXI9C2W <Q^9-8#.MZMELUF[B,[_84<W2ZF-1I,_<U'\P OL-<EI+31:Q G<
M" X+A0017#/EX#^E.R5VV%;%E,CB>"LMA0: =9_5"5KTQDZG/T!A_K33,!MH
M"UY-(&0Y5I5C;I%E1" I+0U)D&!=Z:%'FW=3,?VQ.(P*\;P!] !3WL"JP_E#
M*E9M[*C%UD9AD68ZDZ(Y<A'N?TH#35PYI6WIA.PMVZF8XE@</Z6X7MLAW:P'
M2V*^W+C_'?W\<O+NKV_#Y84^L($&K*U%RFIPWUW.ILL#"U70G!DIHGV:"["I
MX';WQ2NF,Y9U/?MF? ,GT^_C:?23JW'VIH%M*_]Z-O!*L>B21#;E*CW+P(&6
MAJ' <J<Q3VS I<=$;-A*Q9S&XB=2"6ZW"YH[=GV.8SO*C3O/QN'#&-8%3_?,
M^^E-#(/@'1'*Y#YV5.0!*P(Y0C"2CEBKDD[!E,YS.V"[%=,HCP6^XE([J<RF
M^SF&;R;7WR;CG#4V2?<\F4Z^#V>P\(I;9?*?]ERTORRI$EPX0BY5?APGC!,D
ML/6(*^J1H9(C+SS\OJ<\DMZ2!\J/95REG]ZMD,>SCF=QQ>.!=1PN!<6R^8 1
M9Y* BQ,XDEHQ1X6WI/C4[^T[:N3A^T!</#T5"TJA@9OY-O*R@9QUH;\[+H(_
MG;SE"26P1G)C!KV\6R@32F@>6!*EXQ@';+>1Q_/":#R6_!J"ZOL(HK*C30J(
ME18^48ITL@'QX(&;DB1D");:)1\C[@N5VW=6]S@\&E V +2@U!K"XJ/TE4VT
M18U9"DZ"&2SRE< LTC%2)(BSG(-V6]L7(KOLK^[!6!N7Q278$#I7;W*;J%*@
M<!$#04I+G\><92]14T2 <80+03$O7T'696=UQWG61F1!J36$Q8WV<N*16V.1
MM#CEL2Q #B? ,4Z= .(P=\6S=+=OJ>[ SMKH*R&G!L9\;2*#)!P%,1RI1<=Y
M9C72U#K$ F4I14-,\6G&31YR??DC)?C>?J?_M9&PB^@G8S\<#1<+3=)3BS?W
M-"P=#MQES6-$ _?FP1&"@8PG[4(@*#$#L+9.(6W@G,0\:&P%S8GFIQ,,? =:
MXW.=ZB/>/N;_V7S%_VSDWN2>*H_^\@!S:EF0N3FP!-M6Y=&-1N>&8\$'@;%4
M5A?F2(%MMQM6W 5A3P_.8\NS =.P"\GKW;,X&R@.)R1)#LEEFK;//9!-1%Y[
MPH@*T=C2T>Y#]MMN]+%OT!:18-7AB;M0^^:K'5_!7^B2T8BE4\[(B(QP&/&D
M##*1B#R@TF'LDDRF=%YI81+:M6'[1G5?<JX_);0+]7>)<@/OL<3*4R FU_[E
MYRYMN0.'(2D2$\<NL)<LV]V7K>NBE\9=SVP_=)3QY5$O_$^3[ ;<P%]SH[AR
M(K]\!;G\8F<QY&P#^)VE"N9.N<83DP2SR'+@!C>,(BN<13Y%*8P5S+C2)4SE
MJ:B3@]W",=JCM&LGX>Y+_F]Q>A6GJU_<SD"P&BQ[Y35BWF7S/J=QR< 1%BH*
M'C5GPA8[9KONJD[J=_53N!>AG8@[MH[V#]??['!ZVYL5#'M#'5<I8 3,S]R7
M')D@/)*>A< PU4&7[F!5:N]U,M%;/8D/DNR)(/I\_C5.S\+_OIDM.P .'%5&
M*J(04S$@'O.(VRASHS^1O$E."5^Z[<<^^ZR3Y=X"4@^26,.!A'5/>P-E0B)$
MP/41F )#GP1DB'1 &_;,"T>3+IT[TGUW=9+=ZV#P8.F\DE>M9P$/.PZW\R7R
M[-V>'[@Z+E_CK6L?SASAV2OR%(-T#'E.'5BAX#-IH0+2-J?6R8!9ZJ?)1R_/
M7L^8_"G.'XRH)\'K:!%E,B+NL4?6&H>8 RO%$682[2N79-U^VGVHV@43+];J
M[RN!)J[B9]1LJ2$G0MD0,4>1$KA4)'?(L6B0U880:YT6Q2>G[;"]-M*+#T?%
M2W K)* VT;>V GUV ;*$G7X=@'82,'834HKK_*R+D3,<]%;32#)?=?&6A#MN
ML8UDXOY16%!0]9]\GE%W^QNK., ;^VTX7S90NZ7P;!S>QN]Q-/F6?; <G 7U
MLYYS82DR0N;!F!$C&[T&3 4<0O#)\F[=O<OLIXTLXF)0K"6I!N(XZ[3O">$#
M3:1-(3"D!(>S7V.-C!$D9Q,X2_(P!5U^EL6+VVHCE_@HQ^$A FGO"'R37^Y'
MHV7 *>5)B6X>PSC.5N7O#TK>;PFV5&GE/47$$ ,$RX2L81X)SA.P4T3:<9CE
MX7NI^Z!XG*.O9PF=QK'W\(44"+YMT;#E"55H+W *+H?").) /X++P"(<57 X
M2:9QZ<>9/NBH^_98\V#M5^2U7\VWN'MY.O*#>-H@<!:\"Q1,%YJ?5V-$8+9@
MP)\@R3AJE37[F9L;UZS[/'@DD[(,QUL\/W^=YN&A0C 2N!/("RT0=U(CIP5%
MG*6(?8C:"M?W";C82=TGO..=8;NSO8$"LBZ)G3($0P272#&+$9<^@#Y8BX3D
MS"H9>32E^Q.72LKM[57N>+ Z4""'ID7V@S+@UH %8!'+XTE3IB+DIVSO*,+4
MLBAH4BS*OF$%^Z@TV//X0-J5YVV=3@\NZ%\GD_#G<#1:NCYV?)5S>98T/OWU
MP-J00BXC!P+!/<?4(*O /;>6".V2!(24KOTZ>-/M%M$4>E [@BQ;._8>D/QY
M.@'3<_[C\\B.YT#WN__<#!=!RP&1(=H0.7)>TDP@SOTW$G*.:VT<5K3/X%Z7
M+;9;"5,>FF7D5!6(3SV?!]1=#*^^SL_3[[,[[9*!&8PEHHD9Q*G*'=TB1DH:
M!;=%PCH\L?)>]C.WK-=N;<L^2.J+T4T=8W=,>^@L,Y>L2((CHG)YH\<6F0 >
MLU<T:(JU$+AT@>JV_;1;8U+B@#I8 @<72?5LV@V(98D'N-ZIM":WH K(@,>,
M$N=*$Z.2(*4;EZS?2;M5'^5ONIVX7O!(JIOBN;[O\YGWN85][QF>W5:OD>"Y
M!U^.D-_)E0<&*XH"%0)Q32URBH#-I9Q1V@LN1.EH08_YG4]2_3?P?/;N+S^Z
M"</QU7*NPNSS<HX?_$:>K6"OA^/%7[^(\YOI>'8Q&8W>+U-T!I)[H@08&1A3
MAGC,T]-L;I3!%';<:N)$Z22^OFEJ-\]T%VP^/9&;0D(#KQF;1D$HQ9CGA""J
M?6[ZAEFNB?4H.BMX,@3H.-)\A+HX; LO'>=X["*\O3$(SOIPDAN=3N=](O%M
M]-/\8IBS(&]&^0$Q#P_\#&M//R]V<'D_974VX (S*D- V% ,1X, XYS9B")5
M04>AC:&EXX\E]ETW!'F*&.\/%DW$ #8/2=F!:B&,(#Z_/K H,]L5LLX0Q&D
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MHJ ,@:O=:?JT=/7P-COK-E+WD"HHZ*<]=0[F>@/0@>U?YW[6H&&_Q6L7IX-
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M0T'JG('.$W+44A0(CBX%L+'BZ;P)[T+YB4;*?ZHCH#<DOVK]W\&7XBP&9WQ
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MM0O"VY)+FX@.7*-(*3"):@Q&HN$(/"WG2=34L]('[=8-U05B,;%W@],>,F@
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M@Z05==E'$-LX\<<$O.WA:#C_<0%>]V_#\?#ZYGJ0O%0VYT5Z(A>-O@.RQG$
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MU1;\,N2VVC@QE HC!*(>YPYS4B(=M(5?QDA36 P6+2'XAXO6>64O)OB]^==
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M4/5;^\%.XFHI +6-+;4[U&:#*E-42&#KOM=)7BT%C+8PI840?Y&I9@\_U$E
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MS:QNX&?H1^B@_1@^0#\#87::ME6%>@.N03!7"9^4WP2?AC!B&HJ?4CW*\XA
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MPS81?.\=@-^5U'V>S"M!Y(V2^M>Z>Y3@&[I[T(\&<_D'#VYAMULGK:78(XK
M 0F_)66?5.+76C%9OS:ULC'8*GFO:[@!?AP-LE_*,H,/50U_AT][S7!9'7\'
MYRPW&LED;5@E_]-B\LTU;C6$B]@+I3]/=O-Y2-<%G;.E6!^ROTAA?C2.'-AD
MXZ;:2.30Z_3>W<X1<L^AR<>5?"UZV3_8'+,<F<$0S),'3YXC')(-;F@-M;Y2
M0)AG*D?WB6/<&Z:<%6BLDKR=+P#_YZ !U#.K,"7ZW^C?16W F[),$F+/A@%Q
MI_34=.9Q0MX)4@*]SH!L"V.'<(E?3W?8+#T,AR >/F M:J $<53:% LV5?1
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MD204/;Q/*/I&7"^N%AIE@J=CVSBS&W68FJI&;>R\S565 SVG,S!:T8P&U*]
M1@EY%L@RXLYVGTY[P-4.D3'JNJD,C9V@/N,)#@I !V\06N_YJ)ZI2KR_-M_/
M.KVF+0:DJ+^YY&BPN6P]:]HYVWI='M;A] :7^0<MPPZX.)MA@GZ\AGP,HY4%
M6@[DCD=Q*%\T:Q5'X+V#SZJOL;>MXV,[1W]B82^ -\.N2P $=D>U<P?H+7'\
MVN4S='('A$<EF9EB9RKL!25,3Q8U>/<$M9+"<#:PU\/@.K#8>W[8\6-$"DP
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M']P!6D%-KLF&=_8;RGJK6C\=J1T\K/S]EQ_W7^R]?3H:[_B0Z3]QW%'>"0#
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MCI9T&5U700J-0P[D5B;[ )!M1;$2(6;XK-@T]:-?>A,MJ3 ;9,.H-DA]9^.
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M7W!S1"1WXHYZ ^#$/\M*"&VFL9VUY3'O2IQA,T*3/G8%WL-2%-X3#CN,VVB
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MUSNV8AK"R"'<0MK.F2?=4$O3F%DKFFHF\[>\>A*:)\91"&;/UNU?EVV5:!-
M )M0#"F.-)I9:*PL/:64M&>C=(?X[O.M(($'Y;/X'8V4C78^)7^M9[HN!P5M
M\4>9BH^43*M4IN\D4\ -FC-IN^#P+TT)"OVZ"GZ-)384"S?3MGP?KT3$ JM1
M%4(3IM*/G*2BCW3[ZWD9X':%'3ZG[ 66DD1T=F@("=O9-[$TM<8@%V@FQ@+F
M.9M X*EMKK@.<.+,\3TG/64SR@)HXI'QJI>X5MR8<K'B5]1-4Z  N+(59/V0
M3(U?M<*?;SK2?X@F@O(F<9J.@E/97]367@**EP90L8.10L1%QMZUB982XB)?
MR*A+DI 4 5>$WSUNOFU O0?5=>2X:$!9<3>P<5LWP"Q_3 959O)N75Y4:<9>
M5U08+)YF0MX6$T9TJDV66%;)XPUGTG$FL)]#4F+;48*-R?8P?S<T^9:M3_/N
MVF4#TI@YU-.DOM9/!90<.I9_&<H'G>YT]AV+C]/DEWRBK?G.;RN+0*9@;:+K
M,.8+3RL3)J&#N2]WQX@6.QZ8Y?%*X4KA4D^:=I)OUMP$.V2-@YXR&6<\^6T;
MJ?\A=1(YFI82P?E-76V<\JG-;)925X9P9+/,RZFX<H"]/I(3JFP=>2]V7U!D
MW'5W-BE1^/_GC12!'V&=00FFDP*2-I$+MHB$J#C\6TSRC,<WTC*.O'8D=$=A
MH-HEJ*G$]N6CB4RDT_GS'B7UJH)E,#316H;&'G=X%IM@CW5SA1D+/GT%9B,2
M&Q"NQX](U)IU^W)>=X+ 'DIJ8E SV!OV.V Y3R8G0ZF*)L!+*^K/WX+HIA)M
M,1)!<?X;_%%2:!MOSP$T[DS'[DX=QYU3._4QF,HF=ABT6J1D,%VT=I@9#^K!
M36P%OWA0A=7GV/U] 'VXA%]DA<<Q<J(YT].E+6Q&J53@BMO%MXUN%I!$1EQ%
MU 0,RKR,YFCTODGL./L^1'4T%;VX;:5G-$ZJB":8]TBK$,)SX5(LY-++V80C
MHD6(#_ 64BI\,NTV:+<6,EVPY'X$>JI2\5]1B)[BF_>7?_E8AGQ;_PY('^D&
M.P#RLAX2BK*0S[(BGZ0W)LJF\MJHS%(/>4PTP;XD">+<3F<T.@?;Z06F)Q.*
M@93*!)VS4GR>)%MMTC!J\6YE(Z!B%EDQB:@\]L-/15GL4EY;HZZU-]7*NFRO
M'/S9!(;WXG@(V0]QBF&.3_0P9Z-^!#,9"5#HDU]J:9S6PAS9%UXON<3(K6;N
M=W6MSKUAYF,>A,F#V-_^/(@-B2"?^654QS)#-T'J\3F9U8($+!WIB"%UZT@\
M'=GA<&$"2W6+#NY,NHQAJ44]X;B0QR1]/K$T'\8/+]52F<.TB"X(<8'[]%=(
MI/YKR,\3!)RMX#7A0P4K\WJGN)H_2K%3BYYL!.;IQN;AT8N5&%+H5RE7"Y(^
M1K,='9"G#TG[(?,1S'XP<3?M"__<6WXER2,I3V5PFXTC"01%85*F&0*!QD8&
M*(/JR!B3;KB0EW_LS0T.<G3(96#L90K?9*3Q?[6G+*'Y+[?* KSM*M];?)51
M]#&*5C<[><R*O"=MX."A:P.#3+LBH)^<1K^??#X]/C^/?O_U^.SXXP?'/@(/
MNJH=P^DJP9UD;5^LCA?DKNSZZR7Z3>:8:4RD.#*'?5N]['=J"OQU0YMN35!#
M5-;H=HX^_NW3X>G_K**,3X=')Q].CJ)W)Q_/CTZ.3X^.SZ./'Z*CP]]./GP\
M.STYC*.3TZ/5P+L!+0_V[P^ *Q?^WB!]M^"RK@V)=-C#.J6#? ,U_1N4XQS4
MSEET7&5);4H4_OB_M^$23T$!X6M<=<H.\+;AT)^S)N=3KSKTD5_6#G^094>-
MI;)JM0$1*L;/!\4 @TG2\(<=5_TM+O2!"HGC_W=\]/?/)_\X7HD6OYZ=G'\^
M.3R-/CZ)?CT^/?N?1XEP9VY\- 5;OLG >D(@ZJ):W!=#WF9&[7C62D[]"4L9
M4M,1Y&B::;_6[2,KBH^VD+&%GJZQA?XZ+M,%_&?:S/*?_Q=02P,$%     @
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MV.I_AP2^^_)M%:(1O@1^/"O@!Z"RM.ETIJ[,#,! V[I06:.[>YP(&H[!D)C
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M=\V5X$/^]..X_*GOM7?2B-:D #EBB3LJ/]$.\!QG0&I T]H QX'/!>N+,9Q
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M^^>C-7%$7<>R<NH$ETCH,&B_LI0D-0>GN_W5VTE,+7QM*_-;=K\+Q0:T3TY
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M^\-6F+&;\<,KN8HU2DQ2USW1?"9%:S/PL-U2#!'T2Q3+Z;\/"S:C8_V#:O!
MYA>8S6 BKMN7_+FW>$B2+U*>HN,W&T<22(G:J6QV: _JB 90!J7(&)-6N R5
M?QQ,BF_EN)#);>U-"G\84M2^VM.44.ND)TN-GZ]8Y8\V((LH.HVBXCLDKZR&
MQY_.'M\=J#T^R&PD@N7Q2?3;\>>3H[.SZ+>_'WTZ.OW@N4++L:PJST>ZBD<G
M<S64EN-K\N)UW=@2%(ZEK1D^<>1:G;U'J>N3@=6XN+AK=/2NE#+$;I5T/X>G
MOWX\./E_RU#^X\'A\8?CP^C=\>G9X?'1R>'1673Z(3H\^.7XP^FGD^.#.#H^
M.;PW0W9O=WV8^NZ:BH2606)-DG=OM?%!EE=%_XU.%!HSH,OJ+)DN.\9]_7<3
M;OP$M <N#%MVRA9(-^'(GTV=Z95X?C@U>A)]U,4<S*)39J/?X^0/E%\>_<_1
MX3\^'__S:!G\A(U\[S$5]\ O?E7EE^B?H(6?:EL?^L@O;L<O"'07 KHU: [?
M:9&A*-J/!H<U./96&!Q_'1?I-?S?M)YE/_TO4$L#!!0    (  !$<5HP=GM>
M!3$! !+U"  >    <&%C8BUE>'@Q,#$X>'!A8V)X;&5A<V5E9&<N:'1M[+UI
M=]M(EC;X?7X%)K.K6JP#,45J3U?7.;(L5ZI?;V,I)[L_S0&)H(0T"+"P2&+]
M^KE;+%A(46D["5'LTU5ED40@EAMWO\_]^VTQC?_Q]UL5A/_XO_[^?^_N>F_2
M<3E52>&-,Q44*O3*/$INO-]"E7_Q=G?E5^?I;)Y%-[>%-]P;'GJ_I=F7Z"[@
M[XNHB-4_]#A__XG__OM/])*_C])P_H^_A]&=%X7_]4,T#/>&PV#OX# \.3XX
M/!J>' Y/E1I/AD?#R?'QP='_-_@!'H6?\S-Y,8_5?_TPC9+=6X7O__GP8%:\
MNH_"XO;GP=[>7WZ@W_WC[Y,T*>!E&3S,_^0QFB,%V0T,-DJ+(IW^? 1CS8(P
MA!7OTO)^WNOOPV>%>BAV@SBZ27ZFCW_@%^A!1L'XRTV6EDFX.T[C-/OYQPG]
MWROY:X_^[Q4^LCL)IE$\__D_KZ.IRKT/ZM[[G$Z#Y#_]/$CRW5QET81_F$?_
M5K D>#O]><_+/89QXBA1>OF#(:[YXN$V&D7%7W\<'.V]&NSU!R?597_-@G\O
M\R*:S->WY(/6)9]??+X^N_S@77YX^_'S^[/KRX_X;^_ZE\LK[^)_?KE\?7GM
M7;ZY^'!]^?;RXHWW^G^]O_YX.GCUM[_]#?YW_Y4'/SO_^.$M_^3LG7?VX8WW
MR]F5]_KBX@,,</[NUS?XV,7YV:]7%][.9<_# :^\#Q^O/7C=Q6?]T,XE?'?]
MRX7W^>*?EU?7G\\^7'OGOUY=?WQ_]OGRW?_2;\[.KW\]>P=_7'^^.+N^@I^?
M75=F#B_^]/GR_X5QO8^?*Q/K+SQ)?6ZQF@!=#!LG21\Y!SF&VZBRVCG^613Z
M[N+LZF(SEO*:S_3UQ?5O0"N;L:;W%Q_>??0^G7W^/]ZGCY^OWWY\=_G1N[ST
MO7?OSN&_+JZN/G[>C)7"T6W&0CZ=G0-K._=>7WZ\.K^\^'!^<>5]?.N=G[V[
M!+[RX?+,!PYSWO>]P'NCXN ^R)0W3K-9F@5%E";^9NP"DN;%AC"6]RJ)4^\U
M*EPJS[U/0?9E,Q8VV!\<>A__^N/)<'#\ZG46J<1[DT5WBD7R=>J-E)>I75A
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M;*/N[+=Q[G%0YIPN!:(7;?XQ^08"N/!3C.PB> 2F,DPBS*O"KSZ"')W![^;
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M8'X)>DWQXTF9U?3UW%H/VC"0EY.(*5C)=WZN'F:(*@#V>EYF=Y'DTY&710P
MZUTQ:KU>WC=T8:R9D1A.8LBF0=P5<A&%\Y!E#CF-G"^/])<5P_(&=U=74&7H
M=$J(P#CFX)J0PINBB1Y@,_/IAEMHPDW/M0,ND2;!*$;E)XZ O4E-L(J(<6&.
M<^764<YW K_+D.=A3(YOGHT19?(;]M+(+U"$()_WS N!C\%"^&7T0("9,?H^
M 4\<2QZ%S9N U[P!#LWB8, &);YO9U2;Y)1TN;;9L;NW*578DT.3F:8AAQ.)
M_0IS=KS3M=(DS1G,R]W7T<* ?Y/4D*61<)#%Z?2%A<MK95]VTC)D31(JI<6?
MYF*/BD%E4N\YQ;+M9<]5"/[UQ\/35\;CYGNWZ3W2K\_'7=U"C)%E8_30<=Z^
M3D4=8[ BKOK3*+ZQ$_4,I%M3^GA<C+'PX,8I)IC"6>2LFNFR"RR(0Y_<30K*
M&,@<^ I.*,T*(L@0IA^G,ZYQ1CHB&R0 WH%#W<QYPCI[E@@1?75X&ZKWI%V3
MX])I& ^X"\5N<)OH=N:66+DH96QRG5KOYHYQ<YJM5JIUT1*O7+1H2M2%R3 1
MTU.R"3H%V.R#*1<QN\%$J]^* ^!A<_Z06K#%O'VUT@0IS@&U. F!/8?,I60Q
M>'%@@O!$D,T9>0;M'U,L!U]3*@->R_9WLB+3T(U9[T#_K]%5FX36]SZD!>X+
ME=9HM@)/J9N4BF.B%NU)^&/ ]XW8<0LI'SU"RE$B104^4PU-]6O9NN,JJ":$
M)*F]E"XG4^9:LGT/]W2F?< ;HP7?:2789+]_HNBHMU.QG'ODU2 PCZ>V1]&;
M7'!FHY6@,!*0X6#PC=VXG?:R_?"/MU&6%]XY,?^8><='ZKK6!?.^ZDY#GM8J
MVM.D;LQ(< <.!BV>Q-Y^UHZJ1TV48CB/FX351HBK$=Z"C,V-\7O=/2U(TL+]
MOLGU^AH"88[J$$G%42*S=PBAI:Z^(W?XBI- .GJ)-Z2T2.B="0J+)&R^C\%F
ML$'OSD;LJADF.VL.V?D=W:5.Q#.[O3EW:]X;QR79P>U9]^Y4S(I,3<K$S7A!
M=6B6J=U9$(4<1-0Z"XB2,D-S^HTB'Z5V:TW0([%SV/-&&C:/8GJ%P0S?D%3"
M$/4:I]I)USHYZ41DT7$J43!G[L^1E;R,"YVZ7U-1%B8YDYI1*<);X>7W:1F'
MM9HZ=.YIU=1]?2YA1Q97BY)3C::DZ<"IXNJ9/.N&G6HSTB;DWIC#$J;!#:%*
M1#DJS>PBJ\QH4[*$5:\)(9+;Y/=@-HNC,;F!8;.CQ+4IR&$E^9%YQ7,T+7,=
M[X%M.]=.6* %]&LX)L@OP;^#+$S+' P1CBK"2:]=%UW&%V'&.%=TSG1!+:T5
M?D03:T5$!(GL5-=+_J!A@EC&0)[QC-'&X5A;S^,YI' YR(-[:T7=ZGMGQ)?@
MNF,>A&9F$J\WIU7S6$[(?W%!..\729'!D[4<"YO00OQ5AP]&?,;XN4.9-:J0
MU'SD9)L9_]S?QC\W//XI] [*GV9L7\_7EB-WY0S&M<O#'G/Z3=ZK)8Z;V5"0
M"61@TC*/]O?7YM^O#@Q3F<X07PPEL-9,0OF2,%&*G/$/LC'7LSL16R=N$8)F
M<X/JFALT085L;I.,D$D85B0"G9V FGT9=Z+5OD4)<+A.OZI>!3DB!-;2TR<P
M'8D$P0HQ"B-)0(ZRP06-\F9G_ I@H>P29D01$$2.+DMX.VQ&H1.HR&DMZ_:=
M0G34,M&WISLVB;-,!H%W3!3FV2?6\_?/#+WL%\E=E*7)5)L:;RZN;,*<M#U/
MX$8IE1$XU[VB;6 F3&/69UA;X<((:%M=!:9?(0HC'GCCG!:=CMDY*2' !,YT
M-F_YO>-];FQ[G8"<J'O!16%+U.,_+FDZH"Y/%JO+J.N&4GLA%.5NIT6GHT(#
MX3EN4I2&Y=21;E>)1E0E-S,3&UYD*7."F<26.JTW-Q)+NZ ]8Q>Q,?!LQM9[
M-GLIP>&.["!B'II^+68#.Q%46*7)@)BC7=A,;V=<3DO6/I]%$O4Y)O&.X3[S
M'G8CF;IF^[CAL+'KOX(;CRC&15:.M6\*?3^+(Z([BS&">@OC]#N$4KJLFU=G
M;>HMYLU7;U@7,&]Z6]";)SIP<H8W#W4:&FK7:&YA[H4O!@5WX&4X8K\&<J62
M&S#D+=YOE(5T^=&HS.ZBL6I-E"/?CLJCFT2Z^[(EX=A'Q$K^<-:&'C6X(0SK
M1/NEM&O(M;ZDQ1T\R]TCT5 S1D:=Z[,.X)1Y=Y/8=)7GX&#=Y9TUX6%<"@0=
MG7-Y730=E5EN<CNZK9#6O)D5(&_Q]FOD[FZH")C>'4W8-8J>2V_G<.\O/3UE
MK@AT[RVY!GRQX>W%KSH)M+7<8N,[]]JY<?7*?O;QRC!289E7TT&KRHV^[8]6
MB>4+2L0>*09[8B%8[QFH_6B*G^-I=H$0?8TZ+[>=1 :Z=[ EU,-8P<:[#01,
MVX W:0Q:)"B7_S'<XW8:->\.4E1A/3@-S/UE-U0'RPLB**?NM3:&4X07)7<I
MY:,91 ^F4RH<2>E_W2X!;9XJF_ L-$T$:^!8EQ/X]Z5J[9$Q*[?^,//1+)BS
MO'>*(>CVRRC: C'DYY1B/!+55II)80L ="F/3>T$>RQM#X#NFA)&]JX;Y:.&
MN!SU5=^O%;4P2 P[@\5LTW385*O@*L'63^!<_*9KND8DRYYV#[G0P%I4W %K
MNL6RKR"/F/0:M?<Z;4$3(9 !<H^\[=:N.@=*JC%.22F6UU>Q+C?IQQ5+NWZ]
M6>KQ_"LWNWJ1L2RII-;<Y"3%QBN5HY'9T/NL?]IPLSHG,QM3[6)T#JOA2V@*
M07#/V->J&90M*@;>DBN6_34'/"8D4<"EX2%OU$!4>;S39XDFR;4C%'4P$7R3
MFIF[%-O"(KIYY4U$/M_F:&YS-+\N1W.-T_OA']L4S<5[LRE9<#>]3SKGW:D#
MY*P<$;<AE9"R!,2/22X;L6J!;':VCI _Z@AQJC%)ATCR,B,Q-[;0T;E%9.02
MPF[NL9./MFY@.S'&R*5G0%2K+=PJ4"VDNH".00DM:=5#X= VUZUJD\[-&JEV
M># J$5^;<<IYI 5GL,A[I/.QJD9D_HT%5)N9L7;06-8V8VVS,M9(-2>/O9-%
M@R3^3Y4HRH& (;)@7,!7(PWRBU>)J@2=9*X@O",FR#5_F++ L<.9&[6\M[7^
M@D+JYI1X89F9>GNY<L0/X$F=LP(SBA)\D+T+7-@H !TN"*X CBQ8"?R_:2",
MO'S8:SJW@Q$(6AS*Z;?3',HV&@PFRB::$X>I)',I23O _8JI(2<P9($Z0!P3
M1*1@G/P[M?AU'F,GD*\JQ]7'+J1JC2>!D>9X;2I&)#X 5TM1DIESBFC99I4B
MB.8<^MZ5<T!UWENQKY? S;NXKU+0![I,IYVR3N)S!]RR?>\-7Q<^? K#R#6K
M9&@3N;1UP:YA% MRB@Z?.9C @A_\7EP\CA+YO'+N#]>J2#*6@N^=64[V'#?Q
MJ .;R. N!59#(5S0<^K?.NC _ODZ]1ESMFOIT*;%KG$)1M,9.A8= >S("X>=
ME+,TJ;MQ'4;$L#J3%=0,([- ]<;:/P=4S,HPQ"U*08150*LR=9=^:52MN),P
MA2Y96BB34,5B.=?YWKJ]9[M8K<6PJ"DRJN@@SIQ@2#UGR]B02].S'N]"IO4A
MTI',>U'QXII(29H(N&)2O^3<G8W)_]DQ_5=$7%?:R76U;4,S?>FP"PDY#K &
M"$Y*=Y=ZC2I&C<NL*(IOP?4K!["XQO>K,]/7".RPW]&>L8S@@6=R0; HV_ZQ
MWZ!_K/91<@=ZD'])X?;%U+@SJ=E[AJ01WO<,^\YVB8HJ642!CEPBO&3T@%#A
M1WL]=@[GSV!C+S1646<Z^T9@V(81U^!-*BDC+HSDQ-!RW_5=&E1(_+9.-.@0
MN(D(,+N)&FR?M&5/A1<K;%Y5W*L8:_H&0W.R7$+&>=U2]>=DJ,B/*A9[<_91
M$A$^PG.^D1=ZVS[1->@"!?D:(=%)L4,* 56N6E\G95L3"NRT@2N::NMTTNC"
M9^A%2,CZVK0"CA37=M*4W>%1+H=78OJ@PAY_DP!Q-["L*TI*]FM1CP-RT5D0
M!GD;.1RP11)SGYR 9 R,I5+2_SKA)H5S77*)1@7JJK@Q&F33YO7^:NJ?BN=A
M,9^NU>*K%?U.BODN"EZ;&3.P&:7:B2=(;V1CR%$:[?8NC4(Z)7@&6 N<"G*F
M3"!_N<MDA5T;L- &HXMR0Y^A;]] AB0Y*(.I:G=="0S,8M94SW77.4<C%](8
MOZA[8YZ3+V&MK@3C,"3VU BCM3H,"973<4D'M:S 9]$L<'^]NQY:IV_MFDDW
M^<RYK'!!';]-7=&N=DHV1X>._5FMJ2S[$:*,&8.(_ "[O(D\L[>S[UV:Y+ P
M57D5![N=$:## F4:$(M!B6[Y'<^/$O.6B,\-L9^X,6IC#\B,JK34(X3X[<5Y
M3 [F9NL<M!N*Q@$5)6H2F?39))BJT-634+OY9%2.:Q@F1Z^;0G0,K("UD!<C
MHW(Q&%6"*;&,X"]!KM4'9UG:(  -+6]?)4%$5,%R+.!0)) +&4EB;"BBZS_/
MRU',$]E)ZM\;(QU>!$N;Z-B2\TPKUKX+L*75.WHF( P-G+ECCJ385Q>[5UF%
MY."TJ9#T>M*IDIY:M&/?PV76@22,P\:RMDD8WRD)HS/,?TS,OQEQU:S+".9%
MZD!KX4;=]^P HFCMN?-"9,VMFAU>+]WW;A4S.=W.81)$&(VBTE?\ '[3.+54
MQY:<] AMPC>/LJHT(^_&)!6V9QP?0!,&)U,<WGG$P]/N)#%-J3&6P3).))FN
MM(7'1UGZ!8-%LUD6@,R+M:VG.[F,09M+"YZ(G?:&:&AA[U=MJFI/':;_J-RU
M,ZVCSF3H.D68CCO'N<G<;QXT<RYKT\[;/W2,5<#]BD^H80S7=8TG-32K59\Y
MX%[85L699[UY):5H-B_-71"7JJX(F*M4N2&D*0DVKF_]!_HP3'F1WW)'Y"ZC
M?.?\3F?BB;J!Y8G_R3D?F$P045JO+L6M'MBC/M4%1\402E*Y3]4XE6NCV89V
M>WR%>/B&-W"],/'- \4BJU):@J6\>98DOCWM^=J3:NCO#W);F;Z^G?F"&YEC
M49DLHTW&4SIA#'<R047>0N\A,0&=YP6*&6';E*U@XP>ZDG:NL&J7H@W(>2B[
M0!()WJLD3CT0QU_@^TF$ONJ#XU>?__KC_LFK-_1O.-1R$B" %B=<TW[R[OK>
M#AM!-L&[T\&#LVP48=>G-.M"P(#-P19BU8?/5&9HHI)@BRY?NYRZE,8KTW)A
MJ@^17Z?^5.M%JSXGSF1B90(OHK./TH@@"MV9Z;!$<9\Z'^N2QIPZSZ&SB% /
MW,EM"D,CET']N')9.1>)PXUUOC1I2-BOSST?;/9%?<S@?E-*#[72DE9^5:)9
M43*O('">IMD:P/MJW7SNA%2C0B^>?(M7Q/Z,NFFH?11QGS)YOZ%19J/R@ J-
MEBZ,IWF=M#^SL3).-;<O#' XHO=[ZFA'_<G(Q0&T("X2!H\G^$_"G],_B5EJ
M\=?B;\4QLJG1GV*5W!34J8UP+,$ PHLV<QRR%5Z,1QW% 5R@&U!SD.9\#X^1
M>FC6(,3(A)FIL=.7$GTY3KC$R#_43B,W_ZR>[CT-0N49CX_M;9?FA=N.SR(0
MD'#4VB-.BU!?V9.$S2)1DMY'E1@?"PV=R1!3Z%DOE^931=0/OG 2'$'(N@!)
M&BZ>\O2,@WR2D:6$T0EGI=QH#BL:?"=WXB[ SHW4E93]441+\!:"B(67^?AZ
M1:GL<-JW::R(;4XQ,P]OHLO2D'_::TW\L7&M%X%<L-];/PVG\$5UZ%JW<AZ6
M'\#6,4[A@!Y3%,[=%A(D*,FLIB,()%83;MQ[H^')S5]MVYE@9$[U']5E6WU*
M:]G:!2J?$#W^?JK017H'1'_CPA<PP\SKV+W<C1-N^2V((3P6;*]H?NY[8329
M,+J7P?291F$8.V/B^ZU+%TG5^'('#EQ1_3$GXAM&>:9N@DR:.8V#>$SXDK(B
M6<R&NG>/MN[=M;AW.Z_FM2G-J$JD.)Q$9(C?-."^Z(N*EBC*.[*Q1T20^[:1
M"K)EKZC.OI"A^)<KSE(U5?G-< ZJWG7%)]#2N1B+][&;=Y26V(N:&R-*&+S1
M6[.>T+6Z\Z[I['I0XQ);#(.< '$3DLBI*E+H)F#V*QUVOH'/R0F1NN*RJK*,
MYE9";(:3ZJ"C*>^?J< 'B(>[TGY$.;]>D(X67YZ%K_?J[=5W,+DUDO:G7*Q(
MD>Z>-79 !T=CS*!^=QN>$E^@X;Z[X'#R@O#W8&QX@].=-]*%UY5[C\*$8-]4
MB"7"%0@&,;NQ[ODARHFUT$UM)( I^P,R]')MA3H?(VGD58_D:]TI#\UAC%Q5
M$J6TGQ;DVBRPSDRS'C2WW"_<DP!^!:HY+N\N (M3M[$(HPR7Q\:H9H&,'5&/
MYA#O$ZRT[F=,GYEE7N&6=($0?4Q/0?@/O.HH0L@,+^3,C%31QCYP@=HBN/:0
MN(4P$##-38<176UX3ZDJ3 =Y8P@\0(9R 2(AIU0JB&I:@7:*YWMM#>>9.E+D
MLW@MF'1(B:J]JI+:)1G=DCL35;Y^-M3$?0L_T/R[0%']NENJ5NW.VIJ)=>JB
MSI;5.'1A"#$@Y9?8@-/9.FC25)T/ 351# 5(9L%/*YQI)R+6V&MA42W8GUS0
MNWRZ_)N W'QD#=3[LFOWO#L/7Z#^J)<<1RG:-DI[\#6[)]V?DKO%B8H"Y9WK
M&!TIXS!][+[HB !9+_4T8QMO=Z^NO:VUBEXJ@5[0@Y4C5PZF["*R@#F5R=BV
ME,066>SGC;@_NLB=3+&8-)O1D(<MH_O(S-@%2&>9%QBS=DP+V[$/GL4"# HF
M8R.F4+L4&<NQ;97:W^FXFA2&D0*9K'@6:0":<VO&[^.K?]J:5YYWI4U]E?IS
M >-Z%IE.ZX4]<U*M^=)KF,]F@UHTZ)(B*F).-%U^3T$'8\\Y^QE22@[5/7AC
M#F"Y=1^$@RS-IQ831UO%%"=J4(0TPWGON($!Y%CHN 45M\P+VT6.VNJ2RQ-Y
M=F[RJ_(4O9*X0A&WB2ITI$CT5-P7^?(F2_.\^K53'XZ]?&'_3.* #A8MB#XP
MD_<KSSON5EQJ"M0=\34C]:*2'KYXU]Q[R]<S_^/W4ZY=K9,HG&Q6.'$Y[=BN
MB=]ZV=H"CNID3:M$@E6UQ!N;B/$,M*/? M[I+E4E-GKX.:E1>#MTP,7&8I;>
M>4XQJ=]Z$Q]I>P1)B :L(!Q5]VJE3*[ Q!D7N;DHH,CQ6JIG#;I-+V\0.B0B
MA+ SO?W=H!JRO7(J ##:\A-D.SF,3>17>,7CH%45!F;%$BH]7.6D_9RATTC2
MV40F K.5)MK:0FY;G>([ZA3^=U J1#E%#4(&QNXFF>Y@VVQ3*MB!6"K#)OI2
MRUS\.P3;;I(WV8;!%,X[Z:JD*Z;1U2^V( >=H]RIHNY[;\L,%X!R'9MH4\6N
M>D!,0(P,(''"F<JCW/'(ZD/U9 HC7O7><%409Y!F7(PCO91RJS/I\DLIG\6!
M-S/>>KR-J6X ;FFFHQ>M7K4M2_[.59$:L7-)_2)]N6JQHE-5Z!;ZM0[<\U8K
M5K2#?L\VSVN,+!YV-++8B!%OT;2^ 9J68.DZQG0375>490W.DNIN]L@BT4.&
M.?WHUAT',1A$0<800*[1S,W=* YG@6$X?M; =[#)"< *= .@* &;/X[9I4+-
MQAD7FF)U=<)H)@\@7$EP/REC'% 9A\"OH+'#5;\J"%L_T G"#.*^X@F?](\/
MZ0 +TNB,\,Z <'?'V*L,%-.?]3]>A5$^BX/YSU%"QT$/O1)V(1(?U80[!/V'
M_135ANB%OQ9!?++?W]_?1UE<@  N0OUB$=-]$M,_%6'+=Z?]@^.CA5_O]0>+
M'UTV+&S$WO$W'W9XV-\[W/_FP^X/^_M'!RL-^Q-M<%93YP9\:PN\&7$^"Y+_
M^F'_AQJ%_+SG#>A7^AWK_:DL9-$S0K)$U? 4AC.BT--,2+XEB=;X4K]N.'OP
M]ON#DS:]O$'2Z>S/YWJDO1*_,"T0E^SBB]F1JW^5F&;Q5JEBNRUV6_Z#PJ97
M;^E_WJ=]^M\/'SY\JSUBA6"CMW"ATK;E2,XN#78'P^W%<_;CA!J[;K?$X47[
M_;V]OVTYS^H;=GA 1-38MBW3D4NVOSL\V%ZQ+==9SG4&AUNF\P2F<W0L3&?+
M<UKV9WBXNW^TO6!;GK.<YPR_V8:\")YS?+3E.8OW9_]X]^!D>\&V/.<1GK/5
M<Y["<TX.MSQG\?X<G.X>;2_8EN<\PG/VMSSG"?MUM+>_Y3F+]^=HL'N\]2)O
M><XC/.=@RW.>PG.&@RW/6;P_Q_N[)UL?\I;G/,)S#K<\YRD\9_]TRW,6[\_)
MX>[IUH>\Y3F/\)RC+<]Y"L\YW,:MENS/Z?'N8&_K1-XRG4>8SO&6Z3R%Z1QO
MG<C+KMC>Z>[@VX5"-V)+MERGA>N<;+G.4[C.Z5>XD:5$9^$.;3Z]#8:#W<'^
M$QS-VRU[,M?:;AEPM=,G<+6OV["7P/6.!XL=V3]1%>(?K&5=4^GJW^JP*<TJ
M4 M%. K<4G0N7,VC!V_GJ,<5I@8VG+%;"%O5-HMIKXKM/A#4&:Z;)MPE*"A"
M'N/3R%,O3ADQQ/;VQ<)^K/R%N6>(#8X5NT60S0WJB0/#T,#K&9<9S)EP6E8?
MP(75K>^9 2#3Q$!CXVM6)4"IG":8%TN,@2$Y#5YF!JXWT[A-[]6=ROP*RGL%
M9L;%M.$F[*UKJ<.HX000G],=]S[(E^]^Y:+8MJ4M,\F *,L9@]FDF09X;&Y3
M4!19-"H+W1?E6\X0:$/PGPD[)T!\SAFB-W%G$#S0^UM%V!#!DB$K0#NXB[,R
MFZ6"(ZTQ00D&<.)0LKL99WSL=M58Q$X IU3'7H.WTGA4%M #R!HFPI7L4:%1
M94W'(&J>J@R8JLQA,Z%V3AK+VK8VV2P8'FQ?$40Q-YM#MKB<Y"LX:NU(7\1U
M%Z!%_!'^@Z":\)MX[B(",X-_ F]"4.,B12Q1!=<J(HAEP[-;>66]US;P(G63
M$J \=8[3#4GSO)S.;'NR)TC7);+0;NTU]7QYCS#*:>)[U_>I]PM(5>2.;U,$
M2[N^3<N<<7Q">"=53@/1YMX;!,+(<F_G/_;]H:G0TVTHS6H>VX9@3J=E07HJ
M4DA:-;"81<0?=S2+Z\;MV<Y"C2=,8_M(8>-;N"Q S_H]RU0.V3B+V%=GXH)]
M1K(2B5GOM,/2]4.5%FM&/5D@*JI]UKL)VF,%V'!_K9!4.]_Y[33BSQ'<Y6B\
MPGP^(_9UI/)U[DFO3J'$19&RRB28HL;V;V6: NN6;\OO97&;I>7-;5.O=8F[
MV_U2ZHI:-XPF>Q[8:1/FD07XNUU\!ED_'&)Z)]Q'-U5B?"5FC-$4Z0U6!L?%
MN/[ Z%E_USP.81N#C ZVQA*;!I-KO<QM:^KZ49/V31^2^NUS TO]%H;2'J<$
MT5P!=-WRLF5444-3;K&ZR%HDE"P^QRJ<*=_HG B VB_J-O:%;3VI$;/K5@L^
M\XQ@$ ]W@MY:Q0ZVYZA>IF_94WJ=T'&CGM.,J9MT<"5M)0;K1<.4N_1;FGV!
MJU90Y[Z=J&>;RS*BM.ZA7$6M-RS7J+I+(?.HT4$YY09L=^KI6KE%S>C5>U,'
MLUD<,9-A,6,@^=J5 >(O%9\KXP(:2./F(Y%PI4=<KSC]G<AN80VMGS$'Z=&H
MF!L'792CZ30VK0U_A;>>__HIMQT3"$-:=Y:L=0_'Y2NXPV(9HA:>EH7^= <[
MTJ-GD_Z43IOT>O(=@4$".S!58?7%R*)A;XTQALU4L-5E;]4S_I@8*\R[BA[,
M<5_?PUZM=-X#_VCX!TX\?_S(<X4 Z[ZTT&&7+^)1:X_[5Y,!V8RF%^82__\,
M^RM;)$D#'KDBD&6MD4\0YVGM1+#W1E!H?-GW009C# Y];[@W.*J+53PR?4P7
MR"96.Z83>TCPPEJC"U+<=0]ZE1?15'3ONB*W [3((+M\1T)$K5<AT)N C/,T
M%Q% ?;CJ[:[!?SHHGYO1<O/7C64V[)K82O,_*LTK_$'WA*@R;)A]F>$)O5'D
M2*:K*-?O.9@\)VO=])$"0=#[EJKS&OG(44<!MFO<G<.0'X$%<=/F"]UA&[G%
M=?"P7N?5IIA10>^R:J>WQRB:#F\W$M!->G+,\/6Z2\:/8YPO4[C);=5MGV7U
MYG; 90F:3*^>(/$I2[W/01%X5[>(-EP3@+I33-=I^6C-+J6>UD!:./,STRF.
M=D;K]<ZQ6J$W]!.%=+'1Z\[P,>*51U)S!DJ?@;:)6CJ(XU-NAW-^'5J[XA1O
M#?1M[\3C![G#009]!IF:J$S:;NF>,F0E=YN-$XWHR]P!)BZ6X<[^BK>!E,+G
MQX3&76!"_6Z39NW\-S.Q['2;6+8QB65/YKT5CM8!YNM$=_]5!K$V#6GFIGE:
M.1VIC)(LN(/'1*G"JC/2_$@_B5VKJ461_#9-"R 4_?/79113_NB..)+CN?\(
MVP?-Y&38/SKZ"VC[[)\FUS7\UC\^WNOU5DED-F-WFOUUCSI(.107+IYP17?0
M21])7J@@K-#0\A.=EG$1L<M_-'\BO;VC"$8<IV,WD=)HN?(WISLN'"BF+J9)
MF_9,9G@.-)2@%=]-M>+BX38:184FYM=R6NMU?P12$!'KUHG4-G$&?V$Z$:9!
MAN48\]HQ%X3375/^7VRI&)H>R=1/L<B",?^M#Q@);W6>L9QN@:,,3ON')^T<
MQ?N;-]SO'YW\I0?JTJ\F>A[ YC,QC5VWCI"EY(*.;5ZEHJTU_$[WBH.)X)]7
M]&.L[Y O0C5-X\A]W#QJVOM&U"<WD0@%-;[#A?I/8;QM.[?K[)S-ZU_TBU5X
M @;UPM_+O.!9!]C6FON=@[Z '3IQHD!TB<I,J"J4WM:\ ^9&FP$SM>LH_,N&
MY#3?ZKP,Z<##X[@,\;<1:(&)&S[#D\7\"!R10L]M_&$F1QBGA1?C%6!QEE(G
M5T_%L"U9-,8@#-^$QELFT0.>/(;$6KY-5'&/41\,:Y<19K-1W^DDS,?!K#IK
MXF)99G+6%TRX%L8%?EUF]#RE< 4W:O%:<QU/F@5%EL9ZNV,,_^H4">EY2E89
MNB5B'6.F]/4[Q8%\[7-N\5=(4#BS07VG>RNN'FMB@)$4)AVP992V,T<NI$^;
M9TE7-QM',.K<I9NH4-.\A34Y:>K4D+N6+%/J(+9ZX+=@^IOX!UC]B*A+->?P
ML]0J;* ;A QRE$S_S0U?\VKZ^$BS 4G@;EU[2[D!'$ ]D(Y;W.*T !F!1 M6
M!$ZRXSK2NCW/_9JP_?9->=>;;M?IPV\ZH]>J\V@M&>Y,B64Q?)],,K1P'J[.
M;.<[(<AUD*(H/'(/5)Z2?@!/<@V@Q.&X22U>?I@S\.LI%Y#P9F!EC",4?!A^
M9B7C+ ZJBHIU/_/\-'O3\HN3-QK#Y;X,F!=R+O4!,8L$^/>T,NUG%#X$G?!P
MW9$"W.)N;A/LS9H=F'BYT@G9&4XQ')#:#2@+&=V;8#Q6,RI['H\QPPQI>P8"
M? S&)KJ,RP0EK!;68GQJ:=YS;H1/HCTA!6\:L<1^2K?F;F>&?%)93DK!S%C-
MI+R1+]%J)]JSP_X5JJ\6S9=_CM=;J\+J+E)4KY@ZY8%N7VS2>TLR>-#<@\%N
M4/E,D#7!3("I)>.YO,GA<FBQ2YF<K2MWOB;]4_/!)=HAURDD.O/0^"DP01KS
M19%YC2EU\> O)E+'3H2;+,UQ"53- MQ:@9[DLCA6&F]UH3X,:?CJ2EI9SVU;
M;HU,4]LDK]%&9[[,4JP:B*:$[RN-4RS"Q.C,7&&6J%GODH1I?L;LZ?Z?OZ>%
M[0K??00-(T+?6\I^J[K@ )38'')"M.97"= !/YTH09>XIW1EROM4]\H4O.HO
M\T(14D*:!S%_MM ^,S;K#)E*.653L\V4)>4ET,+A^>DAWF"X;C6$12V?2!R-
M4='V\39/R1U!KE/R_B [@;.6\]35S'@PCA?$A^%(9X='HXS<&G15Z9.;0!1+
M:^^6P SA!RBO'7FL<Y-)'HO6B\^ W3Z#W<0Z%F+BL'@J):1!YAZ0!T_+%O2K
M!W8M]K2<(RB3@IV7]N5(STCV.:B_&5<T3E'M4&&EG)$5>"QWG)O+@9NA'2?\
M5XM"[2]2T+,4_C%5TQ$0M@9IP<<UZ 8_3IN"@U)1)'Z.R\ _&F]L>]$D3N6Q
M>]!'TGN^/S"HG*6>8WV8S8S(#O:V8==G%79MYULU&F]R&\.(I@JX0H*0:7QU
MA%O!G_D\1U>@CY_=!6#K(ALB=QR(PEE<3D?Z'H)$0_>Z/,#7YG<8%)[!N@=8
MPQVP3GI:QR:M0)*@I7;K"B_,P#)@1HDN<52A8%93.,L;_OE-'/S;_-%R17UO
M'*N A\COE>)Q0?6+9F98A(/()@&GJ3+'T5H\NKUY;,U+K(9H'-W,_)H><&%[
M)97RY+XI ,&M_%<9S8RZ7J1I+/X2X]1H.,&U1J2U G2/H%QQ##O9X-QZ2V0X
M.,9Q&1N+8%EJN><D$;'S1AL[8=4I8J03'A8AJ>!80%H$!$8S@Y]4'-Z,[Y'<
MV-"XV4SK\#:A':",.+C/$18$?H);0?^6MU9LI4S=R/)@_F'*!J\M#VKF'*-"
MK6=(?NYTP3KN@$'!*[((A5T0*D>!LE.FLPH%[P;VZ3:X8\@;-9F@+PNVBT)]
MN-#FWB\/UH-E#@8\S59/L+*G=KO4."BYL*FFDJ)B$DVBL5?F#6KR-7 6JH[.
M:+ 2^*2Z^B\:X*UM(K7:> V;4*&9',L!JQ2AH1-@:I,RAJLS4>V_U"0LH:Y:
MLN;J#H\BO6'4,7J.U 6%LVOB;XR"F(5\H>/QM8P0/ETL]LVDZL\=KA9B&@7)
M%X] (S!<"EL<%7ID"JMP$!7FJ"]I8PO8 P.+3U(!58-_(WGD' 12B34O!WM@
M7\[(T$C*:4_0>!JT]S5;Z6O2)#*M1T!;:94N$*)5X/UH84)$7'( S*PJX$(!
MPLC15M\ 6S95GU3E27YB'!@5-EQ66Y*V&]7Q.V[_DFF!FW\N.]D%][XV@9EE
M"6_%:0F^3.>S3_-RE(N5MA/V=H[6N9D])PN>@J1P^].Y(KO,1#C9L0?"P"A,
M^%-.NE[R>Q!.J1>FBF''0G67%EBZ/LH+L/C9E4!1Y(F'S@D8@,Q 'C"T\=X%
MT6E;WYWA'FOXDTE,EQ\?!CZ0$!>T>?H<^8?9Z?!*V\AW4;[[UQ^'PX-7N_#/
MVEB@/\&E1[@OQRW[M!<87<9OY3^VS-Q$JAS,,N-ZT>%L@U>V+$[E&YQ+JE?'
MT\C'630R^A7;U"*C:1#7&V\@]QS$,1<ZBK60KQ&)]VD9AQJ\#4B,[7F[R(G9
M5=_NMF^<2HX:+59X1<'H>Q_2 B>$I&=":P9OKE;^932G=*;EX"R8XU./NMG,
MO2!M8[)(H:,\&:"(&SA'L%UFNPCH .\@Y5"[5/@4V7TL$MUL1V+$%&+Y;$:!
M?=L1S= )'8I3!6GC]S*I.=$E>T,K+&Q]K!9Z154!R6VDG4O/RAVYYK)*DAM^
M"X@SRN%\@MM)_,\Q(C^S8L]Z6/?EM+O7:W;]]GSM$6 GZ TY(1J T,;K20B@
MJDK@<^1'/@%28Q:G_3%=)>)<XAL1,9_E_(3X5>T#!OA#([14 41$AOEUD&^2
M&$&6H?$]%:"7F5$Q'5E%&:HB?2CDU.8K&(%&_XUCOX.]D_6E^$0]TH:>Q,!0
M==*^,S3&HEB[X!L^MD==:T0&42U"C >($S+R5#XW@4#TBA?I#.@CU-%*ZU:"
M#_,*]F 0_AZ0;;@@E!WZFW*8?_ T*YY,$T:HNC3;#FH)'L+SC@ ,MD59?U9T
MH#/)CN/>9]7,@J%H),BZ/&?]P>#G62^B9 43B%=,F<"8&B$),02*ZGRZ/(5X
M04JNS<(E/_6C2:?/2?\^JV5+=MHUM78$FFJ=WE0%R;=61@X.UG<%!SU<E5M1
M0)?0=V^@;S(+JHD"?%UM8(*2T$@[X(?1LK\)L#JM!H10R7M]%R2";&8K9*3$
MK.K/-;G[E!V1N/FS%%E)QIF&4;^6=#H$7L?O28L)R*FB5^6@#E(: RBK^80S
MOZ@J(+^-9HT,6QW$T69Z(=R" CSN<&V5%]60&BQQ0TAH2"34) DI01.JH(8F
MJN3HU')JLS4MF-MBJ(^_X$Q'7SN<.!*,[JP@UK&[;*[S,;) ?^)[98)NH!SA
M]X"YWROTO9'=0Y_YVJGS)=( C8&;+!F4Q6V:,?2>T9(E>9SRH.3?L_2>,>%@
M82Z%-M-G6G(PS3N:X4P;B@PCC"?S:X%FR$\G=V+B2].:41R-:]$<':VE:*24
M][B75U]97P[,M_B"OLXKE6<I:3# XTP(_Z=%0,,&4D6?+"16-[ ^3$L"DZ&0
MA#(=O)HX*?:2Y%KH!?%=@>\0JD6CP.9\6X.Q;A2"3X7IN)R*Q<&KLLTP&'9E
MCH$P-B[1@)$+GUG^(1.*DO;K2BF8Q"N"!UK+PSA"GZA$4*VGU>Q7#9O;9TIA
MSWA4,!2P*"SQG,N0"O[GQ#=OPB8I45KFMG N= V#:M&>J[-HP24;A&-1>1O3
MM<&HP3XG;>]HCO]]%:)UFG$?J%O*']E<I(MJS1O7<,ZQC% 2;"F<@M?--U0'
M%Q73)F^)@)@5 DN+)H7/9:2Q>91(!BX#7!OTK#&#U?35FLFMN4B_?<(8;["!
M3AUY@,D',;F<Z(5R%8S<U_(<-@)Q+Y-_E7C56,PNZ^ZF>Z#(?FK/=RNH,+RX
M7B\W4O,4V3'FM'"Y.8P;22H<-6=CY-1OZ1A?)QW^5HMKD^1Q3*$VP:I5+-B^
M!B/6GAK6L?AIV[X&\UWP'P3*!H)CK$S9.'H%DS%36*L4&L&YL"R11PA\F3AX
M4@9Q!4,:?I;$##-@\9$YK-'XL;?#3LH9&H49>I,D["=W4 L(M/'0NNNQ @ 7
MJ"S2S.'B)FK8=J\Q]Z$L*C4+,A4FZ=K65B),FX%'&?;J41C86=R?&ZVNLOL8
MME2;B15'L*2$=;O'RSG.L0.V8\\!>:FXNYLR9D&R7$7$;);]28>$%>8!:K(6
MD034.V <TRC/1<L##<4F%0+O<@,)UBC5I>H+*^J9)4:9YK.848753\BG=)(#
M9^A)_"3-V&V](3L^E!V?F*1"4;]OJ6L/39FMM&@Z*K-<RL"07&F'<]>L:?F1
M*0E9OFG/VUL]W'JKU^*M7NO-V>]=BG91]8BAE\*FXI"*/"K8&3V7Q%.V;$.E
MN-=D5K+"=I.!.A2*L[IA1,,/%B45;0@O.NB=A=0[/1>K''2]:2H6 &L81N/D
M/]LK\[%'J'CY,?166'A65Q.6Y";N4;P(<F63MO=06+V;H.]4+SDY58P/A1%*
M[0[)I025FI;J_.E:M6M#A%!.MV0BQ,\+NWRP]AYBCL=K0^COJ'<&E(0A;4PG
M3Y-2,@T,%)"3S+MV0P+-!3NA3E@-B&9E-%+*@Z'[!P0;D@.OGH=K@0(JB=*Z
M?F8RB<:<&,K.ZC2SSE=^=$/H[KCW3XD.\)JI\.,6(1)17+N1@R#$AN[89I/L
M (,L;?;%U!T$>35KUF1(/X.LMG4#L&\4<9WT,'$@<K'@D9)&6?I%\,W89,WK
MS3SDDFW(-IRV&N[P[]+ZD<625P^(*&"KP3A&1LPMHF+Q,$559)-V9[ GVX/%
M26E&H4'DP14@D%!1O9[X)!M8(#H%3ST @XJ6-#79J(TS#B$66IE*TCO)=70<
MT;XMR6=D4^& 7%-+3F)6\]M"^(O*03!F045CP5T0Q71U)]*$SZD% "5FHS9\
MV&(DU#%L$G4#5EE@ &(1,Z0L5&XSBB7\3]87J7B.&V[1?E,0AX'7,K8 C5/4
M^OJLG2=QS#_R)HU]H[)I+J]-#-ZM6UTLEGC&B==3W1YK4\YZ?X6SEFJ,7$DU
M.&[.+\&_@RQ,R]Q[KZO*Z^X*.HK$%A#I5)_6\^ B3B4('U1)S.5'?#DY<8=>
MCIA8U;ZX%*"$-1C-V#?N6\=CBT[*NZB@K_-R),">^._QF,@IESREZ";)-RTC
M9W#0TR6W>)#9G4Z\WI3U'?9TG2KS#]'1%Y>Q>CM4HA4#HT$%GN7)DI^[P+65
MS&U$U\42O!R[H.K\;E1E="X\NE7&MS!GR4+2N=RV\)TR\CE"#MJ!KO3*@ZGJ
M;;++?'_K,G]Y+O/!T<+XWGT4QPC" $HN(6V/M4<<A 3H&T"QZM$@TC/;C&/9
M#,J5P/2.R22*,<?!<3AP+96&5C&@'"HTB0NJB,A982I/S:^Y)ED+Z Q10L15
MCD 2P/G@#UO./",42I*#6%'$1MO$RR-8>P"C?HFPM(O?J#3^%+*K+*(_!= Q
MFQK5.%;)#6H0-CMOHX[OQ(F<YN,RGF$BG;5$<LR^+,FC[G@Y4VJWS&IFMEG:
MY&GO_#;())^3:@<)%A-+S<(T86MADQ8\U$8]BNXDS::Z!M\D3.IP..U(2]-
M!!G2VB<CL 09NXC$^#=0K7"A,2MDWHBYF) +YW&UU-T[Z*PSZN(Q-F7W FWR
M%:7W'"=R*N]MTCXFH#&^+TMG3B4*O(DR&:>5E>!DV- @'XCF.RMOA4 6:9Q
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M[XF5^RR&.8&%+0"JD>7OW#9^2&KU)NVMN]3WZB@U,%&4O3=:"G*7;E!I&$7
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MF?VLL!J.#(-?6>=LHPQ7.Q>EM5TM=THOR *(Z'YQ^($N_(XXC)TN)@*9TY.
M":RT2<7];O/CZBYV@17KF%&0$*P%)2%Q(W5CEXB-082$Q7[LV\0$@ILL+3$I
M"DQ/LER"!"PZPE+ <=B\94<_V$1 :3G7;_'/?2[OI00JVA7^)1I"$7R0<PRC
MC<HH5"7N6R!-MF')1TN/USWG8NVB4P]>XTM0#PWJ&[&S>9TC;9G.8FRWE5<\
MQ)B@1JD/.+K/$'*(-Z")+RB!\C.*$3N\"?8BTLV[L98,\SF*Y9=OR<UJ650;
M*]?SSG6!F$0Q80F<0EE0"W#*A"'?H;2&83>%-I'U!/WZ#.F#!&EIE-*C,_XB
M4BU0%5P&"3N=DK%=*Y TMI+;4*M;^K.#C[:CUHM4X"2@U9.@3&Z?$0+IB#'3
MD)B0C*@+H8ECD;=%0#:,URI*\)&\(1XX3'[8 \D;QV379NRI%Z;00JX]UQ>F
M47W:R+K^+@/G$4=4!9EV%3?OXH'\,%K<7 @_72^415$$6*#M<5B))"O0C*2X
M*$DEI@R"L3(!%0U2Q)Z];"[(ACG6&6 +*W9.YB4#QOG>.&:_EM&!I>*6?73F
M0S?%L\9(K>Z/11;9E%",&$-O4A?Z</D4NRWK?B[@)BG7ZE!"J%2(X@^CG-$!
MC#*Q1&'@N8>IXC(\T#%2(5?[GE6XWUP'NEJ\?ICB%%C\&NWIJR4\.1GB%N(%
M78]:99(7U#0QBF%QI)HBVY2@;',(@EQ2G4C!EW<X1X-91GFU2A=65""3AG>K
M>"*ET%3M[E<OJ_;=VKUQ1!^I@':[#?8/K]VO;@JF>_U>,NWI 1S(Q$>@NQI*
MRP[[GZ?I'=7!>!91B"U--_>W B[4TSQ-]@ YWS0-.9M:X%GI/<I%&I'J7#JI
M,=P\7/@8WD.!_%X-?7"D*K%1'73$N.5LWG(!VKBF]:&CIA(P^!DE<X3L\;<U
MVI2Z["1Q5K.1:>(TB,TUEOP0P_6-6F1SGVC*BXVG9QW1'.YM(YIKB6BNTX(>
M]SIM-C;%5L=,1]$TC.-.$FY]+% O&,,I3M'W!LP3/0H8L[SW;3 1Q0&ZDA 4
MT7< $>DGBC/L86NPB$=_B<+ P=/C)/PIWB+XV\@.RN&5(OE<9#'Z@XA5@_5&
MP^",C6?.^ Y)3B<W*C/>/-]QRV$2&T=?4<] ,]CWIM%#(:G26@TBH!L$!^0B
M#L.GK:?-YLDY4D[[44C*R4XXB)._J" N.!!\%4P4+)/0)__ZX^#H^!7_]_ 0
M+K&G$*WV7WV_]M6^^Y5@5N;>\'!X,MB14KCAX>'>0*M<C[[:M\B7^WN'>P:#
MBNKQ^ =N'C:B567J%C,;0<A4J?LSV+@I(2.?:S3E*&4*>V=.]6Q<T,Y2<@X"
M8AP,O5_[5_WS?F6EIT>P!EGHGUPO_U1[XOSB\_F[LPY<:VD,?U5B!B-Z=\XT
M-!<K?)^5N#K^S0=#1_'X]E<)X)J<W%?Z-N5PU@EZBWFTP6';:,.%HP')@/E
MV?R2A:TIYC.#0A+!K$ O1Z>+7M'4PKSKBN-*]N&T;=C!R:)AS]&6\LZBK'T;
MCP\6/<@WZU,:@Z: ;Z_LW_Y^=9@!,(/J,)\E]SB$A65@R.2T08A^=7)ZVAR
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MP;?0D%(.W\,9PB<D<N[2^$YG-+?R 0+ H'9I(G*6\*>6S&[D'6GFU,19?H+
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MC$#:\L%&XFG&XG4DC_((+ ?XKQ FXR2.6\$C2!J1"ZM;;:WP,5&F\Y[MJ3?
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M'5%UF';34HEP)M"B&%?F/S NBWNE DJ+RG56>DG2F&*YZ$.'"UP6&I61DG6
MNM$]A-!]":6.W55=]P["E+5L9-:6)7!M-'*3"'/#GB!LI$'Z'9 6[8 DM<UG
MHG3H'7&*9#<L(#;<!L0V/"!F;XPM0TRY;0+G==1;X^CZ?HM5IVM2([>BE$HZ
MIMC\@6XT8]'5/AV)?SK7SH<[4&@2 9QS'=A+NT37O)*FAX.>:**XRL/67A(C
M044TE>;FR$A%X1&US8DNC6-2E)@-N$"UZ@'--O3N4-6U-#C!6IB=_9XTE,:%
MI>A_=HP_7"(J8(/](::; <>_-CDA2@?7SB@Z1TUQC%479%E4R8]S6[D$W,SE
MT08N)IL')ET0&(F<LXT*CNR[2""Q.1GI,G#IC::-5=XXS!=2SBDL[\EW5E%!
M,-E'FF(N>NX\#O)</_T_#FB."21I-[.2"ET8XK7*"Z=;H]Y'#EZ0AXMV6/<2
MD'<CWJUN^F3WDK"QW1!AS:N(>QC<<>3P)DU#Q!1')T$JR:Q<,+S$TA?Z<SIX
MF$[#W'DVJ[^)DIXU^#<VU9EC1YU* YIF2C0C)=I ;6T9W"R:.D5+AB$WCK*>
M!;XZC@H5:802MFCHGHC,-=U,$#IS6DY%8N[DO8H&YJ9"93*[.O'KZ!0G\NNV
M._5E:]6M=?7V"CC!?Q/A<GA*4)@43GDT0K2%3,*5%GJ\D2>UY'SY1F5:^^1F
MTK1/)A_/M.LV3BA,44T)SEJ?'^XF];^J'N)'MYB:@K(Z?I^RN8S/:B 9PD$V
M>>MXSC(!+.&8RTI)[\AKB!.I!L8/<BX.7Y)I5PT27Q!L]$529)R:9M!HFI8$
M95ES];R!S.=.6&+QUGB#J8A>VE!.]DZGWTF"+E-S+2-2]P"P!..T[LHY1<1>
M".I+9DK\C6PQO1LX64O_OH(EW^AW9*I7T$GP*$1J9.H_#$Z"I1RWVYCT(8BH
M'37OJ;E"U=U#01+>N6ZV>C^OVCXB.339@XD,DZ5 V1*"PXV7F,V)R@S;KE-=
M\C5+X&OM09:<.!="53HP,,.MJA:>"]C"]X !6W*_1G3(5\!0_2JB,WDM=J6C
M+/V"3"C0O49 ;<DHG-2@QKDTWC(2P,Z<?*5ASEH0ZC]-T@2.5@1?+#(%YRH'
MW.K<$7P5! H>#&?,F[>#[B>D&>)GC3M?W0@#!:+G06D)VL1'K 5I36_+?]@Z
MUX#&2YAKQ<M8\YE'JH$8U=2D;(O(*MJA WO\"2XJT%J4>I>7W+.;G(\+8M2X
ME5K9L9KG)?>0-_"#8T[Y6A+I'ASN[WD?Y4Z\AEF#J9H1JN)5&<'%.?>=.?K>
M^9EW>K W/)0D+VNU:F IJ^6WZ/5X"(Q%%'$9&/TO$H5= BLC81/YRCF-NJ/?
M%>]XEMP70%<DRA' 85Q>?60M%AXX_R?F^0R\O8%W>J1-$CS&NR F+U&UE?/:
M$X&6.?^:%- %H( >8TZS?V86D.<(S]JDT/2!QBI*6!6D1+NJ#5\QK4 Q_H+>
M'+SY)M6?Z;#5G)&$="2-$=SM2>3@$/IU \_<<^KH)R $/'ASGTUNH3- ?3UL
M/TDDH-"M/R[)6<2M;_AW.#TQ#]-)73\=D2J N2L9(Z#2+[54<N)IAMX7-M%!
MT1-$7.B&6*((7<!>/$8"LS:!JU&$EH>YF$6<'[ZHP8K@.-07L[#ZK"U5T_4"
MRD$R_G9.DDW<?#:ULKW32NU]9MA:1]:)-MJT[ZW>ELTA@<]<*&S,6@.$H0L_
MPBBG=X2^G2?E*Y+_R9VTH^K^_^R]:W/;R+4N_%=0DTHB5L':ULV7I$ZJ9%G.
M:,=C^Y4T>][S:1=(@A)L$&  4#+SZT^O6_?J!DA)MF8(T3RUS\222*#1Z%Z]
M+L]ZGG U<2\*3Y"T7-L&W&YP,,Z!%:@AA$<A2-,S^?VY\8Q^%X&2'A3HAX(X
M]6GQH)1K[ (RH@8379BH!PT4GT#< QY]I,/$O)E37J2V0,R&(I"<ZF>!R%5^
M7YC)62_>KX546%)4M*9X0]/?!]L4]T:EN*VGLL.'$$&#R[HKQ44GF<BJ0G]>
MD4:+-*D&P&@.*3Y54V0LX)*(Q.(>7 W2B9^A+$W;_-FSF"$YRI>'+5A3J@RA
M/YE'(BCGLJ(2I#:-]$["OI5Y/L<,S>JMY*J9B*RRM GCE#[85',S9,HOI>9H
M!=A^[1EE?:*:.6VN_STG_&[K-5AP4LN-TVKVRMQGA?4.V"E0Y[%'.:&J'*VP
MAV3CD<L]'==> -OA0 J<$U!EN<JVQVV/"7,\QK6D0@7Q#"@_("L"8D+YO&M^
M(013C7ZA +9@#;MPMHV5N LIJO ;UIUN0S><]YHM W 0. ?>E_7\*0-^>YTT
M=0DY5ON F!CBJ@)F%;KJN*C4AG-+.GZ44:/RBD[2DW-*9*&LL%J2,S #)GH0
MOC8?,"9G7,>Z"@7U;6--PG<VP<;YY;6J-V;;'IN;H]*<Q=)M2#_0:!"F'JU8
M=" /3?UH" ?S5".8GC0A1@1IZ$*< BXNVW:751(,H&XS<UCAIN6F$CQ1_;9S
M(K\%<@?"&"#/@UD?54IU*/,31X?P+^P:@OYHL$KX?6>Z,@9ZH_!2C4QRC0AG
MF3V1-?Q;UIY6Q J:NL2S]N[.;@=@+SDA)#PUJ:5TXS@[G!ZS^[6U(6-,XN)#
M ]0<1*,<(YB&]0#\(L--[:R?MY/OT!Z(74ZOL<366/RUE!:(_H3^2'IL.J26
ME'DH#9=)C,Y&#"P"HC;S1>MOJA5H19Y/Y13T\B/ ">-X@WX^:]6% !=/+3!3
MD(6ZPI[G"@Z##-@&B9^+*)=#_A0,]-&7, ?/W+[B(KTRAAO1BCMP/ #O"%@5
MXL^RO58#=<!ZS?D;O4<@Q>11SRM2>EPOMHD4^\IP^EV1&IBD4ZX849D=\C6V
M>$? ([OEP-%R!1:W<(.7Q-$C'X$)^2I0+V]/5@?=BL<\TWI<YGC &;.55RO5
M%U1\5Z:P)1GD9;$[>F(Q$T-I(YX^S%T-JY)]">/^E)QGJ0EV8->AZ_1J\SF9
ME9=DE0"]@$ $W(-5_;GVM05B SRL]CG2]SA];]^<DVM%:%-17.A"Z)4(:3A4
M8=WZ3EAJIV2J(95XI]5]UU*V0H76%'B+&?:<[J%G0FI<(XK$'?VR9?E<Z_$[
MGX^J<^;"6&SF\E&;!\X<6K# (?K**6[CPPZ&Q*,0^JK2)MPF3RTQM'>TY@7'
MQV"'30Z,BGWE+ON*/\UFN27D=XZ0U*:@.U<6 [D27A@1-/1VI-2?E$CF\TWI
M\UIG,]]!;YOYB%2+]0FVTHZ/T-%WT>DW!);'06J>@D$'#T)"O2?+%Q<[PCA+
M\";E.K#=0J16@V!SS% 3:@G4#&YP;-L E[K'X Z)>95<^ O\>2J/LL@+Q:/
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M UIV'[AYYW%.?,7O:U56OL\ABG:4X>[*ZVPH^.;%%GRSX>";IY"0[-B9%]=
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MWB_U\$ &39M@V\A7=&NKX[0N>TI5(]JP+/'>-DN\X5EB)XCTT'VOL?SNO,6
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M[1ZA&IUU:H09C-@/ MIZ40W3)RX8W6]V%'RE+CE%$^:QQ<%]$[^9YR]HFC,
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M-\>S167DB5S4OH*Q7R2#RR19Q2GXNI$@V3X2$L.,C9D&C4<A2*?H,W"%;3D
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M-CK&$B0?=Y:I3DL\6-@^L IP/8".278PW-=;!Z!.(65C\H?&C&J2]BFZE@4
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ME+^P_=+D7' K==V!+*,(#N(]CJN!AHSZ^9*<6$X0:%<L2&0N)3,\Y!<_R6R
MQ1=%B&&'2)UK#*-.&NAX[EQ-7;M;_25U3\DN<XF<4]4T%RH2_7C4<)2KYD<^
MM&O"7(,$=I9G ')2:M>V36E#"^[M//:VX+Y9C<NHP<DD;1#/ <C5;+8*N:^X
MSS?<*ZPS?*^]?7LM*O#J F!#1-P7[I33K\"40.#@-C[FG[ KI$BP:Y:,W*8X
MTJ][ZDA#-&JFK _.<YCOL$WL#HD^H]&:(#<9D3Q>!*G!FL+G@AKFZW_/(1,R
M25,ETBF=7(TYT73,A^&OZ]L9$S\&!:09"?Y9E>S4,4)):A!' QJOEHO.QJW
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M&%NA4?UV4[@>#OK*+G?Q]D/T/JO7[-,\;$UZU;'8.C?HPF<I-V&6MU@TQ*Z
M,K?Y)+D&0[,A!3-6G\N]I,,.^"60"DDHUM8-E1@3D5.ETSBS^="X,0#6KQ*L
M78\S7-,8X<B_[1>LDOD@VL'(J ?0HSN P)\%PYBF_6'"<V1H.]D 0MB;K'1,
M.Q R'3OW\GUR6U-63KI'TJHJJZQ&<3,27\T3?&I$T$.A,3.7-1&<[5XT9B@;
MST'1B=B6:.&A8 *+[A1XV]QL+;1EV'F@.05.$0X"N?F/%7C$>P?[^X?4S2N=
MA1P3?IQ,,G+0WY55"AQ#QV;V&V _P34;1[_N7NP"D9QY'8*81,!\A3FY1<\I
M.3Z^.S[IQ2(2)TLRMV8:^8TBWV ]Q^84.-MXP9"ZEV5L@E?--'OXWMMOTCRI
MJ!&7$RR$Y]%M.H2>OSBZ;IH9TJLB4@3_<WM[N]O 6]R]*F\(0#))2#:FR?-Z
M7.S.QIA+H=RSA>+*11U"2/_1WIJ,E0]JPI%3BL(N9\14\AJZ  HLA 2]%5&E
M<?2!5:&$S,3<EC\^S,O1%Q):K:%W@/Z^PZ1[-AM"DEZ3M.+>+"IL4GVRUXO7
MG)]]6+N4SU.YZ>Y^7SY%H;,,,ERU=YXBV@ 3="D=J(#=N2JI#X@/9L6@QJ>S
M-.WQI55180AJZC>I?Q->JUT'"?-U/I[IC@*'X:Y[.^M-*&+S;H/2NA.%@Z9'
M#W2C'%I'>>N:ZQ'9%^B.87Y1'!M;-J"6P-AK]:7K@#@;Y4+LL!A(Z"XMF+Y8
MOPE"5_O:O7&'+]6:?KQY./_!K.ZPU>R:5FR'<YF=@=PG4; N/#T7G;.OT0\.
MSM>!@Q#M<;M@8:W2-&BE;&DNH/F/N_ .OK1Z/WUVAT8X.%JG\6GK2 -NU!R!
MN%;:$XO]D<B82PE%7QM6-0Y:=(ENX 2/'5,G"/K3V*J@'=]X964' ":;PD7-
M<07.>1<8!J_;E@94;-=2&%B>J-F01'Q?"62%2O^3S6YMNP\?H?OP0TF=]! $
M)UDA!K6ME,K[G.)E0!<YWU8ZLL%S,[L&NN8).&VN4XG_AP!G<S UO#=39EZ1
MX-F<VJ-L)@2B5^BLHI<(5[=1-O[FL['S302P,^:%QFJF,0/&.T7C,DR;6\!.
M!C"$5%J+V 5%USTUY\.80%/3V;RQYQ]64PKV&UJ,TLNF2[Z0C%Q_<S ]'1JS
M/"_DR:MY6?H<(<%3.)NY^:A90E2 H7;K#5FQPP%R[TD?ZUW%8E?(S@C@BY:>
MJ)!A\7!J4N$BVF\LUG@2SQT13F",B:Q'DN9U>HO\Y][:P%IP5@G1 83_\',M
M758E_#,9F\/)A&%50C^;LVZ$+Y\K<(3IJ!VKD8;0Q&9EFS/*W(;<2&D.E09
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M>B9K:?Y:8V/]V8?HM[/+#Z<7%]%O/Y^>GWY\%]MLC)^[QGJ CYSS=3OXB$-
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M?EN].]JP["+,C8R:@3T<ERBA+LD:NP2+?ZX-*H<S8@;;U_@%"V0.RT@*V&7
M36_8/#8B4N^&:T:;8"]M^J$=M/?0,K%#.T[OCXW^V8%VOA',^(*[:'RU9.@=
M'A^<K$\XQ!Q5X)B+J*X0=-9T1NPXXPP,JU%(.B<+<@4+=X>D+?, F3=@#8,P
M!P\=:> J2EYER$N'.P*3DID)+&E1N^B#!1=95+$SMN='SJRB. 89QEF(SFIM
MZ*F_Q;S-U<AE<4JS4L8'SZ/0T] ,!;R&$RK0/SP,9E,82A2/X@@;\:7#,!\&
MN B&$\N&5)#7SQ^$^Q*1O 1%RU(:.P[S/@OVCN"K"N811H=T-X6E+N.1P1(D
M%6:;X#1-&AQ(7C@)R-"H,@JET/S<YVB%I/C",<S9'A'IT&WY$Z0!;'7L6HS_
M"]ER[VG4+0AF=SC>Y0<Q:<I!*!592GN"SE94)7!02O!%>QV8[0(;.M+NU[Q&
M>-7<>*%:5'+,$]9J.L64$5(MYF/9HD4UF\$NX^P_<HRYO\$-A;L@Q2@Q!4#B
M,E'Z%*HO*JI0: ?WDPP&#*//U0Q.-XZ(;X;#H1_B,^&X\W8"BQ9>R_X*3^)T
MAM][MWVT!_14H<D]B]8D,S^O.K><*<+9(%F0JW]7,89],-4Z%#M'+T/CMBXX
MECZD[R@":Z:5HJ D 'QY/47J3%BT,)A69>50^G&8-Y8M,$O"");FUS3!T=*"
MWH/_$8!\4BQQ45#@?AKP>J9J#$-B62Y/Y,&% Y"9^S9B92[$3":SS>&^Y4AP
ME!@$F2;TP@$+=:CS<DY#4[R_1W'73KGTAM[F';]-&^3107"#8AVG'+2%K 7J
M.3C<+)TP[12G%<U^'B1(6> N'X**1K3Y\E4DCUMPBJ]X0^J3A K6-7'H#&H3
MIV1;PEONKO=SK0*0RQ%^,8 WI+Q</HA+WC>HG",X9_!QP3HB3,WWL!08:D1J
MN8B/(H\#[R&C*-BN,CD^D1",.)A.51[%ML4P#JG]QT?DWYF9A#8<H:Z$ZZTH
M9?%8S42UY@J!?!S)=[> (S_I6I%L&@02%T+KF>76\H-3,-_/4I!U1V 7D (I
M#5$BV:M->Y1&) ,*%B91WYT,/.<1R*(XD_"IBEF=DY:?PA=HP\[USCJ#W00&
MK;TIOL09F)R1R'@V[+.8^"^=1SM8-^]<%& @EY3G#N4N*.2'X)K%!=W_COB?
MX0WS;/JX(>"#+.,O&RX\^M\J\$B&L8>_>?!VJ)XY^\R(YX)!)(N3RR]$G-0F
M%2])Z9(F,)IDJ.\TF3=-AEAF<"9]Q&8XQ6[?.$CQBS@DHNUZ>!Q]T*G[-<M-
M!W!K[A7-,XYEJ- M@LWZ-4_K@GD7HX.@PYA@PH2)GMVTF@Y@Y\!-9+>"<%3$
MQ6@7SW&(WL3(BGJFO<"+A_PC+=OP.I-+UG+8Q\NN="7C0DMR<TX7UM*<KX95
M5@CT*20ZZ/']Z,749AI.H9FJT)O)KWB DX%ZX 'NVJW>I+E"40L_ >E+670C
M=V!?[O4.E[N<@D\1W*D^1)[ZVVK;P V)L+"%?4E1/([>@T>FX'O<I&?X-6T^
M$XI86 __1&D_T2,H=Z .W+E\48CR0+#* LLN2*+2R405!5^3_,R6[3=8=5C0
M5+%47#Y4FP<U."%AZ-7>*H<C\&%R5L/ZOD.1@2CW2)$(&,S)@8RRBBL^T&-4
M!$AQ)34C2@@J+_>%S4 $RSA#=*.*M[,5+DEXWV4Q-R)_(T7+::BF*6RF8$\S
MQ,,%-_+>O;Y$D;I+IHE$6)2$\11>?!@BC0#AHZ*P*GAZ0[Z3(\@=5S\LX2:I
MFAOP$LY3IQXB<Y967Q=&C,/*IG'!>!=^6=]LH-E>N%(<=,:3127#LL0XA%TU
M8J+R4$>'**0DB\LNP(!_,M7T9<LV"X;2GMVS7W<X-.Y\YOA-,9/-0Q)8_&4+
M39)//=0&[+B946=X4,F/[8(#YJD%G&Q/ YMC,T110@8^V199%%4$,=VE)G:I
MB3\F-;&F<X>6/$L\UE6V"4+%T2J4[6"\HO\CTG/.<MI$R$,QE:@_@X:NUB+?
MHEDRQ_G!8P[O;2QR<1L(*LE_<XA71\OY4AD O!<H'NZ&4\8E>>GARK-.%KJC
MPK"X+LNHLPTVE8CALRZ8924%;3@Z(R*'E/_Q\G"C" LBSQ<M/;0VXH-C\HQR
M+S?PH'22=@>,0]8*SK?@U1TY:+#UQLHP]_-ZF=L(DD%'IW2MTX+#84I**0$$
MH_UWI0K65"'IKA$L'-\<[XHK,HQS%.8@U*O$&C&+:]VU.\<"61OV&H\<'/P\
MDFY(.@!#A0'&'E CG%*RE*8@7\8P)Q1?,Y?,G54W4X*/@5_BB$UYT'26<-#!
MFB#.N+<7N[#.>IZ5#3BEG/,"TY7LW+<4O? ]=@#U6UM?AKJ=6^ ->CC!N_ W
MA:%VDJ3KKWIR2S#:&?1MV;29"A5PN0I=>:-<GZNQ<@$+;Q@&0:I ?N4J)G'+
M4!?Q;<A5E&R@M7<X,L!5?^!(5*4NS2C@G[?H?R=9=+L/KF.!7<ZX0,("_KK@
MFA95F'!NCIW#4? /C/&R8U?F605WI&+Q<! G&*4<F'0MZ2_\A:.TAG#1F.P(
M& 4F+7"=C'/XQ/MD Q*7F+-.:*BH5N$_MKHGPSP4^*0%)KIM]$& #WCO67:/
M)29<-(+A"/!ID_ >+J+N, 5C3\95HC-9K!QI1KP?Z7@M#22/,RZE+] ,$3/@
M/B1+E U%<?X':IY)=-MY2W*[L\08%60NX(C(@"''''].O8XP<F2W1*K&B:/C
M7:-4"C]1PY>%]D4Q2([S$G+9[YC+?\T$PH+#C*4%_2F/EG2],5X&<S0S8$>,
M)WB)CC&HZ?,:$.M5'VW5'ZY)OE,<FS-?WU5C+*F^UQ0 >)<:*JZ=F[D]-?@/
MX03A6?@C)T@@2^&5E)C2]BTHQE_G:G1U;3R7*\/&QR36$+4$9^;.)V$Z5L$'
MU.#=6NA?="9&4FLY,FT5<'@6054/IP3%6L' Q$;42>BDQ7$K#I1E,D(9YH63
M.(06+RE;KP7T'-(B+I?$I AR8I32>7KA]B[^PL%8^-E*+S<9[&EY20'X#B=$
M)!6^/!_LA\'HIUOM5[?6,G*#DSO+:'/F:V<9[2RC%J[ %EM&(:MC'9U!=(K*
M1XK30*:;NUUCHN:4(R3TJ;BZ#G @ILJ"@443%+K9<@T'Y92T"G9C@)4-.N/F
MCGZ13*Q#H3!5U)K.8^*+H'7^V_JU0PU&!T5>W"?*B"*>GN4__"[6BH^F6Z.U
M(F\]Y-*/V,5OX3B+;#\">:L,%4^2P=,3%0ZUX/8@('0/ERMCC[-F:'T/\CBB
M(%Z*(F.,4<A\)IA^'3:+2S45@""2RF!",X=GQ8A7N@/[G<)G@D@#>PCV/0;^
M=($5#HM$4@&C/>W]K [&!_ 8N"J;<BMOY_X25^52!R=J:4)V< W_-,QC2M$Y
M51GFD73#+A\";^B<6"WAAX+@@3M%MV012^T,/QZV:QZ:00Q"N";CW7AZS!Q(
M^#S!@E6Q=+A&/2>Y8_4E+LK.:G*=6!83UV+9.N+X,::,<U[;[\H(\,(C.=Q!
M3'80D\5G?G]^F35Y.XM$5S&QHFH1:2ME+):C!K;54!1Q3J6"E(^6Z%D+%=$G
M,%Q]1@G%#C<:PQ9*#1F05SW(W":H D6N2,GJHHRG#_"N'I\$EW^5.M&$]-Q5
M,A1;^V$C6W2*ZM3UOQ."$5'5U=)\Q0MT:P3(-2. G 04<H6+D;!Y(0T*>>RX
M*6@Q6C7V:7C+]<P:XFIT@X/ ="T$C:&>F%>S$I9J-W",>S#/ T6(F.@VS>Y!
MZ8XUJ"0V1<@XC,(,0BM.JLD3>"%\84 G,D#04#)3:#.")IJQ5>=RI\&VJ')B
M,2IDW>6)\"[9("$@"DG]$;PD65VZ'GJ.%@6^.>-QK%=&R%@!6M'S\,DH@E@%
M+D#3.XMT*$E,&V*DZT2D9CED_#*/UB%=*O@U?,XLWS"DU!I]7<?%;W'8YJZE
M49ME9]*C&(;3+-^IX?K)>IR(LL\NUNIP3PNGT^7YE)/JT)6BG4F^S*9,J[-_
MVS"K;LSK'IDCJ 3-^3 N-*<XF_E-X1W#=&$S(B3AK?_"'\)]SRP^]6UX[T'?
M,1>39NF^B3C,JC2:[!-UO?A/)E'@&$H,_T"E G)ZBM2BH,P10X>L&H@4A:=^
MB*(*',IH'NRU>I]\.O_0@DW1,;:0H1'3)8R\7)K+1.H;=6W>>5P'/0O.U=P&
MRR116ZLQR1?$Y\[ N#G (D/<3>0OZT@&#$*-,PH!>.<>]MITAAXS[@9! N$_
MB:I165"KL=NH3)1AQRMVEVM]F0$_;'4^+[QEC:V9CEO*U@AK0_5QLK@?J2<)
M;H4EH63XYB.6QP_!*E\SD/;"(>F@G6S&/LS#>ZK>=ZG?=1"QG>M@<LAKS3O8
MLD $O.59&D==[4TOT) T\>,>+'ZDBR+SG**^6A@V-M(@%=FL%1V:)=F,5'ZY
MM7CZMA)XWM#6D$4[RZ,)B/N(.7@OTS%<HM9*#H&\*J::M!9,T!1G77*@F3RB
M2IWP!6ZVB4J&78O;Q4*.7->HU%0GEX8S.XB>AW9;1)R;6.\*&;.(PQ:!DEW3
M\JEKP^:V%B7>/0Z%-8X\@XJ@XQZJ.K82EO7BS&AN,ONJA,-+5I#?+U344BX+
M?ON7/_5?_DP=D1RQ+?;=ZRI.R,[<<_NN<)U4J]?4#/S:\:M:L<"<L9*UK7EY
M!RN"I&[(N7 E-7Z@M["N4-?2P-KJS:6+IHV(>:++CU:KW-3P>OMT(X@7"A07
M&#*$3Z<F9T%"8/@2YP1F&/_T1N^JGJWU'ZY&W5IJFF=EZJ3=S8S(^NI),=-9
MI3%5JI*[B%PC0R&'H!0V>O="-[3Z;D]! -D ,!J']0H:(D"20=@DC]TH=:Z6
M;YT+)&5:,A=2@>I$L=L^.?XINAHUF."&(HM?U'^MU>^S2&_"=%F81O"@(T3)
M=H?^P8)Y;WJFH80"VQ[)C731S5?.E2&NRAUQDF9^_D^Z'5E@JN6R(J%*4\IS
MXL[L\[7LV*76=ZGU-CJ9;26<-X89Q:/:D'X28<,E@I[$1,(I$RTA(5M4@VEL
M6.X,XH !/9A0CPPKG([P>S1'%PKLYVSF5T58QCXO,F=S!-_62'C33/=5!22M
ML.!W12S?@GVN';LP*3(Y>X\Z=W_TF:LWOZ+<GX$,(S+1 "EK: M#34D*0QM1
MBJMX7&]NU89?C4.$J2-,DZ"85Y9>$8C2-B(D:ZFE^[6E#<;3X<9,6.O[=W>7
M17 =%."C8KA=)XC+B";"1_EWLPD.N"?C_)PD)J'S1GDX585))1F9>1!\=)%\
MYL8[Z?\DZ=]UH'>"/!20MP'4"18P(@_4,%RNDFW&\U^ OA!*KLS&BM'P]5XJ
M-D/NL#E_W;,=8&29.4;DRM]P@F(GC7?2N"W26 --9VBC9%61S"U8:=56WK&>
M_>&45SZ;-[9N:X-WA'K2I>WSQ+#A!_#L]]7F:HE(_0+4*W+N[)T(,S]""(9W
MFMRIR0T3->,C%!YI;2]S[;CZOMU9S :6]U:XRX_-:3UF71XBM;<8EW@<"\Z]
M5AJX43;;T=Z@LU;N/=0;U ?(6E9-ZZC=\^]VJ)LV\Y+EK:4#=LO[A.5]K!9_
M=?"2><&E;%+G #!+M(]A1NQ!\7?]Q\_8,P)6Y>]Q2@^F'_TL@79)'" I\AUB
MD*,P$4. )HZ_EGC^J^.#WLMC#.F7.?QOJ!\LT?X#BO;_K1PN?G?2/SAYU5_Z
M]>%!;^EWJV[;/SXXZKUXU&W_1D,V60TS^3R-R+:;%+,P_:^?CG^JS?G?#X,>
M7:6?\=A+Y9'+?B/+Q=W19QA$2N)AH+>:?$MYD(4O]>..9E^"DX/CEW !_MEK
MMN3JZYK-GMV66U":AT^.-?L8Q.5+\*CI9)/W1Y_M!JF^.,L_\.Y=$-&4QUP>
MYM[MSJ^?S?^IP+4].NS"_WHGNXVW:JI6Y4]V6^_KY_.L&L.0@M[IDS>?&$U+
MI^L'VIS-:;O';\MOF\H?:=M^B,H,NS^\6K9M_T:&_?8!,_LM+>QJ((U"]_R:
ML\NZU&NMP<"MC0IO1.W.X@9I!<XJEDX]98;4A,'9^2?N##.6X3K=TS"5I@6\
MPS78>NQ2NV;>MM-E I)["H_A1J$H/7/0A](,,"9R^T%,IY'K28KB(#BSS9'<
MCCGX<AR)[3:1V'F0.DIVSJ@:%?/U5,;)"0'.1BV FKLT*#"5L*<0UB%;- [A
MA'7C1QA(C!)!RJB9O03V_UZOTX3=D;+XH\[3P70(/;!@NN4ED5&&+: )@HVX
MZ$D,-C3V$XHC["X=*T/N1J_I L;IX5D _G&E]DT!U=)+]>/2D91+Z#[B:C';
M#>N'T C3+)-:%[-/_KH:CCENZIPV!TF!$':Z9 /P@^X;M>'T'=1+7IP6IAZ6
M7LL_6QG;<++:+P,]RUR/O T+H<^<[<%L4PV\76I+); [C\$3UVPV-RU$\PP[
M5==JZO5+6Q(PVX=<IRR:H$\.(=.#3S;GLOG)MHC&/II**["L"^^VN+46$G6A
MDV->0$J:)WEXK5V9Q:[,8O&96\-@^'5P1%.Q!2<XH\KU0K<?PM*DO:+S.#%2
M S,8T!J!V^@PVY(V:;C.*$AL'Z[R%"VX0+CE="_=1]1CK4K<$T_UW,O?KY(.
MBTW3M[68\Q'\/"L XGZ%HD-=O%#5MRB^S3(QOW3Z#14C8H,Z) @)/)V>7??1
MF/#JJ<8TLAXZ<Y%FRZ;B:]Z_U@"NP1$ K\8M3_RJ,L[:F7#[KA&JSBWGI)=Q
MZ*L;V*ME%/;^7FGWLJEWJO;KOX>)I USGS7XU8:B#"\9QB-B*0<S)<M-DS;'
MRUKL.;MXCH,KWFC27%8COY3PS!2/63ES+$953CA=<E$$%HQDJ<SO'$\'5<Y-
M#,AC30N\I6P077.*_);4&*]+_E)7$UEB"[^"Z+FXH[S;/'Y)QWA+VJEY/BN<
M,*8G1V[/@>XSJ\OHW7WAE,@__/XK=\A"@?X(7XBV1S!@GP[^-LZ#=*85Q%2#
M!T'\UWF6CD>57R.[:AGJ9?Z@9121>!<S1#%+0;-=I-JRP OB5/E^;^&)$'/6
MA%?_&R9T>\./;:WJK.U1"45?Z]V!)S)>-ZF8KA'@7<W-S+%E):KJPG+PY2:,
M[C \,@$9$>>A[&N 4#M4*W&ACP>7&!![4$E,T7"ADB"55?(>T8K6EYI9K[M8
MU""^%EXUKL(<!H2TQ2/D/LJ]$TDLOWS:J*TF\7[@B<1VWV$T-TT)B-J87E&$
M*XA1MXDY?T>FY@)CR=:>M;8"P#^B]!/+2F-I6G*TZCO5AD%AFSN-V*43+7DS
MSMOH@(.<1NG'8LC &Y,"7=/302/+,Z;+G/L$E:Z^A\>>HV$=@=8PL^FU,>+J
M;FH^(JTBM.(S+*KFO'>VUIDY:6D"M,&7V+4HV[AIT\S*?+3X>*IZDZ6%SBFK
MZP")NP].$ECXW6"$BEX[XN@5%Z7F3QN NL43%E#D#>X.&@T&6!+/6J1FXIH5
MMW+/$LW/;#JML""=OD2AQ)@HE#_Z-O=Q3GZ^9G7FECPLW49)1MKU3N$UXOTV
MN=]6R\ND.'VD0XK_P-\E<>& P0M?C^(O)5&_&3]D:T72BY:*I/,EG*=K+\F2
M^E8,[39D*YD:7J<2'J[?$./4S9ETE_F9O(V1K-S-9OC/-XF-!DHI7_7"4<AR
M)"TOV<YPC\:B^UWKGK:WRL'NHL.;QGB"@CN5#N$'W?H-T+ZX^H0MM@;<:^OL
MGYRM46!)Q^6\XU"NHYR@WF_+>'!97_C-#B1H)=3QAJV[RRE<X@R$ZV%+P,!O
ML55=BD09R.4W#E+8+J9KV,+-R9RG.!?3S!,#9-' ODM0;&IG5VJ.<ACT.Y4F
M6? QA/L9'^4\&_(B,,LYBE44MVJ(6P F*6;A].\J+.+],0J\E%C0DR !EP$C
M,T-%3;[@;NAG%")#'8)+,,<HLH$VX"ZIM$LJ;7%2"8L:YT*,K6/]&(>H$B(Z
M%\%!T@B.*H%S*I!"$7R#>!(\<>&8\!RZZQ^;"DY'2.NSZT9[YKYG4Q@UMANX
M2HLJ)Z__3#CU4&SMD53*-7'4>_H497^&W?K@'F^PZ=ZOJ @Q5P$/[A@M82Z^
M)#(?<K=0=#AMH:(.F6+TWJ;A ,QH-0+!"P+9AI3$$&3KRQ"E4M]3;#UD.SPY
MH1PG=EOW(PF9!-8<2F9L=IF$ TXS(.E("=+W=Z2'!F643=62^/@#72FG"EDD
M\*6[PF9$$T!DO4DU!7-S?!"<E7IQG1YBKMY8JEWQ/H8PR5B,L(L;M*P,^S$I
MOZ</R*%SJI5[(VKE?I+5:L&C;!8K,Z7$IF2BOATR&T0RGA7[J'E*[2](H,KG
ME9_@=B1\A&'[$-MB&(_CDK(@\.6>;E1*2CJ/N'V/T[."^Z)1':E-?Y!'X=$I
MN_H^B9%.)L27*B@K X*78]VFX<>2]9, H[1[W7<-CER-*.#M=@=9 (!A5Y>!
M@J?/PI@,AU&5),\<D5NC[?^RI;;_9Z5N81?]3S;0[637'(Y8#LC,TB$&S^YY
MQ+_!B*<R8A)V(,!K$"@_1\T^*WJFH#"DB1W+A RS:$I(1)S['@07W+F8K#DZ
M>LZW#\B2*7*;Z<9'-$CM26"?&93*Q'R6+=+2"B7Z.,>(=S@.D2]]F7O3Z'QL
MK0/]JJ6'R"4<7O/Q69K21DV0*]LMLH$JZE&D.34<"/QU6\_R,G)0$["[2#R3
ML-%/'F"W2SJD<R+YH\;,A@E-KB*/ZAX!$ BYKS?,AI>J$GT@0?6 W@(#!HO5
M0/\)Q%IB<&%JWU$/3Q2UW_Q;E+5&0!*@7!D7W!O<]JJL<W]W-)#&+8@NPZB]
MBK )5[&=YWB1_>JD/4%FLD[1I,M2%=S%(?91E3WL$9Y;T+LV^+96'YRV5!^(
MA%Q_#/4,@X]N>!Z-=P1EL2=J#Z_-49BDH\&+!=D"ZMNU]KUFT><2/V2=X?$:
M%;8!DA>Z\[I'/G_SK#5N5PQ/GFD-"&/)YUQ*\:1I7S:OOO+%!7;:3[ \T,%I
M_:7$&#0FV$6#+""X$!P";FD1Y>2 KZ;XO0QSL-0OZ4UU><ZLRA$N7-,DEE5H
MU+&#!4?4OB?'8EFNT=WE-]NK@#'\=8-[Y=Y&Q-%_$7,DJ,"T2=PNJ4;T.^A;
M74\FA2-H6U$:#W&$,-$2CC/00^U]<)8NUG&UKHO5[I+7;R[BYC<<%9C"@H[#
M,8PG#3$A@(,:,KX\3/AV:HA1]##/XT90JH\4I8JWT-H5>A?AC&RM6L/(XIDF
M@+6A'-3[,1UI#/3@6DF4"(SK>"A@%.;XUN'"KE-X4\."4-ZHF'A5C&*-%V;/
M<5]@DNA#\BW(:R!HB>FW>K\B%U1KF-C8->K'SI!\S9;]:54Z99=J64N;E#6*
MB=YA2\W?FS(<H^HY@Y6EH/)YQNE2';*_9#1=*W!_;K4WJC77QI)D4)S74^I8
M8&)<79L7B*VW;/+-CMYT8/ F*@]:E*RW7,UR57"[;>IX+PVVZ)W=B+Y3Q,5E
M)E)Z@5<[]_7O5WM;J4^1&H7%=];9+!#\Q'9 6:9RDA74- +;L5=E@:%,L=2,
M\8KJN9#5=V^$K:[4=)"(Y8:1'F>LG&J(IZ8ZRUJ@3DRI:9YJ[R5J3QYB$Q0/
MO9^30W& GI'>M4HV 58GW!$8W&7@7T _FP\P)/W$]>>B-XQ,WV6@VTFI@_AE
M:#28WWDU,P4%.J."9C_]=\1QY\91;J^UW.NU5!S:Y'1;^GER8&#1F]09"M\_
M-TZ <1P><--]EM2MZ$C65NH<FW^2E6E=\FY/)XMK6>*.T;QY/J\C9PW<88#H
MAOLN"38'4&%JZ+C=K[<_-4J>=5.<:]@8BE4UG2797.G*%*^+$PQCT1MV'& +
MPS.>+Y?CL2]$<IXP%-3BF)+QME\N#CA,8];EJ/Y<0 >VTZC[PPMLT"8B\F [
MR&TZ=VVM&;M!1$][SEVM&2!N97$\2>\[)P<%_W5<W.K<@CT\DA_C,)%C92[F
M$^PY6T@ +; !4402K,-J*M9AY08A! @[#&*?4<B]YP''P):\3_.[. ^0-RJ<
M Z_AMQR'18F#0S!1,8;1ZA+PPD*PS)2XXLE$2@V@2L,,2!C0">]*<9[1_A87
MLP)=4X?5N*NKOB##52UL]S'/$"'!KRH@*7C^AYG$^\UN=<4:81N<::*1X[UA
MB&GPYUX7]B[^#R,[^):44>T&?SXV7^"/Q^-<C0E)R_CFG?C['@>[X5@OAF:7
M=?OK+B<VX%5J*-^H^5.TZ[V23!Z%IP3]@1"DG2NP;9[I!UPS=.;R.U7X'!F\
MAEA,,T1W386PN_]=(1S#D<,C&V9/&5_GYURZX#]R%;G&BPHJ4!]NIZ_7CS3S
MK2UZU3+^$RS:F@V%<R3F)22R1&M8'QH#6N3P0K%X.R?V8P@;/@]GDZ#76VLC
M$@=ON\@-:3%.)IDRE9SL2MO)^=T*QAA;RP?+-"5#+=-)9<9$GNE,S2Q+XDAP
MRW;-"2J%=@95-7,,H&#*-8/=1>T]-RG% A&[=+,Y\YN@ 17>,0H .U0:YIM)
MC!IB[_A0FN7XR6G$?'.AOJ:5,C'B/* N+'I.U&@D'ARBD +1,S#-,G4>.5YA
M2O_-2S;AXBP"NQ!'CNP/SG!A5'!8.38NL[>,%BU>(:;K+K#O<?$:,H>"#[I'
MJE/W5]2 <=*O^+T:=C#DFV9L 1LL.1=$?;6-.(6E-$7J,FA#Y-00SQ&#+5*2
M4G:G!F'9<\-T,N3M9':2%AAT*'>BXM&B@C/AC>RQA80M+.$&.B#@A8&UX"$A
M5[@/M6TA0"#'Z/^"=<*TQ@3\9^J@'SL3NTN@/C:!ZMJ,FUV^=N[$$;M&;&J,
MT4.2MRF KG1H89!G7& 01$D83TT;0#[YN0'V@[YA8 =!8UB=D-R2N$<]J&%C
M]$PP%I-6G8:YZXD1X;44R^)#L_M4 #J<&C-.FF,&>"_//X@+'6@@=N8LI3>.
M!U5I,IOFE>@FQJUWWN*3'_JPW>F;-)(%.<%O<0*5+40RE@G? AV.:6K*ZAQ:
M(AM%T&K)$*(P$_AH%!-$A;]NI\+2B+A>?ZWJ2E,#.OCM'\JG'+;4ISP/P4%+
M*!<M=JK+XK#^:+2#K,@]T61L3CS#S&LXHB0\N3Q("H#RAHP?G>2V!)&1?6L2
M9$B6E.L)\"L]%_B<-$NGC9G:CK[UL: 0:1P*.PI%\Y :QM$8FE\^&1AXQZJN
M;WEAGZ*UZ86%V] ^[^O?:FM!!$<M!1'8X.[ZS[9;DNDRFOGQY\ TTG;2M@4C
MD(78U-Q.5\([I)U-=S1A%K=NH;"5X4(54D.=XIT,$$DENA)".G"K(LKCF1>
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M[C@@-[J$:5U[[*$4]?DOEQ>_OKU<#@I]COJ-ED[&A0_SK2$2OIL%]0>]?5/
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M2%(97J%4PG'C#UNCG2W]10T+Z4 SEH&A-W;WKSDI_@Y5\%O&::[_!"C').
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M>Y$%^;_F8_$T\T!5\)FV#<8>&'OPUNQ!7T;NCQJ$+*V_$8:2?@*-+<Z*/LM
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M?A62<4P5W5Z>H#C1GHQC3RP7MQ#EI3PL2\DQ)M8.Y,1Q%AIH&-:[/J-9JK'
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M16]ZQD.-9I[:-:K\L.O>LQEJ"TX-<+]"5V#ZG,<9BI0T TJT*E&AD5#_MQD
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M<]6A?!^#*$@K(7$()B_BY,--,;#,PS5P],T?,#[*^4XNY<.4"\GAIRB^#U5
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M;3JVK71J5 G;6N2KF9HRO(VCS;+C"CTM'V/.17N/R'E%C6PHA9J3K:J>BQ=
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M8\ Z"5X"&$H?A1:,4@BVZ=^B+(!X\VCO*&&Q9:,65R#%N2JNZ%^4\BO-<5>
M%#L-S5'JDTPW-\1HP#Y&@4A@!+Q4W\A$,%\L@&:?P=]"1CUX42P-$09D"ATF
MX*7#/V%;&5Q]M[XW,@C8DE];ZD/!(R3R"G9EQ)+46])0.Z@Y.?!+ANS4$@PV
M&38V[N;W 6SNSL@-$-,%J1FP4P[<;.PYXO]<L$0%(D Y26(5)7(>"!0LAKK,
M\,],S<%5(W%!X?-2K6$IYRN[1(V'@OO(\5%I8#+%F(D5R!I)8,Q7(2GB]B?
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M7[_\--H='C7___H+SQ'$<P3Q32*(Z4,BB)=SY:_@/TL3!J__'U!+ P04
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ME<?;0QBO^CZQ+B 9^8,BT[E(T@5P<WHT^F$414+ADACR4>:[ZP0!RIXU6@P
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M!ZUI<OFQ5$\B0Y_R72$86I2,1 VJZK0$F-B8[5I)/[R&M&38FS731Y?GI(Y
M.]>=VV$']Q;!NEJ+LQ[XYE8CZMUJ9$N/.'5R@IR<7<>DABWX,:4/YQ:L)+A5
MF\SC*C+P_1]M(O9HQ9:]6S%&61 NPR"XEI)2$Y/ <2^I"A >%[6&8U=S$J\3
MN$I!NFX1EC2$SW<61G1)4U#$6BYJD*"J%(PQ; IT"%L<RQ]4]:$G+4"C*0W
MMU2,27X1F>9C\,^3YB:J%*U"2>"G!$4 >>+B,#-Y0\U?$U#9K"I#*\/K&;*H
M89]@)/*/^;Y8E$&X1!A\_E+6:ZCRN(7T? ?Q\('DT/GY\9&8^@%Z(*U+)K^=
MXH9#C$.QHR49-5]$'0Z*Z%S6.F0#8Z$0S;JD*&:A>C O.M2"PQ6NB#,A;!@A
M5B=)%$\HDBROG"!CJ'\1;:INY T%TH+JA15Q%F"X R,F#HP *QP^92!3FDCD
M(T@9C6WI8'&M>4<XY1)IY_;L9TTD0N4J%4 HW1690_*@'@"]RR_=!Y W6@XL
M$IZ>^7M*EBF2 !-] 5^>'IY_//R'.*?//C.0&>\8+3&8Q4R&V23!<A&"9S^V
M*HF)8+O:?"C3*,OL5&:+B:E<3N=^>$EX8/ROF5C@SVS@=?W)0[H000L$$??;
M:;11#3I[L[-)^9V+H07'Q@5Y$8*.DOIB(CUC1)Y!5428C7IH.4\]WU/?BV.W
M^V/"MBGE4>QJGO@01Y<OQ097RQUVQS"'HDO-_D(/KQ>G8]QRJHI$4QCY3!#0
MK, G8&T9IAQ#E)/SY"A2$\6-8PPVQN$PG2L&#5 @<@*^"LMK%@88I&,[@<M_
M\'A0Q9E>F1P%!H2!0@P%\:V'=,I4TN%93-?8S^61P.'_.8IGH(_.4P>>G?,L
M(,NG,@'.YTXLKZ/X,L'A%J_7QZ)&>,!!%SR*^*]GQ.5'_:'^,\3EQV?G7T[/
MQ1%2EQ]_%!]^%Q>_G)ROP)]?7\#<"*MJ=3ITR*548%LF;%JB*'GUX8FU0G?N
M7IODRN:XLBBNQ!HZ;*IZ::#QZ71!"O\1RMOU2OTQ<<CR1N9:]V*=\F\A52Z=
M$RDT;-U(%:!0P0J]B:M]5'B+0;%2.$BP1O *,T54!^\OR/<#+Z/('C!0T66%
M8+F>1PM5U<RS GYL(C'G9%TXCVC*Z+YP>H31 NPP@\UG> RJ*\5 P-Q?EBI-
M2HQPM!3A-,@DE?#P0AB-&07,U8"/-#3. 9?I+YQ+M _SR!W,4**(2RW29!X2
M#0>?5V0*7Y&0M"9OMKU9UURB/:](3S8'SK8?9KP]4+XX3&W1"2F"-IOO(E:S
M?>TGTBJS<*885:"SA*:9LUM77)QJ3H,B/FO K)()W0/_9>*!A4.U'RM10I:(
M*ZQ]KJG1R9[6OIF)*U9(:H4J)B&'OS +;["K-]C5B\"NMEX;[.H>!J;:8.'F
M3I=D$ 7:6++-G0D>Q,K\ML]:I3&H8M!7IUD&>C/( W)T2H>>/L8QM'A%2?:'
M9"_JRLW #*Y6NG1J!W_LGQVL^T8]R@Y^ALQ19T)^?./*92H4GU&6)$Q#=:XX
MJ'X"6R^6T[^^^ZX-T]L+1UG*D0HX].6[GW_YZ0?G9['VS*)'=WSOI["L;NMI
M9J:JG-S[S-(7708WUDMN0NX/(7E#R49OA[JS( YT#7RDKBIC[YA4"W6LLN7N
MHUA[,%U:L<<.#H[3&_G[MF>#>'K6H\Y40&?4^'614BHW)3"&@EP.B&!K .:_
M$^9"13(YU7U;BA@V]#'_S-#'M"1MS0*!1HL%]H'!$)W&<7(9!VU&Z:GH'6;E
M$%_LQ+&C'=@E$7K%^IIU568R21N>!5\Q3@\)CB/=TRF,P'<O>_XJD>/.R_LF
MASCG/K F.;6?5=BGE/2-0MX0$SEW@BD:+O#B2*E!:+ X61\8KYS @T2_&\Z<
MF>'LP?TQB\IW?T0=U*O<)J-.V39'=VT36_CS-5LP0F;F3U.])9Z :_\;6LS.
MB-[N6TPNC570#H/JGE*!&&HH)LX,=13-GRK'(E545E8DPSK25P.I?3,6+J%_
M.DL$UG5^,4NMJD[Q:%&X7.XS2&@.A";.P,;A_FED%3%W);)C. EW?K5 OH0I
MB7W5BY/.$&N[VZ<1U1I@D8Q]7!5BU/*&;[Q!=-<([N"@*UJ"YJQ,KATL'7?A
M?U798Q X=)[,I3=C/"7\-%!_V&?' *DQXY1I,_G',D:#SIX,&YG)#$W^TM$Z
M#DY4.<6</A*&// $>PY8TRL(ZTJT=HD##==9>R0D6N7^?M0+,RJ&/8WL$54?
M=K941XF=$5646.GMDK[6."%=(<Y)R0=SY#4E^UYB5NNC',?]B7* =.W948ZS
MX_.+LY.CBY,OI^?_89H?B73.[;-0VA*/M2R@&, ]G,@@NBZZO]H12,Q>\(@"
MS"@JCM2Q\@*;.O\X HV'H11N&YJLPBU8KVA>'1BYEP[E79"6?V1PO$@D__N@
M [%?>7F[I<Q]B\N]Q>4P+H=FUX-[;9%II)MME:(-E-  $8I1=9$%@*R:F9M6
M0@FM0WY*3?YIME0IM]$&KM#\8PN]\.+@A<$SH!>.K2RZYJ6EDA:LOD2@/G<E
MF/I,:#N1C&DP1UKS3 UL!GIY(V,7T_"NPW[E-5+4DXVL <CV6]R[AC 0N%/>
M/X$%EI#(V,>\KE6TO%E2&=53\\GWV/Z@[?N/YDFD7D!)"M]K+ %W%X'98Z*#
M?/;2ZTA<2WF9*""?MF8XETA0X"D<$4Z@%XUDE1Z US#>O+8<P(:EL\FB-[F*
MNGN%ABT5)E4*WY/;6AS ,S3$*&??^V?T7,SSOJ)$?TX.?%JV(:G[:5$:6+%Q
M<1+-)N,L$]W_:IH%4Y^\;QEJ?K529!?CXJ'Y8]J!?E24CT^E'@=WS)=-Z*#0
MIMS:A>=&HTN9Y#ZGM^?.(JDN' 0MJ^G@<1I3O7'4'>'R99L;1@B[-_$70V.O
M>".XVM<\45;C;V^436_8H9?&#FV_%NS0XWF9:HI7%*BH&$(:=1F7(]51Z'5M
MF7D5TX% DW+#Q4:.5/2C6N8J.B3+]$LBE3<GU:S0^[G.9[:(T#I7,(% _3F\
M L+13_,O'@[3;[D4G5ILG] /HG=&*PO^'51(PY557NRLQB>DFO:);&>F/WE[
MI?M-I.U1EZP"_8D+C?>XO<(=@:%SQ2[0K[#0A8T7T-6 *:6*##,4\4DNJ&F=
M!CLS YI"85?PS<;!MOH=$AD^@[D#(OC!VIXG"41@G7!-R2(Y+,39?UNNPBB@
MLQM8'S 0FV/)526'H\FPP/C$^B?%J'3E.P(!Y$&ICU(I?]ZAL-XAE\<WY&*(
M#]T*XDDA<,%1"M/0LNVB*6BM:K>9Y^U("@M%=BTC4(RY)0N\04S(YPTQL:F
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M=C$%>4*,>L$?L=#B!90Z4_Z";$EEPB<R'6AR"R9%XC>L7$.>FL26B4FI][E
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M;A?5 C77; [*L,')TYYA_"&:PBG8OIH4,[&NBAK &?:=$YNR"YPB34Y@&,?
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MWE*H*K6JSB+*T)N&I7999'-YKJ(JZT)3GI3<O$Z6A:.:'=%9-ML#JY'>M1[
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M'0C6E_9(7=1(0= HN81:1X8,F.%!(5,*'\;2@8?2J+BEF6:^*!38.*:Q3<'
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M(*34_TXB[Q;^F:>+X.?_#U!+ P04    "   1'%:Y V^O]D#  #V*@  %
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M]+K)CF;/Y7_>=]K,^EW_ E!+ P04    "   1'%:X/\"X1P$  #O$0  %
M '!A8V(M97AX,C,Q>#(P,C0N:'1MU5AM3]PX$/Y^O\*WZ&B1-A#'>=W=(G%
MI:J4(C@)W:>3-W%8B\1.;8?MWJ^_L9-0*J#=I=Q=V0_1>#WO,\_$\6QAZFI_
MMF"TV/]E]JOGH2.9MS43!N6*4<,*U&HNKM!EP?0U\KR>ZU V*\6O%@8%?A"A
M2ZFN^0WM]@TW%=L?],SVNO5LSQF9S66QVI\5_ ;QXLV(^UF6Q'Z6ET59AE'
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M-W$C#4!T[\IBD)I+8V0]\;^(T#F N37W1;YSR]$_NPN7/7?1\P]02P,$%
M  @  $1Q6N=LJCL#"   J28  !0   !P86-B+65X>#,Q,7@R,#(T+FAT;>U:
M;5/C.!+^?K]"!W6S4)6$)!!@$H:J#(2=U.T!!9E]^72EV#)684M>R4[(_?I[
M6G)>(&$FU.[.)EL[50-8:K6ZU8^>;LD^B_,T.3^+!0_/_W'VSVJ57>J@2(7*
M66 $ST7("BO5 _LI%/:15:NEU(7.)D8^Q#EKUILM]I,VCW+$?7\N\T2<3_6<
M'?CGLP,WR=E0AY/SLU".F P_[$@>-=]'C6-^6@_%T8F(WA^UHD,Q;!W6&T']
M\.CTOXT=#(6X'V/S22(^[*1256-!\[>/6EG>&<LPC]N->OU?.T[N_"S2*L=D
M!H/]GU['LB9N'J LUUG[&(IR\917>2(?5-NYM^,U3:4#G6C3WJV[?QWJJ48\
ME<FD_=U IL*R:S%F=SKEZKN*Y<I6K3 R\H)6_D_ 1$SB'L?>_!/H2:024W<:
M3?*A]Q3+H<S98:/68,\]6,OV  LOS)]D_$7O;M"_ZE]T!_V;:W9SQ2X^]7M7
MK/=S[^+SH/]C#TWH[=VQV\]W]Y^[UP,VN'G=R4WQZA[6W_4'_=X]/+GXU+W^
MOL>Z%P-V]_D'-#4.>;5QM,?WW^T>G70:K= _55CWGG4O;VX'O<NYNQOO*^(!
M=UWX#NM-"N'@4X_==^\^=J][]]6;GW_H_>*<1T^S#HDU(?J'NW.TTIU^A5W$
M1MI<<L4^"64F%18(D\MHPO*8Y^]V6Z>=MVTSJ4($J-T\^=.<:M2F!G_[V3L9
M#T-DA6HB(K346K0*?1;SD6!&C*08(V_DL;2,*U7P!(V9-CG3BEUID[)&O?IO
MIB-VRP,9R8!]E-H&4J@ !J+Y EL@TD9)7F%]%=00G_=;%Y_FIL7G([>("D*0
M3MBCTN-$A ^BXL-4QB?4L$!IY'Y,P*5"^":L4+DI!!Q -> * T2(LQ1/1B*T
M$0_09)A.D:]R[>66!)1 ;"TW$Q))^:/ O LZ+=I"&(,I$U=58 X2"*1!%0$Q
M!XT"035L',L@9K:@'_/Q8V%$J80<2*5-4&Y0Y3*6>0P';28"9R#IS6":#N'F
M",-"-IPL+L-6PNUP:^ F6"05 DK8F >P JQ!'-UFH5\J\ "0)*%'JB I0N@$
M2!:B50' I$DF+$.,"9X$VR29XZ\,O7TQ-2 >2E)<(8DBR1WU:"##36>=/0&W
M,8L2/;931!KQ@$1B.";BU.CMAI65!6#9J3%+UFXEMHXV#5N#9X%XMWO:;)QT
M;(F>,K/3UM<1LHLP>W;?1:G/N!$.#XBO'":"XL8$0#A,I(UI!(FE8#YB/WH.
MI0T2;0N,(TXT.O' R(P.1(AFR_: @U  6#[8O:<@YNI!L"[HYJY((.&*P]:>
M\%:XXI">_*.D.D]Y0))^1IRT@%./&[)E[8FB9Q-%F(C\?(E>2%#"WLKBA^]O
M#B*;1[0,E\*B;$=D7&+Z.FPJE#,#7MCUAU#R&@I H)S)IT-=&"@ [XRD=6P&
M*:&<'JIMYSRXR*5&)-QAJLR'<UQ42IZE3@E.A"U6)S)T5P&V&%H92FXD.2!]
MUG;LKDA382F3NEUH7=IUW*>M@$$YN)8&91Q@#HJ$$V7#+6?$/"-CA,_OBV4)
M_AH*$@2K8KP(MY)%AQN#V7KM^&09LVL3T1)TUZ>PM1$,U(]D2,#D5BM.7,TM
M0$V%(*&5FW"*'&!9\J%,9#ZA)+UJ6MI'#F0./WX+/!-=*"1=2G@J'<H*DP&_
MUA450:!-Z QP)>6#4*@5$L 8/2*C_4$B*)<]5+&/9 96=F#=,JP&&X/5*;_V
M1CPI' E1($44H:23(X3 KBC-9A7!&J3J'U=7:PZ:& A"M+XF'.HB?]V"=6B?
MSZ0%%;S1U\\C;#@MI=UN$WXE8(^G09I@R^ 5;@R\9E3H([>, #H!EW66ZUD)
MLS<0(*5D'02%H3@OY+\56E-M<[3332!TV0"*?BV0/J%Z[Y4A$0 +:GHA71J.
MPXQPAW?U_%IFWUL5<SLK%HC4',!%Z-C>K4?)Q!,<T1]%4I[D7\A7?O,2;2VH
M6W^94Y*[QPNG.Z(RYQ^BPT54SJF(</6& F*I[)Q9QU%ZYMK86<YV#5"9IC+/
MA?@"V0\UJ@+J#R7L<TKV@%UPJR7NQF\J@*<;3OQ:2)CO-E>A G?FW__[,/2[
M).MN@I(*)1Y=[M)9DTZM[GY7E@EW=B@9"_Y(&=276"Z'NN+0W2A.[V+>!*[R
M_.!/^BLHBX<8:,6,L5X%8EE28@C0A,JOXM.X10ZW10HH8)&<,V6F6'EKM;5L
MMGFGE2XR<61 !Q6$6#@2 TC<96^)IHI/9%*-=#(2E,T4?RCOK$W)>R+-$CT1
MZ!W'VC,=?X958.MW2?6U#7\I=HE%\W3W'VZ"^-UNX[C>:9Q4W O]]4W/W=FL
M[!UBFPA3A0L)SZQH3__H()ED"9^TI7*&N$&=4M=0Y[E.V_0:?T1)"95+^0[4
M;07?/7_#7ZO[M_RYP?]P.G/977-=!WFXW'?<K-5/&Z]VUVNO]WU)[6&K=M)X
MOY;: V>R-QLK8S.N/NP<[DP'E*!O-[,GUECQ*<++U?$+\^W1XY;_X\1A9X:3
MTO>WN>7?<6^47^[UO74_%]X9W]3\:^-G[JX9SCIYO?/%)2JW#6TJR#)WW\;(
MU\YV+=XW6[#M6I9;G/LEY7/Z#$&*B/6>1%#0W0&[\:6WK[O)<)F6,E>SC%+*
MT+=,>[?^5@FMJW7,^Y?&[R_'XL#Q\ J67_RT*M/6O29K^SOCD5CZV&H.8T?D
M]?D0/@26BWQYR%>^SRI_^D_%#MPG:O\'4$L#!!0    (  !$<5J%JM<]#0@
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M#X'ETBX/^<Y77=5/_X'9@?NP[7=02P,$%     @  $1Q6E_3 YZ/!   <1$
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M+3(P,C0Q,C,Q7V1E9BYX;6Q02P$"% ,4    "   1'%:#Q)W%M(9  "@&@
M%               @ '$8P0 <&%C8BTR,#(T,3(S,5]G,2YJ<&=02P$"% ,4
M    "   1'%:V&B(/:6H  "9N   %               @ '(?00 <&%C8BTR
M,#(T,3(S,5]G,BYJ<&=02P$"% ,4    "   1'%:2PU@BZ2T  "XM   %
M            @ &?)@4 <&%C8BTR,#(T,3(S,5]G,RYG:6902P$"% ,4
M"   1'%:M]-CJKIN   6=P  %               @ %UVP4 <&%C8BTR,#(T
M,3(S,5]G-"YJ<&=02P$"% ,4    "   1'%:)DM#["K+ @ *? 0 %
M        @ %A2@8 <&%C8BTR,#(T,3(S,5]G-2YJ<&=02P$"% ,4    "
M1'%:BVE?S#<X  #G20  %               @ &]%0D <&%C8BTR,#(T,3(S
M,5]G-BYJ<&=02P$"% ,4    "   1'%:T38/E6,U  #B00  %
M    @ $F3@D <&%C8BTR,#(T,3(S,5]G-RYJ<&=02P$"% ,4    "   1'%:
M?F;LJ+PU  #=1   %               @ &[@PD <&%C8BTR,#(T,3(S,5]G
M."YJ<&=02P$"% ,4    "   1'%:4ULD3="# 0#F#P\ %0
M@ &IN0D <&%C8BTR,#(T,3(S,5]L86(N>&UL4$L! A0#%     @  $1Q6K">
M':GP[0  C@,+ !4              ( !K#T+ '!A8V(M,C R-#$R,S%?<')E
M+GAM;%!+ 0(4 Q0    (  !$<5J[N-'YZC(  )E: 0 >              "
M <\K# !P86-B+65X>#$P,3-X<&%C8FEO8VAA;F=E:2YH=&U02P$"% ,4
M"   1'%:#E_%V6$T  "J9 $ '@              @ 'U7@P <&%C8BUE>'@Q
M,#$U>'!A8V)I;WAC96]A;64N:'1M4$L! A0#%     @  $1Q6ASE2 QJ,P
M)5<! !X              ( !DI,, '!A8V(M97AX,3 Q-WAP86-B:6]X87)C
M:&%N+FAT;5!+ 0(4 Q0    (  !$<5HP=GM>!3$! !+U"  >
M  "  3C'# !P86-B+65X>#$P,3AX<&%C8GAL96%S965D9RYH=&U02P$"% ,4
M    "   1'%:BIMO*B<>   /D $ '@              @ %Y^ T <&%C8BUE
M>'@Q,#$Y>&9I<G-T86UE;F1M96XN:'1M4$L! A0#%     @  $1Q6OJ!]4B]
M$   -6T  !X              ( !W!8. '!A8V(M97AX,3 R,'AP86-B:6]S
M96-O;F1A+FAT;5!+ 0(4 Q0    (  !$<5KI__%@(3   ,Y> 0 >
M      "  =4G#@!P86-B+65X>#$P,C%X<&%C8FEO>#$S,#5O8BYH=&U02P$"
M% ,4    "   1'%:RR5F\:,6   =GP  '@              @ $R6 X <&%C
M8BUE>'@Q,#,S>'!A8V)I;V]U='-I9&4N:'1M4$L! A0#%     @  $1Q6FX@
M^%V71   U/P! !X              ( !$6\. '!A8V(M97AX,3DQ>'!A8V)I
M;VEN<VED97)T+FAT;5!+ 0(4 Q0    (  !$<5KD#;Z_V0,  /8J   4
M          "  >2S#@!P86-B+65X>#(Q,7@R,#(T+FAT;5!+ 0(4 Q0    (
M  !$<5K@_P+A' 0  .\1   4              "  >^W#@!P86-B+65X>#(S
M,7@R,#(T+FAT;5!+ 0(4 Q0    (  !$<5KG;*H[ P@  *DF   4
M      "  3V\#@!P86-B+65X>#,Q,7@R,#(T+FAT;5!+ 0(4 Q0    (  !$
M<5J%JM<]#0@  -\F   4              "  7+$#@!P86-B+65X>#,Q,G@R
M,#(T+FAT;5!+ 0(4 Q0    (  !$<5I?TP.>CP0  '$1   4
M  "  ;',#@!P86-B+65X>#,R,7@R,#(T+FAT;5!+ 0(4 Q0    (  !$<5II
M"ZM\H 0  (<1   4              "  7+1#@!P86-B+65X>#,R,G@R,#(T
M+FAT;5!+ 0(4 Q0    (  !$<5J6QR"9*Q(  %II   >              "
M 436#@!P86-B+65X>#0R>&1E<V-R:7!T:6]N;V9S92YH=&U02P4&     !X
,'@ >"   J^@.

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>pacb-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pacb="http://www.pacificbiosciences.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pacb-20241231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:NoteExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:NoteExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:NoteExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:BusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:BusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:BusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:LiquidityBonusEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:LiquidityBonusEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:LiquidityBonusEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-02</startDate>
            <endDate>2023-08-02</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-02</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">pacb:AchievementOfMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-02</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-02</startDate>
            <endDate>2023-08-02</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-20</startDate>
            <endDate>2023-09-20</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-20</startDate>
            <endDate>2023-09-20</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-20</startDate>
            <endDate>2023-09-20</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-20</startDate>
            <endDate>2023-09-20</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashCashEquivalentsAndInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashCashEquivalentsAndInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pacb:LaboratoryEquipmentAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pacb:LaboratoryEquipmentAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pacb:InProcessResearchAndDevelopmentIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pacb:InProcessResearchAndDevelopmentIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:CostOfRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:CostOfRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:CostOfRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-07</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-07</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-07</startDate>
            <endDate>2024-11-07</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2010-10-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:ShelfOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-22</startDate>
            <endDate>2022-05-22</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-18</startDate>
            <endDate>2024-06-18</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:A2020PlanInducementPlanAndTheOmniomePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedAndPerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedAndPerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsPSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-07</startDate>
            <endDate>2025-03-07</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-07</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="unit">
        <measure>pacb:unit</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <unit id="vote">
        <measure>pacb:vote</measure>
    </unit>
    <unit id="period">
        <measure>pacb:period</measure>
    </unit>
    <unit id="segment">
        <measure>pacb:segment</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-33">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-34">0001299130</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-35">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-36">2024</dei:DocumentFiscalYearFocus>
    <pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition contextRef="c-74" id="f-527">P20D</pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition>
    <pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition contextRef="c-162" id="f-661">P20D</pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition>
    <us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-814">http://fasb.org/us-gaap/2024#GoodwillAndIntangibleAssetImpairment</us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="c-248"
      decimals="7"
      id="f-1000"
      unitRef="number">0.2045157</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="c-224"
      decimals="7"
      id="f-1001"
      unitRef="number">0.0465116</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-1008">http://fasb.org/us-gaap/2024#CostOfRevenue</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-34899</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">Pacific Biosciences of California, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">16-1590339</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">1305 O&#x2019;Brien Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Menlo Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">94025</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">94025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-15">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">521-8000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">PACB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-30" unitRef="usd">371400000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">297852228</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">Portions of the registrant&#x2019;s definitive Proxy Statement relating to its 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-38">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes. We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct periodic risk assessments to identify cybersecurity threats, as well as assessments in the event of a material change in our business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following these risk assessments, we evaluate whether and how to re-design, implement, and maintain reasonable safeguards to minimize identified risks; reasonably address any identified gaps in existing safeguards; and regularly monitor the effectiveness of our safeguards. We devote resources and designate high-level personnel, including our Vice President and Head of Information Technology who reports to our Chief Operating Officer, to manage the risk assessment and mitigation process. &lt;/span&gt;&lt;/div&gt;As part of our overall risk management system, we monitor and test our safeguards, including through annual third-party vulnerability assessments. We train our employees on these safeguards, in collaboration with human resources, IT, and departmental management. Personnel at all levels and departments are made aware of our cybersecurity policies through training.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-37">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes. We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct periodic risk assessments to identify cybersecurity threats, as well as assessments in the event of a material change in our business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following these risk assessments, we evaluate whether and how to re-design, implement, and maintain reasonable safeguards to minimize identified risks; reasonably address any identified gaps in existing safeguards; and regularly monitor the effectiveness of our safeguards. We devote resources and designate high-level personnel, including our Vice President and Head of Information Technology who reports to our Chief Operating Officer, to manage the risk assessment and mitigation process. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of our overall risk management system, we monitor and test our safeguards, including through annual third-party vulnerability assessments. We train our employees on these safeguards, in collaboration with human resources, IT, and departmental management. Personnel at all levels and departments are made aware of our cybersecurity policies through training. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We engage assessors, consultants, auditors, or other third parties in connection with our risk assessment processes. These service providers assist us in designing and implement our cybersecurity policies and procedures, as well as to monitor and test our safeguards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established procedures to evaluate and respond to cybersecurity incidents, including cybersecurity incidents at third-party service providers which have a potential to impact our data and systems. Our cybersecurity risk management is intended to address such risks, as well as other risks related to third parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not previously experienced a cybersecurity incident that was determined to be material. For additional information regarding whether any risks from cybersecurity threats are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to Item 1A, &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_19" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Risk Factors&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#x201d; in this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-39">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-40">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-41">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-42">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-43">One of the key functions of our board of directors is to provide oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through the audit committee.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-45">Our Vice President and Head of Information Technology and our cyber committee, which includes Facilities, HR, IT, Legal, and Management, are primarily responsible to assess and manage our material risks from cybersecurity threats.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-44">Our Vice President and Head of Information Technology and our cyber committee, which includes Facilities, HR, IT, Legal, and Management, are primarily responsible to assess and manage our material risks from cybersecurity threats.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-46">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-47">Our Vice President and Head of Information Technology has years of cybersecurity experience and expertise including holding numerous applicable cybersecurity certifications, such as ISC2 Certified Information Systems Security Professional (CISSP).</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-48">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Vice President and Head of Information Technology and our management committee on cybersecurity oversee our cybersecurity policies and processes, including those described in &#x201c;Risk Management and Strategy&#x201d; above. Our Vice President and Head of Information Technology is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents by leading cybersecurity risk management and working directly with our IT team. Our Vice President and Head of Information Technology also provides appropriate information and updates to our management committee on cybersecurity.&lt;/span&gt;&lt;/div&gt;Our Vice President and Head of Information Technology and representatives from our management committee on cybersecurity provide annual briefings to the audit committee regarding our company&#x2019;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-49">Our Vice President and Head of Information Technology is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents by leading cybersecurity risk management and working directly with our IT team. Our Vice President and Head of Information Technology also provides appropriate information and updates to our management committee on cybersecurity.Our Vice President and Head of Information Technology and representatives from our management committee on cybersecurity provide annual briefings to the audit committee regarding our company&#x2019;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like. Our audit committee provides regular updates to the board of directors on such reports.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-50">Our audit committee provides regular updates to the board of directors on such reports.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-51">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <pacb:GoodwillImpairmentDiscountedCashFlowModelDiscountRate contextRef="c-4" decimals="3" id="f-52" unitRef="number">0.120</pacb:GoodwillImpairmentDiscountedCashFlowModelDiscountRate>
    <pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate contextRef="c-4" decimals="4" id="f-53" unitRef="number">0.0100</pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate>
    <pacb:AdditionalGoodwillImpairmentChangeInDiscountRate contextRef="c-5" decimals="-6" id="f-54" unitRef="usd">95000000</pacb:AdditionalGoodwillImpairmentChangeInDiscountRate>
    <pacb:IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate contextRef="c-4" decimals="3" id="f-55" unitRef="number">0.140</pacb:IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate>
    <pacb:IntangibleAssetImpairmentDiscountedCashFlowModelTerm contextRef="c-4" id="f-56">P13Y</pacb:IntangibleAssetImpairmentDiscountedCashFlowModelTerm>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-6" decimals="-3" id="f-57" unitRef="usd">40000000.0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate contextRef="c-4" decimals="4" id="f-58" unitRef="number">0.0100</pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate>
    <pacb:AdditionalIntangibleAssetImpairmentChangeInDiscountRate contextRef="c-5" decimals="-6" id="f-59" unitRef="usd">5000000</pacb:AdditionalIntangibleAssetImpairmentChangeInDiscountRate>
    <pacb:IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm contextRef="c-4" id="f-60">P1Y</pacb:IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm>
    <pacb:AdditionalIntangibleAssetImpairmentChangeInTerm contextRef="c-5" decimals="-6" id="f-61" unitRef="usd">5000000</pacb:AdditionalIntangibleAssetImpairmentChangeInTerm>
    <dei:AuditorFirmId contextRef="c-1" id="f-62">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-63">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-64">San Mateo, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">55370000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-66" unitRef="usd">179911000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">334561000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-7" decimals="-3" id="f-68" unitRef="usd">451505000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">27524000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-7" decimals="-3" id="f-70" unitRef="usd">36615000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">58755000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-7" decimals="-3" id="f-72" unitRef="usd">56676000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">18781000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-74" unitRef="usd">17040000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">690000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-7" decimals="-3" id="f-76" unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">495681000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-7" decimals="-3" id="f-78" unitRef="usd">742047000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">30505000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-80" unitRef="usd">36432000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">16091000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-7" decimals="-3" id="f-82" unitRef="usd">32593000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-4" decimals="-3" id="f-83" unitRef="usd">1532000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-7" decimals="-3" id="f-84" unitRef="usd">2422000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-85" unitRef="usd">389572000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-7" decimals="-3" id="f-86" unitRef="usd">456984000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-87" unitRef="usd">317761000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-7" decimals="-3" id="f-88" unitRef="usd">462261000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-89" unitRef="usd">9305000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-7" decimals="-3" id="f-90" unitRef="usd">13274000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">1260447000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-7" decimals="-3" id="f-92" unitRef="usd">1746013000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-93" unitRef="usd">16590000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-7" decimals="-3" id="f-94" unitRef="usd">15062000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-95" unitRef="usd">22595000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-96" unitRef="usd">45708000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-97" unitRef="usd">13864000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-7" decimals="-3" id="f-98" unitRef="usd">16342000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-99" unitRef="usd">10026000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-100" unitRef="usd">9591000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-101" unitRef="usd">3224000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-102" unitRef="usd">8326000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-103" unitRef="usd">66299000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-104" unitRef="usd">95029000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-105" unitRef="usd">5900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-106" unitRef="usd">5530000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-107" unitRef="usd">18700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-108" unitRef="usd">19550000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-109" unitRef="usd">14914000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-110" unitRef="usd">31606000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-4" decimals="-3" id="f-111" unitRef="usd">647494000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-7" decimals="-3" id="f-112" unitRef="usd">892243000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-113" unitRef="usd">546000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-7" decimals="-3" id="f-114" unitRef="usd">751000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-115" unitRef="usd">753853000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-7" decimals="-3" id="f-116" unitRef="usd">1044709000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-117" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-7" id="f-118" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-119"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-120"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-121" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-122" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-123" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-124" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-125" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-7" decimals="INF" id="f-126" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-127" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-7" decimals="-3" id="f-128" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-129"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-130"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-131" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-132" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-133" unitRef="shares">294418000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-134" unitRef="shares">294418000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-7" decimals="-3" id="f-135" unitRef="shares">267744000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="-3" id="f-136" unitRef="shares">267744000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-137" unitRef="usd">294000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-7" decimals="-3" id="f-138" unitRef="usd">268000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-139" unitRef="usd">2654804000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-7" decimals="-3" id="f-140" unitRef="usd">2539892000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-141" unitRef="usd">422000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-7" decimals="-3" id="f-142" unitRef="usd">219000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-143" unitRef="usd">-2148926000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-7" decimals="-3" id="f-144" unitRef="usd">-1839075000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-145" unitRef="usd">506594000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-146" unitRef="usd">701304000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-147" unitRef="usd">1260447000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-7" decimals="-3" id="f-148" unitRef="usd">1746013000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-8" decimals="-3" id="f-149" unitRef="usd">136149000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-9" decimals="-3" id="f-150" unitRef="usd">183872000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-10" decimals="-3" id="f-151" unitRef="usd">108699000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-11" decimals="-3" id="f-152" unitRef="usd">17865000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-12" decimals="-3" id="f-153" unitRef="usd">16649000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-13" decimals="-3" id="f-154" unitRef="usd">19605000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-155" unitRef="usd">154014000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-14" decimals="-3" id="f-156" unitRef="usd">200521000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-15" decimals="-3" id="f-157" unitRef="usd">128304000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-8" decimals="-3" id="f-158" unitRef="usd">92284000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-9" decimals="-3" id="f-159" unitRef="usd">127568000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-10" decimals="-3" id="f-160" unitRef="usd">60932000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-11" decimals="-3" id="f-161" unitRef="usd">14057000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-12" decimals="-3" id="f-162" unitRef="usd">14754000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-13" decimals="-3" id="f-163" unitRef="usd">13899000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-1" decimals="-3" id="f-164" unitRef="usd">9393000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-14" decimals="-3" id="f-165" unitRef="usd">1983000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-15" decimals="-3" id="f-166" unitRef="usd">733000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <pacb:LossOnPurchaseCommitment contextRef="c-1" decimals="-3" id="f-167" unitRef="usd">998000</pacb:LossOnPurchaseCommitment>
    <pacb:LossOnPurchaseCommitment contextRef="c-14" decimals="-3" id="f-168" unitRef="usd">3436000</pacb:LossOnPurchaseCommitment>
    <pacb:LossOnPurchaseCommitment contextRef="c-15" decimals="-3" id="f-169" unitRef="usd">3705000</pacb:LossOnPurchaseCommitment>
    <us-gaap:CostOfRevenue contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">116732000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-14" decimals="-3" id="f-171" unitRef="usd">147741000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-15" decimals="-3" id="f-172" unitRef="usd">79269000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-173" unitRef="usd">37282000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-14" decimals="-3" id="f-174" unitRef="usd">52780000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-15" decimals="-3" id="f-175" unitRef="usd">49035000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-176" unitRef="usd">134922000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-14" decimals="-3" id="f-177" unitRef="usd">187170000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-15" decimals="-3" id="f-178" unitRef="usd">193000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">175017000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-14" decimals="-3" id="f-180" unitRef="usd">169818000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-15" decimals="-3" id="f-181" unitRef="usd">160854000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">184500000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-14" decimals="-3" id="f-183" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-15" decimals="-3" id="f-184" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-14" decimals="-3" id="f-186" unitRef="usd">9042000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-15" decimals="-3" id="f-187" unitRef="usd">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">-850000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-14" decimals="-3" id="f-189" unitRef="usd">15060000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-15" decimals="-3" id="f-190" unitRef="usd">2377000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <pacb:AmortizationOfAcquiredIntangibleAssets contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">18006000</pacb:AmortizationOfAcquiredIntangibleAssets>
    <pacb:AmortizationOfAcquiredIntangibleAssets contextRef="c-14" decimals="-3" id="f-192" unitRef="usd">6157000</pacb:AmortizationOfAcquiredIntangibleAssets>
    <pacb:AmortizationOfAcquiredIntangibleAssets contextRef="c-15" decimals="-3" id="f-193" unitRef="usd">0</pacb:AmortizationOfAcquiredIntangibleAssets>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">511595000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-14" decimals="-3" id="f-195" unitRef="usd">387247000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-15" decimals="-3" id="f-196" unitRef="usd">356231000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">-474313000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-14" decimals="-3" id="f-198" unitRef="usd">-334467000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-15" decimals="-3" id="f-199" unitRef="usd">-307196000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-14" decimals="-3" id="f-201" unitRef="usd">-2033000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-15" decimals="-3" id="f-202" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">154407000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c-14" decimals="-3" id="f-204" unitRef="usd">0</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c-15" decimals="-3" id="f-205" unitRef="usd">0</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-206" unitRef="usd">13412000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-14" decimals="-3" id="f-207" unitRef="usd">14343000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-15" decimals="-3" id="f-208" unitRef="usd">14690000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">23783000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-210" unitRef="usd">32684000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-15" decimals="-3" id="f-211" unitRef="usd">7638000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">-309535000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-213" unitRef="usd">-318159000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-214" unitRef="usd">-314248000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">316000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-216" unitRef="usd">-11424000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-217" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-218" unitRef="usd">-309851000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-14" decimals="-3" id="f-219" unitRef="usd">-306735000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-15" decimals="-3" id="f-220" unitRef="usd">-314248000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">203000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-14" decimals="-3" id="f-222" unitRef="usd">4984000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-223" unitRef="usd">-3678000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">-309648000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-14" decimals="-3" id="f-225" unitRef="usd">-301751000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-15" decimals="-3" id="f-226" unitRef="usd">-317926000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-227"
      unitRef="usdPerShare">-1.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-228"
      unitRef="usdPerShare">-1.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-229"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-230"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-231"
      unitRef="usdPerShare">-1.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-232"
      unitRef="usdPerShare">-1.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-233"
      unitRef="usdPerShare">-1.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-234"
      unitRef="usdPerShare">-1.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-235"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-236"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-237"
      unitRef="usdPerShare">-1.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-238"
      unitRef="usdPerShare">-1.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-239" unitRef="shares">274488000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-240" unitRef="shares">274488000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-14" decimals="-3" id="f-241" unitRef="shares">253629000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-14" decimals="-3" id="f-242" unitRef="shares">253629000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="-3" id="f-243" unitRef="shares">224550000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="-3" id="f-244" unitRef="shares">224550000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-245" unitRef="shares">288366000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-14" decimals="-3" id="f-246" unitRef="shares">253629000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="-3" id="f-247" unitRef="shares">224550000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-16" decimals="-3" id="f-248" unitRef="shares">220978000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-249" unitRef="usd">221000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-250" unitRef="usd">2009945000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-251" unitRef="usd">-1087000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-252" unitRef="usd">-1218092000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-253" unitRef="usd">790987000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-3" id="f-254" unitRef="usd">-314248000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-255" unitRef="usd">-314248000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-22" decimals="-3" id="f-256" unitRef="usd">-3678000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-257" unitRef="usd">-3678000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-23" decimals="-3" id="f-258" unitRef="shares">5527000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-23" decimals="-3" id="f-259" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-24" decimals="-3" id="f-260" unitRef="usd">11224000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-15" decimals="-3" id="f-261" unitRef="usd">11230000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-24" decimals="-3" id="f-262" unitRef="usd">78613000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-15" decimals="-3" id="f-263" unitRef="usd">78613000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-25" decimals="-3" id="f-264" unitRef="shares">226505000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-265" unitRef="usd">227000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-266" unitRef="usd">2099782000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-267" unitRef="usd">-4765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-268" unitRef="usd">-1532340000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-269" unitRef="usd">562904000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-30" decimals="-3" id="f-270" unitRef="usd">-306735000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-271" unitRef="usd">-306735000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-31" decimals="-3" id="f-272" unitRef="usd">4984000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-14" decimals="-3" id="f-273" unitRef="usd">4984000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c-32" decimals="-3" id="f-274" unitRef="shares">8988000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-32" decimals="-3" id="f-275" unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-33" decimals="-3" id="f-276" unitRef="usd">84752000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-14" decimals="-3" id="f-277" unitRef="usd">84761000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c-32" decimals="-3" id="f-278" unitRef="shares">6121000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-32" decimals="-3" id="f-279" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-33" decimals="-3" id="f-280" unitRef="usd">76636000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-14" decimals="-3" id="f-281" unitRef="usd">76642000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <pacb:StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan contextRef="c-32" decimals="-3" id="f-282" unitRef="shares">169000</pacb:StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan>
    <pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan contextRef="c-33" decimals="-3" id="f-283" unitRef="usd">2111000</pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan>
    <pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan contextRef="c-14" decimals="-3" id="f-284" unitRef="usd">2111000</pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-32" decimals="-3" id="f-285" unitRef="shares">20125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-32" decimals="-3" id="f-286" unitRef="usd">20000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-33" decimals="-3" id="f-287" unitRef="usd">189180000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-14" decimals="-3" id="f-288" unitRef="usd">189200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-32" decimals="-3" id="f-289" unitRef="shares">5836000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-32" decimals="-3" id="f-290" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-33" decimals="-3" id="f-291" unitRef="usd">15313000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-14" decimals="-3" id="f-292" unitRef="usd">15319000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-33" decimals="-3" id="f-293" unitRef="usd">72118000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-294" unitRef="usd">72118000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-34" decimals="-3" id="f-295" unitRef="shares">267744000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-296" unitRef="usd">268000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-297" unitRef="usd">2539892000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-298" unitRef="usd">219000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-299" unitRef="usd">-1839075000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-300" unitRef="usd">701304000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-38" decimals="-3" id="f-301" unitRef="usd">-309851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-302" unitRef="usd">-309851000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-39" decimals="-3" id="f-303" unitRef="usd">203000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-304" unitRef="usd">203000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-40" decimals="-3" id="f-305" unitRef="shares">6222000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-40" decimals="-3" id="f-306" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-41" decimals="-3" id="f-307" unitRef="usd">7697000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">7703000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c-40" decimals="-3" id="f-309" unitRef="shares">20452000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-40" decimals="-3" id="f-310" unitRef="usd">20000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-41" decimals="-3" id="f-311" unitRef="usd">36179000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">36199000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-41" decimals="-3" id="f-313" unitRef="usd">71036000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">71036000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="-3" id="f-315" unitRef="shares">294418000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-316" unitRef="usd">294000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-317" unitRef="usd">2654804000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-318" unitRef="usd">422000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-319" unitRef="usd">-2148926000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-320" unitRef="usd">506594000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">-309851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-322" unitRef="usd">-306735000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-323" unitRef="usd">-314248000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">13774000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-14" decimals="-3" id="f-325" unitRef="usd">11463000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-15" decimals="-3" id="f-326" unitRef="usd">9480000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-327" unitRef="usd">27412000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-14" decimals="-3" id="f-328" unitRef="usd">8261000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-15" decimals="-3" id="f-329" unitRef="usd">913000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">12165000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-14" decimals="-3" id="f-331" unitRef="usd">6810000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-15" decimals="-3" id="f-332" unitRef="usd">6925000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">71036000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-14" decimals="-3" id="f-334" unitRef="usd">72118000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-15" decimals="-3" id="f-335" unitRef="usd">78613000</us-gaap:ShareBasedCompensation>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">184500000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-14" decimals="-3" id="f-337" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-15" decimals="-3" id="f-338" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:NoncashMergerRelatedCosts contextRef="c-1" decimals="-3" id="f-339" unitRef="usd">0</us-gaap:NoncashMergerRelatedCosts>
    <us-gaap:NoncashMergerRelatedCosts contextRef="c-14" decimals="-3" id="f-340" unitRef="usd">3395000</us-gaap:NoncashMergerRelatedCosts>
    <us-gaap:NoncashMergerRelatedCosts contextRef="c-15" decimals="-3" id="f-341" unitRef="usd">0</us-gaap:NoncashMergerRelatedCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-14" decimals="-3" id="f-343" unitRef="usd">-2033000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-15" decimals="-3" id="f-344" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c-1" decimals="-3" id="f-345" unitRef="usd">154407000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c-14" decimals="-3" id="f-346" unitRef="usd">0</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c-15" decimals="-3" id="f-347" unitRef="usd">0</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">13044000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-14" decimals="-3" id="f-349" unitRef="usd">12840000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-15" decimals="-3" id="f-350" unitRef="usd">244000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-3" id="f-351" unitRef="usd">-850000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-14" decimals="-3" id="f-352" unitRef="usd">15060000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-15" decimals="-3" id="f-353" unitRef="usd">2377000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:InventoryWriteDown contextRef="c-1" decimals="-3" id="f-354" unitRef="usd">4618000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-14" decimals="-3" id="f-355" unitRef="usd">10584000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-15" decimals="-3" id="f-356" unitRef="usd">6027000</us-gaap:InventoryWriteDown>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-3" id="f-357" unitRef="usd">-205000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-14" decimals="-3" id="f-358" unitRef="usd">-11424000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-15" decimals="-3" id="f-359" unitRef="usd">0</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-360" unitRef="usd">628000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-14" decimals="-3" id="f-361" unitRef="usd">-1059000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-15" decimals="-3" id="f-362" unitRef="usd">-918000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-363" unitRef="usd">-9091000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-14" decimals="-3" id="f-364" unitRef="usd">17829000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-15" decimals="-3" id="f-365" unitRef="usd">-5455000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">8320000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-14" decimals="-3" id="f-367" unitRef="usd">13841000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-15" decimals="-3" id="f-368" unitRef="usd">33906000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-369" unitRef="usd">-2228000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-14" decimals="-3" id="f-370" unitRef="usd">8984000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-15" decimals="-3" id="f-371" unitRef="usd">12324000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-372" unitRef="usd">1405000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-14" decimals="-3" id="f-373" unitRef="usd">206000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-15" decimals="-3" id="f-374" unitRef="usd">1025000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-375" unitRef="usd">-26342000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-14" decimals="-3" id="f-376" unitRef="usd">13103000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-15" decimals="-3" id="f-377" unitRef="usd">-3651000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-378" unitRef="usd">-2108000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-14" decimals="-3" id="f-379" unitRef="usd">-10420000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-15" decimals="-3" id="f-380" unitRef="usd">-3734000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-381" unitRef="usd">-11920000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-14" decimals="-3" id="f-382" unitRef="usd">-8759000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-15" decimals="-3" id="f-383" unitRef="usd">-7724000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <pacb:IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability contextRef="c-1" decimals="-3" id="f-384" unitRef="usd">0</pacb:IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability>
    <pacb:IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability contextRef="c-14" decimals="-3" id="f-385" unitRef="usd">-14882000</pacb:IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability>
    <pacb:IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability contextRef="c-15" decimals="-3" id="f-386" unitRef="usd">0</pacb:IncreaseDecreaseInBusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-387" unitRef="usd">-4612000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-14" decimals="-3" id="f-388" unitRef="usd">2449000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-15" decimals="-3" id="f-389" unitRef="usd">887000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-390" unitRef="usd">-206058000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-14" decimals="-3" id="f-391" unitRef="usd">-259173000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-15" decimals="-3" id="f-392" unitRef="usd">-263211000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-393" unitRef="usd">6188000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-14" decimals="-3" id="f-394" unitRef="usd">8843000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-15" decimals="-3" id="f-395" unitRef="usd">16750000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-3" id="f-396" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-14" decimals="-3" id="f-397" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-15" decimals="-3" id="f-398" unitRef="usd">179000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-3" id="f-399" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-14" decimals="-3" id="f-400" unitRef="usd">102000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-15" decimals="-3" id="f-401" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-1" decimals="-3" id="f-402" unitRef="usd">498635000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-14" decimals="-3" id="f-403" unitRef="usd">756567000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-15" decimals="-3" id="f-404" unitRef="usd">442788000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-405" unitRef="usd">34856000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-14" decimals="-3" id="f-406" unitRef="usd">595000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-15" decimals="-3" id="f-407" unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-408" unitRef="usd">593971000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-14" decimals="-3" id="f-409" unitRef="usd">769521000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-15" decimals="-3" id="f-410" unitRef="usd">575800000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-411" unitRef="usd">124004000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-14" decimals="-3" id="f-412" unitRef="usd">4604000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-15" decimals="-3" id="f-413" unitRef="usd">116083000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-414" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-14" decimals="-3" id="f-415" unitRef="usd">189200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-15" decimals="-3" id="f-416" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-417" unitRef="usd">7703000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-14" decimals="-3" id="f-418" unitRef="usd">15319000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-15" decimals="-3" id="f-419" unitRef="usd">11230000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-420" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-14" decimals="-3" id="f-421" unitRef="usd">7375000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-15" decimals="-3" id="f-422" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-1" decimals="-3" id="f-423" unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-14" decimals="-3" id="f-424" unitRef="usd">86411000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-15" decimals="-3" id="f-425" unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <pacb:PaymentsInConjunctionWithNotesExchange contextRef="c-1" decimals="-3" id="f-426" unitRef="usd">50200000</pacb:PaymentsInConjunctionWithNotesExchange>
    <pacb:PaymentsInConjunctionWithNotesExchange contextRef="c-14" decimals="-3" id="f-427" unitRef="usd">0</pacb:PaymentsInConjunctionWithNotesExchange>
    <pacb:PaymentsInConjunctionWithNotesExchange contextRef="c-15" decimals="-3" id="f-428" unitRef="usd">0</pacb:PaymentsInConjunctionWithNotesExchange>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-1" decimals="-3" id="f-429" unitRef="usd">490000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-14" decimals="-3" id="f-430" unitRef="usd">1842000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-15" decimals="-3" id="f-431" unitRef="usd">1608000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-432" unitRef="usd">-42987000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-14" decimals="-3" id="f-433" unitRef="usd">108891000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-15" decimals="-3" id="f-434" unitRef="usd">9622000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-435" unitRef="usd">-125041000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-14" decimals="-3" id="f-436" unitRef="usd">-145678000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-15" decimals="-3" id="f-437" unitRef="usd">-137506000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-438" unitRef="usd">182633000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="-3" id="f-439" unitRef="usd">328311000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-20" decimals="-3" id="f-440" unitRef="usd">465817000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-441" unitRef="usd">57592000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-442" unitRef="usd">182633000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="-3" id="f-443" unitRef="usd">328311000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-444" unitRef="usd">55370000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-445" unitRef="usd">179911000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-29" decimals="-3" id="f-446" unitRef="usd">325089000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-447" unitRef="usd">2222000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-7" decimals="-3" id="f-448" unitRef="usd">2722000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-29" decimals="-3" id="f-449" unitRef="usd">3222000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-450" unitRef="usd">57592000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-451" unitRef="usd">182633000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="-3" id="f-452" unitRef="usd">328311000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-453" unitRef="usd">14805000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-14" decimals="-3" id="f-454" unitRef="usd">15687000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-15" decimals="-3" id="f-455" unitRef="usd">14049000</us-gaap:InterestPaidNet>
    <pacb:TransferOfInventoryToPropertyAndEquipment contextRef="c-46" decimals="-3" id="f-456" unitRef="usd">4194000</pacb:TransferOfInventoryToPropertyAndEquipment>
    <pacb:TransferOfInventoryToPropertyAndEquipment contextRef="c-47" decimals="-3" id="f-457" unitRef="usd">3984000</pacb:TransferOfInventoryToPropertyAndEquipment>
    <pacb:TransferOfInventoryToPropertyAndEquipment contextRef="c-48" decimals="-3" id="f-458" unitRef="usd">2812000</pacb:TransferOfInventoryToPropertyAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-46" decimals="-3" id="f-459" unitRef="usd">-2572000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-47" decimals="-3" id="f-460" unitRef="usd">-7022000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-48" decimals="-3" id="f-461" unitRef="usd">-715000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-46" decimals="-3" id="f-462" unitRef="usd">18253000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-47" decimals="-3" id="f-463" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-48" decimals="-3" id="f-464" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1 contextRef="c-49" decimals="-3" id="f-465" unitRef="usd">36199000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-50" decimals="-3" id="f-466" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-51" decimals="-3" id="f-467" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-52" decimals="-3" id="f-468" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-53" decimals="-3" id="f-469" unitRef="usd">76642000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-54" decimals="-3" id="f-470" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-55" decimals="-3" id="f-471" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-56" decimals="-3" id="f-472" unitRef="usd">2111000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-57" decimals="-3" id="f-473" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:NotesIssued1 contextRef="c-1" decimals="-3" id="f-474" unitRef="usd">0</us-gaap:NotesIssued1>
    <us-gaap:NotesIssued1 contextRef="c-14" decimals="-3" id="f-475" unitRef="usd">441000000</us-gaap:NotesIssued1>
    <us-gaap:NotesIssued1 contextRef="c-15" decimals="-3" id="f-476" unitRef="usd">0</us-gaap:NotesIssued1>
    <us-gaap:StockIssued1 contextRef="c-58" decimals="-3" id="f-477" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-59" decimals="-3" id="f-478" unitRef="usd">84761000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-60" decimals="-3" id="f-479" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-480">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 1.  ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing technology and our Sequencing by Binding (SBB) short-read sequencing technology. Our products address solutions across a broad set of applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Long-read sequencing was recognized by the journal Nature Methods as its &#x201c;method of the year&#x201d; for 2022 for its contributions to biological understanding and future potential. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-read sequencing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has been applied to produce telomere-to-telomere genomes of humans, pangenome references, and has been recognized for its ability to provide more complete views of human variation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our focus is on creating some of the world's most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References in this report to &#x201c;PacBio,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; the &#x201c;Company,&#x201d; and &#x201c;our&#x201d; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates, including those relating to the valuation of inventory, fair value of contingent consideration, valuation of acquired intangible assets, useful lives assigned to finite-lived assets, asset impairment assessments, computation of provisions for income taxes, and valuations related to our convertible senior notes. While the extent of the potential impact of current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of December&#160;31, 2024. Actual results could differ materially from these estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Functional Currency&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. dollar is the functional currency of our international operations. We remeasure foreign subsidiaries monetary assets and liabilities to the U.S. dollar and record net gains or losses from remeasurement in other income, net, on our consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash, and Investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#x2019; securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive income (loss) in stockholders&#x2019; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net. We have the ability to hold, and do not intend to sell investments in unrealized loss positions before the recovery of their amortized cost bases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities, and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash includes cash that is not readily available for use in the Company&#x2019;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Concentration and Other Risks&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to credit risk consist principally of interest-bearing investments and trade receivables. We maintain cash, cash equivalents, and investments with various major financial institutions. The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing. At December&#160;31, 2024, most of our cash was deposited with U.S. financial institutions. Our investment policy generally restricts the amount of credit exposure to any one issuer. There is no limit to the percentage of the portfolio that may be maintained in securities issued by the U.S. Treasury and U.S. Government Agencies, or other securities fully backed by U.S. Treasury or Government agencies. We have not experienced significant credit losses from financial institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our trade receivables are derived from revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers&#x2019; financial condition and, generally, require no collateral from our customers. The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review our trade receivables including consideration of factors such as historical experience, the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#x2019;s ability to pay. We have not experienced any significant credit losses to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2024, and 2023, no customer accounted for 10% or more of our total revenue. For the year ended December&#160;31, 2022, one customer exceeded 10% of our total revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, 36% and 49% of our accounts receivable were from domestic customers, respectively. As of December&#160;31, 2024, no customer represented 10% or more of our net accounts receivable. As of December&#160;31, 2023, one customer represented 10% of our net accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We currently purchase several key parts and components used in the manufacture of our products from a limited number of suppliers. Generally, we have been able to obtain an adequate supply of such parts and components but in certain instances have incurred additional costs to secure a supply of constrained material. An extended interruption in the supply of parts and components currently obtained from our suppliers could adversely affect our business and consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Inventory, Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value on a first-in, first-out (&#x201c;FIFO&#x201d;) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs. Determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, reviewed regularly for impairment, and depreciated over the estimated useful lives of the assets, using the straight-line method. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred. Transfers of assets between property and equipment, net, and inventory are transferred at standard cost and recognized at carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated useful lives of the major classes of property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have various operating lease agreements for office, research and development, manufacturing and distribution facilities, including our headquarters location in Menlo Park, California. As of December 31, 2024, these leases had remaining lease terms that expire between 2025 and 2027. We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. Operating lease expense is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with certain acquisitions, contingent consideration can be earned by the sellers upon completion of certain future performance milestones. In these cases, a liability is recorded on the acquisition date for an estimate of the acquisition date fair value of the contingent consideration. These estimates require significant management judgment, including probabilities of achieving certain future milestones. Changes in the fair value of the contingent consideration subsequent to the acquisition date are recognized in operating expense on our consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded on our consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets with Indefinite Lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired, including intangible assets and capitalized in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;amp;D asset is assessed for impairment and then amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;amp;D asset is expensed in the period of abandonment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and IPR&amp;amp;D are not amortized; however, they are reviewed for impairment at least annually. We perform annual impairment testing of goodwill as of the first day of the second quarter, or more frequently if indicators of impairment exist. We perform annual impairment testing of IPR&amp;amp;D as of the first day of the third quarter, or more frequently if indicators of impairment exist. Events that would indicate impairment and trigger an interim impairment test include, but are not limited to, unexpected adverse business conditions, weak demand for a specific product line or business, economic factors, shifting focus to certain lines of business, unanticipated technological changes or competitive activities, loss of key personnel, changes in business strategy and acts by governments or courts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level. We have one reporting unit, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test. We generally perform our impairment test using a combination of an income and a market approach to determine the fair value of goodwill. The income approach utilizes estimated discounted cash flows, while the market approach utilizes comparable company information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the IPR&amp;amp;D impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the IPR&amp;amp;D is less than the carrying amount. The qualitative factors include, but are not limited to, macroeconomic conditions, industry-specific conditions, and company-specific conditions. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the IPR&amp;amp;D is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the IPR&amp;amp;D with the carrying value. If the carrying amount of the IPR&amp;amp;D exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Intangible Assets and Other Finite-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangibles assets include our acquired developed technology and customer relationships. We capitalize finite-lived intangibles assets and generally amortize them on a straight-line basis over the estimated useful lives. Intangible assets purchased as part of an acquisition are included in Intangible assets, net, on our consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We regularly review intangible assets with finite lives and other finite-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. We assess the recoverability of assets based on the estimated undiscounted future cash flows expected to result from the use and eventual disposition of the asset. If the undiscounted future cash flows are less than the carrying amount, the asset is impaired. In light of the changes in circumstances that led to the recoverability assessment, we also assess the remaining estimated useful life of the assets. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to net book value, significant changes in the ability of an asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to estimate the fair values of identifiable intangible assets with finite lives and other finite-lived assets, we estimate the present value of future cash flows from those assets. The key assumptions that we use in our cash flow model are the amount and timing of estimated future cash flows to be generated by the asset over an extended period of time and a rate of return that considers the relative risk of achieving the cash flows, the time value of money, and other factors that a willing market participant would consider. Management judgment is required to estimate the amount and timing of future cash flows and the relative risk of achieving those cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables; service and other revenue consist primarily of revenue earned from product maintenance agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods are transferred to our customers, or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Invoicing typically occurs upon shipment, or delivery in the case of an instrument, and payment is typically due within 30 days from invoice. In instances where the right to payment or transfer of title is contingent upon customer acceptance of the product, revenue is deferred until the acceptance criteria has been met. Revenue from instrument service contracts is recognized as the services are rendered, typically evenly over the contract term. Revenue from development agreements generally includes upfront and milestone payments. Revenue for these agreements is recognized when each distinct performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may enter into, or periodically modify, contracts with customers that include a combination of promised products and services, resulting in arrangements containing multiple performance obligations. We determine whether each product or service is distinct, in order to identify the performance obligations in the contract and allocate the contract transaction price among the distinct performance obligations. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Therefore, instrument revenue is recognized upon transfer of control of the asset to the customer, which is generally upon delivery for sales made to our non-distributor customers and upon shipment for sales made to our distributor customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration for contracts with multiple performance obligations is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using historical average selling prices combined with an assessment of current market conditions. If the standalone selling price is not directly observable, we rely on estimates by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices, and other observable inputs. We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts and sales taxes collected on behalf of governmental authorities. We update the transaction price for expected consideration, subject to constraint. Where we expect, at contract inception, the timing of payments to be consistent with the transfer of goods or services or the contract duration to be one year or less, we do not adjust the transaction price for the effects of a significant financing component &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically modify existing contracts with customers, which could change the scope or the price of the contract, or both. When a contract modification occurs, we exercise judgment to determine if the modification should be accounted for as: (i) a separate contract, (ii) the termination of the original contract and creation of a new contract, (iii) a cumulative catch-up adjustment to the original contract, or a combination thereof. Further, contract modifications require the identification and evaluation of the performance obligations of the modified contract, allocation of revenue to the remaining performance obligations and determination of the period of recognition for each identified performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our agreements provide options to customers which can be exercised at a future date, such as the option to purchase our product at discounted prices, among others. In accounting for customer options, we determine whether an option is a material right and this may require us to exercise judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right and, therefore, a performance obligation. If the contract gives the customer the option to acquire additional goods or services at their normal standalone selling prices, we would likely determine that the option is not a material right and, therefore, account for it when the customer exercises the option. If the standalone selling price of the option is not directly observable, an estimated standalone selling price is utilized which considers adjustments for discounts that the customer could receive without exercising the option and the likelihood that the option will be exercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we generally provide a one-year warranty on instruments. We accrue the cost of the assurance warranty when revenue of the instrument is recognized. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee sales commissions are generally recorded as selling, general, and administrative expense when incurred as the amortization period for such costs, if capitalized, would have been one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Cost of Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue reflects the direct cost of product components, third-party manufacturing services, and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain, and support our instruments, consumables, and services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Manufacturing overhead is predominantly comprised of labor and facility costs. We capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support our installed customer base. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expense consists primarily of expenses for personnel engaged in the development of our core technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, partner development costs, facilities costs, and other related overhead. We expense research and development costs during the period in which the costs are incurred. We defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review the allowance by considering factors such as the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#x2019;s ability to pay. Credit loss expense was immaterial for the years ended December&#160;31, 2024, 2023, and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment portfolio contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities. We regularly assess whether our securities in an unrealized loss position are credit related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income. Unrealized losses that are not credit related are included in accumulated other comprehensive income (loss). The unrealized losses on our investments are mainly attributable to government securities, including U.S. government and U.S. agency bond securities, impacted by movements in market rates and not due to issuer credit risk. We have the ability to hold and do not intend to sell the investments in unrealized loss positions before the recovery of their amortized cost bases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruptions associated with epidemics or pandemics, or other customer-specific factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. The effect of a change in tax rates on the deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We regularly review our positions taken relative to income taxes. To the extent our tax positions are more likely than not going to result in additional taxes, we accrue the estimated amount of tax related to such uncertain positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize share-based compensation expense for share-based payments, including stock options, restricted stock units, performance stock units and stock issued under our employee stock purchase plan ("ESPP") based on the grant-date fair value. We estimate the fair value of stock options and ESPP using an option-pricing model. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_124" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 9. Stockholders&#x2019; Equity&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information regarding share-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive income (loss) is comprised of unrealized gains (losses) on our investment securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Shipping and Handling&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs related to shipping and handling are included in cost of revenues for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Earnings per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing diluted net loss by the weighted-average number of shares of common stock outstanding and potentially dilutive shares outstanding during the period. We calculate the potential dilutive effect of outstanding stock options, restricted stock units, and common stock issuable pursuant to our ESPP, using the treasury stock method. Potentially dilutive common shares issuable upon conversion of convertible senior notes are determined using the if-converted method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This ASU improves segment disclosure requirements, primarily through enhanced disclosure requirements for significant segment expenses on an annual and interim basis. The improved disclosure requirements apply to all public entities that are required to report segment information, including those with only one reportable segment. The standard was effective for us beginning in fiscal year 2024 and interim periods within fiscal year 2025. We adopted this ASU for our fiscal year ending December 31, 2024 and applied the amendments retrospectively to all prior periods presented in the consolidated financial statements. There was no impact on the Company&#x2019;s reportable segments identified. Additional required disclosures have been included in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_130" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 11. Segment and Geographic Information&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Pending Adoption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt With Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard will be effective for us beginning in the first quarter of fiscal year 2026, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-04 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard requires a company to provide disaggregated disclosures, within the notes to the financial statements, of specified categories of expenses that are included in line items on the face of the income statement. The standard will be effective for us beginning in fiscal year 2027, and interim periods within fiscal year 2028, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard will be effective for us beginning in fiscal year 2025, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2023-09 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-481">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-482">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates, including those relating to the valuation of inventory, fair value of contingent consideration, valuation of acquired intangible assets, useful lives assigned to finite-lived assets, asset impairment assessments, computation of provisions for income taxes, and valuations related to our convertible senior notes. While the extent of the potential impact of current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of December&#160;31, 2024. Actual results could differ materially from these estimates.</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-483">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Functional Currency&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. dollar is the functional currency of our international operations. We remeasure foreign subsidiaries monetary assets and liabilities to the U.S. dollar and record net gains or losses from remeasurement in other income, net, on our consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-484">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash, and Investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#x2019; securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive income (loss) in stockholders&#x2019; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net. We have the ability to hold, and do not intend to sell investments in unrealized loss positions before the recovery of their amortized cost bases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities, and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash includes cash that is not readily available for use in the Company&#x2019;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-485">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Concentration and Other Risks&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to credit risk consist principally of interest-bearing investments and trade receivables. We maintain cash, cash equivalents, and investments with various major financial institutions. The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing. At December&#160;31, 2024, most of our cash was deposited with U.S. financial institutions. Our investment policy generally restricts the amount of credit exposure to any one issuer. There is no limit to the percentage of the portfolio that may be maintained in securities issued by the U.S. Treasury and U.S. Government Agencies, or other securities fully backed by U.S. Treasury or Government agencies. We have not experienced significant credit losses from financial institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our trade receivables are derived from revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers&#x2019; financial condition and, generally, require no collateral from our customers. The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review our trade receivables including consideration of factors such as historical experience, the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#x2019;s ability to pay. We have not experienced any significant credit losses to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2024, and 2023, no customer accounted for 10% or more of our total revenue. For the year ended December&#160;31, 2022, one customer exceeded 10% of our total revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, 36% and 49% of our accounts receivable were from domestic customers, respectively. As of December&#160;31, 2024, no customer represented 10% or more of our net accounts receivable. As of December&#160;31, 2023, one customer represented 10% of our net accounts receivable.&lt;/span&gt;&lt;/div&gt;We currently purchase several key parts and components used in the manufacture of our products from a limited number of suppliers. Generally, we have been able to obtain an adequate supply of such parts and components but in certain instances have incurred additional costs to secure a supply of constrained material. An extended interruption in the supply of parts and components currently obtained from our suppliers could adversely affect our business and consolidated financial statements.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-61" decimals="2" id="f-486" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-62" decimals="2" id="f-487" unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-63" decimals="2" id="f-488" unitRef="number">0.49</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-64" decimals="2" id="f-489" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-490">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Inventory, Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value on a first-in, first-out (&#x201c;FIFO&#x201d;) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs. Determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-491">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, reviewed regularly for impairment, and depreciated over the estimated useful lives of the assets, using the straight-line method. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred. Transfers of assets between property and equipment, net, and inventory are transferred at standard cost and recognized at carrying value.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-492">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated useful lives of the major classes of property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, consisted of the following components: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Laboratory equipment and machinery &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(81,948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-65" id="f-493">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-66" id="f-494">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-67" id="f-495">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-68" id="f-496">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-69" id="f-497">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-70" id="f-498">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-71" id="f-499">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-72" id="f-500">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-73" id="f-501">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-502">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;We have various operating lease agreements for office, research and development, manufacturing and distribution facilities, including our headquarters location in Menlo Park, California. As of December 31, 2024, these leases had remaining lease terms that expire between 2025 and 2027. We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. Operating lease expense is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period incurred.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-503">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with certain acquisitions, contingent consideration can be earned by the sellers upon completion of certain future performance milestones. In these cases, a liability is recorded on the acquisition date for an estimate of the acquisition date fair value of the contingent consideration. These estimates require significant management judgment, including probabilities of achieving certain future milestones. Changes in the fair value of the contingent consideration subsequent to the acquisition date are recognized in operating expense on our consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded on our consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-504">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets with Indefinite Lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired, including intangible assets and capitalized in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;amp;D asset is assessed for impairment and then amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;amp;D asset is expensed in the period of abandonment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and IPR&amp;amp;D are not amortized; however, they are reviewed for impairment at least annually. We perform annual impairment testing of goodwill as of the first day of the second quarter, or more frequently if indicators of impairment exist. We perform annual impairment testing of IPR&amp;amp;D as of the first day of the third quarter, or more frequently if indicators of impairment exist. Events that would indicate impairment and trigger an interim impairment test include, but are not limited to, unexpected adverse business conditions, weak demand for a specific product line or business, economic factors, shifting focus to certain lines of business, unanticipated technological changes or competitive activities, loss of key personnel, changes in business strategy and acts by governments or courts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level. We have one reporting unit, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test. We generally perform our impairment test using a combination of an income and a market approach to determine the fair value of goodwill. The income approach utilizes estimated discounted cash flows, while the market approach utilizes comparable company information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the IPR&amp;amp;D impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the IPR&amp;amp;D is less than the carrying amount. The qualitative factors include, but are not limited to, macroeconomic conditions, industry-specific conditions, and company-specific conditions. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the IPR&amp;amp;D is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the IPR&amp;amp;D with the carrying value. If the carrying amount of the IPR&amp;amp;D exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative impairment test.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments contextRef="c-1" decimals="0" id="f-505" unitRef="unit">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c-1" id="f-506">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Intangible Assets and Other Finite-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangibles assets include our acquired developed technology and customer relationships. We capitalize finite-lived intangibles assets and generally amortize them on a straight-line basis over the estimated useful lives. Intangible assets purchased as part of an acquisition are included in Intangible assets, net, on our consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We regularly review intangible assets with finite lives and other finite-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. We assess the recoverability of assets based on the estimated undiscounted future cash flows expected to result from the use and eventual disposition of the asset. If the undiscounted future cash flows are less than the carrying amount, the asset is impaired. In light of the changes in circumstances that led to the recoverability assessment, we also assess the remaining estimated useful life of the assets. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to net book value, significant changes in the ability of an asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to estimate the fair values of identifiable intangible assets with finite lives and other finite-lived assets, we estimate the present value of future cash flows from those assets. The key assumptions that we use in our cash flow model are the amount and timing of estimated future cash flows to be generated by the asset over an extended period of time and a rate of return that considers the relative risk of achieving the cash flows, the time value of money, and other factors that a willing market participant would consider. Management judgment is required to estimate the amount and timing of future cash flows and the relative risk of achieving those cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-507">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables; service and other revenue consist primarily of revenue earned from product maintenance agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods are transferred to our customers, or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Invoicing typically occurs upon shipment, or delivery in the case of an instrument, and payment is typically due within 30 days from invoice. In instances where the right to payment or transfer of title is contingent upon customer acceptance of the product, revenue is deferred until the acceptance criteria has been met. Revenue from instrument service contracts is recognized as the services are rendered, typically evenly over the contract term. Revenue from development agreements generally includes upfront and milestone payments. Revenue for these agreements is recognized when each distinct performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may enter into, or periodically modify, contracts with customers that include a combination of promised products and services, resulting in arrangements containing multiple performance obligations. We determine whether each product or service is distinct, in order to identify the performance obligations in the contract and allocate the contract transaction price among the distinct performance obligations. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Therefore, instrument revenue is recognized upon transfer of control of the asset to the customer, which is generally upon delivery for sales made to our non-distributor customers and upon shipment for sales made to our distributor customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration for contracts with multiple performance obligations is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using historical average selling prices combined with an assessment of current market conditions. If the standalone selling price is not directly observable, we rely on estimates by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices, and other observable inputs. We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts and sales taxes collected on behalf of governmental authorities. We update the transaction price for expected consideration, subject to constraint. Where we expect, at contract inception, the timing of payments to be consistent with the transfer of goods or services or the contract duration to be one year or less, we do not adjust the transaction price for the effects of a significant financing component &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically modify existing contracts with customers, which could change the scope or the price of the contract, or both. When a contract modification occurs, we exercise judgment to determine if the modification should be accounted for as: (i) a separate contract, (ii) the termination of the original contract and creation of a new contract, (iii) a cumulative catch-up adjustment to the original contract, or a combination thereof. Further, contract modifications require the identification and evaluation of the performance obligations of the modified contract, allocation of revenue to the remaining performance obligations and determination of the period of recognition for each identified performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our agreements provide options to customers which can be exercised at a future date, such as the option to purchase our product at discounted prices, among others. In accounting for customer options, we determine whether an option is a material right and this may require us to exercise judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right and, therefore, a performance obligation. If the contract gives the customer the option to acquire additional goods or services at their normal standalone selling prices, we would likely determine that the option is not a material right and, therefore, account for it when the customer exercises the option. If the standalone selling price of the option is not directly observable, an estimated standalone selling price is utilized which considers adjustments for discounts that the customer could receive without exercising the option and the likelihood that the option will be exercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we generally provide a one-year warranty on instruments. We accrue the cost of the assurance warranty when revenue of the instrument is recognized. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee sales commissions are generally recorded as selling, general, and administrative expense when incurred as the amortization period for such costs, if capitalized, would have been one year or less.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <pacb:StandardProductWarrantyPeriod contextRef="c-1" id="f-508">P1Y</pacb:StandardProductWarrantyPeriod>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-509">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Cost of Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue reflects the direct cost of product components, third-party manufacturing services, and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain, and support our instruments, consumables, and services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Manufacturing overhead is predominantly comprised of labor and facility costs. We capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support our installed customer base. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Shipping and Handling&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs related to shipping and handling are included in cost of revenues for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-510">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expense consists primarily of expenses for personnel engaged in the development of our core technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, partner development costs, facilities costs, and other related overhead. We expense research and development costs during the period in which the costs are incurred. We defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock contextRef="c-1" id="f-511">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review the allowance by considering factors such as the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#x2019;s ability to pay. Credit loss expense was immaterial for the years ended December&#160;31, 2024, 2023, and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment portfolio contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities. We regularly assess whether our securities in an unrealized loss position are credit related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income. Unrealized losses that are not credit related are included in accumulated other comprehensive income (loss). The unrealized losses on our investments are mainly attributable to government securities, including U.S. government and U.S. agency bond securities, impacted by movements in market rates and not due to issuer credit risk. We have the ability to hold and do not intend to sell the investments in unrealized loss positions before the recovery of their amortized cost bases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruptions associated with epidemics or pandemics, or other customer-specific factors.&lt;/span&gt;&lt;/div&gt;</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-512">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. The effect of a change in tax rates on the deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized. &lt;/span&gt;&lt;/div&gt;We regularly review our positions taken relative to income taxes. To the extent our tax positions are more likely than not going to result in additional taxes, we accrue the estimated amount of tax related to such uncertain positions.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-513">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize share-based compensation expense for share-based payments, including stock options, restricted stock units, performance stock units and stock issued under our employee stock purchase plan ("ESPP") based on the grant-date fair value. We estimate the fair value of stock options and ESPP using an option-pricing model. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_124" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 9. Stockholders&#x2019; Equity&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information regarding share-based compensation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-514">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Other comprehensive income (loss) is comprised of unrealized gains (losses) on our investment securities.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-515">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Earnings per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing diluted net loss by the weighted-average number of shares of common stock outstanding and potentially dilutive shares outstanding during the period. We calculate the potential dilutive effect of outstanding stock options, restricted stock units, and common stock issuable pursuant to our ESPP, using the treasury stock method. Potentially dilutive common shares issuable upon conversion of convertible senior notes are determined using the if-converted method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <pacb:RecentlyAdoptedAccountingStandardsPolicyTextBlock contextRef="c-1" id="f-516">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This ASU improves segment disclosure requirements, primarily through enhanced disclosure requirements for significant segment expenses on an annual and interim basis. The improved disclosure requirements apply to all public entities that are required to report segment information, including those with only one reportable segment. The standard was effective for us beginning in fiscal year 2024 and interim periods within fiscal year 2025. We adopted this ASU for our fiscal year ending December 31, 2024 and applied the amendments retrospectively to all prior periods presented in the consolidated financial statements. There was no impact on the Company&#x2019;s reportable segments identified. Additional required disclosures have been included in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_130" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 11. Segment and Geographic Information&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</pacb:RecentlyAdoptedAccountingStandardsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-517">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Pending Adoption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt With Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard will be effective for us beginning in the first quarter of fiscal year 2026, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-04 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard requires a company to provide disaggregated disclosures, within the notes to the financial statements, of specified categories of expenses that are included in line items on the face of the income statement. The standard will be effective for us beginning in fiscal year 2027, and interim periods within fiscal year 2028, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard will be effective for us beginning in fiscal year 2025, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2023-09 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-518">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 2.  BUSINESS ACQUISITIONS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Apton Biosystems&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 2, 2023, we acquired Apton Biosystems, Inc. (&#x201c;Apton&#x201d;), a California-based genomics company focused on developing a high throughput short-read sequencer using highly differentiated optics and image processing, paired with novel clustering and chemistry (the &#x201c;Apton acquisition&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Apton acquisition, all outstanding equity securities of Apton were cancelled in exchange for shares of our common stock with a fair value of $76.6 million, cash of $0.2 million, and contingent consideration with an estimated fair value of $18.5 million. Excluded from consideration transferred was $1.3 million attributable to accelerated share-based compensation expense. The fair value of the 6,121,571 common shares issued was determined based on the closing market price of our common stock on the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Apton acquisition, contingent consideration of $25.0&#160;million, which we may elect to pay in cash, shares of our common stock or a combination of cash and shares of our common stock, is due upon the achievement of a milestone, defined as the achievement of $50.0&#160;million in revenue associated with Apton's technology, provided that the milestone event occurs prior to the five-year anniversary of the closing date of the acquisition. At this time, the number of shares, if any, to be issued in connection with the achievement of the specified milestone is not known and will be calculated based on the daily volume-weighted average price of our common stock for the &lt;span style="-sec-ix-hidden:f-527"&gt;twenty&lt;/span&gt; trading days ending on and including the fifth trading day immediately prior to the occurrence of the specified milestone. Upon achievement of the milestone, we may pay cash in lieu of our common stock to ensure that the issuance of our common stock does not exceed 19.9% of our outstanding shares of common stock then outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized on our consolidated statements of operations and comprehensive loss. The fair value of the contingent consideration liability is calculated, with the assistance from a third-party valuation firm, using a Monte Carlo simulation to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition was accounted for as a business combination and, accordingly, the total fair value of the consideration transferred was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values on the acquisition date. As of December 31, 2023, the major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have finalized the purchase price allocation for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Apton acquisition. There&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were no material adjustments from those amounts disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred costs related to the Apton acquisition of approximately $9.0&#160;million during the year ended December 31, 2023, which are included in merger-related expenses on our consolidated statement of operations and comprehensive loss. Merger-related expenses include $2.8&#160;million relating to a liquidity event bonus plan that was treated as a separate transaction and included the issuance of 168,621 shares of common stock that were issued with a fair value of $2.1&#160;million based on the closing market price of our common stock on the acquisition date. As a result, the total shares issued in connection with the Apton acquisition were 6.3&#160;million shares of common stock. &lt;/span&gt;&lt;/div&gt;The excess of the value of consideration paid over the aggregate fair value of those net assets has been recorded as goodwill. We recognized goodwill of $52.3&#160;million, which is primarily attributable to the synergies expected to occur from the integration of Apton and is not deductible for income tax purposes. We allocated $55.0 million of the purchase price to acquired IPR&amp;amp;D. The fair value of the IPR&amp;amp;D was determined, with the assistance of a third-party valuation firm, using an income approach based on a forecast of expected future cash flows. Expected future cash flows utilize significant assumptions such as revenue projections and discount rate.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-74" decimals="-5" id="f-519" unitRef="usd">76600000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-74" decimals="-5" id="f-520" unitRef="usd">200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-75" decimals="-5" id="f-521" unitRef="usd">18500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <pacb:StockBasedCompensationExpenseExcludedFromConsiderationTransferred contextRef="c-74" decimals="-5" id="f-522" unitRef="usd">1300000</pacb:StockBasedCompensationExpenseExcludedFromConsiderationTransferred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c-74" decimals="0" id="f-523" unitRef="shares">6121571</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-76" decimals="-5" id="f-524" unitRef="usd">25000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <pacb:BusinessCombinationConsiderationTransferredRevenueAchievementMilestone contextRef="c-74" decimals="-5" id="f-525" unitRef="usd">50000000</pacb:BusinessCombinationConsiderationTransferredRevenueAchievementMilestone>
    <pacb:BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod contextRef="c-75" id="f-526">P5Y</pacb:BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod>
    <pacb:PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger contextRef="c-77" decimals="3" id="f-528" unitRef="number">0.199</pacb:PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c-1" id="f-529">As of December 31, 2023, the major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-78" decimals="-3" id="f-530" unitRef="usd">97000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-78" decimals="-3" id="f-531" unitRef="usd">55000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:Goodwill contextRef="c-78" decimals="-3" id="f-532" unitRef="usd">52287000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef="c-78" decimals="-3" id="f-533" unitRef="usd">153000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-78" decimals="-3" id="f-534" unitRef="usd">11338000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-78" decimals="-3" id="f-535" unitRef="usd">2191000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-78" decimals="-3" id="f-536" unitRef="usd">94008000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c-78" decimals="-5" id="f-537" unitRef="usd">9000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized contextRef="c-79" decimals="-5" id="f-538" unitRef="usd">2800000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <pacb:StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan contextRef="c-80" decimals="0" id="f-539" unitRef="shares">168621</pacb:StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan>
    <pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan contextRef="c-79" decimals="-5" id="f-540" unitRef="usd">2100000</pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c-79" decimals="-5" id="f-541" unitRef="shares">6300000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-79" decimals="-5" id="f-542" unitRef="usd">52300000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-75" decimals="-5" id="f-543" unitRef="usd">55000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="c-1" id="f-544">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 3.  FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy established under GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Level 1: quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.172%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.756%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;561,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;634,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration - Apton acquisition&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2024, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and our valuation techniques did not change compared to the prior year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Contingent Consideration - Apton&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify contingent consideration, which was incurred in connection with the acquisition of Apton, within Level 3 as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value. Estimates and assumptions used in the Monte Carlo simulation include risk-adjusted forecasted revenues for products and services leveraging Apton's technology and an estimated credit spread.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of the contingent consideration liability based on the simulated revenue of the Company through the five-year anniversary of the closing date of the acquisition. As of December&#160;31, 2024, the key input used in the determination of the fair value included projected revenues of the Company relating to the high-throughput short-read products and services leveraging Apton's technology. The assumptions used in our valuation are inherently subject to uncertainty. A decrease in the projected revenues would result in a decrease in the fair value of the liability. The discount rates used are the sum of the U.S. risk-free rate and the estimated subordinated credit spread for CCC+ credit rating, which ranges from 9.4% to 9.6%. Changes in our estimated subordinated credit spread can result in changes in the fair value of the contingent consideration liability, where a lower credit spread may result in an increased liability valuation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the estimated fair value of the contingent consideration liability related to the Apton acquisition for the year ended December&#160;31, 2024 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to the fair value are recorded as the change in fair value of contingent consideration on our consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Contingent Consideration - Omniome&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 20, 2023, we achieved the commercial milestone in connection with the 2021 acquisition of Omniome. Consequently, former Omniome securityholders were entitled to receive as milestone consideration, among other things, an aggregate of approximately $100.9&#160;million in cash and approximately 9.0&#160;million shares of our common stock, representing $95.9&#160;million divided by the volume-weighted average of the trading prices of our common stock for the &lt;span style="-sec-ix-hidden:f-661"&gt;twenty&lt;/span&gt; trading days ending with and including the trading day that was two days immediately prior to the achievement of the milestone. The $95.9&#160;million represents the $100.0&#160;million that was to be paid in shares of our common stock offset by $4.1&#160;million attributable to stock options issued by PacBio in replacement of Omniome&#x2019;s unvested options as part of the transaction, pursuant to the terms of the Omniome merger agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the achievement of the commercial milestone, $101.3&#160;million of the contingent consideration, which includes certain payroll taxes, was paid during the year ended December 31, 2023. Additionally, 8,988,391 shares were issued at a value of $84.8&#160;million to the former Omniome securityholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash, and Investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our cash, cash equivalents, restricted cash, and investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and investments &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(585)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and investments &lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due in one year or less &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after one year through 5 years &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment income included in other income, net on our consolidated statements of operations and comprehensive loss was $24.9&#160;million and $32.8&#160;million for the years ended December&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-545">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. &lt;/span&gt;&lt;/div&gt;The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-546">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.172%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.756%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;561,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;634,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration - Apton acquisition&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-81" decimals="-3" id="f-547" unitRef="usd">55370000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-82" decimals="-3" id="f-548" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-83" decimals="-3" id="f-549" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-84" decimals="-3" id="f-550" unitRef="usd">55370000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-85" decimals="-3" id="f-551" unitRef="usd">70172000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-86" decimals="-3" id="f-552" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-87" decimals="-3" id="f-553" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-88" decimals="-3" id="f-554" unitRef="usd">70172000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-89" decimals="-3" id="f-555" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-90" decimals="-3" id="f-556" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-91" decimals="-3" id="f-557" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-92" decimals="-3" id="f-558" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-93" decimals="-3" id="f-559" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-94" decimals="-3" id="f-560" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-95" decimals="-3" id="f-561" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-96" decimals="-3" id="f-562" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-97" decimals="-3" id="f-563" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-98" decimals="-3" id="f-564" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-99" decimals="-3" id="f-565" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-100" decimals="-3" id="f-566" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-101" decimals="-3" id="f-567" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-102" decimals="-3" id="f-568" unitRef="usd">109739000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-103" decimals="-3" id="f-569" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-104" decimals="-3" id="f-570" unitRef="usd">109739000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-105" decimals="-3" id="f-571" unitRef="usd">55370000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-106" decimals="-3" id="f-572" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-107" decimals="-3" id="f-573" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-108" decimals="-3" id="f-574" unitRef="usd">55370000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-109" decimals="-3" id="f-575" unitRef="usd">70172000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-110" decimals="-3" id="f-576" unitRef="usd">109739000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-111" decimals="-3" id="f-577" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-112" decimals="-3" id="f-578" unitRef="usd">179911000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-113" decimals="-3" id="f-579" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-114" decimals="-3" id="f-580" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-115" decimals="-3" id="f-581" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-116" decimals="-3" id="f-582" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-117" decimals="-3" id="f-583" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-118" decimals="-3" id="f-584" unitRef="usd">9947000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-119" decimals="-3" id="f-585" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-120" decimals="-3" id="f-586" unitRef="usd">9947000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-121" decimals="-3" id="f-587" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-122" decimals="-3" id="f-588" unitRef="usd">46905000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-123" decimals="-3" id="f-589" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-124" decimals="-3" id="f-590" unitRef="usd">46905000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-125" decimals="-3" id="f-591" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-126" decimals="-3" id="f-592" unitRef="usd">88579000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-127" decimals="-3" id="f-593" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-128" decimals="-3" id="f-594" unitRef="usd">88579000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-129" decimals="-3" id="f-595" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-130" decimals="-3" id="f-596" unitRef="usd">287656000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-131" decimals="-3" id="f-597" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-132" decimals="-3" id="f-598" unitRef="usd">287656000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-133" decimals="-3" id="f-599" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-134" decimals="-3" id="f-600" unitRef="usd">352979000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-135" decimals="-3" id="f-601" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-136" decimals="-3" id="f-602" unitRef="usd">352979000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-137" decimals="-3" id="f-603" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-138" decimals="-3" id="f-604" unitRef="usd">334561000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-139" decimals="-3" id="f-605" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-140" decimals="-3" id="f-606" unitRef="usd">334561000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-141" decimals="-3" id="f-607" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-142" decimals="-3" id="f-608" unitRef="usd">451505000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-143" decimals="-3" id="f-609" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-144" decimals="-3" id="f-610" unitRef="usd">451505000</us-gaap:InvestmentsFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-145" decimals="-3" id="f-611" unitRef="usd">690000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-146" decimals="-3" id="f-612" unitRef="usd">0</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-147" decimals="-3" id="f-613" unitRef="usd">0</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-4" decimals="-3" id="f-614" unitRef="usd">690000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-148" decimals="-3" id="f-615" unitRef="usd">300000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-149" decimals="-3" id="f-616" unitRef="usd">0</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-150" decimals="-3" id="f-617" unitRef="usd">0</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-7" decimals="-3" id="f-618" unitRef="usd">300000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-145" decimals="-3" id="f-619" unitRef="usd">1532000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-146" decimals="-3" id="f-620" unitRef="usd">0</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-147" decimals="-3" id="f-621" unitRef="usd">0</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-4" decimals="-3" id="f-622" unitRef="usd">1532000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-148" decimals="-3" id="f-623" unitRef="usd">2422000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-149" decimals="-3" id="f-624" unitRef="usd">0</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-150" decimals="-3" id="f-625" unitRef="usd">0</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-7" decimals="-3" id="f-626" unitRef="usd">2422000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-145" decimals="-3" id="f-627" unitRef="usd">57592000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-146" decimals="-3" id="f-628" unitRef="usd">334561000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-147" decimals="-3" id="f-629" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-630" unitRef="usd">392153000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-148" decimals="-3" id="f-631" unitRef="usd">72894000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-149" decimals="-3" id="f-632" unitRef="usd">561244000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-150" decimals="-3" id="f-633" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-7" decimals="-3" id="f-634" unitRef="usd">634138000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-151" decimals="-3" id="f-635" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-152" decimals="-3" id="f-636" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-153" decimals="-3" id="f-637" unitRef="usd">18700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-154" decimals="-3" id="f-638" unitRef="usd">18700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-155" decimals="-3" id="f-639" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-156" decimals="-3" id="f-640" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-157" decimals="-3" id="f-641" unitRef="usd">19550000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-78" decimals="-3" id="f-642" unitRef="usd">19550000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-145" decimals="-3" id="f-643" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-146" decimals="-3" id="f-644" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-147" decimals="-3" id="f-645" unitRef="usd">18700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-4" decimals="-3" id="f-646" unitRef="usd">18700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-148" decimals="-3" id="f-647" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-149" decimals="-3" id="f-648" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-150" decimals="-3" id="f-649" unitRef="usd">19550000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-7" decimals="-3" id="f-650" unitRef="usd">19550000</us-gaap:LiabilitiesFairValueDisclosure>
    <pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod contextRef="c-75" id="f-651">P5Y</pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-158" decimals="3" id="f-652" unitRef="number">0.094</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-159" decimals="3" id="f-653" unitRef="number">0.096</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-654">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the estimated fair value of the contingent consideration liability related to the Apton acquisition for the year ended December&#160;31, 2024 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-150" decimals="-3" id="f-655" unitRef="usd">19550000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-160" decimals="-3" id="f-656" unitRef="usd">-850000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-147" decimals="-3" id="f-657" unitRef="usd">18700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-161" decimals="-5" id="f-658" unitRef="usd">100900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-161"
      decimals="-5"
      id="f-659"
      unitRef="shares">9000000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-161" decimals="-5" id="f-660" unitRef="usd">95900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-161" decimals="-5" id="f-662" unitRef="usd">95900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-163" decimals="-5" id="f-663" unitRef="usd">100000000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-164" decimals="-5" id="f-664" unitRef="usd">4100000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <pacb:PaymentsForContingentConsiderationRevenueAchievementMilestone contextRef="c-165" decimals="-5" id="f-665" unitRef="usd">101300000</pacb:PaymentsForContingentConsiderationRevenueAchievementMilestone>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c-14" decimals="0" id="f-666" unitRef="shares">8988391</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-14" decimals="-5" id="f-667" unitRef="usd">84800000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c-1" id="f-668">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our cash, cash equivalents, restricted cash, and investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and investments &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(585)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and investments &lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due in one year or less &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after one year through 5 years &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-166" decimals="-3" id="f-669" unitRef="usd">55370000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-166" decimals="-3" id="f-670" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-166" decimals="-3" id="f-671" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-166" decimals="-3" id="f-672" unitRef="usd">55370000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-167" decimals="-3" id="f-673" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-167" decimals="-3" id="f-674" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-167" decimals="-3" id="f-675" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-167" decimals="-3" id="f-676" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-108" decimals="-3" id="f-677" unitRef="usd">55370000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-108" decimals="-3" id="f-678" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-108" decimals="-3" id="f-679" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-108" decimals="-3" id="f-680" unitRef="usd">55370000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-168" decimals="-3" id="f-681" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-168" decimals="-3" id="f-682" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-168" decimals="-3" id="f-683" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-168" decimals="-3" id="f-684" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-169" decimals="-3" id="f-685" unitRef="usd">46746000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-169" decimals="-3" id="f-686" unitRef="usd">184000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-169" decimals="-3" id="f-687" unitRef="usd">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-169" decimals="-3" id="f-688" unitRef="usd">46905000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-170" decimals="-3" id="f-689" unitRef="usd">287393000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-170" decimals="-3" id="f-690" unitRef="usd">418000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-170" decimals="-3" id="f-691" unitRef="usd">155000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-170" decimals="-3" id="f-692" unitRef="usd">287656000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-140" decimals="-3" id="f-693" unitRef="usd">334139000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-140" decimals="-3" id="f-694" unitRef="usd">602000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-140" decimals="-3" id="f-695" unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-140" decimals="-3" id="f-696" unitRef="usd">334561000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-171" decimals="-3" id="f-697" unitRef="usd">389509000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-171" decimals="-3" id="f-698" unitRef="usd">602000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-171" decimals="-3" id="f-699" unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-171" decimals="-3" id="f-700" unitRef="usd">389931000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-701" unitRef="usd">690000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-702" unitRef="usd">690000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-4" decimals="-3" id="f-703" unitRef="usd">1532000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-4" decimals="-3" id="f-704" unitRef="usd">1532000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-172" decimals="-3" id="f-705" unitRef="usd">70172000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-172" decimals="-3" id="f-706" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-172" decimals="-3" id="f-707" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-172" decimals="-3" id="f-708" unitRef="usd">70172000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-173" decimals="-3" id="f-709" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-173" decimals="-3" id="f-710" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-173" decimals="-3" id="f-711" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-173" decimals="-3" id="f-712" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-174" decimals="-3" id="f-713" unitRef="usd">109786000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-174" decimals="-3" id="f-714" unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-174" decimals="-3" id="f-715" unitRef="usd">60000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-174" decimals="-3" id="f-716" unitRef="usd">109739000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-112" decimals="-3" id="f-717" unitRef="usd">179958000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-112" decimals="-3" id="f-718" unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-112" decimals="-3" id="f-719" unitRef="usd">60000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-112" decimals="-3" id="f-720" unitRef="usd">179911000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-175" decimals="-3" id="f-721" unitRef="usd">9947000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-175" decimals="-3" id="f-722" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-175" decimals="-3" id="f-723" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-175" decimals="-3" id="f-724" unitRef="usd">9947000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-176" decimals="-3" id="f-725" unitRef="usd">88263000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-176" decimals="-3" id="f-726" unitRef="usd">373000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-176" decimals="-3" id="f-727" unitRef="usd">57000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-176" decimals="-3" id="f-728" unitRef="usd">88579000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-177" decimals="-3" id="f-729" unitRef="usd">353029000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-177" decimals="-3" id="f-730" unitRef="usd">478000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-177" decimals="-3" id="f-731" unitRef="usd">528000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-177" decimals="-3" id="f-732" unitRef="usd">352979000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-144" decimals="-3" id="f-733" unitRef="usd">451239000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-144" decimals="-3" id="f-734" unitRef="usd">851000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-144" decimals="-3" id="f-735" unitRef="usd">585000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-144" decimals="-3" id="f-736" unitRef="usd">451505000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-178" decimals="-3" id="f-737" unitRef="usd">631197000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-178" decimals="-3" id="f-738" unitRef="usd">864000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-178" decimals="-3" id="f-739" unitRef="usd">645000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-178" decimals="-3" id="f-740" unitRef="usd">631416000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:RestrictedCashCurrent contextRef="c-7" decimals="-3" id="f-741" unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-7" decimals="-3" id="f-742" unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-7" decimals="-3" id="f-743" unitRef="usd">2422000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-7" decimals="-3" id="f-744" unitRef="usd">2422000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue contextRef="c-4" decimals="-3" id="f-745" unitRef="usd">238957000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue contextRef="c-4" decimals="-3" id="f-746" unitRef="usd">95604000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate contextRef="c-4" decimals="-3" id="f-747" unitRef="usd">334561000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:InvestmentIncomeNet contextRef="c-1" decimals="-5" id="f-748" unitRef="usd">24900000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-14" decimals="-5" id="f-749" unitRef="usd">32800000</us-gaap:InvestmentIncomeNet>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-750">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;NOTE 4.  BALANCE SHEET COMPONENTS &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Inventory, Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, net, consisted of the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchased materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, consisted of the following components: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Laboratory equipment and machinery &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(81,948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress consists of capitalizable costs that have been incurred for the construction of finite-lived assets and is primarily comprised of amounts that will be classified as lab equipment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense during the years ended December&#160;31, 2024, 2023, and 2022 was $13.8 million, $11.5 million, and $9.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the interim impairment test of goodwill in the second and fourth quarter of 2024, we also performed a recoverability test for the definite-lived asset group, which includes property and equipment, noting no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is reviewed for impairment at least annually as of the first day of the second quarter, or more frequently if an event occurs indicating impairment. We performed our annual assessment for goodwill impairment, noting no impairment. Based primarily on the sustained decrease in our stock price during the second quarter and overall market capitalization as of the end of the second quarter of 2024 as well as other factors, we concluded that there was an indicator that it was more likely than not that the fair value of the reporting unit was less than its carrying amount that required an interim impairment test be performed on goodwill. As a result of the interim impairment test performed as of June 30, 2024, we concluded that the carrying amount of the entity-level reporting unit exceeded fair value and recorded $93.2 million of goodwill impairment. The impairment charge is included on our consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decline in the fair value of the reporting unit below its carrying value as of June 30, 2024 resulted primarily from the decline in our stock price and changes in the timing of expected future cash flows as compared to our initial long-term plan, due to continued impact of longer than expected median sales cycles resulting from various factors. We performed our impairment test using a combination of an income and a market approach to determine the fair value of the reporting unit. The income approach utilized estimated discounted cash flows, while the market approach utilized comparable company information. Significant assumptions used in the income approach included revenue growth expectations and a selected discount rate of 12.0%. The discount rate was based on the weighted average cost of capital, determined using market, peer company, industry data, and related risk factors. The assessment is a level 3 fair value measurement due to its reliance on certain unobservable inputs and significant management judgment. The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. An increase of 100 basis points to the discount rate used in our assessment would have resulted in additional goodwill impairment of approximately $85&#160;million. The assessed fair value was deemed reasonable based on a market capitalization reconciliation and a supportable control premium. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the end of the fourth quarter of 2024, we concluded that the significant increase in the carrying value of the reporting unit resulting primarily from the debt restructuring during the quarter and changes in the timing and amount of expected future cash flows due to macroeconomic headwinds, among other factors, indicated that it was more likely than not that the fair value of the reporting unit was less than its carrying amount that required an interim impairment test be performed on goodwill. As a result of the impairment test performed as of December 31, 2024, we concluded that the carrying amount of the entity-level reporting unit exceeded fair value and recorded $51.3&#160;million of goodwill impairment. The impairment charge is included on our consolidated statements of operations and comprehensive loss for the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We performed our impairment test consistent with the approach used to determine the fair value of the reporting unit in the second quarter of 2024. Significant assumptions used in the income approach included revenue growth expectations and a selected discount rate of 12.0%. The assessment is a Level 3 fair value measurement due to its reliance on certain unobservable inputs and significant management judgment. The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. An increase of 100 basis points to the discount rate used in our assessment would have resulted in additional goodwill impairment of approximately $95&#160;million. The assessed fair value was deemed reasonable based on a market capitalization reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the impairments, the carrying value of goodwill now approximates fair value. Changes in our future operating results, cash flows, share price, market capitalization or discount rates, among others, used when conducting future goodwill impairment tests could affect the estimated implied fair value of goodwill and may result in additional impairment charges in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to goodwill during the year ended December&#160;31, 2024 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(144,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;317,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets include developed technology, customer relationships, and acquired IPR&amp;amp;D.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Apton acquisition in August 2023, we allocated $55.0 million of the purchase price to IPR&amp;amp;D. As of December&#160;31, 2024, the research and development project had not been completed or abandoned and, therefore, the IPR&amp;amp;D is not currently subject to amortization. During the year ended December 31, 2023, acquired IPR&amp;amp;D of $400.0 million as a result of the Omniome acquisition in September 2021 was completed and became subject to amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D is reviewed for impairment at least annually, or more frequently if an event occurs indicating the potential for impairment. Based on the interim impairment test of goodwill in the second quarter of 2024 and our annual IPR&amp;amp;D impairment assessment in the third quarter of 2024, no impairment of IPR&amp;amp;D was identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the end of the fourth quarter of 2024, we concluded that due to significant macroeconomic uncertainties and the related changes in the timing and amount of expected future cash flows, among other factors, it was more likely than not that the fair value of the IPR&amp;amp;D was less than its carrying amount that required an interim impairment test be performed on IPR&amp;amp;D. We performed our impairment test by comparing the carrying value of the IPR&amp;amp;D to its estimated fair value, which was determined by the income approach, using a discounted cash flow model. Significant estimates and assumptions used in the income approach, which represent a Level 3 fair value measurement, include revenue growth assumptions, a selected discount rate of 14.0%, and a selected obsolescence factor of 13 years. The discount rate was based primarily on the weighted average cost of capital, determined using market, peer company, industry data, and related risk factors. Based on our analysis, the carrying value of the IPR&amp;amp;D exceeded its estimated fair value, and we recorded an impairment of $40.0 million in the fourth quarter of 2024. The impairment charge is included on our consolidated statements of operations and comprehensive loss for the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. An increase of 100 basis points to the discount rate used in our analysis would have resulted in additional IPR&amp;amp;D impairment of approximately $5&#160;million. A decrease of one year to the obsolescence factor used in our analysis would have resulted in additional IPR&amp;amp;D impairment of approximately $5&#160;million. We also performed a recoverability test for the definite-lived asset group, which includes developed technology, noting no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the impairment, the carrying value of the IPR&amp;amp;D now approximates fair value. Changes in macroeconomic conditions, industry-specific conditions and company-specific conditions may impact the estimates and assumptions used when conducting future IPR&amp;amp;D impairment tests. These changes could affect the estimated fair value of the IPR&amp;amp;D and may result in additional impairment charges in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to IPR&amp;amp;D during the year ended December&#160;31, 2024 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-814"&gt;Impairment charge&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to IPR&amp;amp;D, we had the following acquired finite-lived intangible assets as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated &lt;br/&gt;Useful Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;411,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;411,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense of intangibles was $27.4 million, $8.3 million and $0.9&#160;million for the years ended December&#160;31, 2024, 2023, and 2022, respectively. For the years ended December&#160;31, 2024, 2023, and 2022 amortization expense of intangibles in cost of revenue was $9.4&#160;million, $2.0 million, and $0.7&#160;million, respectively. For the years ended December&#160;31, 2024, 2023, and 2022, amortization expense of intangibles in operating expenses was $18.0 million, $6.3 million, and $0.2&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of acquired intangible assets is included within our cost of revenue if the costs and expenses related to the intangible assets are attributable to revenue generating activities. Amortization expense for intangible assets that are not directly related to sales generating activities are amortized to operating expenses. For developed technology intangible assets that are utilized in both revenue generating activities and in research and development activities, we allocate the amortization expense between cost of revenue and operating expenses. The finite-lived intangible assets are amortized using the straight-line method over their estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization expense of acquisition-related intangible assets with finite lives is estimated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Accrued Expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following components: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Salaries and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued purchase commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued product development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued professional services and legal fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warranty accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Product Warranties&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally provide a one-year warranty on instruments. In addition, we provide a limited warranty on consumables. At the time revenue is recognized, an accrual is established for estimated warranty costs based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranties are recorded as part of accrued expenses on our consolidated balance sheets and warranty expense is recorded as a component of cost of product revenue on our consolidated statements of operations and comprehensive loss. There were no material changes in estimates for the periods presented below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the reserve for product warranties were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions charged to cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repairs and replacements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Deferred Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, we had a total of $19.8 million of deferred revenue, $13.9 million of which was recorded as deferred revenue, current and $5.9 million of which was recorded as deferred revenue, non-current, which primarily relates to deferred service contract revenues and is scheduled to be recognized in the next five years. Revenue recorded in the year ended December&#160;31, 2024 includes $14.9 million that was included in deferred revenue, current as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We regularly enter into contracts with multiple performance obligations. These contracts are believed to be firm as of the balance sheet date. However, we may allow customers to make product substitutions or certain modifications at our discretion. The timing of shipments depends on several factors, including agreed upon shipping schedules, which may span multiple quarters. Most performance obligations are generally satisfied within a year of the contract execution date. As of December&#160;31, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations was $58.6 million, of which approximately 62% is expected to be converted to revenue in 2025, approximately 30% in the following twelve months, and the remainder thereafter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Other Liabilities, Current&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities, current, consisted of the following components: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-751">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, net, consisted of the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchased materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c-4" decimals="-3" id="f-752" unitRef="usd">45270000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c-7" decimals="-3" id="f-753" unitRef="usd">32434000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c-4" decimals="-3" id="f-754" unitRef="usd">22172000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c-7" decimals="-3" id="f-755" unitRef="usd">27653000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c-4" decimals="-3" id="f-756" unitRef="usd">14081000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c-7" decimals="-3" id="f-757" unitRef="usd">15746000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross contextRef="c-4" decimals="-3" id="f-758" unitRef="usd">81523000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="c-7" decimals="-3" id="f-759" unitRef="usd">75833000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves contextRef="c-4" decimals="-3" id="f-760" unitRef="usd">22768000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c-7" decimals="-3" id="f-761" unitRef="usd">19157000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-762" unitRef="usd">58755000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-7" decimals="-3" id="f-763" unitRef="usd">56676000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-179" decimals="-3" id="f-764" unitRef="usd">47273000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-180" decimals="-3" id="f-765" unitRef="usd">44907000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-181" decimals="-3" id="f-766" unitRef="usd">33770000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-182" decimals="-3" id="f-767" unitRef="usd">35226000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-183" decimals="-3" id="f-768" unitRef="usd">18882000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-184" decimals="-3" id="f-769" unitRef="usd">19528000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-71" decimals="-3" id="f-770" unitRef="usd">7280000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-185" decimals="-3" id="f-771" unitRef="usd">6628000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-186" decimals="-3" id="f-772" unitRef="usd">2972000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-187" decimals="-3" id="f-773" unitRef="usd">3594000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-188" decimals="-3" id="f-774" unitRef="usd">2276000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-189" decimals="-3" id="f-775" unitRef="usd">1343000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-776" unitRef="usd">112453000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-7" decimals="-3" id="f-777" unitRef="usd">111226000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-778" unitRef="usd">81948000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-779" unitRef="usd">74794000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-780" unitRef="usd">30505000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-781" unitRef="usd">36432000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-782" unitRef="usd">13800000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-14" decimals="-5" id="f-783" unitRef="usd">11500000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-15" decimals="-5" id="f-784" unitRef="usd">9500000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-190" decimals="-3" id="f-785" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-191" decimals="-3" id="f-786" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-192" decimals="-5" id="f-787" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-193" decimals="-5" id="f-788" unitRef="usd">93200000</us-gaap:GoodwillImpairmentLoss>
    <pacb:GoodwillImpairmentDiscountedCashFlowModelDiscountRate contextRef="c-2" decimals="3" id="f-789" unitRef="number">0.120</pacb:GoodwillImpairmentDiscountedCashFlowModelDiscountRate>
    <pacb:GoodwillImpairmentIncreaseInBasisPointDiscountRate contextRef="c-2" decimals="4" id="f-790" unitRef="number">0.0100</pacb:GoodwillImpairmentIncreaseInBasisPointDiscountRate>
    <pacb:AdditionalGoodwillImpairmentChangeInDiscountRate contextRef="c-193" decimals="-6" id="f-791" unitRef="usd">85000000</pacb:AdditionalGoodwillImpairmentChangeInDiscountRate>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-5" decimals="-5" id="f-792" unitRef="usd">51300000</us-gaap:GoodwillImpairmentLoss>
    <pacb:GoodwillImpairmentDiscountedCashFlowModelDiscountRate contextRef="c-4" decimals="3" id="f-793" unitRef="number">0.120</pacb:GoodwillImpairmentDiscountedCashFlowModelDiscountRate>
    <pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate contextRef="c-4" decimals="4" id="f-794" unitRef="number">0.0100</pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate>
    <pacb:AdditionalGoodwillImpairmentChangeInDiscountRate contextRef="c-5" decimals="-6" id="f-795" unitRef="usd">95000000</pacb:AdditionalGoodwillImpairmentChangeInDiscountRate>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-796">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to goodwill during the year ended December&#160;31, 2024 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(144,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;317,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-7" decimals="-3" id="f-797" unitRef="usd">462261000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-3" id="f-798" unitRef="usd">144500000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-799" unitRef="usd">317761000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-75" decimals="-5" id="f-800" unitRef="usd">55000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-194" decimals="-5" id="f-801" unitRef="usd">400000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-195" decimals="-3" id="f-802" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <pacb:IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate contextRef="c-4" decimals="3" id="f-803" unitRef="number">0.140</pacb:IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate>
    <pacb:IntangibleAssetImpairmentDiscountedCashFlowModelTerm contextRef="c-4" id="f-804">P13Y</pacb:IntangibleAssetImpairmentDiscountedCashFlowModelTerm>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-6" decimals="-3" id="f-805" unitRef="usd">40000000.0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate contextRef="c-4" decimals="4" id="f-806" unitRef="number">0.0100</pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate>
    <pacb:AdditionalIntangibleAssetImpairmentChangeInDiscountRate contextRef="c-5" decimals="-6" id="f-807" unitRef="usd">5000000</pacb:AdditionalIntangibleAssetImpairmentChangeInDiscountRate>
    <pacb:IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm contextRef="c-4" id="f-808">P1Y</pacb:IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm>
    <pacb:AdditionalIntangibleAssetImpairmentChangeInTerm contextRef="c-5" decimals="-6" id="f-809" unitRef="usd">5000000</pacb:AdditionalIntangibleAssetImpairmentChangeInTerm>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-190" decimals="-3" id="f-810" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-191" decimals="-3" id="f-811" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock contextRef="c-1" id="f-812">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to IPR&amp;amp;D during the year ended December&#160;31, 2024 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-814"&gt;Impairment charge&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-196" decimals="-3" id="f-813" unitRef="usd">55000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-6" decimals="-3" id="f-815" unitRef="usd">40000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-197" decimals="-3" id="f-816" unitRef="usd">15000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c-1" id="f-817">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to IPR&amp;amp;D, we had the following acquired finite-lived intangible assets as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated &lt;br/&gt;Useful Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;411,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;411,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-198" id="f-818">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-198" decimals="-3" id="f-819" unitRef="usd">411179000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-198" decimals="-3" id="f-820" unitRef="usd">36607000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-198" decimals="-3" id="f-821" unitRef="usd">374572000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-199" id="f-822">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-199" decimals="-3" id="f-823" unitRef="usd">360000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-199" decimals="-3" id="f-824" unitRef="usd">360000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-199" decimals="-3" id="f-825" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-4" decimals="-3" id="f-826" unitRef="usd">411539000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-827" unitRef="usd">36967000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-828" unitRef="usd">374572000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AdjustmentForAmortization contextRef="c-1" decimals="-5" id="f-829" unitRef="usd">27400000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization contextRef="c-14" decimals="-5" id="f-830" unitRef="usd">8300000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization contextRef="c-15" decimals="-5" id="f-831" unitRef="usd">900000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-200" decimals="-5" id="f-832" unitRef="usd">9400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-201" decimals="-5" id="f-833" unitRef="usd">2000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-202" decimals="-5" id="f-834" unitRef="usd">700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-203" decimals="-5" id="f-835" unitRef="usd">18000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-204" decimals="-5" id="f-836" unitRef="usd">6300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-205" decimals="-5" id="f-837" unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-838">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization expense of acquisition-related intangible assets with finite lives is estimated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-4" decimals="-3" id="f-839" unitRef="usd">27412000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-4" decimals="-3" id="f-840" unitRef="usd">27412000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-4" decimals="-3" id="f-841" unitRef="usd">27412000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-4" decimals="-3" id="f-842" unitRef="usd">27412000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-4" decimals="-3" id="f-843" unitRef="usd">27412000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-4" decimals="-3" id="f-844" unitRef="usd">237512000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-845" unitRef="usd">374572000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <pacb:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-846">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following components: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Salaries and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued purchase commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued product development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued professional services and legal fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warranty accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pacb:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-847" unitRef="usd">11706000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-848" unitRef="usd">29337000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <pacb:AccruedTenantImprovementsCurrent contextRef="c-4" decimals="-3" id="f-849" unitRef="usd">2470000</pacb:AccruedTenantImprovementsCurrent>
    <pacb:AccruedTenantImprovementsCurrent contextRef="c-7" decimals="-3" id="f-850" unitRef="usd">2834000</pacb:AccruedTenantImprovementsCurrent>
    <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="c-4" decimals="-3" id="f-851" unitRef="usd">0</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="c-7" decimals="-3" id="f-852" unitRef="usd">2613000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <pacb:AccruedProductDevelopmentCostsCurrent contextRef="c-4" decimals="-3" id="f-853" unitRef="usd">1111000</pacb:AccruedProductDevelopmentCostsCurrent>
    <pacb:AccruedProductDevelopmentCostsCurrent contextRef="c-7" decimals="-3" id="f-854" unitRef="usd">1033000</pacb:AccruedProductDevelopmentCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="-3" id="f-855" unitRef="usd">824000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-7" decimals="-3" id="f-856" unitRef="usd">2641000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:LossContingencyAccrualProductLiabilityNet contextRef="c-4" decimals="-3" id="f-857" unitRef="usd">1237000</us-gaap:LossContingencyAccrualProductLiabilityNet>
    <us-gaap:LossContingencyAccrualProductLiabilityNet contextRef="c-7" decimals="-3" id="f-858" unitRef="usd">353000</us-gaap:LossContingencyAccrualProductLiabilityNet>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent contextRef="c-4" decimals="-3" id="f-859" unitRef="usd">3100000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent contextRef="c-7" decimals="-3" id="f-860" unitRef="usd">4681000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-861" unitRef="usd">2147000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-862" unitRef="usd">2216000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-863" unitRef="usd">22595000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-864" unitRef="usd">45708000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock contextRef="c-1" id="f-865">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the reserve for product warranties were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions charged to cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repairs and replacements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock>
    <us-gaap:ProductWarrantyAccrual contextRef="c-7" decimals="-3" id="f-866" unitRef="usd">4681000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="c-29" decimals="-3" id="f-867" unitRef="usd">1651000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued contextRef="c-1" decimals="-3" id="f-868" unitRef="usd">6144000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued contextRef="c-14" decimals="-3" id="f-869" unitRef="usd">8227000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualPayments contextRef="c-1" decimals="-3" id="f-870" unitRef="usd">7725000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrualPayments contextRef="c-14" decimals="-3" id="f-871" unitRef="usd">5197000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrual contextRef="c-4" decimals="-3" id="f-872" unitRef="usd">3100000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="c-7" decimals="-3" id="f-873" unitRef="usd">4681000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ContractWithCustomerLiability contextRef="c-206" decimals="-5" id="f-874" unitRef="usd">19800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-206" decimals="-5" id="f-875" unitRef="usd">13900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-206" decimals="-5" id="f-876" unitRef="usd">5900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <pacb:ContractWithCustomerLiabilityNoncurrentRecognitionPeriod contextRef="c-207" id="f-877">P5Y</pacb:ContractWithCustomerLiabilityNoncurrentRecognitionPeriod>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-207" decimals="-5" id="f-878" unitRef="usd">14900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-4" decimals="-5" id="f-879" unitRef="usd">58600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c-4" decimals="2" id="f-880" unitRef="number">0.62</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c-208" decimals="2" id="f-881" unitRef="number">0.30</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-208" id="f-882">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-883">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities, current, consisted of the following components: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent contextRef="c-4" decimals="-3" id="f-884" unitRef="usd">2014000</pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent>
    <pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent contextRef="c-7" decimals="-3" id="f-885" unitRef="usd">3715000</pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent>
    <us-gaap:ShortTermBorrowings contextRef="c-4" decimals="-3" id="f-886" unitRef="usd">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c-7" decimals="-3" id="f-887" unitRef="usd">490000</us-gaap:ShortTermBorrowings>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-888" unitRef="usd">1210000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-889" unitRef="usd">4121000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-890" unitRef="usd">3224000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-891" unitRef="usd">8326000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-892">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 5.  CONVERTIBLE SENIOR NOTES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;2029 Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 7, 2024, we entered into an exchange agreement with SB Northstar LP (&#x201c;SBN&#x201d;), a subsidiary of SoftBank Group Corp., pursuant to which we have agreed to exchange the remaining approximately $459.0&#160;million in aggregate principal amount of 2028 Notes outstanding for (i) $200.0&#160;million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 (the &#x201c;2029 Notes&#x201d;), (ii) 20,451,570 shares of common stock (the &#x201c;Exchange Shares&#x201d;) and (iii) $50.0&#160;million of cash (the &#x201c;2024 Exchange Transaction&#x201d;). The Exchange Shares were issued on November 21, 2024 (the &#x201c;Closing Date&#x201d;). The 2029 Notes, the Exchange Shares, and shares of common stock issuable upon conversion of the 2029 Notes are subject to certain lock-up restrictions for a six-month period (the &#x201c;Lock-Up Period&#x201d;) beginning on the Closing Date of the 2024 Exchange Transaction; the lock-up restrictions will terminate immediately prior to the consummation of any change in control of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon any conversion of the 2029 Notes, SBN will not be entitled to be issued a number of shares of the Company&#x2019;s common stock which would cause SBN's beneficial ownership of common stock to exceed either 9.9% of the total number of issued and outstanding shares of common stock or 9.9% of the combined voting power of all of the securities of the Company, in each case, following such conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2029 Notes are governed by an indenture (the &#x201c;2029 Indenture&#x201d;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2029 Notes bear interest at a rate of 1.50% per annum. Interest on the 2029 Notes is payable semi-annually in arrears on February 15 and August 15 and commencing on February 15, 2025. The 2029 Notes will mature on August 15, 2029, subject to earlier conversion, redemption or repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2029 Notes are convertible at the option of the holder at any time from the expiration of the Lock-Up Period until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2029 Notes are convertible into shares of our common stock based on an initial conversion rate of 204.5157 shares of common stock per $1,000 principal amount of the 2029 Notes (which is equal to an initial conversion price of approximately $4.89 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2029 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after August 20, 2027, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2029 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2029 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a Fundamental Change (as defined in the 2029 Indenture), the holders of the 2029 Notes may require that we repurchase all or part of the principal amount of the 2029 Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2029 Notes are subject to certain debt and lien covenants as well as springing guarantees, in each case, the terms of which are set forth in a second letter agreement between the Company and SBN entered into in connection with the Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2029 Indenture includes customary &#x201c;events of default,&#x201d; which may result in the acceleration of the maturity of the 2029 Notes under the 2029 Indenture. The 2029 Indenture also includes customary covenants for convertible notes of this type.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2029 Notes at a rate equal to (i) 0.25% per annum of the principal amount of the 2029 Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the 2029 Notes outstanding for each day from, and including, the 181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; calendar day to, and including, the 360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2029 Indenture). On the 361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; day), the 2029 Notes shall be subject to acceleration as provided for in the 2029 Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2029 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2029 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2029 Notes were not issued at a substantial premium; therefore, the 2029 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The requirement to repurchase the 2029 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exchange qualified as a troubled debt restructuring under ASC 470-60 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Troubled Debt Restructurings by Debtors&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Since the undiscounted cash flows of the 2029 Notes were less than the carrying amount of the exchanged 2028 Notes, the carrying value of the 2029 Notes was determined based on the total undiscounted cash flows. As a result, no interest expense will be recognized for the 2029 Notes. The Company recorded a gain on debt restructuring of $154.4&#160;million, which resulted in a decrease of basic net loss per share of $0.56, during the year ended December&#160;31, 2024 on our consolidated statements of operations and comprehensive loss. The gain was calculated as the difference between the carrying amount of the old debt and the carrying amount of the new debt, adjusted for debt issuance costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred issuance costs related to the 2029 Notes of approximately $3.1&#160;million, including $0.2&#160;million of lender fees, which were recorded as a reduction to the gain on debt restructuring on our consolidated statements of operations and comprehensive loss. We also paid accrued but unpaid interest of $1.8&#160;million on the 2028 Notes in connection with the 2024 Exchange Transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not receive any cash proceeds from the 2024 Exchange Transaction. In exchange for issuing the 2029 Notes, Exchange Shares and paying $50.0&#160;million of cash pursuant to the 2024 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. Following the closing of the 2024 Exchange Transaction, no amounts were outstanding on the 2028 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of the liability for the 2029 Notes as of December&#160;31, 2024 is $214.2&#160;million, of which $212.0&#160;million is included as convertible senior notes, net, non-current, and $2.2&#160;million is included as accrued expenses on our consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the estimated fair value (Level 2) of the 2029 Notes was $175.0&#160;million. The fair value of the 2029 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;2030 Convertible Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, we entered into a privately negotiated exchange agreement with a holder of our outstanding 1.50% Convertible Senior Notes due 2028 (the &#x201c;2028 Notes&#x201d;), pursuant to which we issued $441.0&#160;million in aggregate principal amount of our 1.375% Convertible Senior Notes due 2030 (the &#x201c;2030 Notes&#x201d; and together with the 2029 Notes, the &#x201c;Notes&#x201d;) in exchange for $441.0&#160;million principal amount of the 2028 Notes (the &#x201c;2023 Exchange Transaction&#x201d;), pursuant to exemptions from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder. The 2030 Notes were issued on June&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Notes are governed by an indenture (the &#x201c;2030 Indenture&#x201d;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2030 Notes bear interest at a rate of 1.375% per annum. Interest on the 2030 Notes is payable semi-annually in arrears on June 15 and December 15, commencing on December 15, 2023. The 2030 Notes will mature on December&#160;15, 2030, subject to earlier conversion, redemption or repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2030 Notes are convertible into shares of our common stock based on an initial conversion rate of 46.5116 shares of common stock per $1,000 principal amount of the 2030 Notes (which is equal to an initial conversion price of approximately $21.50 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2030 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after June 20, 2028, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2030 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2030 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a Fundamental Change (as defined in the 2030 Indenture), the holders of the 2030 Notes may require that we repurchase all or part of the principal amount of the 2030 Notes at a purchase price equal to 100% of the principal amount of the notes to be repurchased, plus any accrued and unpaid interest up to, but excluding, the fundamental change repurchase date, and all unpaid interest from the fundamental change repurchase date thereon, but excluding, the maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Indenture includes customary &#x201c;events of default,&#x201d; which may result in the acceleration of the maturity of the 2030 Notes under the 2030 Indenture. The 2030 Indenture also includes customary covenants for convertible notes of this type.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2030 Notes at a rate equal to (i) 0.25% per annum of the principal amount of the 2030 Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the 2030 Notes outstanding for each day from, and including, the 181st calendar day to, and including, the 360th calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2030 Indenture). On the 361st day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361st day), the 2030 Notes shall be subject to acceleration as provided for in the 2030 Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2030 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2030 Notes were not issued at a substantial premium; therefore, the 2030 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The requirement to repurchase the 2030 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 Exchange Transaction was accounted for as an extinguishment driven by the change in fair value of the embedded conversion option. We recorded a loss on extinguishment of debt of approximately $2.0 million in connection with the 2023 Exchange Transaction during the year ended December 31, 2023, which represents the difference between the fair value and the principal amount of the 2030 Notes of the debt at the modification date, plus unamortized debt issuance costs of $1.5 million related to the respective portion of the 2028 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred issuance costs related to the 2030 Notes of approximately $7.3 million, which were recorded as debt issuance costs and are presented as a reduction to the 2030 Notes on our consolidated balance sheets. The debt issuance costs are amortized to interest expense using the effective interest method over the term of the 2030 Notes, resulting in an effective interest rate of 1.6%. We also paid accrued but unpaid interest of $2.5 million on the 2028 Notes in connection with the 2023 Exchange Transaction on June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not receive any cash proceeds from the 2023 Exchange Transaction. In exchange for issuing the 2030 Notes pursuant to the 2023 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. Following the closing of the 2023 Exchange Transaction, $459.0 million in aggregate principal amount of 2028 Notes remained outstanding with terms unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current on our consolidated balance sheets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;441,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;441,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;435,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;434,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the 2030 Notes for the years ended December&#160;31, 2024, 2023, and 2022 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the estimated fair value (Level 2) of the 2030 Notes was $293.9 million. The fair value of the 2030 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;2028 Convertible Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;9, 2021, we entered into an investment agreement with SBN relating to the issuance and sale to SBN of $900.0 million in aggregate principal amount of the 2028 Notes. The 2028 Notes were issued on February&#160;16, 2021 and bore interest at a rate of 1.50% per annum. As discussed above, in June 2023 we completed an exchange of $441.0 million in aggregate principal amount of our 2028 Notes for $441.0 million aggregate principal amount of the 2030 Notes, leaving approximately $459.0 million in aggregate principal amount of 2028 Notes outstanding. Also as discussed above, in November 2024 we completed an exchange of the remaining $459.0&#160;million in aggregate principal amount of the 2028 Notes outstanding for (i) $200.0&#160;million aggregate principal amount of the 2029 Notes, (ii) the Exchange Shares and (iii) $50.0&#160;million of cash. As of December&#160;31, 2024 no amounts were outstanding on the 2028 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred issuance costs related to the 2028 Notes of approximately $4.5 million, which were recorded as debt issuance costs and are presented as a reduction to the 2028 Notes on our consolidated balance sheets. The debt issuance costs were amortized to interest expense using the effective interest method over the term of the 2028 Notes, resulting in an effective interest rate of 1.6%. In connection with the 2024 Exchange Transaction, the remaining unamortized debt issuance costs related to the 2028 Notes of $1.1 million were extinguished by offsetting the carrying amount of the convertible senior notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying amount of the liability for the 2028 Notes is included as convertible senior notes, net, non-current on our consolidated balance sheets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;459,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;457,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the 2028 Notes was as follows for the years ended December&#160;31, 2024, 2023, and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-209" decimals="-5" id="f-893" unitRef="usd">459000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-210" decimals="-5" id="f-894" unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-210" decimals="4" id="f-895" unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c-211" decimals="0" id="f-896" unitRef="shares">20451570</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <pacb:PaymentsInConjunctionWithNotesExchange contextRef="c-212" decimals="-5" id="f-897" unitRef="usd">50000000</pacb:PaymentsInConjunctionWithNotesExchange>
    <pacb:HoldingPeriodForTransferAssignmentOrSaleOfFounderShares contextRef="c-213" id="f-898">P6M</pacb:HoldingPeriodForTransferAssignmentOrSaleOfFounderShares>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c-212" decimals="4" id="f-899" unitRef="number">0.099</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c-212" decimals="4" id="f-900" unitRef="number">0.099</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-210" decimals="4" id="f-901" unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-210"
      decimals="2"
      id="f-902"
      unitRef="usdPerShare">4.89</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c-211" decimals="2" id="f-903" unitRef="number">1.50</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="c-211" decimals="INF" id="f-904" unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-211" decimals="INF" id="f-905" unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c-211" decimals="2" id="f-906" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-211" id="f-907">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentInterestInTheEventOfDefault contextRef="c-214" decimals="4" id="f-908" unitRef="number">0.0025</pacb:DebtInstrumentInterestInTheEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-214" id="f-909">P180D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-211" id="f-910">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentAdditionalInterestInEventOfDefault contextRef="c-215" decimals="4" id="f-911" unitRef="number">0.0050</pacb:DebtInstrumentAdditionalInterestInEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-216" id="f-912">P181D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-217" id="f-913">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-215" id="f-914">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-215" id="f-915">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c-1" decimals="-5" id="f-916" unitRef="usd">154400000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <pacb:RestructuringOfDebtPricePerShare
      contextRef="c-1"
      decimals="2"
      id="f-917"
      unitRef="usdPerShare">0.56</pacb:RestructuringOfDebtPricePerShare>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-218" decimals="-5" id="f-918" unitRef="usd">3100000</us-gaap:DeferredFinanceCostsGross>
    <pacb:DebtIssuanceCostLenderFees contextRef="c-218" decimals="-3" id="f-919" unitRef="usd">200000</pacb:DebtIssuanceCostLenderFees>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-219" decimals="-5" id="f-920" unitRef="usd">1800000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <pacb:PaymentsInConjunctionWithNotesExchange contextRef="c-212" decimals="-5" id="f-921" unitRef="usd">50000000</pacb:PaymentsInConjunctionWithNotesExchange>
    <us-gaap:LongTermDebt contextRef="c-209" decimals="0" id="f-922" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:ConvertibleNotesPayable contextRef="c-220" decimals="-5" id="f-923" unitRef="usd">214200000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-220" decimals="-5" id="f-924" unitRef="usd">212000000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-220" decimals="-5" id="f-925" unitRef="usd">2200000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-221" decimals="-5" id="f-926" unitRef="usd">175000000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-222" decimals="4" id="f-927" unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-222" decimals="-5" id="f-928" unitRef="usd">441000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-223" decimals="5" id="f-929" unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-223" decimals="-5" id="f-930" unitRef="usd">441000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-223" decimals="5" id="f-931" unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-223"
      decimals="2"
      id="f-932"
      unitRef="usdPerShare">21.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice contextRef="c-224" decimals="2" id="f-933" unitRef="number">1.50</pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice>
    <pacb:DebtInstrumentRedemptionPriceTradingDays contextRef="c-224" id="f-934">P20D</pacb:DebtInstrumentRedemptionPriceTradingDays>
    <pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays contextRef="c-224" id="f-935">P30D</pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c-224" decimals="2" id="f-936" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c-224" decimals="2" id="f-937" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-224" id="f-938">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentInterestInTheEventOfDefault contextRef="c-224" decimals="4" id="f-939" unitRef="number">0.0025</pacb:DebtInstrumentInterestInTheEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-225" id="f-940">P180D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-224" id="f-941">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentAdditionalInterestInEventOfDefault contextRef="c-224" decimals="4" id="f-942" unitRef="number">0.0050</pacb:DebtInstrumentAdditionalInterestInEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-226" id="f-943">P181D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-227" id="f-944">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-228" id="f-945">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-228" id="f-946">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-229" decimals="-5" id="f-947" unitRef="usd">-2000000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-230" decimals="-5" id="f-948" unitRef="usd">1500000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-231" decimals="-5" id="f-949" unitRef="usd">7300000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-223" decimals="3" id="f-950" unitRef="number">0.016</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-232" decimals="-5" id="f-951" unitRef="usd">2500000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:LongTermDebt contextRef="c-222" decimals="-5" id="f-952" unitRef="usd">459000000.0</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-953">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current on our consolidated balance sheets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;441,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;441,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;435,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;434,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying amount of the liability for the 2028 Notes is included as convertible senior notes, net, non-current on our consolidated balance sheets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;459,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;457,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-233" decimals="-3" id="f-954" unitRef="usd">441000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-234" decimals="-3" id="f-955" unitRef="usd">441000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedPremium contextRef="c-233" decimals="-3" id="f-956" unitRef="usd">453000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:DebtInstrumentUnamortizedPremium contextRef="c-234" decimals="-3" id="f-957" unitRef="usd">524000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-233" decimals="-3" id="f-958" unitRef="usd">5959000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-234" decimals="-3" id="f-959" unitRef="usd">6907000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:LongTermDebt contextRef="c-233" decimals="-3" id="f-960" unitRef="usd">435494000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-234" decimals="-3" id="f-961" unitRef="usd">434617000</us-gaap:LongTermDebt>
    <pacb:ScheduleOfInterestExpenseTableTextBlock contextRef="c-1" id="f-962">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the 2030 Notes for the years ended December&#160;31, 2024, 2023, and 2022 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the 2028 Notes was as follows for the years ended December&#160;31, 2024, 2023, and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pacb:ScheduleOfInterestExpenseTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-235" decimals="-3" id="f-963" unitRef="usd">6081000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-236" decimals="-3" id="f-964" unitRef="usd">3032000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-237" decimals="-3" id="f-965" unitRef="usd">0</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-235" decimals="-3" id="f-966" unitRef="usd">950000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-236" decimals="-3" id="f-967" unitRef="usd">463000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-237" decimals="-3" id="f-968" unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt contextRef="c-235" decimals="-3" id="f-969" unitRef="usd">7031000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-236" decimals="-3" id="f-970" unitRef="usd">3495000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-237" decimals="-3" id="f-971" unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-238" decimals="-5" id="f-972" unitRef="usd">293900000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-239" decimals="-5" id="f-973" unitRef="usd">900000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-239" decimals="4" id="f-974" unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-222" decimals="-5" id="f-975" unitRef="usd">441000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-222" decimals="-5" id="f-976" unitRef="usd">441000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebt contextRef="c-222" decimals="-5" id="f-977" unitRef="usd">459000000.0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-240" decimals="-5" id="f-978" unitRef="usd">459000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-241" decimals="-5" id="f-979" unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <pacb:PaymentsInConjunctionWithNotesExchange contextRef="c-212" decimals="-5" id="f-980" unitRef="usd">50000000</pacb:PaymentsInConjunctionWithNotesExchange>
    <us-gaap:LongTermDebt contextRef="c-242" decimals="-3" id="f-981" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-239" decimals="-5" id="f-982" unitRef="usd">4500000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-239" decimals="3" id="f-983" unitRef="number">0.016</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-243" decimals="-5" id="f-984" unitRef="usd">1100000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-242" decimals="-3" id="f-985" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-244" decimals="-3" id="f-986" unitRef="usd">459000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-242" decimals="-3" id="f-987" unitRef="usd">0</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-244" decimals="-3" id="f-988" unitRef="usd">1374000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:LongTermDebt contextRef="c-242" decimals="-3" id="f-989" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-244" decimals="-3" id="f-990" unitRef="usd">457626000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-245" decimals="-3" id="f-991" unitRef="usd">6139000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-246" decimals="-3" id="f-992" unitRef="usd">10133000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-247" decimals="-3" id="f-993" unitRef="usd">13500000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-245" decimals="-3" id="f-994" unitRef="usd">289000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-246" decimals="-3" id="f-995" unitRef="usd">472000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-247" decimals="-3" id="f-996" unitRef="usd">617000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt contextRef="c-245" decimals="-3" id="f-997" unitRef="usd">6428000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-246" decimals="-3" id="f-998" unitRef="usd">10605000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-247" decimals="-3" id="f-999" unitRef="usd">14117000</us-gaap:InterestExpenseDebt>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-1002">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 6.  RESTRUCTURING&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2024, we implemented an expense reduction initiative that included workforce reductions, the closing of our San Diego office, and other actions to reduce annualized run-rate operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the pre-tax restructuring charges are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.172%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative amount incurred to date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee separation costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="-sec-ix-hidden:f-1008"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total restructuring charges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; For the year ended December&#160;31, 2024, cumulative charges incurred to date include $14.9 million in sales, general and administrative expense; $5.9 million in research and development expense; and $4.4 million in cost of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumulative charges incurred to date include employee separation costs comprised of approximately $5.5&#160;million related to salaries, wages and other employee benefits paid to terminated employees pursuant to the Worker Adjustment and Retraining Notification (WARN) Act and approximately $4.5&#160;million of severance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other costs in the year ended December&#160;31, 2024 are primarily related to accelerated amortization and depreciation of $8.1&#160;million for the right-of-use asset, leasehold improvements, and furniture and fixtures relating to the abandonment of the San Diego office. We also incurred cumulative charges to date for excess inventory of $3.6&#160;million primarily relating to a decrease in internal demand resulting from the expense reduction initiatives which were recognized in cost of product revenues. The accelerated amortization and depreciation, which was recognized in sales, general and administrative expense, was determined as a result of the Company's change in estimate pertaining to its remaining useful life of the San Diego office utilizing the estimated date on which it planned to abandon the San Diego office. The lease liability pertaining to the San Diego office was also remeasured during the year ended December&#160;31, 2024 resulting in a reduction in the operating lease liability balance of $4.4&#160;million, which was offset against the right-of-use asset on our consolidated balance sheets. We exited our San Diego office in September 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the liabilities related to the restructuring is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Employee Separation Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expense recorded in YTD 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid during YTD 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount recorded in current liabilities as of December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated total restructuring costs to still be incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table above excludes noncash activities and amounts incurred relating to the San Diego office lease liability. The ending balance of the San Diego office lease liability as of December&#160;31, 2024 is $2.6&#160;million, and is included in operating lease liabilities, current on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other restructuring costs are expected to be incurred and paid by the end of 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-1003">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the pre-tax restructuring charges are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.172%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative amount incurred to date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee separation costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="-sec-ix-hidden:f-1008"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total restructuring charges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; For the year ended December&#160;31, 2024, cumulative charges incurred to date include $14.9 million in sales, general and administrative expense; $5.9 million in research and development expense; and $4.4 million in cost of revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-249" decimals="-3" id="f-1004" unitRef="usd">10008000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-249" decimals="-3" id="f-1005" unitRef="usd">10008000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringCharges contextRef="c-250" decimals="-3" id="f-1006" unitRef="usd">15214000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-250" decimals="-3" id="f-1007" unitRef="usd">15214000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringCharges contextRef="c-251" decimals="-3" id="f-1009" unitRef="usd">25222000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-251" decimals="-3" id="f-1010" unitRef="usd">25222000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-252" decimals="-5" id="f-1011" unitRef="usd">14900000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-253" decimals="-5" id="f-1012" unitRef="usd">5900000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-254" decimals="-5" id="f-1013" unitRef="usd">4400000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits contextRef="c-1" decimals="-5" id="f-1014" unitRef="usd">5500000</pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits>
    <us-gaap:SeveranceCosts1 contextRef="c-1" decimals="-5" id="f-1015" unitRef="usd">4500000</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="c-251" decimals="-5" id="f-1016" unitRef="usd">8100000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:InventoryWriteDown contextRef="c-251" decimals="-5" id="f-1017" unitRef="usd">3600000</us-gaap:InventoryWriteDown>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-251" decimals="-5" id="f-1018" unitRef="usd">-4400000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c-1" id="f-1019">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the liabilities related to the restructuring is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Employee Separation Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expense recorded in YTD 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid during YTD 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount recorded in current liabilities as of December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated total restructuring costs to still be incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-255" decimals="-3" id="f-1020" unitRef="usd">10008000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-256" decimals="-3" id="f-1021" unitRef="usd">2816000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-3" id="f-1022" unitRef="usd">12824000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-255" decimals="-3" id="f-1023" unitRef="usd">10008000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-256" decimals="-3" id="f-1024" unitRef="usd">2646000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-1" decimals="-3" id="f-1025" unitRef="usd">12654000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-257" decimals="-3" id="f-1026" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-258" decimals="-3" id="f-1027" unitRef="usd">170000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-4" decimals="-3" id="f-1028" unitRef="usd">170000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-257" decimals="-3" id="f-1029" unitRef="usd">0</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-258" decimals="-3" id="f-1030" unitRef="usd">946000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-4" decimals="-3" id="f-1031" unitRef="usd">946000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:OperatingLeaseLiability contextRef="c-259" decimals="-5" id="f-1032" unitRef="usd">2600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LossContingencyDisclosures contextRef="c-1" id="f-1033">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 7.  COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. All of our leases are operating leases. Lease payments comprise the base rent per the term of the lease. Lease expense for these leases is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period those payments are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We often have options to renew lease terms for buildings. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the maturities of our operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use our incremental borrowing rate to determine the present value of lease payments, as the implicit rates in our leases are not readily determinable. The weighted-average discount rate used to measure our operating lease liabilities was 7.7%. The weighted-average remaining lease term for our operating leases as of December&#160;31, 2024 was 2.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the present value of operating lease liabilities was $14.2 million and $12.1&#160;million for the years ended December&#160;31, 2024 and 2023, respectively, and were included in operating cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Lease Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs were $14.5 million and $10.4 million for the years ended December&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Contingencies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please see subsection titled &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_31" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Legal Proceedings&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in Part I, Item 3 of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Indemnification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification obligations has been recorded as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Purchase Commitments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, we enter into agreements to purchase goods or services or license intellectual property, certain of which are not cancellable without penalty. For those agreements with variable terms, we do not estimate the total obligation beyond any minimum quantities or pricing as of the reporting date. Licensing agreements under which we commit to ongoing minimum royalty payments, some of which are subject to adjustment, may be terminated under certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our purchase orders and contractual obligations are approximately $57.6 million as of December&#160;31, 2024, which consist of open purchase orders and contractual obligations in the ordinary course of business, including commitments with contract manufacturers and suppliers for which we have not received the goods or services. A majority of these purchase obligations are due within a year. Although open purchase orders are considered enforceable and legally binding, the terms generally allow us the option to cancel, reschedule and adjust our requirements based on our business needs prior to the delivery of goods or performance of services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized a loss on purchase commitment of $1.0 million for the year ended December&#160;31, 2024, which was recorded as part of accrued expenses on our consolidated balance sheet and is included in the aforementioned purchase orders and contractual obligations amount. The purchase commitment loss is based on an estimate of future excess inventory related to supply agreements with third-party vendors, for which we do not expect to have related sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a long-term supply agreement, which was most recently amended in September 2024 (the &#x201c;Supply Agreement&#x201d;), for the purchase of certain products with a semiconductor manufacturer (&#x201c;Supplier&#x201d;). The Supply Agreement provides for minimum purchase commitments through 2027 in exchange for guaranteed capacity at Supplier. We are responsible for providing certain materials to allow our Supplier to perform its obligations under the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We paid our Supplier a deposit of $9.0 million in November 2022 and an additional deposit of $6.0 million in 2023, for a total of $15.0 million (the &#x201c;Deposit&#x201d;). The Deposit is fully refundable to us, in accordance with the Supply Agreement, if we meet the minimum volume purchase commitment for the applicable year. $3.0 million was refunded to us during the year ended December&#160;31, 2024. As of December&#160;31, 2024, $4.0 million related to the Deposit was included in prepaid expenses and other current assets on our consolidated balance sheets and $8.0 million related to the Deposit was included in other long-term assets on our consolidated balance sheets, as we believe it is probable the minimum volume purchase commitment level will be achieved.&lt;/span&gt;&lt;/div&gt;</us-gaap:LossContingencyDisclosures>
    <pacb:LesseeOperatingLeaseDescriptionTableTextBlock contextRef="c-1" id="f-1034">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the maturities of our operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pacb:LesseeOperatingLeaseDescriptionTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-1035" unitRef="usd">11481000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-1036" unitRef="usd">8780000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-1037" unitRef="usd">7110000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-1038" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-4" decimals="-3" id="f-1039" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-4" decimals="-3" id="f-1040" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-1041" unitRef="usd">27371000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-1042" unitRef="usd">2431000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-1043" unitRef="usd">24940000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-1044" unitRef="usd">10026000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-1045" unitRef="usd">14914000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-1046" unitRef="usd">24940000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-1047" unitRef="number">0.077</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-1048">P2Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:PaymentsForRent contextRef="c-1" decimals="-5" id="f-1049" unitRef="usd">14200000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c-14" decimals="-5" id="f-1050" unitRef="usd">12100000</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-1051" unitRef="usd">14500000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-14" decimals="-5" id="f-1052" unitRef="usd">10400000</us-gaap:OperatingLeaseCost>
    <pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations contextRef="c-4" decimals="INF" id="f-1053" unitRef="usd">0</pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations>
    <us-gaap:PurchaseObligation contextRef="c-4" decimals="-5" id="f-1054" unitRef="usd">57600000</us-gaap:PurchaseObligation>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss contextRef="c-1" decimals="-5" id="f-1055" unitRef="usd">1000000.0</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:PaymentsForDeposits contextRef="c-260" decimals="-5" id="f-1056" unitRef="usd">9000000.0</us-gaap:PaymentsForDeposits>
    <us-gaap:PaymentsForDeposits contextRef="c-14" decimals="-5" id="f-1057" unitRef="usd">6000000.0</us-gaap:PaymentsForDeposits>
    <us-gaap:PaymentsForDeposits contextRef="c-261" decimals="-5" id="f-1058" unitRef="usd">15000000.0</us-gaap:PaymentsForDeposits>
    <pacb:RefundFromDeposits contextRef="c-1" decimals="-5" id="f-1059" unitRef="usd">3000000.0</pacb:RefundFromDeposits>
    <us-gaap:DepositsAssetsCurrent contextRef="c-4" decimals="-5" id="f-1060" unitRef="usd">4000000.0</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="c-4" decimals="-5" id="f-1061" unitRef="usd">8000000.0</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1062">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 8.  INCOME TAXES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to income taxes both in the United States and certain foreign jurisdictions in which we operate, and we use estimates in determining our provisions for income taxes. Significant management judgement is required in determining our provision for income taxes, deferred tax assets and liabilities, and valuation allowances recorded against net deferred tax assets in accordance with U.S. GAAP. These estimates and judgements occur in the calculation of tax credits, benefits, and deductions, and in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes, as well as the interest and penalties related to uncertain tax positions. Significant changes to these estimates may result in an increase or decrease to our tax provision in the current or subsequent period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether the factors underlying the sustainability assertion have changed and the amount of the recognized tax benefit is still appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for Global Intangible Low-taxed Income as a period cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2024, 2023, and 2022 income/(loss) before taxes from U.S. operations were ($311.0) million, ($318.9) million, and ($315.7) million, respectively, and income/(loss) before taxes from foreign operations was $1.5 million, $0.7 million, and $1.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Income Tax Provision (Benefit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax provision (benefit) consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax provision (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of 21% to pretax loss as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Statutory tax rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State tax rate, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Merger Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets for federal and state income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;434,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;435,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credits &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research and experimental expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cancellation of indebtedness income and interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;653,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(558,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(525,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(91,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(109,488)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(548)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(95,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2024, we maintained a valuation allowance against our net deferred tax assets which totaled $558.8 million, including net operating loss carryforwards and research and development credits of $434.1 million and $91.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. We regularly assess the need for a valuation allowance against our deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that our deferred income tax assets will be realized. In evaluating our ability to recover our deferred income tax assets within the jurisdiction from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. We maintain a valuation allowance on the net deferred tax assets of our U.S. entities as we have concluded that it is more likely than not that we will not realize our deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2024, the Company's valuation allowance increased to $558.8 million, primarily because of an increase in our credits and capitalized research &amp;amp; experimental expenses that were fully offset by a valuation allowance. For the year ended December&#160;31, 2023, the Company's valuation allowance increased to $525.7 million, primarily because of an increase in our net operating losses, credits, and capitalized research and experimental expenses that were fully offset by a valuation allowance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, we had a net operating loss carryforward for federal income tax purposes of approximately $1,704.2 million, of which $783.2 million is subject to expiration beginning in 2025. We had a total state net operating loss carryforward of approximately $1,170.6 million, which is subject to annual expirations. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the &#x201c;change in ownership&#x201d; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have federal credits of approximately $64.4 million, a portion of which will begin to expire in 2025 if not utilized and state research credits of approximately $54.6 million, which have no expiration date. These tax credits are subject to the same limitations discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, our total unrecognized tax benefit was $17.7 million. A reconciliation of the beginning and ending unrecognized tax benefit balance is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decrease in balance related to tax positions taken in prior year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken during current year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken in prior year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken during current year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decrease in balance related to tax positions taken in prior year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken during current year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December&#160;31, 2024 and 2023, we had no accrued interest or penalties due to our net operating losses available to offset any tax adjustment. If total unrecognized tax benefits were realized in the future, it would not result in any tax benefit as we currently have a full valuation allowance. We file U.S. federal and various state income tax returns. For U.S. federal and state income tax purposes, the statute of limitations currently remains open for the years ending December 31, 2021 to present and December 31, 2020 to present, respectively. In addition, all of the net operating losses and research and development credit carryforwards that may be utilized in future years may be subject to examination. We are not currently under examination by income tax authorities in any jurisdiction.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <pacb:ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition contextRef="c-1" decimals="2" id="f-1063" unitRef="number">0.50</pacb:ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-5" id="f-1064" unitRef="usd">-311000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-14" decimals="-5" id="f-1065" unitRef="usd">-318900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-15" decimals="-5" id="f-1066" unitRef="usd">-315700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-5" id="f-1067" unitRef="usd">1500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-14" decimals="-5" id="f-1068" unitRef="usd">700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-15" decimals="-5" id="f-1069" unitRef="usd">1800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1070">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax provision (benefit) consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax provision (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1071" unitRef="usd">521000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1072" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1073" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1074" unitRef="usd">-8000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1075" unitRef="usd">-9956000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1076" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1077" unitRef="usd">-197000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1078" unitRef="usd">-1468000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1079" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1080" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1081" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1082" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1083" unitRef="usd">-205000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1084" unitRef="usd">-11424000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1085" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1086" unitRef="usd">316000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1087" unitRef="usd">-11424000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1088" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1089">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of 21% to pretax loss as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Statutory tax rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State tax rate, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Merger Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-1090" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-14" decimals="3" id="f-1091" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-15" decimals="3" id="f-1092" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-1093" unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-14" decimals="3" id="f-1094" unitRef="number">0.030</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-15" decimals="3" id="f-1095" unitRef="number">0.044</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-1096" unitRef="number">-0.108</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-14" decimals="3" id="f-1097" unitRef="number">-0.200</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-15" decimals="3" id="f-1098" unitRef="number">-0.251</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <pacb:EffectiveIncomeTaxRateReconciliationTaxCredit contextRef="c-1" decimals="3" id="f-1099" unitRef="number">-0.015</pacb:EffectiveIncomeTaxRateReconciliationTaxCredit>
    <pacb:EffectiveIncomeTaxRateReconciliationTaxCredit contextRef="c-14" decimals="3" id="f-1100" unitRef="number">-0.020</pacb:EffectiveIncomeTaxRateReconciliationTaxCredit>
    <pacb:EffectiveIncomeTaxRateReconciliationTaxCredit contextRef="c-15" decimals="3" id="f-1101" unitRef="number">-0.022</pacb:EffectiveIncomeTaxRateReconciliationTaxCredit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-1102" unitRef="number">-0.037</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-14" decimals="3" id="f-1103" unitRef="number">-0.021</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-15" decimals="3" id="f-1104" unitRef="number">-0.022</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent contextRef="c-1" decimals="3" id="f-1105" unitRef="number">0</pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent>
    <pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent contextRef="c-14" decimals="3" id="f-1106" unitRef="number">-0.001</pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent>
    <pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent contextRef="c-15" decimals="3" id="f-1107" unitRef="number">0</pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses contextRef="c-1" decimals="4" id="f-1108" unitRef="number">-0.098</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses contextRef="c-14" decimals="4" id="f-1109" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses contextRef="c-15" decimals="4" id="f-1110" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-1111" unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-14" decimals="3" id="f-1112" unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-15" decimals="3" id="f-1113" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1114" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-14" decimals="3" id="f-1115" unitRef="number">0.036</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-15" decimals="3" id="f-1116" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1117">Significant components of our deferred tax assets for federal and state income taxes are as follows:&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;434,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;435,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credits &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research and experimental expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cancellation of indebtedness income and interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;653,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(558,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(525,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(91,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(109,488)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(548)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(95,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-3" id="f-1118" unitRef="usd">434122000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-7" decimals="-3" id="f-1119" unitRef="usd">435488000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-4" decimals="-3" id="f-1120" unitRef="usd">91416000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-7" decimals="-3" id="f-1121" unitRef="usd">83922000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <pacb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c-4" decimals="-3" id="f-1122" unitRef="usd">73281000</pacb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <pacb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c-7" decimals="-3" id="f-1123" unitRef="usd">63196000</pacb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense contextRef="c-4" decimals="-3" id="f-1124" unitRef="usd">10506000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense contextRef="c-7" decimals="-3" id="f-1125" unitRef="usd">16872000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <pacb:DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense contextRef="c-4" decimals="-3" id="f-1126" unitRef="usd">20424000</pacb:DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense>
    <pacb:DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense contextRef="c-7" decimals="-3" id="f-1127" unitRef="usd">14907000</pacb:DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-4" decimals="-3" id="f-1128" unitRef="usd">18195000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-7" decimals="-3" id="f-1129" unitRef="usd">18584000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <pacb:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-4" decimals="-3" id="f-1130" unitRef="usd">5618000</pacb:DeferredTaxAssetsOperatingLeaseLiabilities>
    <pacb:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-7" decimals="-3" id="f-1131" unitRef="usd">9510000</pacb:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-3" id="f-1132" unitRef="usd">653562000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-7" decimals="-3" id="f-1133" unitRef="usd">642479000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-1134" unitRef="usd">558794000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-3" id="f-1135" unitRef="usd">525703000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-4" decimals="-3" id="f-1136" unitRef="usd">94768000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-7" decimals="-3" id="f-1137" unitRef="usd">116776000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-4" decimals="-3" id="f-1138" unitRef="usd">91504000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-7" decimals="-3" id="f-1139" unitRef="usd">109488000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-1140" unitRef="usd">261000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-1141" unitRef="usd">548000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <pacb:DeferredTaxLiabilitiesRightOfUseAssets contextRef="c-4" decimals="-3" id="f-1142" unitRef="usd">3549000</pacb:DeferredTaxLiabilitiesRightOfUseAssets>
    <pacb:DeferredTaxLiabilitiesRightOfUseAssets contextRef="c-7" decimals="-3" id="f-1143" unitRef="usd">7491000</pacb:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-3" id="f-1144" unitRef="usd">95314000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-7" decimals="-3" id="f-1145" unitRef="usd">117527000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-4" decimals="-3" id="f-1146" unitRef="usd">546000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-7" decimals="-3" id="f-1147" unitRef="usd">751000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-5" id="f-1148" unitRef="usd">558800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c-4" decimals="-5" id="f-1149" unitRef="usd">434100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-4" decimals="-5" id="f-1150" unitRef="usd">91400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-5" id="f-1151" unitRef="usd">558800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-5" id="f-1152" unitRef="usd">525700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c-262" decimals="-5" id="f-1153" unitRef="usd">1704200000</us-gaap:OperatingLossCarryforwards>
    <pacb:OperatingLossCarryforwardsAmountSubjectToExpiration contextRef="c-262" decimals="-5" id="f-1154" unitRef="usd">783200000</pacb:OperatingLossCarryforwardsAmountSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards contextRef="c-263" decimals="-5" id="f-1155" unitRef="usd">1170600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-262" decimals="-5" id="f-1156" unitRef="usd">64400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-263" decimals="-5" id="f-1157" unitRef="usd">54600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-1158">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, our total unrecognized tax benefit was $17.7 million. A reconciliation of the beginning and ending unrecognized tax benefit balance is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decrease in balance related to tax positions taken in prior year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken during current year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken in prior year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken during current year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decrease in balance related to tax positions taken in prior year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken during current year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-5" id="f-1159" unitRef="usd">17700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-20" decimals="-3" id="f-1160" unitRef="usd">8335000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-15" decimals="-3" id="f-1161" unitRef="usd">10000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-15" decimals="-3" id="f-1162" unitRef="usd">2085000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-29" decimals="-3" id="f-1163" unitRef="usd">10410000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-14" decimals="-3" id="f-1164" unitRef="usd">2044000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-14" decimals="-3" id="f-1165" unitRef="usd">2100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-7" decimals="-3" id="f-1166" unitRef="usd">14554000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1167" unitRef="usd">6000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1168" unitRef="usd">3128000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-3" id="f-1169" unitRef="usd">17676000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-7" decimals="-5" id="f-1170" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-4" decimals="-5" id="f-1171" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1172">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 9.  STOCKHOLDERS' EQUITY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Common and Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Certificate of Incorporation, as amended and restated in October 2010 in connection with the closing of our initial public offering, authorizes us to issue 1,000,000,000 shares of $0.001 par value common stock and 50,000,000 shares of $0.001 par value preferred stock. As of December&#160;31, 2024 and 2023, there were no shares of preferred stock issued or outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stockholders are entitled to dividends when and if declared by our board of directors. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Underwritten Public Equity Offerings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, we entered into an underwriting agreement, relating to the public offering of 17.5&#160;million shares of our common stock, $0.001 par value per share, at a price to the public of $10.00 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 2.6&#160;million shares of our common stock, which was subsequently exercised in full, and the offering, including the sale of shares of common stock subject to the underwriters' option, closed in January 2023. In total, we sold 20.1&#160;million shares of our common stock. We paid a commission equal to 5.75% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $189.7&#160;million, excluding approximately $0.5&#160;million of offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Equity Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;), the 2020 Inducement Equity Incentive Plan (the &#x201c;Inducement Plan&#x201d;), and the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#x201c;Omniome Plan&#x201d;) allow for the issuance of stock options, restric&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ted units and awards, and performance-based awards. The 2010 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) allows eligible employees to acquire common stock at a discounted price through payroll deductions during designated offering periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 25, 2022, stockholders approved an amendment to the 2020 Plan, and we reserved an additional 18.0&#160;million shares of our common stock for issuance pursuant to equity awards granted under the 2020 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 18, 2024, stockholders approved an amendment to the 2020 Plan, and we reserved an additional 20.0&#160;million shares of our common stock for issuance pursuant to equity awards granted under the 2020 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, we had 28.4&#160;million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan. Shares remaining and available for future issuance reflect shares that may become eligible to vest upon the achievement of maximum targets for certain equity awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for time-based awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(shares in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;493&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(515)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,153)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,509&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of the outstanding options presented in the table above as of December&#160;31, 2024, totaled $0.1 million, and had a weighted-average remaining contractual life of 5.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of outstanding options represents the total pre-tax intrinsic value (i.e. the difference between $1.83, our closing stock price on the last trading day of our fourth quarter of 2024, and the option exercise price multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December&#160;31, 2024. The aggregate intrinsic value changes at each reporting date based on the fair market value of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The vested and exercisable options as of December&#160;31, 2024, totaled 9,429,082 shares, had an aggregate intrinsic value that was not significant, a weighted-average exercise price per share of $11.26, and a weighted-average remaining contractual life of 5.1 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The vested and expected to vest options as of December&#160;31, 2024, totaled 10,957,644 shares, had an aggregate intrinsic value of $0.1 million, a weighted-average exercise price per share of $11.13, and a weighted-average remaining contractual life of 5.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of stock options exercised during the years ended December&#160;31, 2024, 2023, and 2022 was $0.8 million, $8.8 million, and $5.0 million, respectively. The total intrinsic value of options exercised represents the difference between our closing stock price on the exercise date and the option exercise price, multiplied by the number of in-the-money options exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of all options granted was $1.40 in 2024, $7.32 in 2023, and $5.93 in 2022, each determined by the Black-Scholes option valuation method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units ("RSU") and Performance Stock Units ("PSU")&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have awarded both Restricted Stock Units (RSUs) and Performance Stock Units (PSUs). Each RSU represents the right to receive one share of our common stock upon meeting the required service-based vesting conditions. RSUs typically vest over four years, with equal annual installments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2023, PSUs were granted and are based on performance against predefined revenue targets and require continued employment throughout the vesting period. These shares become issuable after the third year of the performance period. Achieving the maximum revenue goal allows up to 200% of the target PSU shares to become eligible for vesting, while failing to meet the minimum revenue goal results in no shares vesting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the time-based RSU and PSU activity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(shares in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance Stock Units (PSUs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;PSU&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,308&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;541&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,722&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,801)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,018)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,211&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of shares vested related to RSUs during the years ended December&#160;31, 2024, 2023, and 2022 was $47.2 million, $39.3 million, and $39.2 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of all RSUs granted was $5.02 in 2024, $9.65 in 2023, and $10.15 in 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, a total of 33.5&#160;million shares of our common stock have been reserved for issuance under the ESPP, which allows eligible employees to acquire common stock at a discounted price through payroll deductions during designated offering periods. Each offering period typically consists of four purchase periods, each lasting approximately six months. Shares are purchased at the lower of 85% of the fair market value of the common stock at either the beginning of the offering period or the end of the purchase period. If the stock price at the end of a purchase period is lower than at the start of the offering period, the existing offering period will be reset, and a new offering period will begin. The ESPP provides for an annual increase to the shares available for issuance at the beginning of each fiscal year equal to the lesser of 2% of the common shares then outstanding, 4,000,000 shares, or an amount determined by the ESPP&#x2019;s administrator.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2024, 2023, and 2022, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,906,529&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares, 1,735,058 shares, and 1,878,168 shares of common stock were purchased under the ESPP, respectivel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;y. As of December&#160;31, 2024, 14.3&#160;million sh&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ares of our common stock remain available for issuance under our ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Share-based Compensation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, $0.6 million and $0.6 million of share-based compensation cost was capitalized in inventory, net, on our consolidated balance sheets, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate forfeitures related to our share-based compensation plans. The estimated forfeiture rate is based on historical data, trends, and other relevant factors, such as employee turnover rates and expectations about future forfeitures. The estimated forfeiture rate is reviewed periodically and adjusted as necessary to reflect changes in these factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax benefit of share-based compensation expense was immaterial for the years ended December&#160;31, 2024, 2023, and 2022 due to a valuation allowance on the net deferred tax assets of our U.S. entities, for which we have concluded that it is more likely than not that we will not realize our deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Determining Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of share options granted using the Black-Scholes valuation method and a single option award approach. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSU awards granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting period. For shares purchased under the ESPP, we estimate the grant-date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Expected Term &#x2013; The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, considering the contractual terms of the stock options and vesting schedules.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Expected Volatility &#x2013; The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Expected Dividend &#x2013; We have never paid dividends on our shares and, accordingly, the dividend yield percentage is zero for all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Risk-Free Interest Rate &#x2013; The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference observable market prices of similar or identical instruments in active markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee stock options was estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81% - 93%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77% - 78%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70% - 76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.48% &#x2013; 4.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.73% &#x2013; 4.60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.41% &#x2013; 3.66%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash received from option exercises for the years ended December&#160;31, 2024, 2023, and 2022 was $1.6 million, $6.5 million and $3.4 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ESPP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of shares to be issued under the ESPP was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81% - 118%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79% - 97%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70% - 97%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.9% - 5.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9% - 5.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6% - 3.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash received through the ESPP for the years ended December&#160;31, 2024, 2023, and 2022 was $6.1 million, $8.8 million, and $7.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, $80.1 million of total unrecognized compensation expense related to stock options, restricted stock, and ESPP shares was expected to be recognized over a weighted-average period of 2.2 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-264"
      decimals="INF"
      id="f-1173"
      unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-264"
      decimals="3"
      id="f-1174"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-264"
      decimals="INF"
      id="f-1175"
      unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-264"
      decimals="3"
      id="f-1176"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-4"
      decimals="INF"
      id="f-1177"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-4"
      decimals="INF"
      id="f-1178"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-7"
      decimals="INF"
      id="f-1179"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-7"
      decimals="INF"
      id="f-1180"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-1"
      decimals="INF"
      id="f-1181"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockVotingRights contextRef="c-1" id="f-1183">one</us-gaap:CommonStockVotingRights>
    <pacb:CommonStockVotingRightsNumberOfVotesPerShareOwned contextRef="c-1" decimals="INF" id="f-1182" unitRef="vote">1</pacb:CommonStockVotingRightsNumberOfVotesPerShareOwned>
    <pacb:PublicOfferingShares
      contextRef="c-265"
      decimals="-5"
      id="f-1184"
      unitRef="shares">17500000</pacb:PublicOfferingShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-266"
      decimals="3"
      id="f-1185"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <pacb:OfferingShareAmountMaximum
      contextRef="c-266"
      decimals="2"
      id="f-1186"
      unitRef="usdPerShare">10.00</pacb:OfferingShareAmountMaximum>
    <pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod contextRef="c-265" id="f-1187">P30D</pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod>
    <pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares
      contextRef="c-265"
      decimals="-5"
      id="f-1188"
      unitRef="shares">2600000</pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-267"
      decimals="-5"
      id="f-1189"
      unitRef="shares">20100000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering
      contextRef="c-265"
      decimals="4"
      id="f-1190"
      unitRef="number">0.0575</pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering>
    <pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts contextRef="c-265" decimals="-5" id="f-1191" unitRef="usd">189700000</pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-265" decimals="-5" id="f-1192" unitRef="usd">500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-268"
      decimals="-6"
      id="f-1193"
      unitRef="shares">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-269"
      decimals="-6"
      id="f-1194"
      unitRef="shares">20000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-270"
      decimals="-5"
      id="f-1195"
      unitRef="shares">28400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-1196">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for time-based awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(shares in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;493&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(515)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,153)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,509&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-271"
      decimals="-3"
      id="f-1197"
      unitRef="shares">13011000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-271"
      decimals="2"
      id="f-1198"
      unitRef="usdPerShare">10.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-272"
      decimals="-3"
      id="f-1199"
      unitRef="shares">493000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-272"
      decimals="2"
      id="f-1200"
      unitRef="usdPerShare">1.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-272"
      decimals="-3"
      id="f-1201"
      unitRef="shares">515000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-272"
      decimals="2"
      id="f-1202"
      unitRef="usdPerShare">3.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-272"
      decimals="-3"
      id="f-1203"
      unitRef="shares">2153000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-272"
      decimals="2"
      id="f-1204"
      unitRef="usdPerShare">8.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c-272"
      decimals="-3"
      id="f-1205"
      unitRef="shares">327000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-272"
      decimals="2"
      id="f-1206"
      unitRef="usdPerShare">5.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-273"
      decimals="-3"
      id="f-1207"
      unitRef="shares">10509000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-273"
      decimals="2"
      id="f-1208"
      unitRef="usdPerShare">11.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-274" decimals="-5" id="f-1209" unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-275" id="f-1210">P5Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharePrice
      contextRef="c-276"
      decimals="2"
      id="f-1211"
      unitRef="usdPerShare">1.83</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-274"
      decimals="0"
      id="f-1212"
      unitRef="shares">9429082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-275"
      decimals="2"
      id="f-1213"
      unitRef="usdPerShare">11.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-1214">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-274"
      decimals="0"
      id="f-1215"
      unitRef="shares">10957644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-4" decimals="-5" id="f-1216" unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-1217"
      unitRef="usdPerShare">11.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-1218">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-1219" unitRef="usd">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-14" decimals="-5" id="f-1220" unitRef="usd">8800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-15" decimals="-5" id="f-1221" unitRef="usd">5000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-1222"
      unitRef="usdPerShare">1.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-14"
      decimals="2"
      id="f-1223"
      unitRef="usdPerShare">7.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-15"
      decimals="2"
      id="f-1224"
      unitRef="usdPerShare">5.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <pacb:ShareInstrumentNumberOfSharesConversionRatio
      contextRef="c-277"
      decimals="0"
      id="f-1225"
      unitRef="shares">1</pacb:ShareInstrumentNumberOfSharesConversionRatio>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-277" id="f-1226">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <pacb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal
      contextRef="c-278"
      decimals="2"
      id="f-1227"
      unitRef="number">2</pacb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-1228">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the time-based RSU and PSU activity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(shares in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance Stock Units (PSUs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;PSU&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,308&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;541&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,722&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,801)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,018)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,211&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-279"
      decimals="-3"
      id="f-1229"
      unitRef="shares">11308000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-280"
      decimals="-3"
      id="f-1230"
      unitRef="shares">541000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-279"
      decimals="2"
      id="f-1231"
      unitRef="usdPerShare">12.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-280"
      decimals="2"
      id="f-1232"
      unitRef="usdPerShare">9.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-277"
      decimals="-3"
      id="f-1233"
      unitRef="shares">12722000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-281"
      decimals="-3"
      id="f-1234"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-277"
      decimals="2"
      id="f-1235"
      unitRef="usdPerShare">5.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-281"
      decimals="2"
      id="f-1236"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-277"
      decimals="-3"
      id="f-1237"
      unitRef="shares">3801000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-281"
      decimals="-3"
      id="f-1238"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-277"
      decimals="2"
      id="f-1239"
      unitRef="usdPerShare">12.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-281"
      decimals="2"
      id="f-1240"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-277"
      decimals="-3"
      id="f-1241"
      unitRef="shares">6018000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-281"
      decimals="-3"
      id="f-1242"
      unitRef="shares">149000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-277"
      decimals="2"
      id="f-1243"
      unitRef="usdPerShare">7.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-281"
      decimals="2"
      id="f-1244"
      unitRef="usdPerShare">9.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-282"
      decimals="-3"
      id="f-1245"
      unitRef="shares">14211000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-283"
      decimals="-3"
      id="f-1246"
      unitRef="shares">392000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-282"
      decimals="2"
      id="f-1247"
      unitRef="usdPerShare">7.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-283"
      decimals="2"
      id="f-1248"
      unitRef="usdPerShare">9.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-277" decimals="-5" id="f-1249" unitRef="usd">47200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-284" decimals="-5" id="f-1250" unitRef="usd">39300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-285" decimals="-5" id="f-1251" unitRef="usd">39200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-277"
      decimals="2"
      id="f-1252"
      unitRef="usdPerShare">5.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-284"
      decimals="2"
      id="f-1253"
      unitRef="usdPerShare">9.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-285"
      decimals="2"
      id="f-1254"
      unitRef="usdPerShare">10.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-286"
      decimals="-5"
      id="f-1255"
      unitRef="shares">33500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pacb:NumberOfPurchasePeriods
      contextRef="c-286"
      decimals="INF"
      id="f-1256"
      unitRef="period">4</pacb:NumberOfPurchasePeriods>
    <pacb:PurchasePeriodOfEmployeeStockPurchasePlan contextRef="c-287" id="f-1257">P6M</pacb:PurchasePeriodOfEmployeeStockPurchasePlan>
    <pacb:PercentageOfFairMarketValueAtWhichStockCanBePurchased
      contextRef="c-287"
      decimals="2"
      id="f-1258"
      unitRef="number">0.85</pacb:PercentageOfFairMarketValueAtWhichStockCanBePurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c-287"
      decimals="2"
      id="f-1259"
      unitRef="number">0.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-286"
      decimals="-6"
      id="f-1260"
      unitRef="shares">4000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="c-287"
      decimals="0"
      id="f-1261"
      unitRef="shares">1906529</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="c-288"
      decimals="0"
      id="f-1262"
      unitRef="shares">1735058</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="c-289"
      decimals="0"
      id="f-1263"
      unitRef="shares">1878168</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-286"
      decimals="-5"
      id="f-1264"
      unitRef="shares">14300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-1265">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-290" decimals="-3" id="f-1266" unitRef="usd">5691000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-291" decimals="-3" id="f-1267" unitRef="usd">5399000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-292" decimals="-3" id="f-1268" unitRef="usd">4802000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-293" decimals="-3" id="f-1269" unitRef="usd">19172000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-294" decimals="-3" id="f-1270" unitRef="usd">22435000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-295" decimals="-3" id="f-1271" unitRef="usd">30676000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-296" decimals="-3" id="f-1272" unitRef="usd">46173000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-297" decimals="-3" id="f-1273" unitRef="usd">44284000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-298" decimals="-3" id="f-1274" unitRef="usd">43135000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-299" decimals="-3" id="f-1275" unitRef="usd">71036000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-300" decimals="-3" id="f-1276" unitRef="usd">72118000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-301" decimals="-3" id="f-1277" unitRef="usd">78613000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-1" decimals="-5" id="f-1278" unitRef="usd">600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-14" decimals="-5" id="f-1279" unitRef="usd">600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-15"
      decimals="INF"
      id="f-1280"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-1"
      decimals="INF"
      id="f-1281"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-14"
      decimals="INF"
      id="f-1282"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1283">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee stock options was estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81% - 93%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77% - 78%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70% - 76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.48% &#x2013; 4.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.73% &#x2013; 4.60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.41% &#x2013; 3.66%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-302" id="f-1284">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-303" id="f-1285">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-304" id="f-1286">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="c-302"
      decimals="2"
      id="f-1287"
      unitRef="number">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="c-302"
      decimals="2"
      id="f-1288"
      unitRef="number">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="c-303"
      decimals="2"
      id="f-1289"
      unitRef="number">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="c-303"
      decimals="2"
      id="f-1290"
      unitRef="number">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="c-304"
      decimals="2"
      id="f-1291"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="c-304"
      decimals="2"
      id="f-1292"
      unitRef="number">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-302"
      decimals="4"
      id="f-1293"
      unitRef="number">0.0348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-302"
      decimals="4"
      id="f-1294"
      unitRef="number">0.0432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-303"
      decimals="4"
      id="f-1295"
      unitRef="number">0.0373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-303"
      decimals="4"
      id="f-1296"
      unitRef="number">0.0460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-304"
      decimals="4"
      id="f-1297"
      unitRef="number">0.0041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-304"
      decimals="4"
      id="f-1298"
      unitRef="number">0.0366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-302"
      decimals="0"
      id="f-1299"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-303"
      decimals="0"
      id="f-1300"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-304"
      decimals="0"
      id="f-1301"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-302"
      decimals="2"
      id="f-1302"
      unitRef="usdPerShare">1.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-303"
      decimals="2"
      id="f-1303"
      unitRef="usdPerShare">7.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-304"
      decimals="2"
      id="f-1304"
      unitRef="usdPerShare">5.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-302" decimals="-5" id="f-1305" unitRef="usd">1600000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-303" decimals="-5" id="f-1306" unitRef="usd">6500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-304" decimals="-5" id="f-1307" unitRef="usd">3400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1308">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of shares to be issued under the ESPP was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81% - 118%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79% - 97%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70% - 97%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.9% - 5.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9% - 5.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6% - 3.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-305" id="f-1309">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-306" id="f-1310">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-307" id="f-1311">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-308" id="f-1312">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-309" id="f-1313">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-310" id="f-1314">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="c-311"
      decimals="2"
      id="f-1315"
      unitRef="number">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="c-311"
      decimals="2"
      id="f-1316"
      unitRef="number">1.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="c-312"
      decimals="2"
      id="f-1317"
      unitRef="number">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="c-312"
      decimals="2"
      id="f-1318"
      unitRef="number">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="c-313"
      decimals="2"
      id="f-1319"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="c-313"
      decimals="2"
      id="f-1320"
      unitRef="number">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-311"
      decimals="3"
      id="f-1321"
      unitRef="number">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-311"
      decimals="3"
      id="f-1322"
      unitRef="number">0.053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-312"
      decimals="3"
      id="f-1323"
      unitRef="number">0.049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-312"
      decimals="3"
      id="f-1324"
      unitRef="number">0.055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-313"
      decimals="3"
      id="f-1325"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-313"
      decimals="3"
      id="f-1326"
      unitRef="number">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-311"
      decimals="4"
      id="f-1327"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-312"
      decimals="4"
      id="f-1328"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-313"
      decimals="4"
      id="f-1329"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-311"
      decimals="2"
      id="f-1330"
      unitRef="usdPerShare">1.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-312"
      decimals="2"
      id="f-1331"
      unitRef="usdPerShare">5.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-313"
      decimals="2"
      id="f-1332"
      unitRef="usdPerShare">4.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-287" decimals="-5" id="f-1333" unitRef="usd">6100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-288" decimals="-5" id="f-1334" unitRef="usd">8800000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-289" decimals="-5" id="f-1335" unitRef="usd">7800000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-276" decimals="-5" id="f-1336" unitRef="usd">80100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-314" id="f-1337">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1338">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 10.  NET LOSS PER SHARE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of the basic and diluted net loss per share amounts presented on our consolidated statements of operations and comprehensive loss: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.781%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(309,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(306,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(314,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(309,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(306,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(314,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Interest charges applicable to convertible notes (2028 Notes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Gain on debt restructuring (2029 Notes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(154,407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(457,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(306,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(314,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in computing basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in computing basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274,488&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,550&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Weighted average shares issuable upon conversion of convertible notes (2028 Notes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,395&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Weighted average shares issuable upon conversion of convertible notes (2029 Notes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,483&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in computing diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288,366&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,550&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following shares issuable upon conversion of the convertible senior notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares issuable upon conversion of convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,512&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,690&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,136&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,246&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,291&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_97" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 2. Business Acquisitions&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for detailed information on contingently issuable shares that would be due upon achievement of a milestone. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_124" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note &lt;/a&gt;&lt;a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_124" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;9&lt;/a&gt;&lt;a href="#icb85bf3e8a0c45b3a91f3aa50919c5f5_124" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;. Stockholders&#x2019; Equity&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for detailed information on equity awards.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-1339">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of the basic and diluted net loss per share amounts presented on our consolidated statements of operations and comprehensive loss: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.781%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(309,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(306,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(314,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(309,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(306,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(314,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Interest charges applicable to convertible notes (2028 Notes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Gain on debt restructuring (2029 Notes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(154,407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(457,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(306,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(314,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in computing basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in computing basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274,488&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,550&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Weighted average shares issuable upon conversion of convertible notes (2028 Notes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,395&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Weighted average shares issuable upon conversion of convertible notes (2029 Notes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,483&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in computing diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288,366&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,550&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-1340" unitRef="usd">-309851000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-14" decimals="-3" id="f-1341" unitRef="usd">-306735000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-15" decimals="-3" id="f-1342" unitRef="usd">-314248000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-1343" unitRef="usd">-309851000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-14" decimals="-3" id="f-1344" unitRef="usd">-306735000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-15" decimals="-3" id="f-1345" unitRef="usd">-314248000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c-245" decimals="-3" id="f-1346" unitRef="usd">6428000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c-246" decimals="-3" id="f-1347" unitRef="usd">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c-247" decimals="-3" id="f-1348" unitRef="usd">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c-315" decimals="-3" id="f-1349" unitRef="usd">154407000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c-316" decimals="-3" id="f-1350" unitRef="usd">0</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c-317" decimals="-3" id="f-1351" unitRef="usd">0</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-1" decimals="-3" id="f-1352" unitRef="usd">-457830000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-14" decimals="-3" id="f-1353" unitRef="usd">-306735000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-15" decimals="-3" id="f-1354" unitRef="usd">-314248000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-1355" unitRef="shares">274488000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-1356" unitRef="shares">274488000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-14"
      decimals="-3"
      id="f-1357"
      unitRef="shares">253629000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-14"
      decimals="-3"
      id="f-1358"
      unitRef="shares">253629000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-15"
      decimals="-3"
      id="f-1359"
      unitRef="shares">224550000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-15"
      decimals="-3"
      id="f-1360"
      unitRef="shares">224550000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1361"
      unitRef="usdPerShare">-1.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1362"
      unitRef="usdPerShare">-1.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-1363"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-1364"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-1365"
      unitRef="usdPerShare">-1.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-1366"
      unitRef="usdPerShare">-1.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-1367" unitRef="shares">274488000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-14"
      decimals="-3"
      id="f-1368"
      unitRef="shares">253629000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-15"
      decimals="-3"
      id="f-1369"
      unitRef="shares">224550000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="c-245"
      decimals="INF"
      id="f-1370"
      unitRef="shares">9395000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="c-246"
      decimals="INF"
      id="f-1371"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="c-247"
      decimals="INF"
      id="f-1372"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="c-315"
      decimals="INF"
      id="f-1373"
      unitRef="shares">4483000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="c-316"
      decimals="INF"
      id="f-1374"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="c-317"
      decimals="INF"
      id="f-1375"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-1376" unitRef="shares">288366000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-14"
      decimals="-3"
      id="f-1377"
      unitRef="shares">253629000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-15"
      decimals="-3"
      id="f-1378"
      unitRef="shares">224550000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1379"
      unitRef="usdPerShare">-1.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1380"
      unitRef="usdPerShare">-1.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-1381"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-1382"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-1383"
      unitRef="usdPerShare">-1.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-1384"
      unitRef="usdPerShare">-1.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-1385">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following shares issuable upon conversion of the convertible senior notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares issuable upon conversion of convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,512&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,690&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,136&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,246&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,291&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-318"
      decimals="-3"
      id="f-1386"
      unitRef="shares">20512000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-319"
      decimals="-3"
      id="f-1387"
      unitRef="shares">31063000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-320"
      decimals="-3"
      id="f-1388"
      unitRef="shares">20690000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-321"
      decimals="-3"
      id="f-1389"
      unitRef="shares">34136000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-322"
      decimals="-3"
      id="f-1390"
      unitRef="shares">27246000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-323"
      decimals="-3"
      id="f-1391"
      unitRef="shares">27291000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1392">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 11.  SEGMENT AND GEOGRAPHIC INFORMATION&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are organized as, and operate in, one reportable segment: the development, manufacturing, and marketing of integrated platforms for genetic analysis. Our chief operating decision-maker (CODM) is our Chief Executive Officer. Our CODM reviews financial information presented on a consolidated basis for the purposes of evaluating financial performance and allocating resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a regular basis, our CODM reviews:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;total revenues by category&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;total expenses and expenses by function, including sales and marketing and general and administrative, which include depreciation and share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;net loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our assets are primarily located in the United States of America and not allocated to any specific region, and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the segment profit or loss, including significant segment expenses is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Merger-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain on debt restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(154,407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax provision (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(309,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(306,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(314,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by geographic location is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Americas &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Europe, Middle East, and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asia-Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes United States revenue of $75.3 million, $100.5 million, and $66.8 million for the years ended December 31, 2024, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by category is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Instrument revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumable revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1393"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1394">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the segment profit or loss, including significant segment expenses is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Merger-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain on debt restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(154,407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax provision (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(309,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(306,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(314,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-324" decimals="-3" id="f-1395" unitRef="usd">154014000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-325" decimals="-3" id="f-1396" unitRef="usd">200521000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-326" decimals="-3" id="f-1397" unitRef="usd">128304000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfRevenue contextRef="c-324" decimals="-3" id="f-1398" unitRef="usd">116732000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-325" decimals="-3" id="f-1399" unitRef="usd">147741000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-326" decimals="-3" id="f-1400" unitRef="usd">79269000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-324" decimals="-3" id="f-1401" unitRef="usd">134922000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-325" decimals="-3" id="f-1402" unitRef="usd">187170000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-326" decimals="-3" id="f-1403" unitRef="usd">193000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-324" decimals="-3" id="f-1404" unitRef="usd">87244000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-325" decimals="-3" id="f-1405" unitRef="usd">79287000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-326" decimals="-3" id="f-1406" unitRef="usd">84465000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-324" decimals="-3" id="f-1407" unitRef="usd">87773000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-325" decimals="-3" id="f-1408" unitRef="usd">90531000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-326" decimals="-3" id="f-1409" unitRef="usd">76389000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-324" decimals="-3" id="f-1410" unitRef="usd">184500000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-325" decimals="-3" id="f-1411" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-326" decimals="-3" id="f-1412" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-324" decimals="-3" id="f-1413" unitRef="usd">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-325" decimals="-3" id="f-1414" unitRef="usd">9042000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-326" decimals="-3" id="f-1415" unitRef="usd">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-324" decimals="-3" id="f-1416" unitRef="usd">-850000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-325" decimals="-3" id="f-1417" unitRef="usd">15060000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-326" decimals="-3" id="f-1418" unitRef="usd">2377000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-324" decimals="-3" id="f-1419" unitRef="usd">18006000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-325" decimals="-3" id="f-1420" unitRef="usd">6157000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-326" decimals="-3" id="f-1421" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-324" decimals="-3" id="f-1422" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-325" decimals="-3" id="f-1423" unitRef="usd">-2033000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-326" decimals="-3" id="f-1424" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c-324" decimals="-3" id="f-1425" unitRef="usd">154407000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c-325" decimals="-3" id="f-1426" unitRef="usd">0</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c-326" decimals="-3" id="f-1427" unitRef="usd">0</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-324" decimals="-3" id="f-1428" unitRef="usd">10371000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-325" decimals="-3" id="f-1429" unitRef="usd">18341000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-326" decimals="-3" id="f-1430" unitRef="usd">-7052000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-324" decimals="-3" id="f-1431" unitRef="usd">316000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-325" decimals="-3" id="f-1432" unitRef="usd">-11424000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-326" decimals="-3" id="f-1433" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-324" decimals="-3" id="f-1434" unitRef="usd">-309851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-325" decimals="-3" id="f-1435" unitRef="usd">-306735000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-326" decimals="-3" id="f-1436" unitRef="usd">-314248000</us-gaap:NetIncomeLoss>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-1437">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by geographic location is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Americas &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Europe, Middle East, and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asia-Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes United States revenue of $75.3 million, $100.5 million, and $66.8 million for the years ended December 31, 2024, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-327" decimals="-3" id="f-1438" unitRef="usd">78711000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-328" decimals="-3" id="f-1439" unitRef="usd">105410000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-329" decimals="-3" id="f-1440" unitRef="usd">69561000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-330" decimals="-3" id="f-1441" unitRef="usd">34594000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-331" decimals="-3" id="f-1442" unitRef="usd">40658000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-332" decimals="-3" id="f-1443" unitRef="usd">22598000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-333" decimals="-3" id="f-1444" unitRef="usd">40709000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-334" decimals="-3" id="f-1445" unitRef="usd">54453000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-335" decimals="-3" id="f-1446" unitRef="usd">36145000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-1447" unitRef="usd">154014000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-14" decimals="-3" id="f-1448" unitRef="usd">200521000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-15" decimals="-3" id="f-1449" unitRef="usd">128304000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-336" decimals="-3" id="f-1450" unitRef="usd">75300000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-337" decimals="-3" id="f-1451" unitRef="usd">100500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-338" decimals="-3" id="f-1452" unitRef="usd">66800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c-1" id="f-1453">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by category is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Instrument revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumable revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-339" decimals="-3" id="f-1454" unitRef="usd">65776000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-340" decimals="-3" id="f-1455" unitRef="usd">120451000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-341" decimals="-3" id="f-1456" unitRef="usd">48719000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-342" decimals="-3" id="f-1457" unitRef="usd">70373000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-343" decimals="-3" id="f-1458" unitRef="usd">63421000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-344" decimals="-3" id="f-1459" unitRef="usd">59980000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-8" decimals="-3" id="f-1460" unitRef="usd">136149000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-9" decimals="-3" id="f-1461" unitRef="usd">183872000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-10" decimals="-3" id="f-1462" unitRef="usd">108699000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-11" decimals="-3" id="f-1463" unitRef="usd">17865000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-12" decimals="-3" id="f-1464" unitRef="usd">16649000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-13" decimals="-3" id="f-1465" unitRef="usd">19605000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-1466" unitRef="usd">154014000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-14" decimals="-3" id="f-1467" unitRef="usd">200521000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-15" decimals="-3" id="f-1468" unitRef="usd">128304000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1469">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 12.  SUBSEQUENT EVENTS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 7, 2025, we entered into an amendment to our existing lease for our corporate headquarters, research and development facilities, and manufacturing and distribution centers in Menlo Park, California. The lease amendment extends the term from the prior expiration on October 31, 2027 to its new expiration on April 30, 2034. We will pay approximately $97.7 million in base rent over the life of the amended lease, and receive base rent abatement of approximately $11.6&#160;million for the period beginning on March 1, 2025 and ending on July 31, 2026. We are also entitled to a tenant improvement allowance of $7.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 7, 2025, we entered into an agreement to acquire certain technology and related intellectual property from the Chinese University of Hong Kong for $9.7&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <pacb:OperatingLeaseExpectedBaseRentExpense contextRef="c-345" decimals="-5" id="f-1470" unitRef="usd">97700000</pacb:OperatingLeaseExpectedBaseRentExpense>
    <pacb:LesseeOperatingLeaseLiabilityBaseRentAbatementAmount contextRef="c-346" decimals="-5" id="f-1471" unitRef="usd">11600000</pacb:LesseeOperatingLeaseLiabilityBaseRentAbatementAmount>
    <us-gaap:TenantImprovements contextRef="c-346" decimals="-5" id="f-1472" unitRef="usd">7200000</us-gaap:TenantImprovements>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-345" decimals="-5" id="f-1473" unitRef="usd">9700000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-5" id="f-1474">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-5" id="f-1475">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-5" id="f-1476">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-5" id="f-1477">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-1478">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
